Page last updated: 2024-08-04 03:04:57
olanzapine
Description
Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy. [MeSH]
olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4. [CHeBI]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 135398745 |
| CHEMBL ID | 715 |
| SCHEMBL ID | 117695 |
| SCHEMBL ID | 28763 |
| CHEBI ID | 7735 |
| CHEBI ID | 94534 |
| MeSH ID | M0204623 |
Synonyms (172)
| Synonym |
|---|
| AC-665 |
| BIDD:PXR0138 |
| BIDD:GT0332 |
| AKOS005566122 |
| HMS3393H05 |
| AB00639907-06 |
| AB00639907-07 |
| us8802672, olanzapine |
| bdbm35254 |
| gtpl47 |
| lanzac |
| zyprexa velotab |
| alks-7921 |
| c17h20n4s |
| 10h-thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- |
| zyprexa intramuscular |
| zyprexa zydis |
| ly-170053 |
| zalasta |
| midax |
| ly 170053 |
| olansek |
| 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno(2,3-b)(1,5)benzodiazepine |
| olanzapina |
| olanzapinum |
| CHEBI:7735 , |
| 2-methyl-4-(4-methylpiperazin-1-yl)-10h-thieno[2,3-b][1,5]benzodiazepine |
| zyprexa |
| 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5]benzodiazepine |
| MLS001424057 |
| C07322 |
| 132539-06-1 |
| olanzapine |
| MLS000759457 |
| smr000466345 |
| DB00334 |
| olanzapin |
| NCGC00096077-03 |
| NCGC00096077-04 |
| olanzapine (jan/usp/inn) |
| D00454 |
| NCGC00096077-01 |
| SPECTRUM1505024 |
| zolafren |
| MLS001195646 |
| MLS001165781 |
| HMS2089M04 |
| HMS2093I04 |
| HMS2051H05 |
| olanzapine mylan |
| olanzapine teva |
| olazax disperzi |
| olanzapine cipla |
| olanzapine glenmark |
| olanzapine apotex |
| olazax |
| CHEMBL715 , |
| ly170053 |
| AKOS000282888 |
| L005958 |
| L000455 |
| 2-methyl-4-(4-methylpiperazin-1-yl)-5h-thieno[3,2-c][1,5]benzodiazepine |
| 2-methyl-4-(4-methyl-1-piperazinyl)-5h-thieno[3,2-c][1,5]benzodiazepine |
| A806453 |
| olanzapine teva |
| hsdb 8155 |
| zypadhera |
| olanzapine neopharma |
| olanzapine [usan:usp:inn:ban] |
| unii-n7u69t4szr |
| n7u69t4szr , |
| cas-132539-06-1 |
| tox21_111556 |
| dtxcid503388 |
| dtxsid9023388 , |
| O0393 |
| nsc_4585 |
| bdbm82479 |
| cas_132539-06-1 |
| HMS2233F24 |
| CCG-100922 |
| BCP9001021 |
| olzapin |
| 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene |
| oferta |
| HY-14541 |
| CS-1114 |
| FT-0673219 |
| 10h-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- |
| NCGC00096077-05 |
| olanzapine [usp monograph] |
| olanzapine [ep monograph] |
| olanzapine [jan] |
| olanzapine glenmark europe |
| olanzapine component of symbyax |
| olanzapine [inn] |
| olanzapine [usp-rs] |
| symbyax component olanzapine |
| lybalvi component olanzapine |
| olanzapine [orange book] |
| olanzapine [who-dd] |
| olanzapine component of lybalvi |
| olanzapine [ema epar] |
| olanzapine [mart.] |
| olanzapine [usan] |
| olanzapine [vandf] |
| olanzapine [mi] |
| S2493 |
| 2-methyl-4-(4-methylpiperazin-1-yl)-10h-benzo[b]thieno[2,3-e][1,4]diazepine |
| HMS3374L02 |
| 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno-[2,3-b][1,5]benzodiazepine |
| SCHEMBL117695 |
| NC00172 |
| SCHEMBL28763 |
| NCGC00096077-06 |
| tox21_111556_1 |
| KS-1090 , |
| 2-methyl-10-(4-methyl-piperazin-1-yl)-4h-3-thia-4,9-diaza-benzo[f]azulene |
| 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5]benzodiazepine # |
| AB00639907_09 |
| AB00639907_08 |
| mfcd00866702 |
| SR-01000759343-4 |
| SR-01000759343-6 |
| sr-01000759343 |
| CHEBI:94534 |
| olanzapine, united states pharmacopeia (usp) reference standard |
| HMS3657I15 |
| olanzapine, pharmaceutical secondary standard; certified reference material |
| olanzapine for system suitability, european pharmacopoeia (ep) reference standard |
| olanzapine, >=98% (hplc) |
| olanzapine, european pharmacopoeia (ep) reference standard |
| olanzapine 1.0 mg/ml in acetonitrile |
| olanzapine; 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno[2,3-b][1,5]benzodiazepine; ly 170053; lanzac; zyprexa |
| J-006186 |
| SBI-0206786.P001 |
| HMS3714J03 |
| NCGC00389791-02 |
| olanzapine-d8, 100 mug/ml in acetonitrile, ampule of 1 ml, certified reference material |
| SW220248-1 |
| BCP04917 |
| HB1786 |
| 2-methyl-4-(4-methyl-1-piperazinyl) -10h-thieno[2,3-b][1,5]benzodiazepine |
| Z1521553472 |
| olanzapine (zyprexa) |
| (e)-2-methyl-4-(4-methylpiperazin-1-yl)-10h-benzo[b]thieno[2,3-e][1,4]diazepine |
| Q201872 |
| EN300-119499 |
| 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0,3,7]tetradeca-1(10),3(7),5,8,11,13-hexaene |
| NCGC00096077-18 |
| HMS3884J21 |
| AMY7709 |
| HMS3743A09 |
| 2-methyl-4-(4-methylpiperazin-1-yl)-10h- thieno[2,3-b][1,5]benzodiazepin |
| olanzapine (ly-170053) |
| nsc-754829 |
| nsc-801187 |
| nsc801187 |
| nsc754829 |
| BO164166 |
| olanzapine- bio-x |
| ps15 - olanzapine |
| olanzapine (usp-rs) |
| olanzapine (mart.) |
| n05ah03 |
| zyprexazydis |
| olanzapine (ep monograph) |
| olanzapine (usp monograph) |
| olanzapine (usan:usp:inn:ban) |
| 2-methyl-4-(4-methyl-1-piperazinyl)-10h-thieno(2,3- b)(1,5)benzodiazepine |
| zyprexaintramuscular |
| olanzapine, 1mg/ml in acetonitrile |
Roles (7)
| Role | Description |
|---|
| histamine antagonist | Histamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. |
| muscarinic antagonist | A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists. |
| serotonergic antagonist | Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. |
| dopaminergic antagonist | A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. |
| antiemetic | A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors. |
| second generation antipsychotic | Antipsychotic drugs which can have different modes of action but which tend to be less likely than first generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements. |
| serotonin uptake inhibitor | A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent. |
Drug Classes (3)
Protein Targets (81)
Potency Measurements
Inhibition Measurements
Activation Measurements
Other Measurements
Bioassays (459)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
ISSN: 1945-7170 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
ISSN: 1945-7170 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1601981 | Displacement of [3H]-LSD from recombinant human 5HT6 receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting analysis | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166ISSN: 1768-3254 | Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID298481 | Displacement of [3H]8-OH-DPAT from human 5HT1A receptor expressed in CHO cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID171680 | Effect of compound on apomorphine induced catalepsy, from rat brain striatum at 30 umol/kg upon subcutaneous administration; Catalepsy = 0/4 | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID114862 | Effective dose required for to antagonize apomorphine-induced climbing in mice after administration of 0.12 mg/kg dose subcutaneously | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID298486 | Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID3657 | Binding affinity towards human 5-hydroxytryptamine 1 receptor | 2001 | Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
ISSN: 0022-2623 | Current and novel approaches to the drug treatment of schizophrenia. |
| AID298485 | Displacement of [3H]mesulergine from 5HT2C receptor expressed in CHO cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID238855 | Inhibition of [3H]SCH-23390 binding to rat Dopamine receptor D1 | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID588216 | FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1185962 | Displacement of [3H]SCH23390 from human dopamine D1 receptor by liquid scintillation counting | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
ISSN: 1464-3405 | Further evaluation of the tropane analogs of haloperidol. |
| AID177351 | In vivo inhibition against catalepsy in rats after oral administration evaluated by metal bar | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID229416 | Selectivity ratio (D1/D2) | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID130696 | In vivo inhibitory activity against 5-MeO-DMT-Induced Head-Twitches in mouse after oral administration | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID458633 | Displacement of [3H]spiperone from human dopamine D2 receptor at high affinity state expressed in HEK293 cells | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID694795 | Displacement of [3H]-8-OH-DPAT from human 5-HT1A receptor expressed in HEK293 cells after 1 hr | 2012 | European journal of medicinal chemistry, Oct, Volume: 56ISSN: 1768-3254 | The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT₇ receptor antagonists. |
| AID410338 | Binding affinity to human ERG expressed in HEK293 cells by whole cell patch clamp method | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
ISSN: 1520-4804 | Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. |
| AID1169864 | Binding affinity to 5HT2C receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
ISSN: 1520-4804 | Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. |
| AID374351 | Antiviral activity against BKV Gardner ATCC VR837 infected in human WI38 cells assessed as reduction in viral DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
ISSN: 0066-4804 | BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport. |
| AID624633 | Drug glucuronidation reaction catalyzed by human recombinant UGT1A4 | 2005 | Pharmacology & therapeutics, Apr, Volume: 106, Issue:1
ISSN: 0163-7258 | UDP-glucuronosyltransferases and clinical drug-drug interactions. |
| AID1393475 | Reversal of ketamine-induced cognitive flexibility in ip dosed Sprague-Dawley rat administered 30 mins prior to ketamine administration by attentional set-shifting test | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID1217705 | Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID342781 | Binding affinity to human cloned 5HT2C receptor | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID588215 | FDA HLAED, alkaline phosphatase increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID35289 | In vitro binding affinity towards alpha-1 adrenergic receptor in rat frontal cortex homogenate using of [3H]prazosin as radioligand | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID1393469 | Toxicity in ip dosed Sprague-Dawley rat assessed as sedation pretreated for 60 mins followed by PCP addition measured for 30 mins starting 15 min after rat reintroduction to auto-tracks | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID29359 | Ionization constant (pKa) | 2000 | Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
ISSN: 0022-2623 | QSAR model for drug human oral bioavailability. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1152652 | Antagonist activity at human recombinant at D2S receptor assessed as inhibition of dopamine-induced cAMP accumulation | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
ISSN: 1520-4804 | Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia. |
| AID185010 | Effect of compound on apomorphine induced locomotor hyperactivity (APO-induced LMA), from rat brain striatum at 30 umol/kg upon subcutaneous administration; LMA (locomotor activity) | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID246865 | In vivo effective dose against spontaneous locomotor activity was determined in rats | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. |
| AID588214 | FDA HLAED, liver enzyme composite activity | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1823823 | Displacement of [3H]-ketanserin from human human 5-HT2A receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method | 2021 | Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
ISSN: 1520-4804 | |
| AID61679 | pKi value for Dopamine receptor D1 binding site | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID238990 | Inhibition of [3H]rauwolscine binding to Alpha-2C adrenergic receptor | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID588219 | FDA HLAED, gamma-glutamyl transferase (GGT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1128453 | Displacement of [125]DOI from human recombinant full length 5HT2C receptor expressed in HEK293E cells | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID1169862 | Binding affinity to 5HT1A receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
ISSN: 1520-4804 | Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. |
| AID171545 | Effect of compound on apomorphine induced catalepsy, from rat brain striatum at 10 umol/kg upon subcutaneous administration; Catalepsy = 0/4 | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID1185965 | Displacement of [3H]N-methylspiperone from rat dopamine D4 receptor by liquid scintillation counting | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
ISSN: 1464-3405 | Further evaluation of the tropane analogs of haloperidol. |
| AID177349 | In vivo inhibition against MK-801 induced hyperactivity in rats after oral administration | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID1823833 | Displacement of [3H]-pyrilamine from human recombinant histamine H1 receptor expressed in human recombinant CHO-K1 cells at 1 uM incubated for 60 mins by solid scintillation counting method relative to control | 2021 | Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
ISSN: 1520-4804 | |
| AID1760276 | Displacement of [3H]LSD from human 5-HT6 receptor expressed in HEK293 cells incubated for 1 hr by microbeta counting method | 2020 | European journal of medicinal chemistry, Oct-01, Volume: 203ISSN: 1768-3254 | Chlorine substituents and linker topology as factors of 5-HT |
| AID177353 | In vivo inhibition against conditioned avoidance response in rats after oral administration | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID576612 | Inhibition of human ERG | 2011 | European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
ISSN: 1768-3254 | Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model. |
| AID330557 | Binding affinity to alphaMSH receptor at 10 nM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
ISSN: 0027-8424 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. |
| AID738112 | Displacement of [3H]raclopride from D2 receptor in human corpus striatum after 30 mins by scintillation counting | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405 | [11C]olanzapine, radiosynthesis and lipophilicity of a new potential PET 5-HT2 and D2 receptor radioligand. |
| AID301041 | Antipsychotic activity in orally dosed Wistar rat assessed as inhibition of conditioned avoidance response after 1 hr | 2007 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 17, Issue:19
ISSN: 0960-894X | Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile. |
| AID61675 | Half-maximal inhibition of [3H]-SCH- 23390 binding to Dopamine receptor D1 in rat striatal homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID1393368 | Displacement of [3H]-raclopride from human D2LR expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID65253 | Binding affinity which represents concentration giving half-maximal inhibition of [3H]spiperone (Dopamine receptor D2) binding to rat tissue homogenate | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID1595145 | Displacement of [3H] LSD from human recombinant 5-HT6 receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting method | 2019 | European journal of medicinal chemistry, May-15, Volume: 170ISSN: 1768-3254 | |
| AID1128456 | Selectivity ratio of Ki for rat recombinant dopamine D2 short receptor to Ki for human recombinant full length 5HT2A receptor | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID599883 | Displacement of [3H]mesulergine from human 5HT2C receptor in human tsA201 cells | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
ISSN: 1464-3405 | Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands. |
| AID243151 | Inhibitory concentration against potassium channel HERG | 2005 | Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
ISSN: 0960-894X | A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. |
| AID161281 | Inhibition of human Potassium channel HERG expressed in mammalian cells | 2003 | Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
ISSN: 0960-894X | Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. |
| AID5250 | Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID246836 | In vivo effective dose was determined against apomorphine climbing in rats | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. |
| AID64005 | Binding affinity towards human Dopamine receptor D4.2 in CHO cells | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
ISSN: 0022-2623 | Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate. |
| AID1185959 | Displacement of [3H] 8-OH-DPAT from human 5-HT1A receptor by liquid scintillation counting | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
ISSN: 1464-3405 | Further evaluation of the tropane analogs of haloperidol. |
| AID1823832 | Displacement of [3H]-scopolamine from human recombinant muscarinic M1 receptor expressed in human recombinant CHO-K1 cells at 1 uM incubated for 120 mins by solid scintillation counting method relative to control | 2021 | Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
ISSN: 1520-4804 | |
| AID342784 | Binding affinity to human cloned 5HT2A receptor | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID1393473 | Reversal of ketamine-induced working social withdrawal in ip dosed Sprague-Dawley rat pretreated for 60 mins followed by ketamine administration | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1568824 | Displacement of [3H]-LSD from human 5-HT6R expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178ISSN: 1768-3254 | Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT |
| AID1677164 | In vivo receptor occupancy at human dopamine D2 receptor in schizophrenia patient brain at 10 mCi, iv by PET scanning | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
ISSN: 1464-3405 | |
| AID5614 | Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
ISSN: 0022-2623 | Selective optimization of side activities: another way for drug discovery. |
| AID1409608 | AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells). | 2020 | Nature, 07, Volume: 583, Issue:7816
ISSN: 1476-4687 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. |
| AID63347 | Binding affinity towards human Dopamine receptor D1 | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
ISSN: 0022-2623 | Selective optimization of side activities: another way for drug discovery. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID63537 | Binding affinity towards human dopamine receptor D4 | 2001 | Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
ISSN: 0022-2623 | Current and novel approaches to the drug treatment of schizophrenia. |
| AID238941 | Inhibition of [3H]spiperone binding to rat dopamine D2 receptor | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. |
| AID1520007 | Binding affinity to human 5-HT2AR expressed in HEK293 cells by competitive binding assay | 2020 | European journal of medicinal chemistry, Jan-01, Volume: 185ISSN: 1768-3254 | |
| AID588217 | FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1128468 | Selectivity ratio of Ki for adrenergic alpha1A receptor (unknown origin) to Ki for human recombinant full length 5HT2A receptor | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID24452 | logY value was determined | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID230094 | Ratio of pKi of compound towards 5-HT2 receptor to that of D1 receptor | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID65620 | Half-maximal inhibition of [3H]-spiperone binding to Dopamine receptor D3 in rat tissue homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID342775 | Binding affinity to human cloned dopamine D1 receptor | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID298492 | Displacement of [3H]prazosin from adrenergic alpha1 receptor in rat cerebral cortex | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID738353 | Displacement of [3H]mesulergine from 5-HT2C receptor in human frontal cortex after 30 mins by scintillation counting | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405 | [11C]olanzapine, radiosynthesis and lipophilicity of a new potential PET 5-HT2 and D2 receptor radioligand. |
| AID1185960 | Displacement of [3H]Ketanserin from human 5-HT2A receptor by liquid scintillation counting | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
ISSN: 1464-3405 | Further evaluation of the tropane analogs of haloperidol. |
| AID1393467 | Toxicity in Wistar rat assessed as increase in prolactin level at 3 mg/kg, po after 60 mins by ELISA | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID1217707 | Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID438555 | Binding affinity to 5HT1A receptor | 2009 | Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19
ISSN: 1520-4804 | Physical binding pocket induction for affinity prediction. |
| AID298494 | Displacement of [3H]pyrilamine from histaminergic H1 receptor guinea pig cerebellum | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID246864 | In vivo effective dose against conditioned avoidance response was determined in rats | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. |
| AID239149 | Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 7 receptor | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID87244 | Binding affinity towards human H1 receptor | 2001 | Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
ISSN: 0022-2623 | Current and novel approaches to the drug treatment of schizophrenia. |
| AID238991 | Inhibition of [3H]prazosin binding to rat Alpha-1 adrenergic receptor | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID298493 | Displacement of [3H]RX 821002 from adrenergic alpha-2 receptor in rat cerebral cortex | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID1172033 | Displacement of [3H]-spiperone from dopamine D2 receptor in rat striatum | 2015 | Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
ISSN: 1464-3391 | Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile. |
| AID298482 | Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHO cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID1677162 | Binding affinity to human dopamine D1 receptor | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
ISSN: 1464-3405 | |
| AID1125021 | Displacement of [3H]spiperone from human dopamine D2S receptor S5.43T/S5.46A mutant expressed in CHO-K1 cell membrane after 2 hrs by beta counting | 2014 | European journal of medicinal chemistry, Apr-22, Volume: 77ISSN: 1768-3254 | Novel insights on the structural determinants of clozapine and olanzapine multi-target binding profiles. |
| AID298480 | Displacement of [3H]spiperone from human dopamine D4.4 receptor expressed in CHO cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID678713 | Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
ISSN: 1520-5010 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID1556427 | Displacement of [3H]LSD from human 5HT6 receptor expressed in HEK293 cells measured after 1 hr by liquid scintillation counter method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179ISSN: 1768-3254 | 2-Aminoimidazole-based antagonists of the 5-HT |
| AID1204345 | Displacement of [3H]N-methylspiperone from dopamine D3 receptor (unknown origin) assessed as total radioligand binding at 1 uM incubated for 60 mins by microbeta plate reader based method | 2015 | European journal of medicinal chemistry, Jun-05, Volume: 97ISSN: 1768-3254 | Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity. |
| AID1128474 | Inhibition of quipazine-induced head twitches in po dosed rat head twitch model administered 25 mins prior to quipazine challenge measured after 30 mins | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID1823851 | Sedative activity in ip dosed Wistar rat assessed as effect on spontaneous locomotor activity measured for 10 mins by social interaction test | 2021 | Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
ISSN: 1520-4804 | |
| AID230935 | Ratio of the catalepsy to that of conditioned avoidance response in rats | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID1409613 | Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay. | 2020 | Nature, 07, Volume: 583, Issue:7816
ISSN: 1476-4687 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. |
| AID330561 | Displacement of [3H]mepyramine from H1R in rat brain | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
ISSN: 0027-8424 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. |
| AID1409607 | IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells). | 2020 | Nature, 07, Volume: 583, Issue:7816
ISSN: 1476-4687 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. |
| AID395326 | Fraction unbound in rat brain | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
ISSN: 1520-4804 | Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. |
| AID1677154 | Ratio of RO50 for in vivo receptor occupancy at dopamine D2 receptor in sc dosed rat brain by measuring free plasma concentration pretreated 1 hr in presence of raclopride to RO50 for in vivo receptor occupancy at dopamine D1 receptor in sc dosed rat brai | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
ISSN: 1464-3405 | |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1128452 | Displacement of [125]DOI from human recombinant full length 5HT2A receptor expressed in HEK293E cells | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID113515 | In vivo inhibitory activity tested in apomorphine climbing mice after oral administration | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID246931 | In vivo effective dose for reversal of tryptamine-induced backward locomotion in rats | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID246835 | In vivo effective dose against catalepsy response was determined in rats | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. |
| AID298491 | Displacement of [3H]4-DAMP from human M4 receptor expressed in CHO cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID229417 | Selectivity ratio (D3/D1) | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID1430530 | Displacement of [3H]-LSD from 5-HT6 receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
ISSN: 1948-5875 | |
| AID61502 | Binding affinity which represents concentration giving half-maximal inhibition of [3H]SCH-23390 (Dopamine receptor D1) binding to rat tissue homogenate | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID5326 | Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID678714 | Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
ISSN: 1520-5010 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID25470 | Area under curve (AUC) value of Dopamine level after second treatment (24.8 uM/Kg) in dialysates collected from rat striatum | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID1281952 | Displacement of [3H]-Raclopride from human dopamine D2L receptor expressed in HEK293 cells | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112ISSN: 1768-3254 | Rational design in search for 5-phenylhydantoin selective 5-HT7R antagonists. Molecular modeling, synthesis and biological evaluation. |
| AID61415 | Binding affinity towards Dopamine receptor D2 was determined in rat striatal homogenate using [3H]- spiperone as radioligand | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
ISSN: 0022-2623 | Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate. |
| AID25466 | Area under curve (AUC) value of DOPAC level after first treatment (7.4 uM/Kg) in dialysates collected from rat striatum. | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID298487 | Displacement of [3H]LSD from human 5HT7 receptor expressed in CHO cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID458640 | Reduction in 3,4-dihydroxyphenylacetic acid level in Sprague-Dawley rat striatum at 10.5 umol/kg, sc relative to saline treated control | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID410332 | Displacement of [3H]spiperone from dopamine D2 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
ISSN: 1520-4804 | Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. |
| AID251584 | Relative binding affinity against 5-hydroxytryptamine 2A and dopamine D2 receptors | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4
ISSN: 1878-5832 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID1413420 | Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by microbeta counting method | 2018 | MedChemComm, Jun-01, Volume: 9, Issue:6
ISSN: 2040-2503 | |
| AID1570061 | Displacement of [3H]-5-CT from human 5HT7 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180ISSN: 1768-3254 | Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT |
| AID36116 | Binding affinity towards human alpha-1 adrenergic receptor | 2001 | Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
ISSN: 0022-2623 | Current and novel approaches to the drug treatment of schizophrenia. |
| AID239091 | Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID298483 | Displacement of [3H]LSD from 5HT2B receptor expressed in CHO cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID1682828 | Binding affinity to H1 histamine receptor (unknown origin) | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31ISSN: 1464-3405 | |
| AID395324 | Lipophilicity, log D at pH 7.4 by liquid chromatography | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
ISSN: 1520-4804 | Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. |
| AID1823850 | Anxiolytic activity in stress-induced anxiety ip dosed Wistar rat model assessed as increase in open arm entry measured after 30 mins by elevated plus maze test | 2021 | Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
ISSN: 1520-4804 | |
| AID342782 | Binding affinity to human cloned histamine H1 receptor | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID1409611 | AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay. | 2020 | Nature, 07, Volume: 583, Issue:7816
ISSN: 1476-4687 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. |
| AID171544 | Effect of compound on apomorphine induced catalepsy, from rat brain striatum at 1 umol/kg upon subcutaneous administration; Catalepsy = 0/4 | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID395325 | Lipophilicity, log P by microemulsion electrokinetic chromatography | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
ISSN: 1520-4804 | Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. |
| AID65121 | Binding affinity towards human dopamine receptor D3 | 2001 | Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
ISSN: 0022-2623 | Current and novel approaches to the drug treatment of schizophrenia. |
| AID678722 | Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
ISSN: 1520-5010 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID298479 | Displacement of [3H]spiperone from human dopamine D3 receptor expressed in CHO cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID1128459 | Inhibition of human 5HT1A receptor | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID230095 | Ratio of pKi of compound towards 5-HT2 receptor to that of D2 receptor | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID247009 | In vivo effective dose to inhibit apomorphine induced agitation in rats upon subcutaneous administration | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID1125020 | Displacement of [3H]spiperone from wild-type human dopamine D2S receptor expressed in CHO-K1 cell membrane after 2 hrs by beta counting | 2014 | European journal of medicinal chemistry, Apr-22, Volume: 77ISSN: 1768-3254 | Novel insights on the structural determinants of clozapine and olanzapine multi-target binding profiles. |
| AID238940 | Inhibition of [3H]-SCH- 23390 binding to rat dopamine D1 receptor | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID25474 | Area under curve (AUC) value of HVA level after total treatment in dialysates collected from rat striatum. | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID397743 | Inhibition of human ERG channel | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
ISSN: 1520-4804 | Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers. |
| AID5196 | Binding affinity towards human 5-HT2A receptor in BEK cells | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
ISSN: 0022-2623 | Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate. |
| AID781326 | pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X | 2014 | Pharmaceutical research, Apr, Volume: 31, Issue:4
ISSN: 1573-904X | Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds. |
| AID588220 | Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset | 2008 | Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
ISSN: 1537-6524 | Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. |
| AID1393480 | Effect on failure incidence during conditioned avoidance response test in Sprague-Dawley rat at 2 mg/kg, ip administered 60 mins prior to testing | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID25469 | Area under curve (AUC) value of Dopamine level after first treatment (7.4 uM/Kg) in dialysates collected from rat striatum. | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID238989 | Inhibition of [3H]rauwolscine binding to Alpha-2A adrenergic receptor | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID65785 | Binding affinity towards human Dopamine receptor D3 | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
ISSN: 0022-2623 | Selective optimization of side activities: another way for drug discovery. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID395329 | Dissociation constant, pKa by mass spectrometry | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
ISSN: 1520-4804 | Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. |
| AID1217727 | Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID185006 | Effect of compound on apomorphine induced locomotor hyperactivity (APO-induced LMA), from rat brain striatum at 1 umol/kg upon subcutaneous administration; LMA (locomotor activity) | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID246918 | In vivo effective dose to inhibit tryptamine-induced bilateral convulsions in rats | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID678716 | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
ISSN: 1520-5010 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID298478 | Displacement of [3H]spiperone from human dopamine D2 receptor short form expressed in CHO cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID1393366 | Displacement of [3H]-8-OH-DPAT from human 5-HT1AR expressed in HEK293 cell membranes after 1 hr by microbeta counting method | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID1204346 | Displacement of [3H]N-methylspiperone from dopamine D3 receptor (unknown origin) assessed as total radioligand binding at 1.66 x 10'-7 M incubated for 60 mins by microbeta plate reader based method | 2015 | European journal of medicinal chemistry, Jun-05, Volume: 97ISSN: 1768-3254 | Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity. |
| AID1393470 | Therapeutic index, ratio of MED for sedation in ip dosed Sprague-Dawley rat to MED for antipsychotic activity in ip dosed Sprague-Dawley rat assessed as reduction in PCP-induced hyper-locomotion | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID298490 | Displacement of [3H]pirenzepine from human M1 receptor expressed in CHO cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID1677158 | Binding affinity to human 5HT2A receptor | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
ISSN: 1464-3405 | |
| AID230096 | Ratio of pKi of compound towards D1 receptor to that of D2 receptor | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID1823849 | Antipsychotic activity in ip dosed Wistar rat assessed as induction of MK801-induced hyperlocomotor activity by measuring minimum effective dose measured for 15 mins | 2021 | Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
ISSN: 1520-4804 | |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID1677155 | In vivo receptor occupancy at dopamine D1 receptor in sc dosed rat brain by measuring free plasma concentration pretreated for 1 hr in presence of SCH-23390 by LC-MS/MS analysis | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
ISSN: 1464-3405 | |
| AID63345 | Binding affinity against dopamine receptor D1 | 2001 | Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
ISSN: 0022-2623 | Current and novel approaches to the drug treatment of schizophrenia. |
| AID177692 | In vivo inhibition of spontaneous locomotory activity tested in rats after oral administration | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID492638 | Binding affinity to human ERG expressed in HEK293 cells | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
ISSN: 1520-4804 | Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. |
| AID1217712 | Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID238747 | Binding affinity for human 5-hydroxytryptamine 6 receptor | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. |
| AID458645 | Reduction in spontaneous locomotor activity in Sprague-Dawley rat striatum at 10.5 umol/kg, sc relative to control | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID239069 | Inhibition of [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID5199 | Binding affinity for human 5-hydroxytryptamine 2A receptor | 2001 | Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
ISSN: 0022-2623 | Current and novel approaches to the drug treatment of schizophrenia. |
| AID374353 | Cytotoxicity against human WI38 cells assessed as reduction in cellular DNA level preincubated for 2 hrs before viral infection measured after 7 days by real time PCR assay | 2007 | Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12
ISSN: 0066-4804 | BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport. |
| AID61527 | In vitro binding affinity towards Dopamine receptor D1 in rat tissue homogenate using [3H]-SCH- 23390 as radioligand | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID298488 | Displacement of [3H]BLR-43694 from human 5HT3 receptor expressed in HEK293 cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID539464 | Solubility of the compound in 0.1 M phosphate buffer at 600 uM at pH 7.4 after 24 hrs by LC/MS/MS analysis | 2010 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
ISSN: 1464-3405 | Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. |
| AID458651 | Reduction in amphetamine-induced locomotor activity in Sprague-Dawley rat striatum at 10.5 umol/kg, sc relative to control | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID5197 | Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
ISSN: 0022-2623 | Selective optimization of side activities: another way for drug discovery. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID715349 | Toxicity in rat assessed as decrease in lean body mass at 4 mg/kg, po administered for 7 days relative to vehicle-treated control | 2012 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
ISSN: 1464-3405 | Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. |
| AID1570060 | Displacement of [3H]LSD from human 5-HT6 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180ISSN: 1768-3254 | Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT |
| AID1128469 | Selectivity ratio of Ki for adrenergic alpha1B receptor (unknown origin) to Ki for human recombinant full length 5HT2A receptor | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID1677161 | Binding affinity to human dopamine D2 receptor | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
ISSN: 1464-3405 | |
| AID1393367 | Displacement of [3H]-5-CT from human 5-HT7R expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID1601983 | Displacement of [3H]-raclopride from recombinant human D2 receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting analysis | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166ISSN: 1768-3254 | Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT |
| AID715351 | Toxicity in rat assessed as decrease in weight gain at 4 mg/kg, po administered for 7 days relative to vehicle-treated control | 2012 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
ISSN: 1464-3405 | Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID61517 | Half-maximal inhibition of [3H]-SCH- 23390 binding to Dopamine receptor D1 in rat striatal homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID492642 | Displacement of [3H]spiperone from dopamine D2 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
ISSN: 1520-4804 | Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. |
| AID678715 | Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
ISSN: 1520-5010 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID246894 | In vivo effective dose for reversal of RO-4-1284 induced hypothermia in mouse | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID330558 | Binding affinity to alphaMSH receptor at 100 nM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
ISSN: 0027-8424 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. |
| AID1128466 | Inhibition of human dopamine D4 receptor | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID1760279 | Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cells measured after 1 hr by microbeta counting method | 2020 | European journal of medicinal chemistry, Oct-01, Volume: 203ISSN: 1768-3254 | Chlorine substituents and linker topology as factors of 5-HT |
| AID330539 | Increase in alpha-2AMPK activity in H1RKO mouse hyphalamic slices | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
ISSN: 0027-8424 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. |
| AID65622 | In vitro binding affinity towards Dopamine receptor D3 in Sf9 cell membranes using [3H]7-OH-DPAT as radioligand | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID25471 | Area under curve (AUC) value of Dopamine level after total treatment in dialysates collected from rat striatum. | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID87242 | Binding affinity towards human histamine H1 receptor | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
ISSN: 0022-2623 | Selective optimization of side activities: another way for drug discovery. |
| AID1169861 | Binding affinity to dopamine D3 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
ISSN: 1520-4804 | Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID330551 | Increase in phospho-AMPK level in arcuate hyphalamic nuclei intact H1RKO mouse at 5 mg/kg after 3 hrs by immunohistochemistry | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
ISSN: 0027-8424 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. |
| AID588218 | FDA HLAED, lactate dehydrogenase (LDH) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID410334 | Displacement of [3H]8OH-DPAT from 5HT1A receptor in CRL:CD(SD)BR-COBS rat hippocampus by scintillation spectrometry | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
ISSN: 1520-4804 | Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. |
| AID1601980 | Displacement of [3H]-ketanserin from recombinant human 5HT2A receptor expressed in HEK293 cells measured after 1.5 hrs by microbeta scintillation counting analysis | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166ISSN: 1768-3254 | Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT |
| AID246883 | In vivo effective dose for reversal of tryptamine-induced cyanosis in rats | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1601982 | Displacement of [3H]-5-CT from recombinant human 5HT7 receptor expressed in HEK293 cells measured after 1 hr by microbeta scintillation counting analysis | 2019 | European journal of medicinal chemistry, Mar-15, Volume: 166ISSN: 1768-3254 | Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1393471 | Reversal of PCP-induced cognitive impairment in ip dosed Sprague-Dawley rat assessed as reduction in time spent exploring novel object over familiar object pretreated for 60 mins followed by PCP addition by novel object recognition assay | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID681619 | TP_TRANSPORTER: ATP hydrolysis in membranes from MDR1-expressing insect cells | 2002 | Life sciences, May-31, Volume: 71, Issue:2
ISSN: 0024-3205 | In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. |
| AID1185964 | Displacement of [3H]N-methylspiperone from human dopamine D3 receptor by liquid scintillation counting | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
ISSN: 1464-3405 | Further evaluation of the tropane analogs of haloperidol. |
| AID1409609 | Cytotoxicity of compound against Vero E6 cells by MTT assay. | 2020 | Nature, 07, Volume: 583, Issue:7816
ISSN: 1476-4687 | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. |
| AID25472 | Area under curve (AUC) value of HVA level after first treatment (7.4 uM/Kg) in dialysates collected from rat striatum. | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID410335 | Displacement of [3H]ketanserin from 5HT2A receptor in CRL:CD(SD)BR-COBS rat cortex by scintillation spectrometry | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
ISSN: 1520-4804 | Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. |
| AID114868 | Effective dose required to antagonize apomorphine-induced climbing in mice after administration of 2.69 mg/kg dose through oral route | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID25473 | Area under curve (AUC) value of HVA level after second treatment (24.8 uM/Kg) in dialysates collected from rat striatum. | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID1217729 | Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1677159 | Drug metabolism in human hepatocyte microsome fraction assessed as GSH conjugate formation by LC-MS/MS analysis | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
ISSN: 1464-3405 | |
| AID342774 | Binding affinity to human cloned muscarinic M1 receptor | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID738352 | Displacement of [3H]ketanserin from 5-HT2A receptor in human frontal cortex after 30 mins by scintillation counting | 2013 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 23, Issue:7
ISSN: 1464-3405 | [11C]olanzapine, radiosynthesis and lipophilicity of a new potential PET 5-HT2 and D2 receptor radioligand. |
| AID114866 | Effective dose required to antagonize apomorphine-induced climbing in mice after administration of 0.18 mg/kg dose subcutaneously | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID1570062 | Displacement of [3H]-raclopride from human D2 receptor expressed in HEK cells incubated for 1 hr by Cheng-Prusoff analysis based microbeta scintillation counting method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180ISSN: 1768-3254 | Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT |
| AID29813 | Oral bioavailability in human | 2000 | Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
ISSN: 0022-2623 | QSAR model for drug human oral bioavailability. |
| AID63866 | Inhibitory concentration against human Dopamine receptor D4.2 in CHO cells | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
ISSN: 0022-2623 | Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID386536 | Inhibition of human ERG potassium channel | 2008 | Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
ISSN: 1464-3391 | A binary QSAR model for classification of hERG potassium channel blockers. |
| AID238882 | Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2A receptor | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. |
| AID1185963 | Displacement of [3H]N-methylspiperone from human dopamine D2 receptor by liquid scintillation counting | 2014 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
ISSN: 1464-3405 | Further evaluation of the tropane analogs of haloperidol. |
| AID1568825 | Displacement of [3H]-raclopride from human D2L receptor expressed in human HEK293 cells incubated for 1 hr by radioligand binding assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178ISSN: 1768-3254 | Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT |
| AID25468 | Area under curve (AUC) value of DOPAC level after total treatment in dialysates collected from rat striatum. | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID1128460 | Inhibition of histamine H1 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID185007 | Effect of compound on apomorphine induced locomotor hyperactivity (APO-induced LMA), from rat brain striatum at 10 umol/kg upon subcutaneous administration; LMA (locomotor activity) | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID1128454 | Displacement of [3H]-N-methylspiperone from rat recombinant dopamine D2 short receptor expressed in CHO cells | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID87529 | Half-maximal inhibition of [3H]7-OH-DPAT binding to Histamine H1 receptor in rat tissue homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID492640 | Displacement of [3H]ketanserin from 5HT2A receptor in CRL:CD(SD)BR-COBS rat cortex by scintillation spectrometry | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
ISSN: 1520-4804 | Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. |
| AID61808 | Binding affinity towards human dopamine-4.2 receptor | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
ISSN: 0022-2623 | Selective optimization of side activities: another way for drug discovery. |
| AID63809 | Half-maximal inhibition of [3H]spiperone binding to Dopamine receptor D2 in rat striatal homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID87531 | In vitro binding affinity towards Histamine H1 receptor of rat frontal cortex homogenate by using radioligand [3H]pyrilamine | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID1128455 | Selectivity ratio of Ki for human recombinant full length 5HT2C receptor to Ki for human recombinant full length 5HT2A receptor | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID232153 | Ratio of 5-HT2A receptor to that of dopamine 2 (D2) receptor in rat tissue homogenate | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID492643 | Displacement of [3H]SCH23390 from dopamine D1 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
ISSN: 1520-4804 | Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. |
| AID5090 | pKi value for 5-hydroxytryptamine 2 receptor binding site | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID1757456 | Agonist activity at muscarinic M1 receptor (unknown origin) expressed in CHO cells | 2021 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 40ISSN: 1464-3405 | Identification of 2-fluoro-8-methyl-11-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepine with clozapine-like mixed activities at muscarinic acetylcholine, dopamine, and serotonin receptors. |
| AID141100 | Binding affinity towards human muscarinic receptor | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
ISSN: 0022-2623 | Selective optimization of side activities: another way for drug discovery. |
| AID35276 | Inhibition of [3H]-prazosin binding to Alpha-1 adrenergic receptor in rat frontal cortex homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID1570059 | Displacement of [3H]ketanserin from human 5HT2A receptor expressed in HEK293 cells incubated for 1.5 hrs by Cheng-Prusoff analysis based microbeta scintillation counting method | 2019 | European journal of medicinal chemistry, Oct-15, Volume: 180ISSN: 1768-3254 | Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT |
| AID63060 | Binding affinity towards human Dopamine receptor D2 | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
ISSN: 0022-2623 | Selective optimization of side activities: another way for drug discovery. |
| AID678721 | Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
ISSN: 1520-5010 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID114871 | Effective dose required to induce catalepsy in mice after administration of 21.2 mg/kg dose through oral route | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID1172030 | Displacement of [3H]-ketanserin from 5-HT2AR in rat cortex | 2015 | Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
ISSN: 1464-3391 | Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID141837 | Half-maximal inhibition of [3H]QNB binding to Muscarinic acetylcholine receptor M1 in rat frontal cortex homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1393472 | Antipsychotic activity in ip dosed Sprague-Dawley rat assessed as suppression of avoidance behavior by avoiding foot shock administered 60 mins prior to test by conditioned avoidance response test | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID1126945 | Displacement of [3H]-LSD from human recombinant 5-HT6 receptor expressed in HEK293 cell membrane after 1 hr by Microbeta scintillation counting analysis | 2014 | European journal of medicinal chemistry, May-06, Volume: 78ISSN: 1768-3254 | SAR-studies on the importance of aromatic ring topologies in search for selective 5-HT(7) receptor ligands among phenylpiperazine hydantoin derivatives. |
| AID1393474 | Toxicity in ip dosed Sprague-Dawley rat assessed as induction of catalepsy measured every 30 mins up to 240 mins by bar test | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID238962 | Inhibition of [3H]nisoxetine binding to rat Norepinephrine transporter | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID180551 | The compound was tested in vivo for induction of catalepsy in rat after ip administration | 1999 | Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
ISSN: 0022-2623 | N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents. |
| AID1128464 | Inhibition of rat adrenergic alpha1B receptor | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID408340 | Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique | 2008 | Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
ISSN: 1464-3391 | Support vector machines classification of hERG liabilities based on atom types. |
| AID715350 | Toxicity in rat assessed as decrease in total body fat at 4 mg/kg, po administered for 7 days relative to vehicle-treated control | 2012 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 22, Issue:18
ISSN: 1464-3405 | Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1217728 | Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID27167 | Delta logD (logD6.5 - logD7.4) | 2000 | Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
ISSN: 0022-2623 | QSAR model for drug human oral bioavailability. |
| AID1217706 | Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID342787 | Binding affinity to human SERT | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID132467 | Antagonistic activity against apomorphine induced climbing in the mouse after po administration | 1999 | Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
ISSN: 0022-2623 | N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents. |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID342786 | Binding affinity to rat NET | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID4782 | Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
ISSN: 0022-2623 | Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate. |
| AID36113 | Binding affinity towards human alpha-1 adrenergic receptor | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
ISSN: 0022-2623 | Selective optimization of side activities: another way for drug discovery. |
| AID37376 | In vitro binding affinity towards alpha-2 adrenergic receptor in rat frontal cortex homogenate using of [3H]clonidine as radioligand | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID246858 | In vivo effective dose of compound against 5-MeO-DMT induced head twitches in rats | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. |
| AID1823834 | Displacement of [3H]-prazosin from rat cortex membrane alpha1 adrenergic receptor expressed in human recombinant CHO-K1 cells at 1 uM after 30 mins by solid scintillation counting method relative to control | 2021 | Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
ISSN: 1520-4804 | |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID458632 | Displacement of [3H]spiperone from human dopamine D2 receptor at low affinity state expressed in HEK293 cells | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID1353520 | Displacement of [3H]-raclopride from human D2L receptor expressed in HEK293 cell membranes after 1 hr by Microbeta scintillation counting method | 2018 | European journal of medicinal chemistry, Mar-10, Volume: 147ISSN: 1768-3254 | Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT |
| AID342783 | Binding affinity to human cloned 5HT1A receptor | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID1595144 | Displacement of [3H] ketanserin from human recombinant 5-HT2A receptor expressed in CHOK1 cells after 1 hr by microbeta scintillation counting method | 2019 | European journal of medicinal chemistry, May-15, Volume: 170ISSN: 1768-3254 | |
| AID1393365 | Displacement of [3H]-LSD from human 5-HT6R expressed in HEK293 cell membranes after 1 hr at 37 degC by microbeta counting method | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID28681 | Partition coefficient (logD6.5) | 2000 | Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
ISSN: 0022-2623 | QSAR model for drug human oral bioavailability. |
| AID1217710 | Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID694796 | Displacement of [3H]-LSD from human 5-HT6 receptor expressed in HEK293 cells after 1 hr | 2012 | European journal of medicinal chemistry, Oct, Volume: 56ISSN: 1768-3254 | The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT₇ receptor antagonists. |
| AID1393369 | Selectivity index, ratio of pKi for 5-HT2AR to pKi for human D2LR | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID1682829 | Binding affinity to adrenergic alpha1 receptor (unknown origin) | 2021 | Bioorganic & medicinal chemistry letters, 01-01, Volume: 31ISSN: 1464-3405 | |
| AID229410 | Selectivity ratio (5-HT2A/D2 ) | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID239052 | Inhibition of [3H]-spiperone binding to human Dopamine receptor D2 | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID330537 | Increase in phospho-AMPK levels in H1RKO mouse hyphalamic slices at 500 nM after 30 mins by Western blotting | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
ISSN: 0027-8424 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. |
| AID1393364 | Displacement of [3H]-ketanserin from human 5-HT2AR expressed in CHO-K1 cell membranes after 1.5 hrs by microbeta counting method | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID5171 | Inhibitory concentration against human 5-HT2A receptor in BEK cells | 1996 | Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
ISSN: 0022-2623 | Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate. |
| AID246870 | In vivo effective dose against 5-MeO-DMT-induced head twitches in rats was determined | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. |
| AID141838 | In vitro binding affinity towards M1 receptor of rat frontal cortex homogenate by using radioligand [3H]QNB | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID1677163 | In vivo receptor occupancy at human dopamine D1 receptor in schizophrenia patient brain at 10 mCi, iv by PET scanning | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
ISSN: 1464-3405 | |
| AID330556 | Binding affinity to leptin receptor at 100 nM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
ISSN: 0027-8424 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. |
| AID114872 | Effective dose required to induce catalepsy in mice after administration of 6.5 mg/kg dose subcutaneously | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID458635 | Activity at dopamine D2L receptor expressed in HEK293 cells coexpressing Galphaqi5 assessed as maximal efficacy relative to control | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID330559 | Binding affinity to neuropeptide Y receptor at 10 nM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
ISSN: 0027-8424 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. |
| AID330538 | Orexigenic activity in H1RKO mouse | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
ISSN: 0027-8424 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. |
| AID1217709 | Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID458634 | Selectivity ratio of Ki for human dopamine D2 receptor at low affinity state to Ki for human dopamine D2 receptor at high affinity state | 2010 | Journal of medicinal chemistry, Mar-25, Volume: 53, Issue:6
ISSN: 1520-4804 | Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16). |
| AID342778 | Binding affinity to human cloned dopamine D3 receptor | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID1677160 | Selectivity ratio of Ki for human dopamine D1 receptor to human dopamine D2 receptor | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
ISSN: 1464-3405 | |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID36197 | Binding affinity towards human alpha-2 adrenergic receptor | 2001 | Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
ISSN: 0022-2623 | Current and novel approaches to the drug treatment of schizophrenia. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID342773 | Binding affinity to human cloned 5HT6 receptor | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID1128462 | Inhibition of adrenergic alpha1A receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
ISSN: 1520-4804 | Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. |
| AID410331 | Displacement of [3H]SCH23390 from dopamine D1 receptor in CRL:CD(SD)BR-COBS rat striatum by scintillation spectrometry | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
ISSN: 1520-4804 | Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. |
| AID410333 | Displacement of [3H]7OH-DPAT from dopamine D3 receptor expressed in Sf9 cells by scintillation spectrometry | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
ISSN: 1520-4804 | Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. |
| AID63070 | Binding affinity towards human D2 dopamine receptor. | 2001 | Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
ISSN: 0022-2623 | Current and novel approaches to the drug treatment of schizophrenia. |
| AID1823826 | Displacement of [3H]-methylspiperone from human D2 receptor transfected in CHO-K1 cells measured after 60 mins by scintillation counting method | 2021 | Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
ISSN: 1520-4804 | |
| AID1430532 | Binding affinity to 5HT2A receptor (unknown origin) | 2017 | ACS medicinal chemistry letters, Apr-13, Volume: 8, Issue:4
ISSN: 1948-5875 | |
| AID492641 | Displacement of [3H]8OH-DPAT from 5HT1A receptor in rat CRL:CD(SD)BR-COBS hippocampus by scintillation spectrometry | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
ISSN: 1520-4804 | Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. |
| AID692513 | Binding affinity to human histamine H1 receptor | 2011 | Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
ISSN: 1520-4804 | Histamine H3 receptor as a drug discovery target. |
| AID342777 | Binding affinity to human cloned dopamine D2 receptor | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID342779 | Binding affinity to human cloned dopamine D4 receptor | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
ISSN: 1464-3391 | Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. |
| AID5616 | Binding affinity towards human 5-hydroxytryptamine 2C receptor | 2001 | Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
ISSN: 0022-2623 | Current and novel approaches to the drug treatment of schizophrenia. |
| AID694797 | Binding affinity to human dopamine D2L receptor expressed in HEK293 cells after 1 hr | 2012 | European journal of medicinal chemistry, Oct, Volume: 56ISSN: 1768-3254 | The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT₇ receptor antagonists. |
| AID114864 | Effective dose required to antagonize 5-MeO-DMT-induced head twitches in mice after administration of 1.45 mg/kg dose orally | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID239150 | Inhibition of [125I]iodosulpiride binding to human Dopamine receptor D3 | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID5560 | Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID4066 | Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand | 1999 | Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
ISSN: 0022-2623 | N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents. |
| AID452390 | Antagonist activity at 5HT2A receptor | 2009 | Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
ISSN: 1464-3391 | Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID678712 | Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
ISSN: 1520-5010 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID5569 | In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID330555 | Binding affinity to leptin receptor at 10 nM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
ISSN: 0027-8424 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. |
| AID37370 | Half-maximal inhibition of [3H]clonidine binding to Alpha-2 adrenergic receptor in rat frontal cortex homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID410336 | Displacement of [3H]mesulergine from 5HT2C receptor in CRL:(HA) BR albino guinea pig cortex by scintillation spectrometry | 2009 | Journal of medicinal chemistry, Jan-08, Volume: 52, Issue:1
ISSN: 1520-4804 | Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. |
| AID694794 | Displacement of [3H]-5-CT from human 5-HT7b receptor expressed in HEK293 cells after 1 hr | 2012 | European journal of medicinal chemistry, Oct, Volume: 56ISSN: 1768-3254 | The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT₇ receptor antagonists. |
| AID599884 | Displacement of [3H]5-LSD from human 5HT6 receptor expressed in human HeLa cells | 2010 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
ISSN: 1464-3405 | Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands. |
| AID395327 | Dissociation constant, pKa by capillary electrophoresis | 2009 | Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
ISSN: 1520-4804 | Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs. |
| AID298489 | Displacement of [3H]paraxetine from human 5HT transporter expressed in HEK293 cells | 2007 | Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21
ISSN: 0022-2623 | Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs. |
| AID1757457 | Agonist activity at muscarinic M1 receptor (unknown origin) expressed in CHO cells at 10 uM relative to control | 2021 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 40ISSN: 1464-3405 | Identification of 2-fluoro-8-methyl-11-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepine with clozapine-like mixed activities at muscarinic acetylcholine, dopamine, and serotonin receptors. |
| AID503306 | Antiproliferative activity against human PC3 cells at 2 uM after 120 hrs by MTT assay relative to DMSO | 2006 | Nature chemical biology, Jun, Volume: 2, Issue:6
ISSN: 1552-4450 | Identifying off-target effects and hidden phenotypes of drugs in human cells. |
| AID330560 | Binding affinity to neuropeptide Y receptor at 100 nM | 2007 | Proceedings of the National Academy of Sciences of the United States of America, Feb-27, Volume: 104, Issue:9
ISSN: 0027-8424 | From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. |
| AID185009 | Effect of compound on apomorphine induced locomotor hyperactivity (APO-induced LMA), from rat brain striatum at 3 umol/kg upon subcutaneous administration; LMA (locomotor activity) ND = not determined | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID246985 | Effective dose for antagonistic activity against m-chlorophenyl-piperazine induced anxiety in rats | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID1556425 | Displacement of [3H]ketanserin from human 5HT2A receptor expressed in CHOK1 cells incubated for 1 hr by liquid scintillation counter method | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179ISSN: 1768-3254 | 2-Aminoimidazole-based antagonists of the 5-HT |
| AID239010 | Inhibition of [125I]R91150 binding to human 5-hydroxytryptamine 2A receptor | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. |
| AID1677157 | In vivo receptor occupancy at dopamine D1 receptor in sc dosed rat brain by measuring free plasma concentration pretreated for 1 hr in presence of raclopride by LC-MS/MS analysis | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
ISSN: 1464-3405 | |
| AID1217704 | Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID1242912 | Antagonist activity against 5-HT2A receptor (unknown origin) expressed in HEK293 cell membranes assessed as reduction in [35S]-GTPgammaS binding incubated for 30 mins by liquid scintillation counting method | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18
ISSN: 1464-3405 | Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold. |
| AID25467 | Area under curve (AUC) value of DOPAC level after second treatment (24.8 uM/Kg) in dialysates collected from rat striatum. | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID65733 | In vitro binding affinity towards Dopamine receptor D2 in rat tissue homogenate using [3H]-spiperone as radioligand | 2004 | Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. |
| AID603953 | In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat | 2008 | European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
ISSN: 0223-5234 | Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs. |
| AID36118 | Binding affinity towards Alpha-1 adrenergic receptor in human cortex membranes | 1999 | Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
ISSN: 0022-2623 | N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4
ISSN: 1878-5832 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID1169863 | Binding affinity to 5HT2A receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
ISSN: 1520-4804 | Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. |
| AID678717 | Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins | 2012 | Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
ISSN: 1520-5010 | Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. |
| AID1217711 | Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID239151 | Inhibition of [3H]7-OH-DPAT binding to Dopamine D3 receptor expressed in Sf9 cells | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
ISSN: 0022-2623 | Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID492639 | Displacement of [3H]mesulergine from 5HT2C receptor in CRL:(HA) BR albino guinea pig cortex by scintillation spectrometry | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
ISSN: 1520-4804 | Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors. |
| AID1172031 | Displacement of [3H]LSD from human cloned 5-HT6R expressed in HEK293 cells | 2015 | Bioorganic & medicinal chemistry, Jan-01, Volume: 23, Issue:1
ISSN: 1464-3391 | Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile. |
| AID1677156 | Inhibition of human ERG | 2020 | Bioorganic & medicinal chemistry letters, 11-01, Volume: 30, Issue:21
ISSN: 1464-3405 | |
| AID1520006 | Displacement of [3H]-LSD from human 5-HT6R expressed in HEK293 cells after 1 hr by microbeta plate reader analysis | 2020 | European journal of medicinal chemistry, Jan-01, Volume: 185ISSN: 1768-3254 | |
| AID1393468 | Antipsychotic activity in ip dosed Sprague-Dawley rat assessed as reduction in PCP-induced hyper-locomotion pretreated for 60 mins followed by PCP addition measured for 30 mins starting 15 min after rat reintroduction to auto-tracks | 2018 | European journal of medicinal chemistry, Feb-10, Volume: 145ISSN: 1768-3254 | |
| AID141174 | Binding affinity towards human M1 receptor. | 2001 | Journal of medicinal chemistry, Feb-15, Volume: 44, Issue:4
ISSN: 0022-2623 | Current and novel approaches to the drug treatment of schizophrenia. |
| AID61623 | Binding affinity to the dopamine receptor D2L in rat brain membranes | 1999 | Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
ISSN: 0022-2623 | N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents. |
| AID1217708 | Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system | 2011 | Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 39, Issue:7
ISSN: 1521-009X | Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. |
| AID65767 | Half-maximal inhibition of [3H]7-OH-DPAT binding to Dopamine receptor D3 in rat tissue homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID36199 | Binding affinity towards human alpha-2 adrenergic receptor | 2004 | Journal of medicinal chemistry, Mar-11, Volume: 47, Issue:6
ISSN: 0022-2623 | Selective optimization of side activities: another way for drug discovery. |
| AID1449628 | Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method | 2012 | Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
ISSN: 1521-009X | Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. |
| AID65563 | Half-maximal inhibition of [3H]spiperone binding to Dopamine receptor D2 in rat striatal homogenate | 2002 | Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
ISSN: 0022-2623 | Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies. |
| AID63824 | pKi value for Dopamine receptor D2 binding site | 1998 | Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20
ISSN: 0022-2623 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. |
| AID1823847 | Anti-antidepressant like activity in Wistar rat assessed as reduction in locomotor activity by measuring total immobility time by Forced swim test | 2021 | Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
ISSN: 1520-4804 | |
| AID1169860 | Binding affinity to dopamine D2 receptor (unknown origin) | 2014 | Journal of medicinal chemistry, Nov-26, Volume: 57, Issue:22
ISSN: 1520-4804 | Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X | |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X | |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346603 | Human 5-ht1e receptor (5-Hydroxytryptamine receptors) | 1996 | Psychopharmacology, Mar, Volume: 124, Issue:1-2
ISSN: 0033-3158 | Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. |
| AID624233 | Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F | 1996 | Psychopharmacology, Mar, Volume: 124, Issue:1-2
ISSN: 0033-3158 | Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. |
| AID1346893 | Human 5-HT2C receptor (5-Hydroxytryptamine receptors) | 2009 | Journal of psychopharmacology (Oxford, England), Jan, Volume: 23, Issue:1
ISSN: 0269-8811 | Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. |
| AID1345857 | Rat alpha1A-adrenoceptor (Adrenoceptors) | 2008 | Psychopharmacology, Jul, Volume: 199, Issue:1
ISSN: 0033-3158 | Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. |
| AID624223 | Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A | 1996 | Psychopharmacology, Mar, Volume: 124, Issue:1-2
ISSN: 0033-3158 | Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. |
| AID1346037 | Human H1 receptor (Histamine receptors) | 2003 | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3
ISSN: 0893-133X | H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. |
| AID1345235 | Rat 5-HT7 receptor (5-Hydroxytryptamine receptors) | 1996 | European journal of pharmacology, Dec-19, Volume: 317, Issue:2-3
ISSN: 0014-2999 | Iloperidone binding to human and rat dopamine and 5-HT receptors. |
| AID1345170 | Human 5-HT6 receptor (5-Hydroxytryptamine receptors) | 2005 | Psychopharmacology, May, Volume: 179, Issue:2
ISSN: 0033-3158 | Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs. |
| AID1345615 | Human 5-HT1A receptor (5-Hydroxytryptamine receptors) | 1996 | Psychopharmacology, Mar, Volume: 124, Issue:1-2
ISSN: 0033-3158 | Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. |
| AID624210 | Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A | 1996 | Psychopharmacology, Mar, Volume: 124, Issue:1-2
ISSN: 0033-3158 | Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. |
| AID1345235 | Rat 5-HT7 receptor (5-Hydroxytryptamine receptors) | 1994 | The Journal of pharmacology and experimental therapeutics, Mar, Volume: 268, Issue:3
ISSN: 0022-3565 | Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. |
| AID1346893 | Human 5-HT2C receptor (5-Hydroxytryptamine receptors) | 2003 | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3
ISSN: 0893-133X | H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. |
| AID1346739 | Human 5-HT1F receptor (5-Hydroxytryptamine receptors) | 1996 | Psychopharmacology, Mar, Volume: 124, Issue:1-2
ISSN: 0033-3158 | Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. |
| AID1345170 | Human 5-HT6 receptor (5-Hydroxytryptamine receptors) | 1996 | Journal of neurochemistry, Jan, Volume: 66, Issue:1
ISSN: 0022-3042 | Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. |
| AID1345291 | Human 5-HT7 receptor (5-Hydroxytryptamine receptors) | 1998 | British journal of pharmacology, Jul, Volume: 124, Issue:6
ISSN: 0007-1188 | Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719. |
| AID1259419 | Human 5-HT2A receptor (5-Hydroxytryptamine receptors) | 2003 | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3
ISSN: 0893-133X | H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. |
| AID1345788 | Human D2 receptor (Dopamine receptors) | 1998 | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Feb, Volume: 18, Issue:2
ISSN: 0893-133X | Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. |
| AID624223 | Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A | 2002 | European journal of pharmacology, Aug-16, Volume: 450, Issue:1
ISSN: 0014-2999 | A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. |
| AID1345920 | Rat alpha1D-adrenoceptor (Adrenoceptors) | 2008 | Psychopharmacology, Jul, Volume: 199, Issue:1
ISSN: 0033-3158 | Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function. |
| AID1345154 | Rat 5-HT6 receptor (5-Hydroxytryptamine receptors) | 1994 | The Journal of pharmacology and experimental therapeutics, Mar, Volume: 268, Issue:3
ISSN: 0022-3565 | Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. |
| AID1346037 | Human H1 receptor (Histamine receptors) | 1996 | Psychopharmacology, Mar, Volume: 124, Issue:1-2
ISSN: 0033-3158 | Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. |
| AID1259419 | Human 5-HT2A receptor (5-Hydroxytryptamine receptors) | 2002 | European journal of pharmacology, Aug-16, Volume: 450, Issue:1
ISSN: 0014-2999 | A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. |
| AID624223 | Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A | 2003 | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3
ISSN: 0893-133X | H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. |
| AID624230 | Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e | 1996 | Psychopharmacology, Mar, Volume: 124, Issue:1-2
ISSN: 0033-3158 | Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. |
| AID1345615 | Human 5-HT1A receptor (5-Hydroxytryptamine receptors) | 1998 | European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3
ISSN: 0014-2999 | Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. |
| AID1259419 | Human 5-HT2A receptor (5-Hydroxytryptamine receptors) | 2009 | Journal of psychopharmacology (Oxford, England), Jan, Volume: 23, Issue:1
ISSN: 0269-8811 | Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. |
| AID1346528 | Human 5-HT1D receptor (5-Hydroxytryptamine receptors) | 1996 | Psychopharmacology, Mar, Volume: 124, Issue:1-2
ISSN: 0033-3158 | Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. |
| AID1346264 | Human 5-HT1B receptor (5-Hydroxytryptamine receptors) | 1996 | Psychopharmacology, Mar, Volume: 124, Issue:1-2
ISSN: 0033-3158 | Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. |
| AID1346893 | Human 5-HT2C receptor (5-Hydroxytryptamine receptors) | 2000 | The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
ISSN: 0022-3565 | Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. |
| AID624210 | Agonists at Human 5-Hydroxytryptamine receptor 5-HT1A | 1998 | European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3
ISSN: 0014-2999 | Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. |
| AID1259419 | Human 5-HT2A receptor (5-Hydroxytryptamine receptors) | 1996 | Psychopharmacology, Mar, Volume: 124, Issue:1-2
ISSN: 0033-3158 | Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. |
| AID1345154 | Rat 5-HT6 receptor (5-Hydroxytryptamine receptors) | 1996 | European journal of pharmacology, Dec-19, Volume: 317, Issue:2-3
ISSN: 0014-2999 | Iloperidone binding to human and rat dopamine and 5-HT receptors. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
ISSN: 1095-9203 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1799301 | Radioligand Binding Assay (Ki) from Article 10.1016/j.bmc.2009.09.023: \\Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.\\ | 2009 | Bioorganic & medicinal chemistry, Nov-15, Volume: 17, Issue:22
ISSN: 1464-3391 | Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1802951 | In Vitro Inhibition Assay from Article 10.3109/14756360903489581: \\Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.\\ | 2010 | Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 25, Issue:6
ISSN: 1475-6374 | Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6
ISSN: 1552-454X | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2022 | Journal of enzyme inhibition and medicinal chemistry, Dec, Volume: 37, Issue:1
ISSN: 1475-6374 | |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6
ISSN: 1552-454X | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
Research
Studies (5,880)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 437 (7.43) | 18.2507 |
| 2000's | 2795 (47.53) | 29.6817 |
| 2010's | 2015 (34.27) | 24.3611 |
| 2020's | 633 (10.77) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 1,340 (21.14%) | 5.53% |
| Reviews | 792 (12.49%) | 6.00% |
| Case Studies | 1,328 (20.95%) | 4.05% |
| Observational | 41 (0.65%) | 0.25% |
| Other | 2,838 (44.77%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| chlordiazepoxide | | benzodiazepine | | 1995 | 2014 | 17.4 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| gyki 52466 | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lorazepam | | benzodiazepine | | 1998 | 2023 | 13.1 | low | 8 | 0 | 1 | 20 | 19 | 4 |
| cm 7116 | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prazepam | | benzodiazepine | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sch 16134 | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| telenzepine | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| temazepam | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlordesmethyldiazepam | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-Methyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetrazepam | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ketazolam | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxefazepam | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pinazepam | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metaclazepam | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-aminonitrazepam | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-desmethylclobazam | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 20-1815 | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-acetamidonitrazepam | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| afdx 116 | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tifluadom | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| afdx 384 | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aq-ra 741 | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| auranthine | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-aminoclonazepam | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,7,8-Trimethyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-one | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bms 214662 | | benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes | antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 11-[2-[4-(2-aminoethyl)-1-piperazinyl]-1-oxoethyl]-5H-pyrido[2,3-b][1,4]benzodiazepin-6-one | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-methyl-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,4-bis(4-methoxyphenyl)-4-methyl-1,2,3,5-tetrahydro-1,5-benzodiazepine | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7,8-dimethyl-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-4-phenyl-3H-1,5-benzodiazepin-2-one | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 364373 | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cycloanthranilylproline | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(2-hydroxyphenyl)-8,9-dimethyl-2,3-dihydro-1H-1,5-benzodiazepin-2-one | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methyl-3-phenyl-3H-1,5-benzodiazepin-4-amine | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-(4-chlorophenyl)-2-methyl-3H-1,5-benzodiazepin-4-yl]benzamide | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-chloro-5-(4-fluorophenyl)-4-(1-oxopropyl)-3,5-dihydro-1H-1,4-benzodiazepin-2-one | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methyl-1-piperazinecarbodithioic acid [2-[(2-methyl-3-phenyl-3H-1,5-benzodiazepin-4-yl)amino]-2-oxoethyl] ester | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-ethyl-4-[[(3-methyl-2-benzofuranyl)-oxomethyl]amino]-1H-1,5-benzodiazepine-3-carboxylic acid ethyl ester | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[(2-chloro-6-fluorophenyl)-oxomethyl]-7-methyl-5-phenyl-3,5-dihydro-1H-1,4-benzodiazepin-2-one | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-chloro-4-[(2-fluorophenyl)-oxomethyl]-5-phenyl-3,5-dihydro-1H-1,4-benzodiazepin-2-one | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cfm 2 | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,8-dimethyl-1-(phenylmethyl)-3H-1,5-benzodiazepin-2-one | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gv 150013x | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 365260 | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-[[11-[2-(4-methyl-1-piperazinyl)-1-oxoethyl]-6-oxo-5H-pyrido[2,3-b][1,4]benzodiazepin-8-yl]sulfonylamino]ethyl]carbamic acid tert-butyl ester | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aszonalenin | | benzodiazepine;
zwitterion | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk525762a | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clozapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound | adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic | 1992 | 2023 | 16.7 | medium | 113 | 0 | 173 | 467 | 225 | 54 |
| flumezapine | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 24-7429 | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| desmethylolanzapine | | benzodiazepine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hoe 33342 | | bibenzimidazole;
N-methylpiperazine | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bisbenzimidazole | | bibenzimidazole;
N-methylpiperazine | anthelminthic drug;
fluorochrome | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diethylcarbamazine | | N-carbamoylpiperazine;
N-methylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ofloxacin | | 3-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perazine | | N-alkylpiperazine;
N-methylpiperazine;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug | 2003 | 2014 | 15.7 | low | 2 | 0 | 0 | 6 | 4 | 0 |
| prochlorperazine | | N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines | alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic | 2009 | 2023 | 9.0 | low | 0 | 0 | 0 | 1 | 3 | 1 |
| imatinib | | aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines | antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiethylperazine | | N-methylpiperazine;
phenothiazines | antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trifluoperazine | | N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines | antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug | 2005 | 2022 | 12.6 | low | 3 | 0 | 0 | 5 | 2 | 1 |
| thioproperazine | | N-alkylpiperazine;
N-methylpiperazine;
phenothiazines;
sulfonamide | phenothiazine antipsychotic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-methylpiperazine | | N-methylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiothixene | | N-methylpiperazine | anticoronaviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,1-dimethyl-4-acetylpiperazinium | | N-methylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bosutinib | | aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amocarzine | | C-nitro compound;
N-methylpiperazine;
secondary amino compound;
thioureas | antinematodal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd2858 | | aromatic amine;
N-methylpiperazine;
pyrazines;
pyridines;
secondary carboxamide;
sulfonamide | antineoplastic agent;
bone density conservation agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| saracatinib | | aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ponatinib | | (trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| asp3026 | | aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone | antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| entrectinib | | benzamides;
difluorobenzene;
indazoles;
N-methylpiperazine;
oxanes;
secondary amino compound;
secondary carboxamide | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gilteritinib | | aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rifampin | | cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion | angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor | 2019 | 2021 | 4.0 | low | 1 | 0 | 0 | 0 | 1 | 1 |
| 1-(1-naphthyl)piperazine | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-chlorophenyl)piperazine | | monochlorobenzenes;
N-arylpiperazine | drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| buspirone | | azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines | anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist | 2005 | 2023 | 9.3 | low | 1 | 0 | 0 | 2 | 3 | 1 |
| cgs 12066 | | N-arylpiperazine;
organofluorine compound;
pyrroloquinoxaline | serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ciprofloxacin | | aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion | antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic | 1999 | 2006 | 21.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-2,3,4a,5,6,7,8,8a-octahydroquinoxalin-1-yl]-(2-furanyl)methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxazosin | | aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines | alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enoxacin | | 1,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ketoconazole | | dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine | | 2003 | 2013 | 14.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| lomefloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antimicrobial agent;
antitubercular agent;
photosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly 303511 | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-trifluoromethylphenyl)piperazine | | (trifluoromethyl)benzenes;
N-arylpiperazine | environmental contaminant;
psychotropic drug;
serotonergic agonist;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nan 190 | | N-alkylpiperazine;
N-arylpiperazine;
phthalimides | serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nefazodone | | aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles | alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| norfloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pipemidic acid | | amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| piribedil | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quetiapine | | dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine | adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-methylquipazine | | aminoquinoline;
N-alkylpiperazine;
N-arylpiperazine | serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gatifloxacin | | N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trazodone | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine | adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 2005 | 2018 | 11.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| dimethylphenylpiperazinium iodide | | N-arylpiperazine;
organic iodide salt;
piperazinium salt;
quaternary ammonium salt | nicotinic acetylcholine receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azaperone | | aminopyridine;
aromatic ketone;
monofluorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
tertiary amino compound | antipsychotic agent;
dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trimazosin | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pefloxacin | | fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone | antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gepirone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| itraconazole | | aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles | EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| difloxacin | | fluoroquinolone antibiotic;
monocarboxylic acid;
monofluorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone | antibacterial drug;
Mycoplasma genitalium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ipsapirone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| temafloxacin | | amino acid;
monocarboxylic acid;
N-arylpiperazine;
organofluorine compound;
quinolone antibiotic;
quinolone;
secondary amino compound;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sparfloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aripiprazole | | aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist | 2002 | 2023 | 10.5 | medium | 49 | 0 | 0 | 131 | 187 | 56 |
| tiodazosin | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enrofloxacin | | cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone | antibacterial agent;
antimicrobial agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kampirone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tandospirone | | bridged compound;
dicarboximide;
N-alkylpiperazine;
N-arylpiperazine;
pyrimidines | antidepressant;
anxiolytic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gr 127935 | | 1,2,4-oxadiazole;
benzamides;
N-alkylpiperazine;
N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-chloro-2-(1-piperazinyl)pyrazine | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perospirone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine | | (trifluoromethyl)benzenes;
N-alkylpiperazine;
N-arylpiperazine;
primary arylamine;
substituted aniline | geroprotector;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| piperaquine | | aminoquinoline;
N-arylpiperazine;
organochlorine compound | antimalarial | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vb 20b7 | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxociprofloxacin | | cyclopropanes;
N-arylpiperazine;
piperazinone;
quinolinemonocarboxylic acid;
quinolone | drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay-s 9435 | | cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
organosulfonic acid;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | drug metabolite;
human urinary metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pitrazepin | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eptapirone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lurasidone | | 1,2-benzisothiazole;
bridged compound;
dicarboximide;
N-arylpiperazine | adrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| posaconazole | | aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles | trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-(4-fluorophenyl)sulfonyl-1-piperazinyl]-4-(3-methoxyphenyl)thiazole | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[4-methyl-6-(4-methyl-1-piperazinyl)-2-pyrimidinyl]morpholine | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-[(1-cyclopentyl-5-tetrazolyl)-(6-quinolinyl)methyl]-1-piperazinyl]-1,3-benzothiazole | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-furanyl-[4-[3-(4-methoxyphenyl)-7-isothiazolo[4,5-d]pyrimidinyl]-1-piperazinyl]methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [4-[5-tert-butyl-3-[(2-chlorophenyl)methyl]-7-triazolo[4,5-d]pyrimidinyl]-1-piperazinyl]-(2-furanyl)methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [4-[2-(3-chlorophenyl)-5-methyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]-(2-furanyl)methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[4-(1,3-benzothiazol-2-yl)-1-piperazinyl]-[1-(2-methylbutan-2-yl)-5-tetrazolyl]methyl]-2-methoxyphenol | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-[1-[1-[(4-methylphenyl)sulfonylmethyl]-5-tetrazolyl]propyl]-1-piperazinyl]-1,3-benzothiazole | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-cyano-2-[3-[4-(phenylmethyl)-1-piperazinyl]-2-quinoxalinyl]acetic acid 2-methoxyethyl ester | | 2-methoxyethyl ester;
N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[4-(1H-benzimidazol-2-ylmethyl)-1-piperazinyl]benzofuro[3,2-d]pyrimidine | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-furanyl)-5-[4-(phenylmethyl)-1-piperazinyl]-4-oxazolecarbonitrile | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-32568 | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-(3,4-dimethoxyphenyl)-4-methyl-2-[4-(phenylmethyl)-1-piperazinyl]-7,8-dihydro-6H-quinazolin-5-one | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(4-methoxyphenyl)-2-(4-methyl-1-piperazinyl)-6,7,8,9-tetrahydro-5H-cyclohepta[2,3]thieno[2,4-b]pyrimidin-4-one | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-[(3-fluorophenyl)methyl]-1-piperazinyl]pyrimidine | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(1,3-benzothiazol-2-yl)-N-phenyl-1-piperazinecarboxamide | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-furanyl-[4-(2-methyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)-1-piperazinyl]methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [4-(2-methyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)-1-piperazinyl]-thiophen-2-ylmethanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3-chlorophenyl)-9-[4-(2-pyrazinyl)-1-piperazinyl]-5,6,7,8-tetrahydropyrazolo[5,1-b]quinazoline | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-(4-chlorophenyl)sulfonyl-1-piperazinyl]-1-ethylbenzimidazole | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-butylphenyl)-4-(2-pyrimidinyl)-1-piperazinecarbothioamide | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [2-[(2-bromophenyl)methoxy]phenyl]-[4-(2-pyrimidinyl)-1-piperazinyl]methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jnj-1661010 | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (5-methyl-3-isoxazolyl)[4-(5-propyl-2-pyrimidinyl)piperazino]methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-[[4-(4-acetamidoanilino)-6-(4-ethyl-1-piperazinyl)-1,3,5-triazin-2-yl]amino]phenyl]acetamide | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[4-methyl-6-(trifluoromethyl)-2-pyrimidinyl]-1-piperazinecarboxylic acid ethyl ester | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dapiprazole | | N-alkylpiperazine;
N-arylpiperazine;
pyridines | alpha-adrenergic antagonist;
antipsychotic agent;
miotic;
ophthalmology drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tandutinib | | aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dasatinib | | 1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| CID 3192987 | | N-arylpiperazine | anticoronaviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [4-(2,7-dimethyl-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d]pyrimidin-4-yl)-1-piperazinyl]-(2-furanyl)methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[4-(1,3-benzothiazol-2-yl)-1-piperazinyl]-[1-(2-phenylethyl)-5-tetrazolyl]methyl]phenol | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-chlorophenyl)-4-[4-(3-methoxyphenyl)-2-thiazolyl]-1-piperazinecarbothioamide | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [4-[5-tert-butyl-3-(phenylmethyl)-7-triazolo[4,5-d]pyrimidinyl]-1-piperazinyl]-(2-furanyl)methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [5-[(2-methylphenyl)sulfonylmethyl]-2-furanyl]-[4-(2-pyrimidinyl)-1-piperazinyl]methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-furanyl-[4-(4-tetrazolo[1,5-a]quinoxalinyl)-1-piperazinyl]methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N4-(3,4-dimethylphenyl)-2-(4-ethyl-1-piperazinyl)-5-nitropyrimidine-4,6-diamine | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brl 15572 | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
secondary alcohol | geroprotector;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-tert-butyl-7-(4-ethyl-1-piperazinyl)-2-methyl-3-phenylpyrazolo[1,5-a]pyrimidine | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (4-chlorophenyl)-[4-(8-nitro-5-quinolinyl)-1-piperazinyl]methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2-methoxyphenyl)-2,5-dimethyl-7-[4-(phenylmethyl)-1-piperazinyl]pyrazolo[1,5-a]pyrimidine | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(4-chlorophenyl)-6-(4-methyl-1-piperazinyl)-1H-pyrimidine-2,4-dione | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(3,4-dimethoxyphenyl)-2,5-dimethyl-7-[4-(phenylmethyl)-1-piperazinyl]pyrazolo[1,5-a]pyrimidine | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[[4-[6-(4-morpholinyl)-3-pyridazinyl]-1-piperazinyl]-oxomethyl]-1-benzopyran-2-one | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-phenylethyl)-4-([1,2,4]triazolo[4,3-a]quinoxalin-4-yl)piperazine-2,6-dione | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vx680 | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| netupitant | | aminopyridine;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
toluenes | antiemetic;
neurokinin-1 receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl]-[(3R)-2,3-dihydro-1,4-benzodioxin-3-yl]methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flibanserin | | benzimidazoles;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound | antidepressant;
serotonergic agonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vilazodone | | 1-benzofurans;
indoles;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
nitrile | antidepressant;
serotonergic agonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-hydroxybuspirone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vortioxetine | | aryl sulfide;
N-arylpiperazine | antidepressant;
anxiolytic drug;
serotonergic agonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sotrastaurin | | indoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines | anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| PDGF receptor tyrosine kinase inhibitor III | | aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
quinazolines;
tertiary amino compound | EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abt-737 | | aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound | anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mp470 | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bgt226 | | aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brexpiprazole | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2,5-difluorophenyl)-5-methyl-4-[[4-(2-pyrazinyl)-1-piperazinyl]methyl]oxazole | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2,4-dimethoxyphenyl)-5-methyl-4-[[4-(4-quinazolinyl)-1-piperazinyl]methyl]oxazole | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tg101209 | | N-alkylpiperazine;
N-arylpiperazine;
pyrimidines;
secondary amino compound;
sulfonamide | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gdc-0068 | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sch772984 | | biaryl;
indazoles;
N-acylpiperazine;
N-alkylpyrrolidine;
N-arylpiperazine;
pyridines;
pyrimidines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary amino compound;
tertiary carboxamide | analgesic;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-furanyl-[4-[5-(2-furanyl)-2-phenyl-7-pyrazolo[1,5-a]pyrimidinyl]-1-piperazinyl]methanone | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[5-oxo-7-(1-piperazinyl)-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl]benzoic acid | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-ethyl-6-fluoro-7-(1-piperazinyl)-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one | | N-arylpiperazine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aripiprazole lauroxil | | aromatic ether;
delta-lactam;
dichlorobenzene;
dodecanoate ester;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | H1-receptor antagonist;
prodrug;
second generation antipsychotic;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| torin 1 | | N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines | antineoplastic agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abt-199 | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine | antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd4547 | | benzamides;
N-arylpiperazine;
pyrazoles | fibroblast growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea | | aminopyrimidine;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas | antineoplastic agent;
fibroblast growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[4-(5,5-dimethyl-4H-thiazol-2-yl)-1-piperazinyl]-6-propylthieno[2,3-d]pyrimidine | | N-arylpiperazine;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk343 | | aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hg-9-91-01 | | aminopyrimidine;
dimethoxybenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas;
secondary amino compound | antineoplastic agent;
salt-inducible kinase 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| chlorpheniramine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clemizole | | benzimidazoles;
monochlorobenzenes;
pyrrolidines | histamine antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxylamine | | pyridines;
tertiary amine | anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| epinastine | | benzazepine;
guanidines | anti-allergic agent;
H1-receptor antagonist;
histamine antagonist;
ophthalmology drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| profenamine | | phenothiazines;
tertiary amino compound | adrenergic antagonist;
antidyskinesia agent;
antiparkinson drug;
histamine antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methixene | | piperidines;
thioxanthenes | antiparkinson drug;
histamine antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mirtazapine | | benzazepine;
tetracyclic antidepressant | alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist | 2001 | 2023 | 14.1 | low | 5 | 0 | 0 | 21 | 8 | 3 |
| propiomazine | | aromatic ketone;
phenothiazines;
tertiary amino compound | dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
sedative;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quetiapine | | dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine | adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiethylperazine | | N-methylpiperazine;
phenothiazines | antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| buclizine | | monochlorobenzenes;
N-alkylpiperazine | antiemetic;
central nervous system depressant;
cholinergic antagonist;
histamine antagonist;
local anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methdilazine | | N-alkylpyrrolidine;
phenothiazines | antipruritic drug;
cholinergic antagonist;
histamine antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pizotyline | | benzocycloheptathiophene | histamine antagonist;
muscarinic antagonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ziprasidone | | 1,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines | antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cubebin | | benzodioxoles;
cyclic acetal;
lactol;
lignan;
secondary alcohol | analgesic;
anti-inflammatory agent;
antimicrobial agent;
histamine antagonist;
plant metabolite;
trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| profenamine hydrochloride | | hydrochloride | adrenergic antagonist;
antiparkinson drug;
histamine antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cinnarizine | | diarylmethane;
N-alkylpiperazine;
olefinic compound | anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quercetin 3-o-glucopyranoside | | beta-D-glucoside;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone | antineoplastic agent;
antioxidant;
antipruritic drug;
bone density conservation agent;
geroprotector;
histamine antagonist;
osteogenesis regulator;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| demethylmirtazapine | | benzazepine;
tetracyclic antidepressant | alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
human xenobiotic metabolite;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clozapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound | adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic | 1992 | 2023 | 16.7 | medium | 113 | 0 | 173 | 467 | 225 | 54 |
| 4-diphenylacetoxy-1,1-dimethylpiperidinium | | quaternary ammonium ion | cholinergic antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzquinamide | | monocarboxylic acid amide | antiemetic;
antipsychotic agent;
H1-receptor antagonist;
muscarinic antagonist;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| biperiden | | piperidines;
tertiary alcohol;
tertiary amino compound | antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic | 1998 | 2022 | 13.7 | low | 1 | 0 | 1 | 2 | 2 | 1 |
| bromodiphenhydramine | | organobromine compound;
tertiary amino compound | antimicrobial agent;
H1-receptor antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbinoxamine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclopentolate | | carboxylic ester;
tertiary alcohol;
tertiary amino compound | diagnostic agent;
muscarinic antagonist;
mydriatic agent;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cycrimine | | piperidines;
tertiary alcohol;
tertiary amino compound | antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dicyclomine | | carboxylic ester;
tertiary amine | antispasmodic drug;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diphenhydramine | | ether;
tertiary amino compound | anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative | 2000 | 2019 | 16.7 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| flavoxate | | carboxylic ester;
flavones;
piperidines;
tertiary amino compound | antispasmodic drug;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methoctramine | | aromatic ether;
tetramine | muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| orphenadrine | | ether;
tertiary amino compound | antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxybutynin | | acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound | antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic | 2012 | 2022 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| pirenzepine | | pyridobenzodiazepine | anti-ulcer drug;
antispasmodic drug;
muscarinic antagonist | 1992 | 2020 | 23.4 | high | 302 | 0 | 618 | 717 | 7 | 0 |
| procyclidine | | pyrrolidines;
tertiary alcohol | antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| promazine | | phenothiazines;
tertiary amine | antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist | 2004 | 2009 | 17.0 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| diphemanil methylsulfate | | piperidines;
quaternary ammonium salt | bronchodilator agent;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diphenhydramine hydrochloride | | hydrochloride;
organoammonium salt | anti-allergic agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| orphenadrine hydrochloride | | hydrochloride | antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tridihexethyl | | quaternary ammonium ion;
tertiary alcohol | anti-ulcer drug;
antispasmodic drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clemastine | | monochlorobenzenes;
N-alkylpyrrolidine | anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tramadol | | 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol | adrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
metabolite;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tramadol hydrochloride | | hydrochloride | adrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| propyromazine | | organic bromide salt;
quaternary ammonium salt | antispasmodic drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tiquizium bromide | | organic bromide salt;
quaternary ammonium salt | anti-ulcer drug;
antispasmodic drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| orphenadrine citrate | | citrate salt | H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| biperiden hydrochloride | | hydrochloride;
piperidines;
tertiary alcohol | antiparkinson drug;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methoctramine | | hydrochloride | muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nsc 23766 | | aminopyrimidine;
aminoquinoline;
primary amino compound;
secondary amino compound;
tertiary amino compound | antiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quinidine | | cinchona alkaloid | alpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dicyclomine hydrochloride | | hydrochloride | antispasmodic drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flavoxate hydrochloride | | hydrochloride | antispasmodic drug;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tolterodine | | tertiary amine | antispasmodic drug;
muscarinic antagonist;
muscle relaxant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| darifenacin hydrobromide | | hydrobromide | muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| darifenacin | | 1-benzofurans;
monocarboxylic acid amide;
pyrrolidines | antispasmodic drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-diphenylacetoxy-n-methylpiperidine methiodide | | iodide salt;
quaternary ammonium salt | cholinergic antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clemastine fumarate | | fumarate salt | anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbinoxamine maleate | | maleate salt | anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| himbacine | | gamma-lactone;
organic heterotricyclic compound;
piperidine alkaloid | muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aclidinium bromide | | organic bromide salt;
quaternary ammonium salt | bronchodilator agent;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nsc 23766 | | hydrochloride | antiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| octotropine methylbromide | | organic bromide salt;
quaternary ammonium salt | anti-ulcer drug;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (S)-carbinoxamine maleate | | carbinoxamine maleate | anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-hydroxy-2-(di-n-propylamino)tetralin | | phenols;
tertiary amino compound;
tetralins | serotonergic antagonist | 1999 | 2009 | 19.0 | low | 0 | 0 | 1 | 5 | 0 | 0 |
| alosetron | | imidazoles;
pyridoindole | antiemetic;
gastrointestinal drug;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clomipramine | | dibenzoazepine | anticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor | 1998 | 2020 | 16.5 | low | 2 | 0 | 4 | 8 | 7 | 0 |
| cyproheptadine | | piperidines;
tertiary amine | anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist | 2003 | 2019 | 10.7 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 1995 | 2024 | 16.2 | low | 212 | 0 | 91 | 446 | 205 | 36 |
| ketanserin | | aromatic ketone;
organofluorine compound;
piperidines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 1999 | 2023 | 15.4 | low | 0 | 0 | 1 | 3 | 0 | 1 |
| methiothepin | | aryl sulfide;
dibenzothiepine;
N-alkylpiperazine;
tertiary amino compound | antipsychotic agent;
dopaminergic antagonist;
geroprotector;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mianserin | | dibenzoazepine | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist | 1999 | 2023 | 16.2 | low | 5 | 0 | 1 | 24 | 6 | 1 |
| nan 190 | | N-alkylpiperazine;
N-arylpiperazine;
phthalimides | serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nefazodone | | aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles | alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxatomide | | benzimidazoles;
diarylmethane;
N-alkylpiperazine | anti-allergic agent;
anti-inflammatory agent;
geroprotector;
H1-receptor antagonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pindolol | | indoles;
secondary amine | antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pipamperone | | aromatic ketone;
bipiperidines;
monocarboxylic acid amide;
organofluorine compound;
tertiary amino compound | dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| risperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist | 1995 | 2024 | 15.6 | high | 361 | 0 | 156 | 847 | 435 | 82 |
| ritanserin | | organofluorine compound;
piperidines;
thiazolopyrimidine | antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 1997 | 2000 | 25.3 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| setiptiline | | tertiary amino compound;
tetracyclic antidepressant | alpha-adrenergic antagonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spiperone | | aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound | alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist | 2004 | 2006 | 19.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| thioridazine | | phenothiazines;
piperidines | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 1996 | 2017 | 19.4 | low | 2 | 0 | 1 | 15 | 2 | 0 |
| gramine | | aminoalkylindole;
indole alkaloid;
tertiary amino compound | antibacterial agent;
antiviral agent;
plant metabolite;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| yohimbine | | methyl 17-hydroxy-20xi-yohimban-16-carboxylate | alpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clopenthixol | | N-alkylpiperazine;
primary alcohol;
thioxanthenes | alpha-adrenergic antagonist;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 1998 | 2022 | 13.5 | low | 1 | 0 | 2 | 10 | 4 | 4 |
| pimozide | | benzimidazoles;
heteroarylpiperidine;
organofluorine compound | antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 1999 | 2022 | 17.8 | low | 1 | 0 | 3 | 7 | 1 | 1 |
| metergoline | | carbamate ester;
ergoline alkaloid | dopamine agonist;
geroprotector;
serotonergic antagonist | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| dotarizine | | cyclic ketal;
dioxolane;
N-alkylpiperazine | calcium channel blocker;
serotonergic antagonist;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sertindole | | heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole | alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alosetron hydrochloride | | hydrochloride | antiemetic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spiramide | | aromatic ether;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound | dopaminergic antagonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clomipramine hydrochloride | | hydrochloride | anticoronaviral agent;
antidepressant;
serotonergic antagonist;
serotonergic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mesulergine | | ergot alkaloid;
sulfamides | antiparkinson drug;
dopamine agonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hp 873 | | 1,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound | dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methotrimeprazine | | phenothiazines;
tertiary amine | anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist | 1999 | 2022 | 13.1 | low | 1 | 0 | 2 | 3 | 4 | 2 |
| amperozide | | diarylmethane;
monofluorobenzenes;
N-alkylpiperazine;
secondary carboxamide;
ureas | anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amperozide hydrochloride | | hydrochloride | anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine | | hydrobromide | serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gr 113808 | | indolyl carboxylate ester;
piperidines;
sulfonamide | serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fk 1052 | | imidazoles;
organic heterotricyclic compound | antiemetic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lurasidone | | 1,2-benzisothiazole;
bridged compound;
dicarboximide;
N-arylpiperazine | adrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| picrotoxinin | | epoxide;
gamma-lactone;
organic heteropentacyclic compound;
picrotoxane sesquiterpenoid;
tertiary alcohol | GABA antagonist;
plant metabolite;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(1-methyl-5-indolyl)-n'-(3-methyl-5-isothiazolyl)urea | | 1,2-thiazoles;
indoles;
ureas | receptor modulator;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sb-224289 | | 1,2,4-oxadiazole;
azaspiro compound;
benzamides;
organic heterotetracyclic compound | serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brl 15572 | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
secondary alcohol | geroprotector;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LY-310762 | | aromatic ketone;
monofluorobenzenes;
oxindoles;
piperidines;
tertiary amino compound | receptor modulator;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly 367265 | | dihydropyridine;
fluoroindole;
tertiary amino compound;
thiadiazoloquinoline | antidepressant;
geroprotector;
serotonergic antagonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zuclopenthixol | | clopenthixol | alpha-adrenergic antagonist;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| palonosetron | | azabicycloalkane;
delta-lactam;
organic heterotricyclic compound | antiemetic;
serotonergic antagonist | 2006 | 2023 | 8.8 | low | 11 | 0 | 0 | 5 | 14 | 2 |
| 1-methyl-d-lysergic acid butanolamide | | ergot alkaloid;
monocarboxylic acid amide | serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flibanserin | | benzimidazoles;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound | antidepressant;
serotonergic agonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rs 25259-197 | | hydrochloride | antiemetic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vortioxetine | | aryl sulfide;
N-arylpiperazine | antidepressant;
anxiolytic drug;
serotonergic agonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pimavanserin | | aromatic ether;
monofluorobenzenes;
piperidines;
tertiary amino compound;
ureas | 5-hydroxytryptamine 2A receptor inverse agonist;
antipsychotic agent;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lurasidone hydrochloride | | hydrochloride | adrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 2011 | 2023 | 6.3 | low | 7 | 0 | 0 | 0 | 22 | 7 |
| GR 127935 hydrochloride | | hydrochloride | serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pipamperone dihydrochloride | | hydrochloride | dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brl 15572 | | hydrochloride | prodrug;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-(4-(4-fluoro-benzoyl)-piperidin-1-yl)-ethyl)-3,3-dimethyl-1,2-dihydro-indol-2-one | | hydrochloride | receptor modulator;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rs 39604 | | hydrochloride | serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3alpha-hydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid | | 11-oxo steroid;
3alpha-hydroxy steroid;
7-oxo steroid;
monocarboxylic acid;
steroid acid | antineoplastic agent;
cholinergic antagonist;
metabolite;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| norclozapine | | dibenzodiazepine;
organochlorine compound;
piperazines | delta-opioid receptor agonist;
metabolite;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amoxapine | | dibenzooxazepine | adrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor | 1999 | 2015 | 17.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| chlorpromazine | | organochlorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug | 1997 | 2023 | 15.9 | low | 9 | 0 | 7 | 45 | 21 | 3 |
| domperidone | | benzimidazoles;
heteroarylpiperidine | antiemetic;
dopaminergic antagonist | 2015 | 2021 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| droperidol | | aromatic ketone;
benzimidazoles;
organofluorine compound | anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 2008 | 2023 | 7.2 | low | 5 | 0 | 0 | 1 | 10 | 3 |
| fenoldopam | | benzazepine | alpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluphenazine | | N-alkylpiperazine;
organofluorine compound;
phenothiazines | anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 1998 | 2022 | 16.3 | low | 6 | 0 | 1 | 20 | 5 | 2 |
| fluphenazine depot | | decanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| loxapine | | dibenzooxazepine | antipsychotic agent;
dopaminergic antagonist | 1997 | 2021 | 15.7 | low | 2 | 0 | 3 | 1 | 5 | 1 |
| mesoridazine | | phenothiazines;
sulfoxide;
tertiary amino compound | dopaminergic antagonist;
first generation antipsychotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metoclopramide | | benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound | antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic | 2007 | 2023 | 6.3 | low | 2 | 0 | 0 | 1 | 7 | 2 |
| perazine | | N-alkylpiperazine;
N-methylpiperazine;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug | 2003 | 2014 | 15.7 | low | 2 | 0 | 0 | 6 | 4 | 0 |
| perphenazine | | N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines | antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 1998 | 2024 | 13.8 | low | 25 | 0 | 2 | 26 | 18 | 3 |
| prochlorperazine | | N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines | alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic | 2009 | 2023 | 9.0 | low | 0 | 0 | 0 | 1 | 3 | 1 |
| 7-chloro-3-methyl-1-phenyl-1,2,4,5-tetrahydro-3-benzazepin-8-ol | | benzazepine;
organochlorine compound;
tertiary amino compound | dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulpiride | | benzamides;
N-alkylpyrrolidine;
sulfonamide | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 1998 | 2022 | 15.6 | low | 24 | 0 | 8 | 80 | 48 | 1 |
| trifluoperazine | | N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines | antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug | 2005 | 2022 | 12.6 | low | 3 | 0 | 0 | 5 | 2 | 1 |
| triflupromazine | | organofluorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiopropazate | | acetate ester;
N-alkylpiperazine;
organochlorine compound;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azaperone | | aminopyridine;
aromatic ketone;
monofluorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
tertiary amino compound | antipsychotic agent;
dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| serentil | | organosulfonate salt | dopaminergic antagonist;
first generation antipsychotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| butaclamol | | amino alcohol;
organic heteropentacyclic compound;
tertiary alcohol;
tertiary amino compound | dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetrahydropalmatine | | an (S)-7,8,13,14-tetrahydroprotoberberine;
berberine alkaloid;
organic heterotetracyclic compound | adrenergic agent;
dopaminergic antagonist;
non-narcotic analgesic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aj 76 | | secondary amino compound;
tetralins | dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| levosulpiride | | sulpiride | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nafadotride | | aromatic ether;
naphthalenecarboxamide;
nitrile;
pyrrolidines;
tertiary amino compound | dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flupenthixol | | flupenthixol | dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diphenidol | | benzenes;
piperidines;
tertiary alcohol | antiemetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| promethazine | | phenothiazines;
tertiary amine | anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative | 2007 | 2023 | 10.8 | low | 2 | 0 | 0 | 4 | 4 | 2 |
| propofol | | phenols | anticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative | 2008 | 2012 | 13.7 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| trimethobenzamide | | benzamides;
tertiary amino compound | antiemetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| promethazine hydrochloride | | hydrochloride | anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
geroprotector;
H1-receptor antagonist;
local anaesthetic;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclizine | | N-alkylpiperazine | antiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methylprednisolone | | 6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic | 2003 | 2020 | 8.3 | low | 0 | 0 | 0 | 1 | 5 | 0 |
| zingerone | | methyl ketone;
monomethoxybenzene;
phenols | anti-inflammatory agent;
antiemetic;
antioxidant;
flavouring agent;
fragrance;
plant metabolite;
radiation protective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pachypodol | | dihydroxyflavone;
trimethoxyflavone | antiemetic;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclizine hydrochloride | | hydrochloride | antiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| netupitant | | aminopyridine;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
toluenes | antiemetic;
neurokinin-1 receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rolapitant | | azaspiro compound;
ether;
organofluorine compound;
piperidines;
pyrrolidin-2-ones | antiemetic;
neurokinin-1 receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles | antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist | 2005 | 2023 | 7.6 | low | 16 | 0 | 0 | 4 | 21 | 3 |
| fosaprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles | antiemetic;
neurokinin-1 receptor antagonist;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dan 2163 | | aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone | environmental contaminant;
second generation antipsychotic;
xenobiotic | 1999 | 2023 | 12.5 | medium | 29 | 0 | 6 | 62 | 62 | 13 |
| zotepine | | dibenzothiepine;
tertiary amino compound | alpha-adrenergic drug;
second generation antipsychotic;
serotonergic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aripiprazole | | aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist | 2002 | 2023 | 10.5 | medium | 49 | 0 | 0 | 131 | 187 | 56 |
| aripiprazole lauroxil | | aromatic ether;
delta-lactam;
dichlorobenzene;
dodecanoate ester;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | H1-receptor antagonist;
prodrug;
second generation antipsychotic;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| desipramine | | dibenzoazepine;
secondary amino compound | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor | 1999 | 2010 | 18.0 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| fenfluramine | | (trifluoromethyl)benzenes;
secondary amino compound | appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| minaprine | | morpholines;
pyridazines;
secondary amine | antidepressant;
antiparkinson drug;
cholinergic drug;
dopamine uptake inhibitor;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sibutramine | | organochlorine compound;
tertiary amino compound | anti-obesity agent;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trazodone | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine | adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 2005 | 2018 | 11.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| venlafaxine | | cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound | adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paroxetine | | aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 2000 | 2019 | 17.4 | low | 9 | 0 | 1 | 28 | 5 | 0 |
| paroxetine hydrochloride | | hydrochloride | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trazodone hydrochloride | | hydrochloride | adrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sertraline hydrochloride | | hydrochloride | antidepressant;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dexfenfluramine hydrochloride | | fenfluramine hydrochloride | appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dexfenfluramine | | fenfluramine | appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sertraline | | dichlorobenzene;
secondary amino compound;
tetralins | antidepressant;
serotonin uptake inhibitor | 1999 | 2023 | 12.0 | low | 25 | 0 | 2 | 17 | 21 | 5 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 1997 | 2013 | 18.2 | low | 1 | 0 | 2 | 5 | 2 | 0 |
| fluoxetine | | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | antidepressant;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (R)-fluoxetine | | N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine | antidepressant;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| noribogaine | | monoterpenoid indole alkaloid;
organic heteropentacyclic compound;
secondary amino compound;
tertiary amino compound | kappa-opioid receptor agonist;
NMDA receptor antagonist;
psychotropic drug;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluvoxamine | | (trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime | antidepressant;
anxiolytic drug;
serotonin uptake inhibitor | 1999 | 2023 | 18.8 | low | 5 | 0 | 2 | 17 | 1 | 1 |
| paroxetine maleate | | maleate salt | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vilazodone hydrochloride | | hydrochloride | antidepressant;
serotonergic agonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vilazodone | | 1-benzofurans;
indoles;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
nitrile | antidepressant;
serotonergic agonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (R)-fluoxetine hydrochloride | | hydrochloride | antidepressant;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (S)-fluoxetine hydrochloride | | hydrochloride | antidepressant;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| gamma-aminobutyric acid | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid | human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetic acid | | monocarboxylic acid | antimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| acetamide | | acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetone | | ketone body;
methyl ketone;
propanones;
volatile organic compound | EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| adenine | | 6-aminopurines;
purine nucleobase | Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| allantoin | | imidazolidine-2,4-dione;
ureas | Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinacrine | | acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound | antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| beta-alanine | | amino acid zwitterion;
beta-amino acid | agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzene | | aromatic annulene;
benzenes;
volatile organic compound | carcinogenic agent;
environmental contaminant;
non-polar solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzoic acid | | benzoic acids | algal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzyl alcohol | | benzyl alcohols | antioxidant;
fragrance;
metabolite;
solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betaine | | amino-acid betaine;
glycine derivative | fundamental metabolite | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| carbon monoxide | | carbon oxide;
gas molecular entity;
one-carbon compound | biomarker;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
human metabolite;
ligand;
metabolite;
mitochondrial respiratory-chain inhibitor;
mouse metabolite;
neurotoxin;
neurotransmitter;
P450 inhibitor;
probe;
signalling molecule;
vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| formic acid | | monocarboxylic acid | antibacterial agent;
astringent;
metabolite;
protic solvent;
solvent | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carnitine | | amino-acid betaine | human metabolite;
mouse metabolite | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| citric acid, anhydrous | | tricarboxylic acid | antimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| coumarin | | coumarins | fluorescent dye;
human metabolite;
plant metabolite | 2000 | 2012 | 16.0 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| salicylic acid | | monohydroxybenzoic acid | algal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite | 2000 | 2014 | 16.0 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| gallic acid | | trihydroxybenzoic acid | antineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bupropion | | aromatic ketone;
monochlorobenzenes;
secondary amino compound | antidepressant;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.3 | low | 0 | 0 | 0 | 4 | 3 | 0 |
| guaiacol | | guaiacols | disinfectant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
expectorant;
plant metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aminocaproic acid | | amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid | antifibrinolytic drug;
hematologic agent;
metabolite | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| creatine | | glycine derivative;
guanidines;
zwitterion | geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lactic acid | | 2-hydroxy monocarboxylic acid | algal metabolite;
Daphnia magna metabolite | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| dimethyl sulfoxide | | sulfoxide;
volatile organic compound | alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| formaldehyde | | aldehyde;
one-carbon compound | allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycine | | alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid | EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical | 2008 | 2014 | 13.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| glycerol | | alditol;
triol | algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| alpha-glycerophosphoric acid | | glycerol monophosphate | algal metabolite;
human metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| histamine | | aralkylamino compound;
imidazoles | human metabolite;
mouse metabolite;
neurotransmitter | 2008 | 2014 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| hydroquinone | | benzenediol;
hydroquinones | antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| dihydroxyphenylalanine | | hydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative | human metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methanol | | alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound | amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| inositol | | cyclitol;
hexol | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| melatonin | | acetamides;
tryptamines | anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetanilide | | acetamides;
anilide | analgesic | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| niacinamide | | pyridine alkaloid;
pyridinecarboxamide;
vitamin B3 | anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| niacin | | pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3 | antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| 3-(1-methylpyrrolidin-2-yl)pyridine | | N-alkylpyrrolidine;
pyridine alkaloid;
pyrrolidine alkaloid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nitrous oxide | | gas molecular entity;
nitrogen oxide | analgesic;
bacterial metabolite;
food packaging gas;
food propellant;
general anaesthetic;
greenhouse gas;
inhalation anaesthetic;
NMDA receptor antagonist;
raising agent;
refrigerant;
vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| orotic acid | | pyrimidinemonocarboxylic acid | Escherichia coli metabolite;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-aminobenzoic acid | | aminobenzoic acid;
aromatic amino-acid zwitterion | allergen;
Escherichia coli metabolite;
plant metabolite | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phenol | | phenols | antiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylacetic acid | | benzenes;
monocarboxylic acid;
phenylacetic acids | allergen;
Aspergillus metabolite;
auxin;
EC 6.4.1.1 (pyruvate carboxylase) inhibitor;
Escherichia coli metabolite;
human metabolite;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite;
toxin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| picolinic acid | | pyridinemonocarboxylic acid | human metabolite;
MALDI matrix material | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-propanol | | propan-1-ols;
short-chain primary fatty alcohol | metabolite;
protic solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propionic acid | | saturated fatty acid;
short-chain fatty acid | antifungal drug | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyrazinamide | | monocarboxylic acid amide;
N-acylammonia;
pyrazines | antitubercular agent;
prodrug | 2010 | 2016 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| pyridoxal phosphate | | methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate | coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridoxamine | | aminoalkylpyridine;
hydroxymethylpyridine;
monohydroxypyridine;
vitamin B6 | Escherichia coli metabolite;
human metabolite;
iron chelator;
mouse metabolite;
nephroprotective agent;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyridoxine | | hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6 | cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| succinic acid | | alpha,omega-dicarboxylic acid;
C4-dicarboxylic acid | anti-ulcer drug;
fundamental metabolite;
micronutrient;
nutraceutical;
radiation protective agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiamine | | primary alcohol;
vitamin B1 | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| toluene | | methylbenzene;
toluenes;
volatile organic compound | cholinergic antagonist;
fuel additive;
neurotoxin;
non-polar solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trimethylamine | | methylamines;
tertiary amine | Escherichia coli metabolite;
human xenobiotic metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tryptophan | | alpha-amino acid;
amino acid zwitterion;
aminoalkylindole;
aromatic amino acid;
polar amino acid | Daphnia magna metabolite | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| uracil | | pyrimidine nucleobase;
pyrimidone | allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| urea | | isourea;
monocarboxylic acid amide;
one-carbon compound | Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| catechin | | hydroxyflavan | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 8-hydroxy-2-(di-n-propylamino)tetralin | | phenols;
tertiary amino compound;
tetralins | serotonergic antagonist | 1998 | 2019 | 15.2 | low | 0 | 0 | 2 | 0 | 3 | 0 |
| 4-iodo-2,5-dimethoxyphenylisopropylamine | | amphetamines;
dimethoxybenzene;
organoiodine compound | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| octoclothepine | | dibenzothiepine | | 2002 | 2005 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| menthol | | p-menthane monoterpenoid;
secondary alcohol | volatile oil component | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate | | catechin | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-(3-chlorophenyl)piperazine | | monochlorobenzenes;
N-arylpiperazine | drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic | 2009 | 2013 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 2,4-dichlorophenoxyacetic acid | | chlorophenoxyacetic acid;
dichlorobenzene | agrochemical;
defoliant;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
environmental contaminant;
phenoxy herbicide;
synthetic auxin | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enprofylline | | oxopurine | anti-arrhythmia drug;
anti-asthmatic drug;
bronchodilator agent;
non-steroidal anti-inflammatory drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-aminopyridine | | aminopyridine;
aromatic amine | avicide;
orphan drug;
potassium channel blocker | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenytoin | | imidazolidine-2,4-dione | anticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent | 2000 | 2016 | 14.9 | low | 0 | 0 | 1 | 4 | 4 | 0 |
| 5-carboxamidotryptamine | | tryptamines | | 1996 | 2016 | 20.6 | low | 0 | 0 | 3 | 1 | 1 | 0 |
| 5-methoxytryptamine | | aromatic ether;
primary amino compound;
tryptamines | 5-hydroxytryptamine 2A receptor agonist;
5-hydroxytryptamine 2B receptor agonist;
5-hydroxytryptamine 2C receptor agonist;
antioxidant;
cardioprotective agent;
human metabolite;
mouse metabolite;
neuroprotective agent;
radiation protective agent;
serotonergic agonist | 1996 | 2005 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| oxyquinoline | | monohydroxyquinoline | antibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tacrine | | acridines;
aromatic amine | EC 3.1.1.7 (acetylcholinesterase) inhibitor | 2000 | 2014 | 14.6 | low | 0 | 0 | 1 | 3 | 5 | 0 |
| acebutolol | | aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent | 2000 | 2016 | 15.3 | low | 0 | 0 | 1 | 4 | 2 | 0 |
| acetaminophen | | acetamides;
phenols | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2000 | 2016 | 14.9 | low | 0 | 0 | 1 | 4 | 5 | 0 |
| acetarsol | | acetamides;
anilide | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetazolamide | | monocarboxylic acid amide;
sulfonamide;
thiadiazoles | anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| acetohexamide | | acetophenones;
N-sulfonylurea | hypoglycemic agent;
insulin secretagogue | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetohydroxamic acid | | acetohydroxamic acids;
carbohydroximic acid | algal metabolite;
EC 3.5.1.5 (urease) inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| methacholine | | acetate ester;
quaternary ammonium ion | bronchoconstrictor agent;
cholinergic agonist;
epitope;
muscarinic agonist;
vasodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethacridine | | acridines | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-(acetylamino)benzeneacetic acid | | acetamides;
anilide | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| adiphenine | | diarylmethane | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ag-1296 | | quinoxaline derivative | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aklomide | | carbonyl compound;
organohalogen compound | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alaproclate | | alpha-amino acid ester | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| albendazole | | aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester | anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| albuterol | | phenols;
phenylethanolamines;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic | 2000 | 2016 | 15.3 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| alendronate | | 1,1-bis(phosphonic acid);
primary amino compound | bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| alfuzosin | | monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| alosetron | | imidazoles;
pyridoindole | antiemetic;
gastrointestinal drug;
serotonergic antagonist | 2003 | 2016 | 15.8 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| alprazolam | | organochlorine compound;
triazolobenzodiazepine | anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic | 2000 | 2016 | 16.4 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| alprenolol | | secondary alcohol;
secondary amino compound | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2000 | 2014 | 15.0 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| altretamine | | triamino-1,3,5-triazine | | 2004 | 2016 | 13.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| amantadine | | adamantanes;
primary aliphatic amine | analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic | 2000 | 2016 | 15.3 | low | 0 | 0 | 1 | 4 | 2 | 0 |
| ambenonium | | quaternary ammonium ion | EC 3.1.1.8 (cholinesterase) inhibitor | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ambroxol | | aromatic amine | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| diatrizoic acid | | acetamides;
benzoic acids;
organoiodine compound | environmental contaminant;
radioopaque medium;
xenobiotic | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| amifostine anhydrous | | diamine;
organic thiophosphate | antioxidant;
prodrug;
radiation protective agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| aminoglutethimide | | dicarboximide;
piperidones;
substituted aniline | adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2004 | 2013 | 15.2 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| pimagedine | | guanidines;
one-carbon compound | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| p-aminohippuric acid | | N-acylglycine | Daphnia magna metabolite | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| theophylline | | dimethylxanthine | adenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| amiodarone | | 1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound | cardiovascular drug | 2000 | 2016 | 15.1 | low | 0 | 0 | 1 | 6 | 6 | 0 |
| dan 2163 | | aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone | environmental contaminant;
second generation antipsychotic;
xenobiotic | 2007 | 2014 | 13.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| amitriptyline | | carbotricyclic compound;
tertiary amine | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic | 1996 | 2016 | 16.5 | low | 0 | 0 | 2 | 7 | 5 | 0 |
| amlexanox | | monocarboxylic acid;
pyridochromene | anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| amlodipine | | dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2000 | 2016 | 13.8 | low | 0 | 0 | 1 | 2 | 6 | 0 |
| amobarbital | | barbiturates | | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| amodiaquine | | aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug | 2011 | 2012 | 12.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| amoxapine | | dibenzooxazepine | adrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor | 1994 | 2016 | 16.8 | low | 0 | 0 | 2 | 2 | 4 | 0 |
| amprolium | | pyridinium ion | coccidiostat | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amsacrine | | acridines;
aromatic ether;
sulfonamide | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2008 | 2013 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| anastrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| anethole trithione | | methoxybenzenes | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aniracetam | | N-acylpyrrolidine;
pyrrolidin-2-ones | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| antazoline | | aromatic amine;
imidazolines;
tertiary amino compound | cholinergic antagonist;
H1-receptor antagonist;
xenobiotic | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| anthralin | | anthracenes | antipsoriatic | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| antipyrine | | pyrazolone | antipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol | | aporphine alkaloid | | 2011 | 2012 | 12.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| apraclonidine | | dichlorobenzene;
guanidines;
imidazolines | alpha-adrenergic agonist;
antiglaucoma drug;
beta-adrenergic agonist;
diagnostic agent;
ophthalmology drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arecoline | | enoate ester;
methyl ester;
pyridine alkaloid;
tetrahydropyridine | metabolite;
muscarinic agonist | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| aspirin | | benzoic acids;
phenyl acetates;
salicylates | anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent | 2000 | 2016 | 14.1 | low | 0 | 0 | 1 | 2 | 4 | 0 |
| astemizole | | benzimidazoles;
piperidines | anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist | 2003 | 2020 | 14.5 | low | 0 | 0 | 0 | 4 | 4 | 0 |
| atenolol | | ethanolamines;
monocarboxylic acid amide;
propanolamine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic | 2000 | 2016 | 14.7 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| azathioprine | | aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine | antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| azelaic acid | | alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid | antibacterial agent;
antineoplastic agent;
dermatologic drug;
plant metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azelastine | | monochlorobenzenes;
phthalazines;
tertiary amino compound | anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor | 2004 | 2014 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| baclofen | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound | central nervous system depressant;
GABA agonist;
muscle relaxant | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| barbital | | barbiturates | drug allergen | 2008 | 2010 | 15.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| bendazac | | indazoles;
monocarboxylic acid | non-steroidal anti-inflammatory drug;
radical scavenger | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bendroflumethiazide | | benzothiadiazine;
sulfonamide | antihypertensive agent;
diuretic | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| benserazide | | carbohydrazide;
catechols;
primary alcohol;
primary amino compound | antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzamide | | benzamides | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzbromarone | | 1-benzofurans;
aromatic ketone | uricosuric drug | 2010 | 2016 | 11.6 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| benzocaine | | benzoate ester;
substituted aniline | allergen;
antipruritic drug;
sensitiser;
topical anaesthetic | 2009 | 2013 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| benzquinamide | | monocarboxylic acid amide | antiemetic;
antipsychotic agent;
H1-receptor antagonist;
muscarinic antagonist;
sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzothiazide | | benzothiadiazine;
sulfonamide | antihypertensive agent;
diuretic | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bepridil | | pyrrolidines;
tertiary amine | anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2000 | 2012 | 17.6 | low | 0 | 0 | 1 | 5 | 2 | 0 |
| berberine | | alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound | antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bethanidine | | guanidines | adrenergic antagonist;
antihypertensive agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betaxolol | | propanolamine | antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2000 | 2016 | 15.1 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| bethanechol | | carbamate ester;
quaternary ammonium ion | muscarinic agonist | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bevantolol | | propanolamine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
calcium channel blocker | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| bicalutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol | | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| bay h 4502 | | biphenyls;
imidazoles | | 2009 | 2013 | 13.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| biperiden | | piperidines;
tertiary alcohol;
tertiary amino compound | antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bisacodyl | | diarylmethane | | 2008 | 2016 | 11.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| bisindolylmaleimide i | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bisoprolol | | secondary alcohol;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2000 | 2016 | 15.3 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| bretylium | | quaternary ammonium ion | adrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| brimonidine | | imidazoles;
quinoxaline derivative;
secondary amine | adrenergic agonist;
alpha-adrenergic agonist;
antihypertensive agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromazepam | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromhexine | | organobromine compound;
substituted aniline;
tertiary amino compound | mucolytic | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bromopride | | benzamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bromisovalum | | N-acylurea;
organobromine compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| seratrodast | | organic molecular entity | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bronopol | | nitro compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| brotizolam | | organic molecular entity | | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| bumetanide | | amino acid;
benzoic acids;
sulfonamide | diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor | 2000 | 2016 | 14.1 | low | 0 | 0 | 1 | 2 | 4 | 0 |
| bunitrolol | | aromatic ether | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bupivacaine | | aromatic amide;
piperidinecarboxamide;
tertiary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| bupranolol | | aromatic ether | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| buspirone | | azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines | anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist | 1998 | 2019 | 11.7 | low | 0 | 0 | 1 | 6 | 12 | 0 |
| busulfan | | methanesulfonate ester | alkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| secbutabarbital | | barbiturates | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| butacaine | | benzoate ester | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| butalbital | | barbiturates | analgesic;
sedative | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| butamben | | amino acid ester;
benzoate ester;
primary amino compound;
substituted aniline | local anaesthetic | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| butenafine | | naphthalenes;
tertiary amine | antifungal drug;
EC 1.14.13.132 (squalene monooxygenase) inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 2000 | 2016 | 14.2 | low | 0 | 0 | 1 | 4 | 6 | 0 |
| verapamil | | aromatic ether;
nitrile;
polyether;
tertiary amino compound | | 2000 | 2016 | 15.1 | low | 0 | 0 | 1 | 7 | 6 | 0 |
| metrizoate | | monocarboxylic acid | radioopaque medium | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| camostat | | benzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide | anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| candesartan cilexetil | | biphenyls | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| candesartan | | benzimidazolecarboxylic acid;
biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbamylcholine | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbamazepine | | dibenzoazepine;
ureas | analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic | 2000 | 2016 | 14.7 | low | 0 | 0 | 1 | 6 | 6 | 0 |
| carbazochrome | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbetapentane | | benzenes | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbidopa | | benzenes;
monocarboxylic acid | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| carbinoxamine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| carisoprodol | | carbamate ester | muscle relaxant | 2009 | 2016 | 12.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| carmustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 2004 | 2013 | 14.2 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| carprofen | | carbazoles;
organochlorine compound | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carteolol | | quinolone;
secondary alcohol | anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2000 | 2012 | 18.7 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| carvedilol | | carbazoles;
secondary alcohol;
secondary amino compound | alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent | 2000 | 2016 | 15.6 | low | 0 | 0 | 1 | 5 | 4 | 0 |
| celecoxib | | organofluorine compound;
pyrazoles;
sulfonamide;
toluenes | cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2006 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| celiprolol | | aromatic ketone | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cetirizine | | ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines | anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic | 2003 | 2016 | 15.9 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| chloral hydrate | | aldehyde hydrate;
ethanediol;
organochlorine compound | general anaesthetic;
mouse metabolite;
sedative;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorambucil | | aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent | 2000 | 2016 | 14.2 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| chlorcyclizine | | diarylmethane | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| chlordiazepoxide | | benzodiazepine | | 2000 | 2016 | 14.2 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| chlormezanone | | 1,3-thiazine;
lactam;
monochlorobenzenes;
sulfone | antipsychotic agent;
anxiolytic drug;
muscle relaxant | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| chloroquine | | aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug | 2000 | 2020 | 13.4 | low | 0 | 0 | 1 | 4 | 5 | 0 |
| chlorothiazide | | benzothiadiazine | antihypertensive agent;
diuretic | 2000 | 2016 | 16.0 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| chloroxine | | monohydroxyquinoline;
organochlorine compound | antibacterial agent;
antifungal drug;
antiseborrheic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chloroxylenol | | monochlorobenzenes;
phenols | antiseptic drug;
disinfectant;
molluscicide | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| chlorpheniramine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor | 2000 | 2016 | 15.1 | low | 0 | 0 | 1 | 5 | 4 | 0 |
| chlorpromazine | | organochlorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug | 1994 | 2019 | 16.7 | low | 0 | 0 | 5 | 13 | 9 | 0 |
| chlorpropamide | | monochlorobenzenes;
N-sulfonylurea | hypoglycemic agent;
insulin secretagogue | 2000 | 2016 | 13.9 | low | 0 | 0 | 1 | 2 | 4 | 0 |
| chlorthalidone | | isoindoles;
monochlorobenzenes;
sulfonamide | | 2000 | 2016 | 14.3 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| chlorzoxazone | | 1,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound | muscle relaxant;
sedative | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cifenline | | diarylmethane | | 2000 | 2013 | 17.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| ciclopirox | | cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone | antibacterial agent;
antiseborrheic | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ciglitazone | | aromatic ether;
thiazolidinone | antineoplastic agent;
insulin-sensitizing drug | 2006 | 2013 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cilostazol | | lactam;
tetrazoles | anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent | 2012 | 2016 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| cimetidine | | aliphatic sulfide;
guanidines;
imidazoles;
nitrile | adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 2000 | 2016 | 14.5 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| aricine | | cinchona alkaloid | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cinoxacin | | cinnolines;
oxacycle;
oxo carboxylic acid | antibacterial drug;
antiinfective agent | 2004 | 2014 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ciprofibrate | | cyclopropanes;
monocarboxylic acid;
organochlorine compound | antilipemic drug | 2006 | 2013 | 14.8 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| ciprofloxacin | | aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion | antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic | 2003 | 2016 | 14.2 | low | 0 | 0 | 0 | 5 | 6 | 0 |
| cisapride | | benzamides | | 2000 | 2012 | 17.1 | low | 0 | 0 | 1 | 6 | 2 | 0 |
| citalopram | | 2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound | | 2000 | 2016 | 15.1 | low | 0 | 0 | 1 | 7 | 4 | 0 |
| clebopride | | piperidines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clenbuterol | | amino alcohol;
dichlorobenzene;
ethanolamines;
primary arylamine;
secondary amino compound;
substituted aniline | beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clioquinol | | monohydroxyquinoline;
organochlorine compound;
organoiodine compound | antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| clobazam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
GABA modulator | 2000 | 2013 | 16.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| clofazimine | | monochlorobenzenes;
phenazines | dye;
leprostatic drug;
non-steroidal anti-inflammatory drug | 2004 | 2013 | 15.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| clofibrate | | aromatic ether;
ethyl ester;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist | 2006 | 2016 | 12.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| clofilium | | benzenes;
organic amino compound | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clomiphene | | tertiary amine | estrogen antagonist;
estrogen receptor modulator | 2010 | 2016 | 11.2 | medium | 0 | 0 | 0 | 1 | 3 | 0 |
| clomipramine | | dibenzoazepine | anticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 5 | 4 | 0 |
| clonazepam | | 1,4-benzodiazepinone;
monochlorobenzenes | anticonvulsant;
anxiolytic drug;
GABA modulator | 2000 | 2016 | 15.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| clonidine | | clonidine;
imidazoline | | 2000 | 2016 | 16.2 | low | 0 | 0 | 1 | 4 | 1 | 0 |
| 4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide | | sulfonamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cloperastine | | diarylmethane | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chlorazepate | | 1,4-benzodiazepinone | anticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug | 2004 | 2016 | 14.0 | high | 0 | 0 | 0 | 2 | 1 | 0 |
| clotiazepam | | organic molecular entity | | 2008 | 2010 | 15.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| clotrimazole | | conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | antiinfective agent;
environmental contaminant;
xenobiotic | 2006 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| cloxyquin | | organochlorine compound;
quinolines | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cocaine | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| cromolyn | | chromones;
dicarboxylic acid | anti-asthmatic drug;
calcium channel blocker | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| cyclandelate | | carboxylic ester;
secondary alcohol | vasodilator agent | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cyclobenzaprine | | carbotricyclic compound | antidepressant;
muscle relaxant;
tranquilizing drug | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| cyclofenil | | organic molecular entity | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cyproheptadine | | piperidines;
tertiary amine | anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist | 1996 | 2016 | 17.2 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| danthron | | dihydroxyanthraquinone | apoptosis inducer;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dapsone | | substituted aniline;
sulfone | anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug | 2005 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| debrisoquin | | carboxamidine;
isoquinolines | adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| deferoxamine | | acyclic desferrioxamine | bacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| desipramine | | dibenzoazepine;
secondary amino compound | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 7 | 5 | 0 |
| nordazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| amphetamine | | primary amine | | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| eflornithine | | alpha-amino acid;
fluoroamino acid | trypanocidal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic | 2000 | 2018 | 13.9 | low | 0 | 0 | 1 | 7 | 5 | 0 |
| diazoxide | | benzothiadiazine;
organochlorine compound;
sulfone | antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent | 2000 | 2016 | 13.8 | low | 0 | 0 | 1 | 1 | 3 | 0 |
| dibenzothiophene | | dibenzothiophenes;
mancude organic heterotricyclic parent | keratolytic drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dibucaine | | aromatic ether;
monocarboxylic acid amide;
tertiary amino compound | topical anaesthetic | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diclofenac | | amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound | antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2000 | 2016 | 14.7 | low | 0 | 0 | 1 | 3 | 5 | 0 |
| ddt | | benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide | bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dichlorphenamide | | dichlorobenzene;
sulfonamide | antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| dicyclomine | | carboxylic ester;
tertiary amine | antispasmodic drug;
muscarinic antagonist;
parasympatholytic | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| pentetic acid | | pentacarboxylic acid | copper chelator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diphenidol | | benzenes;
piperidines;
tertiary alcohol | antiemetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diflunisal | | monohydroxybenzoic acid;
organofluorine compound | non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2000 | 2016 | 15.8 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| dilacor xr | | acetate ester;
aromatic ether;
benzothiazepine;
lactam;
tertiary amino compound | | 2011 | 2012 | 12.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| dimercaprol | | dithiol;
primary alcohol | chelator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dimethadione | | oxazolidinone | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diphenhydramine | | ether;
tertiary amino compound | anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative | 2000 | 2016 | 15.2 | low | 0 | 0 | 1 | 5 | 4 | 0 |
| diphenylpyraline | | piperidines;
tertiary amine | cholinergic antagonist;
H1-receptor antagonist | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dipivefrin | | ethanolamines;
pivalate ester | adrenergic agonist;
antiglaucoma drug;
ophthalmology drug;
prodrug;
sympathomimetic agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dipyridamole | | piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol | adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| disopyramide | | monocarboxylic acid amide;
pyridines;
tertiary amino compound | anti-arrhythmia drug | 2000 | 2016 | 15.6 | low | 0 | 0 | 1 | 6 | 4 | 0 |
| disulfiram | | organic disulfide;
organosulfur acaricide | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| valproic acid | | branched-chain fatty acid;
branched-chain saturated fatty acid | anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent | 2000 | 2020 | 14.3 | low | 0 | 0 | 1 | 6 | 5 | 0 |
| domperidone | | benzimidazoles;
heteroarylpiperidine | antiemetic;
dopaminergic antagonist | 2000 | 2014 | 15.4 | low | 0 | 0 | 1 | 1 | 3 | 0 |
| donepezil | | aromatic ether;
indanones;
piperidines;
racemate | EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent | 2010 | 2019 | 10.9 | low | 0 | 0 | 0 | 1 | 8 | 0 |
| doxapram | | morpholines;
pyrrolidin-2-ones | central nervous system stimulant | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| doxazosin | | aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines | alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent | 2000 | 2016 | 16.2 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| doxepin | | dibenzooxepine;
tertiary amino compound | antidepressant | 2000 | 2016 | 15.3 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| doxylamine | | pyridines;
tertiary amine | anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| droperidol | | aromatic ketone;
benzimidazoles;
organofluorine compound | anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 2003 | 2016 | 14.8 | low | 0 | 0 | 0 | 5 | 4 | 0 |
| dyclonine | | aromatic ketone;
piperidines | topical anaesthetic | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| dyphylline | | oxopurine;
propane-1,2-diols | bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| e 4031 | | sulfonamide | | 2003 | 2011 | 17.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| ebastine | | organic molecular entity | | 2005 | 2013 | 14.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ebselen | | benzoselenazole | anti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| econazole | | dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes | | 2004 | 2012 | 15.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| edrophonium | | phenols;
quaternary ammonium ion | antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enflurane | | ether;
organochlorine compound;
organofluorine compound | anaesthetic | 2004 | 2010 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| enoxacin | | 1,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor | 2004 | 2013 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| epinastine | | benzazepine;
guanidines | anti-allergic agent;
H1-receptor antagonist;
histamine antagonist;
ophthalmology drug | 2003 | 2008 | 18.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| estazolam | | triazoles;
triazolobenzodiazepine | anticonvulsant;
anxiolytic drug;
GABA modulator | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ethacrynic acid | | aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid | EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic | 2010 | 2016 | 10.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| ethenzamide | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ether | | ether;
volatile organic compound | inhalation anaesthetic;
non-polar solvent;
refrigerant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| profenamine | | phenothiazines;
tertiary amino compound | adrenergic antagonist;
antidyskinesia agent;
antiparkinson drug;
histamine antagonist;
muscarinic antagonist | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ethosuximide | | dicarboximide;
pyrrolidinone | anticonvulsant;
geroprotector;
T-type calcium channel blocker | 2000 | 2016 | 13.8 | low | 0 | 0 | 1 | 0 | 3 | 0 |
| ethotoin | | imidazolidine-2,4-dione | anticonvulsant | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ethoxzolamide | | aromatic ether;
benzothiazoles;
sulfonamide | antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethyl loflazepate | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etidronate | | 1,1-bis(phosphonic acid) | antineoplastic agent;
bone density conservation agent;
chelator | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| etilefrine | | phenols | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| etizolam | | organic molecular entity | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| etodolac | | monocarboxylic acid;
organic heterotricyclic compound | antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2000 | 2016 | 16.5 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| brl 42810 | | 2-aminopurines;
acetate ester | antiviral drug;
prodrug | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| felbamate | | carbamate ester | anticonvulsant;
neuroprotective agent | 2004 | 2016 | 13.3 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| 4-biphenylylacetic acid | | biphenyls;
monocarboxylic acid | non-steroidal anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| felodipine | | dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester | anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| fendiline | | diarylmethane | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenfluramine | | (trifluoromethyl)benzenes;
secondary amino compound | appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor | 2000 | 2008 | 20.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| fenofibrate | | aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2006 | 2016 | 12.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| fenoldopam | | benzazepine | alpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| fenoprofen | | monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2005 | 2016 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| berotek | | resorcinols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent | 2000 | 2012 | 17.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| fentanyl | | anilide;
monocarboxylic acid amide;
piperidines | adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 2004 | 2014 | 15.5 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| fexofenadine | | piperidines;
tertiary amine | anti-allergic agent;
H1-receptor antagonist | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| fipexide | | benzodioxoles | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flavoxate | | carboxylic ester;
flavones;
piperidines;
tertiary amino compound | antispasmodic drug;
muscarinic antagonist;
parasympatholytic | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| flecainide | | aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines | anti-arrhythmia drug | 2000 | 2016 | 15.7 | low | 0 | 0 | 1 | 6 | 4 | 0 |
| fleroxacin | | difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines | antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor | 2013 | 2014 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| fluconazole | | conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug | environmental contaminant;
P450 inhibitor;
xenobiotic | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 4 | 3 | 0 |
| flucytosine | | aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone | prodrug | 2000 | 2016 | 15.5 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| flufenamic acid | | aromatic amino acid;
organofluorine compound | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2005 | 2014 | 14.8 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| fluphenazine | | N-alkylpiperazine;
organofluorine compound;
phenothiazines | anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 1994 | 2016 | 18.4 | low | 0 | 0 | 1 | 4 | 2 | 0 |
| flumazenil | | ethyl ester;
imidazobenzodiazepine;
organofluorine compound | antidote to benzodiazepine poisoning;
GABA antagonist | 2000 | 2016 | 14.9 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| flumequine | | 3-oxo monocarboxylic acid;
organofluorine compound;
pyridoquinoline;
quinolone antibiotic | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flunitrazepam | | 1,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes | anxiolytic drug;
GABAA receptor agonist;
sedative | 2000 | 2010 | 17.8 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| fluorescite | | benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye | fluorescent dye;
radioopaque medium | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| fluorouracil | | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| fluoxetine | | (trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound | | 2000 | 2016 | 15.2 | low | 0 | 0 | 1 | 9 | 6 | 0 |
| fluphenazine depot | | decanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| fluphenazine enanthate | | phenothiazines | | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| flurazepam | | 1,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound | anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| flurbiprofen | | fluorobiphenyl;
monocarboxylic acid | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2000 | 2016 | 15.3 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| fluspirilene | | diarylmethane | | 1996 | 2014 | 19.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| flutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide | androgen antagonist;
antineoplastic agent | 2004 | 2016 | 12.9 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| flutazolam | | hemiaminal ether;
organic molecular entity | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| fomepizole | | pyrazoles | antidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| foscarnet | | carboxylic acid;
one-carbon compound;
phosphonic acids | antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| furosemide | | chlorobenzoic acid;
furans;
sulfonamide | environmental contaminant;
loop diuretic;
xenobiotic | 2000 | 2016 | 14.4 | low | 0 | 0 | 1 | 5 | 6 | 0 |
| gabapentin | | gamma-amino acid | anticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| gemfibrozil | | aromatic ether | antilipemic drug | 2000 | 2016 | 15.9 | low | 0 | 0 | 1 | 4 | 2 | 0 |
| glafenine | | aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound | inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 11.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| gliclazide | | N-sulfonylurea | hypoglycemic agent;
insulin secretagogue;
radical scavenger | 2008 | 2013 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| glimepiride | | sulfonamide | | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| glipizide | | aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines | EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue | 2000 | 2016 | 15.8 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| glutethimide | | piperidines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glyburide | | monochlorobenzenes;
N-sulfonylurea | anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent | 2000 | 2016 | 14.8 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester | | benzenes | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| go 6976 | | indolocarbazole;
organic heterohexacyclic compound | EC 2.7.11.13 (protein kinase C) inhibitor | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gossypol | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| granisetron | | aromatic amide;
indazoles | | 2004 | 2016 | 14.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| guaiazulene | | sesquiterpene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| guaifenesin | | methoxybenzenes | | 2012 | 2016 | 10.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| guanethidine | | azocanes;
guanidines | adrenergic antagonist;
antihypertensive agent;
sympatholytic agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| guanfacine | | acetamides | | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| guanidine | | carboxamidine;
guanidines;
one-carbon compound | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fasudil | | isoquinolines;
N-sulfonyldiazepane | antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 1994 | 2020 | 16.4 | low | 0 | 0 | 7 | 23 | 14 | 0 |
| halothane | | haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound | inhalation anaesthetic | 2004 | 2010 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| hexachlorophene | | bridged diphenyl fungicide;
polyphenol;
trichlorobenzene | acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| miltefosine | | phosphocholines;
phospholipid | anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexestrol | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexetidine | | organic heteromonocyclic compound;
organonitrogen heterocyclic compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexobarbital | | barbiturates | | 2000 | 2010 | 18.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| hexoprenaline | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hexylresorcinol | | resorcinols | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexamethylene bisacetamide | | acetamides | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| homochlorocyclizine | | diarylmethane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hycanthone | | thioxanthenes | mutagen;
schistosomicide drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| hydralazine | | azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines | antihypertensive agent;
vasodilator agent | 2000 | 2016 | 14.3 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| hydrochlorothiazide | | benzothiadiazine;
organochlorine compound;
sulfonamide | antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| hydroflumethiazide | | benzothiadiazine;
thiazide | antihypertensive agent;
diuretic | 2008 | 2016 | 11.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| hydroxychloroquine | | aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug | 2016 | 2020 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| hydroxyurea | | one-carbon compound;
ureas | antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| hydroxyzine | | hydroxyether;
monochlorobenzenes;
N-alkylpiperazine | anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist | 2004 | 2016 | 14.1 | low | 0 | 0 | 0 | 5 | 3 | 0 |
| ibuprofen | | monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic | 2000 | 2016 | 14.8 | low | 0 | 0 | 1 | 4 | 4 | 0 |
| phenelzine | | primary amine | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| lidocaine | | benzenes;
monocarboxylic acid amide;
tertiary amino compound | anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic | 2000 | 2016 | 14.1 | low | 0 | 0 | 1 | 5 | 4 | 0 |
| mephentermine | | amphetamines | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alverine | | tertiary amine | antispasmodic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| idebenone | | 1,4-benzoquinones;
primary alcohol | antioxidant;
ferroptosis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ifenprodil | | piperidines | | 2011 | 2020 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ifosfamide | | ifosfamides | alkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| imetit | | imidazoles;
imidothiocarbamic ester | H3-receptor agonist;
H4-receptor agonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imipramine | | dibenzoazepine | adrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2000 | 2019 | 13.1 | low | 0 | 0 | 1 | 8 | 11 | 0 |
| amrinone | | bipyridines | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| indapamide | | indoles;
organochlorine compound;
sulfonamide | antihypertensive agent;
diuretic | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 2000 | 2020 | 13.3 | low | 0 | 0 | 1 | 3 | 8 | 0 |
| iodamide | | benzoic acids;
organoiodine compound | radioopaque medium | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iodixanol | | organoiodine compound | radioopaque medium | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iodoquinol | | monohydroxyquinoline;
organoiodine compound | antiamoebic agent;
antibacterial agent;
antiprotozoal drug;
antiseptic drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| iohexol | | benzenedicarboxamide;
organoiodine compound | environmental contaminant;
radioopaque medium;
xenobiotic | 2004 | 2013 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| iopromide | | dicarboxylic acid diamide;
organoiodine compound | environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iothalamic acid | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iodipamide | | benzoic acids;
organoiodine compound;
secondary carboxamide | radioopaque medium | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ioversol | | amidobenzoic acid | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| iproniazid | | carbohydrazide;
pyridines | | 2010 | 2016 | 11.4 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| avapro | | azaspiro compound;
biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| isocarboxazid | | benzenes | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| isoetharine | | catecholamine | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| isoflurane | | organofluorine compound | inhalation anaesthetic | 2004 | 2010 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| isoniazid | | carbohydrazide | antitubercular agent;
drug allergen | 2000 | 2016 | 14.6 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| isopropamide iodide | | diarylmethane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-propanol | | secondary alcohol;
secondary fatty alcohol | protic solvent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 2000 | 2016 | 14.3 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| isoxsuprine | | alkylbenzene | | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| isradipine | | benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester | | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| itraconazole | | piperazines | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ketamine | | cyclohexanones;
monochlorobenzenes;
secondary amino compound | analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic | 2000 | 2016 | 14.2 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| ketanserin | | aromatic ketone;
organofluorine compound;
piperidines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 1998 | 2014 | 16.5 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| ketoconazole | | dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine | | 2003 | 2016 | 14.5 | low | 0 | 0 | 0 | 8 | 6 | 0 |
| ketoprofen | | benzophenones;
oxo monocarboxylic acid | antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic | 2000 | 2016 | 15.8 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| ketorolac | | amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate | analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2000 | 2016 | 15.2 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| ketotifen | | cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound | anti-asthmatic drug;
H1-receptor antagonist | 2005 | 2012 | 15.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| khellin | | furanochromone;
organic heterotricyclic compound;
oxacycle | anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| labetalol | | benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound | | 2000 | 2016 | 14.5 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| lamotrigine | | 1,2,4-triazines;
dichlorobenzene;
primary arylamine | anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic | 2000 | 2016 | 14.8 | low | 0 | 0 | 1 | 4 | 3 | 0 |
| lansoprazole | | benzimidazoles;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| beta-lapachone | | benzochromenone;
orthoquinones | anti-inflammatory agent;
antineoplastic agent;
plant metabolite | 2006 | 2010 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| leflunomide | | (trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide | antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| letrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2006 | 2016 | 12.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| lidoflazine | | diarylmethane | | 2005 | 2011 | 16.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lofepramine | | aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound | antidepressant | 2000 | 2013 | 16.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| lomefloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antimicrobial agent;
antitubercular agent;
photosensitizing agent | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| lomustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| loperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| loratadine | | benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide | anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist | 2003 | 2020 | 14.2 | low | 0 | 0 | 0 | 5 | 4 | 0 |
| lorazepam | | benzodiazepine | | 2000 | 2016 | 16.2 | low | 0 | 0 | 1 | 4 | 1 | 0 |
| losartan | | biphenylyltetrazole;
imidazoles | angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| loxapine | | dibenzooxazepine | antipsychotic agent;
dopaminergic antagonist | 1994 | 2016 | 19.2 | low | 0 | 0 | 3 | 7 | 2 | 0 |
| ly 171883 | | acetophenones;
aromatic ether;
phenols;
tetrazoles | anti-asthmatic drug;
leukotriene antagonist | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | | chromones;
morpholines;
organochlorine compound | autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mabuterol | | (trifluoromethyl)benzenes | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| malathion | | diester;
ethyl ester;
organic thiophosphate | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diisopropyl 1,3-dithiol-2-ylidenemalonate | | isopropyl ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| maprotiline | | anthracenes | | 2000 | 2016 | 14.6 | low | 0 | 0 | 1 | 4 | 4 | 0 |
| mazindol | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mebendazole | | aromatic ketone;
benzimidazoles;
carbamate ester | antinematodal drug;
microtubule-destabilising agent;
tubulin modulator | 2000 | 2016 | 15.3 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| mecamylamine | | primary aliphatic amine | | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mechlorethamine | | nitrogen mustard;
organochlorine compound | alkylating agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| meclizine | | diarylmethane | | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| meclofenamic acid | | aminobenzoic acid;
organochlorine compound;
secondary amino compound | analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 2004 | 2016 | 13.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| meclofenoxate | | monocarboxylic acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mefenamic acid | | aminobenzoic acid;
secondary amino compound | analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic | 2004 | 2016 | 13.4 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| mefloquine hydrochloride | | organofluorine compound;
piperidines;
quinolines;
secondary alcohol | | 2003 | 2011 | 17.8 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| memantine | | adamantanes;
primary aliphatic amine | antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| vitamin k 3 | | 1,4-naphthoquinones;
vitamin K | angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| mepenzolate | | diarylmethane | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| meperidine | | ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound | antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic | 2000 | 2016 | 14.3 | low | 0 | 0 | 1 | 2 | 4 | 0 |
| mephenesin | | aromatic ether;
glycerol ether | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mephenytoin | | imidazolidine-2,4-dione | anticonvulsant | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| mepivacaine | | piperidinecarboxamide | drug allergen;
local anaesthetic | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| meprobamate | | organic molecular entity | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| benzoic acid [2-methyl-2-(propylamino)propyl] ester | | benzoate ester | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| mesalamine | | amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols | non-steroidal anti-inflammatory drug | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| mesoridazine | | phenothiazines;
sulfoxide;
tertiary amino compound | dopaminergic antagonist;
first generation antipsychotic | 2003 | 2016 | 14.8 | low | 0 | 0 | 0 | 6 | 3 | 0 |
| metaproterenol | | aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound | | 2000 | 2016 | 14.7 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| metformin | | guanidines | environmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic | 2004 | 2020 | 12.1 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| methadone | | benzenes;
diarylmethane;
ketone;
tertiary amino compound | | 2000 | 2016 | 16.8 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| methapyrilene | | ethylenediamine derivative | anti-allergic agent;
carcinogenic agent;
H1-receptor antagonist;
sedative | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| methazolamide | | sulfonamide;
thiadiazoles | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methiothepin | | aryl sulfide;
dibenzothiepine;
N-alkylpiperazine;
tertiary amino compound | antipsychotic agent;
dopaminergic antagonist;
geroprotector;
serotonergic antagonist | 1996 | 2019 | 16.2 | low | 0 | 0 | 3 | 1 | 5 | 0 |
| methocarbamol | | aromatic ether;
carbamate ester;
secondary alcohol | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| methoctramine | | aromatic ether;
tetramine | muscarinic antagonist | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methoxsalen | | aromatic ether;
psoralens | antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| methoxyflurane | | ether;
organochlorine compound;
organofluorine compound | hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methoxyphenamine | | amphetamines | beta-adrenergic agonist;
bronchodilator agent | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methyclothiazide | | benzothiadiazine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methyl salicylate | | benzoate ester;
methyl ester;
salicylates | flavouring agent;
insect attractant;
metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3-Hydroxy-alpha-methyl-DL-tyrosine | | benzenes;
monocarboxylic acid | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methylphenidate | | beta-amino acid ester;
methyl ester;
piperidines | | 2008 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| methyprylon | | organic molecular entity | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| metoclopramide | | benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound | antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic | 2000 | 2016 | 14.6 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| metolazone | | organochlorine compound;
quinazolines;
sulfonamide | antihypertensive agent;
diuretic;
ion transport inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metoprolol | | aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound | antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic | 2000 | 2016 | 14.9 | low | 0 | 0 | 1 | 5 | 3 | 0 |
| metronidazole | | C-nitro compound;
imidazoles;
primary alcohol | antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic | 2000 | 2016 | 15.5 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| metyrapone | | aromatic ketone | antimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| mexiletine | | aromatic ether;
primary amino compound | anti-arrhythmia drug | 2000 | 2016 | 14.3 | low | 0 | 0 | 1 | 1 | 4 | 0 |
| mianserin | | dibenzoazepine | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist | 1996 | 2020 | 13.4 | low | 0 | 0 | 2 | 4 | 5 | 0 |
| miconazole | | dichlorobenzene;
ether;
imidazoles | | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| midazolam | | imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative | 2000 | 2016 | 15.3 | low | 0 | 0 | 1 | 6 | 2 | 0 |
| midodrine | | amino acid amide;
aromatic ether;
secondary alcohol | alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent | 2004 | 2016 | 13.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| milrinone | | bipyridines;
nitrile;
pyridone | cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 2000 | 2016 | 16.7 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| minaprine | | morpholines;
pyridazines;
secondary amine | antidepressant;
antiparkinson drug;
cholinergic drug;
dopamine uptake inhibitor;
serotonin uptake inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| minoxidil | | dialkylarylamine;
tertiary amino compound | | 2004 | 2020 | 11.6 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| mirtazapine | | benzazepine;
tetracyclic antidepressant | alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 6 | 3 | 0 |
| mitotane | | diarylmethane | | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| mitoxantrone | | dihydroxyanthraquinone | analgesic;
antineoplastic agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| moclobemide | | benzamides;
monochlorobenzenes;
morpholines | antidepressant;
environmental contaminant;
xenobiotic | 2000 | 2013 | 15.4 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| modafinil | | monocarboxylic acid amide;
sulfoxide | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| moxisylyte | | monoterpenoid | | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| deet | | benzamides;
monocarboxylic acid amide | environmental contaminant;
insect repellent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-(3-trifluoromethylphenyl)piperazine | | (trifluoromethyl)benzenes;
N-arylpiperazine | environmental contaminant;
psychotropic drug;
serotonergic agonist;
xenobiotic | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| acecainide | | acetamides;
benzamides | anti-arrhythmia drug | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| nabumetone | | methoxynaphthalene;
methyl ketone | cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 2000 | 2016 | 16.5 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| nadolol | | tetralins | | 2012 | 2016 | 10.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| nafamostat | | benzoic acids;
guanidines | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nafronyl | | naphthalenes | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| naftopidil | | piperazines | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nalidixic acid | | 1,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic | antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| nan 190 | | N-alkylpiperazine;
N-arylpiperazine;
phthalimides | serotonergic antagonist | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| naphazoline | | naphthalenes | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| naratriptan | | heteroarylpiperidine;
sulfonamide;
tryptamines | serotonergic agonist;
vasoconstrictor agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nefazodone | | aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles | alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 5 | 5 | 0 |
| nefopam | | benzoxazocine;
tertiary amino compound | | 2009 | 2013 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| neostigmine | | quaternary ammonium ion | antidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| nevirapine | | cyclopropanes;
dipyridodiazepine | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2000 | 2016 | 14.2 | low | 0 | 0 | 1 | 2 | 5 | 0 |
| nialamide | | organonitrogen compound;
organooxygen compound | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nicardipine | | benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound | | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 1 | 3 | 0 |
| niceritrol | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| niclosamide | | benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide | anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nifedipine | | C-nitro compound;
dihydropyridine;
methyl ester | calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent | 2000 | 2016 | 15.5 | low | 0 | 0 | 1 | 5 | 5 | 0 |
| niflumic acid | | aromatic carboxylic acid;
pyridines | | 2005 | 2010 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| nilutamide | | (trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone | androgen antagonist;
antineoplastic agent | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| nilvadipine | | dihydropyridine;
isopropyl ester;
methyl ester;
nitrile | | 2000 | 2012 | 18.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| nimesulide | | aromatic ether;
C-nitro compound;
sulfonamide | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| nimetazepam | | 1,4-benzodiazepinone;
C-nitro compound | anticonvulsant;
antispasmodic drug;
GABA modulator;
sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nimodipine | | 2-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester | antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent | 2000 | 2016 | 15.5 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| nisoldipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester | | 2000 | 2016 | 14.8 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| nisoxetine | | aromatic ether;
secondary amino compound | adrenergic uptake inhibitor;
antidepressant | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitrazepam | | 1,4-benzodiazepinone;
C-nitro compound | anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative | 2000 | 2013 | 16.2 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| nitrendipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester | antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent | 2000 | 2013 | 16.8 | low | 0 | 0 | 1 | 5 | 2 | 0 |
| nitroglycerin | | nitroglycerol | explosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nitromide | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nizatidine | | 1,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound | anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist | 2000 | 2016 | 16.5 | medium | 0 | 0 | 1 | 2 | 1 | 0 |
| nomifensine | | isoquinolines | dopamine uptake inhibitor | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| masoprocol | | catechols;
lignan;
tetrol | antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| norfloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic | 2004 | 2016 | 12.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| norfluoxetine | | (trifluoromethyl)benzenes | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nortriptyline | | organic tricyclic compound;
secondary amine | adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite | 2000 | 2016 | 15.2 | low | 0 | 0 | 1 | 5 | 3 | 0 |
| 6,7-dimethoxy-3-(4-methoxy-6-methyl-7,8-dihydro-5H-[1,3]dioxolo[4,5-g]isoquinolin-5-yl)-3H-isobenzofuran-1-one | | isoquinolines | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| nylidrin | | alkylbenzene | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ofloxacin | | 3-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline | | 2003 | 2016 | 14.4 | low | 0 | 0 | 0 | 5 | 6 | 0 |
| omeprazole | | aromatic ether;
benzimidazoles;
pyridines;
sulfoxide | | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| ondansetron | | carbazoles | | 2000 | 2016 | 16.0 | low | 0 | 0 | 1 | 6 | 3 | 0 |
| orphenadrine | | ether;
tertiary amino compound | antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| oxamniquine | | aromatic primary alcohol;
C-nitro compound;
quinolines;
secondary amino compound | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| oxaprozin | | 1,3-oxazoles;
monocarboxylic acid | analgesic;
non-steroidal anti-inflammatory drug | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| oxazepam | | 1,4-benzodiazepinone;
organochlorine compound | anxiolytic drug;
environmental contaminant;
xenobiotic | 2000 | 2016 | 16.2 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| oxethazaine | | amino acid amide | | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| oxibendazole | | benzimidazoles;
carbamate ester | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxolinic acid | | aromatic carboxylic acid;
organic heterotricyclic compound;
oxacycle;
quinolinemonocarboxylic acid;
quinolone antibiotic | antibacterial drug;
antifungal agent;
antiinfective agent;
antimicrobial agent;
enzyme inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxotremorine | | N-alkylpyrrolidine | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxprenolol | | aromatic ether | | 2000 | 2014 | 15.2 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| oxybenzone | | hydroxybenzophenone;
monomethoxybenzene | dermatologic drug;
environmental contaminant;
protective agent;
ultraviolet filter;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benoxinate | | amino acid ester;
benzoate ester;
substituted aniline;
tertiary amino compound | drug allergen;
local anaesthetic;
topical anaesthetic | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxybutynin | | acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound | antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic | 2012 | 2016 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| oxymetazoline | | carboxamidine;
imidazolines;
phenols | alpha-adrenergic agonist;
nasal decongestant;
sympathomimetic agent;
vasoconstrictor agent | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxyphenbutazone | | phenols;
pyrazolidines | antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| aminosalicylic acid | | aminobenzoic acid;
phenols | antitubercular agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| pamidronate | | phosphonoacetic acid | | 2004 | 2016 | 13.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| pantoprazole | | aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| papaverine | | benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines | antispasmodic drug;
vasodilator agent | 2009 | 2016 | 11.8 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| pargyline | | aromatic amine | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| patulin | | furopyran;
gamma-lactone;
lactol | antimicrobial agent;
Aspergillus metabolite;
carcinogenic agent;
mutagen;
mycotoxin;
Penicillium metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pd 153035 | | aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound | EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pd 158780 | | aromatic amine;
bromobenzenes;
diamine;
pyridopyrimidine;
secondary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pd 98059 | | aromatic amine;
monomethoxyflavone | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pemoline | | 1,3-oxazoles | central nervous system stimulant | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| pentamidine | | aromatic ether;
carboxamidine;
diether | anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| pentobarbital | | barbiturates | GABAA receptor agonist | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| pentoxifylline | | oxopurine | | 2000 | 2016 | 15.5 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| perazine | | N-alkylpiperazine;
N-methylpiperazine;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perhexiline | | piperidines | cardiovascular drug | 2003 | 2016 | 14.0 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| periciazine | | hydroxypiperidine;
nitrile;
phenothiazines | adrenergic antagonist;
first generation antipsychotic;
sedative | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| perphenazine | | N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines | antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 1994 | 2016 | 17.3 | low | 0 | 0 | 2 | 6 | 3 | 0 |
| phenacemide | | acetamides | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phenacetin | | acetamides;
aromatic ether | cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| phenazopyridine | | diaminopyridine;
monoazo compound | anticoronaviral agent;
carcinogenic agent;
local anaesthetic;
non-narcotic analgesic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenindione | | aromatic ketone;
beta-diketone | anticoagulant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pheniramine | | pyridines;
tertiary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenobarbital | | barbiturates | anticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative | 2000 | 2016 | 14.7 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| phenolphthalein | | phenols | | 2000 | 2010 | 18.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| phenoxybenzamine | | aromatic amine | | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| phentermine | | primary amine | adrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| 4-phenylbutyric acid | | monocarboxylic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenylbutazone | | pyrazolidines | antirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug | 2000 | 2012 | 17.2 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| moxonidine | | organohalogen compound;
pyrimidines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate | | pyrroloindole | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pilsicainide | | organic heterobicyclic compound;
secondary carboxamide | anti-arrhythmia drug;
sodium channel blocker | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pinacidil | | pyridines | | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pindolol | | indoles;
secondary amine | antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 5 | 3 | 0 |
| pioglitazone | | aromatic ether;
pyridines;
thiazolidinediones | antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic | 2006 | 2020 | 11.1 | low | 0 | 0 | 0 | 1 | 6 | 0 |
| pipamperone | | aromatic ketone;
bipiperidines;
monocarboxylic acid amide;
organofluorine compound;
tertiary amino compound | dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| pipemidic acid | | amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piperazine | | azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent | anthelminthic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piracetam | | organonitrogen compound;
organooxygen compound | | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| pirbuterol | | pyridines | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pirenperone | | aromatic ketone | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pirenzepine | | pyridobenzodiazepine | anti-ulcer drug;
antispasmodic drug;
muscarinic antagonist | 2000 | 2014 | 15.3 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| piretanide | | aromatic ether | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piribedil | | N-arylpiperazine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| polythiazide | | benzothiadiazine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| practolol | | acetamides;
ethanolamines;
propanolamine;
secondary alcohol;
secondary amino compound | anti-arrhythmia drug;
beta-adrenergic antagonist | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| duodote | | pyridinium ion | antidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator | 2012 | 2016 | 10.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| ono 1078 | | chromones | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyranoprofen | | pyridochromene | | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| prazepam | | benzodiazepine | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| praziquantel | | isoquinolines | | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| prazosin | | aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2000 | 2016 | 14.6 | low | 0 | 0 | 1 | 3 | 5 | 0 |
| primaquine | | aminoquinoline;
aromatic ether;
N-substituted diamine | antimalarial | 2000 | 2016 | 13.4 | low | 0 | 0 | 1 | 2 | 4 | 0 |
| primidone | | pyrimidone | anticonvulsant;
environmental contaminant;
xenobiotic | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| proadifen | | diarylmethane | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| probenecid | | benzoic acids;
sulfonamide | uricosuric drug | 2000 | 2016 | 14.9 | low | 0 | 0 | 1 | 4 | 4 | 0 |
| probucol | | dithioketal;
polyphenol | anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug | 2000 | 2012 | 16.7 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| procainamide | | benzamides | anti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker | 2000 | 2016 | 14.8 | low | 0 | 0 | 1 | 4 | 5 | 0 |
| procaine | | benzoate ester;
substituted aniline;
tertiary amino compound | central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug | 2009 | 2014 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| procarbazine | | benzamides;
hydrazines | antineoplastic agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| prochlorperazine | | N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines | alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic | 2000 | 2016 | 13.5 | low | 0 | 0 | 1 | 1 | 4 | 0 |
| procyclidine | | pyrrolidines;
tertiary alcohol | antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist | 2000 | 2016 | 14.3 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| proglumide | | benzamides;
dicarboxylic acid monoamide;
glutamine derivative;
racemate | anti-ulcer drug;
cholecystokinin antagonist;
cholinergic antagonist;
delta-opioid receptor agonist;
drug metabolite;
gastrointestinal drug;
opioid analgesic;
xenobiotic metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| promazine | | phenothiazines;
tertiary amine | antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist | 2008 | 2014 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| promethazine | | phenothiazines;
tertiary amine | anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative | 2000 | 2016 | 13.8 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| propafenone | | aromatic ketone;
secondary alcohol;
secondary amino compound | anti-arrhythmia drug | 2000 | 2016 | 14.2 | low | 0 | 0 | 1 | 1 | 4 | 0 |
| propantheline | | xanthenes | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| propiomazine | | aromatic ketone;
phenothiazines;
tertiary amino compound | dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
sedative;
serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propofol | | phenols | anticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative | 2004 | 2016 | 15.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 2000 | 2018 | 13.5 | low | 0 | 0 | 1 | 5 | 7 | 0 |
| protriptyline | | carbotricyclic compound | antidepressant | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| proxyphylline | | oxopurine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridinolcarbamate | | pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridostigmine | | pyridinium ion | | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| pyrilamine | | aromatic ether;
ethylenediamine derivative | H1-receptor antagonist | 2009 | 2014 | 12.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| pyrimethamine | | aminopyrimidine;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| sch 16134 | | benzodiazepine | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| quetiapine | | dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine | adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist | 1996 | 2021 | 18.2 | high | 0 | 0 | 3 | 11 | 2 | 1 |
| quipazine | | piperazines;
pyridines | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rabeprazole | | benzimidazoles;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| raloxifene | | 1-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols | bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 2000 | 2016 | 15.5 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| ranitidine | | aralkylamine | | 2000 | 2014 | 15.1 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| opc 12759 | | secondary carboxamide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| riluzole | | benzothiazoles | | 2000 | 2016 | 14.7 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| rimantadine | | alkylamine | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| risperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist | 1994 | 2016 | 18.6 | low | 0 | 0 | 11 | 23 | 8 | 0 |
| ritanserin | | organofluorine compound;
piperidines;
thiazolopyrimidine | antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 1996 | 2009 | 21.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| rizatriptan | | tryptamines | anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| rofecoxib | | butenolide;
sulfone | analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2006 | 2013 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| rolipram | | pyrrolidin-2-ones | antidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ropinirole | | indolones;
tertiary amine | antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| roxarsone | | 2-nitrophenols;
organoarsonic acid | agrochemical;
animal growth promotant;
antibacterial drug;
coccidiostat | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| salicylamide | | phenols;
salicylamides | antirheumatic drug;
non-narcotic analgesic | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| salmeterol xinafoate | | ether;
phenols;
primary alcohol;
secondary alcohol;
secondary amino compound | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| salicylsalicylic acid | | benzoate ester;
benzoic acids;
phenols;
salicylates | antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| sb 206553 | | pyrroloindole | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| secobarbital | | barbiturates | anaesthesia adjuvant;
GABA modulator;
sedative | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sevoflurane | | ether;
organofluorine compound | central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor | 2004 | 2010 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| sibutramine | | organochlorine compound;
tertiary amino compound | anti-obesity agent;
serotonin uptake inhibitor | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| sulfadiazine | | pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic | 2000 | 2016 | 14.8 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| ipodate | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| risedronic acid | | pyridines | | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sotalol | | ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide | anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| 4-phenylbutyric acid, sodium salt | | organic sodium salt | EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| spiperone | | aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound | alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist | 1994 | 2015 | 19.3 | low | 0 | 0 | 3 | 1 | 2 | 0 |
| spiroxatrine | | imidazolidines | | 1998 | 2009 | 20.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| imatinib | | aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines | antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 2006 | 2016 | 12.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| vorinostat | | dicarboxylic acid diamide;
hydroxamic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| succinylcholine | | quaternary ammonium ion;
succinate ester | drug allergen;
muscle relaxant;
neuromuscular agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| succinylsulfathiazole | | 1,3-thiazoles | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulconazole | | dichlorobenzene;
imidazoles;
monochlorobenzenes;
organic sulfide | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfacetamide | | N-sulfonylcarboxamide;
substituted aniline | antibacterial drug;
antiinfective agent;
antimicrobial agent;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulfadimethoxine | | aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| sulfamerazine | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
drug allergen | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sulfameter | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
leprostatic drug;
renal agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfamethazine | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sulfamethizole | | sulfonamide antibiotic;
sulfonamide;
thiadiazoles | antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| sulfamethoxazole | | isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic | 2000 | 2013 | 15.0 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| sulfanilamide | | substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfanitran | | sulfonamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulfaphenazole | | primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sulfapyridine | | pyridines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfasalazine | | | | 2004 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| sulfathiazole | | 1,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic | 2004 | 2016 | 15.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| sulfinpyrazone | | pyrazolidines;
sulfoxide | uricosuric drug | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| sulfisoxazole | | isoxazoles;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
drug allergen | 2000 | 2013 | 17.2 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| sulfobromophthalein | | 2-benzofurans;
organobromine compound;
organosulfonic acid;
phenols | dye | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol | | alkylbenzene | | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| sulpiride | | benzamides;
N-alkylpyrrolidine;
sulfonamide | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 1998 | 2012 | 17.0 | low | 0 | 0 | 2 | 2 | 2 | 0 |
| sumatriptan | | sulfonamide;
tryptamines | serotonergic agonist;
vasoconstrictor agent | 1996 | 2016 | 16.1 | low | 0 | 0 | 2 | 5 | 3 | 0 |
| suprofen | | aromatic ketone;
monocarboxylic acid;
thiophenes | antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug | 2004 | 2014 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| suramin | | naphthalenesulfonic acid;
phenylureas;
secondary carboxamide | angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| talipexole | | azepine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gatifloxacin | | N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2003 | 2014 | 14.9 | low | 0 | 0 | 0 | 4 | 3 | 0 |
| tazarotene | | acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane | keratolytic drug;
prodrug;
teratogenic agent | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tegafur | | organohalogen compound;
pyrimidines | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| telenzepine | | benzodiazepine | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| temazepam | | benzodiazepine | | 2000 | 2016 | 17.0 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| temozolomide | | imidazotetrazine;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
prodrug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| terazosin | | furans;
piperazines;
primary amino compound;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 2000 | 2016 | 14.9 | low | 0 | 0 | 1 | 2 | 4 | 0 |
| terbutaline | | phenylethanolamines;
resorcinols | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent | 2000 | 2016 | 13.8 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| terfenadine | | diarylmethane | | 2003 | 2014 | 15.4 | low | 0 | 0 | 0 | 7 | 4 | 0 |
| tetracaine | | benzoate ester;
tertiary amino compound | local anaesthetic | 2009 | 2014 | 12.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| tetrahydroxy-1,4-quinone | | hydroxybenzoquinone | keratolytic drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thalidomide | | phthalimides;
piperidones | | 2006 | 2016 | 13.6 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| thiabendazole | | 1,3-thiazoles;
benzimidazole fungicide;
benzimidazoles | antifungal agrochemical;
antinematodal drug | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| 2-thiosalicylic acid | | sulfanylbenzoic acid | antipyretic;
non-narcotic analgesic | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thioridazine | | phenothiazines;
piperidines | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 1994 | 2016 | 18.5 | low | 0 | 0 | 4 | 12 | 3 | 0 |
| thiotepa | | aziridines | | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| tiapride | | benzamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tiaprofenic acid | | aromatic ketone;
monocarboxylic acid;
thiophenes | drug allergen;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tiaramide | | benzothiazoles | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ticlopidine | | monochlorobenzenes;
thienopyridine | anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2004 | 2016 | 13.6 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| tilorone | | aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound | anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tinidazole | | imidazoles | antiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tioconazole | | dichlorobenzene;
ether;
imidazoles;
thiophenes | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tiopronin | | N-acyl-amino acid | | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| tizanidine | | benzothiadiazole;
imidazoles | alpha-adrenergic agonist;
muscle relaxant | 2000 | 2016 | 15.3 | low | 0 | 0 | 1 | 4 | 2 | 0 |
| nikethamide | | pyridinecarboxamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tolazamide | | N-sulfonylurea | hypoglycemic agent;
potassium channel blocker | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| tolazoline | | imidazoles | alpha-adrenergic antagonist;
antihypertensive agent;
vasodilator agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tolbutamide | | N-sulfonylurea | human metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker | 2000 | 2016 | 14.2 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| tolmetin | | aromatic ketone;
monocarboxylic acid;
pyrroles | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 2000 | 2016 | 14.0 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| tolnaftate | | monothiocarbamic ester | antifungal drug | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tolperisone | | aromatic ketone | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ultram | | aromatic ether;
tertiary alcohol;
tertiary amino compound | | 2000 | 2016 | 16.0 | high | 0 | 0 | 1 | 4 | 1 | 0 |
| tranexamic acid | | amino acid | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| trapidil | | triazolopyrimidines | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trazodone | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine | adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 2000 | 2016 | 14.6 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| triamterene | | pteridines | diuretic;
sodium channel blocker | 2000 | 2016 | 14.3 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| triazolam | | triazolobenzodiazepine | sedative | 2000 | 2016 | 16.5 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| trichlormethiazide | | benzothiadiazine;
sulfonamide antibiotic | antihypertensive agent;
diuretic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triclosan | | aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols | antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trientine | | polyazaalkane;
tetramine | copper chelator | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trifluoperazine | | N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines | antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug | 2003 | 2016 | 15.4 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| trifluperidol | | aromatic ketone | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| triflupromazine | | organofluorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| trihexyphenidyl | | amine | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| trimebutine | | trihydroxybenzoic acid | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| trimeprazine | | phenothiazines | | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| trimethadione | | oxazolidinone | anticonvulsant;
geroprotector | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| trimethobenzamide | | benzamides;
tertiary amino compound | antiemetic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trimethoprim | | aminopyrimidine;
methoxybenzenes | antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic | 2000 | 2016 | 14.7 | low | 0 | 0 | 1 | 4 | 5 | 0 |
| trimetrexate | | | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| trimipramine | | dibenzoazepine;
tertiary amino compound | antidepressant;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| trioxsalen | | psoralens | dermatologic drug;
photosensitizing agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tripelennamine | | aromatic amine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| troglitazone | | chromanes;
thiazolidinone | anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent | 2005 | 2016 | 13.8 | low | 0 | 0 | 0 | 4 | 4 | 0 |
| tropicamide | | acetamides | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thenoyltrifluoroacetone | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tulobuterol | | organochlorine compound | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tyramine | | monoamine molecular messenger;
primary amino compound;
tyramines | EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| delavirdine | | aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| undecylenic acid | | undecenoic acid | antifungal drug;
plant metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| urapidil | | piperazines | | 2000 | 2013 | 15.7 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| urethane | | carbamate ester | fungal metabolite;
mutagen | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| venlafaxine | | cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound | adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic | 2000 | 2016 | 14.2 | medium | 0 | 0 | 1 | 5 | 5 | 0 |
| vesnarinone | | organic molecular entity | | 2003 | 2011 | 16.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| vigabatrin | | gamma-amino acid | anticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| n-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-n-(2-pyridinyl)cyclohexanecarboxamide | | piperazines | | 1998 | 2019 | 15.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| wb 4101 | | aromatic ether;
benzodioxine;
secondary amino compound | alpha-adrenergic antagonist | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pirinixic acid | | aryl sulfide;
organochlorine compound;
pyrimidines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| xylazine | | 1,3-thiazine;
methylbenzene;
secondary amino compound | alpha-adrenergic agonist;
analgesic;
emetic;
muscle relaxant;
sedative | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| xylometazoline | | alkylbenzene | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ici 204,219 | | carbamate ester;
indoles;
N-sulfonylcarboxamide | anti-asthmatic agent;
leukotriene antagonist | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| zaleplon | | nitrile;
pyrazolopyrimidine | anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| zm 336372 | | benzamides | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zolpidem | | imidazopyridine | central nervous system depressant;
GABA agonist;
sedative | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| zomepirac | | aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles | cardiovascular drug;
non-steroidal anti-inflammatory drug | 2004 | 2012 | 16.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| zonisamide | | 1,2-benzoxazoles;
sulfonamide | anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker | 2006 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| zopiclone | | monochloropyridine;
pyrrolopyrazine | central nervous system depressant;
sedative | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| zotepine | | dibenzothiepine;
tertiary amino compound | alpha-adrenergic drug;
second generation antipsychotic;
serotonergic drug | 1994 | 2009 | 22.7 | low | 0 | 0 | 3 | 4 | 0 | 0 |
| guanidine hydrochloride | | one-carbon compound;
organic chloride salt | protein denaturant | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| hydrocortisone acetate | | cortisol ester;
tertiary alpha-hydroxy ketone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cortisone acetate | | corticosteroid hormone | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mitomycin | | mitomycin | alkylating agent;
antineoplastic agent | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| corticosterone | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prednisolone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2000 | 2016 | 13.8 | low | 0 | 0 | 1 | 1 | 3 | 0 |
| estriol | | 16alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid | estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite | 2010 | 2012 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| lysergic acid diethylamide | | ergoline alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound | dopamine agonist;
hallucinogen;
serotonergic agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| reserpine | | alkaloid ester;
methyl ester;
yohimban alkaloid | adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic | 2010 | 2016 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| cephaloridine | | beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phentolamine | | imidazoles;
phenols;
substituted aniline;
tertiary amino compound | alpha-adrenergic antagonist;
vasodilator agent | 2008 | 2018 | 11.0 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| sorbitol | | glucitol | cathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| thymidine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| floxuridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent | 2004 | 2012 | 15.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| piperonyl butoxide | | benzodioxoles | pesticide synergist | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bromouracil | | nucleobase analogue;
pyrimidines | mutagen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3,3',5-triiodothyroacetic acid | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| histamine dihydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thyroxine | | 2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine | antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dextroamphetamine | | 1-phenylpropan-2-amine | adrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent | 2010 | 2016 | 10.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| carbachol | | ammonium salt;
carbamate ester | cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norethindrone acetate | | 3-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound | progestin;
synthetic oral contraceptive | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| spironolactone | | 3-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester | aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic | 2000 | 2016 | 16.5 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| cyclobarbital | | barbiturates | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| allobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| penicillamine | | non-proteinogenic alpha-amino acid;
penicillamine | antirheumatic drug;
chelator;
copper chelator;
drug allergen | 2004 | 2016 | 12.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| trichlorfon | | organic phosphonate;
organochlorine compound;
phosphonic ester | agrochemical;
anthelminthic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
insecticide | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norethandrolone | | corticosteroid hormone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cysteine | | cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid | EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| prednisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug | 2000 | 2016 | 15.6 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| estrone | | 17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols | antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| methylprednisolone acetate | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
glucocorticoid;
steroid ester;
tertiary alpha-hydroxy ketone | anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxandrolone | | 17beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid | anabolic agent;
androgen | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| dehydroepiandrosterone | | 17-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid | androgen;
human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nad | | NAD | geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| penicillin g | | penicillin allergen;
penicillin | antibacterial drug;
drug allergen;
epitope | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| metaraminol | | phenylethanolamines | alpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| pilocarpine | | pilocarpine | antiglaucoma drug | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| pentylenetetrazole | | organic heterobicyclic compound;
organonitrogen heterocyclic compound | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| triiodothyronine | | 2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine | human metabolite;
mouse metabolite;
thyroid hormone | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| isonicotinic acid | | pyridinemonocarboxylic acid | algal metabolite;
human metabolite | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| carbon tetrachloride | | chlorocarbon;
chloromethanes | hepatotoxic agent;
refrigerant | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| desoxycorticosterone acetate | | corticosteroid hormone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chloramphenicol | | C-nitro compound;
carboxamide;
diol;
organochlorine compound | antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor | 2000 | 2020 | 13.5 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| aspartic acid | | aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
mouse metabolite;
neurotransmitter | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glutamine | | amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lysine | | aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid | algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cetrimonium bromide | | organic bromide salt;
quaternary ammonium salt | detergent;
surfactant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorobutanol | | tertiary alcohol | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vincristine | | acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| physostigmine | | carbamate ester;
indole alkaloid | antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic | 2010 | 2016 | 10.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| sucrose | | glycosyl glycoside | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethinyl estradiol | | 17-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound | xenoestrogen | 2000 | 2013 | 15.1 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| testosterone propionate | | steroid ester | | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tubocurarine | | bisbenzylisoquinoline alkaloid | drug allergen;
muscle relaxant;
nicotinic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| apomorphine | | aporphine alkaloid | alpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug | 2010 | 2019 | 9.9 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| aminopyrine | | pyrazolone;
tertiary amino compound | antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| methyltestosterone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone | anabolic agent;
androgen;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tetrabenazine | | benzoquinolizine;
cyclic ketone;
tertiary amino compound | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cephalothin | | azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes | antibacterial drug;
antimicrobial agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| uridine | | uridines | drug metabolite;
fundamental metabolite;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| kanamycin a | | kanamycins | bacterial metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ethopabate | | amidobenzoic acid | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenylephrine | | phenols;
phenylethanolamines;
secondary amino compound | alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| levodopa | | amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| edetic acid | | ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid | anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tyrosine | | amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine | EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cysteamine | | amine;
thiol | geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| acetylcholine chloride | | quaternary ammonium salt | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mepazine | | phenothiazines | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acepromazine | | aromatic ketone;
methyl ketone;
phenothiazines;
tertiary amino compound | phenothiazine antipsychotic drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methoxamine | | amphetamines | alpha-adrenergic agonist;
antihypotensive agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n,n-dimethyltryptamine | | tryptamine alkaloid;
tryptamines | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| niridazole | | 1,3-thiazoles;
C-nitro compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cloxacillin | | penicillin allergen;
penicillin;
semisynthetic derivative | antibacterial agent;
antibacterial drug | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bretylium tosylate | | organosulfonate salt;
quaternary ammonium salt | adrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| zoxazolamine | | benzoxazole | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| leucine | | amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2008 | 2014 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| berlition | | dithiolanes;
heterocyclic fatty acid;
lipoic acid;
thia fatty acid | cofactor;
nutraceutical;
prosthetic group | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| calcium acetate | | calcium salt | chelator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbaryl | | carbamate ester;
naphthalenes | acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant growth retardant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lactose | | lactose | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methionine | | aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid | antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phenylalanine | | amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid | algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Mebutamate | | organic molecular entity | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| desoxycorticosterone | | 20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| colchicine | | alkaloid;
colchicine | anti-inflammatory agent;
gout suppressant;
mutagen | 2007 | 2016 | 12.3 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| gallamine triethiodide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mebanazine | | benzenes | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxacillin | | penicillin | antibacterial agent;
antibacterial drug | 2000 | 2016 | 16.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| chloroform | | chloromethanes;
one-carbon compound | carcinogenic agent;
central nervous system drug;
inhalation anaesthetic;
non-polar solvent;
refrigerant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triamcinolone diacetate | | corticosteroid hormone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| norethindrone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol | progestin;
synthetic oral contraceptive | 2000 | 2012 | 16.7 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| norethynodrel | | oxo steroid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cycloserine | | 4-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion | antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| benziodarone | | aromatic ketone | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ampicillin | | beta-lactam antibiotic;
penicillin allergen;
penicillin | antibacterial drug | 2010 | 2016 | 10.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| mannitol | | mannitol | allergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cytarabine | | beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside | antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| trifluridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor | 2004 | 2012 | 16.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 4-hydroxypropiophenone | | acetophenones | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1,1,1-trichloroethane | | chloroethanes | polar solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| medroxyprogesterone acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester | adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive | 2004 | 2013 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| mestranol | | 17beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound | prodrug;
xenoestrogen | 2004 | 2012 | 15.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| methaqualone | | quinazolines | GABA agonist;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trypan blue | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| methandrostenolone | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cordycepin | | 3'-deoxyribonucleoside;
adenosines | antimetabolite;
nucleoside antibiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tryptophan | | erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan | antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| quinethazone | | quinazolines | antihypertensive agent;
diuretic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arginine | | arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ethane | | alkane;
gas molecular entity | plant metabolite;
refrigerant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethylene | | alkene;
gas molecular entity | plant hormone;
refrigerant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetylene | | alkyne;
gas molecular entity;
terminal acetylenic compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethylamine | | primary aliphatic amine | human metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methylene chloride | | chloromethanes;
volatile organic compound | carcinogenic agent;
polar aprotic solvent;
refrigerant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclopropane | | cycloalkane;
cyclopropanes | inhalation anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethylene oxide | | gas molecular entity;
oxacycle;
saturated organic heteromonocyclic parent | allergen;
mouse metabolite;
mutagen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tribromoethanol | | alcohol;
organobromine compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1,1,1-trifluoro-2-chloroethane | | organofluorine compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trichloroacetic acid | | monocarboxylic acid;
organochlorine compound | carcinogenic agent;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perflutren | | fluoroalkane;
fluorocarbon | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| triamcinolone acetonide | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone | anti-allergic agent;
anti-inflammatory drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fluoxymesterone | | 11beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid | anabolic agent;
antineoplastic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mepenzolate bromide | | diarylmethane | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| allylpropymal | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phencyclidine | | benzenes;
piperidines | anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| butobarbital | | barbiturates | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methsuximide | | organic molecular entity | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbromal | | N-acylurea | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tromethamine | | primary amino compound;
triol | buffer | 2014 | 2016 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| triparanol | | stilbenoid | anticoronaviral agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isobutyl alcohol | | alkyl alcohol;
primary alcohol | Saccharomyces cerevisiae metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylethyl ketone | | butanone;
dialkyl ketone;
methyl ketone;
volatile organic compound | bacterial metabolite;
polar aprotic solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trichloroethylene | | chloroethenes | inhalation anaesthetic;
mouse metabolite | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| acrylic acid | | alpha,beta-unsaturated monocarboxylic acid | metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pantothenic acid | | pantothenic acid;
vitamin B5 | antidote to curare poisoning;
geroprotector;
human blood serum metabolite | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sulfachlorpyridazine | | organochlorine compound;
pyridazines;
sulfonamide | antibacterial drug;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dehydrocholic acid | | 12-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid | gastrointestinal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclizine | | N-alkylpiperazine | antiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| buclizine | | monochlorobenzenes;
N-alkylpiperazine | antiemetic;
central nervous system depressant;
cholinergic antagonist;
histamine antagonist;
local anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylprednisolone | | 6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic | 2000 | 2016 | 14.8 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| rotenone | | organic heteropentacyclic compound;
rotenones | antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin | 2006 | 2013 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| thiopropazate | | acetate ester;
N-alkylpiperazine;
organochlorine compound;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetrizoic acid | | aminobenzoic acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| brompheniramine | | organobromine compound;
pyridines | anti-allergic agent;
H1-receptor antagonist | 2011 | 2016 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| phensuximide | | pyrrolidines | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dimethisoquin | | isoquinolines | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| penicillin v | | penicillin allergen;
penicillin | | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| isosorbide dinitrate | | glucitol derivative;
nitrate ester | nitric oxide donor;
vasodilator agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pseudoephedrine | | phenylethanolamines;
secondary alcohol;
secondary amino compound | anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| diethylpropion | | aromatic ketone;
tertiary amine | appetite depressant | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenylpiperazine | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-naphthoic acid | | naphthoic acid | mouse metabolite;
xenobiotic metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mecoprop | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| synephrine | | ethanolamines;
phenethylamine alkaloid;
phenols | alpha-adrenergic agonist;
plant metabolite | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| propylparaben | | benzoate ester;
paraben;
phenols | antifungal agent;
antimicrobial agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzoyl peroxide | | carbonyl compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-xylene | | xylene | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3-methylpentane | | alkane;
volatile organic compound | allelochemical;
human metabolite;
non-polar solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylcyclopentane | | cycloalkane;
volatile organic compound | human metabolite;
plant metabolite | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-chloro-alpha,alpha,alpha-trifluorotoluene | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylparaben | | paraben | antifungal agent;
antimicrobial food preservative;
neuroprotective agent;
plant metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridostigmine bromide | | pyridinium salt | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzonatate | | benzoate ester;
secondary amino compound;
substituted aniline | anaesthetic;
antitussive | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 1,3-butadiene | | butadiene | carcinogenic agent;
mutagen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-methylpentane | | alkane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| deanol | | ethanolamines;
tertiary amine | curing agent;
radical scavenger | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-methylmorpholine | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pentane | | alkane;
volatile organic compound | non-polar solvent;
refrigerant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-butylamine | | primary aliphatic amine | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| furan | | furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | carcinogenic agent;
hepatotoxic agent;
Maillard reaction product | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-hexane | | alkane;
volatile organic compound | neurotoxin;
non-polar solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclohexane | | cycloalkane;
volatile organic compound | non-polar solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piperidine | | azacycloalkane;
piperidines;
saturated organic heteromonocyclic parent;
secondary amine | base;
catalyst;
human metabolite;
non-polar solvent;
plant metabolite;
protic solvent;
reagent | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| morpholine | | morpholines;
saturated organic heteromonocyclic parent | NMR chemical shift reference compound | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hexahydroazepine | | azacycloalkane;
azepanes;
saturated organic heteromonocyclic parent | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ergotamine | | peptide ergot alkaloid | alpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| estradiol dipropionate | | steroid ester | | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methylergonovine | | ergoline alkaloid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imipramine hydrochloride | | hydrochloride | antidepressant | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| neostigmine bromide | | bromide salt | | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phenformin | | biguanides | antineoplastic agent;
geroprotector;
hypoglycemic agent | 2010 | 2013 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| propylene | | alkene;
gas molecular entity | refrigerant;
xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mephobarbital | | barbiturates | anticonvulsant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| paramethadione | | oxazolidinone | anticonvulsant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexachlorobenzene | | aromatic fungicide;
chlorobenzenes | antifungal agrochemical;
carcinogenic agent;
persistent organic pollutant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trinitrotoluene | | trinitrotoluene | explosive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| framycetin | | aminoglycoside | allergen;
antibacterial drug;
Escherichia coli metabolite | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| n-methylpyrrolidine | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| triethylamine | | tertiary amine | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyrazolanthrone | | anthrapyrazole;
aromatic ketone;
cyclic ketone | antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| meglumine | | hexosamine;
secondary amino compound | | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cinchophen | | quinolines | | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| chloroprocaine | | benzoate ester;
monochlorobenzenes | central nervous system depressant;
local anaesthetic;
peripheral nervous system drug | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| n-heptane | | alkane;
volatile organic compound | non-polar solvent;
plant metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| anileridine | | ethyl ester;
piperidinecarboxylate ester;
substituted aniline | opioid analgesic;
opioid receptor agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| yohimbine | | methyl 17-hydroxy-20xi-yohimban-16-carboxylate | alpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| nafcillin | | penicillin allergen;
penicillin | antibacterial drug | 2000 | 2016 | 17.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| ditiocarb | | dithiocarbamic acids | chelator;
copper chelator | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mequinol | | methoxybenzenes;
phenols | metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aziridine | | azacycloalkane;
aziridines;
saturated organic heteromonocyclic parent | alkylating agent | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methohexital | | acetylenic compound;
barbiturates | drug allergen;
intravenous anaesthetic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| quinestrol | | 17-hydroxy steroid;
terminal acetylenic compound | xenoestrogen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfalene | | pyrazines;
sulfonamide antibiotic;
sulfonamide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dydrogesterone | | 20-oxo steroid;
3-oxo-Delta(4) steroid | progestin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propantheline bromide | | xanthenes | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ephedrine | | phenethylamine alkaloid;
phenylethanolamines | bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| chlormadinone acetate | | corticosteroid hormone | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| norchlorcyclizine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2,3-dimercaptosuccinic acid | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| estradiol 17 beta-cypionate | | steroid ester | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| evans blue | | organic sodium salt | fluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| testosterone enanthate | | heptanoate ester;
sterol ester | androgen | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| opipramol | | dibenzoazepine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dibenzepin | | dibenzodiazepine | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aminophylline | | mixture | bronchodilator agent;
cardiotonic drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| azacitidine | | N-glycosyl-1,3,5-triazine;
nucleoside analogue | antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phenyramidol | | aminopyridine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbutamide | | benzenes;
sulfonamide | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| glymidine | | diether;
pyrimidines;
sulfonamide | hypoglycemic agent | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| galantamine | | benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound | antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite | 2013 | 2016 | 9.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| nandrolone decanoate | | steroid ester | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| methysergide | | ergoline alkaloid | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| bucladesine | | 3',5'-cyclic purine nucleotide;
butanamides;
butyrate ester | agonist;
cardiotonic drug;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| procarbazine hydrochloride | | hydrochloride | antineoplastic agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N-[(2-chlorophenyl)methyl]-1-[4-[[(2-chlorophenyl)methylamino]methyl]cyclohexyl]methanamine | | aromatic amine | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| trifluoroethylamine | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| betamethasone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent | 2000 | 2013 | 17.2 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| prenylamine | | diarylmethane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perflubron | | haloalkane;
organobromine compound;
perfluorinated compound | blood substitute;
radioopaque medium | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluorometholone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone | anti-inflammatory drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyproterone acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester | androgen antagonist;
geroprotector;
progestin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nandrolone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid | human metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiazolidine-4-carboxylic acid | | alpha-amino acid zwitterion;
non-proteinogenic alpha-amino acid;
sulfur-containing amino acid;
thiazolidinemonocarboxylic acid | antidote;
antioxidant;
hepatoprotective agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-fluoroethylamine | | | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| chlorphentermine | | amphetamines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dextropropoxyphene | | 1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate | mu-opioid receptor agonist;
opioid analgesic | 2000 | 2016 | 14.3 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| glycyrrhetinic acid | | cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid | immunomodulator;
plant metabolite | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| chenodeoxycholic acid | | bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid | human metabolite;
mouse metabolite | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| lucanthone | | thioxanthenes | adjuvant;
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
mutagen;
photosensitizing agent;
prodrug;
schistosomicide drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dichloralantipyrine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| emetine | | isoquinoline alkaloid;
pyridoisoquinoline | antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dihydralazine | | phthalazines | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| bufotenin | | tertiary amine;
tryptamine alkaloid | coral metabolite;
hallucinogen | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylpropanolamine | | amphetamines;
phenethylamine alkaloid | plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arecaidine | | citraconoyl group | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-hydroxybutyric acid | | 4-hydroxy monocarboxylic acid;
hydroxybutyric acid | general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azetidine | | azacycloalkane;
azetidines;
saturated organic heteromonocyclic parent | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dihydroergotamine | | ergot alkaloid;
semisynthetic derivative | dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| methallenestril | | naphthalenes | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| podophyllotoxin | | furonaphthodioxole;
lignan;
organic heterotetracyclic compound | antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| hesperidin | | 3'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside | mutagen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| medroxyprogesterone | | 17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone | contraceptive drug;
progestin;
synthetic oral contraceptive | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| androstenediol | | 17beta-hydroxy steroid;
3beta-hydroxy-Delta(5)-steroid | androgen;
human metabolite;
mouse metabolite;
radiation protective agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dimenhydrinate | | diarylmethane | | 2012 | 2016 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| gluconic acid | | gluconic acid | chelator;
Penicillium metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-(benzoylamino)-2-hydroxybenzoic acid | | benzamides | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chlormethiazole | | thiazoles | | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| methamphetamine | | amphetamines;
secondary amine | central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| levocarnitine | | carnitine | antilipemic drug;
nootropic agent;
nutraceutical;
Saccharomyces cerevisiae metabolite;
water-soluble vitamin (role) | 2004 | 2016 | 14.7 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| decamethonium dibromide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfanilylurea | | benzenes;
sulfonamide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gentian violet | | organic chloride salt | anthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiphenamil | | diarylmethane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-naphthylisothiocyanate | | isothiocyanate | insecticide | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aminopenicillanic acid | | amino acid zwitterion;
penicillanic acids | allergen | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hematoporphyrin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycyl-glycyl-glycine | | tripeptide zwitterion;
tripeptide | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metahexamide | | benzenes;
sulfonamide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenindamine | | indene | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lactulose | | glycosylfructose | gastrointestinal drug;
laxative | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| megestrol acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester | antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive | 2004 | 2013 | 14.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| n,n-dimethylethylamine | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pamabrom | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-amino-2-methyl-1-propanol | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diethylmethylamine | | | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| acetylcysteine | | acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid | antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| glycine ethyl ester | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-methylpiperidine | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phendimetrazine | | | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| trimetozine | | morpholines | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| benzydamine | | aromatic ether;
indazoles;
tertiary amino compound | analgesic;
central nervous system stimulant;
hallucinogen;
local anaesthetic;
non-steroidal anti-inflammatory drug | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| erythromycin stearate | | aminoglycoside | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erythromycin | | cyclic ketone;
erythromycin | | 2004 | 2016 | 13.3 | low | 0 | 0 | 0 | 4 | 5 | 0 |
| butaperazine | | phenothiazines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| docosanol | | docosanol;
long-chain primary fatty alcohol | antiviral drug;
plant metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hydroxychloroquine sulfate | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| levonorgestrel | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound | contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| tempidon | | piperidones | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vinblastine | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| diphenoxylate | | ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine | antidiarrhoeal drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxolamine | | oxadiazole;
ring assembly | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethylestrenol | | 17beta-hydroxy steroid;
tertiary alcohol | anabolic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| estradiol valerate | | steroid ester | | 2004 | 2010 | 17.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| ethambutol hydrochloride | | hydrochloride | antitubercular agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ethambutol | | ethanolamines;
ethylenediamine derivative | antitubercular agent;
environmental contaminant;
xenobiotic | 2000 | 2016 | 17.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| tetramethylpyrazine | | alkaloid;
pyrazines | antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dehydroepiandrosterone acetate | | steroid ester | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| antimycin a | | benzamides;
formamides;
macrodiolide;
phenols | antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vancomycin | | glycopeptide | antibacterial drug;
antimicrobial agent;
bacterial metabolite | 2010 | 2016 | 10.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| d-alpha tocopherol | | alpha-tocopherol | algal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pregnenolone carbonitrile | | aliphatic nitrile | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flurandrenolone | | 21-hydroxy steroid | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ibufenac | | monocarboxylic acid | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metylperon | | aromatic ketone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metaxalone | | aromatic ether | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| spectinomycin | | cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound | antibacterial drug;
antimicrobial agent;
bacterial metabolite | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| clopyralid | | organochlorine pesticide;
pyridines | herbicide | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dimethylaminopropionitrile | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| paraquat | | organic cation | geroprotector;
herbicide | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dronabinol | | benzochromene;
diterpenoid;
phytocannabinoid;
polyketide | cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic | 2000 | 2016 | 16.0 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| 2-chloro-11-(4-methyl-1-piperazinyl)-5h-dibenzo(b,e)(1,4)diazepine | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amiloride | | aromatic amine;
guanidines;
organochlorine compound;
pyrazines | diuretic;
sodium channel blocker | 2000 | 2016 | 14.5 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| clothiapine | | dibenzothiazepine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pimozide | | benzimidazoles;
heteroarylpiperidine;
organofluorine compound | antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 1994 | 2020 | 17.2 | low | 0 | 0 | 3 | 8 | 5 | 0 |
| flumethasone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-inflammatory drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| betamethasone valerate | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
primary alpha-hydroxy ketone;
steroid ester | anti-inflammatory drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azaribine | | acetate ester;
N-glycosyl-1,2,4-triazine | antipsoriatic;
prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5-phenylvaleric acid | | benzenes;
monocarboxylic acid | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methylprednisolone hemisuccinate | | corticosteroid hormone;
hemisuccinate | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexbrompheniramine | | brompheniramine | anti-allergic agent;
H1-receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulfadoxine | | pyrimidines;
sulfonamide | antibacterial drug;
antimalarial | 2008 | 2012 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| sulfur hexafluoride | | sulfur coordination entity | greenhouse gas;
NMR chemical shift reference compound;
ultrasound contrast agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acadesine | | 1-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue | antineoplastic agent;
platelet aggregation inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetophenazine | | N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
phenothiazines | phenothiazine antipsychotic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| toliprolol | | aromatic ether | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| stavudine | | dihydrofuran;
nucleoside analogue;
organic molecular entity | antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| doxifluridine | | organofluorine compound;
pyrimidine 5'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dicloxacillin | | dichlorobenzene;
penicillin | antibacterial drug | 2000 | 2016 | 14.2 | low | 0 | 0 | 1 | 1 | 3 | 0 |
| cyclacillin | | penicillin | antibacterial drug | 2004 | 2014 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| iproclozide | | aromatic ether | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| megestrol | | 17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone | antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cephaloglycin | | beta-lactam antibiotic allergen;
cephalosporin | antimicrobial agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tranylcypromine | | 2-phenylcyclopropan-1-amine | | 2004 | 2012 | 16.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| streptomycin | | antibiotic antifungal drug;
antibiotic fungicide;
streptomycins | antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cladribine | | organochlorine compound;
purine 2'-deoxyribonucleoside | antineoplastic agent;
immunosuppressive agent | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| beclomethasone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-asthmatic drug;
anti-inflammatory drug | 2004 | 2012 | 14.7 | medium | 0 | 0 | 0 | 1 | 2 | 0 |
| carbenicillin | | penicillin allergen;
penicillin | antibacterial drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbenicillin disodium | | organic sodium salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dehydroemetine | | aromatic ether;
isoquinolines;
pyridoisoquinoline | antileishmanial agent;
antimalarial;
antiprotozoal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| estradiol enanthate | | steroid ester | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| noxiptilin | | organic tricyclic compound | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| benorilate | | carbonyl compound | | 2008 | 2010 | 15.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| trimetazidine | | aromatic amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metocurine | | isoquinolines | | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| floxacillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| clomacran | | acridines | | 2008 | 2016 | 12.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| vidarabine | | beta-D-arabinoside;
purine nucleoside | antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iprindole | | indoles | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betamethasone-17,21-dipropionate | | 11beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
propanoate ester;
steroid ester | antipsoriatic | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methenamine hippurate | | N-acylglycine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| isometheptene | | secondary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| olsalazine | | azobenzenes;
dicarboxylic acid | non-steroidal anti-inflammatory drug;
prodrug | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| tiadenol | | aliphatic sulfide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| terodiline | | diarylmethane | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| etidronate disodium | | organic sodium salt | antineoplastic agent;
bone density conservation agent;
chelator | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| molindone | | indoles | | 2003 | 2008 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| helium | | monoatomic helium;
noble gas atom;
s-block element atom | food packaging gas | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zalcitabine | | pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2000 | 2013 | 17.2 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| hexocyclium | | amine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| camptothecin | | delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite | 2006 | 2013 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| sodium thiosulfate | | inorganic sodium salt | antidote to cyanide poisoning;
antifungal drug;
nephroprotective agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ancitabine | | diol;
organic heterotricyclic compound | antimetabolite;
antineoplastic agent;
prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clortermine | | amphetamines | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| stanozolol | | 17beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol | anabolic agent;
androgen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clodronic acid | | 1,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound | antineoplastic agent;
bone density conservation agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nicofuranose | | organooxygen compound | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| mafenide acetate | | carboxylic acid | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| (1S,2R)-tranylcypromine | | 2-phenylcyclopropan-1-amine | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| apazone | | benzotriazines | non-steroidal anti-inflammatory drug;
uricosuric drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diacerein | | anthraquinone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| parbendazole | | benzimidazoles;
carbamate ester | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cloforex | | amphetamines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| xipamide | | benzamides | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| selegiline | | selegiline;
terminal acetylenic compound | geroprotector | 2000 | 2016 | 14.9 | low | 0 | 0 | 1 | 4 | 3 | 0 |
| selegiline hydrochloride, (r)-isomer | | hydrochloride;
terminal acetylenic compound | antiparkinson drug;
dopaminergic agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| levamisole | | 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole | antinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator | 2004 | 2012 | 16.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| clobutinol | | benzenes;
organic amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clemastine | | monochlorobenzenes;
N-alkylpyrrolidine | anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist | 2000 | 2020 | 12.0 | low | 0 | 0 | 1 | 0 | 3 | 0 |
| thiamphenicol | | monocarboxylic acid amide;
sulfone | antimicrobial agent;
immunosuppressive agent | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| pancuronium bromide | | bromide salt | cholinergic antagonist;
muscle relaxant;
nicotinic antagonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pizotyline | | benzocycloheptathiophene | histamine antagonist;
muscarinic antagonist;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cephalexin | | beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative | antibacterial drug | 2004 | 2016 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| isosorbide-5-mononitrate | | glucitol derivative;
nitrate ester | nitric oxide donor;
vasodilator agent | 2004 | 2010 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| ornidazole | | C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol | antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| edifenphos | | organic thiophosphate | antifungal agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
neurotoxin;
phospholipid biosynthesis inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| danazol | | 17beta-hydroxy steroid;
terminal acetylenic compound | anti-estrogen;
estrogen antagonist;
geroprotector | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| metergoline | | carbamate ester;
ergoline alkaloid | dopamine agonist;
geroprotector;
serotonergic antagonist | 1996 | 2012 | 20.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| clonixin | | aminopyridine;
organochlorine compound;
pyridinemonocarboxylic acid | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
vasodilator agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenclozic acid | | | | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| lisuride | | monocarboxylic acid amide | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| laxagetten 4,4'-diacetoxydiphenylpyridylemethane | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-deoxynojirimycin | | 2-(hydroxymethyl)piperidine-3,4,5-triol;
piperidine alkaloid | anti-HIV agent;
anti-obesity agent;
bacterial metabolite;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
hypoglycemic agent;
plant metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| daunorubicin | | aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones | antineoplastic agent;
bacterial metabolite | 2004 | 2020 | 11.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| razoxane | | N-alkylpiperazine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| capobenic acid | | benzamides | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cephapirin | | cephalosporin | antibacterial drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diftalone | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fludarabine phosphate | | nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate | antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| alclofenac | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| carbimazole | | 1,3-dihydroimidazole-2-thiones;
carbamate ester | antithyroid drug;
prodrug | 2010 | 2012 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| bromocriptine | | indole alkaloid | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist | 1996 | 2016 | 17.8 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| pyrrolidine | | azacycloalkane;
pyrrolidines;
saturated organic heteromonocyclic parent | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| triamcinolone | | 11beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-allergic agent;
anti-inflammatory drug | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| oxyphenisatin | | indoles | | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| chloroprene | | chloroolefin | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tetrachloroethylene | | chlorocarbon;
chloroethenes | nephrotoxic agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| fludrocortisone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid | adrenergic agent;
anti-inflammatory drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ursodeoxycholic acid | | bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid | human metabolite;
mouse metabolite | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| butylated hydroxytoluene | | phenols | antioxidant;
ferroptosis inhibitor;
food additive;
geroprotector | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyrene | | ortho- and peri-fused polycyclic arene | fluorescent probe;
persistent organic pollutant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metipranolol | | acetate ester;
aromatic ether;
propanolamine;
secondary amino compound | anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist | 2004 | 2014 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| proquazone | | pyrimidines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzonidazole | | C-nitro compound;
imidazoles;
monocarboxylic acid amide | antiprotozoal drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| halazepam | | organic molecular entity | | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| butachlor | | aromatic amide;
organochlorine compound;
tertiary carboxamide | environmental contaminant;
herbicide;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| du-21220 | | benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound | | 2000 | 2004 | 22.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| rose bengal b disodium salt | | | | 2010 | 2012 | 13.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| propamocarb | | carbamate ester;
carbamate fungicide;
tertiary amino compound | antifungal agrochemical;
environmental contaminant;
xenobiotic | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glutamic acid | | glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexchlorpheniramine | | chlorphenamine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clometacin | | N-acylindole | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefazolin | | beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles | antibacterial drug | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| ripazepam | | benzenes | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| amoxicillin | | penicillin allergen;
penicillin | antibacterial drug | 2004 | 2016 | 12.9 | low | 0 | 0 | 0 | 3 | 5 | 0 |
| timolol | | timolol | anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist | 2000 | 2016 | 14.7 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| indoramin | | tryptamines | | 2000 | 2013 | 15.8 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| nicergoline | | organic heterotetracyclic compound;
organonitrogen heterocyclic compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxcarbazepine | | cyclic ketone;
dibenzoazepine | anticonvulsant;
drug allergen | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| carbidopa | | catechols;
hydrazines;
monocarboxylic acid | antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 2012 | 2016 | 10.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| moricizine | | carbamate ester;
morpholines;
phenothiazines | anti-arrhythmia drug | 2000 | 2016 | 17.0 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| amineptin | | amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound | antidepressant;
dopamine uptake inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bitolterol | | carboxylic ester;
diester;
ethanolamines;
secondary alcohol;
secondary amino compound | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
prodrug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zidovudine | | azide;
pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2000 | 2016 | 15.5 | low | 0 | 0 | 1 | 4 | 3 | 0 |
| feprazone | | organic molecular entity | | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pirprofen | | pyrroline | | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| medifoxamine | | aromatic ether | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| tobramycin | | amino cyclitol glycoside | antibacterial agent;
antimicrobial agent;
toxin | 2004 | 2013 | 15.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| paclitaxel | | taxane diterpenoid;
tetracyclic diterpenoid | antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| etoposide | | beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound | antineoplastic agent;
DNA synthesis inhibitor | 2004 | 2016 | 14.3 | low | 0 | 0 | 0 | 4 | 3 | 0 |
| dobutamine | | catecholamine;
secondary amine | beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent | 2000 | 2016 | 15.6 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| phenyl-2-aminoethyl sulfide | | | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| halofantrine | | phenanthrenes | | 2003 | 2011 | 17.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| butaclamol | | organic heteropentacyclic compound | | 1998 | 2014 | 18.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| butaclamol | | amino alcohol;
organic heteropentacyclic compound;
tertiary alcohol;
tertiary amino compound | dopaminergic antagonist | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| penbutolol | | ethanolamines | | 2000 | 2016 | 17.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| etidocaine | | amino acid amide | local anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ribavirin | | 1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide | anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2004 | 2020 | 12.2 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| miloxacin | | quinolines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amikacin | | alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide | antibacterial drug;
antimicrobial agent;
nephrotoxin | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| tolamolol | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbidopa | | catechols;
hydrate;
hydrazines;
monocarboxylic acid | antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cephradine | | beta-lactam antibiotic allergen;
cephalosporin | antibacterial drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ticrynafen | | aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes | antihypertensive agent;
hepatotoxic agent;
loop diuretic | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| guanadrel | | guanidines;
spiroketal | adrenergic antagonist;
antihypertensive agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methyldopa | | L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent | 2004 | 2016 | 13.1 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| tocainide | | monocarboxylic acid amide | anti-arrhythmia drug;
local anaesthetic;
sodium channel blocker | 2000 | 2004 | 22.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| bezafibrate | | aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sq-11725 | | | | 2000 | 2014 | 17.0 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| diltiazem | | 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2000 | 2016 | 15.5 | low | 0 | 0 | 1 | 5 | 4 | 0 |
| levobunolol | | aromatic ether;
cyclic ketone;
propanolamine | antiglaucoma drug;
beta-adrenergic antagonist | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vecuronium bromide | | organic bromide salt;
quaternary ammonium salt | muscle relaxant;
neuromuscular agent;
nicotinic antagonist | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vecuronium | | acetate ester;
androstane;
quaternary ammonium ion | drug allergen;
muscle relaxant;
neuromuscular agent;
nicotinic antagonist | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| benoxaprofen | | 1,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes | antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| permethrin | | cyclopropanecarboxylate ester;
cyclopropanes | agrochemical;
ectoparasiticide;
pyrethroid ester acaricide;
pyrethroid ester insecticide;
scabicide | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| exifone | | benzophenones | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pirfenidone | | pyridone | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mefloquine | | [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol | antimalarial | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| desogestrel | | 17beta-hydroxy steroid;
terminal acetylenic compound | contraceptive drug;
progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| meptazinol | | azepanes | | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| muzolimine | | dichlorobenzene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitazoxanide | | benzamides;
carboxylic ester | | 2013 | 2020 | 7.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| sufentanil | | anilide;
ether;
piperidines;
thiophenes | anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 2004 | 2016 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| acarbose | | tetrasaccharide derivative | EC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| torsemide | | aminopyridine;
N-sulfonylurea;
secondary amino compound | antihypertensive agent;
loop diuretic | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| epirubicin | | aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2005 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| cefmetazole | | cephalosporin | antibacterial drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| desflurane | | organofluorine compound | inhalation anaesthetic | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| prenalterol | | aromatic ether | | 2000 | 2008 | 20.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Flamprop | | benzamides | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| lorcainide | | acetamides | | 2000 | 2013 | 17.0 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| idarubicin | | anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative | | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cefonicid | | cephalosporin | antibacterial drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piperacillin | | penicillin allergen;
penicillin | antibacterial drug | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| paroxetine | | aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 6 | 3 | 0 |
| captopril | | alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2000 | 2020 | 13.5 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| progabide | | diarylmethane | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefoperazone | | cephalosporin | antibacterial drug | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| staurosporine | | indolocarbazole alkaloid;
organic heterooctacyclic compound | apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| foscarnet sodium | | one-carbon compound;
organic sodium salt | antiviral drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lodoxamide | | organonitrogen compound;
organooxygen compound | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| indalpine | | indoles | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| atracurium | | diester;
quaternary ammonium ion | muscle relaxant;
nicotinic antagonist | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| atracurium besylate | | organosulfonate salt;
quaternary ammonium salt | muscle relaxant;
nicotinic antagonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| butoconazole | | aryl sulfide;
conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| moxalactam | | cephalosporin;
oxacephem | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lidamidine | | ureas | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nicorandil | | nitrate ester;
pyridinecarboxamide | potassium channel opener;
vasodilator agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| naftifine | | allylamine antifungal drug;
naphthalenes;
tertiary amine | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
sterol biosynthesis inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pergolide | | diamine;
methyl sulfide;
organic heterotetracyclic compound | antiparkinson drug;
dopamine agonist | 2004 | 2016 | 14.3 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| pergolide mesylate | | methanesulfonate salt | antiparkinson drug;
dopamine agonist;
geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bicifadine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefadroxil anhydrous | | cephalosporin | antibacterial drug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| encainide | | benzamides;
piperidines | anti-arrhythmia drug;
sodium channel blocker | 2000 | 2010 | 19.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| talniflumate | | benzofurans | | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| fluperlapine | | benzazepine | | 1994 | 2005 | 25.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| fenoldopam mesylate | | benzazepine | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| nedocromil | | dicarboxylic acid;
organic heterotricyclic compound | anti-allergic agent;
anti-asthmatic drug;
non-steroidal anti-inflammatory drug | 2004 | 2012 | 16.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fialuridine | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| doxofylline | | oxopurine | anti-asthmatic drug;
antitussive;
bronchodilator agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefaclor anhydrous | | cephalosporin | antibacterial drug;
drug allergen | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| pefloxacin | | fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone | antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alfentanil | | monocarboxylic acid amide;
piperidines | central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug | 2004 | 2016 | 15.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| miglustat | | piperidines;
tertiary amino compound | anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| haloperidol decanoate | | organic molecular entity | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dazoxiben | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefotetan | | | | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| lovastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug | 2000 | 2020 | 13.9 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| flupirtine | | aminopyridine | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tolrestat | | naphthalenes | EC 1.1.1.21 (aldehyde reductase) inhibitor | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| rimcazole | | carbazoles | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enoximone | | aromatic ketone | | 2000 | 2013 | 16.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| stepronin | | N-acyl-amino acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piritrexim | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| levocabastine | | piperidines | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| simvastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic) | EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug | 2000 | 2016 | 14.9 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| idazoxan | | benzodioxine;
imidazolines | alpha-adrenergic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| remoxipride | | dimethoxybenzene | | 2009 | 2014 | 12.3 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| balsalazide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pravastatin | | 3-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic) | anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| cabergoline | | N-acylurea | antineoplastic agent;
antiparkinson drug;
dopamine agonist | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| atomoxetine hydrochloride | | hydrochloride | adrenergic uptake inhibitor;
antidepressant | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| atomoxetine | | aromatic ether;
secondary amino compound;
toluenes | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic | 2010 | 2016 | 10.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| quinapril | | dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| alpidem | | imidazoles | | 2010 | 2016 | 11.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| gepirone | | N-arylpiperazine | | 2009 | 2010 | 14.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| mifepristone | | 3-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound | abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| dopexamine | | catecholamine | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tiospirone | | | | 1994 | 2000 | 27.0 | medium | 0 | 0 | 4 | 0 | 0 | 0 |
| lonapalene | | naphthalenes;
organochlorine compound | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosphenytoin | | imidazolidine-2,4-dione | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| salmeterol xinafoate | | naphthoic acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ranolazine | | aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ipsapirone | | N-arylpiperazine | | 1998 | 2012 | 17.7 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| flesinoxan | | | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| finasteride | | 3-oxo steroid;
aza-steroid;
delta-lactam | androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| imiquimod | | imidazoquinoline | antineoplastic agent;
interferon inducer | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sematilide | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| esmolol | | aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound | | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| sertindole | | heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole | alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist | 1996 | 2014 | 18.8 | low | 0 | 0 | 4 | 9 | 3 | 0 |
| adapalene | | adamantanes;
monocarboxylic acid;
naphthoic acid | dermatologic drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
non-steroidal anti-inflammatory drug | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| adefovir | | 6-aminopurines;
ether;
phosphonic acids | antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aromasil | | 17-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic | 2006 | 2016 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| sparfloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | | 2003 | 2013 | 16.8 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| zileuton | | 1-benzothiophenes;
ureas | anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| remacemide | | stilbenoid | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clopidogrel | | methyl ester;
monochlorobenzenes;
thienopyridine | anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2010 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cidofovir anhydrous | | phosphonic acids;
pyrimidone | anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| tiagabine | | beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes | anticonvulsant;
GABA reuptake inhibitor | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| mibefradil | | tetralins | T-type calcium channel blocker | 2000 | 2008 | 20.0 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| topotecan | | pyranoindolizinoquinoline | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bromfenac | | aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline | non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2000 | 2016 | 13.8 | low | 0 | 0 | 1 | 1 | 3 | 0 |
| gemcitabine hydrochloride | | hydrochloride;
organofluorine compound | anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gemcitabine | | organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ibutilide | | benzenes;
organic amino compound | | 2003 | 2016 | 16.2 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| fananserin | | naphthalenes;
sulfonic acid derivative | | 2001 | 2009 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| aripiprazole | | aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist | 2003 | 2016 | 13.6 | low | 0 | 0 | 0 | 9 | 6 | 0 |
| remifentanil | | alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester | intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| atorvastatin calcium anhydrous | | organic calcium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| atorvastatin | | aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic) | environmental contaminant;
xenobiotic | 2004 | 2016 | 13.6 | low | 0 | 0 | 0 | 4 | 4 | 0 |
| lamivudine | | monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol | allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| duloxetine hydrochloride | | duloxetine hydrochloride | antidepressant | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| duloxetine | | duloxetine | | 2010 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| irinotecan | | carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| valsartan | | biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2004 | 2016 | 12.9 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| ibandronic acid | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ziprasidone | | 1,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines | antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist | 1996 | 2019 | 17.9 | low | 0 | 0 | 4 | 17 | 3 | 0 |
| zolmitriptan | | oxazolidinone;
tryptamines | anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| adefovir dipivoxil | | 6-aminopurines;
carbonate ester;
ether;
organic phosphonate | antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| emtricitabine | | monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tasosartan | | biphenyls | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tiludronic acid | | organochlorine compound | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tirofiban | | L-tyrosine derivative;
piperidines;
sulfonamide | anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| capecitabine | | carbamate ester;
cytidines;
organofluorine compound | antimetabolite;
antineoplastic agent;
prodrug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| adenosine | | adenosines;
purines D-ribonucleoside | analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| d-lactic acid | | 2-hydroxypropanoic acid | Escherichia coli metabolite;
human metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| octyl glucoside | | beta-D-glucoside | plant metabolite | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| paroxetine hydrochloride | | hydrochloride | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 2012 | 2013 | 11.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| bupropion hydrochloride | | aromatic ketone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| halofuginone | | quinazolines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trazodone hydrochloride | | hydrochloride | adrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ortho-cept | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trovafloxacin | | | | 2014 | 2016 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| verapamil hydrochloride | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefprozil | | cephalosporin;
semisynthetic derivative | antibacterial drug | 2004 | 2016 | 14.0 | high | 0 | 0 | 0 | 2 | 1 | 0 |
| doxazosin mesylate | | methanesulfonate salt | geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methylprednisolone aceponate | | corticosteroid hormone | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexamethasone 17-valerate | | 21-hydroxy steroid | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexamethasone dipropionate | | corticosteroid hormone | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| efavirenz | | acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| nelfinavir | | aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound | antineoplastic agent;
HIV protease inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| doxapram hydrochloride | | hydrochloride | central nervous system stimulant | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| mevastatin | | 2-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite | 2006 | 2013 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bupivacaine hydrochloride | | hydrochloride;
racemate | adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenofibric acid | | aromatic ketone;
chlorobenzophenone;
monocarboxylic acid | drug metabolite;
marine xenobiotic metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1,5-anhydroglucitol | | anhydro sugar | human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betulinic acid | | hydroxy monocarboxylic acid;
pentacyclic triterpenoid | anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| plerixafor | | azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound | anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| amprenavir | | carbamate ester;
sulfonamide;
tetrahydrofuryl ester | antiviral drug;
HIV protease inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| oseltamivir | | acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound | antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ticlopidine hydrochloride | | hydrochloride | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epirubicin hydrochloride | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| glutathione disulfide | | glutathione derivative;
organic disulfide | Escherichia coli metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenclofenac | | aromatic ether | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| iopamidol | | benzenedicarboxamide;
organoiodine compound;
pentol | environmental contaminant;
radioopaque medium;
xenobiotic | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| proxicromil | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| histamine phosphate | | phosphate salt | histamine agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tilbroquinol | | organohalogen compound;
quinolines | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| bendamustine | | benzimidazoles | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| erdosteine | | N-acyl-amino acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| droxicam | | organic heterotricyclic compound;
pyridines | cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ceftezole | | cephalosporin;
thiadiazoles | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| esreboxetine | | aromatic ether | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| inaperisone | | aromatic ketone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ebrotidine | | sulfonamide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| torbafylline | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mizolastine | | benzimidazoles | | 2003 | 2011 | 16.6 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| terikalant | | piperidines | | 2003 | 2008 | 18.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| intoplicine | | pyridoindole | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pazufloxacin | | quinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| repaglinide | | piperidines | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| telmisartan | | benzimidazoles;
biphenyls;
carboxybiphenyl | angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| hexestrol bis(diethylaminoethyl ether) | | stilbenoid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexfenfluramine | | fenfluramine | appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor | 2004 | 2010 | 16.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| 2-methoxyestradiol | | 17beta-hydroxy steroid;
3-hydroxy steroid | angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-phenylbenzoic acid | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiamorpholine | | saturated organic heteromonocyclic parent;
thiomorpholines | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| miconazole nitrate | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| disobutamide | | acetamides | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| medetomidine | | imidazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sertraline | | dichlorobenzene;
secondary amino compound;
tetralins | antidepressant;
serotonin uptake inhibitor | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 5 | 3 | 0 |
| picosulfate sodium | | aryl sulfate;
pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rilmenidine | | isourea | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| zoledronic acid | | 1,1-bis(phosphonic acid);
imidazoles | bone density conservation agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| budipine | | diarylmethane | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| artemisinin | | organic peroxide;
sesquiterpene lactone | antimalarial;
plant metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| brinzolamide | | sulfonamide;
thienothiazine | antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mesulergine | | ergot alkaloid;
sulfamides | antiparkinson drug;
dopamine agonist;
serotonergic antagonist | 1996 | 2009 | 23.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| dienogest | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
aliphatic nitrile;
steroid hormone | progesterone receptor agonist;
progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tianeptine | | dibenzothiazepine;
monocarboxylic acid;
organochlorine compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| drospirenone | | 3-oxo-Delta(4) steroid;
steroid lactone | aldosterone antagonist;
contraceptive drug;
progestin | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| artemether | | artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid | antimalarial | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glycyl-glycyl-glycyl-glycine | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| morphazinamide | | morpholines;
pyrazines;
secondary carboxamide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dipropylacetamide | | fatty amide | geroprotector;
metabolite;
teratogenic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acamprosate | | acetamides;
organosulfonic acid | environmental contaminant;
neurotransmitter agent;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| isaxonine | | aminopyrimidine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enrofloxacin | | cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone | antibacterial agent;
antimicrobial agent;
antineoplastic agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diprafenone | | aromatic compound | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| metaclazepam | | benzodiazepine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erythromycin propionate | | erythromycin derivative | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nebivolol | | chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound | | 2014 | 2016 | 9.0 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| uk 68798 | | aromatic ether;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
potassium channel blocker | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| hp 873 | | 1,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound | dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 1996 | 2016 | 15.7 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| dexrazoxane | | razoxane | antineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| loxapine succinate | | succinate salt | geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenoxypropazine | | aromatic ether | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| antebate | | corticosteroid hormone | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| voriconazole | | conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug | P450 inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| betamipron | | organonitrogen compound;
organooxygen compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mepindolol | | indoles | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fpl 52791 | | | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| bufuralol | | benzofurans | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| carazolol | | carbazoles | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| uroxatral | | hydrochloride | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aceclofenac | | amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mdl 11939 | | primary amine | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clociguanil | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| nitrefazole | | imidazoles | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epanolol | | acetamides | | 2000 | 2012 | 18.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| cyclobutyrol | | hydroxy monocarboxylic acid | bile therapy drug | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| thiocolchicoside | | glycoside | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| terlipressin | | polypeptide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methotrimeprazine | | phenothiazines;
tertiary amine | anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist | 2000 | 2014 | 15.3 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| isoflavone | | isoflavones | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| clevudine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lividomycin | | lividomycins | metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gentamicin c1 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| grepafloxacin | | fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic | | 2003 | 2011 | 17.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| oleandomycin | | oleandomycins | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-(4'-methylpiperazino-1-methyl)-1,3-diazafluoranthene 1-oxide | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| tetrandrine | | bisbenzylisoquinoline alkaloid;
isoquinolines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| doripenem | | carbapenems | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| atovaquone | | hydroxy-1,2-naphthoquinone | | 2000 | 2016 | 17.8 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| phenylalanyl-phenylalanyl-phenylalanine | | oligopeptide | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-(4-methoxybenzoyl)propionic acid | | | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dimethylaminopropanol | | | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| rivastigmine | | carbamate ester;
tertiary amino compound | cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent | 2014 | 2016 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| frovatriptan | | carbazoles | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| eletriptan | | indoles;
N-alkylpyrrolidine;
sulfone | non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| rosiglitazone | | aminopyridine;
thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug | 2006 | 2016 | 12.6 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| tamiflu | | phosphate salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bexarotene | | benzoic acids;
naphthalenes;
retinoid | antineoplastic agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| s20098 | | acetamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flunisolide | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
primary alpha-hydroxy ketone | anti-asthmatic drug;
anti-inflammatory drug;
immunosuppressive agent | 2004 | 2013 | 14.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| 4-phenylbutylamine | | benzenes;
phenylalkylamine;
primary amino compound | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ketorolac tromethamine | | organoammonium salt | analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clarithromycin | | macrolide antibiotic | antibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic | 2003 | 2016 | 14.7 | low | 0 | 0 | 0 | 6 | 4 | 0 |
| glycinexylidide | | amino acid amide | drug metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Trp-Trp | | dipeptide | Mycoplasma genitalium metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| kampirone | | N-arylpiperazine | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nicotine | | 3-(1-methylpyrrolidin-2-yl)pyridine | anxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic | 2000 | 2014 | 16.1 | low | 0 | 0 | 1 | 8 | 3 | 0 |
| moexipril | | peptide | | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| tandospirone | | bridged compound;
dicarboximide;
N-alkylpiperazine;
N-arylpiperazine;
pyrimidines | antidepressant;
anxiolytic drug | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| sennoside B | | oxo dicarboxylic acid;
sennosides | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| gliquidone | | isoquinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| levobupivacaine | | 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide | adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lekoptin | | 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mci 9038 | | peptide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lopinavir | | amphetamines;
dicarboxylic acid diamide | anticoronaviral agent;
antiviral drug;
HIV protease inhibitor | 2010 | 2013 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| isopelletierine | | citraconoyl group | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenpropimorph | | alkylbenzene | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| levcromakalim | | 1-benzopyran | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dimethacrine | | acridines | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-(2-pyridinyl)piperazine | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glucuronic acid | | D-glucuronic acid | algal metabolite | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| moxifloxacin hydrochloride | | hydrochloride | antibacterial drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methyl mannoside, (alpha-d)-isomer | | alpha-D-mannoside;
methyl mannoside | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexylcaine hydrochloride | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fulvestrant | | 17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide | antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist | 2006 | 2016 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| mizoribine | | imidazoles | anticoronaviral agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imipenem, anhydrous | | beta-lactam antibiotic allergen;
carbapenems;
zwitterion | antibacterial drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sn 38 | | delta-lactone;
phenols;
pyranoindolizinoquinoline;
tertiary alcohol | antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sr141716 | | amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles | anti-obesity agent;
appetite depressant;
CB1 receptor antagonist | 2010 | 2013 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| bosentan anhydrous | | primary alcohol;
pyrimidines;
sulfonamide | antihypertensive agent;
endothelin receptor antagonist | 2010 | 2016 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| ecgonine methyl ester | | methyl ester;
tertiary amino compound;
tropane alkaloid | analgesic;
central nervous system depressant;
metabolite;
mouse metabolite;
opioid analgesic;
peripheral nervous system drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fpl 55712 | | aromatic ketone | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| selenomethionine | | amino acid zwitterion;
selenomethionine | plant metabolite | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| l-lactic acid | | (2S)-2-hydroxy monocarboxylic acid;
2-hydroxypropanoic acid | Escherichia coli metabolite;
human metabolite | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| sivelestat | | N-acylglycine;
pivalate ester | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| racecadotril | | N-acyl-amino acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| perindopril | | alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| fingolimod | | aminodiol;
primary amino compound | antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 6-chloro-2-(1-piperazinyl)pyrazine | | N-arylpiperazine | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5-methoxy 3-(1,2,3,6-tetrahydro-4-pyridinyl)1h indole | | indoles | | 1996 | 1998 | 27.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol | | N-arylpiperazine | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| ecteinascidin 743 | | acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound | alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tadalafil | | benzodioxoles;
pyrazinopyridoindole | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2006 | 2016 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| 5-hydroxydopamine | | catecholamine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ibuprofen, (r)-isomer | | ibuprofen | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| norbuprenorphine | | phenanthrenes | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| paliperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol | | 2009 | 2016 | 12.0 | medium | 0 | 0 | 0 | 1 | 2 | 0 |
| nitisinone | | (trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione | EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| plavix | | azaheterocycle sulfate salt;
organoammonium sulfate salt | anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| marimastat | | hydroxamic acid;
secondary carboxamide | antineoplastic agent;
matrix metalloproteinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clofarabine | | adenosines;
organofluorine compound | antimetabolite;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| pramipexole | | benzothiazoles;
diamine | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| mosapride | | aromatic ether;
benzamides;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
secondary carboxamide;
substituted aniline;
tertiary amino compound | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| deramciclane | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valdecoxib | | isoxazoles;
sulfonamide | antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2006 | 2016 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| 293b cpd | | 1-benzopyran | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mitiglinide | | benzenes;
monocarboxylic acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ezogabine | | carbamate ester;
organofluorine compound;
secondary amino compound;
substituted aniline | anticonvulsant;
potassium channel modulator | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fpl-52694 | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-(2-(4-aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine | | (trifluoromethyl)benzenes;
N-alkylpiperazine;
N-arylpiperazine;
primary arylamine;
substituted aniline | geroprotector;
serotonergic agonist | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| uh 301 | | | | 1998 | 2009 | 20.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| ici 169369 | | | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 5-(dimethylamino)-n-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide | | naphthalenes;
sulfonic acid derivative | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| imatinib mesylate | | methanesulfonate salt | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| almotriptan | | indoles;
sulfonamide;
tertiary amine | non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tecastemizole | | | | 2003 | 2008 | 18.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| mk 0663 | | bipyridines;
organochlorine compound;
sulfone | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tazobactam | | penicillanic acids;
triazoles | antiinfective agent;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gefitinib | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine | | adenosines;
monocarboxylic acid amide;
organoiodine compound | adenosine A3 receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ramatroban | | organic molecular entity | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| desloratadine | | benzocycloheptapyridine | anti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| desvenlafaxine | | cyclohexanols;
phenols;
tertiary amino compound | antidepressant;
drug metabolite;
marine xenobiotic metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| r-1-(6-(r-2-carboxypyrrolidin-1-yl)-6-oxohexanoyl)pyrrolidine-2-carboxylic acid | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bd 1008 | | primary amine | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methotrexate | | dicarboxylic acid;
monocarboxylic acid amide;
pteridines | abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent | 2000 | 2016 | 14.4 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| fg 5893 | | | | 1998 | 1998 | 26.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| xaliproden | | (trifluoromethyl)benzenes;
naphthalenes;
tertiary amino compound;
tetrahydropyridine | serotonergic agonist | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tamsulosin | | 5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide | alpha-adrenergic antagonist;
antineoplastic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rufinamide | | aromatic amide;
heteroarene | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| antiprimod | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-isobutyrylcysteine | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulbactam | | penicillanic acids | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nonyl-4-hydroxyquinoline-n-oxide | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| olmesartan medoxomil | | biphenyls | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| dexpanthenol | | amino alcohol;
monocarboxylic acid amide | cholinergic drug;
provitamin | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| fosamprenavir | | sulfonamide | prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| s 14671 | | | | 1998 | 1998 | 26.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| quilostigmine | | pyrroloindole | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ilomastat | | hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| abiraterone | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines | antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| l 741742 | | primary amine | | 2001 | 2001 | 23.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| sonepiprazole | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| imiloxan | | benzodioxine | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| febuxostat | | 1,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile | EC 1.17.3.2 (xanthine oxidase) inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| aspartame | | carboxylic acid;
dipeptide zwitterion;
dipeptide;
methyl ester | apoptosis inhibitor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
environmental contaminant;
micronutrient;
nutraceutical;
sweetening agent;
xenobiotic | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| xylose | | D-xylose | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tempol | | aminoxyls;
hydroxypiperidine | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
catalyst;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
radical scavenger | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cdri 81-470 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| escitalopram | | 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile | antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lexapro | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 10-propargyl-10-deazaaminopterin | | N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound | antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| docetaxel | | hydrate;
secondary alpha-hydroxy ketone | antineoplastic agent | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| docetaxel anhydrous | | secondary alpha-hydroxy ketone;
tetracyclic diterpenoid | antimalarial;
antineoplastic agent;
photosensitizing agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| atazanavir | | carbohydrazide | antiviral drug;
HIV protease inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| levofloxacin | | 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor | 2003 | 2016 | 14.3 | low | 0 | 0 | 0 | 6 | 6 | 0 |
| ezetimibe | | azetidines;
beta-lactam;
organofluorine compound | anticholesteremic drug;
antilipemic drug;
antimetabolite | 2005 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ertapenem | | carbapenemcarboxylic acid;
pyrrolidinecarboxamide | antibacterial drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cox 189 | | amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| conivaptan | | benzazepine | aquaretic;
vasopressin receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cariporide | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tezosentan | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vatalanib | | monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| moxifloxacin | | aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug | 2003 | 2016 | 14.1 | low | 0 | 0 | 0 | 4 | 4 | 0 |
| vx 497 | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pralnacasan | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clevidipine | | dihydropyridine | | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| jtt 501 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| solifenacin | | isoquinolines | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dexmethylphenidate | | methyl phenyl(piperidin-2-yl)acetate | adrenergic agent | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| hyoscyamine | | tropane alkaloid | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| xamoterol | | morpholines | | 2000 | 2013 | 17.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| desmethylastemizole | | benzimidazoles | | 2003 | 2008 | 18.5 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| naproxen | | methoxynaphthalene;
monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2000 | 2016 | 14.4 | low | 0 | 0 | 1 | 3 | 5 | 0 |
| cinacalcet | | (trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound | calcimimetic;
P450 inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lactitol | | glycosyl alditol | cathartic;
excipient;
laxative | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lubiprostone | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| olmesartan | | biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent | 2011 | 2012 | 12.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| telbivudine | | pyrimidine 2'-deoxyribonucleoside | antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mdl 74156 | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| clofibride | | monocarboxylic acid | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cyc 202 | | 2,6-diaminopurines | antiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2006 | 2010 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| fpl 52757 | | | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| asenapine | | 5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole | | 1996 | 2009 | 23.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| zalospirone | | | | 1998 | 1998 | 26.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| paromomycin | | amino cyclitol glycoside;
aminoglycoside antibiotic | anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| anidulafungin | | antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| avasimibe | | monoterpenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminopterin | | dicarboxylic acid | EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 17 alpha-hydroxyprogesterone caproate | | corticosteroid hormone | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| varenicline | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| biotin | | biotins;
vitamin B7 | coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| angiotensin ii | | amino acid zwitterion;
angiotensin II | human metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fiduxosin | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fpl 59257 | | | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| atropine | | | | 2000 | 2016 | 13.8 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| ly 97241 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ropivacaine | | piperidinecarboxamide;
ropivacaine | local anaesthetic | 2004 | 2012 | 16.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sb 203580 | | imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erlotinib | | aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound | antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| zeneca zd 6169 | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| l 694,458 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sibenadet | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| emd 60263 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ngd 94-1 | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbocysteine | | L-cysteine thioether;
non-proteinogenic L-alpha-amino acid | mucolytic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etravirine | | aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound | antiviral agent;
HIV-1 reverse transcriptase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| latrepirdine | | methylpyridines;
pyridoindole | geroprotector | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| troleandomycin | | acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative | EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| yh 1885 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dronedarone | | 1-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
environmental contaminant;
xenobiotic | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ramelteon | | indanes | | 2012 | 2016 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| lapatinib | | furans;
organochlorine compound;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bifeprunox | | biphenyls | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| darunavir | | carbamate ester;
furofuran;
sulfonamide | antiviral drug;
HIV protease inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| deferasirox | | benzoic acids;
monocarboxylic acid;
phenols;
triazoles | iron chelator | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| bms204352 | | | | 2005 | 2013 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tbc-11251 | | benzodioxoles | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| tolvaptan | | benzazepine;
benzenedicarboxamide | aquaretic;
vasopressin receptor antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide | angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| lenalidomide | | aromatic amine;
dicarboximide;
isoindoles;
piperidones | angiogenesis inhibitor;
antineoplastic agent;
immunomodulator | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| regadenoson | | purine nucleoside | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lacosamide | | N-acyl-amino acid | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sitosterol, (3beta)-isomer | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C29-steroid;
phytosterols;
stigmastane sterol | anticholesteremic drug;
antioxidant;
mouse metabolite;
plant metabolite;
sterol methyltransferase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| estradiol 3-benzoate | | 17beta-hydroxy steroid;
benzoate ester | estrogen receptor agonist;
xenoestrogen | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cortisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dromostanolone propionate | | 3-oxo-5alpha-steroid;
steroid ester | antineoplastic agent | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| vincaleukoblastine | | acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 5 alpha-androstane-3 beta,17 beta-diol | | 17beta-hydroxy steroid;
3beta-hydroxy steroid;
androstane-3,17-diol | Daphnia magna metabolite;
human metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vincristine sulfate | | organic sulfate salt | antineoplastic agent;
geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzarone | | 1-benzofurans | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| estramustine | | 17beta-hydroxy steroid;
carbamate ester;
organochlorine compound | alkylating agent;
antineoplastic agent;
radiation protective agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| phenethicillin | | penicillin allergen;
penicillin | | 2008 | 2014 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| noscapine | | aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound | antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| homoharringtonine | | alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| wortmannin | | acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound | anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent | 2006 | 2013 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| menthofuran | | 1-benzofurans;
monoterpenoid | nematicide;
plant metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| o-(chloroacetylcarbamoyl)fumagillol | | carbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide | angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bortezomib | | amino acid amide;
L-phenylalanine derivative;
pyrazines | antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ritonavir | | 1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas | antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| nexavar | | organosulfonate salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rimiterol | | catechols | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| glucosamine | | D-glucosamine | Escherichia coli metabolite;
geroprotector;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5-hydroxytryptophan | | 5-hydroxytryptophan;
amino acid zwitterion;
hydroxy-L-tryptophan;
non-proteinogenic L-alpha-amino acid | human metabolite;
mouse metabolite;
plant metabolite | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxytocin | | heterodetic cyclic peptide;
peptide hormone | oxytocic;
vasodilator agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bekanamycin | | kanamycins | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ouabain | | 11alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone | anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| salicin | | aromatic primary alcohol;
aryl beta-D-glucoside;
benzyl alcohols | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pentostatin | | coformycins | antimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| strychnine | | monoterpenoid indole alkaloid;
organic heteroheptacyclic compound | avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinidine | | cinchona alkaloid | alpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker | 2000 | 2016 | 15.6 | low | 0 | 0 | 1 | 7 | 4 | 0 |
| meropenem | | alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide | antibacterial agent;
antibacterial drug;
drug allergen | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| griseofulvin | | 1-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound | antibacterial agent;
Penicillium metabolite | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| cefoxitin | | beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative | antibacterial drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| digitoxin | | cardenolide glycoside | EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor | 2010 | 2013 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| saquinavir | | L-asparagine derivative;
quinolines | antiviral drug;
HIV protease inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| pancuronium | | acetate ester;
steroid ester | cholinergic antagonist;
muscle relaxant;
nicotinic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| abacavir | | 2,6-diaminopurines | antiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| netilmicin | | | | 2004 | 2010 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| trimethaphan camsylate | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perindopril erbumine | | addition compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| miglitol | | piperidines | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| metyrosine | | L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor | 2004 | 2016 | 13.3 | medium | 0 | 0 | 0 | 1 | 2 | 0 |
| rocuronium bromide | | organic bromide salt;
quaternary ammonium salt | muscle relaxant;
neuromuscular agent | 2004 | 2013 | 15.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| mefloquine hydrochloride | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erythromycin estolate | | aminoglycoside sulfate salt;
erythromycin derivative | enzyme inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| terconazole | | 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bacampicillin | | penicillanic acid ester | prodrug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| linezolid | | acetamides;
morpholines;
organofluorine compound;
oxazolidinone | antibacterial drug;
protein synthesis inhibitor | 2012 | 2016 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| (S)-bicalutamide | | N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| norpseudoephedrine | | amphetamines;
phenethylamine alkaloid | central nervous system stimulant;
plant metabolite;
psychotropic drug | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyclopamine | | piperidines | glioma-associated oncogene inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetylleucyl-leucyl-norleucinal | | aldehyde;
tripeptide | cysteine protease inhibitor | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| devazepide | | 1,4-benzodiazepinone;
indolecarboxamide | antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| clindamycin phosphate | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hetacillin | | penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pemirolast potassium salt | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| eplerenone | | 3-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester | aldosterone antagonist;
antihypertensive agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tolterodine | | tertiary amine | antispasmodic drug;
muscarinic antagonist;
muscle relaxant | 2005 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| doxorubicin hydrochloride | | anthracycline | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| halcinonide | | organic molecular entity | SMO receptor agonist | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metrizamide | | amino sugar | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| medigoxin | | cardenolide glycoside | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dironyl | | organic molecular entity | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| erythromycin ethylsuccinate | | cyclic ketone;
erythromycin derivative;
ethyl ester;
succinate ester | | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| vinpocetine | | alkaloid | geroprotector | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amcinonide | | 11beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
corticosteroid;
fluorinated steroid;
spiroketal | anti-inflammatory drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betamethasone acetate | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
fluorinated steroid;
steroid ester;
tertiary alpha-hydroxy ketone | | 2004 | 2008 | 18.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| ao 128 | | organic molecular entity | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| loteprednol etabonate | | 11beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
etabonate ester;
organochlorine compound;
steroid acid ester;
steroid ester | anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| darifenacin | | 1-benzofurans;
monocarboxylic acid amide;
pyrrolidines | antispasmodic drug;
muscarinic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluticasone propionate | | 11beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester | adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acarbose | | amino cyclitol;
glycoside | | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| e-z cinnamic acid | | cinnamic acid | plant metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trichostatin a | | antibiotic antifungal agent;
hydroxamic acid;
trichostatin | bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tretinoin | | retinoic acid;
vitamin A | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule | 2000 | 2016 | 14.9 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| retinol | | retinol;
vitamin A | human metabolite;
mouse metabolite;
plant metabolite | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| alpha-D-fructofuranose 1,6-bisphosphate | | D-fructofuranose 1,6-bisphosphate | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| docosahexaenoate | | docosahexaenoic acid;
omega-3 fatty acid | algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oleic acid | | octadec-9-enoic acid | antioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tacrolimus | | macrolide lactam | bacterial metabolite;
immunosuppressive agent | 2005 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cerivastatin | | dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic) | | 2006 | 2010 | 15.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| rosuvastatin | | dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide | anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic | 2006 | 2016 | 13.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2003 | 2014 | 16.0 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| eicosapentaenoic acid | | icosapentaenoic acid;
omega-3 fatty acid | anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mycophenolic acid | | 2-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic | 2004 | 2020 | 13.0 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| mupirocin | | alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol | antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| clindamycin | | | | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| brivudine | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosfomycin | | epoxide;
phosphonic acids | antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| zithromax | | macrolide antibiotic | antibacterial drug;
environmental contaminant;
xenobiotic | 2004 | 2020 | 12.6 | low | 0 | 0 | 0 | 4 | 4 | 0 |
| drf 2725 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| y 27632 | | aromatic amide | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diethylstilbestrol | | olefinic compound;
polyphenol | antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| octreotide | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| epothilone a | | epothilone;
epoxide | antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| eptifibatide | | homodetic cyclic peptide;
macrocycle;
organic disulfide | anticoagulant;
platelet aggregation inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alitretinoin | | retinoic acid | antineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| h 89 | | N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide | | 2006 | 2020 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| decitabine | | 2'-deoxyribonucleoside | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| teniposide | | aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2004 | 2016 | 13.2 | medium | 0 | 0 | 0 | 2 | 2 | 0 |
| valrubicin | | anthracycline;
trifluoroacetamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefamandole | | cephalosporin;
semisynthetic derivative | antibacterial drug | 2004 | 2014 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dactinomycin | | actinomycin | mutagen | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| tiazofurin | | 1,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide | antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| melphalan | | L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde | | amino aldehyde;
carbamate ester;
tripeptide | proteasome inhibitor | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tenofovir | | nucleoside analogue;
phosphonic acids | antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| posaconazole | | aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles | trypanocidal drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| dibekacin | | kanamycins | antibacterial agent;
protein synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rubitecan | | C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| micafungin | | antibiotic antifungal drug;
echinocandin | antiinfective agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| riboflavin | | flavin;
vitamin B2 | anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| sodium bicarbonate | | one-carbon compound;
organic sodium salt | antacid;
food anticaking agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sodium acetate, anhydrous | | organic sodium salt | NMR chemical shift reference compound | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium benzoate | | organic sodium salt | algal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arsenic trioxide | | arsenic oxide | antineoplastic agent;
insecticide | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dipyrone | | organic sodium salt | anti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ditiocarb sodium | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| artemisin | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sch 22219 | | 11beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
glucocorticoid;
propanoate ester;
steroid ester | anti-inflammatory drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sr 90107 | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| carbenoxolone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| meglumine iodipamide | | organoammonium salt | radioopaque medium | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thyrotropin-releasing hormone | | peptide hormone;
tripeptide | human metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sorbic acid | | alpha,beta-unsaturated monocarboxylic acid;
sorbic acid | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rauwolscine | | methyl 17-hydroxy-20xi-yohimban-16-carboxylate | | 2009 | 2014 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| discodermolide | | diterpenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flavin mononucleotide | | flavin mononucleotide;
vitamin B2 | bacterial metabolite;
coenzyme;
cofactor;
human metabolite;
mouse metabolite | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cannabidiol | | olefinic compound;
phytocannabinoid;
resorcinols | antimicrobial agent;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arginine vasopressin | | vasopressin | cardiovascular drug;
hematologic agent;
mitogen | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| s 1033 | | (trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mezlocillin | | penicillin allergen;
penicillin | antibacterial drug | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| trilostane | | 17beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile | abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cholinophyllin | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mitobronitol | | alcohol;
organobromine compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tropisetron | | indolyl carboxylic acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prednisolone hemisuccinate | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
hemisuccinate;
tertiary alpha-hydroxy ketone | anti-inflammatory drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| leuprolide acetate | | acetate salt | antineoplastic agent;
gonadotropin releasing hormone agonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| leuprolide | | oligopeptide | anti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| octotropine methylbromide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fludarabine | | purine nucleoside | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propylthiouracil | | pyrimidinethione | antidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| nsc 4347 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ipratropium bromide anhydrous | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ipratropium | | | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| prothionamide | | pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorprothixene | | chlorprothixene | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| doxepin hydrochloride | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| etomidate | | ethyl ester;
imidazoles | intravenous anaesthetic;
sedative | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| mercaptopurine | | aryl thiol;
purines;
thiocarbonyl compound | anticoronaviral agent;
antimetabolite;
antineoplastic agent | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| methylthiouracil | | pyrimidone | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| jrf 12 | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| crotamiton | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| levosulpiride | | sulpiride | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyrantel | | 1,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes | antinematodal drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lobeline | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cotinine | | N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid | antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flunarizine | | diarylmethane | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiothixene | | N-methylpiperazine | anticoronaviral agent | 2003 | 2016 | 15.4 | medium | 0 | 0 | 0 | 3 | 2 | 0 |
| eszopiclone | | zopiclone | central nervous system depressant;
sedative | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| benztropine | | diarylmethane | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| thiouracil | | nucleobase analogue;
thiocarbonyl compound | antithyroid drug;
metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methimazole | | 1,3-dihydroimidazole-2-thiones | antithyroid drug | 2010 | 2016 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| cinnarizine | | diarylmethane;
N-alkylpiperazine;
olefinic compound | anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist | 2006 | 2013 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sulindac | | monocarboxylic acid;
organofluorine compound;
sulfoxide | analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| capsaicin | | capsaicinoid | non-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| enclomiphene | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zuclomiphene | | stilbenoid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| terbinafine | | acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 4 | 2 | 0 |
| epalrestat | | monocarboxylic acid;
thiazolidines | EC 1.1.1.21 (aldehyde reductase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1,4-benzoquinone guanylhydrazone thiosemicarbazone | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| drotaverin | | isoquinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4E2RCat | | organic molecular entity | | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| thioguanine anhydrous | | 2-aminopurines | anticoronaviral agent;
antimetabolite;
antineoplastic agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| tacrine hydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium propionate | | organic sodium salt | antifungal drug;
food preservative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| succimer | | dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid | chelator | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| digoxin | | cardenolide glycoside;
steroid saponin | anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope | 2008 | 2016 | 13.0 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| streptozocin | | | | 2004 | 2016 | 14.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 5 | 7 | 0 |
| 4-methylumbelliferyl glucoside | | beta-D-glucoside;
coumarins;
monosaccharide derivative | chromogenic compound | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ethionamide | | pyridines;
thiocarboxamide | antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| jnj-5207852 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cancidas | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| zeranol | | macrolide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fusidic acid | | 11alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester | EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| scopolamine | | 3-hydroxy carboxylic acid | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| lincomycin | | carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound | antimicrobial agent;
bacterial metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valinomycin | | cyclodepsipeptide;
macrocycle | antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiopental | | barbiturates | anticonvulsant;
drug allergen;
environmental contaminant;
intravenous anaesthetic;
sedative;
xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| estrone sulfate | | 17-oxo steroid;
steroid sulfate | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ranitidine | | C-nitro compound;
furans;
organic sulfide;
tertiary amino compound | anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| aplaviroc | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hmr 3647 | | | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| latoconazole | | conazole antifungal drug;
imidazole antifungal drug | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| maraviroc | | tropane alkaloid | | 2009 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| toremifene citrate | | stilbenoid | anticoronaviral agent | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| toremifene | | aromatic ether;
organochlorine compound;
tertiary amine | antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 2006 | 2016 | 14.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| telaprevir | | cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines | antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nelarabine | | beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside | antineoplastic agent;
DNA synthesis inhibitor;
prodrug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 4-diphenylacetoxy-n-methylpiperidine methiodide | | iodide salt;
quaternary ammonium salt | cholinergic antagonist;
muscarinic antagonist | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine | | aromatic ether | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| albutoin | | organonitrogen compound;
organooxygen compound | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| iodothiouracil | | organohalogen compound;
pyrimidines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dermatan sulfate | | amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dezocine | | phenols;
primary amino compound | opioid analgesic | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dapiprazole | | N-alkylpiperazine;
N-arylpiperazine;
pyridines | alpha-adrenergic antagonist;
antipsychotic agent;
miotic;
ophthalmology drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| droloxifene | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| raclopride | | salicylamides | | 1998 | 2000 | 25.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| dolasetron | | indolyl carboxylic acid | | 2003 | 2016 | 15.6 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| or 1259 | | hydrazone;
nitrile;
pyridazinone | anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| almokalant | | | | 2005 | 2012 | 15.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| gestodene | | steroid | estrogen | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| orlistat | | beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative | anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| idoxifene | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinine | | cinchona alkaloid | antimalarial;
muscle relaxant;
non-narcotic analgesic | 2000 | 2016 | 13.0 | low | 0 | 0 | 1 | 0 | 4 | 0 |
| zofenoprilate | | aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thiol | anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| glyceryl nonivamide | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-(1h-imidazol-4-ylmethyl)piperidine | | piperidines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thioperamide | | primary aliphatic amine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alpha-hydroxytamoxifen | | stilbenoid | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sch 23390 | | benzazepine | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bp 897 | | naphthalenecarboxamide | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fospropofol | | alkylbenzene | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vx-745 | | aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine | anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azilect | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rasagiline | | indanes;
secondary amine;
terminal acetylenic compound | EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| deracoxib | | organofluorine compound;
pyrazoles;
sulfonamide | cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dasatinib | | 1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2012 | 2016 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| 2-aminohippuric acid | | N-acylglycine | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| zd 6474 | | aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine | antineoplastic agent;
tyrosine kinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| silybin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sb 258585 | | piperazines | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rs-130830 | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nafadotride | | aromatic ether;
naphthalenecarboxamide;
nitrile;
pyrrolidines;
tertiary amino compound | dopaminergic antagonist | 1998 | 2004 | 23.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| chloramine-t | | organic sodium salt | allergen;
antifouling biocide;
disinfectant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rs 102221 | | aromatic ketone | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sc 560 | | aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles | angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sitagliptin | | triazolopyrazine;
trifluorobenzene | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic | 2012 | 2016 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| flosequinan | | quinolines | | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tolcapone | | 2-nitrophenols;
benzophenones;
catechols | antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 2005 | 2016 | 13.4 | low | 0 | 0 | 0 | 4 | 3 | 0 |
| quercetin | | 7-hydroxyflavonol;
pentahydroxyflavone | antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger | 2013 | 2020 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bilirubin | | biladienes;
dicarboxylic acid | antioxidant;
human metabolite;
mouse metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dinoprostone | | prostaglandins E | human metabolite;
mouse metabolite;
oxytocic | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| dinoprost | | monocarboxylic acid;
prostaglandins Falpha | human metabolite;
mouse metabolite | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tylosin | | aldehyde;
disaccharide derivative;
enone;
leucomycin;
macrolide antibiotic;
monosaccharide derivative | allergen;
bacterial metabolite;
environmental contaminant;
xenobiotic | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| apigenin | | trihydroxyflavone | antineoplastic agent;
metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| calcitriol | | D3 vitamins;
hydroxycalciol;
triol | antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| vitamin k semiquinone radical | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| beta carotene | | carotenoid beta-end derivative;
cyclic carotene | antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| alprostadil | | prostaglandins E | anticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent | 2004 | 2014 | 13.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| vitamin d 2 | | hydroxy seco-steroid;
seco-ergostane;
vitamin D | bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| cholecalciferol | | D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone | geroprotector;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| genistein | | 7-hydroxyisoflavones | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amphotericin b | | antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic | antiamoebic agent;
antiprotozoal drug;
bacterial metabolite | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| clavulanic acid | | oxapenam | antibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| pulmicort | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone | anti-inflammatory drug;
bronchodilator agent;
drug allergen | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| oxymetholone | | | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| eprosartan | | dicarboxylic acid;
imidazoles;
thiophenes | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| montelukast | | aliphatic sulfide;
monocarboxylic acid;
quinolines | anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| mivacurium | | isoquinolines | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| brompheniramine maleate | | maleate salt | anti-allergic agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dexchlorpheniramine maleate | | organic molecular entity | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| olopatadine | | | | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| hemabate | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ethchlorvynol | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mycophenolate mofetil | | carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound | anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 2 | 0 |
| bw b1090u | | isoquinolines | | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| entacapone | | 2-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile | antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 2005 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| paricalcitol | | hydroxy seco-steroid;
seco-cholestane | antiparathyroid drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| astaxanthine | | carotenol;
carotenone | animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diosmin | | dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside | anti-inflammatory agent;
antioxidant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cynarine | | alkyl caffeate ester;
quinic acid | plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sdz psc 833 | | homodetic cyclic peptide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| l 660,711 | | quinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| coenzyme q10 | | ubiquinones | antioxidant;
ferroptosis inhibitor;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pheniramine maleate | | organic molecular entity | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rokitamycin | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| travoprost | | (trifluoromethyl)benzenes;
isopropyl ester;
prostaglandins Falpha | antiglaucoma drug;
antihypertensive agent;
ophthalmology drug;
prodrug;
prostaglandin receptor agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tranilast | | amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide | anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 7432 s | | cephalosporin;
dicarboxylic acid | antibacterial drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| imipenem | | carbapenems | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| etretinate | | enoate ester;
ethyl ester;
retinoid | keratolytic drug | 2004 | 2013 | 15.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| isotretinoin | | retinoic acid | antineoplastic agent;
keratolytic drug;
teratogenic agent | 2004 | 2016 | 12.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| misoprostol | | | | 2004 | 2010 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| ketotifen fumarate | | organoammonium salt | anti-asthmatic drug;
H1-receptor antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epoprostenol | | prostaglandins I | mouse metabolite | 2004 | 2016 | 14.7 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| indocyanine green | | 1,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dinoprost tromethamine | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ozagrel | | cinnamic acids | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triprolidine | | N-alkylpyrrolidine;
olefinic compound;
pyridines | H1-receptor antagonist | 2007 | 2016 | 12.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| pitavastatin | | cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic) | antioxidant | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| rosuvastatin calcium | | N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine;
organic calcium salt | anti-inflammatory agent;
cardioprotective agent;
CETP inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| terbinafine hydrochloride | | allylamine antifungal drug;
hydrochloride | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ethamolin | | long-chain fatty acid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| betamethasone benzoate | | 21-hydroxy steroid | | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| alatrofloxacin mesylate | | | | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| homatropine | | tropane alkaloid | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| codeine | | morphinane alkaloid;
organic heteropentacyclic compound | antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic | 2000 | 2016 | 15.7 | low | 0 | 0 | 1 | 3 | 2 | 0 |
| cyclosporine | | homodetic cyclic peptide | anti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite | 2005 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| natamycin | | antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic | antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug | 2008 | 2013 | 13.7 | high | 0 | 0 | 0 | 2 | 1 | 0 |
| acitretin | | acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid | keratolytic drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cloprednol | | 21-hydroxy steroid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyproterone | | 17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
chlorinated steroid;
tertiary alpha-hydroxy ketone | androgen antagonist | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dihydrocodeine | | morphinane alkaloid | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dorzolamide | | sulfonamide;
thiophenes | antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dothiepin | | dothiepin | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| estropipate | | piperazinium salt;
steroid sulfate | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| hydrocodone | | morphinane-like compound;
organic heteropentacyclic compound | antitussive;
mu-opioid receptor agonist;
opioid analgesic | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hydromorphone | | morphinane alkaloid;
organic heteropentacyclic compound | mu-opioid receptor agonist;
opioid analgesic | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| hydroxystilbamidine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| levetiracetam | | pyrrolidin-2-ones | anticonvulsant;
environmental contaminant;
xenobiotic | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| ly 163892 | | carbacephem;
zwitterion | antibacterial drug;
antimicrobial agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| meprednisone | | 21-hydroxy steroid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nabilone | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nalmefene | | morphinane alkaloid | | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nalorphine | | morphinane alkaloid | | 2005 | 2010 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| naloxone | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol | antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist | 2000 | 2016 | 14.0 | low | 0 | 0 | 1 | 2 | 4 | 0 |
| oxycodone | | organic heteropentacyclic compound;
semisynthetic derivative | antitussive;
mu-opioid receptor agonist;
opioid analgesic | 2014 | 2016 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| oxymorphone | | morphinane alkaloid | | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| vitamin k 1 | | phylloquinones;
vitamin K | cofactor;
human metabolite;
plant metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acepreval | | corticosteroid hormone | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| proscillaridin | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2006 | 2020 | 11.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| topiramate | | cyclic ketal;
ketohexose derivative;
sulfamate ester | anticonvulsant;
sodium channel blocker | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| trospium chloride | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| brefeldin a | | macrolide antibiotic | Penicillium metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alvocidib | | dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound | antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2005 | 2010 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| seocalcitol | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenretinide | | monocarboxylic acid amide;
retinoid | antineoplastic agent;
antioxidant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| geldanamycin | | 1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound | antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor | 2006 | 2010 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| calcipotriene | | cyclopropanes;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
triol | antipsoriatic;
drug allergen | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| morphine | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound | anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 4 | 3 | 0 |
| demycarosylturimycin h | | | | 2010 | 2013 | 12.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| ar c67085mx | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acipimox | | pyrazinecarboxylic acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| atosiban | | oligopeptide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzphetamine | | amphetamines;
tertiary amine | adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bimatoprost | | monocarboxylic acid amide | antiglaucoma drug;
antihypertensive agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clobetasol | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone | anti-inflammatory drug;
SMO receptor agonist | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| deamino arginine vasopressin | | heterodetic cyclic peptide | diagnostic agent;
renal agent;
vasopressin receptor agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| desoximetasone | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone | anti-inflammatory drug;
antipruritic drug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dexmedetomidine | | medetomidine | alpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluticasone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester | anti-allergic agent;
anti-asthmatic drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| goserelin | | organic molecular entity | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| halobetasol | | corticosteroid hormone | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iloprost | | carbobicyclic compound;
monocarboxylic acid;
secondary alcohol | platelet aggregation inhibitor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| preclamol | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| l 745870 | | piperazines | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| latanoprost | | isopropyl ester;
prostaglandins Falpha;
triol | antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lysophosphatidic acid | | 1-acyl-sn-glycerol 3-phosphate | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mdl 100907 | | | | 2001 | 2009 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| nalbuphine | | organic heteropentacyclic compound | mu-opioid receptor antagonist;
opioid analgesic | 2000 | 2016 | 16.0 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| nateglinide | | phenylalanine derivative | | 2012 | 2016 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| rimexolone | | 20-oxo steroid | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sb 223412 | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vinorelbine | | acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid | antineoplastic agent;
photosensitizing agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| zuclopenthixol | | clopenthixol | alpha-adrenergic antagonist;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 2000 | 2000 | 24.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| silodosin | | indolecarboxamide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ro 63-0563 | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ro 4-6790 | | benzenes;
sulfonamide | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sb 258719 | | | | 1998 | 1998 | 26.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| sb 271046 | | | | 2005 | 2014 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| furazolidone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluvoxamine | | (trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime | antidepressant;
anxiolytic drug;
serotonin uptake inhibitor | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 4 | 2 | 0 |
| semaxinib | | olefinic compound;
oxindoles;
pyrroles | angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| orantinib | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| su 11248 | | monocarboxylic acid amide;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| stilbamidine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bay 11-7082 | | nitrile;
sulfone | apoptosis inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | | dihydroxy monocarboxylic acid;
indoles;
organofluorine compound | | 2000 | 2016 | 15.0 | high | 0 | 0 | 1 | 4 | 3 | 0 |
| molsidomine | | ethyl ester;
morpholines;
oxadiazole;
zwitterion | antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| oxiconazole | | conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
oxime O-ether | antiinfective agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| codeine phosphate | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| levorphanol | | morphinane alkaloid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dihydromorphine | | morphinane alkaloid | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| naltrexone | | cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound | antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic | 2000 | 2016 | 15.9 | low | 0 | 0 | 1 | 4 | 2 | 0 |
| morphine-6-glucuronide | | morphinane alkaloid | | 2005 | 2014 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dextromethorphan | | 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene | antitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic | 2010 | 2020 | 8.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| butorphanol | | morphinane alkaloid | antitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| cefixime | | cephalosporin | antibacterial drug;
drug allergen | 2004 | 2016 | 13.5 | medium | 0 | 0 | 0 | 3 | 3 | 0 |
| lisinopril | | dipeptide | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2004 | 2020 | 11.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| benazepril | | benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ramipril | | azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester | bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| verteporfin | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| indinavir sulfate | | dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide | HIV protease inhibitor | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| zimeldine | | styrenes | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| enalapril maleate | | maleate salt | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enalapril | | dicarboxylic acid monoester;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| nitrofurazone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trientine hydrochloride | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| n-methylscopolamine bromide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bleomycin | | bleomycin | antineoplastic agent;
metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| heroin | | morphinane alkaloid | mu-opioid receptor agonist;
opioid analgesic;
prodrug | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enalaprilat anhydrous | | dicarboxylic acid;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| normorphine | | morphinane alkaloid | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imidapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulindac sulfone | | monocarboxylic acid;
organofluorine compound;
sulfone | apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pepstatin | | pentapeptide;
secondary carboxamide | bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ximelagatran | | amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cefuroxime | | 3-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether | drug allergen | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ceftriaxone | | 1,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| cefepime | | cephalosporin;
oxime O-ether | antibacterial drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pafuramidine | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ceftazidime | | cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| trandolapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| morphine-3-glucuronide | | morphinane alkaloid | | 2005 | 2014 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pregabalin | | gamma-amino acid | anticonvulsant;
calcium channel blocker | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tiotropium | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alvimopan anhydrous | | peptide | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| aliskiren | | monocarboxylic acid amide;
monomethoxybenzene | antihypertensive agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| guanabenz acetate | | dichlorobenzene | geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| guanabenz | | dichlorobenzene | | 2004 | 2012 | 16.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 1-[4-[4-[[(2R)-2-(2,4-dichlorophenyl)-2-(1-imidazolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]ethanone | | piperazines | | 2003 | 2003 | 21.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| famotidine | | 1,3-thiazoles;
guanidines;
sulfonamide | anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| cefotaxime | | 1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| aztreonam | | beta-lactam antibiotic allergen;
monobactam | antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| nw 1029 | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1,2-dielaidoylphosphatidylethanolamine | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| proguanil | | biguanides;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cci 15641 | | cephalosporin | | 2004 | 2013 | 15.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| rifamycin sv | | acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterotetracyclic compound;
polyphenol;
rifamycins | antimicrobial agent;
antitubercular agent;
bacterial metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefpodoxime | | carboxylic acid;
cephalosporin | antibacterial drug | 2004 | 2016 | 14.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| palonosetron | | azabicycloalkane;
delta-lactam;
organic heterotricyclic compound | antiemetic;
serotonergic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epoprostenol sodium | | prostanoid | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| tenofovir disoproxil fumarate | | fumarate salt | antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dexbrompheniramine maleate | | brompheniramine maleate | anti-allergic agent;
H1-receptor antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rifaximin | | acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative | antimicrobial agent;
gastrointestinal drug;
orphan drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bafilomycin a1 | | cyclic hemiketal;
macrolide antibiotic;
oxanes | apoptosis inducer;
autophagy inhibitor;
bacterial metabolite;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
ferroptosis inhibitor;
fungicide;
potassium ionophore;
toxin | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-oxoretinoic acid | | enone;
retinoid | human xenobiotic metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lumefantrine | | fluorenes;
monochlorobenzenes;
secondary alcohol;
tertiary amine | antimalarial | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ici d1542 | | | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| everolimus | | cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol | anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ixabepilone | | 1,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle | antineoplastic agent;
microtubule-destabilising agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| gavestinel | | | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| gt 2331 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dirithromycin | | macrolide antibiotic | prodrug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azlocillin | | penicillin allergen;
penicillin;
semisynthetic derivative | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tanespimycin | | 1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gw 1929 | | benzophenones | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefpodoxime proxetil | | carboxylic acid;
carboxylic ester;
cephalosporin | antibacterial drug;
prodrug | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ceftizoxime | | cephalosporin | antibacterial drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| rosaramicin | | aldehyde;
enone;
epoxide;
macrolide antibiotic;
monosaccharide derivative | bacterial metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole | | aryl sulfide | | 2006 | 2006 | 18.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-methyl-d-lysergic acid butanolamide | | ergot alkaloid;
monocarboxylic acid amide | serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent | 1998 | 2016 | 13.8 | medium | 0 | 0 | 1 | 0 | 3 | 0 |
| fluphenazine | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dantrolene sodium | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitrofurantoin | | imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic | antibacterial drug;
antiinfective agent;
hepatotoxic agent | 2000 | 2016 | 14.6 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| 6-cyano-4-(n-ethylsulfonyl-n-methylamino)-3-hydroxy-2,2-dimethylchromane, (trans-(+))-isomer | | | | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| sb 269970 | | sulfonamide | | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| nifurtimox | | nitrofuran antibiotic | | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| dantrolene | | | | 2004 | 2016 | 13.0 | medium | 0 | 0 | 0 | 1 | 3 | 0 |
| roxithromycin | | roxithromycin | environmental contaminant;
xenobiotic | 2010 | 2014 | 11.7 | medium | 0 | 0 | 0 | 1 | 2 | 0 |
| cefdinir | | cephalosporin;
ketoxime | antibacterial drug | 2013 | 2016 | 9.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| etonogestrel | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound | contraceptive drug;
female contraceptive drug;
progestin | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bisoprolol, fumarate (1:1) salt | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| artesunate | | artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid | antimalarial;
antineoplastic agent;
ferroptosis inducer | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ci 940 | | hydroxy polyunsaturated fatty acid;
leptomycin | antifungal agent;
bacterial metabolite | 2006 | 2006 | 18.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| tipredane | | 3-hydroxy steroid | androgen | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| beraprost | | enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol | anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lanreotide | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| etoposide phosphate | | furonaphthodioxole | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ciclesonide | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| temsirolimus | | macrolide lactam | | 2013 | 2016 | 9.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| dutasteride | | (trifluoromethyl)benzenes;
aza-steroid;
delta-lactam | antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone | | oligopeptide | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tekturna | | fumarate salt | antihypertensive agent | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| lu 208075 | | diarylmethane | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bibx 1382bs | | substituted aniline | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-ethyl-5-methoxy-n,n-dimethyltryptamine | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vildagliptin | | amino acid amide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ms-245 | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fesoterodine | | diarylmethane | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sb 399885 | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bentiromide | | dipeptide | diagnostic agent;
indicator;
reagent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenylalanylphenylalanine | | dipeptide;
L-aminoacyl-L-amino acid zwitterion | human blood serum metabolite;
Mycoplasma genitalium metabolite | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| acetylcarnitine | | O-acetylcarnitine;
saturated fatty acyl-L-carnitine | human metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| sgd 301-76 | | conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt | antiinfective agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluvoxamine maleate | | (trifluoromethyl)benzenes | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thioacetazone | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azimilide | | imidazolidine-2,4-dione | | 2003 | 2011 | 17.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| nifurtoinol | | hydrazone;
imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic | antibacterial drug;
antiinfective agent;
hepatotoxic agent | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| gemifloxacin | | 1,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic | antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor | 2012 | 2016 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| dexlansoprazole | | benzimidazoles;
sulfoxide | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| gemifloxacin mesylate | | methanesulfonate salt | antimicrobial agent;
topoisomerase IV inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosinopril | | | | 2004 | 2016 | 14.5 | high | 0 | 0 | 0 | 3 | 1 | 0 |
| armodafinil | | 2-[(diphenylmethyl)sulfinyl]acetamide | central nervous system stimulant;
eugeroic | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pridopidine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| osu 6162 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nnc 38-1049 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dibutyl phthalate | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| utibapril | | | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| eflucimibe | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ave 0118 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pd 144418 | | | | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| benzonitrile, 4-(2-(2-((2r)-2-methyl-1-pyrrolidinyl)ethyl)-5-benzofuranyl)- | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cp 293019 | | | | 2001 | 2001 | 23.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| midostaurin | | benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound | antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lu 28-179 | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sincalide | | oligopeptide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tapentadol | | alkylbenzene | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| etomoxir | | aromatic ether | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zd 9379 | | | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| bms 193884 | | | | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| ly 450139 | | peptide | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pentagastrin | | organic molecular entity | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cangrelor | | adenosine 5'-phosphate;
aryl sulfide;
nucleoside triphosphate analogue;
organochlorine compound;
organofluorine compound;
secondary amino compound | P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sch 527123 | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| abt-770 | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cefditoren | | carboxylic acid;
cephalosporin | antibacterial drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rivaroxaban | | aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes | anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| slv 313 | | | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hmr 1556 | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 9-n-(1-propyl)erythromyclamine | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| gentamicin sulfate | | | | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| a 304121 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-(3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl)-1-(4-fluorophenyl)butan-1-one | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| hki 272 | | nitrile;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiocolchicoside | | glycoside | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norcodeine | | morphinane alkaloid | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tofacitinib | | N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound | antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pifithrin-alpha | | | | 2006 | 2006 | 18.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| n-(4-tert-butylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2h)-carboxamide | | piperazines;
pyridines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | | | | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| linaprazan | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 5-hydroxyrofecoxib | | | | 2005 | 2005 | 19.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| azacosterol | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sb-656104-a | | | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pazopanib | | aminopyrimidine;
indazoles;
sulfonamide | angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist | 2013 | 2020 | 7.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| lecozotan | | | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| azd 6244 | | benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prasugrel hydrochloride | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| e-6801 | | | | 2005 | 2005 | 19.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| ar c155858 | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| decanoylcarnitine | | decanoate ester;
O-acylcarnitine | human urinary metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| a 317920 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| homatropine methylbromide | | | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cj 033466 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| PB28 | | aromatic ether;
piperazines;
tetralins | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amg 009 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vinflunine | | acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid | antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sch 442416 | | triazolopyrimidines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefotaxime sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-(2,4-difluorophenethyl)-4-(4-fluorophenylsulfonyl)piperidine | | | | 2009 | 2009 | 15.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| baci-im | | homodetic cyclic peptide;
polypeptide;
zwitterion | antibacterial agent;
antimicrobial agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one | | methoxybenzenes;
substituted aniline | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bms 477118 | | adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sb 742457 | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| nystatin a1 | | nystatins | | 2004 | 2016 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| naluzotan | | | | 2009 | 2009 | 15.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| pf-2545920 | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| milnacipran | | acetamides | | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| vindesine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| losartan potassium | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| at 13387 | | benzamides;
isoindoles;
N-alkylpiperazine;
resorcinols;
tertiary carboxamide | antineoplastic agent;
Hsp90 inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| scopolamine hydrobromide | | | | 2000 | 2016 | 14.7 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| dactolisib | | imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pf 03491390 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| octoclothepine, (s)-isomer | | | | 2002 | 2004 | 21.0 | high | 0 | 0 | 0 | 2 | 0 | 0 |
| rabeprazole sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amodiaquine hydrochloride | | | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| pf 03654746 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| bivalirudin | | polypeptide | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| somatostatin | | heterodetic cyclic peptide;
peptide hormone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tannins | | tannin | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enfuvirtide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ganirelix | | polypeptide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| teriparatide | | polypeptide | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| salmon calcitonin | | heterodetic cyclic peptide;
peptide hormone;
polypeptide | bone density conservation agent;
metabolite | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ly-146032 | | heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide | antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide | | polypeptide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| exenatide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| warfarin sodium | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| azd 7545 | | benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide | EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pravastatin sodium | | organic sodium salt;
statin (semi-synthetic) | anticholesteremic drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alendronate sodium | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| gsk 1004723 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| sl 80.0750 | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| lu ae58054 | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mesna | | organosulfonic acid | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cerivastatin sodium | | organic sodium salt;
statin (synthetic) | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clavulanate potassium | | potassium salt | antibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2012 | 2013 | 11.5 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| cefamandole nafate | | organic sodium salt | antibacterial drug;
prodrug | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cytomel | | organic sodium salt | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| sodium lactate | | lactate salt;
organic sodium salt | food acidity regulator;
food preservative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piperacillin sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| monensin | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium iothalamate | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxacillin sodium | | organic sodium salt | | 2010 | 2013 | 12.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| sodium diatrizoate | | organic sodium salt;
organoiodine compound | radioopaque medium | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefazolin sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azlocillin sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| cx 4945 | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ponatinib | | (trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine | antineoplastic agent;
tyrosine kinase inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cetrorelix | | oligopeptide | antineoplastic agent;
GnRH antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-(4-cyanophenylmethyl)-4-(2-diphenyl)-1-piperazinehexanamide | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| incb-018424 | | nitrile;
pyrazoles;
pyrrolopyrimidine | antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| a 967079 | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pht 427 | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| e-52862 | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sk&f 10047 | | | | 2001 | 2001 | 23.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine | | benzoxazole | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| jq1 compound | | carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ML240 | | aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound | antineoplastic agent | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ascorbic acid | | ascorbic acid;
vitamin C | coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| raltegravir | | 1,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide | antiviral drug;
HIV-1 integrase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| novobiocin | | carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols | antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tetracycline | | | | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| chlortetracycline | | | | 2008 | 2014 | 13.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| oxytetracycline, anhydrous | | | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| minocycline | | | | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| dicumarol | | hydroxycoumarin | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| piroxicam | | benzothiazine;
monocarboxylic acid amide;
pyridines | analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 2004 | 2016 | 13.3 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| roquinimex | | aromatic amide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acenocoumarol | | C-nitro compound;
hydroxycoumarin;
methyl ketone | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| meclocycline | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mobic | | 1,3-thiazoles;
benzothiazine;
monocarboxylic acid amide | analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| mobiflex | | heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2000 | 2013 | 16.2 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| isoxicam | | benzothiazine;
isoxazoles;
monocarboxylic acid amide | antirheumatic drug;
non-steroidal anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| warfarin | | benzenes;
hydroxycoumarin;
methyl ketone | | 2000 | 2016 | 14.9 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| bephenium hydroxynaphthoate | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| demeclocycline | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenprocoumon | | hydroxycoumarin | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tipranavir | | sulfonamide | antiviral drug;
HIV protease inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rolitetracycline | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| minocycline hydrochloride | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tigecycline | | | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| lornoxicam | | heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pelabresib | | monochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide | antineoplastic agent;
bromodomain-containing protein 4 inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ajmaline | | | | 2000 | 2010 | 19.0 | high | 0 | 0 | 1 | 1 | 0 | 0 |
| fertinex | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| PF-06446846 | | benzamides;
monochloropyridine;
piperidines;
tertiary carboxamide;
triazolopyridine | antilipemic drug;
EC 3.4.21.61 (kexin) inhibitor | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dBET6 | | organic molecular entity | | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| MZ1 | | organic molecular entity | | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| AZ3451 | | benzimidazoles;
benzodioxoles;
nitrile;
organobromine compound;
secondary carboxamide | anti-inflammatory agent;
autophagy inducer;
PAR2 negative allosteric modulator | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| entecavir | | 2-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol | antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| acyclovir | | 2-aminopurines;
oxopurine | antimetabolite;
antiviral drug | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| inosine | | inosines;
purines D-ribonucleoside | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| folic acid | | folic acids;
N-acyl-amino acid | human metabolite;
mouse metabolite;
nutrient | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| viomycin | | heterodetic cyclic peptide;
peptide antibiotic | antitubercular agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rifampin | | cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion | angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| clozapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound | adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic | 1994 | 2021 | 16.1 | low | 0 | 0 | 11 | 28 | 22 | 1 |
| dacarbazine | | dacarbazine | | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| didanosine | | purine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| ganciclovir | | 2-aminopurines;
oxopurine | antiinfective agent;
antiviral drug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| valtrex | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valacyclovir | | L-valyl ester | antiviral drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sildenafil | | piperazines;
pyrazolopyrimidine;
sulfonamide | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2003 | 2016 | 15.1 | low | 0 | 0 | 0 | 6 | 3 | 0 |
| penciclovir | | 2-aminopurines;
propane-1,3-diols | antiviral drug | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| oxypurinol | | pyrazolopyrimidine | drug metabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| raltitrexed | | N-acyl-amino acid | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vardenafil | | imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent | 2006 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| allopurinol | | nucleobase analogue;
organic heterobicyclic compound | antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| citrovorum factor | | tetrahydrofolic acid | | 2013 | 2016 | 9.5 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| leucovorin | | formyltetrahydrofolic acid | Escherichia coli metabolite;
mouse metabolite | 2010 | 2016 | 11.3 | medium | 0 | 0 | 0 | 1 | 2 | 0 |
| rifapentine | | N-alkylpiperazine;
N-iminopiperazine;
rifamycins | antitubercular agent;
leprostatic drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| alanosine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bl 4162a | | imidazoquinazoline | anticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tegaserod | | carboxamidine;
guanidines;
hydrazines;
indoles | gastrointestinal drug;
serotonergic agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| norclozapine | | dibenzodiazepine;
organochlorine compound;
piperazines | delta-opioid receptor agonist;
metabolite;
serotonergic antagonist | 2003 | 2021 | 13.0 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| pemetrexed | | N-acyl-L-glutamic acid;
pyrrolopyrimidine | antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tirapazamine | | aromatic amine;
benzotriazines;
N-oxide | antibacterial agent;
antineoplastic agent;
apoptosis inducer | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sildenafil citrate | | citrate salt | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valganciclovir | | L-valyl ester;
purines | antiviral drug;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles | antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| fosaprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles | antiemetic;
neurokinin-1 receptor antagonist;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tegaserod maleate | | maleate salt | serotonergic agonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| rifabutin | | | | 2004 | 2016 | 13.2 | medium | 0 | 0 | 0 | 2 | 2 | 0 |
| clozapine n-oxide | | dibenzodiazepine | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| desmethylolanzapine | | benzodiazepine | | 2009 | 2011 | 14.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| carbadox | | quinoxaline derivative | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ver 52296 | | aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols | angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| levomefolate calcium | | organic calcium salt | antidepressant | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| rvx 208 | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenobam | | ureas | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.Bioorganic & medicinal chemistry, , Jan-01, Volume: 23, Issue:1, 2015
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.British journal of pharmacology, , Volume: 124, Issue:6, 1998
Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.Journal of medicinal chemistry, , Jan-17, Volume: 45, Issue:2, 2002
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.British journal of pharmacology, , Volume: 124, Issue:6, 1998
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A binary QSAR model for classification of hERG potassium channel blockers.Bioorganic & medicinal chemistry, , Apr-01, Volume: 16, Issue:7, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.Bioorganic & medicinal chemistry, , Jan-01, Volume: 23, Issue:1, 2015
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:12, 2007
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:12, 2007
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.Psychopharmacology, , Volume: 179, Issue:2, 2005
Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.Life sciences, , May-31, Volume: 71, Issue:2, 2002
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:1, 2000
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.Bioorganic & medicinal chemistry, , Nov-15, Volume: 17, Issue:22, 2009
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.Bioorganic & medicinal chemistry, , Jan-01, Volume: 23, Issue:1, 2015
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.Psychopharmacology, , Volume: 179, Issue:2, 2005
Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.Journal of enzyme inhibition and medicinal chemistry, , Volume: 25, Issue:6, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A binary QSAR model for classification of hERG potassium channel blockers.Bioorganic & medicinal chemistry, , Apr-01, Volume: 16, Issue:7, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.Journal of medicinal chemistry, , Nov-26, Volume: 57, Issue:22, 2014
Further evaluation of the tropane analogs of haloperidol.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 24, Issue:17, 2014
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 22, Issue:18, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.Journal of medicinal chemistry, , Jun-24, Volume: 53, Issue:12, 2010
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).Journal of medicinal chemistry, , Mar-25, Volume: 53, Issue:6, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.Journal of medicinal chemistry, , Jan-08, Volume: 52, Issue:1, 2009
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:1, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.Proceedings of the National Academy of Sciences of the United States of America, , Feb-27, Volume: 104, Issue:9, 2007
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.Journal of medicinal chemistry, , Jan-01, Volume: 47, Issue:1, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.Life sciences, , May-31, Volume: 71, Issue:2, 2002
Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.Journal of medicinal chemistry, , Jan-17, Volume: 45, Issue:2, 2002
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.Journal of medicinal chemistry, , Aug-26, Volume: 42, Issue:17, 1999
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Iloperidone binding to human and rat dopamine and 5-HT receptors.European journal of pharmacology, , Dec-19, Volume: 317, Issue:2-3, 1996
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.Journal of medicinal chemistry, , Sep-27, Volume: 39, Issue:20, 1996
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.Bioorganic & medicinal chemistry, , Jan-01, Volume: 23, Issue:1, 2015
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.British journal of pharmacology, , Volume: 124, Issue:6, 1998
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.Journal of enzyme inhibition and medicinal chemistry, , Volume: 25, Issue:6, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.Psychopharmacology, , Volume: 179, Issue:2, 2005
Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.Journal of medicinal chemistry, , Jan-01, Volume: 47, Issue:1, 2004
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:1, 2000
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.Bioorganic & medicinal chemistry, , Nov-15, Volume: 17, Issue:22, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.Journal of medicinal chemistry, , Jan-17, Volume: 45, Issue:2, 2002
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.British journal of pharmacology, , Volume: 124, Issue:6, 1998
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.Psychopharmacology, , Volume: 179, Issue:2, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.Proceedings of the National Academy of Sciences of the United States of America, , Feb-27, Volume: 104, Issue:9, 2007
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.European journal of pharmacology, , Aug-16, Volume: 450, Issue:1, 2002
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.Life sciences, , May-31, Volume: 71, Issue:2, 2002
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 18, Issue:2, 1998
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.Journal of medicinal chemistry, , Nov-26, Volume: 57, Issue:22, 2014
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 20, Issue:18, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.Journal of medicinal chemistry, , Jan-08, Volume: 52, Issue:1, 2009
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:1, 2009
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:12, 2007
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.Proceedings of the National Academy of Sciences of the United States of America, , Feb-27, Volume: 104, Issue:9, 2007
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.Psychopharmacology, , Volume: 179, Issue:2, 2005
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.European journal of pharmacology, , Aug-16, Volume: 450, Issue:1, 2002
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.Life sciences, , May-31, Volume: 71, Issue:2, 2002
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:1, 2000
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.Journal of medicinal chemistry, , Aug-26, Volume: 42, Issue:17, 1999
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.British journal of pharmacology, , Volume: 124, Issue:6, 1998
Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 18, Issue:2, 1998
Iloperidone binding to human and rat dopamine and 5-HT receptors.European journal of pharmacology, , Dec-19, Volume: 317, Issue:2-3, 1996
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.Journal of medicinal chemistry, , Sep-27, Volume: 39, Issue:20, 1996
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 25, Issue:18, 2015
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:1, 2000
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.Journal of medicinal chemistry, , Sep-24, Volume: 41, Issue:20, 1998
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.Psychopharmacology, , Volume: 179, Issue:2, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.European journal of pharmacology, , Aug-16, Volume: 450, Issue:1, 2002
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:1, 2000
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(phenylsulfonyl)-1H-indoles.Bioorganic & medicinal chemistry, , Nov-15, Volume: 17, Issue:22, 2009
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.Psychopharmacology, , Volume: 179, Issue:2, 2005
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:1, 2000
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).Journal of medicinal chemistry, , Mar-25, Volume: 53, Issue:6, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:12, 2007
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.European journal of pharmacology, , Aug-16, Volume: 450, Issue:1, 2002
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.Psychopharmacology, , Volume: 179, Issue:2, 2005
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:1, 2000
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 20, Issue:18, 2010
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.European journal of pharmacology, , Aug-16, Volume: 450, Issue:1, 2002
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:1, 2000
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 18, Issue:2, 1998
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 25, Issue:18, 2015
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.Journal of medicinal chemistry, , Nov-26, Volume: 57, Issue:22, 2014
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 20, Issue:18, 2010
Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.Journal of medicinal chemistry, , Jun-24, Volume: 53, Issue:12, 2010
Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).Journal of medicinal chemistry, , Mar-25, Volume: 53, Issue:6, 2010
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.Journal of medicinal chemistry, , Jan-08, Volume: 52, Issue:1, 2009
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 17, Issue:19, 2007
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.Proceedings of the National Academy of Sciences of the United States of America, , Feb-27, Volume: 104, Issue:9, 2007
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 20, Issue:18, 2010
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:1, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:12, 2007
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.Proceedings of the National Academy of Sciences of the United States of America, , Feb-27, Volume: 104, Issue:9, 2007
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.Psychopharmacology, , Volume: 179, Issue:2, 2005
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.European journal of pharmacology, , Aug-16, Volume: 450, Issue:1, 2002
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:1, 2000
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 18, Issue:2, 1998
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.British journal of pharmacology, , Volume: 124, Issue:6, 1998
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Iloperidone binding to human and rat dopamine and 5-HT receptors.European journal of pharmacology, , Dec-19, Volume: 317, Issue:2-3, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.Journal of enzyme inhibition and medicinal chemistry, , Volume: 25, Issue:6, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:1, 2009
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Physical binding pocket induction for affinity prediction.Journal of medicinal chemistry, , Oct-08, Volume: 52, Issue:19, 2009
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
A binary QSAR model for classification of hERG potassium channel blockers.Bioorganic & medicinal chemistry, , Apr-01, Volume: 16, Issue:7, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:12, 2007
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.Proceedings of the National Academy of Sciences of the United States of America, , Feb-27, Volume: 104, Issue:9, 2007
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
UDP-glucuronosyltransferases and clinical drug-drug interactions.Pharmacology & therapeutics, , Volume: 106, Issue:1, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.Journal of medicinal chemistry, , Sep-24, Volume: 41, Issue:20, 1998
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:12, 2007
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.Journal of medicinal chemistry, , Jan-01, Volume: 47, Issue:1, 2004
Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.Journal of medicinal chemistry, , Jan-17, Volume: 45, Issue:2, 2002
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Effects of some drugs on human erythrocyte glucose 6-phosphate dehydrogenase: an in vitro study.Journal of enzyme inhibition and medicinal chemistry, , Volume: 25, Issue:6, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.European journal of medicinal chemistry, , Volume: 43, Issue:3, 2008
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 25, Issue:18, 2015
Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT₁A receptor functional profile.Bioorganic & medicinal chemistry, , Jan-01, Volume: 23, Issue:1, 2015
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.Journal of medicinal chemistry, , Nov-26, Volume: 57, Issue:22, 2014
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 39, Issue:7, 2011
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Histamine H3 receptor as a drug discovery target.Journal of medicinal chemistry, , Jan-13, Volume: 54, Issue:1, 2011
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 20, Issue:24, 2010
Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 20, Issue:18, 2010
Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.Journal of medicinal chemistry, , Jun-24, Volume: 53, Issue:12, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.Journal of medicinal chemistry, , Mar-26, Volume: 52, Issue:6, 2009
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.Journal of medicinal chemistry, , Jan-08, Volume: 52, Issue:1, 2009
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:1, 2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.Bioorganic & medicinal chemistry, , Aug-01, Volume: 16, Issue:15, 2008
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
BK Virus replication in vitro: limited effect of drugs interfering with viral uptake and intracellular transport.Antimicrobial agents and chemotherapy, , Volume: 51, Issue:12, 2007
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.Proceedings of the National Academy of Sciences of the United States of America, , Feb-27, Volume: 104, Issue:9, 2007
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.Psychopharmacology, , Volume: 179, Issue:2, 2005
Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Selective optimization of side activities: another way for drug discovery.Journal of medicinal chemistry, , Mar-11, Volume: 47, Issue:6, 2004
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.Journal of medicinal chemistry, , Jan-01, Volume: 47, Issue:1, 2004
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.Life sciences, , May-31, Volume: 71, Issue:2, 2002
Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.Journal of medicinal chemistry, , Jan-17, Volume: 45, Issue:2, 2002
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:1, 2000
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.Journal of medicinal chemistry, , Aug-26, Volume: 42, Issue:17, 1999
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.European journal of pharmacology, , Aug-21, Volume: 355, Issue:2-3, 1998
New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.Journal of medicinal chemistry, , Sep-24, Volume: 41, Issue:20, 1998
Functional characterisation of the human cloned 5-HT7 receptor (long form); antagonist profile of SB-258719.British journal of pharmacology, , Volume: 124, Issue:6, 1998
Iloperidone binding to human and rat dopamine and 5-HT receptors.European journal of pharmacology, , Dec-19, Volume: 317, Issue:2-3, 1996
Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
Structure-activity relationships of a series of novel (piperazinylbutyl)thiazolidinone antipsychotic agents related to 3-[4-[4-(6-fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate.Journal of medicinal chemistry, , Sep-27, Volume: 39, Issue:20, 1996
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.Journal of neurochemistry, , Volume: 66, Issue:1, 1996
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.The Journal of pharmacology and experimental therapeutics, , Volume: 268, Issue:3, 1994
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Identifying off-target effects and hidden phenotypes of drugs in human cells.Nature chemical biology, , Volume: 2, Issue:6, 2006
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.Bioorganic & medicinal chemistry letters, , Jun-02, Volume: 15, Issue:11, 2005
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.Toxicology mechanisms and methods, , Volume: 18, Issue:2-3, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
QSAR model for drug human oral bioavailability.Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.Pharmaceutical research, , Volume: 31, Issue:4, 2014
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.European journal of medicinal chemistry, , Volume: 46, Issue:2, 2011
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.Journal of medicinal chemistry, , Jul-23, Volume: 52, Issue:14, 2009
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.Bioorganic & medicinal chemistry letters, , Aug-18, Volume: 13, Issue:16, 2003
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| gamma-aminobutyric acid | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid | human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule | 1999 | 2022 | 14.2 | low | 0 | 0 | 2 | 8 | 8 | 2 |
| acetic acid | | monocarboxylic acid | antimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetone | | ketone body;
methyl ketone;
propanones;
volatile organic compound | EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent | 2004 | 2013 | 16.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| agmatine | | guanidines;
primary amino compound | Escherichia coli metabolite;
mouse metabolite | 2019 | 2022 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| bromide | | halide anion;
monoatomic bromine | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbamates | | amino-acid anion | | 2003 | 2017 | 12.7 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| carbon monoxide | | carbon oxide;
gas molecular entity;
one-carbon compound | biomarker;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
human metabolite;
ligand;
metabolite;
mitochondrial respiratory-chain inhibitor;
mouse metabolite;
neurotoxin;
neurotransmitter;
P450 inhibitor;
probe;
signalling molecule;
vasodilator agent | 2004 | 2021 | 11.5 | low | 1 | 0 | 0 | 1 | 0 | 1 |
| carnitine | | amino-acid betaine | human metabolite;
mouse metabolite | 2005 | 2022 | 9.8 | low | 1 | 0 | 0 | 1 | 3 | 1 |
| methane | | alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound | bacterial metabolite;
fossil fuel;
greenhouse gas | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| choline | | cholines | allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2000 | 2011 | 18.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| chlorine | | halide anion;
monoatomic chlorine | cofactor;
Escherichia coli metabolite;
human metabolite | 2014 | 2019 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| salicylic acid | | monohydroxybenzoic acid | algal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydrogen sulfide | | gas molecular entity;
hydracid;
mononuclear parent hydride;
sulfur hydride | Escherichia coli metabolite;
genotoxin;
metabolite;
signalling molecule;
toxin;
vasodilator agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 3-hydroxybutyric acid | | (omega-1)-hydroxy fatty acid;
3-hydroxy monocarboxylic acid;
hydroxybutyric acid | human metabolite | 2004 | 2022 | 11.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| bupropion | | aromatic ketone;
monochlorobenzenes;
secondary amino compound | antidepressant;
environmental contaminant;
xenobiotic | 2002 | 2023 | 12.0 | low | 1 | 0 | 0 | 4 | 3 | 1 |
| 3,4-dihydroxyphenylacetic acid | | catechols;
dihydroxyphenylacetic acid | human metabolite | 1999 | 2016 | 18.4 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| creatine | | glycine derivative;
guanidines;
zwitterion | geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical | 2000 | 2002 | 23.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| cytosine | | aminopyrimidine;
pyrimidine nucleobase;
pyrimidone | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lactic acid | | 2-hydroxy monocarboxylic acid | algal metabolite;
Daphnia magna metabolite | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| dimethyl sulfoxide | | sulfoxide;
volatile organic compound | alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger | 2005 | 2022 | 10.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| formaldehyde | | aldehyde;
one-carbon compound | allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycine | | alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid | EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical | 2004 | 2008 | 18.4 | low | 2 | 0 | 0 | 5 | 0 | 0 |
| glycerol | | alditol;
triol | algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| histamine | | aralkylamino compound;
imidazoles | human metabolite;
mouse metabolite;
neurotransmitter | 1999 | 2021 | 13.6 | low | 0 | 0 | 1 | 2 | 3 | 1 |
| hydrogen | | elemental hydrogen;
elemental molecule;
gas molecular entity | antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| iodine | | diatomic iodine | nutrient | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dihydroxyphenylalanine | | hydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative | human metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| kynurenine | | aromatic ketone;
non-proteinogenic alpha-amino acid;
substituted aniline | human metabolite | 2012 | 2022 | 6.2 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| thioctic acid | | dithiolanes;
heterocyclic fatty acid;
thia fatty acid | fundamental metabolite;
geroprotector | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| melatonin | | acetamides;
tryptamines | anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger | 2006 | 2023 | 11.0 | low | 4 | 0 | 0 | 5 | 6 | 1 |
| naphthalene | | naphthalenes;
ortho-fused bicyclic arene | apoptosis inhibitor;
carcinogenic agent;
environmental contaminant;
mouse metabolite;
plant metabolite;
volatile oil component | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nickel | | metal allergen;
nickel group element atom | epitope;
micronutrient | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| niacinamide | | pyridine alkaloid;
pyridinecarboxamide;
vitamin B3 | anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nitrates | | monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nitrites | | monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species | human metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| palmitic acid | | long-chain fatty acid;
straight-chain saturated fatty acid | algal metabolite;
Daphnia magna metabolite;
EC 1.1.1.189 (prostaglandin-E2 9-reductase) inhibitor;
plant metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyruvic acid | | 2-oxo monocarboxylic acid | cofactor;
fundamental metabolite | 2013 | 2019 | 7.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| sarcosine | | N-alkylglycine zwitterion;
N-alkylglycine;
N-methyl-amino acid;
N-methylglycines | Escherichia coli metabolite;
glycine receptor agonist;
glycine transporter 1 inhibitor;
human metabolite;
mouse metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| succinic acid | | alpha,omega-dicarboxylic acid;
C4-dicarboxylic acid | anti-ulcer drug;
fundamental metabolite;
micronutrient;
nutraceutical;
radiation protective agent | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| taurine | | amino sulfonic acid;
zwitterion | antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thymine | | pyrimidine nucleobase;
pyrimidone | Escherichia coli metabolite;
human metabolite;
mouse metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| toluene | | methylbenzene;
toluenes;
volatile organic compound | cholinergic antagonist;
fuel additive;
neurotoxin;
non-polar solvent | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| uric acid | | uric acid | Escherichia coli metabolite;
human metabolite;
mouse metabolite | 2007 | 2017 | 12.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| urea | | isourea;
monocarboxylic acid amide;
one-carbon compound | Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2007 | 2017 | 12.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| 7-hydroxy-2-n,n-dipropylaminotetralin | | tetralins | | 1998 | 2015 | 15.0 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| 8-hydroxy-2-(di-n-propylamino)tetralin | | phenols;
tertiary amino compound;
tetralins | serotonergic antagonist | 1999 | 2009 | 19.0 | low | 0 | 0 | 1 | 5 | 0 | 0 |
| alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | | non-proteinogenic alpha-amino acid | | 2000 | 2012 | 19.0 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-iodo-2,5-dimethoxyphenylisopropylamine | | amphetamines;
dimethoxybenzene;
organoiodine compound | | 2001 | 2020 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| sk&f-38393 | | benzazepine;
catechols;
secondary amino compound | | 2001 | 2002 | 22.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 1-(3-chlorophenyl)piperazine | | monochlorobenzenes;
N-arylpiperazine | drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic | 2001 | 2001 | 23.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| 1-anilino-8-naphthalenesulfonate | | aminonaphthalene;
naphthalenesulfonic acid | fluorescent probe | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-methyl-5-ht | | tryptamines | serotonergic agonist | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3,4-methylenedioxyamphetamine | | benzodioxoles | | 2005 | 2019 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| n-methyl-3,4-methylenedioxyamphetamine | | amphetamines;
benzodioxoles | neurotoxin | 2002 | 2009 | 19.8 | low | 1 | 0 | 0 | 4 | 0 | 0 |
| homovanillic acid | | guaiacols;
monocarboxylic acid | human metabolite;
mouse metabolite | 2001 | 2014 | 17.1 | low | 5 | 0 | 0 | 8 | 1 | 0 |
| phenytoin | | imidazolidine-2,4-dione | anticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent | 1999 | 2018 | 18.4 | low | 0 | 0 | 2 | 2 | 1 | 0 |
| hydroxyindoleacetic acid | | indole-3-acetic acids | drug metabolite;
human metabolite;
mouse metabolite | 2001 | 2016 | 17.8 | low | 1 | 0 | 0 | 3 | 1 | 0 |
| tacrine | | acridines;
aromatic amine | EC 3.1.1.7 (acetylcholinesterase) inhibitor | 1999 | 2005 | 21.4 | low | 0 | 0 | 2 | 3 | 0 | 0 |
| acetaminophen | | acetamides;
phenols | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetazolamide | | monocarboxylic acid amide;
sulfonamide;
thiadiazoles | anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alosetron | | imidazoles;
pyridoindole | antiemetic;
gastrointestinal drug;
serotonergic antagonist | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alpha-cyano-4-hydroxycinnamate | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alpha-methylserotonin | | tryptamines | serotonergic agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alprazolam | | organochlorine compound;
triazolobenzodiazepine | anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic | 1999 | 2023 | 14.0 | low | 1 | 0 | 1 | 2 | 1 | 1 |
| amantadine | | adamantanes;
primary aliphatic amine | analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic | 2001 | 2013 | 16.2 | low | 5 | 0 | 0 | 5 | 3 | 0 |
| theophylline | | dimethylxanthine | adenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent | 2007 | 2019 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dan 2163 | | aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone | environmental contaminant;
second generation antipsychotic;
xenobiotic | 1999 | 2023 | 12.5 | medium | 29 | 0 | 6 | 62 | 62 | 13 |
| amitriptyline | | carbotricyclic compound;
tertiary amine | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic | 2006 | 2021 | 13.0 | low | 1 | 0 | 0 | 4 | 1 | 1 |
| amlodipine | | dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amoxapine | | dibenzooxazepine | adrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor | 1999 | 2015 | 17.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| aspirin | | benzoic acids;
phenyl acetates;
salicylates | anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| astemizole | | benzimidazoles;
piperidines | anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| atenolol | | ethanolamines;
monocarboxylic acid amide;
propanolamine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azasetron | | benzoxazine | | 2009 | 2015 | 12.0 | low | 2 | 0 | 0 | 1 | 1 | 0 |
| baclofen | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound | central nervous system depressant;
GABA agonist;
muscle relaxant | 2011 | 2023 | 7.5 | low | 0 | 0 | 0 | 0 | 5 | 1 |
| benserazide | | carbohydrazide;
catechols;
primary alcohol;
primary amino compound | antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| berberine | | alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound | antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker | 2013 | 2021 | 6.8 | low | 1 | 0 | 0 | 0 | 5 | 1 |
| betahistine | | aminoalkylpyridine;
secondary amino compound | H1-receptor agonist;
vasodilator agent | 2005 | 2023 | 8.9 | low | 5 | 0 | 0 | 1 | 11 | 2 |
| bethanechol | | carbamate ester;
quaternary ammonium ion | muscarinic agonist | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bicalutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| biperiden | | piperidines;
tertiary alcohol;
tertiary amino compound | antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic | 1998 | 2022 | 13.7 | low | 1 | 0 | 1 | 2 | 2 | 1 |
| bisbenzimidazole | | bibenzimidazole;
N-methylpiperazine | anthelminthic drug;
fluorochrome | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bisoprolol | | secondary alcohol;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bromazepam | | organic molecular entity | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bromperidol | | aromatic ketone | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bupivacaine | | aromatic amide;
piperidinecarboxamide;
tertiary amino compound | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| buspirone | | azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines | anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist | 2005 | 2023 | 9.3 | low | 1 | 0 | 0 | 2 | 3 | 1 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 1999 | 2021 | 15.6 | low | 1 | 0 | 1 | 5 | 1 | 1 |
| carbamazepine | | dibenzoazepine;
ureas | analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic | 1998 | 2022 | 16.5 | low | 6 | 0 | 6 | 34 | 12 | 3 |
| carmustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| carpipramine | | dibenzooxazepine | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carvedilol | | carbazoles;
secondary alcohol;
secondary amino compound | alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| celecoxib | | organofluorine compound;
pyrazoles;
sulfonamide;
toluenes | cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2006 | 2013 | 14.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| cetirizine | | ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines | anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic | 1999 | 2018 | 18.0 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| chlordiazepoxide | | benzodiazepine | | 1995 | 2014 | 17.4 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| chloroquine | | aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chlorpheniramine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chlorpromazine | | organochlorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug | 1997 | 2023 | 15.9 | low | 9 | 0 | 7 | 45 | 21 | 3 |
| ciprofloxacin | | aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion | antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic | 1999 | 2006 | 21.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| cisapride | | benzamides | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| citalopram | | 2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound | | 1999 | 2022 | 14.7 | low | 5 | 0 | 2 | 19 | 8 | 4 |
| clomipramine | | dibenzoazepine | anticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor | 1998 | 2020 | 16.5 | low | 2 | 0 | 4 | 8 | 7 | 0 |
| clonazepam | | 1,4-benzodiazepinone;
monochlorobenzenes | anticonvulsant;
anxiolytic drug;
GABA modulator | 2001 | 2023 | 12.8 | low | 2 | 0 | 0 | 11 | 13 | 2 |
| clonidine | | clonidine;
imidazoline | | 2003 | 2019 | 13.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| cyproheptadine | | piperidines;
tertiary amine | anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist | 2003 | 2019 | 10.7 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| dantrolene | | hydrazone;
imidazolidine-2,4-dione | muscle relaxant;
neuroprotective agent;
ryanodine receptor antagonist | 2000 | 2018 | 14.3 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| dapsone | | substituted aniline;
sulfone | anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| desipramine | | dibenzoazepine;
secondary amino compound | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor | 1999 | 2010 | 18.0 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| nordazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative | 2011 | 2019 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| amphetamine | | primary amine | | 1996 | 2021 | 13.4 | low | 1 | 0 | 1 | 8 | 9 | 1 |
| diazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic | 2003 | 2019 | 14.2 | low | 0 | 0 | 0 | 5 | 3 | 0 |
| diclofenac | | amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound | antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| diphenhydramine | | ether;
tertiary amino compound | anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative | 2000 | 2019 | 16.7 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| dipyridamole | | piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol | adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| disulfiram | | organic disulfide;
organosulfur acaricide | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valproic acid | | branched-chain fatty acid;
branched-chain saturated fatty acid | anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent | 1998 | 2023 | 14.9 | low | 33 | 0 | 8 | 108 | 49 | 14 |
| domperidone | | benzimidazoles;
heteroarylpiperidine | antiemetic;
dopaminergic antagonist | 2015 | 2021 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| donepezil | | aromatic ether;
indanones;
piperidines;
racemate | EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent | 2001 | 2022 | 16.2 | low | 3 | 0 | 0 | 10 | 2 | 1 |
| doxepin | | dibenzooxepine;
tertiary amino compound | antidepressant | 2000 | 2015 | 16.2 | low | 2 | 0 | 1 | 2 | 1 | 0 |
| droperidol | | aromatic ketone;
benzimidazoles;
organofluorine compound | anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 2008 | 2023 | 7.2 | low | 5 | 0 | 0 | 1 | 10 | 3 |
| erythrosine | | | | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ethosuximide | | dicarboximide;
pyrrolidinone | anticonvulsant;
geroprotector;
T-type calcium channel blocker | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| famotidine | | 1,3-thiazoles;
guanidines;
sulfonamide | anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 2004 | 2019 | 11.7 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| fenfluramine | | (trifluoromethyl)benzenes;
secondary amino compound | appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenofibrate | | aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fentanyl | | anilide;
monocarboxylic acid amide;
piperidines | adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 2018 | 2022 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| fluphenazine | | N-alkylpiperazine;
organofluorine compound;
phenothiazines | anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 1998 | 2022 | 16.3 | low | 6 | 0 | 1 | 20 | 5 | 2 |
| flumazenil | | ethyl ester;
imidazobenzodiazepine;
organofluorine compound | antidote to benzodiazepine poisoning;
GABA antagonist | 2007 | 2022 | 9.3 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| flunitrazepam | | 1,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes | anxiolytic drug;
GABAA receptor agonist;
sedative | 2007 | 2008 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| fluorouracil | | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluoxetine | | (trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound | | 1998 | 2023 | 16.3 | low | 32 | 0 | 8 | 92 | 30 | 7 |
| fluphenazine depot | | decanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug | 2003 | 2013 | 16.8 | low | 1 | 0 | 0 | 3 | 1 | 0 |
| gabapentin | | gamma-amino acid | anticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic | 1999 | 2023 | 17.1 | low | 0 | 0 | 2 | 4 | 2 | 1 |
| glipizide | | aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines | EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glyburide | | monochlorobenzenes;
N-sulfonylurea | anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent | 2000 | 2014 | 15.3 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| guaifenesin | | methoxybenzenes | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 1995 | 2024 | 16.2 | low | 212 | 0 | 91 | 446 | 205 | 36 |
| tele-methylhistamine | | imidazoles;
primary amino compound | human metabolite;
mouse metabolite | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| alpha-methylhistamine | | aralkylamino compound;
imidazoles | animal metabolite;
H3-receptor agonist | 1996 | 1999 | 26.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| hydroxychloroquine | | aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lidocaine | | benzenes;
monocarboxylic acid amide;
tertiary amino compound | anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mephentermine | | amphetamines | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ifosfamide | | ifosfamides | alkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| imipramine | | dibenzoazepine | adrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 1997 | 2022 | 13.6 | low | 1 | 0 | 1 | 4 | 2 | 2 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iproniazid | | carbohydrazide;
pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| avapro | | azaspiro compound;
biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoniazid | | carbohydrazide | antitubercular agent;
drug allergen | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 2-propanol | | secondary alcohol;
secondary fatty alcohol | protic solvent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-propanol | | secondary alcohol;
secondary fatty alcohol | protic solvent | 2004 | 2021 | 11.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| ketamine | | cyclohexanones;
monochlorobenzenes;
secondary amino compound | analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic | 2000 | 2021 | 11.2 | low | 0 | 0 | 1 | 3 | 6 | 2 |
| ketanserin | | aromatic ketone;
organofluorine compound;
piperidines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 1999 | 2023 | 15.4 | low | 0 | 0 | 1 | 3 | 0 | 1 |
| ketoconazole | | dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine | | 2003 | 2013 | 14.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| kynurenic acid | | monohydroxyquinoline;
quinolinemonocarboxylic acid | G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| labetalol | | benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lamotrigine | | 1,2,4-triazines;
dichlorobenzene;
primary arylamine | anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic | 1999 | 2023 | 15.9 | low | 10 | 0 | 2 | 46 | 10 | 4 |
| lorazepam | | benzodiazepine | | 1998 | 2023 | 13.1 | low | 8 | 0 | 1 | 20 | 19 | 4 |
| loxapine | | dibenzooxazepine | antipsychotic agent;
dopaminergic antagonist | 1997 | 2021 | 15.7 | low | 2 | 0 | 3 | 1 | 5 | 1 |
| 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | | chromones;
morpholines;
organochlorine compound | autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector | 2005 | 2010 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| maprotiline | | anthracenes | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mazindol | | organic molecular entity | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| memantine | | adamantanes;
primary aliphatic amine | antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist | 2004 | 2017 | 14.8 | low | 2 | 0 | 0 | 4 | 2 | 0 |
| mepivacaine | | piperidinecarboxamide | drug allergen;
local anaesthetic | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metformin | | guanidines | environmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic | 2006 | 2023 | 10.4 | low | 8 | 0 | 0 | 9 | 11 | 5 |
| methacrylic acid | | alpha,beta-unsaturated monocarboxylic acid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methadone | | benzenes;
diarylmethane;
ketone;
tertiary amino compound | | 2010 | 2016 | 11.0 | low | 2 | 0 | 0 | 1 | 2 | 0 |
| methylphenidate | | beta-amino acid ester;
methyl ester;
piperidines | | 2003 | 2017 | 15.6 | low | 0 | 0 | 0 | 8 | 1 | 0 |
| metoclopramide | | benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound | antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic | 2007 | 2023 | 6.3 | low | 2 | 0 | 0 | 1 | 7 | 2 |
| metronidazole | | C-nitro compound;
imidazoles;
primary alcohol | antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mianserin | | dibenzoazepine | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist | 1999 | 2023 | 16.2 | low | 5 | 0 | 1 | 24 | 6 | 1 |
| midazolam | | imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative | 2009 | 2022 | 8.2 | low | 6 | 0 | 0 | 3 | 16 | 1 |
| mirtazapine | | benzazepine;
tetracyclic antidepressant | alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist | 2001 | 2023 | 14.1 | low | 5 | 0 | 0 | 21 | 8 | 3 |
| moclobemide | | benzamides;
monochlorobenzenes;
morpholines | antidepressant;
environmental contaminant;
xenobiotic | 2010 | 2023 | 7.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| modafinil | | monocarboxylic acid amide;
sulfoxide | | 2009 | 2010 | 14.3 | low | 3 | 0 | 0 | 3 | 0 | 0 |
| muscimol | | alkaloid;
isoxazoles;
primary amino compound | fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug | 2001 | 2008 | 18.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| fg 7142 | | beta-carbolines | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| clorgyline | | aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound | antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| naratriptan | | heteroarylpiperidine;
sulfonamide;
tryptamines | serotonergic agonist;
vasoconstrictor agent | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nefazodone | | aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles | alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nevirapine | | cyclopropanes;
dipyridodiazepine | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nifedipine | | C-nitro compound;
dihydropyridine;
methyl ester | calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent | 2014 | 2015 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| nisoxetine | | aromatic ether;
secondary amino compound | adrenergic uptake inhibitor;
antidepressant | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| norfluoxetine | | (trifluoromethyl)benzenes | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nortriptyline | | organic tricyclic compound;
secondary amine | adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite | 2005 | 2009 | 16.7 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| ondansetron | | carbazoles | | 2001 | 2023 | 7.6 | low | 12 | 0 | 0 | 3 | 12 | 4 |
| oxazepam | | 1,4-benzodiazepinone;
organochlorine compound | anxiolytic drug;
environmental contaminant;
xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxidopamine | | benzenetriol;
catecholamine;
primary amino compound | drug metabolite;
human metabolite;
neurotoxin | 2001 | 2008 | 20.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| oxotremorine | | N-alkylpyrrolidine | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxybutynin | | acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound | antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic | 2012 | 2022 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| pargyline | | aromatic amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pd 98059 | | aromatic amine;
monomethoxyflavone | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perazine | | N-alkylpiperazine;
N-methylpiperazine;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug | 2003 | 2014 | 15.7 | low | 2 | 0 | 0 | 6 | 4 | 0 |
| perphenazine | | N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines | antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 1998 | 2024 | 13.8 | low | 25 | 0 | 2 | 26 | 18 | 3 |
| phenobarbital | | barbiturates | anticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-phenylbutyric acid | | monocarboxylic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pipamperone | | aromatic ketone;
bipiperidines;
monocarboxylic acid amide;
organofluorine compound;
tertiary amino compound | dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piperazine | | azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent | anthelminthic drug | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piracetam | | organonitrogen compound;
organooxygen compound | | 2014 | 2018 | 8.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| pirenzepine | | pyridobenzodiazepine | anti-ulcer drug;
antispasmodic drug;
muscarinic antagonist | 1992 | 2020 | 23.4 | high | 302 | 0 | 618 | 717 | 7 | 0 |
| prazepam | | benzodiazepine | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prazosin | | aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 1997 | 2015 | 17.8 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| probenecid | | benzoic acids;
sulfonamide | uricosuric drug | 2002 | 2002 | 22.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| prochlorperazine | | N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines | alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic | 2009 | 2023 | 9.0 | low | 0 | 0 | 0 | 1 | 3 | 1 |
| promazine | | phenothiazines;
tertiary amine | antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
muscarinic antagonist;
phenothiazine antipsychotic drug;
serotonergic antagonist | 2004 | 2009 | 17.0 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| promethazine | | phenothiazines;
tertiary amine | anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative | 2007 | 2023 | 10.8 | low | 2 | 0 | 0 | 4 | 4 | 2 |
| propofol | | phenols | anticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative | 2008 | 2012 | 13.7 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 1997 | 2017 | 15.3 | low | 1 | 0 | 2 | 3 | 5 | 0 |
| pyrilamine | | aromatic ether;
ethylenediamine derivative | H1-receptor antagonist | 2000 | 2009 | 19.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| quipazine | | piperazines;
pyridines | | 1992 | 2005 | 26.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| riluzole | | benzothiazoles | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| risperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist | 1995 | 2024 | 15.6 | high | 361 | 0 | 156 | 847 | 435 | 82 |
| ritanserin | | organofluorine compound;
piperidines;
thiazolopyrimidine | antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 1997 | 2000 | 25.3 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| rofecoxib | | butenolide;
sulfone | analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rolipram | | pyrrolidin-2-ones | antidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ropinirole | | indolones;
tertiary amine | antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist | 2016 | 2017 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| saccharin | | 1,2-benzisothiazole;
N-sulfonylcarboxamide | environmental contaminant;
sweetening agent;
xenobiotic | 2020 | 2022 | 2.7 | low | 0 | 0 | 0 | 0 | 1 | 2 |
| salicylsalicylic acid | | benzoate ester;
benzoic acids;
phenols;
salicylates | antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sibutramine | | organochlorine compound;
tertiary amino compound | anti-obesity agent;
serotonin uptake inhibitor | 2005 | 2012 | 15.5 | low | 2 | 0 | 0 | 3 | 1 | 0 |
| spiperone | | aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound | alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist | 2004 | 2006 | 19.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| vorinostat | | dicarboxylic acid diamide;
hydroxamic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulforaphane | | isothiocyanate;
sulfoxide | antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulpiride | | benzamides;
N-alkylpyrrolidine;
sulfonamide | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 1998 | 2022 | 15.6 | low | 24 | 0 | 8 | 80 | 48 | 1 |
| sumatriptan | | sulfonamide;
tryptamines | serotonergic agonist;
vasoconstrictor agent | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| talipexole | | azepine | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| temozolomide | | imidazotetrazine;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
prodrug | 2011 | 2015 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| terfenadine | | diarylmethane | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thalidomide | | phthalimides;
piperidones | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thioridazine | | phenothiazines;
piperidines | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 1996 | 2017 | 19.4 | low | 2 | 0 | 1 | 15 | 2 | 0 |
| thiram | | organic disulfide | antibacterial drug;
antifungal agrochemical;
antiseptic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trazodone | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine | adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 2005 | 2018 | 11.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| trifluoperazine | | N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines | antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug | 2005 | 2022 | 12.6 | low | 3 | 0 | 0 | 5 | 2 | 1 |
| trihexyphenidyl | | amine | | 1997 | 2020 | 14.0 | low | 0 | 0 | 1 | 1 | 4 | 0 |
| trimipramine | | dibenzoazepine;
tertiary amino compound | antidepressant;
environmental contaminant;
xenobiotic | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| troglitazone | | chromanes;
thiazolidinone | anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| urethane | | carbamate ester | fungal metabolite;
mutagen | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vigabatrin | | gamma-amino acid | anticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zonisamide | | 1,2-benzoxazoles;
sulfonamide | anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker | 2003 | 2017 | 13.6 | low | 2 | 0 | 0 | 2 | 3 | 0 |
| zopiclone | | monochloropyridine;
pyrrolopyrazine | central nervous system depressant;
sedative | 2005 | 2006 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| zotepine | | dibenzothiepine;
tertiary amino compound | alpha-adrenergic drug;
second generation antipsychotic;
serotonergic drug | 1996 | 2021 | 20.4 | low | 1 | 0 | 8 | 7 | 1 | 1 |
| corticosterone | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 1992 | 2016 | 19.2 | low | 1 | 0 | 3 | 8 | 2 | 0 |
| prednisolone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2012 | 2020 | 9.6 | low | 0 | 0 | 0 | 0 | 7 | 0 |
| lysergic acid diethylamide | | ergoline alkaloid;
monocarboxylic acid amide;
organic heterotetracyclic compound | dopamine agonist;
hallucinogen;
serotonergic agonist | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| reserpine | | alkaloid ester;
methyl ester;
yohimban alkaloid | adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic | 1999 | 2016 | 19.8 | low | 0 | 0 | 2 | 1 | 1 | 0 |
| thyroxine | | 2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine | antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone | 1998 | 2016 | 14.8 | low | 1 | 0 | 1 | 2 | 2 | 0 |
| dextroamphetamine | | 1-phenylpropan-2-amine | adrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent | 2001 | 2010 | 17.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| carbachol | | ammonium salt;
carbamate ester | cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prednisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug | 2004 | 2022 | 12.6 | low | 1 | 0 | 0 | 3 | 1 | 1 |
| dehydroepiandrosterone | | 17-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid | androgen;
human metabolite;
mouse metabolite | 2007 | 2007 | 17.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| adrenochrome | | indoles | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alanine | | alanine zwitterion;
alanine;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid | EC 4.3.1.15 (diaminopropionate ammonia-lyase) inhibitor;
fundamental metabolite | 2009 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| serine | | L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2004 | 2015 | 15.1 | low | 4 | 0 | 0 | 7 | 3 | 0 |
| aspartic acid | | aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
mouse metabolite;
neurotransmitter | 2000 | 2007 | 19.7 | low | 1 | 0 | 1 | 2 | 0 | 0 |
| lysine | | aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid | algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2008 | 2023 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| cyanides | | pseudohalide anion | EC 1.9.3.1 (cytochrome c oxidase) inhibitor | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| physostigmine | | carbamate ester;
indole alkaloid | antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic | 2004 | 2023 | 13.3 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| sucrose | | glycosyl glycoside | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2006 | 2017 | 11.7 | low | 1 | 0 | 0 | 3 | 3 | 0 |
| ethinyl estradiol | | 17-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound | xenoestrogen | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| apomorphine | | aporphine alkaloid | alpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug | 1992 | 2016 | 19.4 | low | 0 | 0 | 5 | 6 | 4 | 0 |
| tetrabenazine | | benzoquinolizine;
cyclic ketone;
tertiary amino compound | | 2000 | 2017 | 15.2 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| adenosine diphosphate | | adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate | fundamental metabolite;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromodeoxyuridine | | pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent | 2004 | 2017 | 16.5 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| carbostyril | | monohydroxyquinoline;
quinolone | bacterial xenobiotic metabolite | 2002 | 2023 | 14.3 | low | 30 | 0 | 0 | 131 | 89 | 3 |
| phenylephrine | | phenols;
phenylethanolamines;
secondary amino compound | alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| levodopa | | amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug | 1999 | 2016 | 21.3 | low | 2 | 0 | 4 | 4 | 1 | 0 |
| edetic acid | | ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid | anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| adenosine monophosphate | | adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate | adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| n,n-dimethyltryptamine | | tryptamine alkaloid;
tryptamines | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methionine | | aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid | antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2004 | 2016 | 16.2 | low | 1 | 0 | 0 | 3 | 1 | 0 |
| 1,2-dipalmitoylphosphatidylcholine | | | | 2008 | 2010 | 15.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| desoxycorticosterone | | 20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 2003 | 2006 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| colchicine | | alkaloid;
colchicine | anti-inflammatory agent;
gout suppressant;
mutagen | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sodium citrate, anhydrous | | organic sodium salt | anticoagulant;
flavouring agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cycloserine | | 4-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion | antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist | 2002 | 2005 | 20.5 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| cytarabine | | beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside | antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| ornithine | | non-proteinogenic L-alpha-amino acid;
ornithine | algal metabolite;
hepatoprotective agent;
mouse metabolite | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valine | | L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2004 | 2016 | 15.6 | low | 1 | 0 | 0 | 3 | 2 | 0 |
| tryptophan | | erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan | antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2012 | 2017 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| arginine | | arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2003 | 2019 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| acetylene | | alkyne;
gas molecular entity;
terminal acetylenic compound | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| triamcinolone acetonide | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone | anti-allergic agent;
anti-inflammatory drug | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phencyclidine | | benzenes;
piperidines | anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug | 1995 | 2023 | 16.1 | low | 0 | 0 | 8 | 10 | 15 | 1 |
| azobis(isobutyronitrile) | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acrylic acid | | alpha,beta-unsaturated monocarboxylic acid | metabolite | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| methylprednisolone | | 6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic | 2003 | 2020 | 8.3 | low | 0 | 0 | 0 | 1 | 5 | 0 |
| rotenone | | organic heteropentacyclic compound;
rotenones | antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-vinyl-2-pyrrolidinone | | pyrrolidin-2-ones | | 2014 | 2017 | 8.5 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| n-vinyl-2-pyrrolidinone | | pyrrolidin-2-ones | | 2014 | 2017 | 8.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| quinoxalines | | mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenothiazine | | phenothiazine | ferroptosis inhibitor;
plant metabolite;
radical scavenger | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| soman | | phosphonic ester | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethylene dimethacrylate | | enoate ester | allergen;
cross-linking reagent;
polymerisation monomer | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| quinuclidines | | quinuclidines;
saturated organic heterobicyclic parent | | 2006 | 2022 | 10.1 | low | 8 | 0 | 0 | 5 | 11 | 1 |
| cyclohexanol | | cyclohexanols;
secondary alcohol | solvent | 2001 | 2014 | 16.9 | low | 2 | 0 | 0 | 11 | 2 | 0 |
| pyrroles | | pyrrole;
secondary amine | | 2008 | 2017 | 13.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| tetrahydrofuran | | cyclic ether;
oxolanes;
saturated organic heteromonocyclic parent;
volatile organic compound | polar aprotic solvent | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiophenes | | mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound | non-polar solvent | 2001 | 2022 | 11.3 | low | 0 | 0 | 0 | 8 | 9 | 2 |
| n,n'-methylenebisacrylamide | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ergotamine | | peptide ergot alkaloid | alpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| framycetin | | aminoglycoside | allergen;
antibacterial drug;
Escherichia coli metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pregnenolone | | 20-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
C21-steroid | human metabolite;
mouse metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| yohimbine | | methyl 17-hydroxy-20xi-yohimban-16-carboxylate | alpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzoxazoles | | 1,3-benzoxazoles;
mancude organic heterobicyclic parent | | 2007 | 2009 | 16.2 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| adamantane | | adamantanes;
polycyclic alkane | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyclopentane | | cycloalkane;
cyclopentanes;
volatile organic compound | non-polar solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoxazoles | | isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 1995 | 2020 | 13.1 | low | 11 | 0 | 2 | 12 | 30 | 0 |
| oxazoles | | 1,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiazoles | | 1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 1995 | 2022 | 15.2 | low | 78 | 0 | 15 | 174 | 107 | 4 |
| triphenyltetrazolium | | organic cation | | 2006 | 2009 | 16.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| ephedrine | | phenethylamine alkaloid;
phenylethanolamines | bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2000 | 2003 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| hydrazine | | azane;
hydrazines | EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor | 2022 | 2022 | 2.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| azacitidine | | N-glycosyl-1,3,5-triazine;
nucleoside analogue | antineoplastic agent | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| galantamine | | benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound | antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite | 2004 | 2007 | 18.5 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| aminoimidazole carboxamide | | aminoimidazole;
monocarboxylic acid amide | mouse metabolite | 2011 | 2018 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| cuprizone | | organonitrogen compound;
organooxygen compound | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| citrulline | | amino acid zwitterion;
citrulline | Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluorobenzenes | | monofluorobenzenes | NMR chemical shift reference compound | 1998 | 2009 | 21.3 | low | 0 | 0 | 3 | 3 | 0 | 0 |
| bicuculline | | benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines | agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| kainic acid | | dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid | antinematodal drug;
excitatory amino acid agonist | 2002 | 2006 | 20.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| thymoquinone | | 1,4-benzoquinones | adjuvant;
anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
cardioprotective agent;
plant metabolite | 2017 | 2023 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| 4-hydroxybutyric acid | | 4-hydroxy monocarboxylic acid;
hydroxybutyric acid | general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alpha-aminopyridine | | | | 2007 | 2016 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| podophyllotoxin | | furonaphthodioxole;
lignan;
organic heterotetracyclic compound | antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| methoxyhydroxyphenylglycol | | methoxybenzenes;
phenols | | 2006 | 2014 | 14.8 | low | 2 | 0 | 0 | 3 | 1 | 0 |
| methamphetamine | | amphetamines;
secondary amine | central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic | 2000 | 2023 | 10.2 | low | 1 | 0 | 1 | 3 | 5 | 3 |
| malondialdehyde | | dialdehyde | biomarker | 2009 | 2017 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| lithium carbonate | | carbonate salt;
lithium salt | antimanic drug | 1999 | 2023 | 15.7 | low | 12 | 0 | 2 | 41 | 10 | 2 |
| tripalmitin | | triglyceride | | 2013 | 2018 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| megestrol acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester | antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| glycopyrrolate | | organic bromide salt;
quaternary ammonium salt | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetylcysteine | | acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid | antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary | 2009 | 2020 | 8.8 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| clopenthixol | | N-alkylpiperazine;
primary alcohol;
thioxanthenes | alpha-adrenergic antagonist;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 1998 | 2022 | 13.5 | low | 1 | 0 | 2 | 10 | 4 | 4 |
| clopamide | | sulfonamide | | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| benzydamine | | aromatic ether;
indazoles;
tertiary amino compound | analgesic;
central nervous system stimulant;
hallucinogen;
local anaesthetic;
non-steroidal anti-inflammatory drug | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-amino-3-phenylbutyric acid | | organonitrogen compound;
organooxygen compound | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| prothipendyl | | aromatic amine;
tertiary amino compound | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| durapatite | | | | 2015 | 2017 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| arsenic trioxide | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| d-alpha tocopherol | | alpha-tocopherol | algal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite | 2000 | 2020 | 13.4 | low | 1 | 0 | 1 | 2 | 2 | 0 |
| s,n,n'-tripropylthiocarbamate | | tertiary amine | | 2006 | 2021 | 11.8 | low | 1 | 0 | 0 | 6 | 6 | 1 |
| dronabinol | | benzochromene;
diterpenoid;
phytocannabinoid;
polyketide | cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic | 2004 | 2014 | 14.5 | low | 1 | 0 | 0 | 2 | 2 | 0 |
| clothiapine | | dibenzothiazepine | | 1998 | 2011 | 19.7 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| pimozide | | benzimidazoles;
heteroarylpiperidine;
organofluorine compound | antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 1999 | 2022 | 17.8 | low | 1 | 0 | 3 | 7 | 1 | 1 |
| benperidol | | aromatic ketone | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flupenthixol | | thioxanthenes | | 2000 | 2022 | 13.8 | low | 2 | 0 | 1 | 9 | 4 | 3 |
| acadesine | | 1-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue | antineoplastic agent;
platelet aggregation inhibitor | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tranylcypromine | | 2-phenylcyclopropan-1-amine | | 2007 | 2007 | 17.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| carbonates | | carbon oxoanion | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valnoctamide | | fatty amide | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| iodinated glycerol | | dioxolane | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| limonene | | cycloalkene;
p-menthadiene | human metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-methylaspartate | | amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound | neurotransmitter agent | 1996 | 2017 | 17.8 | low | 0 | 0 | 4 | 3 | 4 | 0 |
| molindone | | indoles | | 2000 | 2022 | 12.3 | low | 6 | 0 | 1 | 3 | 3 | 2 |
| platinum | | elemental platinum;
nickel group element atom;
platinum group metal atom | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| silver | | copper group element atom;
elemental silver | Escherichia coli metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| technetium | | manganese group element atom | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| titanium | | titanium group element atom | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cerium | | f-block element atom;
lanthanoid atom | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gold | | copper group element atom;
elemental gold | | 2016 | 2022 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| hypochlorous acid | | chlorine oxoacid;
reactive oxygen species | EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
human metabolite | 1997 | 2002 | 25.2 | low | 0 | 0 | 3 | 1 | 0 | 0 |
| camptothecin | | delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite | 2004 | 2004 | 20.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| deuterium | | dihydrogen | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glycerol 1-stearate | | 1-acylglycerol 18:0;
rac-1-monoacylglycerol | algal metabolite;
Caenorhabditis elegans metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| galactose | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| poloxalene | | epoxide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-chloro-7-nitrobenzofurazan | | benzoxadiazole;
C-nitro compound;
organochlorine compound | EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.6.1.3 (adenosinetriphosphatase) inhibitor;
fluorescent probe;
fluorochrome | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| titanium dioxide | | titanium oxides | food colouring | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metopimazine | | phenothiazines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| selegiline | | selegiline;
terminal acetylenic compound | geroprotector | 1999 | 2012 | 19.3 | low | 1 | 0 | 1 | 4 | 1 | 0 |
| eedq | | | | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| tetradecanoylphorbol acetate | | acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester | antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metergoline | | carbamate ester;
ergoline alkaloid | dopamine agonist;
geroprotector;
serotonergic antagonist | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| cephapirin | | cephalosporin | antibacterial drug | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bromocriptine | | indole alkaloid | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist | 2000 | 2023 | 15.4 | low | 0 | 0 | 1 | 5 | 0 | 1 |
| phenyl acetate | | benzenes;
phenyl acetates | | 1999 | 2003 | 22.8 | low | 0 | 0 | 2 | 3 | 0 | 0 |
| cetylpyridinium chloride anhydrous | | chloride salt;
organic chloride salt | antiseptic drug;
surfactant | 2009 | 2010 | 14.5 | low | 2 | 0 | 0 | 2 | 0 | 0 |
| n-chlorosuccinimide | | dicarboximide;
pyrrolidinone | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pregnanolone | | 3-hydroxy-5beta-pregnan-20-one;
3alpha-hydroxy steroid | human metabolite;
intravenous anaesthetic;
sedative | 2000 | 2009 | 19.0 | low | 0 | 0 | 1 | 5 | 0 | 0 |
| dihydro-beta-erythroidine | | delta-lactone;
organic heterotetracyclic compound;
tertiary amino compound | nicotinic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glutamic acid | | glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical | 1996 | 2017 | 17.1 | low | 0 | 0 | 2 | 4 | 5 | 0 |
| azides | | pseudohalide anion | mitochondrial respiratory-chain inhibitor | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tramadol | | 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol | adrenergic uptake inhibitor;
antitussive;
capsaicin receptor antagonist;
delta-opioid receptor agonist;
kappa-opioid receptor agonist;
metabolite;
mu-opioid receptor agonist;
muscarinic antagonist;
nicotinic antagonist;
NMDA receptor antagonist;
opioid analgesic;
serotonergic antagonist;
serotonin uptake inhibitor | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxcarbazepine | | cyclic ketone;
dibenzoazepine | anticonvulsant;
drug allergen | 2003 | 2019 | 12.9 | low | 0 | 0 | 0 | 4 | 4 | 0 |
| canadine | | aromatic ether;
berberine alkaloid;
organic heteropentacyclic compound;
oxacycle | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| s-adenosylmethionine | | sulfonium betaine | human metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyclindole | | | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| paclitaxel | | taxane diterpenoid;
tetracyclic diterpenoid | antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent | 2019 | 2019 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| etoposide | | beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound | antineoplastic agent;
DNA synthesis inhibitor | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| substance p | | peptide | neurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent | 2016 | 2019 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 1-methyl-4-phenylpyridinium | | pyridinium ion | apoptosis inducer;
herbicide;
human xenobiotic metabolite;
neurotoxin | 2011 | 2014 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| epirubicin | | aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2002 | 2020 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| paroxetine | | aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 2000 | 2019 | 17.4 | low | 9 | 0 | 1 | 28 | 5 | 0 |
| pergolide | | diamine;
methyl sulfide;
organic heterotetracyclic compound | antiparkinson drug;
dopamine agonist | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| fluperlapine | | benzazepine | | 1996 | 1997 | 27.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| fomesafen | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols | agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 2005 | 2020 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fenoxycarb | | aromatic ether;
carbamate ester | environmental contaminant;
insecticide;
juvenile hormone mimic;
xenobiotic | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| haloperidol decanoate | | organic molecular entity | | 2003 | 2017 | 13.5 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| simvastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic) | EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug | 2013 | 2020 | 7.5 | low | 0 | 0 | 0 | 0 | 6 | 0 |
| idazoxan | | benzodioxine;
imidazolines | alpha-adrenergic antagonist | 2003 | 2015 | 17.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| remoxipride | | dimethoxybenzene | | 1996 | 2009 | 24.3 | low | 1 | 0 | 5 | 2 | 0 | 0 |
| quinpirole | | pyrazoloquinoline | dopamine agonist | 1999 | 2008 | 18.9 | low | 0 | 0 | 2 | 6 | 0 | 0 |
| pravastatin | | 3-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic) | anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| atomoxetine hydrochloride | | hydrochloride | adrenergic uptake inhibitor;
antidepressant | 2008 | 2023 | 11.2 | low | 2 | 0 | 0 | 2 | 3 | 1 |
| raloxifene hydrochloride | | hydrochloride | bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mifepristone | | 3-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound | abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive | 2003 | 2009 | 18.0 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| itraconazole | | aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles | EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| eticlopride | | salicylamides | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| finasteride | | 3-oxo steroid;
aza-steroid;
delta-lactam | androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| naxagolide | | organic heterotricyclic compound;
phenols;
tertiary amino compound | anticonvulsant;
antiparkinson drug;
dopamine agonist | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| n 0437, (-)-isomer | | tetralins | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sertindole | | heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole | alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist | 1995 | 2023 | 21.1 | medium | 3 | 0 | 28 | 16 | 9 | 1 |
| tiagabine | | beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes | anticonvulsant;
GABA reuptake inhibitor | 2003 | 2006 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| aripiprazole | | aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist | 2002 | 2023 | 10.5 | medium | 49 | 0 | 0 | 131 | 187 | 56 |
| xanomeline | | tetrahydropyridine;
thiadiazoles | muscarinic agonist;
serotonergic agonist | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| atorvastatin | | aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic) | environmental contaminant;
xenobiotic | 2009 | 2015 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| duloxetine hydrochloride | | duloxetine hydrochloride | antidepressant | 2005 | 2014 | 15.4 | low | 0 | 0 | 0 | 6 | 2 | 0 |
| irinotecan | | carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 2004 | 2004 | 20.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| valsartan | | biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ziprasidone | | 1,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines | antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist | 1995 | 2023 | 15.2 | high | 71 | 0 | 14 | 165 | 96 | 5 |
| capecitabine | | carbamate ester;
cytidines;
organofluorine compound | antimetabolite;
antineoplastic agent;
prodrug | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cathinone | | 2-aminopropiophenone;
monoamine alkaloid | central nervous system stimulant;
psychotropic drug | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tenocyclidine | | piperidines;
tertiary amino compound;
thiophenes | central nervous system stimulant;
hallucinogen;
neuroprotective agent;
NMDA receptor antagonist | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyamemazine | | phenothiazines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pipothiazine | | | | 2021 | 2021 | 3.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| venlafaxine hydrochloride | | hydrochloride | | 2001 | 2023 | 12.2 | low | 3 | 0 | 0 | 10 | 6 | 4 |
| glucose, (beta-d)-isomer | | D-glucopyranose | epitope;
mouse metabolite | 2020 | 2021 | 3.3 | low | 0 | 0 | 0 | 0 | 1 | 2 |
| thiazolyl blue | | organic bromide salt | colorimetric reagent;
dye | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 5-methylcytosine | | methylcytosine;
pyrimidines | human metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-acetylaspartic acid | | N-acetyl-L-amino acid;
N-acyl-L-aspartic acid | antioxidant;
human metabolite;
mouse metabolite;
nutraceutical;
rat metabolite | 2000 | 2007 | 19.7 | low | 1 | 0 | 1 | 2 | 0 | 0 |
| fluorexon | | xanthene dye | fluorochrome | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aica ribonucleotide | | 1-(phosphoribosyl)imidazolecarboxamide;
aminoimidazole | cardiovascular drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| salvin | | abietane diterpenoid;
carbotricyclic compound;
catechols;
monocarboxylic acid | angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
food preservative;
HIV protease inhibitor;
plant metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glutathione disulfide | | glutathione derivative;
organic disulfide | Escherichia coli metabolite;
mouse metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| milnacipran | | acetamides | | 2007 | 2011 | 15.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| telmisartan | | benzimidazoles;
biphenyls;
carboxybiphenyl | angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic | 2008 | 2019 | 10.2 | low | 2 | 0 | 0 | 1 | 3 | 0 |
| bromosuccinimide | | dicarboximide;
organobromine compound;
pyrrolidinone | reagent | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triazoles | | 1,2,3-triazole | | 2008 | 2022 | 9.5 | low | 1 | 0 | 0 | 1 | 2 | 1 |
| setoperone | | | | 1998 | 2005 | 23.3 | low | 2 | 0 | 2 | 1 | 0 | 0 |
| fluorodeoxyglucose f18 | | 2-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose | | 2005 | 2017 | 15.2 | low | 1 | 0 | 0 | 3 | 1 | 0 |
| sertraline | | dichlorobenzene;
secondary amino compound;
tetralins | antidepressant;
serotonin uptake inhibitor | 1999 | 2023 | 12.0 | low | 25 | 0 | 2 | 17 | 21 | 5 |
| budipine | | diarylmethane | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| pirlindole | | carbazoles | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mesulergine | | ergot alkaloid;
sulfamides | antiparkinson drug;
dopamine agonist;
serotonergic antagonist | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tianeptine | | dibenzothiazepine;
monocarboxylic acid;
organochlorine compound | | 2010 | 2016 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| 5-hydroxymethylcytosine | | aminopyrimidine;
aromatic primary alcohol;
nucleobase analogue;
pyrimidone | human metabolite;
mouse metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-methylscopolamine | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| hp 873 | | 1,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound | dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 2002 | 2020 | 11.5 | medium | 4 | 0 | 0 | 3 | 9 | 0 |
| voriconazole | | conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug | P450 inhibitor | 2012 | 2017 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 2-tetradecylglycidic acid | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methotrimeprazine | | phenothiazines;
tertiary amine | anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist | 1999 | 2022 | 13.1 | low | 1 | 0 | 2 | 3 | 4 | 2 |
| amperozide | | diarylmethane;
monofluorobenzenes;
N-alkylpiperazine;
secondary carboxamide;
ureas | anxiolytic drug;
dopamine uptake inhibitor;
geroprotector;
second generation antipsychotic;
serotonergic antagonist | 1995 | 2000 | 26.7 | low | 0 | 0 | 3 | 0 | 0 | 0 |
| 2',7'-dichlorodihydrofluorescein diacetate | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rivastigmine | | carbamate ester;
tertiary amino compound | cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent | 2003 | 2023 | 16.1 | low | 0 | 0 | 0 | 7 | 1 | 1 |
| rosiglitazone | | aminopyridine;
thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug | 2009 | 2014 | 12.3 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| s20098 | | acetamides | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clarithromycin | | macrolide antibiotic | antibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| epidepride | | dimethoxybenzene | | 2000 | 2009 | 19.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| nicotine | | 3-(1-methylpyrrolidin-2-yl)pyridine | anxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic | 2008 | 2022 | 7.3 | low | 1 | 0 | 0 | 1 | 1 | 1 |
| n-desmethylclobazam | | benzodiazepine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fibrinogen | | iditol | fungal metabolite | 2007 | 2009 | 16.0 | low | 2 | 0 | 0 | 3 | 0 | 0 |
| homocysteine | | amino acid zwitterion;
homocysteine;
serine family amino acid | fundamental metabolite;
mouse metabolite | 2006 | 2017 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| 1-methyl-1,2,3,4-tetrahydroisoquinoline | | isoquinolines | | 2019 | 2021 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| glucuronic acid | | D-glucuronic acid | algal metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tetrahydrodeoxycorticosterone | | 21-hydroxy steroid | | 2003 | 2006 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| perindopril | | alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide | | | | 1996 | 2004 | 23.7 | low | 7 | 0 | 7 | 4 | 0 | 0 |
| rx 821002 | | benzodioxine;
cyclic ketal;
imidazolines | alpha-adrenergic antagonist | 2003 | 2015 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tamibarotene | | dicarboxylic acid monoamide;
retinoid;
tetralins | antineoplastic agent;
retinoic acid receptor alpha/beta agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| deoxyglucose | | | | 2000 | 2008 | 19.8 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| n-n-propyl-n-phenylethyl-4(3-hydroxyphenyl)ethylamine hydrochloride | | | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 1-(carboxymethylthio)tetradecane | | straight-chain fatty acid | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| perospirone | | N-arylpiperazine | | 2000 | 2012 | 17.7 | low | 4 | 0 | 1 | 7 | 2 | 0 |
| afdx 384 | | | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pramipexole | | benzothiazoles;
diamine | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger | 1997 | 2014 | 14.7 | low | 1 | 0 | 1 | 2 | 3 | 0 |
| hydroxypropylmethylcellulose acetate succinate | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-quinuclidinyl-4-iodobenzilate | | | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| a 68930 | | 2-benzopyran | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| angiotensin ii, des-phe(8)- | | amino acid zwitterion;
angiotensin | vasodilator agent | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 3-hydroxymethyl-2,2,5,5-tetramethylpyrroline-n-oxyl | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| l 687414 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| blonanserin | | organic molecular entity | | 2014 | 2020 | 7.2 | low | 1 | 0 | 0 | 0 | 4 | 0 |
| reboxetine | | aromatic ether | | 2002 | 2021 | 14.1 | low | 6 | 0 | 0 | 7 | 3 | 1 |
| 3-n-(2-fluoroethyl)spiperone | | | | 2004 | 2004 | 20.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| umifenovir | | indolyl carboxylic acid | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosamprenavir | | sulfonamide | prodrug | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| 4b,5,9b,10-tetrahydroindeno(1,2-b)indole | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-(4-bromophenylaminocarbonyl)-4,5-diphenyl-3-pyrazolidinone | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| sonepiprazole | | | | 2004 | 2007 | 18.5 | medium | 1 | 0 | 0 | 2 | 0 | 0 |
| l 741626 | | piperidines | | 2008 | 2015 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| aspartame | | carboxylic acid;
dipeptide zwitterion;
dipeptide;
methyl ester | apoptosis inhibitor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
environmental contaminant;
micronutrient;
nutraceutical;
sweetening agent;
xenobiotic | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| beta-lactams | | beta-lactam antibiotic allergen;
beta-lactam | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| proline | | amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid | algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2009 | 2018 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| escitalopram | | 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile | antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bdp 12 | | N-acylpiperidine | | 2006 | 2008 | 17.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| moxifloxacin | | aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug | 2020 | 2020 | 4.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| ym 09151-2 | | N-(1-benzyl-2-methylpyrrolidin-3-yl)-5-chloro-2-methoxy-4-(methylamino)benzamide | | 2001 | 2013 | 16.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cerium sulfate | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| asenapine | | 5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole | | 1995 | 2022 | 11.2 | medium | 14 | 0 | 1 | 9 | 29 | 1 |
| clorazepate dipotassium | | potassium salt | anticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| atropine | | | | 2000 | 2012 | 16.2 | low | 1 | 0 | 1 | 2 | 1 | 0 |
| ropivacaine | | piperidinecarboxamide;
ropivacaine | local anaesthetic | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| psyllium | | very long-chain fatty acid | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 24,25-oxidolanosterol | | | | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| bifeprunox | | biphenyls | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| darunavir | | carbamate ester;
furofuran;
sulfonamide | antiviral drug;
HIV protease inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lanosterol | | 14alpha-methyl steroid;
3beta-sterol;
tetracyclic triterpenoid | bacterial metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| benzofurans | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ibogaine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ritonavir | | 1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas | antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic | 2002 | 2016 | 13.3 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| 5-methyl-2-((2-nitrophenyl)amino)-3-thiophenecarbonitrile | | | | 2001 | 2001 | 23.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| dihydropyridines | | | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carboplatin | | | | 2019 | 2022 | 3.9 | low | 8 | 0 | 0 | 0 | 5 | 4 |
| lithium chloride | | inorganic chloride;
lithium salt | antimanic drug;
geroprotector | 2000 | 2011 | 18.1 | low | 1 | 0 | 1 | 6 | 1 | 0 |
| glycogen | | | | 2005 | 2012 | 16.4 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| oxytocin | | heterodetic cyclic peptide;
peptide hormone | oxytocic;
vasodilator agent | 2010 | 2021 | 7.0 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| inositol 1,4,5-trisphosphate | | myo-inositol trisphosphate | mouse metabolite | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ouabain | | 11alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone | anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sb 243213 | | indolyl carboxylic acid | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betadex | | cyclodextrin | | 2001 | 2018 | 13.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| arachidonic acid | | icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid | Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite | 2007 | 2011 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| resveratrol | | resveratrol | antioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| retinol | | retinol;
vitamin A | human metabolite;
mouse metabolite;
plant metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oleic acid | | octadec-9-enoic acid | antioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tacrolimus | | macrolide lactam | bacterial metabolite;
immunosuppressive agent | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 1997 | 2013 | 18.2 | low | 1 | 0 | 2 | 5 | 2 | 0 |
| mycophenolic acid | | 2-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzoylecgonine | | benzoate ester;
tropane alkaloid | epitope;
human xenobiotic metabolite;
marine xenobiotic metabolite;
plant metabolite | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| h 89 | | N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| melphalan | | L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent | 2017 | 2022 | 5.2 | low | 1 | 0 | 0 | 0 | 3 | 1 |
| enkephalin, leucine | | pentapeptide;
peptide zwitterion | analgesic;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist;
neurotransmitter;
rat metabolite | 2002 | 2019 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| sodium acetate, anhydrous | | organic sodium salt | NMR chemical shift reference compound | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| isomethyleugenol | | isomethyleugenol | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cannabidiol | | olefinic compound;
phytocannabinoid;
resorcinols | antimicrobial agent;
plant metabolite | 2010 | 2015 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| malonyl coenzyme a | | malonyl-CoAs | EC 2.3.1.21 (carnitine O-palmitoyltransferase) inhibitor;
Escherichia coli metabolite;
metabolite;
mouse metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tropisetron | | indolyl carboxylic acid | | 2001 | 2022 | 9.0 | low | 1 | 0 | 0 | 1 | 0 | 2 |
| leuprolide | | oligopeptide | anti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorprothixene | | chlorprothixene | | 1999 | 2023 | 15.5 | low | 1 | 0 | 1 | 2 | 0 | 1 |
| cotinine | | N-alkylpyrrolidine;
pyridines;
pyrrolidin-2-ones;
pyrrolidine alkaloid | antidepressant;
biomarker;
human xenobiotic metabolite;
plant metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benztropine | | diarylmethane | | 2000 | 2012 | 18.9 | low | 1 | 0 | 1 | 6 | 1 | 0 |
| methimazole | | 1,3-dihydroimidazole-2-thiones | antithyroid drug | 2009 | 2015 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| capsaicin | | capsaicinoid | non-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| D-fructopyranose | | cyclic hemiketal;
D-fructose;
fructopyranose | sweetening agent | 1999 | 2016 | 17.2 | low | 7 | 0 | 2 | 15 | 5 | 0 |
| capsazepine | | benzazepine;
catechols;
monochlorobenzenes;
thioureas | capsaicin receptor antagonist | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| 1,1-diphenyl-2-picrylhydrazyl | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2h-tetrazolium | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ranitidine | | C-nitro compound;
furans;
organic sulfide;
tertiary amino compound | anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic | 2013 | 2016 | 9.5 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| u 0126 | | aryl sulfide;
dinitrile;
enamine;
substituted aniline | antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pica | | | | 2008 | 2020 | 10.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| lithium | | alkali metal atom | | 1998 | 2023 | 16.0 | low | 16 | 0 | 7 | 40 | 14 | 8 |
| nizatidine | | | | 2000 | 2009 | 19.6 | low | 4 | 0 | 1 | 6 | 0 | 0 |
| raclopride | | salicylamides | | 1998 | 2017 | 17.0 | low | 5 | 0 | 5 | 9 | 6 | 0 |
| orlistat | | beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative | anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor | 2008 | 2016 | 12.0 | low | 4 | 0 | 0 | 1 | 3 | 0 |
| thioperamide | | primary aliphatic amine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sch 23390 | | benzazepine | | 2013 | 2015 | 9.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| dipalmitoylphosphatidylserine | | phosphatidyl-L-serine | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| crocin | | | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| sb 242084 | | | | 2007 | 2016 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 2-chloro-5-hydroxyphenylglycine | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alpha-chymotrypsin | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sb 415286 | | C-nitro compound;
maleimides;
monochlorobenzenes;
phenols;
secondary amino compound;
substituted aniline | antioxidant;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sb 408124 | | organohalogen compound;
quinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol | | alkylbenzene;
ring assembly | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rhodamine 123 | | organic cation;
xanthene dye | fluorochrome | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| myelin basic protein | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dinoprostone | | prostaglandins E | human metabolite;
mouse metabolite;
oxytocic | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| vitamin k semiquinone radical | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 8,11,14-eicosatrienoic acid | | fatty acid 20:3;
long-chain fatty acid | fungal metabolite;
human metabolite;
nutraceutical | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| esculetin | | hydroxycoumarin | antioxidant;
plant metabolite;
ultraviolet filter | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| humulene | | alpha-humulene | | 1999 | 2021 | 10.2 | low | 1 | 0 | 1 | 0 | 4 | 1 |
| sdz psc 833 | | homodetic cyclic peptide | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| coenzyme q10 | | ubiquinones | antioxidant;
ferroptosis inhibitor;
human metabolite | 2005 | 2005 | 19.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| anandamide | | endocannabinoid;
N-acylethanolamine 20:4 | human blood serum metabolite;
neurotransmitter;
vasodilator agent | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-palmitoyl-2-oleoylglycero-3-phosphoglycerol | | phosphatidylglycerol | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-oleoylethanolamine | | endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1 | EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-palmitoyl-2-oleoylglycero-3-phosphoserine | | 3-sn-phosphatidyl-L-serine | | 2008 | 2010 | 15.3 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| codeine | | morphinane alkaloid;
organic heteropentacyclic compound | antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| granisetron | | aromatic amide;
indazoles | | 2007 | 2021 | 7.2 | low | 3 | 0 | 0 | 1 | 3 | 1 |
| levetiracetam | | pyrrolidin-2-ones | anticonvulsant;
environmental contaminant;
xenobiotic | 2014 | 2020 | 7.0 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| nalmefene | | morphinane alkaloid | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| naloxone | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol | antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist | 1998 | 2015 | 19.0 | low | 0 | 0 | 2 | 2 | 1 | 0 |
| vitamin k 1 | | phylloquinones;
vitamin K | cofactor;
human metabolite;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| topiramate | | cyclic ketal;
ketohexose derivative;
sulfamate ester | anticonvulsant;
sodium channel blocker | 1999 | 2020 | 16.7 | low | 7 | 0 | 2 | 15 | 6 | 0 |
| morphine | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound | anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic | 2002 | 2017 | 13.3 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| dexmedetomidine | | medetomidine | alpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative | 2014 | 2021 | 5.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| sb 277011 | | | | 2014 | 2015 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| goserelin | | organic molecular entity | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mdl 100907 | | | | 1998 | 2023 | 15.8 | low | 1 | 0 | 3 | 10 | 4 | 1 |
| mdl 100907 | | | | 2005 | 2020 | 14.9 | low | 1 | 0 | 0 | 10 | 4 | 0 |
| fluvoxamine | | (trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime | antidepressant;
anxiolytic drug;
serotonin uptake inhibitor | 1999 | 2023 | 18.8 | low | 5 | 0 | 2 | 17 | 1 | 1 |
| ag-490 | | catechols;
enamide;
monocarboxylic acid amide;
nitrile;
secondary carboxamide | anti-inflammatory agent;
antioxidant;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector;
STAT3 inhibitor | 2007 | 2010 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| aluminum | | boron group element atom;
elemental aluminium;
metal atom | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| arsenic | | metalloid atom;
pnictogen | micronutrient | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| naltrexone | | cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound | antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic | 2012 | 2023 | 4.2 | low | 14 | 0 | 0 | 0 | 18 | 17 |
| lisinopril | | dipeptide | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ramipril | | azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester | bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulfur | | chalcogen;
nonmetal atom | macronutrient | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methylazoxymethanol acetate | | azoxy compound | | 2020 | 2021 | 3.7 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| cysteine | | cysteinium | fundamental metabolite | 2005 | 2010 | 16.5 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| phosphorus | | monoatomic phosphorus;
nonmetal atom;
pnictogen | macronutrient | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| heroin | | morphinane alkaloid | mu-opioid receptor agonist;
opioid analgesic;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pregabalin | | gamma-amino acid | anticonvulsant;
calcium channel blocker | 2019 | 2023 | 3.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| tiapridex | | benzamides | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| palonosetron | | azabicycloalkane;
delta-lactam;
organic heterotricyclic compound | antiemetic;
serotonergic antagonist | 2006 | 2023 | 8.8 | low | 11 | 0 | 0 | 5 | 14 | 2 |
| dizocilpine maleate | | maleate salt;
tetracyclic antidepressant | anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist | 1995 | 2022 | 13.7 | low | 0 | 0 | 5 | 6 | 13 | 3 |
| ciproxifan | | aromatic ketone | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| methylazoxymethanol | | azoxy compound | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-palmitoyl-2-oleoylphosphatidylcholine | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clopenthixol acetate ester | | thioxanthenes | | 2003 | 2022 | 11.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| clopenthixol decanoate | | | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| netupitant | | aminopyridine;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
toluenes | antiemetic;
neurokinin-1 receptor antagonist | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| oxepins | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| govadine | | | | 2015 | 2015 | 9.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| s-nitroso-n-acetylpenicillamine | | nitroso compound;
nitrosothio compound | nitric oxide donor;
vasodilator agent | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sb 269970 | | sulfonamide | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sb 334867-a | | naphthyridine derivative | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 6 beta-hydroxycortisol | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
6beta-hydroxy steroid;
C21-steroid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | human metabolite;
mammalian metabolite;
probe | 1998 | 1998 | 26.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| morphinans | | isoquinoline alkaloid fundamental parent;
morphinane alkaloid | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ergoline | | diamine;
ergoline alkaloid;
indole alkaloid fundamental parent;
indole alkaloid;
organic heterotetracyclic compound | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enkephalin, leucine-2-alanine | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tiapamil hydrochloride | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vofopitant | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rwj-333369 | | organochlorine compound | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vildagliptin | | amino acid amide | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sb 399885 | | | | 2011 | 2015 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| hypericum | | penicillanic acids | | 2000 | 2000 | 24.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| desvenlafaxine succinate | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amoxicillin-potassium clavulanate combination | | | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etomoxir | | aromatic ether | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cp 91149 | | | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| paliperidone palmitate | | 1,2-benzoxazoles;
fatty acid ester;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine | | 2006 | 2022 | 8.7 | low | 10 | 0 | 0 | 7 | 52 | 7 |
| mocetinostat | | aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline | antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent | 1997 | 1998 | 26.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| slv 313 | | | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flb 457 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sorbitan monooleate | | fatty acid ester | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tofacitinib | | N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound | antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pitolisant | | organochlorine compound | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide | | | | 2005 | 2019 | 12.0 | low | 2 | 0 | 0 | 1 | 1 | 0 |
| 2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pimavanserin | | aromatic ether;
monofluorobenzenes;
piperidines;
tertiary amino compound;
ureas | 5-hydroxytryptamine 2A receptor inverse agonist;
antipsychotic agent;
serotonergic antagonist | 2017 | 2022 | 5.3 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| opc-14857 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| gsk215083 | | | | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| delphinidin 3-sambubioside | | anthocyanidin 3-O-beta-D-sambubioside | apoptosis inducer;
metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ly 379268 | | amino dicarboxylic acid;
bridged compound;
organic heterobicyclic compound | antipsychotic agent;
anxiolytic drug;
metabotropic glutamate receptor agonist;
neuroprotective agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| oxadiazoles | | | | 2011 | 2012 | 12.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 5-formylcytosine | | aminopyrimidine;
heteroarenecarbaldehyde;
nucleobase analogue;
pyrimidone | metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cariprazine | | | | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| brimonidine tartrate | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lurasidone hydrochloride | | hydrochloride | adrenergic antagonist;
dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 2011 | 2023 | 6.3 | low | 7 | 0 | 0 | 0 | 22 | 7 |
| sb 742457 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lisdexamfetamine dimesylate | | | | 2015 | 2016 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ru 66647 | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| losartan potassium | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tp 7 | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| empagliflozin | | aromatic ether;
C-glycosyl compound;
monochlorobenzenes;
tetrahydrofuryl ether | hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| technetium tc 99m exametazime | | | | 1999 | 2003 | 23.0 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| scopolamine hydrobromide | | | | 1999 | 2013 | 19.7 | low | 0 | 0 | 2 | 3 | 1 | 0 |
| brexpiprazole | | N-arylpiperazine | | 2017 | 2023 | 3.2 | low | 0 | 0 | 0 | 0 | 3 | 3 |
| pituitrin | | | | 2010 | 2021 | 7.0 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| rm-493 | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mefloquine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| org 26576 | | | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| jaw | | indolecarboxamide | | 1999 | 2005 | 22.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| cholecystokinin | | | | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| glucagon | | peptide hormone | | 1999 | 2022 | 11.9 | low | 1 | 0 | 1 | 1 | 4 | 1 |
| neuropeptide y | | | | 2003 | 2020 | 11.9 | low | 3 | 0 | 0 | 4 | 10 | 0 |
| liraglutide | | lipopeptide;
polypeptide | glucagon-like peptide-1 receptor agonist;
neuroprotective agent | 2008 | 2022 | 6.5 | low | 5 | 0 | 0 | 1 | 7 | 3 |
| glucagon-like peptide 1 | | | | 2008 | 2017 | 12.0 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| c-peptide | | | | 1999 | 2019 | 14.8 | low | 5 | 0 | 1 | 6 | 5 | 0 |
| cellulose | | glycoside | | 2010 | 2020 | 9.2 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| phosphatidylcholines | | 1,2-diacyl-sn-glycero-3-phosphocholine | | 2010 | 2017 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dihydroceramide | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ubiquinone | | | | 2005 | 2005 | 19.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| chitosan | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ro13-9904 | | | | 2005 | 2007 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ethyl cellulose | | glycoside | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rg 1678 | | | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| ro5166017 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| quetiapine fumarate | | fumarate salt | | 1995 | 2024 | 14.3 | high | 107 | 0 | 53 | 362 | 240 | 63 |
| cardiovascular agents | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| neurotensin | | peptide hormone | human metabolite;
mitogen;
neurotransmitter;
vulnerary | 1998 | 2011 | 19.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| cobicistat | | 1,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas | P450 inhibitor | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glycolipids | | | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piperidines | | | | 1995 | 2020 | 14.5 | low | 13 | 0 | 6 | 21 | 27 | 0 |
| interleukin-8 | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cort 108297 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydroxocobalamin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| exenatide | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| kavain | | 2-pyranones;
aromatic ether | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tak-063 | | | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aripiprazole lauroxil | | aromatic ether;
delta-lactam;
dichlorobenzene;
dodecanoate ester;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | H1-receptor antagonist;
prodrug;
second generation antipsychotic;
serotonergic agonist | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methylcellulose | | | | 2010 | 2020 | 9.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| heme | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ascorbic acid | | ascorbic acid;
vitamin C | coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent | 1998 | 2010 | 19.0 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| minocycline | | | | 2013 | 2020 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| salicylates | | monohydroxybenzoate | plant metabolite | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| piroxicam | | benzothiazine;
monocarboxylic acid amide;
pyridines | analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 2014 | 2017 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| warfarin | | benzenes;
hydroxycoumarin;
methyl ketone | | 2005 | 2017 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| kaolinite | | aluminosilicate mineral;
mixture | antidiarrhoeal drug;
excipient | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| semaglutide | | lipopeptide;
polypeptide | anti-obesity agent;
appetite depressant;
glucagon-like peptide-1 receptor agonist;
hypoglycemic agent;
neuroprotective agent | 2023 | 2023 | 1.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| 2-phytyl-1,4-naphthoquinone | | phylloquinones | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| naloxegol | | aromatic ether;
organic heteropentacyclic compound;
phenols;
polyether;
tertiary alcohol | cathartic;
mu-opioid receptor antagonist | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| okadaic acid | | ketal | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bgp 15 | | | | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| selinexor | | | | 2022 | 2022 | 2.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| ly 2140023 | | | | 2008 | 2013 | 13.0 | medium | 3 | 0 | 0 | 1 | 3 | 0 |
| peptide yy | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| angiotensin i | | angiotensin;
peptide zwitterion | human metabolite;
neurotransmitter agent | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| n-(1-(3,4-difluorobenzyl)piperidin-4-yl)-6-(trifluoromethyl)pyridazin-3-amine | | | | 2012 | 2013 | 11.5 | high | 3 | 0 | 0 | 0 | 4 | 0 |
| peoniflorin | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vitamin b 12 | | | | 2011 | 2020 | 9.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| humulin s | | | | 2022 | 2022 | 2.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| lysergic acid | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclosporine | | | | 2006 | 2018 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| peptide yy | | | | 2008 | 2012 | 13.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| exudates | | | | 2006 | 2019 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cyclic gmp | | 3',5'-cyclic purine nucleotide;
guanyl ribonucleotide | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| guanosine triphosphate | | guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate | Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| folic acid | | folic acids;
N-acyl-amino acid | human metabolite;
mouse metabolite;
nutrient | 2001 | 2014 | 17.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| guanosine 5'-o-(3-thiotriphosphate) | | nucleoside triphosphate analogue | | 1999 | 2001 | 24.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| rifampin | | cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion | angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor | 2019 | 2021 | 4.0 | low | 1 | 0 | 0 | 0 | 1 | 1 |
| clozapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound | adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic | 1992 | 2023 | 16.7 | medium | 113 | 0 | 173 | 467 | 225 | 54 |
| dacarbazine | | dacarbazine | | 2011 | 2015 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| norclozapine | | dibenzodiazepine;
organochlorine compound;
piperazines | delta-opioid receptor agonist;
metabolite;
serotonergic antagonist | 2000 | 2013 | 17.0 | low | 1 | 0 | 1 | 4 | 2 | 0 |
| sildenafil citrate | | citrate salt | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2002 | 2012 | 17.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| aprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles | antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist | 2005 | 2023 | 7.6 | low | 16 | 0 | 0 | 4 | 21 | 3 |
| fosaprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles | antiemetic;
neurokinin-1 receptor antagonist;
prodrug | 2016 | 2023 | 4.4 | low | 4 | 0 | 0 | 0 | 3 | 2 |
| asoxime chloride | | | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| desmethylolanzapine | | benzodiazepine | | 2001 | 2020 | 12.5 | high | 0 | 0 | 0 | 4 | 7 | 0 |
| 5-methyltetrahydrofolate | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| heme arginate | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| olanzapine-fluoxetine combination | | | | 2004 | 2012 | 15.1 | medium | 3 | 0 | 0 | 5 | 2 | 0 |
| maltodextrin | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbidopa | | | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| technetium tc 99m bicisate | | | | 2005 | 2010 | 16.5 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| leptin | | | | 1999 | 2023 | 14.1 | low | 21 | 0 | 2 | 38 | 26 | 3 |
| pyrimidinones | | | | 1998 | 2005 | 23.3 | low | 2 | 0 | 2 | 1 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| 2019 Novel Coronavirus Disease | 0 | | 2020 | 2022 | 3.4 | low | 0 | 0 | 0 | 0 | 9 | 5 |
| 47,XX,+21 | 0 | | 2001 | 2008 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 48,XXYY Syndrome | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| A-V Dissociation | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Abdominal Epilepsy | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Abdominal Migraine | 0 | | 2002 | 2023 | 11.0 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| Abdominal Obesity | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Abdominal Pain | 0 | | 2001 | 2001 | 23.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Abnormal Deep Tendon Reflex | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Abnormal Movements | 0 | | 2003 | 2009 | 18.4 | low | 1 | 0 | 0 | 5 | 0 | 0 |
| Abnormalities, Autosome | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Abnormalities, Drug-Induced | 0 | | 2000 | 2023 | 11.1 | low | 0 | 0 | 1 | 3 | 2 | 3 |
| Abnormalities, Multiple | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Abnormalities, Musculoskeletal | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Abnormality, Heart | 0 | | 2007 | 2023 | 6.3 | low | 0 | 0 | 0 | 1 | 0 | 2 |
| Abortion, Spontaneous | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Abortion, Tubal | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Absence of Brain, Congenital | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Absence Seizure | 0 | | 1996 | 2021 | 17.8 | low | 0 | 0 | 5 | 15 | 5 | 1 |
| Absence Status | 0 | | 2009 | 2017 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Abstinence Syndrome, Neonatal | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Academic Disorder, Developmental | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acathisia, Drug-Induced | 0 | | 1996 | 2021 | 17.8 | low | 19 | 0 | 20 | 23 | 20 | 1 |
| Acetonemia | 0 | | 2002 | 2019 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Acetyl-CoA:alpha-Glucosaminide N-Acetyltransferase Deficiency | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Achalasia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Ache | 0 | | 2002 | 2020 | 15.7 | low | 2 | 0 | 0 | 10 | 4 | 0 |
| Acid Aspiration Syndrome | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Acidosis, Diabetic | 0 | | 1999 | 2023 | 17.5 | low | 1 | 0 | 3 | 20 | 6 | 1 |
| Acne | 0 | | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Acne Vulgaris | 0 | | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Acoustic Perceptual Disorder | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acquired Autoimmune Hemolytic Anemia | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acquired Communication Disorders | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acquired Meningocele | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acrania | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Actinic Reticuloid Syndrome | 0 | | 2007 | 2018 | 13.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Action Tremor | 0 | | 1997 | 2012 | 19.8 | low | 2 | 0 | 4 | 5 | 1 | 0 |
| Acute Brain Injuries | 0 | | 2000 | 2010 | 19.1 | low | 0 | 0 | 1 | 6 | 0 | 0 |
| Acute Confusional Senile Dementia | 0 | | 1996 | 2022 | 17.3 | low | 20 | 0 | 4 | 48 | 5 | 6 |
| Acute Disease | 0 | | 1997 | 2022 | 17.6 | low | 73 | 0 | 23 | 126 | 37 | 1 |
| Acute Disseminated Encephalomyelitis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acute Edematous Pancreatitis | 0 | | 2000 | 2016 | 17.4 | low | 0 | 0 | 2 | 8 | 2 | 0 |
| Acute Hepatic Failure | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Hypercapnic Respiratory Failure | 0 | | 2001 | 2022 | 15.0 | low | 0 | 0 | 0 | 5 | 1 | 1 |
| Acute Kidney Failure | 0 | | 2003 | 2022 | 11.6 | low | 0 | 0 | 0 | 5 | 4 | 2 |
| Acute Kidney Injury | 0 | | 2003 | 2022 | 11.6 | low | 0 | 0 | 0 | 5 | 4 | 2 |
| Acute Liver Injury, Drug-Induced | 0 | | 2000 | 2022 | 11.6 | low | 0 | 0 | 1 | 7 | 15 | 2 |
| Acute Necrotizing Pancreatitis | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acute Onset Vascular Dementia | 0 | | 2002 | 2008 | 19.0 | low | 1 | 0 | 0 | 11 | 0 | 0 |
| Acute Porphyria | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acute Post-Traumatic Stress Disorder | 0 | | 2001 | 2020 | 16.1 | low | 4 | 0 | 0 | 13 | 4 | 0 |
| Acute Promyelocytic Leukemia | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Relapsing Multiple Sclerosis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Respiratory Distress Syndrome | 0 | | 2010 | 2020 | 9.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Acute Stress Disorders | 0 | | 2020 | 2023 | 2.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Acute Symptom Flare | 0 | | 2020 | 2020 | 4.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Acute-Phase Reaction | 0 | | 2001 | 2001 | 23.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| ADDH | 0 | | 1998 | 2017 | 16.6 | low | 4 | 0 | 2 | 7 | 4 | 0 |
| Addiction, Opioid | 0 | | 2009 | 2022 | 7.2 | low | 1 | 0 | 0 | 1 | 3 | 2 |
| Addison Disease and Cerebral Sclerosis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Addison's Anemia | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adenocarcinoma | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Adenocarcinoma, Basal Cell | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Adenoma | 0 | | 2005 | 2010 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Adenoma Sebaceum | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adenoma, Basal Cell | 0 | | 2005 | 2010 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Adenoma, beta-Cell | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adenoma, Prolactin-Secreting, Pituitary | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adenoma, Prostatic | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adiadochokinesis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adipocere | 0 | | 2001 | 2018 | 15.2 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| Adjustment Disorder | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adjustment Disorders | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adjustment Sleep Disorder | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adolescent Gynecomastia | 0 | | 2005 | 2007 | 18.2 | low | 1 | 0 | 0 | 6 | 0 | 0 |
| Adrenocorticotropic Hormone, Inappropriate Secretion | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adrenoleukodystrophy | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adult Neuronal Ceroid Lipofuscinosis | 0 | | 2001 | 2001 | 23.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Adult Spinal Muscular Atrophy | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adult-Onset Dystonias | 0 | | 1999 | 2009 | 21.2 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| Adverse Drug Event | 0 | | 2004 | 2023 | 9.1 | low | 5 | 0 | 0 | 10 | 28 | 7 |
| Affective Disorders | 0 | | 1998 | 2019 | 17.1 | low | 3 | 0 | 3 | 18 | 9 | 0 |
| Affective Disorders, Psychotic | 0 | | 1998 | 2020 | 16.7 | low | 5 | 0 | 4 | 11 | 9 | 0 |
| Affective Psychosis, Bipolar | 0 | | 1997 | 2023 | 15.5 | low | 147 | 0 | 51 | 346 | 175 | 29 |
| Aganglionic Megacolon | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Age-Related Memory Disorders | 0 | | 2004 | 2023 | 13.7 | low | 6 | 0 | 0 | 12 | 8 | 1 |
| Age-Related Osteoporosis | 0 | | 2003 | 2006 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Aggression | 0 | | 1998 | 2021 | 15.6 | low | 27 | 0 | 4 | 45 | 22 | 3 |
| Aging | 0 | | 1998 | 2023 | 13.0 | low | 2 | 0 | 3 | 3 | 3 | 3 |
| Agitated Emergence | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Agitation, Psychomotor | 0 | | 1999 | 2023 | 14.1 | low | 38 | 0 | 3 | 65 | 42 | 9 |
| Agoraphobia | 0 | | 2000 | 2006 | 20.0 | low | 1 | 0 | 1 | 3 | 0 | 0 |
| Agranulocytosis | 0 | | 1997 | 2022 | 21.0 | low | 1 | 0 | 19 | 8 | 4 | 1 |
| Air Sickness | 0 | | 2023 | 2023 | 1.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Airway Hyper-Responsiveness | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Airway Obstruction | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Akinetic Autism | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Akinetic-Rigid Variant of Huntington Disease | 0 | | 1999 | 2019 | 17.8 | low | 2 | 0 | 3 | 12 | 6 | 0 |
| Alcohol Abuse | 0 | | 1999 | 2020 | 15.2 | low | 7 | 0 | 3 | 5 | 6 | 0 |
| Alcohol Drinking | 0 | | 2000 | 2011 | 19.2 | low | 3 | 0 | 1 | 6 | 1 | 0 |
| Alcoholic Intoxication | 0 | | 2012 | 2019 | 9.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| Alcoholism | 1 | | 1999 | 2020 | 15.2 | low | 7 | 0 | 3 | 5 | 6 | 0 |
| Alkalosis, Respiratory | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Allergic Contact Dermatitis | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Allergic Cutaneous Angiitis | 0 | | 2005 | 2006 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Allergic Encephalomyelitis | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Allergic Reaction | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Allergy, Drug | 0 | | 2000 | 2018 | 14.8 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| Allodynia | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Allotriophagy | 0 | | 2008 | 2020 | 10.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Alloxan Diabetes | 0 | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Alpers Diffuse Degeneration of Cerebral Gray Matter with Hepatic Cirrhosis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Altered Level of Consciousness | 0 | | 2010 | 2017 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Alzheimer Disease | 0 | | 1996 | 2022 | 17.3 | low | 20 | 0 | 4 | 48 | 5 | 6 |
| Ambulation Difficulty | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ambulation Disorders, Neurologic | 0 | | 2003 | 2009 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Amenorrhea | 0 | | 1998 | 2011 | 20.1 | low | 1 | 0 | 2 | 4 | 1 | 0 |
| Amentia | 0 | | 1997 | 2023 | 16.4 | low | 7 | 0 | 6 | 64 | 14 | 6 |
| Amnesia | 0 | | 2002 | 2006 | 20.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Amnesia-Memory Loss | 0 | | 2002 | 2006 | 20.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Amphetamine Abuse | 0 | | 2003 | 2018 | 14.7 | low | 2 | 0 | 0 | 5 | 2 | 0 |
| Amphetamine-Related Disorders | 0 | | 2003 | 2018 | 14.7 | low | 2 | 0 | 0 | 5 | 2 | 0 |
| Anankastic Personality | 0 | | 1996 | 2021 | 18.8 | low | 19 | 0 | 17 | 39 | 11 | 1 |
| Anaphylactic Reaction | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anaphylaxis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anaplastic Astrocytoma | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anasarca | 0 | | 2003 | 2022 | 12.9 | low | 0 | 0 | 0 | 6 | 3 | 2 |
| Anemia | 0 | | 2005 | 2020 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Anemia, Aplastic | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anemia, Fanconi | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anemia, Hemolytic, Autoimmune | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anemia, Hypoplastic | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anemia, Megaloblastic | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anesthesia | 0 | | 1996 | 2007 | 22.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Anesthesia Related Hyperthermia | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Aneurysm, Anterior Cerebral Artery | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Aneurysm, Aortic | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Angiitis, Central Nervous System | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Angina Pectoris | 0 | | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Angioedema | 0 | | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Angioneurotic Edema | 0 | | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Angor Pectoris | 0 | | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Anhedonia | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anochlesia | 0 | | 1992 | 2018 | 18.0 | low | 0 | 0 | 9 | 13 | 9 | 0 |
| Anomalous Ventricular Excitation Syndrome | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anorexia | 1 | | 2004 | 2023 | 10.6 | low | 5 | 0 | 0 | 5 | 1 | 4 |
| Anorexia Nervosa | 1 | | 1999 | 2023 | 14.3 | low | 14 | 0 | 3 | 30 | 18 | 4 |
| Anoxemia | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ANS (Autonomic Nervous System) Diseases | 0 | | 2000 | 2018 | 15.0 | low | 1 | 0 | 1 | 0 | 1 | 0 |
| Anterior Cerebral Circulation Infarction | 0 | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Anterior Choroidal Artery Infarction | 0 | | 2004 | 2014 | 15.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Anterior Circulation Transient Ischemic Attack | 0 | | 2005 | 2023 | 14.5 | low | 0 | 0 | 0 | 3 | 0 | 1 |
| Anterior Fascicular Block | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anti-MuSK Myasthenia Gravis | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 0 | | 2015 | 2020 | 6.7 | low | 0 | 0 | 0 | 0 | 7 | 0 |
| Anti-Phospholipid Antibody Syndrome | 0 | | 2005 | 2009 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Anticholinergic Syndrome | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anticipatory Vomiting | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Antidiuretic Hormone, Inappropriate Secretion | 0 | | 2007 | 2010 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Antiphospholipid Syndrome | 0 | | 2005 | 2009 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Antisocial Behavior | 0 | | 1999 | 2021 | 14.0 | low | 0 | 0 | 1 | 0 | 0 | 1 |
| Anton Syndrome | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anxiety | 1 | | 1998 | 2021 | 13.3 | low | 10 | 0 | 2 | 14 | 16 | 3 |
| Anxiety Disorders | 0 | | 2000 | 2023 | 14.8 | low | 6 | 0 | 2 | 13 | 5 | 1 |
| Anxiety Neuroses | 0 | | 2000 | 2023 | 14.8 | low | 6 | 0 | 2 | 13 | 5 | 1 |
| Aortic Aneurysm | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Aortic Arteritis, Giant Cell | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Apoplexy | 0 | | 2004 | 2016 | 17.3 | low | 0 | 0 | 0 | 16 | 3 | 0 |
| Appetite Disorders | 0 | | 2002 | 2022 | 10.6 | low | 0 | 0 | 0 | 2 | 5 | 1 |
| Apraxia | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Apraxias | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Aprosodia | 0 | | 1998 | 2003 | 22.7 | low | 1 | 0 | 1 | 2 | 0 | 0 |
| Aqueductal Stenosis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ARFID | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Arrhythmia | 0 | | 2000 | 2022 | 16.5 | low | 1 | 0 | 1 | 10 | 4 | 1 |
| Arrhythmias, Cardiac | 0 | | 2000 | 2022 | 16.5 | low | 1 | 0 | 1 | 10 | 4 | 1 |
| Arteriosclerosis, Coronary | 0 | | 2004 | 2013 | 15.2 | low | 1 | 0 | 0 | 2 | 2 | 0 |
| Arthritis, Juvenile | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Arthritis, Juvenile Chronic | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| As If Personality | 0 | | 2001 | 2022 | 14.3 | low | 1 | 0 | 0 | 4 | 1 | 1 |
| Asialia | 0 | | 1998 | 2012 | 20.4 | low | 4 | 0 | 2 | 2 | 1 | 0 |
| Asperger Disease | 0 | | 2006 | 2017 | 14.8 | low | 2 | 0 | 0 | 3 | 1 | 0 |
| Asperger Syndrome | 0 | | 2006 | 2017 | 14.8 | low | 2 | 0 | 0 | 3 | 1 | 0 |
| Astasia-Abasia | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Asthenia | 0 | | 2002 | 2002 | 22.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Asthma | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Asthma, Bronchial | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Astrocytoma | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Astrocytoma, Grade IV | 0 | | 2011 | 2022 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Asymptomatic Colonization | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Asystole | 0 | | 2007 | 2022 | 11.5 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| Ataxia | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Atherogenesis | 0 | | 2015 | 2021 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Atherosclerosis | 0 | | 2015 | 2021 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Atherosclerotic Parkinsonism | 0 | | 1997 | 2020 | 17.3 | low | 1 | 0 | 7 | 2 | 7 | 0 |
| Athetoid Movements | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Atrial Fibrillation | 0 | | 2008 | 2015 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Atrial Septal Defect | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Atrioventricular Block | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Atrioventricular Conduction Block | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Atrioventricular Nodal Re-Entrant Tachycardia | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Atrophy | 0 | | 2004 | 2023 | 12.2 | low | 0 | 0 | 0 | 6 | 2 | 2 |
| Attention Deficit and Disruptive Behavior Disorders | 0 | | 2003 | 2013 | 15.1 | low | 3 | 0 | 0 | 5 | 5 | 0 |
| Attention Deficit and Disruptive Behavioral Disorders | 0 | | 2003 | 2013 | 15.1 | low | 3 | 0 | 0 | 5 | 5 | 0 |
| Attention Deficit Disorder with Hyperactivity | 0 | | 1998 | 2017 | 16.6 | low | 4 | 0 | 2 | 7 | 4 | 0 |
| Atypical Cluster Headache | 0 | | 2001 | 2002 | 22.5 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Aura | 0 | | 2005 | 2019 | 11.2 | low | 0 | 0 | 0 | 3 | 9 | 0 |
| Auricular Fibrillation | 0 | | 2008 | 2015 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Autism | 0 | | 1998 | 2023 | 15.8 | low | 3 | 0 | 2 | 9 | 4 | 1 |
| Autism Spectrum Disorder | 0 | | 2019 | 2023 | 3.0 | low | 0 | 0 | 0 | 0 | 1 | 2 |
| Autism-Dementia-Ataxia-Loss of Purposeful Hand Use Syndrome | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Autistic Disorder | 1 | | 1998 | 2023 | 15.8 | low | 3 | 0 | 2 | 9 | 4 | 1 |
| Autoimmune Diabetes | 0 | | 1998 | 2021 | 16.7 | low | 0 | 0 | 2 | 5 | 3 | 1 |
| Autoimmune Thrombocytopenia | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Autokinetic Effect | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Autonomic Dysfunction, Paraneoplastic | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Autosomal Chromosome Disorders | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Autosomal Dominant Juvenile Parkinson Disease | 0 | | 2001 | 2014 | 16.1 | low | 3 | 0 | 0 | 8 | 4 | 0 |
| Autosomal Dominant Striatonigral Degeneration | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Autotomy Human | 0 | | 2000 | 2021 | 15.8 | low | 0 | 0 | 1 | 1 | 1 | 1 |
| Bacterial Pneumonia | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Basal Ganglia Diseases | 0 | | 1996 | 2022 | 19.3 | low | 59 | 0 | 35 | 84 | 20 | 1 |
| Basedow Disease | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Bed Sores | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bedwetting | 0 | | 2007 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Behavior Disorders | 0 | | 1997 | 2023 | 15.6 | low | 27 | 0 | 9 | 91 | 40 | 5 |
| Benign Essential Tremor | 0 | | 2003 | 2005 | 20.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Benign Intracranial Hypertension | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Benign Neoplasms | 0 | | 1999 | 2023 | 8.2 | low | 18 | 0 | 1 | 11 | 36 | 13 |
| Benign Neoplasms, Brain | 0 | | 2003 | 2015 | 13.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Benign Psychomotor Epilepsy, Childhood | 0 | | 2001 | 2021 | 15.4 | low | 0 | 0 | 0 | 3 | 1 | 1 |
| Bernhardt-Roth Syndrome | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Besnier-Boeck Disease | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bewilderment | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bilateral Headache | 0 | | 1998 | 2023 | 11.5 | low | 5 | 0 | 2 | 4 | 4 | 3 |
| Bilateral Periventricular Nodular Heterotopia | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bile Duct Obstruction | 0 | | 2009 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Binge Eating | 0 | | 2003 | 2020 | 13.6 | low | 1 | 0 | 0 | 3 | 2 | 0 |
| Binge-Eating Disorder | 0 | | 2019 | 2022 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Bipolar Disorder | 1 | | 1997 | 2023 | 15.5 | low | 147 | 0 | 51 | 346 | 175 | 29 |
| Birth Weight | 0 | | 2008 | 2019 | 11.7 | low | 1 | 0 | 0 | 2 | 1 | 0 |
| Bites | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Blast Injuries | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bleeding | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Blepharoptosis | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Blepharospasm | 0 | | 2000 | 2017 | 17.0 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| Blepharospasm-Oromandibular Dyskinesia | 0 | | 2002 | 2009 | 18.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Blood Clot | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Blood Coagulation Disorders | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Blood Diseases | 0 | | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Blood Pressure, High | 0 | | 2007 | 2023 | 11.0 | low | 1 | 0 | 0 | 5 | 3 | 2 |
| Blood Pressure, Low | 0 | | 2002 | 2022 | 12.9 | low | 0 | 0 | 0 | 6 | 2 | 3 |
| Body Rocking | 0 | | 1997 | 2000 | 25.0 | low | 1 | 0 | 4 | 0 | 0 | 0 |
| Body Weight | 0 | | 1999 | 2023 | 13.7 | low | 79 | 0 | 3 | 120 | 87 | 14 |
| Body-Weight Trajectory | 0 | | 2019 | 2019 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Bone Diseases, Metabolic | 0 | | 2007 | 2023 | 9.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| Bone Fractures | 0 | | 2012 | 2015 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Bone Marrow Diseases | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bonnevie-Ullrich Syndrome | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Borderline Personality Disorder | 1 | | 1999 | 2023 | 16.4 | low | 13 | 0 | 1 | 17 | 5 | 1 |
| Bowel Incontinence | 0 | | 2003 | 2005 | 20.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Bradyarrhythmia | 0 | | 1999 | 2023 | 16.2 | low | 0 | 0 | 1 | 3 | 1 | 1 |
| Bradycardia | 0 | | 1999 | 2023 | 16.2 | low | 0 | 0 | 1 | 3 | 1 | 1 |
| Brain Concussion | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Diseases | 0 | | 2004 | 2020 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Brain Disorders | 0 | | 2004 | 2020 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Brain Edema | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Hemorrhage | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Brain Hemorrhage, Cerebral | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Infarction | 0 | | 2008 | 2009 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Brain Inflammation | 0 | | 2010 | 2023 | 7.3 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| Brain Injuries | 0 | | 2000 | 2010 | 19.1 | low | 0 | 0 | 1 | 6 | 0 | 0 |
| Brain Injuries, Traumatic | 0 | | 2020 | 2020 | 4.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Brain Injury, Chronic | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Ischemia | 0 | | 2006 | 2009 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Brain Neoplasms | 0 | | 2003 | 2015 | 13.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Brain Swelling | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Thrombosis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Brain Vascular Disorders | 0 | | 2004 | 2015 | 17.1 | low | 1 | 0 | 0 | 6 | 1 | 0 |
| Branch Vein Occlusion | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Breast Cancer | 0 | | 2003 | 2023 | 6.1 | low | 6 | 0 | 0 | 2 | 8 | 6 |
| Breast Neoplasms | 0 | | 2003 | 2023 | 6.1 | low | 6 | 0 | 0 | 2 | 8 | 6 |
| Breathlessness | 0 | | 2001 | 2020 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Briquet Syndrome | 0 | | 2001 | 2010 | 18.8 | low | 2 | 0 | 0 | 5 | 0 | 0 |
| Brown Tendon Sheath Syndrome | 0 | | 2006 | 2009 | 16.8 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| Bulimia | 0 | | 2003 | 2020 | 13.6 | low | 1 | 0 | 0 | 3 | 2 | 0 |
| Bulimia Nervosa | 0 | | 2007 | 2022 | 7.8 | low | 1 | 0 | 0 | 1 | 3 | 1 |
| Bullous Dermatoses | 0 | | 2000 | 2006 | 21.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Burning Mouth Syndrome | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Burns | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cachexia | 0 | | 2007 | 2022 | 9.0 | low | 1 | 0 | 0 | 1 | 2 | 1 |
| Cadaver | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Calcification, Pathologic | 0 | | 2008 | 2019 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Calcinosis | 0 | | 2008 | 2019 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Callous-Unemotional Traits | 0 | | 2002 | 2022 | 10.9 | low | 3 | 0 | 0 | 3 | 1 | 3 |
| Cancer of Cervix | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Colon | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Esophagus | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Gastrointestinal Tract | 0 | | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Lung | 0 | | 2003 | 2023 | 11.0 | low | 4 | 0 | 0 | 4 | 5 | 1 |
| Cancer of Mediastinum | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Ovary | 0 | | 2014 | 2019 | 8.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Cancer of Pancreas | 0 | | 2017 | 2023 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Cancer of Pituitary | 0 | | 2005 | 2019 | 14.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| Cancer of Skin | 0 | | 2009 | 2023 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| Cancer of Stomach | 0 | | 2007 | 2017 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Cancer of the Uterus | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer Pain | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer-Associated Pain | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer, Embryonal | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cannabis Abuse | 0 | | 2005 | 2021 | 12.0 | low | 2 | 0 | 0 | 4 | 6 | 1 |
| Capgras Syndrome | 0 | | 2000 | 2016 | 16.1 | low | 0 | 0 | 2 | 4 | 4 | 0 |
| Carbon Monoxide Poisoning | 0 | | 2021 | 2022 | 2.5 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Carcinoma, Epidermoid | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Carcinoma, Large Cell | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Carcinoma, Non-Small Cell Lung | 0 | | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma, Non-Small-Cell Lung | 0 | | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma, Squamous Cell | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cardiac Arrest, Sudden | 0 | | 2003 | 2013 | 13.9 | low | 3 | 0 | 0 | 2 | 5 | 0 |
| Cardiac Diseases | 0 | | 2002 | 2021 | 12.5 | low | 1 | 0 | 0 | 1 | 0 | 1 |
| Cardiac Failure | 0 | | 2003 | 2023 | 8.0 | low | 0 | 0 | 0 | 2 | 0 | 3 |
| Cardiac Toxicity | 0 | | 2020 | 2021 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Cardiometabolic Syndrome | 0 | | 2001 | 2023 | 11.4 | low | 20 | 0 | 0 | 32 | 36 | 7 |
| Cardiomyopathies | 0 | | 2005 | 2023 | 10.0 | low | 0 | 0 | 0 | 3 | 0 | 2 |
| Cardiomyopathies, Primary | 0 | | 2005 | 2023 | 10.0 | low | 0 | 0 | 0 | 3 | 0 | 2 |
| Cardiotoxicity | 0 | | 2020 | 2021 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Cardiovascular Diseases | 0 | | 2001 | 2023 | 11.6 | low | 4 | 0 | 0 | 9 | 10 | 3 |
| Cardiovascular Stroke | 0 | | 2006 | 2011 | 16.0 | low | 1 | 0 | 0 | 2 | 1 | 0 |
| Carditis | 0 | | 2009 | 2022 | 9.0 | low | 0 | 0 | 0 | 2 | 2 | 2 |
| Caries, Dental | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carotid Artery Narrowing | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carotid Stenosis | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Catatonia | 0 | | 2000 | 2023 | 12.1 | low | 0 | 0 | 1 | 13 | 11 | 4 |
| Catatonic Rigidity | 0 | | 2000 | 2008 | 20.3 | low | 4 | 0 | 1 | 8 | 0 | 0 |
| Catatonic Schizophrenia | 0 | | 2001 | 2013 | 17.0 | low | 1 | 0 | 0 | 3 | 2 | 0 |
| Central Hypothyroidism | 0 | | 2014 | 2016 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Central Nervous System Cysticercosis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Central Nervous System Cysts | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Central Nervous System Disease | 0 | | 1998 | 2015 | 17.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Central Nervous System Diseases | 0 | | 1998 | 2015 | 17.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Central Nervous System Syphilis | 0 | | 2007 | 2019 | 12.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Central Retinal Edema, Cystoid | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cephalgia Syndromes | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cerebellar Ataxia | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cerebral Concussion | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cerebral Hemorrhage | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cerebral Infarction | 0 | | 2004 | 2014 | 15.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Cerebral Infarction, Middle Cerebral Artery | 0 | | 2006 | 2008 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Cerebral Ischemia | 0 | | 2006 | 2009 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Cerebral Pseudosclerosis | 0 | | 2001 | 2008 | 19.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Cerebrovascular Disorders | 0 | | 2004 | 2015 | 17.1 | low | 1 | 0 | 0 | 6 | 1 | 0 |
| Cervical Dystonia | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chemical and Drug Induced Liver Injury | 0 | | 2000 | 2022 | 11.6 | low | 0 | 0 | 1 | 7 | 15 | 2 |
| Chemical and Drug Induced Liver Injury, Chronic | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chemical Dependence | 0 | | 1997 | 2023 | 14.2 | low | 11 | 0 | 4 | 21 | 14 | 5 |
| Chest Injuries | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chest Pain | 0 | | 2003 | 2020 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Child Behavior Disorders | 0 | | 1998 | 2004 | 23.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Child Development Deviations | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Child Development Disorders, Pervasive | 0 | | 1997 | 2010 | 21.1 | low | 3 | 0 | 4 | 11 | 0 | 0 |
| Childhood Eating and Feeding Disorders | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Childhood Schizophrenia | 0 | | 2000 | 2019 | 16.2 | low | 4 | 0 | 2 | 5 | 3 | 0 |
| Childhood Tic Disorders | 0 | | 2000 | 2006 | 20.7 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Childhood Torsion Disease | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cholera Infantum | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cholestasis | 0 | | 2009 | 2012 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Chorea | 0 | | 1999 | 2021 | 15.2 | low | 0 | 0 | 1 | 2 | 0 | 1 |
| Chorea Disorders | 0 | | 1999 | 2021 | 15.2 | low | 0 | 0 | 1 | 2 | 0 | 1 |
| Choriocarcinoma | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chromosome Deletion | 0 | | 2008 | 2017 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Chromosome-Defective Micronuclei | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Chronic Disease | 0 | | 1997 | 2023 | 16.7 | low | 39 | 0 | 8 | 70 | 22 | 2 |
| Chronic Fatigue and Immune Dysfunction Syndrome | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chronic Hepatitis B | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chronic Hepatitis C | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chronic Illness | 0 | | 1997 | 2023 | 16.7 | low | 39 | 0 | 8 | 70 | 22 | 2 |
| Chronic Insomnia | 0 | | 2000 | 2023 | 11.5 | low | 8 | 0 | 2 | 6 | 10 | 4 |
| Chronic Kidney Diseases | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chronic Kidney Failure | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chronic Motor and Vocal Tic Disorder | 0 | | 1998 | 2019 | 20.2 | low | 6 | 0 | 6 | 9 | 2 | 0 |
| Chronic Pain | 0 | | 2016 | 2022 | 5.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| Chronic Progressive Multiple Sclerosis | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chylopericardium | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Circulatory Collapse | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Claustrophobia | 0 | | 2002 | 2002 | 22.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Cleft Spine | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Clerambault Syndrome | 0 | | 2000 | 2011 | 18.0 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| Clinically Isolated CNS Demyelinating Syndrome | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Clubfeet | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Coagulation Disorders, Blood | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Coagulation, Disseminated Intravascular | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cocaine Abuse | 0 | | 2002 | 2016 | 17.7 | low | 6 | 0 | 0 | 13 | 2 | 0 |
| Cocaine-Related Disorders | 0 | | 2002 | 2016 | 17.7 | low | 6 | 0 | 0 | 13 | 2 | 0 |
| Cochlear Hearing Loss | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cognition Disorders | 0 | | 1996 | 2021 | 17.0 | low | 57 | 0 | 10 | 76 | 26 | 1 |
| Cognitive Decline | 0 | | 2015 | 2021 | 5.4 | low | 2 | 0 | 0 | 0 | 7 | 1 |
| Cognitive Dysfunction | 0 | | 2015 | 2021 | 5.4 | low | 2 | 0 | 0 | 0 | 7 | 1 |
| Cognitive Manifestations | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cold Fingers, Hereditary | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Colicky Pain | 0 | | 2001 | 2001 | 23.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Colitis, Ischemic | 0 | | 2012 | 2016 | 9.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Colonic Inertia | 0 | | 1997 | 2019 | 12.8 | low | 4 | 0 | 1 | 1 | 4 | 0 |
| Colonic Neoplasms | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Colorectal Cancer | 0 | | 2021 | 2021 | 3.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Colorectal Neoplasms | 0 | | 2021 | 2021 | 3.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Coma | 0 | | 1998 | 2022 | 12.5 | low | 0 | 0 | 1 | 4 | 3 | 3 |
| Coma, Hyperglycemic Hyperosmolar Nonketotic | 0 | | 2001 | 2017 | 16.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| Combat Disorders | 0 | | 2000 | 2010 | 20.2 | low | 1 | 0 | 1 | 3 | 0 | 0 |
| Communication Disorders | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Compensatory Hyperinsulinemia | 0 | | 2002 | 2019 | 13.8 | low | 2 | 0 | 0 | 6 | 5 | 0 |
| Complex Partial Epilepsy | 0 | | 2001 | 2006 | 20.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Complication, Postoperative | 0 | | 2006 | 2020 | 10.1 | low | 1 | 0 | 0 | 1 | 7 | 0 |
| Complications of Diabetes Mellitus | 0 | | 2002 | 2014 | 19.3 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| Complications, Pregnancy | 0 | | 1998 | 2019 | 15.7 | low | 0 | 0 | 3 | 19 | 9 | 0 |
| Conduct Disorder | 0 | | 2002 | 2022 | 10.9 | low | 3 | 0 | 0 | 3 | 1 | 3 |
| Congenital Dysplasia Of The Hip | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Congenital Fissure of the Abdominal Cavity | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Congenital Hand Deformities | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Congenital Zika Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Consciousness, Loss of | 0 | | 2006 | 2015 | 12.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Constipation | 0 | | 1997 | 2019 | 12.8 | low | 4 | 0 | 1 | 1 | 4 | 0 |
| Constitutional Liver Dysfunction | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Constricted Pupil | 0 | | 1999 | 2022 | 11.8 | low | 0 | 0 | 1 | 1 | 1 | 2 |
| Convergent Strabismus | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Convulsions, Grand Mal | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Convulsive Generalized Seizure Disorder | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cornea Injuries | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Corneal Injuries | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Coronary Artery Disease | 0 | | 2004 | 2013 | 15.2 | low | 1 | 0 | 0 | 2 | 2 | 0 |
| Coronary Disease | 0 | | 2000 | 2014 | 16.8 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| Coronary Heart Disease | 0 | | 2000 | 2014 | 16.8 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| Coronavirus Infections | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 8 | 0 |
| Cortical Lewy Body Disease | 0 | | 2001 | 2022 | 16.6 | low | 1 | 0 | 0 | 8 | 3 | 1 |
| Craniocerebral Injuries | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Craniocerebral Trauma | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Craniofacial Pain Syndromes | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Critical Illness | 0 | | 2004 | 2021 | 12.4 | low | 1 | 0 | 0 | 2 | 2 | 1 |
| Cystic Fibrosis | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cystic Fibrosis of Pancreas | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Day Blindness | 0 | | 2005 | 2006 | 18.5 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Daytime Sleepiness | 0 | | 2001 | 2018 | 13.5 | low | 5 | 0 | 0 | 6 | 7 | 0 |
| Daytime Urinary Incontinence | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| De Morsier Syndrome | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Deafness-Retinitis Pigmentosa Syndrome | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Deafness, Transitory | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Death, Sudden | 0 | | 2001 | 2014 | 17.2 | low | 1 | 0 | 0 | 3 | 2 | 0 |
| Death, Sudden, Cardiac | 0 | | 2003 | 2013 | 13.9 | low | 3 | 0 | 0 | 2 | 5 | 0 |
| Deep Vein Thrombosis | 0 | | 2003 | 2018 | 15.5 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| Deficiency Diseases | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Deficiency, Folic Acid | 0 | | 2007 | 2010 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Deficiency, Mental | 0 | | 1997 | 2020 | 15.6 | low | 3 | 0 | 4 | 11 | 10 | 0 |
| Deficiency, Vitamin B 12 | 0 | | 2007 | 2010 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Degenerative Diseases, Central Nervous System | 0 | | 2007 | 2019 | 10.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Dehydration | 0 | | 1998 | 2008 | 21.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Dejerine-Roussy Syndrome | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Delayed Effects, Prenatal Exposure | 0 | | 2002 | 2023 | 9.6 | low | 1 | 0 | 0 | 5 | 9 | 3 |
| Delirium | 1 | | 1999 | 2023 | 10.8 | low | 6 | 0 | 1 | 25 | 41 | 16 |
| Delirium of Mixed Origin | 0 | | 1999 | 2023 | 10.8 | low | 6 | 0 | 1 | 25 | 41 | 16 |
| Delusional Disorder | 0 | | 1997 | 2020 | 16.6 | low | 4 | 0 | 21 | 58 | 34 | 0 |
| Delusional Parasitosis | 0 | | 2016 | 2021 | 6.3 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Dementia | 1 | | 1997 | 2023 | 16.4 | low | 7 | 0 | 6 | 64 | 14 | 6 |
| Dementia Praecox | 0 | | 1995 | 2024 | 15.6 | medium | 734 | 0 | 263 | 1,152 | 676 | 122 |
| Dementia, Vascular | 0 | | 2002 | 2008 | 19.0 | low | 1 | 0 | 0 | 11 | 0 | 0 |
| Dementias, Transmissible | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Demyelinating Diseases | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Dental Caries | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Depression | 0 | | 1998 | 2023 | 11.9 | low | 27 | 0 | 4 | 33 | 39 | 12 |
| Depression, Endogenous | 0 | | 1997 | 2019 | 18.9 | low | 32 | 0 | 22 | 64 | 18 | 0 |
| Depression, Involutional | 0 | | 1997 | 2023 | 14.2 | low | 37 | 0 | 4 | 61 | 47 | 4 |
| Depression, Postpartum | 0 | | 2002 | 2010 | 18.0 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| Depressive Disorder | 1 | | 1997 | 2019 | 18.9 | low | 32 | 0 | 22 | 64 | 18 | 0 |
| Depressive Disorder, Major | 1 | | 1997 | 2023 | 14.2 | low | 37 | 0 | 4 | 61 | 47 | 4 |
| Depressive Disorder, Treatment-Resistant | 1 | | 2011 | 2021 | 10.3 | low | 2 | 0 | 0 | 0 | 6 | 1 |
| Dermatitis | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Dermatitis Medicamentosa | 0 | | 1999 | 2012 | 18.1 | low | 0 | 0 | 1 | 7 | 2 | 0 |
| Dermatitis, Allergic Contact | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Dermatitis, Occupational | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Dermatoses | 0 | | 2000 | 2006 | 21.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Developmental Coordination Disorder | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Developmental Disabilities | 1 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Developmental Psychomotor Disorders | 0 | | 2003 | 2013 | 18.6 | low | 5 | 0 | 0 | 4 | 1 | 0 |
| Devic Disease | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Diabetes Insipidus | 0 | | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Diabetes Mellitus | 0 | | 1999 | 2023 | 17.7 | low | 4 | 0 | 3 | 51 | 7 | 4 |
| Diabetes Mellitus, Adult-Onset | 0 | | 1998 | 2023 | 15.4 | low | 12 | 0 | 3 | 57 | 14 | 11 |
| Diabetes Mellitus, Gestational | 0 | | 2007 | 2022 | 9.8 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| Diabetes Mellitus, Type 1 | 0 | | 1998 | 2021 | 16.7 | low | 0 | 0 | 2 | 5 | 3 | 1 |
| Diabetes Mellitus, Type 2 | 0 | | 1998 | 2023 | 15.4 | low | 12 | 0 | 3 | 57 | 14 | 11 |
| Diabetes, Gestational | 0 | | 2007 | 2022 | 9.8 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| Diabetic Coma | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Diabetic Ketoacidosis | 0 | | 1999 | 2023 | 17.5 | low | 1 | 0 | 3 | 20 | 6 | 1 |
| Diarrhea | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Diathesis | 0 | | 1998 | 2005 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Diffuse Mixed Small and Large Cell Lymphoma | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Diffuse Myofascial Pain Syndrome | 0 | | 2001 | 2018 | 15.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Direct Hyperbilirubinemia, Neonatal | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Disbacteriosis | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Disease Exacerbation | 0 | | 1999 | 2023 | 16.3 | low | 8 | 0 | 1 | 21 | 5 | 1 |
| Disease Models, Animal | 0 | | 2001 | 2023 | 10.7 | low | 2 | 0 | 0 | 31 | 49 | 13 |
| Diseases in Twins | 0 | | 2001 | 2013 | 15.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Diseases of Endocrine System | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Diseases, Metabolic | 0 | | 2001 | 2023 | 10.1 | low | 11 | 0 | 0 | 12 | 21 | 6 |
| Disorder, Borderline Personality | 0 | | 1999 | 2023 | 16.4 | low | 13 | 0 | 1 | 17 | 5 | 1 |
| Disorders of Excessive Somnolence | 0 | | 2001 | 2018 | 13.5 | low | 5 | 0 | 0 | 6 | 7 | 0 |
| Disruptive, Impulse Control, and Conduct Disorders | 0 | | 2000 | 2022 | 14.8 | low | 2 | 0 | 1 | 3 | 1 | 1 |
| Disseminated Intravascular Coagulation | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Dissociation | 0 | | 2006 | 2008 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Dissociative Identity Disorder | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Dizziness | 0 | | 1997 | 2021 | 12.8 | low | 7 | 0 | 2 | 2 | 5 | 1 |
| Dizzyness | 0 | | 1997 | 2021 | 12.8 | low | 7 | 0 | 2 | 2 | 5 | 1 |
| Down Syndrome | 0 | | 2001 | 2008 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| DRESS Syndrome | 0 | | 2017 | 2023 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Drooling | 0 | | 1998 | 2022 | 14.4 | low | 1 | 0 | 1 | 2 | 1 | 1 |
| Drug Hypersensitivity | 0 | | 2000 | 2018 | 14.8 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| Drug Overdose | 0 | | 1998 | 2023 | 17.1 | low | 0 | 0 | 13 | 32 | 16 | 2 |
| Drug Withdrawal Symptoms | 0 | | 1997 | 2022 | 18.3 | low | 6 | 0 | 11 | 16 | 4 | 2 |
| Drug-Induced Stevens Johnson Syndrome | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Drug-Related Side Effects and Adverse Reactions | 0 | | 2004 | 2023 | 9.1 | low | 5 | 0 | 0 | 10 | 28 | 7 |
| Dry Eye | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Dry Eye Syndromes | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Dysarthosis | 0 | | 2014 | 2015 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Dysesthesia | 0 | | 2007 | 2009 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Dysgeusia | 0 | | 2004 | 2020 | 10.3 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| Dyskinesia Syndromes | 0 | | 2000 | 2015 | 16.1 | low | 5 | 0 | 2 | 7 | 8 | 0 |
| Dyskinesia, Drug-Induced | 1 | | 1996 | 2017 | 20.5 | low | 30 | 0 | 47 | 75 | 13 | 0 |
| Dyskinesia, Medication-Induced | 0 | | 1996 | 2017 | 20.5 | low | 30 | 0 | 47 | 75 | 13 | 0 |
| Dyslipidemia | 0 | | 2006 | 2023 | 10.4 | low | 5 | 0 | 0 | 11 | 14 | 3 |
| Dyslipidemias | 0 | | 2006 | 2023 | 10.4 | low | 5 | 0 | 0 | 11 | 14 | 3 |
| Dysmyelopoietic Syndromes | 0 | | 2007 | 2018 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Dyspnea | 0 | | 2001 | 2020 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Dysthymia | 0 | | 1999 | 2010 | 19.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Dysthymic Disorder | 0 | | 1999 | 2010 | 19.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Dystonia | 0 | | 1997 | 2023 | 16.2 | low | 2 | 0 | 8 | 13 | 8 | 2 |
| Dystonic Disorders | 0 | | 1999 | 2009 | 21.2 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| Ectoparasitic Infestations | 0 | | 2002 | 2016 | 15.6 | low | 0 | 0 | 0 | 5 | 2 | 0 |
| Edema | 0 | | 2003 | 2022 | 12.9 | low | 0 | 0 | 0 | 6 | 3 | 2 |
| Edema, Pulmonary | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Electric Injuries | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Electrocardiogram QT Prolonged | 0 | | 2001 | 2023 | 15.3 | low | 9 | 0 | 0 | 17 | 9 | 3 |
| Electrolytes | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Elevated Cholesterol | 0 | | 2003 | 2018 | 15.4 | low | 4 | 0 | 0 | 7 | 3 | 0 |
| Elevated ICP (Intracranial Pressure) | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Embolism, Pulmonary | 0 | | 2003 | 2023 | 15.0 | low | 0 | 0 | 0 | 12 | 3 | 1 |
| Emergencies | 0 | | 2007 | 2017 | 12.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Emesis | 0 | | 2003 | 2023 | 6.4 | low | 52 | 0 | 0 | 11 | 96 | 37 |
| Emesis, Postoperative | 0 | | 2020 | 2023 | 3.0 | low | 2 | 0 | 0 | 0 | 2 | 1 |
| Emphysema, Mediastinal | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Emphysema, Subcutaneous | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Encephalitis | 0 | | 2010 | 2023 | 7.3 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| Encephalitis Infection | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Encephalitis, Inclusion Body, Measles | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Encephalitis, JC Polyomavirus | 0 | | 2005 | 2010 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Encephalitis, Limbic | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Encephalitis, Viral | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Encephalopathy, Toxic | 0 | | 2002 | 2012 | 16.3 | low | 1 | 0 | 0 | 2 | 1 | 0 |
| Encephalopathy, Traumatic | 0 | | 2020 | 2020 | 4.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Endocarditis | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Endocrine System Diseases | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Enlarged Liver | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Enlarged Spleen | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Enteric Fever | 0 | | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Entrapment Neuropathies | 0 | | 2009 | 2013 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Eosinophilia | 0 | | 2001 | 2023 | 12.4 | low | 1 | 0 | 0 | 3 | 6 | 1 |
| Eosinophilia, Tropical | 0 | | 2001 | 2023 | 12.4 | low | 1 | 0 | 0 | 3 | 6 | 1 |
| Epilepsies, Partial | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Epilepsy | 0 | | 2005 | 2019 | 11.2 | low | 0 | 0 | 0 | 3 | 9 | 0 |
| Epilepsy, Complex Partial | 0 | | 2001 | 2006 | 20.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Epilepsy, Partial, Motor | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Epilepsy, Temporal Lobe | 0 | | 2001 | 2021 | 15.4 | low | 0 | 0 | 0 | 3 | 1 | 1 |
| Epilepsy, Tonic-Clonic | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Erectile Dysfunction | 0 | | 2001 | 2023 | 16.1 | low | 1 | 0 | 0 | 5 | 1 | 1 |
| Erythema | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Erythema Multiforme | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Esophageal Achalasia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Esophageal Hernia | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Esophageal Neoplasms | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Esophageal Stenosis | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Esophageal Stricture | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Esophagitis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Esotropia | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Essential Polyarteritis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Essential Tremor | 0 | | 2003 | 2005 | 20.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Eulenburg Disease | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Exanthem | 0 | | 2006 | 2023 | 8.0 | low | 0 | 0 | 0 | 1 | 1 | 2 |
| Exanthema | 0 | | 2006 | 2023 | 8.0 | low | 0 | 0 | 0 | 1 | 1 | 2 |
| Excessive Periodic Sleep-Related Leg Movements | 0 | | 2002 | 2009 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Experimental Lung Inflammation | 0 | | 2013 | 2023 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 2 |
| Extravascular Hemolysis | 0 | | 2009 | 2013 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Eye Abnormalities | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Eye Diseases | 0 | | 1999 | 2022 | 13.5 | low | 0 | 0 | 1 | 1 | 1 | 1 |
| Eye Disorders | 0 | | 1999 | 2022 | 13.5 | low | 0 | 0 | 1 | 1 | 1 | 1 |
| Eyelid Diseases | 0 | | 2002 | 2007 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Facial Dermatoses | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Facial Neoplasms | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Facies | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Fanconi Anemia | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Fasting Hypoglycemia | 0 | | 2001 | 2014 | 16.4 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Fatigue | 0 | | 2003 | 2018 | 13.3 | low | 2 | 0 | 0 | 3 | 3 | 0 |
| Fatigue Syndrome, Chronic | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Fatty Liver | 0 | | 2003 | 2023 | 6.3 | low | 0 | 0 | 0 | 1 | 4 | 2 |
| Fatty Liver, Nonalcoholic | 0 | | 2019 | 2023 | 2.9 | low | 0 | 0 | 0 | 0 | 2 | 5 |
| Fecal Incontinence | 0 | | 2003 | 2005 | 20.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Feeding and Eating Disorders | 1 | | 2002 | 2022 | 10.6 | low | 0 | 0 | 0 | 2 | 5 | 1 |
| Female Genital Neoplasms | 0 | | 2016 | 2020 | 5.5 | low | 4 | 0 | 0 | 0 | 4 | 0 |
| Fetal Macrosomia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Fever | 0 | | 2000 | 2020 | 16.1 | low | 1 | 0 | 2 | 8 | 5 | 0 |
| Fever of Unknown Origin | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Fibromyalgia | 0 | | 2001 | 2018 | 15.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Flushing | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Focal Clonic Seizures | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Folic Acid Deficiency | 0 | | 2007 | 2010 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Folie a Deux | 0 | | 2008 | 2017 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Foot Diseases | 0 | | 2003 | 2007 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Foreign Bodies | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Foreign-Body Migration | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Fractures, Bone | 0 | | 2012 | 2015 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Frigidity | 0 | | 1998 | 2012 | 19.6 | low | 1 | 0 | 3 | 4 | 3 | 0 |
| Galactorrhea | 0 | | 1998 | 2023 | 17.6 | low | 3 | 0 | 1 | 11 | 1 | 1 |
| Gambling | 1 | | 2008 | 2022 | 12.4 | low | 3 | 0 | 0 | 3 | 1 | 1 |
| Gambling, Pathologic | 0 | | 2008 | 2022 | 12.4 | low | 3 | 0 | 0 | 3 | 1 | 1 |
| Gangliocytoma | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Gastric Ulcer | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Gastrointestinal Hemorrhage | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Gastroschisis | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| Genetic Predisposition | 0 | | 1999 | 2023 | 14.1 | low | 1 | 0 | 1 | 13 | 8 | 1 |
| Genital Diseases, Male | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Genital Neoplasms, Female | 1 | | 2016 | 2020 | 5.5 | low | 4 | 0 | 0 | 0 | 4 | 0 |
| Germinoblastoma | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Giant Cell Arteritis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Glaucoma, Angle Closure | 0 | | 2015 | 2022 | 4.7 | low | 0 | 0 | 0 | 0 | 1 | 2 |
| Glaucoma, Angle-Closure | 0 | | 2015 | 2022 | 4.7 | low | 0 | 0 | 0 | 0 | 1 | 2 |
| Glial Cell Tumors | 0 | | 2014 | 2022 | 6.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| Glioblastoma | 0 | | 2011 | 2022 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| Glioma | 0 | | 2014 | 2022 | 6.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| Glossalgia | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Glucose Intolerance | 0 | | 2002 | 2020 | 12.3 | low | 3 | 0 | 0 | 6 | 9 | 0 |
| Glucose Metabolic Disorder | 0 | | 2005 | 2019 | 12.0 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| Glycine Encephalopathy | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Goiter, Nodular | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Granulomatosis with Polyangiitis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Granulomatosis, Wegener's | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Graves Disease | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Group A Strep Infection | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Gynecomastia | 0 | | 2005 | 2007 | 18.2 | low | 1 | 0 | 0 | 6 | 0 | 0 |
| Habit Chorea | 0 | | 2002 | 2012 | 17.0 | low | 1 | 0 | 0 | 4 | 2 | 0 |
| Hair Diseases | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hallervorden-Spatz Disease | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hallucination of Body Sensation | 0 | | 1998 | 2022 | 16.0 | low | 11 | 0 | 10 | 32 | 24 | 2 |
| Hallucinations | 0 | | 1998 | 2022 | 16.0 | low | 11 | 0 | 10 | 32 | 24 | 2 |
| Hand Dermatoses | 0 | | 2004 | 2018 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Hand Dermatosis | 0 | | 2004 | 2018 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Hangman Fracture | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Headache | 0 | | 1998 | 2023 | 11.5 | low | 5 | 0 | 2 | 4 | 4 | 3 |
| Headache Disorders | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hearing Loss | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hearing Loss, Sensorineural | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Heart Arrest | 0 | | 2007 | 2022 | 11.5 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| Heart Defects, Congenital | 0 | | 2007 | 2023 | 6.3 | low | 0 | 0 | 0 | 1 | 0 | 2 |
| Heart Diseases | 0 | | 2002 | 2021 | 12.5 | low | 1 | 0 | 0 | 1 | 0 | 1 |
| Heart Failure | 0 | | 2003 | 2023 | 8.0 | low | 0 | 0 | 0 | 2 | 0 | 3 |
| Heat Stroke | 0 | | 2015 | 2020 | 5.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Heatstroke | 0 | | 2015 | 2020 | 5.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Hebephrenic Schizophrenia | 0 | | 2001 | 2008 | 18.5 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| Hematemesis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hematochezia | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hematologic Diseases | 0 | | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Hematologic Malignancies | 0 | | 2018 | 2021 | 4.5 | low | 2 | 0 | 0 | 0 | 1 | 1 |
| Hematologic Neoplasms | 1 | | 2018 | 2021 | 4.5 | low | 2 | 0 | 0 | 0 | 1 | 1 |
| Hemiplegia | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hemiplegia, Crossed | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hemisensory Neglect | 0 | | 2000 | 2018 | 17.0 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| Hemolysis | 0 | | 2009 | 2013 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Hemorrhage | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hepatic Failure | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hepatitis | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hepatitis B, Chronic | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hepatitis C | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hepatitis C, Chronic | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hepatolenticular Degeneration | 0 | | 2001 | 2008 | 19.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Heroin Abuse | 0 | | 2006 | 2013 | 15.0 | low | 3 | 0 | 0 | 2 | 1 | 0 |
| Heroin Dependence | 0 | | 2006 | 2013 | 15.0 | low | 3 | 0 | 0 | 2 | 1 | 0 |
| Hiccough | 0 | | 2006 | 2022 | 9.2 | low | 0 | 0 | 0 | 1 | 2 | 1 |
| Hirschsprung Disease | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| HIV Coinfection | 0 | | 1998 | 2016 | 17.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| HIV Infections | 0 | | 1998 | 2016 | 17.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Hospital-Acquired Condition | 0 | | 2002 | 2011 | 18.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Huntington Disease | 1 | | 1999 | 2019 | 17.8 | low | 2 | 0 | 3 | 12 | 6 | 0 |
| Hydrophobia | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyperactivity, Motor | 0 | | 2001 | 2021 | 11.6 | low | 1 | 0 | 0 | 3 | 5 | 1 |
| Hyperammonemia | 0 | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Hypercalcemia | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypercapnia | 0 | | 2007 | 2007 | 17.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Hypercholesterolemia | 0 | | 2003 | 2018 | 15.4 | low | 4 | 0 | 0 | 7 | 3 | 0 |
| Hypercoagulability | 0 | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Hyperemesis Gravidarum | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hyperglycemia | 0 | | 1998 | 2022 | 16.5 | low | 8 | 0 | 4 | 45 | 17 | 2 |
| Hyperglycemia, Postprandial | 0 | | 1998 | 2022 | 16.5 | low | 8 | 0 | 4 | 45 | 17 | 2 |
| Hyperhidrosis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperidrosis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperinsulinism | 0 | | 2002 | 2019 | 13.8 | low | 2 | 0 | 0 | 6 | 5 | 0 |
| Hyperkyphosis | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperlipemia | 0 | | 2001 | 2019 | 17.0 | low | 2 | 0 | 0 | 20 | 6 | 0 |
| Hyperlipidemias | 0 | | 2001 | 2019 | 17.0 | low | 2 | 0 | 0 | 20 | 6 | 0 |
| Hypermelanosis | 0 | | 2004 | 2018 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Hyperphagia | 0 | | 2003 | 2023 | 11.3 | low | 0 | 0 | 0 | 9 | 11 | 3 |
| Hyperpigmentation | 0 | | 2004 | 2018 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Hyperprolactinaemia | 0 | | 1997 | 2023 | 14.9 | low | 11 | 0 | 4 | 31 | 12 | 3 |
| Hyperprolactinemia | 0 | | 1997 | 2023 | 14.9 | low | 11 | 0 | 4 | 31 | 12 | 3 |
| Hypersensitivity | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypertension | 0 | | 2007 | 2023 | 11.0 | low | 1 | 0 | 0 | 5 | 3 | 2 |
| Hypertension, Pulmonary | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypertriglyceridemia | 0 | | 1999 | 2023 | 17.5 | low | 2 | 0 | 2 | 14 | 3 | 1 |
| Hypertrophy | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hyperventilation | 0 | | 2002 | 2021 | 12.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| Hypesthesia | 0 | | 2017 | 2017 | 7.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| Hypochondriacal Neuroses | 0 | | 2000 | 2014 | 18.8 | low | 0 | 0 | 1 | 4 | 1 | 0 |
| Hypoglycemia | 0 | | 2001 | 2014 | 16.4 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Hypokalemia | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypomania | 0 | | 2020 | 2023 | 2.1 | low | 2 | 0 | 0 | 0 | 2 | 12 |
| Hypomenorrhea | 0 | | 2002 | 2007 | 20.3 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| Hyponatremia | 0 | | 1997 | 2019 | 13.2 | low | 0 | 0 | 1 | 2 | 5 | 0 |
| Hypotension | 0 | | 2002 | 2022 | 12.9 | low | 0 | 0 | 0 | 6 | 2 | 3 |
| Hypotension, Orthostatic | 0 | | 1997 | 2016 | 20.8 | low | 2 | 0 | 3 | 1 | 1 | 0 |
| Hypotension, Postural | 0 | | 1997 | 2016 | 20.8 | low | 2 | 0 | 3 | 1 | 1 | 0 |
| Hypothermia | 0 | | 1998 | 2022 | 16.4 | low | 0 | 0 | 4 | 4 | 5 | 1 |
| Hypothermia, Accidental | 0 | | 1998 | 2022 | 16.4 | low | 0 | 0 | 4 | 4 | 5 | 1 |
| Hypothyroidism | 0 | | 2014 | 2016 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Hypoxia | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Idiopathic Parkinson Disease | 0 | | 1996 | 2018 | 21.0 | low | 6 | 0 | 13 | 18 | 4 | 0 |
| Impaired Glucose Tolerance | 0 | | 2002 | 2020 | 12.3 | low | 3 | 0 | 0 | 6 | 9 | 0 |
| Impotence | 0 | | 2001 | 2023 | 16.1 | low | 1 | 0 | 0 | 5 | 1 | 1 |
| Inappropriate ADH Syndrome | 0 | | 2007 | 2010 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Incipient Schizophrenia | 0 | | 2000 | 2007 | 19.5 | low | 2 | 0 | 1 | 5 | 0 | 0 |
| Infant, Small for Gestational Age | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Infarction, Middle Cerebral Artery | 0 | | 2006 | 2008 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Infections, Coronavirus | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 8 | 0 |
| Infections, Plasmodium | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infections, Respiratory | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Infective Endocarditis | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Inflammation | 0 | | 2010 | 2024 | 5.6 | low | 1 | 0 | 0 | 2 | 15 | 6 |
| Injuries | 0 | | 2012 | 2016 | 10.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Innate Inflammatory Response | 0 | | 2010 | 2024 | 5.6 | low | 1 | 0 | 0 | 2 | 15 | 6 |
| Insulin Resistance | 0 | | 2002 | 2023 | 11.6 | low | 32 | 0 | 0 | 48 | 52 | 10 |
| Insulin Sensitivity | 0 | | 2002 | 2023 | 11.6 | low | 32 | 0 | 0 | 48 | 52 | 10 |
| Insulinoma | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Intellectual Disability | 1 | | 1997 | 2020 | 15.6 | low | 3 | 0 | 4 | 11 | 10 | 0 |
| Interstitial Nephritis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Intestinal Obstruction | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Intracranial Aneurysm | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Intracranial Hemorrhages | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Intracranial Hypertension | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Intraocular Pressure | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Ischemia | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ischemic Attack, Transient | 0 | | 2005 | 2023 | 14.5 | low | 0 | 0 | 0 | 3 | 0 | 1 |
| Itching | 0 | | 2001 | 2017 | 16.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Kahler Disease | 0 | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Kidney Diseases | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Kidney Failure | 0 | | 2016 | 2021 | 5.3 | low | 1 | 0 | 0 | 0 | 2 | 1 |
| Kidney Failure, Chronic | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Klinefelter Syndrome | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Labhart-Willi Syndrome | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Laryngeal Diseases | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lassitude | 0 | | 2003 | 2018 | 13.3 | low | 2 | 0 | 0 | 3 | 3 | 0 |
| Late Onset Diseases | 0 | | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Leanness | 0 | | 2008 | 2013 | 13.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Learning Disabilities | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lethargy | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Leukemia, Promyelocytic, Acute | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Leukocytopenia | 0 | | 1999 | 2021 | 18.7 | low | 0 | 0 | 4 | 5 | 1 | 1 |
| Leukoencephalopathy, Progressive Multifocal | 0 | | 2005 | 2010 | 16.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Leukopenia | 0 | | 1999 | 2021 | 18.7 | low | 0 | 0 | 4 | 5 | 1 | 1 |
| Lewy Body Disease | 0 | | 2001 | 2022 | 16.6 | low | 1 | 0 | 0 | 8 | 3 | 1 |
| Libman-Sacks Disease | 0 | | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Licheniform Eruptions | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lipid Metabolism Disorders | 0 | | 2010 | 2017 | 10.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Liver Diseases | 0 | | 2007 | 2021 | 8.6 | low | 1 | 0 | 0 | 2 | 2 | 1 |
| Liver Dysfunction | 0 | | 2007 | 2021 | 8.6 | low | 1 | 0 | 0 | 2 | 2 | 1 |
| Liver Failure | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Liver Failure, Acute | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Liver Steatosis | 0 | | 2003 | 2023 | 6.3 | low | 0 | 0 | 0 | 1 | 4 | 2 |
| Local Neoplasm Recurrence | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Long QT Syndrome | 0 | | 2001 | 2023 | 15.3 | low | 9 | 0 | 0 | 17 | 9 | 3 |
| Long Sleeper Syndrome | 0 | | 1998 | 2016 | 18.4 | low | 9 | 0 | 3 | 12 | 3 | 0 |
| Low Bone Density | 0 | | 2007 | 2023 | 9.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| Lung Neoplasms | 0 | | 2003 | 2023 | 11.0 | low | 4 | 0 | 0 | 4 | 5 | 1 |
| Lupus Erythematosus, Chronic Cutaneous | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lupus Erythematosus, Cutaneous | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lupus Erythematosus, Cutaneous, Subacute | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lupus Erythematosus, Discoid | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lupus Erythematosus, Systemic | 0 | | 2012 | 2013 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Lymphoma | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Lymphoma, Non-Hodgkin | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Machado-Joseph Disease | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Macular Edema | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Malaria | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Malaria, Falciparum | 0 | | 2014 | 2020 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Malassezia furfur Infection | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Malignant Melanoma | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Marijuana Abuse | 0 | | 2005 | 2021 | 12.0 | low | 2 | 0 | 0 | 4 | 6 | 1 |
| Mediastinal Neoplasms | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Medically Unexplained Symptoms | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Melanoma | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Melena | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Memory Disorders | 0 | | 2004 | 2023 | 13.7 | low | 6 | 0 | 0 | 12 | 8 | 1 |
| Menopause | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Mental Disorders | 0 | | 1997 | 2023 | 15.6 | low | 27 | 0 | 9 | 91 | 40 | 5 |
| Metabolic Diseases | 0 | | 2001 | 2023 | 10.1 | low | 11 | 0 | 0 | 12 | 21 | 6 |
| Metabolic Syndrome | 0 | | 2001 | 2023 | 11.4 | low | 20 | 0 | 0 | 32 | 36 | 7 |
| Metaplasia | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Microcephaly | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Microglossia | 0 | | 2002 | 2016 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Migraine Disorders | 0 | | 2002 | 2023 | 11.0 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| Milk-Alkali Syndrome | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Miosis | 0 | | 1999 | 2022 | 11.8 | low | 0 | 0 | 1 | 1 | 1 | 2 |
| Mood Disorders | 1 | | 1998 | 2019 | 17.1 | low | 3 | 0 | 3 | 18 | 9 | 0 |
| Morbid Obesity | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Morning Sickness | 0 | | 2023 | 2023 | 1.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Motion Sickness | 0 | | 2023 | 2023 | 1.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Mouth Diseases | 0 | | 2000 | 2017 | 15.5 | low | 1 | 0 | 1 | 0 | 1 | 0 |
| Mouth Ulcer | 0 | | 2006 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Movement Disorders | 0 | | 2000 | 2015 | 16.1 | low | 5 | 0 | 2 | 7 | 8 | 0 |
| MS (Multiple Sclerosis) | 0 | | 2003 | 2022 | 13.8 | low | 0 | 0 | 0 | 3 | 0 | 1 |
| Mucopolysaccharidosis III | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Multiple Myeloma | 0 | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Multiple Sclerosis | 0 | | 2003 | 2022 | 13.8 | low | 0 | 0 | 0 | 3 | 0 | 1 |
| Multiple Sclerosis, Chronic Progressive | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Multiple Sclerosis, Relapsing-Remitting | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Multiple System Atrophy | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Multiple System Atrophy Syndrome | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Mumps | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Muscle Contraction | 0 | | 2001 | 2021 | 16.3 | low | 0 | 0 | 0 | 2 | 0 | 1 |
| Muscle Disorders | 0 | | 2006 | 2008 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Muscle Rigidity | 0 | | 2000 | 2008 | 20.3 | low | 4 | 0 | 1 | 8 | 0 | 0 |
| Muscle Spasm | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Muscular Atrophy, Spinal | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Muscular Diseases | 0 | | 2006 | 2008 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Myasthenia Gravis | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Myelodysplastic Syndromes | 0 | | 2007 | 2018 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Myocardial Infarction | 0 | | 2006 | 2011 | 16.0 | low | 1 | 0 | 0 | 2 | 1 | 0 |
| Myocarditis | 0 | | 2009 | 2022 | 9.0 | low | 0 | 0 | 0 | 2 | 2 | 2 |
| Myoclonic Jerk | 0 | | 2000 | 2012 | 18.0 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| Myopia | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Myotonic Disorders | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Myxedema | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Narcotic Bowel Syndrome | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Nausea | 1 | | 2002 | 2023 | 6.8 | low | 53 | 0 | 0 | 16 | 99 | 38 |
| Nearsightedness | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Necrosis | 0 | | 2000 | 2013 | 17.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Neonatal Abstinence Syndrome | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neoplasms | 1 | | 1999 | 2023 | 8.2 | low | 18 | 0 | 1 | 11 | 36 | 13 |
| Neoplasms, Germ Cell and Embryonal | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neoplasms, Sweat Gland | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Nephritis, Interstitial | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Nerve Degeneration | 0 | | 2001 | 2006 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Nerve Pain | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Nervous System Diseases | 0 | | 2003 | 2014 | 17.8 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| Nervous System Disorders | 0 | | 2003 | 2014 | 17.8 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| Neural Tube Defects | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neuralgia | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neuralgia, Sciatic | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neurally Mediated Faint | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neurobehavioral Manifestations | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Neuroblastoma | 0 | | 1997 | 2008 | 21.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Neurocysticercosis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neurodegenerative Diseases | 0 | | 2007 | 2019 | 10.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Neuroleptic Malignant Syndrome | 0 | | 1996 | 2023 | 17.1 | low | 0 | 0 | 21 | 45 | 26 | 3 |
| Neuromyelitis Optica | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neuronal Ceroid-Lipofuscinoses | 0 | | 2001 | 2001 | 23.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Neutropenia | 0 | | 1999 | 2017 | 18.4 | low | 0 | 0 | 5 | 10 | 4 | 0 |
| Nicotine Addiction | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Nocturnal Enuresis | 0 | | 2007 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Nocturnal Wandering | 0 | | 2001 | 2021 | 13.7 | low | 0 | 0 | 0 | 3 | 2 | 1 |
| Nodular Goiter | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Non-alcoholic Fatty Liver Disease | 0 | | 2019 | 2023 | 2.9 | low | 0 | 0 | 0 | 0 | 2 | 5 |
| Obesity | 0 | | 1999 | 2023 | 14.5 | low | 52 | 0 | 7 | 106 | 45 | 14 |
| Obesity, Morbid | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Obsessive-Compulsive Disorder | 0 | | 1996 | 2021 | 18.8 | low | 19 | 0 | 17 | 39 | 11 | 1 |
| Onycholysis | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Opioid-Related Disorders | 1 | | 2009 | 2022 | 7.2 | low | 1 | 0 | 0 | 1 | 3 | 2 |
| Oral Ulcer | 0 | | 2006 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Osteoporosis | 0 | | 2003 | 2006 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Ovarian Neoplasms | 0 | | 2014 | 2019 | 8.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Overweight | 0 | | 2005 | 2021 | 12.1 | low | 10 | 0 | 0 | 11 | 10 | 1 |
| Pain | 0 | | 2002 | 2020 | 15.7 | low | 2 | 0 | 0 | 10 | 4 | 0 |
| Pain, Chronic | 0 | | 2016 | 2022 | 5.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| Pain, Intractable | 0 | | 2002 | 2005 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Palmoplantaris Pustulosis | 0 | | 2000 | 2009 | 19.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Palsy | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pancreatic Neoplasms | 0 | | 2017 | 2023 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Pancreatitis | 0 | | 2000 | 2016 | 17.4 | low | 0 | 0 | 2 | 8 | 2 | 0 |
| Pancytopenia | 0 | | 2001 | 2017 | 15.0 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| Panic Attacks | 0 | | 1999 | 2006 | 21.1 | low | 2 | 0 | 3 | 5 | 0 | 0 |
| Panic Disorder | 0 | | 1999 | 2006 | 21.1 | low | 2 | 0 | 3 | 5 | 0 | 0 |
| Pantothenate Kinase-Associated Neurodegeneration | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Paralysis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Paranoia | 0 | | 1997 | 2020 | 15.2 | low | 0 | 0 | 4 | 3 | 6 | 0 |
| Parasite Infections | 0 | | 2006 | 2017 | 14.0 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Parasitic Skin Diseases | 0 | | 2008 | 2018 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Parkinson Disease | 0 | | 1996 | 2018 | 21.0 | low | 6 | 0 | 13 | 18 | 4 | 0 |
| Parkinson Disease, Secondary | 0 | | 1997 | 2020 | 17.3 | low | 1 | 0 | 7 | 2 | 7 | 0 |
| Parkinsonian Disorders | 0 | | 2001 | 2014 | 16.1 | low | 3 | 0 | 0 | 8 | 4 | 0 |
| Perceptual Disorders | 0 | | 2000 | 2018 | 17.0 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| Pericardial Effusion | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pericarditis | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Pericementitis | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Periodontitis | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Peripheral Nerve Diseases | 0 | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Peripheral Nerve Neoplasms | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Peripheral Nervous System Diseases | 0 | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Peripheral Nervous System Neoplasms | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Peritonitis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pernicious Vomiting of Pregnancy | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Personality Disorder, Schizoid | 0 | | 2001 | 2010 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Pervasive Child Development Disorders | 0 | | 1997 | 2010 | 21.1 | low | 3 | 0 | 4 | 11 | 0 | 0 |
| Pharyngitis | 0 | | 2007 | 2020 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Phobic Disorders | 0 | | 2002 | 2002 | 22.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Pituitary ACTH Hypersecretion | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pituitary Neoplasms | 0 | | 2005 | 2019 | 14.0 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| Plasmodium falciparum Malaria | 0 | | 2014 | 2020 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Pleural Effusion | 0 | | 2011 | 2018 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Pleuropericarditis | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Pneumonia | 0 | | 2013 | 2023 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 2 |
| Pneumonia, Aspiration | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Pneumonia, Bacterial | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pneumonia, Viral | 0 | | 2013 | 2020 | 4.8 | low | 0 | 0 | 0 | 0 | 9 | 0 |
| Poisoning | 0 | | 2004 | 2018 | 13.8 | low | 0 | 0 | 0 | 5 | 5 | 0 |
| Polydipsia | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Polydipsia, Primary | 0 | | 2013 | 2015 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Polyuria | 0 | | 2004 | 2021 | 14.3 | low | 1 | 0 | 0 | 2 | 0 | 1 |
| Porphyria Cutanea Tarda | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Porphyria, Acute Intermittent | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Post-Natal Depression | 0 | | 2002 | 2010 | 18.0 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| Postoperative Complications | 0 | | 2006 | 2020 | 10.1 | low | 1 | 0 | 0 | 1 | 7 | 0 |
| Postoperative Nausea and Vomiting | 1 | | 2020 | 2023 | 3.0 | low | 2 | 0 | 0 | 0 | 2 | 1 |
| Postpartum Amenorrhea | 0 | | 1998 | 2011 | 20.1 | low | 1 | 0 | 2 | 4 | 1 | 0 |
| Prader-Willi Syndrome | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Precordial Catch | 0 | | 2003 | 2020 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Prediabetes | 0 | | 2004 | 2023 | 8.9 | low | 7 | 0 | 0 | 3 | 6 | 3 |
| Prediabetic State | 0 | | 2004 | 2023 | 8.9 | low | 7 | 0 | 0 | 3 | 6 | 3 |
| Pregnancy | 0 | | 1998 | 2023 | 12.6 | low | 3 | 0 | 7 | 30 | 26 | 13 |
| Pressure Ulcer | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Priapism | 0 | | 1998 | 2019 | 17.6 | low | 1 | 0 | 3 | 8 | 5 | 0 |
| Primary Peritonitis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Prostatic Hyperplasia | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Prurigo | 0 | | 2006 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Pruritus | 0 | | 2001 | 2017 | 16.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Pseudotumor Cerebri | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Psoriasis | 0 | | 2000 | 2009 | 19.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Psychomotor Agitation | 1 | | 1999 | 2023 | 14.1 | low | 38 | 0 | 3 | 65 | 42 | 9 |
| Psychophysiologic Disorders | 0 | | 2000 | 2009 | 19.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Psychoses | 0 | | 1996 | 2023 | 15.7 | low | 233 | 0 | 98 | 378 | 218 | 37 |
| Psychoses, Drug | 0 | | 1998 | 2020 | 17.3 | low | 5 | 0 | 11 | 15 | 15 | 0 |
| Psychotic Disorders | 1 | | 1996 | 2023 | 15.7 | low | 233 | 0 | 98 | 378 | 218 | 37 |
| Ptosis, Eyelid | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Puerperal Disorders | 0 | | 2004 | 2020 | 12.6 | low | 1 | 0 | 0 | 3 | 2 | 0 |
| Pulmonary Arterial Remodeling | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pulmonary Edema | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pulmonary Embolism | 0 | | 2003 | 2023 | 15.0 | low | 0 | 0 | 0 | 12 | 3 | 1 |
| Pulmonary Hypertension | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Purpura, Thrombocytopenic, Idiopathic | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Pyrexia | 0 | | 2000 | 2020 | 16.1 | low | 1 | 0 | 2 | 8 | 5 | 0 |
| Raynaud Disease | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Recrudescence | 0 | | 1996 | 2023 | 16.1 | low | 17 | 0 | 14 | 38 | 31 | 2 |
| Reflex, Abnormal | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Refractory Depression | 0 | | 2011 | 2021 | 10.3 | low | 2 | 0 | 0 | 0 | 6 | 1 |
| Remission, Spontaneous | 0 | | 2000 | 2010 | 17.0 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| Renal Insufficiency | 0 | | 2016 | 2021 | 5.3 | low | 1 | 0 | 0 | 0 | 2 | 1 |
| Renal Insufficiency, Chronic | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Respiratory Distress Syndrome | 0 | | 2010 | 2020 | 9.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Respiratory Insufficiency | 0 | | 2001 | 2022 | 15.0 | low | 0 | 0 | 0 | 5 | 1 | 1 |
| Respiratory Tract Infections | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Restless Leg Syndrome | 0 | | 1999 | 2014 | 15.4 | low | 0 | 0 | 1 | 5 | 4 | 0 |
| Restless Legs Syndrome | 0 | | 1999 | 2014 | 15.4 | low | 0 | 0 | 1 | 5 | 4 | 0 |
| Retinal Diseases | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Retinal Vein Occlusion | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Rett Syndrome | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Rhabdomyolysis | 0 | | 1999 | 2023 | 12.6 | low | 0 | 0 | 2 | 9 | 2 | 6 |
| Salivary Gland Diseases | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Sarcoidosis | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Schizophrenia | 1 | | 1995 | 2024 | 15.6 | medium | 734 | 0 | 263 | 1,152 | 676 | 122 |
| Schizotypal Personality Disorder | 0 | | 2000 | 2007 | 19.5 | low | 2 | 0 | 1 | 5 | 0 | 0 |
| Sciatica | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Scleroderma, Systemic | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Sclerosis, Systemic | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Seizures | 0 | | 1996 | 2021 | 17.8 | low | 0 | 0 | 5 | 15 | 5 | 1 |
| Sensitivity and Specificity | 0 | | 1996 | 2020 | 16.4 | low | 9 | 0 | 2 | 22 | 13 | 0 |
| Serotonin Syndrome | 0 | | 2002 | 2018 | 15.8 | low | 0 | 0 | 0 | 7 | 4 | 0 |
| Sex Disorders | 0 | | 2004 | 2023 | 15.5 | low | 5 | 0 | 0 | 16 | 3 | 1 |
| Sexual Dysfunction, Physiological | 0 | | 2004 | 2023 | 15.5 | low | 5 | 0 | 0 | 16 | 3 | 1 |
| Sexual Dysfunctions, Psychological | 0 | | 1998 | 2012 | 19.6 | low | 1 | 0 | 3 | 4 | 3 | 0 |
| Shock | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Shock, Cardiogenic | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Sialorrhea | 0 | | 1998 | 2022 | 14.4 | low | 1 | 0 | 1 | 2 | 1 | 1 |
| Sicca Syndrome | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sjogren's Syndrome | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Skin Diseases | 0 | | 2000 | 2006 | 21.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Skin Neoplasms | 0 | | 2009 | 2023 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| Skin Ulcer | 0 | | 2000 | 2013 | 17.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Sleep Initiation and Maintenance Disorders | 0 | | 2000 | 2023 | 11.5 | low | 8 | 0 | 2 | 6 | 10 | 4 |
| Sleep Wake Disorders | 0 | | 1998 | 2016 | 18.4 | low | 9 | 0 | 3 | 12 | 3 | 0 |
| Sleepiness | 0 | | 2018 | 2023 | 3.8 | low | 2 | 0 | 0 | 0 | 2 | 2 |
| Smoking Cessation | 0 | | 2001 | 2022 | 13.6 | low | 1 | 0 | 0 | 5 | 2 | 1 |
| Somatoform Disorders | 0 | | 2001 | 2010 | 18.8 | low | 2 | 0 | 0 | 5 | 0 | 0 |
| Sore Throat | 0 | | 2007 | 2020 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Spasm | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Spinal Curvatures | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Spinal Fractures | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ST Elevated Myocardial Infarction | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ST Elevation Myocardial Infarction | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Stammering | 0 | | 1999 | 2009 | 18.5 | low | 0 | 0 | 1 | 5 | 0 | 0 |
| Status Epilepticus | 0 | | 2009 | 2017 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Stevens-Johnson Syndrome | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Stomach Neoplasms | 0 | | 2007 | 2017 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Stomach Ulcer | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Streptococcal Infections | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Stress Disorders, Post-Traumatic | 0 | | 2001 | 2020 | 16.1 | low | 4 | 0 | 0 | 13 | 4 | 0 |
| Stress Disorders, Traumatic, Acute | 0 | | 2020 | 2023 | 2.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Stroke | 0 | | 2004 | 2016 | 17.3 | low | 0 | 0 | 0 | 16 | 3 | 0 |
| Stuttering | 0 | | 1999 | 2009 | 18.5 | low | 0 | 0 | 1 | 5 | 0 | 0 |
| Substance Withdrawal Syndrome | 0 | | 1997 | 2022 | 18.3 | low | 6 | 0 | 11 | 16 | 4 | 2 |
| Substance-Related Disorders | 0 | | 1997 | 2023 | 14.2 | low | 11 | 0 | 4 | 21 | 14 | 5 |
| Suicidal Ideation | 0 | | 2011 | 2014 | 11.5 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| Symptom Cluster | 0 | | 1998 | 2023 | 14.8 | low | 0 | 0 | 5 | 14 | 15 | 1 |
| Syndrome | 0 | | 1998 | 2023 | 14.8 | low | 0 | 0 | 5 | 14 | 15 | 1 |
| Tachyarrhythmia | 0 | | 2008 | 2013 | 13.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Tachycardia | 0 | | 2008 | 2013 | 13.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Tachycardia, Ventricular | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Tardive Dyskinesia | 0 | | 2017 | 2023 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Tardive Dystonia | 0 | | 2017 | 2023 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Teratogenesis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Thoracic Neoplasms | 0 | | 2017 | 2021 | 5.0 | low | 3 | 0 | 0 | 0 | 2 | 1 |
| Thrombocythemia | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Thrombocytopenia | 0 | | 1998 | 2017 | 17.6 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| Thromboembolism | 0 | | 2003 | 2008 | 18.5 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| Thromboembolism, Venous | 0 | | 2008 | 2013 | 14.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| Thrombopenia | 0 | | 1998 | 2017 | 17.6 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| Thrombophilia | 0 | | 2005 | 2008 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Thrombosis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Thyroid Diseases | 0 | | 2003 | 2016 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Tics | 0 | | 2002 | 2012 | 17.0 | low | 1 | 0 | 0 | 4 | 2 | 0 |
| Tinea Versicolor | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Tobacco Use Disorder | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Tongue, Hairy | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Torsade de Pointes | 0 | | 2001 | 2014 | 16.0 | low | 1 | 0 | 0 | 4 | 4 | 0 |
| Torticollis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Tourette Syndrome | 0 | | 1998 | 2019 | 20.2 | low | 6 | 0 | 6 | 9 | 2 | 0 |
| Tremor | 0 | | 1997 | 2012 | 19.8 | low | 2 | 0 | 4 | 5 | 1 | 0 |
| Trichotillomania | 0 | | 1998 | 2020 | 16.1 | low | 2 | 0 | 2 | 4 | 4 | 0 |
| Tuberous Sclerosis | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Turner Syndrome | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Typhoid Fever | 0 | | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Urinary Incontinence | 0 | | 2000 | 2010 | 19.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Urinary Retention | 0 | | 2006 | 2019 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Urinary Tract Diseases | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Uterine Cervical Neoplasms | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Uterine Neoplasms | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Venous Thromboembolism | 0 | | 2008 | 2013 | 14.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| Venous Thrombosis | 0 | | 2003 | 2018 | 15.5 | low | 0 | 0 | 0 | 4 | 2 | 0 |
| Ventricular Dysfunction | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ventricular Fibrillation | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Vision, Diminished | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Vitamin B 12 Deficiency | 0 | | 2007 | 2010 | 15.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Vomiting | 1 | | 2003 | 2023 | 6.4 | low | 52 | 0 | 0 | 11 | 96 | 37 |
| Vulvar Diseases | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Water Intoxication | 0 | | 1999 | 2014 | 19.2 | low | 1 | 0 | 1 | 4 | 1 | 0 |
| Weight Gain | 1 | | 1996 | 2023 | 14.2 | low | 172 | 0 | 25 | 308 | 178 | 43 |
| Weight Loss | 1 | | 2001 | 2023 | 15.2 | low | 15 | 0 | 0 | 24 | 12 | 1 |
| Weight Reduction | 0 | | 2001 | 2023 | 15.2 | low | 15 | 0 | 0 | 24 | 12 | 1 |
| Wolff-Parkinson-White Syndrome | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Wounds and Injuries | 0 | | 2012 | 2016 | 10.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Wounds, Stab | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Xanthoma | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Xerostomia | 0 | | 1998 | 2012 | 20.4 | low | 4 | 0 | 2 | 2 | 1 | 0 |
| Zika Virus Infection | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Treatment of severe tardive dyskinesia with concurrent administration of olanzapine, clonazepam, baclofen, and gabapentin: a case report.The Journal of international medical research, , Volume: 51, Issue:10, 2023
Clozapine Treatment of Olanzapine-induced Tardive Dyskinesia: A Case Report.Journal of psychiatric practice, , Volume: 23, Issue:1, 2017
Olanzapine-Associated Pisa Syndrome in an Autistic Adolescent.Clinical neuropharmacology, , Volume: 43, Issue:2
Hypertrophic discoid lupus erythematosus.Dermatology online journal, , Nov-15, Volume: 16, Issue:11, 2010
Olanzapine is effective in the management of some self-induced dermatoses: three case reports.Cutis, , Volume: 66, Issue:2, 2000
Olanzapine may be an effective adjunctive therapy in the management of acne excoriée: a case report.Journal of cutaneous medicine and surgery, , Volume: 5, Issue:1
[Isotretinoin Therapy for Acne Vulgaris and First Episode Psychosis in an Adolescent Patient].Revista colombiana de psiquiatria, , Volume: 46, Issue:1
Acute Angle Closure in a Patient Using Olanzapine.Psychiatria Danubina, ,Summer, Volume: 34, Issue:2, 2022
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.European archives of psychiatry and clinical neuroscience, , Volume: 270, Issue:1, 2020
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.The American journal of psychiatry, , 04-01, Volume: 177, Issue:4, 2020
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.The Journal of clinical psychiatry, , 03-03, Volume: 81, Issue:2, 2020
Female mice are protected against acute olanzapine-induced hyperglycemia.Psychoneuroendocrinology, , Volume: 110, 2019
A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-02, Volume: 81, 2018
Midazolam-Droperidol, Droperidol, or Olanzapine for Acute Agitation: A Randomized Clinical Trial.Annals of emergency medicine, , Volume: 69, Issue:3, 2017
Acute massıve pulmonary embolism assocıated wıth olanzapıne.The American journal of emergency medicine, , Volume: 35, Issue:10, 2017
Olanzapine induced delirium-a "probable" adverse drug reaction.Annals of palliative medicine, , Volume: 6, Issue:Suppl 2, 2017
Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study.Nordic journal of psychiatry, , Volume: 71, Issue:7, 2017
Intravenous midazolam-droperidol combination, droperidol or olanzapine monotherapy for methamphetamine-related acute agitation: subgroup analysis of a randomized controlled trial.Addiction (Abingdon, England), , Volume: 112, Issue:7, 2017
Droperidol for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , 12-15, Volume: 12, 2016
Dementia with Lewy bodies presenting marked tongue protrusion and bite due to lingual dystonia: A case report.Rinsho shinkeigaku = Clinical neurology, , 06-22, Volume: 56, Issue:6, 2016
Anti-N-methyl-D-aspartate receptor encephalitis is an important differential diagnosis in acute psychiatric disease.Acta psychiatrica Scandinavica, , Volume: 131, Issue:1, 2015
Serotonin Syndrome Induced by Combined Use of Mirtazapine and Olanzapine Complicated with Rhabdomyolysis, Acute Renal Failure, and Acute Pulmonary Edema-A Case Report.Acta neurologica Taiwanica, , Volume: 24, Issue:4, 2015
Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review.Pediatric blood & cancer, , Volume: 62, Issue:3, 2015
Acute angle closure glaucoma precipitated by olanzapine.International journal of geriatric psychiatry, , Volume: 30, Issue:10, 2015
A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.Human psychopharmacology, , Volume: 29, Issue:1, 2014
A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior.Journal of clinical psychopharmacology, , Volume: 34, Issue:3, 2014
Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.Schizophrenia research, , Volume: 158, Issue:1-3, 2014
Acute and maintenance treatments for bipolar depression.The Journal of clinical psychiatry, , Volume: 75, Issue:4, 2014
Benzodiazepines for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , Apr-30, Issue:4, 2013
Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies.Journal of affective disorders, , Volume: 149, Issue:1-3, 2013
Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial.Annals of emergency medicine, , Volume: 61, Issue:1, 2013
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.Psychiatry research, , Dec-15, Volume: 210, Issue:2, 2013
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.Journal of affective disorders, , Jan-25, Volume: 144, Issue:3, 2013
[Acute catatonia: Questions, diagnosis and prognostics, and the place of atypical antipsychotics].L'Encephale, , Volume: 39, Issue:3, 2013
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 22, Issue:10, 2012
A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.PharmacoEconomics, , Jun-01, Volume: 30, Issue:6, 2012
Antipsychotic treatment of acute paranoid schizophrenia patients with olanzapine results in altered glycosylation of serum glycoproteins.Journal of proteome research, , Jul-06, Volume: 11, Issue:7, 2012
Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.Current medical research and opinion, , Volume: 28, Issue:3, 2012
A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode.Journal of affective disorders, , Volume: 138, Issue:3, 2012
Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients.The Journal of emergency medicine, , Volume: 43, Issue:5, 2012
Acute overdose of enteric-coated valproic acid and olanzapine: unusual presentation and delayed toxicity.Clinical toxicology (Philadelphia, Pa.), , Volume: 50, Issue:4, 2012
A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation.The Journal of emergency medicine, , Volume: 43, Issue:5, 2012
Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.The American journal of psychiatry, , Volume: 168, Issue:9, 2011
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3. Rapid tranquilisation in acute psychotic agitation.Emergency medicine journal : EMJ, , Volume: 28, Issue:1, 2011
Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.Journal of affective disorders, , Volume: 122, Issue:1-2, 2010
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.Journal of clinical psychopharmacology, , Volume: 30, Issue:3, 2010
Efficacy of olanzapine and sodium valproate given alone or as add-on therapy in acute mania. A comparative study.Methods and findings in experimental and clinical pharmacology, , Volume: 32, Issue:5, 2010
Gender, psychosis and psychotropic drugs: differences and similarities.Psychiatria Danubina, , Volume: 22, Issue:2, 2010
Acute pancreatitis associated with lisinopril and olanzapine.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Feb-01, Volume: 67, Issue:3, 2010
Olanzapine vs. lithium in management of acute mania.Journal of affective disorders, , Volume: 122, Issue:3, 2010
[Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection].Gastroenterologia y hepatologia, , Volume: 33, Issue:2, 2010
A Canadian naturalistic study of a community-based cohort treated for bipolar disorder.BMC psychiatry, , Mar-19, Volume: 10, 2010
Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 20, Issue:12, 2010
[Patient with encephalitis presenting with olanzapine-responsive malignant catatonia].Rinsho shinkeigaku = Clinical neurology, , Volume: 50, Issue:5, 2010
Asenapine versus olanzapine in acute mania: a double-blind extension study.Bipolar disorders, , Volume: 11, Issue:8, 2009
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:1, 2009
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 70, Issue:3, 2009
Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
[Acute pancreatitis induced by olanzapine].Annales francaises d'anesthesie et de reanimation, , Volume: 28, Issue:10, 2009
Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study.Pharmacotherapy, , Volume: 29, Issue:8, 2009
Olanzapine induced acute Meige's syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 21, Issue:2, 2009
Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.International journal of clinical practice, , Volume: 63, Issue:8, 2009
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:5, 2008
Olanzapine-associated new-onset atrial fibrillation.Journal of clinical psychopharmacology, , Volume: 28, Issue:3, 2008
Evaluating dose response from flexible dose clinical trials.BMC psychiatry, , Jan-07, Volume: 8, 2008
Treatment of catatonia with electroconvulsive therapy in an 11-year-old girl.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:3, 2008
Three cases of schizophrenia for which olanzapine was effective after early acute phase.Psychiatry and clinical neurosciences, , Volume: 62, Issue:1, 2008
Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study.Journal of affective disorders, , Volume: 106, Issue:1-2, 2008
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Venlafaxine for acute heroin detoxification: a double-blind, randomized, control trial.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
An analysis of the efficacy of treatments for bipolar depression.The Journal of clinical psychiatry, , Volume: 69 Suppl 5, 2008
[Depression in schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:10, 2008
Switching from other agents to extended-release carbamazepine in acute mania.Psychopharmacology bulletin, , Volume: 41, Issue:1, 2008
Influence of olanzapine on QT variability and complexity measures of heart rate in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Olanzapine-induced chylomicronemia presenting as acute pancreatitis.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
[Clinical and therapeutic aspects of agitation].L'Encephale, , Volume: 33 Pt 3, 2007
Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:10, 2007
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.Journal of psychiatric research, , Volume: 41, Issue:8, 2007
Effect of comorbid anxiety on treatment response in bipolar depression.Journal of affective disorders, , Volume: 104, Issue:1-3, 2007
Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium.Journal of psychiatric research, , Volume: 41, Issue:7, 2007
Acute phase results from STORM, a multicountry observational study of bipolar disorder treatment and outcomes.Psychiatria Danubina, , Volume: 19, Issue:4, 2007
[The influence of atypical neuroleptics on the immune system of patients with schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:3, 2007
Olanzapine and acute urinary retention in two geriatric patients.The American journal of geriatric pharmacotherapy, , Volume: 5, Issue:3, 2007
Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine.Indian journal of medical sciences, , Volume: 61, Issue:10, 2007
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.Human psychopharmacology, , Volume: 22, Issue:7, 2007
Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.The Journal of clinical psychiatry, , Volume: 68, Issue:10, 2007
A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Acute generalized exanthematous pustulosis induced by olanzapine.Acta medica (Hradec Kralove), , Volume: 49, Issue:1, 2006
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.Bipolar disorders, , Volume: 8, Issue:6, 2006
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.The Journal of clinical psychiatry, , Volume: 67, Issue:10, 2006
Rapid leptin elevation after initiation of olanzapine?Neuropsychobiology, , Volume: 54, Issue:3, 2006
Olanzapine overdose is associated with acute muscle toxicity.Human & experimental toxicology, , Volume: 25, Issue:12, 2006
[Olanzapine in the treatment of bipolar disorder].Psychiatrische Praxis, , Volume: 33 Suppl 1, 2006
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.The American journal of psychiatry, , Volume: 163, Issue:2, 2006
Selecting antipsychotics in schizophrenia: lessons from CATIE.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:3, 2006
Cerebellar and thalamic metabolic changes visualized by [18]-FDG-PET in olanzapine-induced acute akathisia.Neuro endocrinology letters, , Volume: 27, Issue:6, 2006
A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:6, 2006
Acute olanzapine-induced akathisia and dystonia in a patient discontinued from fluoxetine.The Journal of emergency medicine, , Volume: 30, Issue:3, 2006
Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.Schizophrenia research, , Feb-28, Volume: 82, Issue:2-3, 2006
[New formulations of olanzapine in the treatment of acute agitation].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Olanzapine therapy for subacute prurigo.Clinical and experimental dermatology, , Volume: 31, Issue:3, 2006
[Clinical course of acute poisoning with olanzapine].Przeglad lekarski, , Volume: 62, Issue:6, 2005
Clinical outcome and olanzapine plasma levels in acute schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:1, 2005
Acute psychosis with a mediastinal carcinoma metastasis.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 11, Issue:1, 2005
Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial.Current medical research and opinion, , Volume: 21, Issue:4, 2005
Intramuscular olanzapine: a review of its use in the management of acute agitation.CNS drugs, , Volume: 19, Issue:2, 2005
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.BMC psychiatry, , Jan-13, Volume: 5, 2005
Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: a multivariate analysis of a large naturalistic study in the hospital setting.Medicina clinica, , Apr-09, Volume: 124, Issue:13, 2005
Clinical implications of Brief Psychiatric Rating Scale scores.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Atypical antipsychotics: newer options for mania and maintenance therapy.Bipolar disorders, , Volume: 7 Suppl 4, 2005
Evidence for onset of antipsychotic effects within the first 24 hours of treatment.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:8, 2005
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.The Journal of clinical psychiatry, , Volume: 66 Suppl 3, 2005
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients.The Journal of clinical psychiatry, , Volume: 66, Issue:12, 2005
Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:6, 2004
A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.International clinical psychopharmacology, , Volume: 19, Issue:2, 2004
[A change of immune profile of patients with schizophrenia during treatment].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 104, Issue:4, 2004
Bipolar depression: an overview.IDrugs : the investigational drugs journal, , Volume: 7, Issue:9, 2004
[Introduction of new anti-psychotic drugs and changes in the clinical practice].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 106, Issue:7, 2004
Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.Psychiatry and clinical neurosciences, , Volume: 58, Issue:4, 2004
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.The American journal of emergency medicine, , Volume: 22, Issue:3, 2004
Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania.Current medical research and opinion, , Volume: 20, Issue:9, 2004
Normalization of impaired cognitive functions failed to improve clinical symptomatology in a schizophrenic patient.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:6, 2004
Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:11, 2003
Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia.The international journal of neuropsychopharmacology, , Volume: 6, Issue:2, 2003
The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
Comparison of three antipsychotics in the emergency psychiatric setting.Human psychopharmacology, , Volume: 18, Issue:6, 2003
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.Wiener klinische Wochenschrift, , Jan-31, Volume: 115, Issue:1-2, 2003
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
[Treatment of acute bipolar disorder. Intriguing balancing act between mania and depression].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes.The Journal of clinical psychiatry, , Volume: 64, Issue:3, 2003
Acute dysphoric mania: treatment response to olanzapine versus placebo.Journal of clinical psychopharmacology, , Volume: 23, Issue:2, 2003
The efficacy and safety of olanzapine for the treatment of geriatric psychosis.Journal of clinical psychopharmacology, , Volume: 23, Issue:2, 2003
Treating acute mania.The Journal of family practice, , Volume: Suppl, 2003
Optimal dosing of medications (in bipolar disorder).The Journal of family practice, , Volume: Suppl, 2003
Olanzapine versus placebo in acute mania: treatment responses in subgroups.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.The American journal of psychiatry, , Volume: 160, Issue:7, 2003
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.Archives of general psychiatry, , Volume: 60, Issue:12, 2003
[Long-term therapy with intuition].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
Psychotic disorder in a case with Hallervorden-Spatz disease.Acta psychiatrica Scandinavica, , Volume: 108, Issue:5, 2003
[Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.International clinical psychopharmacology, , Volume: 17, Issue:6, 2002
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.Archives of general psychiatry, , Volume: 59, Issue:1, 2002
A correction.Archives of general psychiatry, , Volume: 59, Issue:1, 2002
Olanzapine in acute bipolar mania.Archives of general psychiatry, , Volume: 59, Issue:2, 2002
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.The Journal of clinical psychiatry, , Volume: 63, Issue:2, 2002
The role of novel antipsychotics in bipolar disorders.The Journal of clinical psychiatry, , Volume: 63 Suppl 3, 2002
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 26, Issue:4, 2002
Eosinophilia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:3, 2002
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.Archives of general psychiatry, , Volume: 59, Issue:5, 2002
The efficacy of olanzapine, as needed, to treat acute agitation in juveniles.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 12, Issue:1, 2002
Olanzapine versus divalproex in the treatment of acute mania.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.International clinical psychopharmacology, , Volume: 17, Issue:5, 2002
Rapid tranquilization with olanzapine in acute psychosis: a case series.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Introduction: a new era in the pharmacotherapy of psychotic disorders.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.The American journal of psychiatry, , Volume: 158, Issue:4, 2001
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.The Journal of clinical psychiatry, , Volume: 62, Issue:3, 2001
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.The American journal of psychiatry, , Volume: 158, Issue:7, 2001
Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam.The Australian and New Zealand journal of psychiatry, , Volume: 35, Issue:3, 2001
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.The Journal of clinical psychiatry, , Volume: 62, Issue:12, 2001
[Atypical antipsychotics].Der Nervenarzt, , Volume: 71, Issue:5, 2000
St. John's wort and schizophrenia.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Aug-08, Volume: 163, Issue:3, 2000
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.Archives of general psychiatry, , Volume: 57, Issue:9, 2000
Olanzapine-induced acute pancreatitis.The Annals of pharmacotherapy, , Volume: 34, Issue:10, 2000
Olanzapine to treat the acute mania of bipolar disorder.South Dakota journal of medicine, , Volume: 53, Issue:12, 2000
Rationale and guidelines for the inpatient treatment of acute psychosis.The Journal of clinical psychiatry, , Volume: 61 Suppl 14, 2000
New treatments for bipolar disorder: the role of atypical neuroleptic agents.The Journal of clinical psychiatry, , Volume: 61 Suppl 14, 2000
Response to placebo among bipolar I disorder patients experiencing their first manic episode.Bipolar disorders, , Volume: 2, Issue:4, 2000
[The experience of application of olanzapine: an atypical neuroleptic in acute schizophrenia].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 100, Issue:4, 2000
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.The British journal of psychiatry : the journal of mental science, , Volume: 174, 1999
Olanzapine in the treatment of adolescent acute mania: a report of seven cases.Journal of affective disorders, , Volume: 53, Issue:3, 1999
Management of acute mania.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Antipsychotic agents and bipolar disorder.The Journal of clinical psychiatry, , Volume: 59 Suppl 1, 1998
Common treatment goals of antipsychotics: acute treatment.The Journal of clinical psychiatry, , Volume: 59 Suppl 19, 1998
Worsening of obsessive-compulsive symptoms following treatment with olanzapine.The American journal of psychiatry, , Volume: 155, Issue:6, 1998
Olanzapine overdose cause of acute extrapyramidal symptoms.The American journal of psychiatry, , Volume: 155, Issue:11, 1998
Acute dystonia with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:7, 1998
[Acute dystonia].Nederlands tijdschrift voor geneeskunde, , Feb-28, Volume: 142, Issue:9, 1998
Emergency treatment of acute psychosis.The Journal of clinical psychiatry, , Volume: 59 Suppl 1, 1998
Safety of olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 48, Issue:12, 1997
Efficacy of olanzapine: an overview of pivotal clinical trials.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia.Clinical neuropharmacology, , Volume: 29, Issue:3
Acute Poisoning with Dapsone and Olanzapine: Severe Methemoglobinemia and Coma with a Favourable Outcome.Folia medica, , Volume: 57, Issue:2
[New therapeutic strategies in schizophrenia: apropos of acute decompensation treated with olanzapine].L'Encephale, , Volume: 26, Issue:2
Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients.General hospital psychiatry, , Volume: 30, Issue:4
[Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: results from NATURA study].Actas espanolas de psiquiatria, , Volume: 36, Issue:3
Acute massive pulmonary embolism associated with olanzapine therapy and no significant personal history in a young male--case report and literature review.Pneumologia (Bucharest, Romania), , Volume: 60, Issue:2
Acute dystonia with intramuscular olanzapine in adolescent mania: a report.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:11-12
Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study.General hospital psychiatry, , Volume: 22, Issue:2
Management of a patient with schizophrenia and underlying pituitary macroadenoma.Annals of the Academy of Medicine, Singapore, , Volume: 39, Issue:11, 2010
Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:1, 2005
Mania in a case of hyperparathyroidism.Psychosomatics, , Volume: 48, Issue:3
Risk and Prevention of Aggression in Patients With Psychotic Disorders.The American journal of psychiatry, , 03-01, Volume: 178, Issue:3, 2021
Brief psychotic disorder with delusion content related to the COVID-19 outbreak.Psychiatrike = Psychiatriki, , Apr-19, Volume: 32, Issue:1, 2021
Olanzapine-Induced Aggression.The primary care companion for CNS disorders, , Feb-18, Volume: 23, Issue:1, 2021
The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.Expert opinion on investigational drugs, , Volume: 29, Issue:3, 2020
The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 57, 2019
Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).The Cochrane database of systematic reviews, , 01-08, Volume: 1, 2018
Hikikomori in Brazil: 29 years of Voluntary social Withdrawal.Asian journal of psychiatry, , Volume: 30, 2017
Haloperidol for long-term aggression in psychosis.The Cochrane database of systematic reviews, , 11-27, Volume: 11, 2016
Droperidol for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , 12-15, Volume: 12, 2016
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.CNS spectrums, , Volume: 19, Issue:5, 2014
Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 26, Issue:3, 2014
Depression and impulsivity as pathways to violence: implications for antiaggressive treatment.Schizophrenia bulletin, , Volume: 40, Issue:4, 2014
Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:6, 2013
A comparative study of beneficial effects of Olanzapine and sodium valproate on aggressive behavior of patients who are on methadone maintenance therapy: a randomized triple blind clinical trial.European review for medical and pharmacological sciences, , Volume: 17, Issue:8, 2013
Benzodiazepines for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , Apr-30, Issue:4, 2013
Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.The Journal of clinical psychiatry, , Volume: 73, Issue:1, 2012
Age-grouped differences in bipolar mania.Comprehensive psychiatry, , Volume: 53, Issue:8, 2012
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).The Journal of clinical psychiatry, , Volume: 72, Issue:7, 2011
The use of Pro Re Nata or Statim medications for behavioral control: a summary of experience at a tertiary care children's mental health center.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:1, 2011
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 13, Issue:3, 2011
[Rapid tranquillisation; review of the literature and recommendations].Tijdschrift voor psychiatrie, , Volume: 53, Issue:10, 2011
Minimum effective and relapse-associated doses of risperidone and olanzapine in aggressive, intellectually disabled adults.Journal of clinical psychopharmacology, , Volume: 31, Issue:2, 2011
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 33, Issue:1, 2011
Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study.Journal of intellectual disability research : JIDR, , Volume: 55, Issue:2, 2011
The effect of Olanzapine and Sertraline on personality disorder in patients with methadone maintenance therapy.Psychiatria Danubina, , Volume: 22, Issue:4, 2010
Manic and psychotic symptoms following subcutaneous leuprolide in a male patient with no prior psychiatric history.The Journal of clinical psychiatry, , Volume: 71, Issue:12, 2010
A prospective longitudinal study of cholesterol and aggression in patients randomized to clozapine, olanzapine, and haloperidol.Journal of clinical psychopharmacology, , Volume: 30, Issue:2, 2010
Haloperidol plus promethazine for psychosis-induced aggression.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.Schizophrenia research, , Volume: 110, Issue:1-3, 2009
Does electroconvulsive therapy afford protection against olanzapine-induced parkinsonism? A case report.The journal of ECT, , Volume: 25, Issue:2, 2009
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.The American journal of psychiatry, , Volume: 165, Issue:7, 2008
Pharmacological treatment of pathologic aggression in children.International review of psychiatry (Abingdon, England), , Volume: 20, Issue:2, 2008
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:5, 2008
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine.The American journal of psychiatry, , Volume: 165, Issue:11, 2008
Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities.Journal of intellectual disability research : JIDR, , Volume: 52, Issue:Pt 2, 2008
Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study.The Journal of clinical psychiatry, , Volume: 69, Issue:6, 2008
[Clinical and therapeutic aspects of agitation].L'Encephale, , Volume: 33 Pt 3, 2007
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 9, Issue:3, 2007
[Study questions the benefit of the treatment. Aggressive Alzheimer patient -- a (not a) case for atypical neuroleptics?].MMW Fortschritte der Medizin, , Nov-23, Volume: 148, Issue:47, 2006
A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.Human psychopharmacology, , Volume: 21, Issue:4, 2006
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.Archives of general psychiatry, , Volume: 63, Issue:6, 2006
A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:6, 2006
Effects of olanzapine on aggressiveness in heroin dependent patients.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].Nederlands tijdschrift voor geneeskunde, , Jul-15, Volume: 150, Issue:28, 2006
Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial.Dementia and geriatric cognitive disorders, , Volume: 21, Issue:1, 2006
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.The Cochrane database of systematic reviews, , Jan-25, Issue:1, 2006
Olanzapine in Rett's disorder.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 44, Issue:8, 2005
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.International psychogeriatrics, , Volume: 17, Issue:2, 2005
Neuroleptic malignant syndrome due to three atypical antipsychotics in a child.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:4, 2005
Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses.The Cochrane database of systematic reviews, , Apr-18, Issue:2, 2005
The clinical picture of olanzapine poisoning with special reference to fluctuating mental status.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:1, 2004
Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 14, Issue:2, 2004
A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.The Journal of clinical psychiatry, , Volume: 65, Issue:7, 2004
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.Journal of clinical psychopharmacology, , Volume: 24, Issue:2, 2004
The management of psychogeriatric patient.Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:3, 2004
Olanzapine for recurrent aggression in a patient with temporal lobe epilepsy who had temporal lobectomy.Journal of psychopharmacology (Oxford, England), , Volume: 17, Issue:3, 2003
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
[Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].Fortschritte der Neurologie-Psychiatrie, , Volume: 70, Issue:3, 2002
A clinical case series of six extremely aggressive youths treated with olanzapine.European child & adolescent psychiatry, , Volume: 11, Issue:3, 2002
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.The Journal of clinical psychiatry, , Volume: 62, Issue:1, 2001
Use of olanzapine in non-psychotic psychiatric disorders.Expert opinion on pharmacotherapy, , Volume: 2, Issue:4, 2001
Antiaggressive action of atypical antipsychotics in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 21, Issue:3, 2001
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 61 Suppl 3, 2000
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
Aggression, agitation, and mania with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:10, 1998
Assessing antipsychotic effectiveness in dementia with the factor structure of the Psychogeriatric Dependency Rating Scale (PGDRS).Journal of the American Medical Directors Association, , Volume: 4, Issue:2
Psychopharmacological treatment in borderline personality disorder.Actas espanolas de psiquiatria, , Volume: 36, Issue:1
Reducing Restraint With Clozapine in Involuntarily Admitted Patients With Schizophrenia.American journal of therapeutics, , Volume: 24, Issue:2
[Initiation of treatment with olanzapine in a patient hospitalized at UMD].L'Encephale, , Volume: 26, Issue:3
Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.American journal of Alzheimer's disease and other dementias, , Volume: 21, Issue:2
Treatment with atypical antipsychotics: new indications and new populations.Journal of psychiatric research, , Volume: 35, Issue:3
Impaired mitophagosome-lysosome fusion mediates olanzapine-induced aging.Aging cell, , Volume: 22, Issue:11, 2023
Interhemispheric differences of pyramidal cells in the primary motor cortices of schizophrenia patients investigated postmortem.Cerebral cortex (New York, N.Y. : 1991), , 06-20, Volume: 33, Issue:13, 2023
Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:6, 2017
Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin.Progress in neuro-psychopharmacology & biological psychiatry, , Apr-03, Volume: 58, 2015
Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats.Neuroscience, , Volume: 255, 2013
Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.Therapeutic drug monitoring, , Volume: 31, Issue:6, 2009
Adulthood olanzapine treatment fails to alleviate decreases of ChAT and BDNF RNA expression in rats quinpirole-primed as neonates.Brain research, , Mar-20, Volume: 1200, 2008
Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:5, 2007
A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers.Journal of psychopharmacology (Oxford, England), , Volume: 13, Issue:2, 1999
Experience with the atypical antipsychotics--risperidone and olanzapine in the elderly.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 11, Issue:3, 1999
New atypical antipsychotics. Experience and utility in the elderly.Drugs & aging, , Volume: 12, Issue:2, 1998
"My new Alfa Romeo GT is not in the garage any more": Cognitive behavioural therapy of panic disorder with agoraphobia co morbid with psychosis.Psychiatria Danubina, , Volume: 18, Issue:3-4, 2006
Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
Olanzapine augmentation in panic disorder: a case report.Pharmacopsychiatry, , Volume: 37, Issue:5, 2004
Olanzapine and panic attacks.The American journal of psychiatry, , Volume: 157, Issue:4, 2000
Severe recurrent hypoglycaemia following discontinuation of olanzapine.Acute medicine, , Volume: 10, Issue:1, 2011
Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats.Alcoholism, clinical and experimental research, , Volume: 31, Issue:9, 2007
The effect of olanzapine on craving and alcohol consumption.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:6, 2006
Alcohol drinking of alcohol-preferring AA rats is differentially affected by clozapine and olanzapine.European journal of pharmacology, , Mar-18, Volume: 534, Issue:1-3, 2006
Olanzapine-induced clitoral priapism.Journal of clinical psychopharmacology, , Volume: 24, Issue:5, 2004
Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:10, 2003
Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol.Psychopharmacology, , Volume: 155, Issue:1, 2001
Olanzapine and pancreatitis.The British journal of psychiatry : the journal of mental science, , Volume: 177, 2000
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.The Journal of clinical psychiatry, , 03-17, Volume: 81, Issue:2, 2020
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.The Journal of clinical psychiatry, , 03-10, Volume: 81, Issue:2, 2020
Hikikomori in Brazil: 29 years of Voluntary social Withdrawal.Asian journal of psychiatry, , Volume: 30, 2017
Dose specific effects of olanzapine in the treatment of alcohol dependence.Psychopharmacology, , Volume: 232, Issue:7, 2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.The Journal of nervous and mental disease, , Volume: 203, Issue:7, 2015
[Buccolingual dyskinesia with justified hallucinations].Revista de neurologia, , Nov-16, Volume: 59, Issue:10, 2014
The effect of olanzapine on craving and alcohol consumption.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:6, 2006
Alcohol drinking of alcohol-preferring AA rats is differentially affected by clozapine and olanzapine.European journal of pharmacology, , Mar-18, Volume: 534, Issue:1-3, 2006
Delusional wife: a case of diagnostic ambiguity and treatment challenge.Journal of psychiatric practice, , Volume: 11, Issue:3, 2005
A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder.Alcoholism, clinical and experimental research, , Volume: 28, Issue:5, 2004
Potential use of olanzapine in treatment of substance dependence disorders.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Stalking behavior in delusional jealousy.Journal of forensic sciences, , Volume: 45, Issue:1, 2000
Olanzapine in the treatment of tardive dyskinesia: a report of two cases.Journal of clinical psychopharmacology, , Volume: 19, Issue:1, 1999
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
Pharmacological treatment of alcohol use disorder. Scientific evidence.Rivista di psichiatria, , Volume: 53, Issue:3
Outcome predictors in cocaine dependence treatment trials.The American journal on addictions, , Volume: 15, Issue:6
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
Clinical study of donepezil combined with olanzapine in the treatment of senile dementia complicated with mental and behavioral disorders.Minerva medica, , Volume: 113, Issue:2, 2022
Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer's disease cognition.Alzheimer's research & therapy, , 06-29, Volume: 14, Issue:1, 2022
Meta-Analysis of the Efficacy and Safety of Olanzapine versus Clozapine when Treating Senile Dementia.Computational and mathematical methods in medicine, , Volume: 2022, 2022
Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine DClinical drug investigation, , Volume: 42, Issue:12, 2022
A comparative study of olanzapine, aripiprazole and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease.Pakistan journal of pharmaceutical sciences, , Volume: 34, Issue:5(Special), 2021
Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.Neuropharmacology, , 10-01, Volume: 197, 2021
Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:7, 2017
Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 26, Issue:3, 2014
Drifting policies are wasting billions.International psychogeriatrics, , Volume: 24, Issue:3, 2012
Olanzapine-associated myoclonus.Epilepsy research, , Volume: 98, Issue:2-3, 2012
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.The American journal of psychiatry, , Volume: 168, Issue:8, 2011
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 22, Issue:1, 2010
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.The American journal of psychiatry, , Volume: 166, Issue:5, 2009
Sex, race, and smoking impact olanzapine exposure.Journal of clinical pharmacology, , Volume: 48, Issue:2, 2008
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.The American journal of psychiatry, , Volume: 165, Issue:7, 2008
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.Clinical drug investigation, , Volume: 28, Issue:5, 2008
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.Medicine and health, Rhode Island, , Volume: 90, Issue:6, 2007
Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances.Journal of geriatric psychiatry and neurology, , Volume: 20, Issue:2, 2007
Effect of antipsychotic medication use on memory in patients with Alzheimer's disease: Assessing the potential risk for accelerated recent autobiographical memory loss.Journal of gerontological nursing, , Volume: 33, Issue:6, 2007
Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
The outpatient use of atypical antipsychotics with Alzheimer's disease.South Dakota medicine : the journal of the South Dakota State Medical Association, , Volume: 60, Issue:3, 2007
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.CNS spectrums, , Volume: 12, Issue:1, 2007
Atypical antipsychotic agents ineffective for AD.DukeMedicine healthnews, , Volume: 13, Issue:1, 2007
[Efficacy of atypical antipsychotics in patients with Alzheimer's dementia. CATIE-AD-Study (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer's Disease)].Der Internist, , Volume: 48, Issue:6, 2007
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.The New England journal of medicine, , Oct-12, Volume: 355, Issue:15, 2006
No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.Minerva medica, , Volume: 97, Issue:2, 2006
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial.Dementia and geriatric cognitive disorders, , Volume: 21, Issue:1, 2006
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.The Cochrane database of systematic reviews, , Jan-25, Issue:1, 2006
[Study questions the benefit of the treatment. Aggressive Alzheimer patient -- a (not a) case for atypical neuroleptics?].MMW Fortschritte der Medizin, , Nov-23, Volume: 148, Issue:47, 2006
Psychosis of Alzheimer disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
Dementia.Clinical evidence, , Issue:14, 2005
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.International psychogeriatrics, , Volume: 17, Issue:2, 2005
The use of olanzapine in the treatment of negative symptoms in Alzheimer's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 17, Issue:3, 2005
Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.International journal of geriatric psychiatry, , Volume: 20, Issue:11, 2005
Responsiveness of the quality of life in late-stage dementia scale to psychotropic drug treatment in late-stage dementia.Dementia and geriatric cognitive disorders, , Volume: 19, Issue:2-3, 2005
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:8, 2005
Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Apr-27, Volume: 170, Issue:9, 2004
Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
The management of psychogeriatric patient.Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.International journal of geriatric psychiatry, , Volume: 19, Issue:2, 2004
Dementia.Clinical evidence, , Issue:11, 2004
[Cerebral infarct and atypical antipsychotic agents].Psychologie & neuropsychiatrie du vieillissement, , Volume: 2, Issue:4, 2004
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.Southern medical journal, , Volume: 96, Issue:7, 2003
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.The Annals of pharmacotherapy, , Volume: 37, Issue:9, 2003
Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.Managed care interface, , Volume: 16, Issue:5, 2003
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Fall, Volume: 9, Issue:4, 2001
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.International journal of geriatric psychiatry, , Volume: 16 Suppl 1, 2001
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.International journal of geriatric psychiatry, , Volume: 16 Suppl 1, 2001
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.International journal of geriatric psychiatry, , Volume: 16 Suppl 1, 2001
Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis.International journal of geriatric psychiatry, , Volume: 16 Suppl 1, 2001
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.The Journal of nervous and mental disease, , Volume: 189, Issue:6, 2001
Dementia with Lewy bodies in Down's syndrome.International journal of geriatric psychiatry, , Volume: 16, Issue:3, 2001
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.The Journal of clinical psychiatry, , Volume: 62, Issue:1, 2001
Tardive dyskinesia in older patients.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.Archives of general psychiatry, , Volume: 57, Issue:10, 2000
Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Nov-01, Volume: 56, Issue:21, 1999
Advances in CNS Drugs. Recent advances and considerations in the treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 57, Issue:7, 1996
Olanzapine-induced myoclonic status.Clinical neuropharmacology, , Volume: 28, Issue:3
Increase in mortality rate in patients with dementia treated with atypical antipsychotics: a cohort study in outpatients in Central Italy.Rivista di psichiatria, , Volume: 49, Issue:1
[Mortality rates in patients with Alzheimer's disease treated with atypical neuroleptic drugs].Revista de neurologia, , Volume: 46, Issue:3
Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.American journal of Alzheimer's disease and other dementias, , Volume: 18, Issue:4
Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATIE-AD Data.The Journal of clinical psychiatry, , Volume: 78, Issue:9
Psychotropic drug effects on gene transcriptomics relevant to Alzheimer disease.Alzheimer disease and associated disorders, , Volume: 26, Issue:1
[Treatment of non cognitive symptoms of Alzheimer's disease].Revista de neurologia, , Volume: 42, Issue:8
No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:3, 2011
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.Journal of clinical pharmacy and therapeutics, , Volume: 32, Issue:2, 2007
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.Pharmacotherapy, , Volume: 26, Issue:6, 2006
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Return of menstruation after switching from risperidone to olanzapine.Journal of clinical psychopharmacology, , Volume: 18, Issue:6, 1998
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.The American journal of psychiatry, , Volume: 155, Issue:10, 1998
Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.Journal of sex & marital therapy, , Volume: 29, Issue:2
Can atypical dysgeusia in depression be related to a deafferentation syndrome?Medical hypotheses, , Volume: 144, 2020
Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression.Medical hypotheses, , Volume: 65, Issue:1, 2005
Risperidone-induced anaemia.The National medical journal of India, , Volume: 36, Issue:1
Analysis of proarrhythmic potential of antipsychotics risperidone and olanzapine in anesthetized dogs.European journal of pharmacology, , Mar-08, Volume: 558, Issue:1-3, 2007
Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Jul-16, Volume: 23, Issue:15, 2003
Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 14, Issue:2, 1996
Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 05-10, Volume: 41, Issue:14, 2023
Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.Annals of palliative medicine, , Volume: 12, Issue:3, 2023
Intranasal administration of olanzapine has beneficial outcome in a rat activity-based anorexia model.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 71, 2023
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.Investigational new drugs, , Volume: 40, Issue:1, 2022
Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 37, Issue:7, 2012
Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 18, Issue:8, 2010
[Olanzapine use in cancer patients for refractory vomiting].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 33, Issue:3, 2006
Successful treatment of anorexia with a combination of high-dose olanzapine, fluoxetine and mirtazapine.International journal of clinical pharmacology and therapeutics, , Volume: 44, Issue:9, 2006
Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?Biological psychiatry, , Oct-15, Volume: 58, Issue:8, 2005
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.Cancer investigation, , Volume: 22, Issue:3, 2004
Efficacy and tolerance of second-generation antipsychotics in anorexia nervosa: A systematic scoping review.PloS one, , Volume: 18, Issue:3, 2023
Intranasal administration of olanzapine has beneficial outcome in a rat activity-based anorexia model.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 71, 2023
Inpatient treatment of anorexia nervosa with adjunctive valproate: a case series of 14 young and adolescent patients.Eating and weight disorders : EWD, , Volume: 27, Issue:3, 2022
Psychopharmacologic Management of Eating Disorders.Current psychiatry reports, , Volume: 24, Issue:7, 2022
Psychotropic Medication for Children and Adolescents with Eating Disorders.Child and adolescent psychiatric clinics of North America, , Volume: 28, Issue:4, 2019
Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial.The American journal of psychiatry, , 06-01, Volume: 176, Issue:6, 2019
Reexamining the Role of Electroconvulsive Therapy in Anorexia Nervosa in Adolescents.The journal of ECT, , Volume: 33, Issue:4, 2017
Olanzapine Treatment for Patients with Anorexia Nervosa.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 62, Issue:7, 2017
Adjunctive Use of Olanzapine in the Treatment of Avoidant Restrictive Food Intake Disorder in Children and Adolescents in an Eating Disorders Program.Journal of child and adolescent psychopharmacology, , Volume: 27, Issue:10, 2017
Olanzapine-induced atypical neuroleptic malignant syndrome in an adolescent man with anorexia nervosa.Eating and weight disorders : EWD, , Volume: 21, Issue:2, 2016
Dopamine D2/3 receptor antagonism reduces activity-based anorexia.Translational psychiatry, , Aug-04, Volume: 5, 2015
Atypical antipsychotics as augmentation therapy in anorexia nervosa.PloS one, , Volume: 10, Issue:4, 2015
Salience network and olanzapine in schizophrenia: implications for treatment in anorexia nervosa.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 60, Issue:3 Suppl 2, 2015
Lack of efficacy of psychological and pharmacological treatments of disorders of eating behavior: neurobiological background.BMC psychiatry, , Dec-24, Volume: 14, 2014
Second generation antipsychotics in adolescent anorexia nervosa: a new hypothesis of eligibility criteria.Journal of child and adolescent psychopharmacology, , Volume: 24, Issue:5, 2014
Olanzapine-induced hypoglycemia in anorexia nervosa.Endocrine, , Volume: 46, Issue:3, 2014
Psychotic symptoms in a woman with severe Anorexia Nervosa : psychotic symptoms in Anorexia Nervosa.Eating and weight disorders : EWD, , Volume: 18, Issue:1, 2013
Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa.The International journal of eating disorders, , Volume: 45, Issue:2, 2012
A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:3, 2011
Olanzapine versus placebo for out-patients with anorexia nervosa.Psychological medicine, , Volume: 41, Issue:10, 2011
Treatment strategy in schizophrenia combined with eating disorder.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:3, 2011
Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity.Journal of child and adolescent psychopharmacology, , Volume: 20, Issue:2, 2010
The case report of treatment strategy for Anorexia nervosa with psychotic elements in adolescent.Collegium antropologicum, , Volume: 34, Issue:3, 2010
[Olanzapine in the treatment of adolescents with anorexia nervosa].Tijdschrift voor psychiatrie, , Volume: 52, Issue:6, 2010
Olanzapine treatment in anorexia nervosa: case report.Psychiatria Danubina, , Volume: 21, Issue:1, 2009
Religious delusions in an evangelical Christian woman with anorexia nervosa.Journal of psychiatric practice, , Volume: 15, Issue:6, 2009
The perplexities of conducting randomized, double-blind, placebo-controlled treatment trials in anorexia nervosa patients.The American journal of psychiatry, , Volume: 165, Issue:10, 2008
Evaluation of the efficacy and safety of olanzapine as an adjunctive treatment for anorexia nervosa in adolescent females: a randomized, double-blind, placebo-controlled trial.BMC pediatrics, , Jan-31, Volume: 8, 2008
Atypical antipsychotics in severe anorexia nervosa in children and adolescents--review and case reports.European eating disorders review : the journal of the Eating Disorders Association, , Volume: 16, Issue:2, 2008
Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial.The American journal of psychiatry, , Volume: 165, Issue:10, 2008
Successful olanzapine treatment of anorexia nervosa in a girl with pervasive developmental disorder not otherwise specified.Psychiatry and clinical neurosciences, , Volume: 62, Issue:6, 2008
Nature against nurture: calcification in the right thalamus in a young man with anorexia nervosa and obsessive-compulsive personality disorder.CNS spectrums, , Volume: 13, Issue:10, 2008
Olanzapine-induced hyperglycemia in anorexia nervosa.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
Olanzapine therapy in anorexia nervosa: psychobiological effects.International clinical psychopharmacology, , Volume: 22, Issue:4, 2007
Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion?Psychoneuroendocrinology, , Volume: 32, Issue:4, 2007
The role of olanzapine in the treatment of anorexia nervosa.The Annals of pharmacotherapy, , Volume: 41, Issue:1, 2007
Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder.Psychiatry and clinical neurosciences, , Volume: 61, Issue:4, 2007
Olanzapine use in adolescent anorexia nervosa.Eating and weight disorders : EWD, , Volume: 11, Issue:2, 2006
Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:2, 2006
Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication.Therapeutic drug monitoring, , Volume: 28, Issue:6, 2006
Use of olanzapine in anorexia nervosa.The Journal of clinical psychiatry, , Volume: 66, Issue:5, 2005
Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 13, Issue:1, 2005
An open trial of olanzapine in anorexia nervosa.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports.The International journal of eating disorders, , Volume: 33, Issue:1, 2003
Olanzapine treatment of anorexia nervosa: a retrospective study.The International journal of eating disorders, , Volume: 33, Issue:2, 2003
Olanzapine in anorexia nervosa.The Australian and New Zealand journal of psychiatry, , Volume: 37, Issue:4, 2003
Olanzapine treatment of an adolescent girl with anorexia nervosa.Human psychopharmacology, , Volume: 18, Issue:5, 2003
Use of dreams by psychopharmacologists.The American journal of psychiatry, , Volume: 159, Issue:2, 2002
Olanzapine in the treatment of anorexia nervosa: an open label trial.The International journal of eating disorders, , Volume: 32, Issue:2, 2002
Antibodies against human putamen in adolescents with anorexia nervosa.The International journal of eating disorders, , Volume: 29, Issue:4, 2001
Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases.European child & adolescent psychiatry, , Volume: 10, Issue:2, 2001
Case reports of olanzapine treatment of anorexia nervosa.The International journal of eating disorders, , Volume: 27, Issue:3, 2000
Anorexia nervosa: treatment with olanzapine.The British journal of psychiatry : the journal of mental science, , Volume: 177, 2000
Olanzapine in the treatment of anorexia nervosa.The British journal of psychiatry : the journal of mental science, , Volume: 175, 1999
Factors influencing research drug trials in adolescents with anorexia nervosa.Eating disorders, , Volume: 18, Issue:3
Olanzapine-Related Somnambulism: A Systematic Review of Literature and a Case Report of Anorexia Nervosa.Journal of clinical psychopharmacology, , Volume: 41, Issue:6
Psychosis in Anorexia Nervosa: A Case Report and Review of the Literature.Psychosomatics, , Volume: 61, Issue:2
Efficacy and safety of antipsychotics and antidepressants in the treatment of anorexia nervosa: a systematic review.Revista Colombiana de psiquiatria (English ed.), , Volume: 51, Issue:3
Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.Pharmacology research & perspectives, , Volume: 9, Issue:5, 2021
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations.Bipolar disorders, , Volume: 23, Issue:8, 2021
Effects of olanzapine on anxiety-related behaviour in male and female rats assessed after 21-24 and 42-45 days of chronic treatment.Behavioural pharmacology, , 04-01, Volume: 32, Issue:2&3, 2021
A Case Report of Neurosyphilis Limbic Encephalitis With Reversible Geschwind Syndrome and Mood Disorder.Journal of psychiatric practice, , Volume: 25, Issue:3, 2019
Comparison of the effects of 1MeTIQ and olanzapine on performance in the elevated plus maze test and monoamine metabolism in the brain after ketamine treatment.Pharmacology, biochemistry, and behavior, , Volume: 181, 2019
Brain Sub/Region-Specific Effects of Olanzapine on c-Fos Expression of Chronically Socially Isolated Rats.Neuroscience, , 01-01, Volume: 396, 2019
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.Medicine, , Volume: 97, Issue:37, 2018
Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.Metabolic brain disease, , Volume: 32, Issue:5, 2017
The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol.Pharmacological reports : PR, , Volume: 68, Issue:2, 2016
Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model.Acta neuropsychiatrica, , Volume: 28, Issue:6, 2016
Early antipsychotic treatment in childhood/adolescent period has long-term effects on depressive-like, anxiety-like and locomotor behaviours in adult rats.Journal of psychopharmacology (Oxford, England), , Volume: 30, Issue:2, 2016
ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 389, Issue:6, 2016
Olanzapine for Nausea, Delirium, Anxiety, Insomnia, and Cachexia #315.Journal of palliative medicine, , Volume: 19, Issue:11, 2016
The effects of valproate and olanzapine on the abnormal behavior of diacylglycerol kinase β knockout mice.Pharmacological reports : PR, , Volume: 67, Issue:2, 2015
Current status of atypical antipsychotics for the treatment of fibromyalgia.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:6, 2014
A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 24, Issue:3, 2014
Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study.Comprehensive psychiatry, , Volume: 55, Issue:5, 2014
Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats.Pharmacological reports : PR, , Volume: 63, Issue:6, 2011
Olanzapine enhances anxiety response to an SSRI in a woman with bipolar disorder.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-15, Volume: 35, Issue:1, 2011
The effect of Olanzapine and Sertraline on personality disorder in patients with methadone maintenance therapy.Psychiatria Danubina, , Volume: 22, Issue:4, 2010
The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia.International clinical psychopharmacology, , Volume: 25, Issue:2, 2010
Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.European journal of pharmacology, , Sep-11, Volume: 592, Issue:1-3, 2008
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.Current medical research and opinion, , Volume: 24, Issue:3, 2008
Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats.Alcoholism, clinical and experimental research, , Volume: 31, Issue:9, 2007
Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 14, Issue:2, 2004
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.International clinical psychopharmacology, , Volume: 19, Issue:1, 2004
[Therapeutic and pharmacological effects of second-generation antipsychotics on drug-resistant bipolar depression].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 106, Issue:8, 2004
The effect of olanzapine on anxiety among patients with schizophrenia: preliminary findings.Journal of clinical psychopharmacology, , Volume: 23, Issue:5, 2003
Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
Visual inspection of medications in preventing unexplained relapses.The Annals of pharmacotherapy, , Volume: 36, Issue:10, 2002
Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis.International journal of geriatric psychiatry, , Volume: 16 Suppl 1, 2001
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Short-term effects of olanzapine in Huntington disease.Neuropsychiatry, neuropsychology, and behavioral neurology, , Volume: 14, Issue:1, 2001
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.Biological psychiatry, , Jun-01, Volume: 43, Issue:11, 1998
Olazapine induced neuroleptic malignant syndrome.Actas espanolas de psiquiatria, , Volume: 34, Issue:2
Olanzapine as a possible treatment for anxiety due to vascular dementia: an open study.American journal of Alzheimer's disease and other dementias, , Volume: 19, Issue:2
Opposite effects of olanzapine and haloperidol in rat ultrasonic vocalization test.Polish journal of pharmacology, , Volume: 53, Issue:6
Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.The Psychiatric quarterly, , Volume: 94, Issue:4, 2023
Cameron lesions and selective serotonin reuptake inhibitors: An uncommon combination.Gastroenterologia y hepatologia, , Volume: 43, Issue:5, 2020
Anxiolytic effects of venlafaxine/olanzapine combination in treatment of anxious depression.Neuro endocrinology letters, , Volume: 38, Issue:8, 2018
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
Role of atypical antipsychotics in the treatment of generalized anxiety disorder.CNS drugs, , Volume: 28, Issue:6, 2014
Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study.Comprehensive psychiatry, , Volume: 55, Issue:5, 2014
Second-generation antipsychotics for anxiety disorders.The Cochrane database of systematic reviews, , Dec-08, Issue:12, 2010
Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.Pharmacotherapy, , Volume: 30, Issue:9, 2010
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study.The Journal of clinical psychiatry, , Volume: 69, Issue:4, 2008
Olanzapine counteracts stress-induced anxiety-like behavior in rats.Neuroscience letters, , Jun-20, Volume: 438, Issue:2, 2008
Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition.European journal of cancer care, , Volume: 16, Issue:3, 2007
Effect of comorbid anxiety on treatment response in bipolar depression.Journal of affective disorders, , Volume: 104, Issue:1-3, 2007
Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study.Biological psychiatry, , Feb-01, Volume: 59, Issue:3, 2006
Olanzapine-induced oculogyric crisis.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.Bipolar disorders, , Volume: 8, Issue:6, 2006
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorders, , Volume: 7 Suppl 3, 2005
An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania.The Journal of clinical psychiatry, , Volume: 64, Issue:1, 2003
Atypical antipsychotics for treatment of mixed depression and anxiety.The Journal of clinical psychiatry, , Volume: 61, Issue:5, 2000
Other clinical uses of olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:3, 2000
Serotonin syndrome: a complex but easily avoidable condition.General hospital psychiatry, , Volume: 30, Issue:3
Atypical presentations of pregnancy-specific generalized anxiety disorders in women without a previous psychiatric background.Psychosomatics, , Volume: 56, Issue:3
Psychopharmacologic Management of Eating Disorders.Current psychiatry reports, , Volume: 24, Issue:7, 2022
Psychotropic Medication for Children and Adolescents with Eating Disorders.Child and adolescent psychiatric clinics of North America, , Volume: 28, Issue:4, 2019
Adjunctive Use of Olanzapine in the Treatment of Avoidant Restrictive Food Intake Disorder in Children and Adolescents in an Eating Disorders Program.Journal of child and adolescent psychopharmacology, , Volume: 27, Issue:10, 2017
[Eating disorders in psychiatric patients during treatment with second generation antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:7, 2015
Olanzapine and food craving: a case control study.Human psychopharmacology, , Volume: 28, Issue:1, 2013
No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:3, 2011
Advancements in neuroendocrine and autonomic control of metabolic functions and their pathological significance.Eating and weight disorders : EWD, , Volume: 13, Issue:3, 2008
Sleep-related eating disorder induced by olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:7, 2002
Microthinking about micronutrients: a case of transition from obsessions about healthy eating to near-fatal "orthorexia nervosa" and proposed diagnostic criteria.Psychosomatics, , Volume: 56, Issue:4
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
Implications of atypical antipsychotic prescribing in the intensive care unit.Journal of critical care, , Volume: 30, Issue:4, 2015
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.Drug safety, , Volume: 36, Issue:6, 2013
[Electrocardiographic abnormalities in acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Analysis of proarrhythmic potential of antipsychotics risperidone and olanzapine in anesthetized dogs.European journal of pharmacology, , Mar-08, Volume: 558, Issue:1-3, 2007
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:7, 2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.The American journal of managed care, , Volume: 13, Issue:7 Suppl, 2007
Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.Journal of the National Medical Association, , Volume: 95, Issue:2, 2003
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.The Journal of clinical psychiatry, , Volume: 62, Issue:3, 2001
Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:2, 2001
[Heart rate variability in schizophrenic patients treated with antipsychotic agents].Harefuah, , Volume: 140, Issue:12, 2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Olanzapine (Zyprexa): suspected serious reactions.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jul-11, Volume: 163, Issue:1, 2000
[Clozapine and Olanzapine Associated Atrial Fibrillation: A Case Report].Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Fall, Volume: 26, Issue:3, 2015
Atrıal fıbrıllatıon due to olanzapıne overdose.Clinical toxicology (Philadelphia, Pa.), , Volume: 49, Issue:5, 2011
Olanzapine-associated new-onset atrial fibrillation.Journal of clinical psychopharmacology, , Volume: 28, Issue:3, 2008
Olanzapine treatment of lactating females causes testicular atrophy in prepuberal rat offspring.Biotechnic & histochemistry : official publication of the Biological Stain Commission, , Volume: 98, Issue:3, 2023
[A case suspected of dystonia with marked cerebellar atrophy with torsion dystonia of the neck and cerebellar ataxia that developed during pharmacologic schizophrenia treatment].Rinsho shinkeigaku = Clinical neurology, , Aug-07, Volume: 60, Issue:8, 2020
Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology.Biological psychiatry, , Jun-15, Volume: 75, Issue:12, 2014
Premorbid combat related ptsd in Huntington's disease - Case report.Psychiatria Danubina, , Volume: 22, Issue:2, 2010
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.CNS spectrums, , Volume: 12, Issue:3 Suppl 4, 2007
Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:10, 2007
Reduced thalamic volume in patients with chronic schizophrenia after switching from typical antipsychotic medications to olanzapine.The American journal of psychiatry, , Volume: 163, Issue:11, 2006
Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia.International clinical psychopharmacology, , Volume: 19, Issue:4, 2004
Reversible neutropenia during treatment with olanzapine: three case reports.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:4, 2004
Psychosis in a Patient with Davidoff-Dyke-Masson Syndrome.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:1
Olanzapine-induced Priapism in a Child with Asperger's Syndrome.Balkan medical journal, , Volume: 34, Issue:1, 2017
Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:6, 2013
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.Boletin de la Asociacion Medica de Puerto Rico, , Volume: 105, Issue:3, 2013
Atomoxetine-induced vocal tics in a patient with schizophrenia.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
[Antipsychotic agents and stimulants: a judicious combination?].Tijdschrift voor psychiatrie, , Volume: 52, Issue:1, 2010
Attention deficit hyperactivity disorder erroneously diagnosed and treated as bipolar disorder.Journal of attention disorders, , Volume: 13, Issue:2, 2009
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:5, 2008
The use of two neuroleptics to treat bipolar illness in two children.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
The impact of the Food and Drug Administration Modernization Act on the recruitment of children for research.Ethical human sciences and services : an international journal of critical inquiry, ,Summer, Volume: 5, Issue:2, 2003
An open-label study of the treatment efficacy of olanzapine for Tourette's disorder.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Mood stabilizer augmentation with olanzapine in acutely manic children.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 10, Issue:1, 2000
Open-label olanzapine treatment in five preadolescent children.Journal of child and adolescent psychopharmacology, , Volume: 8, Issue:2, 1998
The antipsychotic olanzapine reduces memory deficits and neuronal abnormalities in a male rat model of Autism.Journal of chemical neuroanatomy, , Volume: 132, 2023
Second-generation antipsychotic and diabetes mellitus in children and adolescents.La Pediatria medica e chirurgica : Medical and surgical pediatrics, , Dec-13, Volume: 39, Issue:4, 2017
Severe ischemic colitis following olanzapine use - A case report.Revista espanola de enfermedades digestivas, , Volume: 108, Issue:9, 2016
Olanzapine-induced hyponatremia in a patient with autism.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:10, 2013
Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.BMC psychiatry, , Oct-04, Volume: 13, 2013
Rhabdomyolysis associated with olanzapine treatment in a child with Autism.Pediatric emergency care, , Volume: 26, Issue:1, 2010
Excessive masturbation associated with olanzapine in a pediatric case.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 34, Issue:7, 2010
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait.Medical principles and practice : international journal of the Kuwait University, Health Science Centre, , Volume: 17, Issue:5, 2008
Risperidone-induced enuresis in two children with autistic disorder.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:4, 2007
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:5, 2006
Open-label study of olanzapine in children with pervasive developmental disorder.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Mirtazapine for excessive masturbation in an adolescent with autism.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 40, Issue:8, 2001
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 40, Issue:8, 2001
[Neuroleptic malignant syndrome after treatment with olanzapine].Ugeskrift for laeger, , Mar-08, Volume: 161, Issue:10, 1999
Olanzapine for autistic disorder with hyperactivity.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 37, Issue:9, 1998
Treatment of catatonia with olanzapine and amantadine.Psychosomatics, , Volume: 48, Issue:6
Olanzapine-Associated Pisa Syndrome in an Autistic Adolescent.Clinical neuropharmacology, , Volume: 43, Issue:2
Recurrent Catatonia: Infection and Immunity in an Idiopathic Illness.Journal of psychiatric practice, , 01-01, Volume: 29, Issue:1, 2023
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 129, Issue:11, 2022
Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: a retrospective study.BMC psychiatry, , 08-22, Volume: 22, Issue:1, 2022
Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.Pharmacology research & perspectives, , Volume: 9, Issue:5, 2021
Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
30-year journey from the start of the Human Genome Project to clinical application of genomics in psychiatry: are we there yet?The lancet. Psychiatry, , Volume: 7, Issue:1, 2020
Serotonin 2A (5-HTScientific reports, , 12-10, Volume: 10, Issue:1, 2020
Association of First- vs. Second-Generation Antipsychotics with Lipid Abnormalities in Individuals with Severe Mental Illness: A Systematic Review and Meta-Analysis.Clinical drug investigation, , Volume: 39, Issue:3, 2019
Basal Ganglia Calcification: A Case Report of Fahr Disease With Pure Psychiatric Symptoms.Journal of psychiatric practice, , Volume: 25, Issue:5, 2019
The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors.International clinical psychopharmacology, , Volume: 34, Issue:1, 2019
Medication and physical activity and physical fitness in severe mental illness.Psychiatry research, , Volume: 267, 2018
A prospective naturalistic multicenter study on choice of parenteral medication in psychiatric emergency settings in Japan.Neuropsychopharmacology reports, , Volume: 38, Issue:3, 2018
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations: An Observational Study Including 8,288 Patients.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.The Cochrane database of systematic reviews, , Jan-22, Volume: 1, 2018
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 49, 2018
Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial.Medicine, , Volume: 97, Issue:8, 2018
Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.JAMA psychiatry, , 08-01, Volume: 75, Issue:8, 2018
Does early antipsychotic response predict long-term treatment outcome?Human psychopharmacology, , Volume: 32, Issue:6, 2017
Hikikomori in Brazil: 29 years of Voluntary social Withdrawal.Asian journal of psychiatry, , Volume: 30, 2017
[Cushing's disease in a psychiatric setting].L'Encephale, , Volume: 43, Issue:5, 2017
Effects of olanzapine on LPS-induced inflammation in rat primary glia cells.Innate immunity, , Volume: 22, Issue:1, 2016
A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 12, Issue:1, 2015
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 54, Issue:9, 2015
Anti-N-methyl-D-aspartate receptor encephalitis is an important differential diagnosis in acute psychiatric disease.Acta psychiatrica Scandinavica, , Volume: 131, Issue:1, 2015
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
Antipsychotic use in pregnancy.Expert opinion on pharmacotherapy, , Volume: 16, Issue:9, 2015
Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 53, Issue:11, 2014
Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects.Journal of biomedical nanotechnology, , Volume: 10, Issue:6, 2014
The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications.Journal of psychosocial nursing and mental health services, , Volume: 52, Issue:7, 2014
The risk of metabolic disorders in patients treated with asenapine or olanzapine: a study conducted on real-world data in Italy and Spain.Expert opinion on drug safety, , Volume: 13, Issue:9, 2014
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.Diabetes, , Volume: 62, Issue:9, 2013
Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients.The pharmacogenomics journal, , Volume: 13, Issue:6, 2013
Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine.Molecular diagnosis & therapy, , Apr-01, Volume: 16, Issue:2, 2012
Olanzapine-induced neutropenia in a patient with systemiclupus erythematosus: a role of FcγRIIIb polymorphism?Lupus, , Volume: 21, Issue:1, 2012
Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study.International journal of psychiatry in clinical practice, , Volume: 16, Issue:1, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.The Journal of clinical psychiatry, , Volume: 73, Issue:8, 2012
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.European child & adolescent psychiatry, , Volume: 20, Issue:11-12, 2011
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.Psychiatry research, , May-15, Volume: 187, Issue:1-2, 2011
The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela.Schizophrenia research, , Volume: 126, Issue:1-3, 2011
Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics.Clinical nutrition (Edinburgh, Scotland), , Volume: 30, Issue:5, 2011
Arsenic trioxide and olanzapine co-administration: case analysis.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, , Volume: 17, Issue:3, 2011
The use of Pro Re Nata or Statim medications for behavioral control: a summary of experience at a tertiary care children's mental health center.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:1, 2011
Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.Psychiatric services (Washington, D.C.), , Volume: 61, Issue:2, 2010
Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.Clinical therapeutics, , Volume: 32 Suppl 1, 2010
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.Bipolar disorders, , Volume: 12, Issue:2, 2010
[Huntington's disease: a negative family history case report demonstrating reduction of psychiatric symptoms with olanzapine].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 31, Issue:2, 2009
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.The American journal of psychiatry, , Volume: 166, Issue:5, 2009
Comparison of predictive equations for resting metabolic rate in obese psychiatric patients taking olanzapine.Nutrition (Burbank, Los Angeles County, Calif.), , Volume: 25, Issue:2, 2009
Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials.Psychopharmacology bulletin, , Volume: 42, Issue:4, 2009
An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 54, Issue:4, 2009
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents.Progress in neuro-psychopharmacology & biological psychiatry, , Nov-13, Volume: 33, Issue:8, 2009
Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.Journal of intellectual & developmental disability, , Volume: 34, Issue:3, 2009
The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.Pharmacoepidemiology and drug safety, , Volume: 18, Issue:9, 2009
Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?Expert review of neurotherapeutics, , Volume: 9, Issue:7, 2009
Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:5, 2009
Priapism associated with olanzapine.Pakistan journal of biological sciences : PJBS, , Jan-15, Volume: 12, Issue:2, 2009
A naturalistic study of consecutive agitated emergency department patients treated with intramuscular olanzapine prior to consent.The American journal of psychiatry, , Volume: 165, Issue:4, 2008
Critical thinking about adverse drug effects: lessons from the psychology of risk and medical decision-making for clinical psychopharmacology.Psychotherapy and psychosomatics, , Volume: 77, Issue:4, 2008
Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study.The British journal of psychiatry : the journal of mental science, , Volume: 192, Issue:5, 2008
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.Pharmacy world & science : PWS, , Volume: 30, Issue:1, 2008
Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:5, 2008
Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-12, Volume: 32, Issue:8, 2008
Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait.Medical principles and practice : international journal of the Kuwait University, Health Science Centre, , Volume: 17, Issue:5, 2008
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.Clinical drug investigation, , Volume: 28, Issue:9, 2008
A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine.Pharmacopsychiatry, , Volume: 41, Issue:1, 2008
Three cases of schizophrenia for which olanzapine was effective after early acute phase.Psychiatry and clinical neurosciences, , Volume: 62, Issue:1, 2008
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.Molecular psychiatry, , Volume: 12, Issue:5, 2007
[Efficacy of atypical antipsychotics in patients with Alzheimer's dementia. CATIE-AD-Study (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer's Disease)].Der Internist, , Volume: 48, Issue:6, 2007
Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 114, Issue:2, 2007
Effectiveness of olanzapine in neurosyphilis related organic psychosis: a case report.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:5, 2007
The use of atypical antipsychotics in French psychiatric hospitals.Pharmacy world & science : PWS, , Volume: 29, Issue:5, 2007
Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia.Psychotherapy and psychosomatics, , Volume: 76, Issue:4, 2007
Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine.BMJ (Clinical research ed.), , Oct-27, Volume: 335, Issue:7625, 2007
Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances.Journal of geriatric psychiatry and neurology, , Volume: 20, Issue:2, 2007
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Observed clinical and health services outcomes in pediatric inpatients treated with atypical antipsychotics: 1999-2003.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:3, 2007
Metabolic effects of the atypical antipsychotics.Southern medical journal, , Volume: 100, Issue:8, 2007
[Application of neuroleptics for dementia].Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, , Volume: 44, Issue:1, 2007
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.The Cochrane database of systematic reviews, , Jan-25, Issue:1, 2006
Real-life switching strategies with second-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.The New England journal of medicine, , Oct-12, Volume: 355, Issue:15, 2006
[Psychopharmacological treatment of behavioral and psychological symptoms in dementia].Ugeskrift for laeger, , Oct-02, Volume: 168, Issue:40, 2006
Olanzapine for recurrent excessive irritability and psychotic symptoms after mesial temporal lobectomy in a patient with temporal lobe epilepsy.Epilepsy & behavior : E&B, , Volume: 9, Issue:3, 2006
Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions.The New Zealand medical journal, , Jul-07, Volume: 119, Issue:1237, 2006
A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects.Clinical therapeutics, , Volume: 28, Issue:6, 2006
No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.Minerva medica, , Volume: 97, Issue:2, 2006
Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:3, 2006
The effect of long-term antipsychotic treatment on prolactin.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:3, 2006
Effects of age and sex on olanzapine plasma concentrations.Journal of clinical psychopharmacology, , Volume: 25, Issue:6, 2005
Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population.The Journal of nervous and mental disease, , Volume: 193, Issue:6, 2005
A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD). Favour.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Comparison of large versus smaller randomized trials for mental health-related interventions.The American journal of psychiatry, , Volume: 162, Issue:3, 2005
Atypical antipsychotics for nursing home patients: a retrospective chart review.Drugs & aging, , Volume: 22, Issue:3, 2005
Amantadine for weight gain associated with olanzapine treatment.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 15, Issue:1, 2005
Memory-sparing cognitive deterioration in the elderly: what is the diagnosis?Reviews in neurological diseases, ,Spring, Volume: 2, Issue:2, 2005
Antipsychotic use in the elderly: shifting trends and increasing costs.International journal of geriatric psychiatry, , Volume: 20, Issue:8, 2005
Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
Rates and predictors of adherence with atypical antipsychotic medication: a follow-up study of adolescent inpatients.Journal of child and adolescent psychopharmacology, , Volume: 15, Issue:6, 2005
Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
The management of psychogeriatric patient.Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
Weight decline in patients switching from olanzapine to quetiapine.Schizophrenia research, , Sep-01, Volume: 70, Issue:1, 2004
Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate.Clinical therapeutics, , Volume: 26, Issue:6, 2004
Efficacy of atypical antipsychotics in elderly patients with dementia.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:8, 2004
Orally disintegrating olanzapine: a possible alternative to injection of antipsychotic drugs.Journal of psychosocial nursing and mental health services, , Volume: 42, Issue:5, 2004
A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:8, 2004
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.Postgraduate medicine, , Volume: 116, Issue:4, 2004
Neuroleptic malignant syndrome and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
[The value of publishing negative results from a randomized controlled trial: the Rosenheck's study].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 26, Issue:2, 2004
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.The Journal of clinical psychiatry, , Volume: 65 Suppl 6, 2004
Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.Journal of the National Medical Association, , Volume: 95, Issue:2, 2003
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
[Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects)].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
[Brain tumor].Ryoikibetsu shokogun shirizu, , Issue:40, 2003
Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.The Annals of pharmacotherapy, , Volume: 37, Issue:9, 2003
A review of olanzapine-associated toxicity and fatality in overdose.Journal of psychiatry & neuroscience : JPN, , Volume: 28, Issue:4, 2003
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.Southern medical journal, , Volume: 96, Issue:7, 2003
Use of atypical antipsychotic drugs in patients with dementia.American family physician, , Jun-01, Volume: 67, Issue:11, 2003
Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.Managed care interface, , Volume: 16, Issue:5, 2003
Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication.Therapeutic drug monitoring, , Volume: 25, Issue:1, 2003
Uses of olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:3, 2002
The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:3, 2002
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 41, Issue:3, 2002
Hyperinsulinemia in psychiatric patients treated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:1, 2002
Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy.Pharmacotherapy, , Volume: 21, Issue:11, 2001
Hyperglycemia and hypertriglyceridemia secondary to olanzapine.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 11, Issue:3, 2001
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
Six-month outcomes for patients who switched to olanzapine treatment.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:4, 2001
Bodyweight gain with atypical antipsychotics. A comparative review.Drug safety, , Volume: 24, Issue:1, 2001
Possible neuroleptic malignant syndrome associated with olanzapine.The Annals of pharmacotherapy, , Volume: 34, Issue:5, 2000
Body weight and leptin plasma levels during treatment with antipsychotic drugs.The American journal of psychiatry, , Volume: 156, Issue:2, 1999
Olanzapine-induced neuroleptic malignant syndrome with mental retardation.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
Conventional psychotropic-induced tremor extinguished by olanzapine.The American journal of psychiatry, , Volume: 155, Issue:8, 1998
Open-label olanzapine treatment in five preadolescent children.Journal of child and adolescent psychopharmacology, , Volume: 8, Issue:2, 1998
Use of atypical neuroleptics in child and adolescent psychiatry.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Psychiatry.JAMA, , Jun-18, Volume: 277, Issue:23, 1997
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
The dosing of atypical antipsychotics.Psychosomatics, , Volume: 46, Issue:3
Psychiatric manifestations of anti-NMDA receptor encephalitis in a man without tumor.Psychosomatics, , Volume: 52, Issue:1
Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine.Nutrition (Burbank, Los Angeles County, Calif.), , Volume: 25, Issue:7-8
Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy.American journal of therapeutics, , Volume: 10, Issue:5
Antipsychotic medications and extreme weight gain in two health systems.Obesity research & clinical practice, , Volume: 10, Issue:4
Acute Necrotizing Pancreatitis Associated With Orally Disintegrating Formulation of Olanzapine: Implications on Clinical Presentation and Management.Journal of clinical psychopharmacology, , Volume: 39, Issue:5
Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.American journal of Alzheimer's disease and other dementias, , Volume: 18, Issue:4
Psychotic syndrome secondary to meningioma treated with a low dose of olanzapine.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 37, Issue:2
Clinical News.Clinical schizophrenia & related psychoses, , Volume: 11, Issue:1
Spontaneous Ejaculations in an Adolescent With Olanzapine Use: Case Report.Clinical neuropharmacology, , Volume: 39, Issue:3
Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.Psychosomatics, , Volume: 47, Issue:1
[Latin America: clinical responses to the antipsychotic drugs].Vertex (Buenos Aires, Argentina), , Volume: 16, Issue:62
New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment.Psychosomatics, , Volume: 40, Issue:5
Hypersensitivity syndrome with olanzapine confirmed by patch tests.European journal of dermatology : EJD, , Volume: 22, Issue:1
Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.Journal of the American Medical Directors Association, , Volume: 4, Issue:4
Magnitude of metabolic syndrome and its predictors among patients on second-generation antipsychotic drugs at six psychiatry clinics and mental hospitals, in Addis Ababa, Ethiopia, 2019; Multicenter cross-sectional study.Diabetes & metabolic syndrome, , Volume: 15, Issue:4
Mortality in patients with dementia treated with atypical antipsychotics (olanzapine, quetiapine and ziprasidone).Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, , Volume: 33, Issue:4
Effectiveness of atypical antipsychotics for unipolar and bipolar depression in adolescents and young adults: A systematic review and meta-analysis.Journal of affective disorders, , 10-15, Volume: 339, 2023
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.The lancet. Psychiatry, , Volume: 10, Issue:9, 2023
Continuation of depot olanzapine pamoate after post-injection delirium/sedation syndrome (PDSS) in a case of bipolar mania-a clinical conundrum.Bipolar disorders, , Volume: 25, Issue:2, 2023
The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials.Molecular psychiatry, , Volume: 28, Issue:1, 2023
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.BMJ mental health, , Volume: 26, Issue:1, 2023
Personality disorder among youth with first episode psychotic mania: An important target for specific treatment?Early intervention in psychiatry, , Volume: 16, Issue:3, 2022
Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.Die Pharmazie, , 09-01, Volume: 77, Issue:7, 2022
Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.Expert review of clinical pharmacology, , Volume: 15, Issue:9, 2022
Proportion of subjects with psychotic features in bipolar disorder correlated with treatment response by antipsychotics for acute mania.Psychiatry and clinical neurosciences, , Volume: 76, Issue:11, 2022
Manic syndrome in mitochondrial membrane protein-associated neurodegeneration: A case report.Psychiatry and clinical neurosciences, , Volume: 76, Issue:10, 2022
A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder.Acta psychiatrica Scandinavica, , Volume: 146, Issue:4, 2022
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.CNS drugs, , Volume: 36, Issue:6, 2022
Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review.Journal of affective disorders, , 08-15, Volume: 311, 2022
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:5, 2022
Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?Expert review of neurotherapeutics, , Volume: 22, Issue:5, 2022
Serum levels of olanzapine are associated with acute cognitive effects in bipolar disorder.Psychiatry research, , Volume: 310, 2022
[Acute cholestatic hepatitis associated with olanzapine in a patient with bipolar disorder].Revue medicale de Liege, , Volume: 77, Issue:2, 2022
Olanzapine for the Treatment of Somatic Symptom Disorder: Biobehavioral Processes and Clinical Implications.Psychosomatic medicine, , 04-01, Volume: 84, Issue:3, 2022
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.The Annals of pharmacotherapy, , Volume: 56, Issue:9, 2022
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.Molecular psychiatry, , Volume: 27, Issue:2, 2022
Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 54, 2022
Olanzapine/Samidorphan: First Approval.Drugs, , Volume: 81, Issue:12, 2021
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.The international journal of neuropsychopharmacology, , 10-23, Volume: 24, Issue:10, 2021
Bipolar Disorder and Outcomes of Monotherapy with Lithium, Valproate, Quetiapine, Olanzapine, Venlafaxine, and Citalopram.Pharmacopsychiatry, , Volume: 54, Issue:3, 2021
Slowly Working Toward More Treatments for Depression in Bipolar II Disorder.The American journal of psychiatry, , Volume: 178, Issue:12, 2021
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations.Bipolar disorders, , Volume: 23, Issue:8, 2021
Lurasidone-Induced Manic Switch in an Adolescent with Bipolar I Disorder: a Case Report.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 31, Issue:3, 2021
Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis.Journal of affective disorders, , 05-15, Volume: 269, 2020
The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.Expert opinion on investigational drugs, , Volume: 29, Issue:3, 2020
Pica disorder as a symptom of depression in a patient with bipolar disorder and intellectual disability.Actas espanolas de psiquiatria, , Volume: 48, Issue:1, 2020
Prolactin response to antipsychotics: An inpatient study.PloS one, , Volume: 15, Issue:2, 2020
Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics?Journal of affective disorders, , 01-15, Volume: 261, 2020
How to treat mania.Acta psychiatrica Scandinavica, , Volume: 142, Issue:3, 2020
[no title available]Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 65, Issue:4, 2020
Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan.Neuropsychopharmacology reports, , Volume: 40, Issue:4, 2020
Exertional Heatstroke in a Marathon Runner Complicated by Concurrent Use of an Antipsychotic Medication Affecting Thermoregulation.Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, , Volume: 30, Issue:5, 2020
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.Journal of affective disorders, , 12-01, Volume: 277, 2020
Second Generation Antipsychotics Monotherapy as Maintenance Treatment for Bipolar Disorder: a Systematic Review of Long-Term Studies.The Psychiatric quarterly, , Volume: 91, Issue:4, 2020
Pharmacological prevention of mood episodes in women with bipolar disorder during the perinatal period: A systematic review of current literature.Asian journal of psychiatry, , Volume: 52, 2020
Predictors of 1-year rehospitalization in inpatients with bipolar I disorder treated with atypical antipsychotics.International clinical psychopharmacology, , Volume: 35, Issue:5, 2020
[Mirtazapine-Induced Mania: A Case Report].Acta medica portuguesa, , Oct-01, Volume: 32, Issue:10, 2019
The unmasking of hidden severe hyponatremia after long-term combination therapy in exacerbated bipolar patients: a case series.International clinical psychopharmacology, , Volume: 34, Issue:4, 2019
Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder.Bipolar disorders, , Volume: 21, Issue:2, 2019
Erotomania in Depressive Psychosis: Mood Incongruent Delusion in a Depressive Young Woman.Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, , Volume: 29, Issue:6, 2019
Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis.Neuropsychopharmacology reports, , Volume: 39, Issue:3, 2019
Generalised tonic-clonic seizures on the subtherapeutic dose of olanzapine.BMJ case reports, , Dec-29, Volume: 12, Issue:12, 2019
Lurasidone-Induced Mania.The primary care companion for CNS disorders, , Jul-11, Volume: 21, Issue:4, 2019
Evaluation of antioxidant potencial of novel CaAl and NiAl layered double hydroxides loaded with olanzapine.Life sciences, , Aug-15, Volume: 207, 2018
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
A Review of Asenapine in the Treatment of Bipolar Disorder.Clinical drug investigation, , Volume: 38, Issue:2, 2018
Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines.Acta psychiatrica Scandinavica, , Volume: 138, Issue:3, 2018
Tailoring treatment dose according to severity of manic symptoms.Bipolar disorders, , Volume: 20, Issue:2, 2018
Severity of symptoms in mania-clinical guidelines and study design implications.Bipolar disorders, , Volume: 20, Issue:2, 2018
Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 48, 2018
Paradoxical worsening of parkinsonism upon neuroleptic withdrawal: More common than we think?Parkinsonism & related disorders, , Volume: 52, 2018
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.Bipolar disorders, , Volume: 20, Issue:2, 2018
Secondary mania following cancer chemotherapy with capecitabine.BMJ case reports, , Mar-28, Volume: 2018, 2018
Patient Survival After Acute Voluntary Poisoning With a Huge Dose of Oxcarbazepine and Olanzapine.Medical archives (Sarajevo, Bosnia and Herzegovina), , Volume: 72, Issue:4, 2018
Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations.Journal of affective disorders, , 08-01, Volume: 217, 2017
Do not treat the numbers: lithium toxicity.BMJ case reports, , Jun-02, Volume: 2017, 2017
Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.Journal of child and adolescent psychopharmacology, , Volume: 27, Issue:5, 2017
Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder?Expert review of neurotherapeutics, , Volume: 17, Issue:4, 2017
Have antipsychotics a different speed of action in the acute treatment of mania? A single-blind comparative study.Journal of psychopharmacology (Oxford, England), , Volume: 31, Issue:12, 2017
Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Journal of clinical psychopharmacology, , Volume: 37, Issue:2, 2017
Chlorpheniramine dependence presenting as mania.Asian journal of psychiatry, , Volume: 30, 2017
Olanzapine induced neuroleptic malignant syndrome, treated with electroconvulsive therapy (ECT)-A case report.Asian journal of psychiatry, , Volume: 30, 2017
Treatment response in nonpsychotic vs psychotic manias - A follow up study from India.Asian journal of psychiatry, , Volume: 26, 2017
DRESS syndrome: Addressing the drug hypersensitivity syndrome on combination of Sodium Valproate and Olanzapine.Asian journal of psychiatry, , Volume: 28, 2017
Individualising therapy using individual participant data.The lancet. Psychiatry, , Volume: 4, Issue:11, 2017
Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies.The lancet. Psychiatry, , Volume: 4, Issue:11, 2017
Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.Drugs & aging, , Volume: 34, Issue:3, 2017
Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy.BMJ case reports, , Dec-02, Volume: 2017, 2017
Prophylactic use of olanzapine and quetiapine from pregnancy to the postpartum period in women with bipolar disorder: a case series.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, , Volume: 30, Issue:21, 2017
Pharmacological agents to reduce readmissions in bipolar disorder.Journal of psychopharmacology (Oxford, England), , Volume: 31, Issue:3, 2017
The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine.Psychiatry research, , Jul-30, Volume: 241, 2016
Atypical antipsychotic use and outcomes in an urban maternal mental health service.International journal of psychiatry in medicine, , Volume: 51, Issue:6, 2016
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.Molecular psychiatry, , Volume: 21, Issue:8, 2016
Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis.PloS one, , Volume: 11, Issue:3, 2016
Use of Orally Disintegrating Olanzapine During Electroconvulsive Therapy for Prevention of Postictal Agitation.Journal of psychiatric practice, , Volume: 22, Issue:6, 2016
Asenapine: A Review in Schizophrenia.CNS drugs, , Volume: 30, Issue:7, 2016
Changes in mood stabilizer prescription patterns in bipolar disorder.Journal of affective disorders, , Volume: 195, 2016
Treatment of comorbid bipolar disorder and anxiety disorders: A great challenge to modern psychiatry.The Australian and New Zealand journal of psychiatry, , Volume: 50, Issue:7, 2016
Analysis of bipolar maintenance treatment with lithium versus olanzapine utilizing Multi-state Outcome Analysis of Treatments (MOAT).Bipolar disorders, , Volume: 18, Issue:3, 2016
Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study.JAMA psychiatry, , 06-01, Volume: 73, Issue:6, 2016
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 30, Issue:8, 2015
Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study.BMC psychiatry, , Aug-05, Volume: 15, 2015
Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: common and specific effects of key regulators of fat-mass homoeostasis genes.Pharmacogenetics and genomics, , Volume: 25, Issue:7, 2015
Evaluation of the safety profile of Zolafren®, a generic olanzapine formulation, in patients with bipolar disorder: a post-authorization safety study.Advances in therapy, , Volume: 32, Issue:5, 2015
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients.Neuropsychobiology, , Volume: 72, Issue:1, 2015
Olanzapine and quetiapine use during breastfeeding: excretion into breast milk and safe breastfeeding strategy.Journal of clinical psychopharmacology, , Volume: 35, Issue:2, 2015
Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.Bipolar disorders, , Volume: 17, Issue:6, 2015
Case records of the Massachusetts General Hospital. Case 10-2015. A 15-year-old girl with Graves’ disease and psychotic symptoms.The New England journal of medicine, , Mar-26, Volume: 372, Issue:13, 2015
Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.The Journal of clinical psychiatry, , Volume: 76, Issue:6, 2015
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar disorders, , Volume: 17, Issue:5, 2015
Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.The Journal of clinical psychiatry, , Volume: 75, Issue:3, 2014
Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study.Psychopharmacology, , Volume: 231, Issue:14, 2014
Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada.BMC psychiatry, , Jan-22, Volume: 14, 2014
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.Acta psychiatrica Scandinavica, , Volume: 130, Issue:6, 2014
Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysis.Psychiatry and clinical neurosciences, , Volume: 68, Issue:7, 2014
Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring.The Journal of pharmacy and pharmacology, , Volume: 66, Issue:6, 2014
Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial.Acta medica Iranica, , Volume: 52, Issue:10, 2014
Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 26, Issue:3, 2014
Acute and maintenance treatments for bipolar depression.The Journal of clinical psychiatry, , Volume: 75, Issue:4, 2014
Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011.Journal of affective disorders, , Volume: 155, 2014
Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features.Journal of affective disorders, , Volume: 164, 2014
Comparison of health services use associated with ziprasidone and olanzapine among schizophrenia and bipolar disorder patients in the USA.Clinical drug investigation, , Volume: 34, Issue:7, 2014
Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study.BMC psychiatry, , May-19, Volume: 14, 2014
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
The impact of past direct-personal traumatic events on 12-month outcome in first episode psychotic mania: trauma and early psychotic mania.The Australian and New Zealand journal of psychiatry, , Volume: 48, Issue:11, 2014
The impact of insight in a first-episode mania with psychosis population on outcome at 18 months.Journal of affective disorders, , Volume: 167, 2014
Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context.Advances in therapy, , Volume: 31, Issue:8, 2014
Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5.Journal of affective disorders, , Volume: 168, 2014
Sleep architecture and cognitive changes in olanzapine-treated patients with depression: a double blind randomized placebo controlled trial.BMC psychiatry, , Jul-17, Volume: 14, 2014
Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.Journal of affective disorders, , Volume: 166, 2014
Restless legs syndrome associated with the combined use of quetiapine and venlafaxine.Journal of clinical psychopharmacology, , Volume: 34, Issue:1, 2014
Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.Journal of medical economics, , Volume: 17, Issue:7, 2014
SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.Pharmacogenomics, , Volume: 15, Issue:12, 2014
An update on the treatment of mixed bipolar states: what is new in 2013?Journal of affective disorders, , Volume: 158, 2014
Bipolar disorder in Pendred syndrome: a case report of two siblings.The Australian and New Zealand journal of psychiatry, , Volume: 48, Issue:9, 2014
Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review.Journal of affective disorders, , Volume: 152-154, 2014
No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients.Pharmacogenetics and genomics, , Volume: 24, Issue:5, 2014
Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program.Journal of affective disorders, , Sep-25, Volume: 150, Issue:3, 2013
Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies.Journal of affective disorders, , Volume: 149, Issue:1-3, 2013
Inhibition/activation in bipolar disorder: validation of the Multidimensional Assessment of Thymic States scale (MAThyS).BMC psychiatry, , Mar-13, Volume: 13, 2013
The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.Clinical drug investigation, , Volume: 33, Issue:10, 2013
Use of electroconvulsive therapy in an adolescent with systemic lupus erythematosus for management of depression.The journal of ECT, , Volume: 29, Issue:3, 2013
Could pramipexole induce acute mania? A case report.Bipolar disorders, , Volume: 15, Issue:4, 2013
A case of atypical antipsychotic-induced somnambulism: a class effect.The Journal of clinical psychiatry, , Volume: 74, Issue:4, 2013
Olanzapine long-acting injection: When and for how long is oral supplementation required?The Australian and New Zealand journal of psychiatry, , Volume: 47, Issue:12, 2013
Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.BMC psychiatry, , May-14, Volume: 13, 2013
[Olanzapine].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 71, Issue:4, 2013
DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.Journal of affective disorders, , Sep-05, Volume: 150, Issue:2, 2013
Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study.BMC psychiatry, , Jul-17, Volume: 13, 2013
Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression.Expert opinion on drug metabolism & toxicology, , Volume: 9, Issue:2, 2013
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.Current medical research and opinion, , Volume: 29, Issue:3, 2013
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.The Cochrane database of systematic reviews, , Oct-17, Issue:10, 2013
Safety of olanzapine use in adolescents.Expert opinion on drug safety, , Volume: 12, Issue:5, 2013
Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study.The Journal of clinical psychiatry, , Volume: 74, Issue:1, 2013
Effectiveness of short-term olanzapine in patients with bipolar I disorder, with or without comorbidity with substance use disorder.Journal of clinical psychopharmacology, , Volume: 33, Issue:2, 2013
Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.BMC psychiatry, , Oct-04, Volume: 13, 2013
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.Journal of affective disorders, , Jan-25, Volume: 144, Issue:3, 2013
Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice.BMC psychiatry, , Dec-17, Volume: 12, 2012
Olanzapine and benztropine as a cause of ischemic colitis in a 27-year-old man.Journal of clinical gastroenterology, , Volume: 46, Issue:6, 2012
Predictors of relapse or recurrence in bipolar I disorder.Journal of affective disorders, , Volume: 136, Issue:3, 2012
Olanzapine-induced anaphylactic shock: a case report.Pharmacopsychiatry, , Volume: 45, Issue:1, 2012
Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study.Journal of affective disorders, , Volume: 136, Issue:3, 2012
Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009.Psychiatric services (Washington, D.C.), , Volume: 63, Issue:1, 2012
Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.Current medical research and opinion, , Volume: 28, Issue:5, 2012
A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.Journal of clinical psychopharmacology, , Volume: 32, Issue:2, 2012
A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode.Journal of affective disorders, , Volume: 138, Issue:3, 2012
Mortality risk with the use of atypical antipsychotics in later-life bipolar disorder.Journal of geriatric psychiatry and neurology, , Volume: 25, Issue:1, 2012
Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study.Human psychopharmacology, , Volume: 27, Issue:3, 2012
Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine.Comprehensive psychiatry, , Volume: 53, Issue:7, 2012
Pilot study of the efficacy of double-blind, placebo-controlled one-week olanzapine stabilization therapy in heterogeneous symptomatic bipolar disorder patients.Journal of psychiatric research, , Volume: 46, Issue:7, 2012
Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.PharmacoEconomics, , Jun-01, Volume: 30, Issue:6, 2012
Age-grouped differences in bipolar mania.Comprehensive psychiatry, , Volume: 53, Issue:8, 2012
UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.Clinical pharmacology and therapeutics, , Volume: 92, Issue:2, 2012
[Asenapine in bipolar disorder: efficacy, safety and place in clinical practice].L'Encephale, , Volume: 38, Issue:3, 2012
Subtypes of antipsychotics and suicidal behavior in bipolar disorder.Journal of affective disorders, , Dec-20, Volume: 143, Issue:1-3, 2012
Variables as mediators or moderators in predicting relapse to any type of mood episode in a bipolar maintenance study.The Journal of clinical psychiatry, , Volume: 73, Issue:7, 2012
Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.The British journal of psychiatry : the journal of mental science, , Volume: 201, Issue:5, 2012
[Mania associated with Usher syndrome type II].Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Fall, Volume: 23, Issue:3, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.The Journal of clinical psychiatry, , Volume: 73, Issue:8, 2012
Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration.BMC medical genetics, , Oct-02, Volume: 13, 2012
Repeated activation of mania by atypical antipsychotics in a patient.BMJ case reports, , Nov-27, Volume: 2012, 2012
Olanzapine-associated priapism.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
The need to consider mood disorders, and especially chronic mania, in cases of Diogenes syndrome (squalor syndrome).International psychogeriatrics, , Volume: 23, Issue:3, 2011
Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes.Journal of psychiatric research, , Volume: 45, Issue:2, 2011
Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania--a systematic review and meta-analysis.Journal of affective disorders, , Volume: 134, Issue:1-3, 2011
Relationship between African-American or Caucasian origin and outcomes in the olanzapine treatment of acute mania: a pooled analysis of three adult studies conducted in the United States of America.International clinical psychopharmacology, , Volume: 26, Issue:3, 2011
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.Acta psychiatrica Scandinavica, , Volume: 124, Issue:3, 2011
Delirium associated with olanzapine therapy in an elderly man with bipolar affective disorder.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 23, Issue:2, 2011
Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials.BMC psychiatry, , Jun-20, Volume: 11, 2011
Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.Pharmacogenetics and genomics, , Volume: 21, Issue:9, 2011
Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania--results of a two year observational study in bipolar disorder (EMBLEM).Journal of affective disorders, , Volume: 131, Issue:1-3, 2011
Clinical practice. Bipolar disorder--a focus on depression.The New England journal of medicine, , Jan-06, Volume: 364, Issue:1, 2011
One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis.BMC psychiatry, , Jan-07, Volume: 11, 2011
Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.Psychiatry research, , Sep-30, Volume: 189, Issue:2, 2011
Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 23, Issue:3, 2011
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.British journal of clinical pharmacology, , Volume: 71, Issue:3, 2011
Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.The Journal of clinical psychiatry, , Volume: 72, Issue:6, 2011
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.Pharmacotherapy, , Volume: 31, Issue:8, 2011
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.European child & adolescent psychiatry, , Volume: 20, Issue:11-12, 2011
Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention.Bipolar disorders, , Volume: 13, Issue:1, 2011
Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.CNS drugs, , Volume: 25, Issue:3, 2011
[Mood disorder after malaria prophylaxis with mefloquine (two case reports)].L'Encephale, , Volume: 37, Issue:5, 2011
Olanzapine-induced parkinsonism associated with smoking cessation.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Mar-01, Volume: 68, Issue:5, 2011
Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study.Human psychopharmacology, , Volume: 26, Issue:8, 2011
Behavioral and pharmacological assessment of a potential new mouse model for mania.Physiology & behavior, , Jun-01, Volume: 103, Issue:3-4, 2011
[Evidence of treatment for depressive episodes of bipolar disorder].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 113, Issue:9, 2011
Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009.PloS one, , Volume: 6, Issue:12, 2011
[Second generation antipsychotics in bipolar depression: a new therapeutic option?].L'Encephale, , Volume: 37 Suppl 3, 2011
Olanzapine enhances anxiety response to an SSRI in a woman with bipolar disorder.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-15, Volume: 35, Issue:1, 2011
Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone.The Journal of clinical psychiatry, , Volume: 72, Issue:9, 2011
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.Journal of affective disorders, , Volume: 130, Issue:1-2, 2011
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clinical drug investigation, , Volume: 31, Issue:7, 2011
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.The Journal of clinical psychiatry, , Volume: 72, Issue:4, 2011
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 33, Issue:1, 2011
Regulation of glycogen synthase kinase-3 during bipolar mania treatment.Bipolar disorders, , Volume: 12, Issue:7, 2010
Olanzapine: a review of rapid and long-acting parenteral formulations.Drugs of today (Barcelona, Spain : 1998), , Volume: 46, Issue:3, 2010
Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:12, 2010
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).Journal of affective disorders, , Volume: 124, Issue:1-2, 2010
Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied.The Journal of clinical psychiatry, , Volume: 71, Issue:7, 2010
[Intensive care treatment for neuroleptic malignant syndrome].Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, , Volume: 45, Issue:7-8, 2010
Efficacy of olanzapine and sodium valproate given alone or as add-on therapy in acute mania. A comparative study.Methods and findings in experimental and clinical pharmacology, , Volume: 32, Issue:5, 2010
An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.International journal of clinical practice, , Volume: 64, Issue:11, 2010
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Maintenance treatment received by patients with bipolar I and II disorders--a naturalistic prospective study.Journal of affective disorders, , Volume: 121, Issue:1-2, 2010
Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression.The Journal of clinical psychiatry, , Volume: 71, Issue:5, 2010
Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial.Human psychopharmacology, , Volume: 25, Issue:1, 2010
[Quetiapine, an antipsychotic agent to consider in the differential diagnosis of convulsions].Revista espanola de anestesiologia y reanimacion, , Volume: 57, Issue:5, 2010
Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice.International clinical psychopharmacology, , Volume: 25, Issue:5, 2010
Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.Journal of affective disorders, , Volume: 126, Issue:3, 2010
Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.Journal of affective disorders, , Volume: 122, Issue:1-2, 2010
Acute pancreatitis associated with lisinopril and olanzapine.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Feb-01, Volume: 67, Issue:3, 2010
Olanzapine vs. lithium in management of acute mania.Journal of affective disorders, , Volume: 122, Issue:3, 2010
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:2, 2010
Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.The Journal of clinical psychiatry, , Volume: 71, Issue:4, 2010
Treatment options for bipolar depression: a systematic review of randomized, controlled trials.Journal of clinical psychopharmacology, , Volume: 30, Issue:5, 2010
Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.PharmacoEconomics, , Volume: 28, Issue:9, 2010
Manic and psychotic symptoms following subcutaneous leuprolide in a male patient with no prior psychiatric history.The Journal of clinical psychiatry, , Volume: 71, Issue:12, 2010
Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment.The Annals of pharmacotherapy, , Volume: 44, Issue:4, 2010
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.The international journal of neuropsychopharmacology, , Volume: 13, Issue:1, 2010
Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.Paediatric drugs, , Volume: 12, Issue:3, 2010
A Canadian naturalistic study of a community-based cohort treated for bipolar disorder.BMC psychiatry, , Mar-19, Volume: 10, 2010
Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.Psychopharmacology bulletin, , Volume: 43, Issue:4, 2010
Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:4, 2010
Cannabidiol was ineffective for manic episode of bipolar affective disorder.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Olanzapine: in adolescents with schizophrenia or bipolar I disorder.CNS drugs, , Volume: 24, Issue:5, 2010
Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder.Bipolar disorders, , Volume: 12, Issue:2, 2010
Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.Bipolar disorders, , Volume: 12, Issue:2, 2010
In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 25, Issue:8, 2010
Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.The Journal of clinical psychiatry, , Volume: 71, Issue:10, 2010
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.BMC psychiatry, , Mar-28, Volume: 9, 2009
Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder.Journal of affective disorders, , Volume: 116, Issue:1-2, 2009
Clarithromycin-induced mania in a child.International journal of clinical pharmacology and therapeutics, , Volume: 47, Issue:6, 2009
Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients.Journal of affective disorders, , Volume: 119, Issue:1-3, 2009
A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.Bipolar disorders, , Volume: 11, Issue:7, 2009
Delirious mania associated with bipolar disease in a Brazilian patient: response to ECT and olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 21, Issue:4, 2009
The role of divalproex plus olanzapine in outpatient mixed-episode bipolar I disorder.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
Refractory restless legs syndrome likely caused by olanzapine.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, , Feb-15, Volume: 5, Issue:1, 2009
Weight gain with atypical antipsychotic drugs in bipolar disorder.Journal of psychosocial nursing and mental health services, , Volume: 47, Issue:9, 2009
Neuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma.African journal of psychiatry, , Volume: 12, Issue:3, 2009
Treatment-resistant bipolar depression: towards a new definition.Acta psychiatrica Scandinavica, , Volume: 120, Issue:6, 2009
Revised Korean medication algorithm for bipolar disorder.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder.Journal of child and adolescent psychopharmacology, , Volume: 19, Issue:5, 2009
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse.JAMA, , Aug-26, Volume: 302, Issue:8, 2009
Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis.Clinical therapeutics, , Volume: 31 Pt 1, 2009
The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials.The Journal of clinical psychiatry, , Volume: 70, Issue:2, 2009
Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.Therapeutic drug monitoring, , Volume: 31, Issue:6, 2009
Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.Journal of medical economics, , Volume: 12, Issue:2, 2009
Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Attention deficit hyperactivity disorder erroneously diagnosed and treated as bipolar disorder.Journal of attention disorders, , Volume: 13, Issue:2, 2009
Asenapine versus olanzapine in acute mania: a double-blind extension study.Bipolar disorders, , Volume: 11, Issue:8, 2009
Neurotoxicity with therapeutic lithium levels: a case report.Journal of psychiatric practice, , Volume: 15, Issue:1, 2009
Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.International journal of clinical practice, , Volume: 63, Issue:8, 2009
Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
Plasma homovanillic acid and family history of psychotic disorders in bipolar I patients.Pharmacological research, , Volume: 59, Issue:4, 2009
Olanzapine in long-term treatment for bipolar disorder.The Cochrane database of systematic reviews, , Jan-21, Issue:1, 2009
Longer-term treatment of patients with bipolar disorder: a 9-month observational study in Central and Eastern Europe, the Middle East and Africa.Current medical research and opinion, , Volume: 25, Issue:8, 2009
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:1, 2009
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.The Journal of clinical psychiatry, , Volume: 70, Issue:10, 2009
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression.The international journal of neuropsychopharmacology, , Volume: 12, Issue:6, 2009
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:1, 2009
An analysis of the efficacy of treatments for bipolar depression.The Journal of clinical psychiatry, , Volume: 69 Suppl 5, 2008
Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study.Journal of affective disorders, , Volume: 106, Issue:1-2, 2008
Somnambulism secondary to olanzapine treatment in one patient with bipolar disorder.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder.Pharmacopsychiatry, , Volume: 41, Issue:5, 2008
Olanzapine-associated new-onset atrial fibrillation.Journal of clinical psychopharmacology, , Volume: 28, Issue:3, 2008
Evaluating dose response from flexible dose clinical trials.BMC psychiatry, , Jan-07, Volume: 8, 2008
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.The Journal of clinical psychiatry, , Volume: 69, Issue:11, 2008
Olanzapine for the treatment of bipolar disorder in children and adolescents.Expert opinion on pharmacotherapy, , Volume: 9, Issue:3, 2008
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.Journal of affective disorders, , Volume: 105, Issue:1-3, 2008
Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes.Schizophrenia research, , Volume: 100, Issue:1-3, 2008
Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes.The British journal of psychiatry : the journal of mental science, , Volume: 192, Issue:2, 2008
Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania.Journal of affective disorders, , Volume: 110, Issue:1-2, 2008
Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study.The Journal of clinical psychiatry, , Volume: 69, Issue:4, 2008
Hyperthermia and rhabdomyolysis in an adolescent treated with topiramate and olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:1, 2008
The Bipolar Comprehensive Outcomes Study (BCOS): baseline findings of an Australian cohort study.Journal of affective disorders, , Volume: 107, Issue:1-3, 2008
[Olanzapine].Deutsche medizinische Wochenschrift (1946), , Volume: 133, Issue:39, 2008
Photo-onycholysis caused by olanzapine and aripiprazole.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Olanzapine orally disintegrating tablet: a review of efficacy and compliance.CNS neuroscience & therapeutics, ,Fall, Volume: 14, Issue:3, 2008
Treating mania in Wilson's disease with lithium.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 20, Issue:4, 2008
Switching from other agents to extended-release carbamazepine in acute mania.Psychopharmacology bulletin, , Volume: 41, Issue:1, 2008
Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.Journal of affective disorders, , Volume: 105, Issue:1-3, 2008
[Use of olanzapine in adolescent with bipolar disorder after neuroleptic malignant syndrome].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:1, 2008
Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
The clinical dilemma--prescribing in pregnancy.Psychiatria Danubina, , Volume: 20, Issue:1, 2008
The empirical redefinition of the psychometric criteria for remission in bipolar disorder.Journal of affective disorders, , Volume: 106, Issue:1-2, 2008
A case of sodium oxybate treatment of tardive dyskinesia and bipolar disorder.The Journal of clinical psychiatry, , Volume: 69, Issue:5, 2008
Cost-saving effects of olanzapine as long-term treatment for bipolar disorder.The journal of mental health policy and economics, , Volume: 11, Issue:3, 2008
Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Jan-15, Volume: 17, Issue:2, 2007
[Vigency of lithium treatment].Medicina clinica, , Jan-13, Volume: 128, Issue:1, 2007
Atypical antipsychotics related metabolic syndrome in bipolar patients.Journal of affective disorders, , Volume: 98, Issue:3, 2007
A case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain.The Journal of clinical psychiatry, , Volume: 68, Issue:12, 2007
[Olanzapine: a second generation antipsychotic drug and an "atypical" mood stabilizer?].Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata, , Volume: 22, Issue:4, 2007
Acute phase results from STORM, a multicountry observational study of bipolar disorder treatment and outcomes.Psychiatria Danubina, , Volume: 19, Issue:4, 2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.The American journal of managed care, , Volume: 13, Issue:7 Suppl, 2007
Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.Human psychopharmacology, , Volume: 22, Issue:1, 2007
[Electroconvulsive therapy in therapy-resistant mania. A case study].Tijdschrift voor psychiatrie, , Volume: 49, Issue:11, 2007
Measured and expected resting energy expenditure in patients with bipolar disorder on maintenance treatment.Bipolar disorders, , Volume: 9, Issue:7, 2007
Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients.Therapeutic drug monitoring, , Volume: 29, Issue:6, 2007
Practical strategies for assessing and stabilizing bipolar patients in urgent situations.The Journal of clinical psychiatry, , Volume: 68, Issue:10, 2007
Orally disintegrating olanzapine for the treatment of a manic patient with esophageal stricture plus chronic pharyngitis.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 31, Issue:2, 2007
The effectiveness criterion: balancing efficacy against the risks of weight gain.The Journal of clinical psychiatry, , Volume: 68 Suppl 12, 2007
Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.The Annals of pharmacotherapy, , Volume: 41, Issue:11, 2007
Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder.Current medical research and opinion, , Volume: 23, Issue:11, 2007
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.Health technology assessment (Winchester, England), , Volume: 11, Issue:39, 2007
Severe hyperlipidemia associated with olanzapine and quetiapine use.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Olanzapine versus placebo in the treatment of adolescents with bipolar mania.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Olanzapine and pediatric bipolar disorder: evidence for efficacy and safety concerns.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
The use of atypical antipsychotics in French psychiatric hospitals.Pharmacy world & science : PWS, , Volume: 29, Issue:5, 2007
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.Bipolar disorders, , Volume: 9, Issue:6, 2007
Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:6, 2007
Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder.The Tohoku journal of experimental medicine, , Volume: 213, Issue:1, 2007
Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse.Journal of affective disorders, , Volume: 99, Issue:1-3, 2007
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.Human psychopharmacology, , Volume: 22, Issue:7, 2007
Atypical antipsychotics in bipolar disorder: systematic review of randomised trials.BMC psychiatry, , Aug-16, Volume: 7, 2007
A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder.Acta psychiatrica Scandinavica. Supplementum, , Issue:434, 2007
Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium.Journal of psychiatric research, , Volume: 41, Issue:7, 2007
Bilateral pedal edema associated with olanzapine use in manic episode of bipolar disorder: report of two cases.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 31, Issue:7, 2007
Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications.Bipolar disorders, , Volume: 9, Issue:3, 2007
Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study.Journal of affective disorders, , Volume: 104, Issue:1-3, 2007
Effect of comorbid anxiety on treatment response in bipolar depression.Journal of affective disorders, , Volume: 104, Issue:1-3, 2007
Characteristics of psychotic patients with foreign accent syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 19, Issue:1, 2007
A double-blind comparison of the effect of the antipsychotics haloperidol and olanzapine on sleep in mania.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, , Volume: 40, Issue:3, 2007
Stevens-Johnson syndrome (SJS) leading to resolution of mania.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:2, 2006
Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex.The Journal of clinical psychiatry, , Volume: 67, Issue:8, 2006
Stuporous catatonia in an elderly bipolar patient: response to olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:5, 2006
Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes.Current medical research and opinion, , Volume: 22, Issue:5, 2006
Influence of sub-syndromal symptoms after remission from manic or mixed episodes.The British journal of psychiatry : the journal of mental science, , Volume: 189, 2006
Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice.Current medical research and opinion, , Volume: 22, Issue:12, 2006
Maintenance treatment of bipolar disorder: Applying research to clinical practice.Journal of psychiatric practice, , Volume: 12, Issue:5, 2006
Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 67, Issue:2, 2006
Olanzapine/fluoxetine combination for bipolar depression.Expert review of neurotherapeutics, , Volume: 6, Issue:1, 2006
Does olanzapine have any antidepressant effect?The American journal of psychiatry, , Volume: 163, Issue:10, 2006
[New formulations of olanzapine in the treatment of acute agitation].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic states.Nordic journal of psychiatry, , Volume: 60, Issue:2, 2006
Black hairy tongue associated with olanzapine treatment: a case report.The Mount Sinai journal of medicine, New York, , Volume: 73, Issue:6, 2006
[Pharmacotherapy of manic-depressive mixed States].Psychiatrische Praxis, , Volume: 33 Suppl 1, 2006
Clinical relevance of depressive symptom improvement in bipolar I depressed patients.Journal of affective disorders, , Volume: 92, Issue:2-3, 2006
[Olanzapine in the treatment of bipolar disorder].Psychiatrische Praxis, , Volume: 33 Suppl 1, 2006
Early predictors of substantial weight gain in bipolar patients treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.The Journal of clinical psychiatry, , Volume: 67, Issue:11, 2006
A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.The Journal of clinical psychiatry, , Volume: 67, Issue:5, 2006
A review of the evidence for the use of antipsychotics in the maintenance treatment of bipolar disorders.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:2 Suppl, 2006
Efficacy of olanzapine and haloperidol in an animal model of mania.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
Olanzapine - relapse prevention following mania.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:2 Suppl, 2006
Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.Therapeutic drug monitoring, , Volume: 28, Issue:5, 2006
Adjunctive olanzapine treatment in bipolar adolescents responding insufficiently to mood stabilizers. Four case reports.European child & adolescent psychiatry, , Volume: 15, Issue:8, 2006
Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine.Journal of managed care pharmacy : JMCP, , Volume: 12, Issue:3, 2006
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.The American journal of psychiatry, , Volume: 163, Issue:2, 2006
Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder--a preliminary report.Journal of affective disorders, , Volume: 92, Issue:2-3, 2006
Case report: edema related to olanzapine therapy.Canadian family physician Medecin de famille canadien, , Volume: 52, 2006
Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.Bipolar disorders, , Volume: 8, Issue:6, 2006
A retrospective analysis of changing from alternative agents to carbamazepine extended-release capsules in bipolar disorder.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18 Suppl 1, 2006
A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Injectable atypical antipsychotics for agitation in borderline personality disorder.Pharmacopsychiatry, , Volume: 39, Issue:3, 2006
Paradoxical dyskinesia with olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 18, Issue:1, 2006
Haloperidol alone or in combination for acute mania.The Cochrane database of systematic reviews, , Jul-19, Issue:3, 2006
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
Pulmonary embolism associated with olanzapine.Thrombosis and haemostasis, , Volume: 96, Issue:5, 2006
Long-term use of atypical antipsychotics in bipolar disorder.Pharmacotherapy, , Volume: 26, Issue:8, 2006
Lamotrigine-induced severe manic switch.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:8, 2006
Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: a retrospective study.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
Tiagabine withdrawal-emergent mania.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:8, 2006
Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder.Bipolar disorders, , Volume: 8, Issue:4, 2006
A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:1, 2006
Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:6, 2006
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.The Journal of clinical psychiatry, , Volume: 67, Issue:7, 2006
Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-30, Volume: 30, Issue:6, 2006
Olanzapine: a 5-year perspective.Expert review of neurotherapeutics, , Volume: 6, Issue:6, 2006
The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder.Journal of managed care pharmacy : JMCP, , Volume: 12, Issue:4, 2006
Recovery and functional outcomes following olanzapine treatment for bipolar I mania.Bipolar disorders, , Volume: 7, Issue:1, 2005
Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report.Journal of Korean medical science, , Volume: 20, Issue:4, 2005
Typical and atypical antipsychotics in bipolar depression.The Journal of clinical psychiatry, , Volume: 66, Issue:11, 2005
Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.The American journal of psychiatry, , Volume: 162, Issue:7, 2005
Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.Psychopharmacology, , Volume: 181, Issue:1, 2005
Neuroleptic malignant syndrome due to three atypical antipsychotics in a child.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:4, 2005
Memory-sparing cognitive deterioration in the elderly: what is the diagnosis?Reviews in neurological diseases, ,Spring, Volume: 2, Issue:2, 2005
Management options for bipolar disorder in children and adolescents.Paediatric drugs, , Volume: 7, Issue:5, 2005
Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:4, 2005
Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.Journal of managed care pharmacy : JMCP, , Volume: 11, Issue:3, 2005
A typical mood stabilizers: a "typical role for atypical antipsychotics.Acta psychiatrica Scandinavica. Supplementum, , Issue:426, 2005
Effective maintenance treatment--breaking the cycle of bipolar disorder.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Atypical antipsychotics: newer options for mania and maintenance therapy.Bipolar disorders, , Volume: 7 Suppl 4, 2005
Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data.Journal of affective disorders, , Volume: 89, Issue:1-3, 2005
Treatment options for bipolar depression.The Journal of clinical psychiatry, , Volume: 66 Suppl 1, 2005
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:6, 2005
Spotlight on olanzapine in bipolar I disorder.CNS drugs, , Volume: 19, Issue:6, 2005
The treatment of mixed states and the risk of switching to depression.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:2, 2005
Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments.Journal of clinical psychopharmacology, , Volume: 25, Issue:4, 2005
Update on the treatment of bipolar disorder in children and adolescents.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:2, 2005
Newer treatment studies for bipolar depression.Bipolar disorders, , Volume: 7 Suppl 5, 2005
Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction.Journal of affective disorders, , Volume: 87, Issue:1, 2005
Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.The Journal of clinical psychiatry, , Volume: 66, Issue:5, 2005
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorders, , Volume: 7 Suppl 3, 2005
Outcome measurement, outcome management and monitoring.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:8, 2005
Atypical antipsychotics in bipolar depression: potential mechanisms of action.The Journal of clinical psychiatry, , Volume: 66 Suppl 5, 2005
[Humor in bipolar disorder].L'Encephale, , Volume: 31 Pt 2, 2005
Women are not the same as men: specific clinical issues for female patients with bipolar disorder.Bipolar disorders, , Volume: 7 Suppl 1, 2005
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.The Journal of clinical psychiatry, , Volume: 66 Suppl 3, 2005
Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children.Biological psychiatry, , Oct-01, Volume: 58, Issue:7, 2005
Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial.Current medical research and opinion, , Volume: 21, Issue:4, 2005
[Rabbit syndrome due to olanzapine].Psychiatrische Praxis, , Volume: 32, Issue:4, 2005
Olanzapine and olanzapine-fluoxetine combination treatment and bipolar I depression.Archives of general psychiatry, , Volume: 62, Issue:9, 2005
Bipolar disorder.Clinical evidence, , Issue:13, 2005
Olanzapine co-therapy in bipolar disorder.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Clinical highlights in bipolar depression: focus on atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66 Suppl 5, 2005
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
[Therapeutic and pharmacological effects of second-generation antipsychotics on drug-resistant bipolar depression].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 106, Issue:8, 2004
Olanzapine: a review of its use in the management of bipolar I disorder.Drugs, , Volume: 64, Issue:23, 2004
Olanzapine in bipolar disorder.Expert opinion on pharmacotherapy, , Volume: 5, Issue:7, 2004
Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder.Journal of clinical psychopharmacology, , Volume: 24, Issue:4, 2004
Olanzapine/Fluoxetine (Symbyax) for bipolar depression.The Medical letter on drugs and therapeutics, , Mar-15, Volume: 46, Issue:1178, 2004
Strategies for preventing the recurrence of bipolar disorder.The Journal of clinical psychiatry, , Volume: 65 Suppl 10, 2004
The use of two neuroleptics to treat bipolar illness in two children.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
Olanzapine-induced diabetes in a seven-year-old boy.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
Olanzapine-induced neutropenia: mechanism and treatment.Journal of clinical psychopharmacology, , Volume: 24, Issue:2, 2004
Open label study of the effect of amantadine on weight gain induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 58, Issue:2, 2004
A case of bipolar disorder and typhoid fever.International journal of psychiatry in medicine, , Volume: 34, Issue:3, 2004
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial.Clinical therapeutics, , Volume: 26, Issue:1, 2004
Bipolar depression: an overview.IDrugs : the investigational drugs journal, , Volume: 7, Issue:9, 2004
Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania.Current medical research and opinion, , Volume: 20, Issue:9, 2004
Mania and hypomania with olanzapine use.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:3, 2004
Obsessive-compulsive symptoms with olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:3, 2004
The risk of harm in mania and the very early time course of improvement: important but neglected variables in treatment research.Bipolar disorders, , Volume: 6, Issue:5, 2004
A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.Health technology assessment (Winchester, England), , Volume: 8, Issue:19, 2004
Irreversible priapism during olanzapine and lithium therapy.The Australian and New Zealand journal of psychiatry, , Volume: 38, Issue:5, 2004
Major advances in bipolar disorder.The Medical journal of Australia, , Aug-16, Volume: 181, Issue:4, 2004
[Zyprexa--various dosage forms, the goal: improving the prognosis for patients with schizophrenia and bipolar disorders].Krankenpflege Journal, , Volume: 42, Issue:3-4, 2004
Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data.The Journal of clinical psychiatry, , Volume: 65, Issue:10, 2004
Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder.Journal of clinical psychopharmacology, , Volume: 24, Issue:4, 2004
Olanzapine may cause delirium in geriatric patients.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Successful treatment of sexual dysfunction with dronabinol: a case report.The Journal of clinical psychiatry, , Volume: 65, Issue:8, 2004
Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid.Journal of affective disorders, , Volume: 81, Issue:3, 2004
Novel antipsychotics in bipolar and schizoaffective mania.Acta psychiatrica Scandinavica, , Volume: 109, Issue:6, 2004
The antidepressant effects of risperidone and olanzapine in bipolar disorder.The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, ,Fall, Volume: 11, Issue:2, 2004
An open-label trial of olanzapine for corticosteroid-induced mood symptoms.Journal of affective disorders, , Volume: 83, Issue:2-3, 2004
Olanzapine-induced clitoral priapism.Journal of clinical psychopharmacology, , Volume: 24, Issue:5, 2004
Employing pharmacologic treatment of bipolar disorder to greatest effect.The Journal of clinical psychiatry, , Volume: 65 Suppl 15, 2004
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.The Journal of clinical psychiatry, , Volume: 65 Suppl 6, 2004
Bipolar depression: the role of atypical antipsychotics.Expert review of neurotherapeutics, , Volume: 4, Issue:6 Suppl 2, 2004
An excitement subscale of the Positive and Negative Syndrome Scale.Schizophrenia research, , Jun-01, Volume: 68, Issue:2-3, 2004
An overview of primary care assessment and management of bipolar disorder.The Journal of the American Osteopathic Association, , Volume: 104, Issue:6 Suppl 6, 2004
Use of olanzapine in the treatment of bipolar I disorder.Expert review of neurotherapeutics, , Volume: 4, Issue:5, 2004
Effective use of olanzapine for obsessive-compulsive symptoms in a patient with bipolar disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:8, 2004
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.The British journal of psychiatry : the journal of mental science, , Volume: 184, 2004
Weight gain during treatment of bipolar I patients with olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
DO comments on bipolar disorder supplement.The Journal of the American Osteopathic Association, , Volume: 104, Issue:12, 2004
New drug available for bipolar disorder.The Nurse practitioner, , Volume: 29, Issue:3, 2004
Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics.Bipolar disorders, , Volume: 5 Suppl 2, 2003
[Bipolar disorders. Differential therapy for control of mood swings].Krankenpflege Journal, , Volume: 41, Issue:7-9, 2003
[Long-term therapy with intuition].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
[Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
[Treatment of acute bipolar disorder. Intriguing balancing act between mania and depression].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
[Manic phase (manic episode)].Ryoikibetsu shokogun shirizu, , Issue:38, 2003
[Olanzapine (Zyprexa)--reliable in acute treatment, prevention of recurrence and long-term mood stabilization].Krankenpflege Journal, , Volume: 41, Issue:10-12, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.The American journal of psychiatry, , Volume: 160, Issue:7, 2003
The combination of olanzapine and fluoxetine in mood disorders.Expert opinion on pharmacotherapy, , Volume: 4, Issue:7, 2003
Calming versus sedative effects of intramuscular olanzapine in agitated patients.The American journal of emergency medicine, , Volume: 21, Issue:3, 2003
Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder.Bipolar disorders, , Volume: 5, Issue:3, 2003
Effect of olanzapine on the liver transaminases.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:3, 2003
Selecting effective long-term treatment for bipolar patients: monotherapy and combinations.The Journal of clinical psychiatry, , Volume: 64 Suppl 5, 2003
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes.The Journal of clinical psychiatry, , Volume: 64, Issue:3, 2003
The efficacy of olanzapine monotherapy for acute hypomania or mania in an outpatient setting.International clinical psychopharmacology, , Volume: 18, Issue:3, 2003
Assessment of treatment response in mania: commentary and new findings.Bipolar disorders, , Volume: 5, Issue:2, 2003
Improving identification of treatment effectiveness in bipolar disorders.Bipolar disorders, , Volume: 5, Issue:2, 2003
Divalproex versus olanzapine in mania.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
Safety in treating bipolar disorder.The Journal of family practice, , Volume: Suppl, 2003
Optimal dosing of medications (in bipolar disorder).The Journal of family practice, , Volume: Suppl, 2003
Long-term therapy of bipolar illness.The Journal of family practice, , Volume: Suppl, 2003
Treating bipolar depression.The Journal of family practice, , Volume: Suppl, 2003
Treating acute mania.The Journal of family practice, , Volume: Suppl, 2003
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.Archives of general psychiatry, , Volume: 60, Issue:12, 2003
Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania.Bipolar disorders, , Volume: 5, Issue:1, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Acute dysphoric mania: treatment response to olanzapine versus placebo.Journal of clinical psychopharmacology, , Volume: 23, Issue:2, 2003
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.Southern medical journal, , Volume: 96, Issue:7, 2003
Difficult-to-treat depressions: a primary care perspective.The Journal of clinical psychiatry, , Volume: 64 Suppl 1, 2003
Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.Pharmacotherapy, , Volume: 23, Issue:2, 2003
Olanzapine induced "typical" neuroleptic malignant syndrome.Journal of clinical psychopharmacology, , Volume: 23, Issue:1, 2003
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling.Journal of affective disorders, , Volume: 73, Issue:1-2, 2003
Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania.Journal of affective disorders, , Volume: 73, Issue:1-2, 2003
The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
Olanzapine-associated bilateral pedal edema.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.Archives of general psychiatry, , Volume: 60, Issue:11, 2003
Potential use of olanzapine in treatment of substance dependence disorders.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Olanzapine versus placebo in acute mania: treatment responses in subgroups.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Antipsychotic-induced weight gain: bipolar disorder and leptin.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Olanzapine alone or in combination for acute mania.The Cochrane database of systematic reviews, , Issue:3, 2003
Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial.Journal of affective disorders, , Volume: 69, Issue:1-3, 2002
Olanzapine-associated type 2 diabetes mellitus.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Olanzapine-induced mania in bipolar disorders.Journal of psychiatry & neuroscience : JPN, , Volume: 27, Issue:3, 2002
The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania.Bipolar disorders, , Volume: 4, Issue:1, 2002
Olanzapine versus divalproex in the treatment of acute mania.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited.The Journal of clinical psychiatry, , Volume: 63 Suppl 3, 2002
The role of novel antipsychotics in bipolar disorders.The Journal of clinical psychiatry, , Volume: 63 Suppl 3, 2002
Olanzapine in acute bipolar mania.Archives of general psychiatry, , Volume: 59, Issue:2, 2002
A correction.Archives of general psychiatry, , Volume: 59, Issue:1, 2002
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.Archives of general psychiatry, , Volume: 59, Issue:1, 2002
Olanzapine and improvement of tardive dyskinesia.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:7, 2002
A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:4, 2002
Olanzapine-induced hair loss.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 47, Issue:9, 2002
Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders.Bipolar disorders, , Volume: 4, Issue:5, 2002
Pharmacotherapy of bipolar disorder: the role of atypical antipsychotics and experimental strategies.Human psychopharmacology, , Volume: 17, Issue:8, 2002
Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder.Psychopharmacology, , Volume: 162, Issue:1, 2002
Can olanzapine be implicated in causing serotonin syndrome?Psychiatry and clinical neurosciences, , Volume: 56, Issue:5, 2002
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.International clinical psychopharmacology, , Volume: 17, Issue:5, 2002
Sleep-related eating disorder induced by olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:7, 2002
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.Journal of affective disorders, , Volume: 67, Issue:1-3, 2001
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.Schizophrenia bulletin, , Volume: 27, Issue:4, 2001
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.The Journal of clinical psychiatry, , Volume: 62, Issue:12, 2001
Lethal catatonia responding to high-dose olanzapine therapy.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:4, 2001
Use of atypical antipsychotics in mood disorders.Current opinion in investigational drugs (London, England : 2000), , Volume: 2, Issue:7, 2001
Olanzapine: a review of its use in the treatment of bipolar I disorder.CNS drugs, , Volume: 15, Issue:11, 2001
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 11, Issue:3, 2001
Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.Journal of clinical psychopharmacology, , Volume: 21, Issue:5, 2001
Use of olanzapine in dysphoric mania.Journal of affective disorders, , Volume: 66, Issue:2-3, 2001
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.The Journal of clinical psychiatry, , Volume: 62, Issue:7, 2001
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Cognitive behavior therapy for weight gain.The American journal of psychiatry, , Volume: 158, Issue:6, 2001
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Use of olanzapine in non-psychotic psychiatric disorders.Expert opinion on pharmacotherapy, , Volume: 2, Issue:4, 2001
Manic symptoms induced by olanzapine.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 11, Issue:2, 2001
Olanzapine-lnduced hyperglycemic nonketonic coma.The Annals of pharmacotherapy, , Volume: 35, Issue:3, 2001
Introduction: a new era in the pharmacotherapy of psychotic disorders.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.South Dakota journal of medicine, , Volume: 53, Issue:2, 2000
Treatment of bipolar I disorder in an adolescent with olanzapine.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 10, Issue:2, 2000
Does olanzapine have antidepressant properties? A retrospective preliminary study.Bipolar disorders, , Volume: 2, Issue:3 Pt 1, 2000
Response to placebo among bipolar I disorder patients experiencing their first manic episode.Bipolar disorders, , Volume: 2, Issue:4, 2000
Summary from the 153rd meeting of the American Psychiatric Association. 13-18 May 2000, Chicago, Illinois, USA.Expert opinion on pharmacotherapy, , Volume: 1, Issue:5, 2000
New treatments for bipolar disorder: the role of atypical neuroleptic agents.The Journal of clinical psychiatry, , Volume: 61 Suppl 14, 2000
An ever-increasing pharmacopoeia for the management of patients with bipolar disorder.The Journal of clinical psychiatry, , Volume: 61 Supp 13, 2000
Olanzapine to treat the acute mania of bipolar disorder.South Dakota journal of medicine, , Volume: 53, Issue:12, 2000
Improvement of tardive dyskinesia in a bipolar patient with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 15, Issue:7, 2000
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
Possible risperidone-induced visual hallucinations.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 39, Issue:9, 2000
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.Archives of general psychiatry, , Volume: 57, Issue:9, 2000
Olanzapine-induced urinary incontinence: treatment with ephedrine.The Journal of clinical psychiatry, , Volume: 61, Issue:8, 2000
Failure to consider drug-drug interactions as a likely cause of behavioral deterioration in a patient with bipolar disorder.Journal of clinical psychopharmacology, , Volume: 20, Issue:3, 2000
Antipsychotic drug side effect issues in bipolar manic patients.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.East African medical journal, , Volume: 77, Issue:2, 2000
Mood stabilizer augmentation with olanzapine in acutely manic children.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 10, Issue:1, 2000
Is olanzapine a mood stabilizer?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
Hypomania-like syndrome induced by olanzapine.International clinical psychopharmacology, , Volume: 14, Issue:6, 1999
Olanzapine compared to lithium in mania: a double-blind randomized controlled trial.International clinical psychopharmacology, , Volume: 14, Issue:6, 1999
Recurrence of neuroleptic malignant syndrome with olanzapine treatment.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
Olanzapine-induced tardive dystonia.The American journal of psychiatry, , Volume: 156, Issue:10, 1999
Olanzapine-induced psychotic mania in bipolar schizoaffective disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:6, 1999
Olanzapine for mixed episodes of bipolar disorder.Journal of psychopharmacology (Oxford, England), , Volume: 13, Issue:2, 1999
Treatment of bipolar mixed state with olanzapine.Journal of psychiatry & neuroscience : JPN, , Volume: 24, Issue:1, 1999
Olanzapine response in psychotic depression.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Management of acute mania.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Tardive dyskinesia in affective disorders.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
High-dose olanzapine in an adolescent.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 38, Issue:5, 1999
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Olanzapine-induced mania.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
New treatments of bipolar disorder.Current psychiatry reports, , Volume: 1, Issue:2, 1999
Olanzapine in the treatment of adolescent acute mania: a report of seven cases.Journal of affective disorders, , Volume: 53, Issue:3, 1999
Olanzapine-induced psychotic mania in bipolar schizo-affective disorder.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 14, Issue:7, 1999
Olanzapine-induced manic-like syndrome.The Journal of clinical psychiatry, , Volume: 59, Issue:6, 1998
Olanzapine in treatment-resistant bipolar disorder.Journal of affective disorders, , Volume: 49, Issue:2, 1998
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics.Journal of affective disorders, , Volume: 48, Issue:2-3, 1998
Olanzapine and negative symptoms.The Journal of clinical psychiatry, , Volume: 59, Issue:10, 1998
Olanzapine-induced mania.The Journal of the American Osteopathic Association, , Volume: 98, Issue:10, 1998
Neuroleptic malignant syndrome associated with olanzapine.The Annals of pharmacotherapy, , Volume: 32, Issue:11, 1998
Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment.Journal of psychiatry & neuroscience : JPN, , Volume: 23, Issue:5, 1998
Aggression, agitation, and mania with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:10, 1998
Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states.The Journal of clinical psychiatry, , Volume: 59, Issue:2, 1998
Clinical predictors of acute response with olanzapine in psychotic mood disorders.The Journal of clinical psychiatry, , Volume: 59, Issue:1, 1998
Mania associated with olanzapine.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 37, Issue:2, 1998
Antipsychotic agents and bipolar disorder.The Journal of clinical psychiatry, , Volume: 59 Suppl 1, 1998
Adjunctive use of olanzapine in mood disorders: five case reports.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 9, Issue:4, 1997
Effective treatment of mania with olanzapine: 2 case reports.Journal of psychiatry & neuroscience : JPN, , Volume: 22, Issue:5, 1997
[Methodological proposals for the evaluation of the mood stabilizing effect of an antipsychotic drug].L'Encephale, , Volume: 25, Issue:6
Profound hypertriglyceridemia and weight gain in the first week following initiation of olanzapine: a case report with implications for lipid monitoring guidelines.Psychosomatics, , Volume: 54, Issue:4
The diagnosis of Asperger's syndrome in an adult presenting with an index episode of mania by Ng et al.General hospital psychiatry, , Volume: 26, Issue:2
Priapism following olanzapine administration in a patient with multiple sclerosis.Psychosomatics, , Volume: 39, Issue:3
Acute dystonia with intramuscular olanzapine in adolescent mania: a report.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:11-12
Olanzapine induced neuroleptic malignant syndrome.Indian journal of pharmacology, , Volume: 45, Issue:1
Pseudotumor cerebri in a patient being treated for bipolar disorder.General hospital psychiatry, , Volume: 32, Issue:4
The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression.Harvard review of psychiatry, , Volume: 18, Issue:1
Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials.Journal of clinical psychopharmacology, , Volume: 40, Issue:2
Secondary mania in a patient with delayed anoxic encephalopathy after carbon monoxide intoxication caused by a suicide attempt.General hospital psychiatry, , Volume: 36, Issue:1
[Olanzapine in manic/mixed patients with or without substance abuse].Rivista di psichiatria, , Volume: 48, Issue:2
Olanzapine and quetiapine in the prevention of a new mood episode in women with bipolar disorder during the postpartum period: a retrospective cohort study.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 43, Issue:6
Long-Term Treatment of Bipolar Disorder with Valproate: Updated Systematic Review and Meta-analyses.Harvard review of psychiatry, , Volume: 29, Issue:3
Cost analysis of the adverse reactions of bipolar disorder treatment with aripiprazole and olanzapine in Spain.Actas espanolas de psiquiatria, , Volume: 42, Issue:5
Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine: Results From a 3-Week, Randomized, Placebo-Controlled Trial.The Journal of clinical psychiatry, , Volume: 78, Issue:9
Fahr's Disease Presenting with Manic Symptoms.JNMA; journal of the Nepal Medical Association, , Volume: 56, Issue:209
The case for atypical antipsychotics in bipolar disorder.Perspectives in psychiatric care, , Volume: 40, Issue:1
Recurrent mania associated with repeated brain injury.General hospital psychiatry, , Volume: 26, Issue:6
A case of mania due to cryptococcal meningitis, successfully treated with adjunctive olanzapine, in a patient with acquired immunodeficiency syndrome.General hospital psychiatry, , Volume: 33, Issue:3
Mania: psychiatric manifestations of the antiphospholipid syndrome.Psychosomatics, , Volume: 49, Issue:5
Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic.The journal of behavioral health services & research, , Volume: 32, Issue:4
Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder.Rivista di psichiatria, , Volume: 54, Issue:1
Challenges Faced When Caring for Foreign Nationals With Comorbid Medical and Psychiatric Problems in the General Hospital.Psychosomatics, , Volume: 59, Issue:1
Long-term observational comparison of risperidone and olanzapine in bipolar disorder.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:2
Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder.Indian journal of pharmacology, , Volume: 46, Issue:4
Acute massive pulmonary embolism associated with olanzapine therapy and no significant personal history in a young male--case report and literature review.Pneumologia (Bucharest, Romania), , Volume: 60, Issue:2
Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone With Olanzapine as a Comparator.Journal of clinical psychopharmacology, , Volume: 41, Issue:1
Mania secondary to right-sided stroke--responsive to olanzapine.General hospital psychiatry, , Volume: 28, Issue:3
Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients.Comprehensive psychiatry, , Volume: 52, Issue:6
[Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].Actas espanolas de psiquiatria, , Volume: 32, Issue:5
[Therapeutic options in manic states].L'Encephale, , Volume: 29, Issue:Pt 2
The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:3
Breastfed Infants Exposed to Combined Antipsychotics: Two Case Reports.American journal of therapeutics, , Volume: 23, Issue:6
Mania in a case of hyperparathyroidism.Psychosomatics, , Volume: 48, Issue:3
Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.Journal of clinical psychopharmacology, , Volume: 39, Issue:4
Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study.Advances in therapy, , Volume: 24, Issue:1
Olanzapine usage associated with neuroleptic malignant syndrome.Psychosomatics, , Volume: 42, Issue:6
Olanzapine-lithium encephalopathy.Psychosomatics, , Volume: 42, Issue:4
The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.Journal of clinical psychopharmacology, , Volume: 39, Issue:6
[Antipsychotics in bipolar disorders].L'Encephale, , Volume: 30, Issue:5
Olanzapine-induced bilateral pedal edema: a case report.General hospital psychiatry, , Volume: 22, Issue:4
[Mood stabilizers in the treatment of bipolar disorder mixed states].Rivista di psichiatria, , Volume: 47, Issue:4
[A case of mania following olanzapine administration].Psychiatria polska, , Volume: 34, Issue:2
Antipsychotic Therapy-Induced New Onset Diabetic Ketoacidosis.American journal of therapeutics, , Volume: 23, Issue:6
Milieu management of a child with bipolar illness.Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc, , Volume: 18, Issue:3
Blepharospasm: an uncommon adverse effect caused by long-term administration of olanzapine.Journal of basic and clinical physiology and pharmacology, , Jan-01, Volume: 28, Issue:1, 2017
Olanzapine and blepharoclonus.The Journal of clinical psychiatry, , Volume: 68, Issue:9, 2007
Blepharospasm associated with olanzapine: a case report.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:6, 2004
Risperidone and tardive dyskinesia: a case of blepharospasm.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:5, 2000
Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.The Psychiatric quarterly, , Volume: 94, Issue:4, 2023
Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.CNS drugs, , Volume: 31, Issue:9, 2017
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.The Journal of clinical psychiatry, , Volume: 73, Issue:8, 2012
Open-label treatment with olanzapine for patients with borderline personality disorder.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Randomized controlled trials of olanzapine treatment of borderline personality disorder: two similar studies with different results.The Journal of clinical psychiatry, , Volume: 72, Issue:10, 2011
A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study.The Journal of clinical psychiatry, , Volume: 72, Issue:10, 2011
The effect of Olanzapine and Sertraline on personality disorder in patients with methadone maintenance therapy.Psychiatria Danubina, , Volume: 22, Issue:4, 2010
Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial.Journal of clinical psychopharmacology, , Volume: 30, Issue:1, 2010
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Differential diagnosis of coagulation abnormalities in borderline personality disorder.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 9, Issue:1, 2008
Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study.The Journal of clinical psychiatry, , Volume: 69, Issue:6, 2008
Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study.The British journal of psychiatry : the journal of mental science, , Volume: 193, Issue:6, 2008
Treatment of borderline personality disorder with olanzapine.Archives of Iranian medicine, , Volume: 9, Issue:4, 2006
Injectable atypical antipsychotics for agitation in borderline personality disorder.Pharmacopsychiatry, , Volume: 39, Issue:3, 2006
Emerging evidence for the use of atypical antipsychotics in borderline personality disorder.Pharmacopsychiatry, , Volume: 38, Issue:1, 2005
[Borderline personality disorder].L'Encephale, , Volume: 31 Pt 2, 2005
Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder.The American journal of psychiatry, , Volume: 162, Issue:6, 2005
Olanzapine versus placebo in the treatment of borderline personality disorder.The Journal of clinical psychiatry, , Volume: 65, Issue:1, 2004
A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.The Journal of clinical psychiatry, , Volume: 65, Issue:7, 2004
Polyuria after olanzapine overdose.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
Treatment of perinatal delusional disorder: a case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.The Journal of clinical psychiatry, , Volume: 62, Issue:11, 2001
Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.Biological psychiatry, , Nov-15, Volume: 46, Issue:10, 1999
[Olanzapine and cognitive-behavioural group therapy in borderline personality disorder].Actas espanolas de psiquiatria, , Volume: 29, Issue:2
Intramuscular olanzapine in patients with borderline personality disorder: an observational study in an emergency room.General hospital psychiatry, , Volume: 29, Issue:1
Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report.Psycho-oncology, , Volume: 9, Issue:1
Psychopharmacological treatment in borderline personality disorder.Actas espanolas de psiquiatria, , Volume: 36, Issue:1
[Pharmacotherapy in the treatment of borderline personality disorder].Rivista di psichiatria, , Volume: 44, Issue:6
Olanzapine-Induced Bradycardia.The primary care companion for CNS disorders, , 08-15, Volume: 25, Issue:4, 2023
Cardiotoxicity in a citalopram and olanzapine overdose.The Journal of emergency medicine, , Volume: 45, Issue:4, 2013
Bradyarrhythmic shock associated with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:1, 2007
Severe cardiovascular side effects of olanzapine in an elderly patient: case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine.Journal of clinical pharmacology, , Volume: 42, Issue:1, 2002
[Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon].Annales francaises d'anesthesie et de reanimation, , Volume: 18, Issue:6, 1999
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder.General hospital psychiatry, , Volume: 31, Issue:4
Case Report: An Adolescent Girl with Isolated Neuropsychiatric Features and Apparent Post-Malaria Neurological Syndrome.The American journal of tropical medicine and hygiene, , Volume: 102, Issue:5, 2020
Peduncular hallucinosis.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:2, 2011
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats.Brain research, , Aug-27, Volume: 1018, Issue:2, 2004
Posttraumatic brain injury psychosis successfully treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-01, Volume: 34, Issue:1, 2010
Psychosis secondary to traumatic brain injury.Brain injury, , Volume: 23, Issue:4, 2009
Treatment of intractable hiccups with olanzapine following recent severe traumatic brain injury.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 18, Issue:4, 2006
Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury.NeuroRehabilitation, , Volume: 18, Issue:3, 2003
Reversal of antipsychotic-induced weight gain during quetiapine treatment.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats.American journal of physical medicine & rehabilitation, , Volume: 82, Issue:11, 2003
Diurnal variation in Cotard's syndrome (copresent with Capgras delusion) following traumatic brain injury.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:4, 2000
Recurrent mania associated with repeated brain injury.General hospital psychiatry, , Volume: 26, Issue:6
The use of atypical antipsychotics after traumatic brain injury.The Journal of head trauma rehabilitation, , Volume: 23, Issue:2
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.Journal of neuro-oncology, , Volume: 122, Issue:1, 2015
Autophagy involvement in olanzapine-mediated cytotoxic effects in human glioma cells.Asian Pacific journal of cancer prevention : APJCP, , Volume: 15, Issue:19, 2014
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?British journal of pharmacology, , Volume: 164, Issue:5, 2011
[Brain tumor].Ryoikibetsu shokogun shirizu, , Issue:40, 2003
Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).BMJ open, , 04-03, Volume: 13, Issue:4, 2023
Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 29, Issue:1, 2023
Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracyBMJ open, , Mar-02, Volume: 12, Issue:3, 2022
[Administration Period of Olanzapine as an Antiemetic Drug for Patients on FEC Therapy-A Survey].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 49, Issue:6, 2022
Olanzapine Improves Cachexia in a Breast Cancer Patient under Home Hospice Care.Journal of palliative medicine, , Volume: 25, Issue:1, 2022
A pooled analysis of adding olanzapine to guideline-recommended antiemetic therapy for breast cancer patients treated with an anthracycline and cyclophosphamide in prospective and retrospective studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 30, Issue:3, 2022
[Effect of the Antiemetic Drug Olanzapine on Blood Sugar Levels in Patients Treated with Adjuvant or Neoadjuvant Chemotherapy for Breast Cancer].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 47, Issue:10, 2020
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.Breast (Edinburgh, Scotland), , Volume: 50, 2020
A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.Breast (Edinburgh, Scotland), , Volume: 54, 2020
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.Annals of palliative medicine, , Volume: 8, Issue:4, 2019
Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.Anticancer research, , Volume: 38, Issue:2, 2018
Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.Scientific reports, , 11-02, Volume: 8, Issue:1, 2018
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.JAMA oncology, , Volume: 2, Issue:2, 2016
Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy.Japanese journal of clinical oncology, , Volume: 46, Issue:5, 2016
Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.Journal of pain and symptom management, , Volume: 25, Issue:6, 2003
Flushing and sweating in an advanced breast cancer patient relieved by olanzapine.Journal of pain and symptom management, , Volume: 25, Issue:6, 2003
Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.Indian journal of pharmacology, , Volume: 49, Issue:6
Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review.Nutrients, , Dec-18, Volume: 12, Issue:12, 2020
Effects of lisdexamfetamine in a rat model of binge-eating.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:12, 2015
Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder.Psychiatry and clinical neurosciences, , Volume: 61, Issue:4, 2007
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:1, 2003
Olanzapine Improves Cachexia in a Breast Cancer Patient under Home Hospice Care.Journal of palliative medicine, , Volume: 25, Issue:1, 2022
Olanzapine for Nausea, Delirium, Anxiety, Insomnia, and Cachexia #315.Journal of palliative medicine, , Volume: 19, Issue:11, 2016
Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 23, Issue:9, 2015
Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.European journal of cancer care, , Volume: 16, Issue:4, 2007
Basal Ganglia Calcification: A Case Report of Fahr Disease With Pure Psychiatric Symptoms.Journal of psychiatric practice, , Volume: 25, Issue:5, 2019
Capgras syndrome associated with Fahr's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 21, Issue:3, 2009
Nature against nurture: calcification in the right thalamus in a young man with anorexia nervosa and obsessive-compulsive personality disorder.CNS spectrums, , Volume: 13, Issue:10, 2008
Fahr's Disease Presenting with Manic Symptoms.JNMA; journal of the Nepal Medical Association, , Volume: 56, Issue:209
[Mineralization of the basal ganglia as the supposed cause of poor tolerance of zuclopenthixol in a patient with long-term untreated paranoid schizophrenia].Psychiatria polska, , Volume: 47, Issue:4
Treatment of Cannabinoid Hyperemesis With Olanzapine: A Case Series.Journal of psychiatric practice, , 07-28, Volume: 27, Issue:4, 2021
Multidisciplinary Management of Adolescent Early-Onset, Treatment-Resistant Schizophrenia Complicated by Avoidant/Restrictive Food Intake Disorder and Catatonia in Acute Exacerbations.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:9, 2018
Cannabis and schizophrenia.The Cochrane database of systematic reviews, , Oct-14, Issue:10, 2014
[Combination of second generation antipsychotics -- case report].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 15, Issue:3, 2013
Synthetic cannabinoid-induced psychosis: two adolescent cases.Journal of child and adolescent psychopharmacology, , Volume: 22, Issue:5, 2012
Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:1, 2012
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 13, Issue:3, 2011
Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:6, 2008
Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Delusional wife: a case of diagnostic ambiguity and treatment challenge.Journal of psychiatric practice, , Volume: 11, Issue:3, 2005
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
Introduction.The Journal of clinical psychiatry, , Volume: 78, Issue:8
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.Schizophrenia bulletin, , 03-15, Volume: 49, Issue:2, 2023
Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.The international journal of neuropsychopharmacology, , 07-31, Volume: 26, Issue:7, 2023
Associations between off-label low-dose olanzapine or quetiapine and cardiometabolic mortality.Journal of psychiatric research, , Volume: 149, 2022
Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.Psychopharmacology, , Volume: 237, Issue:11, 2020
Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study.Basic & clinical pharmacology & toxicology, , Volume: 123, Issue:6, 2018
Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins.Cellular signalling, , Volume: 42, 2018
Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine.Schizophrenia research, , Volume: 183, 2017
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in Denmark.CNS drugs, , Volume: 28, Issue:10, 2014
Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis.Scientific reports, , Dec-09, Volume: 4, 2014
Association of serum retinol-binding protein 4 with insulin resistance and metabolic parameters during olanzapine therapy.Clinical endocrinology, , Volume: 76, Issue:2, 2012
[Metabolic syndrome in patients with schizophrenia and antipsychotic treatment].Medicina clinica, , Nov-17, Volume: 139, Issue:12, 2012
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clinical drug investigation, , Volume: 31, Issue:7, 2011
Metabolic syndrome with the atypical antipsychotics.Current opinion in endocrinology, diabetes, and obesity, , Volume: 17, Issue:5, 2010
Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
All-cause mortality associated with atypical and typical antipsychotics in demented outpatients.Pharmacoepidemiology and drug safety, , Volume: 16, Issue:5, 2007
Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued?International journal of geriatric psychiatry, , Volume: 21, Issue:2, 2006
Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients.International clinical psychopharmacology, , Volume: 20, Issue:6, 2005
Dyslipidemia and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
Severe cardiovascular side effects of olanzapine in an elderly patient: case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 21, Issue:1, 2001
Comparing the side effect profile of the atypical antipsychotics.West African journal of medicine, , Volume: 21, Issue:4
[Cardiovascular risk of haloperidol vs. atypical anti-psychotic drugs in schizophrenia treatment].Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, , Volume: 114, Issue:3
Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders.Mini reviews in medicinal chemistry, , Volume: 15, Issue:8, 2015
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Comparing the side effect profile of the atypical antipsychotics.West African journal of medicine, , Volume: 21, Issue:4
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
A potential case of peduncular hallucinosis treated successfully with olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Olanzapine attenuates brain damage after focal cerebral ischemia in vivo.Brain research bulletin, , Dec-11, Volume: 71, Issue:1-3, 2006
[Cerebral infarct and atypical antipsychotic agents].Psychologie & neuropsychiatrie du vieillissement, , Volume: 2, Issue:4, 2004
Comparative Safety Analysis of Oral Antipsychotics for In-Hospital Adverse Clinical Events in Older Adults After Major Surgery : A Nationwide Cohort Study.Annals of internal medicine, , Volume: 176, Issue:9, 2023
A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD). Favour.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:5, 2005
Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 23, Issue:12, 2015
[The use of antipsychotics in patients with dementia].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:3, 2008
Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued?International journal of geriatric psychiatry, , Volume: 21, Issue:2, 2006
Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.International psychogeriatrics, , Volume: 17, Issue:4, 2005
Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Apr-27, Volume: 170, Issue:9, 2004
Academy of Medicine Singapore-Ministry of Health clinical practice guidelines: Autism Spectrum Disorders in pre-school children.Singapore medical journal, , Volume: 51, Issue:3, 2010
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Successful olanzapine treatment of anorexia nervosa in a girl with pervasive developmental disorder not otherwise specified.Psychiatry and clinical neurosciences, , Volume: 62, Issue:6, 2008
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:5, 2006
NMS after clozapine initiation.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 44, Issue:11, 2005
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.The Journal of clinical psychiatry, , Volume: 65 Suppl 6, 2004
Olanzapine in the treatment of pervasive developmental disorders: a case series analysis.Journal of psychiatry & neuroscience : JPN, , Volume: 29, Issue:1, 2004
Open-label study of olanzapine in children with pervasive developmental disorder.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Broad therapeutic uses of atypical antipsychotic medications.Biological psychiatry, , Dec-01, Volume: 50, Issue:11, 2001
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 40, Issue:8, 2001
Reply to comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study".Journal of clinical psychopharmacology, , Volume: 21, Issue:2, 2001
Comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study".Journal of clinical psychopharmacology, , Volume: 20, Issue:5, 2000
Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.Journal of clinical psychopharmacology, , Volume: 19, Issue:1, 1999
Use of atypical neuroleptics in child and adolescent psychiatry.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Olanzapine in PDD.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 36, Issue:9, 1997
Liver toxicity due to olanzapine.Revista espanola de enfermedades digestivas, , Volume: 104, Issue:11, 2012
Possible olanzapine-induced hepatotoxicity in a young Chinese patient.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 15, Issue:5, 2009
Late-onset cholestatic hepatitis induced by olanzapine in a patient with schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Nov-13, Volume: 33, Issue:8, 2009
Olanzapine Treatment for Chorea in a Patient With Delayed Neuropsychiatric Syndrome After Carbon Monoxide Intoxication.American journal of therapeutics, , 01-14, Volume: 29, Issue:1, 2021
[Sydenham chorea and psychosis].Tijdschrift voor psychiatrie, , Volume: 52, Issue:4, 2010
Persistent choreoathetosis in a fatal olanzapine overdose: drug kinetics, neuroimaging, and neuropathology.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Successful treatment of hemichorea with olanzapine.Movement disorders : official journal of the Movement Disorder Society, , Volume: 14, Issue:3, 1999
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
[Olanzapine improves chorea in patients with Huntington's disease].Revista de neurologia, , Volume: 35, Issue:6
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.Psychiatry research, , Volume: 322, 2023
Predictors of relapse of psychotic depression: Findings from the STOP-PD II randomized clinical trial.Journal of psychiatric research, , Volume: 157, 2023
Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.Schizophrenia research, , Volume: 212, 2019
Effects of Antipsychotic Drugs on the Epigenetic Modification of Brain-Derived Neurotrophic Factor Gene Expression in the Hippocampi of Chronic Restraint Stress Rats.Neural plasticity, , Volume: 2018, 2018
Inverse association between negative symptoms and body mass index in chronic schizophrenia.Schizophrenia research, , Volume: 192, 2018
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.Journal of medical economics, , Volume: 20, Issue:11, 2017
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.Journal of medical economics, , Volume: 19, Issue:2, 2016
Delusional infestation: a case series from a university dermatology center in São Paulo, Brazil.International journal of dermatology, , Volume: 55, Issue:8, 2016
Chronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin Resistance.PloS one, , Volume: 11, Issue:12, 2016
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.Journal of medical economics, , Volume: 19, Issue:9, 2016
A Case of Chronic Peduncular Hallucinosis in a 90-Year-Old Woman Successfully Treated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 36, Issue:3, 2016
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.Schizophrenia research, , Volume: 161, Issue:2-3, 2015
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.The journal of mental health policy and economics, , Volume: 18, Issue:4, 2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.The Journal of nervous and mental disease, , Volume: 203, Issue:7, 2015
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.The Journal of nervous and mental disease, , Volume: 202, Issue:1, 2014
Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.European journal of pharmacology, , Jan-05, Volume: 722, 2014
Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.Journal of medical economics, , Volume: 16, Issue:9, 2013
Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.Journal of medical economics, , Volume: 16, Issue:9, 2013
Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.Pharmacopsychiatry, , Volume: 46, Issue:3, 2013
Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study.Human psychopharmacology, , Volume: 27, Issue:4, 2012
The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study.International clinical psychopharmacology, , Volume: 27, Issue:6, 2012
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-15, Volume: 35, Issue:1, 2011
Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:10, 2011
Antibodies to measles in individuals with recent onset psychosis.Schizophrenia research, , Volume: 119, Issue:1-3, 2010
Valid grounds for the switch of original antipsychotics with generics.Psychiatria Danubina, , Volume: 22, Issue:1, 2010
Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Severe dopaminergic pathways damage in a case of chronic toluene abuse.Clinical neurology and neurosurgery, , Volume: 111, Issue:10, 2009
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 54, Issue:4, 2009
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.Human psychopharmacology, , Volume: 24, Issue:3, 2009
Results of phase 3 of the CATIE schizophrenia trial.Schizophrenia research, , Volume: 107, Issue:1, 2009
Clinical experiences and clinical trials.CNS spectrums, , Volume: 13, Issue:6, 2008
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.Human psychopharmacology, , Volume: 23, Issue:4, 2008
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.Schizophrenia research, , Volume: 99, Issue:1-3, 2008
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.Schizophrenia research, , Volume: 100, Issue:1-3, 2008
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.Human psychopharmacology, , Volume: 23, Issue:3, 2008
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.Psychiatry research, , May-30, Volume: 159, Issue:1-2, 2008
[The possibility of high-quality remission in the long chronic course of schizophrenia].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 108, Issue:11, 2008
An open-label study of olanzapine in children and adolescents with schizophrenia.Journal of psychiatric practice, , Volume: 13, Issue:2, 2007
Modification of spatial recognition memory and object discrimination after chronic administration of haloperidol, amitriptyline, sodium valproate or olanzapine in normal and anhedonic rats.The international journal of neuropsychopharmacology, , Volume: 10, Issue:3, 2007
A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Orally disintegrating olanzapine for the treatment of a manic patient with esophageal stricture plus chronic pharyngitis.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 31, Issue:2, 2007
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.Schizophrenia research, , Volume: 89, Issue:1-3, 2007
Changes in cortical volume with olanzapine in chronic schizophrenia.Pharmacopsychiatry, , Volume: 40, Issue:4, 2007
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder.Psychiatry and clinical neurosciences, , Volume: 61, Issue:4, 2007
Alteration in serum neural cell adhesion molecule in patients of schizophrenia.Human psychopharmacology, , Volume: 22, Issue:2, 2007
Impairment in error monitoring predicts poor executive function in schizophrenia patients.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
[Glutamate dysmetabolism in patients with schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:3, 2007
Reduced thalamic volume in patients with chronic schizophrenia after switching from typical antipsychotic medications to olanzapine.The American journal of psychiatry, , Volume: 163, Issue:11, 2006
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.Journal of psychiatric research, , Volume: 40, Issue:7, 2006
Prolongation of clozapine-induced leukopenia with olanzapine treatment.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:5, 2006
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.Acta psychiatrica Scandinavica, , Volume: 114, Issue:5, 2006
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.Human psychopharmacology, , Volume: 21, Issue:4, 2006
Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report.Psychiatria Danubina, , Volume: 18, Issue:1-2, 2006
Neurological soft signs and positive treatment response to olanzapine in chronic schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:1, 2006
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.Schizophrenia research, , Volume: 83, Issue:1, 2006
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorders, , Volume: 7 Suppl 3, 2005
Olanzapine for the management of pain in an adolescent girl.Journal of child and adolescent psychopharmacology, , Volume: 15, Issue:6, 2005
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.The New England journal of medicine, , Sep-22, Volume: 353, Issue:12, 2005
Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression.Medical hypotheses, , Volume: 65, Issue:1, 2005
Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.Journal of clinical pharmacy and therapeutics, , Volume: 30, Issue:1, 2005
Neurologic soft signs and olanzapine treatment in chronic schizophrenia.Journal of clinical psychopharmacology, , Volume: 24, Issue:5, 2004
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.International clinical psychopharmacology, , Volume: 19, Issue:1, 2004
Switching elderly chronic psychotic patients to olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:2, 2004
Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.Pharmacological research, , Volume: 48, Issue:4, 2003
Treatment noncompliance with orally disintegrating olanzapine tablets.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.Psychopharmacology, , Volume: 169, Issue:3-4, 2003
Optimal dosing of medications (in bipolar disorder).The Journal of family practice, , Volume: Suppl, 2003
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.The Journal of clinical psychiatry, , Volume: 64, Issue:2, 2003
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
Report of three case studies with olanzapine for chronic pain.The journal of pain, , Volume: 4, Issue:3, 2003
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.Biological psychiatry, , Mar-15, Volume: 51, Issue:6, 2002
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.The American journal of psychiatry, , Volume: 159, Issue:2, 2002
Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:6, 2002
[Mnestic impairment under olanzapine overdosage in an elderly patient].Psychiatrische Praxis, , Volume: 29, Issue:8, 2002
Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Emergence of compulsive symptoms with olanzapine treatment.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:4, 2002
Olanzapine in the treatment of refractory migraine and chronic daily headache.Headache, , Volume: 42, Issue:6, 2002
Service use and costs of treating schizophrenia with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 62, Issue:10, 2001
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.The international journal of neuropsychopharmacology, , Volume: 4, Issue:3, 2001
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.Schizophrenia research, , Mar-01, Volume: 48, Issue:1, 2001
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.The American journal of psychiatry, , Volume: 158, Issue:2, 2001
Olanzapine and pancreatitis.The British journal of psychiatry : the journal of mental science, , Volume: 177, 2000
Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment.Acta psychiatrica Scandinavica, , Volume: 102, Issue:3, 2000
Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.South Dakota journal of medicine, , Volume: 53, Issue:2, 2000
[Chronic and therapy refractory Fregoli syndrome].Psychiatrische Praxis, , Volume: 27, Issue:1, 2000
Marked elevation of serum creatine kinase associated with olanzapine therapy.The Annals of pharmacotherapy, , Volume: 33, Issue:6, 1999
Aggression, agitation, and mania with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:10, 1998
New antipsychotic medications: strategies for evaluation and selected findings.Schizophrenia research, , Oct-30, Volume: 27, Issue:2-3, 1997
High-dose olanzapine for treatment-refractory schizophrenia.The American journal of psychiatry, , Volume: 154, Issue:11, 1997
Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 7, Issue:5
Persistent psychosis after a single ingestion of 'ecstasy'.Psychosomatics, , Volume: 42, Issue:6
International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 11, Issue:6
Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 8, Issue:2
Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 15, Issue:3-4
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.The American journal of psychiatry, , 06-01, Volume: 176, Issue:6, 2019
Clinical Pearls in palliative medicine.Disease-a-month : DM, , Volume: 63, Issue:6, 2017
"Schizophrenia past clozapine": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing.Pharmacopsychiatry, , Volume: 48, Issue:1, 2015
In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation.International clinical psychopharmacology, , Volume: 28, Issue:2, 2013
Plasma concentrations of high-dose olanzapine in a double-blind crossover study.Human psychopharmacology, , Volume: 21, Issue:6, 2006
Olanzapine for schizophrenia.The Medical letter on drugs and therapeutics, , Jan-17, Volume: 39, Issue:992, 1997
Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.Journal of the American Medical Directors Association, , Volume: 4, Issue:4
Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics.PloS one, , Volume: 8, Issue:5, 2013
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.Schizophrenia research, , Volume: 146, Issue:1-3, 2013
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:1, 2005
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.Acta psychiatrica Scandinavica, , Volume: 124, Issue:3, 2011
Dyslipidemia and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
Overdose and death with olanzapine: two case reports.The American journal of forensic medicine and pathology, , Volume: 21, Issue:3, 2000
Case series profile of olanzapine post-injection delirium/sedation syndrome.British journal of clinical pharmacology, , Volume: 89, Issue:2, 2023
Continuation of depot olanzapine pamoate after post-injection delirium/sedation syndrome (PDSS) in a case of bipolar mania-a clinical conundrum.Bipolar disorders, , Volume: 25, Issue:2, 2023
[no title available]Ugeskrift for laeger, , May-08, Volume: 185, Issue:19, 2023
Olanzapine in oncology palliative care.Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, ,Summer, Volume: 35, Issue:4, 2022
Post-Injection Delirium/Sedation Syndrome: A Case Report and 2-Year Follow-Up.The American journal of case reports, , Oct-17, Volume: 23, 2022
Delirium with visual hallucinations induced by low-dose olanzapine.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 22, Issue:3, 2022
Delirium in the Neonate.Clinics in perinatology, , Volume: 49, Issue:1, 2022
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.The American journal of case reports, , Dec-01, Volume: 23, 2022
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home.Trials, , Apr-14, Volume: 23, Issue:1, 2022
Are dexmedetomidine and olanzapine suitable to control delirium in critically ill elderly patients? A retrospective cohort study.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 139, 2021
Case report: Olanzapine post-injection delirium/sedation syndrome mimicking brainstem-thrombosis.Acta neurologica Belgica, , Volume: 121, Issue:5, 2021
Extrapyramidal Symptoms Induced by Treatment for Delirium: A Case Report.Critical care nurse, , Jun-01, Volume: 41, Issue:3, 2021
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.The oncologist, , Volume: 25, Issue:3, 2020
Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.The Australian and New Zealand journal of psychiatry, , Volume: 54, Issue:7, 2020
Antipsychotics for treatment of delirium in hospitalised non-ICU patients.The Cochrane database of systematic reviews, , 06-18, Volume: 6, 2018
Occurrence of post-injection delirium/sedation syndrome after application of olanzapine long-acting injection during one year period.Psychiatria Danubina, , Volume: 29, Issue:4, 2017
Olanzapine induced delirium-a "probable" adverse drug reaction.Annals of palliative medicine, , Volume: 6, Issue:Suppl 2, 2017
Delirium associated with olanzapine use in the elderly.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 17, Issue:2, 2017
Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation.L'Encephale, , Volume: 43, Issue:4, 2017
[Post-injection syndrome and olanzapine pamoate: A severe case report].L'Encephale, , Volume: 43, Issue:4, 2017
Delirium in hospitalized patients: Risks and benefits of antipsychotics.Cleveland Clinic journal of medicine, , Volume: 84, Issue:8, 2017
Olanzapine for Nausea, Delirium, Anxiety, Insomnia, and Cachexia #315.Journal of palliative medicine, , Volume: 19, Issue:11, 2016
Delirium with anticholinergic symptoms after a combination of paliperidone and olanzapine pamoate in a patient known to smoke cannabis: an unfortunate coincidence.BMJ case reports, , Jun-22, Volume: 2016, 2016
Postinjection Delirium Syndrome Associated With Olanzapine Long-Acting Injectable.Journal of clinical psychopharmacology, , Volume: 36, Issue:4, 2016
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.The American journal of hospice & palliative care, , Volume: 33, Issue:5, 2016
Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?Basic & clinical pharmacology & toxicology, , Volume: 117, Issue:3, 2015
Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.CNS drugs, , Volume: 29, Issue:1, 2015
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.Palliative & supportive care, , Volume: 13, Issue:4, 2015
Case records of the Massachusetts General Hospital. Case 10-2015. A 15-year-old girl with Graves’ disease and psychotic symptoms.The New England journal of medicine, , Mar-26, Volume: 372, Issue:13, 2015
Treatment of delirium in the context of anti-N-methyl-D-aspartate receptor antibody encephalitis.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 54, Issue:3, 2015
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.BMC psychiatry, , Apr-02, Volume: 15, 2015
Management of delirium in palliative care: a review.Current psychiatry reports, , Volume: 17, Issue:3, 2015
Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.BMC psychiatry, , Nov-13, Volume: 15, 2015
Implications of atypical antipsychotic prescribing in the intensive care unit.Journal of critical care, , Volume: 30, Issue:4, 2015
Olanzapine postinjection delirium/sedation syndrome: an unrecognized diagnosis in the emergency department.The Journal of emergency medicine, , Volume: 47, Issue:1, 2014
[Sparse evidence of antipsychotic drugs for the treatment of delirium].Ugeskrift for laeger, , Sep-29, Volume: 176, Issue:40, 2014
[Sparse evidence of antipsychotic drugs for the treatment of delirium].Ugeskrift for laeger, , Apr-14, Volume: 176, Issue:16, 2014
The pharmacologic management of delirium in children and adolescents.Paediatric drugs, , Volume: 16, Issue:4, 2014
[Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].Tijdschrift voor psychiatrie, , Volume: 56, Issue:4, 2014
A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.BMC psychiatry, , Jan-14, Volume: 14, 2014
Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.International clinical psychopharmacology, , Volume: 29, Issue:6, 2014
Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.BMC psychiatry, , Sep-30, Volume: 13, 2013
Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient.Clinical toxicology (Philadelphia, Pa.), , Volume: 51, Issue:3, 2013
Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy.Current medical research and opinion, , Volume: 29, Issue:11, 2013
[Pharmacological treatment of delirium in palliative care patients. A systematic literature review].Schmerz (Berlin, Germany), , Volume: 27, Issue:2, 2013
Atypical antipsychotics in the treatment of delirium.Psychiatry and clinical neurosciences, , Volume: 67, Issue:5, 2013
The diagnosis and management of delirium in infancy.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:5, 2013
Long-acting injectable olanzapine can give rise to a condition consistent with central anticholinergic syndrome.Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Nov-12, Volume: 133, Issue:21, 2013
Atypical antipsychotic medications to control symptoms of delirium in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 22, Issue:2, 2012
A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study.Minerva anestesiologica, , Volume: 78, Issue:9, 2012
Successful use of olanzapine for catatonia following delirium.Psychiatry and clinical neurosciences, , Volume: 66, Issue:5, 2012
Delirium associated with olanzapine therapy in an elderly man with bipolar affective disorder.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 23, Issue:2, 2011
Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium.Journal of psychosomatic research, , Volume: 71, Issue:4, 2011
Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study.Journal of pain and symptom management, , Volume: 40, Issue:5, 2010
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.BMC psychiatry, , Jun-10, Volume: 10, 2010
Treatment of delirium in supportive and palliative care.Current opinion in supportive and palliative care, , Volume: 2, Issue:1, 2008
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Atypical antipsychotics for the treatment of delirious elders.Journal of the American Medical Directors Association, , Volume: 9, Issue:1, 2008
Antipsychotics for delirium.The Cochrane database of systematic reviews, , Apr-18, Issue:2, 2007
Olanzapine overdose: a series of analytically confirmed cases.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Delirium dilemma.Orthopedics, , Volume: 30, Issue:4, 2007
Elderly patient with delirium after myocardial infarction.Journal of the National Medical Association, , Volume: 98, Issue:4, 2006
Altered mental status from olanzapine overdose treated with physostigmine.Clinical toxicology (Philadelphia, Pa.), , Volume: 44, Issue:3, 2006
Can olanzapine cause delirium in the elderly?The Annals of pharmacotherapy, , Volume: 40, Issue:1, 2006
Atypical antipsychotics in the management of delirium: a review of the empirical literature.Palliative & supportive care, , Volume: 3, Issue:3, 2005
Olanzapine-induced vasculitis.The American journal of geriatric pharmacotherapy, , Volume: 3, Issue:1, 2005
Re: Olanzapine-induced delirium.Journal of pain and symptom management, , Volume: 29, Issue:2, 2005
Atypical neuroleptic malignant syndrome caused by olanzapine.Acta psychiatrica Scandinavica, , Volume: 112, Issue:3, 2005
Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report.Journal of Korean medical science, , Volume: 20, Issue:4, 2005
Development of opioid-induced delirium while on olanzapine: a two-case report.Journal of pain and symptom management, , Volume: 29, Issue:4, 2005
Olanzapine for delirium in parkinsonism: therapeutic benefits in lieu of adverse consequences.Neurology India, , Volume: 52, Issue:2, 2004
Olanzapine vs haloperidol: treating delirium in a critical care setting.Intensive care medicine, , Volume: 30, Issue:3, 2004
Olanzapine-induced delirium in a terminally ill cancer patient.Journal of pain and symptom management, , Volume: 28, Issue:2, 2004
Olanzapine may cause delirium in geriatric patients.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Reply to the comment by Skrobik et al.Intensive care medicine, , Volume: 30, Issue:7, 2004
Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury.NeuroRehabilitation, , Volume: 18, Issue:3, 2003
[A case of delirium after olanzapine intoxication].Der Nervenarzt, , Volume: 74, Issue:11, 2003
An open pilot trial of olanzapine for delirium in the Korean population.Psychiatry and clinical neurosciences, , Volume: 55, Issue:5, 2001
Olanzapine in an intensive care unit.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:4, 1999
Risperidone versus olanzapine for the treatment of delirium.Human psychopharmacology, , Volume: 25, Issue:4
Fever, delirium, autonomic instability, and monocytosis associated with olanzapine.Journal of postgraduate medicine, , Volume: 49, Issue:1
Old disease, new look? A first report of parkinsonism due to scurvy, and of refeeding-induced worsening of scurvy.Psychosomatics, , Volume: 54, Issue:3
Delirium Associated With Fluoxetine Discontinuation: A Case Report.Clinical neuropharmacology, , Volume: 40, Issue:3
Antipsychotic prophylaxis in surgical patients modestly decreases delirium incidence--but not duration--in high-incidence samples: a meta-analysis.General hospital psychiatry, , Volume: 35, Issue:4
An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients.Psychosomatics, , Volume: 43, Issue:3
The role of atypical antipsychotics in the treatment of delirium.Psychosomatics, , Volume: 43, Issue:3
Olanzapine in the treatment of delirium.Psychosomatics, , Volume: 39, Issue:5
Clocking delirium: the value of the Clock Drawing Test with case illustrations.The American journal of hospice & palliative care, , Volume: 25, Issue:5
Management of Parkinson disease.The Journal of the American Board of Family Practice, , Volume: 11, Issue:2
Efficacy and Tolerability of Atypical Antipsychotics in the Treatment of Delirium: A Systematic Review of the Literature.Psychosomatics, , Volume: 60, Issue:1
Delayed Onset Postinjection Delirium/Sedation Syndrome Associated With Olanzapine Pamoate: A Case Report.Journal of clinical psychopharmacology, , Volume: 39, Issue:5
Individual risk profiles for postoperative delirium after joint replacement surgery.Psychosomatics, , Volume: 52, Issue:5
Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial.Psychosomatics, , Volume: 51, Issue:5
Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection.Clinical neuropharmacology, , Volume: 42, Issue:2
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.Drugs & aging, , Volume: 40, Issue:1, 2023
Lessons of the month 2: Olanzapine-induced hypothermia and hand oedema.Clinical medicine (London, England), , Volume: 22, Issue:3, 2022
Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.Advances in therapy, , Volume: 39, Issue:5, 2022
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review.The journal of prevention of Alzheimer's disease, , Volume: 8, Issue:4, 2021
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia.Psychiatry research, , Volume: 295, 2021
Bethanechol as a Corrective for Urinary Retention Associated With Olanzapine Administration.The primary care companion for CNS disorders, , Oct-31, Volume: 21, Issue:5, 2019
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study.CNS drugs, , Volume: 30, Issue:11, 2016
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.Palliative & supportive care, , Volume: 13, Issue:4, 2015
Biological Perspectives: Huntington's Disease.Perspectives in psychiatric care, , Volume: 51, Issue:3, 2015
Treatment changes among older patients with dementia treated with antipsychotics.International journal of geriatric psychiatry, , Volume: 30, Issue:12, 2015
Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.JAMA psychiatry, , Volume: 72, Issue:5, 2015
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study.PloS one, , Volume: 8, Issue:5, 2013
Olanzapine: palliative medicine update.The American journal of hospice & palliative care, , Volume: 30, Issue:1, 2013
Risk of mortality among individual antipsychotics in patients with dementia.The American journal of psychiatry, , Volume: 169, Issue:1, 2012
Pisa syndrome secondary to rivastigmine: a case report.La Clinica terapeutica, , Volume: 163, Issue:1, 2012
Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.The American journal of geriatric pharmacotherapy, , Volume: 10, Issue:6, 2012
[A case of affective disorder with psychotic symptoms as late manifestation of Huntington's Chorea].Psychiatrische Praxis, , Volume: 38, Issue:6, 2011
[Descriptive analysis of the use of atypical antipsychotics under compassionate-use in a health area in Ferrol (La Coruña, Spain)].Neurologia (Barcelona, Spain), , Volume: 25, Issue:5, 2010
Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara.European journal of clinical pharmacology, , Volume: 66, Issue:7, 2010
Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?Journal of the American Geriatrics Society, , Volume: 58, Issue:6, 2010
Olanzapine treatment in Jarisch-Herxheimer reaction due to neurosyphilis with dementia: a case report.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:8, 2009
The promotion of olanzapine in primary care: an examination of internal industry documents.Social science & medicine (1982), , Volume: 69, Issue:1, 2009
Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain.Drug safety, , Volume: 32, Issue:11, 2009
[Atypical antipsychotics in elderly patients with dementia].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , May-01, Volume: 128, Issue:9, 2008
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.Current medical research and opinion, , Volume: 24, Issue:3, 2008
[The use of antipsychotics in patients with dementia].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:3, 2008
Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis.International journal of geriatric psychiatry, , Volume: 23, Issue:4, 2008
Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS).International journal of geriatric psychiatry, , Volume: 23, Issue:9, 2008
Some treatment dilemmas in rapidly developing dementia: a case report.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 9, Issue:1, 2008
Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics?European journal of neurology, , Volume: 15, Issue:2, 2008
Neuroleptic malignant syndrome and catatonia in a patient with dementia.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:6, 2008
Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy.Pharmacotherapy, , Volume: 28, Issue:3, 2008
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.Medicine and health, Rhode Island, , Volume: 90, Issue:6, 2007
Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 15, Issue:11, 2007
All-cause mortality associated with atypical and typical antipsychotics in demented outpatients.Pharmacoepidemiology and drug safety, , Volume: 16, Issue:5, 2007
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe?Archives of gerontology and geriatrics, , Volume: 44 Suppl 1, 2007
Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia.Psychotherapy and psychosomatics, , Volume: 76, Issue:4, 2007
[Application of neuroleptics for dementia].Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, , Volume: 44, Issue:1, 2007
Can olanzapine cause delirium in the elderly?The Annals of pharmacotherapy, , Volume: 40, Issue:1, 2006
A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia.The Journal of clinical psychiatry, , Volume: 67, Issue:6, 2006
Anticholinergics in dementia and other confounding problems.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:4, 2006
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].Nederlands tijdschrift voor geneeskunde, , Jul-15, Volume: 150, Issue:28, 2006
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
Survival among elderly Italian patients with dementia treated with atypical antipsychotics: observational study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 27, Issue:6, 2006
[Psychopharmacological treatment of behavioral and psychological symptoms in dementia].Ugeskrift for laeger, , Oct-02, Volume: 168, Issue:40, 2006
Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued?International journal of geriatric psychiatry, , Volume: 21, Issue:2, 2006
[New formulations of olanzapine in the treatment of acute agitation].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:1, 2006
FDA warns antipsychotic drugs may be risky for elderly.JAMA, , May-25, Volume: 293, Issue:20, 2005
Atypical antipsychotics for nursing home patients: a retrospective chart review.Drugs & aging, , Volume: 22, Issue:3, 2005
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Jan-22, Volume: 149, Issue:4, 2005
Do atypical antipsychotics cause stroke?CNS drugs, , Volume: 19, Issue:2, 2005
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Mar-26, Volume: 149, Issue:13, 2005
Dementia.Clinical evidence, , Issue:14, 2005
Memory-sparing cognitive deterioration in the elderly: what is the diagnosis?Reviews in neurological diseases, ,Spring, Volume: 2, Issue:2, 2005
A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD). Favour.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:5, 2005
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.International psychogeriatrics, , Volume: 17, Issue:4, 2005
Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Mar-26, Volume: 149, Issue:13, 2005
Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Optimizing atypical antipsychotic treatment strategies in the elderly.Journal of the American Geriatrics Society, , Volume: 52, Issue:12 Suppl, 2004
CSM warning on atypical psychotics and stroke may be detrimental for dementia.BMJ (Clinical research ed.), , May-22, Volume: 328, Issue:7450, 2004
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
Clinical effectiveness of atypical antipsychotics in dementia.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Dementia.Clinical evidence, , Issue:11, 2004
Efficacy of atypical antipsychotics in elderly patients with dementia.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Atypical antipsychotics and risk of cerebrovascular accidents.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
Neuroleptic malignant syndrome and low-dose olanzapine.The American journal of psychiatry, , Volume: 160, Issue:4, 2003
Psychotic disorder in a case with Hallervorden-Spatz disease.Acta psychiatrica Scandinavica, , Volume: 108, Issue:5, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
Severe cardiovascular side effects of olanzapine in an elderly patient: case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Use of atypical antipsychotic drugs in patients with dementia.American family physician, , Jun-01, Volume: 67, Issue:11, 2003
Calming versus sedative effects of intramuscular olanzapine in agitated patients.The American journal of emergency medicine, , Volume: 21, Issue:3, 2003
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.Southern medical journal, , Volume: 96, Issue:7, 2003
A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities.The Journal of clinical psychiatry, , Volume: 64, Issue:6, 2003
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 26, Issue:4, 2002
Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis.Pharmacotherapy, , Volume: 22, Issue:1, 2002
Atypical antipsychotics: experience and use in the elderly.International journal of clinical practice, , Volume: 56, Issue:7, 2002
Broad therapeutic uses of atypical antipsychotic medications.Biological psychiatry, , Dec-01, Volume: 50, Issue:11, 2001
Olanzapine in dementia with Lewy bodies: a clinical study.International journal of geriatric psychiatry, , Volume: 14, Issue:6, 1999
Conventional vs. newer antipsychotics in elderly patients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Winter, Volume: 7, Issue:1, 1999
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 11, Issue:3, 1999
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Managing the behavioral and psychological signs and symptoms of dementia.International clinical psychopharmacology, , Volume: 12 Suppl 4, 1997
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.Journal of the American Medical Directors Association, , Volume: 4, Issue:4
Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.American journal of Alzheimer's disease and other dementias, , Volume: 18, Issue:4
Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia.Psychosomatics, , Volume: 42, Issue:6
Mortality in patients with dementia treated with atypical antipsychotics (olanzapine, quetiapine and ziprasidone).Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, , Volume: 33, Issue:4
Assessing antipsychotic effectiveness in dementia with the factor structure of the Psychogeriatric Dependency Rating Scale (PGDRS).Journal of the American Medical Directors Association, , Volume: 4, Issue:2
Increase in mortality rate in patients with dementia treated with atypical antipsychotics: a cohort study in outpatients in Central Italy.Rivista di psichiatria, , Volume: 49, Issue:1
Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.Journal of the American Medical Directors Association, , Volume: 4, Issue:4
Black Hairy Tongue Associated With Olanzapine Use in a Female Dementia Patient: A Case Report.Journal of clinical psychopharmacology, , Volume: 42, Issue:2
Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature.Harvard review of psychiatry, , Volume: 13, Issue:6
Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.American journal of Alzheimer's disease and other dementias, , Volume: 21, Issue:2
Residual or re-emergent impaired insight into delusions following remission is unrelated to later relapse during a randomized clinical trial of continuation pharmacotherapy for psychotic depression - The STOP-PD II Study.Journal of affective disorders, , 03-15, Volume: 325, 2023
Predictors of relapse of psychotic depression: Findings from the STOP-PD II randomized clinical trial.Journal of psychiatric research, , Volume: 157, 2023
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.The lancet. Psychiatry, , Volume: 10, Issue:9, 2023
Genomic Investigation of Remission and Relapse of Psychotic Depression Treated with Sertraline plus Olanzapine: The STOP-PD II Study.Neuropsychobiology, , Volume: 82, Issue:3, 2023
Are antipsychotics effective adjunctive Tx for patients with moderate-to-severe depression?The Journal of family practice, , Volume: 71, Issue:6, 2022
Association between the improvement in depressive symptoms and serum BDNF levels in drug-naive first episode patients with schizophrenia: A longitudinal follow-up.Psychoneuroendocrinology, , Volume: 133, 2021
Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 29, Issue:7, 2021
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.The international journal of neuropsychopharmacology, , 10-23, Volume: 24, Issue:10, 2021
Slowly Working Toward More Treatments for Depression in Bipolar II Disorder.The American journal of psychiatry, , Volume: 178, Issue:12, 2021
Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression.Journal of affective disorders, , 02-01, Volume: 280, Issue:Pt A, 2021
The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study.Schizophrenia research, , Volume: 231, 2021
Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.Pharmacology research & perspectives, , Volume: 9, Issue:5, 2021
Pica disorder as a symptom of depression in a patient with bipolar disorder and intellectual disability.Actas espanolas de psiquiatria, , Volume: 48, Issue:1, 2020
Can atypical dysgeusia in depression be related to a deafferentation syndrome?Medical hypotheses, , Volume: 144, 2020
Pupillary capture of implantable collamer lens after oral antidepressants.Digital journal of ophthalmology : DJO, , Volume: 25, Issue:4, 2019
Maintenance Treatment for Psychotic Depressive Disorders: Progress and Remaining Challenges.JAMA, , 08-20, Volume: 322, Issue:7, 2019
[The Protective Effect of Olanzapine on the Hippocampal Neuron of Depression Model Rats via Inhibiting NLRP3 Inflammasome Activation].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, , Volume: 50, Issue:5, 2019
Continuing Antipsychotic Medication for Patients With Psychotic Depression in Remission.JAMA, , 12-24, Volume: 322, Issue:24, 2019
Erotomania in Depressive Psychosis: Mood Incongruent Delusion in a Depressive Young Woman.Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, , Volume: 29, Issue:6, 2019
Brain Sub/Region-Specific Effects of Olanzapine on c-Fos Expression of Chronically Socially Isolated Rats.Neuroscience, , 01-01, Volume: 396, 2019
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.Psychopharmacology, , Volume: 236, Issue:2, 2019
Basal Ganglia Calcification: A Case Report of Fahr Disease With Pure Psychiatric Symptoms.Journal of psychiatric practice, , Volume: 25, Issue:5, 2019
Olanzapine-induced peripheral eosinophilia and eosinophilic pleural effusion: A case report.Medicine, , Volume: 97, Issue:7, 2018
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.Medicine, , Volume: 97, Issue:37, 2018
Drug-induced Pressure Ulcers in a Middle-aged Patient with Early-stage Parkinson's Disease.Internal medicine (Tokyo, Japan), , May-15, Volume: 57, Issue:10, 2018
Mesoporous hydroxyapatite as a carrier of olanzapine for long-acting antidepression treatment in rats with induced depression.Journal of controlled release : official journal of the Controlled Release Society, , 06-10, Volume: 255, 2017
Acute massıve pulmonary embolism assocıated wıth olanzapıne.The American journal of emergency medicine, , Volume: 35, Issue:10, 2017
Activation of indoleamine 2, 3- dioxygenase pathway by olanzapine augments antidepressant effects of venlafaxine in mice.Psychiatry research, , Volume: 258, 2017
H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice.Metabolic brain disease, , Volume: 31, Issue:5, 2016
Early antipsychotic treatment in childhood/adolescent period has long-term effects on depressive-like, anxiety-like and locomotor behaviours in adult rats.Journal of psychopharmacology (Oxford, England), , Volume: 30, Issue:2, 2016
Atypical antipsychotics as augmentation therapy in anorexia nervosa.PloS one, , Volume: 10, Issue:4, 2015
GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.Metabolic brain disease, , Volume: 30, Issue:2, 2015
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:11, 2015
Erotomania and psychotic depression.The Australian and New Zealand journal of psychiatry, , Volume: 49, Issue:11, 2015
A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 24, Issue:3, 2014
Depression and impulsivity as pathways to violence: implications for antiaggressive treatment.Schizophrenia bulletin, , Volume: 40, Issue:4, 2014
Acute and maintenance treatments for bipolar depression.The Journal of clinical psychiatry, , Volume: 75, Issue:4, 2014
The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats.Pharmacological reports : PR, , Volume: 66, Issue:3, 2014
The impact of insight in a first-episode mania with psychosis population on outcome at 18 months.Journal of affective disorders, , Volume: 167, 2014
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.Acta psychiatrica Scandinavica, , Volume: 130, Issue:6, 2014
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.The Journal of clinical psychiatry, , Volume: 75, Issue:6, 2014
Current status of atypical antipsychotics for the treatment of fibromyalgia.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:6, 2014
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.Journal of affective disorders, , Jan-25, Volume: 144, Issue:3, 2013
Inhibition/activation in bipolar disorder: validation of the Multidimensional Assessment of Thymic States scale (MAThyS).BMC psychiatry, , Mar-13, Volume: 13, 2013
DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.Journal of affective disorders, , Sep-05, Volume: 150, Issue:2, 2013
Capgras syndrome presenting in an adolescent girl in the Caribbean.The West Indian medical journal, , Volume: 62, Issue:1, 2013
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.Pharmacological reports : PR, , Volume: 65, Issue:1, 2013
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.Molecular psychiatry, , Volume: 18, Issue:5, 2013
Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice.Life sciences, , Dec-17, Volume: 91, Issue:25-26, 2012
Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials.BMC psychiatry, , Jun-20, Volume: 11, 2011
Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.BMC psychiatry, , Aug-31, Volume: 11, 2011
Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial.Human psychopharmacology, , Volume: 25, Issue:1, 2010
The effect of Olanzapine and Sertraline on personality disorder in patients with methadone maintenance therapy.Psychiatria Danubina, , Volume: 22, Issue:4, 2010
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.Expert review of neurotherapeutics, , Volume: 10, Issue:5, 2010
Efficacy, tolerability, and preference of mirtazapine orally disintegrating tablets in depressed patients: a 17-week naturalistic study in Lithuania.Medicina (Kaunas, Lithuania), , Volume: 45, Issue:10, 2009
Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder.Journal of affective disorders, , Volume: 116, Issue:1-2, 2009
Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:4, 2009
Case report: excellent response to long-term higher dose single olanzapine in a case of recurrent brief depression.Pharmacopsychiatry, , Volume: 41, Issue:4, 2008
Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility.Expert review of neurotherapeutics, , Volume: 8, Issue:9, 2008
Weight gain during olanzapine treatment for psychotic depression: effects of dose and age.International clinical psychopharmacology, , Volume: 23, Issue:3, 2008
Some treatment dilemmas in rapidly developing dementia: a case report.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 9, Issue:1, 2008
Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study.The Journal of clinical psychiatry, , Volume: 69, Issue:6, 2008
[Vigency of lithium treatment].Medicina clinica, , Jan-13, Volume: 128, Issue:1, 2007
Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine.Pharmacopsychiatry, , Volume: 40, Issue:2, 2007
Effect of comorbid anxiety on treatment response in bipolar depression.Journal of affective disorders, , Volume: 104, Issue:1-3, 2007
[Atypical neuroleptics in the treatment of atypical facial neuralgia. Two case reports].Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, , Volume: 42, Issue:9, 2007
Item response analysis of the Positive and Negative Syndrome Scale.BMC psychiatry, , Nov-15, Volume: 7, 2007
Clinical relevance of depressive symptom improvement in bipolar I depressed patients.Journal of affective disorders, , Volume: 92, Issue:2-3, 2006
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.Acta psychiatrica Scandinavica, , Volume: 114, Issue:5, 2006
[Molecular pharmacogenetic study on antipsychotic-drug therapy responders with depression or schizophrenia].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 108, Issue:6, 2006
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.Journal of clinical psychopharmacology, , Volume: 26, Issue:2, 2006
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.International clinical psychopharmacology, , Volume: 20, Issue:4, 2005
Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients.Schizophrenia research, , Oct-15, Volume: 78, Issue:2-3, 2005
Olanzapine- and clozapine-induced stuttering. A case series.Pharmacopsychiatry, , Volume: 37, Issue:3, 2004
The antidepressant effects of risperidone and olanzapine in bipolar disorder.The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, ,Fall, Volume: 11, Issue:2, 2004
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.Archives of general psychiatry, , Volume: 60, Issue:11, 2003
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:5, 2003
Clinical and neuropsychological correlates of the P300 in schizophrenia.Schizophrenia research, , May-01, Volume: 55, Issue:1-2, 2002
Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Visual inspection of medications in preventing unexplained relapses.The Annals of pharmacotherapy, , Volume: 36, Issue:10, 2002
Olanzapine: an updated review of its use in the management of schizophrenia.Drugs, , Volume: 61, Issue:1, 2001
The economic consequences of a drug-drug interaction.Journal of clinical psychopharmacology, , Volume: 21, Issue:1, 2001
Short-term effects of olanzapine in Huntington disease.Neuropsychiatry, neuropsychology, and behavioral neurology, , Volume: 14, Issue:1, 2001
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 61 Suppl 3, 2000
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Olanzapine in dementia with Lewy bodies: a clinical study.International journal of geriatric psychiatry, , Volume: 14, Issue:6, 1999
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.Biological psychiatry, , Jun-01, Volume: 43, Issue:11, 1998
[Treatment of non cognitive symptoms of Alzheimer's disease].Revista de neurologia, , Volume: 42, Issue:8
Olanzapine usage associated with neuroleptic malignant syndrome.Psychosomatics, , Volume: 42, Issue:6
[Use of high-dose olanzapine for treatment of acute relapse of schizophrenia in a patient with bad tolerance of typical neuroleptics. Case report].Psychiatria polska, , Volume: 38, Issue:3
[Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].Psychiatria polska, , Volume: 38, Issue:3
Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice.Acta poloniae pharmaceutica, , Volume: 66, Issue:3
[Subjective and objective evaluation of treating schizophrenia with classic or atypical drugs].Psychiatria polska, , Volume: 35, Issue:1
Olanzapine and mirtazapine for multiple palliation.The journal of supportive oncology, , Volume: 1, Issue:1
Effects of antipsychotic medication on functional connectivity in major depressive disorder with psychotic features.Molecular psychiatry, , Volume: 28, Issue:8, 2023
Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.Psychological medicine, , Volume: 53, Issue:9, 2023
Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis.Medicine, , Sep-22, Volume: 102, Issue:38, 2023
Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis.Psychological medicine, , Volume: 52, Issue:12, 2022
Neuroleptic malignant syndrome with abnormally elevated cardiac troponin I: a case report.The Journal of international medical research, , Volume: 48, Issue:11, 2020
New-onset psychosis following initiation of eye movement desensitization and reprocessing therapy.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 32, Issue:2, 2020
Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial.JAMA psychiatry, , 07-01, Volume: 77, Issue:7, 2020
Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.JAMA, , 08-20, Volume: 322, Issue:7, 2019
Maintenance Treatment for Psychotic Depressive Disorders: Progress and Remaining Challenges.JAMA, , 08-20, Volume: 322, Issue:7, 2019
Stabilization treatment of remitted psychotic depression: the STOP-PD study.Acta psychiatrica Scandinavica, , Volume: 138, Issue:3, 2018
[Electroconvulsive Therapy (ECT) of a 15-year-old female patient suffering from a severe delusional depression: a case report].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 46, Issue:6, 2018
Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines.Acta psychiatrica Scandinavica, , Volume: 138, Issue:3, 2018
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
Anxiolytic effects of venlafaxine/olanzapine combination in treatment of anxious depression.Neuro endocrinology letters, , Volume: 38, Issue:8, 2018
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 49, 2018
Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.Drugs & aging, , Volume: 34, Issue:3, 2017
Clinical Pearls in palliative medicine.Disease-a-month : DM, , Volume: 63, Issue:6, 2017
Reexamining the Role of Electroconvulsive Therapy in Anorexia Nervosa in Adolescents.The journal of ECT, , Volume: 33, Issue:4, 2017
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.Journal of affective disorders, , Jan-01, Volume: 207, 2017
Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:6, 2017
A Woman in Her 60s With Fever and Altered Mental Status in a Psychiatric Hospital.Chest, , Volume: 150, Issue:6, 2016
A Woman With Major Depression With Psychotic Features Requesting a Termination of Pregnancy.The American journal of psychiatry, , Volume: 173, Issue:1, 2016
SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study.Human psychopharmacology, , Volume: 31, Issue:3, 2016
Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS).Journal of affective disorders, , Jan-15, Volume: 190, 2016
Use of Orally Disintegrating Olanzapine During Electroconvulsive Therapy for Prevention of Postictal Agitation.Journal of psychiatric practice, , Volume: 22, Issue:6, 2016
Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.The Journal of clinical psychiatry, , Volume: 76, Issue:6, 2015
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.Clinical pharmacokinetics, , Volume: 54, Issue:11, 2015
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.Schizophrenia research, , Volume: 161, Issue:2-3, 2015
Management of depressive symptoms in schizophrenia.Clinical schizophrenia & related psychoses, , Volume: 9, Issue:1, 2015
Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 23, Issue:12, 2015
Sleep architecture and cognitive changes in olanzapine-treated patients with depression: a double blind randomized placebo controlled trial.BMC psychiatry, , Jul-17, Volume: 14, 2014
Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.Journal of affective disorders, , Volume: 160, 2014
Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 22, Issue:4, 2014
Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study.Comprehensive psychiatry, , Volume: 55, Issue:5, 2014
Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, , Volume: 47, Issue:7, 2014
Effects of low-dose olanzapine on duloxetine-related nausea and vomiting for the treatment of major depressive disorder.Journal of clinical psychopharmacology, , Volume: 34, Issue:4, 2014
A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.The Journal of clinical psychiatry, , Volume: 74, Issue:10, 2013
Prevention of relapse with maintenance electroconvulsive therapy in elderly patients with major depressive episode.The journal of ECT, , Volume: 29, Issue:1, 2013
Use of electroconvulsive therapy in an adolescent with systemic lupus erythematosus for management of depression.The journal of ECT, , Volume: 29, Issue:3, 2013
The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.Journal of clinical psychopharmacology, , Volume: 33, Issue:3, 2013
Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.Clinical therapeutics, , Volume: 33, Issue:9, 2011
Adjunctive antipsychotics for major depression.The Medical letter on drugs and therapeutics, , Sep-19, Volume: 53, Issue:1373, 2011
Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial.Journal of psychiatric research, , Volume: 45, Issue:7, 2011
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.Pharmacotherapy, , Volume: 31, Issue:8, 2011
[Mood disorder after malaria prophylaxis with mefloquine (two case reports)].L'Encephale, , Volume: 37, Issue:5, 2011
Effect of augmentation with olanzapine in outpatients with depression in partial remission with melancholic features: consecutive case series.Psychiatry and clinical neurosciences, , Volume: 65, Issue:2, 2011
Switching among antipsychotics--focus on side effects.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
A case of Klingsor Syndrome: when there is no longer psychosis.The Israel journal of psychiatry and related sciences, , Volume: 48, Issue:1, 2011
[A case of affective disorder with psychotic symptoms as late manifestation of Huntington's Chorea].Psychiatrische Praxis, , Volume: 38, Issue:6, 2011
Second-generation antipsychotics in major depressive disorder: update and clinical perspective.Current opinion in psychiatry, , Volume: 24, Issue:1, 2011
Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study.Human psychopharmacology, , Volume: 26, Issue:3, 2011
Major depression with catatonic features in a child remitted with olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 20, Issue:3, 2010
Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.Postgraduate medicine, , Volume: 122, Issue:4, 2010
Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.The Journal of clinical psychiatry, , Volume: 71, Issue:10, 2010
Second-generation antipsychotics for major depressive disorder and dysthymia.The Cochrane database of systematic reviews, , Dec-08, Issue:12, 2010
Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder.CNS drugs, , Volume: 24, Issue:3, 2010
Steroid responsive psychotic depression.The Australian and New Zealand journal of psychiatry, , Volume: 43, Issue:7, 2009
Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting.Human psychopharmacology, , Volume: 24, Issue:2, 2009
A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).Archives of general psychiatry, , Volume: 66, Issue:8, 2009
Psychogenic tremor in a patient with a major depressive episode.South Dakota medicine : the journal of the South Dakota State Medical Association, , Volume: 62, Issue:6, 2009
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.The Journal of clinical psychiatry, , Volume: 70, Issue:10, 2009
Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.Expert opinion on pharmacotherapy, , Volume: 10, Issue:13, 2009
An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.The Journal of clinical psychiatry, , Volume: 70, Issue:3, 2009
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.Acta psychiatrica Scandinavica, , Volume: 117, Issue:4, 2008
Nonfatal suicidal olanzapine intoxication: a case report.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Augmentation of antidepressants with atypical antipsychotics: a review of the current literature.Journal of psychiatric practice, , Volume: 14, Issue:1, 2008
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.Journal of clinical pharmacy and therapeutics, , Volume: 32, Issue:2, 2007
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.The Journal of clinical psychiatry, , Volume: 68, Issue:2, 2007
Atypical antipsychotics in bipolar disorder: systematic review of randomised trials.BMC psychiatry, , Aug-16, Volume: 7, 2007
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 46, Issue:8, 2007
Insight in first-episode psychosis.Psychological medicine, , Volume: 36, Issue:10, 2006
A delusion assessment scale for psychotic major depression: Reliability, validity, and utility.Biological psychiatry, , Dec-15, Volume: 60, Issue:12, 2006
Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:2, 2006
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.Depression and anxiety, , Volume: 23, Issue:6, 2006
Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:11, 2006
Massive creatine kinase elevations with quetiapine: report of two cases.Pharmacopsychiatry, , Volume: 39, Issue:1, 2006
Combined use of ECT with duloxetine and olanzapine: a case report.The journal of ECT, , Volume: 22, Issue:2, 2006
Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study.Psychiatry research, , Mar-31, Volume: 146, Issue:2, 2006
Creating more effective antidepressants: clues from the clinic.Drug discovery today, , Volume: 11, Issue:13-14, 2006
Duloxetine for childhood depression with pain and dissociative symptoms.European child & adolescent psychiatry, , Volume: 15, Issue:8, 2006
Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients.The Journal of clinical psychiatry, , Volume: 66, Issue:4, 2005
[Love, humor and psychosis in an atypical depression].L'Encephale, , Volume: 31 Pt 2, 2005
Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone?The American journal of psychiatry, , Volume: 162, Issue:4, 2005
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:6, 2005
[Brief case report. Duloxetine in Cotard syndrome].Psychiatrische Praxis, , Volume: 32, Issue:8, 2005
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.The Journal of clinical psychiatry, , Volume: 66, Issue:10, 2005
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:11, 2005
Olanzapine plus venlafaxine in treatment-resistant depression.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:4, 2005
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:8, 2005
Delusional wife: a case of diagnostic ambiguity and treatment challenge.Journal of psychiatric practice, , Volume: 11, Issue:3, 2005
Olanzapine-induced leucopenia and neutropenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:6, 2005
Obsessive-compulsive symptoms with olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:3, 2004
Cotard's syndrome and electroconvulsive therapy.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:11, 2004
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Open label study of the effect of amantadine on weight gain induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 58, Issue:2, 2004
Adolescent weight loss during treatment with olanzapine.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.Journal of clinical psychopharmacology, , Volume: 24, Issue:4, 2004
Antipsychotic-associated weight gain.The Annals of pharmacotherapy, , Volume: 38, Issue:5, 2004
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
Usefulness of olanzapine in refractory panic attacks.Journal of clinical psychopharmacology, , Volume: 23, Issue:1, 2003
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study.Psychopharmacology bulletin, ,Summer, Volume: 37, Issue:3, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Serotonin syndrome and atypical antipsychotics.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
[Improvement of tardive dyskinesia after treatment with olanzapine].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
Fluoxetine and olanzapine for resistant depression.The American journal of psychiatry, , Volume: 159, Issue:1, 2002
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.Schizophrenia bulletin, , Volume: 27, Issue:4, 2001
An open trial of olanzapine in the treatment of patients with psychotic depression.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 13, Issue:3, 2001
Use of atypical antipsychotics in mood disorders.Current opinion in investigational drugs (London, England : 2000), , Volume: 2, Issue:7, 2001
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
Does olanzapine have antidepressant properties? A retrospective preliminary study.Bipolar disorders, , Volume: 2, Issue:3 Pt 1, 2000
[Effective treatment of depressive disorder with psychotic symptoms by olanzapine combination therapy].Deutsche medizinische Wochenschrift (1946), , Dec-15, Volume: 125, Issue:50, 2000
Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration.Journal of clinical psychopharmacology, , Volume: 19, Issue:3, 1999
Adjunctive use of olanzapine in mood disorders: five case reports.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 9, Issue:4, 1997
Masturbatory guilt leading to severe depression and erectile dysfunction.Journal of sex & marital therapy, , Volume: 28, Issue:4
The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression.The Journal of clinical psychiatry, , Volume: 78, Issue:8
Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV.Psychosomatics, , Volume: 44, Issue:5
Comment on Nasrallah et al: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 12, Issue:6
Delirium Associated With Fluoxetine Discontinuation: A Case Report.Clinical neuropharmacology, , Volume: 40, Issue:3
Erotomania in Depressive Psychosis: Mood Incongruent Delusion in a Depressive Young Woman.Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, , Volume: 29, Issue:6, 2019
Antiepileptic effect of olanzapine in epilepsy patients with atypical depressive comorbidity.Epileptic disorders : international epilepsy journal with videotape, , Jun-01, Volume: 20, Issue:3, 2018
Thrombocytopenia and Spontaneous Intracranial Hemorrhage After Olanzapine Therapy.The Journal of the American Osteopathic Association, , Jul-01, Volume: 117, Issue:7, 2017
Elucidation of the Role of Dorsal Raphe Serotonergic Neurons in Mood Regulation Using Pharmacological and Viral Vector-based Approaches.Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, , Volume: 137, Issue:3, 2017
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
Olanzapine augments the effect of selective serotonin reuptake inhibitors by suppressing GABAergic inhibition via antagonism of 5-HT₆ receptors in the dorsal raphe nucleus.Neuropharmacology, , Volume: 95, 2015
[Hemoperfusion with activated charcoal on valproic acid poisoning. A case report].Medicina intensiva, , Volume: 39, Issue:7, 2015
[Woman in her 30s with chronic fatigue].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Feb-25, Volume: 134, Issue:4, 2014
[Electroconvulsion therapy for neuroleptic malignant syndrome].Tijdschrift voor psychiatrie, , Volume: 56, Issue:9, 2014
Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study.BMC psychiatry, , May-19, Volume: 14, 2014
[Buccolingual dyskinesia with justified hallucinations].Revista de neurologia, , Nov-16, Volume: 59, Issue:10, 2014
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.Journal of affective disorders, , Jan-25, Volume: 144, Issue:3, 2013
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.Boletin de la Asociacion Medica de Puerto Rico, , Volume: 105, Issue:3, 2013
[The comparative study on the efficacy of the combination of serotonin reuptake inhibitor antidepressants and antipsychotics in the treatment of recurrent depressive disorders].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 112, Issue:11 Pt 2, 2012
Electroconvulsive therapy in the presence of atrial septal defect: a case report.The journal of ECT, , Volume: 28, Issue:2, 2012
Clinical practice. Bipolar disorder--a focus on depression.The New England journal of medicine, , Jan-06, Volume: 364, Issue:1, 2011
Symptoms of agitated depression and/or akathisia.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Serotonin syndrome after discontinuation of olanzapine in a combined treatment with duloxetine -- case report.Pharmacopsychiatry, , Volume: 44, Issue:2, 2011
The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia.International clinical psychopharmacology, , Volume: 25, Issue:2, 2010
Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.The Journal of clinical psychiatry, , Volume: 71, Issue:4, 2010
In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 25, Issue:8, 2010
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.The pharmacogenomics journal, , Volume: 10, Issue:1, 2010
[Medication associated long QT syndrome].Praxis, , Dec-02, Volume: 98, Issue:24, 2009
Rowell's syndrome in the course of treatment with sodium valproate: a case report and review of the literature data.Clinical and experimental dermatology, , Volume: 34, Issue:6, 2009
Septo-optic dysplasia and psychiatric disorders: a case report.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 21, Issue:4, 2008
Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.Journal of affective disorders, , Volume: 105, Issue:1-3, 2008
Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.Psychopharmacology, , Volume: 201, Issue:2, 2008
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
[Depression in schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:10, 2008
Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series.Human psychopharmacology, , Volume: 23, Issue:3, 2008
Water, water, everywhere, nor any drop to drink: climate change delusion.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:4, 2008
Plasma lipids, lipoproteins and hormones levels during olanzapine treatment in psychosis and depression.Medicinski arhiv, , Volume: 61, Issue:2, 2007
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.Bipolar disorders, , Volume: 9, Issue:6, 2007
Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Motor cortex excitability after vagus nerve stimulation in major depression.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.Psychopharmacology bulletin, , Volume: 40, Issue:2, 2007
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.The Journal of clinical psychiatry, , Volume: 67, Issue:7, 2006
A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.The Journal of clinical psychiatry, , Volume: 67, Issue:5, 2006
Does olanzapine have any antidepressant effect?The American journal of psychiatry, , Volume: 163, Issue:10, 2006
Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
Influence of sub-syndromal symptoms after remission from manic or mixed episodes.The British journal of psychiatry : the journal of mental science, , Volume: 189, 2006
[Effects of antidepressant therapy in patients with suspected "angina pectoris" and negative coronary angiogram complicating comorbid depression].Zhonghua xin xue guan bing za zhi, , Volume: 34, Issue:12, 2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.Molecular psychiatry, , Volume: 11, Issue:7, 2006
A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.The Journal of nervous and mental disease, , Volume: 193, Issue:6, 2005
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Treatment options for bipolar depression.The Journal of clinical psychiatry, , Volume: 66 Suppl 1, 2005
Olanzapine co-therapy in bipolar disorder.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.International clinical psychopharmacology, , Volume: 19, Issue:1, 2004
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
An open-label trial of olanzapine for corticosteroid-induced mood symptoms.Journal of affective disorders, , Volume: 83, Issue:2-3, 2004
The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder.The Journal of clinical psychiatry, , Volume: 65, Issue:7, 2004
Cognitive function and depression in symptom resolution in schizophrenia patients treated with an atypical antipsychotic.Brain and cognition, , Volume: 55, Issue:3, 2004
Bipolar depression: an overview.IDrugs : the investigational drugs journal, , Volume: 7, Issue:9, 2004
A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.The Journal of clinical psychiatry, , Volume: 65, Issue:7, 2004
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial.The American journal of psychiatry, , Volume: 161, Issue:8, 2004
Difficult-to-treat depressions: a primary care perspective.The Journal of clinical psychiatry, , Volume: 64 Suppl 1, 2003
Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex.Neuroscience letters, , Oct-09, Volume: 349, Issue:3, 2003
New approaches to managing psychotic depression.The Journal of clinical psychiatry, , Volume: 64 Suppl 1, 2003
An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania.The Journal of clinical psychiatry, , Volume: 64, Issue:1, 2003
Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics.Psychopharmacology bulletin, ,Summer, Volume: 37, Issue:3, 2003
Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.The Journal of clinical psychiatry, , Volume: 64, Issue:11, 2003
[Olanzapine in therapy of a somatoform disorder].Psychiatrische Praxis, , Volume: 30, Issue:8, 2003
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
Dependence and chronic psychosis with D-nor-pseudoephedrine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:8, 2003
Influence of fluoxetine on olanzapine pharmacokinetics.AAPS pharmSci, , Volume: 4, Issue:2, 2002
Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Are the atypical antipsychotic drugs antidepressants?Journal of clinical psychopharmacology, , Volume: 22, Issue:1, 2002
Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 159, Issue:10, 2002
Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
[Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].Fortschritte der Neurologie-Psychiatrie, , Volume: 70, Issue:4, 2002
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.The Journal of clinical psychiatry, , Volume: 62, Issue:7, 2001
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.The Journal of nervous and mental disease, , Volume: 189, Issue:6, 2001
Interaction of olanzapine with fluvoxamine.Psychopharmacology, , Volume: 155, Issue:2, 2001
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Addition of olanzapine for treatment-resistant depression.The American journal of psychiatry, , Volume: 158, Issue:10, 2001
Use of olanzapine in non-psychotic psychiatric disorders.Expert opinion on pharmacotherapy, , Volume: 2, Issue:4, 2001
[What does olanzapine give us?].Atencion primaria, , Mar-31, Volume: 27, Issue:5, 2001
Dementia with Lewy bodies in Down's syndrome.International journal of geriatric psychiatry, , Volume: 16, Issue:3, 2001
First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression.Neuropsychobiology, , Volume: 43, Issue:3, 2001
A novel augmentation strategy for treating resistant major depression.The American journal of psychiatry, , Volume: 158, Issue:1, 2001
Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.Therapeutic drug monitoring, , Volume: 23, Issue:4, 2001
Esotropia associated with olanzapine.Journal of clinical psychopharmacology, , Volume: 20, Issue:4, 2000
Atypical antipsychotics for treatment of mixed depression and anxiety.The Journal of clinical psychiatry, , Volume: 61, Issue:5, 2000
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.East African medical journal, , Volume: 77, Issue:2, 2000
Summary from the 153rd meeting of the American Psychiatric Association. 13-18 May 2000, Chicago, Illinois, USA.Expert opinion on pharmacotherapy, , Volume: 1, Issue:5, 2000
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 61 Suppl 3, 2000
Melancholic symptoms during concurrent olanzapine and fluoxetine.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 12, Issue:3, 2000
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17, Issue:6, 2000
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Olanzapine response in psychotic depression.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Treatment of corticosteroid-induced mood changes with olanzapine.The American journal of psychiatry, , Volume: 156, Issue:6, 1999
Hyperglycemia and olanzapine.The American journal of psychiatry, , Volume: 156, Issue:6, 1999
Review of recent clinical studies with olanzapine.The British journal of psychiatry. Supplement, , Issue:37, 1999
Olanzapine in the treatment of psychotic depression.The British journal of psychiatry : the journal of mental science, , Volume: 174, 1999
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.Biological psychiatry, , Aug-01, Volume: 46, Issue:3, 1999
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
[The hyperglycemic dehydration syndrome].Nederlands tijdschrift voor geneeskunde, , Oct-10, Volume: 142, Issue:41, 1998
[Schizophrenia and depression. Special aspects in the therapy of women].Der Nervenarzt, , Volume: 69, Issue:7 Suppl Be, 1998
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Emergence of koro after abrupt cessation of olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:2, 1998
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.The American journal of psychiatry, , Volume: 154, Issue:4, 1997
Treatment of psychotic depression.The American journal of psychiatry, , Volume: 154, Issue:11, 1997
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Citalopram-induced diplopia.Psychosomatics, , Volume: 46, Issue:1
Serotonin syndrome: a complex but easily avoidable condition.General hospital psychiatry, , Volume: 30, Issue:3
Olanzapine and quick-response hyperglycemia.Psychosomatics, , Volume: 44, Issue:2
Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression.Clinical neuropharmacology, , Volume: 31, Issue:4
A suspected case of olanzapine induced hyponatremia.Indian journal of pharmacology, , Volume: 46, Issue:4
Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine.Clinical neuropharmacology, , Volume: 31, Issue:5
Olanzapine in the treatment of resistant depression.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:1-2
Coadministration of olanzapine causes minor impacts on the diabetogenic outcomes induced by dexamethasone treatment in rats.Life sciences, , Jun-01, Volume: 322, 2023
Risk evaluation of diabetic ketoacidosis associated with antipsychotics among patients with schizophrenia in the Japanese adverse event report database.Journal of psychosomatic research, , Volume: 175, 2023
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Atypical diabetes mellitus caused by olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 55, Issue:12, 2021
Antipsychotic olanzapine-induced misfolding of proinsulin in the endoplasmic reticulum accounts for atypical development of diabetes.eLife, , 11-17, Volume: 9, 2020
Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder.The Journal of clinical psychiatry, , Volume: 77, Issue:12, 2016
[The perception gap between clinical trials and clinical practice].Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology, , Volume: 28, Issue:1, 2015
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation.Cell structure and function, , Volume: 38, Issue:2, 2013
Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 64, Issue:1, 2013
Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.Human psychopharmacology, , Volume: 26, Issue:6, 2011
Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.The Journal of clinical psychiatry, , Volume: 70, Issue:5, 2009
The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.Pharmacoepidemiology and drug safety, , Volume: 18, Issue:9, 2009
How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 24, Issue:3, 2009
Olanzapine for the treatment of bipolar disorder in children and adolescents.Expert opinion on pharmacotherapy, , Volume: 9, Issue:3, 2008
Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.Acta psychiatrica Scandinavica, , Volume: 117, Issue:5, 2008
Olanzapine: review of safety 2008.Expert opinion on drug safety, , Volume: 7, Issue:6, 2008
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:12, 2008
Metabolic effects of the atypical antipsychotics.Southern medical journal, , Volume: 100, Issue:8, 2007
Drug company seeks to suppress internal memos.BMJ (Clinical research ed.), , Jan-13, Volume: 334, Issue:7584, 2007
Atypical antipsychotics: new drugs, new challenges.Cleveland Clinic journal of medicine, , Volume: 74, Issue:8, 2007
[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].Medicina clinica, , Apr-01, Volume: 126, Issue:12, 2006
Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.Pharmacoepidemiology and drug safety, , Volume: 14, Issue:6, 2005
Diabetes mellitus during olanzapine and quetiapine treatment in Japan.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:11, 2005
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current opinion in pediatrics, , Volume: 17, Issue:2, 2005
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.Journal of the Indian Medical Association, , Volume: 103, Issue:12, 2005
[Atypical antipsychotic-associated impaired glucose tolerance].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 107, Issue:8, 2005
Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population.The Journal of nervous and mental disease, , Volume: 193, Issue:6, 2005
Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine.Pharmacoepidemiology and drug safety, , Volume: 14, Issue:6, 2005
Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.Pharmacopsychiatry, , Volume: 37, Issue:1, 2004
Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.The American journal of psychiatry, , Volume: 161, Issue:9, 2004
Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.MedGenMed : Medscape general medicine, , Jan-20, Volume: 6, Issue:1, 2004
Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:9, 2004
Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:1, 2004
Atypical antipsychotics and diabetes mellitus: an association.The Israel Medical Association journal : IMAJ, , Volume: 6, Issue:5, 2004
A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine.Journal of clinical psychopharmacology, , Volume: 24, Issue:3, 2004
[Olanzapine and diabetic decompensation: concerning a case].Atencion primaria, , Jun-15, Volume: 34, Issue:1, 2004
Atypical antipsychotics and diabetes mellitus.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:2, 2004
Weight gain and new onset diabetes associated with olanzapine and risperidone.Journal of general internal medicine, , Volume: 19, Issue:12, 2004
[Diabetes mellitus as a complication of treatment with atypical neuroleptics. Possible pathomechanisms and treatment recommendations].Der Nervenarzt, , Volume: 75, Issue:5, 2004
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.Southern medical journal, , Volume: 96, Issue:7, 2003
Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine.Pharmacotherapy, , Volume: 23, Issue:8, 2003
New-onset diabetes and ketoacidosis with atypical antipsychotics.Schizophrenia research, , Jan-01, Volume: 59, Issue:1, 2003
Potential risk of diabetes mellitus with the use of atypical antipsychotic medication.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics.Psychopharmacology bulletin, ,Summer, Volume: 37, Issue:3, 2003
Olanzapine/risperidone and diabetes risk.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
Safety in treating bipolar disorder.The Journal of family practice, , Volume: Suppl, 2003
Diabetes mellitus associated with atypical anti-psychotic medications.Diabetes technology & therapeutics, , Volume: 5, Issue:4, 2003
Efficacy should drive atypical antipsychotic treatment.BMJ (Clinical research ed.), , Feb-01, Volume: 326, Issue:7383, 2003
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.BMJ (Clinical research ed.), , Aug-03, Volume: 325, Issue:7358, 2002
Clinical issues associated with maintenance treatment of patients with schizophrenia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Sep-01, Volume: 59, Issue:17 Suppl 5, 2002
Olanzapine-induced destabilization of diabetes in the absence of weight gain.Acta psychiatrica Scandinavica, , Volume: 105, Issue:3, 2002
Glucose intolerance with atypical antipsychotics.Drug safety, , Volume: 25, Issue:15, 2002
Olanzapine-associated diabetes mellitus.Pharmacotherapy, , Volume: 22, Issue:7, 2002
The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
Hyperglycemia associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 23, 2001
[Diabetes mellitus induced by olanzapine. A case report].Revista medica de Chile, , Volume: 129, Issue:10, 2001
Olanzapine-induced diabetes mellitus.The Annals of pharmacotherapy, , Volume: 35, Issue:5, 2001
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17, Issue:6, 2000
Olanzapine-induced ketoacidosis with diabetes mellitus.The American journal of psychiatry, , Volume: 156, Issue:9, 1999
Hyperglycemia and olanzapine.The American journal of psychiatry, , Volume: 156, Issue:6, 1999
Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature.The Journal of the American Board of Family Practice, , Volume: 14, Issue:4
Olanzapine-induced diabetes due to pancreatitis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, , Volume: 24, Issue:6
Recovery from new-onset diabetes in a schizophrenic man after withdrawal of olanzapine.Psychosomatics, , Volume: 43, Issue:1
Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States.Journal of the American Medical Directors Association, , Volume: 5, Issue:1
New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment.Psychosomatics, , Volume: 40, Issue:5
Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy.American journal of therapeutics, , Volume: 10, Issue:5
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.Internal medicine (Tokyo, Japan), , Volume: 56, Issue:3, 2017
Second-generation antipsychotic and diabetes mellitus in children and adolescents.La Pediatria medica e chirurgica : Medical and surgical pediatrics, , Dec-13, Volume: 39, Issue:4, 2017
Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.Psychopharmacology, , Volume: 233, Issue:21-22, 2016
Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.Southern medical journal, , Volume: 96, Issue:7, 2003
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
[Olanzapine-induced diabetes mellitus].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.The Journal of clinical psychiatry, , Volume: 62, Issue:12, 2001
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
Hyperglycemia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Antipsychotic-Induced Metabolic Syndrome: A Review.Metabolic syndrome and related disorders, , Volume: 21, Issue:6, 2023
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).BMJ open, , 01-31, Volume: 13, Issue:1, 2023
Effects of the second-generation antipsychotic drugs aripiprazole and olanzapine on human adipocyte differentiation.Molecular and cellular endocrinology, , 02-05, Volume: 561, 2023
The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice.Diabetologia, , Volume: 65, Issue:3, 2022
Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.CNS spectrums, , Volume: 27, Issue:3, 2022
Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls.PloS one, , Volume: 17, Issue:11, 2022
Anthocyanins from Molecules (Basel, Switzerland), , Oct-12, Volume: 26, Issue:20, 2021
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Olanzapine-induced insulin resistance may occur via attenuation of central KSchizophrenia research, , Volume: 228, 2021
The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C.The Journal of clinical investigation, , Sep-01, Volume: 127, Issue:9, 2017
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis.JAMA psychiatry, , Volume: 73, Issue:3, 2016
What evidence is there to show which antipsychotics are more diabetogenic than others?Psychiatria Danubina, , Volume: 27 Suppl 1, 2015
The risk of metabolic disorders in patients treated with asenapine or olanzapine: a study conducted on real-world data in Italy and Spain.Expert opinion on drug safety, , Volume: 13, Issue:9, 2014
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 15, Issue:3, 2014
A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes.Cellular signalling, , Volume: 26, Issue:6, 2014
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone.Schizophrenia research, , Volume: 143, Issue:2-3, 2013
Comparative safety of antipsychotics: another look at the risk of diabetes.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 58, Issue:4, 2013
Diabetes resolution following discontinuation of a second-generation antipsychotic.Clinical schizophrenia & related psychoses, , Volume: 6, Issue:4, 2013
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level.Progress in neuro-psychopharmacology & biological psychiatry, , Jul-01, Volume: 35, Issue:5, 2011
Metabolic effects of olanzapine in patients with newly diagnosed psychosis.Journal of clinical psychopharmacology, , Volume: 31, Issue:2, 2011
Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats.Neuropsychobiology, , Volume: 61, Issue:3, 2010
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:9, 2010
The risks and benefits of switching antipsychotics: a case study approach.Perspectives in psychiatric care, , Volume: 45, Issue:1, 2009
Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 70, Issue:1, 2009
Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation.Journal of psychiatric practice, , Volume: 15, Issue:4, 2009
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 54, Issue:4, 2009
Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia.Schizophrenia research, , Volume: 104, Issue:1-3, 2008
Considerations regarding the use of metformin with olanzapine.The American journal of psychiatry, , Volume: 165, Issue:9, 2008
[Olanzapine].Deutsche medizinische Wochenschrift (1946), , Volume: 133, Issue:39, 2008
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 69, Issue:3, 2008
A patient treated with olanzapine developing diabetes de novo: proposal for hyperglycaemia screening.The Netherlands journal of medicine, , Volume: 65, Issue:9, 2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.The American journal of managed care, , Volume: 13, Issue:7 Suppl, 2007
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs.Diabetologia, , Volume: 50, Issue:8, 2007
Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.Collegium antropologicum, , Volume: 31, Issue:4, 2007
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:1, 2006
Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.American journal of epidemiology, , Oct-01, Volume: 164, Issue:7, 2006
Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.Psychiatry and clinical neurosciences, , Volume: 60, Issue:1, 2006
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:3, 2006
Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine.Journal of managed care pharmacy : JMCP, , Volume: 12, Issue:3, 2006
Newer antipsychotics and glucose metabolism: a comparison between olanzapine and risperidone.Psychiatria Danubina, , Volume: 17, Issue:1-2, 2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Archives of general psychiatry, , Volume: 62, Issue:1, 2005
Unusual suspect for antipsychotic-induced diabetes.Drug discovery today, , Oct-15, Volume: 10, Issue:20, 2005
Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.Pharmacoepidemiology and drug safety, , Volume: 14, Issue:6, 2005
Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism.Essential psychopharmacology, , Volume: 6, Issue:2, 2005
Olanzapine-induced diabetes in a seven-year-old boy.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:8, 2004
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.Postgraduate medicine, , Volume: 116, Issue:4, 2004
Hyperglycemia associated with antipsychotic treatment in a multicenter drug safety project.Pharmacopsychiatry, , Volume: 37 Suppl 1, 2004
Modulating effects of olanzapine on the development of diabetic ketoacidosis.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 21, Issue:3, 2004
Potential for detection bias in the association between olanzapine and diabetes.The Journal of clinical psychiatry, , Volume: 65, Issue:2, 2004
Olanzapine use in a patient with schizophrenia and the risk of diabetes.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:1, 2004
Dyslipidemia and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
[Diabetes as a complication in treatment with second-generation antipsychotics].Ugeskrift for laeger, , Aug-23, Volume: 166, Issue:35, 2004
[Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].Medizinische Klinik (Munich, Germany : 1983), , Jul-15, Volume: 98, Issue:7, 2003
Hyperglycemia from olanzapine treatment in adolescents.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 13, Issue:1, 2003
Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.Clinical therapeutics, , Volume: 25, Issue:4, 2003
Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.Psychopharmacology, , Volume: 170, Issue:2, 2003
Atypical neuroleptics and diabetes.Diabetes & metabolism, , Volume: 29, Issue:3, 2003
High-dose olanzapine-induced improvement of preexisting type 2 diabetes mellitus in schizophrenic patients.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Olanzapine-associated type 2 diabetes mellitus.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Ziprasidone alternative for olanzapine-induced hyperglycemia.The American journal of psychiatry, , Volume: 159, Issue:9, 2002
The effects of novel antipsychotics on glucose and lipid levels.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
Are African American patients at a higher risk for olanzapine-induced glucose intolerance?Psychopharmacology, , Volume: 157, Issue:3, 2001
[Importance of blood glucose level when starting antipsychotic treatment].Presse medicale (Paris, France : 1983), , Sep-22, Volume: 30, Issue:26, 2001
Atypical antipsychotics and hyperglycaemia.International clinical psychopharmacology, , Volume: 16, Issue:2, 2001
Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy.Pharmacotherapy, , Volume: 21, Issue:11, 2001
Treatment of preexisting diabetes with olanzapine.The Journal of clinical psychiatry, , Volume: 62, Issue:9, 2001
Novel antipsychotics and new onset diabetes.Biological psychiatry, , Oct-15, Volume: 44, Issue:8, 1998
[The hyperglycemic dehydration syndrome].Nederlands tijdschrift voor geneeskunde, , Oct-10, Volume: 142, Issue:41, 1998
Hyperglycemia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:3
Olanzapine-induced glucose dysregulation.The Annals of pharmacotherapy, , Volume: 34, Issue:7-8
A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:1
Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial.Human psychopharmacology, , Volume: 36, Issue:1, 2021
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.The American journal of psychiatry, , 06-01, Volume: 176, Issue:6, 2019
A Review of Asenapine in the Treatment of Bipolar Disorder.Clinical drug investigation, , Volume: 38, Issue:2, 2018
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.BMC psychiatry, , Apr-02, Volume: 15, 2015
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.Clinical schizophrenia & related psychoses, , Volume: 8, Issue:4, 2015
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.The Journal of clinical psychiatry, , Volume: 67, Issue:11, 2006
Olanzapine for schizophrenia.The Medical letter on drugs and therapeutics, , Jan-17, Volume: 39, Issue:992, 1997
Safety of olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Olanzapine-induced photo-allergic reaction.The Australian and New Zealand journal of psychiatry, , Volume: 52, Issue:8, 2018
Suspicion of a new cross-reaction between carbamazepine and olanzapine.Journal of investigational allergology & clinical immunology, , Volume: 24, Issue:1, 2014
Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Olanzapine-induced anaphylactic shock: a case report.Pharmacopsychiatry, , Volume: 45, Issue:1, 2012
Successful clozapine retrial after suspected myocarditis.The American journal of psychiatry, , Volume: 167, Issue:3, 2010
Photosensitivity might be associated with drug-induced hypersensitivity syndrome.Dermatology (Basel, Switzerland), , Volume: 214, Issue:4, 2007
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
[Bullae induced by acute neuroleptic intoxication].Annales de dermatologie et de venereologie, , Volume: 127, Issue:10, 2000
Guillain-Barré-like syndrome associated with olanzapine hypersensitivity reaction.Clinical neuropharmacology, , Volume: 28, Issue:3
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.Journal of psychiatric research, , Volume: 85, 2017
Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines.BMC psychiatry, , Dec-08, Volume: 17, Issue:1, 2017
Olanzapine as a possible replacement choice for paliperidone-induced Pisa syndrome: a case report.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 24, Issue:6, 2016
Dementia with Lewy bodies presenting marked tongue protrusion and bite due to lingual dystonia: A case report.Rinsho shinkeigaku = Clinical neurology, , 06-22, Volume: 56, Issue:6, 2016
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 54, Issue:9, 2015
Neurological Adverse Effects of Antipsychotics in Children and Adolescents.Journal of clinical psychopharmacology, , Volume: 35, Issue:6, 2015
Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.Clinical schizophrenia & related psychoses, , Volume: 7, Issue:4, 2014
The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.Journal of clinical psychopharmacology, , Volume: 33, Issue:3, 2013
Paliperidone-related Pisa syndrome.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.The Journal of clinical psychiatry, , Volume: 74, Issue:11, 2013
The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 72, Issue:7, 2011
Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 36, Issue:8, 2011
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:6, 2011
Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.BMC psychiatry, , Mar-24, Volume: 10, 2010
Tardive dystonia induced by switch of atypical antipsychotics.Pharmacopsychiatry, , Volume: 43, Issue:5, 2010
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 19, Issue:8, 2009
Clinical trials design lessons from the CATIE study.The American journal of psychiatry, , Volume: 166, Issue:11, 2009
[Neuroleptic adverse effects with emphasis on weight gain].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 37, Issue:4, 2009
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 24, Issue:3, 2009
Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:4, 2009
Clinical experiences and clinical trials.CNS spectrums, , Volume: 13, Issue:6, 2008
What CATIE found: results from the schizophrenia trial.Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
A case of sodium oxybate treatment of tardive dyskinesia and bipolar disorder.The Journal of clinical psychiatry, , Volume: 69, Issue:5, 2008
Olanzapine-induced tardive dystonia successfully treated by tetrabenazine.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 19, Issue:4, 2007
Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-30, Volume: 31, Issue:1, 2007
Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.Psychoneuroendocrinology, , Volume: 32, Issue:2, 2007
A 6-month longitudinal study of early-onset tardive dyskinesia: association with olanzapine treatment and mild cognitive impairment in an elderly woman.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.The international journal of neuropsychopharmacology, , Volume: 10, Issue:2, 2007
Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
[Gilles-de-la-Tourette Syndrome as a Tardive Dyskinesia].Psychiatrische Praxis, , Volume: 34, Issue:5, 2007
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.Psychopharmacology bulletin, , Volume: 40, Issue:2, 2007
Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Clozapine effective in olanzapine-induced Pisa syndrome.The Annals of pharmacotherapy, , Volume: 40, Issue:12, 2006
Selecting antipsychotics in schizophrenia: lessons from CATIE.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:3, 2006
[The use of atypical antipsychotics in the long-term care of schizophrenia].L'Encephale, , Volume: 32 Pt 3, 2006
Antipsychotic drugs and schizophrenia.The New England journal of medicine, , Jan-19, Volume: 354, Issue:3, 2006
Paradoxical dyskinesia with olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 18, Issue:1, 2006
Atypical antipsychotics, tardive dyskinesia, and D(2) receptors.The American journal of psychiatry, , Volume: 163, Issue:8, 2006
Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:7, 2005
Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats.Biological psychiatry, , Feb-15, Volume: 57, Issue:4, 2005
The choice of antipsychotic drugs for schizophrenia.The New England journal of medicine, , Sep-22, Volume: 353, Issue:12, 2005
Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.Psychiatry and clinical neurosciences, , Volume: 59, Issue:4, 2005
[Rabbit syndrome due to olanzapine].Psychiatrische Praxis, , Volume: 32, Issue:4, 2005
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:5 Suppl, 2005
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:11, 2005
Tardive dyskinesia associated with olanzapine in a neuroleptic-naive patient with schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:5, 2004
Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:1, 2004
The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.European archives of psychiatry and clinical neuroscience, , Volume: 254, Issue:6, 2004
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:8, 2004
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.The American journal of psychiatry, , Volume: 161, Issue:3, 2004
Tardive dystonia induced by atypical neuroleptics: a case report with olanzapine.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 14, Issue:1, 2004
Tardive dyskinesia rates with atypical antipsychotics in older adults.The Journal of clinical psychiatry, , Volume: 65 Suppl 9, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Olanzepine-induced tardive dyskinesia.The British journal of psychiatry : the journal of mental science, , Volume: 182, 2003
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:5, 2003
Rapid onset of dyskinesia induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 57, Issue:6, 2003
Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride.International journal of clinical practice, , Volume: 57, Issue:2, 2003
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.Wiener klinische Wochenschrift, , Jan-31, Volume: 115, Issue:1-2, 2003
Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine.Behavioural pharmacology, , Volume: 14, Issue:3, 2003
Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat.European journal of pharmacology, , Sep-12, Volume: 477, Issue:2, 2003
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.The international journal of neuropsychopharmacology, , Volume: 6, Issue:4, 2003
Olanzapine and improvement of tardive dyskinesia.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:7, 2002
Use of atypical antipsychotics in a Veterans Affairs hospital.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:6, 2002
Effects of development on olanzapine-associated adverse events.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 41, Issue:12, 2002
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.Journal of pain and symptom management, , Volume: 23, Issue:6, 2002
Tardive dyskinesias and antipsychotics: a review.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:3, 2002
Clozapine is more efficacious for tongue dystonia than olanzapine.Psychopharmacology, , Volume: 162, Issue:1, 2002
Movement disorders associated with atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 63 Suppl 4, 2002
[Improvement of tardive dyskinesia after treatment with olanzapine].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
Improvement of tardive dyskinesia following switch from neuroleptics to olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:4, 2002
Rapid onset of tardive dyskinesia in Huntington disease with olanzapine.Journal of clinical psychopharmacology, , Volume: 22, Issue:4, 2002
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 13, Issue:4, 2001
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.The international journal of neuropsychopharmacology, , Volume: 4, Issue:3, 2001
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Aug-28, Volume: 57, Issue:4, 2001
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 16, Issue:4, 2001
Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Ondansetron for tardive dyskinesia.The American journal of psychiatry, , Volume: 158, Issue:4, 2001
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.Biological psychiatry, , Jan-01, Volume: 49, Issue:1, 2001
Effect of chronic olanzapine treatment on striatal synaptic organization.Synapse (New York, N.Y.), , Volume: 39, Issue:1, 2001
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.Schizophrenia bulletin, , Volume: 27, Issue:4, 2001
Tardive dystonia associated with olanzapine therapy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 22, Issue:4, 2001
New antipsychotic medications: more than old wine and new bottles.Bulletin of the Menninger Clinic, ,Winter, Volume: 64, Issue:1, 2000
Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.South Dakota journal of medicine, , Volume: 53, Issue:2, 2000
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Tardive dyskinesia in older patients.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
The treatment of tardive dyskinesia and tardive dystonia.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Rabbit syndrome treated with olanzapine.The British journal of psychiatry : the journal of mental science, , Volume: 176, 2000
Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 12, Issue:1, 2000
[Atypical antipsychotics].Der Nervenarzt, , Volume: 71, Issue:5, 2000
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].Der Nervenarzt, , Volume: 71, Issue:5, 2000
Drug review "surprises" reader.Canadian family physician Medecin de famille canadien, , Volume: 46, 2000
Olanzapine to treat the acute mania of bipolar disorder.South Dakota journal of medicine, , Volume: 53, Issue:12, 2000
Improvement of tardive dyskinesia in a bipolar patient with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 15, Issue:7, 2000
Risperidone and tardive dyskinesia: a case of blepharospasm.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:5, 2000
Low-dose olanzapine for levodopa induced dyskinesias.Neurology, , Sep-26, Volume: 55, Issue:6, 2000
Remission of tardive dyskinesia after changing from flupenthixol to olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 15, Issue:5, 2000
Olanzapine-induced tardive dystonia.The American journal of psychiatry, , Volume: 156, Issue:10, 1999
Olanzapine. A pharmacoeconomic review of its use in schizophrenia.PharmacoEconomics, , Volume: 15, Issue:6, 1999
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
Tardive dyskinesia associated with olanzapine monotherapy.The Journal of clinical psychiatry, , Volume: 60, Issue:12, 1999
Olanzapine and tardive dyskinesia.The British journal of psychiatry : the journal of mental science, , Volume: 175, 1999
Olanzapine in the treatment of tardive dyskinesia: a report of two cases.Journal of clinical psychopharmacology, , Volume: 19, Issue:1, 1999
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.Biological psychiatry, , Feb-15, Volume: 45, Issue:4, 1999
Tardive dyskinesia associated with olanzapine.Annals of internal medicine, , Jul-06, Volume: 131, Issue:1, 1999
Improvement of tardive dyskinesia following treatment with olanzapine.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 9, Issue:4, 1999
Tardive dyskinesia and atypical antipsychotic drugs.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.International clinical psychopharmacology, , Volume: 14, Issue:3, 1999
Tardive dyskinesia in affective disorders.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Conventional vs. newer antipsychotics in elderly patients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Winter, Volume: 7, Issue:1, 1999
Olanzapine in the long-term treatment of schizophrenia.The British journal of psychiatry. Supplement, , Issue:37, 1999
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.The British journal of psychiatry : the journal of mental science, , Volume: 174, 1999
Emerging roles for novel antipsychotic medications in the treatment of schizophrenia.The Psychiatric clinics of North America, , Volume: 21, Issue:1, 1998
Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 19, Issue:5, 1998
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Metronome or alternating Pisa syndrome: a form of tardive dystonia under clozapine treatment.International clinical psychopharmacology, , Volume: 13, Issue:5, 1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:6, 1998
The routine use of atypical antipsychotic agents: maintenance treatment.The Journal of clinical psychiatry, , Volume: 59 Suppl 19, 1998
Olanzapine for the treatment of tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 59, Issue:7, 1998
Marked reduction of tardive dyskinesia with olanzapine.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
The relationship of pharmacology to side effects.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.The American journal of psychiatry, , Volume: 154, Issue:9, 1997
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.Journal of clinical psychopharmacology, , Volume: 17, Issue:5, 1997
Olanzapine motor side effect.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 16, Issue:1, 1997
Olanzapine: a new typical antipsychotic drug.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 14, Issue:2, 1996
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 14, Issue:2, 1996
Side effect profiles of new antipsychotic agents.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Treatment of respiratory dyskinesia with olanzapine.Psychosomatics, , Volume: 40, Issue:3
[Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions].Psychiatria polska, , Volume: 48, Issue:6
Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study.General hospital psychiatry, , Volume: 22, Issue:2
Treatment with atypical antipsychotics: new indications and new populations.Journal of psychiatric research, , Volume: 35, Issue:3
Dose-Dependent Effects of Lithium Treatment on the Aggravation of Antipsychotic-Induced Pisa Syndrome.Clinical neuropharmacology, , Volume: 43, Issue:3
Comment on Nasrallah et al: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 12, Issue:6
The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:3
Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases.Clinical neuropharmacology, , Volume: 28, Issue:4
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.Journal of affective disorders, , 12-01, Volume: 277, 2020
Clinical Pearls in palliative medicine.Disease-a-month : DM, , Volume: 63, Issue:6, 2017
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Delusional infestation: a case series from a university dermatology center in São Paulo, Brazil.International journal of dermatology, , Volume: 55, Issue:8, 2016
Delusional infestation: a clinical profile.Asian journal of psychiatry, , Volume: 6, Issue:2, 2013
Atypical anti-psychotics in delusional parasitosis: a retrospective case series of 20 patients.International journal of dermatology, , Volume: 49, Issue:1, 2010
Second-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacy.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Primary delusional parasitosis treated with olanzapine.International psychogeriatrics, , Volume: 19, Issue:6, 2007
[A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy].Der Nervenarzt, , Volume: 74, Issue:7, 2003
[Delusional ectoparasitic infestation in multiple system atrophy].Der Nervenarzt, , Volume: 73, Issue:4, 2002
Lessons of the month 2: Olanzapine-induced hypothermia and hand oedema.Clinical medicine (London, England), , Volume: 22, Issue:3, 2022
Facial edema as an adverse drug reaction to olanzapine in a patient with cancer receiving palliative care.Palliative & supportive care, , Volume: 20, Issue:5, 2022
Olanzapine associated palpebral edema: An uncommon adverse effect of a commonly prescribed drug.Asian journal of psychiatry, , Volume: 36, 2018
Olanzapine as a cause of peripheric edema in an elderly man.Aging clinical and experimental research, , Volume: 25, Issue:1, 2013
Olanzapine-induced limb edema simulating episodic angioedema with eosinophilia.The Journal of dermatology, , Volume: 39, Issue:12, 2012
[Edema related to treatment with olanzapine].Psychiatrische Praxis, , Volume: 36, Issue:3, 2009
Olanzapine-associated bilateral eyelid edema.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Bilateral pedal edema associated with olanzapine use in manic episode of bipolar disorder: report of two cases.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 31, Issue:7, 2007
Case report: edema related to olanzapine therapy.Canadian family physician Medecin de famille canadien, , Volume: 52, 2006
Peripheral oedema in patients taking olanzapine.International clinical psychopharmacology, , Volume: 18, Issue:1, 2003
Olanzapine-associated bilateral pedal edema.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
Facial edema with olanzapine.General hospital psychiatry, , Volume: 35, Issue:6
Olanzapine-induced bilateral pedal edema: a case report.General hospital psychiatry, , Volume: 22, Issue:4
Olanzapine-associated Edema Decreasing Serum Lithium Concentrations: A Case Report.Journal of clinical psychopharmacology, , Volume: 40, Issue:5
Dose-Dependent Facial Edema Secondary to Olanzapine in a Medium-Long Stay Psychiatry Ward: Case Report and Review of Cases.Journal of clinical psychopharmacology, , Volume: 42, Issue:2
Recurrent Catatonia: Infection and Immunity in an Idiopathic Illness.Journal of psychiatric practice, , 01-01, Volume: 29, Issue:1, 2023
Reversible splenial lesion syndrome with a hyperosmolar hyperglycemic state and neuroleptic malignant syndrome caused by olanzapine.Journal of diabetes investigation, , Volume: 8, Issue:3, 2017
[Patient with encephalitis presenting with olanzapine-responsive malignant catatonia].Rinsho shinkeigaku = Clinical neurology, , Volume: 50, Issue:5, 2010
Pediatric Acute-Onset Neuropsychiatric Syndrome and Catatonia: A Case Report.Psychosomatics, , Volume: 61, Issue:1
A Case of Olanzapine-Induced Cutaneous Eruption.The American journal of case reports, , Oct-01, Volume: 24, 2023
Olanzapine-induced peripheral eosinophilia and eosinophilic pleural effusion: A case report.Medicine, , Volume: 97, Issue:7, 2018
Eosinophilic myocarditis during treatment with olanzapine - report of two possible cases.BMC psychiatry, , Mar-17, Volume: 16, 2016
Eosinophilia Associated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
Olanzapine-induced limb edema simulating episodic angioedema with eosinophilia.The Journal of dermatology, , Volume: 39, Issue:12, 2012
[Eosinophilic myocarditis and sudden unexpected death in a younger patient treated with antipsychotics].Ugeskrift for laeger, , Oct-31, Volume: 173, Issue:44, 2011
Iatrogenic eosinophilic pleural effusion.European respiratory review : an official journal of the European Respiratory Society, , Volume: 20, Issue:120, 2011
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
Eosinophilia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:3, 2002
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Antipsychotic drugs in epilepsy.Neurologia i neurochirurgia polska, , Volume: 53, Issue:6, 2019
Antiepileptic effect of olanzapine in epilepsy patients with atypical depressive comorbidity.Epileptic disorders : international epilepsy journal with videotape, , Jun-01, Volume: 20, Issue:3, 2018
Development of forced normalisation psychosis with ethosuximide.BMJ case reports, , Dec-07, Volume: 2017, 2017
Levetiracetam associated acute hepatic failure requiring liver transplantation: case report.Journal of neurology, , Volume: 263, Issue:4, 2016
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 12, Issue:1, 2015
Interventions for psychotic symptoms concomitant with epilepsy.The Cochrane database of systematic reviews, , Dec-21, Issue:12, 2015
Complete atrioventricular block-induced Torsade de pointes, manifested by epilepsy.The Korean journal of internal medicine, , Volume: 26, Issue:1, 2011
Weight gain induced with olanzapine in adolescent.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Folie à deux: double case-report of shared delusions with a fatal outcome.La Clinica terapeutica, , Volume: 162, Issue:1, 2011
Possession states precipitated by nortriptyline.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Interventions for psychotic symptoms concomitant with epilepsy.The Cochrane database of systematic reviews, , Oct-08, Issue:4, 2008
Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine.Epilepsia, , Volume: 46, Issue:5, 2005
First case of lacosamide-induced psychosis.Clinical neuropharmacology, , Volume: 36, Issue:1
Psychiatric symptoms in a case of intracranial tuberculosis.Psychosomatics, , Volume: 43, Issue:1
Long-term chemogenetic suppression of seizures in a multifocal rat model of temporal lobe epilepsy.Epilepsia, , Volume: 62, Issue:3, 2021
Postictal psychosis treated successfully with olanzapine.The Journal of clinical psychiatry, , Volume: 73, Issue:9, 2012
Olanzapine for recurrent excessive irritability and psychotic symptoms after mesial temporal lobectomy in a patient with temporal lobe epilepsy.Epilepsy & behavior : E&B, , Volume: 9, Issue:3, 2006
Olanzapine for recurrent aggression in a patient with temporal lobe epilepsy who had temporal lobectomy.Journal of psychopharmacology (Oxford, England), , Volume: 17, Issue:3, 2003
Misdiagnosis of schizophrenia for a patient with epilepsy.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:1, 2001
A Case of Olanzapine-Induced Cutaneous Eruption.The American journal of case reports, , Oct-01, Volume: 24, 2023
Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.Die Pharmazie, , 09-01, Volume: 77, Issue:7, 2022
Skin rash occurring with olanzapine pamoate, but not with oral olanzapine, in a male with juvenile idiopathic arthritis.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:3, 2013
Acute generalized exanthematous pustulosis induced by olanzapine.Acta medica (Hradec Kralove), , Volume: 49, Issue:1, 2006
Acute Angle Closure in a Patient Using Olanzapine.Psychiatria Danubina, ,Summer, Volume: 34, Issue:2, 2022
A Case Report: Anti-Psychotic Agents Related Ocular Toxicity.Medicine, , Volume: 95, Issue:15, 2016
Olanzapine therapy in hallucinatory visions related to Bonnet syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 26, Issue:3, 2005
Side effects of olanzapine.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.The Cochrane database of systematic reviews, , 09-21, Volume: 9, 2018
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.Journal of affective disorders, , Jan-01, Volume: 207, 2017
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:5, 2003
[Olanzapine in therapy of a somatoform disorder].Psychiatrische Praxis, , Volume: 30, Issue:8, 2003
Hypothalamic JNK1-hepatic fatty acid synthase axis mediates a metabolic rewiring that prevents hepatic steatosis in male mice treated with olanzapine via intraperitoneal: Additional effects of PTP1B inhibition.Redox biology, , Volume: 63, 2023
Anthocyanins from Molecules (Basel, Switzerland), , Oct-12, Volume: 26, Issue:20, 2021
Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane.The Journal of nutritional biochemistry, , Volume: 81, 2020
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.Psychoneuroendocrinology, , Volume: 108, 2019
Up-regulation of hepatic fatty acid transporters and inhibition/down-regulation of hepatic OCTN2 contribute to olanzapine-induced liver steatosis.Toxicology letters, , Volume: 316, 2019
Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway.Acta pharmacologica Sinica, , Volume: 40, Issue:8, 2019
Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.Journal of affective disorders, , 12-01, Volume: 277, 2020
Olanzapine-Induced Fever.The primary care companion for CNS disorders, , 02-28, Volume: 21, Issue:1, 2019
A Case of Olanzapine-Induced Fever.Psychopharmacology bulletin, , 01-26, Volume: 47, Issue:1, 2017
Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine.Pharmacological reports : PR, , Volume: 65, Issue:2, 2013
Unexpected hospitalisation side effects in an elderly man.Internal and emergency medicine, , Volume: 6, Issue:2, 2011
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
Hyperthermia and rhabdomyolysis in an adolescent treated with topiramate and olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:1, 2008
Olanzapine withdrawal/discontinuation-induced hyperthermia in rats.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 31, Issue:7, 2007
Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats.Brain research, , Aug-27, Volume: 1018, Issue:2, 2004
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].Minerva anestesiologica, , Volume: 69, Issue:6, 2003
New treatment for Ecstasy-related hyperthermia.Internal medicine journal, , Volume: 33, Issue:12, 2003
Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Jul-16, Volume: 23, Issue:15, 2003
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat.The Journal of pharmacology and experimental therapeutics, , Volume: 292, Issue:2, 2000
Possible neuroleptic malignant syndrome associated with olanzapine.The Annals of pharmacotherapy, , Volume: 34, Issue:5, 2000
Fever, delirium, autonomic instability, and monocytosis associated with olanzapine.Journal of postgraduate medicine, , Volume: 49, Issue:1
Reconsidering Olanzapine as a Possible Culprit for Drug Fever, defying "Incomplete Neuromalignant Syndrome".The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, , Volume: 168, Issue:4
The Utilization of Atypical Antipsychotics in the Pain Medicine Physician's Armamentarium.Psychopharmacology bulletin, , 06-20, Volume: 48, Issue:4, 2018
Current status of atypical antipsychotics for the treatment of fibromyalgia.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:6, 2014
Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic.Pain practice : the official journal of World Institute of Pain, , Volume: 6, Issue:2, 2006
Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:1, 2005
Olanzapine for the treatment of fibromyalgia symptoms.Journal of pain and symptom management, , Volume: 22, Issue:2, 2001
Olanzapine treatment improved quality of life in a patient with fibromyalgia syndrome: a psychological evaluation.Acta reumatologica portuguesa, , Volume: 36, Issue:3
Pharmacological interventions for the treatment of disordered and problem gambling.The Cochrane database of systematic reviews, , 09-22, Volume: 9, 2022
Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics.Psychopharmacology, , Volume: 222, Issue:1, 2012
Three cases of schizophrenia for which olanzapine was effective after early acute phase.Psychiatry and clinical neurosciences, , Volume: 62, Issue:1, 2008
Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial.The Journal of clinical psychiatry, , Volume: 69, Issue:3, 2008
A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers.Pharmacology, biochemistry, and behavior, , Volume: 89, Issue:3, 2008
Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists: A Retrospective Cohort Study.Journal of clinical psychopharmacology, , Volume: 39, Issue:6
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.Gynecologic oncology, , Volume: 156, Issue:3, 2020
Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.BMJ open, , 01-17, Volume: 9, Issue:1, 2019
Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study.Tumori, , Volume: 105, Issue:3, 2019
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
Olanzapine treatment for tics in an adult woman with severe tourette syndrome.Acta neurologica Taiwanica, , Volume: 21, Issue:4, 2012
[Neuroleptic adverse effects with emphasis on weight gain].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 37, Issue:4, 2009
Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:5, 2008
[Gilles-de-la-Tourette Syndrome as a Tardive Dyskinesia].Psychiatrische Praxis, , Volume: 34, Issue:5, 2007
Olanzapine in Gilles de la Tourette syndrome: beyond tics.Acta neurologica Belgica, , Volume: 105, Issue:4, 2005
Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 14, Issue:2, 2004
[Treatment of tics in Tourette syndrome with atypical antipsychotic drugs].Ugeskrift for laeger, , Aug-05, Volume: 164, Issue:32, 2002
An open-label study of the treatment efficacy of olanzapine for Tourette's disorder.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Ziprasidone: a new atypical antipsychotic.Expert opinion on pharmacotherapy, , Volume: 2, Issue:6, 2001
Low blood glucose and olanzapine.The American journal of psychiatry, , Volume: 158, Issue:3, 2001
Olanzapine in Tourette's disorder.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 39, Issue:2, 2000
Olanzapine in Tourette's disorder.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 39, Issue:2, 2000
Effective open-label treatment of tourette's disorder with olanzapine.International clinical psychopharmacology, , Volume: 15, Issue:1, 2000
Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide.Journal of neurology, , Volume: 247, Issue:6, 2000
Olanzapine in Tourette syndrome.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
Open-label olanzapine treatment in five preadolescent children.Journal of child and adolescent psychopharmacology, , Volume: 8, Issue:2, 1998
[Olanzapine in Tourette's syndrome: a report of three cases].Actas espanolas de psiquiatria, , Volume: 30, Issue:2
The Radiosensitizing Effect of Olanzapine as an Antipsychotic Medication on Glioblastoma Cell.Current radiopharmaceuticals, , Volume: 15, Issue:1, 2022
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.Journal of neuro-oncology, , Volume: 122, Issue:1, 2015
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?British journal of pharmacology, , Volume: 164, Issue:5, 2011
The Radiosensitizing Effect of Olanzapine as an Antipsychotic Medication on Glioblastoma Cell.Current radiopharmaceuticals, , Volume: 15, Issue:1, 2022
Olanzapine induced autophagy through suppression of NF-κB activation in human glioma cells.CNS neuroscience & therapeutics, , Volume: 25, Issue:9, 2019
Olanzapine inhibits the proliferation and induces the differentiation of glioma stem-like cells through modulating the Wnt signaling pathway in vitro.European review for medical and pharmacological sciences, , Volume: 19, Issue:13, 2015
Autophagy involvement in olanzapine-mediated cytotoxic effects in human glioma cells.Asian Pacific journal of cancer prevention : APJCP, , Volume: 15, Issue:19, 2014
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 9, Issue:3, 2007
[Endocrine side effects among psychiatric patients treated with antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:2, 2006
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.Pharmacotherapy, , Volume: 26, Issue:6, 2006
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.Psychoneuroendocrinology, , Volume: 31, Issue:5, 2006
Olanzapine-induced gynecomastia.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:8, 2005
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.Journal of sex & marital therapy, , Volume: 29, Issue:2
Refractory Psychosis After Carbon Monoxide Poisoning: a Case Report.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 32, Issue:2, 2022
Delirium with visual hallucinations induced by low-dose olanzapine.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 22, Issue:3, 2022
Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India.Asian journal of psychiatry, , Volume: 54, 2020
Delusional.Schizophrenia bulletin, , Dec-01, Volume: 46, Issue:6, 2020
Can typical and atypical antipsychotics show differential effectiveness in treating paranoia and hallucinations in schizophrenia?BMJ case reports, , Mar-31, Volume: 12, Issue:3, 2019
Acute transient psychotic disorder precipitated by Brexit vote.BMJ case reports, , Oct-01, Volume: 12, Issue:10, 2019
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
[A case of late-onset paraphrenia in a very elderly patient receiving home medical care].Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, , Volume: 55, Issue:4, 2018
Dhat syndrome as the prodrome of schizophrenia: Understanding the cultural distress.Asian journal of psychiatry, , Volume: 25, 2017
Development of forced normalisation psychosis with ethosuximide.BMJ case reports, , Dec-07, Volume: 2017, 2017
Anti-NMDA (a-NMDAR) receptor encephalitis related to acute consumption of metamphetamine: Relevance of differential diagnosis.Revista espanola de anestesiologia y reanimacion, , Volume: 64, Issue:3, 2017
"Musical Ear Syndrome"-Musical hallucinations in a patient with severe hearing loss-A report.Asian journal of psychiatry, , Volume: 29, 2017
Delusional infestation.The American journal of emergency medicine, , Volume: 35, Issue:2, 2017
A Case of Chronic Peduncular Hallucinosis in a 90-Year-Old Woman Successfully Treated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 36, Issue:3, 2016
Topiramate improves psychiatric symptoms in a patient with Lewy body dementia.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 27, Issue:4, 2014
Add-on oral olanzapine worsens hallucinations in schizoaffective disorder.BMJ case reports, , Oct-21, Volume: 2014, 2014
[Buccolingual dyskinesia with justified hallucinations].Revista de neurologia, , Nov-16, Volume: 59, Issue:10, 2014
Psychiatric manifestations of primary Sjögren's syndrome: a case report and literature review.BMJ case reports, , May-23, Volume: 2014, 2014
A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.The Journal of clinical psychiatry, , Volume: 74, Issue:10, 2013
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.BMC psychiatry, , Sep-30, Volume: 13, 2013
Postictal psychosis treated successfully with olanzapine.The Journal of clinical psychiatry, , Volume: 73, Issue:9, 2012
Repetitive transcranial magnetic stimulation to treat early-onset auditory hallucinations.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:9, 2012
Lilliputian hallucinations in schizophrenia: a case report.African journal of psychiatry, , Volume: 15, Issue:5, 2012
Peduncular hallucinosis.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:2, 2011
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 13, Issue:3, 2011
A potential case of peduncular hallucinosis treated successfully with olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Evaluation of the therapeutic effect of theta burst stimulation on drug-resistant auditory hallucinations in a schizophrenic patient and its impact on cognitive function and neuronal excitability: a case study.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, , Volume: 121, Issue:5, 2010
[Turner-syndrome and psychosis: a case report and brief review of the literature].Psychiatrische Praxis, , Volume: 36, Issue:5, 2009
Psychosis secondary to traumatic brain injury.Brain injury, , Volume: 23, Issue:4, 2009
Reversal of head drop after discontinuation of olanzapine in a DLB patient.Movement disorders : official journal of the Movement Disorder Society, , Sep-15, Volume: 23, Issue:12, 2008
Treatment of catatonia with electroconvulsive therapy in an 11-year-old girl.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:3, 2008
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Item response analysis of the Positive and Negative Syndrome Scale.BMC psychiatry, , Nov-15, Volume: 7, 2007
Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.Schizophrenia research, , Feb-28, Volume: 82, Issue:2-3, 2006
Homatropine and psychosis in Weill-Marchesani syndrome.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 45, Issue:7, 2006
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 13, Issue:2, 2006
Olanzapine-induced gynecomastia.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:8, 2005
Evidence-based medicine and medicine-based evidence.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 26, Issue:3, 2005
Olanzapine therapy in hallucinatory visions related to Bonnet syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 26, Issue:3, 2005
P300 alterations in schizophrenic patients experiencing auditory hallucinations.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 14, Issue:3, 2004
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
Hypnopompic hallucinations during olanzapine treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:7, 2004
Charles-Bonnet syndrome and musical hallucination.International psychogeriatrics, , Volume: 16, Issue:4, 2004
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.International journal of geriatric psychiatry, , Volume: 19, Issue:2, 2004
Do atypical antipsychotics fail to exert cognitive sparing effects?Neuroreport, , Mar-03, Volume: 14, Issue:3, 2003
Dependence and chronic psychosis with D-nor-pseudoephedrine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:8, 2003
Using antipsychotics in elderly patients.The Practitioner, , Volume: 246, Issue:1639, 2002
Olanzapine treatment for dopaminergic-induced hallucinations.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:5, 2002
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.Dementia and geriatric cognitive disorders, , Volume: 13, Issue:2, 2002
Atypical neuroleptic malignant syndrome associated with olanzapine.Pharmacotherapy, , Volume: 22, Issue:5, 2002
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.The Journal of clinical psychiatry, , Volume: 62, Issue:1, 2001
Diabetic ketoacidosis associated with olanzapine in an adolescent patient.The Journal of pediatrics, , Volume: 138, Issue:6, 2001
Olanzapine for psychosis in Parkinson's disease.Neurology, , Jun-26, Volume: 56, Issue:12, 2001
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Aug-28, Volume: 57, Issue:4, 2001
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Aug-28, Volume: 57, Issue:4, 2001
Possible risperidone-induced visual hallucinations.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 39, Issue:9, 2000
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Sep-26, Volume: 55, Issue:6, 2000
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 14, Issue:6, 1999
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
Olanzapine in dementia with Lewy bodies: a clinical study.International journal of geriatric psychiatry, , Volume: 14, Issue:6, 1999
Olanzapine overdose.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Olanzapine: extrapyramidal side effects in the elderly.Australian and New Zealand journal of medicine, , Volume: 29, Issue:3, 1999
Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.Journal of neurology, neurosurgery, and psychiatry, , Volume: 65, Issue:5, 1998
Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
Uncommon side effects associated with olanzapine. A case report.Pharmacopsychiatry, , Volume: 36, Issue:2
Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.American journal of Alzheimer's disease and other dementias, , Volume: 18, Issue:4
Hereditary spastic paraplegia and psychosis: connected by the corpus callosum?Psychosomatics, , Volume: 53, Issue:1
[Psychotic episode due to Hashimoto's thyroiditis].Psychiatrike = Psychiatriki, , Volume: 27, Issue:2
Psychosis in a Patient with Davidoff-Dyke-Masson Syndrome.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:1
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.Journal of clinical psychopharmacology, , Volume: 41, Issue:4
Antipsychotic-induced paroxysmal perceptual alteration.Clinical neuropharmacology, , Volume: 31, Issue:3
Psychiatric symptoms in a case of intracranial tuberculosis.Psychosomatics, , Volume: 43, Issue:1
Isolated nocturnal auditory hallucinations: a case report.General hospital psychiatry, , Volume: 33, Issue:5
Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients.The American journal of emergency medicine, , Volume: 65, 2023
Pharmacological interventions for the treatment of disordered and problem gambling.The Cochrane database of systematic reviews, , 09-22, Volume: 9, 2022
Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial.Human psychopharmacology, , Volume: 36, Issue:1, 2021
Neurotropism of SARS-CoV-2: COVID-19 presenting with an acute manic episode.BMJ case reports, , Jun-14, Volume: 13, Issue:6, 2020
The Use, Safety, and Efficacy of Olanzapine in a Level I Pediatric Trauma Center Emergency Department Over a 10-Year Period.Pediatric emergency care, , Volume: 36, Issue:2, 2020
The Utilization of Atypical Antipsychotics in the Pain Medicine Physician's Armamentarium.Psychopharmacology bulletin, , 06-20, Volume: 48, Issue:4, 2018
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Olanzapine versus droperidol for the treatment of primary headache in the emergency department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, , Volume: 15, Issue:9, 2008
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.The Journal of clinical psychiatry, , Volume: 67, Issue:11, 2006
Olanzapine for the management of pain in an adolescent girl.Journal of child and adolescent psychopharmacology, , Volume: 15, Issue:6, 2005
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
Lipid resuscitation: listening to our patients and learning from our models.Anesthesia and analgesia, , Volume: 114, Issue:4, 2012
Fatal pulmonary embolism following antipsychotic treatment and physical restraint.Pharmacopsychiatry, , Volume: 42, Issue:5, 2009
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Developed catatonia with rhabdomyolysis and exacerbated cardiac failure upon switching from clozapine to olanzapine owing to cardiomyopathy during clozapine medication - A case report.Asian journal of psychiatry, , Volume: 80, 2023
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
Fatal pulmonary embolism following antipsychotic treatment and physical restraint.Pharmacopsychiatry, , Volume: 42, Issue:5, 2009
[A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy].Der Nervenarzt, , Volume: 74, Issue:7, 2003
Effects of lactational exposure of olanzapine and risperidone on hematology and lymphoid organs histopathology: a comparative study in mice neonates.European journal of pharmacology, , May-25, Volume: 634, Issue:1-3, 2010
Olanzapine (Zyprexa): suspected serious reactions.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jul-11, Volume: 163, Issue:1, 2000
Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum.Forensic science international, , Jun-10, Volume: 229, Issue:1-3, 2013
LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood.Forensic science international, , Jun-10, Volume: 229, Issue:1-3, 2013
Assessing the matrix effects of hemolyzed samples in bioanalysis.Bioanalysis, , Volume: 1, Issue:6, 2009
Treating mania in Wilson's disease with lithium.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 20, Issue:4, 2008
Wilson's disease associated with delusional disorder.Psychiatry and clinical neurosciences, , Volume: 60, Issue:6, 2006
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 13, Issue:4, 2001
A comparative study of beneficial effects of Olanzapine and sodium valproate on aggressive behavior of patients who are on methadone maintenance therapy: a randomized triple blind clinical trial.European review for medical and pharmacological sciences, , Volume: 17, Issue:8, 2013
Venlafaxine for acute heroin detoxification: a double-blind, randomized, control trial.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Effects of olanzapine on aggressiveness in heroin dependent patients.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders.Clinical neuropharmacology, , Volume: 30, Issue:3
Olanzapine in the management of psychosis in Huntington’s disease: a case report.Actas espanolas de psiquiatria, , Volume: 47, Issue:5, 2019
Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.Drugs, , Volume: 77, Issue:1, 2017
Biological Perspectives: Huntington's Disease.Perspectives in psychiatric care, , Volume: 51, Issue:3, 2015
Neuroleptic Malignant Syndrome Induced by Olanzapine in a Patient with Huntington's Disease.Journal of Huntington's disease, , Volume: 1, Issue:1, 2012
[A case of affective disorder with psychotic symptoms as late manifestation of Huntington's Chorea].Psychiatrische Praxis, , Volume: 38, Issue:6, 2011
Hypersexual features in Huntington's disease.Singapore medical journal, , Volume: 52, Issue:6, 2011
Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 22, Issue:3, 2010
Premorbid combat related ptsd in Huntington's disease - Case report.Psychiatria Danubina, , Volume: 22, Issue:2, 2010
[Huntington's disease: a negative family history case report demonstrating reduction of psychiatric symptoms with olanzapine].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 31, Issue:2, 2009
Functional and motor response to low dose olanzapine in Huntington's disease: case report.Arquivos de neuro-psiquiatria, , Volume: 62, Issue:4, 2004
Olanzapine-associated seizure.The Annals of pharmacotherapy, , Volume: 37, Issue:1, 2003
Rapid onset of tardive dyskinesia in Huntington disease with olanzapine.Journal of clinical psychopharmacology, , Volume: 22, Issue:4, 2002
Apraxia of eyelid closure in Huntington's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 109, Issue:2, 2002
Olanzapine in Huntington's disease.Acta neurologica Scandinavica, , Volume: 105, Issue:6, 2002
High-dose olanzapine in Huntington's disease.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
Riluzole and olanzapine in Huntington's disease.European journal of neurology, , Volume: 9, Issue:2, 2002
Short-term effects of olanzapine in Huntington disease.Neuropsychiatry, neuropsychology, and behavioral neurology, , Volume: 14, Issue:1, 2001
Olanzapine and Huntington's disease.Journal of clinical psychopharmacology, , Volume: 21, Issue:2, 2001
Improvement of Huntington's disease with olanzapine and valproate.The New England journal of medicine, , Sep-28, Volume: 343, Issue:13, 2000
Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.Arquivos de neuro-psiquiatria, , Volume: 57, Issue:3B, 1999
The use of olanzapine for movement disorder in Huntington's disease: a first case report.Journal of neurology, neurosurgery, and psychiatry, , Volume: 67, Issue:1, 1999
[Olanzapine improves chorea in patients with Huntington's disease].Revista de neurologia, , Volume: 35, Issue:6
Olanzapine for Huntington's disease: an open label study.Clinical neuropharmacology, , Volume: 25, Issue:5
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
Mania in a case of hyperparathyroidism.Psychosomatics, , Volume: 48, Issue:3
Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , 06-08, Volume: 84, Issue:Pt A, 2018
Switching antipsychotic medications: not enough, too often, or just right?The American journal of psychiatry, , Volume: 168, Issue:9, 2011
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).The American journal of psychiatry, , Volume: 168, Issue:9, 2011
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 70, Issue:3, 2009
The risks and benefits of switching antipsychotics: a case study approach.Perspectives in psychiatric care, , Volume: 45, Issue:1, 2009
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.Schizophrenia research, , Volume: 98, Issue:1-3, 2008
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:3, 2006
[Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].Medizinische Klinik (Munich, Germany : 1983), , Jul-15, Volume: 98, Issue:7, 2003
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Fasting or the short-term consumption of a ketogenic diet protects against antipsychotic-induced hyperglycaemia in mice.The Journal of physiology, , Volume: 600, Issue:11, 2022
Voluntary physical activity protects against olanzapine-induced hyperglycemia.Journal of applied physiology (Bethesda, Md. : 1985), , 02-01, Volume: 130, Issue:2, 2021
GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia.American journal of physiology. Endocrinology and metabolism, , 12-01, Volume: 319, Issue:6, 2020
Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.International journal of molecular sciences, , Feb-01, Volume: 20, Issue:3, 2019
Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome.Psychopharmacology, , Volume: 236, Issue:5, 2019
AMPK β1 activation suppresses antipsychotic-induced hyperglycemia in mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology, , Volume: 33, Issue:12, 2019
Female mice are protected against acute olanzapine-induced hyperglycemia.Psychoneuroendocrinology, , Volume: 110, 2019
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.Toxicology and applied pharmacology, , 09-01, Volume: 378, 2019
Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL/6J Mice.Scientific reports, , 01-15, Volume: 8, Issue:1, 2018
AICAR Prevents Acute Olanzapine-Induced Disturbances in Glucose Homeostasis.The Journal of pharmacology and experimental therapeutics, , Volume: 365, Issue:3, 2018
Obesity exacerbates the acute metabolic side effects of olanzapine.Psychoneuroendocrinology, , Volume: 88, 2018
Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia.Psychoneuroendocrinology, , Volume: 82, 2017
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.Internal medicine (Tokyo, Japan), , Volume: 56, Issue:3, 2017
Mechanism Underlying Induction of Hyperglycemia in Rats by Single Administration of Olanzapine.Biological & pharmaceutical bulletin, , Volume: 39, Issue:5, 2016
Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data.Schizophrenia research, , Volume: 154, Issue:1-3, 2014
The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation.Cell structure and function, , Volume: 38, Issue:2, 2013
Olanzapine-induced hyperglycemia: possible involvement of histaminergic, dopaminergic and adrenergic functions in the central nervous system.Neuroendocrinology, , Volume: 98, Issue:3, 2013
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance.PloS one, , Volume: 7, Issue:8, 2012
Severe hyperglycemia induced by olanzapine was improved with a recovery of insulin secretion after switching to risperidone and introducing insulin therapy.Internal medicine (Tokyo, Japan), , Volume: 49, Issue:23, 2010
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.Journal of psychiatric research, , Volume: 43, Issue:11, 2009
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.Human psychopharmacology, , Volume: 24, Issue:3, 2009
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:12, 2008
Rapidly developing hyperglycemia during treatment with olanzapine.The Annals of pharmacotherapy, , Volume: 42, Issue:4, 2008
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks.Diabetes care, , Volume: 30, Issue:1, 2007
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population.International clinical psychopharmacology, , Volume: 22, Issue:1, 2007
Olanzapine-induced hyperglycemia in anorexia nervosa.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].Medicina clinica, , Apr-01, Volume: 126, Issue:12, 2006
Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine.Journal of managed care pharmacy : JMCP, , Volume: 12, Issue:3, 2006
Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.Psychiatry and clinical neurosciences, , Volume: 60, Issue:1, 2006
Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.Journal of the Indian Medical Association, , Volume: 103, Issue:12, 2005
Diabetes mellitus during olanzapine and quetiapine treatment in Japan.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
[Atypical antipsychotic-associated impaired glucose tolerance].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 107, Issue:8, 2005
Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors.Journal of clinical psychopharmacology, , Volume: 25, Issue:2, 2005
Newer antipsychotics and glucose metabolism: a comparison between olanzapine and risperidone.Psychiatria Danubina, , Volume: 17, Issue:1-2, 2005
Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
The incidence of hyperglycemia in patients treated with olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Hyperglycemia associated with antipsychotic treatment in a multicenter drug safety project.Pharmacopsychiatry, , Volume: 37 Suppl 1, 2004
Safety in treating bipolar disorder.The Journal of family practice, , Volume: Suppl, 2003
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Should lipids be monitored during the first year of treatment with an atypical antipsychotic?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Diabetes mellitus associated with atypical anti-psychotic medications.Diabetes technology & therapeutics, , Volume: 5, Issue:4, 2003
Hyperglycemia from olanzapine treatment in adolescents.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 13, Issue:1, 2003
Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report.International journal of geriatric psychiatry, , Volume: 17, Issue:4, 2002
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.The Journal of clinical endocrinology and metabolism, , Volume: 87, Issue:6, 2002
Weight gain and hyperglycaemia associated with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:2, 2002
Glucose intolerance with atypical antipsychotics.Drug safety, , Volume: 25, Issue:15, 2002
Olanzapine-associated diabetes mellitus.Pharmacotherapy, , Volume: 22, Issue:7, 2002
Fatality from olanzapine induced hyperglycemia.Journal of forensic sciences, , Volume: 47, Issue:4, 2002
Olanzapine-induced destabilization of diabetes in the absence of weight gain.Acta psychiatrica Scandinavica, , Volume: 105, Issue:3, 2002
Ziprasidone alternative for olanzapine-induced hyperglycemia.The American journal of psychiatry, , Volume: 159, Issue:9, 2002
[Uncontrolled hyperglycemia with ketosis associated with olanzapine therapy].Revista clinica espanola, , Volume: 202, Issue:12, 2002
Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy.Pharmacotherapy, , Volume: 21, Issue:11, 2001
Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature.Pharmacotherapy, , Volume: 21, Issue:11, 2001
Atypical antipsychotic drugs and hyperglycemia in adolescents.JAMA, , Nov-28, Volume: 286, Issue:20, 2001
Atypical antipsychotics and hyperglycaemia.International clinical psychopharmacology, , Volume: 16, Issue:2, 2001
Hyperglycemia in patients with schizophrenia who are treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 21, Issue:3, 2001
Olanzapine-related hyperglycemia in a nondiabetic woman.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:5, 2001
Hyperglycemia associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 23, 2001
Hyperglycemia and hypertriglyceridemia secondary to olanzapine.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 11, Issue:3, 2001
[Hyperglycemia and ketoacidosis associated with olanzapine].Der Nervenarzt, , Volume: 70, Issue:9, 1999
Hyperglycemia and olanzapine.The American journal of psychiatry, , Volume: 156, Issue:6, 1999
Hyperglycemia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
[The hyperglycemic dehydration syndrome].Nederlands tijdschrift voor geneeskunde, , Oct-10, Volume: 142, Issue:41, 1998
Olanzapine and quick-response hyperglycemia.Psychosomatics, , Volume: 44, Issue:2
Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature.Journal of intensive care medicine, , Volume: 22, Issue:1
Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy.American journal of therapeutics, , Volume: 10, Issue:5
Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.International journal of molecular sciences, , Feb-01, Volume: 20, Issue:3, 2019
Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia.American journal of physiology. Endocrinology and metabolism, , 08-01, Volume: 315, Issue:2, 2018
Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance.The Journal of endocrinology, , Volume: 227, Issue:2, 2015
Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.PloS one, , Volume: 8, Issue:1, 2013
Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.Psychopharmacology, , Volume: 213, Issue:1, 2011
Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance.Diabetes, , Volume: 59, Issue:10, 2010
Insulin resistance following continuous, chronic olanzapine treatment: an animal model.Schizophrenia research, , Volume: 104, Issue:1-3, 2008
Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
A parametric analysis of olanzapine-induced weight gain in female rats.Psychopharmacology, , Volume: 181, Issue:1, 2005
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp.The Journal of clinical endocrinology and metabolism, , Volume: 88, Issue:12, 2003
Hyperinsulinemia in psychiatric patients treated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:1, 2002
Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.International journal of molecular sciences, , Feb-01, Volume: 20, Issue:3, 2019
Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, , Volume: 50, Issue:4, 2018
Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis.Drug safety, , Volume: 38, Issue:7, 2015
The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation.Cell structure and function, , Volume: 38, Issue:2, 2013
Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 64, Issue:1, 2013
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.Schizophrenia research, , Volume: 98, Issue:1-3, 2008
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.The Journal of clinical psychiatry, , Volume: 68, Issue:10, 2007
Severe hyperlipidemia associated with olanzapine and quetiapine use.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Confounding by indication and the risk of hyperlipidemia in observational studies of antipsychotics.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].Medicina clinica, , Apr-01, Volume: 126, Issue:12, 2006
Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.Psychiatry and clinical neurosciences, , Volume: 60, Issue:1, 2006
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine.Pharmacoepidemiology and drug safety, , Volume: 14, Issue:6, 2005
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current opinion in pediatrics, , Volume: 17, Issue:2, 2005
Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.International clinical psychopharmacology, , Volume: 20, Issue:2, 2005
Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders.Schizophrenia research, , Dec-01, Volume: 80, Issue:1, 2005
Dyslipidemia and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine.Journal of pharmaceutical and biomedical analysis, , Sep-03, Volume: 35, Issue:5, 2004
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
Eruptive xanthomas associated with olanzapine use.Archives of dermatology, , Volume: 139, Issue:8, 2003
Should lipids be monitored during the first year of treatment with an atypical antipsychotic?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
The effects of novel antipsychotics on glucose and lipid levels.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.Archives of general psychiatry, , Volume: 59, Issue:11, 2002
Novel antipsychotics and severe hyperlipidemia.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 62, Issue:9, 2023
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.Psychiatry research, , Volume: 322, 2023
Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation.Psychiatry and clinical neurosciences, , Volume: 77, Issue:9, 2023
Paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuating impairment of the dopamine D2 receptor and TGF-β1 signaling pathways in the hypothalamus and pituitary.Journal of ethnopharmacology, , Jul-15, Volume: 257, 2020
The ancient Chinese formula Longdan Xiegan Tang improves antipsychotic-induced hyperprolactinemia by repairing the hypothalamic and pituitary TGF-β1 signaling in rats.Journal of ethnopharmacology, , May-23, Volume: 254, 2020
Prolactin response to antipsychotics: An inpatient study.PloS one, , Volume: 15, Issue:2, 2020
Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions.Clinical pharmacology in drug development, , Volume: 9, Issue:5, 2020
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.The Journal of clinical psychiatry, , Volume: 77, Issue:12, 2016
[Treatment of Olanzapine-induced Hyperprolactinemia by Shaoyao Gancao Decoction].Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, , Volume: 36, Issue:12, 2016
Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses.BMJ (Clinical research ed.), , Nov-24, Volume: 355, 2016
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.CNS spectrums, , Volume: 21, Issue:6, 2016
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:11, 2015
Herbal medicine (Shakuyaku-kanzo-to) improves olanzapine-associated hyperprolactinemia: a case report.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-01, Volume: 45, 2013
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.Neuro endocrinology letters, , Volume: 32, Issue:4, 2011
Effects of lactational exposure of olanzapine and risperidone on hematology and lymphoid organs histopathology: a comparative study in mice neonates.European journal of pharmacology, , May-25, Volume: 634, Issue:1-3, 2010
Hyperprolactinaemia and acute psychosis: prolactinoma or medication-induced phenomenon?The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:5, 2010
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
Management of a patient with schizophrenia and underlying pituitary macroadenoma.Annals of the Academy of Medicine, Singapore, , Volume: 39, Issue:11, 2010
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.Human psychopharmacology, , Volume: 25, Issue:3, 2010
Neuroleptics and migraine.Central nervous system agents in medicinal chemistry, , Volume: 9, Issue:1, 2009
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.Pharmacy world & science : PWS, , Volume: 30, Issue:1, 2008
Olanzapine for the treatment of bipolar disorder in children and adolescents.Expert opinion on pharmacotherapy, , Volume: 9, Issue:3, 2008
A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:2, 2007
Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.Neuro endocrinology letters, , Volume: 28, Issue:6, 2007
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.Journal of clinical pharmacy and therapeutics, , Volume: 32, Issue:2, 2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.The American journal of managed care, , Volume: 13, Issue:7 Suppl, 2007
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
A crossover study of prolactin changes associated with risperidone and olanzapine.The Journal of clinical psychiatry, , Volume: 67, Issue:9, 2006
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.Pharmacotherapy, , Volume: 26, Issue:6, 2006
Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.The Journal of clinical psychiatry, , Volume: 66, Issue:6, 2005
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
Possible impact of dropout in a study of high-dose olanzapine and prolactin levels.The Journal of clinical psychiatry, , Volume: 65, Issue:8, 2004
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.Postgraduate medicine, , Volume: 116, Issue:4, 2004
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.Annals of the New York Academy of Sciences, , Volume: 1032, 2004
A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.Psychoneuroendocrinology, , Volume: 28 Suppl 2, 2003
Safety in treating bipolar disorder.The Journal of family practice, , Volume: Suppl, 2003
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder.Psychiatry research, , Aug-05, Volume: 111, Issue:1, 2002
Risperidone side effects.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Hyperprolactinemia and male sexual dysfunction.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.The American journal of psychiatry, , Volume: 155, Issue:10, 1998
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.Schizophrenia research, , Jul-25, Volume: 26, Issue:1, 1997
[Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine].Psychiatria polska, , Volume: 39, Issue:6
Haloperidol-induced impotence improved by switching to olanzapine.General hospital psychiatry, , Volume: 22, Issue:5
Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder.Rivista di psichiatria, , Volume: 54, Issue:1
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.The Cochrane database of systematic reviews, , 09-21, Volume: 9, 2018
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.Journal of affective disorders, , Jan-01, Volume: 207, 2017
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Implications of atypical antipsychotic prescribing in the intensive care unit.Journal of critical care, , Volume: 30, Issue:4, 2015
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.BMC psychiatry, , Apr-02, Volume: 15, 2015
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Clinical schizophrenia & related psychoses, , Volume: 6, Issue:2, 2012
Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine.Schizophrenia research, , Volume: 135, Issue:1-3, 2012
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:1, 2008
The clinical picture of olanzapine poisoning with special reference to fluctuating mental status.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:1, 2004
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 11, Issue:3, 2001
Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.Journal of clinical psychopharmacology, , Volume: 21, Issue:5, 2001
Use of olanzapine in hereditary coproporphyria.Psychosomatics, , Volume: 40, Issue:5
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.Schizophrenia bulletin, , 03-15, Volume: 49, Issue:2, 2023
Antipsychotic-Induced Metabolic Syndrome: A Review.Metabolic syndrome and related disorders, , Volume: 21, Issue:6, 2023
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
[The clinical picture of acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
Acute pancreatitis associated with lisinopril and olanzapine.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Feb-01, Volume: 67, Issue:3, 2010
An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 54, Issue:4, 2009
Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.The Journal of clinical psychiatry, , Volume: 68, Issue:10, 2007
Speech and language difficulties in a patient with schizophrenia-like disorder: a case report.Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria, , Volume: 20, Issue:3
Uncommon side effects associated with olanzapine. A case report.Pharmacopsychiatry, , Volume: 36, Issue:2
Challenges Faced When Caring for Foreign Nationals With Comorbid Medical and Psychiatric Problems in the General Hospital.Psychosomatics, , Volume: 59, Issue:1
Olanzapine-induced hypoglycemia in anorexia nervosa.Endocrine, , Volume: 46, Issue:3, 2014
Severe recurrent hypoglycaemia following discontinuation of olanzapine.Acute medicine, , Volume: 10, Issue:1, 2011
Hypoglycaemia induced by second generation antipsychotic agents in schizophrenic non-diabetic patients.BMJ (Clinical research ed.), , May-26, Volume: 338, 2009
Olanzapine and hypoglycemic coma in a frail elderly woman. A case report.Pharmacopsychiatry, , Volume: 36, Issue:4, 2003
Low blood glucose and olanzapine.The American journal of psychiatry, , Volume: 158, Issue:3, 2001
The unmasking of hidden severe hyponatremia after long-term combination therapy in exacerbated bipolar patients: a case series.International clinical psychopharmacology, , Volume: 34, Issue:4, 2019
Hyponatremia as a result of posttraumatic primary polydipsia.The American journal of medicine, , Volume: 128, Issue:6, 2015
Fatal water intoxication during olanzapine treatment: a case report.Legal medicine (Tokyo, Japan), , Volume: 16, Issue:2, 2014
Olanzapine-induced hyponatremia in a patient with autism.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:10, 2013
Life-threatening hyponatraemia and intramuscular olanzapine: the world's longest therapeutic trial.BMJ case reports, , Dec-20, Volume: 2011, 2011
Olanzapine induced hyponatraemia.The Ulster medical journal, , Volume: 79, Issue:2, 2010
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Effects of olanzapine on polydipsia and intermittent hyponatremia.The Journal of clinical psychiatry, , Volume: 58, Issue:12, 1997
A suspected case of olanzapine induced hyponatremia.Indian journal of pharmacology, , Volume: 46, Issue:4
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.The American journal of case reports, , Dec-01, Volume: 23, 2022
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study.Annals of internal medicine, , Aug-19, Volume: 161, Issue:4, 2014
Cardiotoxicity in a citalopram and olanzapine overdose.The Journal of emergency medicine, , Volume: 45, Issue:4, 2013
Massive pulmonary emboli associated with olanzapine.Irish medical journal, , Volume: 101, Issue:6, 2008
Elderly patient with delirium after myocardial infarction.Journal of the National Medical Association, , Volume: 98, Issue:4, 2006
Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam.The Journal of clinical psychiatry, , Volume: 66, Issue:12, 2005
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current opinion in pediatrics, , Volume: 17, Issue:2, 2005
Severe cardiovascular side effects of olanzapine in an elderly patient: case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine.Journal of clinical pharmacology, , Volume: 42, Issue:1, 2002
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder.General hospital psychiatry, , Volume: 31, Issue:4
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function.Psychopharmacology, , Volume: 199, Issue:1, 2008
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Olanzapine: interaction study with imipramine.Journal of clinical pharmacology, , Volume: 37, Issue:10, 1997
Olanzapine for schizophrenia.The Medical letter on drugs and therapeutics, , Jan-17, Volume: 39, Issue:992, 1997
Lessons of the month 2: Olanzapine-induced hypothermia and hand oedema.Clinical medicine (London, England), , Volume: 22, Issue:3, 2022
The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors.International clinical psychopharmacology, , Volume: 34, Issue:1, 2019
Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy.BMJ case reports, , Dec-02, Volume: 2017, 2017
Hypothermia associated with antipsychotic drug use: a clinical case series and review of current literature.Journal of clinical pharmacology, , Volume: 52, Issue:7, 2012
A case of severe hypothermia following single-dose administration of olanzapine: a case report.Journal of clinical pharmacology, , Volume: 52, Issue:2, 2012
[Hypothermia under olanzapine treatment: clinical case series and review of current literature].Der Nervenarzt, , Volume: 83, Issue:5, 2012
Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats.Pharmacology, biochemistry, and behavior, , Volume: 97, Issue:1, 2010
Severe cardiovascular side effects of olanzapine in an elderly patient: case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Hypothermia in a hemodialysis patient treated with olanzapine monotherapy.Journal of clinical psychopharmacology, , Volume: 23, Issue:3, 2003
Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine.Journal of clinical psychopharmacology, , Volume: 21, Issue:1, 2001
Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat.The Journal of pharmacology and experimental therapeutics, , Volume: 292, Issue:2, 2000
[Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon].Annales francaises d'anesthesie et de reanimation, , Volume: 18, Issue:6, 1999
Antagonism by pimozide of olanzapine-induced hypothermia.Fundamental & clinical pharmacology, , Volume: 13, Issue:5, 1999
Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome.The Medical journal of Australia, , Aug-17, Volume: 169, Issue:4, 1998
Olanzapine-associated hypothermia.Psychosomatics, , Volume: 45, Issue:2
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder.General hospital psychiatry, , Volume: 31, Issue:4
Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 62, Issue:9, 2023
Management of sexual dysfunction due to antipsychotic drug therapy.The Cochrane database of systematic reviews, , Nov-14, Volume: 11, 2012
Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 19, Issue:8, 2009
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 9, Issue:3, 2007
Sildenafil use in patients with olanzapine-induced erectile dysfunction.International journal of impotence research, , Volume: 14, Issue:6, 2002
Olanzapine-induced priapism.The American journal of psychiatry, , Volume: 158, Issue:12, 2001
Priapism associated with conventional and atypical antipsychotic medications: a review.The Journal of clinical psychiatry, , Volume: 62, Issue:5, 2001
Paliperidone Palmitate-Induced Retrograde Ejaculation.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:2
Spontaneous Ejaculations in an Adolescent With Olanzapine Use: Case Report.Clinical neuropharmacology, , Volume: 39, Issue:3
Masturbatory guilt leading to severe depression and erectile dysfunction.Journal of sex & marital therapy, , Volume: 28, Issue:4
Haloperidol-induced impotence improved by switching to olanzapine.General hospital psychiatry, , Volume: 22, Issue:5
The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.Current neuropharmacology, , Volume: 22, Issue:1, 2024
Hypothalamic JNK1-hepatic fatty acid synthase axis mediates a metabolic rewiring that prevents hepatic steatosis in male mice treated with olanzapine via intraperitoneal: Additional effects of PTP1B inhibition.Redox biology, , Volume: 63, 2023
Olanzapine Induces Inflammation and Immune Response via Activating ER Stress in the Rat Prefrontal Cortex.Current medical science, , Volume: 41, Issue:4, 2021
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 133, 2021
JNK downregulation improves olanzapine-induced insulin resistance by suppressing IRS1Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 142, 2021
Human macrophages stimulate expression of inflammatory mediators in adipocytes; effects of second-generation antipsychotics and glucocorticoids on cellular cross-talk.Psychoneuroendocrinology, , Volume: 125, 2021
Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats.Behavioural brain research, , 01-27, Volume: 378, 2020
Role of TRPV1/TRPV3 channels in olanzapine-induced metabolic alteration: Possible involvement in hypothalamic energy-sensing, appetite regulation, inflammation and mesolimbic pathway.Toxicology and applied pharmacology, , 09-01, Volume: 402, 2020
Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting.Pharmacopsychiatry, , Volume: 53, Issue:1, 2020
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons.Psychoneuroendocrinology, , Volume: 104, 2019
Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.International journal of molecular sciences, , Feb-01, Volume: 20, Issue:3, 2019
Lithium is able to minimize olanzapine oxidative-inflammatory induction on macrophage cells.PloS one, , Volume: 14, Issue:1, 2019
Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons.Psychoneuroendocrinology, , Volume: 109, 2019
Olanzapine-induced endoplasmic reticulum stress and inflammation in the hypothalamus were inhibited by an ER stress inhibitor 4-phenylbutyrate.Psychoneuroendocrinology, , Volume: 104, 2019
Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue.Psychoneuroendocrinology, , Volume: 95, 2018
Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, , Volume: 50, Issue:4, 2018
Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells.Journal of psychiatric research, , Volume: 105, 2018
Activation of indoleamine 2, 3- dioxygenase pathway by olanzapine augments antidepressant effects of venlafaxine in mice.Psychiatry research, , Volume: 258, 2017
Effects of olanzapine on LPS-induced inflammation in rat primary glia cells.Innate immunity, , Volume: 22, Issue:1, 2016
Olanzapine modulation of hepatic oxidative stress and inflammation in socially isolated rats.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Jan-01, Volume: 81, 2016
Effects of olanzapine on the elevation of macrophage infiltration and pro-inflammatory cytokine expression in female rats.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:12, 2014
Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state.Brain research, , Sep-02, Volume: 1350, 2010
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.Current protocols in cytometry, , Volume: Chapter 13, 2010
Açaí (Euterpe oleracea Mart.) reduces the inflammatory response triggered in vitro by the antipsychotic drug olanzapine in RAW 264.7 macrophage cells.Acta scientiarum polonorum. Technologia alimentaria, , Volume: 20, Issue:2
Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.Annals of palliative medicine, , Volume: 12, Issue:3, 2023
Manic syndrome in mitochondrial membrane protein-associated neurodegeneration: A case report.Psychiatry and clinical neurosciences, , Volume: 76, Issue:10, 2022
Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report.Neuropsychopharmacology reports, , Volume: 42, Issue:3, 2022
Hyperventilation and Respiratory Alkalosis After Olanzapine for Insomnia: A Case Report.A&A practice, , Oct-20, Volume: 15, Issue:10, 2021
Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.Medicine, , Volume: 98, Issue:3, 2019
Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.Scientific reports, , 11-02, Volume: 8, Issue:1, 2018
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Treatment of Subjective Total Insomnia After Suicide Attempt With Olanzapine and Electroconvulsive Therapy.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
Betahistine decreases olanzapine-induced weight gain and somnolence in humans.Journal of psychopharmacology (Oxford, England), , Volume: 30, Issue:3, 2016
Olanzapine for Nausea, Delirium, Anxiety, Insomnia, and Cachexia #315.Journal of palliative medicine, , Volume: 19, Issue:11, 2016
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
Could pramipexole induce acute mania? A case report.Bipolar disorders, , Volume: 15, Issue:4, 2013
Treatment of paradoxical insomnia with atypical antipsychotic drugs. A comparison of olanzapine and risperidone.Neurosciences (Riyadh, Saudi Arabia), , Volume: 18, Issue:1, 2013
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 22, Issue:10, 2012
Insomnia treatment by olanzapine. Is sleep state misperception a psychotic disorder?Neurosciences (Riyadh, Saudi Arabia), , Volume: 15, Issue:2, 2010
Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 44, Issue:3, 2010
Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:5, 2005
A case report of olanzapine-induced fecal incontinence.The Journal of clinical psychiatry, , Volume: 64, Issue:3, 2003
Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports.Acta psychiatrica Scandinavica, , Volume: 107, Issue:5, 2003
Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder (PTSD)Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 45, Issue:7, 2000
Zolpidem related persistent genital arousal disorder: An interesting case.Psychiatrike = Psychiatriki, , Volume: 30, Issue:4
Thymoquinone attenuates olanzapine-induced metabolic disorders in rats.Molecular biology reports, , Volume: 50, Issue:11, 2023
Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls.PloS one, , Volume: 17, Issue:11, 2022
The mechanisms underlying olanzapine-induced insulin resistance via the brown adipose tissue and the therapy in rats.Adipocyte, , Volume: 11, Issue:1, 2022
JNK downregulation improves olanzapine-induced insulin resistance by suppressing IRS1Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 142, 2021
Anthocyanins from Molecules (Basel, Switzerland), , Oct-12, Volume: 26, Issue:20, 2021
Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats.Journal of ethnopharmacology, , Jun-28, Volume: 274, 2021
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 133, 2021
Olanzapine-induced insulin resistance may occur via attenuation of central KSchizophrenia research, , Volume: 228, 2021
Fenofibrate ameliorates olanzapine's side effects without altering its central effect: emphasis on FGF-21-adiponectin axis.Behavioural pharmacology, , 12-01, Volume: 32, Issue:8, 2021
Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice.Molecular neurobiology, , Volume: 57, Issue:1, 2020
Identification and characterization of proteins that are differentially expressed in adipose tissue of olanzapine-induced insulin resistance rat by iTRAQ quantitative proteomics.Journal of proteomics, , 02-10, Volume: 212, 2020
Female mice are protected against acute olanzapine-induced hyperglycemia.Psychoneuroendocrinology, , Volume: 110, 2019
Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance.Scientific reports, , 02-07, Volume: 9, Issue:1, 2019
Berberine attenuates olanzapine induced-metabolic syndrome.JPMA. The Journal of the Pakistan Medical Association, , Volume: 69(Suppl 3), Issue:8, 2019
Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.International journal of molecular sciences, , Feb-01, Volume: 20, Issue:3, 2019
Insulin resistance induced by olanzapine and other second-generation antipsychotics in Chinese patients with schizophrenia: a comparative review and meta-analysis.European journal of clinical pharmacology, , Volume: 75, Issue:12, 2019
The IRS/PI3K/Akt signaling pathway mediates olanzapine-induced hepatic insulin resistance in male rats.Life sciences, , Jan-15, Volume: 217, 2019
One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects.The international journal of neuropsychopharmacology, , 05-01, Volume: 22, Issue:5, 2019
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons.Psychoneuroendocrinology, , Volume: 104, 2019
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.Psychoneuroendocrinology, , Volume: 108, 2019
The Probiotic Mixture VSL#3 Reverses Olanzapine-Induced Metabolic Dysfunction in Mice.Methods in molecular biology (Clifton, N.J.), , Volume: 2011, 2019
Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.JAMA psychiatry, , 08-01, Volume: 75, Issue:8, 2018
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5, 2018
Antenatal antipsychotic exposure induces multigenerational and gender-specific programming of adiposity and glucose tolerance in adult mouse offspring.Diabetes & metabolism, , Volume: 44, Issue:3, 2018
Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy.The Journal of clinical investigation, , 11-01, Volume: 128, Issue:11, 2018
Neuropsychiatric disorders: Side effects of olanzapine worsened by metabolic dysfunction.Nature reviews. Endocrinology, , Volume: 14, Issue:3, 2018
Obesity exacerbates the acute metabolic side effects of olanzapine.Psychoneuroendocrinology, , Volume: 88, 2018
Effects of acute olanzapine exposure on central insulin-mediated regulation of whole body fuel selection and feeding.Psychoneuroendocrinology, , Volume: 98, 2018
Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue.Psychoneuroendocrinology, , Volume: 95, 2018
Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.Human psychopharmacology, , Volume: 32, Issue:4, 2017
Roman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expression.Journal of psychopharmacology (Oxford, England), , Volume: 31, Issue:11, 2017
In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact.Journal of psychiatry & neuroscience : JPN, , Volume: 42, Issue:6, 2017
Chronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin Resistance.PloS one, , Volume: 11, Issue:12, 2016
Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder.The Journal of clinical psychiatry, , Volume: 77, Issue:12, 2016
Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female Sprague-Dawley rats.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:12, 2015
Meal-induced insulin sensitization is preserved after acute olanzapine administration in female Sprague-Dawley rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 388, Issue:5, 2015
Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance.The Journal of endocrinology, , Volume: 227, Issue:2, 2015
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar disorders, , Volume: 17, Issue:5, 2015
An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine.PloS one, , Volume: 9, Issue:9, 2014
Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study.Pharmacopsychiatry, , Volume: 47, Issue:4-5, 2014
Subchronic olanzapine treatment decreases the expression of pancreatic glucose transporter 2 in rat pancreatic β cells.Journal of endocrinological investigation, , Volume: 37, Issue:7, 2014
The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:4, 2014
A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes.Cellular signalling, , Volume: 26, Issue:6, 2014
Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls.Journal of clinical psychopharmacology, , Volume: 33, Issue:6, 2013
Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.PloS one, , Volume: 8, Issue:1, 2013
A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.Psychopharmacology, , Volume: 230, Issue:1, 2013
Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.Diabetes, , Volume: 62, Issue:9, 2013
Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats.Neuropharmacology, , Volume: 62, Issue:3, 2012
Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study.International journal of psychiatry in clinical practice, , Volume: 16, Issue:1, 2012
The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study.Pharmacopsychiatry, , Volume: 45, Issue:3, 2012
Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 22, Issue:1, 2012
Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance.PloS one, , Volume: 7, Issue:8, 2012
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.Schizophrenia bulletin, , Volume: 38, Issue:1, 2012
Association of serum retinol-binding protein 4 with insulin resistance and metabolic parameters during olanzapine therapy.Clinical endocrinology, , Volume: 76, Issue:2, 2012
Insulin secretion and sensitivity after single-dose amisulpride, olanzapine or placebo in young male subjects: double blind, cross-over glucose clamp study.Pharmacopsychiatry, , Volume: 45, Issue:6, 2012
Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.Journal of psychiatry & neuroscience : JPN, , Volume: 37, Issue:6, 2012
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.Diabetes, obesity & metabolism, , Volume: 13, Issue:8, 2011
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.Neuro endocrinology letters, , Volume: 32, Issue:4, 2011
Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.Archives of physiology and biochemistry, , Volume: 117, Issue:4, 2011
Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.Psychopharmacology, , Volume: 213, Issue:1, 2011
The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-16, Volume: 34, Issue:6, 2010
Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance.Diabetes, , Volume: 59, Issue:10, 2010
Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.International journal of obesity (2005), , Volume: 34, Issue:6, 2010
Increased food intake and energy expenditure following administration of olanzapine to healthy men.Obesity (Silver Spring, Md.), , Volume: 18, Issue:8, 2010
Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats.Neuropsychobiology, , Volume: 61, Issue:3, 2010
Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state.Brain research, , Sep-02, Volume: 1350, 2010
Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 70, Issue:1, 2009
Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.Journal of psychiatric practice, , Volume: 15, Issue:4, 2009
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.Pharmacopsychiatry, , Volume: 42, Issue:1, 2009
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.Human psychopharmacology, , Volume: 24, Issue:3, 2009
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.Journal of psychiatric research, , Volume: 42, Issue:13, 2008
Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: a case report.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-01, Volume: 32, Issue:1, 2008
Insulin resistance following continuous, chronic olanzapine treatment: an animal model.Schizophrenia research, , Volume: 104, Issue:1-3, 2008
Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.Collegium antropologicum, , Volume: 31, Issue:4, 2007
Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks: response to Hardy et al.Diabetes care, , Volume: 30, Issue:7, 2007
Metabolic effects of the atypical antipsychotics.Southern medical journal, , Volume: 100, Issue:8, 2007
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.Schizophrenia research, , Volume: 89, Issue:1-3, 2007
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.International clinical psychopharmacology, , Volume: 22, Issue:2, 2007
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia.International clinical psychopharmacology, , Volume: 22, Issue:4, 2007
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.Psychopharmacology, , Volume: 186, Issue:4, 2006
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:3, 2006
Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:1, 2006
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain.European journal of pharmacology, , Dec-03, Volume: 551, Issue:1-3, 2006
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.The Journal of clinical psychiatry, , Volume: 67, Issue:5, 2006
Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors.Journal of clinical psychopharmacology, , Volume: 25, Issue:2, 2005
Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs.Diabetes, , Volume: 54, Issue:3, 2005
Newer antipsychotics and glucose metabolism: a comparison between olanzapine and risperidone.Psychiatria Danubina, , Volume: 17, Issue:1-2, 2005
Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells.Molecular psychiatry, , Volume: 10, Issue:12, 2005
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 7, Issue:3, 2005
A parametric analysis of olanzapine-induced weight gain in female rats.Psychopharmacology, , Volume: 181, Issue:1, 2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Archives of general psychiatry, , Volume: 62, Issue:1, 2005
Atypical antipsychotics and diabetes mellitus.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:2, 2004
[Effect of atypical antipsychotics on metabolism].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 6, Issue:2, 2004
Olanzapine induces insulin resistance: results from a prospective study.The Journal of clinical psychiatry, , Volume: 64, Issue:12, 2003
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp.The Journal of clinical endocrinology and metabolism, , Volume: 88, Issue:12, 2003
Hyperinsulinemia in psychiatric patients treated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:1, 2002
[The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].Psychiatria polska, , Volume: 49, Issue:2
Insulin Resistance-Related Proteins Are Overexpressed in Patients and Rats Treated With Olanzapine and Are Reverted by Pueraria in the Rat Model.Journal of clinical psychopharmacology, , Volume: 39, Issue:3
Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 35, Issue:3
Increased infection rates associated with second-generation antipsychotics.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , 02-01, Volume: 33, Issue:1, 2021
Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction?Journal of psychiatric practice, , Volume: 24, Issue:2, 2018
Reversible delayed onset olanzapine-associated leukopenia and neutropenia in a clozapine-naive patient on concomitant depot antipsychotic.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Prolongation of clozapine-induced leukopenia with olanzapine treatment.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:5, 2006
Olanzapine-induced leucopenia and neutropenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:6, 2005
Dose-dependent olanzapine-associated leukopenia: three case reports.International clinical psychopharmacology, , Volume: 16, Issue:2, 2001
Continuing treatment with novel antipsychotic drugs despite leukopenia or thrombocytopenia.Archives of general psychiatry, , Volume: 58, Issue:7, 2001
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
[Is bone marrow inhibition a special risk in connection with olanzapine (Zyprexa) treatment?].Ugeskrift for laeger, , Oct-30, Volume: 162, Issue:44, 2000
Olanzapine appears haematologically safe in patients who developed blood dyscrasia on clozapine and risperidone.International clinical psychopharmacology, , Volume: 15, Issue:4, 2000
Reversible leucopenia related to olanzapine.Movement disorders : official journal of the Movement Disorder Society, , Volume: 14, Issue:5, 1999
[A case of leukopenia in treatment with risperidone in an adolescent].L'Encephale, , Volume: 26, Issue:5
Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.CPT: pharmacometrics & systems pharmacology, , Volume: 10, Issue:9, 2021
Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats.Behavioural brain research, , 01-27, Volume: 378, 2020
Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.Drug design, development and therapy, , Volume: 13, 2019
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.Expert review of neurotherapeutics, , Volume: 10, Issue:5, 2010
Serum levels of olanzapine in a non-fatal overdose.Journal of analytical toxicology, , Volume: 31, Issue:2, 2007
Antipsychotic Safety in Liver Disease: A Narrative Review and Practical Guide for the Clinician.Journal of the Academy of Consultation-Liaison Psychiatry, , Volume: 64, Issue:1
Olanzapine for Non-Chemotherapy Related Nausea and Emesis in Patients with a Palliative Care Consult.Journal of pain and symptom management, , Volume: 66, Issue:4, 2023
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTScientific reports, , 01-11, Volume: 11, Issue:1, 2021
'Hidden' corrected QT interval prolongation induced by olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 53, Issue:11, 2019
Absence of Change in Corrected QT Interval in Children and Adolescents Receiving Antipsychotic Treatment: A 12 Month Study.Journal of child and adolescent psychopharmacology, , Volume: 26, Issue:5, 2016
Effects of olanzapine on the PR and QT intervals in patients with schizophrenia.Schizophrenia research, , Volume: 152, Issue:1, 2014
Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care.Clinical toxicology (Philadelphia, Pa.), , Volume: 52, Issue:1, 2014
Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.Human psychopharmacology, , Volume: 28, Issue:3, 2013
Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Arsenic trioxide and olanzapine co-administration: case analysis.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, , Volume: 17, Issue:3, 2011
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).The American journal of psychiatry, , Volume: 168, Issue:2, 2011
Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.Human psychopharmacology, , Volume: 26, Issue:6, 2011
[Medication associated long QT syndrome].Praxis, , Dec-02, Volume: 98, Issue:24, 2009
QTc changes after 6 months of second-generation antipsychotic treatment in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:4, 2008
A pilot observational crossover study of QTc interval changes associated with switching between olanzapine and risperidone.The Journal of clinical psychiatry, , Volume: 68, Issue:5, 2007
[Long QT syndrome due to olanzapine administration].Kardiologia polska, , Volume: 64, Issue:9, 2006
Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine.International journal of cardiology, , May-10, Volume: 109, Issue:2, 2006
Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.Journal of clinical psychopharmacology, , Volume: 24, Issue:1, 2004
Antipsychotic drugs and QT interval prolongation.The Psychiatric quarterly, ,Fall, Volume: 74, Issue:3, 2003
Antipsychotic induced prolongation of QTc interval treated with magnesium.Journal of psychopharmacology (Oxford, England), , Volume: 17, Issue:3, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
[A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy].Der Nervenarzt, , Volume: 74, Issue:7, 2003
QTc prolongation: chlorpromazine and high-dosage olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Olanzapine: a proarrhythmic drug?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 47, Issue:7, 2002
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.European journal of pharmacology, , Aug-16, Volume: 450, Issue:1, 2002
Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:2, 2001
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.The Journal of clinical psychiatry, , Volume: 62, Issue:3, 2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
[QT prolongation and second-generation antipsychotics: overdose and therapeutic dosage].Therapie, , Volume: 59, Issue:5
Reversal of pathologic cardiac parameters after transition from clozapine to olanzapine treatment: a case report.Clinical neuropharmacology, , Volume: 24, Issue:2
The utility of intramuscular ziprasidone in the management of acute psychotic agitation.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:3
QTc prolongation and high-dose olanzapine.Psychosomatics, , Volume: 44, Issue:2
Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 05-10, Volume: 41, Issue:14, 2023
Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.Cancer chemotherapy and pharmacology, , Volume: 84, Issue:1, 2019
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.Medicine, , Volume: 97, Issue:37, 2018
Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.Anticancer research, , Volume: 37, Issue:11, 2017
Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses.BMJ (Clinical research ed.), , Nov-24, Volume: 355, 2016
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.Cell biochemistry and biophysics, , Volume: 72, Issue:2, 2015
Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 18, Issue:8, 2010
Re: Olanzapine-induced delirium.Journal of pain and symptom management, , Volume: 29, Issue:2, 2005
Olanzapine-induced delirium in a terminally ill cancer patient.Journal of pain and symptom management, , Volume: 28, Issue:2, 2004
Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.Journal of pain and symptom management, , Volume: 25, Issue:6, 2003
Use of electroconvulsive therapy in an adolescent with systemic lupus erythematosus for management of depression.The journal of ECT, , Volume: 29, Issue:3, 2013
Olanzapine-induced neutropenia in a patient with systemiclupus erythematosus: a role of FcγRIIIb polymorphism?Lupus, , Volume: 21, Issue:1, 2012
Olanzapine-induced agranulocytosis in systemic lupus erythematosus: a case report.General hospital psychiatry, , Volume: 29, Issue:1
The antipsychotic olanzapine reduces memory deficits and neuronal abnormalities in a male rat model of Autism.Journal of chemical neuroanatomy, , Volume: 132, 2023
Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.Metabolic brain disease, , Volume: 32, Issue:5, 2017
Neuroleptics and enrichment environment treatment in memory disorders and other central nervous system function observed in prenatally stressed rats.Human & experimental toxicology, , Volume: 34, Issue:5, 2015
The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats.Pharmacological reports : PR, , Volume: 66, Issue:3, 2014
A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia.Schizophrenia research, , Volume: 144, Issue:1-3, 2013
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.Pharmacological reports : PR, , Volume: 65, Issue:1, 2013
Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function.PloS one, , Volume: 8, Issue:2, 2013
Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice.Pharmacology, biochemistry, and behavior, , Volume: 99, Issue:4, 2011
Effects of olanzapine and clozapine on memory acquisition, consolidation and retrieval in mice using the elevated plus maze test.Neuroscience letters, , Sep-01, Volume: 501, Issue:3, 2011
Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:4, 2010
Aripiprazole add-on treatment in a patient with schizoaffective disorder: neurocognitive outcomes.Pharmacopsychiatry, , Volume: 43, Issue:6, 2010
Influence of olanzapine on memory functions.Psychiatria Danubina, , Volume: 21, Issue:1, 2009
Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia.Pharmacopsychiatry, , Volume: 41, Issue:3, 2008
Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300.Schizophrenia research, , Volume: 101, Issue:1-3, 2008
The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:6, 2007
Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 17, Issue:19, 2007
The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:3, 2006
Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 30, Issue:8, 2005
Patient outcomes in schizophrenia II: the impact of cognition.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.Psychosomatics, , Volume: 47, Issue:1
Pica disorder as a symptom of depression in a patient with bipolar disorder and intellectual disability.Actas espanolas de psiquiatria, , Volume: 48, Issue:1, 2020
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 30, Issue:9, 2020
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
Phelan-McDermid syndrome due to BMJ case reports, , Sep-28, Volume: 2017, 2017
Psychopharmacological Management of Problem Behaviors in Mowat-Wilson Syndrome.Journal of child and adolescent psychopharmacology, , Volume: 25, Issue:8, 2015
Obsessive slowness presenting as catatonia in a patient with Borderline Intelligence.Asian journal of psychiatry, , Volume: 18, 2015
Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.BMC psychiatry, , Oct-04, Volume: 13, 2013
The use of Pro Re Nata or Statim medications for behavioral control: a summary of experience at a tertiary care children's mental health center.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:1, 2011
Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study.Journal of intellectual disability research : JIDR, , Volume: 55, Issue:2, 2011
Minimum effective and relapse-associated doses of risperidone and olanzapine in aggressive, intellectually disabled adults.Journal of clinical psychopharmacology, , Volume: 31, Issue:2, 2011
Does electroconvulsive therapy afford protection against olanzapine-induced parkinsonism? A case report.The journal of ECT, , Volume: 25, Issue:2, 2009
Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine.The American journal of psychiatry, , Volume: 165, Issue:11, 2008
Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities.Journal of intellectual disability research : JIDR, , Volume: 52, Issue:Pt 2, 2008
Effect of olanzapine on disruptive behavior in institutionalized patients with severe intellectual disability--a case series.Collegium antropologicum, , Volume: 32, Issue:2, 2008
Treatment of pica behavior with olanzapine.CNS spectrums, , Volume: 13, Issue:1, 2008
Risperidone-induced enuresis in two children with autistic disorder.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:4, 2007
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:8, 2001
Olanzapine for chronic, stereotypic self-injurious behaviour: a pilot study in seven adults with intellectual disability.Journal of intellectual disability research : JIDR, , Volume: 44 ( Pt 6), 2000
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.Journal of intellectual disability research : JIDR, , Volume: 44 ( Pt 2), 2000
Olanzapine-induced neuroleptic malignant syndrome with mental retardation.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Metabolic disorders induced by psychotropic drugs.Annales d'endocrinologie, , Volume: 84, Issue:3, 2023
Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:2, 2022
Occurrence of metabolic diseases associated with antipsychotic use among Korean patients with schizophrenia.International journal of clinical pharmacology and therapeutics, , Volume: 59, Issue:4, 2021
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.The American journal of Chinese medicine, , Volume: 49, Issue:8, 2021
Peripheral mechanisms of acute olanzapine induced metabolic dysfunction: A review of in vivo models and treatment approaches.Behavioural brain research, , 02-26, Volume: 400, 2021
Coadministration of metformin prevents olanzapine-induced metabolic dysfunction and regulates the gut-liver axis in rats.Psychopharmacology, , Volume: 238, Issue:1, 2021
Epigenetic histone modulations of PPARγ and related pathways contribute to olanzapine-induced metabolic disorders.Pharmacological research, , Volume: 155, 2020
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.Life sciences, , Apr-15, Volume: 247, 2020
Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.Psychopharmacology, , Volume: 237, Issue:11, 2020
Carnosic acid prevented olanzapine-induced metabolic disorders through AMPK activation.Molecular biology reports, , Volume: 47, Issue:10, 2020
Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome.Psychopharmacology, , Volume: 236, Issue:5, 2019
The Probiotic Mixture VSL#3 Reverses Olanzapine-Induced Metabolic Dysfunction in Mice.Methods in molecular biology (Clifton, N.J.), , Volume: 2011, 2019
Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 48, 2018
Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies.Drug safety, , Volume: 40, Issue:9, 2017
Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics.Journal of clinical psychopharmacology, , Volume: 35, Issue:5, 2015
Exercise prevents downregulation of hippocampal presynaptic proteins following olanzapine-elicited metabolic dysregulation in rats: Distinct roles of inhibitory and excitatory terminals.Neuroscience, , Aug-20, Volume: 301, 2015
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients.Neuropsychobiology, , Volume: 72, Issue:1, 2015
GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.Metabolic brain disease, , Volume: 30, Issue:2, 2015
Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.Journal of psychiatric research, , Volume: 53, 2014
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.The international journal of neuropsychopharmacology, , Volume: 17, Issue:1, 2014
Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.The international journal of neuropsychopharmacology, , Volume: 17, Issue:1, 2014
No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia.Schizophrenia research, , Volume: 146, Issue:1-3, 2013
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study.Pharmacopsychiatry, , Volume: 45, Issue:3, 2012
Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats.Behavioural brain research, , Mar-01, Volume: 217, Issue:2, 2011
The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela.Schizophrenia research, , Volume: 126, Issue:1-3, 2011
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.Acta psychiatrica Scandinavica, , Volume: 124, Issue:3, 2011
A murine model of atypical antipsychotic-induced weight gain and metabolic dysregulation.Current protocols in neuroscience, , Volume: Chapter 9, 2010
Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 118, Issue:1-3, 2010
Beneficial effect of the insulin sensitizer (HSP inducer) BGP-15 on olanzapine-induced metabolic disorders.Brain research bulletin, , Nov-20, Volume: 83, Issue:6, 2010
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.Pharmacopsychiatry, , Volume: 42, Issue:1, 2009
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagiaThe Journal of pharmacology and experimental therapeutics, , Volume: 326, Issue:3, 2008
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:4, 2007
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.The Annals of pharmacotherapy, , Volume: 40, Issue:12, 2006
A parametric analysis of olanzapine-induced weight gain in female rats.Psychopharmacology, , Volume: 181, Issue:1, 2005
Atypical antipsychotics: impaired glucose metabolism.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Oct-02, Volume: 165, Issue:7, 2001
Is Sitagliptin Effective for Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients? A Double-blind Placebo-controlled Clinical Trial.Journal of clinical psychopharmacology, , Volume: 40, Issue:5
Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients.The American journal of emergency medicine, , Volume: 65, 2023
The Utilization of Atypical Antipsychotics in the Pain Medicine Physician's Armamentarium.Psychopharmacology bulletin, , 06-20, Volume: 48, Issue:4, 2018
Neuroleptics and migraine.Central nervous system agents in medicinal chemistry, , Volume: 9, Issue:1, 2009
Olanzapine in the treatment of refractory migraine and chronic daily headache.Headache, , Volume: 42, Issue:6, 2002
Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.Journal of geriatric psychiatry and neurology, , Volume: 28, Issue:1, 2015
Olanzapine-induced tardive dystonia: a case report.The Journal of neuropsychiatry and clinical neurosciences, , Apr-01, Volume: 26, Issue:2, 2014
[Buccolingual dyskinesia with justified hallucinations].Revista de neurologia, , Nov-16, Volume: 59, Issue:10, 2014
Perphenazine suspension: a new, old treatment, side effects and continuous use.The Psychiatric quarterly, , Volume: 83, Issue:3, 2012
Pisa syndrome secondary to rivastigmine: a case report.La Clinica terapeutica, , Volume: 163, Issue:1, 2012
Olanzapine induced tardive dyskinesia treated successfully with quetiapine: a case report.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-15, Volume: 35, Issue:1, 2011
Blood lactate levels in patients receiving first- or second- generation antipsychotics.Croatian medical journal, , Volume: 52, Issue:1, 2011
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.The Journal of clinical psychiatry, , Volume: 72, Issue:3, 2011
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?The Journal of clinical psychiatry, , Volume: 71, Issue:11, 2010
Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats.Biological psychiatry, , Mar-01, Volume: 55, Issue:5, 2004
The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.European archives of psychiatry and clinical neuroscience, , Volume: 254, Issue:6, 2004
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.Psychopharmacology, , Volume: 169, Issue:3-4, 2003
Clinical issues associated with maintenance treatment of patients with schizophrenia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Sep-01, Volume: 59, Issue:17 Suppl 5, 2002
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:8, 2001
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.The Journal of clinical psychiatry, , Volume: 61 Suppl 3, 2000
Risperidone side effects.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Olanzapine-induced task specific tardive dystonia and its response to carbamazepine: a case report.Neurology India, , Volume: 60, Issue:6
Atypical antipsychotics in multiple sclerosis: A review of their in vivo immunomodulatory effects.Multiple sclerosis and related disorders, , Volume: 58, 2022
Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia.The journal of ECT, , Volume: 26, Issue:4, 2010
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 13, Issue:2, 2006
[Demyelinating disease].Ryoikibetsu shokogun shirizu, , Issue:40, 2003
Priapism following olanzapine administration in a patient with multiple sclerosis.Psychosomatics, , Volume: 39, Issue:3
Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.European journal of pharmacology, , Nov-02, Volume: 430, Issue:2-3, 2001
Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats.BMC pharmacology, , Volume: 1, 2001
Neuroleptic malignant syndrome and catatonia in a patient with dementia.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:6, 2008
The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 31, Issue:2, 2007
Stuporous catatonia in an elderly bipolar patient: response to olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:5, 2006
[Alterations of gait parameters under external cueing in schizophrenic patients: a switch study].Psychiatrische Praxis, , Volume: 31 Suppl 1, 2004
Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects.Journal of psychiatry & neuroscience : JPN, , Volume: 28, Issue:4, 2003
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].Minerva anestesiologica, , Volume: 69, Issue:6, 2003
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 13, Issue:4, 2001
Possible neuroleptic malignant syndrome associated with olanzapine.The Annals of pharmacotherapy, , Volume: 34, Issue:5, 2000
Atypical Neuroleptic Malignant Syndrome: Case Reports and Diagnostic Challenges.Journal of psychoactive drugs, , Volume: 54, Issue:3
Cyclosporine-Olanzapine Drug-Drug Interaction.The primary care companion for CNS disorders, , Apr-26, Volume: 20, Issue:2, 2018
Fatal agranulocytosis: the use of olanzapine in a patient with schizophrenia and myelodysplasia.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-30, Volume: 31, Issue:1, 2007
Developed catatonia with rhabdomyolysis and exacerbated cardiac failure upon switching from clozapine to olanzapine owing to cardiomyopathy during clozapine medication - A case report.Asian journal of psychiatry, , Volume: 80, 2023
Adolescent with treatment-refractory schizophrenia and clozapine-induced cardiomyopathy managed with high-dose olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 20, Issue:6, 2010
[Neuroleptic adverse effects with emphasis on weight gain].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 37, Issue:4, 2009
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current opinion in pediatrics, , Volume: 17, Issue:2, 2005
Challenges in managing a mother with a dual diagnosis of peripartum cardiomyopathy and paranoid schizophrenia - a case report.General hospital psychiatry, , Volume: 35, Issue:6
Determination of olanzapine in a postmortem case.Journal of analytical toxicology, , Volume: 22, Issue:7
Masked clozapine-induced cardiomyopathy.Journal of the American Board of Family Medicine : JABFM, , Volume: 21, Issue:1
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).The American journal of psychiatry, , Volume: 168, Issue:2, 2011
Atypical antipsychotic drugs in the treatment of delusional parasitosis.International journal of psychiatry in medicine, , Volume: 37, Issue:1, 2007
Elderly patient with delirium after myocardial infarction.Journal of the National Medical Association, , Volume: 98, Issue:4, 2006
Delayed olanzapine induced myocarditis and rhabdomyolysis.Postgraduate medical journal, , Volume: 98, Issue:1165, 2022
Clozapine-Induced Myocarditis in a Young Man with Refractory Schizophrenia: Case Report of a Rare Adverse Event and Review of the Literature.The American journal of case reports, , Jul-06, Volume: 23, 2022
Eosinophilic myocarditis during treatment with olanzapine - report of two possible cases.BMC psychiatry, , Mar-17, Volume: 16, 2016
[Eosinophilic myocarditis and sudden unexpected death in a younger patient treated with antipsychotics].Ugeskrift for laeger, , Oct-31, Volume: 173, Issue:44, 2011
Successful clozapine retrial after suspected myocarditis.The American journal of psychiatry, , Volume: 167, Issue:3, 2010
[Neuroleptic adverse effects with emphasis on weight gain].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 37, Issue:4, 2009
The Use of Olanzapine for Nonmedical Opioid Use in a Patient with Cancer Receiving Palliative Care.Journal of palliative medicine, , Volume: 25, Issue:2, 2022
A Case of Blunted Orally Disintegrating Olanzapine Effect Due to Coadministered Psyllium.The Journal of clinical psychiatry, , 02-23, Volume: 82, Issue:2, 2021
An open-label randomized trial of intramuscular olanzapine versus oral clonidine for symptomatic treatment of opioid withdrawal in the emergency department.Clinical toxicology (Philadelphia, Pa.), , Volume: 57, Issue:8, 2019
Craving Behavior from Opioid Addiction Controlled with Olanzapine in an Advanced Cancer Patient: A Case Report.Journal of palliative medicine, , Volume: 21, Issue:9, 2018
Olanzapine suppresses the rewarding and discriminative stimulus effects induced by morphine.Synapse (New York, N.Y.), , Volume: 66, Issue:2, 2012
Steroid responsive psychotic depression.The Australian and New Zealand journal of psychiatry, , Volume: 43, Issue:7, 2009
Serotonin syndrome: a complex but easily avoidable condition.General hospital psychiatry, , Volume: 30, Issue:3
Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.Cancer treatment reviews, , Volume: 115, 2023
Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 29, Issue:1, 2023
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.JAMA network open, , 05-01, Volume: 6, Issue:5, 2023
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).The oncologist, , 08-03, Volume: 28, Issue:8, 2023
A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy.BMC medical genomics, , 11-03, Volume: 16, Issue:1, 2023
Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.Annals of palliative medicine, , Volume: 12, Issue:3, 2023
Olanzapine for Non-Chemotherapy Related Nausea and Emesis in Patients with a Palliative Care Consult.Journal of pain and symptom management, , Volume: 66, Issue:4, 2023
Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).BMJ open, , 04-03, Volume: 13, Issue:4, 2023
Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Journal of pediatric hematology/oncology, , 10-01, Volume: 45, Issue:7, 2023
Olanzapine was an effective additional antiemetic for children and young people undergoing highly emetogenic chemotherapy.Archives of disease in childhood. Education and practice edition, , Volume: 107, Issue:4, 2022
Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.Annals of hematology, , Volume: 101, Issue:8, 2022
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 30, Issue:2, 2022
Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug.Current oncology (Toronto, Ont.), , 10-31, Volume: 29, Issue:11, 2022
Slow Uptake of an Effective Therapy: Patterns of Olanzapine Prescribing for Those Receiving Highly Emetogenic Chemotherapy.JCO oncology practice, , Volume: 18, Issue:12, 2022
Efficacy of Olanzapine for Symptom Relief in Cancer Patients.Journal of pain & palliative care pharmacotherapy, , Volume: 36, Issue:4, 2022
Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor Antagonist.Asian Pacific journal of cancer prevention : APJCP, , Jun-01, Volume: 23, Issue:6, 2022
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.Investigational new drugs, , Volume: 40, Issue:1, 2022
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.Journal of pediatric hematology/oncology, , 11-01, Volume: 44, Issue:8, 2022
Pharmacological interventions for the treatment of disordered and problem gambling.The Cochrane database of systematic reviews, , 09-22, Volume: 9, 2022
Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracyBMJ open, , Mar-02, Volume: 12, Issue:3, 2022
Olanzapine in oncology palliative care.Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, ,Summer, Volume: 35, Issue:4, 2022
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.BMC cancer, , Mar-23, Volume: 22, Issue:1, 2022
Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 30, Issue:7, 2022
The emerging role of olanzapine in paediatric CINV control: A review.Medicine, , Dec-16, Volume: 101, Issue:50, 2022
[Administration Period of Olanzapine as an Antiemetic Drug for Patients on FEC Therapy-A Survey].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 49, Issue:6, 2022
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 29, Issue:8, 2021
Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTScientific reports, , 01-11, Volume: 11, Issue:1, 2021
Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?Annals of palliative medicine, , Volume: 10, Issue:3, 2021
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 29, Issue:7, 2021
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Treatment of Cannabinoid Hyperemesis With Olanzapine: A Case Series.Journal of psychiatric practice, , 07-28, Volume: 27, Issue:4, 2021
Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial.Human psychopharmacology, , Volume: 36, Issue:1, 2021
Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial.Annals of palliative medicine, , Volume: 10, Issue:3, 2021
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.BMC cancer, , Jul-19, Volume: 21, Issue:1, 2021
Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 29, Issue:10, 2021
Olanzapine Administration Reduces Chemotherapy-Induced Nausea Behavior in Rats.Biological research for nursing, , Volume: 23, Issue:4, 2021
Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.Future oncology (London, England), , Volume: 17, Issue:16, 2021
Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.The oncologist, , Volume: 26, Issue:6, 2021
Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction.Journal of palliative medicine, , Volume: 23, Issue:7, 2020
Olanzapine is an effective antiemetic agent.Annals of palliative medicine, , Volume: 9, Issue:3, 2020
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.Breast (Edinburgh, Scotland), , Volume: 50, 2020
Olanzapine: is it enough for CINV prevention?Annals of palliative medicine, , Volume: 9, Issue:4, 2020
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.Gynecologic oncology, , Volume: 156, Issue:3, 2020
Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:4, 2020
Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.JAMA oncology, , 06-01, Volume: 6, Issue:6, 2020
Time to re-think the olanzapine dose.The Lancet. Oncology, , Volume: 21, Issue:2, 2020
[no title available]Revue medicale suisse, , 09-09, Volume: 16, Issue:705, 2020
Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:3, 2020
The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.International journal of clinical oncology, , Volume: 25, Issue:2, 2020
The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature.BMC palliative care, , Apr-22, Volume: 19, Issue:1, 2020
Olanzapine for the Treatment of Breakthrough Vomiting in Children Receiving Moderate and High Emetogenic Chemotherapy.Indian pediatrics, , 11-15, Volume: 57, Issue:11, 2020
A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.Breast (Edinburgh, Scotland), , Volume: 54, 2020
The Benefits of Olanzapine in Palliating Symptoms.Current treatment options in oncology, , 11-26, Volume: 22, Issue:1, 2020
Olanzapine as a rescue antiemetic in hematopoietic stem cell transplant.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, , Volume: 26, Issue:4, 2020
A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin.International journal of clinical pharmacy, , Volume: 42, Issue:2, 2020
A new standard prophylaxis for emesis caused by cisplatin? - Authors' reply.The Lancet. Oncology, , Volume: 21, Issue:3, 2020
A new standard prophylaxis for emesis caused by cisplatin?The Lancet. Oncology, , Volume: 21, Issue:3, 2020
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:11, 2020
Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analyESMO open, , Volume: 5, Issue:1, 2020
Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study.Tumori, , Volume: 105, Issue:3, 2019
Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.Cancer chemotherapy and pharmacology, , Volume: 84, Issue:1, 2019
Comment on: Olanzapine for chemotherapy-induced nausea: Lessons learned from child and adolescent psychiatry.Pediatric blood & cancer, , Volume: 66, Issue:1, 2019
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West OncologCancer research and treatment, , Volume: 51, Issue:1, 2019
Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:8, 2019
Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.The oncologist, , Volume: 24, Issue:6, 2019
Resurgence of Eating Disorders with Olanzapine.Journal of palliative medicine, , Volume: 22, Issue:2, 2019
Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.BMJ open, , 01-17, Volume: 9, Issue:1, 2019
The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:8, 2019
Reply to: Comment on: Olanzapine for chemotherapy-induced nausea: Lessons learned from child and adolescent psychiatry.Pediatric blood & cancer, , Volume: 66, Issue:1, 2019
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.Journal of global oncology, , Volume: 5, 2019
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.Annals of palliative medicine, , Volume: 8, Issue:4, 2019
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.BMJ open, , 07-04, Volume: 9, Issue:7, 2019
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:3, 2019
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.Medicine, , Volume: 97, Issue:37, 2018
Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiviJapanese journal of clinical oncology, , Oct-01, Volume: 48, Issue:10, 2018
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving HigBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, , Volume: 24, Issue:10, 2018
Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.Anticancer research, , Volume: 38, Issue:2, 2018
Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation.Clinical lymphoma, myeloma & leukemia, , Volume: 18, Issue:2, 2018
Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.The oncologist, , Volume: 23, Issue:5, 2018
Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.Scientific reports, , 11-02, Volume: 8, Issue:1, 2018
Olanzapine for chemotherapy-induced nausea: Lessons learned from child and adolescent psychiatry.Pediatric blood & cancer, , Volume: 65, Issue:10, 2018
Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 26, Issue:2, 2018
Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.International journal of clinical pharmacy, , Volume: 40, Issue:5, 2018
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.Investigational new drugs, , Volume: 36, Issue:1, 2018
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.The Cochrane database of systematic reviews, , 09-21, Volume: 9, 2018
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.Journal of global oncology, , Volume: 4, 2018
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 25, Issue:2, 2017
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.Japanese journal of clinical oncology, , Sep-01, Volume: 47, Issue:9, 2017
[Differential diagnosis and treatment of nausea and vomiting associated with cancer or its treatment].Magyar onkologia, , Sep-20, Volume: 61, Issue:3, 2017
Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy.Medical oncology (Northwood, London, England), , Dec-16, Volume: 35, Issue:1, 2017
Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy.Anticancer research, , Volume: 37, Issue:12, 2017
Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.British journal of clinical pharmacology, , Volume: 83, Issue:7, 2017
Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.Clinical lymphoma, myeloma & leukemia, , Volume: 17, Issue:9, 2017
Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 25, Issue:1, 2017
Olanzapine induced delirium-a "probable" adverse drug reaction.Annals of palliative medicine, , Volume: 6, Issue:Suppl 2, 2017
Clinical Pearls in palliative medicine.Disease-a-month : DM, , Volume: 63, Issue:6, 2017
Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.Critical reviews in oncology/hematology, , Volume: 112, 2017
New options and controversies in the management of chemotherapy-induced nausea and vomiting.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Jun-01, Volume: 74, Issue:11, 2017
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.The New England journal of medicine, , Jul-14, Volume: 375, Issue:2, 2016
Olanzapine for Nausea, Delirium, Anxiety, Insomnia, and Cachexia #315.Journal of palliative medicine, , Volume: 19, Issue:11, 2016
Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:5, 2016
Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.Pharmacotherapy, , Volume: 36, Issue:2, 2016
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.Annals of palliative medicine, , Volume: 5, Issue:3, 2016
Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:6, 2016
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.The New England journal of medicine, , Jul-14, Volume: 375, Issue:2, 2016
Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.Current opinion in supportive and palliative care, , Volume: 10, Issue:2, 2016
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.JAMA oncology, , Volume: 2, Issue:2, 2016
Olanzapine in the Management of Difficult to Control Nausea and Vomiting in a Palliative Care Population: A Case Series.Journal of palliative medicine, , Volume: 19, Issue:1, 2016
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy.Japanese journal of clinical oncology, , Volume: 46, Issue:5, 2016
A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.Asia-Pacific journal of clinical oncology, , Volume: 12, Issue:3, 2016
Administration of olanzapine as an antiemetic agent changes glucose homeostasis in cisplatin-treated rats.Biological & pharmaceutical bulletin, , Volume: 38, Issue:4, 2015
Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy.BioMed research international, , Volume: 2015, 2015
QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist.European journal of cancer care, , Volume: 24, Issue:3, 2015
A double-blind randomized Phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy.Japanese journal of clinical oncology, , Volume: 45, Issue:2, 2015
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.Critical reviews in oncology/hematology, , Volume: 95, Issue:2, 2015
Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.Hospital practice (1995), , Volume: 43, Issue:4, 2015
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.Biochimica et biophysica acta, , Volume: 1848, Issue:10 Pt B, 2015
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.Cell biochemistry and biophysics, , Volume: 72, Issue:2, 2015
Pharmacological and psychosomatic treatments for an elderly patient with severe nausea and vomiting in reaction to postoperative stress.Clinical journal of gastroenterology, , Volume: 8, Issue:5, 2015
Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature.Journal of pain & palliative care pharmacotherapy, , Volume: 29, Issue:2, 2015
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.Journal of palliative medicine, , Volume: 18, Issue:11, 2015
Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.Journal of pain and symptom management, , Volume: 47, Issue:3, 2014
Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.Asian Pacific journal of cancer prevention : APJCP, , Volume: 15, Issue:22, 2014
A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting.Scientific reports, , Apr-28, Volume: 4, 2014
Effects of low-dose olanzapine on duloxetine-related nausea and vomiting for the treatment of major depressive disorder.Journal of clinical psychopharmacology, , Volume: 34, Issue:4, 2014
Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 22, Issue:4, 2014
The safety of olanzapine in young children: a systematic review and meta-analysis.Drug safety, , Volume: 37, Issue:10, 2014
Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.European journal of pharmacology, , Jan-05, Volume: 722, 2014
Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.Journal of cancer research and clinical oncology, , Volume: 140, Issue:1, 2014
Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 97, Issue:3, 2014
Olanzapine for intractable nausea and vomiting in palliative care patients not receiving chemotherapy.Journal of palliative medicine, , Volume: 17, Issue:5, 2014
Olanzapine: palliative medicine update.The American journal of hospice & palliative care, , Volume: 30, Issue:1, 2013
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 21, Issue:6, 2013
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Clinical schizophrenia & related psychoses, , Volume: 6, Issue:2, 2012
Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction.Journal of pain and symptom management, , Volume: 44, Issue:4, 2012
Olanzapine for nausea and vomiting.The American journal of hospice & palliative care, , Volume: 27, Issue:6, 2010
Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 18, Issue:8, 2010
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.Journal of experimental & clinical cancer research : CR, , Sep-23, Volume: 28, 2009
Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.Current opinion in supportive and palliative care, , Volume: 2, Issue:1, 2008
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 15, Issue:11, 2007
Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.European journal of cancer care, , Volume: 16, Issue:4, 2007
Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine.Pharmacopsychiatry, , Volume: 40, Issue:2, 2007
[Medical treatment of chemotherapy-induced nausea and vomiting].Ugeskrift for laeger, , Feb-26, Volume: 169, Issue:9, 2007
Emerging drugs for chemotherapy-induced emesis.Expert opinion on emerging drugs, , Volume: 11, Issue:1, 2006
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 13, Issue:7, 2005
Re: Olanzapine-induced delirium.Journal of pain and symptom management, , Volume: 29, Issue:2, 2005
Olanzapine-induced delirium in a terminally ill cancer patient.Journal of pain and symptom management, , Volume: 28, Issue:2, 2004
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.Cancer investigation, , Volume: 22, Issue:3, 2004
Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.Journal of pain and symptom management, , Volume: 25, Issue:6, 2003
Olanzapine for intractable nausea in palliative care patients.Journal of palliative medicine, , Volume: 6, Issue:2, 2003
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.Journal of pain and symptom management, , Volume: 23, Issue:6, 2002
Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.The journal of supportive oncology, , Volume: 9, Issue:5
Olanzapine Treatment for Refractory Nausea and Vomiting After Transarterial Embolization for Cerebral Arteriovenous Malformation.American journal of therapeutics, , Volume: 27, Issue:6
Olanzapine and mirtazapine for multiple palliation.The journal of supportive oncology, , Volume: 1, Issue:1
Mania in a case of hyperparathyroidism.Psychosomatics, , Volume: 48, Issue:3
Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.Indian journal of pharmacology, , Volume: 49, Issue:6
Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Journal of pediatric hematology/oncology, , 10-01, Volume: 45, Issue:7, 2023
Olanzapine was an effective additional antiemetic for children and young people undergoing highly emetogenic chemotherapy.Archives of disease in childhood. Education and practice edition, , Volume: 107, Issue:4, 2022
Facial edema as an adverse drug reaction to olanzapine in a patient with cancer receiving palliative care.Palliative & supportive care, , Volume: 20, Issue:5, 2022
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.Investigational new drugs, , Volume: 40, Issue:1, 2022
Olanzapine Improves Cachexia in a Breast Cancer Patient under Home Hospice Care.Journal of palliative medicine, , Volume: 25, Issue:1, 2022
Efficacy of Olanzapine for Symptom Relief in Cancer Patients.Journal of pain & palliative care pharmacotherapy, , Volume: 36, Issue:4, 2022
The Use of Olanzapine for Nonmedical Opioid Use in a Patient with Cancer Receiving Palliative Care.Journal of palliative medicine, , Volume: 25, Issue:2, 2022
Olanzapine in oncology palliative care.Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, ,Summer, Volume: 35, Issue:4, 2022
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.Journal of pediatric hematology/oncology, , 11-01, Volume: 44, Issue:8, 2022
Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.Future oncology (London, England), , Volume: 17, Issue:16, 2021
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 29, Issue:10, 2021
Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTScientific reports, , 01-11, Volume: 11, Issue:1, 2021
Olanzapine for the Treatment of Breakthrough Vomiting in Children Receiving Moderate and High Emetogenic Chemotherapy.Indian pediatrics, , 11-15, Volume: 57, Issue:11, 2020
Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:4, 2020
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.The oncologist, , Volume: 25, Issue:3, 2020
Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.JAMA oncology, , 06-01, Volume: 6, Issue:6, 2020
[no title available]Revue medicale suisse, , 09-09, Volume: 16, Issue:705, 2020
The Benefits of Olanzapine in Palliating Symptoms.Current treatment options in oncology, , 11-26, Volume: 22, Issue:1, 2020
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:11, 2020
Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction.Journal of palliative medicine, , Volume: 23, Issue:7, 2020
Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial.Pediatric blood & cancer, , Volume: 67, Issue:9, 2020
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.Journal of global oncology, , Volume: 5, 2019
Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:8, 2019
The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:8, 2019
Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.The oncologist, , Volume: 24, Issue:6, 2019
Efficacy of olanzapine for quality of life improvement among patients with malignant tumor: A systematic review.Cancer reports (Hoboken, N.J.), , Volume: 2, Issue:4, 2019
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.The Cochrane database of systematic reviews, , 09-21, Volume: 9, 2018
Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins.Cellular signalling, , Volume: 42, 2018
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.International journal of clinical oncology, , Volume: 23, Issue:2, 2018
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.Journal of global oncology, , Volume: 4, 2018
[Differential diagnosis and treatment of nausea and vomiting associated with cancer or its treatment].Magyar onkologia, , Sep-20, Volume: 61, Issue:3, 2017
NCCN Guidelines Insights: Antiemesis, Version 2.2017.Journal of the National Comprehensive Cancer Network : JNCCN, , Volume: 15, Issue:7, 2017
Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.British journal of clinical pharmacology, , Volume: 83, Issue:7, 2017
Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.Current opinion in supportive and palliative care, , Volume: 10, Issue:2, 2016
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.The American journal of hospice & palliative care, , Volume: 33, Issue:5, 2016
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.Annals of palliative medicine, , Volume: 5, Issue:3, 2016
Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:6, 2016
Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 23, Issue:9, 2015
Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.Hospital practice (1995), , Volume: 43, Issue:4, 2015
Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review.Pediatric blood & cancer, , Volume: 62, Issue:3, 2015
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.Biochimica et biophysica acta, , Volume: 1848, Issue:10 Pt B, 2015
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.Journal of palliative medicine, , Volume: 18, Issue:11, 2015
Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 97, Issue:3, 2014
Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.Asian Pacific journal of cancer prevention : APJCP, , Volume: 15, Issue:22, 2014
Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.Journal of cancer research and clinical oncology, , Volume: 140, Issue:1, 2014
Olanzapine: palliative medicine update.The American journal of hospice & palliative care, , Volume: 30, Issue:1, 2013
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 21, Issue:6, 2013
Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction.Journal of pain and symptom management, , Volume: 44, Issue:4, 2012
Olanzapine for nausea and vomiting.The American journal of hospice & palliative care, , Volume: 27, Issue:6, 2010
Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study.Journal of pain and symptom management, , Volume: 40, Issue:5, 2010
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.Journal of experimental & clinical cancer research : CR, , Sep-23, Volume: 28, 2009
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 15, Issue:11, 2007
Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.European journal of cancer care, , Volume: 16, Issue:4, 2007
[Olanzapine use in cancer patients for refractory vomiting].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 33, Issue:3, 2006
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.Cancer investigation, , Volume: 22, Issue:3, 2004
A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients.Journal of pain and symptom management, , Volume: 25, Issue:5, 2003
Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project.Expert review of anticancer therapy, , Volume: 2, Issue:4, 2002
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.Journal of pain and symptom management, , Volume: 23, Issue:6, 2002
Olanzapine in the management of cancer pain.Journal of pain and symptom management, , Volume: 23, Issue:4, 2002
Are antipsychotic drugs potentially chemopreventive agents for cancer?European journal of clinical pharmacology, , Volume: 55, Issue:6, 1999
Olanzapine and mirtazapine for multiple palliation.The journal of supportive oncology, , Volume: 1, Issue:1
Clocking delirium: the value of the Clock Drawing Test with case illustrations.The American journal of hospice & palliative care, , Volume: 25, Issue:5
An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients.Psychosomatics, , Volume: 43, Issue:3
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics.Journal of clinical psychopharmacology, , Volume: 25, Issue:4, 2005
[Clinical course of acute poisoning with olanzapine].Przeglad lekarski, , Volume: 62, Issue:6, 2005
The clinical picture of olanzapine poisoning with special reference to fluctuating mental status.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:1, 2004
Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.Journal of the National Medical Association, , Volume: 95, Issue:2, 2003
Protective effects of olanzapine and haloperidol on serum withdrawal-induced apoptosis in SH-SY5Y cells.Progress in neuro-psychopharmacology & biological psychiatry, , Apr-01, Volume: 32, Issue:3, 2008
Olanzapine produces trophic effects in vitro and stimulates phosphorylation of Akt/PKB, ERK1/2, and the mitogen-activated protein kinase p38.Brain research, , Jun-11, Volume: 1011, Issue:1, 2004
BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex.Journal of neurochemistry, , Volume: 69, Issue:1, 1997
[Treatment-resistant schizophrenia: Neutropenia with olanzapine and clozapine, and stabilization with two depot antipsychotics].Vertex (Buenos Aires, Argentina), , Volume: 28, Issue:132, 2017
Olanzapine-induced neutropenia in a patient with systemiclupus erythematosus: a role of FcγRIIIb polymorphism?Lupus, , Volume: 21, Issue:1, 2012
Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Neutropenia associated with quetiapine, olanzapine, and aripiprazole.The Australian and New Zealand journal of psychiatry, , Volume: 45, Issue:1, 2011
Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Fatal agranulocytosis: the use of olanzapine in a patient with schizophrenia and myelodysplasia.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-30, Volume: 31, Issue:1, 2007
Prolongation of clozapine-induced neutropenia with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:2, 2007
[Hematological alterations associated to olanzapine use after clozapine-induced neutropenia].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 29, Issue:1, 2007
Reversible delayed onset olanzapine-associated leukopenia and neutropenia in a clozapine-naive patient on concomitant depot antipsychotic.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Reversible neutropenia with olanzapine following clozapine-induced neutropenia.The American journal of psychiatry, , Volume: 163, Issue:7, 2006
Olanzapine-induced leucopenia and neutropenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:6, 2005
Reversible neutropenia during treatment with olanzapine: three case reports.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:4, 2004
Olanzapine-induced neutropenia: mechanism and treatment.Journal of clinical psychopharmacology, , Volume: 24, Issue:2, 2004
Agranulocytosis and neutropenia with typical and atypical neuroleptics.The American journal of psychiatry, , Volume: 158, Issue:10, 2001
Olanzapine appears haematologically safe in patients who developed blood dyscrasia on clozapine and risperidone.International clinical psychopharmacology, , Volume: 15, Issue:4, 2000
[Is bone marrow inhibition a special risk in connection with olanzapine (Zyprexa) treatment?].Ugeskrift for laeger, , Oct-30, Volume: 162, Issue:44, 2000
Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution.The Journal of clinical psychiatry, , Volume: 61, Issue:11, 2000
Two cases of olanzapine-induced reversible neutropenia.Pharmacopsychiatry, , Volume: 32, Issue:4, 1999
Olanzapine-induced neutropenia after clozapine-induced neutropenia.Lancet (London, England), , Aug-14, Volume: 354, Issue:9178, 1999
Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia.General hospital psychiatry, , Volume: 28, Issue:1
Olanzapine and haloperidol: potential for neutropenia?Psychosomatics, , Volume: 44, Issue:1
Olanzapine-induced neutropenia.Psychosomatics, , Volume: 41, Issue:2
Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain.Microbiology spectrum, , 08-17, Volume: 11, Issue:4, 2023
Olanzapine-induced nonalcoholic fatty liver disease: The effects of differential food pattern and the involvement of PGRMC1 signaling.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 176, 2023
Thermoneutral housing and preexisting obesity do not abolish the sexually dimorphic effects of olanzapine on weight gain in mice.Obesity (Silver Spring, Md.), , Volume: 31, Issue:2, 2023
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.Schizophrenia bulletin, , 03-15, Volume: 49, Issue:2, 2023
Risk factors for abnormal glucose metabolism during antipsychotic treatment: A prospective cohort study.Journal of psychiatric research, , Volume: 168, 2023
Thymoquinone attenuates olanzapine-induced metabolic disorders in rats.Molecular biology reports, , Volume: 50, Issue:11, 2023
Sex Differences in Fish Oil and Olanzapine Effects on Gut Microbiota in Diet-Induced Obese Mice.Nutrients, , Jan-14, Volume: 14, Issue:2, 2022
Gold nanoclusters eliminate obesity induced by antipsychotics.Scientific reports, , 04-01, Volume: 12, Issue:1, 2022
Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance.BMB reports, , Volume: 55, Issue:6, 2022
Chronic agmatine treatment prevents olanzapine-induced obesity and metabolic dysregulation in female rats.Brain research bulletin, , Volume: 191, 2022
Crosstalk of hypothalamic chemerin, histamine, and AMPK in diet-and olanzapine-induced obesity in rats.Life sciences, , Nov-01, Volume: 284, 2021
Anthocyanins from Molecules (Basel, Switzerland), , Oct-12, Volume: 26, Issue:20, 2021
Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis.International journal of molecular sciences, , Nov-16, Volume: 22, Issue:22, 2021
The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain.The Journal of experimental medicine, , 07-05, Volume: 218, Issue:7, 2021
Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice.Molecular neurobiology, , Volume: 57, Issue:1, 2020
30-year journey from the start of the Human Genome Project to clinical application of genomics in psychiatry: are we there yet?The lancet. Psychiatry, , Volume: 7, Issue:1, 2020
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.Life sciences, , Apr-15, Volume: 247, 2020
Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane.The Journal of nutritional biochemistry, , Volume: 81, 2020
Carnosic acid prevented olanzapine-induced metabolic disorders through AMPK activation.Molecular biology reports, , Volume: 47, Issue:10, 2020
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.Psychoneuroendocrinology, , Volume: 108, 2019
Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.Schizophrenia research, , Volume: 212, 2019
Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine.Schizophrenia research, , Volume: 206, 2019
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.Acta psychiatrica Scandinavica, , Volume: 139, Issue:1, 2019
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5, 2018
Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue.Psychoneuroendocrinology, , Volume: 95, 2018
Neuropsychiatric disorders: Side effects of olanzapine worsened by metabolic dysfunction.Nature reviews. Endocrinology, , Volume: 14, Issue:3, 2018
Regulation of obesity-associated metabolic disturbance by the antipsychotic drug olanzapine: Role of the autophagy-lysosome pathway.Biochemical pharmacology, , Volume: 158, 2018
Obesity exacerbates the acute metabolic side effects of olanzapine.Psychoneuroendocrinology, , Volume: 88, 2018
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.JAMA psychiatry, , 07-01, Volume: 74, Issue:7, 2017
Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain.JAMA psychiatry, , 11-01, Volume: 74, Issue:11, 2017
Roman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expression.Journal of psychopharmacology (Oxford, England), , Volume: 31, Issue:11, 2017
Time-dependent effects of olanzapine treatment on the expression of histidine decarboxylase, H1 and H3 receptor in the rat brain: The roles in olanzapine-induced obesity.Psychoneuroendocrinology, , Volume: 85, 2017
The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study.European child & adolescent psychiatry, , Volume: 26, Issue:1, 2017
[Impacts of abdominal acupuncture on lipid metabolism in olanzapine-induced obesity].Zhongguo zhen jiu = Chinese acupuncture & moxibustion, , Jun-12, Volume: 37, Issue:6, 2017
Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?Nordic journal of psychiatry, , Volume: 70, Issue:3, 2016
Effects of glucose and disorders in lipid metabolism on cytokine levels and cognitive impairment in the olanzapine-induced obesity rat model.Genetics and molecular research : GMR, , Sep-25, Volume: 14, Issue:3, 2015
[Eating disorders in psychiatric patients during treatment with second generation antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:7, 2015
Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis.TheScientificWorldJournal, , Volume: 2015, 2015
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar disorders, , Volume: 17, Issue:5, 2015
Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female Sprague-Dawley rats.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:12, 2015
Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats.Endocrinology, , Volume: 155, Issue:12, 2014
Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.BMJ open, , Mar-25, Volume: 4, Issue:3, 2014
Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine.Psychopharmacology, , Volume: 231, Issue:20, 2014
The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications.Journal of psychosocial nursing and mental health services, , Volume: 52, Issue:7, 2014
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 15, Issue:3, 2014
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation.International clinical psychopharmacology, , Volume: 28, Issue:2, 2013
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-10, Volume: 40, 2013
Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:8, 2013
The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain.CNS drugs, , Volume: 27, Issue:6, 2013
Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.Journal of psychopharmacology (Oxford, England), , Volume: 27, Issue:4, 2013
The effect of ranitidine on olanzapine-induced weight gain.BioMed research international, , Volume: 2013, 2013
Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells.Prostaglandins, leukotrienes, and essential fatty acids, , Volume: 87, Issue:1, 2012
Subjective and biological weight-related parameters in adolescents and young adults with schizophrenia spectrum disorder under clozapine or olanzapine treatment.Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 40, Issue:3, 2012
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.The Journal of clinical psychiatry, , Volume: 72, Issue:3, 2011
Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:5, 2011
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.Archives of physiology and biochemistry, , Volume: 117, Issue:4, 2011
Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.Physiology & behavior, , Sep-26, Volume: 104, Issue:4, 2011
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).Journal of affective disorders, , Volume: 124, Issue:1-2, 2010
Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.International journal of obesity (2005), , Volume: 34, Issue:6, 2010
Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.BMC psychiatry, , Nov-03, Volume: 10, 2010
Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.Obesity (Silver Spring, Md.), , Volume: 18, Issue:10, 2010
What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?Journal of clinical psychopharmacology, , Volume: 30, Issue:4, 2010
Metabolic syndrome with the atypical antipsychotics.Current opinion in endocrinology, diabetes, and obesity, , Volume: 17, Issue:5, 2010
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.Bipolar disorders, , Volume: 12, Issue:2, 2010
Metabolic and behavioral effects of chronic olanzapine treatment and cafeteria diet in rats.Behavioural pharmacology, , Volume: 21, Issue:7, 2010
Comparison of predictive equations for resting metabolic rate in obese psychiatric patients taking olanzapine.Nutrition (Burbank, Los Angeles County, Calif.), , Volume: 25, Issue:2, 2009
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 70, Issue:3, 2009
An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 54, Issue:4, 2009
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.The American journal of psychiatry, , Volume: 166, Issue:5, 2009
How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 24, Issue:3, 2009
Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
Meralgia paresthetica: another complication of antipsychotic-induced weight gain.Obesity reviews : an official journal of the International Association for the Study of Obesity, , Volume: 10, Issue:6, 2009
Advancements in neuroendocrine and autonomic control of metabolic functions and their pathological significance.Eating and weight disorders : EWD, , Volume: 13, Issue:3, 2008
[Psychiatric consequences of bariatric surgery in a schizophrenic patient: case report].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:4, 2008
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.Journal of affective disorders, , Volume: 105, Issue:1-3, 2008
Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics.The American journal of psychiatry, , Volume: 165, Issue:9, 2008
Considerations regarding the use of metformin with olanzapine.The American journal of psychiatry, , Volume: 165, Issue:9, 2008
The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.Psychiatry research, , Sep-30, Volume: 160, Issue:3, 2008
Contribution of leptin to the formation of neuroleptic obesity in patients with schizophrenia during antipsychotic therapy.Bulletin of experimental biology and medicine, , Volume: 146, Issue:3, 2008
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine.Pharmacopsychiatry, , Volume: 41, Issue:1, 2008
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial.The Journal of clinical psychiatry, , Volume: 69, Issue:5, 2008
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 23, Issue:8, 2008
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.Psychiatry research, , May-30, Volume: 159, Issue:1-2, 2008
Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.Journal of affective disorders, , Volume: 105, Issue:1-3, 2008
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 165, Issue:3, 2008
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:12, 2008
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder.BMC psychiatry, , Sep-15, Volume: 8, 2008
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 114, Issue:8, 2007
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
Olanzapine and pediatric bipolar disorder: evidence for efficacy and safety concerns.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Olanzapine versus placebo in the treatment of adolescents with bipolar mania.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment.Molecular psychiatry, , Volume: 12, Issue:6, 2007
Changes in cortical volume with olanzapine in chronic schizophrenia.Pharmacopsychiatry, , Volume: 40, Issue:4, 2007
Metabolic effects of the atypical antipsychotics.Southern medical journal, , Volume: 100, Issue:8, 2007
Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Dec-05, Volume: 144B, Issue:8, 2007
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.The American journal of psychiatry, , Volume: 163, Issue:5, 2006
Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis.The American journal of psychiatry, , Volume: 163, Issue:10, 2006
Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.The Journal of clinical psychiatry, , Volume: 67, Issue:4, 2006
Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 12, Issue:2, 2006
A model for antipsychotic-induced obesity in the male rat.Psychopharmacology, , Volume: 187, Issue:4, 2006
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.The American journal of psychiatry, , Volume: 163, Issue:2, 2006
Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.The Journal of clinical psychiatry, , Volume: 67, Issue:9, 2006
Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.Psychopharmacology, , Volume: 186, Issue:4, 2006
Weight change in treatment with olanzapine and a psychoeducational approach.Eating behaviors, , Volume: 7, Issue:2, 2006
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.The American journal of psychiatry, , Volume: 163, Issue:12, 2006
A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia.Schizophrenia research, , Feb-15, Volume: 82, Issue:1, 2006
Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.Obesity (Silver Spring, Md.), , Volume: 14, Issue:1, 2006
Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 28, Issue:4, 2006
Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:5, 2006
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:3, 2006
Antipsychotic drug-induced weight gain: development of an animal model.International journal of obesity (2005), , Volume: 29, Issue:6, 2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Archives of general psychiatry, , Volume: 62, Issue:1, 2005
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.The American journal of psychiatry, , Volume: 162, Issue:8, 2005
Olanzapine and weight gain.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:6, 2005
Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Olanzapine treatment of residual positive and negative symptoms.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:11, 2005
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 7, Issue:3, 2005
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.Journal of the Indian Medical Association, , Volume: 103, Issue:12, 2005
Antipsychotic-induced weight gain.Diabetes, obesity & metabolism, , Volume: 7, Issue:5, 2005
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.BMC psychiatry, , Jan-13, Volume: 5, 2005
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.Clinical therapeutics, , Volume: 27, Issue:12, 2005
Complications from olanzapine in a mentally healthy patient.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
Weight gain during treatment of bipolar I patients with olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
[Expectations and developments in atypical antipsychotics].Praxis, , Aug-25, Volume: 93, Issue:35, 2004
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone.The Journal of clinical psychiatry, , Volume: 65, Issue:6, 2004
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
Dyslipidemia and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
[Psychotropics and weight gain].Praxis, , Aug-25, Volume: 93, Issue:35, 2004
Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan.Psychiatry and clinical neurosciences, , Volume: 58, Issue:4, 2004
Atypical antipsychotics and diabetes mellitus.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:2, 2004
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study.Human psychopharmacology, , Volume: 18, Issue:6, 2003
Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.Human psychopharmacology, , Volume: 18, Issue:6, 2003
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.Southern medical journal, , Volume: 96, Issue:7, 2003
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
Weight change after an atypical antipsychotic switch.The Annals of pharmacotherapy, , Volume: 37, Issue:10, 2003
Reversal of antipsychotic-induced weight gain during quetiapine treatment.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
The effects of an educational intervention on antipsychotic-induced weight gain.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing, , Volume: 35, Issue:3, 2003
Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Weight gain associated with atypical antipsychotics.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 41, Issue:11, 2002
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited.The Journal of clinical psychiatry, , Volume: 63 Suppl 3, 2002
Antipsychotic-induced weight gain: a review of the literature.The Journal of clinical psychiatry, , Volume: 62 Suppl 7, 2001
Weight change and atypical antipsychotic treatment in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Body weight gain, insulin, and leptin in olanzapine-treated patients.The Journal of clinical psychiatry, , Volume: 62, Issue:11, 2001
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.The Journal of clinical psychiatry, , Volume: 62, Issue:9, 2001
Maternal obesity and risk of neural tube defects.Canadian family physician Medecin de famille canadien, , Volume: 47, 2001
Cognitive behavior therapy for weight gain.The American journal of psychiatry, , Volume: 158, Issue:6, 2001
H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.Biological psychiatry, , Jul-15, Volume: 48, Issue:2, 2000
Olanzapine and weight gain.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 45, Issue:5, 2000
Novel antipsychotics: comparison of weight gain liabilities.The Journal of clinical psychiatry, , Volume: 60, Issue:6, 1999
Weight gain and antipsychotic medications.The Journal of clinical psychiatry, , Volume: 60, Issue:5, 1999
Body mass index increase of 58% associated with olanzapine.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
Relative weight gain among antipsychotics.The Journal of clinical psychiatry, , Volume: 60, Issue:10, 1999
Weight gain associated with antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 60 Suppl 21, 1999
Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain.Journal of psychiatric research, , Volume: 41, Issue:1-2
Antipsychotic medications and extreme weight gain in two health systems.Obesity research & clinical practice, , Volume: 10, Issue:4
Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine.Nutrition (Burbank, Los Angeles County, Calif.), , Volume: 25, Issue:7-8
Using Caenorhabditis elegans as a Model for Obesity Pharmacology Development.American journal of therapeutics, , Volume: 23, Issue:6
[Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration].Vertex (Buenos Aires, Argentina), , Volume: 14, Issue:52
[Prescription of olanzapine in children and adolescent psychiatric patients].L'Encephale, , Volume: 33, Issue:2
A Comparative Study of Aripiprazole, Olanzapine, and L-Methylfolate Augmentation in Treatment Resistant Obsessive-Compulsive Disorder.The Psychiatric quarterly, , Volume: 92, Issue:4, 2021
Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life.Psychiatry research, , Volume: 276, 2019
Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Journal of clinical psychopharmacology, , Volume: 37, Issue:2, 2017
Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients.Journal of clinical psychopharmacology, , Volume: 36, Issue:4, 2016
Treatment of comorbid bipolar disorder and anxiety disorders: A great challenge to modern psychiatry.The Australian and New Zealand journal of psychiatry, , Volume: 50, Issue:7, 2016
[The Usefulness of Clonazepam as an Augmentative Treatment in a Case of Severe Childhood Onset Obsessive-Compulsive Disorder].Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Winter, Volume: 26, Issue:4, 2015
Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.BMC psychiatry, , Nov-29, Volume: 14, 2014
Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.Journal of affective disorders, , Volume: 166, 2014
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.CNS spectrums, , Volume: 19, Issue:4, 2014
Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.The Journal of clinical psychiatry, , Volume: 73, Issue:11, 2012
Raynaud’s phenomenon in a patient with schizophrenia and obsessive-compulsive disorder: a case report.Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Summer, Volume: 22, Issue:2, 2011
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.Psychological medicine, , Volume: 41, Issue:11, 2011
Second-generation antipsychotics for obsessive compulsive disorder.The Cochrane database of systematic reviews, , Dec-08, Issue:12, 2010
Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder.Bipolar disorders, , Volume: 12, Issue:2, 2010
Fronto-limbic abnormalities in a patient with compulsive hoarding: a 99mTc-ECD SPECT study.Psychiatry and clinical neurosciences, , Volume: 64, Issue:5, 2010
A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.The Journal of clinical psychiatry, , Volume: 70, Issue:6, 2009
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 18, Issue:5, 2008
Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder.Psychiatry and clinical neurosciences, , Volume: 62, Issue:3, 2008
Nature against nurture: calcification in the right thalamus in a young man with anorexia nervosa and obsessive-compulsive personality disorder.CNS spectrums, , Volume: 13, Issue:10, 2008
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:6, 2008
Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients.Psychiatry research, , Jan-15, Volume: 154, Issue:1, 2007
Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine.Pharmacopsychiatry, , Volume: 40, Issue:2, 2007
Creating more effective antidepressants: clues from the clinic.Drug discovery today, , Volume: 11, Issue:13-14, 2006
[Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 108, Issue:12, 2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.Molecular psychiatry, , Volume: 11, Issue:7, 2006
Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:4, 2005
The paradox of quetiapine in obsessive-compulsive disorder.CNS spectrums, , Volume: 10, Issue:5, 2005
[Obsessive-compulsive symptoms treatment in: schizophrenia].Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:7, 2005
Olanzapine in Gilles de la Tourette syndrome: beyond tics.Acta neurologica Belgica, , Volume: 105, Issue:4, 2005
Effective use of olanzapine for obsessive-compulsive symptoms in a patient with bipolar disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:8, 2004
A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.Biological psychiatry, , Mar-01, Volume: 55, Issue:5, 2004
Obsessive-compulsive symptoms with olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:3, 2004
Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 14, Issue:2, 2004
Adolescent weight loss during treatment with olanzapine.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
Reply to Dr Mahendran. We have not found reported cases of [obsessive-compulsive] OC arising from de novo with olanzapine treatment.The Australian and New Zealand journal of psychiatry, , Volume: 37, Issue:1, 2003
Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:4, 2003
Refractory obsessive-compulsive disorder: state-of-the-art treatment.The Journal of clinical psychiatry, , Volume: 63 Suppl 6, 2002
Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder.Psychopharmacology, , Volume: 162, Issue:1, 2002
Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:5, 2002
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.The Journal of clinical psychiatry, , Volume: 63, Issue:2, 2002
Emergence of compulsive symptoms with olanzapine treatment.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:4, 2002
Norepinephrine in the treatment of olanzapine overdose.Anaesthesia, , Volume: 57, Issue:10, 2002
Short-term effects of olanzapine in Huntington disease.Neuropsychiatry, neuropsychology, and behavioral neurology, , Volume: 14, Issue:1, 2001
Priapism associated with polypharmacy.The Journal of clinical psychiatry, , Volume: 62, Issue:2, 2001
Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:4, 2001
Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Antibodies against human putamen in adolescents with anorexia nervosa.The International journal of eating disorders, , Volume: 29, Issue:4, 2001
Olanzapine treatment of obsessive-compulsive disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 45, Issue:4, 2000
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.East African medical journal, , Volume: 77, Issue:2, 2000
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.The Journal of clinical psychiatry, , Volume: 61, Issue:7, 2000
Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.Psychiatry research, , Oct-30, Volume: 96, Issue:2, 2000
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.International clinical psychopharmacology, , Volume: 15, Issue:3, 2000
Olanzapine and obsessive-compulsive symptoms.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 10, Issue:5, 2000
Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.Pharmacopsychiatry, , Volume: 33, Issue:6, 2000
Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder.The British journal of psychiatry : the journal of mental science, , Volume: 177, 2000
Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
Olanzapine-induced obsessive-compulsive disorder.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.The Journal of clinical psychiatry, , Volume: 60, Issue:8, 1999
Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.Journal of clinical psychopharmacology, , Volume: 18, Issue:5, 1998
Worsening of obsessive-compulsive symptoms following treatment with olanzapine.The American journal of psychiatry, , Volume: 155, Issue:6, 1998
Provocation of obsessive-compulsive behaviour and tremor by olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:6, 1998
Open-label olanzapine treatment in five preadolescent children.Journal of child and adolescent psychopharmacology, , Volume: 8, Issue:2, 1998
Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , May-15, Volume: 55, Issue:10, 1998
Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.Psychopharmacology bulletin, , Volume: 32, Issue:1, 1996
Olanzapine-lithium encephalopathy.Psychosomatics, , Volume: 42, Issue:4
Pediatric Acute-Onset Neuropsychiatric Syndrome and Catatonia: A Case Report.Psychosomatics, , Volume: 61, Issue:1
Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia.Clinical neuropharmacology, , Volume: 34, Issue:6
Obsessive-compulsive disorder with mitochondrial disease.Psychosomatics, , Volume: 49, Issue:6
Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia.Indian journal of pharmacology, , Volume: 44, Issue:5
Adjunct Aripiprazole for Obsessive-Compulsive Symptoms Associated With Second-Generation Antipsychotics in 2 Patients With Schizophrenia: Anti-obsessional Efficacy of Partial Agonism.Journal of clinical psychopharmacology, , Volume: 40, Issue:4
Neuropsychiatric sequelae in a case of St. Louis encephalitis.General hospital psychiatry, , Volume: 22, Issue:2
Olanzapine-induced clinical seizure: a case report.Clinical neuropharmacology, , Volume: 32, Issue:5
[Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia].Psychiatria polska, , Volume: 35, Issue:1
[Osteoporosis risk factors among patients with schizophrenia].Przeglad lekarski, , Volume: 63, Issue:3, 2006
Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
[Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics].Psychiatria polska, , Volume: 39, Issue:6
Resurgence of Eating Disorders with Olanzapine.Journal of palliative medicine, , Volume: 22, Issue:2, 2019
Chemotherapy-induced acute psychosis in a patient with malignant germ cell tumour.BMJ case reports, , Apr-09, Volume: 2015, 2015
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
The Use, Safety, and Efficacy of Olanzapine in a Level I Pediatric Trauma Center Emergency Department Over a 10-Year Period.Pediatric emergency care, , Volume: 36, Issue:2, 2020
A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, , Volume: 23, Issue:1, 2016
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.Journal of palliative medicine, , Volume: 18, Issue:11, 2015
A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.BMC psychiatry, , Jan-14, Volume: 14, 2014
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
A clinical paradigm of delusions of parasitosis.Journal of the American Academy of Dermatology, , Volume: 59, Issue:4, 2008
Massive creatine kinase elevations with quetiapine: report of two cases.Pharmacopsychiatry, , Volume: 39, Issue:1, 2006
Duloxetine for childhood depression with pain and dissociative symptoms.European child & adolescent psychiatry, , Volume: 15, Issue:8, 2006
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 13, Issue:2, 2006
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.Schizophrenia research, , Oct-15, Volume: 78, Issue:2-3, 2005
Report of three case studies with olanzapine for chronic pain.The journal of pain, , Volume: 4, Issue:3, 2003
[Olanzapine in therapy of a somatoform disorder].Psychiatrische Praxis, , Volume: 30, Issue:8, 2003
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.Journal of pain and symptom management, , Volume: 23, Issue:6, 2002
Olanzapine in the management of cancer pain.Journal of pain and symptom management, , Volume: 23, Issue:4, 2002
Central dopaminergic system plays a role in the analgesic action of paracetamol: Preclinical evidence.Indian journal of pharmacology, , Volume: 49, Issue:1
Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.Annals of palliative medicine, , Volume: 12, Issue:3, 2023
Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.Anticancer research, , Volume: 37, Issue:11, 2017
Asymptomatic Elevation of Amylase and Lipase After Olanzapine Treatment.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
Olanzapine-induced acute pancreatitis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, , Volume: 26, Issue:3, 2015
Acute pancreatitis associated with lisinopril and olanzapine.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Feb-01, Volume: 67, Issue:3, 2010
[Acute pancreatitis induced by olanzapine].Annales francaises d'anesthesie et de reanimation, , Volume: 28, Issue:10, 2009
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Olanzapine-induced chylomicronemia presenting as acute pancreatitis.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Olanzapine-induced pancreatitis: a case report.JOP : Journal of the pancreas, , Sep-10, Volume: 5, Issue:5, 2004
Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 42, Issue:10, 2003
Olanzapine-induced diabetic ketoacidosis.The Annals of pharmacotherapy, , Volume: 35, Issue:12, 2001
Olanzapine and pancreatitis.The British journal of psychiatry : the journal of mental science, , Volume: 177, 2000
Olanzapine-induced acute pancreatitis.The Annals of pharmacotherapy, , Volume: 34, Issue:10, 2000
Olanzapine-induced diabetes due to pancreatitis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, , Volume: 24, Issue:6
[Pancreatitis coincident with valproate and olanzapine use].Neurologia (Barcelona, Spain), , Volume: 21, Issue:1
Drug-induced Pressure Ulcers in a Middle-aged Patient with Early-stage Parkinson's Disease.Internal medicine (Tokyo, Japan), , May-15, Volume: 57, Issue:10, 2018
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.Brain and behavior, , Volume: 7, Issue:6, 2017
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.The Annals of pharmacotherapy, , Volume: 51, Issue:8, 2017
Atypical antipsychotic drugs in the treatment of Parkinson's disease.Journal of pharmacy practice, , Volume: 24, Issue:6, 2011
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 22, Issue:1, 2010
Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 17, Issue:3, 2007
Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis.Medicinski arhiv, , Volume: 60, Issue:4, 2006
[The efficacy of olanzapine for delusion in patients with Parkinson's disease].No to shinkei = Brain and nerve, , Volume: 57, Issue:6, 2005
[Clozapine for the treatment of psychosis in 3 elderly patients with Parkinson's disease].Nederlands tijdschrift voor geneeskunde, , Nov-27, Volume: 148, Issue:48, 2004
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Optimizing atypical antipsychotic treatment strategies in the elderly.Journal of the American Geriatrics Society, , Volume: 52, Issue:12 Suppl, 2004
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.Psychiatry and clinical neurosciences, , Volume: 57, Issue:6, 2003
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.Biological psychiatry, , Sep-01, Volume: 52, Issue:5, 2002
Olanzapine treatment for dopaminergic-induced hallucinations.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:5, 2002
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
[Usefulness of olanzapine in the levodopa-induced psychosis in patients with Parkinson's disease].Neurologia (Barcelona, Spain), , Volume: 17, Issue:1, 2002
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Aug-28, Volume: 57, Issue:4, 2001
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Aug-28, Volume: 57, Issue:4, 2001
The economic consequences of a drug-drug interaction.Journal of clinical psychopharmacology, , Volume: 21, Issue:1, 2001
One further case of pancytopenia induced by olanzapine in a Parkinson's disease patient.European neurology, , Volume: 45, Issue:1, 2001
Olanzapine for psychosis in Parkinson's disease.Neurology, , Jun-26, Volume: 56, Issue:12, 2001
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Sep-26, Volume: 55, Issue:6, 2000
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
Quetiapine for l-dopa-induced psychosis in PD.Neurology, , Apr-11, Volume: 54, Issue:7, 2000
Olanzapine: extrapyramidal side effects in the elderly.Australian and New Zealand journal of medicine, , Volume: 29, Issue:3, 1999
Olanzapine in dementia with Lewy bodies: a clinical study.International journal of geriatric psychiatry, , Volume: 14, Issue:6, 1999
Management of psychotic aspects of Parkinson's disease.The Journal of clinical psychiatry, , Volume: 60 Suppl 8, 1999
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 11, Issue:3, 1999
Worsening of motor features of parkinsonism with olanzapine.Movement disorders : official journal of the Movement Disorder Society, , Volume: 14, Issue:6, 1999
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 14, Issue:6, 1999
Olanzapine can worsen parkinsonism.Neurology, , Volume: 50, Issue:4, 1998
Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.Journal of neurology, neurosurgery, and psychiatry, , Volume: 65, Issue:5, 1998
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.Neurology, , Volume: 50, Issue:4, 1998
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.Neurology, , Volume: 47, Issue:4, 1996
Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia.Psychosomatics, , Volume: 42, Issue:6
Olanzapine and neuroleptic malignant syndrome.Psychosomatics, , Volume: 43, Issue:6
[The role of olanzapine in Parkinsonian dopaminergic psychosis].Revista de neurologia, , Volume: 35, Issue:7
[Clozapine and olanzapine in the treatment of the psychotic disorders in Parkinson's disease].Revista de neurologia, , Volume: 39, Issue:7
Olanzapine usage associated with neuroleptic malignant syndrome.Psychosomatics, , Volume: 42, Issue:6
Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study.Clinical neuropharmacology, , Volume: 21, Issue:5
Management of Parkinson disease.The Journal of the American Board of Family Practice, , Volume: 11, Issue:2
Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study.Pharmacoepidemiology and drug safety, , Volume: 29, Issue:6, 2020
Paradoxical worsening of parkinsonism upon neuroleptic withdrawal: More common than we think?Parkinsonism & related disorders, , Volume: 52, 2018
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 54, Issue:9, 2015
Secondary parkinsonism with Mumps infection.Parkinsonism & related disorders, , Volume: 21, Issue:10, 2015
Neurological Adverse Effects of Antipsychotics in Children and Adolescents.Journal of clinical psychopharmacology, , Volume: 35, Issue:6, 2015
Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.The American journal of geriatric pharmacotherapy, , Volume: 10, Issue:6, 2012
Blood lactate levels in patients receiving first- or second- generation antipsychotics.Croatian medical journal, , Volume: 52, Issue:1, 2011
Does electroconvulsive therapy afford protection against olanzapine-induced parkinsonism? A case report.The journal of ECT, , Volume: 25, Issue:2, 2009
Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia.Human psychopharmacology, , Volume: 20, Issue:1, 2005
Worsening of motor features of parkinsonism with olanzapine.Movement disorders : official journal of the Movement Disorder Society, , Volume: 14, Issue:6, 1999
In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.Psychiatry research, , Apr-26, Volume: 90, Issue:2, 1999
Interaction between olanzapine and haloperidol.Journal of clinical psychopharmacology, , Volume: 19, Issue:3, 1999
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
Safety of olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
The relationship of pharmacology to side effects.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Old disease, new look? A first report of parkinsonism due to scurvy, and of refeeding-induced worsening of scurvy.Psychosomatics, , Volume: 54, Issue:3
Schizophrenia-like olfactory dysfunction induced by acute and postnatal phencyclidine exposure in rats.Schizophrenia research, , Volume: 199, 2018
Local-global processing in early-onset schizophrenia: evidence for an impairment in shifting the spatial scale of attention.Brain and cognition, , Volume: 51, Issue:1, 2003
Diurnal variation in Cotard's syndrome (copresent with Capgras delusion) following traumatic brain injury.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:4, 2000
Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance).International clinical psychopharmacology, , Volume: 34, Issue:2, 2019
Management of a patient with schizophrenia and underlying pituitary macroadenoma.Annals of the Academy of Medicine, Singapore, , Volume: 39, Issue:11, 2010
Hyperprolactinaemia and acute psychosis: prolactinoma or medication-induced phenomenon?The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:5, 2010
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.Pharmacotherapy, , Volume: 26, Issue:6, 2006
Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:1, 2005
Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder.Rivista di psichiatria, , Volume: 54, Issue:1
A case-control study of antipsychotic use and pneumonia-related mortality in the United Kingdom.Acta psychiatrica Scandinavica, , Volume: 147, Issue:3, 2023
Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.Schizophrenia bulletin, , 04-29, Volume: 47, Issue:3, 2021
Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study.The Journal of clinical psychiatry, , Volume: 74, Issue:1, 2013
Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).Medical hypotheses, , Volume: 141, 2020
Two cases report of epidemic stress disorder to novel coronavirus pneumonia.Asian journal of psychiatry, , Volume: 51, 2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.The Australian and New Zealand journal of psychiatry, , Volume: 54, Issue:7, 2020
Neurotropism of SARS-CoV-2: COVID-19 presenting with an acute manic episode.BMJ case reports, , Jun-14, Volume: 13, Issue:6, 2020
Three Cases of COVID-19-related First Onset Brief Reactive Psychosis.The Israel Medical Association journal : IMAJ, , Volume: 22, Issue:10, 2020
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.Journal of affective disorders, , 12-01, Volume: 277, 2020
Reactive Psychosis in a Health Care Worker During the COVID-19 Pandemic.The primary care companion for CNS disorders, , 07-09, Volume: 22, Issue:4, 2020
Atypical neuroleptic malignant syndrome in H1N1 pneumonia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 25, Issue:1, 2013
Patient Survival After Acute Voluntary Poisoning With a Huge Dose of Oxcarbazepine and Olanzapine.Medical archives (Sarajevo, Bosnia and Herzegovina), , Volume: 72, Issue:4, 2018
Anti-NMDA (a-NMDAR) receptor encephalitis related to acute consumption of metamphetamine: Relevance of differential diagnosis.Revista espanola de anestesiologia y reanimacion, , Volume: 64, Issue:3, 2017
Antipsychotic-related fatal poisoning, England and Wales, 1993-2013: impact of the withdrawal of thioridazine.Clinical toxicology (Philadelphia, Pa.), , Volume: 54, Issue:6, 2016
[The clinical picture of acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
[Laboratory investigations in acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
The effect of olanzapine pretreatment on acute cocaine toxicity in mice.Clinical toxicology (Philadelphia, Pa.), , Volume: 47, Issue:6, 2009
[A 74-year-old unconscious woman with myoclonia and seizures].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Sep-07, Volume: 126, Issue:17, 2006
Antipsychotic poisoning in young children: a systematic review.Drug safety, , Volume: 28, Issue:11, 2005
[Clinical course of acute poisoning with olanzapine].Przeglad lekarski, , Volume: 62, Issue:6, 2005
Are 1 or 2 dangerous? Clozapine and olanzapine exposure in toddlers.The Journal of emergency medicine, , Volume: 27, Issue:3, 2004
Antipsychotic-Related Fatal Poisoning, England and Wales, 1993-2019: The Impact of Second-Generation Antipsychotics.Journal of clinical psychopharmacology, , Volume: 41, Issue:6
Cotard's syndrome with catatonia: a case presentation and discussion.Psychosomatics, , Volume: 54, Issue:2
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:7, 2021
Polyuria after olanzapine overdose.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
Absence of effect of olanzapine on primary polydipsia: results of a double-blind, randomized study.Journal of clinical psychopharmacology, , Volume: 24, Issue:6, 2004
The Benefits of Olanzapine in Palliating Symptoms.Current treatment options in oncology, , 11-26, Volume: 22, Issue:1, 2020
A patient with schizophrenia presenting with post-lobotomy catatonia treated with olanzapine: a case report.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 17, Issue:3, 2017
Delirium associated with olanzapine use in the elderly.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 17, Issue:2, 2017
Pharmacological and psychosomatic treatments for an elderly patient with severe nausea and vomiting in reaction to postoperative stress.Clinical journal of gastroenterology, , Volume: 8, Issue:5, 2015
[Chronic conversion somatic disorder: a case report].Recenti progressi in medicina, , Volume: 104, Issue:2, 2013
A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study.Minerva anestesiologica, , Volume: 78, Issue:9, 2012
A potential case of peduncular hallucinosis treated successfully with olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Olanzapine for recurrent excessive irritability and psychotic symptoms after mesial temporal lobectomy in a patient with temporal lobe epilepsy.Epilepsy & behavior : E&B, , Volume: 9, Issue:3, 2006
Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial.Psychosomatics, , Volume: 51, Issue:5
Heart transplantation and schizophrenia.Psychosomatics, , Volume: 44, Issue:3
Antipsychotic prophylaxis in surgical patients modestly decreases delirium incidence--but not duration--in high-incidence samples: a meta-analysis.General hospital psychiatry, , Volume: 35, Issue:4
Individual risk profiles for postoperative delirium after joint replacement surgery.Psychosomatics, , Volume: 52, Issue:5
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).BMJ open, , 01-31, Volume: 13, Issue:1, 2023
Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.CNS spectrums, , Volume: 27, Issue:3, 2022
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.Psychiatry research, , Volume: 296, 2021
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.Acta psychiatrica Scandinavica, , Volume: 139, Issue:1, 2019
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.JAMA psychiatry, , 07-01, Volume: 74, Issue:7, 2017
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.Internal medicine (Tokyo, Japan), , Volume: 56, Issue:3, 2017
Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain.JAMA psychiatry, , 11-01, Volume: 74, Issue:11, 2017
Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.BMJ open, , Mar-25, Volume: 4, Issue:3, 2014
Prediabetes in patients treated with antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 73, Issue:4, 2012
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.Journal of psychiatric research, , Volume: 43, Issue:11, 2009
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Potential for detection bias in the association between olanzapine and diabetes.The Journal of clinical psychiatry, , Volume: 65, Issue:2, 2004
The antipsychotic olanzapine reduces memory deficits and neuronal abnormalities in a male rat model of Autism.Journal of chemical neuroanatomy, , Volume: 132, 2023
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.JAMA network open, , 05-01, Volume: 6, Issue:5, 2023
Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 62, Issue:9, 2023
Association of In Utero Antipsychotic Medication Exposure With Risk of Congenital Malformations in Nordic Countries and the US.JAMA psychiatry, , 02-01, Volume: 80, Issue:2, 2023
The long-lasting effects of early antipsychotic exposure during juvenile period on adult behaviours - A study in a poly I:C rat model.Pharmacology, biochemistry, and behavior, , Volume: 219, 2022
Association of Maternal Antipsychotic Prescription During Pregnancy With Standardized Test Scores of Schoolchildren in Denmark.JAMA internal medicine, , 10-01, Volume: 182, Issue:10, 2022
Novel report on congenital talipes equinovarus (CTEV) following olanzapine exposure during pregnancy: case report and short review.Archives of women's mental health, , Volume: 25, Issue:3, 2022
A potential role for olanzapine in the treatment of hyperemesis gravidarum.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, , Volume: 35, Issue:25, 2022
Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden.CNS drugs, , Volume: 36, Issue:5, 2022
Second-generation antipsychotic use during pregnancy and risk of congenital malformations.European journal of clinical pharmacology, , Volume: 77, Issue:11, 2021
Maternal immune activation and repeated maternal separation alter offspring conditioned avoidance response learning and antipsychotic response in male rats.Behavioural brain research, , 04-09, Volume: 403, 2021
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.Progress in neuro-psychopharmacology & biological psychiatry, , 06-08, Volume: 108, 2021
Pharmacological prevention of mood episodes in women with bipolar disorder during the perinatal period: A systematic review of current literature.Asian journal of psychiatry, , Volume: 52, 2020
Memory deterioration based on the tobacco smoke exposure and methylazoxymethanol acetate administration vs. aripiprazole, olanzapine and enrichment environment conditions.Pharmacology, biochemistry, and behavior, , Volume: 189, 2020
[Miss V: Delusion of pregnancy during pre-menopause].L'Encephale, , Volume: 46, Issue:1, 2020
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatinBMJ open, , 12-17, Volume: 10, Issue:12, 2020
Delusion of denial of pregnancy: A case report.Asian journal of psychiatry, , Volume: 45, 2019
Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model.Journal of psychiatric research, , Volume: 115, 2019
Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance).International clinical psychopharmacology, , Volume: 34, Issue:2, 2019
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.The American journal of psychiatry, , 06-01, Volume: 175, Issue:6, 2018
Long-acting olanzapine injection during pregnancy and breastfeeding: a case report.Archives of women's mental health, , Volume: 21, Issue:5, 2018
Antenatal antipsychotic exposure induces multigenerational and gender-specific programming of adiposity and glucose tolerance in adult mouse offspring.Diabetes & metabolism, , Volume: 44, Issue:3, 2018
Prophylactic use of olanzapine and quetiapine from pregnancy to the postpartum period in women with bipolar disorder: a case series.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, , Volume: 30, Issue:21, 2017
Dilemma of treating schizophrenia during pregnancy: a Case series and a review of literature.BMC psychiatry, , 08-29, Volume: 17, Issue:1, 2017
A Woman With Major Depression With Psychotic Features Requesting a Termination of Pregnancy.The American journal of psychiatry, , Volume: 173, Issue:1, 2016
The influence of aripiprazole and olanzapine on neurotransmitters level in frontal cortex of prenatally stressed rats.Environmental toxicology and pharmacology, , Volume: 46, 2016
Atypical antipsychotic use and outcomes in an urban maternal mental health service.International journal of psychiatry in medicine, , Volume: 51, Issue:6, 2016
The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol.Pharmacological reports : PR, , Volume: 68, Issue:2, 2016
Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.Bipolar disorders, , Volume: 17, Issue:6, 2015
Neuroleptics and enrichment environment treatment in memory disorders and other central nervous system function observed in prenatally stressed rats.Human & experimental toxicology, , Volume: 34, Issue:5, 2015
Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.Brain research, , Aug-27, Volume: 1618, 2015
Antipsychotic use in pregnancy.Expert opinion on pharmacotherapy, , Volume: 16, Issue:9, 2015
Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review.Basic & clinical pharmacology & toxicology, , Volume: 116, Issue:4, 2015
Olanzapine treatment during pregnancy and breastfeeding: a chance for women with psychotic illness?Psychopharmacology, , Volume: 231, Issue:15, 2014
The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats.Pharmacological reports : PR, , Volume: 66, Issue:3, 2014
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.Pharmacological reports : PR, , Volume: 65, Issue:1, 2013
Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance.BMC pharmacology & toxicology, , Aug-01, Volume: 14, 2013
Outcome of infants exposed to olanzapine during breastfeeding.Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, , Volume: 6, Issue:2, 2011
Antipsychotics in pregnancy.Journal of psychiatric and mental health nursing, , Volume: 17, Issue:2, 2010
Birth weight and use of olanzapine in pregnancy: a prospective comparative study.Journal of clinical psychopharmacology, , Volume: 30, Issue:3, 2010
The role of neural stem cells for in vitro models of schizophrenia: neuroprotection via Akt/ERK signal regulation.Schizophrenia research, , Volume: 122, Issue:1-3, 2010
[Epidural labor analgesia for a primipara with schizophrenia].Masui. The Japanese journal of anesthesiology, , Volume: 59, Issue:8, 2010
Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study.The British journal of psychiatry : the journal of mental science, , Volume: 192, Issue:5, 2008
Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:1, 2008
Olanzapine plasma concentration in a newborn.Journal of psychopharmacology (Oxford, England), , Volume: 22, Issue:8, 2008
The clinical dilemma--prescribing in pregnancy.Psychiatria Danubina, , Volume: 20, Issue:1, 2008
Managing psychosis in pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:3, 2007
Olanzapine potentiates neuronal survival and neural stem cell differentiation: regulation of endoplasmic reticulum stress response proteins.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 114, Issue:9, 2007
Psychopharmacology news. New side effects of agents.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:3, 2007
Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.The American journal of psychiatry, , Volume: 164, Issue:8, 2007
Olanzapine exposure during pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:8, 2007
The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities.The American journal of psychiatry, , Volume: 164, Issue:11, 2007
[Practice of pharmaceutical care based on clinical pharmaceutical research in a community pharmacy].Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, , Volume: 127, Issue:11, 2007
A case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain.The Journal of clinical psychiatry, , Volume: 68, Issue:12, 2007
Hip dysplasia following a case of olanzapine exposed pregnancy: a questionable association.Archives of women's mental health, , Volume: 9, Issue:4, 2006
Meningocele and ankyloblepharon following in utero exposure to olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:5, 2006
Women are not the same as men: specific clinical issues for female patients with bipolar disorder.Bipolar disorders, , Volume: 7 Suppl 1, 2005
Treatment of perinatal delusional disorder: a case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats.Pharmacology, biochemistry, and behavior, , Volume: 72, Issue:3, 2002
Olanzapine and pregnancy.Pharmacopsychiatry, , Volume: 35, Issue:3, 2002
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.Southern medical journal, , Volume: 94, Issue:3, 2001
Maternal obesity and risk of neural tube defects.Canadian family physician Medecin de famille canadien, , Volume: 47, 2001
The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:4, 2001
[Olanzapine and pregnancy. 2 case reports].Der Nervenarzt, , Volume: 72, Issue:11, 2001
Olanzapine and pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 35, Issue:6, 2001
Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia.Neuroscience, , Volume: 107, Issue:4, 2001
[Olanzapine and pregnancy].Orvosi hetilap, , Jan-21, Volume: 142, Issue:3, 2001
Olanzapine in pregnancy.The Annals of pharmacotherapy, , Volume: 35, Issue:10, 2001
Olanzapine-exposed pregnancies and lactation: early experience.Journal of clinical psychopharmacology, , Volume: 20, Issue:4, 2000
Antipsychotics during pregnancy.The American journal of psychiatry, , Volume: 157, Issue:8, 2000
Healthy outcome under olanzapine treatment in a pregnant woman.Pharmacopsychiatry, , Volume: 33, Issue:2, 2000
Olanzapine transfer by human placenta.Clinical and experimental pharmacology & physiology, , Volume: 26, Issue:9, 1999
Olanzapine and pregnancy.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:2, 1998
Disposition of the novel anti-schizophrenic drug [14C]olanzapine in male Fischer 344 and female CD rats following single oral dose administration.Arzneimittel-Forschung, , Volume: 48, Issue:5, 1998
[Schizophrenia and depression. Special aspects in the therapy of women].Der Nervenarzt, , Volume: 69, Issue:7 Suppl Be, 1998
Atypical presentations of pregnancy-specific generalized anxiety disorders in women without a previous psychiatric background.Psychosomatics, , Volume: 56, Issue:3
Risk of Major Malformations Following First-Trimester Exposure to Olanzapine: Preliminary Data From the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications.Journal of clinical psychopharmacology, , Volume: 43, Issue:2
Diagnosis and Treatment of Eclamptic Psychosis in the Postpartum Period: A Case Report.Psychosomatics, , Volume: 56, Issue:5
Intractable acute ischaemic priapism occurring secondary to newly commenced olanzapine.BMJ case reports, , Mar-31, Volume: 12, Issue:3, 2019
Priapism Associated With Antipsychotic Medication Use: Case Report.Journal of clinical psychopharmacology, , Volume: 37, Issue:4, 2017
Olanzapine-induced Priapism in a Child with Asperger's Syndrome.Balkan medical journal, , Volume: 34, Issue:1, 2017
[Antipsychotic-induced priapism and management challenges: a case report].L'Encephale, , Volume: 40, Issue:6, 2014
Olanzapine-associated priapism.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
Priapism associated with olanzapine.Pakistan journal of biological sciences : PJBS, , Jan-15, Volume: 12, Issue:2, 2009
[Priapism in childhood--case report of 14-year-old boy].Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti, , Volume: 85, Issue:7, 2006
Irreversible priapism during olanzapine and lithium therapy.The Australian and New Zealand journal of psychiatry, , Volume: 38, Issue:5, 2004
Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report.International journal of psychiatry in medicine, , Volume: 33, Issue:1, 2003
Olanzapine-induced priapism.The American journal of psychiatry, , Volume: 158, Issue:12, 2001
Priapism associated with conventional and atypical antipsychotic medications: a review.The Journal of clinical psychiatry, , Volume: 62, Issue:5, 2001
Olanzapine-associated priapism.Journal of clinical psychopharmacology, , Volume: 21, Issue:2, 2001
Priapism associated with polypharmacy.The Journal of clinical psychiatry, , Volume: 62, Issue:2, 2001
Recurrent priapism during treatment with clozapine and olanzapine.The American journal of psychiatry, , Volume: 157, Issue:4, 2000
Olanzapine-associated priapism.Journal of clinical psychopharmacology, , Volume: 19, Issue:2, 1999
Olanzapine-induced reversible priaprism: a case report.Journal of clinical psychopharmacology, , Volume: 18, Issue:4, 1998
Olanzapine-associated priapism.Psychosomatics, , Volume: 44, Issue:4
Priapism after a suicide attempt by ingestion of olanzapine and gabapentin.Psychosomatics, , Volume: 42, Issue:3
Priapism following olanzapine administration in a patient with multiple sclerosis.Psychosomatics, , Volume: 39, Issue:3
Clinical Pearls in palliative medicine.Disease-a-month : DM, , Volume: 63, Issue:6, 2017
Switching among antipsychotics--focus on side effects.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Primary delusional parasitosis treated with olanzapine.International psychogeriatrics, , Volume: 19, Issue:6, 2007
[A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy].Der Nervenarzt, , Volume: 74, Issue:7, 2003
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Lithium, antipsychotics, and risk of psoriasis.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
Exacerbation of chronic large plaque psoriasis associated with Olanzepine therapy.Journal of the European Academy of Dermatology and Venereology : JEADV, , Volume: 14, Issue:4, 2000
Psoriasis during therapy with olanzapine.European journal of dermatology : EJD, , Volume: 13, Issue:4
Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients.The American journal of emergency medicine, , Volume: 65, 2023
Cost-Effectiveness of Midazolam Versus Haloperidol Versus Olanzapine for the Management of Acute Agitation in the Accident and Emergency Department.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 25, Issue:7, 2022
An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home.Trials, , Apr-14, Volume: 23, Issue:1, 2022
Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular.International clinical psychopharmacology, , 01-01, Volume: 37, Issue:1, 2022
Psychopharmacology of agitation in acute psychotic and manic episodes.Current opinion in psychiatry, , 05-01, Volume: 35, Issue:3, 2022
Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report.Neuropsychopharmacology reports, , Volume: 42, Issue:3, 2022
Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis.Schizophrenia research, , Volume: 229, 2021
Brief psychotic disorder with delusion content related to the COVID-19 outbreak.Psychiatrike = Psychiatriki, , Apr-19, Volume: 32, Issue:1, 2021
A Prospective Study of Intramuscular Droperidol or Olanzapine for Acute Agitation in the Emergency Department: A Natural Experiment Owing to Drug Shortages.Annals of emergency medicine, , Volume: 78, Issue:2, 2021
The Use, Safety, and Efficacy of Olanzapine in a Level I Pediatric Trauma Center Emergency Department Over a 10-Year Period.Pediatric emergency care, , Volume: 36, Issue:2, 2020
CSF studies which ultimately led to the possible diagnosis of anti-NMDAR encephalitis.BMJ case reports, , May-07, Volume: 13, Issue:5, 2020
The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.Expert opinion on investigational drugs, , Volume: 29, Issue:3, 2020
Neurotropism of SARS-CoV-2: COVID-19 presenting with an acute manic episode.BMJ case reports, , Jun-14, Volume: 13, Issue:6, 2020
Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial.Trials, , Jul-20, Volume: 21, Issue:1, 2020
Rescue Sedation When Treating Acute Agitation in the Emergency Department With Intramuscular Antipsychotics.The Journal of emergency medicine, , Volume: 56, Issue:5, 2019
Parenteral Antipsychotic Choice and Its Association With Emergency Department Length of Stay for Acute Agitation Secondary to Alcohol Intoxication.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, , Volume: 26, Issue:1, 2019
The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 57, 2019
Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).The Cochrane database of systematic reviews, , 01-08, Volume: 1, 2018
Management of a complex patient - intravenous olanzapine use.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 26, Issue:6, 2018
Evidence-Based Review of Pharmacotherapy for Acute Agitation. Part 1: Onset of Efficacy.The Journal of emergency medicine, , Volume: 54, Issue:3, 2018
Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department.Annals of emergency medicine, , Volume: 72, Issue:4, 2018
A Prospective Observational Study of Patients Receiving Intravenous and Intramuscular Olanzapine in the Emergency Department.Annals of emergency medicine, , Volume: 69, Issue:3, 2017
Midazolam-Droperidol, Droperidol, or Olanzapine for Acute Agitation: A Randomized Clinical Trial.Annals of emergency medicine, , Volume: 69, Issue:3, 2017
Droperidol for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , 12-15, Volume: 12, 2016
Assessment and management of agitation in psychiatry: Expert consensus.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 17, Issue:2, 2016
A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, , Volume: 23, Issue:1, 2016
Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.Schizophrenia research, , Volume: 176, Issue:2-3, 2016
Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.Journal of child and adolescent psychopharmacology, , Volume: 26, Issue:5, 2016
Use of Orally Disintegrating Olanzapine During Electroconvulsive Therapy for Prevention of Postictal Agitation.Journal of psychiatric practice, , Volume: 22, Issue:6, 2016
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.Journal of the Formosan Medical Association = Taiwan yi zhi, , Volume: 114, Issue:5, 2015
Intramuscular olanzapine for agitated patients: A systematic review and meta-analysis of randomized controlled trials.Journal of psychiatric research, , Volume: 68, 2015
[Emergency psychopharmacotherapy in Hungary -- preliminary data].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 16, Issue:1, 2014
A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.Human psychopharmacology, , Volume: 29, Issue:1, 2014
A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior.Journal of clinical psychopharmacology, , Volume: 34, Issue:3, 2014
Topiramate improves psychiatric symptoms in a patient with Lewy body dementia.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 27, Issue:4, 2014
A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 24, Issue:3, 2014
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.Journal of clinical psychopharmacology, , Volume: 34, Issue:1, 2014
A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.BMC psychiatry, , Jan-11, Volume: 13, 2013
Benzodiazepines for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , Apr-30, Issue:4, 2013
Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial.Annals of emergency medicine, , Volume: 61, Issue:1, 2013
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.Current medical research and opinion, , Volume: 29, Issue:3, 2013
A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation.The Journal of emergency medicine, , Volume: 43, Issue:5, 2012
Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients.The Journal of emergency medicine, , Volume: 43, Issue:5, 2012
Olanzapine in ED patients: differential effects on oxygenation in patients with alcohol intoxication.The American journal of emergency medicine, , Volume: 30, Issue:7, 2012
A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.American journal of therapeutics, , Volume: 18, Issue:4, 2011
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3. Rapid tranquilisation in acute psychotic agitation.Emergency medicine journal : EMJ, , Volume: 28, Issue:1, 2011
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 33, Issue:1, 2011
Symptoms of agitated depression and/or akathisia.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
[The clinical picture of acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
A new clinical protocol for the pharmacological management of acute behavioural disturbance.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 19, Issue:5, 2011
Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.The Journal of clinical psychiatry, , Volume: 71, Issue:4, 2010
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.Journal of clinical psychopharmacology, , Volume: 30, Issue:3, 2010
Intravenous olanzapine--another option for the acutely agitated patient?Emergency medicine Australasia : EMA, , Volume: 21, Issue:3, 2009
Does electroconvulsive therapy afford protection against olanzapine-induced parkinsonism? A case report.The journal of ECT, , Volume: 25, Issue:2, 2009
[Haloperidol plus promethazine for agitated patients--a systematic review].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 31, Issue:3, 2009
Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study.Pharmacotherapy, , Volume: 29, Issue:8, 2009
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:1, 2009
Haloperidol plus promethazine for psychosis-induced aggression.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
Akathisia and second-generation antipsychotic drugs.Current opinion in psychiatry, , Volume: 22, Issue:3, 2009
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder.Pharmacopsychiatry, , Volume: 41, Issue:5, 2008
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.Clinical drug investigation, , Volume: 28, Issue:5, 2008
A naturalistic study of consecutive agitated emergency department patients treated with intramuscular olanzapine prior to consent.The American journal of psychiatry, , Volume: 165, Issue:4, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.The American journal of psychiatry, , Volume: 165, Issue:7, 2008
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.Medicine and health, Rhode Island, , Volume: 90, Issue:6, 2007
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.The Journal of clinical psychiatry, , Volume: 68, Issue:12, 2007
Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 19, Issue:4, 2007
Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine.BMJ (Clinical research ed.), , Oct-27, Volume: 335, Issue:7625, 2007
Managing the acutely agitated and psychotic patient.CNS spectrums, , Volume: 12, Issue:10 Suppl 1, 2007
Atypical antipsychotic agents ineffective for AD.DukeMedicine healthnews, , Volume: 13, Issue:1, 2007
[Clinical and therapeutic aspects of agitation].L'Encephale, , Volume: 33 Pt 3, 2007
Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe?Archives of gerontology and geriatrics, , Volume: 44 Suppl 1, 2007
An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.Human psychopharmacology, , Volume: 22, Issue:7, 2007
A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:6, 2006
[New formulations of olanzapine in the treatment of acute agitation].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial.Dementia and geriatric cognitive disorders, , Volume: 21, Issue:1, 2006
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.The Cochrane database of systematic reviews, , Jan-25, Issue:1, 2006
Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
Injectable atypical antipsychotics for agitation in borderline personality disorder.Pharmacopsychiatry, , Volume: 39, Issue:3, 2006
Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.Schizophrenia research, , Feb-28, Volume: 82, Issue:2-3, 2006
A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.International journal of geriatric psychiatry, , Volume: 20, Issue:11, 2005
Atypical antipsychotics: special formulations for acute agitation.Journal of psychosocial nursing and mental health services, , Volume: 43, Issue:10, 2005
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:8, 2005
A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.Clinical therapeutics, , Volume: 27, Issue:10, 2005
Intramuscular olanzapine: a review of its use in the management of acute agitation.CNS drugs, , Volume: 19, Issue:2, 2005
Olanzapine in the treatment of agitation in hospitalized patients with schizophrenia and schizoaffective and schizofreniform disorders.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 10, Issue:5, 2004
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.The American journal of emergency medicine, , Volume: 22, Issue:3, 2004
Score tests for dose effect in the presence of non-responders.Statistics in medicine, , Dec-15, Volume: 23, Issue:23, 2004
Are high initial doses of olanzapine required to reduce agitation associated with schizophrenia?Journal of clinical psychopharmacology, , Volume: 24, Issue:1, 2004
The clinical picture of olanzapine poisoning with special reference to fluctuating mental status.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:1, 2004
Intramuscular olanzapine in the management of acute agitation.The Annals of pharmacotherapy, , Volume: 38, Issue:12, 2004
Calming versus sedative effects of intramuscular olanzapine in agitated patients.The American journal of emergency medicine, , Volume: 21, Issue:3, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Olanzapine and hypoglycemic coma in a frail elderly woman. A case report.Pharmacopsychiatry, , Volume: 36, Issue:4, 2003
The efficacy of olanzapine, as needed, to treat acute agitation in juveniles.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 12, Issue:1, 2002
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.Archives of general psychiatry, , Volume: 59, Issue:5, 2002
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 26, Issue:4, 2002
[Drug-induced akathisia].Nederlands tijdschrift voor geneeskunde, , Jan-19, Volume: 146, Issue:3, 2002
Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Continuum of care: stabilizing the acutely agitated patient.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Sep-01, Volume: 59, Issue:17 Suppl 5, 2002
Recent developments in pharmacotherapy for the acutely psychotic patient.Journal of emergency nursing, , Volume: 28, Issue:6 Suppl, 2002
Lethal catatonia responding to high-dose olanzapine therapy.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:4, 2001
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Fall, Volume: 9, Issue:4, 2001
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.The American journal of psychiatry, , Volume: 158, Issue:7, 2001
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.The Journal of clinical psychiatry, , Volume: 62, Issue:1, 2001
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Neuroleptic malignant syndrome due to olanzapine.Psychopharmacology bulletin, ,Summer, Volume: 35, Issue:3, 2001
Rationale and guidelines for the inpatient treatment of acute psychosis.The Journal of clinical psychiatry, , Volume: 61 Suppl 14, 2000
Measuring neuroleptic-induced akathisia by three-channel actometry.Schizophrenia research, , Nov-30, Volume: 40, Issue:2, 1999
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
The utility of intramuscular ziprasidone in the management of acute psychotic agitation.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:3
[Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: results from NATURA study].Actas espanolas de psiquiatria, , Volume: 36, Issue:3
Treatment with atypical antipsychotics: new indications and new populations.Journal of psychiatric research, , Volume: 35, Issue:3
Fahr's Disease Presenting with Manic Symptoms.JNMA; journal of the Nepal Medical Association, , Volume: 56, Issue:209
Atypical presentations of pregnancy-specific generalized anxiety disorders in women without a previous psychiatric background.Psychosomatics, , Volume: 56, Issue:3
Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients.General hospital psychiatry, , Volume: 30, Issue:4
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study.Actas espanolas de psiquiatria, , Volume: 35, Issue:1
A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients.General hospital psychiatry, , Volume: 32, Issue:4
Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.American journal of Alzheimer's disease and other dementias, , Volume: 21, Issue:2
[Proposal for Latin America of an algorithm for the management of agitated patients with olanzapine and its switch to oral administration].Vertex (Buenos Aires, Argentina), , Volume: 14, Issue:51
The use of atypical antipsychotics after traumatic brain injury.The Journal of head trauma rehabilitation, , Volume: 23, Issue:2
Mania in a case of hyperparathyroidism.Psychosomatics, , Volume: 48, Issue:3
Psychosis susceptibility zinc finger protein 804A (ZNF804A) gene polymorphism in schizophrenia patients treated with olanzapine in North Indian population.The International journal of neuroscience, , Volume: 133, Issue:5, 2023
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.Drugs & aging, , Volume: 40, Issue:1, 2023
Residual or re-emergent impaired insight into delusions following remission is unrelated to later relapse during a randomized clinical trial of continuation pharmacotherapy for psychotic depression - The STOP-PD II Study.Journal of affective disorders, , 03-15, Volume: 325, 2023
Olanzapine and Weight Loss in Early-Onset Schizophrenia.The primary care companion for CNS disorders, , 04-06, Volume: 25, Issue:2, 2023
Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.The international journal of neuropsychopharmacology, , 07-31, Volume: 26, Issue:7, 2023
Probable Olanzapine-Related Idiopathic Intracranial Hypertension in an Adolescent With First-Episode Psychosis.Psychopharmacology bulletin, , 08-11, Volume: 53, Issue:3, 2023
Unraveling ethnic disparities in antipsychotic prescribing among patients with psychosis: A retrospective cohort study based on electronic clinical records.Schizophrenia research, , Volume: 260, 2023
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).Journal of psychopharmacology (Oxford, England), , Volume: 37, Issue:10, 2023
Predictors of hospitalisation and recovery following full antipsychotic discontinuation in first episode psychosis. A naturalistic retrospective cohort study.Schizophrenia research, , Volume: 261, 2023
Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular.International clinical psychopharmacology, , 01-01, Volume: 37, Issue:1, 2022
Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.Advances in therapy, , Volume: 39, Issue:5, 2022
Psychopharmacology of agitation in acute psychotic and manic episodes.Current opinion in psychiatry, , 05-01, Volume: 35, Issue:3, 2022
Refractory Psychosis After Carbon Monoxide Poisoning: a Case Report.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 32, Issue:2, 2022
Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study.Psychiatry research, , Volume: 314, 2022
Proportion of subjects with psychotic features in bipolar disorder correlated with treatment response by antipsychotics for acute mania.Psychiatry and clinical neurosciences, , Volume: 76, Issue:11, 2022
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 129, Issue:11, 2022
Case Report: De Novo and Persistent Psychosis After Withdrawal From Chronic Opioid Therapy.Journal of psychiatric practice, , 09-01, Volume: 28, Issue:5, 2022
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis.The American journal of psychiatry, , 12-01, Volume: 179, Issue:12, 2022
Early intervention services, patterns of prescription and rates of discontinuation of antipsychotic treatment in first-episode psychosis.Early intervention in psychiatry, , Volume: 15, Issue:6, 2021
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.Drug and alcohol dependence, , 02-01, Volume: 219, 2021
Prescribing pattern of antipsychotic medication for first-episode psychosis: a retrospective cohort study.BMJ open, , 01-31, Volume: 11, Issue:1, 2021
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.The American journal of psychiatry, , 05-01, Volume: 178, Issue:5, 2021
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:1, 2021
Risk and Prevention of Aggression in Patients With Psychotic Disorders.The American journal of psychiatry, , 03-01, Volume: 178, Issue:3, 2021
Brief psychotic disorder with delusion content related to the COVID-19 outbreak.Psychiatrike = Psychiatriki, , Apr-19, Volume: 32, Issue:1, 2021
The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study.Schizophrenia research, , Volume: 231, 2021
The Antipsychotic Risperidone Alters Dihydroceramide and Ceramide Composition and Plasma Membrane Function in Leukocytes In Vitro and In Vivo.International journal of molecular sciences, , Apr-10, Volume: 22, Issue:8, 2021
A Case of Blunted Orally Disintegrating Olanzapine Effect Due to Coadministered Psyllium.The Journal of clinical psychiatry, , 02-23, Volume: 82, Issue:2, 2021
Effect of Bifidobacterium on olanzapine-induced body weight and appetite changes in patients with psychosis.Psychopharmacology, , Volume: 238, Issue:9, 2021
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:6, 2021
The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis.Substance use & misuse, , Volume: 56, Issue:12, 2021
Using Claims Data to Assess Treatment Quality of First-Episode Psychosis.Psychiatric services (Washington, D.C.), , 03-01, Volume: 72, Issue:3, 2021
The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.Psychopharmacology, , Volume: 238, Issue:3, 2021
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review.The journal of prevention of Alzheimer's disease, , Volume: 8, Issue:4, 2021
New Antipsychotic Medications in the Last Decade.Current psychiatry reports, , 11-29, Volume: 23, Issue:12, 2021
Situational analysis of prevailing practices in the management of first-episode psychosis in Chennai, India.Early intervention in psychiatry, , Volume: 15, Issue:3, 2021
Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review.Nutrients, , Dec-18, Volume: 12, Issue:12, 2020
Antipsychotics in Postpartum Psychosis.American journal of therapeutics, , Jun-22, Volume: 28, Issue:3, 2020
Reactive Psychosis in a Health Care Worker During the COVID-19 Pandemic.The primary care companion for CNS disorders, , 07-09, Volume: 22, Issue:4, 2020
A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.Asian journal of psychiatry, , Volume: 53, 2020
Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial.Schizophrenia research, , Volume: 223, 2020
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.The lancet. Psychiatry, , Volume: 7, Issue:11, 2020
Three Cases of COVID-19-related First Onset Brief Reactive Psychosis.The Israel Medical Association journal : IMAJ, , Volume: 22, Issue:10, 2020
Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India.Asian journal of psychiatry, , Volume: 54, 2020
Delusional.Schizophrenia bulletin, , Dec-01, Volume: 46, Issue:6, 2020
Clozapine Treatment and Offending: A Within-Subject Study of Patients With Psychotic Disorders in Sweden.Schizophrenia bulletin, , 02-26, Volume: 46, Issue:2, 2020
Men and women respond differently to antipsychotic drugs.Neuropharmacology, , Volume: 163, 2020
Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects.Therapeutic drug monitoring, , Volume: 42, Issue:2, 2020
Reduction in the prescription of Olanzapine as a first-line treatment for first episode psychosis following the implementation of clinical practice guidelines.Schizophrenia research, , Volume: 215, 2020
[Miss V: Delusion of pregnancy during pre-menopause].L'Encephale, , Volume: 46, Issue:1, 2020
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.The international journal of neuropsychopharmacology, , 04-23, Volume: 23, Issue:4, 2020
Prolactin response to antipsychotics: An inpatient study.PloS one, , Volume: 15, Issue:2, 2020
Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 32, 2020
Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial.JAMA psychiatry, , 07-01, Volume: 77, Issue:7, 2020
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.The Journal of clinical psychiatry, , 03-17, Volume: 81, Issue:2, 2020
New-onset psychosis following initiation of eye movement desensitization and reprocessing therapy.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 32, Issue:2, 2020
Neurotropism of SARS-CoV-2: COVID-19 presenting with an acute manic episode.BMJ case reports, , Jun-14, Volume: 13, Issue:6, 2020
Immunomodulatory effects of antipsychotic treatment on gene expression in first-episode psychosis.Journal of psychiatric research, , Volume: 109, 2019
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.Early intervention in psychiatry, , Volume: 13, Issue:3, 2019
Examination of heterogeneity in treatment response to antipsychotic medications.Schizophrenia research, , Volume: 211, 2019
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.Toxicology and applied pharmacology, , 09-01, Volume: 378, 2019
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis.BMJ open, , 06-27, Volume: 9, Issue:6, 2019
Erotomania in Depressive Psychosis: Mood Incongruent Delusion in a Depressive Young Woman.Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, , Volume: 29, Issue:6, 2019
Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model.Journal of psychiatric research, , Volume: 115, 2019
Complexity in Evaluation and Pharmacological Treatment of Early Onset Psychosis with Mood Symptoms: Childhood Onset Schizophrenia or Affective Disorder?Journal of child and adolescent psychopharmacology, , Volume: 29, Issue:3, 2019
Maintenance Treatment for Psychotic Depressive Disorders: Progress and Remaining Challenges.JAMA, , 08-20, Volume: 322, Issue:7, 2019
Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.Schizophrenia research, , Volume: 212, 2019
Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.The Journal of clinical psychiatry, , 08-27, Volume: 80, Issue:5, 2019
Acute transient psychotic disorder precipitated by Brexit vote.BMJ case reports, , Oct-01, Volume: 12, Issue:10, 2019
[Amisulpride, a one-of-a-kind and highly efficacious antipsychotic agent in the treatment of first-episode psychosis].Nederlands tijdschrift voor geneeskunde, , 10-17, Volume: 163, 2019
Olanzapine in the management of psychosis in Huntington’s disease: a case report.Actas espanolas de psiquiatria, , Volume: 47, Issue:5, 2019
The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 57, 2019
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
Continuing Antipsychotic Medication for Patients With Psychotic Depression in Remission.JAMA, , 12-24, Volume: 322, Issue:24, 2019
[Evidence-based treatment of acute psychotic episode and schizophrenia in children and adolescents].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 119, Issue:12, 2019
Do reductions in ghrelin contribute towards antipsychotic-induced weight gain?Schizophrenia research, , Volume: 210, 2019
l-Arginine metabolism before and after 10 weeks of antipsychotic treatment in first-episode psychotic patients.Schizophrenia research, , Volume: 206, 2019
Call for "High-Dose" Olanzapine Research in Treatment-Resistant Psychosis.The Journal of nervous and mental disease, , Volume: 207, Issue:1, 2019
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
Antipsychotic treatments: who is really failing here?The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Antipsychotic treatments: who is really failing here? - Authors' reply.The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 19, Issue:sup3, 2018
Association between olanzapine treatment and brain cortical thickness and gray/white matter contrast is moderated by cholesterol in psychotic disorders.Psychiatry research. Neuroimaging, , 12-30, Volume: 282, 2018
Rapid remission of first-episode schizophrenia with standardised treatment.The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Switch-associated adverse events: focus on olanzapine.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 26, Issue:6, 2018
Olanzapine associated palpebral edema: An uncommon adverse effect of a commonly prescribed drug.Asian journal of psychiatry, , Volume: 36, 2018
Stabilization treatment of remitted psychotic depression: the STOP-PD study.Acta psychiatrica Scandinavica, , Volume: 138, Issue:3, 2018
Quasi-psychosis in covert Narcissistic Personality Disorder-A case report.Asian journal of psychiatry, , Volume: 32, 2018
Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:4, 2018
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 49, 2018
No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment.Acta psychiatrica Scandinavica, , Volume: 138, Issue:2, 2018
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.The American journal of psychiatry, , 06-01, Volume: 175, Issue:6, 2018
Management of a complex patient - intravenous olanzapine use.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 26, Issue:6, 2018
Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice.Therapeutic drug monitoring, , Volume: 39, Issue:3, 2017
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.The Annals of pharmacotherapy, , Volume: 51, Issue:8, 2017
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.Journal of psychiatric research, , Volume: 85, 2017
Treatment response in nonpsychotic vs psychotic manias - A follow up study from India.Asian journal of psychiatry, , Volume: 26, 2017
Psychosis and catatonia as presenting features of anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis.Asian journal of psychiatry, , Volume: 27, 2017
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.Psychopharmacology, , Volume: 234, Issue:17, 2017
Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.Human psychopharmacology, , Volume: 32, Issue:4, 2017
Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study.Psychiatry research, , Volume: 255, 2017
Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.Psychiatria Danubina, , Volume: 29, Issue:2, 2017
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.Brain and behavior, , Volume: 7, Issue:6, 2017
Anti-NMDA receptor encephalitis presenting as a primary psychotic disorder.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 29, Issue:3, 2017
A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.Journal of clinical psychopharmacology, , Volume: 37, Issue:5, 2017
The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.Acta psychiatrica Scandinavica, , Volume: 136, Issue:5, 2017
Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines.BMC psychiatry, , Dec-08, Volume: 17, Issue:1, 2017
Development of forced normalisation psychosis with ethosuximide.BMJ case reports, , Dec-07, Volume: 2017, 2017
Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance.BMC medicine, , Dec-11, Volume: 15, Issue:1, 2017
Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics.Psychiatry research, , Volume: 247, 2017
Cognition and Dopamine DThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:1, 2017
Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.Journal of clinical psychopharmacology, , Volume: 37, Issue:3, 2017
Delusional infestation.The American journal of emergency medicine, , Volume: 35, Issue:2, 2017
Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:6, 2017
Trends in the Outpatient Utilization of Antipsychotic Drugs in the City of Zagreb in the Ten-Year Period as a Tool to Assess Drug Prescribing Rationality.Psychiatria Danubina, , Volume: 28, Issue:4, 2016
Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder.The Journal of clinical psychiatry, , Volume: 77, Issue:12, 2016
Porencephalic cyst and late onset brief psychotic disorder.BMJ case reports, , Apr-06, Volume: 2016, 2016
Droperidol for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , 12-15, Volume: 12, 2016
Atypical antipsychotic use and outcomes in an urban maternal mental health service.International journal of psychiatry in medicine, , Volume: 51, Issue:6, 2016
Haloperidol for long-term aggression in psychosis.The Cochrane database of systematic reviews, , 11-27, Volume: 11, 2016
SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study.Human psychopharmacology, , Volume: 31, Issue:3, 2016
Antiepileptic-induced Psychosis as a Possible Predictor of Post-temporal Lobectomy Alternative Psychosis.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 26, Issue:3, 2016
The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine.Psychiatry research, , Jul-30, Volume: 241, 2016
First episode psychosis in an adult patient with tuberous sclerosis.The Australian and New Zealand journal of psychiatry, , Volume: 50, Issue:3, 2016
Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.The Journal of clinical psychiatry, , Volume: 77, Issue:10, 2016
Olanzapine-induced ischemic colitis.Revista espanola de enfermedades digestivas, , Volume: 108, Issue:8, 2016
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.Journal of clinical psychopharmacology, , Volume: 36, Issue:3, 2016
Use of Orally Disintegrating Olanzapine During Electroconvulsive Therapy for Prevention of Postictal Agitation.Journal of psychiatric practice, , Volume: 22, Issue:6, 2016
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.Clinical pharmacokinetics, , Volume: 54, Issue:11, 2015
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.Schizophrenia bulletin, , Volume: 41, Issue:3, 2015
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.Journal of the Formosan Medical Association = Taiwan yi zhi, , Volume: 114, Issue:5, 2015
Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 23, Issue:12, 2015
Case records of the Massachusetts General Hospital. Case 10-2015. A 15-year-old girl with Graves’ disease and psychotic symptoms.The New England journal of medicine, , Mar-26, Volume: 372, Issue:13, 2015
Graves' hyperthyroidism-induced psychosis in a patient with periventricular nodular heterotopia.Psychiatry and clinical neurosciences, , Volume: 69, Issue:8, 2015
Phosphorylation of transcription factor specificity protein 4 is increased in peripheral blood mononuclear cells of first-episode psychosis.PloS one, , Volume: 10, Issue:4, 2015
The impact of antipsychotic polytherapy costs in the public health care in Sao Paulo, Brazil.PloS one, , Volume: 10, Issue:4, 2015
Chemotherapy-induced acute psychosis in a patient with malignant germ cell tumour.BMJ case reports, , Apr-09, Volume: 2015, 2015
Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms.Human psychopharmacology, , Volume: 30, Issue:4, 2015
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar disorders, , Volume: 17, Issue:5, 2015
Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 30, Issue:8, 2015
Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.Journal of geriatric psychiatry and neurology, , Volume: 28, Issue:1, 2015
The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.Journal of primary health care, , Jun-01, Volume: 7, Issue:2, 2015
Interventions for psychotic symptoms concomitant with epilepsy.The Cochrane database of systematic reviews, , Dec-21, Issue:12, 2015
Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.Journal of child and adolescent psychopharmacology, , Volume: 25, Issue:7, 2015
[Eating disorders in psychiatric patients during treatment with second generation antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:7, 2015
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 15, Issue:3, 2014
Olanzapine treatment during pregnancy and breastfeeding: a chance for women with psychotic illness?Psychopharmacology, , Volume: 231, Issue:15, 2014
Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.International clinical psychopharmacology, , Volume: 29, Issue:6, 2014
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.Psychological medicine, , Volume: 44, Issue:1, 2014
Psychotic disorder after contact with a potentially rabid animal and post-exposure prophylactic anti-rabies treatment.Clinical schizophrenia & related psychoses, , Volume: 8, Issue:3, 2014
Effects of antipsychotic drugs on insight in schizophrenia.Psychiatry research, , Aug-15, Volume: 218, Issue:1-2, 2014
Olanzapine-induced tardive dystonia: a case report.The Journal of neuropsychiatry and clinical neurosciences, , Apr-01, Volume: 26, Issue:2, 2014
Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects.Journal of biomedical nanotechnology, , Volume: 10, Issue:6, 2014
Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain.Human psychopharmacology, , Volume: 29, Issue:4, 2014
[Emergency psychopharmacotherapy in Hungary -- preliminary data].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 16, Issue:1, 2014
Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study.Comprehensive psychiatry, , Volume: 55, Issue:5, 2014
No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain.Psychiatry research, , Oct-30, Volume: 219, Issue:2, 2014
An atypical case of neuroleptic malignant syndrome precipitated by valproate.BMJ case reports, , Mar-06, Volume: 2014, 2014
Efficacy and safety of combined paliperidone palmitate and olanzapine pamoate in resistant schizoaffective disorder.Journal of clinical psychopharmacology, , Volume: 34, Issue:5, 2014
[Woman in her 30s with chronic fatigue].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Feb-25, Volume: 134, Issue:4, 2014
An exploratory randomized controlled study of a healthy living intervention in early intervention services for psychosis: the INTERvention to encourage ACTivity, improve diet, and reduce weight gain (INTERACT) study.The Journal of clinical psychiatry, , Volume: 75, Issue:5, 2014
The impact of insight in a first-episode mania with psychosis population on outcome at 18 months.Journal of affective disorders, , Volume: 167, 2014
Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.Journal of affective disorders, , Volume: 160, 2014
A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.BMC psychiatry, , Jan-14, Volume: 14, 2014
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.CNS spectrums, , Volume: 19, Issue:5, 2014
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.Journal of clinical psychopharmacology, , Volume: 34, Issue:1, 2014
Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care.Clinical toxicology (Philadelphia, Pa.), , Volume: 52, Issue:1, 2014
The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:4, 2014
Olanzapine-induced methylation alters cadherin gene families and associated pathways implicated in psychosis.BMC neuroscience, , Sep-29, Volume: 15, 2014
Use of very-high-dose olanzapine in treatment-resistant schizophrenia.Schizophrenia research, , Volume: 159, Issue:2-3, 2014
Add-on oral olanzapine worsens hallucinations in schizoaffective disorder.BMJ case reports, , Oct-21, Volume: 2014, 2014
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.The international journal of neuropsychopharmacology, , Volume: 17, Issue:1, 2014
Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study.PloS one, , Volume: 8, Issue:5, 2013
Benzodiazepines for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , Apr-30, Issue:4, 2013
The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.Journal of clinical psychopharmacology, , Volume: 33, Issue:3, 2013
Skin rash occurring with olanzapine pamoate, but not with oral olanzapine, in a male with juvenile idiopathic arthritis.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:3, 2013
[Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 15, Issue:2, 2013
Comparative safety of antipsychotics: another look at the risk of diabetes.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 58, Issue:4, 2013
Pharmaco-epidemiological description of the population of the Marche Region (central Italy) treated with the antipsychotic drug olanzapine.Annali dell'Istituto superiore di sanita, , Volume: 49, Issue:1, 2013
Psychotic symptoms in a woman with severe Anorexia Nervosa : psychotic symptoms in Anorexia Nervosa.Eating and weight disorders : EWD, , Volume: 18, Issue:1, 2013
Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.The Journal of clinical psychiatry, , Volume: 74, Issue:2, 2013
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.Psychopharmacology, , Volume: 227, Issue:4, 2013
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.The Journal of clinical psychiatry, , Volume: 74, Issue:1, 2013
In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation.International clinical psychopharmacology, , Volume: 28, Issue:2, 2013
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.Psychiatry research, , Apr-30, Volume: 206, Issue:2-3, 2013
[Acute catatonia: Questions, diagnosis and prognostics, and the place of atypical antipsychotics].L'Encephale, , Volume: 39, Issue:3, 2013
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-10, Volume: 40, 2013
The investigation of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: olanzapine monotherapy.Psychoneuroendocrinology, , Volume: 38, Issue:3, 2013
Atypical antipsychotics for psychosis in adolescents.The Cochrane database of systematic reviews, , Oct-15, Issue:10, 2013
[Combination of second generation antipsychotics -- case report].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 15, Issue:3, 2013
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:3, 2013
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.BMC psychiatry, , Sep-30, Volume: 13, 2013
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.Psychiatry research, , Dec-15, Volume: 210, Issue:2, 2013
Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.Behavioral and brain functions : BBF, , Jul-19, Volume: 9, 2013
Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 28, Issue:3, 2013
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.Psychopharmacology, , Volume: 219, Issue:1, 2012
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.The Journal of clinical psychiatry, , Volume: 73, Issue:2, 2012
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.Schizophrenia bulletin, , Volume: 38, Issue:4, 2012
Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice.BMC psychiatry, , Dec-17, Volume: 12, 2012
Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis.Asian journal of psychiatry, , Volume: 5, Issue:4, 2012
Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.Journal of clinical psychopharmacology, , Volume: 32, Issue:6, 2012
Postictal psychosis treated successfully with olanzapine.The Journal of clinical psychiatry, , Volume: 73, Issue:9, 2012
Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis.Schizophrenia research, , Volume: 141, Issue:2-3, 2012
One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.Psychiatry research, , Dec-30, Volume: 200, Issue:2-3, 2012
A father with postpartum psychosis.BMJ case reports, , May-08, Volume: 2012, 2012
Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol?Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:10, 2012
A case of akathisia after switching from branded to generic high-dose olanzapine.The Journal of clinical psychiatry, , Volume: 73, Issue:4, 2012
Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial.European archives of psychiatry and clinical neuroscience, , Volume: 262, Issue:7, 2012
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:5, 2012
The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:5, 2012
Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
A case of prolonged duration of untreated psychosis: barriers to treatment and strategies to improve the outcome.Clinical schizophrenia & related psychoses, , Volume: 6, Issue:1, 2012
Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.Clinical schizophrenia & related psychoses, , Volume: 6, Issue:1, 2012
Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.Clinical drug investigation, , Apr-01, Volume: 32, Issue:4, 2012
Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
Antipsychotics and mortality in Parkinsonism.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 20, Issue:2, 2012
Olanzapine-associated myoclonus.Epilepsy research, , Volume: 98, Issue:2-3, 2012
Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.The Journal of clinical psychiatry, , Volume: 73, Issue:1, 2012
Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study.International journal of psychiatry in clinical practice, , Volume: 16, Issue:1, 2012
[Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].La Clinica terapeutica, , Volume: 162, Issue:4, 2011
Switching antipsychotic medications: not enough, too often, or just right?The American journal of psychiatry, , Volume: 168, Issue:9, 2011
Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.BMC psychiatry, , Aug-31, Volume: 11, 2011
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.Neuro endocrinology letters, , Volume: 32, Issue:4, 2011
A six-to-ten weeks' follow-up study on the effects of olanzapine on abdominal fat and other metabolic parameters in patients with psychoses--an imaging-based study with controls.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 21, Issue:1, 2011
Does propofol induction in patients on olanzapine increase the susceptibility to dystonic reactions?Acta anaesthesiologica Scandinavica, , Volume: 55, Issue:5, 2011
Atypical antipsychotic drugs in the treatment of Parkinson's disease.Journal of pharmacy practice, , Volume: 24, Issue:6, 2011
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).The Journal of clinical psychiatry, , Volume: 72, Issue:7, 2011
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).The American journal of psychiatry, , Volume: 168, Issue:9, 2011
[Rapid tranquillisation; review of the literature and recommendations].Tijdschrift voor psychiatrie, , Volume: 53, Issue:10, 2011
Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.Pharmacotherapy, , Volume: 31, Issue:8, 2011
[A case of affective disorder with psychotic symptoms as late manifestation of Huntington's Chorea].Psychiatrische Praxis, , Volume: 38, Issue:6, 2011
Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.BMC psychiatry, , May-17, Volume: 11, 2011
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 33, Issue:1, 2011
Olanzapine-induced agranulocytosis in an adolescent male with psychosis.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:2, 2011
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Folie à deux: double case-report of shared delusions with a fatal outcome.La Clinica terapeutica, , Volume: 162, Issue:1, 2011
Metabolic effects of olanzapine in patients with newly diagnosed psychosis.Journal of clinical psychopharmacology, , Volume: 31, Issue:2, 2011
Blood lactate levels in patients receiving first- or second- generation antipsychotics.Croatian medical journal, , Volume: 52, Issue:1, 2011
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:6, 2011
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.The Journal of clinical psychiatry, , Volume: 72, Issue:10, 2011
High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.Journal of clinical psychopharmacology, , Volume: 31, Issue:1, 2011
Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.Journal of psychiatric research, , Volume: 45, Issue:6, 2011
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.Psychiatry research, , May-15, Volume: 187, Issue:1-2, 2011
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.Schizophrenia research, , Volume: 125, Issue:2-3, 2011
The heterogeneity of antipsychotic response in the treatment of schizophrenia.Psychological medicine, , Volume: 41, Issue:6, 2011
Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.Neuro endocrinology letters, , Volume: 32, Issue:5, 2011
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment.The Annals of pharmacotherapy, , Volume: 44, Issue:4, 2010
Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics.The journal of sexual medicine, , Volume: 7, Issue:10, 2010
Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.Pharmacopsychiatry, , Volume: 43, Issue:4, 2010
Successful clozapine retrial after suspected myocarditis.The American journal of psychiatry, , Volume: 167, Issue:3, 2010
An unusual late presentation of subacute sclerosing panencephalitis with psychotic symptoms.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 22, Issue:1, 2010
Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis.International clinical psychopharmacology, , Volume: 25, Issue:3, 2010
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.Bipolar disorders, , Volume: 12, Issue:2, 2010
Antibodies to measles in individuals with recent onset psychosis.Schizophrenia research, , Volume: 119, Issue:1-3, 2010
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:2, 2010
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.BMC psychiatry, , Mar-24, Volume: 10, 2010
Switching and combining antipsychotics.CNS spectrums, , Volume: 15, Issue:4 Suppl 6, 2010
Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?The Journal of clinical psychiatry, , Volume: 71, Issue:11, 2010
Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.BMC psychiatry, , Nov-03, Volume: 10, 2010
The case report of treatment strategy for Anorexia nervosa with psychotic elements in adolescent.Collegium antropologicum, , Volume: 34, Issue:3, 2010
An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.International journal of clinical practice, , Volume: 64, Issue:11, 2010
Association between symptom improvement and change of body mass index, lipid profile, and leptin, ghrelin, and cholecystokinin levels during 6-week olanzapine treatment in patients with first-episode psychosis.Journal of clinical psychopharmacology, , Volume: 30, Issue:5, 2010
Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders.Journal of clinical psychopharmacology, , Volume: 30, Issue:5, 2010
The potential role of appetite in predicting weight changes during treatment with olanzapine.BMC psychiatry, , Sep-14, Volume: 10, 2010
Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis.Pharmacopsychiatry, , Volume: 43, Issue:7, 2010
Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness.Schizophrenia research, , Volume: 123, Issue:1, 2010
Metabolic syndrome with the atypical antipsychotics.Current opinion in endocrinology, diabetes, and obesity, , Volume: 17, Issue:5, 2010
Olanzapine and breast-feeding: changes of plasma concentrations of olanzapine in a breast-fed infant over a period of 5 months.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 22, Issue:3, 2010
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 49, Issue:6, 2010
Insomnia treatment by olanzapine. Is sleep state misperception a psychotic disorder?Neurosciences (Riyadh, Saudi Arabia), , Volume: 15, Issue:2, 2010
Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics.International clinical psychopharmacology, , Volume: 25, Issue:4, 2010
Gender, psychosis and psychotropic drugs: differences and similarities.Psychiatria Danubina, , Volume: 22, Issue:2, 2010
Antipsychotic dosing: still a work in progress.The American journal of psychiatry, , Volume: 167, Issue:6, 2010
[Sydenham chorea and psychosis].Tijdschrift voor psychiatrie, , Volume: 52, Issue:4, 2010
Aripiprazole add-on treatment in a patient with schizoaffective disorder: neurocognitive outcomes.Pharmacopsychiatry, , Volume: 43, Issue:6, 2010
Practical limitations of prescribing olanzapine depot (Relprevv).Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 18, Issue:3, 2010
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.Journal of clinical psychopharmacology, , Volume: 30, Issue:3, 2010
Antipsychotics in pregnancy.Journal of psychiatric and mental health nursing, , Volume: 17, Issue:2, 2010
Hyperprolactinaemia and acute psychosis: prolactinoma or medication-induced phenomenon?The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:5, 2010
Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis.The British journal of psychiatry : the journal of mental science, , Volume: 194, Issue:5, 2009
Hunger and negative alliesthesia to aspartame and sucrose in patients treated with antipsychotic drugs and controls.Eating and weight disorders : EWD, , Volume: 14, Issue:4, 2009
Asenapine effects in animal models of psychosis and cognitive function.Psychopharmacology, , Volume: 206, Issue:4, 2009
Akathisia and second-generation antipsychotic drugs.Current opinion in psychiatry, , Volume: 22, Issue:3, 2009
Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.Current medical research and opinion, , Volume: 25, Issue:7, 2009
Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.The Israel journal of psychiatry and related sciences, , Volume: 46, Issue:3, 2009
Olanzapine for the treatment of acquired neurogenic stuttering.Journal of psychiatric practice, , Volume: 15, Issue:6, 2009
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.Therapeutic drug monitoring, , Volume: 31, Issue:6, 2009
Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Medication adherence for children and adolescents with first-episode psychosis following hospitalization.European child & adolescent psychiatry, , Volume: 18, Issue:10, 2009
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.The Journal of clinical psychiatry, , Volume: 70, Issue:7, 2009
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.The Journal of clinical psychiatry, , Apr-21, Volume: 70, Issue:5, 2009
[Therapeutic intervention for group with risk of psychosis--Sendai At-risk Mental State And First Episode].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 111, Issue:3, 2009
A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).Archives of general psychiatry, , Volume: 66, Issue:8, 2009
Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation.Journal of psychiatric practice, , Volume: 15, Issue:4, 2009
Olanzapine treatment in Jarisch-Herxheimer reaction due to neurosyphilis with dementia: a case report.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:8, 2009
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.International clinical psychopharmacology, , Volume: 24, Issue:5, 2009
Haloperidol plus promethazine for psychosis-induced aggression.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.Schizophrenia research, , Volume: 113, Issue:1, 2009
The risks and benefits of switching antipsychotics: a case study approach.Perspectives in psychiatric care, , Volume: 45, Issue:1, 2009
Plasma homovanillic acid and family history of psychotic disorders in bipolar I patients.Pharmacological research, , Volume: 59, Issue:4, 2009
Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics.Early intervention in psychiatry, , Volume: 3, Issue:1, 2009
Olanzapine compared to quetiapine in adolescents with a first psychotic episode.European child & adolescent psychiatry, , Volume: 18, Issue:7, 2009
Status epilepticus in a patient treated with olanzapine and mirtazapine.International journal of clinical pharmacology and therapeutics, , Volume: 47, Issue:2, 2009
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
[Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL].L'Encephale, , Volume: 35, Issue:1, 2009
Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone.Psychoneuroendocrinology, , Volume: 34, Issue:7, 2009
Steroid responsive psychotic depression.The Australian and New Zealand journal of psychiatry, , Volume: 43, Issue:7, 2009
Impact of patient selection criteria and treatment history on comparisons of alternative therapies: a case study of atypical antipsychotics.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12, Issue:4, 2009
Psychosis secondary to traumatic brain injury.Brain injury, , Volume: 23, Issue:4, 2009
[Turner-syndrome and psychosis: a case report and brief review of the literature].Psychiatrische Praxis, , Volume: 36, Issue:5, 2009
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.Journal of psychiatric research, , Volume: 43, Issue:5, 2009
[Edema related to treatment with olanzapine].Psychiatrische Praxis, , Volume: 36, Issue:3, 2009
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
Interventions for psychotic symptoms concomitant with epilepsy.The Cochrane database of systematic reviews, , Oct-08, Issue:4, 2008
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.Human psychopharmacology, , Volume: 23, Issue:4, 2008
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.The Journal of clinical psychiatry, , Volume: 69, Issue:1, 2008
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.Journal of psychiatric research, , Volume: 42, Issue:13, 2008
Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:1, 2008
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.Clinical drug investigation, , Volume: 28, Issue:5, 2008
Neuroleptic malignant syndrome presenting with acute renal failure.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs.Psychiatry research, , Mar-15, Volume: 158, Issue:2, 2008
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.Current medical research and opinion, , Volume: 24, Issue:3, 2008
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.Human psychopharmacology, , Volume: 23, Issue:3, 2008
Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia.Biological psychiatry, , Apr-15, Volume: 63, Issue:8, 2008
Evaluating dose response from flexible dose clinical trials.BMC psychiatry, , Jan-07, Volume: 8, 2008
Resolution of low voltage electrical injury induced psychosis with olanzapine.Brain injury, , Volume: 22, Issue:4, 2008
Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:1, 2008
Rapidly developing hyperglycemia during treatment with olanzapine.The Annals of pharmacotherapy, , Volume: 42, Issue:4, 2008
Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.Schizophrenia research, , Volume: 98, Issue:1-3, 2008
Clinical and pharmacoeconomic evaluation of switch to olanzapine in veterans with schizophrenia or schizoaffective disorder.Psychopharmacology bulletin, , Volume: 41, Issue:1, 2008
[Atypical antipsychotics in first-episode psychosis: a review].L'Encephale, , Volume: 34, Issue:2, 2008
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Septo-optic dysplasia and psychiatric disorders: a case report.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 21, Issue:4, 2008
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 69, Issue:3, 2008
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
The Bipolar Comprehensive Outcomes Study (BCOS): baseline findings of an Australian cohort study.Journal of affective disorders, , Volume: 107, Issue:1-3, 2008
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Water, water, everywhere, nor any drop to drink: climate change delusion.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:4, 2008
Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.Schizophrenia research, , Volume: 99, Issue:1-3, 2008
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.Journal of clinical psychopharmacology, , Volume: 28, Issue:4, 2008
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:12, 2008
Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis.International journal of geriatric psychiatry, , Volume: 23, Issue:4, 2008
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.BMC medicine, , Jun-30, Volume: 6, 2008
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:4, 2008
Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder.Pharmacopsychiatry, , Volume: 41, Issue:5, 2008
The InterSePT suicide scale for prediction of imminent suicidal behaviors.Psychiatry research, , Oct-30, Volume: 161, Issue:1, 2008
Olanzapine-induced rabbit syndrome.Southern medical journal, , Volume: 101, Issue:10, 2008
Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder.BMC psychiatry, , Sep-15, Volume: 8, 2008
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.The American journal of psychiatry, , Volume: 165, Issue:11, 2008
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.The American journal of psychiatry, , Volume: 165, Issue:7, 2008
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.Journal of clinical psychopharmacology, , Volume: 28, Issue:3, 2008
Did CATIE influence antipsychotic use?Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
Lessons to be learned from CATIE and CUtLASS.Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia.Archives of general psychiatry, , Volume: 65, Issue:10, 2008
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial.The Journal of clinical psychiatry, , Volume: 69, Issue:5, 2008
Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.Human psychopharmacology, , Volume: 22, Issue:1, 2007
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.CNS spectrums, , Volume: 12, Issue:1, 2007
Quetiapine in the successful combination treatment of an assaultive patient with treatment-resistant schizoaffective disorder.Behavioral medicine (Washington, D.C.), ,Spring, Volume: 33, Issue:1, 2007
Datapoints: The ups and downs of dosing second-generation antipsychotics.Psychiatric services (Washington, D.C.), , Volume: 58, Issue:1, 2007
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Item response analysis of the Positive and Negative Syndrome Scale.BMC psychiatry, , Nov-15, Volume: 7, 2007
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.Journal of psychiatric research, , Volume: 41, Issue:8, 2007
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:5, 2007
Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?Psychiatric services (Washington, D.C.), , Volume: 58, Issue:2, 2007
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
Analysis of treatment effectiveness in longitudinal observational data.Journal of biopharmaceutical statistics, , Volume: 17, Issue:5, 2007
Characteristics of psychotic patients with foreign accent syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 19, Issue:1, 2007
Plasma lipids, lipoproteins and hormones levels during olanzapine treatment in psychosis and depression.Medicinski arhiv, , Volume: 61, Issue:2, 2007
Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Dec-05, Volume: 144B, Issue:8, 2007
Olanzapine exposure during pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:8, 2007
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Early use of clozapine for poorly responding first-episode psychosis.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Atypical antipsychotics: new drugs, new challenges.Cleveland Clinic journal of medicine, , Volume: 74, Issue:8, 2007
Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.Human psychopharmacology, , Volume: 22, Issue:7, 2007
Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.The American journal of psychiatry, , Volume: 164, Issue:8, 2007
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.CNS spectrums, , Volume: 12, Issue:3 Suppl 4, 2007
The use of atypical antipsychotics in French psychiatric hospitals.Pharmacy world & science : PWS, , Volume: 29, Issue:5, 2007
Olanzapine-induced chylomicronemia presenting as acute pancreatitis.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Olanzapine-associated bilateral eyelid edema.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Managing psychosis in pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:3, 2007
Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 17, Issue:3, 2007
Late-onset neuroleptic malignant syndrome in a patient using olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:3, 2007
Psychosis of Alzheimer disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
Massive creatine kinase elevations with quetiapine: report of two cases.Pharmacopsychiatry, , Volume: 39, Issue:1, 2006
Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.Schizophrenia research, , Feb-28, Volume: 82, Issue:2-3, 2006
[New formulations of olanzapine in the treatment of acute agitation].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Anticholinergics in dementia and other confounding problems.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:4, 2006
Treatment of psychosis: 30 years of progress.Journal of clinical pharmacy and therapeutics, , Volume: 31, Issue:6, 2006
Hypersalivation induced by olanzapine with fluvoxamine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:4, 2006
Stevens-Johnson syndrome (SJS) leading to resolution of mania.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:2, 2006
Serum creatine kinase levels in chronic psychosis patients--a comparison between atypical and conventional antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 18, Issue:1, 2006
Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder--a preliminary report.Journal of affective disorders, , Volume: 92, Issue:2-3, 2006
Management of psychosis in Australian general practice.Australian family physician, , Volume: 35, Issue:3, 2006
Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.Acta psychiatrica Scandinavica. Supplementum, , Issue:430, 2006
Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis.Psychopathology, , Volume: 39, Issue:3, 2006
Persistent psychosis after treatment with interferon alpha: a case report.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Jan-31, Volume: 81, Issue:2-3, 2006
Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder.Bipolar disorders, , Volume: 8, Issue:4, 2006
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].Nederlands tijdschrift voor geneeskunde, , Jul-15, Volume: 150, Issue:28, 2006
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.Biological psychiatry, , Jan-15, Volume: 59, Issue:2, 2006
Olanzapine and haloperidol in first episode psychosis: two-year data.Schizophrenia research, , Volume: 86, Issue:1-3, 2006
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.Journal of psychiatric research, , Volume: 40, Issue:7, 2006
Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis.Medicinski arhiv, , Volume: 60, Issue:4, 2006
Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.Journal of clinical psychopharmacology, , Volume: 26, Issue:5, 2006
Hip dysplasia following a case of olanzapine exposed pregnancy: a questionable association.Archives of women's mental health, , Volume: 9, Issue:4, 2006
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.Archives of general psychiatry, , Volume: 63, Issue:6, 2006
Insight in first-episode psychosis.Psychological medicine, , Volume: 36, Issue:10, 2006
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.Acta psychiatrica Scandinavica, , Volume: 114, Issue:5, 2006
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.Schizophrenia research, , Volume: 86, Issue:1-3, 2006
Injectable atypical antipsychotics for agitation in borderline personality disorder.Pharmacopsychiatry, , Volume: 39, Issue:3, 2006
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Monosymptomatic hypochondriacal psychosis presenting with recurrent oral mucosal ulcers and multiple skin lesions responding to olanzapine treatment.International journal of dermatology, , Volume: 45, Issue:10, 2006
Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
The rational use of medications in acute psychotic presentations -- the case for less is more.Journal of psychiatry & neuroscience : JPN, , Volume: 31, Issue:3, 2006
A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Real-life switching strategies with second-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
"My new Alfa Romeo GT is not in the garage any more": Cognitive behavioural therapy of panic disorder with agoraphobia co morbid with psychosis.Psychiatria Danubina, , Volume: 18, Issue:3-4, 2006
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.The Journal of clinical psychiatry, , Volume: 67, Issue:10, 2006
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 13, Issue:2, 2006
Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.The Journal of clinical psychiatry, , Volume: 67, Issue:4, 2006
Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:11, 2006
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.The Cochrane database of systematic reviews, , Jan-25, Issue:1, 2006
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.Journal of clinical psychopharmacology, , Volume: 26, Issue:2, 2006
Persistent amnesia as a sequel of olanzapine-induced neuroleptic malignant syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 18, Issue:4, 2006
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.The American journal of psychiatry, , Volume: 163, Issue:12, 2006
Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:8, 2005
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.Clinical therapeutics, , Volume: 27, Issue:12, 2005
Monosymptomatic hypochondriacal psychosis: atypical presentation and response to olanzapine.The Journal of clinical psychiatry, , Volume: 66, Issue:6, 2005
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.Schizophrenia research, , Oct-15, Volume: 78, Issue:2-3, 2005
Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients.Schizophrenia research, , Oct-15, Volume: 78, Issue:2-3, 2005
Serum creatine kinase elevation as a possible complication of therapy with olanzapine.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 372, Issue:2, 2005
Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.Bulletin of experimental biology and medicine, , Volume: 140, Issue:6, 2005
Atypical anti-psychotics in the real world--a naturalistic comparative outcome study.Scottish medical journal, , Volume: 50, Issue:3, 2005
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:5 Suppl, 2005
Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses.The Cochrane database of systematic reviews, , Apr-18, Issue:2, 2005
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Apr-18, Issue:2, 2005
Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders.Schizophrenia research, , Dec-01, Volume: 80, Issue:1, 2005
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients.The Journal of clinical psychiatry, , Volume: 66, Issue:12, 2005
Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.Schizophrenia research, , Sep-15, Volume: 77, Issue:2-3, 2005
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Acute psychosis with a mediastinal carcinoma metastasis.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 11, Issue:1, 2005
Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone.International clinical psychopharmacology, , Volume: 20, Issue:3, 2005
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Delusional wife: a case of diagnostic ambiguity and treatment challenge.Journal of psychiatric practice, , Volume: 11, Issue:3, 2005
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.Schizophrenia research, , Jul-01, Volume: 76, Issue:1, 2005
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.International psychogeriatrics, , Volume: 17, Issue:4, 2005
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.The American journal of psychiatry, , Volume: 162, Issue:8, 2005
Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy.Journal of clinical psychopharmacology, , Volume: 25, Issue:2, 2005
[Love, humor and psychosis in an atypical depression].L'Encephale, , Volume: 31 Pt 2, 2005
Comments on article by Albers et al: "Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy".Journal of clinical psychopharmacology, , Volume: 25, Issue:6, 2005
Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
Atypical antipsychotics: special formulations for acute agitation.Journal of psychosocial nursing and mental health services, , Volume: 43, Issue:10, 2005
Olanzapine in the treatment of agitation in hospitalized patients with schizophrenia and schizoaffective and schizofreniform disorders.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 10, Issue:5, 2004
Novel antipsychotics in bipolar and schizoaffective mania.Acta psychiatrica Scandinavica, , Volume: 109, Issue:6, 2004
Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder.Psychopharmacology, , Volume: 175, Issue:4, 2004
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:9, 2004
Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:6, 2004
Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior.The Journal of clinical psychiatry, , Volume: 65, Issue:5, 2004
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.Annals of the New York Academy of Sciences, , Volume: 1032, 2004
Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:3, 2004
Tardive dyskinesia rates with atypical antipsychotics in older adults.The Journal of clinical psychiatry, , Volume: 65 Suppl 9, 2004
Weight gain during long-term treatment with olanzapine: a case series.International clinical psychopharmacology, , Volume: 19, Issue:4, 2004
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.Journal of clinical psychopharmacology, , Volume: 24, Issue:2, 2004
The management of psychogeriatric patient.Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.Journal of clinical psychopharmacology, , Volume: 24, Issue:4, 2004
Antipsychotic drug prescribing in the elderly is cause for concern.International clinical psychopharmacology, , Volume: 19, Issue:6, 2004
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
A male case of monosymptomatic hypochondriacal psychosis responding to olanzapine: a case report.Pharmacopsychiatry, , Volume: 37, Issue:5, 2004
[Intoxications with atypical antipsychotic drugs--data of the Acute Intoxication Unit in Wrocław].Przeglad lekarski, , Volume: 61, Issue:4, 2004
Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:1, 2004
Variables associated with high olanzapine dosing in a state hospital.The Journal of clinical psychiatry, , Volume: 65, Issue:8, 2004
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.The American journal of psychiatry, , Volume: 161, Issue:9, 2004
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
Blepharospasm associated with olanzapine: a case report.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:6, 2004
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.Schizophrenia bulletin, , Volume: 30, Issue:3, 2004
[Clozapine for the treatment of psychosis in 3 elderly patients with Parkinson's disease].Nederlands tijdschrift voor geneeskunde, , Nov-27, Volume: 148, Issue:48, 2004
A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.Psychiatry research, , Dec-15, Volume: 129, Issue:2, 2004
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 29, Issue:1, 2004
Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.Psychopharmacology, , Volume: 172, Issue:3, 2004
Bipolar depression: the role of atypical antipsychotics.Expert review of neurotherapeutics, , Volume: 4, Issue:6 Suppl 2, 2004
[Management of the atypical antipsychotic olanzapine in a clinical environment with particular regard to therapeutic drug monitoring (TDM) in a German State hospital].Psychiatrische Praxis, , Volume: 31 Suppl 1, 2004
A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Dropout rates with olanzapine or risperidone: a multi-centre observational study.European journal of clinical pharmacology, , Volume: 59, Issue:12, 2004
Olanzapine excretion into breast milk: a case report.Journal of clinical psychopharmacology, , Volume: 24, Issue:1, 2004
Olanzapine treatment of eight adolescent patients with psychosis.Human psychopharmacology, , Volume: 19, Issue:1, 2004
Switching elderly chronic psychotic patients to olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:2, 2004
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.International journal of geriatric psychiatry, , Volume: 19, Issue:2, 2004
New antipsychotics and schizophrenia: a review on efficacy and side effects.Current medicinal chemistry, , Volume: 11, Issue:3, 2004
Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:1, 2004
[Cerebral infarct and atypical antipsychotic agents].Psychologie & neuropsychiatrie du vieillissement, , Volume: 2, Issue:4, 2004
Optimizing atypical antipsychotic treatment strategies in the elderly.Journal of the American Geriatrics Society, , Volume: 52, Issue:12 Suppl, 2004
Pharmacology of antipsychotics in the elderly: a focus on atypicals.Journal of the American Geriatrics Society, , Volume: 52, Issue:12 Suppl, 2004
Open label study of the effect of amantadine on weight gain induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 58, Issue:2, 2004
Olanzapine-induced galactorrhea in a woman with psychotic illness.The Australian and New Zealand journal of psychiatry, , Volume: 38, Issue:4, 2004
Hyperglycemia associated with antipsychotic treatment in a multicenter drug safety project.Pharmacopsychiatry, , Volume: 37 Suppl 1, 2004
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
Hyperglycemia from olanzapine treatment in adolescents.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 13, Issue:1, 2003
High-dose olanzapine-induced improvement of preexisting type 2 diabetes mellitus in schizophrenic patients.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
QTc prolongation: chlorpromazine and high-dosage olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
[Life threatening neuroleptic malignant syndrome due to olanzapine].Psychiatrische Praxis, , Volume: 30, Issue:5, 2003
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.The American journal of psychiatry, , Volume: 160, Issue:8, 2003
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.Biological psychiatry, , Aug-15, Volume: 54, Issue:4, 2003
Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Potential use of olanzapine in treatment of substance dependence disorders.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.The Annals of pharmacotherapy, , Volume: 37, Issue:9, 2003
Comparison of three antipsychotics in the emergency psychiatric setting.Human psychopharmacology, , Volume: 18, Issue:6, 2003
Olanzapine for cocaine cravings and relapse prevention.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.Southern medical journal, , Volume: 96, Issue:7, 2003
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.International journal of geriatric psychiatry, , Volume: 18, Issue:9, 2003
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
Psychotic disorder in a case with Hallervorden-Spatz disease.Acta psychiatrica Scandinavica, , Volume: 108, Issue:5, 2003
Effects of olanzapine on lipid abnormalities in elderly psychotic patients.Drugs & aging, , Volume: 20, Issue:12, 2003
Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.Current medical research and opinion, , Volume: 19, Issue:6, 2003
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.The international journal of neuropsychopharmacology, , Volume: 6, Issue:4, 2003
Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:6, 2003
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:9, 2003
A 1-year open-label trial of olanzapine in school-age children with schizophrenia.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 13, Issue:3, 2003
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
High-dose olanzapine and prolactin levels.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
Pulmonary embolism possibly associated with olanzapine treatment.BMJ (Clinical research ed.), , Dec-13, Volume: 327, Issue:7428, 2003
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).Archives of general psychiatry, , Volume: 60, Issue:1, 2003
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Issue:1, 2003
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Comparative effectiveness of antipsychotic drugs.The American journal of psychiatry, , Volume: 160, Issue:3, 2003
The efficacy and safety of olanzapine for the treatment of geriatric psychosis.Journal of clinical psychopharmacology, , Volume: 23, Issue:2, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.Pharmacopsychiatry, , Volume: 35, Issue:3, 2002
One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.Psychiatric services (Washington, D.C.), , Volume: 53, Issue:7, 2002
Clinical and economic outcomes associated with olanzapine for the treatment of psychotic symptoms in a county mental health population.Clinical therapeutics, , Volume: 24, Issue:5, 2002
Tardive dyskinesias and antipsychotics: a review.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:3, 2002
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.Schizophrenia bulletin, , Volume: 28, Issue:4, 2002
Weight gain and hyperglycaemia associated with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:2, 2002
Olanzapine-induced destabilization of diabetes in the absence of weight gain.Acta psychiatrica Scandinavica, , Volume: 105, Issue:3, 2002
Eosinophilia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:3, 2002
Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis.The Journal of clinical psychiatry, , Volume: 63, Issue:2, 2002
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.The Journal of clinical psychiatry, , Volume: 63, Issue:2, 2002
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.Dementia and geriatric cognitive disorders, , Volume: 13, Issue:2, 2002
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.The American journal of psychiatry, , Volume: 159, Issue:2, 2002
Are the atypical antipsychotic drugs antidepressants?Journal of clinical psychopharmacology, , Volume: 22, Issue:1, 2002
Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis.Pharmacotherapy, , Volume: 22, Issue:1, 2002
Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication.Therapeutic drug monitoring, , Volume: 24, Issue:4, 2002
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 12, Issue:2, 2002
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.Schizophrenia research, , Oct-01, Volume: 57, Issue:2-3, 2002
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:3, 2002
Olanzapine-induced hyperventilation: case report.Journal of psychiatry & neuroscience : JPN, , Volume: 27, Issue:5, 2002
Using antipsychotics in elderly patients.The Practitioner, , Volume: 246, Issue:1639, 2002
Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.International clinical psychopharmacology, , Volume: 17, Issue:6, 2002
The effects of novel antipsychotics on glucose and lipid levels.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Recent developments in pharmacotherapy for the acutely psychotic patient.Journal of emergency nursing, , Volume: 28, Issue:6 Suppl, 2002
The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
[Schizoaffective disorder: clinical symptoms and present-day approach to treatment].Medicina (Kaunas, Lithuania), , Volume: 38, Issue:11, 2002
Olanzapine and pregnancy.Pharmacopsychiatry, , Volume: 35, Issue:3, 2002
Use of olanzapine for elderly patients with psychotic disorders: a review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 13, Issue:4, 2001
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.Journal of affective disorders, , Volume: 67, Issue:1-3, 2001
An open trial of olanzapine in the treatment of patients with psychotic depression.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 13, Issue:3, 2001
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.The Journal of clinical psychiatry, , Volume: 62, Issue:12, 2001
[Diabetes mellitus induced by olanzapine. A case report].Revista medica de Chile, , Volume: 129, Issue:10, 2001
Body weight gain, insulin, and leptin in olanzapine-treated patients.The Journal of clinical psychiatry, , Volume: 62, Issue:11, 2001
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.International journal of geriatric psychiatry, , Volume: 16 Suppl 1, 2001
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 13, Issue:4, 2001
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Fall, Volume: 9, Issue:4, 2001
Olanzapine-induced priapism.The American journal of psychiatry, , Volume: 158, Issue:12, 2001
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:8, 2001
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:11, 2001
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.The Journal of clinical psychiatry, , Volume: 62, Issue:9, 2001
Olanzapine in pregnancy.The Annals of pharmacotherapy, , Volume: 35, Issue:10, 2001
[Importance of blood glucose level when starting antipsychotic treatment].Presse medicale (Paris, France : 1983), , Sep-22, Volume: 30, Issue:26, 2001
Olanzapine induces remarkable weight gain in adolescent patients.European child & adolescent psychiatry, , Volume: 10, Issue:3, 2001
Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database.The American journal of psychiatry, , Volume: 158, Issue:9, 2001
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.The Journal of clinical psychiatry, , Volume: 62, Issue:7, 2001
Priapism associated with conventional and atypical antipsychotic medications: a review.The Journal of clinical psychiatry, , Volume: 62, Issue:5, 2001
Hypothesis and hypothesis testing in the clinical trial.The Journal of clinical psychiatry, , Volume: 62 Suppl 9, 2001
The pharmacology of weight gain with antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 7, 2001
Use of olanzapine in non-psychotic psychiatric disorders.Expert opinion on pharmacotherapy, , Volume: 2, Issue:4, 2001
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 158, Issue:5, 2001
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates.Neurocase, , Volume: 7, Issue:2, 2001
Effect of amantadine on weight gain during olanzapine treatment.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 11, Issue:2, 2001
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.The Journal of clinical psychiatry, , Volume: 62, Issue:2, 2001
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.The Journal of clinical psychiatry, , Volume: 62, Issue:1, 2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Introduction: a new era in the pharmacotherapy of psychotic disorders.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Rapid tranquilization with olanzapine in acute psychosis: a case series.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.The American journal of psychiatry, , Volume: 158, Issue:3, 2001
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials.Biological psychiatry, , Jan-01, Volume: 49, Issue:1, 2001
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
Switching clozapine responders to olanzapine.The Journal of clinical psychiatry, , Volume: 61, Issue:12, 2000
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.Journal of psychopharmacology (Oxford, England), , Volume: 14, Issue:4, 2000
[Effective treatment of depressive disorder with psychotic symptoms by olanzapine combination therapy].Deutsche medizinische Wochenschrift (1946), , Dec-15, Volume: 125, Issue:50, 2000
New treatments for bipolar disorder: the role of atypical neuroleptic agents.The Journal of clinical psychiatry, , Volume: 61 Suppl 14, 2000
Rationale and guidelines for the inpatient treatment of acute psychosis.The Journal of clinical psychiatry, , Volume: 61 Suppl 14, 2000
A case of monosymptomatic hypochondriacal psychosis treated with olanzapine.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 12, Issue:4, 2000
Comparison of cost, dosage and clinical preference for risperidone and olanzapine.Schizophrenia research, , Dec-15, Volume: 46, Issue:2-3, 2000
Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution.The Journal of clinical psychiatry, , Volume: 61, Issue:11, 2000
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.The Journal of clinical psychiatry, , Volume: 61, Issue:11, 2000
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.The Journal of clinical psychiatry, , Volume: 61, Issue:10, 2000
Polypharmacy of 2 atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.Archives of general psychiatry, , Volume: 57, Issue:10, 2000
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17, Issue:6, 2000
Remission of tardive dyskinesia after changing from flupenthixol to olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 15, Issue:5, 2000
Esotropia associated with olanzapine.Journal of clinical psychopharmacology, , Volume: 20, Issue:4, 2000
Electroencephalogram alterations during treatment with olanzapine.Psychopharmacology, , Volume: 150, Issue:2, 2000
Olanzapine and weight gain.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 45, Issue:5, 2000
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.Journal of intellectual disability research : JIDR, , Volume: 44 ( Pt 2), 2000
Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine.Journal of clinical psychopharmacology, , Volume: 20, Issue:3, 2000
Adverse events related to olanzapine.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 12, Issue:1, 2000
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Issue:2, 2000
Recurrent priapism during treatment with clozapine and olanzapine.The American journal of psychiatry, , Volume: 157, Issue:4, 2000
Olanzapine use in the elderly: a retrospective analysis.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 45, Issue:2, 2000
Tardive dyskinesia in older patients.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
[Away from life into a trance. Story of an admission].Psychiatrische Praxis, , Volume: 27, Issue:1, 2000
Risperidone-induced tardive dystonia and psychosis.Lancet (London, England), , Mar-20, Volume: 353, Issue:9157, 1999
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?The Journal of clinical psychiatry, , Volume: 60, Issue:7, 1999
Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:4, 1999
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 11, Issue:3, 1999
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.European journal of nuclear medicine, , Volume: 26, Issue:8, 1999
The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.Biological psychiatry, , Aug-01, Volume: 46, Issue:3, 1999
Hypofrontal symptoms from olanzapine: a case report.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 11, Issue:1, 1999
Clozapine: a comparison with other novel antipsychotics.The Journal of clinical psychiatry, , Volume: 60 Suppl 12, 1999
Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:3, 1999
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
Management of psychotic aspects of Parkinson's disease.The Journal of clinical psychiatry, , Volume: 60 Suppl 8, 1999
Antipsychotics from theory to practice: integrating clinical and basic data.The Journal of clinical psychiatry, , Volume: 60 Suppl 8, 1999
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.The British journal of psychiatry : the journal of mental science, , Volume: 174, 1999
Review of recent clinical studies with olanzapine.The British journal of psychiatry. Supplement, , Issue:37, 1999
Use of high-dose olanzapine in refractory psychosis.The American journal of psychiatry, , Volume: 156, Issue:4, 1999
Tardive dyskinesia in affective disorders.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Olanzapine and tardive dyskinesia.The British journal of psychiatry : the journal of mental science, , Volume: 175, 1999
Olanzapine-induced psychotic mania in bipolar schizo-affective disorder.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 14, Issue:7, 1999
Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.Therapeutic drug monitoring, , Volume: 21, Issue:1, 1999
Olanzapine in the treatment of tardive dyskinesia: a report of two cases.Journal of clinical psychopharmacology, , Volume: 19, Issue:1, 1999
An open trial of olanzapine in patients with treatment-refractory psychoses.Journal of clinical psychopharmacology, , Volume: 19, Issue:1, 1999
Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service.The Australian and New Zealand journal of psychiatry, , Volume: 33, Issue:6, 1999
[New antipsychotic agents].L'Encephale, , Volume: 25 Spec No 3, 1999
Olanzapine increases weight and serum triglyceride levels.The Journal of clinical psychiatry, , Volume: 60, Issue:11, 1999
Conventional vs. newer antipsychotics in elderly patients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Winter, Volume: 7, Issue:1, 1999
Hypomania-like syndrome induced by olanzapine.International clinical psychopharmacology, , Volume: 14, Issue:6, 1999
Olanzapine versus haloperidol treatment in first-episode psychosis.The American journal of psychiatry, , Volume: 156, Issue:1, 1999
Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Nov-01, Volume: 56, Issue:21, 1999
Recurrence of neuroleptic malignant syndrome with olanzapine treatment.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
Weight gain associated with antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 60 Suppl 21, 1999
Early relapse of psychotic symptoms after an initial response to olanzapine.Acta psychiatrica Scandinavica, , Volume: 100, Issue:4, 1999
Olanzapine-induced psychotic mania in bipolar schizoaffective disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:6, 1999
Reversible leucopenia related to olanzapine.Movement disorders : official journal of the Movement Disorder Society, , Volume: 14, Issue:5, 1999
Experience with the atypical antipsychotics--risperidone and olanzapine in the elderly.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 11, Issue:3, 1999
Neuroleptic malignant syndrome associated with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 32, Issue:6, 1998
Hyperglycemia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Return of menstruation after switching from risperidone to olanzapine.Journal of clinical psychopharmacology, , Volume: 18, Issue:6, 1998
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
Olanzapine-induced mania.The Journal of the American Osteopathic Association, , Volume: 98, Issue:10, 1998
Olanzapine and negative symptoms.The Journal of clinical psychiatry, , Volume: 59, Issue:10, 1998
Metronome or alternating Pisa syndrome: a form of tardive dystonia under clozapine treatment.International clinical psychopharmacology, , Volume: 13, Issue:5, 1998
Novel antipsychotics and new onset diabetes.Biological psychiatry, , Oct-15, Volume: 44, Issue:8, 1998
Quality of life and atypical antipsychotics.Journal of clinical psychopharmacology, , Volume: 18, Issue:5, 1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome.The Medical journal of Australia, , Aug-17, Volume: 169, Issue:4, 1998
Open-label olanzapine treatment in five preadolescent children.Journal of child and adolescent psychopharmacology, , Volume: 8, Issue:2, 1998
Acute dystonia with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:7, 1998
Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.Journal of clinical psychopharmacology, , Volume: 18, Issue:4, 1998
Olanzapine-induced weight gain.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 10, Issue:1, 1998
Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".Journal of clinical psychopharmacology, , Volume: 18, Issue:2, 1998
Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".Journal of clinical psychopharmacology, , Volume: 18, Issue:2, 1998
Paranoia and agitation associated with olanzapine treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:2, 1998
Emergency treatment of acute psychosis.The Journal of clinical psychiatry, , Volume: 59 Suppl 1, 1998
Antipsychotic agents and bipolar disorder.The Journal of clinical psychiatry, , Volume: 59 Suppl 1, 1998
New antipsychotic drugs produce better outcomes.Healthcare benchmarks, , Volume: 4, Issue:10, 1997
New antipsychotic medications: strategies for evaluation and selected findings.Schizophrenia research, , Oct-30, Volume: 27, Issue:2-3, 1997
[New antipsychotic drugs].Harefuah, , Volume: 133, Issue:1-2, 1997
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.Journal of clinical psychopharmacology, , Volume: 17, Issue:5, 1997
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.The American journal of psychiatry, , Volume: 154, Issue:9, 1997
From chlorpromazine to olanzapine: a brief history of antipsychotics.Psychiatric services (Washington, D.C.), , Volume: 48, Issue:9, 1997
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Olanzapine: a novel atypical neuroleptic agent.Lancet (London, England), , May-03, Volume: 349, Issue:9061, 1997
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.The American journal of psychiatry, , Volume: 154, Issue:4, 1997
Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.Drugs, , Volume: 53, Issue:2, 1997
Antipsychotic drug choices now include olanzapine.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Dec-01, Volume: 53, Issue:23, 1996
Evaluating outcomes of treatments for persons with psychotic disorders.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Side effect profiles of new antipsychotic agents.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.Neurology, , Volume: 47, Issue:4, 1996
Olanzapine: a new typical antipsychotic drug.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 14, Issue:2, 1996
A case report of confusional psychosis with abrupt onset and rapid resolution of symptoms.Psychosomatics, , Volume: 52, Issue:5
Psychiatric symptoms in a case of intracranial tuberculosis.Psychosomatics, , Volume: 43, Issue:1
[Cycloid psychoses. A case report].Actas espanolas de psiquiatria, , Volume: 32, Issue:5
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia.Psychosomatics, , Volume: 42, Issue:6
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 9, Issue:2
Psychosis in a Patient with Davidoff-Dyke-Masson Syndrome.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:1
[Protective effect of olanzapine in psychotic disorder induced by interferon-alpha].Recenti progressi in medicina, , Volume: 94, Issue:7-8
Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.Human psychopharmacology, , Volume: 26, Issue:4-5
[Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration].Vertex (Buenos Aires, Argentina), , Volume: 14, Issue:52
[Clozapine and olanzapine in the treatment of the psychotic disorders in Parkinson's disease].Revista de neurologia, , Volume: 39, Issue:7
Clinical News.Clinical schizophrenia & related psychoses, , Volume: 11, Issue:1
Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 12, Issue:4
[Treatment of non cognitive symptoms of Alzheimer's disease].Revista de neurologia, , Volume: 42, Issue:8
The utility of intramuscular ziprasidone in the management of acute psychotic agitation.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:3
Treatment of narcolepsy complicated by psychotic symptoms.Psychosomatics, , Volume: 50, Issue:4
Introduction.The Journal of clinical psychiatry, , Volume: 78, Issue:8
Priapism after a suicide attempt by ingestion of olanzapine and gabapentin.Psychosomatics, , Volume: 42, Issue:3
The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:3
[Treatment of schizophrenia in subjects with substance use disorders: A review].Actas espanolas de psiquiatria, , Volume: 29, Issue:2
Olanzapine-induced agranulocytosis in systemic lupus erythematosus: a case report.General hospital psychiatry, , Volume: 29, Issue:1
Authors' response to comments regarding risperidone versus olanzapine Markov model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 8, Issue:5
[Prescription of olanzapine in children and adolescent psychiatric patients].L'Encephale, , Volume: 33, Issue:2
Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 7, Issue:5
Diagnosis and Treatment of Eclamptic Psychosis in the Postpartum Period: A Case Report.Psychosomatics, , Volume: 56, Issue:5
Psychosis in Anorexia Nervosa: A Case Report and Review of the Literature.Psychosomatics, , Volume: 61, Issue:2
[Psychosis associated to megacisterna magna].Anales del sistema sanitario de Navarra, , Volume: 28, Issue:1
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder.General hospital psychiatry, , Volume: 31, Issue:4
[Psychotic episode due to Hashimoto's thyroiditis].Psychiatrike = Psychiatriki, , Volume: 27, Issue:2
Combination Therapy of Long-Acting Injectable Second-Generation Antipsychotics and Oral Antipsychotics: A Retrospective Chart Review and Prescribers' Attitude Survey.Journal of clinical psychopharmacology, , Volume: 42, Issue:1
Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients.General hospital psychiatry, , Volume: 30, Issue:4
Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:3
Neuropsychiatric sequelae in a case of St. Louis encephalitis.General hospital psychiatry, , Volume: 22, Issue:2
Thrombocytopenia possibly associated with olanzapine and subsequently with benztropine mesylate.Psychosomatics, , Volume: 41, Issue:3
Metabolic Syndrome Reversal With Cariprazine.Journal of clinical psychopharmacology, , Volume: 39, Issue:4
Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study.General hospital psychiatry, , Volume: 22, Issue:2
Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy.Journal of psychiatric research, , Volume: 41, Issue:3-4
Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 8, Issue:2
[Methodological proposals for the evaluation of the mood stabilizing effect of an antipsychotic drug].L'Encephale, , Volume: 25, Issue:6
Use of olanzapine in hereditary coproporphyria.Psychosomatics, , Volume: 40, Issue:5
Relationship between smoking and psychotic symptoms in a patient treated with oral olanzapine. A case report.Actas espanolas de psiquiatria, , Volume: 42, Issue:5
Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders.Clinical neuropharmacology, , Volume: 30, Issue:2
Tuberous sclerosis with psychosis.Psychosomatics, , Volume: 44, Issue:6
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
Olanzapine for the treatment of psychiatric illness and urticaria: a case report.Psychosomatics, , Volume: 55, Issue:6
A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning.Journal of sex & marital therapy, , Volume: 32, Issue:4
Psychotic syndrome secondary to meningioma treated with a low dose of olanzapine.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 37, Issue:2
Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows, 2001.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:11-12
Management of Parkinson disease.The Journal of the American Board of Family Practice, , Volume: 11, Issue:2
Olanzapine treatment of premenstrual onset psychosis: a case report.General hospital psychiatry, , Volume: 35, Issue:4
The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.Journal of clinical psychopharmacology, , Volume: 39, Issue:6
Low voltage electrical injury induces psychosis.Psychosomatics, , Volume: 53, Issue:2
Acute necrotizing pancreatitis following olanzapine therapy.Tropical gastroenterology : official journal of the Digestive Diseases Foundation, , Volume: 35, Issue:2
Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.American journal of Alzheimer's disease and other dementias, , Volume: 21, Issue:2
Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine.Clinical neuropharmacology, , Volume: 31, Issue:5
[Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: results from NATURA study].Actas espanolas de psiquiatria, , Volume: 36, Issue:3
Propofol infusion for the retrieval of the acutely psychotic patient.Air medical journal, , Volume: 31, Issue:1
Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.Irish journal of medical science, , Volume: 172, Issue:4
Olanzapine treatment of monosymptomatic hypochondriacal psychosis.General hospital psychiatry, , Volume: 26, Issue:2
Hereditary spastic paraplegia and psychosis: connected by the corpus callosum?Psychosomatics, , Volume: 53, Issue:1
Acute massive pulmonary embolism during antipsychotic treatment: case report with opinion.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 23, Issue:6, 2023
Acute massıve pulmonary embolism assocıated wıth olanzapıne.The American journal of emergency medicine, , Volume: 35, Issue:10, 2017
Pulmonary thromboembolism associated with olanzapine treatment.Chinese medical journal, , Feb-05, Volume: 128, Issue:3, 2015
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
Fatal pulmonary embolism following antipsychotic treatment and physical restraint.Pharmacopsychiatry, , Volume: 42, Issue:5, 2009
Thrombosis and psychosis--possible association with the antiphospholipid syndrome and anticardiolipin antibodies.Irish medical journal, , Volume: 102, Issue:2, 2009
Pulmonary thromboembolism associated with olanzapine and risperidone.The Journal of emergency medicine, , Volume: 35, Issue:2, 2008
Massive pulmonary emboli associated with olanzapine.Irish medical journal, , Volume: 101, Issue:6, 2008
Olanzapine: a new risk factor for pulmonary embolus?The American journal of forensic medicine and pathology, , Volume: 29, Issue:4, 2008
Pulmonary embolism associated with olanzapine.Thrombosis and haemostasis, , Volume: 96, Issue:5, 2006
[Venous thromboembolic disease and olanzapine].Medicina clinica, , Oct-21, Volume: 127, Issue:15, 2006
Adverse drug reactions in Canada.Canadian family physician Medecin de famille canadien, , Volume: 51, 2005
Olanzapine-induced vasculitis.The American journal of geriatric pharmacotherapy, , Volume: 3, Issue:1, 2005
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
Olanzapine and venous thromboembolism.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Pulmonary embolism possibly associated with olanzapine treatment.BMJ (Clinical research ed.), , Dec-13, Volume: 327, Issue:7428, 2003
Acute massive pulmonary embolism associated with olanzapine therapy and no significant personal history in a young male--case report and literature review.Pneumologia (Bucharest, Romania), , Volume: 60, Issue:2
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
A Prospective Observational Study of Patients Receiving Intravenous and Intramuscular Olanzapine in the Emergency Department.Annals of emergency medicine, , Volume: 69, Issue:3, 2017
Acute respiratory distress due to antipsychotic drugs.Pharmacopsychiatry, , Volume: 43, Issue:3, 2010
Neonatal withdrawal syndrome following in utero exposure to paroxetine, clonazepam and olanzapine.Journal of perinatology : official journal of the California Perinatal Association, , Volume: 27, Issue:8, 2007
Olanzapine overdose in children and adolescents: two case reports and a review of the literature.Journal of child and adolescent psychopharmacology, , Volume: 15, Issue:6, 2005
Olanzapine-induced respiratory failure.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Restless legs syndrome associated with the combined use of quetiapine and venlafaxine.Journal of clinical psychopharmacology, , Volume: 34, Issue:1, 2014
Olanzapine-induced restless legs syndrome.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 21, Issue:9, 2014
Successful treatment of antipsychotic-induced restless legs syndrome with gabapentin.Asian journal of psychiatry, , Volume: 9, 2014
Could pramipexole induce acute mania? A case report.Bipolar disorders, , Volume: 15, Issue:4, 2013
Restless leg syndrome associated with olanzapine: a case series.Current drug safety, , Volume: 5, Issue:2, 2010
Refractory restless legs syndrome likely caused by olanzapine.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, , Feb-15, Volume: 5, Issue:1, 2009
Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:5, 2009
[Drug-induced akathisia].Nederlands tijdschrift voor geneeskunde, , Jan-19, Volume: 146, Issue:3, 2002
Restless legs syndrome and periodic limb movements of sleep: global therapeutic considerations.Sleep medicine reviews, , Volume: 6, Issue:4, 2002
Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Olanzapine-induced restless leg syndrome: a case report and review of literature.Indian journal of pharmacology, , Volume: 46, Issue:4
Zolpidem related persistent genital arousal disorder: An interesting case.Psychiatrike = Psychiatriki, , Volume: 30, Issue:4
Delayed-Onset olanzapine-induced rhabdomyolysis.BMJ case reports, , Mar-10, Volume: 16, Issue:3, 2023
Developed catatonia with rhabdomyolysis and exacerbated cardiac failure upon switching from clozapine to olanzapine owing to cardiomyopathy during clozapine medication - A case report.Asian journal of psychiatry, , Volume: 80, 2023
Aripiprazole-Associated Rhabdomyolysis in a 17-Year-Old Male.Archives of Iranian medicine, , 01-01, Volume: 26, Issue:1, 2023
Delayed olanzapine induced myocarditis and rhabdomyolysis.Postgraduate medical journal, , Volume: 98, Issue:1165, 2022
Gluteal muscle damage and rhabdomyolysis after olanzapine poisoning: a case report.The Journal of international medical research, , Volume: 49, Issue:10, 2021
Serotonin Syndrome Induced by Combined Use of Mirtazapine and Olanzapine Complicated with Rhabdomyolysis, Acute Renal Failure, and Acute Pulmonary Edema-A Case Report.Acta neurologica Taiwanica, , Volume: 24, Issue:4, 2015
Electroconvulsive in a Schizophrenic Patient With Neuroleptic Malignant Syndrome and Rhabdomyolysis.The journal of ECT, , Volume: 31, Issue:3, 2015
Rhabdomyolysis associated with olanzapine treatment in a child with Autism.Pediatric emergency care, , Volume: 26, Issue:1, 2010
[Olanzapine induced rhabdomyolysis and serum creatine kinase increase].La Revue de medecine interne, , Volume: 30, Issue:6, 2009
Hyperthermia and rhabdomyolysis in an adolescent treated with topiramate and olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:1, 2008
Olanzapine overdose is associated with acute muscle toxicity.Human & experimental toxicology, , Volume: 25, Issue:12, 2006
Successful switch to olanzapine after rhabdomyolysis caused by water intoxication and clozapine use.Pharmacopsychiatry, , Volume: 39, Issue:4, 2006
Olanzapine-induced acute rhabdomyolysis-a case report.Pharmacopsychiatry, , Volume: 38, Issue:1, 2005
Adverse drug reactions in Canada.Canadian family physician Medecin de famille canadien, , Volume: 51, 2005
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].Minerva anestesiologica, , Volume: 69, Issue:6, 2003
Olanzapine-induced rhabdomyolysis.The Annals of pharmacotherapy, , Volume: 35, Issue:9, 2001
Olanzapine and rhabdomyolysis.Nursing, , Volume: 30, Issue:9, 2000
Marked elevation of serum creatine kinase associated with olanzapine therapy.The Annals of pharmacotherapy, , Volume: 33, Issue:6, 1999
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder.General hospital psychiatry, , Volume: 31, Issue:4
The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.Current neuropharmacology, , Volume: 22, Issue:1, 2024
Psychosis susceptibility zinc finger protein 804A (ZNF804A) gene polymorphism in schizophrenia patients treated with olanzapine in North Indian population.The International journal of neuroscience, , Volume: 133, Issue:5, 2023
Risk evaluation of diabetic ketoacidosis associated with antipsychotics among patients with schizophrenia in the Japanese adverse event report database.Journal of psychosomatic research, , Volume: 175, 2023
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).Journal of psychopharmacology (Oxford, England), , Volume: 37, Issue:10, 2023
Association of smoking cigarettes, age, and sex with serum concentrations of olanzapine in patients with schizophrenia.Biochemia medica, , Oct-15, Volume: 33, Issue:3, 2023
Prefrontal cortex-specific Dcc deletion induces schizophrenia-related behavioral phenotypes and fail to be rescued by olanzapine treatment.European journal of pharmacology, , Oct-05, Volume: 956, 2023
Neonatal phencyclidine as a model of sex-biased schizophrenia symptomatology in adolescent mice.Psychopharmacology, , Volume: 240, Issue:10, 2023
Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric Trial.Pharmacopsychiatry, , Volume: 56, Issue:5, 2023
Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.BMC medicine, , 07-19, Volume: 21, Issue:1, 2023
Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting.Psychopharmacology, , Volume: 240, Issue:9, 2023
Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial.BMC psychiatry, , 06-29, Volume: 23, Issue:1, 2023
Antipsychotic-Induced Metabolic Syndrome: A Review.Metabolic syndrome and related disorders, , Volume: 21, Issue:6, 2023
Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.The international journal of neuropsychopharmacology, , 07-31, Volume: 26, Issue:7, 2023
Short-term antipsychotic treatment response in early-onset, typical-onset, and late-onset first episode schizophrenia.Schizophrenia research, , Volume: 257, 2023
Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis.Military Medical Research, , 06-02, Volume: 10, Issue:1, 2023
Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation.Psychiatry and clinical neurosciences, , Volume: 77, Issue:9, 2023
[no title available]Ugeskrift for laeger, , May-08, Volume: 185, Issue:19, 2023
Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China.Asian journal of psychiatry, , Volume: 84, 2023
Herbal Therapies for Weight Gain and Metabolic Abnormalities Induced by Atypical Antipsychotics: A Review Article.Current drug discovery technologies, , Volume: 20, Issue:5, 2023
Olanzapine and Weight Loss in Early-Onset Schizophrenia.The primary care companion for CNS disorders, , 04-06, Volume: 25, Issue:2, 2023
Interhemispheric differences of pyramidal cells in the primary motor cortices of schizophrenia patients investigated postmortem.Cerebral cortex (New York, N.Y. : 1991), , 06-20, Volume: 33, Issue:13, 2023
Delayed-Onset olanzapine-induced rhabdomyolysis.BMJ case reports, , Mar-10, Volume: 16, Issue:3, 2023
Analysis of the correlation between clinical efficacy and blood concentration of olanzapine in schizophrenia patients.Medicine, , Mar-10, Volume: 102, Issue:10, 2023
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.Psychiatry research, , Volume: 322, 2023
Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: A systematic review and meta-analysis.Journal of psychiatric research, , Volume: 160, 2023
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.BMJ mental health, , Volume: 26, Issue:1, 2023
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).BMJ open, , 01-31, Volume: 13, Issue:1, 2023
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.Current neuropharmacology, , Volume: 21, Issue:2, 2023
Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse.Schizophrenia bulletin, , 01-03, Volume: 49, Issue:1, 2023
Association Between Sexual Dysfunction and Dose of Atypical Antipsychotics: Essential to Learn the Basics.Journal of clinical pharmacology, , Volume: 63, Issue:1, 2023
Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study.European archives of psychiatry and clinical neuroscience, , Volume: 272, Issue:4, 2022
Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions.CNS spectrums, , Volume: 27, Issue:5, 2022
Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use.Adicciones, , Apr-01, Volume: 34, Issue:2, 2022
Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.CNS spectrums, , Volume: 27, Issue:3, 2022
Practice of prescribing antipsychotics in schizophrenia during 2013-2018 based on data from the National Health Fund.Psychiatria polska, , Aug-31, Volume: 56, Issue:4, 2022
Reviewing the Potential Therapeutic Approaches Targeting the Modulation of Gastrointestinal Microflora in Schizophrenia.International journal of molecular sciences, , Dec-17, Volume: 23, Issue:24, 2022
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis.The American journal of psychiatry, , 12-01, Volume: 179, Issue:12, 2022
Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.Frontiers in public health, , Volume: 10, 2022
Second-generation antipsychotic olanzapine attenuates behavioral and prefrontal cortex synaptic plasticity deficits in a neurodevelopmental schizophrenia-related rat model.Journal of chemical neuroanatomy, , Volume: 125, 2022
Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.Schizophrenia research, , Volume: 248, 2022
Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.Expert review of clinical pharmacology, , Volume: 15, Issue:9, 2022
Driving fitness in clinically stable outpatients with chronic schizophrenia.Comprehensive psychiatry, , Volume: 118, 2022
Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia.Schizophrenia bulletin, , 11-18, Volume: 48, Issue:6, 2022
Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States.Advances in therapy, , Volume: 39, Issue:9, 2022
Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia.Metabolomics : Official journal of the Metabolomic Society, , 07-11, Volume: 18, Issue:7, 2022
Clozapine-Induced Myocarditis in a Young Man with Refractory Schizophrenia: Case Report of a Rare Adverse Event and Review of the Literature.The American journal of case reports, , Jul-06, Volume: 23, 2022
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.Pharmacopsychiatry, , Volume: 55, Issue:5, 2022
Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study.CNS neuroscience & therapeutics, , Volume: 28, Issue:10, 2022
Analysis of color vision and cognitive function in first-episode schizophrenia before and after antipsychotic treatment.Journal of psychiatric research, , Volume: 152, 2022
Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial.Schizophrenia research, , Volume: 246, 2022
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:9, 2022
miR143-3p-Mediated NRG-1-Dependent Mitochondrial Dysfunction Contributes to Olanzapine Resistance in Refractory Schizophrenia.Biological psychiatry, , 09-01, Volume: 92, Issue:5, 2022
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.CNS drugs, , Volume: 36, Issue:6, 2022
Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials.Schizophrenia bulletin, , 06-21, Volume: 48, Issue:4, 2022
Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications.Psychiatry research, , Volume: 313, 2022
Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.Schizophrenia bulletin, , 06-21, Volume: 48, Issue:4, 2022
Clinical Outcomes after Clozapine Discontinuation in Patients with Schizophrenia: A Systematic Review.Pharmacopsychiatry, , Volume: 55, Issue:4, 2022
The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:4, 2022
Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia.Molecules (Basel, Switzerland), , Apr-14, Volume: 27, Issue:8, 2022
Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?Expert review of neurotherapeutics, , Volume: 22, Issue:5, 2022
Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments.BMC psychiatry, , 03-21, Volume: 22, Issue:1, 2022
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.The lancet. Psychiatry, , Volume: 9, Issue:4, 2022
The promise and pitfalls of antipsychotic co-initiation in schizophrenia.The lancet. Psychiatry, , Volume: 9, Issue:4, 2022
Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, , Jun-05, Volume: 274, 2022
Risk of treatment discontinuation and psychiatric hospitalization associated with early dose reduction of antipsychotic treatment in first-episode schizophrenia: A nationwide, health insurance data-based study.Psychiatry and clinical neurosciences, , Volume: 76, Issue:5, 2022
Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study.Acta psychiatrica Scandinavica, , Volume: 145, Issue:5, 2022
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.The Annals of pharmacotherapy, , Volume: 56, Issue:9, 2022
PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients.Psychopharmacology, , Volume: 239, Issue:1, 2022
A longitudinal study of alterations of circulating DJ-1 and miR203a-3p in association to olanzapine medication in a sample of first episode patients with schizophrenia.Journal of psychiatric research, , Volume: 146, 2022
New insight into the CATIE study by constrained confidence partitioning. An innovative technique towards personalized antipsychotic drug therapy in schizophrenia treatment.Schizophrenia research, , Volume: 239, 2022
Antipsychotic medication for women with schizophrenia spectrum disorders.Psychological medicine, , Volume: 52, Issue:4, 2022
Association between the improvement in depressive symptoms and serum BDNF levels in drug-naive first episode patients with schizophrenia: A longitudinal follow-up.Psychoneuroendocrinology, , Volume: 133, 2021
Olanzapine Induces Inflammation and Immune Response via Activating ER Stress in the Rat Prefrontal Cortex.Current medical science, , Volume: 41, Issue:4, 2021
Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.Neuropharmacology, , 10-01, Volume: 197, 2021
What to Do About Missed Doses? A Retrospective Study of Olanzapine in the Elderly.Drug design, development and therapy, , Volume: 15, 2021
Alteration in the mRNA expression profile of the autophagy-related mTOR pathway in schizophrenia patients treated with olanzapine.BMC psychiatry, , 08-04, Volume: 21, Issue:1, 2021
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Olanzapine/Samidorphan: First Approval.Drugs, , Volume: 81, Issue:12, 2021
Comparative Study of Sexual Side Effects in Female Patients With Schizophrenia Receiving Risperidone or Olanzapine.The primary care companion for CNS disorders, , Jul-22, Volume: 23, Issue:4, 2021
Conserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain.Translational psychiatry, , 07-22, Volume: 11, Issue:1, 2021
Second-Generation Antipsychotics and Suicide: A Commentary.The Journal of clinical psychiatry, , 07-20, Volume: 82, Issue:5, 2021
Patterns of antipsychotic prescriptions in patients with schizophrenia in China: A national survey.Asian journal of psychiatry, , Volume: 62, 2021
Rethinking olanzapine therapy for schizophrenia.Asian journal of psychiatry, , Volume: 62, 2021
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.The international journal of neuropsychopharmacology, , 10-23, Volume: 24, Issue:10, 2021
Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia.Journal of psychiatric research, , Volume: 140, 2021
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.Journal of clinical pharmacology, , Volume: 61, Issue:11, 2021
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.Schizophrenia research, , Volume: 232, 2021
Catatonic Symptoms Successfully Treated with Olanzapine in an Adolescent with Schizophrenia.Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:4, 2021
Case report: Olanzapine post-injection delirium/sedation syndrome mimicking brainstem-thrombosis.Acta neurologica Belgica, , Volume: 121, Issue:5, 2021
The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study.Annals of palliative medicine, , Volume: 10, Issue:5, 2021
The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study.Schizophrenia research, , Volume: 231, 2021
A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.Scientific reports, , 04-07, Volume: 11, Issue:1, 2021
A Case of Self-Cannibalism: An Extremely Rare Type of Self-Mutilation With Multiple Risk Factors.The Journal of nervous and mental disease, , 04-01, Volume: 209, Issue:4, 2021
Antipsychotic Treatment Duration in Children and Adolescents: A Register-Based Nationwide Study.Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:6, 2021
Risk and Prevention of Aggression in Patients With Psychotic Disorders.The American journal of psychiatry, , 03-01, Volume: 178, Issue:3, 2021
Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis.Schizophrenia research, , Volume: 229, 2021
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.The American journal of psychiatry, , 05-01, Volume: 178, Issue:5, 2021
Maternal immune activation and repeated maternal separation alter offspring conditioned avoidance response learning and antipsychotic response in male rats.Behavioural brain research, , 04-09, Volume: 403, 2021
Transcriptome analysis of human induced excitatory neurons supports a strong effect of clozapine on cholesterol biosynthesis.Schizophrenia research, , Volume: 228, 2021
Nanostructured Lipid Carriers for Intranasal Administration of Olanzapine in the Management of Schizophrenia.Current molecular pharmacology, , Volume: 14, Issue:3, 2021
Altered mRNA expression levels of autophagy- and apoptosis-related genes in the FOXO pathway in schizophrenia patients treated with olanzapine.Neuroscience letters, , 02-16, Volume: 746, 2021
Pragmatic antipsychotics trial-caution in interpretation - Authors' reply.The lancet. Psychiatry, , Volume: 8, Issue:2, 2021
Pragmatic antipsychotics trial-caution in interpretation.The lancet. Psychiatry, , Volume: 8, Issue:2, 2021
The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol.The American journal of psychiatry, , 03-01, Volume: 178, Issue:3, 2021
1MeTIQ and olanzapine, despite their neurochemical impact, did not ameliorate performance in fear conditioning and social interaction tests in an MK-801 rat model of schizophrenia.Pharmacological reports : PR, , Volume: 73, Issue:2, 2021
The two-cell model of glucose metabolism: a hypothesis of schizophrenia.Molecular psychiatry, , Volume: 26, Issue:6, 2021
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.Drug and alcohol dependence, , 02-01, Volume: 219, 2021
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.Psychiatry research, , Volume: 296, 2021
Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications.Expert review of clinical pharmacology, , Volume: 14, Issue:2, 2021
MicroRNA-195 predicts olanzapine response in drug-free patients with schizophrenia: A prospective cohort study.Journal of psychopharmacology (Oxford, England), , Volume: 35, Issue:1, 2021
Occurrence of metabolic diseases associated with antipsychotic use among Korean patients with schizophrenia.International journal of clinical pharmacology and therapeutics, , Volume: 59, Issue:4, 2021
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.Progress in neuro-psychopharmacology & biological psychiatry, , 06-08, Volume: 108, 2021
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:1, 2021
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.CNS spectrums, , Volume: 26, Issue:4, 2021
Increased regional homogeneity modulated by metacognitive training predicts therapeutic efficacy in patients with schizophrenia.European archives of psychiatry and clinical neuroscience, , Volume: 271, Issue:4, 2021
Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia.Scientific reports, , 11-30, Volume: 11, Issue:1, 2021
New Antipsychotic Medications in the Last Decade.Current psychiatry reports, , 11-29, Volume: 23, Issue:12, 2021
A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials?Translational psychiatry, , 10-06, Volume: 11, Issue:1, 2021
Increased Homotopic Connectivity in the Prefrontal Cortex Modulated by Olanzapine Predicts Therapeutic Efficacy in Patients with Schizophrenia.Neural plasticity, , Volume: 2021, 2021
Therapeutic potential of TAK-071, a muscarinic MNeuroscience letters, , 11-01, Volume: 764, 2021
Men and women respond differently to antipsychotic drugs.Neuropharmacology, , Volume: 163, 2020
Amisulpride - is it as all other medicines or is it different? An update.Psychiatria polska, , Oct-31, Volume: 54, Issue:5, 2020
The side effect profile of Clozapine in real world data of three large mental health hospitals.PloS one, , Volume: 15, Issue:12, 2020
How Much of an Advance Is the Addition of Samidorphan to Olanzapine?The American journal of psychiatry, , 12-01, Volume: 177, Issue:12, 2020
Nitrogen and sulfur co-doped graphene quantum dots/nanocellulose nanohybrid for electrochemical sensing of anti-schizophrenic drug olanzapine in pharmaceuticals and human biological fluids.International journal of biological macromolecules, , Dec-15, Volume: 165, Issue:Pt B, 2020
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.The lancet. Psychiatry, , Volume: 7, Issue:11, 2020
What is the "best intro"-explanatory versus pragmatic antipsychotic drug trials.The lancet. Psychiatry, , Volume: 7, Issue:12, 2020
Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis.Scientific reports, , 10-12, Volume: 10, Issue:1, 2020
Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial.Schizophrenia research, , Volume: 223, 2020
A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.Asian journal of psychiatry, , Volume: 53, 2020
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.Toxicology and applied pharmacology, , 11-01, Volume: 406, 2020
Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis.Journal of psychiatric research, , Volume: 129, 2020
FADS1 modulates metabolic syndrome in schizophrenia patients receiving olanzapine monotherapy.Asian journal of psychiatry, , Volume: 54, 2020
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.The American journal of psychiatry, , 12-01, Volume: 177, Issue:12, 2020
Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis.Journal of analytical toxicology, , Dec-12, Volume: 44, Issue:8, 2020
Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.Expert review of pharmacoeconomics & outcomes research, , Volume: 20, Issue:5, 2020
Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.Psychopharmacology, , Volume: 237, Issue:11, 2020
[A case suspected of dystonia with marked cerebellar atrophy with torsion dystonia of the neck and cerebellar ataxia that developed during pharmacologic schizophrenia treatment].Rinsho shinkeigaku = Clinical neurology, , Aug-07, Volume: 60, Issue:8, 2020
Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia.Scientific reports, , 06-22, Volume: 10, Issue:1, 2020
Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia.Nordic journal of psychiatry, , Volume: 74, Issue:8, 2020
Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients.Journal of proteomics, , 07-30, Volume: 224, 2020
Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.Drug development research, , Volume: 81, Issue:6, 2020
Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics.Clinical and translational science, , Volume: 13, Issue:6, 2020
Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia.Journal of clinical pharmacology, , Volume: 60, Issue:10, 2020
Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine.International journal of psychiatry in clinical practice, , Volume: 24, Issue:3, 2020
Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome.Brain, behavior, and immunity, , Volume: 88, 2020
Remission Is not Associated with DRD2 rs1800497 and DAT1 rs28363170 Genetic Variants in Male Schizophrenic Patients after 6-months Monotherapy with Olanzapine.Psychiatria Danubina, ,Spring, Volume: 32, Issue:1, 2020
Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China.Expert review of pharmacoeconomics & outcomes research, , Volume: 20, Issue:3, 2020
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.The Journal of clinical psychiatry, , 03-24, Volume: 81, Issue:3, 2020
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.The Journal of clinical psychiatry, , 03-17, Volume: 81, Issue:2, 2020
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.The Journal of clinical psychiatry, , 03-10, Volume: 81, Issue:2, 2020
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.The Journal of clinical psychiatry, , 03-03, Volume: 81, Issue:2, 2020
The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine.BMC psychiatry, , 02-18, Volume: 20, Issue:1, 2020
A Retrospective Analysis of Steady-State Olanzapine Concentrations in Chinese Patients Using Therapeutic Drug Monitoring: Effects of Valproate and Other Factors.Therapeutic drug monitoring, , Volume: 42, Issue:4, 2020
The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.Expert opinion on investigational drugs, , Volume: 29, Issue:3, 2020
Prolactin response to antipsychotics: An inpatient study.PloS one, , Volume: 15, Issue:2, 2020
Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.Progress in neuro-psychopharmacology & biological psychiatry, , 06-08, Volume: 100, 2020
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.The international journal of neuropsychopharmacology, , 04-23, Volume: 23, Issue:4, 2020
Memory deterioration based on the tobacco smoke exposure and methylazoxymethanol acetate administration vs. aripiprazole, olanzapine and enrichment environment conditions.Pharmacology, biochemistry, and behavior, , Volume: 189, 2020
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.Clinical therapeutics, , Volume: 42, Issue:1, 2020
[Pharmacotherapy of schizophrenia].Der Nervenarzt, , Volume: 91, Issue:1, 2020
In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine.The British journal of psychiatry : the journal of mental science, , Volume: 217, Issue:3, 2020
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.The American journal of psychiatry, , 04-01, Volume: 177, Issue:4, 2020
Differential benefits of olanzapine on executive function in schizophrenia patients: Preliminary findings.Human psychopharmacology, , Volume: 35, Issue:1, 2020
In vivo 5-HTPsychiatry research. Neuroimaging, , 01-30, Volume: 295, 2020
Relationship between metabolic syndrome and acylated/desacylated ghrelin ratio in patients with schizophrenia under olanzapine medication.Journal of psychopharmacology (Oxford, England), , Volume: 34, Issue:1, 2020
Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats.Behavioural brain research, , 01-27, Volume: 378, 2020
Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole.Psychopharmacology, , Volume: 237, Issue:1, 2020
Open-Label, Randomized, Single-Dose, 2-Period, 2-Sequence Crossover, Comparative Pharmacokinetic Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine Under Fasting and Fed Conditions.Clinical pharmacology in drug development, , Volume: 9, Issue:5, 2020
Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naive, first-episode schizophrenia: A global-brain functional connectivity analysis.Schizophrenia research, , Volume: 215, 2020
Reduction in the prescription of Olanzapine as a first-line treatment for first episode psychosis following the implementation of clinical practice guidelines.Schizophrenia research, , Volume: 215, 2020
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.European archives of psychiatry and clinical neuroscience, , Volume: 270, Issue:1, 2020
Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects.Therapeutic drug monitoring, , Volume: 42, Issue:2, 2020
Quantitative efficacy of three antipsychotic drugs for schizophrenia based on a real-world study in China.Acta pharmacologica Sinica, , Volume: 40, Issue:12, 2019
Examination of heterogeneity in treatment response to antipsychotic medications.Schizophrenia research, , Volume: 211, 2019
Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.Medical decision making : an international journal of the Society for Medical Decision Making, , Volume: 39, Issue:5, 2019
Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.The American journal of managed care, , Volume: 25, Issue:14 Suppl, 2019
Involuntary Facial Twitching in a Patient with Schizophrenia on Treatment with Long Acting Injectable Olanzapine.Psychopharmacology bulletin, , 06-20, Volume: 49, Issue:2, 2019
Enhanced baseline activity in the left ventromedial putamen predicts individual treatment response in drug-naive, first-episode schizophrenia: Results from two independent study samples.EBioMedicine, , Volume: 46, 2019
Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients.Human psychopharmacology, , Volume: 34, Issue:4, 2019
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.Toxicology and applied pharmacology, , 09-01, Volume: 378, 2019
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis.BMJ open, , 06-27, Volume: 9, Issue:6, 2019
Acute followed by continuation right unilateral ultrabrief ECT for 12 months in first episode schizophrenia-a single case report.Asian journal of psychiatry, , Volume: 43, 2019
Prefrontal Coexpression of Schizophrenia Risk Genes Is Associated With Treatment Response in Patients.Biological psychiatry, , 07-01, Volume: 86, Issue:1, 2019
Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life.Psychiatry research, , Volume: 276, 2019
Can typical and atypical antipsychotics show differential effectiveness in treating paranoia and hallucinations in schizophrenia?BMJ case reports, , Mar-31, Volume: 12, Issue:3, 2019
Effects of olanzapine during cognitive and emotional processing in schizophrenia: A review of functional magnetic resonance imaging findings.Human psychopharmacology, , Volume: 34, Issue:3, 2019
Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report.Journal of psychiatric practice, , Volume: 25, Issue:2, 2019
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.The American journal of psychiatry, , 06-01, Volume: 176, Issue:6, 2019
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons.Psychoneuroendocrinology, , Volume: 104, 2019
Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial.Journal of psychiatric research, , Volume: 112, 2019
Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial.Psychopharmacology, , Volume: 236, Issue:6, 2019
Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance.Scientific reports, , 02-07, Volume: 9, Issue:1, 2019
Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.Journal of medical economics, , Volume: 22, Issue:5, 2019
Butyl Methacrylate-Co-Ethylene Glycol Dimethacrylate Monolith for Online in-Tube SPME-UHPLC-MS/MS to Determine Chlopromazine, Clozapine, Quetiapine, Olanzapine, and Their Metabolites in Plasma Samples.Molecules (Basel, Switzerland), , Jan-16, Volume: 24, Issue:2, 2019
Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.Medicine, , Volume: 98, Issue:3, 2019
The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial.Schizophrenia research, , Volume: 206, 2019
[Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year].L'Encephale, , Volume: 45, Issue:3, 2019
Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine.European archives of psychiatry and clinical neuroscience, , Volume: 269, Issue:8, 2019
Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine.Schizophrenia research, , Volume: 206, 2019
Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial.Psychopharmacology, , Volume: 236, Issue:4, 2019
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.Psychopharmacology, , Volume: 236, Issue:2, 2019
Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment.Expert opinion on pharmacotherapy, , Volume: 20, Issue:1, 2019
The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors.International clinical psychopharmacology, , Volume: 34, Issue:1, 2019
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.Acta psychiatrica Scandinavica, , Volume: 139, Issue:1, 2019
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.Early intervention in psychiatry, , Volume: 13, Issue:3, 2019
Algorithm-based pharmacotherapy for first-episode schizophrenia involuntarily hospitalized: A retrospective analysis of real-world practice.Early intervention in psychiatry, , Volume: 13, Issue:1, 2019
[Evidence-based treatment of acute psychotic episode and schizophrenia in children and adolescents].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 119, Issue:12, 2019
Antipsychotic drugs in epilepsy.Neurologia i neurochirurgia polska, , Volume: 53, Issue:6, 2019
An unusual bullous eruption: olanzapine induced pseudoporphyria.BMJ case reports, , Nov-02, Volume: 12, Issue:11, 2019
[Amisulpride, a one-of-a-kind and highly efficacious antipsychotic agent in the treatment of first-episode psychosis].Nederlands tijdschrift voor geneeskunde, , 10-17, Volume: 163, 2019
Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial.Medicine, , Volume: 98, Issue:38, 2019
Risk Factors for Noncompliance with Antipsychotic Medication in Long-Term Treated Chronic Schizophrenia Patients.Psychiatria Danubina, , Volume: 31, Issue:Suppl 3, 2019
An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes.Journal of psychopharmacology (Oxford, England), , Volume: 33, Issue:10, 2019
Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.Schizophrenia research, , Volume: 212, 2019
Insulin resistance induced by olanzapine and other second-generation antipsychotics in Chinese patients with schizophrenia: a comparative review and meta-analysis.European journal of clinical pharmacology, , Volume: 75, Issue:12, 2019
Ketogenic diet and olanzapine treatment alone and in combination reduce a pharmacologically-induced prepulse inhibition deficit in female mice.Schizophrenia research, , Volume: 212, 2019
[Schizophrenia and antipsychotics: Metabolic alterations and therapeutic effectivity].Vertex (Buenos Aires, Argentina), , Volume: 29, Issue:138, 2018
Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.BMC psychiatry, , 12-04, Volume: 18, Issue:1, 2018
Multidisciplinary Management of Adolescent Early-Onset, Treatment-Resistant Schizophrenia Complicated by Avoidant/Restrictive Food Intake Disorder and Catatonia in Acute Exacerbations.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:9, 2018
Switch-associated adverse events: focus on olanzapine.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 26, Issue:6, 2018
Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.Psychopharmacology, , Volume: 235, Issue:12, 2018
Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.Clinical therapeutics, , Volume: 40, Issue:11, 2018
One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia.Psychiatry research, , Volume: 270, 2018
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
Antipsychotic treatments: who is really failing here?The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Antipsychotic treatments: who is really failing here? - Authors' reply.The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis.BMC psychiatry, , 09-05, Volume: 18, Issue:1, 2018
The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia.Acta psychiatrica Scandinavica, , Volume: 138, Issue:5, 2018
Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia.BMJ open, , 08-17, Volume: 8, Issue:8, 2018
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Rapid remission of first-episode schizophrenia with standardised treatment.The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Dorsal hand skin hyperpigmentation following oral olanzapine (Zyprexa) use.Contact dermatitis, , Volume: 79, Issue:4, 2018
Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.Applied health economics and health policy, , Volume: 16, Issue:5, 2018
Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia.BMC psychiatry, , 07-17, Volume: 18, Issue:1, 2018
Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia.PloS one, , Volume: 13, Issue:7, 2018
Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study.Basic & clinical pharmacology & toxicology, , Volume: 123, Issue:6, 2018
Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:7, 2018
High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.BMC psychiatry, , 06-08, Volume: 18, Issue:1, 2018
A Longitudinal Study of Alterations of S100B, sRAGE and Fas Ligand in Association to Olanzapine Medication in a Sample of First Episode Patients with Schizophrenia.CNS & neurological disorders drug targets, , Volume: 17, Issue:5, 2018
Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.Schizophrenia research, , Volume: 201, 2018
Evaluation of antioxidant potencial of novel CaAl and NiAl layered double hydroxides loaded with olanzapine.Life sciences, , Aug-15, Volume: 207, 2018
[The effect of antipsychotic drug on monoamine receptors in peripheral blood mononuclear cells: affinity linked mechanism].Biomeditsinskaia khimiia, , Volume: 64, Issue:2, 2018
Long-acting olanzapine injection during pregnancy and breastfeeding: a case report.Archives of women's mental health, , Volume: 21, Issue:5, 2018
Early prediction of olanzapine-induced weight gain for schizophrenia patients.Psychiatry research, , Volume: 263, 2018
Schizophrenia-like olfactory dysfunction induced by acute and postnatal phencyclidine exposure in rats.Schizophrenia research, , Volume: 199, 2018
Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction?Journal of psychiatric practice, , Volume: 24, Issue:2, 2018
Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5, 2018
Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , 06-08, Volume: 84, Issue:Pt A, 2018
Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study.Psychopharmacology, , Volume: 235, Issue:4, 2018
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 49, 2018
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.The Cochrane database of systematic reviews, , Jan-22, Volume: 1, 2018
Understanding the influence of antipsychotic drugs on global methylation events and its relevance in treatment response.Epigenomics, , Volume: 10, Issue:3, 2018
Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 48, 2018
Frontal activity measured by near-infrared spectroscopy in patients taking different atypical antipsychotic drugs: A cross-sectional study.Psychiatry research. Neuroimaging, , 03-30, Volume: 273, 2018
Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.Schizophrenia bulletin, , 10-17, Volume: 44, Issue:6, 2018
Olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia.Schizophrenia research, , Volume: 197, 2018
A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-02, Volume: 81, 2018
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.The pharmacogenomics journal, , 05-22, Volume: 18, Issue:3, 2018
Effects of four atypical antipsychotics on autonomic nervous system activity in schizophrenia.Schizophrenia research, , Volume: 193, 2018
Treatment effects of olanzapine on homotopic connectivity in drug-free schizophrenia at rest.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 19, Issue:sup3, 2018
Inverse association between negative symptoms and body mass index in chronic schizophrenia.Schizophrenia research, , Volume: 192, 2018
Importance of intervention timing in the effectiveness of antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-02, Volume: 81, 2018
Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 19, Issue:sup3, 2018
An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia.Psychiatric services (Washington, D.C.), , 03-01, Volume: 68, Issue:3, 2017
Cognition and Dopamine DThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:1, 2017
A patient with schizophrenia presenting with post-lobotomy catatonia treated with olanzapine: a case report.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 17, Issue:3, 2017
[Post-injection syndrome and olanzapine pamoate: A severe case report].L'Encephale, , Volume: 43, Issue:4, 2017
[Treatment-resistant schizophrenia: Neutropenia with olanzapine and clozapine, and stabilization with two depot antipsychotics].Vertex (Buenos Aires, Argentina), , Volume: 28, Issue:132, 2017
Occurrence of post-injection delirium/sedation syndrome after application of olanzapine long-acting injection during one year period.Psychiatria Danubina, , Volume: 29, Issue:4, 2017
The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis.BMC psychiatry, , 11-21, Volume: 17, Issue:1, 2017
Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain.JAMA psychiatry, , 11-01, Volume: 74, Issue:11, 2017
Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.Journal of psychiatric research, , Volume: 95, 2017
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.Clinical therapeutics, , Volume: 39, Issue:10, 2017
Roman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expression.Journal of psychopharmacology (Oxford, England), , Volume: 31, Issue:11, 2017
Dilemma of treating schizophrenia during pregnancy: a Case series and a review of literature.BMC psychiatry, , 08-29, Volume: 17, Issue:1, 2017
The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.Acta psychiatrica Scandinavica, , Volume: 136, Issue:5, 2017
Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.Brain and behavior, , Volume: 7, Issue:8, 2017
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.Journal of medical economics, , Volume: 20, Issue:11, 2017
Sleepwalking Is Associated With Coadministration of Olanzapine and Propranolol: A Case Report.Journal of clinical psychopharmacology, , Volume: 37, Issue:5, 2017
Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation.L'Encephale, , Volume: 43, Issue:4, 2017
Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study.Nordic journal of psychiatry, , Volume: 71, Issue:7, 2017
Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.Psychiatria Danubina, , Volume: 29, Issue:2, 2017
Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders.Psychopharmacology bulletin, , 05-15, Volume: 47, Issue:2, 2017
Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.PloS one, , Volume: 12, Issue:6, 2017
Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy.Psychopharmacology, , Volume: 234, Issue:18, 2017
Olanzapine modulates the default-mode network homogeneity in recurrent drug-free schizophrenia at rest.The Australian and New Zealand journal of psychiatry, , Volume: 51, Issue:10, 2017
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.JAMA psychiatry, , 07-01, Volume: 74, Issue:7, 2017
Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study.Psychiatry research, , Volume: 255, 2017
Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.Human psychopharmacology, , Volume: 32, Issue:4, 2017
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.Psychopharmacology, , Volume: 234, Issue:17, 2017
A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy.Nordic journal of psychiatry, , Volume: 71, Issue:6, 2017
Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.Psychoneuroendocrinology, , Volume: 81, 2017
Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia.Psychiatria polska, , Feb-26, Volume: 51, Issue:1, 2017
Pharmacoepigenomic responses of antipsychotic drugs on pharmacogenes are likely to be modulated by miRNAs.Epigenomics, , Volume: 9, Issue:6, 2017
Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Jun-15, Volume: 104, 2017
Recurrent Hyperammonemia Associated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 37, Issue:3, 2017
Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.Journal of clinical psychopharmacology, , Volume: 37, Issue:3, 2017
Dhat syndrome as the prodrome of schizophrenia: Understanding the cultural distress.Asian journal of psychiatry, , Volume: 25, 2017
Leukocyte telomere length in Hispanic schizophrenia patients under treatment with olanzapine.Journal of psychiatric research, , Volume: 90, 2017
Real-world Effectiveness of Antipsychotics for the Treatment of Negative Symptoms in Patients with Schizophrenia with Predominantly Negative Symptoms.Pharmacopsychiatry, , Volume: 50, Issue:2, 2017
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.Internal medicine (Tokyo, Japan), , Volume: 56, Issue:3, 2017
A Case of Olanzapine-Induced Fever.Psychopharmacology bulletin, , 01-26, Volume: 47, Issue:1, 2017
Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.Drugs & aging, , Volume: 34, Issue:3, 2017
A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia.Schizophrenia research, , Volume: 185, 2017
Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.Current medical research and opinion, , Volume: 33, Issue:5, 2017
Genetic and epigenetic regulation on the transcription of GABRB2: Genotype-dependent hydroxymethylation and methylation alterations in schizophrenia.Journal of psychiatric research, , Volume: 88, 2017
Prescription preferences in antipsychotics and attitude towards the pharmaceutical industry in Belgium.Journal of medical ethics, , Volume: 43, Issue:6, 2017
Olanzapine modulation of long- and short-range functional connectivity in the resting brain in a sample of patients with schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 27, Issue:1, 2017
Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine.Schizophrenia research, , Volume: 183, 2017
Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics.Psychiatry research, , Volume: 247, 2017
The atypical antipsychotic olanzapine disturbs depotentiation by modulating mAChRs and impairs reversal learning.Neuropharmacology, , 03-01, Volume: 114, 2017
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.Journal of psychiatric research, , Volume: 85, 2017
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.Psychopharmacology, , Volume: 234, Issue:1, 2017
Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.The Journal of clinical psychiatry, , Volume: 77, Issue:10, 2016
[Cognitive effectiveness of risperidone and olanzapine in first-episode schizophrenia].Zhonghua yi xue za zhi, , Oct-11, Volume: 96, Issue:37, 2016
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.CNS spectrums, , Volume: 21, Issue:6, 2016
First and second generation antipsychotics differentially affect structural and functional properties of rat hippocampal neuron synapses.Neuroscience, , Nov-19, Volume: 337, 2016
Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.Schizophrenia research, , Volume: 176, Issue:2-3, 2016
LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 37, 2016
Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats.Pharmacological reports : PR, , Volume: 68, Issue:5, 2016
Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study.Acta psychiatrica Scandinavica, , Volume: 134, Issue:5, 2016
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Jul-02, Volume: 7, 2016
The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia.Psychiatric services (Washington, D.C.), , 12-01, Volume: 67, Issue:12, 2016
Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.Clinical pharmacology in drug development, , Volume: 5, Issue:6, 2016
Asenapine: A Review in Schizophrenia.CNS drugs, , Volume: 30, Issue:7, 2016
Delirium with anticholinergic symptoms after a combination of paliperidone and olanzapine pamoate in a patient known to smoke cannabis: an unfortunate coincidence.BMJ case reports, , Jun-22, Volume: 2016, 2016
Post authorization safety study comparing quetiapine to risperidone and olanzapine.Human psychopharmacology, , Volume: 31, Issue:4, 2016
Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients.Journal of clinical psychopharmacology, , Volume: 36, Issue:4, 2016
[The effects of blood serum from schizophrenia patients under olanzapine monotherapy on the ultrastructure of astrocytes in human fetal brain organotypic culture].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 116, Issue:5, 2016
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.Journal of medical economics, , Volume: 19, Issue:9, 2016
Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis.European journal of clinical pharmacology, , Volume: 72, Issue:8, 2016
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.Translational psychiatry, , Apr-19, Volume: 6, 2016
A Case Report: Anti-Psychotic Agents Related Ocular Toxicity.Medicine, , Volume: 95, Issue:15, 2016
Risperidone (depot) for schizophrenia.The Cochrane database of systematic reviews, , Apr-14, Volume: 4, 2016
[Treatment-resistant psychosis due to interaction between ritonavir and olanzapine: case report and literature review].Tijdschrift voor psychiatrie, , Volume: 58, Issue:4, 2016
Chlorpromazine versus atypical antipsychotic drugs for schizophrenia.The Cochrane database of systematic reviews, , Apr-05, Volume: 4, 2016
Multiple Long-Acting Injectable Antipsychotics for Treatment-Resistant Schizophrenia: Case Report.Journal of clinical psychopharmacology, , Volume: 36, Issue:3, 2016
Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis.PloS one, , Volume: 11, Issue:3, 2016
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.Journal of clinical psychopharmacology, , Volume: 36, Issue:3, 2016
Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.Clinical trials (London, England), , Volume: 13, Issue:3, 2016
Eosinophilic myocarditis during treatment with olanzapine - report of two possible cases.BMC psychiatry, , Mar-17, Volume: 16, 2016
Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 17, Issue:6, 2016
Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia.Schizophrenia research, , Volume: 177, Issue:1-3, 2016
Antipsychotic Drugs Differentially Affect mRNA Expression of Genes Encoding the Neuregulin 1-Downstream ErbB4-PI3K Pathway.Pharmacology, , Volume: 98, Issue:1-2, 2016
Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia.PloS one, , Volume: 11, Issue:3, 2016
Plasma metabonomics study of first-Episode schizophrenia treated with olanzapine in female patients.Neuroscience letters, , Mar-23, Volume: 617, 2016
The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol.Pharmacological reports : PR, , Volume: 68, Issue:2, 2016
Eosinophilia Associated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.Psychopharmacology, , Volume: 233, Issue:8, 2016
Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.PloS one, , Volume: 11, Issue:2, 2016
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.JAMA psychiatry, , Volume: 73, Issue:3, 2016
Effects of antipsychotics on insight in schizophrenia: results from independent samples of first-episode and acutely relapsed patients.International clinical psychopharmacology, , Volume: 31, Issue:4, 2016
Antipsychotic prescribing and its correlates in New Zealand.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 24, Issue:4, 2016
A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine.Journal of psychiatric practice, , Volume: 22, Issue:1, 2016
Olanzapine Prevents the PCP-induced Reduction in the Neurite Outgrowth of Prefrontal Cortical Neurons via NRG1.Scientific reports, , Jan-19, Volume: 6, 2016
Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.Expert opinion on drug safety, , Volume: 15, Issue:3, 2016
Tyrosine hydroxylase localization in the nucleus accumbens in schizophrenia.Brain structure & function, , Volume: 221, Issue:9, 2016
Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 31, 2016
Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients.Brain, behavior, and immunity, , Volume: 52, 2016
Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?Nordic journal of psychiatry, , Volume: 70, Issue:3, 2016
Association of orexin receptor polymorphisms with antipsychotic-induced weight gain.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 17, Issue:3, 2016
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.Journal of medical economics, , Volume: 19, Issue:2, 2016
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.Acta psychiatrica Scandinavica, , Volume: 133, Issue:1, 2016
Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.Schizophrenia bulletin, , Volume: 42, Issue:1, 2016
Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users.The Psychiatric quarterly, , Volume: 87, Issue:2, 2016
Efficacy of ranitidine in olanzapine-induced weight gain: a dose-response study.Early intervention in psychiatry, , Volume: 10, Issue:6, 2016
[Treatment of Olanzapine-induced Hyperprolactinemia by Shaoyao Gancao Decoction].Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, , Volume: 36, Issue:12, 2016
[Using the cumulative odds Logit model to explore the application of the questionnaire derived from PANSS].Yao xue xue bao = Acta pharmaceutica Sinica, , Volume: 51, Issue:10, 2016
Olanzapine vs. Risperidone in Schizophrenia: A Cross-sectional Comparison of Quality of Life of Caregivers.Indian journal of physiology and pharmacology, , Volume: 60, Issue:2, 2016
Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder.The Journal of clinical psychiatry, , Volume: 77, Issue:12, 2016
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.The Journal of clinical psychiatry, , Volume: 77, Issue:12, 2016
Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.Acta medica Iranica, , Volume: 54, Issue:11, 2016
Dimensions of schizophrenia and their time course of response to a second generation antipsychotic olanzapine-A clinical study.Asian journal of psychiatry, , Volume: 24, 2016
Haloperidol for long-term aggression in psychosis.The Cochrane database of systematic reviews, , 11-27, Volume: 11, 2016
The effects of olanzapine treatment on brain regional glucose metabolism in neuroleptic-naive first-episode schizophrenic patients.Human psychopharmacology, , Volume: 31, Issue:6, 2016
Trends in the Outpatient Utilization of Antipsychotic Drugs in the City of Zagreb in the Ten-Year Period as a Tool to Assess Drug Prescribing Rationality.Psychiatria Danubina, , Volume: 28, Issue:4, 2016
Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.Psychopharmacology, , Volume: 232, Issue:17, 2015
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:11, 2015
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.The journal of mental health policy and economics, , Volume: 18, Issue:4, 2015
Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.The Journal of clinical psychiatry, , Volume: 76, Issue:11, 2015
Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.BMC psychiatry, , Nov-13, Volume: 15, 2015
Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study.Pharmacopsychiatry, , Volume: 48, Issue:7, 2015
Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia.Acta neuropsychiatrica, , Volume: 27, Issue:6, 2015
What evidence is there to show which antipsychotics are more diabetogenic than others?Psychiatria Danubina, , Volume: 27 Suppl 1, 2015
[The perception gap between clinical trials and clinical practice].Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology, , Volume: 28, Issue:1, 2015
Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.Journal of child and adolescent psychopharmacology, , Volume: 25, Issue:7, 2015
[Clozapine and Olanzapine Associated Atrial Fibrillation: A Case Report].Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Fall, Volume: 26, Issue:3, 2015
[Eating disorders in psychiatric patients during treatment with second generation antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:7, 2015
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients.Neuropsychobiology, , Volume: 72, Issue:1, 2015
Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats.Journal of biomedical nanotechnology, , Volume: 11, Issue:8, 2015
Mucoadhesive Amphiphilic Methacrylic Copolymer-Functionalized Poly(ε-caprolactone) Nanocapsules for Nose-to-Brain Delivery of Olanzapine.Journal of biomedical nanotechnology, , Volume: 11, Issue:8, 2015
Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study.BMC psychiatry, , Aug-05, Volume: 15, 2015
A double amino-acid change in the HLA-A peptide-binding groove is associated with response to psychotropic treatment in patients with schizophrenia.Translational psychiatry, , Jul-28, Volume: 5, 2015
Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia.BMC psychiatry, , Jul-25, Volume: 15, 2015
Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.JAMA psychiatry, , Volume: 72, Issue:9, 2015
A2BP1 gene polymorphisms association with olanzapine-induced weight gain.Pharmacological research, , Volume: 99, 2015
Olanzapine-Induced Reversible Pellagroid Skin Lesion.Current drug safety, , Volume: 10, Issue:3, 2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.The Journal of nervous and mental disease, , Volume: 203, Issue:7, 2015
Treating Schizophrenia With 2 Long-Acting Injectable Antipsychotic Drugs: A Case Report.Journal of clinical psychopharmacology, , Volume: 35, Issue:4, 2015
Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.Brain research, , Aug-27, Volume: 1618, 2015
Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia.Schizophrenia research, , Volume: 166, Issue:1-3, 2015
Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:8, 2015
Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.European child & adolescent psychiatry, , Volume: 24, Issue:12, 2015
Olanzapine-induced acute pancreatitis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, , Volume: 26, Issue:3, 2015
Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia.Biological psychiatry, , Dec-01, Volume: 78, Issue:11, 2015
A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.Applied health economics and health policy, , Volume: 13, Issue:5, 2015
Salience network and olanzapine in schizophrenia: implications for treatment in anorexia nervosa.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 60, Issue:3 Suppl 2, 2015
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.BMC psychiatry, , Apr-02, Volume: 15, 2015
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar disorders, , Volume: 17, Issue:5, 2015
Generic Olanzapine Substitution in Patients With Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching.Therapeutic drug monitoring, , Volume: 37, Issue:6, 2015
Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia.Proteomics. Clinical applications, , Volume: 9, Issue:9-10, 2015
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.Journal of the Formosan Medical Association = Taiwan yi zhi, , Volume: 114, Issue:5, 2015
Olanzapine: evaluation of the in vivo cytogenetic effect.Human psychopharmacology, , Volume: 30, Issue:3, 2015
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.Schizophrenia bulletin, , Volume: 41, Issue:3, 2015
Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?Basic & clinical pharmacology & toxicology, , Volume: 117, Issue:3, 2015
Clozapine revisited: Impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 27, Issue:2, 2015
Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis.TheScientificWorldJournal, , Volume: 2015, 2015
Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 25, Issue:3, 2015
Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain.Psychiatry research, , Feb-28, Volume: 225, Issue:3, 2015
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.Schizophrenia research, , Volume: 161, Issue:2-3, 2015
"Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.International journal of psychiatry in clinical practice, , Volume: 19, Issue:2, 2015
Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review.Basic & clinical pharmacology & toxicology, , Volume: 116, Issue:4, 2015
Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin.Progress in neuro-psychopharmacology & biological psychiatry, , Apr-03, Volume: 58, 2015
Olanzapine-induced DNA methylation in the hippocampus and cerebellum in genes mapped to human 22q11 and implicated in schizophrenia.Psychiatric genetics, , Volume: 25, Issue:2, 2015
"Schizophrenia past clozapine": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing.Pharmacopsychiatry, , Volume: 48, Issue:1, 2015
Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.JAMA psychiatry, , Volume: 72, Issue:1, 2015
Anandamide is involved in appetite-related amygdala hyperactivations in schizophrenia patients treated with olanzapine: a functional magnetic resonance imaging study.Journal of clinical psychopharmacology, , Volume: 35, Issue:1, 2015
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.Clinical schizophrenia & related psychoses, , Volume: 8, Issue:4, 2015
Management of depressive symptoms in schizophrenia.Clinical schizophrenia & related psychoses, , Volume: 9, Issue:1, 2015
GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine.The Journal of neuropsychiatry and clinical neurosciences, , Volume: 27, Issue:2, 2015
Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.Journal of psychiatry & neuroscience : JPN, , Volume: 40, Issue:2, 2015
Electroconvulsive in a Schizophrenic Patient With Neuroleptic Malignant Syndrome and Rhabdomyolysis.The journal of ECT, , Volume: 31, Issue:3, 2015
CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.Therapeutic drug monitoring, , Volume: 37, Issue:2, 2015
Lower phosphorylated glycogen synthase kinase-3B levels in platelets of patients with schizophrenia: increment by olanzapine treatment.European archives of psychiatry and clinical neuroscience, , Volume: 265, Issue:2, 2015
[Ultrastructural changes in platelets of schizophrenia patients: a link with serotonin metabolism and therapeutic efficacy].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 114, Issue:11, 2014
[Post-injection syndrome after depot injection of olanzapine].Nederlands tijdschrift voor geneeskunde, , Volume: 159, 2014
Topiramate improves psychiatric symptoms in a patient with Lewy body dementia.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 27, Issue:4, 2014
Schizophrenia gene expression profile reverted to normal levels by antipsychotics.The international journal of neuropsychopharmacology, , Oct-31, Volume: 18, Issue:4, 2014
Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis.Scientific reports, , Dec-09, Volume: 4, 2014
The Chinese First-Episode Schizophrenia Trial: background and study design.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 24, Issue:4, 2014
Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.Schizophrenia research, , Volume: 160, Issue:1-3, 2014
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.BMC psychiatry, , Dec-02, Volume: 14, 2014
SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.Pharmacogenomics, , Volume: 15, Issue:12, 2014
Cannabis and schizophrenia.The Cochrane database of systematic reviews, , Oct-14, Issue:10, 2014
Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.European journal of clinical pharmacology, , Volume: 70, Issue:12, 2014
Use of very-high-dose olanzapine in treatment-resistant schizophrenia.Schizophrenia research, , Volume: 159, Issue:2-3, 2014
Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.Schizophrenia research, , Volume: 159, Issue:2-3, 2014
HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.International journal of psychiatry in clinical practice, , Volume: 18, Issue:4, 2014
Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.The Journal of clinical psychiatry, , Volume: 75, Issue:11, 2014
Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.Schizophrenia research, , Volume: 158, Issue:1-3, 2014
Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.Journal of psychiatric practice, , Volume: 20, Issue:4, 2014
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.The Journal of clinical psychiatry, , Volume: 75, Issue:6, 2014
Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment.International journal of methods in psychiatric research, , Volume: 23, Issue:4, 2014
Safety of antipsychotic drugs: focus on therapeutic and adverse effects.Expert opinion on drug safety, , Volume: 13, Issue:8, 2014
Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 17, Issue:4, 2014
Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study.Pharmacopsychiatry, , Volume: 47, Issue:4-5, 2014
Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 34, Issue:4, 2014
Comparison of health services use associated with ziprasidone and olanzapine among schizophrenia and bipolar disorder patients in the USA.Clinical drug investigation, , Volume: 34, Issue:7, 2014
Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.International clinical psychopharmacology, , Volume: 29, Issue:6, 2014
[Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].Tijdschrift voor psychiatrie, , Volume: 56, Issue:4, 2014
Quality of life in patients with schizophrenia: the impact of socio-economic factors and adverse effects of atypical antipsychotics drugs.The Psychiatric quarterly, , Volume: 85, Issue:3, 2014
Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 34, Issue:4, 2014
Effects of antipsychotic drugs on insight in schizophrenia.Psychiatry research, , Aug-15, Volume: 218, Issue:1-2, 2014
Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia.Psychiatry research, , Aug-15, Volume: 218, Issue:1-2, 2014
Blonanserin improved dystonia induced by risperidone or olanzapine in two patients with schizophrenia.The Journal of neuropsychiatry and clinical neurosciences, , Apr-01, Volume: 26, Issue:2, 2014
A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior.Journal of clinical psychopharmacology, , Volume: 34, Issue:3, 2014
Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain.Human psychopharmacology, , Volume: 29, Issue:4, 2014
A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 24, Issue:7, 2014
Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial.The Journal of clinical psychiatry, , Volume: 75, Issue:3, 2014
[Antipsychotic-induced priapism and management challenges: a case report].L'Encephale, , Volume: 40, Issue:6, 2014
Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.BMJ open, , Mar-25, Volume: 4, Issue:3, 2014
[Ultrastructural changes in platelets and their relationship with serotonin metabolism in patients with schizophrenia treated with olanzapine].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 114, Issue:2, 2014
Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone.Neuro endocrinology letters, , Volume: 35, Issue:1, 2014
Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.Pharmacogenomics, , Volume: 15, Issue:4, 2014
Do prior authorization policies discourage first-line antipsychotic use in patients newly discharged from a hospitalization for schizophrenia in Saskatchewan?Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, , Volume: 21, Issue:1, 2014
Olanzapine ameliorates neuropathological changes and increases IGF-1 expression in frontal cortex of C57BL/6 mice exposed to cuprizone.Psychiatry research, , May-30, Volume: 216, Issue:3, 2014
Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.Journal of psychiatric research, , Volume: 53, 2014
Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.Journal of biopharmaceutical statistics, , Volume: 24, Issue:2, 2014
Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients.Psychopharmacology, , Volume: 231, Issue:18, 2014
Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine.BMJ open, , Mar-04, Volume: 4, Issue:3, 2014
No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients.Pharmacogenetics and genomics, , Volume: 24, Issue:5, 2014
Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment.Schizophrenia research, , Volume: 154, Issue:1-3, 2014
Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia.Expert review of pharmacoeconomics & outcomes research, , Volume: 14, Issue:2, 2014
Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.BMC psychiatry, , Feb-23, Volume: 14, 2014
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.Schizophrenia research, , Volume: 153, Issue:1-3, 2014
The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.Journal of clinical psychopharmacology, , Volume: 34, Issue:2, 2014
Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.The Journal of clinical psychiatry, , Volume: 75, Issue:3, 2014
Quantitative drug benefit-risk assessment: utility of modeling and simulation to optimize drug safety in older adults.The Annals of pharmacotherapy, , Volume: 48, Issue:3, 2014
Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:4, 2014
A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.Human psychopharmacology, , Volume: 29, Issue:1, 2014
A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.BMC psychiatry, , Jan-14, Volume: 14, 2014
Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia.Psychiatry and clinical neurosciences, , Volume: 68, Issue:5, 2014
A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 24, Issue:3, 2014
Fatal water intoxication during olanzapine treatment: a case report.Legal medicine (Tokyo, Japan), , Volume: 16, Issue:2, 2014
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.The Journal of nervous and mental disease, , Volume: 202, Issue:1, 2014
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.Journal of clinical psychopharmacology, , Volume: 34, Issue:1, 2014
Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature.Schizophrenia research, , Volume: 152, Issue:1, 2014
Predictive value of prospective memory for remission in first-episode schizophrenia.Perspectives in psychiatric care, , Volume: 50, Issue:2, 2014
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.CNS spectrums, , Volume: 19, Issue:5, 2014
Effects of olanzapine on the PR and QT intervals in patients with schizophrenia.Schizophrenia research, , Volume: 152, Issue:1, 2014
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.Nordic journal of psychiatry, , Volume: 68, Issue:6, 2014
Predictors of response to second generation antipsychotics in drug naïve patients with schizophrenia: a 1 year follow-up study in Shanghai.Psychiatry research, , Jan-30, Volume: 215, Issue:1, 2014
The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:4, 2014
Elevated viral restriction factor levels in cortical blood vessels in schizophrenia.Biological psychiatry, , Jul-15, Volume: 76, Issue:2, 2014
Olanzapine postinjection delirium/sedation syndrome: an unrecognized diagnosis in the emergency department.The Journal of emergency medicine, , Volume: 47, Issue:1, 2014
A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 39, Issue:6, 2014
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.CNS spectrums, , Volume: 19, Issue:4, 2014
Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics.Early intervention in psychiatry, , Volume: 8, Issue:3, 2014
Depression and impulsivity as pathways to violence: implications for antiaggressive treatment.Schizophrenia bulletin, , Volume: 40, Issue:4, 2014
Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia.British journal of clinical pharmacology, , Volume: 77, Issue:5, 2014
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.Psychological medicine, , Volume: 44, Issue:1, 2014
Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.Clinical schizophrenia & related psychoses, , Volume: 7, Issue:4, 2014
Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data.Schizophrenia research, , Volume: 154, Issue:1-3, 2014
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 15, Issue:3, 2014
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.Journal of medicinal chemistry, , Nov-26, Volume: 57, Issue:22, 2014
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Clozapine and visuospatial processing in treatment-resistant schizophrenia.Cognitive neuropsychiatry, , Volume: 18, Issue:6, 2013
Diabetes resolution following discontinuation of a second-generation antipsychotic.Clinical schizophrenia & related psychoses, , Volume: 6, Issue:4, 2013
Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.Journal of psychopharmacology (Oxford, England), , Volume: 27, Issue:4, 2013
In vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophrenia.PloS one, , Volume: 8, Issue:12, 2013
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.The Journal of clinical psychiatry, , Volume: 74, Issue:11, 2013
Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.Pharmacopsychiatry, , Volume: 46, Issue:3, 2013
Quetiapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Nov-18, Issue:11, 2013
Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.Clinical therapeutics, , Volume: 35, Issue:12, 2013
Atypical antipsychotics for psychosis in adolescents.The Cochrane database of systematic reviews, , Oct-15, Issue:10, 2013
Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia.Journal of clinical psychopharmacology, , Volume: 33, Issue:6, 2013
Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia.Psychiatry research, , Dec-30, Volume: 210, Issue:3, 2013
Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:8, 2013
A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia.Schizophrenia research, , Volume: 150, Issue:2-3, 2013
Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia.BMC psychiatry, , Oct-03, Volume: 13, 2013
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.BMC psychiatry, , Sep-30, Volume: 13, 2013
Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis.Schizophrenia research, , Volume: 150, Issue:2-3, 2013
Drug therapy versus electroconvulsive therapy for refractory schizophrenia: report of a case with 14 years of follow-up.International journal of psychiatry in medicine, , Volume: 45, Issue:3, 2013
Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.BMC psychiatry, , Sep-16, Volume: 13, 2013
Drug safety evaluation of olanzapine pamoate.Expert opinion on drug safety, , Volume: 12, Issue:6, 2013
Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy.Current medical research and opinion, , Volume: 29, Issue:11, 2013
Antipsychotics promote the differentiation of oligodendrocyte progenitor cells by regulating oligodendrocyte lineage transcription factors 1 and 2.Life sciences, , Oct-06, Volume: 93, Issue:12-14, 2013
Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 25, Issue:3, 2013
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.Psychiatry research, , Dec-15, Volume: 210, Issue:2, 2013
Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.Journal of clinical psychopharmacology, , Volume: 33, Issue:5, 2013
Safety of olanzapine use in adolescents.Expert opinion on drug safety, , Volume: 12, Issue:5, 2013
Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.Behavioral and brain functions : BBF, , Jul-19, Volume: 9, 2013
Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy.The journal of ECT, , Volume: 29, Issue:4, 2013
Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.Journal of medical economics, , Volume: 16, Issue:9, 2013
Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment.JAMA psychiatry, , Volume: 70, Issue:9, 2013
The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.Psychopharmacology, , Volume: 230, Issue:1, 2013
Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.Schizophrenia bulletin, , Volume: 39, Issue:5, 2013
[Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 15, Issue:2, 2013
The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation.Cell structure and function, , Volume: 38, Issue:2, 2013
Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.Journal of medical economics, , Volume: 16, Issue:9, 2013
Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.Neuro endocrinology letters, , Volume: 34, Issue:4, 2013
Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine.Pharmacological reports : PR, , Volume: 65, Issue:2, 2013
Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.PloS one, , Volume: 8, Issue:5, 2013
Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-01, Volume: 45, 2013
Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:9, 2013
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.BMC psychiatry, , May-22, Volume: 13, 2013
[Olanzapine].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 71, Issue:4, 2013
[Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, , Volume: 38, Issue:4, 2013
Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Expert opinion on drug metabolism & toxicology, , Volume: 9, Issue:9, 2013
Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain.Journal of clinical psychopharmacology, , Volume: 33, Issue:3, 2013
A latent variable approach in simultaneous modeling of longitudinal and dropout data in schizophrenia trials.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:11, 2013
A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia.Schizophrenia research, , Volume: 147, Issue:1, 2013
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.Pharmacological reports : PR, , Volume: 65, Issue:1, 2013
Endocannabinoid metabolism in the prefrontal cortex in schizophrenia.Schizophrenia research, , Volume: 147, Issue:1, 2013
A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.Psychopharmacology, , Volume: 230, Issue:1, 2013
Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.Human psychopharmacology, , Volume: 28, Issue:3, 2013
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.Journal of psychosocial nursing and mental health services, , Volume: 51, Issue:3, 2013
Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.The Journal of clinical psychiatry, , Volume: 74, Issue:5, 2013
Socio demographic profile and utilization pattern of antipsychotic drugs among schizophrenic inpatients: a cross sectional study from western region of Nepal.BMC psychiatry, , Mar-22, Volume: 13, 2013
Schizophrenia presenting with Koro-like symptoms.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 25, Issue:1, 2013
Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.The Journal of clinical psychiatry, , Volume: 74, Issue:2, 2013
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.Psychopharmacology, , Volume: 227, Issue:4, 2013
Aripiprazole versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Feb-28, Issue:2, 2013
White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.Psychological medicine, , Volume: 43, Issue:11, 2013
No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia.Schizophrenia research, , Volume: 146, Issue:1-3, 2013
A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia.Schizophrenia research, , Volume: 144, Issue:1-3, 2013
Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 64, Issue:1, 2013
Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
Atypical neuroleptic malignant syndrome in H1N1 pneumonia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 25, Issue:1, 2013
Schizophrenia past clozapine: what works?Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
A case of catatonia in a 14-year-old girl with schizophrenia treated with electroconvulsive therapy.Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 41, Issue:1, 2013
Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia.Asian journal of psychiatry, , Volume: 6, Issue:1, 2013
Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses.CNS spectrums, , Volume: 18, Issue:2, 2013
Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia.Contemporary clinical trials, , Volume: 34, Issue:2, 2013
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.Psychopharmacology, , Volume: 226, Issue:3, 2013
Effects of olanzapine on 31P MRS metabolic markers in schizophrenia.Human psychopharmacology, , Volume: 28, Issue:1, 2013
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.The Journal of clinical psychiatry, , Volume: 74, Issue:1, 2013
In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation.International clinical psychopharmacology, , Volume: 28, Issue:2, 2013
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.Psychiatry research, , Apr-30, Volume: 206, Issue:2-3, 2013
Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type.Psychiatry research, , Jan-30, Volume: 211, Issue:1, 2013
Early prediction of clinical and functional outcome in schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:8, 2013
Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:9, 2013
Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia.The Journal of steroid biochemistry and molecular biology, , Volume: 133, 2013
Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.Psychopharmacology, , Volume: 225, Issue:3, 2013
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia.The Psychiatric quarterly, , Volume: 84, Issue:1, 2013
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:3, 2013
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.Molecular psychiatry, , Volume: 18, Issue:5, 2013
Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:2, 2013
Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India.International journal of psychiatry in clinical practice, , Volume: 17, Issue:1, 2013
Effectiveness of sulpiride in adult patients with schizophrenia.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.Current medical research and opinion, , Volume: 29, Issue:3, 2013
Paliperidone-related Pisa syndrome.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
A comparison of the PANSS pentagonal and Van Der Gaag 5-factor models for assessing change over time.Psychiatry research, , May-15, Volume: 207, Issue:1-2, 2013
Efficacy and safety of long acting injectable atypical antipsychotics: a review.Current clinical pharmacology, , Volume: 8, Issue:3, 2013
A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.BMC psychiatry, , Jan-11, Volume: 13, 2013
Inclusion complex of methyl-β-cyclodextrin and olanzapine as potential drug delivery system for schizophrenia.Carbohydrate polymers, , Aug-01, Volume: 89, Issue:4, 2012
[The lipid metabolism abnormality in patients administered with olanzapine].Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, , Volume: 32, Issue:5-6, 2012
Atomoxetine-induced vocal tics in a patient with schizophrenia.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.The Journal of clinical psychiatry, , Volume: 73, Issue:11, 2012
Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.BMC psychiatry, , Dec-04, Volume: 12, 2012
Repeated activation of mania by atypical antipsychotics in a patient.BMJ case reports, , Nov-27, Volume: 2012, 2012
Olanzapine in schizophrenia and affective disorders.Drug safety, , Dec-01, Volume: 35, Issue:12, 2012
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
Lilliputian hallucinations in schizophrenia: a case report.African journal of psychiatry, , Volume: 15, Issue:5, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.The Journal of clinical psychiatry, , Volume: 73, Issue:8, 2012
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Drug safety, , Oct-01, Volume: 35, Issue:10, 2012
Second-generation long-acting injectable antipsychotic agents: an overview.Drug and therapeutics bulletin, , Volume: 50, Issue:9, 2012
One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.Psychiatry research, , Dec-30, Volume: 200, Issue:2-3, 2012
Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis.BMC psychiatry, , Aug-31, Volume: 12, 2012
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:5, 2012
Nitric oxide in patients with schizophrenia: the relationship with the severity of illness and the antipsychotic treatment.Expert opinion on pharmacotherapy, , Volume: 13, Issue:14, 2012
Repetitive transcranial magnetic stimulation to treat early-onset auditory hallucinations.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:9, 2012
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.Behavioural pharmacology, , Volume: 23, Issue:7, 2012
Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey.BMC oral health, , Aug-18, Volume: 12, 2012
Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.Schizophrenia research, , Volume: 141, Issue:1, 2012
The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study.International clinical psychopharmacology, , Volume: 27, Issue:6, 2012
[Metabolic syndrome in patients with schizophrenia and antipsychotic treatment].Medicina clinica, , Nov-17, Volume: 139, Issue:12, 2012
Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.Singapore medical journal, , Volume: 53, Issue:7, 2012
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Clinical schizophrenia & related psychoses, , Volume: 6, Issue:2, 2012
Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.The Journal of nervous and mental disease, , Volume: 200, Issue:7, 2012
A review of olanzapine pamoate.Expert opinion on pharmacotherapy, , Volume: 13, Issue:11, 2012
Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.Journal of clinical psychopharmacology, , Volume: 32, Issue:4, 2012
Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment.Translational psychiatry, , Jun-19, Volume: 2, 2012
UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.Clinical pharmacology and therapeutics, , Volume: 92, Issue:2, 2012
Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.Psychiatry research, , Dec-30, Volume: 200, Issue:2-3, 2012
Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells.Prostaglandins, leukotrienes, and essential fatty acids, , Volume: 87, Issue:1, 2012
Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.BMC psychiatry, , May-30, Volume: 12, 2012
Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.Psychiatry and clinical neurosciences, , Volume: 66, Issue:4, 2012
State and trait markers of emotionally charged visual event-related potentials (P300) in drug-naïve schizophrenia.Psychiatry and clinical neurosciences, , Volume: 66, Issue:4, 2012
Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Subjective and biological weight-related parameters in adolescents and young adults with schizophrenia spectrum disorder under clozapine or olanzapine treatment.Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 40, Issue:3, 2012
Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial.European archives of psychiatry and clinical neuroscience, , Volume: 262, Issue:7, 2012
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:5, 2012
The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:5, 2012
Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:9, 2012
Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.The Journal of pharmacology and experimental therapeutics, , Volume: 342, Issue:1, 2012
Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.Acta psychiatrica Scandinavica, , Volume: 126, Issue:1, 2012
Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.Psychiatry research, , Oct-30, Volume: 199, Issue:3, 2012
Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study.Human psychopharmacology, , Volume: 27, Issue:3, 2012
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 22, Issue:10, 2012
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.Journal of medical economics, , Volume: 15, Issue:5, 2012
Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.Clinical schizophrenia & related psychoses, , Volume: 6, Issue:1, 2012
Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version).East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 22, Issue:1, 2012
A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.Psychiatry research, , Jul-30, Volume: 198, Issue:2, 2012
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.International clinical psychopharmacology, , Volume: 27, Issue:4, 2012
A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.Journal of clinical psychopharmacology, , Volume: 32, Issue:2, 2012
Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility.Schizophrenia research, , Volume: 137, Issue:1-3, 2012
Development and validation of a GC-EI-MS method with reduced adsorption loss for the quantification of olanzapine in human plasma.Analytical and bioanalytical chemistry, , Volume: 403, Issue:7, 2012
Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.Clinical drug investigation, , Apr-01, Volume: 32, Issue:4, 2012
Antipsychotic drug treatment for elderly people with late-onset schizophrenia.The Cochrane database of systematic reviews, , Feb-15, Issue:2, 2012
Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 15, Issue:1, 2012
Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine.Schizophrenia research, , Volume: 135, Issue:1-3, 2012
Olanzapine-induced eccrine squamous syringometaplasia.The American Journal of dermatopathology, , Volume: 34, Issue:4, 2012
Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics.Psychopharmacology, , Volume: 222, Issue:1, 2012
Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.Current medical research and opinion, , Volume: 28, Issue:3, 2012
Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study.Progress in neuro-psychopharmacology & biological psychiatry, , Apr-27, Volume: 37, Issue:1, 2012
The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.The Journal of clinical psychiatry, , Volume: 73, Issue:4, 2012
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 18, Issue:1, 2012
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study.Pharmacopsychiatry, , Volume: 45, Issue:3, 2012
Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.The Journal of clinical psychiatry, , Volume: 73, Issue:1, 2012
Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 36, Issue:2, 2012
Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.Pharmacopsychiatry, , Volume: 45, Issue:2, 2012
Addressing non-adherence to antipsychotic medication: a harm-reduction approach.Journal of psychiatric and mental health nursing, , Volume: 19, Issue:1, 2012
Hypothermia associated with antipsychotic drug use: a clinical case series and review of current literature.Journal of clinical pharmacology, , Volume: 52, Issue:7, 2012
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.The Journal of clinical psychiatry, , Volume: 73, Issue:3, 2012
Cortical opioid markers in schizophrenia and across postnatal development.Cerebral cortex (New York, N.Y. : 1991), , Volume: 22, Issue:5, 2012
Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:1, 2012
Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine.The pharmacogenomics journal, , Volume: 12, Issue:6, 2012
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.The Journal of clinical psychiatry, , Volume: 73, Issue:2, 2012
Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 22, Issue:18, 2012
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:6, 2012
Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 22, Issue:1, 2012
Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 13, Issue:1, 2012
A case of severe hypothermia following single-dose administration of olanzapine: a case report.Journal of clinical pharmacology, , Volume: 52, Issue:2, 2012
Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.Comprehensive psychiatry, , Volume: 53, Issue:1, 2012
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.Schizophrenia bulletin, , Volume: 38, Issue:4, 2012
Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.The pharmacogenomics journal, , Volume: 12, Issue:3, 2012
Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia.Schizophrenia bulletin, , Volume: 38, Issue:3, 2012
Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.The pharmacogenomics journal, , Volume: 12, Issue:1, 2012
Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.Schizophrenia bulletin, , Volume: 38, Issue:3, 2012
An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Human psychopharmacology, , Volume: 26, Issue:1, 2011
Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.Neuro endocrinology letters, , Volume: 32, Issue:5, 2011
Cost-effectiveness analysis of olanzapine and risperidone in Norway.The journal of mental health policy and economics, , Volume: 14, Issue:3, 2011
[Sexual disturbances during the treatment with neuroleptics in patients with schizophrenia and schizophrenia spectrum disorders].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 111, Issue:9 Pt 2, 2011
The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 56, Issue:10, 2011
Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome.The Annals of pharmacotherapy, , Volume: 45, Issue:11, 2011
TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.Neuroscience letters, , Oct-31, Volume: 504, Issue:3, 2011
Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.Neuromolecular medicine, , Volume: 13, Issue:4, 2011
Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.BMC psychiatry, , Sep-23, Volume: 11, 2011
Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.European child & adolescent psychiatry, , Volume: 20, Issue:11-12, 2011
[Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].La Clinica terapeutica, , Volume: 162, Issue:4, 2011
Impact of olanzapine on cognitive functions in patients with schizophrenia during an observation period of six months.Psychiatria Danubina, , Volume: 23 Suppl 1, 2011
Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress.Neuroscience research, , Volume: 71, Issue:4, 2011
Switching antipsychotic medications: not enough, too often, or just right?The American journal of psychiatry, , Volume: 168, Issue:9, 2011
Ibogaine-associated psychosis in schizophrenia: a case report.Journal of clinical psychopharmacology, , Volume: 31, Issue:5, 2011
Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study.The British journal of psychiatry : the journal of mental science, , Volume: 199, Issue:3, 2011
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.Neuro endocrinology letters, , Volume: 32, Issue:4, 2011
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 13, Issue:3, 2011
The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 72, Issue:7, 2011
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).The Journal of clinical psychiatry, , Volume: 72, Issue:7, 2011
Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.Human psychopharmacology, , Volume: 26, Issue:6, 2011
Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.Human psychopharmacology, , Volume: 26, Issue:6, 2011
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Clozapine-induced weight loss?Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 23, Issue:3, 2011
Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.Psychiatry research, , Sep-30, Volume: 189, Issue:2, 2011
Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC).Pharmacoepidemiology and drug safety, , Volume: 20, Issue:11, 2011
Raynaud’s phenomenon in a patient with schizophrenia and obsessive-compulsive disorder: a case report.Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Summer, Volume: 22, Issue:2, 2011
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden.Nordic journal of psychiatry, , Volume: 65, Issue:6, 2011
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).The American journal of psychiatry, , Volume: 168, Issue:9, 2011
Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.Pharmacogenetics and genomics, , Volume: 21, Issue:9, 2011
Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol.Pharmacopsychiatry, , Volume: 44, Issue:5, 2011
Changes in the metabolic parameters and QTc interval after switching from olanzapine to aripiprazole in Japanese patients with stable schizophrenia.Journal of clinical psychopharmacology, , Volume: 31, Issue:4, 2011
Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.Pharmacopsychiatry, , Volume: 44, Issue:4, 2011
Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone.Journal of psychiatric research, , Volume: 45, Issue:10, 2011
Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.The American journal of psychiatry, , Volume: 168, Issue:9, 2011
Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.Archives of physiology and biochemistry, , Volume: 117, Issue:4, 2011
Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?Clinical pharmacokinetics, , Volume: 50, Issue:7, 2011
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.Psychiatry research, , Aug-15, Volume: 188, Issue:3, 2011
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.Acta psychiatrica Scandinavica, , Volume: 124, Issue:3, 2011
Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.BMC psychiatry, , May-17, Volume: 11, 2011
Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.Schizophrenia research, , Volume: 131, Issue:1-3, 2011
The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia.Contemporary clinical trials, , Volume: 32, Issue:5, 2011
Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.Schizophrenia research, , Volume: 130, Issue:1-3, 2011
Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling.Psychopharmacology, , Volume: 218, Issue:2, 2011
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.The Journal of clinical psychiatry, , Volume: 72, Issue:4, 2011
Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response.Pharmacogenomics, , Volume: 12, Issue:4, 2011
Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.Molecular psychiatry, , Volume: 16, Issue:6, 2011
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.Progress in neuro-psychopharmacology & biological psychiatry, , Jul-01, Volume: 35, Issue:5, 2011
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.Journal of clinical psychopharmacology, , Volume: 31, Issue:3, 2011
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clinical drug investigation, , Volume: 31, Issue:7, 2011
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.Psychological medicine, , Volume: 41, Issue:11, 2011
A potential case of peduncular hallucinosis treated successfully with olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.The Journal of clinical psychiatry, , Volume: 72, Issue:11, 2011
Antipsychotic treatment--side-effect and/or metabolic syndrome.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Treatment strategy in schizophrenia combined with eating disorder.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.Diabetes, obesity & metabolism, , Volume: 13, Issue:8, 2011
EEG alterations during treatment with olanzapine.European archives of psychiatry and clinical neuroscience, , Volume: 261, Issue:7, 2011
Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.Schizophrenia research, , Volume: 128, Issue:1-3, 2011
Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.BMC psychiatry, , Feb-15, Volume: 11, 2011
Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.The Journal of clinical psychiatry, , Volume: 72, Issue:6, 2011
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.British journal of clinical pharmacology, , Volume: 71, Issue:3, 2011
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.Current medical research and opinion, , Volume: 27, Issue:4, 2011
Olanzapine pamoate for the treatment of schizophrenia.Expert opinion on pharmacotherapy, , Volume: 12, Issue:4, 2011
Risperidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Jan-19, Issue:1, 2011
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.The Journal of clinical psychiatry, , Volume: 72, Issue:10, 2011
High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.Journal of clinical psychopharmacology, , Volume: 31, Issue:1, 2011
DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.Proceedings of the National Academy of Sciences of the United States of America, , Jan-18, Volume: 108, Issue:3, 2011
Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.Schizophrenia research, , Volume: 125, Issue:2-3, 2011
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3. Rapid tranquilisation in acute psychotic agitation.Emergency medicine journal : EMJ, , Volume: 28, Issue:1, 2011
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 35, Issue:2, 2011
Phospholipase A₂ activity in first episode schizophrenia: associations with symptom severity and outcome at week 12.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 12, Issue:8, 2011
Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.Current medical research and opinion, , Volume: 27, Issue:1, 2011
Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials.Schizophrenia research, , Volume: 126, Issue:1-3, 2011
Neutropenia associated with quetiapine, olanzapine, and aripiprazole.The Australian and New Zealand journal of psychiatry, , Volume: 45, Issue:1, 2011
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.Psychopharmacology, , Volume: 214, Issue:3, 2011
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.Schizophrenia research, , Volume: 125, Issue:2-3, 2011
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-15, Volume: 35, Issue:1, 2011
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).The American journal of psychiatry, , Volume: 168, Issue:2, 2011
The different trajectories of antipsychotic response: antipsychotics versus placebo.Psychological medicine, , Volume: 41, Issue:7, 2011
Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching.International clinical psychopharmacology, , Volume: 26, Issue:1, 2011
The heterogeneity of antipsychotic response in the treatment of schizophrenia.Psychological medicine, , Volume: 41, Issue:6, 2011
"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial.The Journal of clinical psychiatry, , Volume: 72, Issue:8, 2011
Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.Psychopharmacology, , Volume: 213, Issue:1, 2011
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.The Journal of clinical psychiatry, , Volume: 72, Issue:3, 2011
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.The Journal of clinical psychiatry, , Volume: 72, Issue:3, 2011
Anterior internal capsule volumes increase in patients with schizophrenia switched from typical antipsychotics to olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:5, 2011
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.American journal of therapeutics, , Volume: 18, Issue:4, 2011
Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia.The pharmacogenomics journal, , Volume: 11, Issue:1, 2011
Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.Molecular psychiatry, , Volume: 16, Issue:1, 2011
Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.Psychopharmacology bulletin, , Volume: 43, Issue:4, 2010
Adolescent with treatment-refractory schizophrenia and clozapine-induced cardiomyopathy managed with high-dose olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 20, Issue:6, 2010
Management of a patient with schizophrenia and underlying pituitary macroadenoma.Annals of the Academy of Medicine, Singapore, , Volume: 39, Issue:11, 2010
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.The Cochrane database of systematic reviews, , Dec-08, Issue:12, 2010
Switching and combining antipsychotics.CNS spectrums, , Volume: 15, Issue:4 Suppl 6, 2010
Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?The Journal of clinical psychiatry, , Volume: 71, Issue:11, 2010
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controllJournal of clinical psychopharmacology, , Volume: 30, Issue:6, 2010
Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.Drugs, , Dec-03, Volume: 70, Issue:17, 2010
Clozapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Nov-10, Issue:11, 2010
Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.Psychopharmacology bulletin, , Volume: 43, Issue:2, 2010
Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.BMC psychiatry, , Nov-03, Volume: 10, 2010
A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients.Experimental and clinical psychopharmacology, , Volume: 18, Issue:5, 2010
Lipid peroxidation in patients with schizophrenia.Psychiatry and clinical neurosciences, , Volume: 64, Issue:5, 2010
Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia.The American journal of psychiatry, , Volume: 167, Issue:12, 2010
The potential role of appetite in predicting weight changes during treatment with olanzapine.BMC psychiatry, , Sep-14, Volume: 10, 2010
Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 20, Issue:12, 2010
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.The Journal of clinical psychiatry, , Volume: 71, Issue:11, 2010
Long-acting injectable olanzaoine. Inadequate assessment and a risk of overdose.Prescrire international, , Volume: 19, Issue:107, 2010
[Epidural labor analgesia for a primipara with schizophrenia].Masui. The Japanese journal of anesthesiology, , Volume: 59, Issue:8, 2010
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.Schizophrenia research, , Volume: 123, Issue:2-3, 2010
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia.Pharmacogenetics and genomics, , Volume: 20, Issue:9, 2010
Olanzapine-associated pica in a schizophrenia patient.Psychiatry and clinical neurosciences, , Volume: 64, Issue:4, 2010
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:7, 2010
What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?Journal of clinical psychopharmacology, , Volume: 30, Issue:4, 2010
Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra.Nordic journal of psychiatry, , Volume: 64, Issue:4, 2010
Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics.Neuroscience letters, , Aug-02, Volume: 479, Issue:3, 2010
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.BMC psychiatry, , Jun-10, Volume: 10, 2010
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.BMC psychiatry, , Jun-10, Volume: 10, 2010
Cochrane for clinicians. Aripiprazole vs. other atypical antipsychotics for schizophrenia.American family physician, , Jun-01, Volume: 81, Issue:11, 2010
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:9, 2010
Higher motor activity in schizophrenia patients treated with olanzapine versus risperidone.Journal of clinical psychopharmacology, , Volume: 30, Issue:2, 2010
[Effect of side-effects and complications caused by atypical neuroleptics on the effectiveness of therapy in patients with schizophrenia].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 110, Issue:3, 2010
Impact of smoking cessation on psychiatric inpatients treated with clozapine or olanzapine.Journal of psychiatric practice, , Volume: 16, Issue:2, 2010
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 49, Issue:6, 2010
Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
Tardive dystonia induced by switch of atypical antipsychotics.Pharmacopsychiatry, , Volume: 43, Issue:5, 2010
Olanzapine in male and female adolescent patients with schizophrenia and related disorders: minor sex differences in outcomes.Journal of clinical psychopharmacology, , Volume: 30, Issue:3, 2010
Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia.Psychiatry research, , Aug-30, Volume: 179, Issue:1, 2010
Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
Olanzapine: a review of rapid and long-acting parenteral formulations.Drugs of today (Barcelona, Spain : 1998), , Volume: 46, Issue:3, 2010
Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
Acute respiratory distress due to antipsychotic drugs.Pharmacopsychiatry, , Volume: 43, Issue:3, 2010
The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs.Pharmacopsychiatry, , Volume: 43, Issue:3, 2010
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-16, Volume: 34, Issue:6, 2010
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.Pharmacogenetics and genomics, , Volume: 20, Issue:6, 2010
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.Human psychopharmacology, , Volume: 25, Issue:3, 2010
Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 55, Issue:3, 2010
Olanzapine: in adolescents with schizophrenia or bipolar I disorder.CNS drugs, , Volume: 24, Issue:5, 2010
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.Paediatric drugs, , Volume: 12, Issue:3, 2010
Olanzapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Mar-17, Issue:3, 2010
Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:2 Pt 2, 2010
Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:2 Pt 2, 2010
Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics.The journal of sexual medicine, , Volume: 7, Issue:10, 2010
Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 118, Issue:1-3, 2010
Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.Pharmacopsychiatry, , Volume: 43, Issue:4, 2010
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 20, Issue:5, 2010
Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia.Psychopharmacology, , Volume: 209, Issue:2, 2010
Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Apr-16, Volume: 34, Issue:3, 2010
Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors.The international journal of neuropsychopharmacology, , Volume: 13, Issue:10, 2010
Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.The Journal of clinical psychiatry, , Volume: 71, Issue:4, 2010
Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.European journal of clinical pharmacology, , Volume: 66, Issue:5, 2010
Quetiapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Jan-20, Issue:1, 2010
Amisulpride versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Jan-20, Issue:1, 2010
The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia.International clinical psychopharmacology, , Volume: 25, Issue:2, 2010
Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.Journal of clinical pharmacology, , Volume: 50, Issue:3, 2010
[Antipsychotic agents and stimulants: a judicious combination?].Tijdschrift voor psychiatrie, , Volume: 52, Issue:1, 2010
Antibodies to measles in individuals with recent onset psychosis.Schizophrenia research, , Volume: 119, Issue:1-3, 2010
Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 44, Issue:3, 2010
Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.The American journal of psychiatry, , Volume: 167, Issue:2, 2010
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:4, 2010
Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration.International journal of geriatric psychiatry, , Volume: 25, Issue:4, 2010
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:2, 2010
Extrastriatal dopamine D(2) receptor occupancy in olanzapine-treated patients with schizophrenia.European archives of psychiatry and clinical neuroscience, , Volume: 260, Issue:4, 2010
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.The pharmacogenomics journal, , Volume: 10, Issue:1, 2010
Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:1, 2009
Hunger and negative alliesthesia to aspartame and sucrose in patients treated with antipsychotic drugs and controls.Eating and weight disorders : EWD, , Volume: 14, Issue:4, 2009
Expression changes of serotonin receptor gene subtype 5HT3a in peripheral blood mononuclear cells from schizophrenic patients treated with haloperidol and Olanzapin.Iranian journal of allergy, asthma, and immunology, , Volume: 8, Issue:3, 2009
Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.The Israel journal of psychiatry and related sciences, , Volume: 46, Issue:3, 2009
Severe psychotic disorder and agranulocytosis--a therapeutic dilemma.Pharmacopsychiatry, , Volume: 42, Issue:6, 2009
Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12, Issue:4, 2009
Ziprasidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Oct-07, Issue:4, 2009
Aripiprazole versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Oct-07, Issue:4, 2009
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
Possible olanzapine-induced hepatotoxicity in a young Chinese patient.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 15, Issue:5, 2009
Clinical trials design lessons from the CATIE study.The American journal of psychiatry, , Volume: 166, Issue:11, 2009
[Effect of antipsychotic drugs on life quality of schizophrenic patients: one year follow-up study].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, , Volume: 34, Issue:9, 2009
Late-onset cholestatic hepatitis induced by olanzapine in a patient with schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Nov-13, Volume: 33, Issue:8, 2009
[Influence of serotonin (5-HT) 2A-receptor and transporter (5HTT) gene polymorphism upon the effect of olanzapine].Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, , Volume: 29, Issue:4, 2009
[Comment on: "Lack of insight in schizophrenia: a review. Part I: theoretical concept, clinical aspects and Amador's model" of S. Raffard, S. Bayard, D., Capdevielle, F. Garcia, J.-P. Boulenger et M.-C. Gely-Nargeot].L'Encephale, , Volume: 35, Issue:4, 2009
Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
[Complex therapy of schizophrenia].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 11, Issue:1, 2009
Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse.JAMA, , Aug-26, Volume: 302, Issue:8, 2009
Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 34, Issue:13, 2009
Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.Revista de saude publica, , Volume: 43 Suppl 1, 2009
Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.Journal of psychiatric practice, , Volume: 15, Issue:4, 2009
The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia.DNA and cell biology, , Volume: 28, Issue:10, 2009
Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.BMC psychiatry, , Jul-14, Volume: 9, 2009
Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.Current medical research and opinion, , Volume: 25, Issue:9, 2009
Aripiprazole for the management of olanzapine-induced weight gain.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
Validating novel targets for pharmacological interventions in schizophrenia.The American journal of psychiatry, , Volume: 166, Issue:7, 2009
Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.International journal of clinical practice, , Volume: 63, Issue:8, 2009
Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant schizophrenia.Psychiatria Danubina, , Volume: 21, Issue:2, 2009
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.International clinical psychopharmacology, , Volume: 24, Issue:5, 2009
Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia.Psychopharmacology, , Volume: 206, Issue:1, 2009
Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 19, Issue:8, 2009
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.The Journal of clinical psychiatry, , Volume: 70, Issue:7, 2009
Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.Psychiatry and clinical neurosciences, , Volume: 63, Issue:4, 2009
Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres.International journal of clinical practice, , Volume: 63, Issue:6, 2009
The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.Archives of general psychiatry, , Volume: 66, Issue:6, 2009
Targeting cognition in schizophrenia research: from etiology to treatment.The American journal of psychiatry, , Volume: 166, Issue:6, 2009
The promotion of olanzapine in primary care: an examination of internal industry documents.Social science & medicine (1982), , Volume: 69, Issue:1, 2009
Hypoglycaemia induced by second generation antipsychotic agents in schizophrenic non-diabetic patients.BMJ (Clinical research ed.), , May-26, Volume: 338, 2009
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.Journal of clinical psychopharmacology, , Volume: 29, Issue:3, 2009
Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia.Psychiatry research, , Jul-15, Volume: 173, Issue:1, 2009
Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis.The British journal of psychiatry : the journal of mental science, , Volume: 194, Issue:5, 2009
Thrombosis and psychosis--possible association with the antiphospholipid syndrome and anticardiolipin antibodies.Irish medical journal, , Volume: 102, Issue:2, 2009
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.The Journal of clinical psychiatry, , Volume: 70, Issue:4, 2009
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.BMC psychiatry, , Mar-31, Volume: 9, 2009
Olanzapine pamoate - blockbuster or damp squib?International journal of clinical practice, , Volume: 63, Issue:4, 2009
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.BMC psychiatry, , Mar-28, Volume: 9, 2009
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 70, Issue:4, 2009
Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund.Pharmacopsychiatry, , Volume: 42, Issue:2, 2009
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.Human psychopharmacology, , Volume: 24, Issue:3, 2009
Psychosis secondary to traumatic brain injury.Brain injury, , Volume: 23, Issue:4, 2009
Weight loss during therapy with olanzapine orally disintegrating tablets: two case reports.Psychiatria Danubina, , Volume: 21, Issue:1, 2009
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.Schizophrenia research, , Volume: 110, Issue:1-3, 2009
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.Journal of psychiatric research, , Volume: 43, Issue:11, 2009
[Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL].L'Encephale, , Volume: 35, Issue:1, 2009
Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients.Neuropsychobiology, , Volume: 59, Issue:1, 2009
The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials.The Journal of clinical psychiatry, , Volume: 70, Issue:2, 2009
Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population.Current medical research and opinion, , Volume: 25, Issue:3, 2009
Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 24, Issue:5, 2009
[Acquired stuttering in a psychotic patient].Tijdschrift voor psychiatrie, , Volume: 51, Issue:1, 2009
Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.Behavioural pharmacology, , Volume: 20, Issue:1, 2009
Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.PharmacoEconomics, , Volume: 27, Issue:1, 2009
[The European Schizophrenia Outpatient Health Outcomes Study: observational study over 36 months of the French cohort of schizophrenic outpatients treated with antipsychotics].Revue d'epidemiologie et de sante publique, , Volume: 57, Issue:1, 2009
The risks and benefits of switching antipsychotics: a case study approach.Perspectives in psychiatric care, , Volume: 45, Issue:1, 2009
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.Pharmacopsychiatry, , Volume: 42, Issue:1, 2009
Olanzapine-induced "restless arms syndrome".Journal of clinical psychopharmacology, , Volume: 29, Issue:1, 2009
Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.Journal of clinical psychopharmacology, , Volume: 29, Issue:1, 2009
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:1, 2009
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 24, Issue:3, 2009
Four cases of venous thromboembolism associated with olanzapine.Psychiatry and clinical neurosciences, , Volume: 63, Issue:1, 2009
Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 48, Issue:1, 2009
Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 34, Issue:5, 2009
Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Results of phase 3 of the CATIE schizophrenia trial.Schizophrenia research, , Volume: 107, Issue:1, 2009
Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 70, Issue:1, 2009
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.Schizophrenia research, , Volume: 107, Issue:1, 2009
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.Biological psychiatry, , Mar-15, Volume: 65, Issue:6, 2009
Time-lapse mapping of cortical changes in schizophrenia with different treatments.Cerebral cortex (New York, N.Y. : 1991), , Volume: 19, Issue:5, 2009
Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.International journal of clinical practice, , Volume: 63, Issue:1, 2009
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.Journal of psychiatric research, , Volume: 43, Issue:5, 2009
Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Impact of patient selection criteria and treatment history on comparisons of alternative therapies: a case study of atypical antipsychotics.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12, Issue:4, 2009
Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.Journal of psychiatric research, , Volume: 43, Issue:3, 2009
Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:4, 2009
Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:6, 2009
Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients.Journal of psychiatric research, , Volume: 42, Issue:2, 2008
D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:2, 2008
Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia.Molecular psychiatry, , Volume: 13, Issue:2, 2008
Emerging from schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:3, 2008
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:3, 2008
Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.Biological psychiatry, , Mar-01, Volume: 63, Issue:5, 2008
Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.The pharmacogenomics journal, , Volume: 8, Issue:3, 2008
Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-01, Volume: 32, Issue:1, 2008
Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.Schizophrenia research, , Volume: 99, Issue:1-3, 2008
Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: a case report.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-01, Volume: 32, Issue:1, 2008
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:3, 2008
A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.Schizophrenia research, , Volume: 98, Issue:1-3, 2008
Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients.European journal of clinical pharmacology, , Volume: 64, Issue:1, 2008
Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 23, Issue:1, 2008
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Jun-05, Volume: 147B, Issue:4, 2008
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.Journal of psychiatric research, , Volume: 42, Issue:11, 2008
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.Psychopharmacology, , Volume: 196, Issue:4, 2008
Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:6, 2008
Evaluating dose response from flexible dose clinical trials.BMC psychiatry, , Jan-07, Volume: 8, 2008
Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.Schizophrenia bulletin, , Volume: 34, Issue:2, 2008
Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia.Biological psychiatry, , Apr-15, Volume: 63, Issue:8, 2008
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.Schizophrenia research, , Volume: 100, Issue:1-3, 2008
Sex, race, and smoking impact olanzapine exposure.Journal of clinical pharmacology, , Volume: 48, Issue:2, 2008
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.Journal of clinical psychopharmacology, , Volume: 28, Issue:1, 2008
Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.Journal of clinical psychopharmacology, , Volume: 28, Issue:1, 2008
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients.Journal of clinical pharmacy and therapeutics, , Volume: 33, Issue:1, 2008
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.Human psychopharmacology, , Volume: 23, Issue:3, 2008
The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).Therapeutic drug monitoring, , Volume: 30, Issue:1, 2008
Large intraindividual variability of olanzapine serum concentrations in adolescent patients.Therapeutic drug monitoring, , Volume: 30, Issue:1, 2008
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.Current medical research and opinion, , Volume: 24, Issue:3, 2008
A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes.Schizophrenia research, , Volume: 100, Issue:1-3, 2008
Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia.Internal medicine (Tokyo, Japan), , Volume: 47, Issue:3, 2008
Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients.The international journal of neuropsychopharmacology, , Volume: 11, Issue:5, 2008
Metabotropic glutamate receptor agonists for schizophrenia.The British journal of psychiatry : the journal of mental science, , Volume: 192, Issue:2, 2008
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 165, Issue:3, 2008
Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 18, Issue:5, 2008
Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex.Schizophrenia research, , Volume: 101, Issue:1-3, 2008
Frequency and effects of psychosocial interventions additional to olanzapine treatment in routine care of schizophrenic patients.Social psychiatry and psychiatric epidemiology, , Volume: 43, Issue:5, 2008
Applying long-acting injectable antipsychotics in first-episode schizophrenia to achieve first remission.CNS drugs, , Volume: 22, Issue:3, 2008
Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:1, 2008
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.Journal of psychiatric research, , Volume: 42, Issue:13, 2008
Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.Acta psychiatrica Scandinavica, , Volume: 117, Issue:5, 2008
Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study.Schizophrenia research, , Volume: 101, Issue:1-3, 2008
Olanzapine plasma concentration in a newborn.Journal of psychopharmacology (Oxford, England), , Volume: 22, Issue:8, 2008
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.The Journal of clinical psychiatry, , Volume: 69, Issue:1, 2008
Inconclusive evidence for the efficacy of olanzapine in the treatment of negative symptoms in schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:1, 2008
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.Human psychopharmacology, , Volume: 23, Issue:4, 2008
Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300.Schizophrenia research, , Volume: 101, Issue:1-3, 2008
Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia.Pharmacoepidemiology and drug safety, , Volume: 17, Issue:7, 2008
Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain.Human psychopharmacology, , Volume: 23, Issue:4, 2008
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 69, Issue:3, 2008
Clinical and pharmacoeconomic evaluation of switch to olanzapine in veterans with schizophrenia or schizoaffective disorder.Psychopharmacology bulletin, , Volume: 41, Issue:1, 2008
High-dose olanzapine for treatment-resistant schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Olanzapine metabolic side effects: a weight gain issue?Internal and emergency medicine, , Volume: 3, Issue:3, 2008
Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.PharmacoEconomics, , Volume: 26, Issue:4, 2008
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.Psychiatry research, , May-30, Volume: 159, Issue:1-2, 2008
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 23, Issue:8, 2008
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.Lancet (London, England), , Mar-29, Volume: 371, Issue:9618, 2008
Weight gain due to long term antipsychotic treatment of persistent mental disorders.Psychiatria Danubina, , Volume: 20, Issue:1, 2008
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.BMC psychiatry, , Apr-04, Volume: 8, 2008
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.Current medical research and opinion, , Volume: 24, Issue:5, 2008
Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.Schizophrenia research, , Volume: 102, Issue:1-3, 2008
Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
Lessons to be learned from CATIE and CUtLASS.Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
Did CATIE influence antipsychotic use?Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
What CATIE found: results from the schizophrenia trial.Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:5, 2008
Problems with CATIE. Phase 1: Looking back--what the clinician needs to know.Connecticut medicine, , Volume: 72, Issue:4, 2008
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.Journal of clinical psychopharmacology, , Volume: 28, Issue:3, 2008
Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia.Pharmacopsychiatry, , Volume: 41, Issue:3, 2008
Olanzapine in adolescents with schizophrenia who manifest suicidal behaviour.Early intervention in psychiatry, , Volume: 2, Issue:2, 2008
Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine.Drug metabolism letters, , Volume: 2, Issue:2, 2008
Olanzapine: a new risk factor for pulmonary embolus?The American journal of forensic medicine and pathology, , Volume: 29, Issue:4, 2008
Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.The Journal of clinical psychiatry, , Volume: 69, Issue:9, 2008
High-dose olanzapine versus clozapine.The Journal of clinical psychiatry, , Volume: 69, Issue:10, 2008
[Psychiatric consequences of bariatric surgery in a schizophrenic patient: case report].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:4, 2008
[Depression in schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:10, 2008
[The possibility of high-quality remission in the long chronic course of schizophrenia].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 108, Issue:11, 2008
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).BMC psychiatry, , Dec-22, Volume: 8, 2008
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:12, 2008
Bofu-tsusho-san effectively attenuates the weight gain observed after receiving olanzapine.Psychiatry and clinical neurosciences, , Volume: 62, Issue:6, 2008
Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.The Journal of clinical psychiatry, , Volume: 69, Issue:12, 2008
Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Influence of olanzapine on QT variability and complexity measures of heart rate in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Correlates of response to Olanzapine in a North Indian Schizophrenia sample.Psychiatry research, , Dec-15, Volume: 161, Issue:3, 2008
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, ,Fall, Volume: 15, Issue:3, 2008
Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .Current medical research and opinion, , Volume: 24, Issue:11, 2008
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia.Archives of general psychiatry, , Volume: 65, Issue:10, 2008
Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: a prospective, randomized study.International journal of technology assessment in health care, ,Fall, Volume: 24, Issue:4, 2008
Olanzapine orally disintegrating tablet: a review of efficacy and compliance.CNS neuroscience & therapeutics, ,Fall, Volume: 14, Issue:3, 2008
[Olanzapine].Deutsche medizinische Wochenschrift (1946), , Volume: 133, Issue:39, 2008
Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-12, Volume: 32, Issue:8, 2008
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.The American journal of psychiatry, , Volume: 165, Issue:11, 2008
Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder.BMC psychiatry, , Sep-15, Volume: 8, 2008
The InterSePT suicide scale for prediction of imminent suicidal behaviors.Psychiatry research, , Oct-30, Volume: 161, Issue:1, 2008
LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia.Neuropsychobiology, , Volume: 58, Issue:1, 2008
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.Schizophrenia research, , Volume: 105, Issue:1-3, 2008
Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics.The American journal of psychiatry, , Volume: 165, Issue:9, 2008
Considerations regarding the use of metformin with olanzapine.The American journal of psychiatry, , Volume: 165, Issue:9, 2008
Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder.Pharmacopsychiatry, , Volume: 41, Issue:5, 2008
A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:4, 2008
Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:4, 2008
Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine.Journal of Korean medical science, , Volume: 23, Issue:4, 2008
The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.Psychiatry research, , Sep-30, Volume: 160, Issue:3, 2008
A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.Acta psychiatrica Scandinavica, , Volume: 118, Issue:3, 2008
Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia.Acta psychiatrica Scandinavica, , Volume: 118, Issue:3, 2008
Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study.Diabetes & metabolism, , Volume: 34, Issue:5, 2008
Olanzapine improves deficient sensory inhibition in DBA/2 mice.Brain research, , Oct-03, Volume: 1233, 2008
Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes.Pharmacogenomics, , Volume: 9, Issue:8, 2008
Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications.Human psychopharmacology, , Volume: 23, Issue:7, 2008
Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine. 3-month follow-up.Neuropsychobiology, , Volume: 57, Issue:4, 2008
Statistical evaluation of olanzapine efficacy in catamnesticly investigated patients.Medicinski arhiv, , Volume: 62, Issue:2, 2008
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.Clinical drug investigation, , Volume: 28, Issue:9, 2008
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.Journal of clinical psychopharmacology, , Volume: 28, Issue:4, 2008
Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia.Schizophrenia research, , Volume: 104, Issue:1-3, 2008
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:6, 2008
Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 18, Issue:10, 2008
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Olanzapine-induced oculogyric crisis in a patient with schizophrenia.Indian journal of medical sciences, , Volume: 62, Issue:6, 2008
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.BMC medicine, , Jun-30, Volume: 6, 2008
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-01, Volume: 32, Issue:6, 2008
Clinical experiences and clinical trials.CNS spectrums, , Volume: 13, Issue:6, 2008
Intramuscular olanzapine in patients with schizophrenia: an observational study in an emergency room.Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg, , Issue:2, 2008
Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 18, Issue:8, 2008
Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 18, Issue:9, 2008
Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone.International clinical psychopharmacology, , Volume: 23, Issue:4, 2008
Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study.International clinical psychopharmacology, , Volume: 23, Issue:4, 2008
Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.Human psychopharmacology, , Volume: 23, Issue:6, 2008
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.Journal of psychiatric research, , Volume: 41, Issue:5, 2007
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.Journal of psychiatric research, , Volume: 41, Issue:8, 2007
Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-30, Volume: 31, Issue:1, 2007
Is the superior efficacy of new generation antipsychotics an artifact of LOCF?Schizophrenia bulletin, , Volume: 33, Issue:1, 2007
A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics.The international journal of neuropsychopharmacology, , Volume: 10, Issue:4, 2007
Comparison of the in-vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine.The international journal of neuropsychopharmacology, , Volume: 10, Issue:2, 2007
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.Schizophrenia research, , Volume: 89, Issue:1-3, 2007
Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:7, 2007
The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 31, Issue:2, 2007
Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients.International clinical psychopharmacology, , Volume: 22, Issue:1, 2007
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.CNS spectrums, , Volume: 12, Issue:1, 2007
Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.Psychoneuroendocrinology, , Volume: 32, Issue:2, 2007
The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined.Schizophrenia research, , Volume: 90, Issue:1-3, 2007
The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.Psychopharmacology, , Volume: 191, Issue:2, 2007
Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications.Schizophrenia research, , Volume: 91, Issue:1-3, 2007
Lilly investigated in US over the marketing of olanzapine.BMJ (Clinical research ed.), , Jan-27, Volume: 334, Issue:7586, 2007
An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia.Current medical research and opinion, , Volume: 23, Issue:1, 2007
Alteration in serum neural cell adhesion molecule in patients of schizophrenia.Human psychopharmacology, , Volume: 22, Issue:2, 2007
Olanzapine-induced diabetic ketoacidosis in a Chinese man.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 13, Issue:1, 2007
Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia.Psychopharmacology bulletin, , Volume: 40, Issue:1, 2007
Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?Psychiatric services (Washington, D.C.), , Volume: 58, Issue:2, 2007
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.International clinical psychopharmacology, , Volume: 22, Issue:2, 2007
Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia.Biological psychiatry, , Oct-01, Volume: 62, Issue:7, 2007
Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.Schizophrenia research, , Volume: 91, Issue:1-3, 2007
Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.Psychopharmacology, , Volume: 192, Issue:3, 2007
Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:10, 2007
Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.Pharmacopsychiatry, , Volume: 40, Issue:1, 2007
A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:2, 2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.CNS spectrums, , Volume: 12, Issue:3 Suppl 4, 2007
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.Proceedings of the National Academy of Sciences of the United States of America, , Feb-27, Volume: 104, Issue:9, 2007
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.The Journal of clinical psychiatry, , Volume: 68, Issue:3, 2007
Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.The American journal of psychiatry, , Volume: 164, Issue:4, 2007
An open-label study of olanzapine in children and adolescents with schizophrenia.Journal of psychiatric practice, , Volume: 13, Issue:2, 2007
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Megaloblastic anemia and osteopenia in an adolescent diagnosed with schizophrenia.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 46, Issue:4, 2007
Pisa syndrome resolved after switching to olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 19, Issue:2, 2007
Comments on "Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine".Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 29, Issue:1, 2007
[Hematological alterations associated to olanzapine use after clozapine-induced neutropenia].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 29, Issue:1, 2007
Comments on the report of neuroleptic malignant syndrome induced by ziprasidone.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 8, Issue:2, 2007
Prolongation of clozapine-induced neutropenia with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:2, 2007
Managing psychosis in pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:3, 2007
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.Psychopharmacology, , Volume: 193, Issue:4, 2007
The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
[The influence of atypical neuroleptics on the immune system of patients with schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:3, 2007
[Glutamate dysmetabolism in patients with schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:3, 2007
All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis.Journal of clinical psychopharmacology, , Volume: 27, Issue:3, 2007
Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Oct-05, Volume: 144B, Issue:7, 2007
Decreased lipoprotein lipase as a risk factor for atypical neuroleptic-induced hypertriglyceridemia.The Journal of clinical psychiatry, , Volume: 68, Issue:5, 2007
A pilot observational crossover study of QTc interval changes associated with switching between olanzapine and risperidone.The Journal of clinical psychiatry, , Volume: 68, Issue:5, 2007
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.Psychopharmacology bulletin, , Volume: 40, Issue:2, 2007
Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.Journal of evaluation in clinical practice, , Volume: 13, Issue:3, 2007
Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia.International clinical psychopharmacology, , Volume: 22, Issue:4, 2007
Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Dec-05, Volume: 144B, Issue:8, 2007
Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 17, Issue:11, 2007
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.Archives of general psychiatry, , Volume: 64, Issue:6, 2007
Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia.Neuropsychobiology, , Volume: 55, Issue:1, 2007
Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol.Cognitive neuropsychiatry, , Volume: 12, Issue:4, 2007
Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Impairment in error monitoring predicts poor executive function in schizophrenia patients.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Perazine and carbamazepine in comparison to olanzapine in schizophrenia.Neuropsychobiology, , Volume: 55, Issue:2, 2007
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.European archives of psychiatry and clinical neuroscience, , Volume: 257, Issue:7, 2007
Low baseline serotonin-2A receptors predict clinical response to olanzapine in first-episode schizophrenia patients.Psychiatry research, , Oct-31, Volume: 153, Issue:2, 2007
Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Early use of clozapine for poorly responding first-episode psychosis.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Reversible delayed onset olanzapine-associated leukopenia and neutropenia in a clozapine-naive patient on concomitant depot antipsychotic.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
Diabetes and psychosis: olanzapine may not be the culprit.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 13, Issue:4, 2007
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.The British journal of psychiatry : the journal of mental science, , Volume: 191, 2007
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 46, Issue:8, 2007
First- vs second-generation antipsychotic drugs in schizophrenia.Archives of general psychiatry, , Volume: 64, Issue:8, 2007
CUtLASS confirms CATIE.Archives of general psychiatry, , Volume: 64, Issue:8, 2007
Gender differences in response to antipsychotic treatment in outpatients with schizophrenia.Psychiatry research, , Dec-03, Volume: 153, Issue:3, 2007
Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.Human psychopharmacology, , Volume: 22, Issue:7, 2007
Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:7, 2007
Changes in cortical volume with olanzapine in chronic schizophrenia.Pharmacopsychiatry, , Volume: 40, Issue:4, 2007
How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.Psychopharmacology, , Volume: 195, Issue:2, 2007
An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.Human psychopharmacology, , Volume: 22, Issue:7, 2007
Metabolic effects of the atypical antipsychotics.Southern medical journal, , Volume: 100, Issue:8, 2007
Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.Schizophrenia research, , Volume: 96, Issue:1-3, 2007
Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 22, Issue:7, 2007
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.Nature medicine, , Volume: 13, Issue:9, 2007
Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting.Human psychopharmacology, , Volume: 22, Issue:8, 2007
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Analysis of treatment effectiveness in longitudinal observational data.Journal of biopharmaceutical statistics, , Volume: 17, Issue:5, 2007
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Evidence-based psychiatry: outcomes and decisions.Southern medical journal, , Volume: 100, Issue:9, 2007
Show me the evidence: using number needed to treat.Southern medical journal, , Volume: 100, Issue:9, 2007
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?Archives of general psychiatry, , Volume: 64, Issue:10, 2007
Risperidone versus olanzapine for treatment of schizophrenia.Schizophrenia bulletin, , Volume: 33, Issue:6, 2007
Managing the acutely agitated and psychotic patient.CNS spectrums, , Volume: 12, Issue:10 Suppl 1, 2007
The effectiveness criterion: balancing efficacy against the risks of weight gain.The Journal of clinical psychiatry, , Volume: 68 Suppl 12, 2007
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.The Journal of clinical psychiatry, , Volume: 68, Issue:10, 2007
The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities.The American journal of psychiatry, , Volume: 164, Issue:11, 2007
Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 15, Issue:6, 2007
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Item response analysis of the Positive and Negative Syndrome Scale.BMC psychiatry, , Nov-15, Volume: 7, 2007
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
The roadmap for antipsychotic psychopharmacology: an overview.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.Neuro endocrinology letters, , Volume: 28, Issue:6, 2007
Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 19, Issue:4, 2007
Olanzapine-induced tardive dystonia successfully treated by tetrabenazine.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 19, Issue:4, 2007
Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.The Journal of clinical psychiatry, , Volume: 68, Issue:12, 2007
Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:12, 2007
Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.Collegium antropologicum, , Volume: 31, Issue:4, 2007
[Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 107, Issue:2, 2007
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 9, Issue:3, 2007
[Clinical and therapeutic aspects of agitation].L'Encephale, , Volume: 33 Pt 3, 2007
Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine.Biological psychiatry, , Mar-15, Volume: 59, Issue:6, 2006
Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine.The international journal of neuropsychopharmacology, , Volume: 9, Issue:2, 2006
The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:3, 2006
Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine.Psychoneuroendocrinology, , Volume: 31, Issue:2, 2006
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.Schizophrenia research, , Jan-01, Volume: 81, Issue:1, 2006
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:1, 2006
Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach.Statistics in medicine, , Sep-15, Volume: 25, Issue:17, 2006
An economic comparison of risperidone and olanzapine use within an integrated managed mental health program.Administration and policy in mental health, , Volume: 33, Issue:2, 2006
Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.Psychopharmacology, , Volume: 183, Issue:4, 2006
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Jan-31, Volume: 81, Issue:2-3, 2006
Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia.The international journal of neuropsychopharmacology, , Volume: 9, Issue:6, 2006
Treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions.Child and adolescent psychiatric clinics of North America, , Volume: 15, Issue:1, 2006
A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia.Schizophrenia research, , Feb-15, Volume: 82, Issue:1, 2006
The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.International journal of geriatric psychiatry, , Volume: 21, Issue:2, 2006
Antipsychotic drugs and schizophrenia.The New England journal of medicine, , Jan-19, Volume: 354, Issue:3, 2006
Antipsychotic drugs and schizophrenia.The New England journal of medicine, , Jan-19, Volume: 354, Issue:3, 2006
Antipsychotic drugs and schizophrenia.The New England journal of medicine, , Jan-19, Volume: 354, Issue:3, 2006
Antipsychotic drugs and schizophrenia.The New England journal of medicine, , Jan-19, Volume: 354, Issue:3, 2006
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
Pharmacological management of akathisia in combination with psychological interventions by a mental health nurse consultant.Journal of psychiatric and mental health nursing, , Volume: 13, Issue:1, 2006
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.The American journal of psychiatry, , Volume: 163, Issue:2, 2006
Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 12, Issue:2, 2006
Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.Journal of clinical pharmacy and therapeutics, , Volume: 31, Issue:1, 2006
Galantamine may improve attention and speech in schizophrenia.Human psychopharmacology, , Volume: 21, Issue:2, 2006
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.Psychoneuroendocrinology, , Volume: 31, Issue:5, 2006
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.BMC psychiatry, , Feb-21, Volume: 6, 2006
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.The American journal of psychiatry, , Volume: 163, Issue:3, 2006
Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 18, Issue:1, 2006
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.Schizophrenia research, , Volume: 83, Issue:1, 2006
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:4, 2006
Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:10, 2006
Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.Acta psychiatrica Scandinavica. Supplementum, , Issue:430, 2006
Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report.Pharmacopsychiatry, , Volume: 39, Issue:2, 2006
Selecting antipsychotics in schizophrenia: lessons from CATIE.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:3, 2006
Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Jun-05, Volume: 141B, Issue:4, 2006
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
Weight change in treatment with olanzapine and a psychoeducational approach.Eating behaviors, , Volume: 7, Issue:2, 2006
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.Psychopharmacology, , Volume: 186, Issue:4, 2006
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:3, 2006
[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].Medicina clinica, , Apr-01, Volume: 126, Issue:12, 2006
Risperidone versus olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Apr-19, Issue:2, 2006
Prolongation of clozapine-induced leukopenia with olanzapine treatment.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:5, 2006
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.Journal of clinical psychopharmacology, , Volume: 26, Issue:2, 2006
Pharmacogenetics of antipsychotic-induced weight gain.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 12, Issue:5, 2006
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.The American journal of psychiatry, , Volume: 163, Issue:5, 2006
Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.The Journal of clinical psychiatry, , Volume: 67, Issue:4, 2006
Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:5, 2006
Effect of olanzapine treatment on platelet glutamine synthetase-like protein and glutamate dehydrogenase immunoreactivity in schizophrenia.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 7, Issue:2, 2006
A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Why do physicians switch from one antipsychotic agent to another? The "physician drug stereotype".Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics.Psychopharmacology, , Volume: 187, Issue:2, 2006
Injectable atypical antipsychotics for agitation in borderline personality disorder.Pharmacopsychiatry, , Volume: 39, Issue:3, 2006
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.Schizophrenia research, , Volume: 86, Issue:1-3, 2006
Long-term treatment with atypical antipsychotics and risk of weight gain.Drug safety, , Volume: 29, Issue:6, 2006
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.Archives of general psychiatry, , Volume: 63, Issue:6, 2006
Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-30, Volume: 30, Issue:6, 2006
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.Journal of psychiatric research, , Volume: 40, Issue:7, 2006
Electrical brain activity and response to olanzapine in schizophrenia: a study with LORETA images of P300.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia.Human psychopharmacology, , Volume: 21, Issue:4, 2006
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.Human psychopharmacology, , Volume: 21, Issue:4, 2006
Olanzapine: a 5-year perspective.Expert review of neurotherapeutics, , Volume: 6, Issue:6, 2006
Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report.Psychiatria Danubina, , Volume: 18, Issue:1-2, 2006
Reversible neutropenia with olanzapine following clozapine-induced neutropenia.The American journal of psychiatry, , Volume: 163, Issue:7, 2006
Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.Archives of general psychiatry, , Volume: 63, Issue:7, 2006
Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-30, Volume: 30, Issue:8, 2006
Gender differences in prolactin elevation induced by olanzapine in Japanese drug-naïve schizophrenic patients.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-30, Volume: 30, Issue:8, 2006
Growth hormone therapy may diminish olanzapine serum level.Medical hypotheses, , Volume: 67, Issue:4, 2006
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.The Journal of clinical psychiatry, , Volume: 67, Issue:5, 2006
The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-30, Volume: 30, Issue:8, 2006
Plasma concentrations of high-dose olanzapine in a double-blind crossover study.Human psychopharmacology, , Volume: 21, Issue:6, 2006
Hospitalization risks in the treatment of schizophrenia: comparison of antipsychotic medications.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Decision models in the evaluation of psychotropic drugs : useful tool or useless toy?The European journal of health economics : HEPAC : health economics in prevention and care, , Volume: 7, Issue:3, 2006
Successful switch to olanzapine after rhabdomyolysis caused by water intoxication and clozapine use.Pharmacopsychiatry, , Volume: 39, Issue:4, 2006
Atypical antipsychotics, tardive dyskinesia, and D(2) receptors.The American journal of psychiatry, , Volume: 163, Issue:8, 2006
A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.The European journal of health economics : HEPAC : health economics in prevention and care, , Volume: 7, Issue:3, 2006
[Molecular pharmacogenetic study on antipsychotic-drug therapy responders with depression or schizophrenia].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 108, Issue:6, 2006
Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.CNS & neurological disorders drug targets, , Volume: 5, Issue:4, 2006
Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Dec-05, Volume: 141B, Issue:8, 2006
A model of anticholinergic activity of atypical antipsychotic medications.Schizophrenia research, , Volume: 88, Issue:1-3, 2006
[Optimizing the antipsychotic potency of olanzapine by augmentation--a critical review].Psychiatrische Praxis, , Volume: 33, Issue:6, 2006
Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.American journal of epidemiology, , Oct-01, Volume: 164, Issue:7, 2006
An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:4, 2006
Self-cannibalism: an unusual case of self-mutilation.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:10, 2006
[Osteoporosis risk factors among patients with schizophrenia].Przeglad lekarski, , Volume: 63, Issue:3, 2006
Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.Journal of clinical psychopharmacology, , Volume: 26, Issue:5, 2006
The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 26, Issue:5, 2006
Constructing an Index for the Subjective Well-being Under Neuroleptics scale (SWN), short form: applying structural equation modeling for testing reliability and validity of the index.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, , Volume: 15, Issue:7, 2006
Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.Psychiatry research, , Nov-15, Volume: 144, Issue:2-3, 2006
Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis.The American journal of psychiatry, , Volume: 163, Issue:10, 2006
Early changes of plasma lipids during treatment with atypical antipsychotics.International clinical psychopharmacology, , Volume: 21, Issue:6, 2006
The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone.The Journal of clinical psychiatry, , Volume: 67, Issue:9, 2006
A crossover study of prolactin changes associated with risperidone and olanzapine.The Journal of clinical psychiatry, , Volume: 67, Issue:9, 2006
Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.The Journal of clinical psychiatry, , Volume: 67, Issue:9, 2006
Positive findings for negative symptoms of schizophrenia: no longer untreatable?Acta psychiatrica Scandinavica, , Volume: 114, Issue:5, 2006
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.Acta psychiatrica Scandinavica, , Volume: 114, Issue:5, 2006
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.Therapeutic drug monitoring, , Volume: 28, Issue:5, 2006
The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia.Therapeutic drug monitoring, , Volume: 28, Issue:5, 2006
Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 89, Issue:8, 2006
[Long QT syndrome due to olanzapine administration].Kardiologia polska, , Volume: 64, Issue:9, 2006
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.Psychopharmacology, , Volume: 189, Issue:2, 2006
Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design.Psychopharmacology bulletin, , Volume: 39, Issue:1, 2006
[Endocrine side effects among psychiatric patients treated with antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:2, 2006
Reduced thalamic volume in patients with chronic schizophrenia after switching from typical antipsychotic medications to olanzapine.The American journal of psychiatry, , Volume: 163, Issue:11, 2006
Is olanzapine a brain-sparing medication?Archives of general psychiatry, , Volume: 63, Issue:11, 2006
The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.European journal of clinical pharmacology, , Volume: 62, Issue:12, 2006
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.The Journal of clinical psychiatry, , Volume: 67, Issue:10, 2006
Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.The Journal of clinical psychiatry, , Volume: 67, Issue:10, 2006
Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.Journal of clinical psychopharmacology, , Volume: 26, Issue:6, 2006
Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.Journal of clinical psychopharmacology, , Volume: 26, Issue:6, 2006
Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.Journal of clinical psychopharmacology, , Volume: 26, Issue:6, 2006
A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.The Annals of pharmacotherapy, , Volume: 40, Issue:12, 2006
Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:11, 2006
Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.PharmacoEconomics, , Volume: 24, Issue:12, 2006
Clinical trial-based cost-effectiveness analyses of antipsychotic use.The American journal of psychiatry, , Volume: 163, Issue:12, 2006
Effectiveness of switching antipsychotic medications.The American journal of psychiatry, , Volume: 163, Issue:12, 2006
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.The American journal of psychiatry, , Volume: 163, Issue:12, 2006
Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication.Therapeutic drug monitoring, , Volume: 28, Issue:6, 2006
Treatment of psychosis: 30 years of progress.Journal of clinical pharmacy and therapeutics, , Volume: 31, Issue:6, 2006
Cerebellar and thalamic metabolic changes visualized by [18]-FDG-PET in olanzapine-induced acute akathisia.Neuro endocrinology letters, , Volume: 27, Issue:6, 2006
Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 67, Issue:11, 2006
[New formulations of olanzapine in the treatment of acute agitation].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
[Akathisia in the course of olanzapine treatment].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 28, Issue:4, 2006
Rapid leptin elevation after initiation of olanzapine?Neuropsychobiology, , Volume: 54, Issue:3, 2006
[The use of atypical antipsychotics in the long-term care of schizophrenia].L'Encephale, , Volume: 32 Pt 3, 2006
Electroencephalogram slowing, sleepiness and treatment response in patients with schizophrenia during olanzapine treatment.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:1, 2006
Neurological soft signs and positive treatment response to olanzapine in chronic schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:1, 2006
The effects of celecoxib augmentation on cytokine levels in schizophrenia.The international journal of neuropsychopharmacology, , Volume: 9, Issue:3, 2006
[Obsessive-compulsive symptoms treatment in: schizophrenia].Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:7, 2005
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.The Journal of clinical psychiatry, , Volume: 66, Issue:8, 2005
Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients.Schizophrenia research, , Oct-15, Volume: 78, Issue:2-3, 2005
Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 30, Issue:12, 2005
Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:8, 2005
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
Olanzapine and weight gain.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
[Prescription of psychotropic drugs for schizophrenic outpatients in Hungary].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 7, Issue:1, 2005
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Patient outcomes in schizophrenia II: the impact of cognition.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.The New England journal of medicine, , Sep-22, Volume: 353, Issue:12, 2005
The choice of antipsychotic drugs for schizophrenia.The New England journal of medicine, , Sep-22, Volume: 353, Issue:12, 2005
Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone.Human psychopharmacology, , Volume: 20, Issue:8, 2005
Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients.International clinical psychopharmacology, , Volume: 20, Issue:6, 2005
Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.Psychiatry and clinical neurosciences, , Volume: 59, Issue:5, 2005
Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.Nordic journal of psychiatry, , Volume: 59, Issue:3, 2005
Olanzapine: a critical review of recent literature.Expert opinion on pharmacotherapy, , Volume: 6, Issue:12, 2005
Clinical implications of Brief Psychiatric Rating Scale scores.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.The American journal of psychiatry, , Volume: 162, Issue:10, 2005
NMS after clozapine initiation.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 44, Issue:11, 2005
A crossover study on lipid and weight changes associated with olanzapine and risperidone.Psychopharmacology, , Volume: 183, Issue:3, 2005
Unusual suspect for antipsychotic-induced diabetes.Drug discovery today, , Oct-15, Volume: 10, Issue:20, 2005
[Atypical antipsychotic-associated impaired glucose tolerance].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 107, Issue:8, 2005
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:6 Suppl, 2005
The CATIE schizophrenia effectiveness trial.Schizophrenia research, , Dec-01, Volume: 80, Issue:1, 2005
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Augmentation of olanzapine in treatment-resistant schizophrenia.Journal of psychiatry & neuroscience : JPN, , Volume: 30, Issue:6, 2005
A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.Clinical therapeutics, , Volume: 27, Issue:10, 2005
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:11, 2005
Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.BMC medicine, , Dec-23, Volume: 3, 2005
Early effects of treatment on regional cerebral blood flow in first episode schizophrenia patients evaluated with 99Tc-ECD-SPECT.Neuro endocrinology letters, , Volume: 26, Issue:6, 2005
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients.The Journal of clinical psychiatry, , Volume: 66, Issue:12, 2005
The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia.Psychiatry and clinical neurosciences, , Volume: 59, Issue:6, 2005
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.PharmacoEconomics, , Volume: 23 Suppl 1, 2005
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.PharmacoEconomics, , Volume: 23 Suppl 1, 2005
[Neuroleptic drug utilization among schizophrenic outpatients].Revue d'epidemiologie et de sante publique, , Volume: 53, Issue:6, 2005
Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:14, 2005
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.Clinical therapeutics, , Volume: 27, Issue:12, 2005
Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 88, Issue:9, 2005
Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.Journal of the Indian Medical Association, , Volume: 103, Issue:12, 2005
Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.Bulletin of experimental biology and medicine, , Volume: 140, Issue:6, 2005
Olanzapine increases plasma ghrelin level in patients with schizophrenia.Psychoneuroendocrinology, , Volume: 30, Issue:1, 2005
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.Statistics in medicine, , Jan-15, Volume: 24, Issue:1, 2005
Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 30, Issue:2, 2005
Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia.International clinical psychopharmacology, , Volume: 20, Issue:1, 2005
Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients.International clinical psychopharmacology, , Volume: 20, Issue:1, 2005
Switching depot antipsychotic drug responders to oral olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:1, 2005
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Olanzapine treatment of residual positive and negative symptoms.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Archives of general psychiatry, , Volume: 62, Issue:1, 2005
Clinical outcome and olanzapine plasma levels in acute schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:1, 2005
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.BMC psychiatry, , Jan-13, Volume: 5, 2005
The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire.Human psychopharmacology, , Volume: 20, Issue:2, 2005
Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.Journal of clinical pharmacy and therapeutics, , Volume: 30, Issue:1, 2005
Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.Acta psychiatrica Scandinavica, , Volume: 111, Issue:2, 2005
Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:1, 2005
Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study.Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
Diabetes mellitus during olanzapine and quetiapine treatment in Japan.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being.Pharmacopsychiatry, , Volume: 38, Issue:1, 2005
The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.International clinical psychopharmacology, , Volume: 20, Issue:2, 2005
Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.International clinical psychopharmacology, , Volume: 20, Issue:2, 2005
Comparison of large versus smaller randomized trials for mental health-related interventions.The American journal of psychiatry, , Volume: 162, Issue:3, 2005
Comparison of clozapine use in Maryland and in Victoria, Australia.Psychiatric services (Washington, D.C.), , Volume: 56, Issue:3, 2005
Capgras syndrome in the modern era: self misidentification on an ID picture.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:1, 2005
Health care costs for schizophrenia patients started on olanzapine versus risperidone.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Mar-15, Volume: 62, Issue:6, 2005
Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?The international journal of neuropsychopharmacology, , Volume: 8, Issue:2, 2005
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.Biological psychiatry, , Mar-15, Volume: 57, Issue:6, 2005
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.The international journal of neuropsychopharmacology, , Volume: 8, Issue:3, 2005
Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.Pharmacoepidemiology and drug safety, , Volume: 14, Issue:6, 2005
Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection.Therapeutic drug monitoring, , Volume: 27, Issue:2, 2005
Antipsychotic drug effects on brain morphology in first-episode psychosis.Archives of general psychiatry, , Volume: 62, Issue:4, 2005
Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone.International clinical psychopharmacology, , Volume: 20, Issue:3, 2005
The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study.Schizophrenia research, , Jun-01, Volume: 75, Issue:1, 2005
[Parameters of platelet serotonin system in patients with schizophrenia treated with olanzapine: a search for the serotonergic predictors of therapeutic efficacy].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 105, Issue:3, 2005
Internet in clinical research based on a pilot experience.Contemporary clinical trials, , Volume: 26, Issue:2, 2005
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Apr-18, Issue:2, 2005
Risperidone versus olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Apr-18, Issue:2, 2005
Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: a multivariate analysis of a large naturalistic study in the hospital setting.Medicina clinica, , Apr-09, Volume: 124, Issue:13, 2005
The paradox of quetiapine in obsessive-compulsive disorder.CNS spectrums, , Volume: 10, Issue:5, 2005
Evidence for onset of antipsychotic effects within the first 24 hours of treatment.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.Pharmacogenetics and genomics, , Volume: 15, Issue:4, 2005
Brain electrical activity changes in treatment refractory schizophrenics after olanzapine treatment.International journal of psychophysiology : official journal of the International Organization of Psychophysiology, , Volume: 56, Issue:3, 2005
Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:4, 2005
The association of weight gain and olanzapine plasma concentrations.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia--preliminary results of a facial electromyogram study.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:5, 2005
Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.Schizophrenia research, , Sep-15, Volume: 77, Issue:2-3, 2005
Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.CNS drugs, , Volume: 19, Issue:5, 2005
Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.Schizophrenia research, , Sep-15, Volume: 77, Issue:2-3, 2005
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.The Journal of nervous and mental disease, , Volume: 193, Issue:6, 2005
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.BMC psychiatry, , May-27, Volume: 5, 2005
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.Schizophrenia research, , Jul-01, Volume: 76, Issue:1, 2005
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.International clinical psychopharmacology, , Volume: 20, Issue:4, 2005
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:6, 2005
Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:6, 2005
Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia.Psychiatry research, , May-30, Volume: 139, Issue:1, 2005
Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved.Acta psychiatrica Scandinavica, , Volume: 112, Issue:1, 2005
Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.The Journal of clinical psychiatry, , Volume: 66, Issue:6, 2005
Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review.CNS drugs, , Volume: 19, Issue:6, 2005
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.Drug metabolism and pharmacokinetics, , Volume: 20, Issue:3, 2005
Executive function assessment of patients with schizophrenic disorder residual type in olanzapine treatment: an open study.Human psychopharmacology, , Volume: 20, Issue:6, 2005
Methodological concerns in a trial of ziprasidone and olanzapine.The American journal of psychiatry, , Volume: 162, Issue:7, 2005
Methodological concerns in a trial of ziprasidone and olanzapine.The American journal of psychiatry, , Volume: 162, Issue:7, 2005
Olanzapine and haloperidol for residual symptoms.The American journal of psychiatry, , Volume: 162, Issue:7, 2005
Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics.Journal of clinical psychopharmacology, , Volume: 25, Issue:4, 2005
Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments.Journal of clinical psychopharmacology, , Volume: 25, Issue:4, 2005
Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:7, 2005
Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey.Pharmacopsychiatry, , Volume: 38, Issue:4, 2005
Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.Psychiatry and clinical neurosciences, , Volume: 59, Issue:4, 2005
A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia.Schizophrenia research, , Nov-15, Volume: 79, Issue:2-3, 2005
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.The American journal of psychiatry, , Volume: 162, Issue:8, 2005
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Serum ghrelin concentrations in patients receiving olanzapine or risperidone.Psychopharmacology, , Volume: 172, Issue:2, 2004
Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.Psychopharmacology, , Volume: 172, Issue:3, 2004
Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Jan-01, Volume: 124B, Issue:1, 2004
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:1, 2004
A neurobehavioral screening of the ckr mouse mutant: implications for an animal model of schizophrenia.Brain research bulletin, , Jan-15, Volume: 62, Issue:4, 2004
Are high initial doses of olanzapine required to reduce agitation associated with schizophrenia?Journal of clinical psychopharmacology, , Volume: 24, Issue:1, 2004
Olanzapine treatment of eight adolescent patients with psychosis.Human psychopharmacology, , Volume: 19, Issue:1, 2004
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.Biological psychiatry, , Jan-15, Volume: 55, Issue:2, 2004
Cost comparisons of olanzapine and risperidone in treating schizophrenia.The Annals of pharmacotherapy, , Volume: 38, Issue:1, 2004
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:1, 2004
Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe.European journal of clinical pharmacology, , Volume: 60, Issue:1, 2004
Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.Pharmacopsychiatry, , Volume: 37, Issue:1, 2004
Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:2, 2004
Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period.Psychopharmacology, , Volume: 175, Issue:2, 2004
Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:2, 2004
Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database.CNS drugs, , Volume: 18, Issue:3, 2004
Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.Current medicinal chemistry, , Volume: 11, Issue:3, 2004
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.Current medicinal chemistry, , Volume: 11, Issue:3, 2004
New antipsychotics and schizophrenia: a review on efficacy and side effects.Current medicinal chemistry, , Volume: 11, Issue:3, 2004
The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia.Life sciences, , Mar-05, Volume: 74, Issue:16, 2004
Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:1, 2004
Olanzapine use in a patient with schizophrenia and the risk of diabetes.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:1, 2004
Valproate for hostility in schizophrenia patients.The Journal of clinical psychiatry, , Volume: 65, Issue:1, 2004
Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 16, Issue:1, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:3, 2004
Potential for detection bias in the association between olanzapine and diabetes.The Journal of clinical psychiatry, , Volume: 65, Issue:2, 2004
Open label study of the effect of amantadine on weight gain induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 58, Issue:2, 2004
Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial.Biological psychiatry, , Mar-01, Volume: 55, Issue:5, 2004
[Current pharmacotherapy of schizophrenia].Orvosi hetilap, , Jan-18, Volume: 145, Issue:3, 2004
Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.Pharmacopsychiatry, , Volume: 37, Issue:2, 2004
P300 alterations in schizophrenic patients experiencing auditory hallucinations.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 14, Issue:3, 2004
Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Treatment of tardive pharyngolaryngeal dystonia with olanzapine.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Improvement in social cognition in patients with schizophrenia associated with treatment with olanzapine.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Aripirazole-olanzapine combination for treatment of schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:2, 2004
A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.International clinical psychopharmacology, , Volume: 19, Issue:2, 2004
Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.Psychopharmacology, , Volume: 175, Issue:4, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Adherence to conventional and atypical antipsychotics after hospital discharge.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
The incidence of hyperglycemia in patients treated with olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
An excitement subscale of the Positive and Negative Syndrome Scale.Schizophrenia research, , Jun-01, Volume: 68, Issue:2-3, 2004
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.International clinical psychopharmacology, , Volume: 19, Issue:1, 2004
Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study.International clinical psychopharmacology, , Volume: 19, Issue:1, 2004
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.The Journal of clinical psychiatry, , Volume: 65 Suppl 6, 2004
Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:1, 2004
COMT158 polymorphism and hostility.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , May-15, Volume: 127B, Issue:1, 2004
Olanzapine in the treatment of agitation in hospitalized patients with schizophrenia and schizoaffective and schizofreniform disorders.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 10, Issue:5, 2004
Improvement in prosocial functioning after a switch to ziprasidone treatment.CNS spectrums, , Volume: 9, Issue:5, 2004
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.The American journal of emergency medicine, , Volume: 22, Issue:3, 2004
Atypical antipsychotics and diabetes mellitus: an association.The Israel Medical Association journal : IMAJ, , Volume: 6, Issue:5, 2004
Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior.The Journal of clinical psychiatry, , Volume: 65, Issue:5, 2004
The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 14, Issue:4, 2004
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
Atypical antipsychotics and diabetes mellitus.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:2, 2004
Olanzapine- and clozapine-induced stuttering. A case series.Pharmacopsychiatry, , Volume: 37, Issue:3, 2004
A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia.Human psychopharmacology, , Volume: 19, Issue:4, 2004
Tardive dyskinesia rates with atypical antipsychotics in older adults.The Journal of clinical psychiatry, , Volume: 65 Suppl 9, 2004
Tardive dyskinesia associated with olanzapine in a neuroleptic-naive patient with schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:5, 2004
Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia.International clinical psychopharmacology, , Volume: 19, Issue:4, 2004
Weight gain during long-term treatment with olanzapine: a case series.International clinical psychopharmacology, , Volume: 19, Issue:4, 2004
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.Journal of clinical psychopharmacology, , Volume: 24, Issue:2, 2004
Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.MedGenMed : Medscape general medicine, , Jan-20, Volume: 6, Issue:1, 2004
Cognitive function and depression in symptom resolution in schizophrenia patients treated with an atypical antipsychotic.Brain and cognition, , Volume: 55, Issue:3, 2004
Obsessive-compulsive symptoms with olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:3, 2004
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.Current medical research and opinion, , Volume: 20, Issue:7, 2004
Cognitive effects of olanzapine treatment in schizophrenia.MedGenMed : Medscape general medicine, , May-10, Volume: 6, Issue:2, 2004
[A change of immune profile of patients with schizophrenia during treatment].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 104, Issue:4, 2004
Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine.Biological psychiatry, , Aug-01, Volume: 56, Issue:3, 2004
Re: treatment noncompliance with orally disintegrating olanzapine tablets.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:6, 2004
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial.The American journal of psychiatry, , Volume: 161, Issue:8, 2004
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone.The Journal of clinical psychiatry, , Volume: 65, Issue:6, 2004
Comments on cost analysis of risperidone versus olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:6, 2004
A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:8, 2004
Long-term olanzapine treatment and p300 parameters in schizophrenia.Neuropsychobiology, , Volume: 50, Issue:2, 2004
Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.Psychiatry and clinical neurosciences, , Volume: 58, Issue:4, 2004
Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan.Psychiatry and clinical neurosciences, , Volume: 58, Issue:4, 2004
[Zyprexa--various dosage forms, the goal: improving the prognosis for patients with schizophrenia and bipolar disorders].Krankenpflege Journal, , Volume: 42, Issue:3-4, 2004
Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets.Psychopharmacology, , Volume: 175, Issue:3, 2004
Variables associated with high olanzapine dosing in a state hospital.The Journal of clinical psychiatry, , Volume: 65, Issue:8, 2004
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.The American journal of psychiatry, , Volume: 161, Issue:9, 2004
Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.The American journal of psychiatry, , Volume: 161, Issue:9, 2004
Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:9, 2004
Neurologic soft signs and olanzapine treatment in chronic schizophrenia.Journal of clinical psychopharmacology, , Volume: 24, Issue:5, 2004
Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
Hypnopompic hallucinations during olanzapine treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:7, 2004
Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:6, 2004
Normalization of impaired cognitive functions failed to improve clinical symptomatology in a schizophrenic patient.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:6, 2004
Effects of typical and atypical antipsychotics on human glycine transporters.Schizophrenia research, , Nov-01, Volume: 71, Issue:1, 2004
Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:6, 2004
Heavy smoking, reduced olanzapine levels, and treatment effects: a case report.Therapeutic drug monitoring, , Volume: 26, Issue:5, 2004
[Diabetes as a complication in treatment with second-generation antipsychotics].Ugeskrift for laeger, , Aug-23, Volume: 166, Issue:35, 2004
Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms.Pharmacopsychiatry, , Volume: 37, Issue:4, 2004
[Expectations and developments in atypical antipsychotics].Praxis, , Aug-25, Volume: 93, Issue:35, 2004
Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.CNS spectrums, , Volume: 9, Issue:10 Suppl 1, 2004
[Introduction of new anti-psychotic drugs and changes in the clinical practice].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 106, Issue:7, 2004
Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.Journal of clinical pharmacy and therapeutics, , Volume: 29, Issue:5, 2004
Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent.International journal of dermatology, , Volume: 43, Issue:10, 2004
Heart rate variability during sleep in patients with schizophrenia treated with olanzapine.International clinical psychopharmacology, , Volume: 19, Issue:6, 2004
Score tests for dose effect in the presence of non-responders.Statistics in medicine, , Dec-15, Volume: 23, Issue:23, 2004
Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.Journal of clinical psychopharmacology, , Volume: 24, Issue:6, 2004
Absence of effect of olanzapine on primary polydipsia: results of a double-blind, randomized study.Journal of clinical psychopharmacology, , Volume: 24, Issue:6, 2004
The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.European archives of psychiatry and clinical neuroscience, , Volume: 254, Issue:6, 2004
Reversible neutropenia during treatment with olanzapine: three case reports.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:4, 2004
Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia.Journal of clinical pharmacology, , Volume: 44, Issue:12, 2004
Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial.Pharmacopsychiatry, , Volume: 37, Issue:6, 2004
EEG abnormalities under treatment with atypical antipsychotics: effects of olanzapine and amisulpride as compared to haloperidol.Pharmacopsychiatry, , Volume: 37, Issue:6, 2004
Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
[Rehospitalization rates of newly diagnosed schizophrenic patients on atypical neuroleptic medication].Psychiatrische Praxis, , Volume: 31 Suppl 1, 2004
[Alterations of gait parameters under external cueing in schizophrenic patients: a switch study].Psychiatrische Praxis, , Volume: 31 Suppl 1, 2004
The validity and reliability of the global index of safety (GIS).Current medical research and opinion, , Volume: 20, Issue:11, 2004
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.Controlled clinical trials, , Volume: 25, Issue:6, 2004
Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:8, 2004
Dyslipidemia and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
Weight gain and new onset diabetes associated with olanzapine and risperidone.Journal of general internal medicine, , Volume: 19, Issue:12, 2004
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.Schizophrenia bulletin, , Volume: 30, Issue:3, 2004
Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia.Schizophrenia bulletin, , Volume: 30, Issue:3, 2004
Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.Annals of the New York Academy of Sciences, , Volume: 1032, 2004
[Treatment of "the premonitory state of schizophrenia" with atypical antipsychotics].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 106, Issue:11, 2004
Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.Current medical research and opinion, , Volume: 20, Issue:12, 2004
Schizophrenia.Clinical evidence, , Issue:12, 2004
First person account: My dream life, a normal life.Schizophrenia bulletin, , Volume: 30, Issue:4, 2004
An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.Schizophrenia research, , Jan-01, Volume: 59, Issue:1, 2003
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 13, Issue:1, 2003
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.International clinical psychopharmacology, , Volume: 18, Issue:1, 2003
Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.International clinical psychopharmacology, , Volume: 18, Issue:1, 2003
Peripheral oedema in patients taking olanzapine.International clinical psychopharmacology, , Volume: 18, Issue:1, 2003
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:1, 2003
Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.Schizophrenia research, , Mar-01, Volume: 60, Issue:1, 2003
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).Archives of general psychiatry, , Volume: 60, Issue:1, 2003
Reply to Dr Mahendran. We have not found reported cases of [obsessive-compulsive] OC arising from de novo with olanzapine treatment.The Australian and New Zealand journal of psychiatry, , Volume: 37, Issue:1, 2003
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Issue:1, 2003
A prospective, open-label trial of olanzapine in adolescents with schizophrenia.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 42, Issue:2, 2003
Effects of olanzapine on auditory P300 in schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:1, 2003
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment.Acta psychiatrica Scandinavica, , Volume: 107, Issue:3, 2003
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.Psychopharmacology, , Volume: 169, Issue:3-4, 2003
Economic evaluations of novel antipsychotic medications: a literature review.Schizophrenia research, , Apr-01, Volume: 60, Issue:2-3, 2003
Comparative effectiveness of antipsychotic drugs.The American journal of psychiatry, , Volume: 160, Issue:3, 2003
Comparative effectiveness of antipsychotic drugs.The American journal of psychiatry, , Volume: 160, Issue:3, 2003
Comparative effectiveness of antipsychotic drugs.The American journal of psychiatry, , Volume: 160, Issue:3, 2003
Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.The Journal of clinical psychiatry, , Volume: 64, Issue:2, 2003
Local-global processing in early-onset schizophrenia: evidence for an impairment in shifting the spatial scale of attention.Brain and cognition, , Volume: 51, Issue:1, 2003
Do atypical antipsychotics fail to exert cognitive sparing effects?Neuroreport, , Mar-03, Volume: 14, Issue:3, 2003
Olanzapine and risperidone.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Mar-01, Volume: 60, Issue:5, 2003
Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.Journal of clinical psychopharmacology, , Volume: 23, Issue:2, 2003
Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex.Neuropharmacology, , Volume: 44, Issue:4, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.Psychoneuroendocrinology, , Volume: 28 Suppl 2, 2003
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 13, Issue:2, 2003
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.Wiener klinische Wochenschrift, , Jan-31, Volume: 115, Issue:1-2, 2003
Clinical trial response and dropout rates with olanzapine versus risperidone.The Annals of pharmacotherapy, , Volume: 37, Issue:4, 2003
Tc-99 HMPAO SPECT study of regional cerebral blood flow in olanzapine-treated schizophrenic patients.European archives of psychiatry and clinical neuroscience, , Volume: 253, Issue:1, 2003
Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:3, 2003
The influence of olanzapine on immune cells in patients with schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:3, 2003
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.International clinical psychopharmacology, , Volume: 18, Issue:3, 2003
Role of ethnicity in predicting antipsychotic medication adherence.The Annals of pharmacotherapy, , Volume: 37, Issue:5, 2003
Cost evaluation of risperidone compared with olanzapine.Psychiatric services (Washington, D.C.), , Volume: 54, Issue:5, 2003
Pharmacological approaches to the management of schizophrenia.The Medical journal of Australia, , 05-05, Volume: 178, Issue:S9, 2003
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:5, 2003
Acute dystonia caused by low dosage of olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 15, Issue:2, 2003
Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.Schizophrenia research, , Jun-01, Volume: 61, Issue:2-3, 2003
Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity.Journal of neuroscience research, , Jun-01, Volume: 72, Issue:5, 2003
Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study.Acta psychiatrica Scandinavica, , Volume: 107, Issue:5, 2003
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment.Acta psychiatrica Scandinavica. Supplementum, , Issue:416, 2003
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.Schizophrenia research, , Jul-01, Volume: 62, Issue:1-2, 2003
The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.International journal of geriatric psychiatry, , Volume: 18, Issue:5, 2003
Treatment of cervical dystonia by olanzapine.Human psychopharmacology, , Volume: 18, Issue:4, 2003
Olanzapine induced neuroleptic malignant syndrome--a case review.Human psychopharmacology, , Volume: 18, Issue:4, 2003
Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:4, 2003
Calming versus sedative effects of intramuscular olanzapine in agitated patients.The American journal of emergency medicine, , Volume: 21, Issue:3, 2003
Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia.The Journal of clinical psychiatry, , Volume: 64, Issue:6, 2003
Chlorpromazine equivalent doses for the newer atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 64, Issue:6, 2003
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.Psychopharmacology, , Volume: 169, Issue:3-4, 2003
Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.PharmacoEconomics, , Volume: 21, Issue:10, 2003
Rehospitalization risk with second-generation and depot antipsychotics.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 15, Issue:1, 2003
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.Psychopharmacology, , Volume: 169, Issue:3-4, 2003
Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.Psychopharmacology, , Volume: 170, Issue:2, 2003
[3H]RX 821002 in human dorsolateral prefrontal cortex: no changes in postmortem tissue from subjects with schizophrenia.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
Should lipids be monitored during the first year of treatment with an atypical antipsychotic?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Potential risk of diabetes mellitus with the use of atypical antipsychotic medication.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Treatment noncompliance with orally disintegrating olanzapine tablets.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.Clinical therapeutics, , Volume: 25, Issue:5, 2003
[An introduction to antipsychotics].Ryoikibetsu shokogun shirizu, , Issue:38, 2003
Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia.The international journal of neuropsychopharmacology, , Volume: 6, Issue:2, 2003
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.The American journal of psychiatry, , Volume: 160, Issue:8, 2003
Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.Pharmacological research, , Volume: 48, Issue:4, 2003
Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:11, 2003
Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report.International journal of psychiatry in medicine, , Volume: 33, Issue:1, 2003
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome.Biological psychiatry, , Aug-15, Volume: 54, Issue:4, 2003
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.Biological psychiatry, , Aug-15, Volume: 54, Issue:4, 2003
Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study.Human psychopharmacology, , Volume: 18, Issue:6, 2003
Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.Human psychopharmacology, , Volume: 18, Issue:6, 2003
Eruptive xanthomas associated with olanzapine use.Archives of dermatology, , Volume: 139, Issue:8, 2003
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.International journal of geriatric psychiatry, , Volume: 18, Issue:9, 2003
Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial.Psychiatry and clinical neurosciences, , Volume: 57, Issue:5, 2003
Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex.Neuroscience letters, , Oct-09, Volume: 349, Issue:3, 2003
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:11, 2003
Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol.Psychiatry research, , Aug-30, Volume: 120, Issue:1, 2003
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
[Neuroleptics and cognition].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
[3-D ultrasound-assisted gait analysis of schizophrenic patients. Comparison between conventional neuroleptics and olanzapine].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
Schizophrenia, VI: Treatments.The American journal of psychiatry, , Volume: 160, Issue:10, 2003
Racial disparity in the use of atypical antipsychotic medications among veterans.The American journal of psychiatry, , Volume: 160, Issue:10, 2003
Weight change after an atypical antipsychotic switch.The Annals of pharmacotherapy, , Volume: 37, Issue:10, 2003
The effect of olanzapine on anxiety among patients with schizophrenia: preliminary findings.Journal of clinical psychopharmacology, , Volume: 23, Issue:5, 2003
The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain.Human psychopharmacology, , Volume: 18, Issue:7, 2003
The effects of an educational intervention on antipsychotic-induced weight gain.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing, , Volume: 35, Issue:3, 2003
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].Minerva anestesiologica, , Volume: 69, Issue:6, 2003
Effects of olanzapine on lipid abnormalities in elderly psychotic patients.Drugs & aging, , Volume: 20, Issue:12, 2003
5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia.Psychopharmacology bulletin, ,Spring, Volume: 37, Issue:2, 2003
Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
New generation antipsychotics for first episode schizophrenia.The Cochrane database of systematic reviews, , Issue:4, 2003
Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.Current medical research and opinion, , Volume: 19, Issue:6, 2003
Olanzapine effects on auditory sensory gating in schizophrenia.The American journal of psychiatry, , Volume: 160, Issue:11, 2003
[A case of delirium after olanzapine intoxication].Der Nervenarzt, , Volume: 74, Issue:11, 2003
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.The international journal of neuropsychopharmacology, , Volume: 6, Issue:4, 2003
Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults.Schizophrenia bulletin, , Volume: 29, Issue:3, 2003
Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:6, 2003
Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity.Schizophrenia research, , Nov-15, Volume: 64, Issue:2-3, 2003
Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.International journal of geriatric psychiatry, , Volume: 18, Issue:11, 2003
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
Reducing the risk for suicide in schizophrenia and affective disorders.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.Psychiatry and clinical neurosciences, , Volume: 57, Issue:6, 2003
Rapid onset of dyskinesia induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 57, Issue:6, 2003
Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:9, 2003
Fungal dermatitis with olanzapine in schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:9, 2003
Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia.Therapeutic drug monitoring, , Volume: 25, Issue:6, 2003
Optimal treatment project for schizophrenia: results from a randomized, controlled, longitudinal study.Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 105, Issue:9, 2003
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.JAMA, , Nov-26, Volume: 290, Issue:20, 2003
High-dose olanzapine and prolactin levels.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
Similarities and differences among antipsychotics.The Journal of clinical psychiatry, , Volume: 64 Suppl 17, 2003
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Olanzapine induces insulin resistance: results from a prospective study.The Journal of clinical psychiatry, , Volume: 64, Issue:12, 2003
Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:11, 2003
High-dose olanzapine-induced improvement of preexisting type 2 diabetes mellitus in schizophrenic patients.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
The impact of the Food and Drug Administration Modernization Act on the recruitment of children for research.Ethical human sciences and services : an international journal of critical inquiry, ,Summer, Volume: 5, Issue:2, 2003
Schizophrenia.Clinical evidence, , Issue:10, 2003
Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine?Pharmacopsychiatry, , Volume: 35, Issue:3, 2002
A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia.Psychopharmacology, , Volume: 162, Issue:1, 2002
One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.Psychiatric services (Washington, D.C.), , Volume: 53, Issue:7, 2002
Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine.Psychiatric services (Washington, D.C.), , Volume: 53, Issue:7, 2002
A possible association between high normal and high dose olanzapine and prolongation of the PR interval.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:2, 2002
Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 27, Issue:1, 2002
Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.Schizophrenia bulletin, , Volume: 28, Issue:1, 2002
Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients.Psychiatric services (Washington, D.C.), , Volume: 53, Issue:6, 2002
Atypical antipsychotics and cognition in schizophrenia.Archives of general psychiatry, , Volume: 59, Issue:6, 2002
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Sex differences in clinical response to olanzapine compared with haloperidol.Psychiatry research, , May-15, Volume: 110, Issue:1, 2002
Effect of olanzapine on glutamate levels in cerebrospinal fluid of patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 22, Issue:3, 2002
Motor-induced brain activation in cortical, subcortical and cerebellar regions in schizophrenic inpatients. A whole brain fMRI fingertapping study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:3, 2002
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.Archives of general psychiatry, , Volume: 59, Issue:5, 2002
Clinical and neuropsychological correlates of the P300 in schizophrenia.Schizophrenia research, , May-01, Volume: 55, Issue:1-2, 2002
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.CNS drugs, , Volume: 16, Issue:4, 2002
Subcortical overactivation in untreated schizophrenic patients: a functional magnetic resonance image finger-tapping study.Psychiatry and clinical neurosciences, , Volume: 56, Issue:1, 2002
Serotonin syndrome and atypical antipsychotics.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.Biological psychiatry, , Mar-15, Volume: 51, Issue:6, 2002
Significant dissociation of brain and plasma kinetics with antipsychotics.Molecular psychiatry, , Volume: 7, Issue:3, 2002
New-onset seizure associated with quetiapine and olanzapine.The Annals of pharmacotherapy, , Volume: 36, Issue:3, 2002
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
Implicit and explicit learning in schizophrenics treated with olanzapine and with classic neuroleptics.Psychopharmacology, , Volume: 160, Issue:3, 2002
[Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].Fortschritte der Neurologie-Psychiatrie, , Volume: 70, Issue:3, 2002
A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.Managed care interface, , Volume: 15, Issue:2, 2002
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.The Journal of clinical psychiatry, , Volume: 63, Issue:2, 2002
Olanzapine for violent schizophrenia and Klinefelter syndrome.The American journal of psychiatry, , Volume: 159, Issue:3, 2002
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.The American journal of psychiatry, , Volume: 159, Issue:3, 2002
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.The American journal of psychiatry, , Volume: 159, Issue:2, 2002
Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication.International clinical psychopharmacology, , Volume: 17, Issue:1, 2002
Increasing insulin dose for olanzapine-related diabetes.The American journal of psychiatry, , Volume: 159, Issue:1, 2002
Elevation of prolactin levels by atypical antipsychotics.The American journal of psychiatry, , Volume: 159, Issue:1, 2002
The first-episode of schizophrenia: a challenge for treatment.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17 Suppl 4, 2002
Economic evaluations of olanzapine and risperidone.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Jul-15, Volume: 59, Issue:14, 2002
Excessive recruitment of neural systems subserving logical reasoning in schizophrenia.Brain : a journal of neurology, , Volume: 125, Issue:Pt 8, 2002
Fatality from olanzapine induced hyperglycemia.Journal of forensic sciences, , Volume: 47, Issue:4, 2002
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder.Psychiatry research, , Aug-05, Volume: 111, Issue:1, 2002
Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific.The Journal of clinical psychiatry, , Volume: 63, Issue:7, 2002
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.BMJ (Clinical research ed.), , Aug-03, Volume: 325, Issue:7358, 2002
Marked improvement of Meige's syndrome with olanzapine in a schizophrenic patient.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 14, Issue:3, 2002
Emergence of compulsive symptoms with olanzapine treatment.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:4, 2002
Weight loss associated with olanzapine treatment.Journal of clinical psychopharmacology, , Volume: 22, Issue:4, 2002
The value of atypical antipsychotics in the treatment of schizophrenia.Managed care (Langhorne, Pa.), , Volume: 11, Issue:7 Suppl, 2002
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 12, Issue:2, 2002
[Zyprexa with superior effectiveness-risk relation. For every therapy situation a suitable dosage form].Krankenpflege Journal, , Volume: 40, Issue:3-4, 2002
Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial.The journal of ECT, , Volume: 18, Issue:2, 2002
From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications.The American journal of psychiatry, , Volume: 159, Issue:9, 2002
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.Schizophrenia research, , Oct-01, Volume: 57, Issue:2-3, 2002
Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.Schizophrenia research, , Oct-01, Volume: 57, Issue:2-3, 2002
Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients.Schizophrenia research, , Oct-01, Volume: 57, Issue:2-3, 2002
[Olanzapine-induced diabetes mellitus].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
Continuum of care: stabilizing the acutely agitated patient.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Sep-01, Volume: 59, Issue:17 Suppl 5, 2002
Clinical issues associated with maintenance treatment of patients with schizophrenia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Sep-01, Volume: 59, Issue:17 Suppl 5, 2002
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:3, 2002
Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Olanzapine-associated neuroleptic malignant syndrome.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:5, 2002
"Normalization" of brain activation in schizophrenia. An fMRI study.Schizophrenia research, , Dec-01, Volume: 58, Issue:2-3, 2002
Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.International clinical psychopharmacology, , Volume: 17, Issue:6, 2002
Weight gain associated with atypical antipsychotics.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 41, Issue:11, 2002
Effects of olanzapine and clozapine upon pulse rate variability.Depression and anxiety, , Volume: 16, Issue:3, 2002
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.Archives of general psychiatry, , Volume: 59, Issue:11, 2002
Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 47, Issue:8, 2002
Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.The International journal of neuroscience, , Volume: 112, Issue:7, 2002
Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 14, Issue:4, 2002
A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.Current medical research and opinion, , Volume: 18, Issue:6, 2002
[Zyprexa (olanzapine)--new possibilities in the treatment of schizophrenia].Voenno-meditsinskii zhurnal, , Volume: 323, Issue:9, 2002
Comparable dopamine 2 receptor occupancy.The American journal of psychiatry, , Volume: 159, Issue:12, 2002
Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:6, 2002
Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:6, 2002
Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study.Journal of clinical psychopharmacology, , Volume: 22, Issue:6, 2002
5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia.Journal of clinical psychopharmacology, , Volume: 22, Issue:6, 2002
D-fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients.Psychiatry research, , Dec-15, Volume: 113, Issue:1-2, 2002
Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia.Journal of clinical pharmacy and therapeutics, , Volume: 27, Issue:6, 2002
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:7-8, 2002
Prescribing second-generation antipsychotics and the evolving standard of care in Italy.Pharmacopsychiatry, , Volume: 35, Issue:6, 2002
Olanzapine treatment for patients with schizophrenia and cocaine abuse.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
Use of olanzapine for elderly patients with psychotic disorders: a review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 13, Issue:4, 2001
Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).BMC psychiatry, , Volume: 1, 2001
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.Schizophrenia bulletin, , Volume: 27, Issue:4, 2001
Olanzapine versus other antipsychotics in the treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 62, Issue:10, 2001
Service use and costs of treating schizophrenia with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 62, Issue:10, 2001
[Clinical and pharmacological studies of the second generation antipsychotics].Fukuoka igaku zasshi = Hukuoka acta medica, , Volume: 92, Issue:11, 2001
[Heart rate variability in schizophrenic patients treated with antipsychotic agents].Harefuah, , Volume: 140, Issue:12, 2001
Olanzapine treatment for patients with schizophrenia and substance abuse.Journal of substance abuse treatment, , Volume: 21, Issue:4, 2001
The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:4, 2001
[Efficacy of rispolept and zyprexa in the treatment of patients with schizophrenia].Voenno-meditsinskii zhurnal, , Volume: 322, Issue:10, 2001
The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia.Journal of clinical psychopharmacology, , Volume: 21, Issue:6, 2001
[Olanzapine and pregnancy. 2 case reports].Der Nervenarzt, , Volume: 72, Issue:11, 2001
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.Biological psychiatry, , Dec-01, Volume: 50, Issue:11, 2001
Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia.Neuroscience, , Volume: 107, Issue:4, 2001
Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.European archives of psychiatry and clinical neuroscience, , Volume: 251, Issue:3, 2001
P300 and symptom improvement in schizophrenia.Psychopharmacology, , Volume: 158, Issue:1, 2001
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:11, 2001
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.The Journal of clinical psychiatry, , Volume: 62, Issue:9, 2001
Global index of safety (GIS): a new instrument to assess drug safety.Journal of clinical epidemiology, , Volume: 54, Issue:11, 2001
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.The international journal of neuropsychopharmacology, , Volume: 4, Issue:3, 2001
Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine.Psychopharmacology, , Volume: 157, Issue:4, 2001
Are African American patients at a higher risk for olanzapine-induced glucose intolerance?Psychopharmacology, , Volume: 157, Issue:3, 2001
Review of atypical antipsychotics and weight gain.The Journal of clinical psychiatry, , Volume: 62 Suppl 23, 2001
Hyperglycemia associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 23, 2001
Ziprasidone: a new atypical antipsychotic.Expert opinion on pharmacotherapy, , Volume: 2, Issue:6, 2001
Re: Weight change with antipsychotic use.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:7, 2001
Agranulocytosis and neutropenia with typical and atypical neuroleptics.The American journal of psychiatry, , Volume: 158, Issue:10, 2001
Association of olanzapine-induced weight gain with an increase in body fat.The American journal of psychiatry, , Volume: 158, Issue:10, 2001
[Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy].Der Nervenarzt, , Volume: 72, Issue:9, 2001
D2 receptor occupancy under recommended and high doses of olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:3, 2001
Tissue distribution of olanzapine in a postmortem case.The American journal of forensic medicine and pathology, , Volume: 22, Issue:3, 2001
The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 25, Issue:4, 2001
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.Psychiatry research, , Aug-25, Volume: 107, Issue:2, 2001
Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task.Psychological medicine, , Volume: 31, Issue:6, 2001
Maternal obesity and risk of neural tube defects.Canadian family physician Medecin de famille canadien, , Volume: 47, 2001
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.The Journal of clinical psychiatry, , Volume: 62, Issue:7, 2001
Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Effectiveness of clozapine and olanzapine: a comparison in severe, psychotically ill patients.The international journal of neuropsychopharmacology, , Volume: 4, Issue:2, 2001
Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study.Psychopharmacology, , Volume: 156, Issue:1, 2001
Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study.International clinical psychopharmacology, , Volume: 16, Issue:4, 2001
Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study.International clinical psychopharmacology, , Volume: 16, Issue:4, 2001
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.Clinical therapeutics, , Volume: 23, Issue:6, 2001
Writer's cramp induced by olanzapine.Journal of neurology, , Volume: 248, Issue:5, 2001
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.The Journal of nervous and mental disease, , Volume: 189, Issue:6, 2001
A program for treating olanzapine-related weight gain.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:7, 2001
Olanzapine-induced somnambulism.The American journal of psychiatry, , Volume: 158, Issue:7, 2001
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.The American journal of psychiatry, , Volume: 158, Issue:7, 2001
Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 16, Issue:4, 2001
Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients.Psychoneuroendocrinology, , Volume: 26, Issue:6, 2001
Interaction of olanzapine with fluvoxamine.Psychopharmacology, , Volume: 155, Issue:2, 2001
Antiaggressive action of atypical antipsychotics in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 21, Issue:3, 2001
Hyperglycemia in patients with schizophrenia who are treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 21, Issue:3, 2001
Cognitive behavior therapy for weight gain.The American journal of psychiatry, , Volume: 158, Issue:6, 2001
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Hypothesis and hypothesis testing in the clinical trial.The Journal of clinical psychiatry, , Volume: 62 Suppl 9, 2001
Dopamine receptor responsivity in schizophrenic patients in a drug-free state and after treatment with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 25, Issue:3, 2001
Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone.Schizophrenia research, , Apr-30, Volume: 49, Issue:3, 2001
The pharmacology of weight gain with antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 7, 2001
Antipsychotic-induced weight gain: a review of the literature.The Journal of clinical psychiatry, , Volume: 62 Suppl 7, 2001
Olanzapine-induced diabetes mellitus.The Annals of pharmacotherapy, , Volume: 35, Issue:5, 2001
Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:5, 2001
Olanzapine and negative and positive symptoms.The American journal of psychiatry, , Volume: 158, Issue:5, 2001
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 158, Issue:5, 2001
Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents.Psychopharmacology, , Mar-01, Volume: 154, Issue:2, 2001
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.The Journal of clinical psychiatry, , Volume: 62, Issue:3, 2001
Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.The American journal of psychiatry, , Volume: 158, Issue:4, 2001
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.Schizophrenia research, , Mar-01, Volume: 48, Issue:1, 2001
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.The Journal of clinical psychiatry, , Volume: 62, Issue:2, 2001
Priapism associated with polypharmacy.The Journal of clinical psychiatry, , Volume: 62, Issue:2, 2001
Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients.International journal of geriatric psychiatry, , Volume: 16, Issue:2, 2001
Dose-dependent olanzapine-associated leukopenia: three case reports.International clinical psychopharmacology, , Volume: 16, Issue:2, 2001
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Weight change and atypical antipsychotic treatment in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Introduction: a new era in the pharmacotherapy of psychotic disorders.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.The American journal of psychiatry, , Volume: 158, Issue:3, 2001
Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:1, 2001
Olanzapine: an updated review of its use in the management of schizophrenia.Drugs, , Volume: 61, Issue:1, 2001
[Olanzapine and pregnancy].Orvosi hetilap, , Jan-21, Volume: 142, Issue:3, 2001
A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure.Journal of chromatography. B, Biomedical sciences and applications, , Jan-05, Volume: 750, Issue:1, 2001
Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.Journal of clinical psychopharmacology, , Volume: 21, Issue:1, 2001
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 21, Issue:1, 2001
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.Biological psychiatry, , Jan-01, Volume: 49, Issue:1, 2001
Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.Schizophrenia research, , Jan-15, Volume: 47, Issue:1, 2001
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.Annual review of medicine, , Volume: 52, 2001
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.The American journal of psychiatry, , Volume: 158, Issue:2, 2001
Misdiagnosis of schizophrenia for a patient with epilepsy.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:1, 2001
Olanzapine: concordant response in monozygotic twins with schizophrenia.The British journal of psychiatry : the journal of mental science, , Volume: 178, Issue:1, 2001
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Olanzapine: an atypical antipsychotic for schizophrenia.Expert opinion on pharmacotherapy, , Volume: 1, Issue:2, 2000
Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.PharmacoEconomics, , Volume: 18, Issue:6, 2000
The effectiveness of combining lithium with olanzapine in the treatment of resistant schizophrenia.The Journal of clinical psychiatry, , Volume: 61, Issue:12, 2000
Switching clozapine responders to olanzapine.The Journal of clinical psychiatry, , Volume: 61, Issue:12, 2000
Exacerbation of chronic large plaque psoriasis associated with Olanzepine therapy.Journal of the European Academy of Dermatology and Venereology : JEADV, , Volume: 14, Issue:4, 2000
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].Wiener klinische Wochenschrift, , Dec-22, Volume: 112, Issue:24, 2000
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.Journal of psychopharmacology (Oxford, England), , Volume: 14, Issue:4, 2000
Epidemic of schizophrenia in children or inappropriate prescribing?The Medical journal of Australia, , Nov-20, Volume: 173, Issue:10, 2000
Reversal of rabbit syndrome with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:1, 2000
Drug review "surprises" reader.Canadian family physician Medecin de famille canadien, , Volume: 46, 2000
[Olanzapine (Zyprexa)].Presse medicale (Paris, France : 1983), , Dec-09, Volume: 29, Issue:38, 2000
Neuroleptic therapy influences basal ganglia activation: a functional magnetic resonance imaging study comparing controls to haloperidol- and olanzapine-treated inpatients.Psychiatry and clinical neurosciences, , Volume: 54, Issue:6, 2000
Atypical neuroleptics in child and adolescent psychiatry.European child & adolescent psychiatry, , Volume: 9 Suppl 1, 2000
Olanzapine prolongation of granulocytopenia after clozapine discontinuation.Journal of clinical psychopharmacology, , Volume: 20, Issue:6, 2000
Neuropletic malignant syndrome and olanzapine.Journal of clinical psychopharmacology, , Volume: 20, Issue:6, 2000
Hematologic reference ranges in a population of patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 20, Issue:6, 2000
Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution.The Journal of clinical psychiatry, , Volume: 61, Issue:11, 2000
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.The Journal of clinical psychiatry, , Volume: 61, Issue:11, 2000
Olanzapine and pancreatitis.The British journal of psychiatry : the journal of mental science, , Volume: 177, 2000
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.BMJ (Clinical research ed.), , Dec-02, Volume: 321, Issue:7273, 2000
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.The Journal of clinical psychiatry, , Volume: 61, Issue:10, 2000
Neuroleptic malignant syndrome associated with olanzapine therapy: a case report.The Journal of emergency medicine, , Volume: 19, Issue:4, 2000
Disposition of olanzapine in Chinese schizophrenic patients.International journal of clinical pharmacology and therapeutics, , Volume: 38, Issue:10, 2000
[Bullae induced by acute neuroleptic intoxication].Annales de dermatologie et de venereologie, , Volume: 127, Issue:10, 2000
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.Clinical therapeutics, , Volume: 22, Issue:9, 2000
The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.Clinical therapeutics, , Volume: 22, Issue:9, 2000
Risperidone and tardive dyskinesia: a case of blepharospasm.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:5, 2000
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment.Acta psychiatrica Scandinavica, , Volume: 102, Issue:3, 2000
Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine.Schizophrenia research, , Jun-16, Volume: 43, Issue:2-3, 2000
Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia.Journal of clinical psychopharmacology, , Volume: 20, Issue:5, 2000
Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group.Psychiatry and clinical neurosciences, , Volume: 54, Issue:4, 2000
First person account: I and I, dancing fool, challenge you the world to a duel.Schizophrenia bulletin, , Volume: 26, Issue:3, 2000
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.International clinical psychopharmacology, , Volume: 15, Issue:5, 2000
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17, Issue:6, 2000
Olanzapine and obsessive-compulsive symptoms.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 10, Issue:5, 2000
[Atypical antipsychotic drugs].Nederlands tijdschrift voor geneeskunde, , Aug-19, Volume: 144, Issue:34, 2000
Olanzapine: keep an eye on this neuroleptic.Canadian family physician Medecin de famille canadien, , Volume: 46, 2000
St. John's wort and schizophrenia.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Aug-08, Volume: 163, Issue:3, 2000
Olanzapine overdose.Anaesthesia, , Volume: 55, Issue:9, 2000
Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.PharmacoEconomics, , Volume: 17, Issue:4, 2000
Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.Acta psychiatrica Scandinavica, , Volume: 102, Issue:2, 2000
Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine.Psychopharmacology, , Volume: 150, Issue:3, 2000
Antipsychotics during pregnancy.The American journal of psychiatry, , Volume: 157, Issue:8, 2000
Risperidone versus other atypical antipsychotic medication for schizophrenia.The Cochrane database of systematic reviews, , Issue:3, 2000
Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.Psychopharmacology, , Volume: 150, Issue:2, 2000
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.International clinical psychopharmacology, , Volume: 15, Issue:3, 2000
In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 23, Issue:1, 2000
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.Clinical therapeutics, , Volume: 22, Issue:5, 2000
A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia.Pharmacopsychiatry, , Volume: 33, Issue:3, 2000
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.The Journal of clinical psychiatry, , Volume: 61, Issue:5, 2000
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].Der Nervenarzt, , Volume: 71, Issue:5, 2000
[Atypical antipsychotics].Der Nervenarzt, , Volume: 71, Issue:5, 2000
Novel antipsychotic use in schizophrenia.The Journal of clinical psychiatry, , Volume: 61, Issue:3, 2000
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.The American journal of psychiatry, , Volume: 157, Issue:6, 2000
Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia.The American journal of psychiatry, , Volume: 157, Issue:6, 2000
Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia.Journal of clinical psychopharmacology, , Volume: 20, Issue:3, 2000
[The experience of application of olanzapine: an atypical neuroleptic in acute schizophrenia].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 100, Issue:4, 2000
Adverse events related to olanzapine.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Risperidone side effects.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Issue:2, 2000
Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.The American journal of psychiatry, , Volume: 157, Issue:5, 2000
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.East African medical journal, , Volume: 77, Issue:2, 2000
Olanzapine: safe during clozapine-induced agranulocytosis.Journal of clinical psychopharmacology, , Volume: 20, Issue:2, 2000
Rabbit syndrome treated with olanzapine.The British journal of psychiatry : the journal of mental science, , Volume: 176, 2000
[Atypical neuroleptics in child- and adolescent psychiatry].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 28, Issue:1, 2000
The treatment of tardive dyskinesia and tardive dystonia.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 61 Suppl 3, 2000
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.Archives of general psychiatry, , Volume: 57, Issue:3, 2000
New antipsychotic medications: more than old wine and new bottles.Bulletin of the Menninger Clinic, ,Winter, Volume: 64, Issue:1, 2000
Olanzapine. Keep an eye on this neuroleptic.Canadian family physician Medecin de famille canadien, , Volume: 46, 2000
Intoxication with olanzapine.The American journal of psychiatry, , Volume: 157, Issue:2, 2000
Quality of life and new antipsychotics in schizophrenia. Are patients better off?The International journal of social psychiatry, ,Winter, Volume: 45, Issue:4, 1999
Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.Psychiatry research, , Nov-08, Volume: 92, Issue:1, 1999
Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.European archives of psychiatry and clinical neuroscience, , Volume: 249 Suppl 2, 1999
Differential olanzapine plasma concentrations by sex in a fixed-dose study.Schizophrenia research, , Nov-30, Volume: 40, Issue:2, 1999
Reduction of tardive dystonia with olanzapine.The American journal of psychiatry, , Volume: 156, Issue:12, 1999
Olanzapine increases weight and serum triglyceride levels.The Journal of clinical psychiatry, , Volume: 60, Issue:11, 1999
Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
Pharmacologic treatment of schizophrenia.Biological psychiatry, , Nov-15, Volume: 46, Issue:10, 1999
High-dose olanzapine therapy in schizophrenia.The Annals of pharmacotherapy, , Volume: 33, Issue:11, 1999
Body mass index increase of 58% associated with olanzapine.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 60, Issue:10, 1999
Weight gain associated with antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 60 Suppl 21, 1999
Evaluation of outcomes for atypical antipsychotic therapy and psychosocial rehabilitation in a community mental health center setting. Based on a presentation by Douglas Noordsy, MD.The American journal of managed care, , Volume: 5, Issue:10 Suppl, 1999
The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.The American journal of managed care, , Volume: 5, Issue:10 Suppl, 1999
Olanzapine. A pharmacoeconomic review of its use in schizophrenia.PharmacoEconomics, , Volume: 15, Issue:6, 1999
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.PharmacoEconomics, , Volume: 15, Issue:5, 1999
Pustular eruption induced by olanzapine, a novel antipsychotic agent.Journal of the American Academy of Dermatology, , Volume: 41, Issue:5 Pt 2, 1999
Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting.The Journal of clinical psychiatry, , Volume: 60 Suppl 19, 1999
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 60 Suppl 19, 1999
Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:7, 1999
A new mechanism for the actions of olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:6, 1999
[Clinical efficacy of olanzapine].Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, , Volume: 19, Issue:3, 1999
Focus on olanzapine.Current medical research and opinion, , Volume: 15, Issue:2, 1999
Olanzapine-induced elevation of plasma triglyceride levels.The American journal of psychiatry, , Volume: 156, Issue:9, 1999
In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.Psychiatry research, , Apr-26, Volume: 90, Issue:2, 1999
Benefits of olanzapine as first-line schizophrenia therapy.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Aug-01, Volume: 56, Issue:15, 1999
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, , Volume: 8, Issue:5, 1999
Olanzapine-induced agranulocytosis.Lancet (London, England), , Aug-14, Volume: 354, Issue:9178, 1999
[Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon].Annales francaises d'anesthesie et de reanimation, , Volume: 18, Issue:6, 1999
Olanzapine versus haloperidol treatment in first-episode psychosis.The American journal of psychiatry, , Volume: 156, Issue:1, 1999
British experience with high-dose olanzapine for treatment-refractory schizophrenia.The American journal of psychiatry, , Volume: 156, Issue:1, 1999
Conventional vs. newer antipsychotics in elderly patients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Winter, Volume: 7, Issue:1, 1999
In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.Psychopharmacology, , Volume: 141, Issue:2, 1999
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.Schizophrenia research, , Jan-04, Volume: 35, Issue:1, 1999
Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.The American journal of psychiatry, , Volume: 156, Issue:2, 1999
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.Biological psychiatry, , Feb-15, Volume: 45, Issue:4, 1999
Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Hyperprolactinemia and male sexual dysfunction.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Cognitive improvement in schizophrenia with novel antipsychotic medications.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Tardive dyskinesia and atypical antipsychotic drugs.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Antipsychotic drugs and relapse prevention.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Tardive dyskinesia in affective disorders.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Cognitive deficit in schizophrenia and its neurochemical basis.The British journal of psychiatry. Supplement, , Issue:37, 1999
Olanzapine in the long-term treatment of schizophrenia.The British journal of psychiatry. Supplement, , Issue:37, 1999
Review of recent clinical studies with olanzapine.The British journal of psychiatry. Supplement, , Issue:37, 1999
Olanzapine: preclinical pharmacology and recent findings.The British journal of psychiatry. Supplement, , Issue:37, 1999
Olanzapine: a basic science update.The British journal of psychiatry. Supplement, , Issue:37, 1999
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.The British journal of psychiatry : the journal of mental science, , Volume: 174, 1999
New-onset panic attacks in a patient treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:2, 1999
Plasma olanzapine and clinical response.Journal of clinical psychopharmacology, , Volume: 19, Issue:2, 1999
Olanzapine-induced obsessive-compulsive disorder.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Side effects of olanzapine.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Antipsychotics from theory to practice: integrating clinical and basic data.The Journal of clinical psychiatry, , Volume: 60 Suppl 8, 1999
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:3, 1999
Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine.Journal of psychiatry & neuroscience : JPN, , Volume: 24, Issue:3, 1999
Weight gain and antipsychotic medications.The Journal of clinical psychiatry, , Volume: 60, Issue:5, 1999
Clozapine: a comparison with other novel antipsychotics.The Journal of clinical psychiatry, , Volume: 60 Suppl 12, 1999
Olanzapine and NMS.Psychiatric services (Washington, D.C.), , Volume: 50, Issue:6, 1999
Tardive dyskinesia associated with olanzapine.Annals of internal medicine, , Jul-06, Volume: 131, Issue:1, 1999
Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.Biological psychiatry, , Jul-01, Volume: 46, Issue:1, 1999
Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency.Biological psychiatry, , Jul-01, Volume: 46, Issue:1, 1999
A dilemma born of progress: switching from clozapine to a newer antipsychotic.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Olanzapine overdose.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Clozapine to olanzapine.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Novel antipsychotics: comparison of weight gain liabilities.The Journal of clinical psychiatry, , Volume: 60, Issue:6, 1999
Marked elevation of serum creatine kinase associated with olanzapine therapy.The Annals of pharmacotherapy, , Volume: 33, Issue:6, 1999
Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 82, Issue:4, 1999
Drug metabolism and atypical antipsychotics.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 9, Issue:4, 1999
Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.Medical care, , Volume: 37, Issue:7, 1999
The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.Biological psychiatry, , Aug-01, Volume: 46, Issue:3, 1999
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.Biological psychiatry, , Aug-01, Volume: 46, Issue:3, 1999
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.European journal of nuclear medicine, , Volume: 26, Issue:8, 1999
Clozapine-olanzapine: a potentially dangerous switch. A report of two cases.Journal of clinical pharmacy and therapeutics, , Volume: 24, Issue:3, 1999
Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:4, 1999
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?The Journal of clinical psychiatry, , Volume: 60, Issue:7, 1999
Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol.PharmacoEconomics, , Volume: 13, Issue:5 Pt 2, 1998
Olanzapine therapy in elderly patients with schizophrenia.Psychopharmacology bulletin, , Volume: 34, Issue:4, 1998
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 18, Issue:1, 1998
Olanzapine on trial.The American journal of psychiatry, , Volume: 155, Issue:1, 1998
Olanzapine on trial.The American journal of psychiatry, , Volume: 155, Issue:1, 1998
Olanzapine on trial.The American journal of psychiatry, , Volume: 155, Issue:1, 1998
Treatment of the refractory schizophrenic patient.The Journal of clinical psychiatry, , Volume: 59 Suppl 1, 1998
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
Marked reduction of tardive dyskinesia with olanzapine.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
Marketing of antipsychotic drugs attacked.BMJ (Clinical research ed.), , Feb-28, Volume: 316, Issue:7132, 1998
Paranoia and agitation associated with olanzapine treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:2, 1998
Management of treatment-resistant schizophrenia with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:2, 1998
Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 37, Issue:4, 1998
Emerging roles for novel antipsychotic medications in the treatment of schizophrenia.The Psychiatric clinics of North America, , Volume: 21, Issue:1, 1998
Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia.The Psychiatric clinics of North America, , Volume: 21, Issue:1, 1998
Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".Journal of clinical psychopharmacology, , Volume: 18, Issue:2, 1998
Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".Journal of clinical psychopharmacology, , Volume: 18, Issue:2, 1998
The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.Psychopharmacology bulletin, , Volume: 34, Issue:1, 1998
The effects of risperidone and olanzapine on the indications for clozapine.Psychopharmacology bulletin, , Volume: 34, Issue:1, 1998
Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , May-15, Volume: 55, Issue:10, 1998
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.Biological psychiatry, , Jun-01, Volume: 43, Issue:11, 1998
Worsening of obsessive-compulsive symptoms following treatment with olanzapine.The American journal of psychiatry, , Volume: 155, Issue:6, 1998
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
Hypersalivation coincident with olanzapine treatment.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
Olanzapine-induced manic-like syndrome.The Journal of clinical psychiatry, , Volume: 59, Issue:6, 1998
Experiences with clozapine and olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 32, Issue:3, 1998
The new antipsychotic compounds: is a clinical choice algorithm possible?The Western journal of medicine, , Volume: 169, Issue:1, 1998
Olanzapine-induced reversible priaprism: a case report.Journal of clinical psychopharmacology, , Volume: 18, Issue:4, 1998
Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.Journal of clinical psychopharmacology, , Volume: 18, Issue:4, 1998
Olanzapine for primary negative symptoms.The American journal of psychiatry, , Volume: 155, Issue:8, 1998
[Schizophrenia and depression. Special aspects in the therapy of women].Der Nervenarzt, , Volume: 69, Issue:7 Suppl Be, 1998
Olanzapine for the treatment of tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 59, Issue:7, 1998
Two new atypical antipsychotics: advantages and disadvantages.South Dakota journal of medicine, , Volume: 51, Issue:8, 1998
Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:6, 1998
Severe akathisia during olanzapine treatment of acute schizophrenia.Pharmacopsychiatry, , Volume: 31, Issue:4, 1998
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.The American journal of psychiatry, , Volume: 155, Issue:10, 1998
Olanzapine augmentation of clozapine.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 10, Issue:3, 1998
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.Schizophrenia research, , Sep-07, Volume: 33, Issue:1-2, 1998
Quality of life and atypical antipsychotics.Journal of clinical psychopharmacology, , Volume: 18, Issue:5, 1998
Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia.Mental health care, , Volume: 1, Issue:6, 1998
Treatment refractory schizophrenia: how should we proceed?The Psychiatric quarterly, ,Winter, Volume: 69, Issue:4, 1998
Novel antipsychotics and new onset diabetes.Biological psychiatry, , Oct-15, Volume: 44, Issue:8, 1998
[Use of novel agents in the treatment of schizophrenia and a look to the future].Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, , Volume: 18, Issue:3, 1998
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
Olanzapine.Hospital medicine (London, England : 1998), , Volume: 59, Issue:9, 1998
Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment.Journal of psychiatry & neuroscience : JPN, , Volume: 23, Issue:5, 1998
Common treatment goals of antipsychotics: acute treatment.The Journal of clinical psychiatry, , Volume: 59 Suppl 19, 1998
Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome.The Journal of clinical psychiatry, , Volume: 59 Suppl 19, 1998
The routine use of atypical antipsychotic agents: maintenance treatment.The Journal of clinical psychiatry, , Volume: 59 Suppl 19, 1998
Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia.International clinical psychopharmacology, , Volume: 13, Issue:6, 1998
Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response.The Journal of clinical psychiatry, , Volume: 59, Issue:11, 1998
Aggression, agitation, and mania with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:10, 1998
Use of atypical neuroleptics in child and adolescent psychiatry.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
A cost-effectiveness clinical decision analysis model for schizophrenia.The American journal of managed care, , Volume: 4, Issue:3, 1998
Atypical antipsychotics and formulary decisions.The American journal of managed care, , Volume: 4 Suppl, 1998
Schizophrenia treatment: the use of atypical drugs--risperdal, zyperexa, and clozaril.The international journal of psychiatric nursing research, , Volume: 4, Issue:2, 1998
Olanzapine for schizophrenia.The Medical letter on drugs and therapeutics, , Jan-17, Volume: 39, Issue:992, 1997
Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.Drugs, , Volume: 53, Issue:2, 1997
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.The American journal of psychiatry, , Volume: 154, Issue:4, 1997
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.The American journal of psychiatry, , Volume: 154, Issue:4, 1997
The promise of new drugs for schizophrenia treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 42, Issue:3, 1997
Olanzapine: a novel atypical neuroleptic agent.Lancet (London, England), , May-03, Volume: 349, Issue:9061, 1997
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 7, Issue:2, 1997
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 58, Issue:5, 1997
Efficacy of olanzapine: an overview of pivotal clinical trials.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Safety of olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Dosing the antipsychotic medication olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Switching antipsychotic medications.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.The American journal of psychiatry, , Volume: 154, Issue:9, 1997
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.Journal of clinical psychopharmacology, , Volume: 17, Issue:5, 1997
High-dose olanzapine for treatment-refractory schizophrenia.The American journal of psychiatry, , Volume: 154, Issue:11, 1997
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.Schizophrenia research, , Jul-25, Volume: 26, Issue:1, 1997
Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia.The Annals of pharmacotherapy, , Volume: 31, Issue:11, 1997
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 48, Issue:12, 1997
Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 17, Issue:6, 1997
Prolongation of clozapine-induced granulocytopenia associated with olanzapine.Journal of clinical psychopharmacology, , Volume: 17, Issue:6, 1997
Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.The Journal of clinical psychiatry, , Volume: 58, Issue:11, 1997
New antipsychotic medications: strategies for evaluation and selected findings.Schizophrenia research, , Oct-30, Volume: 27, Issue:2-3, 1997
[Olanzapine. A new antipsychotic agent].Ugeskrift for laeger, , Nov-24, Volume: 159, Issue:48, 1997
[Olanzapine--a new atypical neuroleptic. A chance for advancement in the therapy of schizophrenia].Der Nervenarzt, , Volume: 68, Issue:7 Suppl Ol, 1997
Olanzapine, sertindole and schizophrenia.Drug and therapeutics bulletin, , Volume: 35, Issue:11, 1997
Effects of antipsychotics on the clinical and psychosocial behavior of patients with schizophrenia.Schizophrenia research, , Dec-19, Volume: 28, Issue:2-3, 1997
Advances in CNS Drugs. Recent advances and considerations in the treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 57, Issue:7, 1996
Using the proportional odds model to assess the relationship between a multi-item and a global item efficacy scale in a psychiatric clinical trial.Journal of biopharmaceutical statistics, , Volume: 6, Issue:2, 1996
The new generation of antipsychotic drugs.International clinical psychopharmacology, , Volume: 11 Suppl 2, 1996
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 14, Issue:2, 1996
Olanzapine: a new atypical antipsychotic.Journal of psychosocial nursing and mental health services, , Volume: 34, Issue:8, 1996
Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.Psychopharmacology bulletin, , Volume: 32, Issue:1, 1996
Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
Cognitive function in schizophrenic patients.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Atypical antipsychotic drugs and long-term outcome in schizophrenia.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Side effect profiles of new antipsychotic agents.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Evaluating outcomes of treatments for persons with psychotic disorders.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
[Olanzapin: a new perspective in the management of schizophrenia. X. Congress of the World Psychiatric Association, Madrid, August 1996].Fortschritte der Neurologie-Psychiatrie, , Volume: 64, Issue:11 Suppl O, 1996
Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics.Journal of clinical psychopharmacology, , Volume: 15, Issue:1 Suppl 1, 1995
First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia.International clinical psychopharmacology, , Volume: 10, Issue:4, 1995
Reconsidering Olanzapine as a Possible Culprit for Drug Fever, defying "Incomplete Neuromalignant Syndrome".The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, , Volume: 168, Issue:4
Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia.The West Virginia medical journal, , Volume: 98, Issue:2
[Ultrastructural changes of lymphocytes in patients with schizophrenia treated with olanzapine].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 116, Issue:3
[Functional status and quality of life in Latin American outpatients with schizophrenia treated with atypical or typical antipsychotics: outcomes of the 12 months schizophrenia outpatient health outcomes (IC-SOHO) Study].Vertex (Buenos Aires, Argentina), , Volume: 16, Issue:63
DEVELOPMENT OF OLANZAPINE LOADED PNA MICROGELS FOR DEPOT DRUG DELIVERY IN TREATMENT OF SCHIZOPHRENIA: IN VITRO AN IN VIVO RELEASE PROFILE.Acta poloniae pharmaceutica, , Volume: 73, Issue:1
Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome.Srpski arhiv za celokupno lekarstvo, , Volume: 143, Issue:11-12
[Clinical impact of atypical antipsychotics: prospective 6-month study of inpatients treated with risperidone or olanzapine].Therapie, , Volume: 56, Issue:6
Paliperidone Palmitate-Induced Retrograde Ejaculation.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:2
Correlation between plasma homovanillic acid levels and the response to atypical antipsychotics in male patients with schizophrenia.Clinical neuropharmacology, , Volume: 28, Issue:6
[Evaluation of therapeutical appropriateness in psychiatric treatment of schizophrenia, by integrating computer data records with clinical audit results].Rivista di psichiatria, , Volume: 50, Issue:6
Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature.Harvard review of psychiatry, , Volume: 13, Issue:6
Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia.General hospital psychiatry, , Volume: 28, Issue:1
Breastfed Infants Exposed to Combined Antipsychotics: Two Case Reports.American journal of therapeutics, , Volume: 23, Issue:6
Acute Necrotizing Pancreatitis Following Olanzapine Treatment and 759C/T Polymorphism of HTR2C Gene: A Case Report.In vivo (Athens, Greece), , Volume: 29, Issue:5
Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain.Journal of psychiatric research, , Volume: 41, Issue:1-2
Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 3, Issue:3
[The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].Psychiatria polska, , Volume: 49, Issue:2
[Guidelines for the use of second-generation long-acting antipsychotics].Psychiatria polska, , Volume: 49, Issue:2
A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:1
[Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].Actas espanolas de psiquiatria, , Volume: 34, Issue:1
[Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine].Psychiatria polska, , Volume: 39, Issue:6
[Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics].Psychiatria polska, , Volume: 39, Issue:6
Improvement of dumping syndrome and oversecretion of glucose-dependent insulinotropic polypeptide following a switch from olanzapine to quetiapine in a patient with schizophrenia.General hospital psychiatry, , Volume: 37, Issue:4
Comparison of olanzapine and risperidone use in psychiatric rehabilitation.Therapie, , Volume: 60, Issue:6
[Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions].Psychiatria polska, , Volume: 48, Issue:6
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 9, Issue:2
Treatment with atypical antipsychotics: new indications and new populations.Journal of psychiatric research, , Volume: 35, Issue:3
Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature.The Journal of the American Board of Family Practice, , Volume: 14, Issue:4
Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: a prospective open label observational study.Indian journal of pharmacology, , Volume: 46, Issue:5
A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning.Journal of sex & marital therapy, , Volume: 32, Issue:4
[Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].Rivista di psichiatria, , Volume: 49, Issue:3
A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia.Clinical neuropharmacology, , Volume: 29, Issue:3
[The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients].Psychiatria polska, , Volume: 47, Issue:4
[Treatment of schizophrenia in subjects with substance use disorders: A review].Actas espanolas de psiquiatria, , Volume: 29, Issue:2
[Cognition, schizophrenia and the effect of antipsychotics].L'Encephale, , Volume: 32, Issue:3 Pt 1
[Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study].Actas espanolas de psiquiatria, , Volume: 29, Issue:1
[Subjective and objective evaluation of treating schizophrenia with classic or atypical drugs].Psychiatria polska, , Volume: 35, Issue:1
[Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia].Psychiatria polska, , Volume: 35, Issue:1
Reversal of pathologic cardiac parameters after transition from clozapine to olanzapine treatment: a case report.Clinical neuropharmacology, , Volume: 24, Issue:2
[Viewpoint of schizophrenic patients: a European survey].L'Encephale, , Volume: 27, Issue:1
Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:3
Cost-effectiveness of olanzapine as a first-line treatment: a comment.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 9, Issue:5
Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy.Journal of psychiatric research, , Volume: 41, Issue:3-4
[A case of leukopenia in treatment with risperidone in an adolescent].L'Encephale, , Volume: 26, Issue:5
Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report.Clinical neuropharmacology, , Volume: 23, Issue:5
Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 35, Issue:3
The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia.Harvard review of psychiatry, , Volume: 21, Issue:1
Cost analysis of schizophrenia treatment with second-generation antipsychotic medications in North Carolina's Medicaid program.Journal of the American Pharmacists Association : JAPhA, , Volume: 47, Issue:1
[Antipsychotics--clever choices].Lakartidningen, , Volume: 104, Issue:7
Betahistine-Associated Weight Loss and Improved Cognitive and Negative Symptoms: Domain in Early-Onset Schizophrenia.American journal of therapeutics, , Volume: 26, Issue:6
Model-Guided Antipsychotic Dose Reduction in Schizophrenia: A Pilot, Single-Blind Randomized Controlled Trial.Journal of clinical psychopharmacology, , Volume: 39, Issue:4
[Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms].Actas espanolas de psiquiatria, , Volume: 35, Issue:2
[Olanzapine-associated neuroleptic malignant syndrome. A case report and favorable response to risperidone].Actas espanolas de psiquiatria, , Volume: 35, Issue:2
[First episode psychoses: psychosocial, interpersonal and cognitive bases for a therapeutic approach].La Clinica terapeutica, , Volume: 158, Issue:1
Olanzapine-Associated Portal and Superior Mesenteric Vein Thrombosis.American journal of therapeutics, , Volume: 27, Issue:4
Insulin Resistance-Related Proteins Are Overexpressed in Patients and Rats Treated With Olanzapine and Are Reverted by Pueraria in the Rat Model.Journal of clinical psychopharmacology, , Volume: 39, Issue:3
A Randomized, 8-Week Study of the Effects of Extended-Release Paliperidone and Olanzapine on Heart Rate Variability in Patients With Schizophrenia.Journal of clinical psychopharmacology, , Volume: 39, Issue:3
A Case of Schizophrenia With Catatonia Resistant to Lorazepam and Olanzapine Monotherapy But Responsive to Combination Treatment: Is It Time to Consider Using Select Second-Generation Antipsychotics Earlier in the Treatment Algorithm for This Patient TypeClinical neuropharmacology, , Volume: 42, Issue:2
Late-Onset Cholestatic Liver Injury During Combination Treatment With Chlorpromazine and Olanzapine: A Case Report.Journal of clinical psychopharmacology, , Volume: 39, Issue:2
Weight and blood pressure changes after switching second-generation antipsychotics in a population of veterans with schizophrenia-related disorders.Journal of the American Pharmacists Association : JAPhA, , Volume: 47, Issue:2
Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.Journal of the American Pharmacists Association : JAPhA, , Volume: 47, Issue:3
Some aspects of psychodynamic response to novel atypical antipsychotics.Harvard review of psychiatry, , Volume: 7, Issue:4
Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study.Advances in therapy, , Volume: 24, Issue:1
[Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].L'Encephale, , Volume: 25, Issue:4
Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders.Clinical neuropharmacology, , Volume: 30, Issue:3
Olanzapine-induced task specific tardive dystonia and its response to carbamazepine: a case report.Neurology India, , Volume: 60, Issue:6
Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia.The American journal on addictions, , Volume: 16, Issue:4
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
A bibliometric analysis of scientific production on atypical antipsychotic drugs from ItalyRivista di psichiatria, , Volume: 52, Issue:6
Near fatal ketoacidosis with olanzapine treatment.Psychosomatics, , Volume: 43, Issue:4
Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia.Indian journal of pharmacology, , Volume: 44, Issue:5
Clinical News.Clinical schizophrenia & related psychoses, , Volume: 11, Issue:1
Olanzapine-induced EDTA-dependent pseudothrombocytopenia.Psychosomatics, , Volume: 43, Issue:5
Treatment of catatonia with olanzapine and amantadine.Psychosomatics, , Volume: 48, Issue:6
[Influence of serotonergic transmission on response to olanzapine].Actas espanolas de psiquiatria, , Volume: 30, Issue:5
Masked clozapine-induced cardiomyopathy.Journal of the American Board of Family Medicine : JABFM, , Volume: 21, Issue:1
Therapeutic drug monitoring of olanzapine: Easy and reliable method for clinical correlation.Indian journal of pharmacology, , Volume: 53, Issue:1
Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.Journal of clinical psychopharmacology, , Volume: 41, Issue:4
Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.Journal of clinical psychopharmacology, , Volume: 41, Issue:3
The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 11, Issue:1
A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.Archives of medical research, , Volume: 33, Issue:6
Is Sitagliptin Effective for Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients? A Double-blind Placebo-controlled Clinical Trial.Journal of clinical psychopharmacology, , Volume: 40, Issue:5
Adjunct Aripiprazole for Obsessive-Compulsive Symptoms Associated With Second-Generation Antipsychotics in 2 Patients With Schizophrenia: Anti-obsessional Efficacy of Partial Agonism.Journal of clinical psychopharmacology, , Volume: 40, Issue:4
[Remission and relapse in the outpatient treatment of patients with schizophrenia. Outcomes at 3 years].Actas espanolas de psiquiatria, , Volume: 36, Issue:4
Esperienze di switch a cariprazina in pazienti schizofrenici con comparsa di effetti collaterali/comorbilità mediche.Rivista di psichiatria, , Volume: 54, Issue:6
[RODOS: risperidone olanzapine drug outcome studies in schizophrenia].L'Encephale, , Volume: 28 Spec No 2 Pt 2
New drug seen as breakthrough in treatment of schizophrenia.Irish medical journal, , Volume: 89, Issue:4
Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.Journal of sex & marital therapy, , Volume: 29, Issue:2
Propofol infusion for the retrieval of the acutely psychotic patient.Air medical journal, , Volume: 31, Issue:1
Treatment of schizophrenia: advances during the decade of the brain.British journal of hospital medicine, , Volume: 56, Issue:11
[Olanzapine in the first episode of schizophrenia in young adults].Psychiatria polska, , Volume: 36, Issue:6 Suppl
Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial.Journal of clinical psychopharmacology, , Volume: 39, Issue:6
Comparing the side effect profile of the atypical antipsychotics.West African journal of medicine, , Volume: 21, Issue:4
Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia.Clinical neuropharmacology, , Volume: 34, Issue:6
High-dose olanzapine for treatment-refractory schizophrenia.Clinical neuropharmacology, , Volume: 26, Issue:2
[Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].Actas luso-espanolas de neurologia, psiquiatria y ciencias afines, , Volume: 25, Issue:4
Lost time, found hope and sorrow: the search for self, connection, and purpose during "awakenings" on the new antipsychotics.Harvard review of psychiatry, , Volume: 5, Issue:4
Speech and language difficulties in a patient with schizophrenia-like disorder: a case report.Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria, , Volume: 20, Issue:3
Olanzapine.British journal of hospital medicine, , Volume: 58, Issue:9
Heart transplantation and schizophrenia.Psychosomatics, , Volume: 44, Issue:3
[Effect of olanzapine treatment on cognitive functions in patients with schizophrenia].Psychiatria polska, , Volume: 36, Issue:6
Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study.General hospital psychiatry, , Volume: 83
[Subjective and objective assessment of memory functions in patients with schizophrenia treated with olanzapine].Psychiatria polska, , Volume: 36, Issue:6
Significant predictors for olanzapine pharmacokinetics: a systematic review of population pharmacokinetic studies.Expert review of clinical pharmacology, , Volume: 16, Issue:6
Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro).Journal of clinical psychopharmacology, , Volume: 43, Issue:3
Effects of Age, Sex, and Comedication on the Plasma Concentrations of Olanzapine in Chinese Patients With Schizophrenia Based on Therapeutic Drug Monitoring Data.Journal of clinical psychopharmacology, , Volume: 42, Issue:6
Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.Clinical therapeutics, , Volume: 20, Issue:6
Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia: A Randomized, Double-Blind, Multicenter Study.Journal of clinical psychopharmacology, , Volume: 42, Issue:4
Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain.Human psychopharmacology, , Volume: 26, Issue:4-5
A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia.Journal of clinical psychopharmacology, , Volume: 41, Issue:6
Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost.The Journal of international medical research, , Volume: 31, Issue:3
Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.Human psychopharmacology, , Volume: 26, Issue:4-5
Psoriasis during therapy with olanzapine.European journal of dermatology : EJD, , Volume: 13, Issue:4
[Cardiovascular risk of haloperidol vs. atypical anti-psychotic drugs in schizophrenia treatment].Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, , Volume: 114, Issue:3
[Olanzapine effects on emotional recognition in treatment refractory schizophrenics].Actas espanolas de psiquiatria, , Volume: 31, Issue:5
[Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial].Psychiatria polska, , Volume: 37, Issue:4
Age and disease severity predict choice of atypical neuroleptic: a signal detection approach to physicians' prescribing decisions.Journal of psychiatric research, , Volume: 37, Issue:6
International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 11, Issue:6
Visceral and subcutaneous fat in patients treated with olanzapine: a case series.Clinical neuropharmacology, , Volume: 33, Issue:5
[The influence of atypical antipsychotics on brain functioning in schizophrenia. A proton magnetic resonance study].Psychiatria polska, , Volume: 44, Issue:3
The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 7, Issue:1
Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 26, Issue:5
Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12 Suppl 3
[Impact of olanzapine on quality of life of patients with schizophrenia: one-year follow-up with the Seville Quality of Life Questionnaire].Actas espanolas de psiquiatria, , Volume: 32, Issue:1
Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 15, Issue:3-4
Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients.Human psychopharmacology, , Volume: 25, Issue:4
Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.Irish journal of medical science, , Volume: 172, Issue:4
Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia.Neuro endocrinology letters, , Volume: 25, Issue:1-2
[SSRI antidepressants and negative schizophrenic symptoms: differences between paroxetine and fluvoxamine in patients treated with olanzapine].Rivista di psichiatria, , Volume: 44, Issue:5
Care maps: atypical antipsychotics. Introduction.Nursing standard (Royal College of Nursing (Great Britain) : 1987), , Volume: 18, Issue:36
[Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].Psychiatria polska, , Volume: 38, Issue:3
[Olanzapine versus haloperidol: effectiveness in functionality and health state in a sample of Venezuelan patients with schizophrenia].Vertex (Buenos Aires, Argentina), , Volume: 19, Issue:81
[The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings of the Spanish sample].Actas espanolas de psiquiatria, , Volume: 32, Issue:4
Olanzapine-induced clinical seizure: a case report.Clinical neuropharmacology, , Volume: 32, Issue:5
Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients.Indian journal of physiology and pharmacology, , Volume: 53, Issue:1
Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 7, Issue:5
Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12, Issue:5
[Antipsychotics in clinical practice. The refractory schizophrenic patients treatment].Psychiatria polska, , Volume: 42, Issue:6
[Antipsychotics in clinical practice. Treatment of the first schizophrenic episode].Psychiatria polska, , Volume: 42, Issue:6
The utility of intramuscular ziprasidone in the management of acute psychotic agitation.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:3
[Subjective and objective evaluation of olanzapine treatment in schizophrenia].Psychiatria polska, , Volume: 38, Issue:5
[Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].Actas espanolas de psiquiatria, , Volume: 32, Issue:5
Allelic frequencies of 3' Ig heavy chain locus enhancer HS1,2-A associated with Ig levels in patients with schizophrenia.International journal of immunopathology and pharmacology, , Volume: 22, Issue:1
Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics.Journal of the American Pharmacists Association : JAPhA, , Volume: 49, Issue:2
Low delta sleep predicted a good clinical response to olanzapine administration in schizophrenic patients.Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, , Volume: 56, Issue:3
Assessing cost-effectiveness of drug interventions for schizophrenia.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:1-2
[Olanzapine--high potency antipsychotic drug inducing significant weight gain: a case report].Srpski arhiv za celokupno lekarstvo, , Volume: 136, Issue:5-6
Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 8, Issue:2
The art of prescribing. Principles of switching novel antipsychotic medications.Perspectives in psychiatric care, , Volume: 41, Issue:1
The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:3
Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:2
Role of 5HT1A and 5HT2A receptors and default mode network in olanzapine-induced somnambulism.Neurology India, , Volume: 65, Issue:2
Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia.Journal of dual diagnosis, , Volume: 13, Issue:1
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].L'Encephale, , Volume: 31, Issue:2
Reducing Restraint With Clozapine in Involuntarily Admitted Patients With Schizophrenia.American journal of therapeutics, , Volume: 24, Issue:2
Rating of textual associations in organized and nonorganized sentences for the assessment of semantic networks in schizophrenia.Comprehensive psychiatry, , Volume: 46, Issue:3
Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases.Clinical neuropharmacology, , Volume: 28, Issue:4
Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder.Psychiatry and clinical neurosciences, , Volume: 61, Issue:4, 2007
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.CNS spectrums, , Volume: 12, Issue:3 Suppl 4, 2007
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.Journal of psychiatric research, , Volume: 41, Issue:8, 2007
Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder.Schizophrenia research, , Nov-01, Volume: 71, Issue:1, 2004
Serotonin syndrome and atypical antipsychotics.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.Psychiatry research, , Oct-30, Volume: 96, Issue:2, 2000
Long-term chemogenetic suppression of seizures in a multifocal rat model of temporal lobe epilepsy.Epilepsia, , Volume: 62, Issue:3, 2021
Generalised tonic-clonic seizures on the subtherapeutic dose of olanzapine.BMJ case reports, , Dec-29, Volume: 12, Issue:12, 2019
Olanzapine-related repetitive focal seizures with lingual dystonia.Epileptic disorders : international epilepsy journal with videotape, , Volume: 18, Issue:1, 2016
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 12, Issue:1, 2015
Cardiotoxicity in a citalopram and olanzapine overdose.The Journal of emergency medicine, , Volume: 45, Issue:4, 2013
Seizure after intrathecal baclofen bolus in a multiple sclerosis patient treated with oxcarbazepine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 32, Issue:2, 2011
The effect of olanzapine pretreatment on acute cocaine toxicity in mice.Clinical toxicology (Philadelphia, Pa.), , Volume: 47, Issue:6, 2009
Neurotoxicity with therapeutic lithium levels: a case report.Journal of psychiatric practice, , Volume: 15, Issue:1, 2009
Long-term cognitive deficits accompanied by reduced neurogenesis after soman poisoning.Neurotoxicology, , Volume: 30, Issue:1, 2009
Serum levels of olanzapine in a non-fatal overdose.Journal of analytical toxicology, , Volume: 31, Issue:2, 2007
Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report.Psychiatria Danubina, , Volume: 18, Issue:1-2, 2006
[A 74-year-old unconscious woman with myoclonia and seizures].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Sep-07, Volume: 126, Issue:17, 2006
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current opinion in pediatrics, , Volume: 17, Issue:2, 2005
Seizures associated with memantine use.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Feb-15, Volume: 62, Issue:4, 2005
The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy.Ideggyogyaszati szemle, , Nov-20, Volume: 57, Issue:11-12, 2004
Olanzapine-associated seizure.The Annals of pharmacotherapy, , Volume: 37, Issue:1, 2003
Antipsychotic medication and seizures: a review.Drugs of today (Barcelona, Spain : 1998), , Volume: 39, Issue:7, 2003
EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects.Human psychopharmacology, , Volume: 18, Issue:8, 2003
[Brain tumor].Ryoikibetsu shokogun shirizu, , Issue:40, 2003
New-onset seizure associated with quetiapine and olanzapine.The Annals of pharmacotherapy, , Volume: 36, Issue:3, 2002
Lowered seizure threshold on olanzapine.The British journal of psychiatry : the journal of mental science, , Volume: 178, Issue:1, 2001
Seizures caused by possible interaction between olanzapine and clomipramine.Journal of clinical psychopharmacology, , Volume: 20, Issue:2, 2000
Electroencephalogram alterations during treatment with olanzapine.Psychopharmacology, , Volume: 150, Issue:2, 2000
Seizure associated with olanzapine.The Annals of pharmacotherapy, , Volume: 33, Issue:5, 1999
The relationship of pharmacology to side effects.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Side effect profiles of new antipsychotic agents.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Olanzapine-induced clinical seizure: a case report.Clinical neuropharmacology, , Volume: 32, Issue:5
Psychosis in a Patient with Davidoff-Dyke-Masson Syndrome.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:1
Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine.International journal of psychiatry in clinical practice, , Volume: 24, Issue:3, 2020
The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia.Acta psychiatrica Scandinavica, , Volume: 138, Issue:5, 2018
DEVELOPMENT OF LC-MS/MS METHOD FOR DETERMINATION OF THE OLANZAPINE IN HUMAN PLASMA.Georgian medical news, , Issue:263, 2017
Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:4, 2014
Atypical antipsychotics olanzapine, quetiapine, and risperidone and risk of acute major cardiovascular events in young and middle-aged adults: a nationwide register-based cohort study in Denmark.CNS drugs, , Volume: 28, Issue:10, 2014
Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-01, Volume: 45, 2013
Development of a rapid and sensitive SPE-LC-MS/MS method for the simultaneous estimation of fluoxetine and olanzapine in human plasma.Biomedical chromatography : BMC, , Volume: 26, Issue:9, 2012
Quantitative analysis of olanzapine in rat brain microdialysates by HPLC-MS/MS coupled with column-switching technique.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Sep-15, Volume: 905, 2012
Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.BMC psychiatry, , Sep-23, Volume: 11, 2011
Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC).Pharmacoepidemiology and drug safety, , Volume: 20, Issue:11, 2011
Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.Schizophrenia research, , Volume: 128, Issue:1-3, 2011
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.Journal of affective disorders, , Volume: 130, Issue:1-2, 2011
Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials.Schizophrenia research, , Volume: 126, Issue:1-3, 2011
Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid.Journal of pharmaceutical and biomedical analysis, , Nov-02, Volume: 53, Issue:3, 2010
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:2, 2010
Development and validation of a liquid chromatography-isotope dilution tandem mass spectrometry for determination of olanzapine in human plasma and its application to bioavailability study.Yao xue xue bao = Acta pharmaceutica Sinica, , Volume: 45, Issue:6, 2010
Identification and quantification of 30 antipsychotics in blood using LC-MS/MS.Journal of mass spectrometry : JMS, , Volume: 45, Issue:8, 2010
Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study.Schizophrenia research, , Volume: 101, Issue:1-3, 2008
Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.Schizophrenia research, , Volume: 102, Issue:1-3, 2008
Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS/MS.Journal of separation science, , Volume: 31, Issue:1, 2008
Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic states.Nordic journal of psychiatry, , Volume: 60, Issue:2, 2006
Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma.Journal of pharmaceutical and biomedical analysis, , Jun-07, Volume: 41, Issue:3, 2006
Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection.Therapeutic drug monitoring, , Volume: 27, Issue:2, 2005
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:8, 2004
Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Apr-05, Volume: 802, Issue:2, 2004
A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine.Journal of pharmaceutical and biomedical analysis, , Sep-03, Volume: 35, Issue:5, 2004
Applicability of an assay for routine monitoring of highly variable concentrations of olanzapine based on HPLC with mass spectrometric detection.Clinical chemistry, , Volume: 49, Issue:12, 2003
[3-D ultrasound-assisted gait analysis of schizophrenic patients. Comparison between conventional neuroleptics and olanzapine].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
Determination of olanzapine in human blood by liquid chromatography-tandem mass spectrometry.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Feb-05, Volume: 767, Issue:1, 2002
Direct-injection high performance liquid chromatography ion trap mass spectrometry for the quantitative determination of olanzapine, clozapine and N-desmethylclozapine in human plasma.Rapid communications in mass spectrometry : RCM, , Volume: 16, Issue:13, 2002
Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Jun-25, Volume: 773, Issue:2, 2002
Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography.Journal of chromatography. B, Biomedical sciences and applications, , Aug-05, Volume: 759, Issue:1, 2001
Quantitative determination of olanzapine in rat brain tissue by high-performance liquid chromatography with electrochemical detection.Journal of chromatography. B, Biomedical sciences and applications, , Mar-05, Volume: 752, Issue:1, 2001
A high-performance liquid chromatography assay with ultraviolet detection for olanzapine in human plasma and urine.Journal of chromatography. B, Biomedical sciences and applications, , Aug-15, Volume: 759, Issue:2, 2001
A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure.Journal of chromatography. B, Biomedical sciences and applications, , Jan-05, Volume: 750, Issue:1, 2001
5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex.Biological psychiatry, , Aug-01, Volume: 48, Issue:3, 2000
Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection.Journal of pharmaceutical and biomedical analysis, , Volume: 14, Issue:5, 1996
A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.Archives of medical research, , Volume: 33, Issue:6
Association Between Sexual Dysfunction and Dose of Atypical Antipsychotics: Essential to Learn the Basics.Journal of clinical pharmacology, , Volume: 63, Issue:1, 2023
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.International clinical psychopharmacology, , Volume: 27, Issue:4, 2012
Management of sexual dysfunction due to antipsychotic drug therapy.The Cochrane database of systematic reviews, , Nov-14, Volume: 11, 2012
Hypersexual features in Huntington's disease.Singapore medical journal, , Volume: 52, Issue:6, 2011
Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics.The journal of sexual medicine, , Volume: 7, Issue:10, 2010
Excessive masturbation associated with olanzapine in a pediatric case.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 34, Issue:7, 2010
Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 19, Issue:8, 2009
Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone.Psychoneuroendocrinology, , Volume: 34, Issue:7, 2009
Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:2, 2007
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.Psychoneuroendocrinology, , Volume: 31, Issue:5, 2006
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:4, 2006
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.Schizophrenia research, , Volume: 86, Issue:1-3, 2006
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Jan-31, Volume: 81, Issue:2-3, 2006
Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients.International clinical psychopharmacology, , Volume: 20, Issue:1, 2005
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:1, 2004
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.Annals of the New York Academy of Sciences, , Volume: 1032, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial.Journal of psychiatric research, , Volume: 36, Issue:3
Olanzapine-induced retarded ejaculation: role of paroxetine comedication? A case report.Therapie, , Volume: 56, Issue:4
Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.Journal of sex & marital therapy, , Volume: 29, Issue:2
Paliperidone Palmitate-Induced Retrograde Ejaculation.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:2
A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning.Journal of sex & marital therapy, , Volume: 32, Issue:4
Olanzapine poisoning in patients treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: a brief review of serum concentrations and clinical symptoms.Arhiv za higijenu rada i toksikologiju, , Jul-07, Volume: 73, Issue:2, 2022
"Schizophrenia past clozapine": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing.Pharmacopsychiatry, , Volume: 48, Issue:1, 2015
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Hypersalivation induced by olanzapine with fluvoxamine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:4, 2006
Hypersalivation coincident with olanzapine treatment.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
Monosymptomatic hypochondriacal psychosis presenting with recurrent oral mucosal ulcers and multiple skin lesions responding to olanzapine treatment.International journal of dermatology, , Volume: 45, Issue:10, 2006
Eruptive xanthomas associated with olanzapine use.Archives of dermatology, , Volume: 139, Issue:8, 2003
Olanzapine is effective in the management of some self-induced dermatoses: three case reports.Cutis, , Volume: 66, Issue:2, 2000
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature.Schizophrenia research, , Volume: 152, Issue:1, 2014
Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain.Anesthesiology, , Volume: 116, Issue:1, 2012
Olanzapine-induced "restless arms syndrome".Journal of clinical psychopharmacology, , Volume: 29, Issue:1, 2009
Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia.Pharmacopsychiatry, , Volume: 41, Issue:3, 2008
A clinical paradigm of delusions of parasitosis.Journal of the American Academy of Dermatology, , Volume: 59, Issue:4, 2008
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
Olanzapine use in adolescent anorexia nervosa.Eating and weight disorders : EWD, , Volume: 11, Issue:2, 2006
Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review.International clinical psychopharmacology, , Volume: 21, Issue:4, 2006
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 159, Issue:10, 2002
Sleep-related eating disorder induced by olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:7, 2002
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.Archives of general psychiatry, , Volume: 57, Issue:9, 2000
Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Isolated nocturnal auditory hallucinations: a case report.General hospital psychiatry, , Volume: 33, Issue:5
[The use of olanzapine in sleep disorders. An open trial with nine patients].Revista de neurologia, , Volume: 38, Issue:9
The effect of Olanzapine and Sertraline on personality disorder in patients with methadone maintenance therapy.Psychiatria Danubina, , Volume: 22, Issue:4, 2010
Atypical antipsychotic drugs in the treatment of delusional parasitosis.International journal of psychiatry in medicine, , Volume: 37, Issue:1, 2007
Olanzapine augmentation of fluoxetine in body dysmorphic disorder.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
[Olanzapine in therapy of a somatoform disorder].Psychiatrische Praxis, , Volume: 30, Issue:8, 2003
Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Anti-NMDA (a-NMDAR) receptor encephalitis related to acute consumption of metamphetamine: Relevance of differential diagnosis.Revista espanola de anestesiologia y reanimacion, , Volume: 64, Issue:3, 2017
Status epilepticus in a patient treated with olanzapine and mirtazapine.International journal of clinical pharmacology and therapeutics, , Volume: 47, Issue:2, 2009
Fatal status epilepticus associated with olanzapine therapy.The Annals of pharmacotherapy, , Volume: 33, Issue:7-8
Diagnosis and Treatment of Eclamptic Psychosis in the Postpartum Period: A Case Report.Psychosomatics, , Volume: 56, Issue:5
Olanzapine-induced myoclonic status.Clinical neuropharmacology, , Volume: 28, Issue:3
Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy.Anticancer research, , Volume: 37, Issue:12, 2017
Pharmacological and psychosomatic treatments for an elderly patient with severe nausea and vomiting in reaction to postoperative stress.Clinical journal of gastroenterology, , Volume: 8, Issue:5, 2015
[Use of orally disintegrating olanzapine tablet for patients with cancerous peritonitis and postoperative gastric cancer receiving home palliative care].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 39, Issue:4, 2012
Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition.European journal of cancer care, , Volume: 16, Issue:3, 2007
Improvement of dumping syndrome and oversecretion of glucose-dependent insulinotropic polypeptide following a switch from olanzapine to quetiapine in a patient with schizophrenia.General hospital psychiatry, , Volume: 37, Issue:4
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 30, Issue:9, 2020
New-onset psychosis following initiation of eye movement desensitization and reprocessing therapy.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 32, Issue:2, 2020
Repeated olanzapine treatment mitigates PTSD like symptoms in rats with changes in cell signaling factors.Brain research bulletin, , Volume: 140, 2018
Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study.Human psychopharmacology, , Volume: 27, Issue:4, 2012
Premorbid combat related ptsd in Huntington's disease - Case report.Psychiatria Danubina, , Volume: 22, Issue:2, 2010
Posttraumatic brain injury psychosis successfully treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-01, Volume: 34, Issue:1, 2010
The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials.International clinical psychopharmacology, , Volume: 23, Issue:1, 2008
[Antipsychotics, anticonvulsants, antiadrenergics and other drugs: what to do when posttraumatic stress disorder does not respond to selective serotonin reuptake inhibitors?].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 29 Suppl 2, 2007
Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review.International clinical psychopharmacology, , Volume: 21, Issue:4, 2006
Creating more effective antidepressants: clues from the clinic.Drug discovery today, , Volume: 11, Issue:13-14, 2006
Combined use of ECT with duloxetine and olanzapine: a case report.The journal of ECT, , Volume: 22, Issue:2, 2006
Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder.Psychopharmacology, , Volume: 175, Issue:4, 2004
Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports.Acta psychiatrica Scandinavica, , Volume: 107, Issue:5, 2003
Olanzapine treatment for post-traumatic stress disorder: an open-label study.International clinical psychopharmacology, , Volume: 16, Issue:6, 2001
Olanzapine in the treatment of post-traumatic stress disorder: a pilot study.International clinical psychopharmacology, , Volume: 16, Issue:4, 2001
Treatment of posttraumatic stress disorder with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:2, 2001
Olanzapine-lnduced hyperglycemic nonketonic coma.The Annals of pharmacotherapy, , Volume: 35, Issue:3, 2001
Olanzapine for the treatment of acquired neurogenic stuttering.Journal of psychiatric practice, , Volume: 15, Issue:6, 2009
[Acquired stuttering in a psychotic patient].Tijdschrift voor psychiatrie, , Volume: 51, Issue:1, 2009
Comments on Bothe, Davidow, Bramlett, Franic, and Ingham (2006).American journal of speech-language pathology, , Volume: 17, Issue:1, 2008
Alleviating stuttering with pharmacological interventions.Expert opinion on pharmacotherapy, , Volume: 5, Issue:7, 2004
Olanzapine- and clozapine-induced stuttering. A case series.Pharmacopsychiatry, , Volume: 37, Issue:3, 2004
Management of child and adolescent stuttering with olanzapine: three case reports.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 11, Issue:4, 1999
Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:2
Stuttering treated with olanzapine: a case report.Actas espanolas de psiquiatria, , Volume: 40, Issue:4
Olanzapine/samidorphan precipitated opioid withdrawal in a patient taking transdermal fentanyl.Clinical toxicology (Philadelphia, Pa.), , Volume: 60, Issue:7, 2022
A Potential Case of Acute Ketamine Withdrawal: Clinical Implications for the Treatment of Refractory Depression.The American journal of psychiatry, , Volume: 178, Issue:7, 2021
An open-label randomized trial of intramuscular olanzapine versus oral clonidine for symptomatic treatment of opioid withdrawal in the emergency department.Clinical toxicology (Philadelphia, Pa.), , Volume: 57, Issue:8, 2019
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.Bosnian journal of basic medical sciences, , May-20, Volume: 19, Issue:2, 2019
Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database.Journal of clinical psychopharmacology, , Volume: 38, Issue:1, 2018
Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.The Journal of clinical psychiatry, , Volume: 74, Issue:12, 2013
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers.Experimental and clinical psychopharmacology, , Volume: 16, Issue:3, 2008
Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:1, 2008
Effects of olanzapine on ethanol withdrawal syndrome in rats.European journal of pharmacology, , Jan-28, Volume: 579, Issue:1-3, 2008
Managing psychosis in pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:3, 2007
Gamma-hydroxybutyric acid (GHB) withdrawal: a case report.Journal of psychoactive drugs, , Volume: 39, Issue:3, 2007
Olanzapine withdrawal/discontinuation-induced hyperthermia in rats.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 31, Issue:7, 2007
Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats.Alcoholism, clinical and experimental research, , Volume: 31, Issue:9, 2007
Tiagabine withdrawal-emergent mania.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:8, 2006
Olanzapine and serotonin toxicity.Psychiatry and clinical neurosciences, , Volume: 57, Issue:2, 2003
Dependence and chronic psychosis with D-nor-pseudoephedrine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:8, 2003
Characterization of olanzapine-induced weight gain in rats.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:4, 2002
Decreased density of [3H]TCP binding following antipsychotic drug withdrawal in rats.Life sciences, , Apr-19, Volume: 70, Issue:22, 2002
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:1, 2001
Case report of withdrawal syndrome after olanzapine discontinuation.Journal of clinical psychopharmacology, , Volume: 20, Issue:4, 2000
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
The treatment of tardive dyskinesia and tardive dystonia.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Clozapine-olanzapine: a potentially dangerous switch. A report of two cases.Journal of clinical pharmacy and therapeutics, , Volume: 24, Issue:3, 1999
Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:4, 1999
Emergence of koro after abrupt cessation of olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:2, 1998
Olanzapine-induced manic-like syndrome.The Journal of clinical psychiatry, , Volume: 59, Issue:6, 1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Olanzapine for the treatment of tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 59, Issue:7, 1998
Similarities and differences between the subchronic and withdrawal effects of clozapine and olanzapine on forelimb force steadiness.Psychopharmacology, , Volume: 132, Issue:4, 1997
Outcome predictors in cocaine dependence treatment trials.The American journal on addictions, , Volume: 15, Issue:6
[Psychotic syndrome after withdrawal of cyproheptadine: remission with olanzapine].Actas espanolas de psiquiatria, , Volume: 28, Issue:4
[Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients. Interaction with plasma levels].Actas espanolas de psiquiatria, , Volume: 29, Issue:4
Delirium Associated With Fluoxetine Discontinuation: A Case Report.Clinical neuropharmacology, , Volume: 40, Issue:3
[no title available]Ugeskrift for laeger, , May-08, Volume: 185, Issue:19, 2023
Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.The Australian and New Zealand journal of psychiatry, , Volume: 54, Issue:7, 2020
Long-acting injectable olanzapine: post-injection syndrome.Prescrire international, , Volume: 26, Issue:179, 2017
Occurrence of post-injection delirium/sedation syndrome after application of olanzapine long-acting injection during one year period.Psychiatria Danubina, , Volume: 29, Issue:4, 2017
Dhat syndrome as the prodrome of schizophrenia: Understanding the cultural distress.Asian journal of psychiatry, , Volume: 25, 2017
Postinjection Delirium Syndrome Associated With Olanzapine Long-Acting Injectable.Journal of clinical psychopharmacology, , Volume: 36, Issue:4, 2016
Olanzapine as a possible replacement choice for paliperidone-induced Pisa syndrome: a case report.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 24, Issue:6, 2016
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.BMC psychiatry, , Apr-02, Volume: 15, 2015
Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?Basic & clinical pharmacology & toxicology, , Volume: 117, Issue:3, 2015
[Post-injection syndrome after depot injection of olanzapine].Nederlands tijdschrift voor geneeskunde, , Volume: 159, 2014
Olanzapine postinjection delirium/sedation syndrome: an unrecognized diagnosis in the emergency department.The Journal of emergency medicine, , Volume: 47, Issue:1, 2014
[Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].Tijdschrift voor psychiatrie, , Volume: 56, Issue:4, 2014
Long-acting injectable olanzapine can give rise to a condition consistent with central anticholinergic syndrome.Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Nov-12, Volume: 133, Issue:21, 2013
Pisa syndrome secondary to rivastigmine: a case report.La Clinica terapeutica, , Volume: 163, Issue:1, 2012
A case of Klingsor Syndrome: when there is no longer psychosis.The Israel journal of psychiatry and related sciences, , Volume: 48, Issue:1, 2011
The need to consider mood disorders, and especially chronic mania, in cases of Diogenes syndrome (squalor syndrome).International psychogeriatrics, , Volume: 23, Issue:3, 2011
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.BMC psychiatry, , Jun-10, Volume: 10, 2010
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.BMC psychiatry, , Jun-10, Volume: 10, 2010
Rowell's syndrome in the course of treatment with sodium valproate: a case report and review of the literature data.Clinical and experimental dermatology, , Volume: 34, Issue:6, 2009
Olanzapine-induced rabbit syndrome.Southern medical journal, , Volume: 101, Issue:10, 2008
Pisa syndrome resolved after switching to olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 19, Issue:2, 2007
Clozapine effective in olanzapine-induced Pisa syndrome.The Annals of pharmacotherapy, , Volume: 40, Issue:12, 2006
Homatropine and psychosis in Weill-Marchesani syndrome.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 45, Issue:7, 2006
[Rabbit syndrome due to olanzapine].Psychiatrische Praxis, , Volume: 32, Issue:4, 2005
[Brief case report. Duloxetine in Cotard syndrome].Psychiatrische Praxis, , Volume: 32, Issue:8, 2005
Olanzapine therapy in hallucinatory visions related to Bonnet syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 26, Issue:3, 2005
Charles-Bonnet syndrome and musical hallucination.International psychogeriatrics, , Volume: 16, Issue:4, 2004
Cotard's syndrome and electroconvulsive therapy.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:11, 2004
Coexistence of Capgras and Frégoli syndromes in a single patient. Clinical, neuroimaging and neuropsychological findings.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:4, 2002
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Diurnal variation in Cotard's syndrome (copresent with Capgras delusion) following traumatic brain injury.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:4, 2000
Reversal of rabbit syndrome with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:1, 2000
[The hyperglycemic dehydration syndrome].Nederlands tijdschrift voor geneeskunde, , Oct-10, Volume: 142, Issue:41, 1998
Metronome or alternating Pisa syndrome: a form of tardive dystonia under clozapine treatment.International clinical psychopharmacology, , Volume: 13, Issue:5, 1998
Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment.Journal of psychiatry & neuroscience : JPN, , Volume: 23, Issue:5, 1998
A case of catatonia due to posterior reversible encephalopathy syndrome treated successfully with antihypertensives and adjunctive olanzapine.General hospital psychiatry, , Volume: 33, Issue:3
Dose-Dependent Effects of Lithium Treatment on the Aggravation of Antipsychotic-Induced Pisa Syndrome.Clinical neuropharmacology, , Volume: 43, Issue:3
Delayed Onset Postinjection Delirium/Sedation Syndrome Associated With Olanzapine Pamoate: A Case Report.Journal of clinical psychopharmacology, , Volume: 39, Issue:5
Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection.Clinical neuropharmacology, , Volume: 42, Issue:2
[Psychotic syndrome after withdrawal of cyproheptadine: remission with olanzapine].Actas espanolas de psiquiatria, , Volume: 28, Issue:4
[Olanzapine long-acting post-injection syndrome: a case report and brief review].Actas espanolas de psiquiatria, , Volume: 41, Issue:1
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.Drug safety, , Volume: 36, Issue:6, 2013
[The clinical picture of acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients.General hospital psychiatry, , Volume: 30, Issue:4
Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.The oncologist, , Volume: 26, Issue:6, 2021
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.BMJ open, , 07-04, Volume: 9, Issue:7, 2019
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.Japanese journal of clinical oncology, , Sep-01, Volume: 47, Issue:9, 2017
Thrombocytopenia and Spontaneous Intracranial Hemorrhage After Olanzapine Therapy.The Journal of the American Osteopathic Association, , Jul-01, Volume: 117, Issue:7, 2017
Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Thrombocytopenia and fatality associated with olanzapine.European journal of clinical pharmacology, , Volume: 60, Issue:4, 2004
Continuing treatment with novel antipsychotic drugs despite leukopenia or thrombocytopenia.Archives of general psychiatry, , Volume: 58, Issue:7, 2001
Olanzapine-induced thrombocytopenia in association with idiopathic thrombocytopenic purpura.The British journal of psychiatry : the journal of mental science, , Volume: 173, 1998
Thrombocytopenia possibly associated with olanzapine and subsequently with benztropine mesylate.Psychosomatics, , Volume: 41, Issue:3
Olanzapine-induced EDTA-dependent pseudothrombocytopenia.Psychosomatics, , Volume: 43, Issue:5
Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation.Clinical and experimental pharmacology & physiology, , Volume: 34, Issue:8, 2007
A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Olanzapine and venous thromboembolism.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
Peripheral oedema in patients taking olanzapine.International clinical psychopharmacology, , Volume: 18, Issue:1, 2003
Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.Psychopharmacology, , Volume: 183, Issue:4, 2006
Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia.Journal of dual diagnosis, , Volume: 13, Issue:1
Clinical News.Clinical schizophrenia & related psychoses, , Volume: 11, Issue:1
Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey.BMC oral health, , Aug-18, Volume: 12, 2012
Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 44, Issue:3, 2010
Psychogenic tremor in a patient with a major depressive episode.South Dakota medicine : the journal of the South Dakota State Medical Association, , Volume: 62, Issue:6, 2009
Severe dopaminergic pathways damage in a case of chronic toluene abuse.Clinical neurology and neurosurgery, , Volume: 111, Issue:10, 2009
Olanzapine-induced rabbit syndrome.Southern medical journal, , Volume: 101, Issue:10, 2008
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Effects of H1 antagonists on cholinomimetic-induced tremulous jaw movements: studies of diphenhydramine, doxepin, and mepyramine.Pharmacology, biochemistry, and behavior, , Volume: 65, Issue:4, 2000
Conventional psychotropic-induced tremor extinguished by olanzapine.The American journal of psychiatry, , Volume: 155, Issue:8, 1998
Provocation of obsessive-compulsive behaviour and tremor by olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:6, 1998
Similarities and differences between the subchronic and withdrawal effects of clozapine and olanzapine on forelimb force steadiness.Psychopharmacology, , Volume: 132, Issue:4, 1997
Pharmacotherapy for trichotillomania in adults.Expert opinion on pharmacotherapy, , Volume: 21, Issue:12, 2020
[Treatment options for paediatric trichotillomania].Tijdschrift voor psychiatrie, , Volume: 58, Issue:6, 2016
Pharmacotherapy of trichotillomania (hair pulling disorder): an updated systematic review.Expert opinion on pharmacotherapy, , Volume: 15, Issue:18, 2014
Pharmacotherapy for trichotillomania.The Cochrane database of systematic reviews, , Nov-08, Issue:11, 2013
A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania.The Journal of clinical psychiatry, , Volume: 71, Issue:10, 2010
Successful treatment of trichotillomania with olanzapine augmentation in an adolescent.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 14, Issue:1, 2004
An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania.The Journal of clinical psychiatry, , Volume: 64, Issue:1, 2003
Olanzapine augmentation for trichotillomania.The American journal of psychiatry, , Volume: 158, Issue:11, 2001
Olanzapine is effective in the management of some self-induced dermatoses: three case reports.Cutis, , Volume: 66, Issue:2, 2000
Olanzapine augmentation of fluoxetine in the treatment of trichotillomania.The American journal of psychiatry, , Volume: 155, Issue:9, 1998
Olanzapine augmentation of fluoxetine in trichotillomania: two cases.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:1-2
Trichotillomania: a treatment overview.The Journal of practical nursing, , Volume: 56(4)-57(1)
Olanzapine: sudden cardiac death, urinary incontinence.Prescrire international, , Volume: 19, Issue:109, 2010
Olanzapine-induced double incontinence.Indian journal of medical sciences, , Volume: 59, Issue:4, 2005
Olanzapine-induced urinary incontinence: treatment with ephedrine.The Journal of clinical psychiatry, , Volume: 61, Issue:8, 2000
A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy.BMC medical genomics, , 11-03, Volume: 16, Issue:1, 2023
Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Journal of pediatric hematology/oncology, , 10-01, Volume: 45, Issue:7, 2023
Olanzapine for Non-Chemotherapy Related Nausea and Emesis in Patients with a Palliative Care Consult.Journal of pain and symptom management, , Volume: 66, Issue:4, 2023
Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 29, Issue:1, 2023
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).The oncologist, , 08-03, Volume: 28, Issue:8, 2023
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.JAMA network open, , 05-01, Volume: 6, Issue:5, 2023
Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.Cancer treatment reviews, , Volume: 115, 2023
Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.Annals of palliative medicine, , Volume: 12, Issue:3, 2023
Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).BMJ open, , 04-03, Volume: 13, Issue:4, 2023
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 30, Issue:2, 2022
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.Journal of pediatric hematology/oncology, , 11-01, Volume: 44, Issue:8, 2022
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.Investigational new drugs, , Volume: 40, Issue:1, 2022
Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracyBMJ open, , Mar-02, Volume: 12, Issue:3, 2022
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.BMC cancer, , Mar-23, Volume: 22, Issue:1, 2022
Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 30, Issue:7, 2022
The emerging role of olanzapine in paediatric CINV control: A review.Medicine, , Dec-16, Volume: 101, Issue:50, 2022
Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.Annals of hematology, , Volume: 101, Issue:8, 2022
Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report.Neuropsychopharmacology reports, , Volume: 42, Issue:3, 2022
Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor Antagonist.Asian Pacific journal of cancer prevention : APJCP, , Jun-01, Volume: 23, Issue:6, 2022
[Administration Period of Olanzapine as an Antiemetic Drug for Patients on FEC Therapy-A Survey].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 49, Issue:6, 2022
Olanzapine in oncology palliative care.Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, ,Summer, Volume: 35, Issue:4, 2022
Efficacy of Olanzapine for Symptom Relief in Cancer Patients.Journal of pain & palliative care pharmacotherapy, , Volume: 36, Issue:4, 2022
Olanzapine was an effective additional antiemetic for children and young people undergoing highly emetogenic chemotherapy.Archives of disease in childhood. Education and practice edition, , Volume: 107, Issue:4, 2022
Slow Uptake of an Effective Therapy: Patterns of Olanzapine Prescribing for Those Receiving Highly Emetogenic Chemotherapy.JCO oncology practice, , Volume: 18, Issue:12, 2022
Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug.Current oncology (Toronto, Ont.), , 10-31, Volume: 29, Issue:11, 2022
A pooled analysis of adding olanzapine to guideline-recommended antiemetic therapy for breast cancer patients treated with an anthracycline and cyclophosphamide in prospective and retrospective studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 30, Issue:3, 2022
Treatment of Cannabinoid Hyperemesis With Olanzapine: A Case Series.Journal of psychiatric practice, , 07-28, Volume: 27, Issue:4, 2021
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.BMC cancer, , Jul-19, Volume: 21, Issue:1, 2021
Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.The oncologist, , Volume: 26, Issue:6, 2021
Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.Future oncology (London, England), , Volume: 17, Issue:16, 2021
Olanzapine Administration Reduces Chemotherapy-Induced Nausea Behavior in Rats.Biological research for nursing, , Volume: 23, Issue:4, 2021
Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 29, Issue:10, 2021
Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial.Annals of palliative medicine, , Volume: 10, Issue:3, 2021
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 29, Issue:7, 2021
Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?Annals of palliative medicine, , Volume: 10, Issue:3, 2021
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 29, Issue:8, 2021
Olanzapine as a rescue antiemetic in hematopoietic stem cell transplant.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, , Volume: 26, Issue:4, 2020
The Use, Safety, and Efficacy of Olanzapine in a Level I Pediatric Trauma Center Emergency Department Over a 10-Year Period.Pediatric emergency care, , Volume: 36, Issue:2, 2020
The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.International journal of clinical oncology, , Volume: 25, Issue:2, 2020
Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:3, 2020
Time to re-think the olanzapine dose.The Lancet. Oncology, , Volume: 21, Issue:2, 2020
Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:4, 2020
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.Gynecologic oncology, , Volume: 156, Issue:3, 2020
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.Breast (Edinburgh, Scotland), , Volume: 50, 2020
Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analyESMO open, , Volume: 5, Issue:1, 2020
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:11, 2020
A new standard prophylaxis for emesis caused by cisplatin?The Lancet. Oncology, , Volume: 21, Issue:3, 2020
A new standard prophylaxis for emesis caused by cisplatin? - Authors' reply.The Lancet. Oncology, , Volume: 21, Issue:3, 2020
A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin.International journal of clinical pharmacy, , Volume: 42, Issue:2, 2020
The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature.BMC palliative care, , Apr-22, Volume: 19, Issue:1, 2020
Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.JAMA oncology, , 06-01, Volume: 6, Issue:6, 2020
Olanzapine: is it enough for CINV prevention?Annals of palliative medicine, , Volume: 9, Issue:4, 2020
Olanzapine is an effective antiemetic agent.Annals of palliative medicine, , Volume: 9, Issue:3, 2020
Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial.Pediatric blood & cancer, , Volume: 67, Issue:9, 2020
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatinBMJ open, , 12-17, Volume: 10, Issue:12, 2020
The Benefits of Olanzapine in Palliating Symptoms.Current treatment options in oncology, , 11-26, Volume: 22, Issue:1, 2020
A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.Breast (Edinburgh, Scotland), , Volume: 54, 2020
Olanzapine for the Treatment of Breakthrough Vomiting in Children Receiving Moderate and High Emetogenic Chemotherapy.Indian pediatrics, , 11-15, Volume: 57, Issue:11, 2020
Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction.Journal of palliative medicine, , Volume: 23, Issue:7, 2020
Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:8, 2019
Reply to: Comment on: Olanzapine for chemotherapy-induced nausea: Lessons learned from child and adolescent psychiatry.Pediatric blood & cancer, , Volume: 66, Issue:1, 2019
Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.Cancer chemotherapy and pharmacology, , Volume: 84, Issue:1, 2019
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.BMJ open, , 07-04, Volume: 9, Issue:7, 2019
Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.The oncologist, , Volume: 24, Issue:6, 2019
Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study.Tumori, , Volume: 105, Issue:3, 2019
The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:8, 2019
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:3, 2019
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.Journal of global oncology, , Volume: 5, 2019
Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.BMJ open, , 01-17, Volume: 9, Issue:1, 2019
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.Annals of palliative medicine, , Volume: 8, Issue:4, 2019
Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.Scientific reports, , 11-02, Volume: 8, Issue:1, 2018
Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 26, Issue:2, 2018
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.Investigational new drugs, , Volume: 36, Issue:1, 2018
Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.The oncologist, , Volume: 23, Issue:5, 2018
Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation.Clinical lymphoma, myeloma & leukemia, , Volume: 18, Issue:2, 2018
Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.Anticancer research, , Volume: 38, Issue:2, 2018
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving HigBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, , Volume: 24, Issue:10, 2018
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.The Cochrane database of systematic reviews, , 09-21, Volume: 9, 2018
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.Journal of global oncology, , Volume: 4, 2018
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.Medicine, , Volume: 97, Issue:37, 2018
Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiviJapanese journal of clinical oncology, , Oct-01, Volume: 48, Issue:10, 2018
Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.International journal of clinical pharmacy, , Volume: 40, Issue:5, 2018
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.International journal of clinical oncology, , Volume: 23, Issue:2, 2018
[Differential diagnosis and treatment of nausea and vomiting associated with cancer or its treatment].Magyar onkologia, , Sep-20, Volume: 61, Issue:3, 2017
Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.Clinical lymphoma, myeloma & leukemia, , Volume: 17, Issue:9, 2017
NCCN Guidelines Insights: Antiemesis, Version 2.2017.Journal of the National Comprehensive Cancer Network : JNCCN, , Volume: 15, Issue:7, 2017
Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy.Medical oncology (Northwood, London, England), , Dec-16, Volume: 35, Issue:1, 2017
Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.British journal of clinical pharmacology, , Volume: 83, Issue:7, 2017
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.Japanese journal of clinical oncology, , Sep-01, Volume: 47, Issue:9, 2017
New options and controversies in the management of chemotherapy-induced nausea and vomiting.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Jun-01, Volume: 74, Issue:11, 2017
Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.Critical reviews in oncology/hematology, , Volume: 112, 2017
Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 25, Issue:1, 2017
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 25, Issue:2, 2017
Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:6, 2016
Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.Pharmacotherapy, , Volume: 36, Issue:2, 2016
Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:5, 2016
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.Asia-Pacific journal of clinical oncology, , Volume: 12, Issue:3, 2016
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.The New England journal of medicine, , Jul-14, Volume: 375, Issue:2, 2016
Olanzapine for Nausea, Delirium, Anxiety, Insomnia, and Cachexia #315.Journal of palliative medicine, , Volume: 19, Issue:11, 2016
Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy.Japanese journal of clinical oncology, , Volume: 46, Issue:5, 2016
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.JAMA oncology, , Volume: 2, Issue:2, 2016
Olanzapine in the Management of Difficult to Control Nausea and Vomiting in a Palliative Care Population: A Case Series.Journal of palliative medicine, , Volume: 19, Issue:1, 2016
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.Annals of palliative medicine, , Volume: 5, Issue:3, 2016
CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.The New England journal of medicine, , Jul-14, Volume: 375, Issue:2, 2016
Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.Current opinion in supportive and palliative care, , Volume: 10, Issue:2, 2016
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.Biochimica et biophysica acta, , Volume: 1848, Issue:10 Pt B, 2015
Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.Hospital practice (1995), , Volume: 43, Issue:4, 2015
A double-blind randomized Phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy.Japanese journal of clinical oncology, , Volume: 45, Issue:2, 2015
Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature.Journal of pain & palliative care pharmacotherapy, , Volume: 29, Issue:2, 2015
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.Cell biochemistry and biophysics, , Volume: 72, Issue:2, 2015
Administration of olanzapine as an antiemetic agent changes glucose homeostasis in cisplatin-treated rats.Biological & pharmaceutical bulletin, , Volume: 38, Issue:4, 2015
Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review.Pediatric blood & cancer, , Volume: 62, Issue:3, 2015
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.Journal of palliative medicine, , Volume: 18, Issue:11, 2015
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.Critical reviews in oncology/hematology, , Volume: 95, Issue:2, 2015
QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist.European journal of cancer care, , Volume: 24, Issue:3, 2015
Pharmacological and psychosomatic treatments for an elderly patient with severe nausea and vomiting in reaction to postoperative stress.Clinical journal of gastroenterology, , Volume: 8, Issue:5, 2015
Olanzapine for intractable nausea and vomiting in palliative care patients not receiving chemotherapy.Journal of palliative medicine, , Volume: 17, Issue:5, 2014
Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 97, Issue:3, 2014
Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.European journal of pharmacology, , Jan-05, Volume: 722, 2014
The safety of olanzapine in young children: a systematic review and meta-analysis.Drug safety, , Volume: 37, Issue:10, 2014
Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.Journal of pain and symptom management, , Volume: 47, Issue:3, 2014
Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.Journal of cancer research and clinical oncology, , Volume: 140, Issue:1, 2014
A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting.Scientific reports, , Apr-28, Volume: 4, 2014
Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 22, Issue:4, 2014
Effects of low-dose olanzapine on duloxetine-related nausea and vomiting for the treatment of major depressive disorder.Journal of clinical psychopharmacology, , Volume: 34, Issue:4, 2014
Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.Asian Pacific journal of cancer prevention : APJCP, , Volume: 15, Issue:22, 2014
Olanzapine: palliative medicine update.The American journal of hospice & palliative care, , Volume: 30, Issue:1, 2013
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 21, Issue:6, 2013
Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction.Journal of pain and symptom management, , Volume: 44, Issue:4, 2012
Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain.Anesthesiology, , Volume: 116, Issue:1, 2012
Olanzapine for nausea and vomiting.The American journal of hospice & palliative care, , Volume: 27, Issue:6, 2010
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.Journal of experimental & clinical cancer research : CR, , Sep-23, Volume: 28, 2009
Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.Current opinion in supportive and palliative care, , Volume: 2, Issue:1, 2008
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 15, Issue:11, 2007
[Medical treatment of chemotherapy-induced nausea and vomiting].Ugeskrift for laeger, , Feb-26, Volume: 169, Issue:9, 2007
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.Journal of the National Comprehensive Cancer Network : JNCCN, , Volume: 5, Issue:1, 2007
Emerging drugs for chemotherapy-induced emesis.Expert opinion on emerging drugs, , Volume: 11, Issue:1, 2006
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 13, Issue:7, 2005
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.Cancer investigation, , Volume: 22, Issue:3, 2004
A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients.Journal of pain and symptom management, , Volume: 25, Issue:5, 2003
Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.Journal of pain and symptom management, , Volume: 25, Issue:6, 2003
Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.The journal of supportive oncology, , Volume: 9, Issue:5
Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.Indian journal of pharmacology, , Volume: 49, Issue:6
Olanzapine Treatment for Refractory Nausea and Vomiting After Transarterial Embolization for Cerebral Arteriovenous Malformation.American journal of therapeutics, , Volume: 27, Issue:6
Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report.Psycho-oncology, , Volume: 9, Issue:1
Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study.JAMA psychiatry, , 06-01, Volume: 73, Issue:6, 2016
A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study.Minerva anestesiologica, , Volume: 78, Issue:9, 2012
Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey.BMC oral health, , Aug-18, Volume: 12, 2012
Plasma concentrations of high-dose olanzapine in a double-blind crossover study.Human psychopharmacology, , Volume: 21, Issue:6, 2006
Influence of fluoxetine on olanzapine pharmacokinetics.AAPS pharmSci, , Volume: 4, Issue:2, 2002
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.The Journal of clinical psychiatry, , Volume: 61, Issue:7, 2000
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
[The use of antipsychotics in patients with dementia].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:3, 2008
Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.CNS spectrums, , Volume: 12, Issue:1, 2007
Psychosis of Alzheimer disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study.Journal of neurology, , Volume: 252, Issue:10, 2005
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:8, 2005
Memory-sparing cognitive deterioration in the elderly: what is the diagnosis?Reviews in neurological diseases, ,Spring, Volume: 2, Issue:2, 2005
[Cerebral infarct and atypical antipsychotic agents].Psychologie & neuropsychiatrie du vieillissement, , Volume: 2, Issue:4, 2004
[A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy].Der Nervenarzt, , Volume: 74, Issue:7, 2003
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.Southern medical journal, , Volume: 96, Issue:7, 2003
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
Olanzapine as a possible treatment for anxiety due to vascular dementia: an open study.American journal of Alzheimer's disease and other dementias, , Volume: 19, Issue:2
Risk factors for abnormal glucose metabolism during antipsychotic treatment: A prospective cohort study.Journal of psychiatric research, , Volume: 168, 2023
Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.Journal of psychiatric practice, , Volume: 20, Issue:4, 2014
Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 13, Issue:1, 2012
Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells.Prostaglandins, leukotrienes, and essential fatty acids, , Volume: 87, Issue:1, 2012
Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.International clinical psychopharmacology, , Volume: 24, Issue:4, 2009
The risks and benefits of switching antipsychotics: a case study approach.Perspectives in psychiatric care, , Volume: 45, Issue:1, 2009
Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:4, 2008
Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.Schizophrenia research, , Volume: 98, Issue:1-3, 2008
Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia.Internal medicine (Tokyo, Japan), , Volume: 47, Issue:3, 2008
Decreased lipoprotein lipase as a risk factor for atypical neuroleptic-induced hypertriglyceridemia.The Journal of clinical psychiatry, , Volume: 68, Issue:5, 2007
Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.The Journal of clinical psychiatry, , Volume: 67, Issue:9, 2006
Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism.Essential psychopharmacology, , Volume: 6, Issue:2, 2005
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
[Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].Medizinische Klinik (Munich, Germany : 1983), , Jul-15, Volume: 98, Issue:7, 2003
Severe hypertriglyceridemia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Olanzapine and hypertriglyceridemia.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 40, Issue:2, 2001
Novel antipsychotics and severe hyperlipidemia.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Hyperglycemia and hypertriglyceridemia secondary to olanzapine.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 11, Issue:3, 2001
Olanzapine increases weight and serum triglyceride levels.The Journal of clinical psychiatry, , Volume: 60, Issue:11, 1999
Olanzapine-induced elevation of plasma triglyceride levels.The American journal of psychiatry, , Volume: 156, Issue:9, 1999
Profound hypertriglyceridemia and weight gain in the first week following initiation of olanzapine: a case report with implications for lipid monitoring guidelines.Psychosomatics, , Volume: 54, Issue:4
Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy.American journal of therapeutics, , Volume: 10, Issue:5
Tuberous xanthomas associated with olanzapine therapy and hypertriglyceridemia in the setting of a rare apolipoprotein E mutation.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, , Volume: 12, Issue:2
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine.CNS spectrums, , Volume: 28, Issue:3, 2023
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.Schizophrenia bulletin, , 03-15, Volume: 49, Issue:2, 2023
Atypical antipsychotics olanzapine and clozapine increase bone loss in female rats with experimental periodontitis.Journal of periodontal research, , Volume: 58, Issue:2, 2023
Thermoneutral housing and preexisting obesity do not abolish the sexually dimorphic effects of olanzapine on weight gain in mice.Obesity (Silver Spring, Md.), , Volume: 31, Issue:2, 2023
Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gain.Psychopharmacology, , Volume: 240, Issue:4, 2023
Nuclear receptor 5A2 regulation of Agrp underlies olanzapine-induced hyperphagia.Molecular psychiatry, , Volume: 28, Issue:5, 2023
Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 05-10, Volume: 41, Issue:14, 2023
Toxicity manifestations and sex differences due to MARTA olanzapine.The Journal of toxicological sciences, , Volume: 48, Issue:4, 2023
Herbal Therapies for Weight Gain and Metabolic Abnormalities Induced by Atypical Antipsychotics: A Review Article.Current drug discovery technologies, , Volume: 20, Issue:5, 2023
Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China.Asian journal of psychiatry, , Volume: 84, 2023
Hypothalamic JNK1-hepatic fatty acid synthase axis mediates a metabolic rewiring that prevents hepatic steatosis in male mice treated with olanzapine via intraperitoneal: Additional effects of PTP1B inhibition.Redox biology, , Volume: 63, 2023
Longitudinal Gut Microbiota Dysbiosis Underlies Olanzapine-Induced Weight Gain.Microbiology spectrum, , 08-17, Volume: 11, Issue:4, 2023
Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.The international journal of neuropsychopharmacology, , 07-31, Volume: 26, Issue:7, 2023
Antipsychotic-Induced Metabolic Syndrome: A Review.Metabolic syndrome and related disorders, , Volume: 21, Issue:6, 2023
Changes in hypothalamic mu-opioid receptor expression following acute olanzapine treatment in female rats: Implications for feeding behavior.Journal of chemical neuroanatomy, , Volume: 132, 2023
Probable Olanzapine-Related Idiopathic Intracranial Hypertension in an Adolescent With First-Episode Psychosis.Psychopharmacology bulletin, , 08-11, Volume: 53, Issue:3, 2023
Salsalate and/or metformin therapy confer beneficial metabolic effects in olanzapine treated female mice.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 168, 2023
Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:2, 2022
Cyperus rotundus L. reverses the olanzapine-induced weight gain and metabolic changes-outcomes from network and experimental pharmacology.Computers in biology and medicine, , Volume: 141, 2022
Sex Differences in Fish Oil and Olanzapine Effects on Gut Microbiota in Diet-Induced Obese Mice.Nutrients, , Jan-14, Volume: 14, Issue:2, 2022
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.Schizophrenia bulletin, , 05-07, Volume: 48, Issue:3, 2022
Olanzapine-associated dose-dependent alterations for weight and metabolic parameters in a prospective cohort.Basic & clinical pharmacology & toxicology, , Volume: 130, Issue:4, 2022
Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?Expert review of neurotherapeutics, , Volume: 22, Issue:5, 2022
Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia.Molecules (Basel, Switzerland), , Apr-14, Volume: 27, Issue:8, 2022
Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials.Schizophrenia bulletin, , 06-21, Volume: 48, Issue:4, 2022
Psychopharmacologic Management of Eating Disorders.Current psychiatry reports, , Volume: 24, Issue:7, 2022
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.CNS drugs, , Volume: 36, Issue:6, 2022
Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study.Psychiatry research, , Volume: 314, 2022
Increased growth hormone secretagogue receptor-1a (GHSR-1a) in hypothalamus during olanzapine treatment in rats.Psychoneuroendocrinology, , Volume: 144, 2022
Long-term effects of adolescent exposure to olanzapine in C57BL/6 J mice and the impact of dietary fish oil supplementation.Psychopharmacology, , Volume: 239, Issue:10, 2022
Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.Expert review of clinical pharmacology, , Volume: 15, Issue:9, 2022
Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight.Metabolism: clinical and experimental, , Volume: 137, 2022
Chronic agmatine treatment prevents olanzapine-induced obesity and metabolic dysregulation in female rats.Brain research bulletin, , Volume: 191, 2022
Fenofibrate ameliorates olanzapine's side effects without altering its central effect: emphasis on FGF-21-adiponectin axis.Behavioural pharmacology, , 12-01, Volume: 32, Issue:8, 2021
Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis.International journal of molecular sciences, , Nov-16, Volume: 22, Issue:22, 2021
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 133, 2021
The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.Psychopharmacology, , Volume: 238, Issue:3, 2021
Effect of liraglutide on neural and peripheral markers of metabolic function during antipsychotic treatment in rats.Journal of psychopharmacology (Oxford, England), , Volume: 35, Issue:3, 2021
A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.Scientific reports, , 04-07, Volume: 11, Issue:1, 2021
The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain.The Journal of experimental medicine, , 07-05, Volume: 218, Issue:7, 2021
Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia.Journal of psychiatric research, , Volume: 140, 2021
Conserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain.Translational psychiatry, , 07-22, Volume: 11, Issue:1, 2021
Olanzapine/Samidorphan: First Approval.Drugs, , Volume: 81, Issue:12, 2021
Effects of long-term antipsychotics treatment on body weight: A population-based cohort study.Journal of psychopharmacology (Oxford, England), , Volume: 34, Issue:1, 2020
30-year journey from the start of the Human Genome Project to clinical application of genomics in psychiatry: are we there yet?The lancet. Psychiatry, , Volume: 7, Issue:1, 2020
Olanzapine increases AMPK-NPY orexigenic signaling by disrupting H1R-GHSR1a interaction in the hypothalamic neurons of mice.Psychoneuroendocrinology, , Volume: 114, 2020
The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats.Pharmacology, biochemistry, and behavior, , Volume: 191, 2020
Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain.Physiology & behavior, , 06-01, Volume: 220, 2020
Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin.BMC pharmacology & toxicology, , 06-30, Volume: 21, Issue:1, 2020
A Novel Synthetic Interfering Peptide Tat-3L4F Attenuates Olanzapine-Induced Weight Gain Through Disrupting Crosstalk Between Serotonin Receptor 2C and Protein Phosphatase and Tensin Homolog in Rats.The international journal of neuropsychopharmacology, , 11-26, Volume: 23, Issue:8, 2020
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.The American journal of psychiatry, , 12-01, Volume: 177, Issue:12, 2020
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.The lancet. Psychiatry, , Volume: 7, Issue:11, 2020
Metabolomic profiles associated with a mouse model of antipsychotic-induced food intake and weight gain.Scientific reports, , 10-29, Volume: 10, Issue:1, 2020
How Much of an Advance Is the Addition of Samidorphan to Olanzapine?The American journal of psychiatry, , 12-01, Volume: 177, Issue:12, 2020
The side effect profile of Clozapine in real world data of three large mental health hospitals.PloS one, , Volume: 15, Issue:12, 2020
Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review.Nutrients, , Dec-18, Volume: 12, Issue:12, 2020
Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice.Molecular neurobiology, , Volume: 57, Issue:1, 2020
Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.Clinical drug investigation, , Volume: 40, Issue:1, 2020
Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics?Journal of affective disorders, , 01-15, Volume: 261, 2020
Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome.Psychopharmacology, , Volume: 236, Issue:5, 2019
The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial.Schizophrenia research, , Volume: 206, 2019
Do reductions in ghrelin contribute towards antipsychotic-induced weight gain?Schizophrenia research, , Volume: 210, 2019
Olanzapine Versus Placebo in Adult Outpatients With Anorexia Nervosa: A Randomized Clinical Trial.The American journal of psychiatry, , 06-01, Volume: 176, Issue:6, 2019
Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.International journal of molecular sciences, , Feb-01, Volume: 20, Issue:3, 2019
Prebiotic reduction of brain histone deacetylase (HDAC) activity and olanzapine-mediated weight gain in rats, are acetate independent.Neuropharmacology, , 05-15, Volume: 150, 2019
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.The American journal of psychiatry, , 06-01, Volume: 176, Issue:6, 2019
One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects.The international journal of neuropsychopharmacology, , 05-01, Volume: 22, Issue:5, 2019
A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.Clinical drug investigation, , Volume: 39, Issue:5, 2019
Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model.Journal of psychiatric research, , Volume: 115, 2019
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.Toxicology and applied pharmacology, , 09-01, Volume: 378, 2019
Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis.Neuropsychopharmacology reports, , Volume: 39, Issue:3, 2019
Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.Journal of psychopharmacology (Oxford, England), , Volume: 33, Issue:10, 2019
Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.Medical decision making : an international journal of the Society for Medical Decision Making, , Volume: 39, Issue:5, 2019
Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.Schizophrenia research, , Volume: 212, 2019
Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.The Journal of clinical psychiatry, , 08-27, Volume: 80, Issue:5, 2019
Berberine attenuates olanzapine induced-metabolic syndrome.JPMA. The Journal of the Pakistan Medical Association, , Volume: 69(Suppl 3), Issue:8, 2019
Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia.American journal of physiology. Endocrinology and metabolism, , 08-01, Volume: 315, Issue:2, 2018
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5, 2018
Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5, 2018
No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment.Acta psychiatrica Scandinavica, , Volume: 138, Issue:2, 2018
A role of neuropeptide CART in hyperphagia and weight gain induced by olanzapine treatment in rats.Brain research, , 09-15, Volume: 1695, 2018
Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:7, 2018
Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:10, 2018
Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.Clinical therapeutics, , Volume: 40, Issue:11, 2018
Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.Psychopharmacology, , Volume: 235, Issue:12, 2018
Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 19, Issue:sup3, 2018
Early prediction of olanzapine-induced weight gain for schizophrenia patients.Psychiatry research, , Volume: 263, 2018
A Review of Asenapine in the Treatment of Bipolar Disorder.Clinical drug investigation, , Volume: 38, Issue:2, 2018
A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.Schizophrenia research, , Volume: 195, 2018
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.Journal of psychiatric research, , Volume: 85, 2017
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study.European child & adolescent psychiatry, , Volume: 26, Issue:1, 2017
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.Journal of affective disorders, , Jan-01, Volume: 207, 2017
Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.Journal of child and adolescent psychopharmacology, , Volume: 27, Issue:5, 2017
Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 27, Issue:7, 2017
Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Jun-15, Volume: 104, 2017
Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats.Scientific reports, , 06-05, Volume: 7, Issue:1, 2017
A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain.Schizophrenia research, , Volume: 187, 2017
Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.CNS drugs, , Volume: 31, Issue:9, 2017
The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C.The Journal of clinical investigation, , Sep-01, Volume: 127, Issue:9, 2017
Time-dependent effects of olanzapine treatment on the expression of histidine decarboxylase, H1 and H3 receptor in the rat brain: The roles in olanzapine-induced obesity.Psychoneuroendocrinology, , Volume: 85, 2017
Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.Journal of psychiatric research, , Volume: 95, 2017
Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain.JAMA psychiatry, , 11-01, Volume: 74, Issue:11, 2017
Lack of Ovarian Secretions Reverts the Anabolic Action of Olanzapine in Female Rats.The international journal of neuropsychopharmacology, , 12-01, Volume: 20, Issue:12, 2017
Adjunctive Use of Olanzapine in the Treatment of Avoidant Restrictive Food Intake Disorder in Children and Adolescents in an Eating Disorders Program.Journal of child and adolescent psychopharmacology, , Volume: 27, Issue:10, 2017
A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers.Psychoneuroendocrinology, , Volume: 66, 2016
Betahistine decreases olanzapine-induced weight gain and somnolence in humans.Journal of psychopharmacology (Oxford, England), , Volume: 30, Issue:3, 2016
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.Molecular psychiatry, , Volume: 21, Issue:8, 2016
A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
Ameliorating antipsychotic-induced weight gain by betahistine: Mechanisms and clinical implications.Pharmacological research, , Volume: 106, 2016
Dysregulation of hypothalamic modulation in olanzapine treated male rats.Progress in neuro-psychopharmacology & biological psychiatry, , 11-03, Volume: 71, 2016
Attenuated Weight Gain with the Novel Analog of Olanzapine Linked to Sarcosinyl Moiety (PGW5) Compared to Olanzapine.Journal of molecular neuroscience : MN, , Volume: 58, Issue:1, 2016
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.Journal of clinical psychopharmacology, , Volume: 36, Issue:3, 2016
Efficacy of ranitidine in olanzapine-induced weight gain: a dose-response study.Early intervention in psychiatry, , Volume: 10, Issue:6, 2016
Association of orexin receptor polymorphisms with antipsychotic-induced weight gain.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 17, Issue:3, 2016
Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia.PloS one, , Volume: 11, Issue:3, 2016
Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats.Psychoneuroendocrinology, , Volume: 73, 2016
Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: common and specific effects of key regulators of fat-mass homoeostasis genes.Pharmacogenetics and genomics, , Volume: 25, Issue:7, 2015
A2BP1 gene polymorphisms association with olanzapine-induced weight gain.Pharmacological research, , Volume: 99, 2015
[Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:3, 2015
Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα-dependent pathways.Pharmacological research, , Volume: 100, 2015
Increased lean body mass as an early indicator of olanzapine-induced weight gain in healthy men.International clinical psychopharmacology, , Volume: 30, Issue:1, 2015
Anandamide is involved in appetite-related amygdala hyperactivations in schizophrenia patients treated with olanzapine: a functional magnetic resonance imaging study.Journal of clinical psychopharmacology, , Volume: 35, Issue:1, 2015
Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:12, 2015
Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 23, Issue:9, 2015
Metformin and berberine prevent olanzapine-induced weight gain in rats.PloS one, , Volume: 9, Issue:3, 2014
Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.Journal of medical economics, , Volume: 17, Issue:7, 2014
Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine.Psychopharmacology, , Volume: 231, Issue:20, 2014
Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain.Human psychopharmacology, , Volume: 29, Issue:4, 2014
Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.PloS one, , Volume: 9, Issue:8, 2014
The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications.Journal of psychosocial nursing and mental health services, , Volume: 52, Issue:7, 2014
The safety of olanzapine in young children: a systematic review and meta-analysis.Drug safety, , Volume: 37, Issue:10, 2014
HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.International journal of psychiatry in clinical practice, , Volume: 18, Issue:4, 2014
Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.The international journal of neuropsychopharmacology, , Volume: 17, Issue:1, 2014
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.The international journal of neuropsychopharmacology, , Volume: 17, Issue:1, 2014
Modelling olanzapine-induced weight gain in rats.The international journal of neuropsychopharmacology, , Volume: 17, Issue:1, 2014
Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.Schizophrenia research, , Volume: 160, Issue:1-3, 2014
Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis.Scientific reports, , Dec-09, Volume: 4, 2014
The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse.PloS one, , Volume: 9, Issue:12, 2014
A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 39, Issue:6, 2014
Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.Psychiatry research, , Oct-30, Volume: 219, Issue:2, 2014
No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain.Psychiatry research, , Oct-30, Volume: 219, Issue:2, 2014
Replication of SULT4A1-1 as a pharmacogenetic marker of olanzapine response and evidence of lower weight gain in the high response group.Pharmacogenomics, , Volume: 15, Issue:7, 2014
Betahistine ameliorates olanzapine-induced weight gain through modulation of histaminergic, NPY and AMPK pathways.Psychoneuroendocrinology, , Volume: 48, 2014
Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada.BMC psychiatry, , Jan-22, Volume: 14, 2014
Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats.The international journal of neuropsychopharmacology, , Volume: 17, Issue:5, 2014
Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.The Journal of clinical psychiatry, , Volume: 75, Issue:3, 2014
Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.Pharmacogenomics, , Volume: 15, Issue:4, 2014
Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats.Psychoneuroendocrinology, , Volume: 42, 2014
Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.Psychopharmacology, , Volume: 226, Issue:3, 2013
Olanzapine and food craving: a case control study.Human psychopharmacology, , Volume: 28, Issue:1, 2013
Early prediction of clinical and functional outcome in schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:8, 2013
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-10, Volume: 40, 2013
Association between second-generation antipsychotics and changes in body mass index in adolescents.The Journal of adolescent health : official publication of the Society for Adolescent Medicine, , Volume: 52, Issue:3, 2013
Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.Paediatric drugs, , Volume: 15, Issue:2, 2013
Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain.Journal of clinical psychopharmacology, , Volume: 33, Issue:3, 2013
The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain.CNS drugs, , Volume: 27, Issue:6, 2013
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.Swiss medical weekly, , Volume: 143, 2013
The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.Psychopharmacology, , Volume: 230, Issue:1, 2013
Central administration of an orexin receptor 1 antagonist prevents the stimulatory effect of Olanzapine on endogenous glucose production.Brain research, , Aug-21, Volume: 1527, 2013
Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.Diabetes, , Volume: 62, Issue:9, 2013
Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.Behavioral and brain functions : BBF, , Jul-19, Volume: 9, 2013
Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs.The Journal of pharmacology and experimental therapeutics, , Volume: 347, Issue:1, 2013
Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:6, 2013
The effect of ranitidine on olanzapine-induced weight gain.BioMed research international, , Volume: 2013, 2013
Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat.Translational psychiatry, , Oct-01, Volume: 3, 2013
Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80.Pharmacopsychiatry, , Volume: 46, Issue:7, 2013
Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:8, 2013
Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.Journal of psychopharmacology (Oxford, England), , Volume: 27, Issue:4, 2013
[The lipid metabolism abnormality in patients administered with olanzapine].Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, , Volume: 32, Issue:5-6, 2012
Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment.PloS one, , Volume: 7, Issue:11, 2012
Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis.Asian journal of psychiatry, , Volume: 5, Issue:4, 2012
Discovery of a novel non-steroidal GR antagonist with in vivo efficacy in the olanzapine-induced weight gain model in the rat.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 22, Issue:24, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.The Journal of clinical psychiatry, , Volume: 73, Issue:8, 2012
[Metabolic syndrome in patients with schizophrenia and antipsychotic treatment].Medicina clinica, , Nov-17, Volume: 139, Issue:12, 2012
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Clinical schizophrenia & related psychoses, , Volume: 6, Issue:2, 2012
Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study.Human psychopharmacology, , Volume: 27, Issue:4, 2012
Energy metabolism, leptin, and biochemical parameters are altered in rats subjected to the chronic administration of olanzapine.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 34, Issue:2, 2012
Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:9, 2012
Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment.Translational psychiatry, , Jun-19, Volume: 2, 2012
Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:9, 2012
Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.BMC psychiatry, , May-30, Volume: 12, 2012
Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.Psychiatry and clinical neurosciences, , Volume: 66, Issue:4, 2012
Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.Psychiatry research, , Oct-30, Volume: 199, Issue:3, 2012
Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.PloS one, , Volume: 7, Issue:3, 2012
Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine.Molecular diagnosis & therapy, , Apr-01, Volume: 16, Issue:2, 2012
Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 22, Issue:2, 2012
A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.Journal of clinical psychopharmacology, , Volume: 32, Issue:2, 2012
Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study.International journal of psychiatry in clinical practice, , Volume: 16, Issue:1, 2012
Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa.The International journal of eating disorders, , Volume: 45, Issue:2, 2012
Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 22, Issue:5, 2012
Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.The international journal of neuropsychopharmacology, , Volume: 15, Issue:2, 2012
Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat.Psychopharmacology, , Volume: 219, Issue:3, 2012
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.The Journal of clinical psychiatry, , Volume: 73, Issue:2, 2012
Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.Molecular psychiatry, , Volume: 16, Issue:6, 2011
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clinical drug investigation, , Volume: 31, Issue:7, 2011
Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics.Clinical nutrition (Edinburgh, Scotland), , Volume: 30, Issue:5, 2011
Weight gain induced with olanzapine in adolescent.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Antipsychotic treatment--side-effect and/or metabolic syndrome.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Switching among antipsychotics--focus on side effects.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Olanzapine versus placebo for out-patients with anorexia nervosa.Psychological medicine, , Volume: 41, Issue:10, 2011
TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.Neuroscience letters, , Oct-31, Volume: 504, Issue:3, 2011
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.British journal of clinical pharmacology, , Volume: 71, Issue:3, 2011
Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.Neuromolecular medicine, , Volume: 13, Issue:4, 2011
Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.European journal of pharmacology, , Mar-25, Volume: 655, Issue:1-3, 2011
Weight gain and ghrelin level after olanzapine monotherapy.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 35, Issue:2, 2011
Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:5, 2011
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.Pharmacotherapy, , Volume: 31, Issue:8, 2011
Metabolic parameters in patients treated with olanzapine or other atypical antipsychotics.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:5, 2011
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.Psychiatry research, , May-15, Volume: 187, Issue:1-2, 2011
Effects of antipsychotics with different weight gain liabilities on human in vitro models of adipose tissue differentiation and metabolism.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-01, Volume: 35, Issue:8, 2011
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 35, Issue:2, 2011
Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats.Behavioural brain research, , Mar-01, Volume: 217, Issue:2, 2011
Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.Behavioural brain research, , Jan-20, Volume: 216, Issue:2, 2011
Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation.PloS one, , Volume: 6, Issue:6, 2011
A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats.Cellular and molecular neurobiology, , Volume: 31, Issue:7, 2011
Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.Archives of physiology and biochemistry, , Volume: 117, Issue:4, 2011
Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.Physiology & behavior, , Sep-26, Volume: 104, Issue:4, 2011
Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controllJournal of clinical psychopharmacology, , Volume: 30, Issue:6, 2010
Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Effect of lactational exposure of olanzapine on body weight of mice: a comparative study on neonates of both the sexes during post-natal development.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?Journal of clinical psychopharmacology, , Volume: 30, Issue:4, 2010
A murine model of atypical antipsychotic-induced weight gain and metabolic dysregulation.Current protocols in neuroscience, , Volume: Chapter 9, 2010
Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats.Pharmacology, biochemistry, and behavior, , Volume: 97, Issue:1, 2010
Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.Diabetes, obesity & metabolism, , Volume: 12, Issue:6, 2010
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 49, Issue:6, 2010
Olanzapine affects locomotor activity and meal size in male rats.Pharmacology, biochemistry, and behavior, , Volume: 97, Issue:1, 2010
Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study.Journal of clinical pharmacy and therapeutics, , Volume: 35, Issue:2, 2010
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.Bipolar disorders, , Volume: 12, Issue:2, 2010
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.Pharmacogenetics and genomics, , Volume: 20, Issue:6, 2010
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.The Cochrane database of systematic reviews, , Dec-08, Issue:12, 2010
Switching and combining antipsychotics.CNS spectrums, , Volume: 15, Issue:4 Suppl 6, 2010
Second-generation antipsychotics cause weight gain in youths.The Harvard mental health letter, , Volume: 26, Issue:7, 2010
Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 118, Issue:1-3, 2010
Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats.Neuropsychobiology, , Volume: 61, Issue:3, 2010
Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.BMC psychiatry, , Nov-03, Volume: 10, 2010
Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.Obesity (Silver Spring, Md.), , Volume: 18, Issue:10, 2010
Increased food intake and energy expenditure following administration of olanzapine to healthy men.Obesity (Silver Spring, Md.), , Volume: 18, Issue:8, 2010
Factors associated with weight gain with olanzapine.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:2, 2010
Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice.Biochemical and biophysical research communications, , Mar-05, Volume: 393, Issue:2, 2010
An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.International journal of clinical practice, , Volume: 64, Issue:11, 2010
The potential role of appetite in predicting weight changes during treatment with olanzapine.BMC psychiatry, , Sep-14, Volume: 10, 2010
Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 44, Issue:3, 2010
Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).Journal of affective disorders, , Volume: 124, Issue:1-2, 2010
Sensitivity of the female rat to olanzapine-induced weight gain--far from the clinic?Schizophrenia research, , Volume: 116, Issue:2-3, 2010
Metabolic syndrome with the atypical antipsychotics.Current opinion in endocrinology, diabetes, and obesity, , Volume: 17, Issue:5, 2010
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.Schizophrenia research, , Volume: 123, Issue:2-3, 2010
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia.Pharmacogenetics and genomics, , Volume: 20, Issue:9, 2010
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.The pharmacogenomics journal, , Volume: 10, Issue:1, 2010
The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia.DNA and cell biology, , Volume: 28, Issue:10, 2009
Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Aripiprazole for the management of olanzapine-induced weight gain.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.Psychopharmacology, , Volume: 206, Issue:1, 2009
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.Journal of clinical psychopharmacology, , Volume: 29, Issue:3, 2009
Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.The pharmacogenomics journal, , Volume: 9, Issue:4, 2009
Meralgia paresthetica: another complication of antipsychotic-induced weight gain.Obesity reviews : an official journal of the International Association for the Study of Obesity, , Volume: 10, Issue:6, 2009
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.BMC psychiatry, , Mar-28, Volume: 9, 2009
How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 24, Issue:3, 2009
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.Schizophrenia research, , Volume: 110, Issue:1-3, 2009
Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting.Human psychopharmacology, , Volume: 24, Issue:2, 2009
Body mass index and weight gain as alternative or complementary hypothesis to explain olanzapine concentration-dose ratio accumulation.Clinical drug investigation, , Volume: 29, Issue:2, 2009
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 24, Issue:3, 2009
Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.Journal of psychiatric research, , Volume: 43, Issue:6, 2009
The role of thermogenesis in antipsychotic drug-induced weight gain.Obesity (Silver Spring, Md.), , Volume: 17, Issue:1, 2009
An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects.Biological psychiatry, , Apr-01, Volume: 65, Issue:7, 2009
Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.Psychopharmacology, , Volume: 203, Issue:4, 2009
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials.Psychopharmacology bulletin, , Volume: 42, Issue:4, 2009
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
[Neuroleptic adverse effects with emphasis on weight gain].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 37, Issue:4, 2009
Mifepristone treatment of olanzapine-induced weight gain in healthy men.Advances in therapy, , Volume: 26, Issue:10, 2009
Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder.Journal of child and adolescent psychopharmacology, , Volume: 19, Issue:5, 2009
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.JAMA, , Oct-28, Volume: 302, Issue:16, 2009
Weight gain with atypical antipsychotic drugs in bipolar disorder.Journal of psychosocial nursing and mental health services, , Volume: 47, Issue:9, 2009
Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.Psychopharmacology, , Volume: 207, Issue:1, 2009
Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.Journal of affective disorders, , Volume: 105, Issue:1-3, 2008
Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes.Pharmacogenomics, , Volume: 9, Issue:8, 2008
Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.The Journal of clinical psychiatry, , Volume: 69, Issue:9, 2008
Successful olanzapine treatment of anorexia nervosa in a girl with pervasive developmental disorder not otherwise specified.Psychiatry and clinical neurosciences, , Volume: 62, Issue:6, 2008
Bofu-tsusho-san effectively attenuates the weight gain observed after receiving olanzapine.Psychiatry and clinical neurosciences, , Volume: 62, Issue:6, 2008
Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study.The British journal of psychiatry : the journal of mental science, , Volume: 193, Issue:6, 2008
Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.The Journal of clinical psychiatry, , Volume: 69, Issue:11, 2008
Chronic administration of olanzapine affects Behavioral Satiety Sequence and feeding behavior in female mice.Eating and weight disorders : EWD, , Volume: 13, Issue:3, 2008
Olanzapine: review of safety 2008.Expert opinion on drug safety, , Volume: 7, Issue:6, 2008
Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:5, 2008
Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagiaThe Journal of pharmacology and experimental therapeutics, , Volume: 326, Issue:3, 2008
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.Journal of clinical psychopharmacology, , Volume: 28, Issue:3, 2008
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.Journal of clinical psychopharmacology, , Volume: 28, Issue:4, 2008
Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Weight gain during olanzapine treatment for psychotic depression: effects of dose and age.International clinical psychopharmacology, , Volume: 23, Issue:3, 2008
Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.European journal of pharmacology, , May-06, Volume: 585, Issue:1, 2008
Weight gain due to long term antipsychotic treatment of persistent mental disorders.Psychiatria Danubina, , Volume: 20, Issue:1, 2008
The perplexities of conducting randomized, double-blind, placebo-controlled treatment trials in anorexia nervosa patients.The American journal of psychiatry, , Volume: 165, Issue:10, 2008
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.Psychiatry research, , May-30, Volume: 159, Issue:1-2, 2008
Olanzapine metabolic side effects: a weight gain issue?Internal and emergency medicine, , Volume: 3, Issue:3, 2008
Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.Psychoneuroendocrinology, , Volume: 33, Issue:5, 2008
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain.Human psychopharmacology, , Volume: 23, Issue:4, 2008
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:12, 2008
Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats.Journal of psychopharmacology (Oxford, England), , Volume: 22, Issue:2, 2008
[Olanzapine].Deutsche medizinische Wochenschrift (1946), , Volume: 133, Issue:39, 2008
Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:1, 2008
The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain.The international journal of neuropsychopharmacology, , Volume: 11, Issue:6, 2008
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 165, Issue:3, 2008
A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Olanzapine for the treatment of bipolar disorder in children and adolescents.Expert opinion on pharmacotherapy, , Volume: 9, Issue:3, 2008
Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients.Journal of clinical pharmacy and therapeutics, , Volume: 33, Issue:1, 2008
Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats.Journal of psychopharmacology (Oxford, England), , Volume: 22, Issue:5, 2008
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.Journal of clinical psychopharmacology, , Volume: 28, Issue:1, 2008
A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels.Journal of clinical psychopharmacology, , Volume: 28, Issue:1, 2008
A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine.Pharmacopsychiatry, , Volume: 41, Issue:1, 2008
Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder.BMC psychiatry, , Sep-15, Volume: 8, 2008
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.Schizophrenia research, , Volume: 99, Issue:1-3, 2008
Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 115, Issue:11, 2008
Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:4, 2008
Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:1, 2008
The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.Psychiatry research, , Sep-30, Volume: 160, Issue:3, 2008
Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-01, Volume: 32, Issue:1, 2008
Atypical antipsychotics: new drugs, new challenges.Cleveland Clinic journal of medicine, , Volume: 74, Issue:8, 2007
Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells.Pharmacological research, , Volume: 56, Issue:3, 2007
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.Proceedings of the National Academy of Sciences of the United States of America, , Feb-27, Volume: 104, Issue:9, 2007
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
Observed clinical and health services outcomes in pediatric inpatients treated with atypical antipsychotics: 1999-2003.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:3, 2007
Plasma lipids, lipoproteins and hormones levels during olanzapine treatment in psychosis and depression.Medicinski arhiv, , Volume: 61, Issue:2, 2007
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Dec-05, Volume: 144B, Issue:8, 2007
Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia.International clinical psychopharmacology, , Volume: 22, Issue:4, 2007
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Comments on "Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine".Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 29, Issue:1, 2007
Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Olanzapine-induced weight gain in anorexia nervosa: involvement of leptin and ghrelin secretion?Psychoneuroendocrinology, , Volume: 32, Issue:4, 2007
Olanzapine treatment decreases the density of muscarinic M2 receptors in the dorsal vagal complex of rats.Progress in neuro-psychopharmacology & biological psychiatry, , May-09, Volume: 31, Issue:4, 2007
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.Proceedings of the National Academy of Sciences of the United States of America, , Feb-27, Volume: 104, Issue:9, 2007
Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.Pharmacopsychiatry, , Volume: 40, Issue:1, 2007
Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.Psychopharmacology, , Volume: 192, Issue:3, 2007
Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?Psychiatric services (Washington, D.C.), , Volume: 58, Issue:2, 2007
Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia.Psychopharmacology bulletin, , Volume: 40, Issue:1, 2007
No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs.International journal of obesity (2005), , Volume: 31, Issue:6, 2007
Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment.Molecular psychiatry, , Volume: 12, Issue:6, 2007
Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.Psychoneuroendocrinology, , Volume: 32, Issue:2, 2007
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.Molecular psychiatry, , Volume: 12, Issue:5, 2007
Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.Human psychopharmacology, , Volume: 22, Issue:1, 2007
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 114, Issue:2, 2007
Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:7, 2007
Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:4, 2007
A case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain.The Journal of clinical psychiatry, , Volume: 68, Issue:12, 2007
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.Schizophrenia research, , Volume: 89, Issue:1-3, 2007
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.The American journal of managed care, , Volume: 13, Issue:7 Suppl, 2007
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Olanzapine: interpreting the label change.International journal of clinical practice, , Volume: 61, Issue:12, 2007
The effectiveness criterion: balancing efficacy against the risks of weight gain.The Journal of clinical psychiatry, , Volume: 68 Suppl 12, 2007
Olanzapine versus placebo in the treatment of adolescents with bipolar mania.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Olanzapine and pediatric bipolar disorder: evidence for efficacy and safety concerns.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.Life sciences, , Sep-01, Volume: 81, Issue:12, 2007
Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 22, Issue:7, 2007
Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Jun-05, Volume: 141B, Issue:4, 2006
Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine.Behavioural pharmacology, , Volume: 17, Issue:3, 2006
Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.Appetite, , Volume: 46, Issue:3, 2006
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 13, Issue:2, 2006
Rapid leptin elevation after initiation of olanzapine?Neuropsychobiology, , Volume: 54, Issue:3, 2006
Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic.Pain practice : the official journal of World Institute of Pain, , Volume: 6, Issue:2, 2006
Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice.Current medical research and opinion, , Volume: 22, Issue:12, 2006
Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 28, Issue:4, 2006
Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Long-term treatment with atypical antipsychotics and risk of weight gain.Drug safety, , Volume: 29, Issue:6, 2006
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.The American journal of psychiatry, , Volume: 163, Issue:12, 2006
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.The Annals of pharmacotherapy, , Volume: 40, Issue:12, 2006
Early predictors of substantial weight gain in bipolar patients treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 12, Issue:2, 2006
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.The American journal of psychiatry, , Volume: 163, Issue:2, 2006
Is olanzapine a brain-sparing medication?Archives of general psychiatry, , Volume: 63, Issue:11, 2006
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.The American journal of psychiatry, , Volume: 163, Issue:5, 2006
Pharmacogenetics of antipsychotic-induced weight gain.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 12, Issue:5, 2006
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:5, 2006
An open trial of olanzapine in children and adolescents with Asperger Disorder.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.Journal of clinical psychopharmacology, , Volume: 26, Issue:2, 2006
Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain.European journal of pharmacology, , Dec-03, Volume: 551, Issue:1-3, 2006
The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia.Therapeutic drug monitoring, , Volume: 28, Issue:5, 2006
A model for antipsychotic-induced obesity in the male rat.Psychopharmacology, , Volume: 187, Issue:4, 2006
Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine.Journal of managed care pharmacy : JMCP, , Volume: 12, Issue:3, 2006
The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.Behavioural brain research, , Aug-10, Volume: 171, Issue:2, 2006
Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.The Journal of clinical psychiatry, , Volume: 67, Issue:9, 2006
Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis.The American journal of psychiatry, , Volume: 163, Issue:10, 2006
No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.Minerva medica, , Volume: 97, Issue:2, 2006
Antipsychotic drugs and schizophrenia.The New England journal of medicine, , Jan-19, Volume: 354, Issue:3, 2006
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:3, 2006
A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia.Schizophrenia research, , Feb-15, Volume: 82, Issue:1, 2006
Olanzapine increases plasma ghrelin level in patients with schizophrenia.Psychoneuroendocrinology, , Volume: 30, Issue:1, 2005
Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.Psychopharmacology, , Volume: 182, Issue:2, 2005
The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study.Schizophrenia research, , Jun-01, Volume: 75, Issue:1, 2005
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:11, 2005
Antipsychotic-induced weight gain.Diabetes, obesity & metabolism, , Volume: 7, Issue:5, 2005
Amantadine for weight gain associated with olanzapine treatment.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 15, Issue:1, 2005
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.The American journal of psychiatry, , Volume: 162, Issue:8, 2005
Switching depot antipsychotic drug responders to oral olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:1, 2005
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:6 Suppl, 2005
Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:1, 2005
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 7, Issue:3, 2005
Current options in the management of olanzapine-associated weight gain.The Annals of pharmacotherapy, , Volume: 39, Issue:2, 2005
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.BMC psychiatry, , Jan-13, Volume: 5, 2005
Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Apr-05, Volume: 134B, Issue:1, 2005
Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.International clinical psychopharmacology, , Volume: 20, Issue:4, 2005
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.Pharmacogenetics and genomics, , Volume: 15, Issue:4, 2005
The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.International clinical psychopharmacology, , Volume: 20, Issue:2, 2005
Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders.Schizophrenia research, , Dec-01, Volume: 80, Issue:1, 2005
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:6, 2005
Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
The association of weight gain and olanzapine plasma concentrations.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism.Essential psychopharmacology, , Volume: 6, Issue:2, 2005
Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors.Journal of clinical psychopharmacology, , Volume: 25, Issue:5, 2005
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
A parametric analysis of olanzapine-induced weight gain in female rats.Psychopharmacology, , Volume: 181, Issue:1, 2005
Use of olanzapine in anorexia nervosa.The Journal of clinical psychiatry, , Volume: 66, Issue:5, 2005
Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.Psychiatry and clinical neurosciences, , Volume: 59, Issue:5, 2005
Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved.Acta psychiatrica Scandinavica, , Volume: 112, Issue:1, 2005
Comment: current options in the management of olanzapine-associated weight gain.The Annals of pharmacotherapy, , Volume: 39, Issue:5, 2005
Complications from olanzapine in a mentally healthy patient.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.The New England journal of medicine, , Sep-22, Volume: 353, Issue:12, 2005
Unusual suspect for antipsychotic-induced diabetes.Drug discovery today, , Oct-15, Volume: 10, Issue:20, 2005
Olanzapine and weight gain.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
[Expectations and developments in atypical antipsychotics].Praxis, , Aug-25, Volume: 93, Issue:35, 2004
[Psychotropics and weight gain].Praxis, , Aug-25, Volume: 93, Issue:35, 2004
Weight loss dynamics during combined fluoxetine and olanzapine treatment.BMC pharmacology, , Oct-21, Volume: 4, 2004
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.Postgraduate medicine, , Volume: 116, Issue:4, 2004
An open trial of olanzapine in anorexia nervosa.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:8, 2004
Dyslipidemia and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
Weight gain and new onset diabetes associated with olanzapine and risperidone.Journal of general internal medicine, , Volume: 19, Issue:12, 2004
Weight gain during treatment of bipolar I patients with olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
Olanzapine treatment of eight adolescent patients with psychosis.Human psychopharmacology, , Volume: 19, Issue:1, 2004
Olanzapine versus placebo in the treatment of borderline personality disorder.The Journal of clinical psychiatry, , Volume: 65, Issue:1, 2004
Antipsychotic-associated weight gain.The Annals of pharmacotherapy, , Volume: 38, Issue:5, 2004
Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
An animal model of antipsychotic-induced weight gain.Behavioural brain research, , Jun-04, Volume: 152, Issue:1, 2004
The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 14, Issue:4, 2004
[Effect of atypical antipsychotics on metabolism].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 6, Issue:2, 2004
Weight gain during long-term treatment with olanzapine: a case series.International clinical psychopharmacology, , Volume: 19, Issue:4, 2004
Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder.Journal of clinical psychopharmacology, , Volume: 24, Issue:4, 2004
Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:2, 2004
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone.The Journal of clinical psychiatry, , Volume: 65, Issue:6, 2004
A retrospective analysis of the short-term effects of olanzapine and quetiapine on weight and body mass index in children and adolescents.Pharmacotherapy, , Volume: 24, Issue:7, 2004
Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 14, Issue:2, 2004
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
Antipsychotic-induced weight gain: bipolar disorder and leptin.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study.Human psychopharmacology, , Volume: 18, Issue:6, 2003
Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.Human psychopharmacology, , Volume: 18, Issue:6, 2003
Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.Schizophrenia research, , Mar-01, Volume: 60, Issue:1, 2003
Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:1, 2003
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 13, Issue:2, 2003
Safety in treating bipolar disorder.The Journal of family practice, , Volume: Suppl, 2003
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.Pharmacology, biochemistry, and behavior, , Volume: 75, Issue:1, 2003
The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain.Human psychopharmacology, , Volume: 18, Issue:7, 2003
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.Schizophrenia research, , Jul-01, Volume: 62, Issue:1-2, 2003
The effects of an educational intervention on antipsychotic-induced weight gain.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing, , Volume: 35, Issue:3, 2003
Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:4, 2003
Reversal of antipsychotic-induced weight gain during quetiapine treatment.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Hyperglycemia from olanzapine treatment in adolescents.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 13, Issue:1, 2003
Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:6, 2003
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
A 1-year open-label trial of olanzapine in school-age children with schizophrenia.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 13, Issue:3, 2003
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Olanzapine in the treatment of anorexia nervosa: an open label trial.The International journal of eating disorders, , Volume: 32, Issue:2, 2002
Clinical issues associated with maintenance treatment of patients with schizophrenia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Sep-01, Volume: 59, Issue:17 Suppl 5, 2002
Weight gain associated with atypical antipsychotics.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 41, Issue:11, 2002
The effects of novel antipsychotics on glucose and lipid levels.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia.The Journal of clinical psychiatry, , Volume: 63, Issue:11, 2002
Characterization of olanzapine-induced weight gain in rats.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:4, 2002
Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.Pharmacopsychiatry, , Volume: 35, Issue:3, 2002
Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.The Journal of clinical endocrinology and metabolism, , Volume: 87, Issue:6, 2002
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report.International journal of geriatric psychiatry, , Volume: 17, Issue:4, 2002
Weight gain and hyperglycaemia associated with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:2, 2002
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 41, Issue:3, 2002
[Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].Fortschritte der Neurologie-Psychiatrie, , Volume: 69, Issue:11, 2001
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.The Journal of clinical psychiatry, , Volume: 62, Issue:9, 2001
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 11, Issue:3, 2001
Review of atypical antipsychotics and weight gain.The Journal of clinical psychiatry, , Volume: 62 Suppl 23, 2001
Olanzapine induces remarkable weight gain in adolescent patients.European child & adolescent psychiatry, , Volume: 10, Issue:3, 2001
Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.Journal of clinical psychopharmacology, , Volume: 21, Issue:5, 2001
Re: Weight change with antipsychotic use.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:7, 2001
Association of olanzapine-induced weight gain with an increase in body fat.The American journal of psychiatry, , Volume: 158, Issue:10, 2001
Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
A program for treating olanzapine-related weight gain.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:7, 2001
Cognitive behavior therapy for weight gain.The American journal of psychiatry, , Volume: 158, Issue:6, 2001
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone.Schizophrenia research, , Apr-30, Volume: 49, Issue:3, 2001
The pharmacology of weight gain with antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 7, 2001
Antipsychotic-induced weight gain: a review of the literature.The Journal of clinical psychiatry, , Volume: 62 Suppl 7, 2001
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 158, Issue:5, 2001
Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents.Psychopharmacology, , Mar-01, Volume: 154, Issue:2, 2001
Effect of amantadine on weight gain during olanzapine treatment.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 11, Issue:2, 2001
Reply to comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study".Journal of clinical psychopharmacology, , Volume: 21, Issue:2, 2001
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.The Journal of clinical psychiatry, , Volume: 62, Issue:2, 2001
Weight change and atypical antipsychotic treatment in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Bodyweight gain with atypical antipsychotics. A comparative review.Drug safety, , Volume: 24, Issue:1, 2001
Olanzapine and hypertriglyceridemia.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 40, Issue:2, 2001
Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group.Psychiatry and clinical neurosciences, , Volume: 54, Issue:4, 2000
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.Archives of general psychiatry, , Volume: 57, Issue:9, 2000
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.The Journal of clinical psychiatry, , Volume: 61, Issue:7, 2000
H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.Biological psychiatry, , Jul-15, Volume: 48, Issue:2, 2000
Olanzapine and weight gain.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 45, Issue:5, 2000
Atypical antipsychotics and weight gain--a systematic review.Acta psychiatrica Scandinavica, , Volume: 101, Issue:6, 2000
Adverse events related to olanzapine.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Risperidone side effects.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.East African medical journal, , Volume: 77, Issue:2, 2000
Mood stabilizer augmentation with olanzapine in acutely manic children.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 10, Issue:1, 2000
Olanzapine-induced elevation of plasma triglyceride levels.The American journal of psychiatry, , Volume: 156, Issue:9, 1999
Novel antipsychotics: comparison of weight gain liabilities.The Journal of clinical psychiatry, , Volume: 60, Issue:6, 1999
Weight gain and antipsychotic medications.The Journal of clinical psychiatry, , Volume: 60, Issue:5, 1999
Olanzapine: weight gain and therapeutic efficacy.Journal of clinical psychopharmacology, , Volume: 19, Issue:3, 1999
Body weight and leptin plasma levels during treatment with antipsychotic drugs.The American journal of psychiatry, , Volume: 156, Issue:2, 1999
Olanzapine increases weight and serum triglyceride levels.The Journal of clinical psychiatry, , Volume: 60, Issue:11, 1999
Body mass index increase of 58% associated with olanzapine.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
Relative weight gain among antipsychotics.The Journal of clinical psychiatry, , Volume: 60, Issue:10, 1999
Weight gain associated with antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 60 Suppl 21, 1999
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Olanzapine-induced weight gain.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 10, Issue:1, 1998
Safety of olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Olanzapine for schizophrenia.The Medical letter on drugs and therapeutics, , Jan-17, Volume: 39, Issue:992, 1997
The relationship of pharmacology to side effects.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Side effect profiles of new antipsychotic agents.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
[Prescription of olanzapine in children and adolescent psychiatric patients].L'Encephale, , Volume: 33, Issue:2
Profound hypertriglyceridemia and weight gain in the first week following initiation of olanzapine: a case report with implications for lipid monitoring guidelines.Psychosomatics, , Volume: 54, Issue:4
Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study.Advances in therapy, , Volume: 24, Issue:1
A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:1
Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.Journal of clinical psychopharmacology, , Volume: 39, Issue:4
Betahistine-Associated Weight Loss and Improved Cognitive and Negative Symptoms: Domain in Early-Onset Schizophrenia.American journal of therapeutics, , Volume: 26, Issue:6
[Antipsychotics--clever choices].Lakartidningen, , Volume: 104, Issue:7
Olanzapine in the treatment of resistant depression.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:1-2
Comparing the side effect profile of the atypical antipsychotics.West African journal of medicine, , Volume: 21, Issue:4
Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:2
Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy.American journal of therapeutics, , Volume: 10, Issue:5
An acute rat in vivo screening model to predict compounds that alter blood glucose and/or insulin regulation.Journal of pharmacological and toxicological methods, , Volume: 68, Issue:2
Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 15, Issue:3-4
Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone With Olanzapine as a Comparator.Journal of clinical psychopharmacology, , Volume: 41, Issue:1
Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 35, Issue:3
Antipsychotic medications and extreme weight gain in two health systems.Obesity research & clinical practice, , Volume: 10, Issue:4
Visceral and subcutaneous fat in patients treated with olanzapine: a case series.Clinical neuropharmacology, , Volume: 33, Issue:5
[Olanzapine--high potency antipsychotic drug inducing significant weight gain: a case report].Srpski arhiv za celokupno lekarstvo, , Volume: 136, Issue:5-6
Effect of Miricorilant, a Selective Glucocorticoid Receptor Modulator, on Olanzapine-Associated Weight Gain in Healthy Subjects: A Proof-of-Concept Study.Journal of clinical psychopharmacology, , Volume: 41, Issue:6
Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain.Human psychopharmacology, , Volume: 26, Issue:4-5
Olanzapine-induced glucose dysregulation.The Annals of pharmacotherapy, , Volume: 34, Issue:7-8
Long-term observational comparison of risperidone and olanzapine in bipolar disorder.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:2
Olanzapine and Weight Loss in Early-Onset Schizophrenia.The primary care companion for CNS disorders, , 04-06, Volume: 25, Issue:2, 2023
Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report.Journal of psychiatric practice, , Volume: 25, Issue:2, 2019
Multidisciplinary Management of Adolescent Early-Onset, Treatment-Resistant Schizophrenia Complicated by Avoidant/Restrictive Food Intake Disorder and Catatonia in Acute Exacerbations.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:9, 2018
Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?Nordic journal of psychiatry, , Volume: 70, Issue:3, 2016
Dopamine D2/3 receptor antagonism reduces activity-based anorexia.Translational psychiatry, , Aug-04, Volume: 5, 2015
Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 23, Issue:9, 2015
Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine.Psychopharmacology, , Volume: 231, Issue:20, 2014
In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation.International clinical psychopharmacology, , Volume: 28, Issue:2, 2013
Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.Journal of psychopharmacology (Oxford, England), , Volume: 27, Issue:4, 2013
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:5, 2012
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.The Journal of clinical psychiatry, , Volume: 72, Issue:3, 2011
Treatment strategy in schizophrenia combined with eating disorder.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Clozapine-induced weight loss?Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 23, Issue:3, 2011
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.BMC psychiatry, , Mar-28, Volume: 9, 2009
Weight loss during therapy with olanzapine orally disintegrating tablets: two case reports.Psychiatria Danubina, , Volume: 21, Issue:1, 2009
Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Considerations regarding the use of metformin with olanzapine.The American journal of psychiatry, , Volume: 165, Issue:9, 2008
A case of paranoid schizophrenia complicated by scleroderma with associated esophageal dysmotility.Journal of psychiatric practice, , Volume: 14, Issue:2, 2008
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.Psychiatry research, , May-30, Volume: 159, Issue:1-2, 2008
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.Human psychopharmacology, , Volume: 23, Issue:3, 2008
Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.The Journal of clinical psychiatry, , Volume: 67, Issue:4, 2006
Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report.Pharmacopsychiatry, , Volume: 39, Issue:2, 2006
Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.Nordic journal of psychiatry, , Volume: 59, Issue:3, 2005
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
Adverse drug reactions in Canada.Canadian family physician Medecin de famille canadien, , Volume: 51, 2005
Adolescent weight loss during treatment with olanzapine.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
Weight decline in patients switching from olanzapine to quetiapine.Schizophrenia research, , Sep-01, Volume: 70, Issue:1, 2004
Weight loss dynamics during combined fluoxetine and olanzapine treatment.BMC pharmacology, , Oct-21, Volume: 4, 2004
Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets.Psychopharmacology, , Volume: 175, Issue:3, 2004
Reversal of antipsychotic-induced weight gain during quetiapine treatment.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Olanzapine treatment of an adolescent girl with anorexia nervosa.Human psychopharmacology, , Volume: 18, Issue:5, 2003
Weight loss associated with olanzapine treatment.Journal of clinical psychopharmacology, , Volume: 22, Issue:4, 2002
A program for treating olanzapine-related weight gain.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:7, 2001
Mania in a case of hyperparathyroidism.Psychosomatics, , Volume: 48, Issue:3
Psychosis in Anorexia Nervosa: A Case Report and Review of the Literature.Psychosomatics, , Volume: 61, Issue:2
Betahistine-Associated Weight Loss and Improved Cognitive and Negative Symptoms: Domain in Early-Onset Schizophrenia.American journal of therapeutics, , Volume: 26, Issue:6
Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine.Nutrition (Burbank, Los Angeles County, Calif.), , Volume: 25, Issue:7-8
[Treatment-resistant psychosis due to interaction between ritonavir and olanzapine: case report and literature review].Tijdschrift voor psychiatrie, , Volume: 58, Issue:4, 2016
Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient.Biological psychiatry, , Oct-15, Volume: 44, Issue:8, 1998
Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV.Psychosomatics, , Volume: 44, Issue:5
Acute Angle Closure in a Patient Using Olanzapine.Psychiatria Danubina, ,Summer, Volume: 34, Issue:2, 2022
Olanzapine-Induced Acute Angle Closure.The American journal of case reports, , Nov-22, Volume: 22, 2021
Acute angle closure glaucoma precipitated by olanzapine.International journal of geriatric psychiatry, , Volume: 30, Issue:10, 2015
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.The American journal of case reports, , Dec-01, Volume: 23, 2022
[The clinical picture of acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
Olanzapine overdose: a series of analytically confirmed cases.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Olanzapine overdose mimicking opioid intoxication.Annals of emergency medicine, , Volume: 34, Issue:2, 1999
Bethanechol as a Corrective for Urinary Retention Associated With Olanzapine Administration.The primary care companion for CNS disorders, , Oct-31, Volume: 21, Issue:5, 2019
Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study.Annals of internal medicine, , Aug-19, Volume: 161, Issue:4, 2014
Olanzapine and acute urinary retention in two geriatric patients.The American journal of geriatric pharmacotherapy, , Volume: 5, Issue:3, 2007
Dose-dependent urinary retention following olanzapine administration.The Annals of pharmacotherapy, , Volume: 40, Issue:9, 2006
Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine.Clinical neuropharmacology, , Volume: 31, Issue:5
[Smoking cessation and drug interactions].Ugeskrift for laeger, , 08-29, Volume: 184, Issue:35, 2022
Prevalence and recognition of highly significant medication-smoking cessation interactions in a smoke-free hospital.Drug and alcohol dependence, , 07-01, Volume: 200, 2019
Olanzapine-induced parkinsonism associated with smoking cessation.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Mar-01, Volume: 68, Issue:5, 2011
Impact of smoking cessation on psychiatric inpatients treated with clozapine or olanzapine.Journal of psychiatric practice, , Volume: 16, Issue:2, 2010
Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment.The Annals of pharmacotherapy, , Volume: 44, Issue:4, 2010
Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers.Experimental and clinical psychopharmacology, , Volume: 16, Issue:3, 2008
Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine.International clinical psychopharmacology, , Volume: 17, Issue:3, 2002
Bodyweight gain with atypical antipsychotics. A comparative review.Drug safety, , Volume: 24, Issue:1, 2001
Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
"My new Alfa Romeo GT is not in the garage any more": Cognitive behavioural therapy of panic disorder with agoraphobia co morbid with psychosis.Psychiatria Danubina, , Volume: 18, Issue:3-4, 2006
Potential effectiveness and safety of olanzapine in refractory panic disorder.Depression and anxiety, , Volume: 21, Issue:1, 2005
Olanzapine augmentation in panic disorder: a case report.Pharmacopsychiatry, , Volume: 37, Issue:5, 2004
Usefulness of olanzapine in refractory panic attacks.Journal of clinical psychopharmacology, , Volume: 23, Issue:1, 2003
Panic disorder associated with clozapine.The American journal of psychiatry, , Volume: 157, Issue:12, 2000
Olanzapine and panic attacks.The American journal of psychiatry, , Volume: 157, Issue:4, 2000
New-onset panic attacks in a patient treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:2, 1999
Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden.CNS drugs, , Volume: 36, Issue:5, 2022
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.The American journal of psychiatry, , 06-01, Volume: 175, Issue:6, 2018
Antipsychotics in pregnancy.Journal of psychiatric and mental health nursing, , Volume: 17, Issue:2, 2010
A case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain.The Journal of clinical psychiatry, , Volume: 68, Issue:12, 2007
Thrombosis and psychosis--possible association with the antiphospholipid syndrome and anticardiolipin antibodies.Irish medical journal, , Volume: 102, Issue:2, 2009
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
Mania: psychiatric manifestations of the antiphospholipid syndrome.Psychosomatics, , Volume: 49, Issue:5
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.Drug safety, , Volume: 36, Issue:6, 2013
Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).The American journal of psychiatry, , Volume: 168, Issue:2, 2011
[Eosinophilic myocarditis and sudden unexpected death in a younger patient treated with antipsychotics].Ugeskrift for laeger, , Oct-31, Volume: 173, Issue:44, 2011
Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC).Pharmacoepidemiology and drug safety, , Volume: 20, Issue:11, 2011
Olanzapine: sudden cardiac death, urinary incontinence.Prescrire international, , Volume: 19, Issue:109, 2010
Antipsychotic drugs and QT interval prolongation.The Psychiatric quarterly, ,Fall, Volume: 74, Issue:3, 2003
Risk evaluation of diabetic ketoacidosis associated with antipsychotics among patients with schizophrenia in the Japanese adverse event report database.Journal of psychosomatic research, , Volume: 175, 2023
An Unexpected Case of Diabetic Ketoacidosis on the Psychiatry Ward: Olanzapine-Associated Adult Ketosis-Prone Type 2 Diabetes Mellitus.Canadian journal of diabetes, , Volume: 44, Issue:3, 2020
Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.Psychiatria Danubina, , Volume: 29, Issue:2, 2017
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.Internal medicine (Tokyo, Japan), , Volume: 56, Issue:3, 2017
Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.Psychopharmacology, , Volume: 233, Issue:21-22, 2016
Severe recurrent hypoglycaemia following discontinuation of olanzapine.Acute medicine, , Volume: 10, Issue:1, 2011
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).The American journal of psychiatry, , Volume: 168, Issue:2, 2011
Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.The Journal of clinical psychiatry, , Volume: 70, Issue:5, 2009
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine.Drug safety, , Volume: 30, Issue:7, 2007
Diabetes and psychosis: olanzapine may not be the culprit.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 13, Issue:4, 2007
Olanzapine-induced hyperglycemic ketoacidosis and corresponding acetone concentrations post-mortem: a forensic interpretation.Forensic science international, , Aug-24, Volume: 171, Issue:1, 2007
Olanzapine-induced diabetic ketoacidosis in a Chinese man.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 13, Issue:1, 2007
Diabetic ketoacidosis and severe dyslipidemia in an adult psychotic man with olanzapine treatment.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
Fatal olanzapine-induced hyperglycemic ketoacidosis.The American journal of forensic medicine and pathology, , Volume: 25, Issue:2, 2004
Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.The American journal of psychiatry, , Volume: 161, Issue:9, 2004
Modulating effects of olanzapine on the development of diabetic ketoacidosis.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 21, Issue:3, 2004
Atypical antipsychotics and diabetes mellitus: an association.The Israel Medical Association journal : IMAJ, , Volume: 6, Issue:5, 2004
New-onset diabetes and ketoacidosis with atypical antipsychotics.Schizophrenia research, , Jan-01, Volume: 59, Issue:1, 2003
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.Southern medical journal, , Volume: 96, Issue:7, 2003
[Olanzapine-induced diabetes mellitus].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
Increasing insulin dose for olanzapine-related diabetes.The American journal of psychiatry, , Volume: 159, Issue:1, 2002
Atypical antipsychotics and hyperglycaemia.International clinical psychopharmacology, , Volume: 16, Issue:2, 2001
Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature.Pharmacotherapy, , Volume: 21, Issue:11, 2001
Diabetic ketoacidosis associated with olanzapine in an adolescent patient.The Journal of pediatrics, , Volume: 138, Issue:6, 2001
Olanzapine-induced diabetic ketoacidosis.The Annals of pharmacotherapy, , Volume: 35, Issue:12, 2001
Olanzapine-induced ketoacidosis with diabetes mellitus.The American journal of psychiatry, , Volume: 156, Issue:9, 1999
[Hyperglycemia and ketoacidosis associated with olanzapine].Der Nervenarzt, , Volume: 70, Issue:9, 1999
Diabetic ketoacidosis with olanzapine treatment.Diabetes care, , Volume: 22, Issue:6, 1999
Antipsychotic Therapy-Induced New Onset Diabetic Ketoacidosis.American journal of therapeutics, , Volume: 23, Issue:6
Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature.Journal of intensive care medicine, , Volume: 22, Issue:1
New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment.Psychosomatics, , Volume: 40, Issue:5
Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature.The Journal of the American Board of Family Practice, , Volume: 14, Issue:4
Near fatal ketoacidosis with olanzapine treatment.Psychosomatics, , Volume: 43, Issue:4
Tiagabine withdrawal-emergent mania.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:8, 2006
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
Misdiagnosis of schizophrenia for a patient with epilepsy.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:1, 2001
Occupational allergic contact dermatitis to olanzapine.Contact dermatitis, , Volume: 62, Issue:2, 2010
Occupational airborne allergic contact dermatitis to olanzapine.Dermatitis : contact, atopic, occupational, drug, , Volume: 23, Issue:6
Dorsal hand skin hyperpigmentation following oral olanzapine (Zyprexa) use.Contact dermatitis, , Volume: 79, Issue:4, 2018
Olanzapine-Induced Reversible Pellagroid Skin Lesion.Current drug safety, , Volume: 10, Issue:3, 2015
Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent.International journal of dermatology, , Volume: 43, Issue:10, 2004
Identification and characterization of proteins that are differentially expressed in adipose tissue of olanzapine-induced insulin resistance rat by iTRAQ quantitative proteomics.Journal of proteomics, , 02-10, Volume: 212, 2020
The Probiotic Mixture VSL#3 Reverses Olanzapine-Induced Metabolic Dysfunction in Mice.Methods in molecular biology (Clifton, N.J.), , Volume: 2011, 2019
Antenatal antipsychotic exposure induces multigenerational and gender-specific programming of adiposity and glucose tolerance in adult mouse offspring.Diabetes & metabolism, , Volume: 44, Issue:3, 2018
Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.BMJ open, , Mar-25, Volume: 4, Issue:3, 2014
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 15, Issue:3, 2014
Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-03, Volume: 48, 2014
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.Journal of psychiatry & neuroscience : JPN, , Volume: 37, Issue:6, 2012
Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats.Neuropharmacology, , Volume: 62, Issue:3, 2012
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.Neuro endocrinology letters, , Volume: 32, Issue:4, 2011
Metabolic and behavioral effects of chronic olanzapine treatment and cafeteria diet in rats.Behavioural pharmacology, , Volume: 21, Issue:7, 2010
30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.Acta psychiatrica Scandinavica, , Volume: 117, Issue:5, 2008
[Atypical antipsychotic-associated impaired glucose tolerance].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 107, Issue:8, 2005
Glucose intolerance with atypical antipsychotics.Drug safety, , Volume: 25, Issue:15, 2002
[Antipsychotics--clever choices].Lakartidningen, , Volume: 104, Issue:7
Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.The Australian and New Zealand journal of psychiatry, , Volume: 54, Issue:7, 2020
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.Journal of affective disorders, , 12-01, Volume: 277, 2020
Two cases report of epidemic stress disorder to novel coronavirus pneumonia.Asian journal of psychiatry, , Volume: 51, 2020
Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).Medical hypotheses, , Volume: 141, 2020
Reactive Psychosis in a Health Care Worker During the COVID-19 Pandemic.The primary care companion for CNS disorders, , 07-09, Volume: 22, Issue:4, 2020
Neurotropism of SARS-CoV-2: COVID-19 presenting with an acute manic episode.BMJ case reports, , Jun-14, Volume: 13, Issue:6, 2020
Three Cases of COVID-19-related First Onset Brief Reactive Psychosis.The Israel Medical Association journal : IMAJ, , Volume: 22, Issue:10, 2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
Exertional Heatstroke in a Marathon Runner Complicated by Concurrent Use of an Antipsychotic Medication Affecting Thermoregulation.Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, , Volume: 30, Issue:5, 2020
An autopsy case of heatstroke under the influence of psychotropic drugs.Soudni lekarstvi, ,Winter, Volume: 65, Issue:4, 2020
Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia.Acta neuropsychiatrica, , Volume: 27, Issue:6, 2015
Olanzapine and breast-feeding: changes of plasma concentrations of olanzapine in a breast-fed infant over a period of 5 months.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Meningocele and ankyloblepharon following in utero exposure to olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:5, 2006
Olanzapine excretion in human breast milk: estimation of infant exposure.The international journal of neuropsychopharmacology, , Volume: 5, Issue:3, 2002
Haematologic malignancies associated with clozapine Psychological medicine, , Volume: 51, Issue:9, 2021
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving HigBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, , Volume: 24, Issue:10, 2018
Basal Ganglia Calcification: A Case Report of Fahr Disease With Pure Psychiatric Symptoms.Journal of psychiatric practice, , Volume: 25, Issue:5, 2019
Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins.Cellular signalling, , Volume: 42, 2018
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 22, Issue:1, 2010
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.CNS spectrums, , Volume: 12, Issue:3 Suppl 4, 2007
Fahr's Disease Presenting with Manic Symptoms.JNMA; journal of the Nepal Medical Association, , Volume: 56, Issue:209
The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting.Journal of the American Medical Directors Association, , Volume: 5, Issue:4
[Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection].Gastroenterologia y hepatologia, , Volume: 33, Issue:2, 2010
Citalopram-induced diplopia.Psychosomatics, , Volume: 46, Issue:1
[Protective effect of olanzapine in psychotic disorder induced by interferon-alpha].Recenti progressi in medicina, , Volume: 94, Issue:7-8
Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:5, 2022
Risk and Prevention of Aggression in Patients With Psychotic Disorders.The American journal of psychiatry, , 03-01, Volume: 178, Issue:3, 2021
The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol.The American journal of psychiatry, , 03-01, Volume: 178, Issue:3, 2021
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
Olanzapine treatment in adolescents with severe conduct disorder.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:1, 2006
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:8, 2005
A clinical case series of six extremely aggressive youths treated with olanzapine.European child & adolescent psychiatry, , Volume: 11, Issue:3, 2002
Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:6, 2013
Atypical antipsychotics for the treatment of disruptive behavior.Pediatric annals, , Volume: 42, Issue:2, 2013
Age-grouped differences in bipolar mania.Comprehensive psychiatry, , Volume: 53, Issue:8, 2012
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.European child & adolescent psychiatry, , Volume: 20, Issue:11-12, 2011
Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations.Clinical psychology review, , Volume: 31, Issue:3, 2011
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Effect of olanzapine on disruptive behavior in institutionalized patients with severe intellectual disability--a case series.Collegium antropologicum, , Volume: 32, Issue:2, 2008
Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 45, Issue:8, 2006
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.The Journal of clinical psychiatry, , Volume: 65 Suppl 6, 2004
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
Complexity in Evaluation and Pharmacological Treatment of Early Onset Psychosis with Mood Symptoms: Childhood Onset Schizophrenia or Affective Disorder?Journal of child and adolescent psychopharmacology, , Volume: 29, Issue:3, 2019
A Case Report of Neurosyphilis Limbic Encephalitis With Reversible Geschwind Syndrome and Mood Disorder.Journal of psychiatric practice, , Volume: 25, Issue:3, 2019
[A case of late-onset paraphrenia in a very elderly patient receiving home medical care].Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, , Volume: 55, Issue:4, 2018
Biological Perspectives: Huntington's Disease.Perspectives in psychiatric care, , Volume: 51, Issue:3, 2015
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.Boletin de la Asociacion Medica de Puerto Rico, , Volume: 105, Issue:3, 2013
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Drug safety, , Oct-01, Volume: 35, Issue:10, 2012
Olanzapine in schizophrenia and affective disorders.Drug safety, , Dec-01, Volume: 35, Issue:12, 2012
Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania--a systematic review and meta-analysis.Journal of affective disorders, , Volume: 134, Issue:1-3, 2011
The need to consider mood disorders, and especially chronic mania, in cases of Diogenes syndrome (squalor syndrome).International psychogeriatrics, , Volume: 23, Issue:3, 2011
Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia.The journal of ECT, , Volume: 26, Issue:4, 2010
Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.Journal of medical economics, , Volume: 12, Issue:2, 2009
Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: a review.Drugs of today (Barcelona, Spain : 1998), , Volume: 42, Issue:3, 2006
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.Bipolar disorders, , Volume: 8, Issue:6, 2006
Valproate lowers plasma concentration of olanzapine.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study.Pharmacopsychiatry, , Volume: 38, Issue:5, 2005
Olanzapine: a critical review of recent literature.Expert opinion on pharmacotherapy, , Volume: 6, Issue:12, 2005
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorders, , Volume: 7 Suppl 3, 2005
Dermatological side effects of olanzapine.Indian journal of medical sciences, , Volume: 59, Issue:7, 2005
Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe.European journal of clinical pharmacology, , Volume: 60, Issue:1, 2004
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.Cancer investigation, , Volume: 22, Issue:3, 2004
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine.Pharmacotherapy, , Volume: 23, Issue:8, 2003
Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.Clinical therapeutics, , Volume: 25, Issue:4, 2003
The combination of olanzapine and fluoxetine in mood disorders.Expert opinion on pharmacotherapy, , Volume: 4, Issue:7, 2003
Broad therapeutic uses of atypical antipsychotic medications.Biological psychiatry, , Dec-01, Volume: 50, Issue:11, 2001
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.Southern medical journal, , Volume: 94, Issue:3, 2001
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.Journal of intellectual disability research : JIDR, , Volume: 44 ( Pt 2), 2000
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Psychotropic Drugs and Liver Toxicity.American journal of therapeutics, , Volume: 25, Issue:5
Treatment with atypical antipsychotics: new indications and new populations.Journal of psychiatric research, , Volume: 35, Issue:3
Olanzapine treatment of corticosteroid-induced mood disorders.Psychosomatics, , Volume: 43, Issue:6
Atypical antipsychotics in the treatment of affective symptoms: a review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:1
[Subjective and objective evaluation of treating schizophrenia with classic or atypical drugs].Psychiatria polska, , Volume: 35, Issue:1
Olanzapine for corticosteroid-induced mood disorders.Psychosomatics, , Volume: 44, Issue:4
Sedative drug-use in Denmark, 2000 to 2019: a nationwide drug utilization study.Social psychiatry and psychiatric epidemiology, , Volume: 58, Issue:10, 2023
Abuse and misuse of second-generation antipsychotics: An analysis using VigiBase, the World Health Organisation pharmacovigilance database.British journal of clinical pharmacology, , Volume: 88, Issue:10, 2022
Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use.Adicciones, , Apr-01, Volume: 34, Issue:2, 2022
The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis.Substance use & misuse, , Volume: 56, Issue:12, 2021
A Case of Self-Cannibalism: An Extremely Rare Type of Self-Mutilation With Multiple Risk Factors.The Journal of nervous and mental disease, , 04-01, Volume: 209, Issue:4, 2021
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.Bosnian journal of basic medical sciences, , May-20, Volume: 19, Issue:2, 2019
Harmala Alkaloids Identify Ayahausca Intoxication in a Urine Drug Screen.Journal of analytical toxicology, , May-01, Volume: 43, Issue:4, 2019
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.The Cochrane database of systematic reviews, , Jan-22, Volume: 1, 2018
Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database.Journal of clinical psychopharmacology, , Volume: 38, Issue:1, 2018
Chlorpheniramine dependence presenting as mania.Asian journal of psychiatry, , Volume: 30, 2017
Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms.Human psychopharmacology, , Volume: 30, Issue:4, 2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.The Journal of nervous and mental disease, , Volume: 203, Issue:7, 2015
Mephentermine dependence syndrome - A new emerging trend of substance use.Asian journal of psychiatry, , Volume: 17, 2015
Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
Olanzapine abuse.Substance abuse, , Volume: 34, Issue:1, 2013
Effectiveness of short-term olanzapine in patients with bipolar I disorder, with or without comorbidity with substance use disorder.Journal of clinical psychopharmacology, , Volume: 33, Issue:2, 2013
A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.Psychiatry research, , Aug-15, Volume: 188, Issue:3, 2011
Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study.The British journal of psychiatry : the journal of mental science, , Volume: 199, Issue:3, 2011
Olanzapine abuse was relieved after switching to aripiprazole in a patient with psychotic depression.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 34, Issue:7, 2010
Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:4, 2010
Severe dopaminergic pathways damage in a case of chronic toluene abuse.Clinical neurology and neurosurgery, , Volume: 111, Issue:10, 2009
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.Schizophrenia research, , Volume: 100, Issue:1-3, 2008
Abuse of olanzapine by substance abusers.Journal of psychoactive drugs, , Volume: 39, Issue:3, 2007
Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.Journal of clinical psychopharmacology, , Volume: 26, Issue:6, 2006
The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis.Acta psychiatrica Scandinavica, , Volume: 112, Issue:2, 2005
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.International clinical psychopharmacology, , Volume: 20, Issue:4, 2005
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorders, , Volume: 7 Suppl 3, 2005
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Olanzapine attenuates cue-elicited craving for tobacco.Psychopharmacology, , Volume: 175, Issue:4, 2004
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.International clinical psychopharmacology, , Volume: 18, Issue:3, 2003
Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report.International journal of psychiatry in medicine, , Volume: 33, Issue:1, 2003
Treatment with the atypical antipsychotic, olanzapine, prevents the expression of amphetamine-induced place conditioning in the rat.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:1, 2003
Potential use of olanzapine in treatment of substance dependence disorders.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Dependence and chronic psychosis with D-nor-pseudoephedrine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:8, 2003
Olanzapine treatment for patients with schizophrenia and substance abuse.Journal of substance abuse treatment, , Volume: 21, Issue:4, 2001
Possible risperidone-induced visual hallucinations.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 39, Issue:9, 2000
Olanzapine-induced ketoacidosis with diabetes mellitus.The American journal of psychiatry, , Volume: 156, Issue:9, 1999
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.Schizophrenia research, , Sep-07, Volume: 33, Issue:1-2, 1998
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.Psychosomatics, , Volume: 47, Issue:1
[Olanzapine in manic/mixed patients with or without substance abuse].Rivista di psichiatria, , Volume: 48, Issue:2
A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients.General hospital psychiatry, , Volume: 32, Issue:4
Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia.The American journal on addictions, , Volume: 16, Issue:4
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
[Treatment of schizophrenia in subjects with substance use disorders: A review].Actas espanolas de psiquiatria, , Volume: 29, Issue:2
Suicidal and homicidal behaviors related to dextromethorphan abuse in a middle-aged woman.Journal of addiction medicine, , Volume: 7, Issue:2
Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial.Medicine, , Volume: 97, Issue:8, 2018
Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.The Journal of clinical psychiatry, , Volume: 74, Issue:12, 2013
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Treatment for amphetamine psychosis.The Cochrane database of systematic reviews, , Jan-21, Issue:1, 2009
Treatment for amphetamine psychosis.The Cochrane database of systematic reviews, , 10-08, Issue:4, 2008
A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 88 Suppl 3, 2005
Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Antipsychotic medications for cocaine dependence.The Cochrane database of systematic reviews, , Mar-19, Volume: 3, 2016
Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.The Journal of clinical psychiatry, , Volume: 74, Issue:12, 2013
The effect of olanzapine pretreatment on acute cocaine toxicity in mice.Clinical toxicology (Philadelphia, Pa.), , Volume: 47, Issue:6, 2009
An unusual case report: treatment of cocaine-dependent patient with an atypical antipsychotic.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:2, 2008
Antipsychotic medications for cocaine dependence.The Cochrane database of systematic reviews, , Jul-18, Issue:3, 2007
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
Olanzapine-induced suppression of cocaine self-administration in rhesus monkeys.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:3, 2006
A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence.Addiction (Abingdon, England), , Volume: 100 Suppl 1, 2005
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.The Journal of nervous and mental disease, , Volume: 193, Issue:6, 2005
A pilot trial of olanzapine for the treatment of cocaine dependence.Drug and alcohol dependence, , Jun-05, Volume: 70, Issue:3, 2003
Olanzapine for cocaine cravings and relapse prevention.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
Potential use of olanzapine in treatment of substance dependence disorders.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Olanzapine treatment for patients with schizophrenia and cocaine abuse.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
Olanzapine for cocaine craving and relapse prevention in 2 patients.The Journal of clinical psychiatry, , Volume: 63, Issue:7, 2002
[Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients. Interaction with plasma levels].Actas espanolas de psiquiatria, , Volume: 29, Issue:4
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
Outcome predictors in cocaine dependence treatment trials.The American journal on addictions, , Volume: 15, Issue:6
Olanzapine in cocaine dependence: a double-blind, placebo-controlled trial.The American journal on addictions, , Volume: 18, Issue:1
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.International clinical psychopharmacology, , Volume: 27, Issue:4, 2012
[Sexual disturbances during the treatment with neuroleptics in patients with schizophrenia and schizophrenia spectrum disorders].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 111, Issue:9 Pt 2, 2011
Hypersexual features in Huntington's disease.Singapore medical journal, , Volume: 52, Issue:6, 2011
Successful treatment of sexual dysfunction with dronabinol: a case report.The Journal of clinical psychiatry, , Volume: 65, Issue:8, 2004
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.Annals of the New York Academy of Sciences, , Volume: 1032, 2004
Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults.Schizophrenia bulletin, , Volume: 29, Issue:3, 2003
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
Hyperprolactinemia and male sexual dysfunction.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning.Journal of sex & marital therapy, , Volume: 32, Issue:4
Zolpidem related persistent genital arousal disorder: An interesting case.Psychiatrike = Psychiatriki, , Volume: 30, Issue:4
The neuroprotective effect of olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 20, Issue:1, 2008
Olanzapine attenuates brain damage after focal cerebral ischemia in vivo.Brain research bulletin, , Dec-11, Volume: 71, Issue:1-3, 2006
A Case of Abulia From Left Middle Cerebral Artery Stroke in an Adolescent Treated Successfully With Short Duration Olanzapine.Clinical neuropharmacology, , Volume: 43, Issue:3
A case of catatonia status-post left middle cerebral artery cerebrovascular accident, treated successfully with olanzapine.Clinical neuropharmacology, , Volume: 36, Issue:4
A case of abulia, status/post right middle cerebral artery territory infarct, treated successfully with olanzapine.Clinical neuropharmacology, , Volume: 37, Issue:6
Venous thrombosis during olanzapine treatment: a complex association.The Netherlands journal of medicine, , Volume: 76, Issue:6, 2018
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation.Clinical and experimental pharmacology & physiology, , Volume: 34, Issue:8, 2007
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Olanzapine and venous thromboembolism.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Olanzapine-Associated Portal and Superior Mesenteric Vein Thrombosis.American journal of therapeutics, , Volume: 27, Issue:4
Olanzapine as an add-on, pre-operative anti-emetic drug for postoperative nausea or vomiting: a randomised controlled trial.Anaesthesia, , Volume: 78, Issue:10, 2023
Olanzapine for the Prevention of Postdischarge Nausea and Vomiting after Ambulatory Surgery: A Randomized Controlled Trial.Anesthesiology, , Volume: 132, Issue:6, 2020
Chronic Atypical Antipsychotic Use Is Associated With Reduced Need for Postoperative Nausea and Vomiting Rescue in the Postanesthesia Care Unit: A Propensity-Matched Retrospective Observational Study.Anesthesia and analgesia, , Volume: 130, Issue:1, 2020
Olanzapine treatment for tics in an adult woman with severe tourette syndrome.Acta neurologica Taiwanica, , Volume: 21, Issue:4, 2012
Atomoxetine-induced vocal tics in a patient with schizophrenia.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Olanzapine in Gilles de la Tourette syndrome: beyond tics.Acta neurologica Belgica, , Volume: 105, Issue:4, 2005
Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 14, Issue:2, 2004
[Treatment of tics in Tourette syndrome with atypical antipsychotic drugs].Ugeskrift for laeger, , Aug-05, Volume: 164, Issue:32, 2002
Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses.BMJ (Clinical research ed.), , Nov-24, Volume: 355, 2016
Risk of ischemic stroke associated with the use of antipsychotic drugs in elderly patients: a retrospective cohort study in Korea.PloS one, , Volume: 10, Issue:3, 2015
Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: a population-based, case-crossover study.Journal of psychopharmacology (Oxford, England), , Volume: 27, Issue:7, 2013
[Atypical antipsychotics in elderly patients with dementia].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , May-01, Volume: 128, Issue:9, 2008
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Psychosis of Alzheimer disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Mar-26, Volume: 149, Issue:13, 2005
Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly.Journal of clinical psychopharmacology, , Volume: 25, Issue:5, 2005
Olanzapine for the treatment of hemiballismus: A case report.Archives of physical medicine and rehabilitation, , Volume: 86, Issue:3, 2005
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Mar-26, Volume: 149, Issue:13, 2005
Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:5, 2005
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Jan-22, Volume: 149, Issue:4, 2005
A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD). Favour.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study.Journal of neurology, , Volume: 252, Issue:10, 2005
Do atypical antipsychotics cause stroke?CNS drugs, , Volume: 19, Issue:2, 2005
CSM warning on atypical psychotics and stroke may be detrimental for dementia.BMJ (Clinical research ed.), , May-22, Volume: 328, Issue:7450, 2004
Clinical effectiveness of atypical antipsychotics in dementia.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Atypical antipsychotics and risk of cerebrovascular accidents.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
Mania secondary to right-sided stroke--responsive to olanzapine.General hospital psychiatry, , Volume: 28, Issue:3
Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.Clinical schizophrenia & related psychoses, , Volume: 7, Issue:4, 2014
Catatonia and parkinsonism as a sequelae of typhoid fever: a rare experience.BMJ case reports, , Jun-27, Volume: 2013, 2013
Antipsychotics and mortality in Parkinsonism.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 20, Issue:2, 2012
Olanzapine-induced parkinsonism associated with smoking cessation.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Mar-01, Volume: 68, Issue:5, 2011
A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics?European journal of neurology, , Volume: 15, Issue:2, 2008
A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.International journal of geriatric psychiatry, , Volume: 21, Issue:2, 2006
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Olanzapine for delirium in parkinsonism: therapeutic benefits in lieu of adverse consequences.Neurology India, , Volume: 52, Issue:2, 2004
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.Dementia and geriatric cognitive disorders, , Volume: 13, Issue:2, 2002
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 13, Issue:4, 2001
Olanzapine-induced Priapism in a Child with Asperger's Syndrome.Balkan medical journal, , Volume: 34, Issue:1, 2017
Asperger's syndrome: from hiding to thriving.The Nurse practitioner, , Volume: 33, Issue:7, 2008
An open trial of olanzapine in children and adolescents with Asperger Disorder.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:5, 2006
The diagnosis of Asperger's syndrome in an adult presenting with an index episode of mania by Ng et al.General hospital psychiatry, , Volume: 26, Issue:2
Olanzapine-induced tardive oculogyric crisis.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:4, 2002
Writer's cramp induced by olanzapine.Journal of neurology, , Volume: 248, Issue:5, 2001
Reduction of tardive dystonia with olanzapine.The American journal of psychiatry, , Volume: 156, Issue:12, 1999
Neuroleptic Sensitivity in Dementia with Lewy Body and Use of Pimavanserin in an Inpatient Setting: A Case Report.The American journal of case reports, , Oct-25, Volume: 23, 2022
Dementia with Lewy bodies presenting marked tongue protrusion and bite due to lingual dystonia: A case report.Rinsho shinkeigaku = Clinical neurology, , 06-22, Volume: 56, Issue:6, 2016
Topiramate improves psychiatric symptoms in a patient with Lewy body dementia.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 27, Issue:4, 2014
Olanzapine-induced neuroleptic malignant syndrome in a patient with probable dementia with Lewy bodies.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
Reversal of head drop after discontinuation of olanzapine in a DLB patient.Movement disorders : official journal of the Movement Disorder Society, , Sep-15, Volume: 23, Issue:12, 2008
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
[Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].Nederlands tijdschrift voor geneeskunde, , Jan-04, Volume: 147, Issue:1, 2003
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.Dementia and geriatric cognitive disorders, , Volume: 13, Issue:2, 2002
Lewy body dementia.Journal of the Mississippi State Medical Association, , Volume: 43, Issue:4, 2002
Dementia with Lewy bodies in Down's syndrome.International journal of geriatric psychiatry, , Volume: 16, Issue:3, 2001
Recurrent Hyperammonemia Associated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 37, Issue:3, 2017
[Hemoperfusion with activated charcoal on valproic acid poisoning. A case report].Medicina intensiva, , Volume: 39, Issue:7, 2015
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.Boletin de la Asociacion Medica de Puerto Rico, , Volume: 105, Issue:3, 2013
Metabolic disorders induced by psychotropic drugs.Annales d'endocrinologie, , Volume: 84, Issue:3, 2023
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.Schizophrenia bulletin, , 03-15, Volume: 49, Issue:2, 2023
Antipsychotic-Induced Metabolic Syndrome: A Review.Metabolic syndrome and related disorders, , Volume: 21, Issue:6, 2023
Herbal Therapies for Weight Gain and Metabolic Abnormalities Induced by Atypical Antipsychotics: A Review Article.Current drug discovery technologies, , Volume: 20, Issue:5, 2023
A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.Scientific reports, , 04-07, Volume: 11, Issue:1, 2021
The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain.The Journal of experimental medicine, , 07-05, Volume: 218, Issue:7, 2021
A potential probiotic bacterium for antipsychotic-induced metabolic syndrome: mechanisms underpinning how Akkermansia muciniphila subtype improves olanzapine-induced glucose homeostasis in mice.Psychopharmacology, , Volume: 238, Issue:9, 2021
FADS1 modulates metabolic syndrome in schizophrenia patients receiving olanzapine monotherapy.Asian journal of psychiatry, , Volume: 54, 2020
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.The Journal of clinical psychiatry, , 03-24, Volume: 81, Issue:3, 2020
Relationship between metabolic syndrome and acylated/desacylated ghrelin ratio in patients with schizophrenia under olanzapine medication.Journal of psychopharmacology (Oxford, England), , Volume: 34, Issue:1, 2020
The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats.Pharmacology, biochemistry, and behavior, , Volume: 191, 2020
Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice.Molecular neurobiology, , Volume: 57, Issue:1, 2020
Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome.Brain, behavior, and immunity, , Volume: 88, 2020
Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial.Psychopharmacology, , Volume: 236, Issue:4, 2019
Berberine attenuates olanzapine induced-metabolic syndrome.JPMA. The Journal of the Pakistan Medical Association, , Volume: 69(Suppl 3), Issue:8, 2019
Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial.Medicine, , Volume: 98, Issue:38, 2019
Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis.Neuropsychopharmacology reports, , Volume: 39, Issue:3, 2019
Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease.Circulation research, , 08-02, Volume: 125, Issue:4, 2019
Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine.Schizophrenia research, , Volume: 206, 2019
Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance.Scientific reports, , 02-07, Volume: 9, Issue:1, 2019
Insulin resistance induced by olanzapine and other second-generation antipsychotics in Chinese patients with schizophrenia: a comparative review and meta-analysis.European journal of clinical pharmacology, , Volume: 75, Issue:12, 2019
Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.Psychoneuroendocrinology, , Volume: 81, 2017
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.Journal of psychiatric research, , Volume: 85, 2017
Protective effects of green tea on olanzapine-induced-metabolic syndrome in rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 92, 2017
Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders.Psychopharmacology bulletin, , 05-15, Volume: 47, Issue:2, 2017
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.Acta psychiatrica Scandinavica, , Volume: 133, Issue:1, 2016
Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 17, Issue:6, 2016
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.International journal of psychiatry in clinical practice, , Volume: 18, Issue:4, 2014
Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study.Pharmacopsychiatry, , Volume: 47, Issue:4-5, 2014
Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics.Early intervention in psychiatry, , Volume: 8, Issue:3, 2014
Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.European journal of clinical pharmacology, , Volume: 70, Issue:12, 2014
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.The Journal of clinical psychiatry, , Volume: 74, Issue:1, 2013
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.Schizophrenia research, , Volume: 146, Issue:1-3, 2013
Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.Journal of clinical psychopharmacology, , Volume: 32, Issue:4, 2012
Association of serum retinol-binding protein 4 with insulin resistance and metabolic parameters during olanzapine therapy.Clinical endocrinology, , Volume: 76, Issue:2, 2012
[Metabolic syndrome in patients with schizophrenia and antipsychotic treatment].Medicina clinica, , Nov-17, Volume: 139, Issue:12, 2012
Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.The pharmacogenomics journal, , Volume: 12, Issue:1, 2012
Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.Singapore medical journal, , Volume: 53, Issue:7, 2012
Antipsychotic treatment--side-effect and/or metabolic syndrome.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.Progress in neuro-psychopharmacology & biological psychiatry, , Jul-01, Volume: 35, Issue:5, 2011
Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.Schizophrenia research, , Volume: 125, Issue:2-3, 2011
Screening for metabolic syndrome-adherence to guidelines.African journal of psychiatry, , Volume: 14, Issue:1, 2011
Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.Psychopharmacology bulletin, , Volume: 43, Issue:4, 2010
Metabolic syndrome with the atypical antipsychotics.Current opinion in endocrinology, diabetes, and obesity, , Volume: 17, Issue:5, 2010
Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation.Journal of psychiatric practice, , Volume: 15, Issue:4, 2009
Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.Journal of clinical psychopharmacology, , Volume: 29, Issue:1, 2009
30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 70, Issue:3, 2009
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
A clinical paradigm of delusions of parasitosis.Journal of the American Academy of Dermatology, , Volume: 59, Issue:4, 2008
Olanzapine metabolic side effects: a weight gain issue?Internal and emergency medicine, , Volume: 3, Issue:3, 2008
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.Psychiatry research, , May-30, Volume: 159, Issue:1-2, 2008
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.The Journal of clinical psychiatry, , Volume: 68, Issue:10, 2007
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
Atypical antipsychotics related metabolic syndrome in bipolar patients.Journal of affective disorders, , Volume: 98, Issue:3, 2007
Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:7, 2007
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.International clinical psychopharmacology, , Volume: 22, Issue:2, 2007
Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice.Current medical research and opinion, , Volume: 22, Issue:12, 2006
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.The Journal of clinical psychiatry, , Volume: 67, Issue:5, 2006
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.Psychopharmacology, , Volume: 186, Issue:4, 2006
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Archives of general psychiatry, , Volume: 62, Issue:1, 2005
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:1, 2005
Complications from olanzapine in a mentally healthy patient.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.Clinical therapeutics, , Volume: 27, Issue:12, 2005
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 7, Issue:3, 2005
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Body weight gain, insulin, and leptin in olanzapine-treated patients.The Journal of clinical psychiatry, , Volume: 62, Issue:11, 2001
Metabolic Syndrome Reversal With Cariprazine.Journal of clinical psychopharmacology, , Volume: 39, Issue:4
Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome.Srpski arhiv za celokupno lekarstvo, , Volume: 143, Issue:11-12
Visceral and subcutaneous fat in patients treated with olanzapine: a case series.Clinical neuropharmacology, , Volume: 33, Issue:5
Magnitude of metabolic syndrome and its predictors among patients on second-generation antipsychotic drugs at six psychiatry clinics and mental hospitals, in Addis Ababa, Ethiopia, 2019; Multicenter cross-sectional study.Diabetes & metabolic syndrome, , Volume: 15, Issue:4
Epigenetic Histone Methylation of PPARγ and CPT1A Signaling Contributes to Betahistine Preventing Olanzapine-Induced Dyslipidemia.International journal of molecular sciences, , May-23, Volume: 24, Issue:11, 2023
Antipsychotic-Induced Metabolic Syndrome: A Review.Metabolic syndrome and related disorders, , Volume: 21, Issue:6, 2023
PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients.Psychopharmacology, , Volume: 239, Issue:1, 2022
Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice.Molecular neurobiology, , Volume: 57, Issue:1, 2020
Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin.BMC pharmacology & toxicology, , 06-30, Volume: 21, Issue:1, 2020
Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway.Acta pharmacologica Sinica, , Volume: 40, Issue:8, 2019
Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients.Human psychopharmacology, , Volume: 34, Issue:4, 2019
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.Psychoneuroendocrinology, , Volume: 108, 2019
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5, 2018
Antenatal antipsychotic exposure induces multigenerational and gender-specific programming of adiposity and glucose tolerance in adult mouse offspring.Diabetes & metabolism, , Volume: 44, Issue:3, 2018
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar disorders, , Volume: 17, Issue:5, 2015
Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα-dependent pathways.Pharmacological research, , Volume: 100, 2015
The risk of metabolic disorders in patients treated with asenapine or olanzapine: a study conducted on real-world data in Italy and Spain.Expert opinion on drug safety, , Volume: 13, Issue:9, 2014
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 15, Issue:3, 2014
The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.Clinical drug investigation, , Volume: 33, Issue:10, 2013
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clinical drug investigation, , Volume: 31, Issue:7, 2011
A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.PloS one, , Volume: 6, Issue:8, 2011
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.International clinical psychopharmacology, , Volume: 24, Issue:4, 2009
30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Olanzapine: review of safety 2008.Expert opinion on drug safety, , Volume: 7, Issue:6, 2008
Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Red Yeast Rice for a patient with olanzapine-induced dyslipidemia: a test-and-retest case report.Progress in neuro-psychopharmacology & biological psychiatry, , Jul-01, Volume: 32, Issue:5, 2008
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Metabolic effects of the atypical antipsychotics.Southern medical journal, , Volume: 100, Issue:8, 2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.The American journal of managed care, , Volume: 13, Issue:7 Suppl, 2007
Diabetic ketoacidosis and severe dyslipidemia in an adult psychotic man with olanzapine treatment.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
Esperienze di switch a cariprazina in pazienti schizofrenici con comparsa di effetti collaterali/comorbilità mediche.Rivista di psichiatria, , Volume: 54, Issue:6
Atypical antipsychotic drugs deregulate the cholesterol metabolism of macrophage-foam cells by activating NOX-ROS-PPARγ-CD36 signaling pathway.Metabolism: clinical and experimental, , Volume: 123, 2021
Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, , Volume: 50, Issue:4, 2018
[Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:3, 2015
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.Journal of clinical pharmacology, , Volume: 61, Issue:11, 2021
Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.Drug design, development and therapy, , Volume: 13, 2019
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
Psychopharmacologic Management of Eating Disorders.Current psychiatry reports, , Volume: 24, Issue:7, 2022
Psychotropic Medication for Children and Adolescents with Eating Disorders.Child and adolescent psychiatric clinics of North America, , Volume: 28, Issue:4, 2019
Resurgence of Eating Disorders with Olanzapine.Journal of palliative medicine, , Volume: 22, Issue:2, 2019
Lack of efficacy of psychological and pharmacological treatments of disorders of eating behavior: neurobiological background.BMC psychiatry, , Dec-24, Volume: 14, 2014
Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 114, Issue:8, 2007
Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats.Scientific reports, , 06-05, Volume: 7, Issue:1, 2017
Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
[The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].Psychiatria polska, , Volume: 49, Issue:2
Neuroleptics: bedwetting.Prescrire international, , Volume: 21, Issue:127, 2012
Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study.The British journal of psychiatry : the journal of mental science, , Volume: 199, Issue:2, 2011
Risperidone-induced enuresis in two children with autistic disorder.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:4, 2007
Thrombotic complications of treatment with antipsychotic drugs.Minerva medica, , Volume: 104, Issue:2, 2013
Four cases of venous thromboembolism associated with olanzapine.Psychiatry and clinical neurosciences, , Volume: 63, Issue:1, 2009
Fatal pulmonary embolism following antipsychotic treatment and physical restraint.Pharmacopsychiatry, , Volume: 42, Issue:5, 2009
Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions.Drug safety, , Volume: 31, Issue:8, 2008
Antipsychotic Drug Aripiprazole Protects Liver Cells from Oxidative Stress.International journal of molecular sciences, , Jul-27, Volume: 23, Issue:15, 2022
Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats.Journal of ethnopharmacology, , Jun-28, Volume: 274, 2021
Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane.The Journal of nutritional biochemistry, , Volume: 81, 2020
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 30, Issue:9, 2020
Up-regulation of hepatic fatty acid transporters and inhibition/down-regulation of hepatic OCTN2 contribute to olanzapine-induced liver steatosis.Toxicology letters, , Volume: 316, 2019
The protective effect of thymoquinone over olanzapine-induced side effects in liver, and metabolic side effects.Bratislavske lekarske listy, , Volume: 118, Issue:10, 2017
Management of Hepatotoxicity Induced by the Use of Olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 27, Issue:3, 2017
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Liver toxicity due to olanzapine.Revista espanola de enfermedades digestivas, , Volume: 104, Issue:11, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Mouse precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury.Chemical research in toxicology, , Sep-17, Volume: 25, Issue:9, 2012
Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature.Psychiatria Danubina, , Volume: 23 Suppl 1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
[Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection].Gastroenterologia y hepatologia, , Volume: 33, Issue:2, 2010
Possible olanzapine-induced hepatotoxicity in a young Chinese patient.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 15, Issue:5, 2009
Serum levels of olanzapine in a non-fatal overdose.Journal of analytical toxicology, , Volume: 31, Issue:2, 2007
Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-30, Volume: 30, Issue:6, 2006
Acute hepatocellular-cholestatic liver injury after olanzapine therapy.Annals of internal medicine, , Feb-18, Volume: 138, Issue:4, 2003
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Olanzapine (Zyprexa): suspected serious reactions.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jul-11, Volume: 163, Issue:1, 2000
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
Psychotropic Drugs and Liver Toxicity.American journal of therapeutics, , Volume: 25, Issue:5
Late-Onset Cholestatic Liver Injury During Combination Treatment With Chlorpromazine and Olanzapine: A Case Report.Journal of clinical psychopharmacology, , Volume: 39, Issue:2
Incidence of hospital contacts with acute kidney injury after initiation of second-generation antipsychotics in older adults: a Danish population-based cohort study.European journal of clinical pharmacology, , Volume: 78, Issue:8, 2022
Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report.Journal of medical case reports, , Oct-06, Volume: 16, Issue:1, 2022
Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.Drugs & aging, , Volume: 34, Issue:3, 2017
Serotonin Syndrome Induced by Combined Use of Mirtazapine and Olanzapine Complicated with Rhabdomyolysis, Acute Renal Failure, and Acute Pulmonary Edema-A Case Report.Acta neurologica Taiwanica, , Volume: 24, Issue:4, 2015
Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study.Annals of internal medicine, , Aug-19, Volume: 161, Issue:4, 2014
Unexpected hospitalisation side effects in an elderly man.Internal and emergency medicine, , Volume: 6, Issue:2, 2011
Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Neuroleptic malignant syndrome presenting with acute renal failure.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Olanzapine and acute urinary retention in two geriatric patients.The American journal of geriatric pharmacotherapy, , Volume: 5, Issue:3, 2007
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].Minerva anestesiologica, , Volume: 69, Issue:6, 2003
[Woman in her 30s with chronic fatigue].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Feb-25, Volume: 134, Issue:4, 2014
Capgras syndrome presenting in an adolescent girl in the Caribbean.The West Indian medical journal, , Volume: 62, Issue:1, 2013
Subtypes of antipsychotics and suicidal behavior in bipolar disorder.Journal of affective disorders, , Dec-20, Volume: 143, Issue:1-3, 2012
[A case of affective disorder with psychotic symptoms as late manifestation of Huntington's Chorea].Psychiatrische Praxis, , Volume: 38, Issue:6, 2011
Suicidal and homicidal behaviors related to dextromethorphan abuse in a middle-aged woman.Journal of addiction medicine, , Volume: 7, Issue:2
The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression.The Journal of clinical psychiatry, , Volume: 78, Issue:8
Case Report: De Novo and Persistent Psychosis After Withdrawal From Chronic Opioid Therapy.Journal of psychiatric practice, , 09-01, Volume: 28, Issue:5, 2022
The Utilization of Atypical Antipsychotics in the Pain Medicine Physician's Armamentarium.Psychopharmacology bulletin, , 06-20, Volume: 48, Issue:4, 2018
A Systematic Review of Atypical Antipsychotics in Chronic Pain Management: Olanzapine Demonstrates Potential in Central Sensitization, Fibromyalgia, and Headache/Migraine.The Clinical journal of pain, , Volume: 34, Issue:6, 2018
Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics.Postgraduate medicine, , Volume: 128, Issue:3, 2016
Therapeutic potential of TAK-071, a muscarinic MNeuroscience letters, , 11-01, Volume: 764, 2021
Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats.Behavioural brain research, , 01-27, Volume: 378, 2020
Differential benefits of olanzapine on executive function in schizophrenia patients: Preliminary findings.Human psychopharmacology, , Volume: 35, Issue:1, 2020
Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome.Brain, behavior, and immunity, , Volume: 88, 2020
2-Aminoimidazole-based antagonists of the 5-HTEuropean journal of medicinal chemistry, , Oct-01, Volume: 179, 2019
Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.Psychoneuroendocrinology, , Volume: 81, 2017
Cognition and Dopamine DThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:1, 2017
Anti-N-methyl-D-aspartate receptor encephalitis is an important differential diagnosis in acute psychiatric disease.Acta psychiatrica Scandinavica, , Volume: 131, Issue:1, 2015
A Potential Case of Acute Ketamine Withdrawal: Clinical Implications for the Treatment of Refractory Depression.The American journal of psychiatry, , Volume: 178, Issue:7, 2021
Activation of indoleamine 2, 3- dioxygenase pathway by olanzapine augments antidepressant effects of venlafaxine in mice.Psychiatry research, , Volume: 258, 2017
[Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].Psychiatrische Praxis, , Volume: 39, Issue:2, 2012
Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis.The Journal of clinical psychiatry, , Volume: 73, Issue:6, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.The Journal of clinical psychiatry, , Volume: 73, Issue:8, 2012
Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study.Human psychopharmacology, , Volume: 26, Issue:3, 2011
Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.Pharmacogenetics and genomics, , Volume: 21, Issue:9, 2011
Predicting serotonin toxicity in serotonin reuptake inhibitor overdose.Clinical toxicology (Philadelphia, Pa.), , Volume: 61, Issue:1, 2023
Delayed Serotonin Syndrome in the Setting of a Mixed Fluoxetine and Serotonin Antagonist Overdose.The American journal of case reports, , May-25, Volume: 19, 2018
Successful intravenous lipid emulsion therapy: Olanzapine intoxication.Acute medicine, , Volume: 17, Issue:2, 2018
Delirium with anticholinergic symptoms after a combination of paliperidone and olanzapine pamoate in a patient known to smoke cannabis: an unfortunate coincidence.BMJ case reports, , Jun-22, Volume: 2016, 2016
[Hemoperfusion with activated charcoal on valproic acid poisoning. A case report].Medicina intensiva, , Volume: 39, Issue:7, 2015
Abnormal olanzapine toxicokinetic profiles--population pharmacokinetic analysis.Toxicology mechanisms and methods, , Volume: 25, Issue:1, 2015
Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care.Clinical toxicology (Philadelphia, Pa.), , Volume: 52, Issue:1, 2014
[Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].Tijdschrift voor psychiatrie, , Volume: 56, Issue:4, 2014
Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient.Clinical toxicology (Philadelphia, Pa.), , Volume: 51, Issue:3, 2013
Acute olanzapine overdose in a toddler: a case report.Therapeutic drug monitoring, , Volume: 35, Issue:5, 2013
Cardiotoxicity in a citalopram and olanzapine overdose.The Journal of emergency medicine, , Volume: 45, Issue:4, 2013
Intravenous lipid infusion restores consciousness associated with olanzapine overdose.Anesthesia and analgesia, , Volume: 114, Issue:4, 2012
Acute overdose of enteric-coated valproic acid and olanzapine: unusual presentation and delayed toxicity.Clinical toxicology (Philadelphia, Pa.), , Volume: 50, Issue:4, 2012
Nonfatal suicidal overdose of olanzapine in an adolescent.Current drug safety, , Volume: 7, Issue:4, 2012
[The clinical picture of acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
Olanzapine intoxication-related transient diabetes insipidus.Renal failure, , Volume: 33, Issue:8, 2011
Atrıal fıbrıllatıon due to olanzapıne overdose.Clinical toxicology (Philadelphia, Pa.), , Volume: 49, Issue:5, 2011
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.BMC psychiatry, , Jun-10, Volume: 10, 2010
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.BMC psychiatry, , Jun-10, Volume: 10, 2010
Long-acting injectable olanzaoine. Inadequate assessment and a risk of overdose.Prescrire international, , Volume: 19, Issue:107, 2010
A systematic review of cardiovascular effects after atypical antipsychotic medication overdose.The American journal of emergency medicine, , Volume: 27, Issue:5, 2009
Neurotoxicity with therapeutic lithium levels: a case report.Journal of psychiatric practice, , Volume: 15, Issue:1, 2009
In response to Morris et al.'s "Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine".Journal of medical toxicology : official journal of the American College of Medical Toxicology, , Volume: 5, Issue:4, 2009
Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine.Journal of medical toxicology : official journal of the American College of Medical Toxicology, , Volume: 5, Issue:1, 2009
Nonfatal suicidal olanzapine intoxication: a case report.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Prolonged toxicity after massive olanzapine overdose: two cases with confirmatory laboratory data.The Journal of toxicological sciences, , Volume: 33, Issue:3, 2008
Olanzapine overdose: a series of analytically confirmed cases.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Serum levels of olanzapine in a non-fatal overdose.Journal of analytical toxicology, , Volume: 31, Issue:2, 2007
A severe case of olanzapine overdose with analytical data.Clinical toxicology (Philadelphia, Pa.), , Volume: 45, Issue:4, 2007
Olanzapine overdose is associated with acute muscle toxicity.Human & experimental toxicology, , Volume: 25, Issue:12, 2006
Acute olanzapine-induced akathisia and dystonia in a patient discontinued from fluoxetine.The Journal of emergency medicine, , Volume: 30, Issue:3, 2006
Pontine haemorrhage mimicked by an olanzapine overdose.Emergency medicine journal : EMJ, , Volume: 23, Issue:4, 2006
Stability study of bupropion and olanzapine in formaldehyde solutions.Rapid communications in mass spectrometry : RCM, , Volume: 20, Issue:8, 2006
Altered mental status from olanzapine overdose treated with physostigmine.Clinical toxicology (Philadelphia, Pa.), , Volume: 44, Issue:3, 2006
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current opinion in pediatrics, , Volume: 17, Issue:2, 2005
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
[Clinical course of acute poisoning with olanzapine].Przeglad lekarski, , Volume: 62, Issue:6, 2005
Postmortem tissue distribution of olanzapine and citalopram in a drug intoxication.Journal of forensic sciences, , Volume: 50, Issue:3, 2005
Persistent choreoathetosis in a fatal olanzapine overdose: drug kinetics, neuroimaging, and neuropathology.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Olanzapine overdose in children and adolescents: two case reports and a review of the literature.Journal of child and adolescent psychopharmacology, , Volume: 15, Issue:6, 2005
The clinical picture of olanzapine poisoning with special reference to fluctuating mental status.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:1, 2004
Polyuria after olanzapine overdose.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
[A case of delirium after olanzapine intoxication].Der Nervenarzt, , Volume: 74, Issue:11, 2003
A review of olanzapine-associated toxicity and fatality in overdose.Journal of psychiatry & neuroscience : JPN, , Volume: 28, Issue:4, 2003
[Mnestic impairment under olanzapine overdosage in an elderly patient].Psychiatrische Praxis, , Volume: 29, Issue:8, 2002
Olanzapine overdose: a pediatric case report.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 12, Issue:4, 2002
Norepinephrine in the treatment of olanzapine overdose.Anaesthesia, , Volume: 57, Issue:10, 2002
Tissue distribution of olanzapine in a postmortem case.The American journal of forensic medicine and pathology, , Volume: 22, Issue:3, 2001
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.The Journal of clinical psychiatry, , Volume: 62, Issue:12, 2001
Overdose and death with olanzapine: two case reports.The American journal of forensic medicine and pathology, , Volume: 21, Issue:3, 2000
Olanzapine overdose.Anaesthesia, , Volume: 55, Issue:9, 2000
Intoxication with olanzapine.The American journal of psychiatry, , Volume: 157, Issue:2, 2000
Olanzapine overdose.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Olanzapine overdose in an 18-month-old child.Journal of child and adolescent psychopharmacology, , Volume: 9, Issue:4, 1999
Olanzapine overdose in a 1-year-old male.Pediatric emergency care, , Volume: 15, Issue:4, 1999
Olanzapine overdose with serum concentrations.Annals of emergency medicine, , Volume: 34, Issue:2, 1999
Olanzapine overdose mimicking opioid intoxication.Annals of emergency medicine, , Volume: 34, Issue:2, 1999
Olanzapine pediatric overdose.Annals of emergency medicine, , Volume: 34, Issue:2, 1999
Fatal overdose of olanzepine.Forensic science international, , Feb-16, Volume: 91, Issue:3, 1998
Olanzapine overdose cause of acute extrapyramidal symptoms.The American journal of psychiatry, , Volume: 155, Issue:11, 1998
Olanzapine overdose.Annals of emergency medicine, , Volume: 32, Issue:2, 1998
Olanzapine-related fatality.Journal of forensic sciences, , Volume: 43, Issue:6, 1998
[QT prolongation and second-generation antipsychotics: overdose and therapeutic dosage].Therapie, , Volume: 59, Issue:5
Postmortem tissue concentrations of olanzapine.Journal of analytical toxicology, , Volume: 33, Issue:1
Antipsychotic-Related Fatal Poisoning, England and Wales, 1993-2019: The Impact of Second-Generation Antipsychotics.Journal of clinical psychopharmacology, , Volume: 41, Issue:6
[Clinical and neuro-physiopathological effects of an olanzapine overdose].Therapie, , Volume: 65, Issue:2
A Fatality Related to Two Novel Hallucinogenic Compounds: 4-Methoxyphencyclidine and 4-Hydroxy-N-methyl-N-ethyltryptamine.Journal of analytical toxicology, , Volume: 39, Issue:9
Nonfatal suicidal olanzapine overdose: a case report.Clinical neuropharmacology, , Volume: 29, Issue:4
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.The lancet. Psychiatry, , Volume: 10, Issue:9, 2023
A national pharmacovigilance study of haematological adverse drug reactions to clozapine vs other second-generation antipsychotics in Italy.Schizophrenia research, , Volume: 257, 2023
Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.Die Pharmazie, , 09-01, Volume: 77, Issue:7, 2022
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:9, 2022
Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: a retrospective study.BMC psychiatry, , 08-22, Volume: 22, Issue:1, 2022
Facial edema as an adverse drug reaction to olanzapine in a patient with cancer receiving palliative care.Palliative & supportive care, , Volume: 20, Issue:5, 2022
Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.Schizophrenia bulletin, , 04-29, Volume: 47, Issue:3, 2021
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 30, Issue:9, 2020
Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study.Tumori, , Volume: 105, Issue:3, 2019
Prevalence and recognition of highly significant medication-smoking cessation interactions in a smoke-free hospital.Drug and alcohol dependence, , 07-01, Volume: 200, 2019
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.Journal of global oncology, , Volume: 4, 2018
Switch-associated adverse events: focus on olanzapine.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 26, Issue:6, 2018
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.The pharmacogenomics journal, , 05-22, Volume: 18, Issue:3, 2018
No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment.Acta psychiatrica Scandinavica, , Volume: 138, Issue:2, 2018
Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.JAMA psychiatry, , 08-01, Volume: 75, Issue:8, 2018
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 25, Issue:2, 2017
Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.British journal of clinical pharmacology, , Volume: 83, Issue:7, 2017
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.Brain and behavior, , Volume: 7, Issue:6, 2017
Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.Psychopharmacology, , Volume: 233, Issue:21-22, 2016
Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats.Psychoneuroendocrinology, , Volume: 73, 2016
Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users.The Psychiatric quarterly, , Volume: 87, Issue:2, 2016
Neurological Adverse Effects of Antipsychotics in Children and Adolescents.Journal of clinical psychopharmacology, , Volume: 35, Issue:6, 2015
[Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].Tijdschrift voor psychiatrie, , Volume: 56, Issue:4, 2014
Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment.International journal of methods in psychiatric research, , Volume: 23, Issue:4, 2014
[Post-injection syndrome after depot injection of olanzapine].Nederlands tijdschrift voor geneeskunde, , Volume: 159, 2014
Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.European journal of pharmacology, , Jan-05, Volume: 722, 2014
Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring.The Journal of pharmacy and pharmacology, , Volume: 66, Issue:6, 2014
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia.The Psychiatric quarterly, , Volume: 84, Issue:1, 2013
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.Swiss medical weekly, , Volume: 143, 2013
Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.Pharmacogenomics, , Volume: 14, Issue:10, 2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Olanzapine-induced limb edema simulating episodic angioedema with eosinophilia.The Journal of dermatology, , Volume: 39, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study.PLoS computational biology, , Volume: 7, Issue:3, 2011
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.BMC psychiatry, , Jun-10, Volume: 10, 2010
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.BMC psychiatry, , Jun-10, Volume: 10, 2010
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.Expert review of neurotherapeutics, , Volume: 10, Issue:5, 2010
Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.BMC psychiatry, , Nov-03, Volume: 10, 2010
Drug research: marketing before evidence, sales before safety.Deutsches Arzteblatt international, , Volume: 107, Issue:16, 2010
The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials.The Journal of clinical psychiatry, , Volume: 70, Issue:2, 2009
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.Journal of psychiatric research, , Volume: 43, Issue:5, 2009
Optimizing patient safety by preventing combined use of intramuscular olanzapine and parenteral benzodiazepines.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Jun-15, Volume: 65, Issue:12, 2008
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.CNS spectrums, , Volume: 12, Issue:1, 2007
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials.Journal of clinical psychopharmacology, , Volume: 40, Issue:2
[Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms].Actas espanolas de psiquiatria, , Volume: 35, Issue:2
[The detection of quentiapine and olanzapine in the biological objects].Sudebno-meditsinskaia ekspertiza, , Volume: 57, Issue:5
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
Antipsychotic-Related Fatal Poisoning, England and Wales, 1993-2019: The Impact of Second-Generation Antipsychotics.Journal of clinical psychopharmacology, , Volume: 41, Issue:6
Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection.Clinical neuropharmacology, , Volume: 42, Issue:2
Olanzapine-induced nonalcoholic fatty liver disease: The effects of differential food pattern and the involvement of PGRMC1 signaling.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 176, 2023
Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway.Scientific reports, , 04-04, Volume: 12, Issue:1, 2022
Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, , Jun-28, Volume: 47, Issue:6, 2022
Hepatoprotective effect of trypsin/chymotrypsin against olanzapine-induced non-alcoholic steatohepatitis in rats.Canadian journal of physiology and pharmacology, , Volume: 99, Issue:10, 2021
Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 141, 2021
Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice.International journal of molecular sciences, , Dec-08, Volume: 21, Issue:24, 2020
Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c, PPAR-alpha and AMPK-alpha.Journal of ethnopharmacology, , Mar-25, Volume: 232, 2019
Occupational allergic contact dermatitis to olanzapine.Contact dermatitis, , Volume: 62, Issue:2, 2010
Occupational airborne allergic contact dermatitis to olanzapine.Dermatitis : contact, atopic, occupational, drug, , Volume: 23, Issue:6
Dorsal hand skin hyperpigmentation following oral olanzapine (Zyprexa) use.Contact dermatitis, , Volume: 79, Issue:4, 2018
Olanzapine-Induced Reversible Pellagroid Skin Lesion.Current drug safety, , Volume: 10, Issue:3, 2015
Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent.International journal of dermatology, , Volume: 43, Issue:10, 2004
Identification and characterization of proteins that are differentially expressed in adipose tissue of olanzapine-induced insulin resistance rat by iTRAQ quantitative proteomics.Journal of proteomics, , 02-10, Volume: 212, 2020
The Probiotic Mixture VSL#3 Reverses Olanzapine-Induced Metabolic Dysfunction in Mice.Methods in molecular biology (Clifton, N.J.), , Volume: 2011, 2019
Antenatal antipsychotic exposure induces multigenerational and gender-specific programming of adiposity and glucose tolerance in adult mouse offspring.Diabetes & metabolism, , Volume: 44, Issue:3, 2018
Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-03, Volume: 48, 2014
Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.BMJ open, , Mar-25, Volume: 4, Issue:3, 2014
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 15, Issue:3, 2014
Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats.Neuropharmacology, , Volume: 62, Issue:3, 2012
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.Journal of psychiatry & neuroscience : JPN, , Volume: 37, Issue:6, 2012
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.Neuro endocrinology letters, , Volume: 32, Issue:4, 2011
Metabolic and behavioral effects of chronic olanzapine treatment and cafeteria diet in rats.Behavioural pharmacology, , Volume: 21, Issue:7, 2010
30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.Acta psychiatrica Scandinavica, , Volume: 117, Issue:5, 2008
The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
[Atypical antipsychotic-associated impaired glucose tolerance].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 107, Issue:8, 2005
Glucose intolerance with atypical antipsychotics.Drug safety, , Volume: 25, Issue:15, 2002
[Antipsychotics--clever choices].Lakartidningen, , Volume: 104, Issue:7
Reactive Psychosis in a Health Care Worker During the COVID-19 Pandemic.The primary care companion for CNS disorders, , 07-09, Volume: 22, Issue:4, 2020
Three Cases of COVID-19-related First Onset Brief Reactive Psychosis.The Israel Medical Association journal : IMAJ, , Volume: 22, Issue:10, 2020
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.Journal of affective disorders, , 12-01, Volume: 277, 2020
Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.The Australian and New Zealand journal of psychiatry, , Volume: 54, Issue:7, 2020
Neurotropism of SARS-CoV-2: COVID-19 presenting with an acute manic episode.BMJ case reports, , Jun-14, Volume: 13, Issue:6, 2020
Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).Medical hypotheses, , Volume: 141, 2020
Two cases report of epidemic stress disorder to novel coronavirus pneumonia.Asian journal of psychiatry, , Volume: 51, 2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
A Case of Olanzapine-Induced Cutaneous Eruption.The American journal of case reports, , Oct-01, Volume: 24, 2023
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
[A case of affective disorder with psychotic symptoms as late manifestation of Huntington's Chorea].Psychiatrische Praxis, , Volume: 38, Issue:6, 2011
Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention.Bipolar disorders, , Volume: 13, Issue:1, 2011
Treatment strategy in schizophrenia combined with eating disorder.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.The American journal of psychiatry, , Volume: 168, Issue:8, 2011
Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia.The journal of ECT, , Volume: 26, Issue:4, 2010
Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis.International clinical psychopharmacology, , Volume: 25, Issue:3, 2010
In response to Morris et al.'s "Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine".Journal of medical toxicology : official journal of the American College of Medical Toxicology, , Volume: 5, Issue:4, 2009
Time-lapse mapping of cortical changes in schizophrenia with different treatments.Cerebral cortex (New York, N.Y. : 1991), , Volume: 19, Issue:5, 2009
Some treatment dilemmas in rapidly developing dementia: a case report.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 9, Issue:1, 2008
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
[The possibility of high-quality remission in the long chronic course of schizophrenia].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 108, Issue:11, 2008
Neuroleptic malignant syndrome and catatonia in a patient with dementia.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:6, 2008
Emerging from schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:3, 2008
Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:10, 2007
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.CNS spectrums, , Volume: 12, Issue:3 Suppl 4, 2007
Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.Psychiatry and clinical neurosciences, , Volume: 60, Issue:1, 2006
The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis.Acta psychiatrica Scandinavica, , Volume: 112, Issue:2, 2005
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.Schizophrenia research, , Oct-15, Volume: 78, Issue:2-3, 2005
Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.International journal of geriatric psychiatry, , Volume: 20, Issue:11, 2005
[Atypical antipsychotic-associated impaired glucose tolerance].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 107, Issue:8, 2005
Memory-sparing cognitive deterioration in the elderly: what is the diagnosis?Reviews in neurological diseases, ,Spring, Volume: 2, Issue:2, 2005
Atypical neuroleptics and diabetes.Diabetes & metabolism, , Volume: 29, Issue:3, 2003
Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania.Journal of affective disorders, , Volume: 73, Issue:1-2, 2003
Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy.Pharmacotherapy, , Volume: 21, Issue:11, 2001
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Exertional Heatstroke in a Marathon Runner Complicated by Concurrent Use of an Antipsychotic Medication Affecting Thermoregulation.Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, , Volume: 30, Issue:5, 2020
An autopsy case of heatstroke under the influence of psychotropic drugs.Soudni lekarstvi, ,Winter, Volume: 65, Issue:4, 2020
Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia.Acta neuropsychiatrica, , Volume: 27, Issue:6, 2015
Olanzapine and breast-feeding: changes of plasma concentrations of olanzapine in a breast-fed infant over a period of 5 months.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Meningocele and ankyloblepharon following in utero exposure to olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:5, 2006
Olanzapine excretion in human breast milk: estimation of infant exposure.The international journal of neuropsychopharmacology, , Volume: 5, Issue:3, 2002
Comment: olanzapine-induced acute pancreatitis.The Annals of pharmacotherapy, , Volume: 35, Issue:4, 2001
Acute necrotizing pancreatitis following olanzapine therapy.Tropical gastroenterology : official journal of the Digestive Diseases Foundation, , Volume: 35, Issue:2
Acute Necrotizing Pancreatitis Following Olanzapine Treatment and 759C/T Polymorphism of HTR2C Gene: A Case Report.In vivo (Athens, Greece), , Volume: 29, Issue:5
Acute Necrotizing Pancreatitis Associated With Orally Disintegrating Formulation of Olanzapine: Implications on Clinical Presentation and Management.Journal of clinical psychopharmacology, , Volume: 39, Issue:5
Haematologic malignancies associated with clozapine Psychological medicine, , Volume: 51, Issue:9, 2021
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving HigBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, , Volume: 24, Issue:10, 2018
Basal Ganglia Calcification: A Case Report of Fahr Disease With Pure Psychiatric Symptoms.Journal of psychiatric practice, , Volume: 25, Issue:5, 2019
Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins.Cellular signalling, , Volume: 42, 2018
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 22, Issue:1, 2010
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.CNS spectrums, , Volume: 12, Issue:3 Suppl 4, 2007
Fahr's Disease Presenting with Manic Symptoms.JNMA; journal of the Nepal Medical Association, , Volume: 56, Issue:209
The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting.Journal of the American Medical Directors Association, , Volume: 5, Issue:4
[Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection].Gastroenterologia y hepatologia, , Volume: 33, Issue:2, 2010
Citalopram-induced diplopia.Psychosomatics, , Volume: 46, Issue:1
[Protective effect of olanzapine in psychotic disorder induced by interferon-alpha].Recenti progressi in medicina, , Volume: 94, Issue:7-8
Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:5, 2022
The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol.The American journal of psychiatry, , 03-01, Volume: 178, Issue:3, 2021
Risk and Prevention of Aggression in Patients With Psychotic Disorders.The American journal of psychiatry, , 03-01, Volume: 178, Issue:3, 2021
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
Olanzapine treatment in adolescents with severe conduct disorder.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:1, 2006
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:8, 2005
A clinical case series of six extremely aggressive youths treated with olanzapine.European child & adolescent psychiatry, , Volume: 11, Issue:3, 2002
Olanzapine for chronic, stereotypic self-injurious behaviour: a pilot study in seven adults with intellectual disability.Journal of intellectual disability research : JIDR, , Volume: 44 ( Pt 6), 2000
Reversal of rabbit syndrome with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:1, 2000
Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine.European journal of pharmacology, , Feb-26, Volume: 368, Issue:1, 1999
Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test.Behavioural pharmacology, , Volume: 8, Issue:2-3, 1997
Atypical antipsychotics for the treatment of disruptive behavior.Pediatric annals, , Volume: 42, Issue:2, 2013
Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:6, 2013
Age-grouped differences in bipolar mania.Comprehensive psychiatry, , Volume: 53, Issue:8, 2012
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.European child & adolescent psychiatry, , Volume: 20, Issue:11-12, 2011
Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations.Clinical psychology review, , Volume: 31, Issue:3, 2011
Effect of olanzapine on disruptive behavior in institutionalized patients with severe intellectual disability--a case series.Collegium antropologicum, , Volume: 32, Issue:2, 2008
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 45, Issue:8, 2006
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.The Journal of clinical psychiatry, , Volume: 65 Suppl 6, 2004
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
A Case Report of Neurosyphilis Limbic Encephalitis With Reversible Geschwind Syndrome and Mood Disorder.Journal of psychiatric practice, , Volume: 25, Issue:3, 2019
Complexity in Evaluation and Pharmacological Treatment of Early Onset Psychosis with Mood Symptoms: Childhood Onset Schizophrenia or Affective Disorder?Journal of child and adolescent psychopharmacology, , Volume: 29, Issue:3, 2019
[A case of late-onset paraphrenia in a very elderly patient receiving home medical care].Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, , Volume: 55, Issue:4, 2018
Biological Perspectives: Huntington's Disease.Perspectives in psychiatric care, , Volume: 51, Issue:3, 2015
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.Boletin de la Asociacion Medica de Puerto Rico, , Volume: 105, Issue:3, 2013
Olanzapine in schizophrenia and affective disorders.Drug safety, , Dec-01, Volume: 35, Issue:12, 2012
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Drug safety, , Oct-01, Volume: 35, Issue:10, 2012
The need to consider mood disorders, and especially chronic mania, in cases of Diogenes syndrome (squalor syndrome).International psychogeriatrics, , Volume: 23, Issue:3, 2011
Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania--a systematic review and meta-analysis.Journal of affective disorders, , Volume: 134, Issue:1-3, 2011
Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia.The journal of ECT, , Volume: 26, Issue:4, 2010
Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.Journal of medical economics, , Volume: 12, Issue:2, 2009
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.Bipolar disorders, , Volume: 8, Issue:6, 2006
Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: a review.Drugs of today (Barcelona, Spain : 1998), , Volume: 42, Issue:3, 2006
Valproate lowers plasma concentration of olanzapine.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Dermatological side effects of olanzapine.Indian journal of medical sciences, , Volume: 59, Issue:7, 2005
Olanzapine: a critical review of recent literature.Expert opinion on pharmacotherapy, , Volume: 6, Issue:12, 2005
Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study.Pharmacopsychiatry, , Volume: 38, Issue:5, 2005
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorders, , Volume: 7 Suppl 3, 2005
Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe.European journal of clinical pharmacology, , Volume: 60, Issue:1, 2004
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.Cancer investigation, , Volume: 22, Issue:3, 2004
The combination of olanzapine and fluoxetine in mood disorders.Expert opinion on pharmacotherapy, , Volume: 4, Issue:7, 2003
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine.Pharmacotherapy, , Volume: 23, Issue:8, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.Clinical therapeutics, , Volume: 25, Issue:4, 2003
Broad therapeutic uses of atypical antipsychotic medications.Biological psychiatry, , Dec-01, Volume: 50, Issue:11, 2001
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.Southern medical journal, , Volume: 94, Issue:3, 2001
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.Journal of intellectual disability research : JIDR, , Volume: 44 ( Pt 2), 2000
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Olanzapine for corticosteroid-induced mood disorders.Psychosomatics, , Volume: 44, Issue:4
Olanzapine treatment of corticosteroid-induced mood disorders.Psychosomatics, , Volume: 43, Issue:6
[Subjective and objective evaluation of treating schizophrenia with classic or atypical drugs].Psychiatria polska, , Volume: 35, Issue:1
Atypical antipsychotics in the treatment of affective symptoms: a review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:1
Psychotropic Drugs and Liver Toxicity.American journal of therapeutics, , Volume: 25, Issue:5
Treatment with atypical antipsychotics: new indications and new populations.Journal of psychiatric research, , Volume: 35, Issue:3
A potential case of peduncular hallucinosis treated successfully with olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Weight gain induced with olanzapine in adolescent.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
[Delusional ectoparasitic infestation in multiple system atrophy].Der Nervenarzt, , Volume: 73, Issue:4, 2002
de Clerambault syndrome successfully treated with olanzapine.The Annals of pharmacotherapy, , Volume: 34, Issue:2, 2000
Sedative drug-use in Denmark, 2000 to 2019: a nationwide drug utilization study.Social psychiatry and psychiatric epidemiology, , Volume: 58, Issue:10, 2023
Abuse and misuse of second-generation antipsychotics: An analysis using VigiBase, the World Health Organisation pharmacovigilance database.British journal of clinical pharmacology, , Volume: 88, Issue:10, 2022
Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use.Adicciones, , Apr-01, Volume: 34, Issue:2, 2022
A Case of Self-Cannibalism: An Extremely Rare Type of Self-Mutilation With Multiple Risk Factors.The Journal of nervous and mental disease, , 04-01, Volume: 209, Issue:4, 2021
The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis.Substance use & misuse, , Volume: 56, Issue:12, 2021
Harmala Alkaloids Identify Ayahausca Intoxication in a Urine Drug Screen.Journal of analytical toxicology, , May-01, Volume: 43, Issue:4, 2019
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.Bosnian journal of basic medical sciences, , May-20, Volume: 19, Issue:2, 2019
Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database.Journal of clinical psychopharmacology, , Volume: 38, Issue:1, 2018
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.The Cochrane database of systematic reviews, , Jan-22, Volume: 1, 2018
Chlorpheniramine dependence presenting as mania.Asian journal of psychiatry, , Volume: 30, 2017
Mephentermine dependence syndrome - A new emerging trend of substance use.Asian journal of psychiatry, , Volume: 17, 2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.The Journal of nervous and mental disease, , Volume: 203, Issue:7, 2015
Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms.Human psychopharmacology, , Volume: 30, Issue:4, 2015
Effectiveness of short-term olanzapine in patients with bipolar I disorder, with or without comorbidity with substance use disorder.Journal of clinical psychopharmacology, , Volume: 33, Issue:2, 2013
Olanzapine abuse.Substance abuse, , Volume: 34, Issue:1, 2013
Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study.The British journal of psychiatry : the journal of mental science, , Volume: 199, Issue:3, 2011
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.Psychiatry research, , Aug-15, Volume: 188, Issue:3, 2011
Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:4, 2010
Olanzapine abuse was relieved after switching to aripiprazole in a patient with psychotic depression.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 34, Issue:7, 2010
Severe dopaminergic pathways damage in a case of chronic toluene abuse.Clinical neurology and neurosurgery, , Volume: 111, Issue:10, 2009
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.Schizophrenia research, , Volume: 100, Issue:1-3, 2008
Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Abuse of olanzapine by substance abusers.Journal of psychoactive drugs, , Volume: 39, Issue:3, 2007
Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.Journal of clinical psychopharmacology, , Volume: 26, Issue:6, 2006
Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorders, , Volume: 7 Suppl 3, 2005
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.International clinical psychopharmacology, , Volume: 20, Issue:4, 2005
The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis.Acta psychiatrica Scandinavica, , Volume: 112, Issue:2, 2005
Olanzapine attenuates cue-elicited craving for tobacco.Psychopharmacology, , Volume: 175, Issue:4, 2004
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Potential use of olanzapine in treatment of substance dependence disorders.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report.International journal of psychiatry in medicine, , Volume: 33, Issue:1, 2003
Treatment with the atypical antipsychotic, olanzapine, prevents the expression of amphetamine-induced place conditioning in the rat.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:1, 2003
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.International clinical psychopharmacology, , Volume: 18, Issue:3, 2003
Dependence and chronic psychosis with D-nor-pseudoephedrine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:8, 2003
Olanzapine treatment for patients with schizophrenia and substance abuse.Journal of substance abuse treatment, , Volume: 21, Issue:4, 2001
Possible risperidone-induced visual hallucinations.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 39, Issue:9, 2000
Olanzapine-induced ketoacidosis with diabetes mellitus.The American journal of psychiatry, , Volume: 156, Issue:9, 1999
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.Schizophrenia research, , Sep-07, Volume: 33, Issue:1-2, 1998
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Suicidal and homicidal behaviors related to dextromethorphan abuse in a middle-aged woman.Journal of addiction medicine, , Volume: 7, Issue:2
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia.The American journal on addictions, , Volume: 16, Issue:4
A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients.General hospital psychiatry, , Volume: 32, Issue:4
[Treatment of schizophrenia in subjects with substance use disorders: A review].Actas espanolas de psiquiatria, , Volume: 29, Issue:2
Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.Psychosomatics, , Volume: 47, Issue:1
[Olanzapine in manic/mixed patients with or without substance abuse].Rivista di psichiatria, , Volume: 48, Issue:2
Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial.Medicine, , Volume: 97, Issue:8, 2018
Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.The Journal of clinical psychiatry, , Volume: 74, Issue:12, 2013
Treatment for amphetamine psychosis.The Cochrane database of systematic reviews, , Jan-21, Issue:1, 2009
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Treatment for amphetamine psychosis.The Cochrane database of systematic reviews, , 10-08, Issue:4, 2008
A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 88 Suppl 3, 2005
Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Antipsychotic medications for cocaine dependence.The Cochrane database of systematic reviews, , Mar-19, Volume: 3, 2016
Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.The Journal of clinical psychiatry, , Volume: 74, Issue:12, 2013
The effect of olanzapine pretreatment on acute cocaine toxicity in mice.Clinical toxicology (Philadelphia, Pa.), , Volume: 47, Issue:6, 2009
An unusual case report: treatment of cocaine-dependent patient with an atypical antipsychotic.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:2, 2008
Antipsychotic medications for cocaine dependence.The Cochrane database of systematic reviews, , Jul-18, Issue:3, 2007
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Olanzapine-induced suppression of cocaine self-administration in rhesus monkeys.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:3, 2006
The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence.Addiction (Abingdon, England), , Volume: 100 Suppl 1, 2005
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.The Journal of nervous and mental disease, , Volume: 193, Issue:6, 2005
Potential use of olanzapine in treatment of substance dependence disorders.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Olanzapine for cocaine cravings and relapse prevention.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
A pilot trial of olanzapine for the treatment of cocaine dependence.Drug and alcohol dependence, , Jun-05, Volume: 70, Issue:3, 2003
Olanzapine for cocaine craving and relapse prevention in 2 patients.The Journal of clinical psychiatry, , Volume: 63, Issue:7, 2002
Olanzapine treatment for patients with schizophrenia and cocaine abuse.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
Olanzapine in cocaine dependence: a double-blind, placebo-controlled trial.The American journal on addictions, , Volume: 18, Issue:1
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
[Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients. Interaction with plasma levels].Actas espanolas de psiquiatria, , Volume: 29, Issue:4
Outcome predictors in cocaine dependence treatment trials.The American journal on addictions, , Volume: 15, Issue:6
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.International clinical psychopharmacology, , Volume: 27, Issue:4, 2012
Hypersexual features in Huntington's disease.Singapore medical journal, , Volume: 52, Issue:6, 2011
[Sexual disturbances during the treatment with neuroleptics in patients with schizophrenia and schizophrenia spectrum disorders].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 111, Issue:9 Pt 2, 2011
Successful treatment of sexual dysfunction with dronabinol: a case report.The Journal of clinical psychiatry, , Volume: 65, Issue:8, 2004
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.Annals of the New York Academy of Sciences, , Volume: 1032, 2004
Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults.Schizophrenia bulletin, , Volume: 29, Issue:3, 2003
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
Hyperprolactinemia and male sexual dysfunction.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning.Journal of sex & marital therapy, , Volume: 32, Issue:4
Zolpidem related persistent genital arousal disorder: An interesting case.Psychiatrike = Psychiatriki, , Volume: 30, Issue:4
Psychosis susceptibility zinc finger protein 804A (ZNF804A) gene polymorphism in schizophrenia patients treated with olanzapine in North Indian population.The International journal of neuroscience, , Volume: 133, Issue:5, 2023
Prefrontal Coexpression of Schizophrenia Risk Genes Is Associated With Treatment Response in Patients.Biological psychiatry, , 07-01, Volume: 86, Issue:1, 2019
Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.Schizophrenia research, , Volume: 212, 2019
A2BP1 gene polymorphisms association with olanzapine-induced weight gain.Pharmacological research, , Volume: 99, 2015
Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: common and specific effects of key regulators of fat-mass homoeostasis genes.Pharmacogenetics and genomics, , Volume: 25, Issue:7, 2015
A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 39, Issue:6, 2014
Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain.Human psychopharmacology, , Volume: 29, Issue:4, 2014
Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain.Journal of clinical psychopharmacology, , Volume: 33, Issue:3, 2013
Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.Schizophrenia research, , Volume: 125, Issue:2-3, 2011
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Clarithromycin-induced mania in a child.International journal of clinical pharmacology and therapeutics, , Volume: 47, Issue:6, 2009
Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.The Journal of clinical psychiatry, , Volume: 69, Issue:9, 2008
Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients.Journal of psychiatric research, , Volume: 42, Issue:2, 2008
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.Journal of psychiatric research, , Volume: 42, Issue:11, 2008
The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.Psychiatry research, , Sep-30, Volume: 160, Issue:3, 2008
Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia.Psychopharmacology bulletin, , Volume: 40, Issue:1, 2007
Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Oct-05, Volume: 144B, Issue:7, 2007
Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Dec-05, Volume: 144B, Issue:8, 2007
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.The American journal of psychiatry, , Volume: 163, Issue:3, 2006
Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder--a preliminary report.Journal of affective disorders, , Volume: 92, Issue:2-3, 2006
[Olanzapine-induced diabetes mellitus].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
[Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy].Der Nervenarzt, , Volume: 72, Issue:9, 2001
Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine?Pharmacopsychiatry, , Volume: 32, Issue:3, 1999
Delayed Serotonin Syndrome in the Setting of a Mixed Fluoxetine and Serotonin Antagonist Overdose.The American journal of case reports, , May-25, Volume: 19, 2018
Serotonin Syndrome Induced by Combined Use of Mirtazapine and Olanzapine Complicated with Rhabdomyolysis, Acute Renal Failure, and Acute Pulmonary Edema-A Case Report.Acta neurologica Taiwanica, , Volume: 24, Issue:4, 2015
Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary.BMJ case reports, , Jun-23, Volume: 2014, 2014
Serotonin syndrome after discontinuation of olanzapine in a combined treatment with duloxetine -- case report.Pharmacopsychiatry, , Volume: 44, Issue:2, 2011
Chronic olanzapine, serotonin receptors, and subsequent serotonin toxicity.Journal of clinical psychopharmacology, , Volume: 30, Issue:5, 2010
Neonatal withdrawal syndrome following in utero exposure to paroxetine, clonazepam and olanzapine.Journal of perinatology : official journal of the California Perinatal Association, , Volume: 27, Issue:8, 2007
Making sense of serotonin toxicity reports, a comment on Chopra et Al. (World J Biol Psychiatry 2004, 5: 114-115).The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:3, 2004
Serotonin syndrome associated with fluoxetine and olanzapine.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:2, 2004
Olanzapine and serotonin toxicity.Psychiatry and clinical neurosciences, , Volume: 57, Issue:2, 2003
Can olanzapine be implicated in causing serotonin syndrome?Psychiatry and clinical neurosciences, , Volume: 56, Issue:5, 2002
Serotonin syndrome and atypical antipsychotics.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
Serotonin syndrome caused by olanzapine and clomipramine.Minerva anestesiologica, , Volume: 74, Issue:7-8
Serotonin syndrome caused by olanzapine and clomipramine.Minerva anestesiologica, , Volume: 74, Issue:1-2
Serotonin syndrome: a complex but easily avoidable condition.General hospital psychiatry, , Volume: 30, Issue:3
The neuroprotective effect of olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 20, Issue:1, 2008
Olanzapine attenuates brain damage after focal cerebral ischemia in vivo.Brain research bulletin, , Dec-11, Volume: 71, Issue:1-3, 2006
A Case of Abulia From Left Middle Cerebral Artery Stroke in an Adolescent Treated Successfully With Short Duration Olanzapine.Clinical neuropharmacology, , Volume: 43, Issue:3
A case of abulia, status/post right middle cerebral artery territory infarct, treated successfully with olanzapine.Clinical neuropharmacology, , Volume: 37, Issue:6
A case of catatonia status-post left middle cerebral artery cerebrovascular accident, treated successfully with olanzapine.Clinical neuropharmacology, , Volume: 36, Issue:4
Venous thrombosis during olanzapine treatment: a complex association.The Netherlands journal of medicine, , Volume: 76, Issue:6, 2018
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation.Clinical and experimental pharmacology & physiology, , Volume: 34, Issue:8, 2007
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Olanzapine and venous thromboembolism.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Olanzapine-Associated Portal and Superior Mesenteric Vein Thrombosis.American journal of therapeutics, , Volume: 27, Issue:4
Olanzapine as an add-on, pre-operative anti-emetic drug for postoperative nausea or vomiting: a randomised controlled trial.Anaesthesia, , Volume: 78, Issue:10, 2023
Olanzapine for the Prevention of Postdischarge Nausea and Vomiting after Ambulatory Surgery: A Randomized Controlled Trial.Anesthesiology, , Volume: 132, Issue:6, 2020
Chronic Atypical Antipsychotic Use Is Associated With Reduced Need for Postoperative Nausea and Vomiting Rescue in the Postanesthesia Care Unit: A Propensity-Matched Retrospective Observational Study.Anesthesia and analgesia, , Volume: 130, Issue:1, 2020
Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol?Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:10, 2012
Severe dopaminergic pathways damage in a case of chronic toluene abuse.Clinical neurology and neurosurgery, , Volume: 111, Issue:10, 2009
Movement disorders associated with atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 63 Suppl 4, 2002
Olanzapine treatment for tics in an adult woman with severe tourette syndrome.Acta neurologica Taiwanica, , Volume: 21, Issue:4, 2012
Atomoxetine-induced vocal tics in a patient with schizophrenia.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Olanzapine in Gilles de la Tourette syndrome: beyond tics.Acta neurologica Belgica, , Volume: 105, Issue:4, 2005
Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 14, Issue:2, 2004
[Treatment of tics in Tourette syndrome with atypical antipsychotic drugs].Ugeskrift for laeger, , Aug-05, Volume: 164, Issue:32, 2002
Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses.BMJ (Clinical research ed.), , Nov-24, Volume: 355, 2016
Risk of ischemic stroke associated with the use of antipsychotic drugs in elderly patients: a retrospective cohort study in Korea.PloS one, , Volume: 10, Issue:3, 2015
Risk of ischemic stroke with the use of risperidone, quetiapine and olanzapine in elderly patients: a population-based, case-crossover study.Journal of psychopharmacology (Oxford, England), , Volume: 27, Issue:7, 2013
[Atypical antipsychotics in elderly patients with dementia].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , May-01, Volume: 128, Issue:9, 2008
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Psychosis of Alzheimer disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Jan-22, Volume: 149, Issue:4, 2005
Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study.Journal of neurology, , Volume: 252, Issue:10, 2005
Second-generation antipsychotics and risk of cerebrovascular accidents in the elderly.Journal of clinical psychopharmacology, , Volume: 25, Issue:5, 2005
Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD). Favour.International psychogeriatrics, , Volume: 17, Issue:1, 2005
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Mar-26, Volume: 149, Issue:13, 2005
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Mar-26, Volume: 149, Issue:13, 2005
Olanzapine for the treatment of hemiballismus: A case report.Archives of physical medicine and rehabilitation, , Volume: 86, Issue:3, 2005
Do atypical antipsychotics cause stroke?CNS drugs, , Volume: 19, Issue:2, 2005
Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:5, 2005
CSM warning on atypical psychotics and stroke may be detrimental for dementia.BMJ (Clinical research ed.), , May-22, Volume: 328, Issue:7450, 2004
Atypical antipsychotics and risk of cerebrovascular accidents.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
Clinical effectiveness of atypical antipsychotics in dementia.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Mania secondary to right-sided stroke--responsive to olanzapine.General hospital psychiatry, , Volume: 28, Issue:3
Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.Clinical schizophrenia & related psychoses, , Volume: 7, Issue:4, 2014
Catatonia and parkinsonism as a sequelae of typhoid fever: a rare experience.BMJ case reports, , Jun-27, Volume: 2013, 2013
Antipsychotics and mortality in Parkinsonism.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 20, Issue:2, 2012
Olanzapine-induced parkinsonism associated with smoking cessation.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Mar-01, Volume: 68, Issue:5, 2011
A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics?European journal of neurology, , Volume: 15, Issue:2, 2008
A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.International journal of geriatric psychiatry, , Volume: 21, Issue:2, 2006
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Olanzapine for delirium in parkinsonism: therapeutic benefits in lieu of adverse consequences.Neurology India, , Volume: 52, Issue:2, 2004
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.Dementia and geriatric cognitive disorders, , Volume: 13, Issue:2, 2002
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 13, Issue:4, 2001
Olanzapine-induced Priapism in a Child with Asperger's Syndrome.Balkan medical journal, , Volume: 34, Issue:1, 2017
Asperger's syndrome: from hiding to thriving.The Nurse practitioner, , Volume: 33, Issue:7, 2008
An open trial of olanzapine in children and adolescents with Asperger Disorder.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:5, 2006
The diagnosis of Asperger's syndrome in an adult presenting with an index episode of mania by Ng et al.General hospital psychiatry, , Volume: 26, Issue:2
Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
Item response analysis of the Positive and Negative Syndrome Scale.BMC psychiatry, , Nov-15, Volume: 7, 2007
Olanzapine for the treatment of hemiballismus: A case report.Archives of physical medicine and rehabilitation, , Volume: 86, Issue:3, 2005
Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:6, 2004
Safety in treating bipolar disorder.The Journal of family practice, , Volume: Suppl, 2003
[Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study].Actas espanolas de psiquiatria, , Volume: 29, Issue:1
Olanzapine-induced tardive oculogyric crisis.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:4, 2002
Writer's cramp induced by olanzapine.Journal of neurology, , Volume: 248, Issue:5, 2001
Reduction of tardive dystonia with olanzapine.The American journal of psychiatry, , Volume: 156, Issue:12, 1999
Neuroleptic Sensitivity in Dementia with Lewy Body and Use of Pimavanserin in an Inpatient Setting: A Case Report.The American journal of case reports, , Oct-25, Volume: 23, 2022
Dementia with Lewy bodies presenting marked tongue protrusion and bite due to lingual dystonia: A case report.Rinsho shinkeigaku = Clinical neurology, , 06-22, Volume: 56, Issue:6, 2016
Topiramate improves psychiatric symptoms in a patient with Lewy body dementia.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 27, Issue:4, 2014
Olanzapine-induced neuroleptic malignant syndrome in a patient with probable dementia with Lewy bodies.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
Reversal of head drop after discontinuation of olanzapine in a DLB patient.Movement disorders : official journal of the Movement Disorder Society, , Sep-15, Volume: 23, Issue:12, 2008
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
[Dementia with Lewy bodies; 2 patients with exacerbation due to an atypical antipsychotic, but with a favorable response to the cholinesterase inhibitor rivastigmine].Nederlands tijdschrift voor geneeskunde, , Jan-04, Volume: 147, Issue:1, 2003
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.Dementia and geriatric cognitive disorders, , Volume: 13, Issue:2, 2002
Lewy body dementia.Journal of the Mississippi State Medical Association, , Volume: 43, Issue:4, 2002
Dementia with Lewy bodies in Down's syndrome.International journal of geriatric psychiatry, , Volume: 16, Issue:3, 2001
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.Schizophrenia bulletin, , 03-15, Volume: 49, Issue:2, 2023
Metabolic disorders induced by psychotropic drugs.Annales d'endocrinologie, , Volume: 84, Issue:3, 2023
Herbal Therapies for Weight Gain and Metabolic Abnormalities Induced by Atypical Antipsychotics: A Review Article.Current drug discovery technologies, , Volume: 20, Issue:5, 2023
Antipsychotic-Induced Metabolic Syndrome: A Review.Metabolic syndrome and related disorders, , Volume: 21, Issue:6, 2023
A potential probiotic bacterium for antipsychotic-induced metabolic syndrome: mechanisms underpinning how Akkermansia muciniphila subtype improves olanzapine-induced glucose homeostasis in mice.Psychopharmacology, , Volume: 238, Issue:9, 2021
The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain.The Journal of experimental medicine, , 07-05, Volume: 218, Issue:7, 2021
A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.Scientific reports, , 04-07, Volume: 11, Issue:1, 2021
Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome.Brain, behavior, and immunity, , Volume: 88, 2020
Relationship between metabolic syndrome and acylated/desacylated ghrelin ratio in patients with schizophrenia under olanzapine medication.Journal of psychopharmacology (Oxford, England), , Volume: 34, Issue:1, 2020
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.The Journal of clinical psychiatry, , 03-24, Volume: 81, Issue:3, 2020
The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats.Pharmacology, biochemistry, and behavior, , Volume: 191, 2020
FADS1 modulates metabolic syndrome in schizophrenia patients receiving olanzapine monotherapy.Asian journal of psychiatry, , Volume: 54, 2020
Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice.Molecular neurobiology, , Volume: 57, Issue:1, 2020
Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis.Neuropsychopharmacology reports, , Volume: 39, Issue:3, 2019
Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial.Psychopharmacology, , Volume: 236, Issue:4, 2019
Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine.Schizophrenia research, , Volume: 206, 2019
Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease.Circulation research, , 08-02, Volume: 125, Issue:4, 2019
Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance.Scientific reports, , 02-07, Volume: 9, Issue:1, 2019
Insulin resistance induced by olanzapine and other second-generation antipsychotics in Chinese patients with schizophrenia: a comparative review and meta-analysis.European journal of clinical pharmacology, , Volume: 75, Issue:12, 2019
Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial.Medicine, , Volume: 98, Issue:38, 2019
Berberine attenuates olanzapine induced-metabolic syndrome.JPMA. The Journal of the Pakistan Medical Association, , Volume: 69(Suppl 3), Issue:8, 2019
Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.Psychoneuroendocrinology, , Volume: 81, 2017
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.Journal of psychiatric research, , Volume: 85, 2017
Protective effects of green tea on olanzapine-induced-metabolic syndrome in rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 92, 2017
Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders.Psychopharmacology bulletin, , 05-15, Volume: 47, Issue:2, 2017
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.Acta psychiatrica Scandinavica, , Volume: 133, Issue:1, 2016
Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 17, Issue:6, 2016
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.International journal of psychiatry in clinical practice, , Volume: 18, Issue:4, 2014
Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study.Pharmacopsychiatry, , Volume: 47, Issue:4-5, 2014
Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics.Early intervention in psychiatry, , Volume: 8, Issue:3, 2014
Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.European journal of clinical pharmacology, , Volume: 70, Issue:12, 2014
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.The Journal of clinical psychiatry, , Volume: 74, Issue:1, 2013
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.Schizophrenia research, , Volume: 146, Issue:1-3, 2013
Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.Journal of clinical psychopharmacology, , Volume: 32, Issue:4, 2012
[Metabolic syndrome in patients with schizophrenia and antipsychotic treatment].Medicina clinica, , Nov-17, Volume: 139, Issue:12, 2012
Association of serum retinol-binding protein 4 with insulin resistance and metabolic parameters during olanzapine therapy.Clinical endocrinology, , Volume: 76, Issue:2, 2012
Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.The pharmacogenomics journal, , Volume: 12, Issue:1, 2012
Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.Singapore medical journal, , Volume: 53, Issue:7, 2012
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.Progress in neuro-psychopharmacology & biological psychiatry, , Jul-01, Volume: 35, Issue:5, 2011
Screening for metabolic syndrome-adherence to guidelines.African journal of psychiatry, , Volume: 14, Issue:1, 2011
Antipsychotic treatment--side-effect and/or metabolic syndrome.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.Schizophrenia research, , Volume: 125, Issue:2-3, 2011
Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.Psychopharmacology bulletin, , Volume: 43, Issue:4, 2010
Metabolic syndrome with the atypical antipsychotics.Current opinion in endocrinology, diabetes, and obesity, , Volume: 17, Issue:5, 2010
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 70, Issue:3, 2009
Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.Journal of clinical psychopharmacology, , Volume: 29, Issue:1, 2009
Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation.Journal of psychiatric practice, , Volume: 15, Issue:4, 2009
30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Olanzapine metabolic side effects: a weight gain issue?Internal and emergency medicine, , Volume: 3, Issue:3, 2008
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.Psychiatry research, , May-30, Volume: 159, Issue:1-2, 2008
Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
A clinical paradigm of delusions of parasitosis.Journal of the American Academy of Dermatology, , Volume: 59, Issue:4, 2008
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:7, 2007
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.The Journal of clinical psychiatry, , Volume: 68, Issue:10, 2007
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.International clinical psychopharmacology, , Volume: 22, Issue:2, 2007
Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
Atypical antipsychotics related metabolic syndrome in bipolar patients.Journal of affective disorders, , Volume: 98, Issue:3, 2007
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.The Journal of clinical psychiatry, , Volume: 67, Issue:5, 2006
Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice.Current medical research and opinion, , Volume: 22, Issue:12, 2006
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.Psychopharmacology, , Volume: 186, Issue:4, 2006
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Archives of general psychiatry, , Volume: 62, Issue:1, 2005
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 7, Issue:3, 2005
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:1, 2005
Complications from olanzapine in a mentally healthy patient.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.Clinical therapeutics, , Volume: 27, Issue:12, 2005
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Body weight gain, insulin, and leptin in olanzapine-treated patients.The Journal of clinical psychiatry, , Volume: 62, Issue:11, 2001
Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome.Srpski arhiv za celokupno lekarstvo, , Volume: 143, Issue:11-12
Magnitude of metabolic syndrome and its predictors among patients on second-generation antipsychotic drugs at six psychiatry clinics and mental hospitals, in Addis Ababa, Ethiopia, 2019; Multicenter cross-sectional study.Diabetes & metabolic syndrome, , Volume: 15, Issue:4
Metabolic Syndrome Reversal With Cariprazine.Journal of clinical psychopharmacology, , Volume: 39, Issue:4
Visceral and subcutaneous fat in patients treated with olanzapine: a case series.Clinical neuropharmacology, , Volume: 33, Issue:5
Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.Journal of psychopharmacology (Oxford, England), , Volume: 33, Issue:10, 2019
Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats.Scientific reports, , 06-05, Volume: 7, Issue:1, 2017
Olanzapine-induced changes in glucose metabolism are independent of the melanin-concentrating hormone system.Psychoneuroendocrinology, , Volume: 38, Issue:11, 2013
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clinical drug investigation, , Volume: 31, Issue:7, 2011
Metabolic effects of the atypical antipsychotics.Southern medical journal, , Volume: 100, Issue:8, 2007
Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells.Molecular psychiatry, , Volume: 10, Issue:12, 2005
Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics.Journal of the American Pharmacists Association : JAPhA, , Volume: 49, Issue:2
Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data.Schizophrenia research, , Volume: 154, Issue:1-3, 2014
[Olanzapine and diabetic decompensation: concerning a case].Atencion primaria, , Jun-15, Volume: 34, Issue:1, 2004
[Expectations and developments in atypical antipsychotics].Praxis, , Aug-25, Volume: 93, Issue:35, 2004
Fatality from olanzapine induced hyperglycemia.Journal of forensic sciences, , Volume: 47, Issue:4, 2002
Olanzapine-induced destabilization of diabetes in the absence of weight gain.Acta psychiatrica Scandinavica, , Volume: 105, Issue:3, 2002
[Drug-induced akathisia].Nederlands tijdschrift voor geneeskunde, , Jan-19, Volume: 146, Issue:3, 2002
New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment.Psychosomatics, , Volume: 40, Issue:5
Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature.The Journal of the American Board of Family Practice, , Volume: 14, Issue:4
Near fatal ketoacidosis with olanzapine treatment.Psychosomatics, , Volume: 43, Issue:4
Epigenetic Histone Methylation of PPARγ and CPT1A Signaling Contributes to Betahistine Preventing Olanzapine-Induced Dyslipidemia.International journal of molecular sciences, , May-23, Volume: 24, Issue:11, 2023
Antipsychotic-Induced Metabolic Syndrome: A Review.Metabolic syndrome and related disorders, , Volume: 21, Issue:6, 2023
PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients.Psychopharmacology, , Volume: 239, Issue:1, 2022
Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin.BMC pharmacology & toxicology, , 06-30, Volume: 21, Issue:1, 2020
Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice.Molecular neurobiology, , Volume: 57, Issue:1, 2020
Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway.Acta pharmacologica Sinica, , Volume: 40, Issue:8, 2019
Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients.Human psychopharmacology, , Volume: 34, Issue:4, 2019
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.Psychoneuroendocrinology, , Volume: 108, 2019
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5, 2018
Antenatal antipsychotic exposure induces multigenerational and gender-specific programming of adiposity and glucose tolerance in adult mouse offspring.Diabetes & metabolism, , Volume: 44, Issue:3, 2018
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar disorders, , Volume: 17, Issue:5, 2015
Betahistine co-treatment ameliorates dyslipidemia induced by chronic olanzapine treatment in rats through modulation of hepatic AMPKα-SREBP-1 and PPARα-dependent pathways.Pharmacological research, , Volume: 100, 2015
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 15, Issue:3, 2014
The risk of metabolic disorders in patients treated with asenapine or olanzapine: a study conducted on real-world data in Italy and Spain.Expert opinion on drug safety, , Volume: 13, Issue:9, 2014
The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.Clinical drug investigation, , Volume: 33, Issue:10, 2013
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clinical drug investigation, , Volume: 31, Issue:7, 2011
A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.PloS one, , Volume: 6, Issue:8, 2011
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.International clinical psychopharmacology, , Volume: 24, Issue:4, 2009
Red Yeast Rice for a patient with olanzapine-induced dyslipidemia: a test-and-retest case report.Progress in neuro-psychopharmacology & biological psychiatry, , Jul-01, Volume: 32, Issue:5, 2008
Olanzapine: review of safety 2008.Expert opinion on drug safety, , Volume: 7, Issue:6, 2008
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Metabolic effects of the atypical antipsychotics.Southern medical journal, , Volume: 100, Issue:8, 2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.The American journal of managed care, , Volume: 13, Issue:7 Suppl, 2007
Diabetic ketoacidosis and severe dyslipidemia in an adult psychotic man with olanzapine treatment.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
Esperienze di switch a cariprazina in pazienti schizofrenici con comparsa di effetti collaterali/comorbilità mediche.Rivista di psichiatria, , Volume: 54, Issue:6
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.Psychiatry research, , Volume: 296, 2021
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.Acta psychiatrica Scandinavica, , Volume: 139, Issue:1, 2019
High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.BMC psychiatry, , 06-08, Volume: 18, Issue:1, 2018
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.JAMA psychiatry, , 07-01, Volume: 74, Issue:7, 2017
Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain.JAMA psychiatry, , 11-01, Volume: 74, Issue:11, 2017
A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers.Psychoneuroendocrinology, , Volume: 66, 2016
No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain.Psychiatry research, , Oct-30, Volume: 219, Issue:2, 2014
Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.Psychiatry research, , Oct-30, Volume: 219, Issue:2, 2014
Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.Journal of psychopharmacology (Oxford, England), , Volume: 27, Issue:4, 2013
In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation.International clinical psychopharmacology, , Volume: 28, Issue:2, 2013
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.British journal of clinical pharmacology, , Volume: 71, Issue:3, 2011
Birth weight and use of olanzapine in pregnancy: a prospective comparative study.Journal of clinical psychopharmacology, , Volume: 30, Issue:3, 2010
Second-generation antipsychotics cause weight gain in youths.The Harvard mental health letter, , Volume: 26, Issue:7, 2010
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).Journal of affective disorders, , Volume: 124, Issue:1-2, 2010
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.Acta psychiatrica Scandinavica, , Volume: 118, Issue:3, 2008
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.Human psychopharmacology, , Volume: 23, Issue:3, 2008
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial.The Journal of clinical psychiatry, , Volume: 69, Issue:5, 2008
[Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 107, Issue:2, 2007
Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice.Current medical research and opinion, , Volume: 22, Issue:12, 2006
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 7, Issue:3, 2005
A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia.Journal of clinical psychopharmacology, , Volume: 41, Issue:6
Atypical antipsychotic drugs deregulate the cholesterol metabolism of macrophage-foam cells by activating NOX-ROS-PPARγ-CD36 signaling pathway.Metabolism: clinical and experimental, , Volume: 123, 2021
Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, , Volume: 50, Issue:4, 2018
[Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:3, 2015
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.Journal of clinical pharmacology, , Volume: 61, Issue:11, 2021
Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.Drug design, development and therapy, , Volume: 13, 2019
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
Neuroleptics: bedwetting.Prescrire international, , Volume: 21, Issue:127, 2012
Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study.The British journal of psychiatry : the journal of mental science, , Volume: 199, Issue:2, 2011
Risperidone-induced enuresis in two children with autistic disorder.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:4, 2007
Thrombotic complications of treatment with antipsychotic drugs.Minerva medica, , Volume: 104, Issue:2, 2013
Four cases of venous thromboembolism associated with olanzapine.Psychiatry and clinical neurosciences, , Volume: 63, Issue:1, 2009
Fatal pulmonary embolism following antipsychotic treatment and physical restraint.Pharmacopsychiatry, , Volume: 42, Issue:5, 2009
Associations between venous thromboembolism and antipsychotics. A study of the WHO database of adverse drug reactions.Drug safety, , Volume: 31, Issue:8, 2008
Antipsychotic Drug Aripiprazole Protects Liver Cells from Oxidative Stress.International journal of molecular sciences, , Jul-27, Volume: 23, Issue:15, 2022
Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats.Journal of ethnopharmacology, , Jun-28, Volume: 274, 2021
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 30, Issue:9, 2020
Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane.The Journal of nutritional biochemistry, , Volume: 81, 2020
Up-regulation of hepatic fatty acid transporters and inhibition/down-regulation of hepatic OCTN2 contribute to olanzapine-induced liver steatosis.Toxicology letters, , Volume: 316, 2019
Management of Hepatotoxicity Induced by the Use of Olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 27, Issue:3, 2017
The protective effect of thymoquinone over olanzapine-induced side effects in liver, and metabolic side effects.Bratislavske lekarske listy, , Volume: 118, Issue:10, 2017
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Liver toxicity due to olanzapine.Revista espanola de enfermedades digestivas, , Volume: 104, Issue:11, 2012
Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Mouse precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury.Chemical research in toxicology, , Sep-17, Volume: 25, Issue:9, 2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.Drug metabolism and disposition: the biological fate of chemicals, , Volume: 40, Issue:12, 2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature.Psychiatria Danubina, , Volume: 23 Suppl 1, 2011
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
[Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection].Gastroenterologia y hepatologia, , Volume: 33, Issue:2, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Possible olanzapine-induced hepatotoxicity in a young Chinese patient.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 15, Issue:5, 2009
Serum levels of olanzapine in a non-fatal overdose.Journal of analytical toxicology, , Volume: 31, Issue:2, 2007
Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-30, Volume: 30, Issue:6, 2006
Acute hepatocellular-cholestatic liver injury after olanzapine therapy.Annals of internal medicine, , Feb-18, Volume: 138, Issue:4, 2003
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Olanzapine (Zyprexa): suspected serious reactions.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jul-11, Volume: 163, Issue:1, 2000
Psychotropic Drugs and Liver Toxicity.American journal of therapeutics, , Volume: 25, Issue:5
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
Late-Onset Cholestatic Liver Injury During Combination Treatment With Chlorpromazine and Olanzapine: A Case Report.Journal of clinical psychopharmacology, , Volume: 39, Issue:2
Incidence of hospital contacts with acute kidney injury after initiation of second-generation antipsychotics in older adults: a Danish population-based cohort study.European journal of clinical pharmacology, , Volume: 78, Issue:8, 2022
Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report.Journal of medical case reports, , Oct-06, Volume: 16, Issue:1, 2022
Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.Drugs & aging, , Volume: 34, Issue:3, 2017
Serotonin Syndrome Induced by Combined Use of Mirtazapine and Olanzapine Complicated with Rhabdomyolysis, Acute Renal Failure, and Acute Pulmonary Edema-A Case Report.Acta neurologica Taiwanica, , Volume: 24, Issue:4, 2015
Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study.Annals of internal medicine, , Aug-19, Volume: 161, Issue:4, 2014
Unexpected hospitalisation side effects in an elderly man.Internal and emergency medicine, , Volume: 6, Issue:2, 2011
Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Neuroleptic malignant syndrome presenting with acute renal failure.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Olanzapine and acute urinary retention in two geriatric patients.The American journal of geriatric pharmacotherapy, , Volume: 5, Issue:3, 2007
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].Minerva anestesiologica, , Volume: 69, Issue:6, 2003
Case Report: De Novo and Persistent Psychosis After Withdrawal From Chronic Opioid Therapy.Journal of psychiatric practice, , 09-01, Volume: 28, Issue:5, 2022
A Systematic Review of Atypical Antipsychotics in Chronic Pain Management: Olanzapine Demonstrates Potential in Central Sensitization, Fibromyalgia, and Headache/Migraine.The Clinical journal of pain, , Volume: 34, Issue:6, 2018
The Utilization of Atypical Antipsychotics in the Pain Medicine Physician's Armamentarium.Psychopharmacology bulletin, , 06-20, Volume: 48, Issue:4, 2018
Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics.Postgraduate medicine, , Volume: 128, Issue:3, 2016
CSF studies which ultimately led to the possible diagnosis of anti-NMDAR encephalitis.BMJ case reports, , May-07, Volume: 13, Issue:5, 2020
Case Report: Overlapping Multiple Sclerosis With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report and Review of Literature.Frontiers in immunology, , Volume: 11, 2020
Psychosis and catatonia as presenting features of anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis.Asian journal of psychiatry, , Volume: 27, 2017
Anti-NMDA receptor encephalitis presenting as a primary psychotic disorder.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 29, Issue:3, 2017
Anti-NMDA (a-NMDAR) receptor encephalitis related to acute consumption of metamphetamine: Relevance of differential diagnosis.Revista espanola de anestesiologia y reanimacion, , Volume: 64, Issue:3, 2017
Anti-N-methyl-D-aspartate receptor encephalitis is an important differential diagnosis in acute psychiatric disease.Acta psychiatrica Scandinavica, , Volume: 131, Issue:1, 2015
Treatment of delirium in the context of anti-N-methyl-D-aspartate receptor antibody encephalitis.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 54, Issue:3, 2015
Therapeutic potential of TAK-071, a muscarinic MNeuroscience letters, , 11-01, Volume: 764, 2021
Differential benefits of olanzapine on executive function in schizophrenia patients: Preliminary findings.Human psychopharmacology, , Volume: 35, Issue:1, 2020
Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome.Brain, behavior, and immunity, , Volume: 88, 2020
Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats.Behavioural brain research, , 01-27, Volume: 378, 2020
2-Aminoimidazole-based antagonists of the 5-HTEuropean journal of medicinal chemistry, , Oct-01, Volume: 179, 2019
Cognition and Dopamine DThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:1, 2017
Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.Psychoneuroendocrinology, , Volume: 81, 2017
Anti-N-methyl-D-aspartate receptor encephalitis is an important differential diagnosis in acute psychiatric disease.Acta psychiatrica Scandinavica, , Volume: 131, Issue:1, 2015
A Potential Case of Acute Ketamine Withdrawal: Clinical Implications for the Treatment of Refractory Depression.The American journal of psychiatry, , Volume: 178, Issue:7, 2021
Activation of indoleamine 2, 3- dioxygenase pathway by olanzapine augments antidepressant effects of venlafaxine in mice.Psychiatry research, , Volume: 258, 2017
Association of common variations in the norepinephrine transporter gene with response to olanzapine-fluoxetine combination versus continued-fluoxetine treatment in patients with treatment-resistant depression: a candidate gene analysis.The Journal of clinical psychiatry, , Volume: 73, Issue:6, 2012
[Augmentation of antidepressants with atypical antipsychotics in non-delusional unipolar depressed patients with non-response to antidepressant-monotherapy].Psychiatrische Praxis, , Volume: 39, Issue:2, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.The Journal of clinical psychiatry, , Volume: 73, Issue:8, 2012
Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study.Human psychopharmacology, , Volume: 26, Issue:3, 2011
Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.Pharmacogenetics and genomics, , Volume: 21, Issue:9, 2011
A comprehensive entomological survey and evaluation of the efficacy of different therapies on a suspected delusional parasitosis case.Brain and behavior, , Volume: 11, Issue:1, 2021
The dermatoscope: a new tool for delusional parasitosis.Clinical and experimental dermatology, , Volume: 41, Issue:6, 2016
Delusional infestation: a case series from a university dermatology center in São Paulo, Brazil.International journal of dermatology, , Volume: 55, Issue:8, 2016
A national pharmacovigilance study of haematological adverse drug reactions to clozapine vs other second-generation antipsychotics in Italy.Schizophrenia research, , Volume: 257, 2023
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.The lancet. Psychiatry, , Volume: 10, Issue:9, 2023
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:9, 2022
Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: a retrospective study.BMC psychiatry, , 08-22, Volume: 22, Issue:1, 2022
Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.Die Pharmazie, , 09-01, Volume: 77, Issue:7, 2022
Facial edema as an adverse drug reaction to olanzapine in a patient with cancer receiving palliative care.Palliative & supportive care, , Volume: 20, Issue:5, 2022
Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.Schizophrenia bulletin, , 04-29, Volume: 47, Issue:3, 2021
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 30, Issue:9, 2020
Prevalence and recognition of highly significant medication-smoking cessation interactions in a smoke-free hospital.Drug and alcohol dependence, , 07-01, Volume: 200, 2019
Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study.Tumori, , Volume: 105, Issue:3, 2019
Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.JAMA psychiatry, , 08-01, Volume: 75, Issue:8, 2018
Switch-associated adverse events: focus on olanzapine.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 26, Issue:6, 2018
No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment.Acta psychiatrica Scandinavica, , Volume: 138, Issue:2, 2018
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.Journal of global oncology, , Volume: 4, 2018
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.The pharmacogenomics journal, , 05-22, Volume: 18, Issue:3, 2018
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.Brain and behavior, , Volume: 7, Issue:6, 2017
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 25, Issue:2, 2017
Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.British journal of clinical pharmacology, , Volume: 83, Issue:7, 2017
Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats.Psychoneuroendocrinology, , Volume: 73, 2016
Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.Psychopharmacology, , Volume: 233, Issue:21-22, 2016
Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users.The Psychiatric quarterly, , Volume: 87, Issue:2, 2016
Neurological Adverse Effects of Antipsychotics in Children and Adolescents.Journal of clinical psychopharmacology, , Volume: 35, Issue:6, 2015
[Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].Tijdschrift voor psychiatrie, , Volume: 56, Issue:4, 2014
[Post-injection syndrome after depot injection of olanzapine].Nederlands tijdschrift voor geneeskunde, , Volume: 159, 2014
Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring.The Journal of pharmacy and pharmacology, , Volume: 66, Issue:6, 2014
Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment.International journal of methods in psychiatric research, , Volume: 23, Issue:4, 2014
Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.European journal of pharmacology, , Jan-05, Volume: 722, 2014
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.Swiss medical weekly, , Volume: 143, 2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia.The Psychiatric quarterly, , Volume: 84, Issue:1, 2013
Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.Pharmacogenomics, , Volume: 14, Issue:10, 2013
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.Chemical research in toxicology, , Oct-15, Volume: 25, Issue:10, 2012
Olanzapine-induced limb edema simulating episodic angioedema with eosinophilia.The Journal of dermatology, , Volume: 39, Issue:12, 2012
Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study.PLoS computational biology, , Volume: 7, Issue:3, 2011
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.BMC psychiatry, , Jun-10, Volume: 10, 2010
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.BMC psychiatry, , Jun-10, Volume: 10, 2010
Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.BMC psychiatry, , Nov-03, Volume: 10, 2010
Drug research: marketing before evidence, sales before safety.Deutsches Arzteblatt international, , Volume: 107, Issue:16, 2010
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.Expert review of neurotherapeutics, , Volume: 10, Issue:5, 2010
The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials.The Journal of clinical psychiatry, , Volume: 70, Issue:2, 2009
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.Journal of psychiatric research, , Volume: 43, Issue:5, 2009
Optimizing patient safety by preventing combined use of intramuscular olanzapine and parenteral benzodiazepines.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Jun-15, Volume: 65, Issue:12, 2008
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.CNS spectrums, , Volume: 12, Issue:1, 2007
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Antipsychotic-Related Fatal Poisoning, England and Wales, 1993-2019: The Impact of Second-Generation Antipsychotics.Journal of clinical psychopharmacology, , Volume: 41, Issue:6
Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials.Journal of clinical psychopharmacology, , Volume: 40, Issue:2
Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection.Clinical neuropharmacology, , Volume: 42, Issue:2
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
[Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms].Actas espanolas de psiquiatria, , Volume: 35, Issue:2
[The detection of quentiapine and olanzapine in the biological objects].Sudebno-meditsinskaia ekspertiza, , Volume: 57, Issue:5
Olanzapine-induced nonalcoholic fatty liver disease: The effects of differential food pattern and the involvement of PGRMC1 signaling.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, , Volume: 176, 2023
Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway.Scientific reports, , 04-04, Volume: 12, Issue:1, 2022
Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, , Jun-28, Volume: 47, Issue:6, 2022
Hepatoprotective effect of trypsin/chymotrypsin against olanzapine-induced non-alcoholic steatohepatitis in rats.Canadian journal of physiology and pharmacology, , Volume: 99, Issue:10, 2021
Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 141, 2021
Understanding Mechanisms Underlying Non-Alcoholic Fatty Liver Disease (NAFLD) in Mental Illness: Risperidone and Olanzapine Alter the Hepatic Proteomic Signature in Mice.International journal of molecular sciences, , Dec-08, Volume: 21, Issue:24, 2020
Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c, PPAR-alpha and AMPK-alpha.Journal of ethnopharmacology, , Mar-25, Volume: 232, 2019
Association of In Utero Antipsychotic Medication Exposure With Risk of Congenital Malformations in Nordic Countries and the US.JAMA psychiatry, , 02-01, Volume: 80, Issue:2, 2023
Second-generation antipsychotic use during pregnancy and risk of congenital malformations.European journal of clinical pharmacology, , Volume: 77, Issue:11, 2021
Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review.Basic & clinical pharmacology & toxicology, , Volume: 116, Issue:4, 2015
Antipsychotic use in pregnancy.Expert opinion on pharmacotherapy, , Volume: 16, Issue:9, 2015
Antipsychotics in pregnancy.Journal of psychiatric and mental health nursing, , Volume: 17, Issue:2, 2010
The clinical dilemma--prescribing in pregnancy.Psychiatria Danubina, , Volume: 20, Issue:1, 2008
Effects of antimanic mood-stabilizing drugs on fetuses, neonates, and nursing infants.Southern medical journal, , Volume: 94, Issue:3, 2001
Olanzapine-exposed pregnancies and lactation: early experience.Journal of clinical psychopharmacology, , Volume: 20, Issue:4, 2000
Risk of Major Malformations Following First-Trimester Exposure to Olanzapine: Preliminary Data From the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications.Journal of clinical psychopharmacology, , Volume: 43, Issue:2
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.The Journal of clinical psychiatry, , 03-03, Volume: 81, Issue:2, 2020
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.The Journal of clinical psychiatry, , 03-17, Volume: 81, Issue:2, 2020
The antipsychotic olanzapine reduces memory deficits and neuronal abnormalities in a male rat model of Autism.Journal of chemical neuroanatomy, , Volume: 132, 2023
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:7, 2021
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
Treatment of severe tardive dyskinesia with concurrent administration of olanzapine, clonazepam, baclofen, and gabapentin: a case report.The Journal of international medical research, , Volume: 51, Issue:10, 2023
Clozapine Treatment of Olanzapine-induced Tardive Dyskinesia: A Case Report.Journal of psychiatric practice, , Volume: 23, Issue:1, 2017
Olanzapine-Associated Pisa Syndrome in an Autistic Adolescent.Clinical neuropharmacology, , Volume: 43, Issue:2
Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Journal of pediatric hematology/oncology, , 10-01, Volume: 45, Issue:7, 2023
Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial.Human psychopharmacology, , Volume: 36, Issue:1, 2021
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.The American journal of psychiatry, , 06-01, Volume: 176, Issue:6, 2019
Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.Scientific reports, , 11-02, Volume: 8, Issue:1, 2018
Switch from Olanzapine Long-Acting Injectable to its Oral Equivalent during COVID-19 Pandemic: a Real World Observational Study.The Psychiatric quarterly, , Volume: 93, Issue:2, 2022
Clozapine-Induced Myocarditis in a Young Man with Refractory Schizophrenia: Case Report of a Rare Adverse Event and Review of the Literature.The American journal of case reports, , Jul-06, Volume: 23, 2022
Olanzapine, risperidone and quetiapine: Do these atypical antipsychotics have a protective effect for SARS-CoV-2?Schizophrenia research, , Volume: 241, 2022
The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study.Annals of palliative medicine, , Volume: 10, Issue:5, 2021
Brief psychotic disorder with delusion content related to the COVID-19 outbreak.Psychiatrike = Psychiatriki, , Apr-19, Volume: 32, Issue:1, 2021
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.Journal of affective disorders, , 12-01, Volume: 277, 2020
Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India.Asian journal of psychiatry, , Volume: 54, 2020
Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.The Australian and New Zealand journal of psychiatry, , Volume: 54, Issue:7, 2020
Two cases report of epidemic stress disorder to novel coronavirus pneumonia.Asian journal of psychiatry, , Volume: 51, 2020
Reactive Psychosis in a Health Care Worker During the COVID-19 Pandemic.The primary care companion for CNS disorders, , 07-09, Volume: 22, Issue:4, 2020
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.Nature, , Volume: 583, Issue:7816, 2020
Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).Medical hypotheses, , Volume: 141, 2020
Neurotropism of SARS-CoV-2: COVID-19 presenting with an acute manic episode.BMJ case reports, , Jun-14, Volume: 13, Issue:6, 2020
Three Cases of COVID-19-related First Onset Brief Reactive Psychosis.The Israel Medical Association journal : IMAJ, , Volume: 22, Issue:10, 2020
Continuation of depot olanzapine pamoate after post-injection delirium/sedation syndrome (PDSS) in a case of bipolar mania-a clinical conundrum.Bipolar disorders, , Volume: 25, Issue:2, 2023
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.BMJ mental health, , Volume: 26, Issue:1, 2023
Personality disorder among youth with first episode psychotic mania: An important target for specific treatment?Early intervention in psychiatry, , Volume: 16, Issue:3, 2022
Typical versus Atypical Antipsychotics for Acute Mania: Psychopharmacological Considerations.American journal of therapeutics, , 07-01, Volume: 29, Issue:4, 2022
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.Molecular psychiatry, , Volume: 27, Issue:2, 2022
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:5, 2022
Psychopharmacology of agitation in acute psychotic and manic episodes.Current opinion in psychiatry, , 05-01, Volume: 35, Issue:3, 2022
Proportion of subjects with psychotic features in bipolar disorder correlated with treatment response by antipsychotics for acute mania.Psychiatry and clinical neurosciences, , Volume: 76, Issue:11, 2022
A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years.Psychopharmacology, , Volume: 239, Issue:10, 2022
Lurasidone-Induced Manic Switch in an Adolescent with Bipolar I Disorder: a Case Report.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 31, Issue:3, 2021
How to treat mania.Acta psychiatrica Scandinavica, , Volume: 142, Issue:3, 2020
Open-Label, Randomized, Single-Dose, 2-Period, 2-Sequence Crossover, Comparative Pharmacokinetic Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine Under Fasting and Fed Conditions.Clinical pharmacology in drug development, , Volume: 9, Issue:5, 2020
Olanzapine-associated Edema Decreasing Serum Lithium Concentrations: A Case Report.Journal of clinical psychopharmacology, , Volume: 40, Issue:5
Hypertrophic discoid lupus erythematosus.Dermatology online journal, , Nov-15, Volume: 16, Issue:11, 2010
Olanzapine is effective in the management of some self-induced dermatoses: three case reports.Cutis, , Volume: 66, Issue:2, 2000
[Isotretinoin Therapy for Acne Vulgaris and First Episode Psychosis in an Adolescent Patient].Revista colombiana de psiquiatria, , Volume: 46, Issue:1
Olanzapine may be an effective adjunctive therapy in the management of acne excoriée: a case report.Journal of cutaneous medicine and surgery, , Volume: 5, Issue:1
Management of a patient with schizophrenia and underlying pituitary macroadenoma.Annals of the Academy of Medicine, Singapore, , Volume: 39, Issue:11, 2010
Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:1, 2005
Mania in a case of hyperparathyroidism.Psychosomatics, , Volume: 48, Issue:3
Reduction in the prescription of Olanzapine as a first-line treatment for first episode psychosis following the implementation of clinical practice guidelines.Schizophrenia research, , Volume: 215, 2020
Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.JAMA, , 08-20, Volume: 322, Issue:7, 2019
Case records of the Massachusetts General Hospital. Case 10-2015. A 15-year-old girl with Graves’ disease and psychotic symptoms.The New England journal of medicine, , Mar-26, Volume: 372, Issue:13, 2015
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II.BMC psychiatry, , Jan-25, Volume: 13, 2013
Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.Psychiatry research, , May-30, Volume: 197, Issue:3, 2012
Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial.Journal of psychiatric research, , Volume: 45, Issue:7, 2011
Switching among antipsychotics--focus on side effects.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Symptoms of agitated depression and/or akathisia.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Olanzapine abuse was relieved after switching to aripiprazole in a patient with psychotic depression.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 34, Issue:7, 2010
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Meningocele and ankyloblepharon following in utero exposure to olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:5, 2006
Lamotrigine-induced severe manic switch.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:8, 2006
[Brief case report. Duloxetine in Cotard syndrome].Psychiatrische Praxis, , Volume: 32, Issue:8, 2005
Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.Pharmacogenetics and genomics, , Volume: 15, Issue:4, 2005
Comparison of olanzapine and risperidone in 367 first-episode patients with non-affective or affective psychosis: results of an open retrospective medical record study.Pharmacopsychiatry, , Volume: 38, Issue:5, 2005
Variables associated with high olanzapine dosing in a state hospital.The Journal of clinical psychiatry, , Volume: 65, Issue:8, 2004
New approaches to managing psychotic depression.The Journal of clinical psychiatry, , Volume: 64 Suppl 1, 2003
[Improvement of tardive dyskinesia after treatment with olanzapine].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.The Journal of clinical psychiatry, , Volume: 62, Issue:7, 2001
[Olanzapine in the treatment of depressive disorders with psychotic symptoms].Der Nervenarzt, , Volume: 70, Issue:1, 1999
Olanzapine response in psychotic depression.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Tardive dyskinesia in affective disorders.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Clinical predictors of acute response with olanzapine in psychotic mood disorders.The Journal of clinical psychiatry, , Volume: 59, Issue:1, 1998
Dysphagia From Long-Term Olanzapine Use: A Rare Adverse Effect.Journal of clinical psychopharmacology, , Volume: 41, Issue:5
Clozapine-specific proliferative response of peripheral blood-derived mononuclear cells in Japanese patients with clozapine-induced agranulocytosis.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:9, 2022
Failure of rechallenge clozapine after agranulocytosis: A case report.L'Encephale, , Volume: 45, Issue:5, 2019
Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis.Chemical research in toxicology, , Jul-21, Volume: 27, Issue:7, 2014
Olanzapine-induced agranulocytosis in an adolescent male with psychosis.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:2, 2011
Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study.PLoS computational biology, , Volume: 7, Issue:3, 2011
[Drug-induced agranulocytosis--case reports and literature review].Przeglad lekarski, , Volume: 66, Issue:6, 2009
Severe psychotic disorder and agranulocytosis--a therapeutic dilemma.Pharmacopsychiatry, , Volume: 42, Issue:6, 2009
Fatal agranulocytosis: the use of olanzapine in a patient with schizophrenia and myelodysplasia.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-30, Volume: 31, Issue:1, 2007
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
Reversible neutropenia with olanzapine following clozapine-induced neutropenia.The American journal of psychiatry, , Volume: 163, Issue:7, 2006
Olanzapine-induced agranulocytosis: a case report and review of the literature.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:2, 2002
Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis.Chemico-biological interactions, , Nov-10, Volume: 142, Issue:1-2, 2002
Agranulocytosis and neutropenia with typical and atypical neuroleptics.The American journal of psychiatry, , Volume: 158, Issue:10, 2001
New antipsychotic medications: more than old wine and new bottles.Bulletin of the Menninger Clinic, ,Winter, Volume: 64, Issue:1, 2000
Are there genetic determinants of olanzapine-induced agranulocytosis?Pharmacopsychiatry, , Volume: 33, Issue:5, 2000
[Atypical antipsychotics].Nederlands tijdschrift voor geneeskunde, , Oct-21, Volume: 144, Issue:43, 2000
Side Effects of Antipsychotic Medications: Physician's Choice of Medication and Patient Compliance. Dallas, Texas, California. January 22, 1999. Proceedings of a roundtable.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Olanzapine prolongation of granulocytopenia after clozapine discontinuation.Journal of clinical psychopharmacology, , Volume: 20, Issue:6, 2000
Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.Acta psychiatrica Scandinavica, , Volume: 102, Issue:2, 2000
Olanzapine: safe during clozapine-induced agranulocytosis.Journal of clinical psychopharmacology, , Volume: 20, Issue:2, 2000
Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine?Pharmacopsychiatry, , Volume: 32, Issue:3, 1999
Olanzapine-induced agranulocytosis.Lancet (London, England), , Aug-14, Volume: 354, Issue:9178, 1999
Response to letter of Professor Tim Lambert.The Australian and New Zealand journal of psychiatry, , Volume: 33, Issue:1, 1999
Olanzapine: hematological reactions.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jul-14, Volume: 159, Issue:1, 1998
Olanzapine after clozapine: the rare case of prolongation of granulocytopaenia.The Australian and New Zealand journal of psychiatry, , Volume: 32, Issue:4, 1998
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis.International clinical psychopharmacology, , Volume: 13, Issue:3, 1998
A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes.Molecular pharmacology, , Volume: 53, Issue:6, 1998
Experiences with clozapine and olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 32, Issue:3, 1998
Structural features associated with reactive metabolite formation in clozapine analogues.Chemico-biological interactions, , May-02, Volume: 104, Issue:2-3, 1997
Prolongation of clozapine-induced granulocytopenia associated with olanzapine.Journal of clinical psychopharmacology, , Volume: 17, Issue:6, 1997
Olanzapine-induced agranulocytosis in systemic lupus erythematosus: a case report.General hospital psychiatry, , Volume: 29, Issue:1
New-Onset Agranulocytosis During Long-term Treatment With Olanzapine.Journal of clinical psychopharmacology, , Volume: 43, Issue:3
Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia.General hospital psychiatry, , Volume: 28, Issue:1
Treatment of akinetic mutism with intramuscular olanzapine: a case series.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 20, Issue:1, 2008
A Case of Abulia From Left Middle Cerebral Artery Stroke in an Adolescent Treated Successfully With Short Duration Olanzapine.Clinical neuropharmacology, , Volume: 43, Issue:3
A case of abulia, status/post right middle cerebral artery territory infarct, treated successfully with olanzapine.Clinical neuropharmacology, , Volume: 37, Issue:6
Parenteral Antipsychotic Choice and Its Association With Emergency Department Length of Stay for Acute Agitation Secondary to Alcohol Intoxication.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, , Volume: 26, Issue:1, 2019
Despite expert recommendations, second-generation antipsychotics are not often prescribed in the emergency department.The Journal of emergency medicine, , Volume: 46, Issue:6, 2014
A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation.The Journal of emergency medicine, , Volume: 43, Issue:5, 2012
Olanzapine in ED patients: differential effects on oxygenation in patients with alcohol intoxication.The American journal of emergency medicine, , Volume: 30, Issue:7, 2012
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.The Journal of clinical psychiatry, , 03-10, Volume: 81, Issue:2, 2020
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.The Journal of clinical psychiatry, , 03-17, Volume: 81, Issue:2, 2020
Hikikomori in Brazil: 29 years of Voluntary social Withdrawal.Asian journal of psychiatry, , Volume: 30, 2017
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.The Journal of nervous and mental disease, , Volume: 203, Issue:7, 2015
Dose specific effects of olanzapine in the treatment of alcohol dependence.Psychopharmacology, , Volume: 232, Issue:7, 2015
[Buccolingual dyskinesia with justified hallucinations].Revista de neurologia, , Nov-16, Volume: 59, Issue:10, 2014
Alcohol drinking of alcohol-preferring AA rats is differentially affected by clozapine and olanzapine.European journal of pharmacology, , Mar-18, Volume: 534, Issue:1-3, 2006
The effect of olanzapine on craving and alcohol consumption.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:6, 2006
Delusional wife: a case of diagnostic ambiguity and treatment challenge.Journal of psychiatric practice, , Volume: 11, Issue:3, 2005
A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder.Alcoholism, clinical and experimental research, , Volume: 28, Issue:5, 2004
Potential use of olanzapine in treatment of substance dependence disorders.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Stalking behavior in delusional jealousy.Journal of forensic sciences, , Volume: 45, Issue:1, 2000
Olanzapine in the treatment of tardive dyskinesia: a report of two cases.Journal of clinical psychopharmacology, , Volume: 19, Issue:1, 1999
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
Outcome predictors in cocaine dependence treatment trials.The American journal on addictions, , Volume: 15, Issue:6
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
Pharmacological treatment of alcohol use disorder. Scientific evidence.Rivista di psichiatria, , Volume: 53, Issue:3
Clinical study of donepezil combined with olanzapine in the treatment of senile dementia complicated with mental and behavioral disorders.Minerva medica, , Volume: 113, Issue:2, 2022
Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer's disease cognition.Alzheimer's research & therapy, , 06-29, Volume: 14, Issue:1, 2022
Meta-Analysis of the Efficacy and Safety of Olanzapine versus Clozapine when Treating Senile Dementia.Computational and mathematical methods in medicine, , Volume: 2022, 2022
Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine DClinical drug investigation, , Volume: 42, Issue:12, 2022
A comparative study of olanzapine, aripiprazole and risperidone in the treatment of psychiatric and behavioral symptoms of Alzheimer's disease.Pakistan journal of pharmaceutical sciences, , Volume: 34, Issue:5(Special), 2021
Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.Neuropharmacology, , 10-01, Volume: 197, 2021
Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:7, 2017
Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 26, Issue:3, 2014
Olanzapine-associated myoclonus.Epilepsy research, , Volume: 98, Issue:2-3, 2012
Drifting policies are wasting billions.International psychogeriatrics, , Volume: 24, Issue:3, 2012
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.The American journal of psychiatry, , Volume: 168, Issue:8, 2011
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 22, Issue:1, 2010
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.The American journal of psychiatry, , Volume: 166, Issue:5, 2009
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.The American journal of psychiatry, , Volume: 165, Issue:7, 2008
Sex, race, and smoking impact olanzapine exposure.Journal of clinical pharmacology, , Volume: 48, Issue:2, 2008
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.Clinical drug investigation, , Volume: 28, Issue:5, 2008
Atypical antipsychotic agents ineffective for AD.DukeMedicine healthnews, , Volume: 13, Issue:1, 2007
Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Effect of antipsychotic medication use on memory in patients with Alzheimer's disease: Assessing the potential risk for accelerated recent autobiographical memory loss.Journal of gerontological nursing, , Volume: 33, Issue:6, 2007
Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.CNS spectrums, , Volume: 12, Issue:1, 2007
Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances.Journal of geriatric psychiatry and neurology, , Volume: 20, Issue:2, 2007
The outpatient use of atypical antipsychotics with Alzheimer's disease.South Dakota medicine : the journal of the South Dakota State Medical Association, , Volume: 60, Issue:3, 2007
[Efficacy of atypical antipsychotics in patients with Alzheimer's dementia. CATIE-AD-Study (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer's Disease)].Der Internist, , Volume: 48, Issue:6, 2007
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.Medicine and health, Rhode Island, , Volume: 90, Issue:6, 2007
Psychosis of Alzheimer disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial.Dementia and geriatric cognitive disorders, , Volume: 21, Issue:1, 2006
[Study questions the benefit of the treatment. Aggressive Alzheimer patient -- a (not a) case for atypical neuroleptics?].MMW Fortschritte der Medizin, , Nov-23, Volume: 148, Issue:47, 2006
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.The New England journal of medicine, , Oct-12, Volume: 355, Issue:15, 2006
No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.Minerva medica, , Volume: 97, Issue:2, 2006
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.The Cochrane database of systematic reviews, , Jan-25, Issue:1, 2006
Dementia.Clinical evidence, , Issue:14, 2005
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:8, 2005
Responsiveness of the quality of life in late-stage dementia scale to psychotropic drug treatment in late-stage dementia.Dementia and geriatric cognitive disorders, , Volume: 19, Issue:2-3, 2005
Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.International journal of geriatric psychiatry, , Volume: 20, Issue:11, 2005
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.International psychogeriatrics, , Volume: 17, Issue:2, 2005
The use of olanzapine in the treatment of negative symptoms in Alzheimer's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 17, Issue:3, 2005
Dementia.Clinical evidence, , Issue:11, 2004
The management of psychogeriatric patient.Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Apr-27, Volume: 170, Issue:9, 2004
[Cerebral infarct and atypical antipsychotic agents].Psychologie & neuropsychiatrie du vieillissement, , Volume: 2, Issue:4, 2004
Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.International journal of geriatric psychiatry, , Volume: 19, Issue:2, 2004
Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.Managed care interface, , Volume: 16, Issue:5, 2003
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.Southern medical journal, , Volume: 96, Issue:7, 2003
Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.The Annals of pharmacotherapy, , Volume: 37, Issue:9, 2003
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.The Journal of clinical psychiatry, , Volume: 62, Issue:1, 2001
Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis.International journal of geriatric psychiatry, , Volume: 16 Suppl 1, 2001
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.International journal of geriatric psychiatry, , Volume: 16 Suppl 1, 2001
A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data.International journal of geriatric psychiatry, , Volume: 16 Suppl 1, 2001
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.International journal of geriatric psychiatry, , Volume: 16 Suppl 1, 2001
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Fall, Volume: 9, Issue:4, 2001
Dementia with Lewy bodies in Down's syndrome.International journal of geriatric psychiatry, , Volume: 16, Issue:3, 2001
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.The Journal of nervous and mental disease, , Volume: 189, Issue:6, 2001
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.Archives of general psychiatry, , Volume: 57, Issue:10, 2000
Tardive dyskinesia in older patients.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Nov-01, Volume: 56, Issue:21, 1999
Advances in CNS Drugs. Recent advances and considerations in the treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 57, Issue:7, 1996
Increase in mortality rate in patients with dementia treated with atypical antipsychotics: a cohort study in outpatients in Central Italy.Rivista di psichiatria, , Volume: 49, Issue:1
[Mortality rates in patients with Alzheimer's disease treated with atypical neuroleptic drugs].Revista de neurologia, , Volume: 46, Issue:3
Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease: Analysis of the CATIE-AD Data.The Journal of clinical psychiatry, , Volume: 78, Issue:9
Olanzapine-induced myoclonic status.Clinical neuropharmacology, , Volume: 28, Issue:3
Psychotropic drug effects on gene transcriptomics relevant to Alzheimer disease.Alzheimer disease and associated disorders, , Volume: 26, Issue:1
[Treatment of non cognitive symptoms of Alzheimer's disease].Revista de neurologia, , Volume: 42, Issue:8
Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.American journal of Alzheimer's disease and other dementias, , Volume: 18, Issue:4
No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:3, 2011
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.Journal of clinical pharmacy and therapeutics, , Volume: 32, Issue:2, 2007
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.Pharmacotherapy, , Volume: 26, Issue:6, 2006
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Return of menstruation after switching from risperidone to olanzapine.Journal of clinical psychopharmacology, , Volume: 18, Issue:6, 1998
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.The American journal of psychiatry, , Volume: 155, Issue:10, 1998
Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.Journal of sex & marital therapy, , Volume: 29, Issue:2
Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.The Psychiatric quarterly, , Volume: 94, Issue:4, 2023
Cameron lesions and selective serotonin reuptake inhibitors: An uncommon combination.Gastroenterologia y hepatologia, , Volume: 43, Issue:5, 2020
Anxiolytic effects of venlafaxine/olanzapine combination in treatment of anxious depression.Neuro endocrinology letters, , Volume: 38, Issue:8, 2018
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study.Comprehensive psychiatry, , Volume: 55, Issue:5, 2014
Role of atypical antipsychotics in the treatment of generalized anxiety disorder.CNS drugs, , Volume: 28, Issue:6, 2014
Second-generation antipsychotics for anxiety disorders.The Cochrane database of systematic reviews, , Dec-08, Issue:12, 2010
Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder.Pharmacotherapy, , Volume: 30, Issue:9, 2010
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study.The Journal of clinical psychiatry, , Volume: 69, Issue:4, 2008
Olanzapine counteracts stress-induced anxiety-like behavior in rats.Neuroscience letters, , Jun-20, Volume: 438, Issue:2, 2008
Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition.European journal of cancer care, , Volume: 16, Issue:3, 2007
Effect of comorbid anxiety on treatment response in bipolar depression.Journal of affective disorders, , Volume: 104, Issue:1-3, 2007
Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study.Biological psychiatry, , Feb-01, Volume: 59, Issue:3, 2006
Olanzapine-induced oculogyric crisis.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.Bipolar disorders, , Volume: 8, Issue:6, 2006
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorders, , Volume: 7 Suppl 3, 2005
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania.The Journal of clinical psychiatry, , Volume: 64, Issue:1, 2003
Other clinical uses of olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:3, 2000
Atypical antipsychotics for treatment of mixed depression and anxiety.The Journal of clinical psychiatry, , Volume: 61, Issue:5, 2000
Atypical presentations of pregnancy-specific generalized anxiety disorders in women without a previous psychiatric background.Psychosomatics, , Volume: 56, Issue:3
Serotonin syndrome: a complex but easily avoidable condition.General hospital psychiatry, , Volume: 30, Issue:3
Psychopharmacologic Management of Eating Disorders.Current psychiatry reports, , Volume: 24, Issue:7, 2022
Psychotropic Medication for Children and Adolescents with Eating Disorders.Child and adolescent psychiatric clinics of North America, , Volume: 28, Issue:4, 2019
Adjunctive Use of Olanzapine in the Treatment of Avoidant Restrictive Food Intake Disorder in Children and Adolescents in an Eating Disorders Program.Journal of child and adolescent psychopharmacology, , Volume: 27, Issue:10, 2017
[Eating disorders in psychiatric patients during treatment with second generation antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:7, 2015
Olanzapine and food craving: a case control study.Human psychopharmacology, , Volume: 28, Issue:1, 2013
No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:3, 2011
Advancements in neuroendocrine and autonomic control of metabolic functions and their pathological significance.Eating and weight disorders : EWD, , Volume: 13, Issue:3, 2008
Sleep-related eating disorder induced by olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:7, 2002
Microthinking about micronutrients: a case of transition from obsessions about healthy eating to near-fatal "orthorexia nervosa" and proposed diagnostic criteria.Psychosomatics, , Volume: 56, Issue:4
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
Implications of atypical antipsychotic prescribing in the intensive care unit.Journal of critical care, , Volume: 30, Issue:4, 2015
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.Drug safety, , Volume: 36, Issue:6, 2013
[Electrocardiographic abnormalities in acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
Support vector machines classification of hERG liabilities based on atom types.Bioorganic & medicinal chemistry, , Jun-01, Volume: 16, Issue:11, 2008
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.The American journal of managed care, , Volume: 13, Issue:7 Suppl, 2007
Analysis of proarrhythmic potential of antipsychotics risperidone and olanzapine in anesthetized dogs.European journal of pharmacology, , Mar-08, Volume: 558, Issue:1-3, 2007
Olanzapine prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:7, 2007
Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.Journal of the National Medical Association, , Volume: 95, Issue:2, 2003
Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:2, 2001
[Heart rate variability in schizophrenic patients treated with antipsychotic agents].Harefuah, , Volume: 140, Issue:12, 2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.The Journal of clinical psychiatry, , Volume: 62, Issue:3, 2001
Olanzapine (Zyprexa): suspected serious reactions.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jul-11, Volume: 163, Issue:1, 2000
[Clozapine and Olanzapine Associated Atrial Fibrillation: A Case Report].Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Fall, Volume: 26, Issue:3, 2015
Atrıal fıbrıllatıon due to olanzapıne overdose.Clinical toxicology (Philadelphia, Pa.), , Volume: 49, Issue:5, 2011
Olanzapine-associated new-onset atrial fibrillation.Journal of clinical psychopharmacology, , Volume: 28, Issue:3, 2008
Olanzapine-induced Priapism in a Child with Asperger's Syndrome.Balkan medical journal, , Volume: 34, Issue:1, 2017
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.Boletin de la Asociacion Medica de Puerto Rico, , Volume: 105, Issue:3, 2013
Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:6, 2013
Atomoxetine-induced vocal tics in a patient with schizophrenia.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
[Antipsychotic agents and stimulants: a judicious combination?].Tijdschrift voor psychiatrie, , Volume: 52, Issue:1, 2010
Attention deficit hyperactivity disorder erroneously diagnosed and treated as bipolar disorder.Journal of attention disorders, , Volume: 13, Issue:2, 2009
Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:5, 2008
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
The use of two neuroleptics to treat bipolar illness in two children.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
The impact of the Food and Drug Administration Modernization Act on the recruitment of children for research.Ethical human sciences and services : an international journal of critical inquiry, ,Summer, Volume: 5, Issue:2, 2003
An open-label study of the treatment efficacy of olanzapine for Tourette's disorder.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Mood stabilizer augmentation with olanzapine in acutely manic children.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 10, Issue:1, 2000
Open-label olanzapine treatment in five preadolescent children.Journal of child and adolescent psychopharmacology, , Volume: 8, Issue:2, 1998
The antipsychotic olanzapine reduces memory deficits and neuronal abnormalities in a male rat model of Autism.Journal of chemical neuroanatomy, , Volume: 132, 2023
Second-generation antipsychotic and diabetes mellitus in children and adolescents.La Pediatria medica e chirurgica : Medical and surgical pediatrics, , Dec-13, Volume: 39, Issue:4, 2017
Severe ischemic colitis following olanzapine use - A case report.Revista espanola de enfermedades digestivas, , Volume: 108, Issue:9, 2016
Olanzapine-induced hyponatremia in a patient with autism.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:10, 2013
Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.BMC psychiatry, , Oct-04, Volume: 13, 2013
Excessive masturbation associated with olanzapine in a pediatric case.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 34, Issue:7, 2010
Rhabdomyolysis associated with olanzapine treatment in a child with Autism.Pediatric emergency care, , Volume: 26, Issue:1, 2010
Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait.Medical principles and practice : international journal of the Kuwait University, Health Science Centre, , Volume: 17, Issue:5, 2008
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Risperidone-induced enuresis in two children with autistic disorder.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:4, 2007
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:5, 2006
Open-label study of olanzapine in children with pervasive developmental disorder.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 40, Issue:8, 2001
Mirtazapine for excessive masturbation in an adolescent with autism.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 40, Issue:8, 2001
[Neuroleptic malignant syndrome after treatment with olanzapine].Ugeskrift for laeger, , Mar-08, Volume: 161, Issue:10, 1999
Olanzapine for autistic disorder with hyperactivity.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 37, Issue:9, 1998
Olanzapine-Associated Pisa Syndrome in an Autistic Adolescent.Clinical neuropharmacology, , Volume: 43, Issue:2
Treatment of catatonia with olanzapine and amantadine.Psychosomatics, , Volume: 48, Issue:6
Effects of four atypical antipsychotics on autonomic nervous system activity in schizophrenia.Schizophrenia research, , Volume: 193, 2018
Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine.Journal of clinical psychopharmacology, , Volume: 20, Issue:3, 2000
Fever, delirium, autonomic instability, and monocytosis associated with olanzapine.Journal of postgraduate medicine, , Volume: 49, Issue:1
Driving fitness in clinically stable outpatients with chronic schizophrenia.Comprehensive psychiatry, , Volume: 118, 2022
Basal Ganglia Calcification: A Case Report of Fahr Disease With Pure Psychiatric Symptoms.Journal of psychiatric practice, , Volume: 25, Issue:5, 2019
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.CNS spectrums, , Volume: 21, Issue:6, 2016
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
Post authorization safety study comparing quetiapine to risperidone and olanzapine.Human psychopharmacology, , Volume: 31, Issue:4, 2016
Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.JAMA psychiatry, , Volume: 72, Issue:9, 2015
Implications of atypical antipsychotic prescribing in the intensive care unit.Journal of critical care, , Volume: 30, Issue:4, 2015
Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.Journal of geriatric psychiatry and neurology, , Volume: 28, Issue:1, 2015
Topiramate improves psychiatric symptoms in a patient with Lewy body dementia.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 27, Issue:4, 2014
Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.Psychiatry research, , Oct-30, Volume: 219, Issue:2, 2014
Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care.Clinical toxicology (Philadelphia, Pa.), , Volume: 52, Issue:1, 2014
Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.Clinical schizophrenia & related psychoses, , Volume: 7, Issue:4, 2014
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.Swiss medical weekly, , Volume: 143, 2013
Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study.Human psychopharmacology, , Volume: 26, Issue:8, 2011
Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.Pharmacopsychiatry, , Volume: 44, Issue:4, 2011
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.Psychiatry research, , May-15, Volume: 187, Issue:1-2, 2011
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
Capgras syndrome associated with Fahr's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 21, Issue:3, 2009
Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.Journal of intellectual & developmental disability, , Volume: 34, Issue:3, 2009
Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.The international journal of neuropsychopharmacology, , Volume: 12, Issue:7, 2009
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:1, 2009
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 24, Issue:3, 2009
Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:4, 2009
A clinical paradigm of delusions of parasitosis.Journal of the American Academy of Dermatology, , Volume: 59, Issue:4, 2008
Problems with CATIE. Phase 1: Looking back--what the clinician needs to know.Connecticut medicine, , Volume: 72, Issue:4, 2008
A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.Schizophrenia research, , Volume: 98, Issue:1-3, 2008
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:1, 2008
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.Journal of affective disorders, , Volume: 105, Issue:1-3, 2008
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 9, Issue:3, 2007
The roadmap for antipsychotic psychopharmacology: an overview.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Atypical antipsychotics in bipolar disorder: systematic review of randomised trials.BMC psychiatry, , Aug-16, Volume: 7, 2007
The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.Schizophrenia bulletin, , Volume: 33, Issue:6, 2007
[The use of atypical antipsychotics in the long-term care of schizophrenia].L'Encephale, , Volume: 32 Pt 3, 2006
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.The American journal of psychiatry, , Volume: 163, Issue:12, 2006
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.Acta psychiatrica Scandinavica, , Volume: 114, Issue:5, 2006
A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:5, 2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.Molecular psychiatry, , Volume: 11, Issue:7, 2006
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.The American journal of psychiatry, , Volume: 162, Issue:10, 2005
Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.Nordic journal of psychiatry, , Volume: 59, Issue:3, 2005
Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report.Journal of Korean medical science, , Volume: 20, Issue:4, 2005
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:8, 2005
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Executive function assessment of patients with schizophrenic disorder residual type in olanzapine treatment: an open study.Human psychopharmacology, , Volume: 20, Issue:6, 2005
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.Drug metabolism and pharmacokinetics, , Volume: 20, Issue:3, 2005
Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:6, 2005
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.The Journal of nervous and mental disease, , Volume: 193, Issue:6, 2005
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current opinion in pediatrics, , Volume: 17, Issue:2, 2005
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.The Journal of clinical psychiatry, , Volume: 66 Suppl 3, 2005
Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.Journal of clinical pharmacy and therapeutics, , Volume: 30, Issue:1, 2005
Olanzapine treatment of residual positive and negative symptoms.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Persistent choreoathetosis in a fatal olanzapine overdose: drug kinetics, neuroimaging, and neuropathology.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia.Human psychopharmacology, , Volume: 20, Issue:1, 2005
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.Statistics in medicine, , Jan-15, Volume: 24, Issue:1, 2005
Selective prescribing of atypical antipsychotics.Pharmacoepidemiology and drug safety, , Volume: 14, Issue:1, 2005
Switching elderly chronic psychotic patients to olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:2, 2004
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:1, 2004
Olanzapine vs haloperidol: treating delirium in a critical care setting.Intensive care medicine, , Volume: 30, Issue:3, 2004
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.Psychiatry research, , Dec-15, Volume: 129, Issue:2, 2004
Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:6, 2004
Neurologic soft signs and olanzapine treatment in chronic schizophrenia.Journal of clinical psychopharmacology, , Volume: 24, Issue:5, 2004
Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 14, Issue:2, 2004
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Efficacy of atypical antipsychotics in elderly patients with dementia.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Clinical effectiveness of atypical antipsychotics in dementia.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Weight decline in patients switching from olanzapine to quetiapine.Schizophrenia research, , Sep-01, Volume: 70, Issue:1, 2004
The management of psychogeriatric patient.Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.International clinical psychopharmacology, , Volume: 19, Issue:1, 2004
Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder.Psychopharmacology, , Volume: 175, Issue:4, 2004
Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:11, 2003
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.The American journal of psychiatry, , Volume: 160, Issue:8, 2003
Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:4, 2003
Pharmacological approaches to the management of schizophrenia.The Medical journal of Australia, , 05-05, Volume: 178, Issue:S9, 2003
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.International clinical psychopharmacology, , Volume: 18, Issue:3, 2003
Comparative effectiveness of antipsychotic drugs.The American journal of psychiatry, , Volume: 160, Issue:3, 2003
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.International clinical psychopharmacology, , Volume: 18, Issue:1, 2003
Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:6, 2002
Effects of development on olanzapine-associated adverse events.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 41, Issue:12, 2002
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.Schizophrenia research, , Oct-01, Volume: 57, Issue:2-3, 2002
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine.International clinical psychopharmacology, , Volume: 17, Issue:3, 2002
A novel augmentation strategy for treating resistant major depression.The American journal of psychiatry, , Volume: 158, Issue:1, 2001
Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).BMC psychiatry, , Volume: 1, 2001
Rapid tranquilization with olanzapine in acute psychosis: a case series.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.The Annals of pharmacotherapy, , Volume: 35, Issue:12, 2001
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.The Journal of clinical psychiatry, , Volume: 62, Issue:12, 2001
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 158, Issue:5, 2001
Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Broad therapeutic uses of atypical antipsychotic medications.Biological psychiatry, , Dec-01, Volume: 50, Issue:11, 2001
Tardive dyskinesia in older patients.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Olanzapine to treat the acute mania of bipolar disorder.South Dakota journal of medicine, , Volume: 53, Issue:12, 2000
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.The Journal of clinical psychiatry, , Volume: 61 Suppl 3, 2000
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.Clinical therapeutics, , Volume: 22, Issue:5, 2000
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.The Journal of clinical psychiatry, , Volume: 61, Issue:5, 2000
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.The American journal of psychiatry, , Volume: 157, Issue:6, 2000
Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia.The American journal of psychiatry, , Volume: 157, Issue:6, 2000
Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia.Journal of clinical psychopharmacology, , Volume: 20, Issue:3, 2000
Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group.Psychiatry and clinical neurosciences, , Volume: 54, Issue:4, 2000
Adverse events related to olanzapine.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Side Effects of Antipsychotic Medications: Physician's Choice of Medication and Patient Compliance. Dallas, Texas, California. January 22, 1999. Proceedings of a roundtable.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.Journal of psychopharmacology (Oxford, England), , Volume: 14, Issue:4, 2000
Reversal of rabbit syndrome with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:1, 2000
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.European journal of nuclear medicine, , Volume: 26, Issue:8, 1999
Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain.Psychopharmacology, , Volume: 144, Issue:3, 1999
Antipsychotics from theory to practice: integrating clinical and basic data.The Journal of clinical psychiatry, , Volume: 60 Suppl 8, 1999
Tardive dyskinesia and atypical antipsychotic drugs.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.Schizophrenia research, , Jan-04, Volume: 35, Issue:1, 1999
Olanzapine versus haloperidol treatment in first-episode psychosis.The American journal of psychiatry, , Volume: 156, Issue:1, 1999
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 14, Issue:6, 1999
Olanzapine overdose cause of acute extrapyramidal symptoms.The American journal of psychiatry, , Volume: 155, Issue:11, 1998
Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.Journal of neurology, neurosurgery, and psychiatry, , Volume: 65, Issue:5, 1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.Psychopharmacology bulletin, , Volume: 34, Issue:1, 1998
Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.The Journal of clinical psychiatry, , Volume: 58, Issue:11, 1997
High-dose olanzapine for treatment-refractory schizophrenia.The American journal of psychiatry, , Volume: 154, Issue:11, 1997
The relationship of pharmacology to side effects.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Dosing the antipsychotic medication olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 58, Issue:5, 1997
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.The American journal of psychiatry, , Volume: 154, Issue:4, 1997
Iloperidone binding to human and rat dopamine and 5-HT receptors.European journal of pharmacology, , Dec-19, Volume: 317, Issue:2-3, 1996
Side effect profiles of new antipsychotic agents.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Comment: risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.The Annals of pharmacotherapy, , Volume: 36, Issue:7-8
[Mineralization of the basal ganglia as the supposed cause of poor tolerance of zuclopenthixol in a patient with long-term untreated paranoid schizophrenia].Psychiatria polska, , Volume: 47, Issue:4
Efficacy and Tolerability of Atypical Antipsychotics in the Treatment of Delirium: A Systematic Review of the Literature.Psychosomatics, , Volume: 60, Issue:1
Fahr's Disease Presenting with Manic Symptoms.JNMA; journal of the Nepal Medical Association, , Volume: 56, Issue:209
Meal patterns of free feeding rats treated with clozapine, olanzapine, or haloperidol.Pharmacology, biochemistry, and behavior, , Volume: 71, Issue:1-2
The utility of intramuscular ziprasidone in the management of acute psychotic agitation.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:3
Recurrent Catatonia: Infection and Immunity in an Idiopathic Illness.Journal of psychiatric practice, , 01-01, Volume: 29, Issue:1, 2023
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 129, Issue:11, 2022
Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: a retrospective study.BMC psychiatry, , 08-22, Volume: 22, Issue:1, 2022
Inhibitory Effects of Antipsychotics on the Contractile Response to Acetylcholine in Rat Urinary Bladder Smooth Muscles.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders.Pharmacology research & perspectives, , Volume: 9, Issue:5, 2021
Serotonin 2A (5-HTScientific reports, , 12-10, Volume: 10, Issue:1, 2020
30-year journey from the start of the Human Genome Project to clinical application of genomics in psychiatry: are we there yet?The lancet. Psychiatry, , Volume: 7, Issue:1, 2020
The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors.International clinical psychopharmacology, , Volume: 34, Issue:1, 2019
Basal Ganglia Calcification: A Case Report of Fahr Disease With Pure Psychiatric Symptoms.Journal of psychiatric practice, , Volume: 25, Issue:5, 2019
Association of First- vs. Second-Generation Antipsychotics with Lipid Abnormalities in Individuals with Severe Mental Illness: A Systematic Review and Meta-Analysis.Clinical drug investigation, , Volume: 39, Issue:3, 2019
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
A prospective naturalistic multicenter study on choice of parenteral medication in psychiatric emergency settings in Japan.Neuropsychopharmacology reports, , Volume: 38, Issue:3, 2018
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 49, 2018
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.The Cochrane database of systematic reviews, , Jan-22, Volume: 1, 2018
Medication and physical activity and physical fitness in severe mental illness.Psychiatry research, , Volume: 267, 2018
Olanzapine and haloperidol for the treatment of acute symptoms of mental disorders induced by amphetamine-type stimulants: A randomized controlled trial.Medicine, , Volume: 97, Issue:8, 2018
Age Impacts Olanzapine Exposure Differently During Use of Oral Versus Long-Acting Injectable Formulations: An Observational Study Including 8,288 Patients.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.JAMA psychiatry, , 08-01, Volume: 75, Issue:8, 2018
Does early antipsychotic response predict long-term treatment outcome?Human psychopharmacology, , Volume: 32, Issue:6, 2017
Hikikomori in Brazil: 29 years of Voluntary social Withdrawal.Asian journal of psychiatry, , Volume: 30, 2017
[Cushing's disease in a psychiatric setting].L'Encephale, , Volume: 43, Issue:5, 2017
Effects of olanzapine on LPS-induced inflammation in rat primary glia cells.Innate immunity, , Volume: 22, Issue:1, 2016
A Naturalistic Randomized Placebo-Controlled Trial of Extended-Release Metformin to Prevent Weight Gain Associated With Olanzapine in a US Community-Dwelling Population.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
Anti-N-methyl-D-aspartate receptor encephalitis is an important differential diagnosis in acute psychiatric disease.Acta psychiatrica Scandinavica, , Volume: 131, Issue:1, 2015
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
Antipsychotic use in pregnancy.Expert opinion on pharmacotherapy, , Volume: 16, Issue:9, 2015
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 12, Issue:1, 2015
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 54, Issue:9, 2015
The risk of metabolic disorders in patients treated with asenapine or olanzapine: a study conducted on real-world data in Italy and Spain.Expert opinion on drug safety, , Volume: 13, Issue:9, 2014
The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications.Journal of psychosocial nursing and mental health services, , Volume: 52, Issue:7, 2014
Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects.Journal of biomedical nanotechnology, , Volume: 10, Issue:6, 2014
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 53, Issue:11, 2014
Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.Diabetes, , Volume: 62, Issue:9, 2013
Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients.The pharmacogenomics journal, , Volume: 13, Issue:6, 2013
Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine.Molecular diagnosis & therapy, , Apr-01, Volume: 16, Issue:2, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.The Journal of clinical psychiatry, , Volume: 73, Issue:8, 2012
Olanzapine-induced neutropenia in a patient with systemiclupus erythematosus: a role of FcγRIIIb polymorphism?Lupus, , Volume: 21, Issue:1, 2012
Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study.International journal of psychiatry in clinical practice, , Volume: 16, Issue:1, 2012
Arsenic trioxide and olanzapine co-administration: case analysis.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, , Volume: 17, Issue:3, 2011
Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.Psychiatry research, , May-15, Volume: 187, Issue:1-2, 2011
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.European child & adolescent psychiatry, , Volume: 20, Issue:11-12, 2011
The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela.Schizophrenia research, , Volume: 126, Issue:1-3, 2011
Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics.Clinical nutrition (Edinburgh, Scotland), , Volume: 30, Issue:5, 2011
The use of Pro Re Nata or Statim medications for behavioral control: a summary of experience at a tertiary care children's mental health center.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:1, 2011
Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.Psychiatric services (Washington, D.C.), , Volume: 61, Issue:2, 2010
Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.Clinical therapeutics, , Volume: 32 Suppl 1, 2010
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.Bipolar disorders, , Volume: 12, Issue:2, 2010
Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:5, 2009
An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 54, Issue:4, 2009
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.The American journal of psychiatry, , Volume: 166, Issue:5, 2009
Olanzapine dosing above the licensed range is more efficacious than lower doses: fact or fiction?Expert review of neurotherapeutics, , Volume: 9, Issue:7, 2009
Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials.Psychopharmacology bulletin, , Volume: 42, Issue:4, 2009
The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.Pharmacoepidemiology and drug safety, , Volume: 18, Issue:9, 2009
[Huntington's disease: a negative family history case report demonstrating reduction of psychiatric symptoms with olanzapine].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 31, Issue:2, 2009
Priapism associated with olanzapine.Pakistan journal of biological sciences : PJBS, , Jan-15, Volume: 12, Issue:2, 2009
Comparison of predictive equations for resting metabolic rate in obese psychiatric patients taking olanzapine.Nutrition (Burbank, Los Angeles County, Calif.), , Volume: 25, Issue:2, 2009
Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.Journal of intellectual & developmental disability, , Volume: 34, Issue:3, 2009
Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents.Progress in neuro-psychopharmacology & biological psychiatry, , Nov-13, Volume: 33, Issue:8, 2009
Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
Three cases of schizophrenia for which olanzapine was effective after early acute phase.Psychiatry and clinical neurosciences, , Volume: 62, Issue:1, 2008
A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine.Pharmacopsychiatry, , Volume: 41, Issue:1, 2008
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.Pharmacy world & science : PWS, , Volume: 30, Issue:1, 2008
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.Clinical drug investigation, , Volume: 28, Issue:9, 2008
Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait.Medical principles and practice : international journal of the Kuwait University, Health Science Centre, , Volume: 17, Issue:5, 2008
Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:5, 2008
Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study.The British journal of psychiatry : the journal of mental science, , Volume: 192, Issue:5, 2008
Critical thinking about adverse drug effects: lessons from the psychology of risk and medical decision-making for clinical psychopharmacology.Psychotherapy and psychosomatics, , Volume: 77, Issue:4, 2008
Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Effect of antipsychotic drugs on brain morphometry. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-12, Volume: 32, Issue:8, 2008
A naturalistic study of consecutive agitated emergency department patients treated with intramuscular olanzapine prior to consent.The American journal of psychiatry, , Volume: 165, Issue:4, 2008
Observed clinical and health services outcomes in pediatric inpatients treated with atypical antipsychotics: 1999-2003.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:3, 2007
Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances.Journal of geriatric psychiatry and neurology, , Volume: 20, Issue:2, 2007
Effectiveness of olanzapine in neurosyphilis related organic psychosis: a case report.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:5, 2007
Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 114, Issue:2, 2007
Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine.BMJ (Clinical research ed.), , Oct-27, Volume: 335, Issue:7625, 2007
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.Molecular psychiatry, , Volume: 12, Issue:5, 2007
Metabolic effects of the atypical antipsychotics.Southern medical journal, , Volume: 100, Issue:8, 2007
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
[Application of neuroleptics for dementia].Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, , Volume: 44, Issue:1, 2007
The use of atypical antipsychotics in French psychiatric hospitals.Pharmacy world & science : PWS, , Volume: 29, Issue:5, 2007
Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia.Psychotherapy and psychosomatics, , Volume: 76, Issue:4, 2007
[Efficacy of atypical antipsychotics in patients with Alzheimer's dementia. CATIE-AD-Study (Clinical Antipsychotic Trials of Intervention Effectiveness Alzheimer's Disease)].Der Internist, , Volume: 48, Issue:6, 2007
No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.Minerva medica, , Volume: 97, Issue:2, 2006
Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:3, 2006
The effect of long-term antipsychotic treatment on prolactin.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:3, 2006
A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects.Clinical therapeutics, , Volume: 28, Issue:6, 2006
Atypical antipsychotic use for adult outpatients in New Zealand's Auckland and Northland regions.The New Zealand medical journal, , Jul-07, Volume: 119, Issue:1237, 2006
Olanzapine for recurrent excessive irritability and psychotic symptoms after mesial temporal lobectomy in a patient with temporal lobe epilepsy.Epilepsy & behavior : E&B, , Volume: 9, Issue:3, 2006
[Psychopharmacological treatment of behavioral and psychological symptoms in dementia].Ugeskrift for laeger, , Oct-02, Volume: 168, Issue:40, 2006
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.The New England journal of medicine, , Oct-12, Volume: 355, Issue:15, 2006
Real-life switching strategies with second-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.The Cochrane database of systematic reviews, , Jan-25, Issue:1, 2006
A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD). Favour.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population.The Journal of nervous and mental disease, , Volume: 193, Issue:6, 2005
Amantadine for weight gain associated with olanzapine treatment.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 15, Issue:1, 2005
Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
Atypical antipsychotics for nursing home patients: a retrospective chart review.Drugs & aging, , Volume: 22, Issue:3, 2005
Antipsychotic use in the elderly: shifting trends and increasing costs.International journal of geriatric psychiatry, , Volume: 20, Issue:8, 2005
Memory-sparing cognitive deterioration in the elderly: what is the diagnosis?Reviews in neurological diseases, ,Spring, Volume: 2, Issue:2, 2005
Rates and predictors of adherence with atypical antipsychotic medication: a follow-up study of adolescent inpatients.Journal of child and adolescent psychopharmacology, , Volume: 15, Issue:6, 2005
Comparison of large versus smaller randomized trials for mental health-related interventions.The American journal of psychiatry, , Volume: 162, Issue:3, 2005
Effects of age and sex on olanzapine plasma concentrations.Journal of clinical psychopharmacology, , Volume: 25, Issue:6, 2005
The management of psychogeriatric patient.Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
Orally disintegrating olanzapine: a possible alternative to injection of antipsychotic drugs.Journal of psychosocial nursing and mental health services, , Volume: 42, Issue:5, 2004
Neuroleptic malignant syndrome and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:8, 2004
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.The Journal of clinical psychiatry, , Volume: 65 Suppl 6, 2004
[The value of publishing negative results from a randomized controlled trial: the Rosenheck's study].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 26, Issue:2, 2004
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.Postgraduate medicine, , Volume: 116, Issue:4, 2004
Efficacy of atypical antipsychotics in elderly patients with dementia.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Results of a naturalistic study of treatment options: switching atypical antipsychotic drugs or augmenting with valproate.Clinical therapeutics, , Volume: 26, Issue:6, 2004
A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:8, 2004
Weight decline in patients switching from olanzapine to quetiapine.Schizophrenia research, , Sep-01, Volume: 70, Issue:1, 2004
Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication.Therapeutic drug monitoring, , Volume: 25, Issue:1, 2003
Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.Journal of the National Medical Association, , Volume: 95, Issue:2, 2003
Inpatient length of stay and atypical antipsychotic use among elderly patients with psychiatric disorders and Alzheimer's disease.Managed care interface, , Volume: 16, Issue:5, 2003
Use of atypical antipsychotic drugs in patients with dementia.American family physician, , Jun-01, Volume: 67, Issue:11, 2003
Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.The Annals of pharmacotherapy, , Volume: 37, Issue:9, 2003
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
A review of olanzapine-associated toxicity and fatality in overdose.Journal of psychiatry & neuroscience : JPN, , Volume: 28, Issue:4, 2003
[Psychotropic drugs used in a psychiatric hospital (pharmaco-epidemiologic aspects)].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.Southern medical journal, , Volume: 96, Issue:7, 2003
[Brain tumor].Ryoikibetsu shokogun shirizu, , Issue:40, 2003
The use of concomitant medications in psychiatric inpatients treated with either olanzapine or other antipsychotic agents: a naturalistic study at a state psychiatric hospital.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:3, 2002
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 41, Issue:3, 2002
Uses of olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:3, 2002
Hyperinsulinemia in psychiatric patients treated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:1, 2002
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
Hyperglycemia and hypertriglyceridemia secondary to olanzapine.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 11, Issue:3, 2001
Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy.Pharmacotherapy, , Volume: 21, Issue:11, 2001
Bodyweight gain with atypical antipsychotics. A comparative review.Drug safety, , Volume: 24, Issue:1, 2001
Six-month outcomes for patients who switched to olanzapine treatment.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:4, 2001
Possible neuroleptic malignant syndrome associated with olanzapine.The Annals of pharmacotherapy, , Volume: 34, Issue:5, 2000
Body weight and leptin plasma levels during treatment with antipsychotic drugs.The American journal of psychiatry, , Volume: 156, Issue:2, 1999
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
Olanzapine-induced neuroleptic malignant syndrome with mental retardation.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Conventional psychotropic-induced tremor extinguished by olanzapine.The American journal of psychiatry, , Volume: 155, Issue:8, 1998
Open-label olanzapine treatment in five preadolescent children.Journal of child and adolescent psychopharmacology, , Volume: 8, Issue:2, 1998
Use of atypical neuroleptics in child and adolescent psychiatry.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Psychiatry.JAMA, , Jun-18, Volume: 277, Issue:23, 1997
Magnitude of metabolic syndrome and its predictors among patients on second-generation antipsychotic drugs at six psychiatry clinics and mental hospitals, in Addis Ababa, Ethiopia, 2019; Multicenter cross-sectional study.Diabetes & metabolic syndrome, , Volume: 15, Issue:4
Clinical News.Clinical schizophrenia & related psychoses, , Volume: 11, Issue:1
The dosing of atypical antipsychotics.Psychosomatics, , Volume: 46, Issue:3
Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine.Nutrition (Burbank, Los Angeles County, Calif.), , Volume: 25, Issue:7-8
Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.Journal of the American Medical Directors Association, , Volume: 4, Issue:4
Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.American journal of Alzheimer's disease and other dementias, , Volume: 18, Issue:4
Mortality in patients with dementia treated with atypical antipsychotics (olanzapine, quetiapine and ziprasidone).Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, , Volume: 33, Issue:4
Psychotic syndrome secondary to meningioma treated with a low dose of olanzapine.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 37, Issue:2
Hypersensitivity syndrome with olanzapine confirmed by patch tests.European journal of dermatology : EJD, , Volume: 22, Issue:1
Psychiatric manifestations of anti-NMDA receptor encephalitis in a man without tumor.Psychosomatics, , Volume: 52, Issue:1
Spontaneous Ejaculations in an Adolescent With Olanzapine Use: Case Report.Clinical neuropharmacology, , Volume: 39, Issue:3
Antipsychotic medications and extreme weight gain in two health systems.Obesity research & clinical practice, , Volume: 10, Issue:4
New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment.Psychosomatics, , Volume: 40, Issue:5
Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.Psychosomatics, , Volume: 47, Issue:1
Acute Necrotizing Pancreatitis Associated With Orally Disintegrating Formulation of Olanzapine: Implications on Clinical Presentation and Management.Journal of clinical psychopharmacology, , Volume: 39, Issue:5
Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy.American journal of therapeutics, , Volume: 10, Issue:5
[Latin America: clinical responses to the antipsychotic drugs].Vertex (Buenos Aires, Argentina), , Volume: 16, Issue:62
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.BMJ mental health, , Volume: 26, Issue:1, 2023
Continuation of depot olanzapine pamoate after post-injection delirium/sedation syndrome (PDSS) in a case of bipolar mania-a clinical conundrum.Bipolar disorders, , Volume: 25, Issue:2, 2023
Effectiveness of atypical antipsychotics for unipolar and bipolar depression in adolescents and young adults: A systematic review and meta-analysis.Journal of affective disorders, , 10-15, Volume: 339, 2023
Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.The lancet. Psychiatry, , Volume: 10, Issue:9, 2023
The impact of pharmacological and non-pharmacological interventions on physical health outcomes in people with mood disorders across the lifespan: An umbrella review of the evidence from randomised controlled trials.Molecular psychiatry, , Volume: 28, Issue:1, 2023
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.CNS drugs, , Volume: 36, Issue:6, 2022
Evidence-based treatment strategies for rapid cycling bipolar disorder, a systematic review.Journal of affective disorders, , 08-15, Volume: 311, 2022
Personality disorder among youth with first episode psychotic mania: An important target for specific treatment?Early intervention in psychiatry, , Volume: 16, Issue:3, 2022
Can pediatric bipolar disorder be successfully treated when comorbid with conduct disorder? A secondary analysis of clinical trials of risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:5, 2022
Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?Expert review of neurotherapeutics, , Volume: 22, Issue:5, 2022
Serum levels of olanzapine are associated with acute cognitive effects in bipolar disorder.Psychiatry research, , Volume: 310, 2022
Manic syndrome in mitochondrial membrane protein-associated neurodegeneration: A case report.Psychiatry and clinical neurosciences, , Volume: 76, Issue:10, 2022
A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder.Acta psychiatrica Scandinavica, , Volume: 146, Issue:4, 2022
[Acute cholestatic hepatitis associated with olanzapine in a patient with bipolar disorder].Revue medicale de Liege, , Volume: 77, Issue:2, 2022
Olanzapine for the Treatment of Somatic Symptom Disorder: Biobehavioral Processes and Clinical Implications.Psychosomatic medicine, , 04-01, Volume: 84, Issue:3, 2022
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.The Annals of pharmacotherapy, , Volume: 56, Issue:9, 2022
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.Molecular psychiatry, , Volume: 27, Issue:2, 2022
Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 54, 2022
Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.Die Pharmazie, , 09-01, Volume: 77, Issue:7, 2022
Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.Expert review of clinical pharmacology, , Volume: 15, Issue:9, 2022
Proportion of subjects with psychotic features in bipolar disorder correlated with treatment response by antipsychotics for acute mania.Psychiatry and clinical neurosciences, , Volume: 76, Issue:11, 2022
Bipolar Disorder and Outcomes of Monotherapy with Lithium, Valproate, Quetiapine, Olanzapine, Venlafaxine, and Citalopram.Pharmacopsychiatry, , Volume: 54, Issue:3, 2021
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.The international journal of neuropsychopharmacology, , 10-23, Volume: 24, Issue:10, 2021
Olanzapine/Samidorphan: First Approval.Drugs, , Volume: 81, Issue:12, 2021
Slowly Working Toward More Treatments for Depression in Bipolar II Disorder.The American journal of psychiatry, , Volume: 178, Issue:12, 2021
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations.Bipolar disorders, , Volume: 23, Issue:8, 2021
Lurasidone-Induced Manic Switch in an Adolescent with Bipolar I Disorder: a Case Report.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 31, Issue:3, 2021
Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan.Neuropsychopharmacology reports, , Volume: 40, Issue:4, 2020
Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis.Journal of affective disorders, , 05-15, Volume: 269, 2020
How to treat mania.Acta psychiatrica Scandinavica, , Volume: 142, Issue:3, 2020
Predictors of 1-year rehospitalization in inpatients with bipolar I disorder treated with atypical antipsychotics.International clinical psychopharmacology, , Volume: 35, Issue:5, 2020
Pharmacological prevention of mood episodes in women with bipolar disorder during the perinatal period: A systematic review of current literature.Asian journal of psychiatry, , Volume: 52, 2020
Second Generation Antipsychotics Monotherapy as Maintenance Treatment for Bipolar Disorder: a Systematic Review of Long-Term Studies.The Psychiatric quarterly, , Volume: 91, Issue:4, 2020
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.Journal of affective disorders, , 12-01, Volume: 277, 2020
Exertional Heatstroke in a Marathon Runner Complicated by Concurrent Use of an Antipsychotic Medication Affecting Thermoregulation.Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine, , Volume: 30, Issue:5, 2020
Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics?Journal of affective disorders, , 01-15, Volume: 261, 2020
[no title available]Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 65, Issue:4, 2020
Prolactin response to antipsychotics: An inpatient study.PloS one, , Volume: 15, Issue:2, 2020
The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.Expert opinion on investigational drugs, , Volume: 29, Issue:3, 2020
Pica disorder as a symptom of depression in a patient with bipolar disorder and intellectual disability.Actas espanolas de psiquiatria, , Volume: 48, Issue:1, 2020
The unmasking of hidden severe hyponatremia after long-term combination therapy in exacerbated bipolar patients: a case series.International clinical psychopharmacology, , Volume: 34, Issue:4, 2019
Incidence and characteristics of the nocebo response from meta-analyses of the placebo arms of clinical trials of olanzapine for bipolar disorder.Bipolar disorders, , Volume: 21, Issue:2, 2019
Quetiapine extended-release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis.Neuropsychopharmacology reports, , Volume: 39, Issue:3, 2019
Lurasidone-Induced Mania.The primary care companion for CNS disorders, , Jul-11, Volume: 21, Issue:4, 2019
Erotomania in Depressive Psychosis: Mood Incongruent Delusion in a Depressive Young Woman.Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, , Volume: 29, Issue:6, 2019
[Mirtazapine-Induced Mania: A Case Report].Acta medica portuguesa, , Oct-01, Volume: 32, Issue:10, 2019
Generalised tonic-clonic seizures on the subtherapeutic dose of olanzapine.BMJ case reports, , Dec-29, Volume: 12, Issue:12, 2019
Patient Survival After Acute Voluntary Poisoning With a Huge Dose of Oxcarbazepine and Olanzapine.Medical archives (Sarajevo, Bosnia and Herzegovina), , Volume: 72, Issue:4, 2018
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
Paradoxical worsening of parkinsonism upon neuroleptic withdrawal: More common than we think?Parkinsonism & related disorders, , Volume: 52, 2018
Secondary mania following cancer chemotherapy with capecitabine.BMJ case reports, , Mar-28, Volume: 2018, 2018
A Review of Asenapine in the Treatment of Bipolar Disorder.Clinical drug investigation, , Volume: 38, Issue:2, 2018
Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 48, 2018
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.Bipolar disorders, , Volume: 20, Issue:2, 2018
Severity of symptoms in mania-clinical guidelines and study design implications.Bipolar disorders, , Volume: 20, Issue:2, 2018
Tailoring treatment dose according to severity of manic symptoms.Bipolar disorders, , Volume: 20, Issue:2, 2018
Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines.Acta psychiatrica Scandinavica, , Volume: 138, Issue:3, 2018
Evaluation of antioxidant potencial of novel CaAl and NiAl layered double hydroxides loaded with olanzapine.Life sciences, , Aug-15, Volume: 207, 2018
Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Journal of clinical psychopharmacology, , Volume: 37, Issue:2, 2017
Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.Drugs & aging, , Volume: 34, Issue:3, 2017
Pharmacological agents to reduce readmissions in bipolar disorder.Journal of psychopharmacology (Oxford, England), , Volume: 31, Issue:3, 2017
Is there a 'weight neutral' second-generation antipsychotic for bipolar disorder?Expert review of neurotherapeutics, , Volume: 17, Issue:4, 2017
Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.Journal of child and adolescent psychopharmacology, , Volume: 27, Issue:5, 2017
Reducing the rehospitalization risk after a manic episode: A population based cohort study of lithium, valproate, olanzapine, quetiapine and aripiprazole in monotherapy and combinations.Journal of affective disorders, , 08-01, Volume: 217, 2017
Have antipsychotics a different speed of action in the acute treatment of mania? A single-blind comparative study.Journal of psychopharmacology (Oxford, England), , Volume: 31, Issue:12, 2017
Treatment response in nonpsychotic vs psychotic manias - A follow up study from India.Asian journal of psychiatry, , Volume: 26, 2017
Do not treat the numbers: lithium toxicity.BMJ case reports, , Jun-02, Volume: 2017, 2017
Chlorpheniramine dependence presenting as mania.Asian journal of psychiatry, , Volume: 30, 2017
Olanzapine induced neuroleptic malignant syndrome, treated with electroconvulsive therapy (ECT)-A case report.Asian journal of psychiatry, , Volume: 30, 2017
DRESS syndrome: Addressing the drug hypersensitivity syndrome on combination of Sodium Valproate and Olanzapine.Asian journal of psychiatry, , Volume: 28, 2017
Individualising therapy using individual participant data.The lancet. Psychiatry, , Volume: 4, Issue:11, 2017
Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies.The lancet. Psychiatry, , Volume: 4, Issue:11, 2017
Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy.BMJ case reports, , Dec-02, Volume: 2017, 2017
Prophylactic use of olanzapine and quetiapine from pregnancy to the postpartum period in women with bipolar disorder: a case series.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, , Volume: 30, Issue:21, 2017
Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study.JAMA psychiatry, , 06-01, Volume: 73, Issue:6, 2016
Asenapine: A Review in Schizophrenia.CNS drugs, , Volume: 30, Issue:7, 2016
Atypical antipsychotic use and outcomes in an urban maternal mental health service.International journal of psychiatry in medicine, , Volume: 51, Issue:6, 2016
The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine.Psychiatry research, , Jul-30, Volume: 241, 2016
Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis.PloS one, , Volume: 11, Issue:3, 2016
Analysis of bipolar maintenance treatment with lithium versus olanzapine utilizing Multi-state Outcome Analysis of Treatments (MOAT).Bipolar disorders, , Volume: 18, Issue:3, 2016
Changes in mood stabilizer prescription patterns in bipolar disorder.Journal of affective disorders, , Volume: 195, 2016
Treatment of comorbid bipolar disorder and anxiety disorders: A great challenge to modern psychiatry.The Australian and New Zealand journal of psychiatry, , Volume: 50, Issue:7, 2016
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.Molecular psychiatry, , Volume: 21, Issue:8, 2016
Use of Orally Disintegrating Olanzapine During Electroconvulsive Therapy for Prevention of Postictal Agitation.Journal of psychiatric practice, , Volume: 22, Issue:6, 2016
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
Olanzapine and quetiapine use during breastfeeding: excretion into breast milk and safe breastfeeding strategy.Journal of clinical psychopharmacology, , Volume: 35, Issue:2, 2015
Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.The Journal of clinical psychiatry, , Volume: 76, Issue:6, 2015
Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 30, Issue:8, 2015
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients.Neuropsychobiology, , Volume: 72, Issue:1, 2015
Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.Bipolar disorders, , Volume: 17, Issue:6, 2015
Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study.BMC psychiatry, , Aug-05, Volume: 15, 2015
Evaluation of the safety profile of Zolafren®, a generic olanzapine formulation, in patients with bipolar disorder: a post-authorization safety study.Advances in therapy, , Volume: 32, Issue:5, 2015
Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder: common and specific effects of key regulators of fat-mass homoeostasis genes.Pharmacogenetics and genomics, , Volume: 25, Issue:7, 2015
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar disorders, , Volume: 17, Issue:5, 2015
Case records of the Massachusetts General Hospital. Case 10-2015. A 15-year-old girl with Graves’ disease and psychotic symptoms.The New England journal of medicine, , Mar-26, Volume: 372, Issue:13, 2015
Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.Acta psychiatrica Scandinavica, , Volume: 130, Issue:6, 2014
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
The impact of past direct-personal traumatic events on 12-month outcome in first episode psychotic mania: trauma and early psychotic mania.The Australian and New Zealand journal of psychiatry, , Volume: 48, Issue:11, 2014
The impact of insight in a first-episode mania with psychosis population on outcome at 18 months.Journal of affective disorders, , Volume: 167, 2014
Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context.Advances in therapy, , Volume: 31, Issue:8, 2014
Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5.Journal of affective disorders, , Volume: 168, 2014
Sleep architecture and cognitive changes in olanzapine-treated patients with depression: a double blind randomized placebo controlled trial.BMC psychiatry, , Jul-17, Volume: 14, 2014
Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.Journal of affective disorders, , Volume: 166, 2014
Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study.BMC psychiatry, , May-19, Volume: 14, 2014
Comparison of health services use associated with ziprasidone and olanzapine among schizophrenia and bipolar disorder patients in the USA.Clinical drug investigation, , Volume: 34, Issue:7, 2014
Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features.Journal of affective disorders, , Volume: 164, 2014
Acute and maintenance treatments for bipolar depression.The Journal of clinical psychiatry, , Volume: 75, Issue:4, 2014
Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 26, Issue:3, 2014
Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes.Journal of medical economics, , Volume: 17, Issue:7, 2014
An update on the treatment of mixed bipolar states: what is new in 2013?Journal of affective disorders, , Volume: 158, 2014
Bipolar disorder in Pendred syndrome: a case report of two siblings.The Australian and New Zealand journal of psychiatry, , Volume: 48, Issue:9, 2014
No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients.Pharmacogenetics and genomics, , Volume: 24, Issue:5, 2014
Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.The Journal of clinical psychiatry, , Volume: 75, Issue:3, 2014
Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study.Psychopharmacology, , Volume: 231, Issue:14, 2014
Cost-effectiveness of asenapine in the treatment of bipolar disorder in Canada.BMC psychiatry, , Jan-22, Volume: 14, 2014
Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysis.Psychiatry and clinical neurosciences, , Volume: 68, Issue:7, 2014
Interactions between valproic acid and quetiapine/olanzapine in the treatment of bipolar disorder and the role of therapeutic drug monitoring.The Journal of pharmacy and pharmacology, , Volume: 66, Issue:6, 2014
Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011.Journal of affective disorders, , Volume: 155, 2014
Restless legs syndrome associated with the combined use of quetiapine and venlafaxine.Journal of clinical psychopharmacology, , Volume: 34, Issue:1, 2014
Is the combination of a mood stabilizer plus an antipsychotic more effective than mono-therapies in long-term treatment of bipolar disorder? A systematic review.Journal of affective disorders, , Volume: 152-154, 2014
Melatonin decreases olanzapine induced metabolic side-effects in adolescents with bipolar disorder: a randomized double-blind placebo-controlled trial.Acta medica Iranica, , Volume: 52, Issue:10, 2014
SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.Pharmacogenomics, , Volume: 15, Issue:12, 2014
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.Journal of affective disorders, , Jan-25, Volume: 144, Issue:3, 2013
Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder.The Cochrane database of systematic reviews, , Oct-17, Issue:10, 2013
Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.BMC psychiatry, , Oct-04, Volume: 13, 2013
The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.Clinical drug investigation, , Volume: 33, Issue:10, 2013
Use of electroconvulsive therapy in an adolescent with systemic lupus erythematosus for management of depression.The journal of ECT, , Volume: 29, Issue:3, 2013
Olanzapine long-acting injection: When and for how long is oral supplementation required?The Australian and New Zealand journal of psychiatry, , Volume: 47, Issue:12, 2013
Safety of olanzapine use in adolescents.Expert opinion on drug safety, , Volume: 12, Issue:5, 2013
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.Current medical research and opinion, , Volume: 29, Issue:3, 2013
Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study.BMC psychiatry, , Jul-17, Volume: 13, 2013
Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression.Expert opinion on drug metabolism & toxicology, , Volume: 9, Issue:2, 2013
DSM-5 mixed specifier for manic episodes: evaluating the effect of depressive features on severity and treatment outcome using asenapine clinical trial data.Journal of affective disorders, , Sep-05, Volume: 150, Issue:2, 2013
[Olanzapine].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 71, Issue:4, 2013
Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study.BMC psychiatry, , May-14, Volume: 13, 2013
A case of atypical antipsychotic-induced somnambulism: a class effect.The Journal of clinical psychiatry, , Volume: 74, Issue:4, 2013
Could pramipexole induce acute mania? A case report.Bipolar disorders, , Volume: 15, Issue:4, 2013
Inhibition/activation in bipolar disorder: validation of the Multidimensional Assessment of Thymic States scale (MAThyS).BMC psychiatry, , Mar-13, Volume: 13, 2013
Efficacy of olanzapine monotherapy in acute bipolar depression: a pooled analysis of controlled studies.Journal of affective disorders, , Volume: 149, Issue:1-3, 2013
Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program.Journal of affective disorders, , Sep-25, Volume: 150, Issue:3, 2013
Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study.The Journal of clinical psychiatry, , Volume: 74, Issue:1, 2013
Effectiveness of short-term olanzapine in patients with bipolar I disorder, with or without comorbidity with substance use disorder.Journal of clinical psychopharmacology, , Volume: 33, Issue:2, 2013
Repeated activation of mania by atypical antipsychotics in a patient.BMJ case reports, , Nov-27, Volume: 2012, 2012
Health-related quality of life as measured by the child health questionnaire in adolescents with bipolar disorder treated with olanzapine.Comprehensive psychiatry, , Volume: 53, Issue:7, 2012
Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.PharmacoEconomics, , Jun-01, Volume: 30, Issue:6, 2012
Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study.Human psychopharmacology, , Volume: 27, Issue:3, 2012
Mortality risk with the use of atypical antipsychotics in later-life bipolar disorder.Journal of geriatric psychiatry and neurology, , Volume: 25, Issue:1, 2012
Pilot study of the efficacy of double-blind, placebo-controlled one-week olanzapine stabilization therapy in heterogeneous symptomatic bipolar disorder patients.Journal of psychiatric research, , Volume: 46, Issue:7, 2012
Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration.BMC medical genetics, , Oct-02, Volume: 13, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.The Journal of clinical psychiatry, , Volume: 73, Issue:8, 2012
A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode.Journal of affective disorders, , Volume: 138, Issue:3, 2012
A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.Journal of clinical psychopharmacology, , Volume: 32, Issue:2, 2012
Safety and efficacy of olanzapine monotherapy and olanzapine with a mood stabilizer in 18-week treatment of manic/mixed episodes for Japanese patients with bipolar I disorder.Current medical research and opinion, , Volume: 28, Issue:5, 2012
[Mania associated with Usher syndrome type II].Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Fall, Volume: 23, Issue:3, 2012
Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice.BMC psychiatry, , Dec-17, Volume: 12, 2012
Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression.The British journal of psychiatry : the journal of mental science, , Volume: 201, Issue:5, 2012
Variables as mediators or moderators in predicting relapse to any type of mood episode in a bipolar maintenance study.The Journal of clinical psychiatry, , Volume: 73, Issue:7, 2012
Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009.Psychiatric services (Washington, D.C.), , Volume: 63, Issue:1, 2012
Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Efficacy and safety of olanzapine in the treatment of Japanese patients with bipolar I disorder in a current manic or mixed episode: a randomized, double-blind, placebo- and haloperidol-controlled study.Journal of affective disorders, , Volume: 136, Issue:3, 2012
Olanzapine-associated priapism.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
Subtypes of antipsychotics and suicidal behavior in bipolar disorder.Journal of affective disorders, , Dec-20, Volume: 143, Issue:1-3, 2012
[Asenapine in bipolar disorder: efficacy, safety and place in clinical practice].L'Encephale, , Volume: 38, Issue:3, 2012
UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.Clinical pharmacology and therapeutics, , Volume: 92, Issue:2, 2012
Olanzapine-induced anaphylactic shock: a case report.Pharmacopsychiatry, , Volume: 45, Issue:1, 2012
Age-grouped differences in bipolar mania.Comprehensive psychiatry, , Volume: 53, Issue:8, 2012
Predictors of relapse or recurrence in bipolar I disorder.Journal of affective disorders, , Volume: 136, Issue:3, 2012
Olanzapine and benztropine as a cause of ischemic colitis in a 27-year-old man.Journal of clinical gastroenterology, , Volume: 46, Issue:6, 2012
Comparative efficacy and acceptability of mood stabilizer and second generation antipsychotic monotherapy for acute mania--a systematic review and meta-analysis.Journal of affective disorders, , Volume: 134, Issue:1-3, 2011
Relationship between African-American or Caucasian origin and outcomes in the olanzapine treatment of acute mania: a pooled analysis of three adult studies conducted in the United States of America.International clinical psychopharmacology, , Volume: 26, Issue:3, 2011
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.European child & adolescent psychiatry, , Volume: 20, Issue:11-12, 2011
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.Pharmacotherapy, , Volume: 31, Issue:8, 2011
Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania--results of a two year observational study in bipolar disorder (EMBLEM).Journal of affective disorders, , Volume: 131, Issue:1-3, 2011
Clinical practice. Bipolar disorder--a focus on depression.The New England journal of medicine, , Jan-06, Volume: 364, Issue:1, 2011
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 23, Issue:3, 2011
Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.Psychiatry research, , Sep-30, Volume: 189, Issue:2, 2011
One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis.BMC psychiatry, , Jan-07, Volume: 11, 2011
Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.Pharmacogenetics and genomics, , Volume: 21, Issue:9, 2011
Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials.BMC psychiatry, , Jun-20, Volume: 11, 2011
Delirium associated with olanzapine therapy in an elderly man with bipolar affective disorder.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 23, Issue:2, 2011
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.Acta psychiatrica Scandinavica, , Volume: 124, Issue:3, 2011
[Second generation antipsychotics in bipolar depression: a new therapeutic option?].L'Encephale, , Volume: 37 Suppl 3, 2011
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 33, Issue:1, 2011
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.The Journal of clinical psychiatry, , Volume: 72, Issue:4, 2011
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clinical drug investigation, , Volume: 31, Issue:7, 2011
Early symptom change and prediction of subsequent remission with olanzapine augmentation in divalproex-resistant bipolar mixed episodes.Journal of psychiatric research, , Volume: 45, Issue:2, 2011
Clinical utility of early improvement to predict response or remission in acute mania: focus on olanzapine and risperidone.The Journal of clinical psychiatry, , Volume: 72, Issue:9, 2011
Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009.PloS one, , Volume: 6, Issue:12, 2011
Behavioral and pharmacological assessment of a potential new mouse model for mania.Physiology & behavior, , Jun-01, Volume: 103, Issue:3-4, 2011
Olanzapine-induced parkinsonism associated with smoking cessation.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Mar-01, Volume: 68, Issue:5, 2011
Asenapine: a review of its use in the management of mania in adults with bipolar I disorder.CNS drugs, , Volume: 25, Issue:3, 2011
Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention.Bipolar disorders, , Volume: 13, Issue:1, 2011
Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.The Journal of clinical psychiatry, , Volume: 72, Issue:6, 2011
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.British journal of clinical pharmacology, , Volume: 71, Issue:3, 2011
[Evidence of treatment for depressive episodes of bipolar disorder].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 113, Issue:9, 2011
Safety and efficacy of olanzapine monotherapy in treatment-resistant bipolar mania: a 12-week open-label study.Human psychopharmacology, , Volume: 26, Issue:8, 2011
The need to consider mood disorders, and especially chronic mania, in cases of Diogenes syndrome (squalor syndrome).International psychogeriatrics, , Volume: 23, Issue:3, 2011
Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
[Mood disorder after malaria prophylaxis with mefloquine (two case reports)].L'Encephale, , Volume: 37, Issue:5, 2011
Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression.Journal of affective disorders, , Volume: 130, Issue:1-2, 2011
Olanzapine enhances anxiety response to an SSRI in a woman with bipolar disorder.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-15, Volume: 35, Issue:1, 2011
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).Journal of affective disorders, , Volume: 124, Issue:1-2, 2010
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Genetic association study of treatment response with olanzapine/fluoxetine combination or lamotrigine in bipolar I depression.The Journal of clinical psychiatry, , Volume: 71, Issue:5, 2010
Olanzapine monotherapy for acute depression in patients with bipolar I or II disorder: results of an 8-week open label trial.Human psychopharmacology, , Volume: 25, Issue:1, 2010
Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment.The Annals of pharmacotherapy, , Volume: 44, Issue:4, 2010
Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.Journal of affective disorders, , Volume: 122, Issue:1-2, 2010
Acute pancreatitis associated with lisinopril and olanzapine.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Feb-01, Volume: 67, Issue:3, 2010
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:2, 2010
Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.The Journal of clinical psychiatry, , Volume: 71, Issue:4, 2010
Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.Paediatric drugs, , Volume: 12, Issue:3, 2010
A Canadian naturalistic study of a community-based cohort treated for bipolar disorder.BMC psychiatry, , Mar-19, Volume: 10, 2010
Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:4, 2010
Olanzapine: in adolescents with schizophrenia or bipolar I disorder.CNS drugs, , Volume: 24, Issue:5, 2010
Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder.Bipolar disorders, , Volume: 12, Issue:2, 2010
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.Bipolar disorders, , Volume: 12, Issue:2, 2010
In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 25, Issue:8, 2010
Manic and psychotic symptoms following subcutaneous leuprolide in a male patient with no prior psychiatric history.The Journal of clinical psychiatry, , Volume: 71, Issue:12, 2010
Olanzapine in the long-term treatment of bipolar disorder: a systematic review and meta-analysis.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:12, 2010
Olanzapine: a review of rapid and long-acting parenteral formulations.Drugs of today (Barcelona, Spain : 1998), , Volume: 46, Issue:3, 2010
Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.Psychopharmacology bulletin, , Volume: 43, Issue:4, 2010
[Quetiapine, an antipsychotic agent to consider in the differential diagnosis of convulsions].Revista espanola de anestesiologia y reanimacion, , Volume: 57, Issue:5, 2010
Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice.International clinical psychopharmacology, , Volume: 25, Issue:5, 2010
Asenapine for long-term treatment of bipolar disorder: a double-blind 40-week extension study.Journal of affective disorders, , Volume: 126, Issue:3, 2010
Maintenance treatment received by patients with bipolar I and II disorders--a naturalistic prospective study.Journal of affective disorders, , Volume: 121, Issue:1-2, 2010
Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder.PharmacoEconomics, , Volume: 28, Issue:9, 2010
Efficacy of olanzapine and sodium valproate given alone or as add-on therapy in acute mania. A comparative study.Methods and findings in experimental and clinical pharmacology, , Volume: 32, Issue:5, 2010
[Intensive care treatment for neuroleptic malignant syndrome].Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, , Volume: 45, Issue:7-8, 2010
Pharmacokinetic drug-drug interactions between olanzapine and valproate need to be better studied.The Journal of clinical psychiatry, , Volume: 71, Issue:7, 2010
Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.The Journal of clinical psychiatry, , Volume: 71, Issue:10, 2010
Cannabidiol was ineffective for manic episode of bipolar affective disorder.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Treatment options for bipolar depression: a systematic review of randomized, controlled trials.Journal of clinical psychopharmacology, , Volume: 30, Issue:5, 2010
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.The international journal of neuropsychopharmacology, , Volume: 13, Issue:1, 2010
An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.International journal of clinical practice, , Volume: 64, Issue:11, 2010
Regulation of glycogen synthase kinase-3 during bipolar mania treatment.Bipolar disorders, , Volume: 12, Issue:7, 2010
Olanzapine vs. lithium in management of acute mania.Journal of affective disorders, , Volume: 122, Issue:3, 2010
Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.Therapeutic drug monitoring, , Volume: 31, Issue:6, 2009
Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder.Journal of child and adolescent psychopharmacology, , Volume: 19, Issue:5, 2009
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.The Journal of clinical psychiatry, , Volume: 70, Issue:10, 2009
Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder.Journal of affective disorders, , Volume: 116, Issue:1-2, 2009
Number needed to treat or harm analyses of olanzapine for maintenance treatment of bipolar disorder.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a double-blind, placebo-controlled study.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression.The international journal of neuropsychopharmacology, , Volume: 12, Issue:6, 2009
Delirious mania associated with bipolar disease in a Brazilian patient: response to ECT and olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 21, Issue:4, 2009
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:1, 2009
The role of divalproex plus olanzapine in outpatient mixed-episode bipolar I disorder.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
Olanzapine in long-term treatment for bipolar disorder.The Cochrane database of systematic reviews, , Jan-21, Issue:1, 2009
Plasma homovanillic acid and family history of psychotic disorders in bipolar I patients.Pharmacological research, , Volume: 59, Issue:4, 2009
Neurotoxicity with therapeutic lithium levels: a case report.Journal of psychiatric practice, , Volume: 15, Issue:1, 2009
The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials.The Journal of clinical psychiatry, , Volume: 70, Issue:2, 2009
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
Revised Korean medication algorithm for bipolar disorder.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Refractory restless legs syndrome likely caused by olanzapine.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, , Feb-15, Volume: 5, Issue:1, 2009
Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients.Journal of affective disorders, , Volume: 119, Issue:1-3, 2009
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.BMC psychiatry, , Mar-28, Volume: 9, 2009
Attention deficit hyperactivity disorder erroneously diagnosed and treated as bipolar disorder.Journal of attention disorders, , Volume: 13, Issue:2, 2009
Asenapine versus olanzapine in acute mania: a double-blind extension study.Bipolar disorders, , Volume: 11, Issue:8, 2009
A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.Bipolar disorders, , Volume: 11, Issue:7, 2009
Clarithromycin-induced mania in a child.International journal of clinical pharmacology and therapeutics, , Volume: 47, Issue:6, 2009
Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.Journal of medical economics, , Volume: 12, Issue:2, 2009
Longer-term treatment of patients with bipolar disorder: a 9-month observational study in Central and Eastern Europe, the Middle East and Africa.Current medical research and opinion, , Volume: 25, Issue:8, 2009
Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.International journal of clinical practice, , Volume: 63, Issue:8, 2009
Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:1, 2009
Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis.Clinical therapeutics, , Volume: 31 Pt 1, 2009
FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse.JAMA, , Aug-26, Volume: 302, Issue:8, 2009
Treatment-resistant bipolar depression: towards a new definition.Acta psychiatrica Scandinavica, , Volume: 120, Issue:6, 2009
Neuropsychiatric complications associated with interferon - alpha -2b treatment of malignant melanoma.African journal of psychiatry, , Volume: 12, Issue:3, 2009
Weight gain with atypical antipsychotic drugs in bipolar disorder.Journal of psychosocial nursing and mental health services, , Volume: 47, Issue:9, 2009
Olanzapine-associated new-onset atrial fibrillation.Journal of clinical psychopharmacology, , Volume: 28, Issue:3, 2008
[Use of olanzapine in adolescent with bipolar disorder after neuroleptic malignant syndrome].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:1, 2008
Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Switching from other agents to extended-release carbamazepine in acute mania.Psychopharmacology bulletin, , Volume: 41, Issue:1, 2008
Photo-onycholysis caused by olanzapine and aripiprazole.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Hyperthermia and rhabdomyolysis in an adolescent treated with topiramate and olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:1, 2008
Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: a randomized, single-blind, pilot study.The Journal of clinical psychiatry, , Volume: 69, Issue:4, 2008
Going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania.Journal of affective disorders, , Volume: 110, Issue:1-2, 2008
Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes.The British journal of psychiatry : the journal of mental science, , Volume: 192, Issue:2, 2008
Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes.Schizophrenia research, , Volume: 100, Issue:1-3, 2008
Olanzapine for the treatment of bipolar disorder in children and adolescents.Expert opinion on pharmacotherapy, , Volume: 9, Issue:3, 2008
Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.The Journal of clinical psychiatry, , Volume: 69, Issue:11, 2008
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Evaluating dose response from flexible dose clinical trials.BMC psychiatry, , Jan-07, Volume: 8, 2008
Treating mania in Wilson's disease with lithium.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 20, Issue:4, 2008
Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
The empirical redefinition of the psychometric criteria for remission in bipolar disorder.Journal of affective disorders, , Volume: 106, Issue:1-2, 2008
Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.Journal of affective disorders, , Volume: 105, Issue:1-3, 2008
Somnambulism secondary to olanzapine treatment in one patient with bipolar disorder.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
An analysis of the efficacy of treatments for bipolar depression.The Journal of clinical psychiatry, , Volume: 69 Suppl 5, 2008
The clinical dilemma--prescribing in pregnancy.Psychiatria Danubina, , Volume: 20, Issue:1, 2008
Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study.Journal of affective disorders, , Volume: 106, Issue:1-2, 2008
The Bipolar Comprehensive Outcomes Study (BCOS): baseline findings of an Australian cohort study.Journal of affective disorders, , Volume: 107, Issue:1-3, 2008
A case of sodium oxybate treatment of tardive dyskinesia and bipolar disorder.The Journal of clinical psychiatry, , Volume: 69, Issue:5, 2008
Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder.Pharmacopsychiatry, , Volume: 41, Issue:5, 2008
[Olanzapine].Deutsche medizinische Wochenschrift (1946), , Volume: 133, Issue:39, 2008
Olanzapine orally disintegrating tablet: a review of efficacy and compliance.CNS neuroscience & therapeutics, ,Fall, Volume: 14, Issue:3, 2008
Cost-saving effects of olanzapine as long-term treatment for bipolar disorder.The journal of mental health policy and economics, , Volume: 11, Issue:3, 2008
Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.Journal of affective disorders, , Volume: 105, Issue:1-3, 2008
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.Bipolar disorders, , Volume: 9, Issue:6, 2007
Atypical antipsychotics in bipolar disorder: systematic review of randomised trials.BMC psychiatry, , Aug-16, Volume: 7, 2007
Effect of comorbid anxiety on treatment response in bipolar depression.Journal of affective disorders, , Volume: 104, Issue:1-3, 2007
Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Jan-15, Volume: 17, Issue:2, 2007
Atypical antipsychotics related metabolic syndrome in bipolar patients.Journal of affective disorders, , Volume: 98, Issue:3, 2007
[Olanzapine: a second generation antipsychotic drug and an "atypical" mood stabilizer?].Psychiatria Hungarica : A Magyar Pszichiatriai Tarsasag tudomanyos folyoirata, , Volume: 22, Issue:4, 2007
A case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain.The Journal of clinical psychiatry, , Volume: 68, Issue:12, 2007
Orally disintegrating olanzapine for the treatment of a manic patient with esophageal stricture plus chronic pharyngitis.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 31, Issue:2, 2007
An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.Human psychopharmacology, , Volume: 22, Issue:7, 2007
Cost effectiveness of olanzapine in prevention of affective episodes in bipolar disorder in the United Kingdom.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:6, 2007
Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse.Journal of affective disorders, , Volume: 99, Issue:1-3, 2007
Simultaneous high-performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients.Therapeutic drug monitoring, , Volume: 29, Issue:6, 2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.The American journal of managed care, , Volume: 13, Issue:7 Suppl, 2007
Acute phase results from STORM, a multicountry observational study of bipolar disorder treatment and outcomes.Psychiatria Danubina, , Volume: 19, Issue:4, 2007
[Electroconvulsive therapy in therapy-resistant mania. A case study].Tijdschrift voor psychiatrie, , Volume: 49, Issue:11, 2007
Measured and expected resting energy expenditure in patients with bipolar disorder on maintenance treatment.Bipolar disorders, , Volume: 9, Issue:7, 2007
Practical strategies for assessing and stabilizing bipolar patients in urgent situations.The Journal of clinical psychiatry, , Volume: 68, Issue:10, 2007
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder.Health technology assessment (Winchester, England), , Volume: 11, Issue:39, 2007
The effectiveness criterion: balancing efficacy against the risks of weight gain.The Journal of clinical psychiatry, , Volume: 68 Suppl 12, 2007
Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.Human psychopharmacology, , Volume: 22, Issue:1, 2007
Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.The Annals of pharmacotherapy, , Volume: 41, Issue:11, 2007
Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study.Journal of affective disorders, , Volume: 104, Issue:1-3, 2007
Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder.Current medical research and opinion, , Volume: 23, Issue:11, 2007
Severe hyperlipidemia associated with olanzapine and quetiapine use.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Olanzapine versus placebo in the treatment of adolescents with bipolar mania.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Olanzapine and pediatric bipolar disorder: evidence for efficacy and safety concerns.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
[Vigency of lithium treatment].Medicina clinica, , Jan-13, Volume: 128, Issue:1, 2007
Characteristics of psychotic patients with foreign accent syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 19, Issue:1, 2007
Outcomes for Latin American versus White patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
A double-blind comparison of the effect of the antipsychotics haloperidol and olanzapine on sleep in mania.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, , Volume: 40, Issue:3, 2007
A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder.Acta psychiatrica Scandinavica. Supplementum, , Issue:434, 2007
Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: post hoc analysis of patients treated with olanzapine or lithium.Journal of psychiatric research, , Volume: 41, Issue:7, 2007
Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications.Bipolar disorders, , Volume: 9, Issue:3, 2007
The use of atypical antipsychotics in French psychiatric hospitals.Pharmacy world & science : PWS, , Volume: 29, Issue:5, 2007
Bilateral pedal edema associated with olanzapine use in manic episode of bipolar disorder: report of two cases.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 31, Issue:7, 2007
Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder.The Tohoku journal of experimental medicine, , Volume: 213, Issue:1, 2007
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Early predictors of substantial weight gain in bipolar patients treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
Open-label olanzapine treatment in bipolar I disorder: clinical and work functional outcomes.Current medical research and opinion, , Volume: 22, Issue:5, 2006
Injectable atypical antipsychotics for agitation in borderline personality disorder.Pharmacopsychiatry, , Volume: 39, Issue:3, 2006
Adjunctive olanzapine treatment in bipolar adolescents responding insufficiently to mood stabilizers. Four case reports.European child & adolescent psychiatry, , Volume: 15, Issue:8, 2006
Case report: edema related to olanzapine therapy.Canadian family physician Medecin de famille canadien, , Volume: 52, 2006
A retrospective analysis of changing from alternative agents to carbamazepine extended-release capsules in bipolar disorder.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18 Suppl 1, 2006
Olanzapine: a 5-year perspective.Expert review of neurotherapeutics, , Volume: 6, Issue:6, 2006
The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder.Journal of managed care pharmacy : JMCP, , Volume: 12, Issue:4, 2006
Efficacy of olanzapine and haloperidol in an animal model of mania.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.The Journal of clinical psychiatry, , Volume: 67, Issue:5, 2006
Haloperidol alone or in combination for acute mania.The Cochrane database of systematic reviews, , Jul-19, Issue:3, 2006
Long-term use of atypical antipsychotics in bipolar disorder.Pharmacotherapy, , Volume: 26, Issue:8, 2006
Lamotrigine-induced severe manic switch.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:8, 2006
Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine.Journal of managed care pharmacy : JMCP, , Volume: 12, Issue:3, 2006
Tiagabine withdrawal-emergent mania.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:8, 2006
Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder.Bipolar disorders, , Volume: 8, Issue:4, 2006
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.The Journal of clinical psychiatry, , Volume: 67, Issue:7, 2006
Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex.The Journal of clinical psychiatry, , Volume: 67, Issue:8, 2006
Maintenance treatment of bipolar disorder: Applying research to clinical practice.Journal of psychiatric practice, , Volume: 12, Issue:5, 2006
Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: a retrospective study.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
Does olanzapine have any antidepressant effect?The American journal of psychiatry, , Volume: 163, Issue:10, 2006
Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-30, Volume: 30, Issue:6, 2006
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.Therapeutic drug monitoring, , Volume: 28, Issue:5, 2006
Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic states.Nordic journal of psychiatry, , Volume: 60, Issue:2, 2006
Pulmonary embolism associated with olanzapine.Thrombosis and haemostasis, , Volume: 96, Issue:5, 2006
Black hairy tongue associated with olanzapine treatment: a case report.The Mount Sinai journal of medicine, New York, , Volume: 73, Issue:6, 2006
Influence of sub-syndromal symptoms after remission from manic or mixed episodes.The British journal of psychiatry : the journal of mental science, , Volume: 189, 2006
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.Bipolar disorders, , Volume: 8, Issue:6, 2006
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.The Journal of clinical psychiatry, , Volume: 67, Issue:11, 2006
[New formulations of olanzapine in the treatment of acute agitation].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Stuporous catatonia in an elderly bipolar patient: response to olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:5, 2006
Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice.Current medical research and opinion, , Volume: 22, Issue:12, 2006
A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:6, 2006
Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine.The American journal of psychiatry, , Volume: 163, Issue:2, 2006
Olanzapine/fluoxetine combination for bipolar depression.Expert review of neurotherapeutics, , Volume: 6, Issue:1, 2006
Stevens-Johnson syndrome (SJS) leading to resolution of mania.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:2, 2006
A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:1, 2006
[Olanzapine in the treatment of bipolar disorder].Psychiatrische Praxis, , Volume: 33 Suppl 1, 2006
[Pharmacotherapy of manic-depressive mixed States].Psychiatrische Praxis, , Volume: 33 Suppl 1, 2006
Paradoxical dyskinesia with olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 18, Issue:1, 2006
Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder--a preliminary report.Journal of affective disorders, , Volume: 92, Issue:2-3, 2006
Olanzapine - relapse prevention following mania.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:2 Suppl, 2006
A review of the evidence for the use of antipsychotics in the maintenance treatment of bipolar disorders.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:2 Suppl, 2006
Clinical relevance of depressive symptom improvement in bipolar I depressed patients.Journal of affective disorders, , Volume: 92, Issue:2-3, 2006
Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 67, Issue:2, 2006
Spotlight on olanzapine in bipolar I disorder.CNS drugs, , Volume: 19, Issue:6, 2005
Recovery and functional outcomes following olanzapine treatment for bipolar I mania.Bipolar disorders, , Volume: 7, Issue:1, 2005
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorders, , Volume: 7 Suppl 3, 2005
Olanzapine and olanzapine-fluoxetine combination treatment and bipolar I depression.Archives of general psychiatry, , Volume: 62, Issue:9, 2005
Treatment options for bipolar depression.The Journal of clinical psychiatry, , Volume: 66 Suppl 1, 2005
Atypical antipsychotics: newer options for mania and maintenance therapy.Bipolar disorders, , Volume: 7 Suppl 4, 2005
Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial.The American journal of psychiatry, , Volume: 162, Issue:7, 2005
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:6, 2005
Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction.Journal of affective disorders, , Volume: 87, Issue:1, 2005
Memory-sparing cognitive deterioration in the elderly: what is the diagnosis?Reviews in neurological diseases, ,Spring, Volume: 2, Issue:2, 2005
Effective maintenance treatment--breaking the cycle of bipolar disorder.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial.Current medical research and opinion, , Volume: 21, Issue:4, 2005
Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression.The Journal of clinical psychiatry, , Volume: 66, Issue:5, 2005
[Humor in bipolar disorder].L'Encephale, , Volume: 31 Pt 2, 2005
Neuroleptic malignant syndrome due to three atypical antipsychotics in a child.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:4, 2005
A typical mood stabilizers: a "typical role for atypical antipsychotics.Acta psychiatrica Scandinavica. Supplementum, , Issue:426, 2005
Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:4, 2005
[Rabbit syndrome due to olanzapine].Psychiatrische Praxis, , Volume: 32, Issue:4, 2005
Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report.Journal of Korean medical science, , Volume: 20, Issue:4, 2005
Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.Journal of managed care pharmacy : JMCP, , Volume: 11, Issue:3, 2005
The treatment of mixed states and the risk of switching to depression.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:2, 2005
Update on the treatment of bipolar disorder in children and adolescents.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:2, 2005
Management options for bipolar disorder in children and adolescents.Paediatric drugs, , Volume: 7, Issue:5, 2005
Newer treatment studies for bipolar depression.Bipolar disorders, , Volume: 7 Suppl 5, 2005
Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children.Biological psychiatry, , Oct-01, Volume: 58, Issue:7, 2005
Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data.Journal of affective disorders, , Volume: 89, Issue:1-3, 2005
Olanzapine co-therapy in bipolar disorder.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Women are not the same as men: specific clinical issues for female patients with bipolar disorder.Bipolar disorders, , Volume: 7 Suppl 1, 2005
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.The Journal of clinical psychiatry, , Volume: 66 Suppl 3, 2005
Bipolar disorder.Clinical evidence, , Issue:13, 2005
Typical and atypical antipsychotics in bipolar depression.The Journal of clinical psychiatry, , Volume: 66, Issue:11, 2005
Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.Psychopharmacology, , Volume: 181, Issue:1, 2005
Outcome measurement, outcome management and monitoring.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:8, 2005
Atypical antipsychotics in bipolar depression: potential mechanisms of action.The Journal of clinical psychiatry, , Volume: 66 Suppl 5, 2005
Clinical highlights in bipolar depression: focus on atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66 Suppl 5, 2005
Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments.Journal of clinical psychopharmacology, , Volume: 25, Issue:4, 2005
Olanzapine-induced diabetes in a seven-year-old boy.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
Obsessive-compulsive symptoms with olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:3, 2004
The use of two neuroleptics to treat bipolar illness in two children.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
An overview of primary care assessment and management of bipolar disorder.The Journal of the American Osteopathic Association, , Volume: 104, Issue:6 Suppl 6, 2004
Olanzapine in bipolar disorder.Expert opinion on pharmacotherapy, , Volume: 5, Issue:7, 2004
[Therapeutic and pharmacological effects of second-generation antipsychotics on drug-resistant bipolar depression].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 106, Issue:8, 2004
DO comments on bipolar disorder supplement.The Journal of the American Osteopathic Association, , Volume: 104, Issue:12, 2004
Olanzapine-induced neutropenia: mechanism and treatment.Journal of clinical psychopharmacology, , Volume: 24, Issue:2, 2004
Weight gain during treatment of bipolar I patients with olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
Mania and hypomania with olanzapine use.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:3, 2004
A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder.Health technology assessment (Winchester, England), , Volume: 8, Issue:19, 2004
Irreversible priapism during olanzapine and lithium therapy.The Australian and New Zealand journal of psychiatry, , Volume: 38, Issue:5, 2004
Olanzapine may cause delirium in geriatric patients.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Novel antipsychotics in bipolar and schizoaffective mania.Acta psychiatrica Scandinavica, , Volume: 109, Issue:6, 2004
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.The Journal of clinical psychiatry, , Volume: 65 Suppl 6, 2004
A case of bipolar disorder and typhoid fever.International journal of psychiatry in medicine, , Volume: 34, Issue:3, 2004
An excitement subscale of the Positive and Negative Syndrome Scale.Schizophrenia research, , Jun-01, Volume: 68, Issue:2-3, 2004
An open-label trial of olanzapine for corticosteroid-induced mood symptoms.Journal of affective disorders, , Volume: 83, Issue:2-3, 2004
Employing pharmacologic treatment of bipolar disorder to greatest effect.The Journal of clinical psychiatry, , Volume: 65 Suppl 15, 2004
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Strategies for preventing the recurrence of bipolar disorder.The Journal of clinical psychiatry, , Volume: 65 Suppl 10, 2004
Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Use of olanzapine in the treatment of bipolar I disorder.Expert review of neurotherapeutics, , Volume: 4, Issue:5, 2004
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.The British journal of psychiatry : the journal of mental science, , Volume: 184, 2004
New drug available for bipolar disorder.The Nurse practitioner, , Volume: 29, Issue:3, 2004
Olanzapine: a review of its use in the management of bipolar I disorder.Drugs, , Volume: 64, Issue:23, 2004
Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder.Journal of clinical psychopharmacology, , Volume: 24, Issue:4, 2004
Olanzapine/Fluoxetine (Symbyax) for bipolar depression.The Medical letter on drugs and therapeutics, , Mar-15, Volume: 46, Issue:1178, 2004
Effects on weight and outcome of long-term olanzapine-topiramate combination treatment in bipolar disorder.Journal of clinical psychopharmacology, , Volume: 24, Issue:4, 2004
The antidepressant effects of risperidone and olanzapine in bipolar disorder.The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, ,Fall, Volume: 11, Issue:2, 2004
Open label study of the effect of amantadine on weight gain induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 58, Issue:2, 2004
Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial.Clinical therapeutics, , Volume: 26, Issue:1, 2004
Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data.The Journal of clinical psychiatry, , Volume: 65, Issue:10, 2004
Bipolar depression: an overview.IDrugs : the investigational drugs journal, , Volume: 7, Issue:9, 2004
Effective use of olanzapine for obsessive-compulsive symptoms in a patient with bipolar disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:8, 2004
Improvement of Positive and Negative Syndrome Scale cognitive score associated with olanzapine treatment of acute mania.Current medical research and opinion, , Volume: 20, Issue:9, 2004
The risk of harm in mania and the very early time course of improvement: important but neglected variables in treatment research.Bipolar disorders, , Volume: 6, Issue:5, 2004
Bipolar depression: the role of atypical antipsychotics.Expert review of neurotherapeutics, , Volume: 4, Issue:6 Suppl 2, 2004
Olanzapine-induced clitoral priapism.Journal of clinical psychopharmacology, , Volume: 24, Issue:5, 2004
Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid.Journal of affective disorders, , Volume: 81, Issue:3, 2004
Successful treatment of sexual dysfunction with dronabinol: a case report.The Journal of clinical psychiatry, , Volume: 65, Issue:8, 2004
[Zyprexa--various dosage forms, the goal: improving the prognosis for patients with schizophrenia and bipolar disorders].Krankenpflege Journal, , Volume: 42, Issue:3-4, 2004
Major advances in bipolar disorder.The Medical journal of Australia, , Aug-16, Volume: 181, Issue:4, 2004
[Long-term therapy with intuition].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
[Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania.Journal of affective disorders, , Volume: 73, Issue:1-2, 2003
Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling.Journal of affective disorders, , Volume: 73, Issue:1-2, 2003
[Treatment of acute bipolar disorder. Intriguing balancing act between mania and depression].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
Effect of olanzapine on the liver transaminases.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:3, 2003
Olanzapine induced "typical" neuroleptic malignant syndrome.Journal of clinical psychopharmacology, , Volume: 23, Issue:1, 2003
Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.Pharmacotherapy, , Volume: 23, Issue:2, 2003
Alternatives to lithium and divalproex in the maintenance treatment of bipolar disorder.Bipolar disorders, , Volume: 5, Issue:3, 2003
Calming versus sedative effects of intramuscular olanzapine in agitated patients.The American journal of emergency medicine, , Volume: 21, Issue:3, 2003
The combination of olanzapine and fluoxetine in mood disorders.Expert opinion on pharmacotherapy, , Volume: 4, Issue:7, 2003
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.The American journal of psychiatry, , Volume: 160, Issue:7, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
Difficult-to-treat depressions: a primary care perspective.The Journal of clinical psychiatry, , Volume: 64 Suppl 1, 2003
[Manic phase (manic episode)].Ryoikibetsu shokogun shirizu, , Issue:38, 2003
Olanzapine alone or in combination for acute mania.The Cochrane database of systematic reviews, , Issue:3, 2003
Antipsychotic-induced weight gain: bipolar disorder and leptin.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Olanzapine versus placebo in acute mania: treatment responses in subgroups.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Potential use of olanzapine in treatment of substance dependence disorders.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Acute dysphoric mania: treatment response to olanzapine versus placebo.Journal of clinical psychopharmacology, , Volume: 23, Issue:2, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Olanzapine-associated bilateral pedal edema.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.Southern medical journal, , Volume: 96, Issue:7, 2003
[Olanzapine (Zyprexa)--reliable in acute treatment, prevention of recurrence and long-term mood stabilization].Krankenpflege Journal, , Volume: 41, Issue:10-12, 2003
Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania.Bipolar disorders, , Volume: 5, Issue:1, 2003
[Bipolar disorders. Differential therapy for control of mood swings].Krankenpflege Journal, , Volume: 41, Issue:7-9, 2003
Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics.Bipolar disorders, , Volume: 5 Suppl 2, 2003
A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.Archives of general psychiatry, , Volume: 60, Issue:12, 2003
Divalproex versus olanzapine in mania.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
Treating acute mania.The Journal of family practice, , Volume: Suppl, 2003
Treating bipolar depression.The Journal of family practice, , Volume: Suppl, 2003
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
Long-term therapy of bipolar illness.The Journal of family practice, , Volume: Suppl, 2003
Optimal dosing of medications (in bipolar disorder).The Journal of family practice, , Volume: Suppl, 2003
Safety in treating bipolar disorder.The Journal of family practice, , Volume: Suppl, 2003
Improving identification of treatment effectiveness in bipolar disorders.Bipolar disorders, , Volume: 5, Issue:2, 2003
Assessment of treatment response in mania: commentary and new findings.Bipolar disorders, , Volume: 5, Issue:2, 2003
The efficacy of olanzapine monotherapy for acute hypomania or mania in an outpatient setting.International clinical psychopharmacology, , Volume: 18, Issue:3, 2003
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes.The Journal of clinical psychiatry, , Volume: 64, Issue:3, 2003
Selecting effective long-term treatment for bipolar patients: monotherapy and combinations.The Journal of clinical psychiatry, , Volume: 64 Suppl 5, 2003
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.Archives of general psychiatry, , Volume: 60, Issue:11, 2003
Sleep-related eating disorder induced by olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:7, 2002
Acute dystonic reaction in an elderly patient with mood disorder after titration of paroxetine: possible mechanisms and implications for clinical care.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:4, 2002
Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders.Bipolar disorders, , Volume: 4, Issue:5, 2002
A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.International clinical psychopharmacology, , Volume: 17, Issue:5, 2002
Olanzapine and improvement of tardive dyskinesia.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:7, 2002
Treatment of bipolar I rapid cycling patients during dysphoric mania with olanzapine.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Olanzapine-induced hair loss.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 47, Issue:9, 2002
Can olanzapine be implicated in causing serotonin syndrome?Psychiatry and clinical neurosciences, , Volume: 56, Issue:5, 2002
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.Archives of general psychiatry, , Volume: 59, Issue:1, 2002
A correction.Archives of general psychiatry, , Volume: 59, Issue:1, 2002
Olanzapine in acute bipolar mania.Archives of general psychiatry, , Volume: 59, Issue:2, 2002
The role of novel antipsychotics in bipolar disorders.The Journal of clinical psychiatry, , Volume: 63 Suppl 3, 2002
Psychotropic drugs and adverse events in the treatment of bipolar disorders revisited.The Journal of clinical psychiatry, , Volume: 63 Suppl 3, 2002
Olanzapine versus divalproex in the treatment of acute mania.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
The impact of response to previous mood stabilizer therapy on response to olanzapine versus placebo for acute mania.Bipolar disorders, , Volume: 4, Issue:1, 2002
Olanzapine-induced mania in bipolar disorders.Journal of psychiatry & neuroscience : JPN, , Volume: 27, Issue:3, 2002
Olanzapine-associated type 2 diabetes mellitus.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial.Journal of affective disorders, , Volume: 69, Issue:1-3, 2002
Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder.Psychopharmacology, , Volume: 162, Issue:1, 2002
Pharmacotherapy of bipolar disorder: the role of atypical antipsychotics and experimental strategies.Human psychopharmacology, , Volume: 17, Issue:8, 2002
Cognitive behavior therapy for weight gain.The American journal of psychiatry, , Volume: 158, Issue:6, 2001
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.The Journal of clinical psychiatry, , Volume: 62, Issue:7, 2001
Use of olanzapine in dysphoric mania.Journal of affective disorders, , Volume: 66, Issue:2-3, 2001
Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.Journal of clinical psychopharmacology, , Volume: 21, Issue:5, 2001
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 11, Issue:3, 2001
Olanzapine: a review of its use in the treatment of bipolar I disorder.CNS drugs, , Volume: 15, Issue:11, 2001
Use of atypical antipsychotics in mood disorders.Current opinion in investigational drugs (London, England : 2000), , Volume: 2, Issue:7, 2001
Lethal catatonia responding to high-dose olanzapine therapy.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:4, 2001
Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania.The Journal of clinical psychiatry, , Volume: 62, Issue:12, 2001
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.Schizophrenia bulletin, , Volume: 27, Issue:4, 2001
Introduction: a new era in the pharmacotherapy of psychotic disorders.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.Journal of affective disorders, , Volume: 67, Issue:1-3, 2001
Olanzapine-lnduced hyperglycemic nonketonic coma.The Annals of pharmacotherapy, , Volume: 35, Issue:3, 2001
Manic symptoms induced by olanzapine.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 11, Issue:2, 2001
Use of olanzapine in non-psychotic psychiatric disorders.Expert opinion on pharmacotherapy, , Volume: 2, Issue:4, 2001
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
Improvement of tardive dyskinesia in a bipolar patient with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 15, Issue:7, 2000
Olanzapine to treat the acute mania of bipolar disorder.South Dakota journal of medicine, , Volume: 53, Issue:12, 2000
Olanzapine-induced urinary incontinence: treatment with ephedrine.The Journal of clinical psychiatry, , Volume: 61, Issue:8, 2000
An ever-increasing pharmacopoeia for the management of patients with bipolar disorder.The Journal of clinical psychiatry, , Volume: 61 Supp 13, 2000
New treatments for bipolar disorder: the role of atypical neuroleptic agents.The Journal of clinical psychiatry, , Volume: 61 Suppl 14, 2000
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.Archives of general psychiatry, , Volume: 57, Issue:9, 2000
Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.South Dakota journal of medicine, , Volume: 53, Issue:2, 2000
Possible risperidone-induced visual hallucinations.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 39, Issue:9, 2000
Mood stabilizer augmentation with olanzapine in acutely manic children.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 10, Issue:1, 2000
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.East African medical journal, , Volume: 77, Issue:2, 2000
Antipsychotic drug side effect issues in bipolar manic patients.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Summary from the 153rd meeting of the American Psychiatric Association. 13-18 May 2000, Chicago, Illinois, USA.Expert opinion on pharmacotherapy, , Volume: 1, Issue:5, 2000
Response to placebo among bipolar I disorder patients experiencing their first manic episode.Bipolar disorders, , Volume: 2, Issue:4, 2000
Does olanzapine have antidepressant properties? A retrospective preliminary study.Bipolar disorders, , Volume: 2, Issue:3 Pt 1, 2000
Failure to consider drug-drug interactions as a likely cause of behavioral deterioration in a patient with bipolar disorder.Journal of clinical psychopharmacology, , Volume: 20, Issue:3, 2000
Treatment of bipolar I disorder in an adolescent with olanzapine.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 10, Issue:2, 2000
Olanzapine response in psychotic depression.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Recurrence of neuroleptic malignant syndrome with olanzapine treatment.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
Olanzapine compared to lithium in mania: a double-blind randomized controlled trial.International clinical psychopharmacology, , Volume: 14, Issue:6, 1999
Hypomania-like syndrome induced by olanzapine.International clinical psychopharmacology, , Volume: 14, Issue:6, 1999
Management of acute mania.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Tardive dyskinesia in affective disorders.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Is olanzapine a mood stabilizer?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
New treatments of bipolar disorder.Current psychiatry reports, , Volume: 1, Issue:2, 1999
Olanzapine-induced psychotic mania in bipolar schizoaffective disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:6, 1999
High-dose olanzapine in an adolescent.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 38, Issue:5, 1999
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Olanzapine-induced psychotic mania in bipolar schizo-affective disorder.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 14, Issue:7, 1999
Olanzapine-induced tardive dystonia.The American journal of psychiatry, , Volume: 156, Issue:10, 1999
Treatment of bipolar mixed state with olanzapine.Journal of psychiatry & neuroscience : JPN, , Volume: 24, Issue:1, 1999
Olanzapine-induced mania.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Olanzapine in the treatment of adolescent acute mania: a report of seven cases.Journal of affective disorders, , Volume: 53, Issue:3, 1999
Olanzapine for mixed episodes of bipolar disorder.Journal of psychopharmacology (Oxford, England), , Volume: 13, Issue:2, 1999
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Olanzapine-induced manic-like syndrome.The Journal of clinical psychiatry, , Volume: 59, Issue:6, 1998
Olanzapine and negative symptoms.The Journal of clinical psychiatry, , Volume: 59, Issue:10, 1998
Olanzapine-induced mania.The Journal of the American Osteopathic Association, , Volume: 98, Issue:10, 1998
Olanzapine in treatment-resistant bipolar disorder.Journal of affective disorders, , Volume: 49, Issue:2, 1998
Neuroleptic malignant syndrome associated with olanzapine.The Annals of pharmacotherapy, , Volume: 32, Issue:11, 1998
Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics.Journal of affective disorders, , Volume: 48, Issue:2-3, 1998
Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states.The Journal of clinical psychiatry, , Volume: 59, Issue:2, 1998
Clinical predictors of acute response with olanzapine in psychotic mood disorders.The Journal of clinical psychiatry, , Volume: 59, Issue:1, 1998
Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment.Journal of psychiatry & neuroscience : JPN, , Volume: 23, Issue:5, 1998
Mania associated with olanzapine.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 37, Issue:2, 1998
Antipsychotic agents and bipolar disorder.The Journal of clinical psychiatry, , Volume: 59 Suppl 1, 1998
Aggression, agitation, and mania with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:10, 1998
Adjunctive use of olanzapine in mood disorders: five case reports.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 9, Issue:4, 1997
Effective treatment of mania with olanzapine: 2 case reports.Journal of psychiatry & neuroscience : JPN, , Volume: 22, Issue:5, 1997
Cost analysis of the adverse reactions of bipolar disorder treatment with aripiprazole and olanzapine in Spain.Actas espanolas de psiquiatria, , Volume: 42, Issue:5
Comparison of the Metabolic Characteristics of Newer Second Generation Antipsychotics: Brexpiprazole, Lurasidone, Asenapine, Cariprazine, and Iloperidone With Olanzapine as a Comparator.Journal of clinical psychopharmacology, , Volume: 41, Issue:1
Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder.Indian journal of pharmacology, , Volume: 46, Issue:4
Fahr's Disease Presenting with Manic Symptoms.JNMA; journal of the Nepal Medical Association, , Volume: 56, Issue:209
Olanzapine-induced bilateral pedal edema: a case report.General hospital psychiatry, , Volume: 22, Issue:4
The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression.Harvard review of psychiatry, , Volume: 18, Issue:1
[Antipsychotics in bipolar disorders].L'Encephale, , Volume: 30, Issue:5
Long-Term Treatment of Bipolar Disorder with Valproate: Updated Systematic Review and Meta-analyses.Harvard review of psychiatry, , Volume: 29, Issue:3
Olanzapine and quetiapine in the prevention of a new mood episode in women with bipolar disorder during the postpartum period: a retrospective cohort study.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 43, Issue:6
[A case of mania following olanzapine administration].Psychiatria polska, , Volume: 34, Issue:2
The case for atypical antipsychotics in bipolar disorder.Perspectives in psychiatric care, , Volume: 40, Issue:1
[Mood stabilizers in the treatment of bipolar disorder mixed states].Rivista di psichiatria, , Volume: 47, Issue:4
Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study.Advances in therapy, , Volume: 24, Issue:1
Mania secondary to right-sided stroke--responsive to olanzapine.General hospital psychiatry, , Volume: 28, Issue:3
[Methodological proposals for the evaluation of the mood stabilizing effect of an antipsychotic drug].L'Encephale, , Volume: 25, Issue:6
Secondary mania in a patient with delayed anoxic encephalopathy after carbon monoxide intoxication caused by a suicide attempt.General hospital psychiatry, , Volume: 36, Issue:1
Recurrent mania associated with repeated brain injury.General hospital psychiatry, , Volume: 26, Issue:6
Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder.Rivista di psichiatria, , Volume: 54, Issue:1
The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:3
[Olanzapine in manic/mixed patients with or without substance abuse].Rivista di psichiatria, , Volume: 48, Issue:2
Baseline Characteristics and Early Response at Week 1 Predict Treatment Outcome in Adolescents With Bipolar Manic or Mixed Episode Treated With Olanzapine: Results From a 3-Week, Randomized, Placebo-Controlled Trial.The Journal of clinical psychiatry, , Volume: 78, Issue:9
Challenges Faced When Caring for Foreign Nationals With Comorbid Medical and Psychiatric Problems in the General Hospital.Psychosomatics, , Volume: 59, Issue:1
Olanzapine induced neuroleptic malignant syndrome.Indian journal of pharmacology, , Volume: 45, Issue:1
The diagnosis of Asperger's syndrome in an adult presenting with an index episode of mania by Ng et al.General hospital psychiatry, , Volume: 26, Issue:2
Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.Journal of clinical psychopharmacology, , Volume: 39, Issue:4
[Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].Actas espanolas de psiquiatria, , Volume: 32, Issue:5
Olanzapine-lithium encephalopathy.Psychosomatics, , Volume: 42, Issue:4
Acute massive pulmonary embolism associated with olanzapine therapy and no significant personal history in a young male--case report and literature review.Pneumologia (Bucharest, Romania), , Volume: 60, Issue:2
A case of mania due to cryptococcal meningitis, successfully treated with adjunctive olanzapine, in a patient with acquired immunodeficiency syndrome.General hospital psychiatry, , Volume: 33, Issue:3
Olanzapine usage associated with neuroleptic malignant syndrome.Psychosomatics, , Volume: 42, Issue:6
Mania in a case of hyperparathyroidism.Psychosomatics, , Volume: 48, Issue:3
[Therapeutic options in manic states].L'Encephale, , Volume: 29, Issue:Pt 2
Pseudotumor cerebri in a patient being treated for bipolar disorder.General hospital psychiatry, , Volume: 32, Issue:4
Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients.Comprehensive psychiatry, , Volume: 52, Issue:6
Mania: psychiatric manifestations of the antiphospholipid syndrome.Psychosomatics, , Volume: 49, Issue:5
Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic.The journal of behavioral health services & research, , Volume: 32, Issue:4
Profound hypertriglyceridemia and weight gain in the first week following initiation of olanzapine: a case report with implications for lipid monitoring guidelines.Psychosomatics, , Volume: 54, Issue:4
Priapism following olanzapine administration in a patient with multiple sclerosis.Psychosomatics, , Volume: 39, Issue:3
Acute dystonia with intramuscular olanzapine in adolescent mania: a report.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:11-12
Antipsychotic Therapy-Induced New Onset Diabetic Ketoacidosis.American journal of therapeutics, , Volume: 23, Issue:6
Milieu management of a child with bipolar illness.Journal of child and adolescent psychiatric nursing : official publication of the Association of Child and Adolescent Psychiatric Nurses, Inc, , Volume: 18, Issue:3
Breastfed Infants Exposed to Combined Antipsychotics: Two Case Reports.American journal of therapeutics, , Volume: 23, Issue:6
Long-term observational comparison of risperidone and olanzapine in bipolar disorder.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:2
The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.Journal of clinical psychopharmacology, , Volume: 39, Issue:6
Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials.Journal of clinical psychopharmacology, , Volume: 40, Issue:2
Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model.Journal of psychiatric research, , Volume: 115, 2019
Birth weight and use of olanzapine in pregnancy: a prospective comparative study.Journal of clinical psychopharmacology, , Volume: 30, Issue:3, 2010
Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study.The British journal of psychiatry : the journal of mental science, , Volume: 192, Issue:5, 2008
Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China.Asian journal of psychiatry, , Volume: 84, 2023
Intranasal administration of olanzapine has beneficial outcome in a rat activity-based anorexia model.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 71, 2023
Chronic agmatine treatment prevents olanzapine-induced obesity and metabolic dysregulation in female rats.Brain research bulletin, , Volume: 191, 2022
Modulation of hypothalamic AMPK phosphorylation by olanzapine controls energy balance and body weight.Metabolism: clinical and experimental, , Volume: 137, 2022
Olanzapine causes non-alcoholic fatty liver disease via inhibiting the secretion of apolipoprotein A5.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, , Jun-28, Volume: 47, Issue:6, 2022
Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments.BMC psychiatry, , 03-21, Volume: 22, Issue:1, 2022
Sex Differences in Fish Oil and Olanzapine Effects on Gut Microbiota in Diet-Induced Obese Mice.Nutrients, , Jan-14, Volume: 14, Issue:2, 2022
Crosstalk of hypothalamic chemerin, histamine, and AMPK in diet-and olanzapine-induced obesity in rats.Life sciences, , Nov-01, Volume: 284, 2021
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.Journal of clinical pharmacology, , Volume: 61, Issue:11, 2021
Effect of Bifidobacterium on olanzapine-induced body weight and appetite changes in patients with psychosis.Psychopharmacology, , Volume: 238, Issue:9, 2021
The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study.Annals of palliative medicine, , Volume: 10, Issue:5, 2021
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.Psychiatry research, , Volume: 296, 2021
Standardizing the Effective Correlated Dosage of Olanzapine and Empagliflozin in Female Wistar Rats.Current gene therapy, , Volume: 21, Issue:1, 2021
Coadministration of metformin prevents olanzapine-induced metabolic dysfunction and regulates the gut-liver axis in rats.Psychopharmacology, , Volume: 238, Issue:1, 2021
Effects of long-term antipsychotics treatment on body weight: A population-based cohort study.Journal of psychopharmacology (Oxford, England), , Volume: 34, Issue:1, 2020
Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane.The Journal of nutritional biochemistry, , Volume: 81, 2020
Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain.Physiology & behavior, , 06-01, Volume: 220, 2020
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.Life sciences, , Apr-15, Volume: 247, 2020
Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial.Psychopharmacology, , Volume: 236, Issue:6, 2019
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.Toxicology and applied pharmacology, , 09-01, Volume: 378, 2019
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.Acta psychiatrica Scandinavica, , Volume: 139, Issue:1, 2019
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.Psychoneuroendocrinology, , Volume: 108, 2019
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5, 2018
A role of neuropeptide CART in hyperphagia and weight gain induced by olanzapine treatment in rats.Brain research, , 09-15, Volume: 1695, 2018
Early prediction of olanzapine-induced weight gain for schizophrenia patients.Psychiatry research, , Volume: 263, 2018
A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-02, Volume: 81, 2018
Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.Psychopharmacology, , Volume: 235, Issue:12, 2018
Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia.BMJ open, , 08-17, Volume: 8, Issue:8, 2018
Liraglutide prevents metabolic side-effects and improves recognition and working memory during antipsychotic treatment in rats.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5, 2018
Regulation of obesity-associated metabolic disturbance by the antipsychotic drug olanzapine: Role of the autophagy-lysosome pathway.Biochemical pharmacology, , Volume: 158, 2018
Stabilization treatment of remitted psychotic depression: the STOP-PD study.Acta psychiatrica Scandinavica, , Volume: 138, Issue:3, 2018
Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:10, 2018
The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study.European child & adolescent psychiatry, , Volume: 26, Issue:1, 2017
Lack of Ovarian Secretions Reverts the Anabolic Action of Olanzapine in Female Rats.The international journal of neuropsychopharmacology, , 12-01, Volume: 20, Issue:12, 2017
Roman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expression.Journal of psychopharmacology (Oxford, England), , Volume: 31, Issue:11, 2017
The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C.The Journal of clinical investigation, , Sep-01, Volume: 127, Issue:9, 2017
Protective effects of green tea on olanzapine-induced-metabolic syndrome in rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 92, 2017
Prevention of the adverse effects of olanzapine on lipid metabolism with the antiepileptic zonisamide.Neuropharmacology, , Sep-01, Volume: 123, 2017
Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 27, Issue:7, 2017
Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.Journal of child and adolescent psychopharmacology, , Volume: 27, Issue:5, 2017
Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female Sprague-Dawley rats.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:12, 2015
Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:12, 2015
[The perception gap between clinical trials and clinical practice].Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology, , Volume: 28, Issue:1, 2015
Effects of glucose and disorders in lipid metabolism on cytokine levels and cognitive impairment in the olanzapine-induced obesity rat model.Genetics and molecular research : GMR, , Sep-25, Volume: 14, Issue:3, 2015
Effects of lisdexamfetamine in a rat model of binge-eating.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:12, 2015
GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.Metabolic brain disease, , Volume: 30, Issue:2, 2015
GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine.The Journal of neuropsychiatry and clinical neurosciences, , Volume: 27, Issue:2, 2015
Meal-induced insulin sensitization is preserved after acute olanzapine administration in female Sprague-Dawley rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 388, Issue:5, 2015
Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 23, Issue:9, 2015
Olanzapine depot exposure in male rats: Dose-dependent lipogenic effects without concomitant weight gain.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 25, Issue:6, 2015
A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 39, Issue:6, 2014
Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.The Journal of clinical psychiatry, , Volume: 75, Issue:3, 2014
Olanzapine reduced brown adipose tissue thermogenesis and locomotor activity in female rats.Progress in neuro-psychopharmacology & biological psychiatry, , Jun-03, Volume: 51, 2014
Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine.Psychopharmacology, , Volume: 231, Issue:20, 2014
Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.International clinical psychopharmacology, , Volume: 29, Issue:6, 2014
Subchronic olanzapine treatment decreases the expression of pancreatic glucose transporter 2 in rat pancreatic β cells.Journal of endocrinological investigation, , Volume: 37, Issue:7, 2014
Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats.Endocrinology, , Volume: 155, Issue:12, 2014
Effects of olanzapine on the elevation of macrophage infiltration and pro-inflammatory cytokine expression in female rats.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:12, 2014
Chronic olanzapine administration in rats: effect of route of administration on weight, food intake and body composition.Pharmacology, biochemistry, and behavior, , Volume: 103, Issue:4, 2013
Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function.The international journal of neuropsychopharmacology, , Volume: 16, Issue:7, 2013
No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia.Schizophrenia research, , Volume: 146, Issue:1-3, 2013
Endocrine and testicular changes induced by olanzapine in adult Wistar rats.Journal of applied toxicology : JAT, , Volume: 33, Issue:1, 2013
A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.Psychopharmacology, , Volume: 230, Issue:1, 2013
Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.Psychopharmacology, , Volume: 225, Issue:3, 2013
Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.Behavioral and brain functions : BBF, , Jul-19, Volume: 9, 2013
Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 25, Issue:3, 2013
Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80.Pharmacopsychiatry, , Volume: 46, Issue:7, 2013
A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.The Journal of clinical psychiatry, , Volume: 74, Issue:10, 2013
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.The Journal of clinical psychiatry, , Volume: 74, Issue:11, 2013
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.Molecular psychiatry, , Volume: 18, Issue:5, 2013
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-10, Volume: 40, 2013
Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study.International journal of psychiatry in clinical practice, , Volume: 16, Issue:1, 2012
Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 36, Issue:2, 2012
Subjective and biological weight-related parameters in adolescents and young adults with schizophrenia spectrum disorder under clozapine or olanzapine treatment.Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 40, Issue:3, 2012
Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.Journal of clinical psychopharmacology, , Volume: 32, Issue:4, 2012
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:5, 2012
Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.The international journal of neuropsychopharmacology, , Volume: 15, Issue:2, 2012
Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.Psychiatry research, , Oct-30, Volume: 199, Issue:3, 2012
Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study.Human psychopharmacology, , Volume: 27, Issue:3, 2012
Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters.Psychopharmacology, , Volume: 221, Issue:1, 2012
Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 37, Issue:7, 2012
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
Chronic treatment with olanzapine via a novel infusion pump induces adiposity in male rats.Life sciences, , Apr-25, Volume: 88, Issue:17-18, 2011
Behavioral and pharmacological assessment of a potential new mouse model for mania.Physiology & behavior, , Jun-01, Volume: 103, Issue:3-4, 2011
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:3, 2011
Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.Schizophrenia research, , Volume: 130, Issue:1-3, 2011
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.Psychiatry research, , Aug-15, Volume: 188, Issue:3, 2011
A placebo-controlled pilot study of adjunctive olanzapine for adolescents with anorexia nervosa.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:3, 2011
No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:3, 2011
Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.Archives of physiology and biochemistry, , Volume: 117, Issue:4, 2011
A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats.Cellular and molecular neurobiology, , Volume: 31, Issue:7, 2011
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).The American journal of psychiatry, , Volume: 168, Issue:9, 2011
Effects of orally disintegrating vs regular olanzapine tablets on body weight, eating behavior, glycemic and lipid indices, and gastrointestinal hormones: a randomized, open comparison in outpatients with bipolar depression.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 23, Issue:3, 2011
Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain.Journal of neurochemistry, , Volume: 119, Issue:2, 2011
Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.Human psychopharmacology, , Volume: 26, Issue:6, 2011
A six-to-ten weeks' follow-up study on the effects of olanzapine on abdominal fat and other metabolic parameters in patients with psychoses--an imaging-based study with controls.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 21, Issue:1, 2011
A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.PloS one, , Volume: 6, Issue:8, 2011
Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:5, 2011
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 35, Issue:2, 2011
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.European child & adolescent psychiatry, , Volume: 20, Issue:11-12, 2011
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.Pharmacogenetics and genomics, , Volume: 20, Issue:6, 2010
The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-16, Volume: 34, Issue:6, 2010
Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity.Journal of child and adolescent psychopharmacology, , Volume: 20, Issue:2, 2010
Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study.Journal of clinical pharmacy and therapeutics, , Volume: 35, Issue:2, 2010
Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.International journal of obesity (2005), , Volume: 34, Issue:6, 2010
Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice.Biochemical and biophysical research communications, , Mar-05, Volume: 393, Issue:2, 2010
Impact of smoking cessation on psychiatric inpatients treated with clozapine or olanzapine.Journal of psychiatric practice, , Volume: 16, Issue:2, 2010
Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.Diabetes, obesity & metabolism, , Volume: 12, Issue:6, 2010
Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.European journal of clinical pharmacology, , Volume: 66, Issue:5, 2010
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.The Cochrane database of systematic reviews, , Dec-08, Issue:12, 2010
Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 18, Issue:8, 2010
Effect of lactational exposure of olanzapine on body weight of mice: a comparative study on neonates of both the sexes during post-natal development.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Additive effects of olanzapine and melanin-concentrating hormone agonism on energy balance.Behavioural brain research, , Feb-11, Volume: 207, Issue:1, 2010
Olanzapine increases cell mitotic activity and oligodendrocyte-lineage cells in the hypothalamus.Neurochemistry international, , Volume: 57, Issue:5, 2010
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:7, 2010
Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 19, Issue:8, 2009
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.Biological psychiatry, , Mar-15, Volume: 65, Issue:6, 2009
A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.Bipolar disorders, , Volume: 11, Issue:7, 2009
A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.Schizophrenia research, , Volume: 113, Issue:1, 2009
30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.Journal of psychiatric research, , Volume: 43, Issue:11, 2009
Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Olanzapine treatment in anorexia nervosa: case report.Psychiatria Danubina, , Volume: 21, Issue:1, 2009
Aripiprazole for the management of olanzapine-induced weight gain.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.Human psychopharmacology, , Volume: 24, Issue:3, 2009
The role of thermogenesis in antipsychotic drug-induced weight gain.Obesity (Silver Spring, Md.), , Volume: 17, Issue:1, 2009
Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.Journal of psychiatric research, , Volume: 43, Issue:6, 2009
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.Pharmacopsychiatry, , Volume: 42, Issue:1, 2009
Listing of metabolic changes in healthy volunteers receiving orally dissolving olanzapine or oral olanzapine: data from a clinical study that was terminated early.Schizophrenia research, , Volume: 115, Issue:2-3, 2009
The risks and benefits of switching antipsychotics: a case study approach.Perspectives in psychiatric care, , Volume: 45, Issue:1, 2009
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 70, Issue:3, 2009
Correlates of response to Olanzapine in a North Indian Schizophrenia sample.Psychiatry research, , Dec-15, Volume: 161, Issue:3, 2008
Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:5, 2008
Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial.The American journal of psychiatry, , Volume: 165, Issue:10, 2008
Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagiaThe Journal of pharmacology and experimental therapeutics, , Volume: 326, Issue:3, 2008
The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
Insulin resistance following continuous, chronic olanzapine treatment: an animal model.Schizophrenia research, , Volume: 104, Issue:1-3, 2008
Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine.Journal of Korean medical science, , Volume: 23, Issue:4, 2008
Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-12, Volume: 32, Issue:8, 2008
Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities.Journal of intellectual disability research : JIDR, , Volume: 52, Issue:Pt 2, 2008
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.Journal of psychiatric research, , Volume: 42, Issue:13, 2008
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:12, 2008
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 23, Issue:8, 2008
Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients.Journal of affective disorders, , Volume: 105, Issue:1-3, 2008
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Weight changes during treatment with olanzapine in older adult patients with dementia and behavioral disturbances.Journal of geriatric psychiatry and neurology, , Volume: 20, Issue:2, 2007
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 22, Issue:7, 2007
The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats.Psychopharmacology, , Volume: 194, Issue:2, 2007
Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:5, 2007
Measured and expected resting energy expenditure in patients with bipolar disorder on maintenance treatment.Bipolar disorders, , Volume: 9, Issue:7, 2007
Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 114, Issue:2, 2007
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation.The pharmacogenomics journal, , Volume: 7, Issue:4, 2007
Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:12, 2007
Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder.Psychiatry and clinical neurosciences, , Volume: 61, Issue:4, 2007
Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.Obesity (Silver Spring, Md.), , Volume: 14, Issue:1, 2006
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.Psychoneuroendocrinology, , Volume: 31, Issue:5, 2006
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:1, 2006
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.Psychopharmacology, , Volume: 189, Issue:2, 2006
Early changes of plasma lipids during treatment with atypical antipsychotics.International clinical psychopharmacology, , Volume: 21, Issue:6, 2006
An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:4, 2006
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.The Journal of clinical psychiatry, , Volume: 67, Issue:5, 2006
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.Human psychopharmacology, , Volume: 21, Issue:4, 2006
A model for antipsychotic-induced obesity in the male rat.Psychopharmacology, , Volume: 187, Issue:4, 2006
The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.Behavioural brain research, , Aug-10, Volume: 171, Issue:2, 2006
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.Journal of psychiatric research, , Volume: 40, Issue:7, 2006
Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.Psychopharmacology, , Volume: 186, Issue:4, 2006
Weight change in treatment with olanzapine and a psychoeducational approach.Eating behaviors, , Volume: 7, Issue:2, 2006
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
Body weights and plasma prolactin levels in female rats treated subchronically with ziprasidone versus olanzapine.Behavioural pharmacology, , Volume: 17, Issue:3, 2006
A crossover study on lipid and weight changes associated with olanzapine and risperidone.Psychopharmacology, , Volume: 183, Issue:3, 2005
Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.Psychiatry and clinical neurosciences, , Volume: 59, Issue:5, 2005
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:5 Suppl, 2005
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.The Journal of pharmacology and experimental therapeutics, , Volume: 315, Issue:3, 2005
Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?Biological psychiatry, , Oct-15, Volume: 58, Issue:8, 2005
Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection.Behavioural brain research, , Sep-08, Volume: 163, Issue:2, 2005
Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats.Psychopharmacology, , Volume: 182, Issue:2, 2005
Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine, or quetiapine.The Journal of pharmacology and experimental therapeutics, , Volume: 315, Issue:1, 2005
Antipsychotic drug-induced weight gain: development of an animal model.International journal of obesity (2005), , Volume: 29, Issue:6, 2005
Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Apr-05, Volume: 134B, Issue:1, 2005
Olanzapine increases plasma ghrelin level in patients with schizophrenia.Psychoneuroendocrinology, , Volume: 30, Issue:1, 2005
Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs.Diabetes, , Volume: 54, Issue:3, 2005
Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.International clinical psychopharmacology, , Volume: 20, Issue:2, 2005
The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.International clinical psychopharmacology, , Volume: 20, Issue:2, 2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Archives of general psychiatry, , Volume: 62, Issue:1, 2005
Olanzapine treatment of residual positive and negative symptoms.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.Journal of the Indian Medical Association, , Volume: 103, Issue:12, 2005
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.Clinical therapeutics, , Volume: 27, Issue:12, 2005
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:1, 2004
Weight decline in patients switching from olanzapine to quetiapine.Schizophrenia research, , Sep-01, Volume: 70, Issue:1, 2004
Open label study of the effect of amantadine on weight gain induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 58, Issue:2, 2004
The antidepressant effects of risperidone and olanzapine in bipolar disorder.The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, ,Fall, Volume: 11, Issue:2, 2004
An animal model of antipsychotic-induced weight gain.Behavioural brain research, , Jun-04, Volume: 152, Issue:1, 2004
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp.The Journal of clinical endocrinology and metabolism, , Volume: 88, Issue:12, 2003
Weight change after an atypical antipsychotic switch.The Annals of pharmacotherapy, , Volume: 37, Issue:10, 2003
[Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].Medizinische Klinik (Munich, Germany : 1983), , Jul-15, Volume: 98, Issue:7, 2003
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.Pharmacology, biochemistry, and behavior, , Volume: 75, Issue:1, 2003
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
Olanzapine induces insulin resistance: results from a prospective study.The Journal of clinical psychiatry, , Volume: 64, Issue:12, 2003
Characterization of fluoxetine plus olanzapine treatment in rats: a behavior, endocrine, and immediate-early gene expression analysis.Synapse (New York, N.Y.), , Dec-15, Volume: 50, Issue:4, 2003
Olanzapine-associated type 2 diabetes mellitus.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Olanzapine-induced destabilization of diabetes in the absence of weight gain.Acta psychiatrica Scandinavica, , Volume: 105, Issue:3, 2002
A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.Current medical research and opinion, , Volume: 18, Issue:6, 2002
Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:6, 2002
[Olanzapine-induced diabetes mellitus].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
A clinical case series of six extremely aggressive youths treated with olanzapine.European child & adolescent psychiatry, , Volume: 11, Issue:3, 2002
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.Biological psychiatry, , Jan-01, Volume: 49, Issue:1, 2001
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 21, Issue:1, 2001
Body weight gain, insulin, and leptin in olanzapine-treated patients.The Journal of clinical psychiatry, , Volume: 62, Issue:11, 2001
Re: Weight change with antipsychotic use.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:7, 2001
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.The Journal of clinical psychiatry, , Volume: 62, Issue:2, 2001
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.The Journal of clinical psychiatry, , Volume: 61, Issue:10, 2000
Body weight and leptin plasma levels during treatment with antipsychotic drugs.The American journal of psychiatry, , Volume: 156, Issue:2, 1999
Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain.Journal of psychiatric research, , Volume: 41, Issue:1-2
Authors' response to comments regarding risperidone versus olanzapine Markov model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 8, Issue:5
Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:2
Insulin Resistance-Related Proteins Are Overexpressed in Patients and Rats Treated With Olanzapine and Are Reverted by Pueraria in the Rat Model.Journal of clinical psychopharmacology, , Volume: 39, Issue:3
Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine.Nutrition (Burbank, Los Angeles County, Calif.), , Volume: 25, Issue:7-8
Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 35, Issue:3
Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.Journal of clinical psychopharmacology, , Volume: 41, Issue:3
Weight and blood pressure changes after switching second-generation antipsychotics in a population of veterans with schizophrenia-related disorders.Journal of the American Pharmacists Association : JAPhA, , Volume: 47, Issue:2
Esperienze di switch a cariprazina in pazienti schizofrenici con comparsa di effetti collaterali/comorbilità mediche.Rivista di psichiatria, , Volume: 54, Issue:6
Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients.Indian journal of physiology and pharmacology, , Volume: 53, Issue:1
Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.The Psychiatric quarterly, , Volume: 94, Issue:4, 2023
Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.CNS drugs, , Volume: 31, Issue:9, 2017
Open-label treatment with olanzapine for patients with borderline personality disorder.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.The Journal of clinical psychiatry, , Volume: 73, Issue:8, 2012
A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study.The Journal of clinical psychiatry, , Volume: 72, Issue:10, 2011
Randomized controlled trials of olanzapine treatment of borderline personality disorder: two similar studies with different results.The Journal of clinical psychiatry, , Volume: 72, Issue:10, 2011
The effect of Olanzapine and Sertraline on personality disorder in patients with methadone maintenance therapy.Psychiatria Danubina, , Volume: 22, Issue:4, 2010
Olanzapine versus haloperidol in the management of borderline personality disorder: a randomized double-blind trial.Journal of clinical psychopharmacology, , Volume: 30, Issue:1, 2010
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Differential diagnosis of coagulation abnormalities in borderline personality disorder.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 9, Issue:1, 2008
Olanzapine plus dialectical behavior therapy for women with high irritability who meet criteria for borderline personality disorder: a double-blind, placebo-controlled pilot study.The Journal of clinical psychiatry, , Volume: 69, Issue:6, 2008
Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study.The British journal of psychiatry : the journal of mental science, , Volume: 193, Issue:6, 2008
Treatment of borderline personality disorder with olanzapine.Archives of Iranian medicine, , Volume: 9, Issue:4, 2006
Injectable atypical antipsychotics for agitation in borderline personality disorder.Pharmacopsychiatry, , Volume: 39, Issue:3, 2006
Emerging evidence for the use of atypical antipsychotics in borderline personality disorder.Pharmacopsychiatry, , Volume: 38, Issue:1, 2005
[Borderline personality disorder].L'Encephale, , Volume: 31 Pt 2, 2005
Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder.The American journal of psychiatry, , Volume: 162, Issue:6, 2005
Olanzapine versus placebo in the treatment of borderline personality disorder.The Journal of clinical psychiatry, , Volume: 65, Issue:1, 2004
Polyuria after olanzapine overdose.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.The Journal of clinical psychiatry, , Volume: 65, Issue:7, 2004
Treatment of perinatal delusional disorder: a case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study.The Journal of clinical psychiatry, , Volume: 62, Issue:11, 2001
Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia.Biological psychiatry, , Nov-15, Volume: 46, Issue:10, 1999
Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report.Psycho-oncology, , Volume: 9, Issue:1
Intramuscular olanzapine in patients with borderline personality disorder: an observational study in an emergency room.General hospital psychiatry, , Volume: 29, Issue:1
[Pharmacotherapy in the treatment of borderline personality disorder].Rivista di psichiatria, , Volume: 44, Issue:6
[Olanzapine and cognitive-behavioural group therapy in borderline personality disorder].Actas espanolas de psiquiatria, , Volume: 29, Issue:2
Psychopharmacological treatment in borderline personality disorder.Actas espanolas de psiquiatria, , Volume: 36, Issue:1
Olanzapine-Induced Bradycardia.The primary care companion for CNS disorders, , 08-15, Volume: 25, Issue:4, 2023
Cardiotoxicity in a citalopram and olanzapine overdose.The Journal of emergency medicine, , Volume: 45, Issue:4, 2013
Bradyarrhythmic shock associated with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:1, 2007
Severe cardiovascular side effects of olanzapine in an elderly patient: case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine.Journal of clinical pharmacology, , Volume: 42, Issue:1, 2002
[Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon].Annales francaises d'anesthesie et de reanimation, , Volume: 18, Issue:6, 1999
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder.General hospital psychiatry, , Volume: 31, Issue:4
Case Report: An Adolescent Girl with Isolated Neuropsychiatric Features and Apparent Post-Malaria Neurological Syndrome.The American journal of tropical medicine and hygiene, , Volume: 102, Issue:5, 2020
Peduncular hallucinosis.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:2, 2011
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats.Brain research, , Aug-27, Volume: 1018, Issue:2, 2004
Posttraumatic brain injury psychosis successfully treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-01, Volume: 34, Issue:1, 2010
Psychosis secondary to traumatic brain injury.Brain injury, , Volume: 23, Issue:4, 2009
Treatment of intractable hiccups with olanzapine following recent severe traumatic brain injury.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 18, Issue:4, 2006
Reversal of antipsychotic-induced weight gain during quetiapine treatment.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats.American journal of physical medicine & rehabilitation, , Volume: 82, Issue:11, 2003
Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury.NeuroRehabilitation, , Volume: 18, Issue:3, 2003
Diurnal variation in Cotard's syndrome (copresent with Capgras delusion) following traumatic brain injury.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:4, 2000
Recurrent mania associated with repeated brain injury.General hospital psychiatry, , Volume: 26, Issue:6
The use of atypical antipsychotics after traumatic brain injury.The Journal of head trauma rehabilitation, , Volume: 23, Issue:2
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.Journal of neuro-oncology, , Volume: 122, Issue:1, 2015
Autophagy involvement in olanzapine-mediated cytotoxic effects in human glioma cells.Asian Pacific journal of cancer prevention : APJCP, , Volume: 15, Issue:19, 2014
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?British journal of pharmacology, , Volume: 164, Issue:5, 2011
[Brain tumor].Ryoikibetsu shokogun shirizu, , Issue:40, 2003
Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 29, Issue:1, 2023
Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).BMJ open, , 04-03, Volume: 13, Issue:4, 2023
Olanzapine Improves Cachexia in a Breast Cancer Patient under Home Hospice Care.Journal of palliative medicine, , Volume: 25, Issue:1, 2022
Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracyBMJ open, , Mar-02, Volume: 12, Issue:3, 2022
A pooled analysis of adding olanzapine to guideline-recommended antiemetic therapy for breast cancer patients treated with an anthracycline and cyclophosphamide in prospective and retrospective studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 30, Issue:3, 2022
[Administration Period of Olanzapine as an Antiemetic Drug for Patients on FEC Therapy-A Survey].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 49, Issue:6, 2022
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.Breast (Edinburgh, Scotland), , Volume: 50, 2020
A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.Breast (Edinburgh, Scotland), , Volume: 54, 2020
[Effect of the Antiemetic Drug Olanzapine on Blood Sugar Levels in Patients Treated with Adjuvant or Neoadjuvant Chemotherapy for Breast Cancer].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 47, Issue:10, 2020
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.Annals of palliative medicine, , Volume: 8, Issue:4, 2019
Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.Scientific reports, , 11-02, Volume: 8, Issue:1, 2018
Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.Anticancer research, , Volume: 38, Issue:2, 2018
Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy.Japanese journal of clinical oncology, , Volume: 46, Issue:5, 2016
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.JAMA oncology, , Volume: 2, Issue:2, 2016
Flushing and sweating in an advanced breast cancer patient relieved by olanzapine.Journal of pain and symptom management, , Volume: 25, Issue:6, 2003
Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.Journal of pain and symptom management, , Volume: 25, Issue:6, 2003
Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.Indian journal of pharmacology, , Volume: 49, Issue:6
Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review.Nutrients, , Dec-18, Volume: 12, Issue:12, 2020
Effects of lisdexamfetamine in a rat model of binge-eating.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:12, 2015
Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder.Psychiatry and clinical neurosciences, , Volume: 61, Issue:4, 2007
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:1, 2003
Basal Ganglia Calcification: A Case Report of Fahr Disease With Pure Psychiatric Symptoms.Journal of psychiatric practice, , Volume: 25, Issue:5, 2019
Capgras syndrome associated with Fahr's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 21, Issue:3, 2009
Nature against nurture: calcification in the right thalamus in a young man with anorexia nervosa and obsessive-compulsive personality disorder.CNS spectrums, , Volume: 13, Issue:10, 2008
[Mineralization of the basal ganglia as the supposed cause of poor tolerance of zuclopenthixol in a patient with long-term untreated paranoid schizophrenia].Psychiatria polska, , Volume: 47, Issue:4
Fahr's Disease Presenting with Manic Symptoms.JNMA; journal of the Nepal Medical Association, , Volume: 56, Issue:209
Treatment of Cannabinoid Hyperemesis With Olanzapine: A Case Series.Journal of psychiatric practice, , 07-28, Volume: 27, Issue:4, 2021
Multidisciplinary Management of Adolescent Early-Onset, Treatment-Resistant Schizophrenia Complicated by Avoidant/Restrictive Food Intake Disorder and Catatonia in Acute Exacerbations.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:9, 2018
Cannabis and schizophrenia.The Cochrane database of systematic reviews, , Oct-14, Issue:10, 2014
[Combination of second generation antipsychotics -- case report].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 15, Issue:3, 2013
Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:1, 2012
Synthetic cannabinoid-induced psychosis: two adolescent cases.Journal of child and adolescent psychopharmacology, , Volume: 22, Issue:5, 2012
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 13, Issue:3, 2011
Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:6, 2008
Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Delusional wife: a case of diagnostic ambiguity and treatment challenge.Journal of psychiatric practice, , Volume: 11, Issue:3, 2005
Introduction.The Journal of clinical psychiatry, , Volume: 78, Issue:8
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
'Myxoedema madness' with Capgras syndrome and catatonic features responsive to combination olanzapine and levothyroxine.BMJ case reports, , Sep-09, Volume: 2016, 2016
Are reduplicative paramnesia and clonal pluralization overlapping constructs?Psychiatria Danubina, , Volume: 27, Issue:1, 2015
Capgras delusion with violent behavior in Alzheimer dementia: case analysis with literature review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 26, Issue:3, 2014
Capgras syndrome presenting in an adolescent girl in the Caribbean.The West Indian medical journal, , Volume: 62, Issue:1, 2013
Capgras syndrome associated with Fahr's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 21, Issue:3, 2009
Olanzapine-induced gynecomastia.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:8, 2005
Capgras syndrome in the modern era: self misidentification on an ID picture.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:1, 2005
Coexistence of Capgras and Frégoli syndromes in a single patient. Clinical, neuroimaging and neuropsychological findings.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:4, 2002
[Chronic and therapy refractory Fregoli syndrome].Psychiatrische Praxis, , Volume: 27, Issue:1, 2000
Diurnal variation in Cotard's syndrome (copresent with Capgras delusion) following traumatic brain injury.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:4, 2000
Refractory Psychosis After Carbon Monoxide Poisoning: a Case Report.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 32, Issue:2, 2022
Olanzapine Treatment for Chorea in a Patient With Delayed Neuropsychiatric Syndrome After Carbon Monoxide Intoxication.American journal of therapeutics, , 01-14, Volume: 29, Issue:1, 2021
Secondary mania in a patient with delayed anoxic encephalopathy after carbon monoxide intoxication caused by a suicide attempt.General hospital psychiatry, , Volume: 36, Issue:1
Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.Pharmacology research & perspectives, , Volume: 6, Issue:1, 2018
DoE based Olanzapine loaded poly-caprolactone nanoparticles decreases extrapyramidal effects in rodent model.International journal of pharmaceutics, , Apr-25, Volume: 541, Issue:1-2, 2018
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.Pharmaceutical research, , Volume: 31, Issue:10, 2014
Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument.Pharmacology, biochemistry, and behavior, , Volume: 120, 2014
Further evaluation of the tropane analogs of haloperidol.Bioorganic & medicinal chemistry letters, , Sep-01, Volume: 24, Issue:17, 2014
Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission.Psychopharmacology, , Volume: 221, Issue:1, 2012
Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.The Journal of pharmacology and experimental therapeutics, , Volume: 342, Issue:1, 2012
Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain.Anesthesiology, , Volume: 116, Issue:1, 2012
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.Behavioural brain research, , Nov-05, Volume: 203, Issue:2, 2009
Neuroleptics and animal models: feasibility of oral treatment monitored by plasma levels and receptor occupancy assays.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 115, Issue:5, 2008
Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms.European journal of pharmacology, , Sep-11, Volume: 592, Issue:1-3, 2008
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 378, Issue:5, 2008
Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 17, Issue:19, 2007
The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.Schizophrenia bulletin, , Volume: 33, Issue:6, 2007
Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.The international journal of neuropsychopharmacology, , Volume: 10, Issue:2, 2007
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.The Journal of pharmacology and experimental therapeutics, , Volume: 315, Issue:3, 2005
Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies.Journal of medicinal chemistry, , Mar-24, Volume: 48, Issue:6, 2005
Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.Journal of medicinal chemistry, , Jan-01, Volume: 47, Issue:1, 2004
Anti-cataleptic effects of clozapine, but not olanzapine and quetiapine, on SCH 23390- or raclopride-induced catalepsy in rats.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 13, Issue:3, 2003
Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.Journal of medicinal chemistry, , Jan-17, Volume: 45, Issue:2, 2002
Behavioral characteristics of olanzapine: an atypical neuroleptic.Acta pharmacologica Sinica, , Volume: 21, Issue:4, 2000
Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine.European journal of pharmacology, , Feb-26, Volume: 368, Issue:1, 1999
Atypical neuroleptics enhance histamine turnover in brain via 5-Hydroxytryptamine2A receptor blockade.The Journal of pharmacology and experimental therapeutics, , Volume: 288, Issue:2, 1999
Quinpirole, 8-OH-DPAT and ketanserin modulate catalepsy induced by high doses of atypical antipsychotics.Methods and findings in experimental and clinical pharmacology, , Volume: 21, Issue:9, 1999
N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.Journal of medicinal chemistry, , Aug-26, Volume: 42, Issue:17, 1999
New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.Journal of medicinal chemistry, , Sep-24, Volume: 41, Issue:20, 1998
[Olanzapine: preclinical pharmacology and recent findings].Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, , Volume: 18, Issue:3, 1998
Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 355, Issue:3, 1997
The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.The Journal of pharmacology and experimental therapeutics, , Volume: 262, Issue:2, 1992
Influence of olanzapine on cognitive functions and catalepsy in rats after single and chronic administration.Polish journal of pharmacology, , Volume: 51, Issue:4
Recurrent Catatonia: Infection and Immunity in an Idiopathic Illness.Journal of psychiatric practice, , 01-01, Volume: 29, Issue:1, 2023
Developed catatonia with rhabdomyolysis and exacerbated cardiac failure upon switching from clozapine to olanzapine owing to cardiomyopathy during clozapine medication - A case report.Asian journal of psychiatry, , Volume: 80, 2023
Catatonic Symptoms Successfully Treated with Olanzapine in an Adolescent with Schizophrenia.Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:4, 2021
Multidisciplinary Management of Adolescent Early-Onset, Treatment-Resistant Schizophrenia Complicated by Avoidant/Restrictive Food Intake Disorder and Catatonia in Acute Exacerbations.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:9, 2018
Psychosis and catatonia as presenting features of anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis.Asian journal of psychiatry, , Volume: 27, 2017
A patient with schizophrenia presenting with post-lobotomy catatonia treated with olanzapine: a case report.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 17, Issue:3, 2017
Anti-NMDA (a-NMDAR) receptor encephalitis related to acute consumption of metamphetamine: Relevance of differential diagnosis.Revista espanola de anestesiologia y reanimacion, , Volume: 64, Issue:3, 2017
'Myxoedema madness' with Capgras syndrome and catatonic features responsive to combination olanzapine and levothyroxine.BMJ case reports, , Sep-09, Volume: 2016, 2016
Obsessive slowness presenting as catatonia in a patient with Borderline Intelligence.Asian journal of psychiatry, , Volume: 18, 2015
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
A case of catatonia in a 14-year-old girl with schizophrenia treated with electroconvulsive therapy.Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 41, Issue:1, 2013
[Acute catatonia: Questions, diagnosis and prognostics, and the place of atypical antipsychotics].L'Encephale, , Volume: 39, Issue:3, 2013
Catatonia and parkinsonism as a sequelae of typhoid fever: a rare experience.BMJ case reports, , Jun-27, Volume: 2013, 2013
Successful use of olanzapine for catatonia following delirium.Psychiatry and clinical neurosciences, , Volume: 66, Issue:5, 2012
Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia.The journal of ECT, , Volume: 26, Issue:4, 2010
Pernicious anaemia presenting as catatonia without signs of anaemia or macrocytosis.The British journal of psychiatry : the journal of mental science, , Volume: 197, Issue:3, 2010
Major depression with catatonic features in a child remitted with olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 20, Issue:3, 2010
[Patient with encephalitis presenting with olanzapine-responsive malignant catatonia].Rinsho shinkeigaku = Clinical neurology, , Volume: 50, Issue:5, 2010
Treatment of catatonia with olanzapine: a case report.Progress in neuro-psychopharmacology & biological psychiatry, , Nov-13, Volume: 33, Issue:8, 2009
Neuroleptic malignant syndrome and catatonia in a patient with dementia.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:6, 2008
Treatment of periodic catatonia with atypical antipsychotic, olanzapine.Psychiatry and clinical neurosciences, , Volume: 62, Issue:4, 2008
Treatment of catatonia with electroconvulsive therapy in an 11-year-old girl.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:3, 2008
Treatment of periodic catatonia with olanzapine: a case report.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 29, Issue:4, 2007
Stuporous catatonia in an elderly bipolar patient: response to olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:5, 2006
Lethal catatonia.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:4, 2002
ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment.The journal of ECT, , Volume: 18, Issue:2, 2002
Lethal catatonia responding to high-dose olanzapine therapy.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:4, 2001
Case report: treatment of catatonia in an adolescent male.The Journal of adolescent health : official publication of the Society for Adolescent Medicine, , Volume: 27, Issue:1, 2000
Cotard's syndrome with catatonia: a case presentation and discussion.Psychosomatics, , Volume: 54, Issue:2
A case of catatonia due to posterior reversible encephalopathy syndrome treated successfully with antihypertensives and adjunctive olanzapine.General hospital psychiatry, , Volume: 33, Issue:3
Prevention of Catatonia With Olanzapine Long-Acting Injectable.American journal of therapeutics, , Volume: 24, Issue:5
Treatment of catatonic stupor with combination of modified electroconvulsive treatment and olanzapine: a case report.Clinical neuropharmacology, , Volume: 29, Issue:3
A case of catatonia status-post left middle cerebral artery cerebrovascular accident, treated successfully with olanzapine.Clinical neuropharmacology, , Volume: 36, Issue:4
Pediatric Acute-Onset Neuropsychiatric Syndrome and Catatonia: A Case Report.Psychosomatics, , Volume: 61, Issue:1
Catatonic episode after kidney transplantation.General hospital psychiatry, , Volume: 36, Issue:3
Treatment of catatonia with olanzapine and amantadine.Psychosomatics, , Volume: 48, Issue:6
A Case of Schizophrenia With Catatonia Resistant to Lorazepam and Olanzapine Monotherapy But Responsive to Combination Treatment: Is It Time to Consider Using Select Second-Generation Antipsychotics Earlier in the Treatment Algorithm for This Patient TypeClinical neuropharmacology, , Volume: 42, Issue:2
Benzo- and thienobenzo- diazepines: multi-target drugs for CNS disorders.Mini reviews in medicinal chemistry, , Volume: 15, Issue:8, 2015
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Comparing the side effect profile of the atypical antipsychotics.West African journal of medicine, , Volume: 21, Issue:4
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
A potential case of peduncular hallucinosis treated successfully with olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Olanzapine attenuates brain damage after focal cerebral ischemia in vivo.Brain research bulletin, , Dec-11, Volume: 71, Issue:1-3, 2006
[Cerebral infarct and atypical antipsychotic agents].Psychologie & neuropsychiatrie du vieillissement, , Volume: 2, Issue:4, 2004
Comparative Safety Analysis of Oral Antipsychotics for In-Hospital Adverse Clinical Events in Older Adults After Major Surgery : A Nationwide Cohort Study.Annals of internal medicine, , Volume: 176, Issue:9, 2023
Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:5, 2005
Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD). Favour.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 23, Issue:12, 2015
[The use of antipsychotics in patients with dementia].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:3, 2008
Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued?International journal of geriatric psychiatry, , Volume: 21, Issue:2, 2006
Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.International psychogeriatrics, , Volume: 17, Issue:4, 2005
Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Apr-27, Volume: 170, Issue:9, 2004
Academy of Medicine Singapore-Ministry of Health clinical practice guidelines: Autism Spectrum Disorders in pre-school children.Singapore medical journal, , Volume: 51, Issue:3, 2010
Successful olanzapine treatment of anorexia nervosa in a girl with pervasive developmental disorder not otherwise specified.Psychiatry and clinical neurosciences, , Volume: 62, Issue:6, 2008
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:5, 2006
NMS after clozapine initiation.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 44, Issue:11, 2005
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.The Journal of clinical psychiatry, , Volume: 65 Suppl 6, 2004
Olanzapine in the treatment of pervasive developmental disorders: a case series analysis.Journal of psychiatry & neuroscience : JPN, , Volume: 29, Issue:1, 2004
Open-label study of olanzapine in children with pervasive developmental disorder.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Reply to comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study".Journal of clinical psychopharmacology, , Volume: 21, Issue:2, 2001
Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 40, Issue:8, 2001
Broad therapeutic uses of atypical antipsychotic medications.Biological psychiatry, , Dec-01, Volume: 50, Issue:11, 2001
Comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study".Journal of clinical psychopharmacology, , Volume: 20, Issue:5, 2000
Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.Journal of clinical psychopharmacology, , Volume: 19, Issue:1, 1999
Use of atypical neuroleptics in child and adolescent psychiatry.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Olanzapine in PDD.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 36, Issue:9, 1997
Liver toxicity due to olanzapine.Revista espanola de enfermedades digestivas, , Volume: 104, Issue:11, 2012
Possible olanzapine-induced hepatotoxicity in a young Chinese patient.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 15, Issue:5, 2009
Late-onset cholestatic hepatitis induced by olanzapine in a patient with schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Nov-13, Volume: 33, Issue:8, 2009
Olanzapine Treatment for Chorea in a Patient With Delayed Neuropsychiatric Syndrome After Carbon Monoxide Intoxication.American journal of therapeutics, , 01-14, Volume: 29, Issue:1, 2021
[Sydenham chorea and psychosis].Tijdschrift voor psychiatrie, , Volume: 52, Issue:4, 2010
Persistent choreoathetosis in a fatal olanzapine overdose: drug kinetics, neuroimaging, and neuropathology.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Successful treatment of hemichorea with olanzapine.Movement disorders : official journal of the Movement Disorder Society, , Volume: 14, Issue:3, 1999
[Olanzapine improves chorea in patients with Huntington's disease].Revista de neurologia, , Volume: 35, Issue:6
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
Predictors of relapse of psychotic depression: Findings from the STOP-PD II randomized clinical trial.Journal of psychiatric research, , Volume: 157, 2023
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.Psychiatry research, , Volume: 322, 2023
Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.Schizophrenia research, , Volume: 212, 2019
Effects of Antipsychotic Drugs on the Epigenetic Modification of Brain-Derived Neurotrophic Factor Gene Expression in the Hippocampi of Chronic Restraint Stress Rats.Neural plasticity, , Volume: 2018, 2018
Inverse association between negative symptoms and body mass index in chronic schizophrenia.Schizophrenia research, , Volume: 192, 2018
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.Journal of medical economics, , Volume: 20, Issue:11, 2017
Chronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin Resistance.PloS one, , Volume: 11, Issue:12, 2016
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.Journal of medical economics, , Volume: 19, Issue:9, 2016
A Case of Chronic Peduncular Hallucinosis in a 90-Year-Old Woman Successfully Treated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 36, Issue:3, 2016
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.Journal of medical economics, , Volume: 19, Issue:2, 2016
Delusional infestation: a case series from a university dermatology center in São Paulo, Brazil.International journal of dermatology, , Volume: 55, Issue:8, 2016
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.Schizophrenia research, , Volume: 161, Issue:2-3, 2015
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.The journal of mental health policy and economics, , Volume: 18, Issue:4, 2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.The Journal of nervous and mental disease, , Volume: 203, Issue:7, 2015
Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.European journal of pharmacology, , Jan-05, Volume: 722, 2014
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.The Journal of nervous and mental disease, , Volume: 202, Issue:1, 2014
Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.Journal of medical economics, , Volume: 16, Issue:9, 2013
Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.Journal of medical economics, , Volume: 16, Issue:9, 2013
Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.Pharmacopsychiatry, , Volume: 46, Issue:3, 2013
Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study.Human psychopharmacology, , Volume: 27, Issue:4, 2012
The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study.International clinical psychopharmacology, , Volume: 27, Issue:6, 2012
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:10, 2011
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-15, Volume: 35, Issue:1, 2011
Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
Antibodies to measles in individuals with recent onset psychosis.Schizophrenia research, , Volume: 119, Issue:1-3, 2010
Valid grounds for the switch of original antipsychotics with generics.Psychiatria Danubina, , Volume: 22, Issue:1, 2010
Results of phase 3 of the CATIE schizophrenia trial.Schizophrenia research, , Volume: 107, Issue:1, 2009
An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 54, Issue:4, 2009
Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.Human psychopharmacology, , Volume: 24, Issue:3, 2009
Severe dopaminergic pathways damage in a case of chronic toluene abuse.Clinical neurology and neurosurgery, , Volume: 111, Issue:10, 2009
[The possibility of high-quality remission in the long chronic course of schizophrenia].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 108, Issue:11, 2008
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.Schizophrenia research, , Volume: 100, Issue:1-3, 2008
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.Human psychopharmacology, , Volume: 23, Issue:3, 2008
Clinical experiences and clinical trials.CNS spectrums, , Volume: 13, Issue:6, 2008
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.Schizophrenia research, , Volume: 99, Issue:1-3, 2008
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.Human psychopharmacology, , Volume: 23, Issue:4, 2008
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.Psychiatry research, , May-30, Volume: 159, Issue:1-2, 2008
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Modification of spatial recognition memory and object discrimination after chronic administration of haloperidol, amitriptyline, sodium valproate or olanzapine in normal and anhedonic rats.The international journal of neuropsychopharmacology, , Volume: 10, Issue:3, 2007
[Glutamate dysmetabolism in patients with schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:3, 2007
Alteration in serum neural cell adhesion molecule in patients of schizophrenia.Human psychopharmacology, , Volume: 22, Issue:2, 2007
Changes in cortical volume with olanzapine in chronic schizophrenia.Pharmacopsychiatry, , Volume: 40, Issue:4, 2007
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
An open-label study of olanzapine in children and adolescents with schizophrenia.Journal of psychiatric practice, , Volume: 13, Issue:2, 2007
Impairment in error monitoring predicts poor executive function in schizophrenia patients.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder.Psychiatry and clinical neurosciences, , Volume: 61, Issue:4, 2007
Orally disintegrating olanzapine for the treatment of a manic patient with esophageal stricture plus chronic pharyngitis.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 31, Issue:2, 2007
A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.Schizophrenia research, , Volume: 89, Issue:1-3, 2007
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.Human psychopharmacology, , Volume: 21, Issue:4, 2006
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.Journal of psychiatric research, , Volume: 40, Issue:7, 2006
Prolongation of clozapine-induced leukopenia with olanzapine treatment.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:5, 2006
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.Schizophrenia research, , Volume: 83, Issue:1, 2006
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
Reduced thalamic volume in patients with chronic schizophrenia after switching from typical antipsychotic medications to olanzapine.The American journal of psychiatry, , Volume: 163, Issue:11, 2006
Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report.Psychiatria Danubina, , Volume: 18, Issue:1-2, 2006
Neurological soft signs and positive treatment response to olanzapine in chronic schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:1, 2006
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.Acta psychiatrica Scandinavica, , Volume: 114, Issue:5, 2006
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorders, , Volume: 7 Suppl 3, 2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.The New England journal of medicine, , Sep-22, Volume: 353, Issue:12, 2005
Olanzapine for the management of pain in an adolescent girl.Journal of child and adolescent psychopharmacology, , Volume: 15, Issue:6, 2005
Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.Journal of clinical pharmacy and therapeutics, , Volume: 30, Issue:1, 2005
Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression.Medical hypotheses, , Volume: 65, Issue:1, 2005
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
Switching elderly chronic psychotic patients to olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:2, 2004
Neurologic soft signs and olanzapine treatment in chronic schizophrenia.Journal of clinical psychopharmacology, , Volume: 24, Issue:5, 2004
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.International clinical psychopharmacology, , Volume: 19, Issue:1, 2004
Treatment noncompliance with orally disintegrating olanzapine tablets.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.Psychopharmacology, , Volume: 169, Issue:3-4, 2003
Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.Pharmacological research, , Volume: 48, Issue:4, 2003
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.The Journal of clinical psychiatry, , Volume: 64, Issue:2, 2003
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
Optimal dosing of medications (in bipolar disorder).The Journal of family practice, , Volume: Suppl, 2003
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
Report of three case studies with olanzapine for chronic pain.The journal of pain, , Volume: 4, Issue:3, 2003
[Mnestic impairment under olanzapine overdosage in an elderly patient].Psychiatrische Praxis, , Volume: 29, Issue:8, 2002
Olanzapine in the treatment of refractory migraine and chronic daily headache.Headache, , Volume: 42, Issue:6, 2002
Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.Biological psychiatry, , Mar-15, Volume: 51, Issue:6, 2002
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.The American journal of psychiatry, , Volume: 159, Issue:2, 2002
Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Emergence of compulsive symptoms with olanzapine treatment.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:4, 2002
Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:6, 2002
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.Schizophrenia research, , Mar-01, Volume: 48, Issue:1, 2001
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Service use and costs of treating schizophrenia with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 62, Issue:10, 2001
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.The international journal of neuropsychopharmacology, , Volume: 4, Issue:3, 2001
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.The American journal of psychiatry, , Volume: 158, Issue:2, 2001
Olanzapine and pancreatitis.The British journal of psychiatry : the journal of mental science, , Volume: 177, 2000
Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment.Acta psychiatrica Scandinavica, , Volume: 102, Issue:3, 2000
Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.South Dakota journal of medicine, , Volume: 53, Issue:2, 2000
[Chronic and therapy refractory Fregoli syndrome].Psychiatrische Praxis, , Volume: 27, Issue:1, 2000
Marked elevation of serum creatine kinase associated with olanzapine therapy.The Annals of pharmacotherapy, , Volume: 33, Issue:6, 1999
Aggression, agitation, and mania with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:10, 1998
New antipsychotic medications: strategies for evaluation and selected findings.Schizophrenia research, , Oct-30, Volume: 27, Issue:2-3, 1997
High-dose olanzapine for treatment-refractory schizophrenia.The American journal of psychiatry, , Volume: 154, Issue:11, 1997
Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 15, Issue:3-4
Persistent psychosis after a single ingestion of 'ecstasy'.Psychosomatics, , Volume: 42, Issue:6
Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 8, Issue:2
Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 7, Issue:5
International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 11, Issue:6
Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.Neuropharmacology, , 10-01, Volume: 197, 2021
Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study.Psychopharmacology, , Volume: 235, Issue:4, 2018
[Cognitive effectiveness of risperidone and olanzapine in first-episode schizophrenia].Zhonghua yi xue za zhi, , Oct-11, Volume: 96, Issue:37, 2016
The effects of valproate and olanzapine on the abnormal behavior of diacylglycerol kinase β knockout mice.Pharmacological reports : PR, , Volume: 67, Issue:2, 2015
Biological Perspectives: Huntington's Disease.Perspectives in psychiatric care, , Volume: 51, Issue:3, 2015
Effects of glucose and disorders in lipid metabolism on cytokine levels and cognitive impairment in the olanzapine-induced obesity rat model.Genetics and molecular research : GMR, , Sep-25, Volume: 14, Issue:3, 2015
Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 23, Issue:12, 2015
Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.The Journal of clinical psychiatry, , Volume: 76, Issue:11, 2015
Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.Schizophrenia research, , Volume: 159, Issue:2-3, 2014
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.Pharmacological reports : PR, , Volume: 65, Issue:1, 2013
Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment.JAMA psychiatry, , Volume: 70, Issue:9, 2013
Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.Schizophrenia bulletin, , Volume: 39, Issue:5, 2013
Clozapine and visuospatial processing in treatment-resistant schizophrenia.Cognitive neuropsychiatry, , Volume: 18, Issue:6, 2013
Early prediction of clinical and functional outcome in schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:8, 2013
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:3, 2013
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis.Schizophrenia research, , Volume: 141, Issue:2-3, 2012
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:5, 2012
The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:5, 2012
A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.Journal of clinical psychopharmacology, , Volume: 32, Issue:2, 2012
Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.Schizophrenia research, , Volume: 141, Issue:1, 2012
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:6, 2012
Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.Schizophrenia research, , Volume: 130, Issue:1-3, 2011
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.The American journal of psychiatry, , Volume: 168, Issue:8, 2011
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-15, Volume: 35, Issue:1, 2011
Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.Psychopharmacology, , Volume: 214, Issue:3, 2011
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.The Journal of clinical psychiatry, , Volume: 71, Issue:11, 2010
Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.BMC psychiatry, , Jun-10, Volume: 10, 2010
Valid grounds for the switch of original antipsychotics with generics.Psychiatria Danubina, , Volume: 22, Issue:1, 2010
The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia.International clinical psychopharmacology, , Volume: 25, Issue:2, 2010
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.The Israel journal of psychiatry and related sciences, , Volume: 46, Issue:3, 2009
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.BMC psychiatry, , Jul-14, Volume: 9, 2009
Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Targeting cognition in schizophrenia research: from etiology to treatment.The American journal of psychiatry, , Volume: 166, Issue:6, 2009
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.The Journal of clinical psychiatry, , Apr-21, Volume: 70, Issue:5, 2009
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.BMC psychiatry, , Mar-28, Volume: 9, 2009
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.Schizophrenia research, , Volume: 105, Issue:1-3, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.The American journal of psychiatry, , Volume: 165, Issue:7, 2008
Adulthood olanzapine treatment fails to alleviate decreases of ChAT and BDNF RNA expression in rats quinpirole-primed as neonates.Brain research, , Mar-20, Volume: 1200, 2008
Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis.International journal of geriatric psychiatry, , Volume: 23, Issue:4, 2008
Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.Schizophrenia research, , Volume: 99, Issue:1-3, 2008
Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:3, 2008
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.The Journal of clinical psychiatry, , Volume: 69, Issue:1, 2008
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:12, 2008
Neuroleptic malignant syndrome and catatonia in a patient with dementia.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:6, 2008
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.The Journal of clinical psychiatry, , Volume: 68, Issue:3, 2007
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?Archives of general psychiatry, , Volume: 64, Issue:10, 2007
FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.Psychopharmacology, , Volume: 193, Issue:4, 2007
The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.Human psychopharmacology, , Volume: 22, Issue:7, 2007
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.Archives of general psychiatry, , Volume: 64, Issue:6, 2007
Impairment in error monitoring predicts poor executive function in schizophrenia patients.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 17, Issue:11, 2007
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.CNS spectrums, , Volume: 12, Issue:3 Suppl 4, 2007
Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
A 6-month longitudinal study of early-onset tardive dyskinesia: association with olanzapine treatment and mild cognitive impairment in an elderly woman.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.European archives of psychiatry and clinical neuroscience, , Volume: 257, Issue:7, 2007
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
A model of anticholinergic activity of atypical antipsychotic medications.Schizophrenia research, , Volume: 88, Issue:1-3, 2006
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.Biological psychiatry, , Jan-15, Volume: 59, Issue:2, 2006
Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 18, Issue:1, 2006
[The use of atypical antipsychotics in the long-term care of schizophrenia].L'Encephale, , Volume: 32 Pt 3, 2006
Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.Schizophrenia research, , Feb-28, Volume: 82, Issue:2-3, 2006
Insight in first-episode psychosis.Psychological medicine, , Volume: 36, Issue:10, 2006
Memory-sparing cognitive deterioration in the elderly: what is the diagnosis?Reviews in neurological diseases, ,Spring, Volume: 2, Issue:2, 2005
Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 13, Issue:1, 2005
Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.International journal of geriatric psychiatry, , Volume: 20, Issue:11, 2005
Patient outcomes in schizophrenia II: the impact of cognition.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Antipsychotic drug effects on brain morphology in first-episode psychosis.Archives of general psychiatry, , Volume: 62, Issue:4, 2005
A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.Psychiatry research, , Dec-15, Volume: 129, Issue:2, 2004
The management of psychogeriatric patient.Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Jan-01, Volume: 124B, Issue:1, 2004
Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.Journal of medicinal chemistry, , Jan-01, Volume: 47, Issue:1, 2004
Normalization of impaired cognitive functions failed to improve clinical symptomatology in a schizophrenic patient.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:6, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.International journal of geriatric psychiatry, , Volume: 19, Issue:2, 2004
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
Charles-Bonnet syndrome and musical hallucination.International psychogeriatrics, , Volume: 16, Issue:4, 2004
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.International journal of geriatric psychiatry, , Volume: 18, Issue:9, 2003
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.Psychopharmacology, , Volume: 169, Issue:3-4, 2003
An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.Schizophrenia research, , Jan-01, Volume: 59, Issue:1, 2003
[Neuroleptics and cognition].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats.American journal of physical medicine & rehabilitation, , Volume: 82, Issue:11, 2003
Atypical antipsychotics and cognition in schizophrenia.Archives of general psychiatry, , Volume: 59, Issue:6, 2002
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:7-8, 2002
Coexistence of Capgras and Frégoli syndromes in a single patient. Clinical, neuroimaging and neuropsychological findings.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:4, 2002
Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication.International clinical psychopharmacology, , Volume: 17, Issue:1, 2002
Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 14, Issue:4, 2002
Comparable dopamine 2 receptor occupancy.The American journal of psychiatry, , Volume: 159, Issue:12, 2002
Olanzapine treatment for dopaminergic-induced hallucinations.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:5, 2002
Olanzapine: an updated review of its use in the management of schizophrenia.Drugs, , Volume: 61, Issue:1, 2001
[Clinical and pharmacological studies of the second generation antipsychotics].Fukuoka igaku zasshi = Hukuoka acta medica, , Volume: 92, Issue:11, 2001
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates.Neurocase, , Volume: 7, Issue:2, 2001
Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task.Psychological medicine, , Volume: 31, Issue:6, 2001
Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.The American journal of psychiatry, , Volume: 157, Issue:5, 2000
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.Archives of general psychiatry, , Volume: 57, Issue:3, 2000
The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia.Schizophrenia bulletin, , Volume: 25, Issue:2, 1999
Cognitive deficit in schizophrenia and its neurochemical basis.The British journal of psychiatry. Supplement, , Issue:37, 1999
Olanzapine in dementia with Lewy bodies: a clinical study.International journal of geriatric psychiatry, , Volume: 14, Issue:6, 1999
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.Biological psychiatry, , Aug-01, Volume: 46, Issue:3, 1999
Cognitive improvement in schizophrenia with novel antipsychotic medications.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
[Use of novel agents in the treatment of schizophrenia and a look to the future].Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, , Volume: 18, Issue:3, 1998
Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Cognitive function in schizophrenic patients.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.American journal of Alzheimer's disease and other dementias, , Volume: 18, Issue:4
Hereditary spastic paraplegia and psychosis: connected by the corpus callosum?Psychosomatics, , Volume: 53, Issue:1
Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.Psychosomatics, , Volume: 47, Issue:1
Olanzapine as a possible treatment for anxiety due to vascular dementia: an open study.American journal of Alzheimer's disease and other dementias, , Volume: 19, Issue:2
[Treatment of non cognitive symptoms of Alzheimer's disease].Revista de neurologia, , Volume: 42, Issue:8
[Cognition, schizophrenia and the effect of antipsychotics].L'Encephale, , Volume: 32, Issue:3 Pt 1
[The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients].Psychiatria polska, , Volume: 47, Issue:4
Clocking delirium: the value of the Clock Drawing Test with case illustrations.The American journal of hospice & palliative care, , Volume: 25, Issue:5
[Effect of olanzapine treatment on cognitive functions in patients with schizophrenia].Psychiatria polska, , Volume: 36, Issue:6
Olanzapine poisoning in patients treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: a brief review of serum concentrations and clinical symptoms.Arhiv za higijenu rada i toksikologiju, , Jul-07, Volume: 73, Issue:2, 2022
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.The American journal of case reports, , Dec-01, Volume: 23, 2022
[Post-injection syndrome and olanzapine pamoate: A severe case report].L'Encephale, , Volume: 43, Issue:4, 2017
Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy.Current medical research and opinion, , Volume: 29, Issue:11, 2013
[The clinical picture of acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
[Intensive care treatment for neuroleptic malignant syndrome].Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, , Volume: 45, Issue:7-8, 2010
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
The clinical picture of olanzapine poisoning with special reference to fluctuating mental status.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:1, 2004
Olanzapine and hypoglycemic coma in a frail elderly woman. A case report.Pharmacopsychiatry, , Volume: 36, Issue:4, 2003
Olanzapine overdose.Annals of emergency medicine, , Volume: 32, Issue:2, 1998
Acute Poisoning with Dapsone and Olanzapine: Severe Methemoglobinemia and Coma with a Favourable Outcome.Folia medica, , Volume: 57, Issue:2
Premorbid combat related ptsd in Huntington's disease - Case report.Psychiatria Danubina, , Volume: 22, Issue:2, 2010
Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports.Acta psychiatrica Scandinavica, , Volume: 107, Issue:5, 2003
Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 159, Issue:10, 2002
Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder (PTSD)Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 45, Issue:7, 2000
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.The American journal of psychiatry, , 06-01, Volume: 176, Issue:6, 2019
Clinical Pearls in palliative medicine.Disease-a-month : DM, , Volume: 63, Issue:6, 2017
"Schizophrenia past clozapine": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing.Pharmacopsychiatry, , Volume: 48, Issue:1, 2015
In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation.International clinical psychopharmacology, , Volume: 28, Issue:2, 2013
Plasma concentrations of high-dose olanzapine in a double-blind crossover study.Human psychopharmacology, , Volume: 21, Issue:6, 2006
Olanzapine for schizophrenia.The Medical letter on drugs and therapeutics, , Jan-17, Volume: 39, Issue:992, 1997
Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.Journal of the American Medical Directors Association, , Volume: 4, Issue:4
Propensity score estimation to address calendar time-specific channeling in comparative effectiveness research of second generation antipsychotics.PloS one, , Volume: 8, Issue:5, 2013
Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.Schizophrenia research, , Volume: 146, Issue:1-3, 2013
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:1, 2005
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.Acta psychiatrica Scandinavica, , Volume: 124, Issue:3, 2011
Dyslipidemia and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
Overdose and death with olanzapine: two case reports.The American journal of forensic medicine and pathology, , Volume: 21, Issue:3, 2000
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC).Pharmacoepidemiology and drug safety, , Volume: 20, Issue:11, 2011
Risk of death associated with antipsychotic drug dispensing in residential aged care facilities.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:9, 2007
Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:2, 2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Water, water, everywhere, nor any drop to drink: climate change delusion.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:4, 2008
Fatality from olanzapine induced hyperglycemia.Journal of forensic sciences, , Volume: 47, Issue:4, 2002
[The hyperglycemic dehydration syndrome].Nederlands tijdschrift voor geneeskunde, , Oct-10, Volume: 142, Issue:41, 1998
Case series profile of olanzapine post-injection delirium/sedation syndrome.British journal of clinical pharmacology, , Volume: 89, Issue:2, 2023
[no title available]Ugeskrift for laeger, , May-08, Volume: 185, Issue:19, 2023
Continuation of depot olanzapine pamoate after post-injection delirium/sedation syndrome (PDSS) in a case of bipolar mania-a clinical conundrum.Bipolar disorders, , Volume: 25, Issue:2, 2023
Delirium with visual hallucinations induced by low-dose olanzapine.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 22, Issue:3, 2022
Delirium in the Neonate.Clinics in perinatology, , Volume: 49, Issue:1, 2022
An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home.Trials, , Apr-14, Volume: 23, Issue:1, 2022
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.The American journal of case reports, , Dec-01, Volume: 23, 2022
Post-Injection Delirium/Sedation Syndrome: A Case Report and 2-Year Follow-Up.The American journal of case reports, , Oct-17, Volume: 23, 2022
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
Olanzapine in oncology palliative care.Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, ,Summer, Volume: 35, Issue:4, 2022
Extrapyramidal Symptoms Induced by Treatment for Delirium: A Case Report.Critical care nurse, , Jun-01, Volume: 41, Issue:3, 2021
Are dexmedetomidine and olanzapine suitable to control delirium in critically ill elderly patients? A retrospective cohort study.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 139, 2021
Case report: Olanzapine post-injection delirium/sedation syndrome mimicking brainstem-thrombosis.Acta neurologica Belgica, , Volume: 121, Issue:5, 2021
Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.The Australian and New Zealand journal of psychiatry, , Volume: 54, Issue:7, 2020
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.The oncologist, , Volume: 25, Issue:3, 2020
Antipsychotics for treatment of delirium in hospitalised non-ICU patients.The Cochrane database of systematic reviews, , 06-18, Volume: 6, 2018
[Post-injection syndrome and olanzapine pamoate: A severe case report].L'Encephale, , Volume: 43, Issue:4, 2017
Delirium in hospitalized patients: Risks and benefits of antipsychotics.Cleveland Clinic journal of medicine, , Volume: 84, Issue:8, 2017
Occurrence of post-injection delirium/sedation syndrome after application of olanzapine long-acting injection during one year period.Psychiatria Danubina, , Volume: 29, Issue:4, 2017
Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation.L'Encephale, , Volume: 43, Issue:4, 2017
Delirium associated with olanzapine use in the elderly.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 17, Issue:2, 2017
Olanzapine induced delirium-a "probable" adverse drug reaction.Annals of palliative medicine, , Volume: 6, Issue:Suppl 2, 2017
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.The American journal of hospice & palliative care, , Volume: 33, Issue:5, 2016
Postinjection Delirium Syndrome Associated With Olanzapine Long-Acting Injectable.Journal of clinical psychopharmacology, , Volume: 36, Issue:4, 2016
Delirium with anticholinergic symptoms after a combination of paliperidone and olanzapine pamoate in a patient known to smoke cannabis: an unfortunate coincidence.BMJ case reports, , Jun-22, Volume: 2016, 2016
Olanzapine for Nausea, Delirium, Anxiety, Insomnia, and Cachexia #315.Journal of palliative medicine, , Volume: 19, Issue:11, 2016
Implications of atypical antipsychotic prescribing in the intensive care unit.Journal of critical care, , Volume: 30, Issue:4, 2015
Case records of the Massachusetts General Hospital. Case 10-2015. A 15-year-old girl with Graves’ disease and psychotic symptoms.The New England journal of medicine, , Mar-26, Volume: 372, Issue:13, 2015
Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.BMC psychiatry, , Nov-13, Volume: 15, 2015
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.Palliative & supportive care, , Volume: 13, Issue:4, 2015
Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?Basic & clinical pharmacology & toxicology, , Volume: 117, Issue:3, 2015
Treatment of delirium in the context of anti-N-methyl-D-aspartate receptor antibody encephalitis.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 54, Issue:3, 2015
Post-injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management.CNS drugs, , Volume: 29, Issue:1, 2015
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.BMC psychiatry, , Apr-02, Volume: 15, 2015
Management of delirium in palliative care: a review.Current psychiatry reports, , Volume: 17, Issue:3, 2015
[Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].Tijdschrift voor psychiatrie, , Volume: 56, Issue:4, 2014
A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.BMC psychiatry, , Jan-14, Volume: 14, 2014
[Sparse evidence of antipsychotic drugs for the treatment of delirium].Ugeskrift for laeger, , Apr-14, Volume: 176, Issue:16, 2014
[Sparse evidence of antipsychotic drugs for the treatment of delirium].Ugeskrift for laeger, , Sep-29, Volume: 176, Issue:40, 2014
The pharmacologic management of delirium in children and adolescents.Paediatric drugs, , Volume: 16, Issue:4, 2014
Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.International clinical psychopharmacology, , Volume: 29, Issue:6, 2014
Olanzapine postinjection delirium/sedation syndrome: an unrecognized diagnosis in the emergency department.The Journal of emergency medicine, , Volume: 47, Issue:1, 2014
The diagnosis and management of delirium in infancy.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:5, 2013
[Pharmacological treatment of delirium in palliative care patients. A systematic literature review].Schmerz (Berlin, Germany), , Volume: 27, Issue:2, 2013
Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient.Clinical toxicology (Philadelphia, Pa.), , Volume: 51, Issue:3, 2013
Long-acting injectable olanzapine can give rise to a condition consistent with central anticholinergic syndrome.Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Nov-12, Volume: 133, Issue:21, 2013
Atypical antipsychotics in the treatment of delirium.Psychiatry and clinical neurosciences, , Volume: 67, Issue:5, 2013
Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy.Current medical research and opinion, , Volume: 29, Issue:11, 2013
Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.BMC psychiatry, , Sep-30, Volume: 13, 2013
Atypical antipsychotic medications to control symptoms of delirium in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 22, Issue:2, 2012
A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study.Minerva anestesiologica, , Volume: 78, Issue:9, 2012
Successful use of olanzapine for catatonia following delirium.Psychiatry and clinical neurosciences, , Volume: 66, Issue:5, 2012
Delirium associated with olanzapine therapy in an elderly man with bipolar affective disorder.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 23, Issue:2, 2011
Comparative efficacy study of haloperidol, olanzapine and risperidone in delirium.Journal of psychosomatic research, , Volume: 71, Issue:4, 2011
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.BMC psychiatry, , Jun-10, Volume: 10, 2010
Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study.Journal of pain and symptom management, , Volume: 40, Issue:5, 2010
Atypical antipsychotics for the treatment of delirious elders.Journal of the American Medical Directors Association, , Volume: 9, Issue:1, 2008
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Treatment of delirium in supportive and palliative care.Current opinion in supportive and palliative care, , Volume: 2, Issue:1, 2008
Delirium dilemma.Orthopedics, , Volume: 30, Issue:4, 2007
Antipsychotics for delirium.The Cochrane database of systematic reviews, , Apr-18, Issue:2, 2007
Olanzapine overdose: a series of analytically confirmed cases.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Altered mental status from olanzapine overdose treated with physostigmine.Clinical toxicology (Philadelphia, Pa.), , Volume: 44, Issue:3, 2006
Can olanzapine cause delirium in the elderly?The Annals of pharmacotherapy, , Volume: 40, Issue:1, 2006
Elderly patient with delirium after myocardial infarction.Journal of the National Medical Association, , Volume: 98, Issue:4, 2006
Olanzapine-induced vasculitis.The American journal of geriatric pharmacotherapy, , Volume: 3, Issue:1, 2005
Delirium and extrapyramidal symptoms due to a lithium-olanzapine combination therapy: a case report.Journal of Korean medical science, , Volume: 20, Issue:4, 2005
Atypical neuroleptic malignant syndrome caused by olanzapine.Acta psychiatrica Scandinavica, , Volume: 112, Issue:3, 2005
Development of opioid-induced delirium while on olanzapine: a two-case report.Journal of pain and symptom management, , Volume: 29, Issue:4, 2005
Atypical antipsychotics in the management of delirium: a review of the empirical literature.Palliative & supportive care, , Volume: 3, Issue:3, 2005
Re: Olanzapine-induced delirium.Journal of pain and symptom management, , Volume: 29, Issue:2, 2005
Olanzapine for delirium in parkinsonism: therapeutic benefits in lieu of adverse consequences.Neurology India, , Volume: 52, Issue:2, 2004
Reply to the comment by Skrobik et al.Intensive care medicine, , Volume: 30, Issue:7, 2004
Olanzapine-induced delirium in a terminally ill cancer patient.Journal of pain and symptom management, , Volume: 28, Issue:2, 2004
Olanzapine may cause delirium in geriatric patients.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Olanzapine vs haloperidol: treating delirium in a critical care setting.Intensive care medicine, , Volume: 30, Issue:3, 2004
Loxapine versus olanzapine in the treatment of delirium following traumatic brain injury.NeuroRehabilitation, , Volume: 18, Issue:3, 2003
[A case of delirium after olanzapine intoxication].Der Nervenarzt, , Volume: 74, Issue:11, 2003
An open pilot trial of olanzapine for delirium in the Korean population.Psychiatry and clinical neurosciences, , Volume: 55, Issue:5, 2001
Olanzapine in an intensive care unit.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:4, 1999
The role of atypical antipsychotics in the treatment of delirium.Psychosomatics, , Volume: 43, Issue:3
Delirium Associated With Fluoxetine Discontinuation: A Case Report.Clinical neuropharmacology, , Volume: 40, Issue:3
Antipsychotic prophylaxis in surgical patients modestly decreases delirium incidence--but not duration--in high-incidence samples: a meta-analysis.General hospital psychiatry, , Volume: 35, Issue:4
Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial.Psychosomatics, , Volume: 51, Issue:5
Management of Parkinson disease.The Journal of the American Board of Family Practice, , Volume: 11, Issue:2
An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients.Psychosomatics, , Volume: 43, Issue:3
Delayed Onset Postinjection Delirium/Sedation Syndrome Associated With Olanzapine Pamoate: A Case Report.Journal of clinical psychopharmacology, , Volume: 39, Issue:5
Old disease, new look? A first report of parkinsonism due to scurvy, and of refeeding-induced worsening of scurvy.Psychosomatics, , Volume: 54, Issue:3
Risperidone versus olanzapine for the treatment of delirium.Human psychopharmacology, , Volume: 25, Issue:4
Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection.Clinical neuropharmacology, , Volume: 42, Issue:2
Fever, delirium, autonomic instability, and monocytosis associated with olanzapine.Journal of postgraduate medicine, , Volume: 49, Issue:1
Clocking delirium: the value of the Clock Drawing Test with case illustrations.The American journal of hospice & palliative care, , Volume: 25, Issue:5
Olanzapine in the treatment of delirium.Psychosomatics, , Volume: 39, Issue:5
Efficacy and Tolerability of Atypical Antipsychotics in the Treatment of Delirium: A Systematic Review of the Literature.Psychosomatics, , Volume: 60, Issue:1
Individual risk profiles for postoperative delirium after joint replacement surgery.Psychosomatics, , Volume: 52, Issue:5
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.Drugs & aging, , Volume: 40, Issue:1, 2023
Lessons of the month 2: Olanzapine-induced hypothermia and hand oedema.Clinical medicine (London, England), , Volume: 22, Issue:3, 2022
Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.Advances in therapy, , Volume: 39, Issue:5, 2022
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia.Psychiatry research, , Volume: 295, 2021
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review.The journal of prevention of Alzheimer's disease, , Volume: 8, Issue:4, 2021
Bethanechol as a Corrective for Urinary Retention Associated With Olanzapine Administration.The primary care companion for CNS disorders, , Oct-31, Volume: 21, Issue:5, 2019
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study.CNS drugs, , Volume: 30, Issue:11, 2016
Biological Perspectives: Huntington's Disease.Perspectives in psychiatric care, , Volume: 51, Issue:3, 2015
Treatment changes among older patients with dementia treated with antipsychotics.International journal of geriatric psychiatry, , Volume: 30, Issue:12, 2015
Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.JAMA psychiatry, , Volume: 72, Issue:5, 2015
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.Palliative & supportive care, , Volume: 13, Issue:4, 2015
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.Journal of medicinal chemistry, , Jun-12, Volume: 57, Issue:11, 2014
Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study.PloS one, , Volume: 8, Issue:5, 2013
Olanzapine: palliative medicine update.The American journal of hospice & palliative care, , Volume: 30, Issue:1, 2013
Pisa syndrome secondary to rivastigmine: a case report.La Clinica terapeutica, , Volume: 163, Issue:1, 2012
Risk of mortality among individual antipsychotics in patients with dementia.The American journal of psychiatry, , Volume: 169, Issue:1, 2012
Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.The American journal of geriatric pharmacotherapy, , Volume: 10, Issue:6, 2012
[A case of affective disorder with psychotic symptoms as late manifestation of Huntington's Chorea].Psychiatrische Praxis, , Volume: 38, Issue:6, 2011
Profile of atypical-antipsychotics use in patients affected by dementia in the University Hospital of Ferrara.European journal of clinical pharmacology, , Volume: 66, Issue:7, 2010
Are all commonly prescribed antipsychotics associated with greater mortality in elderly male veterans with dementia?Journal of the American Geriatrics Society, , Volume: 58, Issue:6, 2010
[Descriptive analysis of the use of atypical antipsychotics under compassionate-use in a health area in Ferrol (La Coruña, Spain)].Neurologia (Barcelona, Spain), , Volume: 25, Issue:5, 2010
Olanzapine treatment in Jarisch-Herxheimer reaction due to neurosyphilis with dementia: a case report.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:8, 2009
The promotion of olanzapine in primary care: an examination of internal industry documents.Social science & medicine (1982), , Volume: 69, Issue:1, 2009
Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain.Drug safety, , Volume: 32, Issue:11, 2009
Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS).International journal of geriatric psychiatry, , Volume: 23, Issue:9, 2008
Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy.Pharmacotherapy, , Volume: 28, Issue:3, 2008
Some treatment dilemmas in rapidly developing dementia: a case report.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 9, Issue:1, 2008
[The use of antipsychotics in patients with dementia].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:3, 2008
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.Current medical research and opinion, , Volume: 24, Issue:3, 2008
[Atypical antipsychotics in elderly patients with dementia].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , May-01, Volume: 128, Issue:9, 2008
Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis.International journal of geriatric psychiatry, , Volume: 23, Issue:4, 2008
Neuroleptic malignant syndrome and catatonia in a patient with dementia.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:6, 2008
Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics?European journal of neurology, , Volume: 15, Issue:2, 2008
[Application of neuroleptics for dementia].Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, , Volume: 44, Issue:1, 2007
Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 15, Issue:11, 2007
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
All-cause mortality associated with atypical and typical antipsychotics in demented outpatients.Pharmacoepidemiology and drug safety, , Volume: 16, Issue:5, 2007
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.Medicine and health, Rhode Island, , Volume: 90, Issue:6, 2007
Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia.Psychotherapy and psychosomatics, , Volume: 76, Issue:4, 2007
Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe?Archives of gerontology and geriatrics, , Volume: 44 Suppl 1, 2007
Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:1, 2006
Can risperidone and olanzapine in elderly patients with dementia and other mental disorders be discontinued?International journal of geriatric psychiatry, , Volume: 21, Issue:2, 2006
Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
A review of treatment-emergent adverse events during olanzapine clinical trials in elderly patients with dementia.The Journal of clinical psychiatry, , Volume: 67, Issue:6, 2006
[New formulations of olanzapine in the treatment of acute agitation].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Survival among elderly Italian patients with dementia treated with atypical antipsychotics: observational study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 27, Issue:6, 2006
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].Nederlands tijdschrift voor geneeskunde, , Jul-15, Volume: 150, Issue:28, 2006
[Psychopharmacological treatment of behavioral and psychological symptoms in dementia].Ugeskrift for laeger, , Oct-02, Volume: 168, Issue:40, 2006
Anticholinergics in dementia and other confounding problems.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:4, 2006
Can olanzapine cause delirium in the elderly?The Annals of pharmacotherapy, , Volume: 40, Issue:1, 2006
A case for judicious use of risperidone and olanzapine in behavioral and psychological symptoms of dementia (BPSD). Favour.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Drugs used to relieve behavioral symptoms in people with dementia or an unacceptable chemical cosh? Argument.International psychogeriatrics, , Volume: 17, Issue:1, 2005
Atypical antipsychotics for nursing home patients: a retrospective chart review.Drugs & aging, , Volume: 22, Issue:3, 2005
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Mar-26, Volume: 149, Issue:13, 2005
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Mar-26, Volume: 149, Issue:13, 2005
Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
FDA warns antipsychotic drugs may be risky for elderly.JAMA, , May-25, Volume: 293, Issue:20, 2005
[Increased risk of stroke during the use of olanzapine or risperidone in patients with dementia].Nederlands tijdschrift voor geneeskunde, , Jan-22, Volume: 149, Issue:4, 2005
Dementia.Clinical evidence, , Issue:14, 2005
Do atypical antipsychotics cause stroke?CNS drugs, , Volume: 19, Issue:2, 2005
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.International psychogeriatrics, , Volume: 17, Issue:4, 2005
Memory-sparing cognitive deterioration in the elderly: what is the diagnosis?Reviews in neurological diseases, ,Spring, Volume: 2, Issue:2, 2005
Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:5, 2005
Dementia.Clinical evidence, , Issue:11, 2004
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
Optimizing atypical antipsychotic treatment strategies in the elderly.Journal of the American Geriatrics Society, , Volume: 52, Issue:12 Suppl, 2004
Efficacy of atypical antipsychotics in elderly patients with dementia.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Clinical effectiveness of atypical antipsychotics in dementia.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Atypical antipsychotics and risk of cerebrovascular accidents.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
CSM warning on atypical psychotics and stroke may be detrimental for dementia.BMJ (Clinical research ed.), , May-22, Volume: 328, Issue:7450, 2004
Severe cardiovascular side effects of olanzapine in an elderly patient: case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Neuroleptic malignant syndrome and low-dose olanzapine.The American journal of psychiatry, , Volume: 160, Issue:4, 2003
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.Southern medical journal, , Volume: 96, Issue:7, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities.The Journal of clinical psychiatry, , Volume: 64, Issue:6, 2003
Calming versus sedative effects of intramuscular olanzapine in agitated patients.The American journal of emergency medicine, , Volume: 21, Issue:3, 2003
Use of atypical antipsychotic drugs in patients with dementia.American family physician, , Jun-01, Volume: 67, Issue:11, 2003
Psychotic disorder in a case with Hallervorden-Spatz disease.Acta psychiatrica Scandinavica, , Volume: 108, Issue:5, 2003
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 26, Issue:4, 2002
Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis.Pharmacotherapy, , Volume: 22, Issue:1, 2002
Atypical antipsychotics: experience and use in the elderly.International journal of clinical practice, , Volume: 56, Issue:7, 2002
Broad therapeutic uses of atypical antipsychotic medications.Biological psychiatry, , Dec-01, Volume: 50, Issue:11, 2001
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 11, Issue:3, 1999
Olanzapine in dementia with Lewy bodies: a clinical study.International journal of geriatric psychiatry, , Volume: 14, Issue:6, 1999
Conventional vs. newer antipsychotics in elderly patients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Winter, Volume: 7, Issue:1, 1999
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Managing the behavioral and psychological signs and symptoms of dementia.International clinical psychopharmacology, , Volume: 12 Suppl 4, 1997
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Increase in mortality rate in patients with dementia treated with atypical antipsychotics: a cohort study in outpatients in Central Italy.Rivista di psichiatria, , Volume: 49, Issue:1
Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.American journal of Alzheimer's disease and other dementias, , Volume: 18, Issue:4
Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia.Psychosomatics, , Volume: 42, Issue:6
The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.Journal of the American Medical Directors Association, , Volume: 4, Issue:4
Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.Journal of the American Medical Directors Association, , Volume: 4, Issue:4
Assessing antipsychotic effectiveness in dementia with the factor structure of the Psychogeriatric Dependency Rating Scale (PGDRS).Journal of the American Medical Directors Association, , Volume: 4, Issue:2
Black Hairy Tongue Associated With Olanzapine Use in a Female Dementia Patient: A Case Report.Journal of clinical psychopharmacology, , Volume: 42, Issue:2
Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.American journal of Alzheimer's disease and other dementias, , Volume: 21, Issue:2
Mortality in patients with dementia treated with atypical antipsychotics (olanzapine, quetiapine and ziprasidone).Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, , Volume: 33, Issue:4
Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature.Harvard review of psychiatry, , Volume: 13, Issue:6
Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.Psychological medicine, , Volume: 53, Issue:9, 2023
Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis.Medicine, , Sep-22, Volume: 102, Issue:38, 2023
Effects of antipsychotic medication on functional connectivity in major depressive disorder with psychotic features.Molecular psychiatry, , Volume: 28, Issue:8, 2023
Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis.Psychological medicine, , Volume: 52, Issue:12, 2022
New-onset psychosis following initiation of eye movement desensitization and reprocessing therapy.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 32, Issue:2, 2020
Neuroleptic malignant syndrome with abnormally elevated cardiac troponin I: a case report.The Journal of international medical research, , Volume: 48, Issue:11, 2020
Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial.JAMA psychiatry, , 07-01, Volume: 77, Issue:7, 2020
Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.JAMA, , 08-20, Volume: 322, Issue:7, 2019
Maintenance Treatment for Psychotic Depressive Disorders: Progress and Remaining Challenges.JAMA, , 08-20, Volume: 322, Issue:7, 2019
Stabilization treatment of remitted psychotic depression: the STOP-PD study.Acta psychiatrica Scandinavica, , Volume: 138, Issue:3, 2018
Anxiolytic effects of venlafaxine/olanzapine combination in treatment of anxious depression.Neuro endocrinology letters, , Volume: 38, Issue:8, 2018
Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines.Acta psychiatrica Scandinavica, , Volume: 138, Issue:3, 2018
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 49, 2018
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
[Electroconvulsive Therapy (ECT) of a 15-year-old female patient suffering from a severe delusional depression: a case report].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 46, Issue:6, 2018
Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.Drugs & aging, , Volume: 34, Issue:3, 2017
Reexamining the Role of Electroconvulsive Therapy in Anorexia Nervosa in Adolescents.The journal of ECT, , Volume: 33, Issue:4, 2017
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.Journal of affective disorders, , Jan-01, Volume: 207, 2017
Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:6, 2017
Clinical Pearls in palliative medicine.Disease-a-month : DM, , Volume: 63, Issue:6, 2017
Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS).Journal of affective disorders, , Jan-15, Volume: 190, 2016
A Woman With Major Depression With Psychotic Features Requesting a Termination of Pregnancy.The American journal of psychiatry, , Volume: 173, Issue:1, 2016
SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study.Human psychopharmacology, , Volume: 31, Issue:3, 2016
A Woman in Her 60s With Fever and Altered Mental Status in a Psychiatric Hospital.Chest, , Volume: 150, Issue:6, 2016
Use of Orally Disintegrating Olanzapine During Electroconvulsive Therapy for Prevention of Postictal Agitation.Journal of psychiatric practice, , Volume: 22, Issue:6, 2016
Management of depressive symptoms in schizophrenia.Clinical schizophrenia & related psychoses, , Volume: 9, Issue:1, 2015
Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: a post hoc analysis.The Journal of clinical psychiatry, , Volume: 76, Issue:6, 2015
Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 23, Issue:12, 2015
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.Schizophrenia research, , Volume: 161, Issue:2-3, 2015
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.Clinical pharmacokinetics, , Volume: 54, Issue:11, 2015
Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, , Volume: 47, Issue:7, 2014
Effects of low-dose olanzapine on duloxetine-related nausea and vomiting for the treatment of major depressive disorder.Journal of clinical psychopharmacology, , Volume: 34, Issue:4, 2014
Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.Journal of affective disorders, , Volume: 160, 2014
Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study.Comprehensive psychiatry, , Volume: 55, Issue:5, 2014
Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 22, Issue:4, 2014
Sleep architecture and cognitive changes in olanzapine-treated patients with depression: a double blind randomized placebo controlled trial.BMC psychiatry, , Jul-17, Volume: 14, 2014
Prevention of relapse with maintenance electroconvulsive therapy in elderly patients with major depressive episode.The journal of ECT, , Volume: 29, Issue:1, 2013
Use of electroconvulsive therapy in an adolescent with systemic lupus erythematosus for management of depression.The journal of ECT, , Volume: 29, Issue:3, 2013
A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.The Journal of clinical psychiatry, , Volume: 74, Issue:10, 2013
The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.Journal of clinical psychopharmacology, , Volume: 33, Issue:3, 2013
Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study.Human psychopharmacology, , Volume: 26, Issue:3, 2011
[A case of affective disorder with psychotic symptoms as late manifestation of Huntington's Chorea].Psychiatrische Praxis, , Volume: 38, Issue:6, 2011
A case of Klingsor Syndrome: when there is no longer psychosis.The Israel journal of psychiatry and related sciences, , Volume: 48, Issue:1, 2011
Switching among antipsychotics--focus on side effects.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Effect of augmentation with olanzapine in outpatients with depression in partial remission with melancholic features: consecutive case series.Psychiatry and clinical neurosciences, , Volume: 65, Issue:2, 2011
[Mood disorder after malaria prophylaxis with mefloquine (two case reports)].L'Encephale, , Volume: 37, Issue:5, 2011
Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial.Journal of psychiatric research, , Volume: 45, Issue:7, 2011
Second-generation antipsychotics in major depressive disorder: update and clinical perspective.Current opinion in psychiatry, , Volume: 24, Issue:1, 2011
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.Pharmacotherapy, , Volume: 31, Issue:8, 2011
Adjunctive antipsychotics for major depression.The Medical letter on drugs and therapeutics, , Sep-19, Volume: 53, Issue:1373, 2011
Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.Clinical therapeutics, , Volume: 33, Issue:9, 2011
Major depression with catatonic features in a child remitted with olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 20, Issue:3, 2010
Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.The Journal of clinical psychiatry, , Volume: 71, Issue:10, 2010
Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.Postgraduate medicine, , Volume: 122, Issue:4, 2010
Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder.CNS drugs, , Volume: 24, Issue:3, 2010
Second-generation antipsychotics for major depressive disorder and dysthymia.The Cochrane database of systematic reviews, , Dec-08, Issue:12, 2010
Steroid responsive psychotic depression.The Australian and New Zealand journal of psychiatry, , Volume: 43, Issue:7, 2009
An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.The Journal of clinical psychiatry, , Volume: 70, Issue:3, 2009
Psychogenic tremor in a patient with a major depressive episode.South Dakota medicine : the journal of the South Dakota State Medical Association, , Volume: 62, Issue:6, 2009
Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.Expert opinion on pharmacotherapy, , Volume: 10, Issue:13, 2009
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.The Journal of clinical psychiatry, , Volume: 70, Issue:10, 2009
A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).Archives of general psychiatry, , Volume: 66, Issue:8, 2009
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting.Human psychopharmacology, , Volume: 24, Issue:2, 2009
Augmentation of antidepressants with atypical antipsychotics: a review of the current literature.Journal of psychiatric practice, , Volume: 14, Issue:1, 2008
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.Acta psychiatrica Scandinavica, , Volume: 117, Issue:4, 2008
Nonfatal suicidal olanzapine intoxication: a case report.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.Journal of clinical pharmacy and therapeutics, , Volume: 32, Issue:2, 2007
Atypical antipsychotics in bipolar disorder: systematic review of randomised trials.BMC psychiatry, , Aug-16, Volume: 7, 2007
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.The Journal of clinical psychiatry, , Volume: 68, Issue:2, 2007
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 46, Issue:8, 2007
Insight in first-episode psychosis.Psychological medicine, , Volume: 36, Issue:10, 2006
Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study.Psychiatry research, , Mar-31, Volume: 146, Issue:2, 2006
Combined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:2, 2006
Duloxetine for childhood depression with pain and dissociative symptoms.European child & adolescent psychiatry, , Volume: 15, Issue:8, 2006
Combined use of ECT with duloxetine and olanzapine: a case report.The journal of ECT, , Volume: 22, Issue:2, 2006
Creating more effective antidepressants: clues from the clinic.Drug discovery today, , Volume: 11, Issue:13-14, 2006
Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:11, 2006
Massive creatine kinase elevations with quetiapine: report of two cases.Pharmacopsychiatry, , Volume: 39, Issue:1, 2006
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.Depression and anxiety, , Volume: 23, Issue:6, 2006
A delusion assessment scale for psychotic major depression: Reliability, validity, and utility.Biological psychiatry, , Dec-15, Volume: 60, Issue:12, 2006
Olanzapine-induced leucopenia and neutropenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:6, 2005
Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients.The Journal of clinical psychiatry, , Volume: 66, Issue:4, 2005
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.The Journal of clinical psychiatry, , Volume: 66, Issue:10, 2005
Olanzapine plus venlafaxine in treatment-resistant depression.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:4, 2005
[Love, humor and psychosis in an atypical depression].L'Encephale, , Volume: 31 Pt 2, 2005
Is combination olanzapine and antidepressant medication associated with a more rapid response trajectory than antidepressant alone?The American journal of psychiatry, , Volume: 162, Issue:4, 2005
[Brief case report. Duloxetine in Cotard syndrome].Psychiatrische Praxis, , Volume: 32, Issue:8, 2005
Delusional wife: a case of diagnostic ambiguity and treatment challenge.Journal of psychiatric practice, , Volume: 11, Issue:3, 2005
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:6, 2005
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:11, 2005
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:8, 2005
Obsessive-compulsive symptoms with olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:3, 2004
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.Journal of clinical psychopharmacology, , Volume: 24, Issue:4, 2004
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Adolescent weight loss during treatment with olanzapine.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
Antipsychotic-associated weight gain.The Annals of pharmacotherapy, , Volume: 38, Issue:5, 2004
Cotard's syndrome and electroconvulsive therapy.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:11, 2004
Open label study of the effect of amantadine on weight gain induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 58, Issue:2, 2004
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
Usefulness of olanzapine in refractory panic attacks.Journal of clinical psychopharmacology, , Volume: 23, Issue:1, 2003
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study.Psychopharmacology bulletin, ,Summer, Volume: 37, Issue:3, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Fluoxetine and olanzapine for resistant depression.The American journal of psychiatry, , Volume: 159, Issue:1, 2002
Serotonin syndrome and atypical antipsychotics.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
[Improvement of tardive dyskinesia after treatment with olanzapine].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
Use of atypical antipsychotics in mood disorders.Current opinion in investigational drugs (London, England : 2000), , Volume: 2, Issue:7, 2001
An open trial of olanzapine in the treatment of patients with psychotic depression.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 13, Issue:3, 2001
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.Schizophrenia bulletin, , Volume: 27, Issue:4, 2001
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
Does olanzapine have antidepressant properties? A retrospective preliminary study.Bipolar disorders, , Volume: 2, Issue:3 Pt 1, 2000
[Effective treatment of depressive disorder with psychotic symptoms by olanzapine combination therapy].Deutsche medizinische Wochenschrift (1946), , Dec-15, Volume: 125, Issue:50, 2000
Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentration.Journal of clinical psychopharmacology, , Volume: 19, Issue:3, 1999
Adjunctive use of olanzapine in mood disorders: five case reports.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 9, Issue:4, 1997
Comment on Nasrallah et al: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 12, Issue:6
Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV.Psychosomatics, , Volume: 44, Issue:5
Masturbatory guilt leading to severe depression and erectile dysfunction.Journal of sex & marital therapy, , Volume: 28, Issue:4
Delirium Associated With Fluoxetine Discontinuation: A Case Report.Clinical neuropharmacology, , Volume: 40, Issue:3
The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression.The Journal of clinical psychiatry, , Volume: 78, Issue:8
Erotomania in Depressive Psychosis: Mood Incongruent Delusion in a Depressive Young Woman.Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, , Volume: 29, Issue:6, 2019
Antiepileptic effect of olanzapine in epilepsy patients with atypical depressive comorbidity.Epileptic disorders : international epilepsy journal with videotape, , Jun-01, Volume: 20, Issue:3, 2018
Elucidation of the Role of Dorsal Raphe Serotonergic Neurons in Mood Regulation Using Pharmacological and Viral Vector-based Approaches.Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, , Volume: 137, Issue:3, 2017
Thrombocytopenia and Spontaneous Intracranial Hemorrhage After Olanzapine Therapy.The Journal of the American Osteopathic Association, , Jul-01, Volume: 117, Issue:7, 2017
Olanzapine augments the effect of selective serotonin reuptake inhibitors by suppressing GABAergic inhibition via antagonism of 5-HT₆ receptors in the dorsal raphe nucleus.Neuropharmacology, , Volume: 95, 2015
[Hemoperfusion with activated charcoal on valproic acid poisoning. A case report].Medicina intensiva, , Volume: 39, Issue:7, 2015
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
[Electroconvulsion therapy for neuroleptic malignant syndrome].Tijdschrift voor psychiatrie, , Volume: 56, Issue:9, 2014
[Woman in her 30s with chronic fatigue].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Feb-25, Volume: 134, Issue:4, 2014
Olanzapine is superior to lamotrigine in the prevention of bipolar depression: a naturalistic observational study.BMC psychiatry, , May-19, Volume: 14, 2014
[Buccolingual dyskinesia with justified hallucinations].Revista de neurologia, , Nov-16, Volume: 59, Issue:10, 2014
Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol.Journal of affective disorders, , Jan-25, Volume: 144, Issue:3, 2013
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.Boletin de la Asociacion Medica de Puerto Rico, , Volume: 105, Issue:3, 2013
[The comparative study on the efficacy of the combination of serotonin reuptake inhibitor antidepressants and antipsychotics in the treatment of recurrent depressive disorders].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 112, Issue:11 Pt 2, 2012
Electroconvulsive therapy in the presence of atrial septal defect: a case report.The journal of ECT, , Volume: 28, Issue:2, 2012
Symptoms of agitated depression and/or akathisia.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Serotonin syndrome after discontinuation of olanzapine in a combined treatment with duloxetine -- case report.Pharmacopsychiatry, , Volume: 44, Issue:2, 2011
Clinical practice. Bipolar disorder--a focus on depression.The New England journal of medicine, , Jan-06, Volume: 364, Issue:1, 2011
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.The pharmacogenomics journal, , Volume: 10, Issue:1, 2010
The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia.International clinical psychopharmacology, , Volume: 25, Issue:2, 2010
Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies.The Journal of clinical psychiatry, , Volume: 71, Issue:4, 2010
In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 25, Issue:8, 2010
[Medication associated long QT syndrome].Praxis, , Dec-02, Volume: 98, Issue:24, 2009
Rowell's syndrome in the course of treatment with sodium valproate: a case report and review of the literature data.Clinical and experimental dermatology, , Volume: 34, Issue:6, 2009
Septo-optic dysplasia and psychiatric disorders: a case report.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 21, Issue:4, 2008
Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series.Human psychopharmacology, , Volume: 23, Issue:3, 2008
[Depression in schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:10, 2008
Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.Psychopharmacology, , Volume: 201, Issue:2, 2008
Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.Journal of affective disorders, , Volume: 105, Issue:1-3, 2008
Water, water, everywhere, nor any drop to drink: climate change delusion.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:4, 2008
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Plasma lipids, lipoproteins and hormones levels during olanzapine treatment in psychosis and depression.Medicinski arhiv, , Volume: 61, Issue:2, 2007
Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.Bipolar disorders, , Volume: 9, Issue:6, 2007
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.Psychopharmacology bulletin, , Volume: 40, Issue:2, 2007
Motor cortex excitability after vagus nerve stimulation in major depression.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Influence of sub-syndromal symptoms after remission from manic or mixed episodes.The British journal of psychiatry : the journal of mental science, , Volume: 189, 2006
A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression.The Journal of clinical psychiatry, , Volume: 67, Issue:5, 2006
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.Molecular psychiatry, , Volume: 11, Issue:7, 2006
Does olanzapine have any antidepressant effect?The American journal of psychiatry, , Volume: 163, Issue:10, 2006
[Effects of antidepressant therapy in patients with suspected "angina pectoris" and negative coronary angiogram complicating comorbid depression].Zhonghua xin xue guan bing za zhi, , Volume: 34, Issue:12, 2006
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.The Journal of clinical psychiatry, , Volume: 67, Issue:7, 2006
A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Differential efficacy of olanzapine and lithium in preventing manic or mixed recurrence in patients with bipolar I disorder based on number of previous manic or mixed episodes.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
Olanzapine co-therapy in bipolar disorder.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Treatment options for bipolar depression.The Journal of clinical psychiatry, , Volume: 66 Suppl 1, 2005
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.The Journal of nervous and mental disease, , Volume: 193, Issue:6, 2005
An open-label trial of olanzapine for corticosteroid-induced mood symptoms.Journal of affective disorders, , Volume: 83, Issue:2-3, 2004
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.International clinical psychopharmacology, , Volume: 19, Issue:1, 2004
Cognitive function and depression in symptom resolution in schizophrenia patients treated with an atypical antipsychotic.Brain and cognition, , Volume: 55, Issue:3, 2004
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial.The American journal of psychiatry, , Volume: 161, Issue:8, 2004
A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder.The Journal of clinical psychiatry, , Volume: 65, Issue:7, 2004
The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder.The Journal of clinical psychiatry, , Volume: 65, Issue:7, 2004
Bipolar depression: an overview.IDrugs : the investigational drugs journal, , Volume: 7, Issue:9, 2004
New approaches to managing psychotic depression.The Journal of clinical psychiatry, , Volume: 64 Suppl 1, 2003
Difficult-to-treat depressions: a primary care perspective.The Journal of clinical psychiatry, , Volume: 64 Suppl 1, 2003
Dependence and chronic psychosis with D-nor-pseudoephedrine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:8, 2003
Disturbed glucose metabolism among patients taking olanzapine and typical antipsychotics.Psychopharmacology bulletin, ,Summer, Volume: 37, Issue:3, 2003
Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.The Journal of clinical psychiatry, , Volume: 64, Issue:11, 2003
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex.Neuroscience letters, , Oct-09, Volume: 349, Issue:3, 2003
An open-label, flexible-dose study of olanzapine in the treatment of trichotillomania.The Journal of clinical psychiatry, , Volume: 64, Issue:1, 2003
[Olanzapine in therapy of a somatoform disorder].Psychiatrische Praxis, , Volume: 30, Issue:8, 2003
Are the atypical antipsychotic drugs antidepressants?Journal of clinical psychopharmacology, , Volume: 22, Issue:1, 2002
Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
[Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].Fortschritte der Neurologie-Psychiatrie, , Volume: 70, Issue:4, 2002
Olanzapine in the treatment of apathy in previously depressed participants maintained with selective serotonin reuptake inhibitors: an open-label, flexible-dose study.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Influence of fluoxetine on olanzapine pharmacokinetics.AAPS pharmSci, , Volume: 4, Issue:2, 2002
Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 159, Issue:10, 2002
Addition of olanzapine for treatment-resistant depression.The American journal of psychiatry, , Volume: 158, Issue:10, 2001
A novel augmentation strategy for treating resistant major depression.The American journal of psychiatry, , Volume: 158, Issue:1, 2001
[What does olanzapine give us?].Atencion primaria, , Mar-31, Volume: 27, Issue:5, 2001
Use of olanzapine in non-psychotic psychiatric disorders.Expert opinion on pharmacotherapy, , Volume: 2, Issue:4, 2001
First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression.Neuropsychobiology, , Volume: 43, Issue:3, 2001
Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Dementia with Lewy bodies in Down's syndrome.International journal of geriatric psychiatry, , Volume: 16, Issue:3, 2001
Interaction of olanzapine with fluvoxamine.Psychopharmacology, , Volume: 155, Issue:2, 2001
Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.Therapeutic drug monitoring, , Volume: 23, Issue:4, 2001
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.The Journal of clinical psychiatry, , Volume: 62, Issue:7, 2001
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.The Journal of nervous and mental disease, , Volume: 189, Issue:6, 2001
Summary from the 153rd meeting of the American Psychiatric Association. 13-18 May 2000, Chicago, Illinois, USA.Expert opinion on pharmacotherapy, , Volume: 1, Issue:5, 2000
Esotropia associated with olanzapine.Journal of clinical psychopharmacology, , Volume: 20, Issue:4, 2000
Atypical antipsychotics for treatment of mixed depression and anxiety.The Journal of clinical psychiatry, , Volume: 61, Issue:5, 2000
Melancholic symptoms during concurrent olanzapine and fluoxetine.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 12, Issue:3, 2000
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17, Issue:6, 2000
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 61 Suppl 3, 2000
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.East African medical journal, , Volume: 77, Issue:2, 2000
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.Biological psychiatry, , Aug-01, Volume: 46, Issue:3, 1999
Olanzapine in the treatment of psychotic depression.The British journal of psychiatry : the journal of mental science, , Volume: 174, 1999
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Olanzapine response in psychotic depression.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Treatment of corticosteroid-induced mood changes with olanzapine.The American journal of psychiatry, , Volume: 156, Issue:6, 1999
Hyperglycemia and olanzapine.The American journal of psychiatry, , Volume: 156, Issue:6, 1999
Review of recent clinical studies with olanzapine.The British journal of psychiatry. Supplement, , Issue:37, 1999
Emergence of koro after abrupt cessation of olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:2, 1998
[The hyperglycemic dehydration syndrome].Nederlands tijdschrift voor geneeskunde, , Oct-10, Volume: 142, Issue:41, 1998
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
[Schizophrenia and depression. Special aspects in the therapy of women].Der Nervenarzt, , Volume: 69, Issue:7 Suppl Be, 1998
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Treatment of psychotic depression.The American journal of psychiatry, , Volume: 154, Issue:11, 1997
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.The American journal of psychiatry, , Volume: 154, Issue:4, 1997
Olanzapine in the treatment of resistant depression.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:1-2
Olanzapine and quick-response hyperglycemia.Psychosomatics, , Volume: 44, Issue:2
Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine.Clinical neuropharmacology, , Volume: 31, Issue:5
Adjunctive use of methylphenidate in the treatment of psychotic unipolar depression.Clinical neuropharmacology, , Volume: 31, Issue:4
Citalopram-induced diplopia.Psychosomatics, , Volume: 46, Issue:1
A suspected case of olanzapine induced hyponatremia.Indian journal of pharmacology, , Volume: 46, Issue:4
Serotonin syndrome: a complex but easily avoidable condition.General hospital psychiatry, , Volume: 30, Issue:3
Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Switching among antipsychotics--focus on side effects.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Mood stabilizer therapy and pravastatin: higher risk for adverse skin reactions?Acta medica (Hradec Kralove), , Volume: 52, Issue:1, 2009
[Lichenoid drug eruption induced by olanzapine].Actas dermo-sifiliograficas, , Volume: 99, Issue:3, 2008
Acute generalized exanthematous pustulosis induced by olanzapine.Acta medica (Hradec Kralove), , Volume: 49, Issue:1, 2006
Olanzapine-induced vasculitis.The American journal of geriatric pharmacotherapy, , Volume: 3, Issue:1, 2005
Dermatological side effects of olanzapine.Indian journal of medical sciences, , Volume: 59, Issue:7, 2005
Fungal dermatitis with olanzapine in schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:9, 2003
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Pustular eruption induced by olanzapine, a novel antipsychotic agent.Journal of the American Academy of Dermatology, , Volume: 41, Issue:5 Pt 2, 1999
Hypersensitivity syndrome with olanzapine confirmed by patch tests.European journal of dermatology : EJD, , Volume: 22, Issue:1
Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Insulin resistance following continuous, chronic olanzapine treatment: an animal model.Schizophrenia research, , Volume: 104, Issue:1-3, 2008
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Second-generation antipsychotic and diabetes mellitus in children and adolescents.La Pediatria medica e chirurgica : Medical and surgical pediatrics, , Dec-13, Volume: 39, Issue:4, 2017
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.Internal medicine (Tokyo, Japan), , Volume: 56, Issue:3, 2017
Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.Psychopharmacology, , Volume: 233, Issue:21-22, 2016
Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.Southern medical journal, , Volume: 96, Issue:7, 2003
[Olanzapine-induced diabetes mellitus].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.The Journal of clinical psychiatry, , Volume: 62, Issue:12, 2001
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
Hyperglycemia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Antipsychotic-Induced Metabolic Syndrome: A Review.Metabolic syndrome and related disorders, , Volume: 21, Issue:6, 2023
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).BMJ open, , 01-31, Volume: 13, Issue:1, 2023
Effects of the second-generation antipsychotic drugs aripiprazole and olanzapine on human adipocyte differentiation.Molecular and cellular endocrinology, , 02-05, Volume: 561, 2023
The second-generation antipsychotic drug aripiprazole modulates the serotonergic system in pancreatic islets and induces beta cell dysfunction in female mice.Diabetologia, , Volume: 65, Issue:3, 2022
Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.CNS spectrums, , Volume: 27, Issue:3, 2022
Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls.PloS one, , Volume: 17, Issue:11, 2022
Anthocyanins from Molecules (Basel, Switzerland), , Oct-12, Volume: 26, Issue:20, 2021
Olanzapine-induced insulin resistance may occur via attenuation of central KSchizophrenia research, , Volume: 228, 2021
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C.The Journal of clinical investigation, , Sep-01, Volume: 127, Issue:9, 2017
Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics: A Systematic Review and Meta-analysis.JAMA psychiatry, , Volume: 73, Issue:3, 2016
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
What evidence is there to show which antipsychotics are more diabetogenic than others?Psychiatria Danubina, , Volume: 27 Suppl 1, 2015
A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes.Cellular signalling, , Volume: 26, Issue:6, 2014
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 15, Issue:3, 2014
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
The risk of metabolic disorders in patients treated with asenapine or olanzapine: a study conducted on real-world data in Italy and Spain.Expert opinion on drug safety, , Volume: 13, Issue:9, 2014
Comparative safety of antipsychotics: another look at the risk of diabetes.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 58, Issue:4, 2013
Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone.Schizophrenia research, , Volume: 143, Issue:2-3, 2013
Diabetes resolution following discontinuation of a second-generation antipsychotic.Clinical schizophrenia & related psychoses, , Volume: 6, Issue:4, 2013
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level.Progress in neuro-psychopharmacology & biological psychiatry, , Jul-01, Volume: 35, Issue:5, 2011
Metabolic effects of olanzapine in patients with newly diagnosed psychosis.Journal of clinical psychopharmacology, , Volume: 31, Issue:2, 2011
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:9, 2010
Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats.Neuropsychobiology, , Volume: 61, Issue:3, 2010
Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation.Journal of psychiatric practice, , Volume: 15, Issue:4, 2009
Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 70, Issue:1, 2009
The risks and benefits of switching antipsychotics: a case study approach.Perspectives in psychiatric care, , Volume: 45, Issue:1, 2009
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 54, Issue:4, 2009
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 69, Issue:3, 2008
Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia.Schizophrenia research, , Volume: 104, Issue:1-3, 2008
Considerations regarding the use of metformin with olanzapine.The American journal of psychiatry, , Volume: 165, Issue:9, 2008
[Olanzapine].Deutsche medizinische Wochenschrift (1946), , Volume: 133, Issue:39, 2008
Stimulation of glycogen synthesis and inactivation of phosphorylase in hepatocytes by serotonergic mechanisms, and counter-regulation by atypical antipsychotic drugs.Diabetologia, , Volume: 50, Issue:8, 2007
A patient treated with olanzapine developing diabetes de novo: proposal for hyperglycaemia screening.The Netherlands journal of medicine, , Volume: 65, Issue:9, 2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.The American journal of managed care, , Volume: 13, Issue:7 Suppl, 2007
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.Collegium antropologicum, , Volume: 31, Issue:4, 2007
Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.American journal of epidemiology, , Oct-01, Volume: 164, Issue:7, 2006
Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.Psychiatry and clinical neurosciences, , Volume: 60, Issue:1, 2006
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:3, 2006
Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine.Journal of managed care pharmacy : JMCP, , Volume: 12, Issue:3, 2006
Retrospective analysis of diabetes risk in elderly patients with dementia in olanzapine clinical trials.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:1, 2006
Unusual suspect for antipsychotic-induced diabetes.Drug discovery today, , Oct-15, Volume: 10, Issue:20, 2005
Newer antipsychotics and glucose metabolism: a comparison between olanzapine and risperidone.Psychiatria Danubina, , Volume: 17, Issue:1-2, 2005
Olanzapine-induced weight gain and disturbances of lipid and glucose metabolism.Essential psychopharmacology, , Volume: 6, Issue:2, 2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Archives of general psychiatry, , Volume: 62, Issue:1, 2005
Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.Pharmacoepidemiology and drug safety, , Volume: 14, Issue:6, 2005
A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:8, 2004
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.Postgraduate medicine, , Volume: 116, Issue:4, 2004
Olanzapine use in a patient with schizophrenia and the risk of diabetes.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:1, 2004
Potential for detection bias in the association between olanzapine and diabetes.The Journal of clinical psychiatry, , Volume: 65, Issue:2, 2004
Modulating effects of olanzapine on the development of diabetic ketoacidosis.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 21, Issue:3, 2004
[Diabetes as a complication in treatment with second-generation antipsychotics].Ugeskrift for laeger, , Aug-23, Volume: 166, Issue:35, 2004
Hyperglycemia associated with antipsychotic treatment in a multicenter drug safety project.Pharmacopsychiatry, , Volume: 37 Suppl 1, 2004
Olanzapine-induced diabetes in a seven-year-old boy.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
Dyslipidemia and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
[Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].Medizinische Klinik (Munich, Germany : 1983), , Jul-15, Volume: 98, Issue:7, 2003
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Atypical neuroleptics and diabetes.Diabetes & metabolism, , Volume: 29, Issue:3, 2003
Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.Psychopharmacology, , Volume: 170, Issue:2, 2003
Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.Clinical therapeutics, , Volume: 25, Issue:4, 2003
Hyperglycemia from olanzapine treatment in adolescents.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 13, Issue:1, 2003
High-dose olanzapine-induced improvement of preexisting type 2 diabetes mellitus in schizophrenic patients.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
The effects of novel antipsychotics on glucose and lipid levels.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Ziprasidone alternative for olanzapine-induced hyperglycemia.The American journal of psychiatry, , Volume: 159, Issue:9, 2002
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Olanzapine-associated type 2 diabetes mellitus.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy.Pharmacotherapy, , Volume: 21, Issue:11, 2001
Treatment of preexisting diabetes with olanzapine.The Journal of clinical psychiatry, , Volume: 62, Issue:9, 2001
Are African American patients at a higher risk for olanzapine-induced glucose intolerance?Psychopharmacology, , Volume: 157, Issue:3, 2001
[Importance of blood glucose level when starting antipsychotic treatment].Presse medicale (Paris, France : 1983), , Sep-22, Volume: 30, Issue:26, 2001
Atypical antipsychotics and hyperglycaemia.International clinical psychopharmacology, , Volume: 16, Issue:2, 2001
Hyperglycemia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
[The hyperglycemic dehydration syndrome].Nederlands tijdschrift voor geneeskunde, , Oct-10, Volume: 142, Issue:41, 1998
Novel antipsychotics and new onset diabetes.Biological psychiatry, , Oct-15, Volume: 44, Issue:8, 1998
Olanzapine-induced glucose dysregulation.The Annals of pharmacotherapy, , Volume: 34, Issue:7-8
A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:1
Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:3
Neonatal phencyclidine as a model of sex-biased schizophrenia symptomatology in adolescent mice.Psychopharmacology, , Volume: 240, Issue:10, 2023
Interhemispheric differences of pyramidal cells in the primary motor cortices of schizophrenia patients investigated postmortem.Cerebral cortex (New York, N.Y. : 1991), , 06-20, Volume: 33, Issue:13, 2023
Intranasal administration of olanzapine has beneficial outcome in a rat activity-based anorexia model.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 71, 2023
The antipsychotic olanzapine reduces memory deficits and neuronal abnormalities in a male rat model of Autism.Journal of chemical neuroanatomy, , Volume: 132, 2023
Second-generation antipsychotic olanzapine attenuates behavioral and prefrontal cortex synaptic plasticity deficits in a neurodevelopmental schizophrenia-related rat model.Journal of chemical neuroanatomy, , Volume: 125, 2022
Peripheral mechanisms of acute olanzapine induced metabolic dysfunction: A review of in vivo models and treatment approaches.Behavioural brain research, , 02-26, Volume: 400, 2021
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.Progress in neuro-psychopharmacology & biological psychiatry, , 06-08, Volume: 108, 2021
Therapeutic potential of TAK-071, a muscarinic MNeuroscience letters, , 11-01, Volume: 764, 2021
Olanzapine Induces Inflammation and Immune Response via Activating ER Stress in the Rat Prefrontal Cortex.Current medical science, , Volume: 41, Issue:4, 2021
Long-term chemogenetic suppression of seizures in a multifocal rat model of temporal lobe epilepsy.Epilepsia, , Volume: 62, Issue:3, 2021
Maternal immune activation and repeated maternal separation alter offspring conditioned avoidance response learning and antipsychotic response in male rats.Behavioural brain research, , 04-09, Volume: 403, 2021
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 133, 2021
1MeTIQ and olanzapine, despite their neurochemical impact, did not ameliorate performance in fear conditioning and social interaction tests in an MK-801 rat model of schizophrenia.Pharmacological reports : PR, , Volume: 73, Issue:2, 2021
Memory deterioration based on the tobacco smoke exposure and methylazoxymethanol acetate administration vs. aripiprazole, olanzapine and enrichment environment conditions.Pharmacology, biochemistry, and behavior, , Volume: 189, 2020
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.Toxicology and applied pharmacology, , 11-01, Volume: 406, 2020
Paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuating impairment of the dopamine D2 receptor and TGF-β1 signaling pathways in the hypothalamus and pituitary.Journal of ethnopharmacology, , Jul-15, Volume: 257, 2020
Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats.Behavioural brain research, , 01-27, Volume: 378, 2020
The Probiotic Mixture VSL#3 Reverses Olanzapine-Induced Metabolic Dysfunction in Mice.Methods in molecular biology (Clifton, N.J.), , Volume: 2011, 2019
Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease.Circulation research, , 08-02, Volume: 125, Issue:4, 2019
Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance.Scientific reports, , 02-07, Volume: 9, Issue:1, 2019
Ketogenic diet and olanzapine treatment alone and in combination reduce a pharmacologically-induced prepulse inhibition deficit in female mice.Schizophrenia research, , Volume: 212, 2019
Schizophrenia-like olfactory dysfunction induced by acute and postnatal phencyclidine exposure in rats.Schizophrenia research, , Volume: 199, 2018
DoE based Olanzapine loaded poly-caprolactone nanoparticles decreases extrapyramidal effects in rodent model.International journal of pharmaceutics, , Apr-25, Volume: 541, Issue:1-2, 2018
Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.Pharmacology research & perspectives, , Volume: 6, Issue:1, 2018
Importance of intervention timing in the effectiveness of antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-02, Volume: 81, 2018
Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats.Scientific reports, , 06-05, Volume: 7, Issue:1, 2017
Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.Brain and behavior, , Volume: 7, Issue:8, 2017
Subchronic olanzapine exposure leads to increased expression of myelination-related genes in rat fronto-medial cortex.Translational psychiatry, , 11-30, Volume: 7, Issue:11, 2017
ADN-1184, a monoaminergic ligand with 5-HT6/7 receptor antagonist action, exhibits activity in animal models of anxiety.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 389, Issue:6, 2016
Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model.Acta neuropsychiatrica, , Volume: 28, Issue:6, 2016
Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia.Schizophrenia research, , Volume: 177, Issue:1-3, 2016
mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.Psychopharmacology, , Volume: 233, Issue:8, 2016
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.Translational psychiatry, , Apr-19, Volume: 6, 2016
The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol.Pharmacological reports : PR, , Volume: 68, Issue:2, 2016
Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.Bipolar disorders, , Volume: 17, Issue:6, 2015
Exercise prevents downregulation of hippocampal presynaptic proteins following olanzapine-elicited metabolic dysregulation in rats: Distinct roles of inhibitory and excitatory terminals.Neuroscience, , Aug-20, Volume: 301, 2015
Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.Brain research, , Aug-27, Volume: 1618, 2015
Dopamine D2/3 receptor antagonism reduces activity-based anorexia.Translational psychiatry, , Aug-04, Volume: 5, 2015
Effects of glucose and disorders in lipid metabolism on cytokine levels and cognitive impairment in the olanzapine-induced obesity rat model.Genetics and molecular research : GMR, , Sep-25, Volume: 14, Issue:3, 2015
Olanzapine augments the effect of selective serotonin reuptake inhibitors by suppressing GABAergic inhibition via antagonism of 5-HT₆ receptors in the dorsal raphe nucleus.Neuropharmacology, , Volume: 95, 2015
Structure-activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity.European journal of medicinal chemistry, , Jun-05, Volume: 97, 2015
The effects of valproate and olanzapine on the abnormal behavior of diacylglycerol kinase β knockout mice.Pharmacological reports : PR, , Volume: 67, Issue:2, 2015
Effects of lisdexamfetamine in a rat model of binge-eating.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:12, 2015
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 12, Issue:1, 2015
Modelling olanzapine-induced weight gain in rats.The international journal of neuropsychopharmacology, , Volume: 17, Issue:1, 2014
Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.Schizophrenia research, , Volume: 159, Issue:2-3, 2014
Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.The international journal of neuropsychopharmacology, , Volume: 17, Issue:1, 2014
Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-03, Volume: 48, 2014
Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.PloS one, , Volume: 9, Issue:8, 2014
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.Pharmacological reports : PR, , Volume: 65, Issue:1, 2013
Neuroprotective effects of olanzapine in N-methyl-D-aspartate-induced retinal injury.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, , Volume: 29, Issue:4, 2013
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.Molecular psychiatry, , Volume: 18, Issue:5, 2013
Olanzapine suppresses the rewarding and discriminative stimulus effects induced by morphine.Synapse (New York, N.Y.), , Volume: 66, Issue:2, 2012
Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice.Life sciences, , Dec-17, Volume: 91, Issue:25-26, 2012
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.Behavioural pharmacology, , Volume: 23, Issue:7, 2012
Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:9, 2012
Olanzapine, but not fluoxetine, treatment increases survival in activity-based anorexia in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 37, Issue:7, 2012
Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations.Pharmacology, biochemistry, and behavior, , Volume: 100, Issue:1, 2011
Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.Behavioural brain research, , Jan-20, Volume: 216, Issue:2, 2011
Behavioral and pharmacological assessment of a potential new mouse model for mania.Physiology & behavior, , Jun-01, Volume: 103, Issue:3-4, 2011
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.Psychopharmacology, , Volume: 214, Issue:3, 2011
A murine model of atypical antipsychotic-induced weight gain and metabolic dysregulation.Current protocols in neuroscience, , Volume: Chapter 9, 2010
Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:9, 2010
The effect of olanzapine pretreatment on acute cocaine toxicity in mice.Clinical toxicology (Philadelphia, Pa.), , Volume: 47, Issue:6, 2009
Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.Behavioural pharmacology, , Volume: 20, Issue:1, 2009
Asenapine effects in animal models of psychosis and cognitive function.Psychopharmacology, , Volume: 206, Issue:4, 2009
Insulin resistance following continuous, chronic olanzapine treatment: an animal model.Schizophrenia research, , Volume: 104, Issue:1-3, 2008
Olanzapine counteracts stress-induced anxiety-like behavior in rats.Neuroscience letters, , Jun-20, Volume: 438, Issue:2, 2008
Haloperidol both prevents and reverses quinpirole-induced nonregulatory water intake, a putative animal model of psychogenic polydipsia.Psychopharmacology, , Volume: 200, Issue:2, 2008
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex.Schizophrenia research, , Volume: 101, Issue:1-3, 2008
Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.European journal of pharmacology, , May-06, Volume: 585, Issue:1, 2008
Olanzapine improves deficient sensory inhibition in DBA/2 mice.Brain research, , Oct-03, Volume: 1233, 2008
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.Psychopharmacology, , Volume: 193, Issue:4, 2007
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.Journal of psychiatric research, , Volume: 41, Issue:5, 2007
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.Nature medicine, , Volume: 13, Issue:9, 2007
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
A model for antipsychotic-induced obesity in the male rat.Psychopharmacology, , Volume: 187, Issue:4, 2006
Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.Obesity (Silver Spring, Md.), , Volume: 14, Issue:1, 2006
Neuroprotective effects of olanzapine in a rat model of neurodevelopmental injury.Pharmacology, biochemistry, and behavior, , Volume: 83, Issue:2, 2006
Efficacy of olanzapine and haloperidol in an animal model of mania.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.Psychopharmacology, , Volume: 186, Issue:4, 2006
Olanzapine attenuates brain damage after focal cerebral ischemia in vivo.Brain research bulletin, , Dec-11, Volume: 71, Issue:1-3, 2006
Antipsychotic-induced weight gain.Diabetes, obesity & metabolism, , Volume: 7, Issue:5, 2005
Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats.Biological psychiatry, , Feb-15, Volume: 57, Issue:4, 2005
Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?Biological psychiatry, , Oct-15, Volume: 58, Issue:8, 2005
A neurobehavioral screening of the ckr mouse mutant: implications for an animal model of schizophrenia.Brain research bulletin, , Jan-15, Volume: 62, Issue:4, 2004
Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Jul-16, Volume: 23, Issue:15, 2003
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.Pharmacology, biochemistry, and behavior, , Volume: 75, Issue:1, 2003
New treatment for Ecstasy-related hyperthermia.Internal medicine journal, , Volume: 33, Issue:12, 2003
Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 27, Issue:1, 2002
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Insulin Resistance-Related Proteins Are Overexpressed in Patients and Rats Treated With Olanzapine and Are Reverted by Pueraria in the Rat Model.Journal of clinical psychopharmacology, , Volume: 39, Issue:3
Central dopaminergic system plays a role in the analgesic action of paracetamol: Preclinical evidence.Indian journal of pharmacology, , Volume: 49, Issue:1
Evaluation of antidepressant like property of amisulpride per se and its comparison with fluoxetine and olanzapine using forced swimming test in albino mice.Acta poloniae pharmaceutica, , Volume: 66, Issue:3
Using Caenorhabditis elegans as a Model for Obesity Pharmacology Development.American journal of therapeutics, , Volume: 23, Issue:6
Selective prescribing of atypical antipsychotics.Pharmacoepidemiology and drug safety, , Volume: 14, Issue:1, 2005
Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:6, 1998
A case of catatonia in a 14-year-old girl with schizophrenia treated with electroconvulsive therapy.Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 41, Issue:1, 2013
Differential weight restoration on olanzapine versus fluoxetine in identical twins with anorexia nervosa.The International journal of eating disorders, , Volume: 45, Issue:2, 2012
Olanzapine: concordant response in monozygotic twins with schizophrenia.The British journal of psychiatry : the journal of mental science, , Volume: 178, Issue:1, 2001
Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial.Human psychopharmacology, , Volume: 36, Issue:1, 2021
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.The American journal of psychiatry, , 06-01, Volume: 176, Issue:6, 2019
A Review of Asenapine in the Treatment of Bipolar Disorder.Clinical drug investigation, , Volume: 38, Issue:2, 2018
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.BMC psychiatry, , Apr-02, Volume: 15, 2015
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.Clinical schizophrenia & related psychoses, , Volume: 8, Issue:4, 2015
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.The Journal of clinical psychiatry, , Volume: 67, Issue:11, 2006
Safety of olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Olanzapine for schizophrenia.The Medical letter on drugs and therapeutics, , Jan-17, Volume: 39, Issue:992, 1997
Olanzapine-induced photo-allergic reaction.The Australian and New Zealand journal of psychiatry, , Volume: 52, Issue:8, 2018
Suspicion of a new cross-reaction between carbamazepine and olanzapine.Journal of investigational allergology & clinical immunology, , Volume: 24, Issue:1, 2014
Olanzapine-induced anaphylactic shock: a case report.Pharmacopsychiatry, , Volume: 45, Issue:1, 2012
Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Successful clozapine retrial after suspected myocarditis.The American journal of psychiatry, , Volume: 167, Issue:3, 2010
Photosensitivity might be associated with drug-induced hypersensitivity syndrome.Dermatology (Basel, Switzerland), , Volume: 214, Issue:4, 2007
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
[Bullae induced by acute neuroleptic intoxication].Annales de dermatologie et de venereologie, , Volume: 127, Issue:10, 2000
Guillain-Barré-like syndrome associated with olanzapine hypersensitivity reaction.Clinical neuropharmacology, , Volume: 28, Issue:3
Can atypical dysgeusia in depression be related to a deafferentation syndrome?Medical hypotheses, , Volume: 144, 2020
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Treatment of glossodynia with olanzapine.Journal of the American Academy of Dermatology, , Volume: 51, Issue:3, 2004
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.Journal of psychiatric research, , Volume: 85, 2017
Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines.BMC psychiatry, , Dec-08, Volume: 17, Issue:1, 2017
Dementia with Lewy bodies presenting marked tongue protrusion and bite due to lingual dystonia: A case report.Rinsho shinkeigaku = Clinical neurology, , 06-22, Volume: 56, Issue:6, 2016
Olanzapine as a possible replacement choice for paliperidone-induced Pisa syndrome: a case report.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 24, Issue:6, 2016
Neurological Adverse Effects of Antipsychotics in Children and Adolescents.Journal of clinical psychopharmacology, , Volume: 35, Issue:6, 2015
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 54, Issue:9, 2015
Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.Clinical schizophrenia & related psychoses, , Volume: 7, Issue:4, 2014
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.The Journal of clinical psychiatry, , Volume: 74, Issue:11, 2013
The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.Journal of clinical psychopharmacology, , Volume: 33, Issue:3, 2013
Paliperidone-related Pisa syndrome.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:6, 2011
Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 36, Issue:8, 2011
The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 72, Issue:7, 2011
Tardive dystonia induced by switch of atypical antipsychotics.Pharmacopsychiatry, , Volume: 43, Issue:5, 2010
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.BMC psychiatry, , Mar-24, Volume: 10, 2010
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 24, Issue:3, 2009
Clinical trials design lessons from the CATIE study.The American journal of psychiatry, , Volume: 166, Issue:11, 2009
Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:4, 2009
[Neuroleptic adverse effects with emphasis on weight gain].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 37, Issue:4, 2009
Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 19, Issue:8, 2009
What CATIE found: results from the schizophrenia trial.Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
A case of sodium oxybate treatment of tardive dyskinesia and bipolar disorder.The Journal of clinical psychiatry, , Volume: 69, Issue:5, 2008
Clinical experiences and clinical trials.CNS spectrums, , Volume: 13, Issue:6, 2008
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.Psychopharmacology bulletin, , Volume: 40, Issue:2, 2007
[Gilles-de-la-Tourette Syndrome as a Tardive Dyskinesia].Psychiatrische Praxis, , Volume: 34, Issue:5, 2007
Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Olanzapine-induced tardive dystonia successfully treated by tetrabenazine.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 19, Issue:4, 2007
A 6-month longitudinal study of early-onset tardive dyskinesia: association with olanzapine treatment and mild cognitive impairment in an elderly woman.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.Psychoneuroendocrinology, , Volume: 32, Issue:2, 2007
Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-30, Volume: 31, Issue:1, 2007
Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Enhanced efficacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade: experimental evidence.The international journal of neuropsychopharmacology, , Volume: 10, Issue:2, 2007
[The use of atypical antipsychotics in the long-term care of schizophrenia].L'Encephale, , Volume: 32 Pt 3, 2006
Antipsychotic drugs and schizophrenia.The New England journal of medicine, , Jan-19, Volume: 354, Issue:3, 2006
Clozapine effective in olanzapine-induced Pisa syndrome.The Annals of pharmacotherapy, , Volume: 40, Issue:12, 2006
Selecting antipsychotics in schizophrenia: lessons from CATIE.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:3, 2006
Paradoxical dyskinesia with olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 18, Issue:1, 2006
Atypical antipsychotics, tardive dyskinesia, and D(2) receptors.The American journal of psychiatry, , Volume: 163, Issue:8, 2006
The choice of antipsychotic drugs for schizophrenia.The New England journal of medicine, , Sep-22, Volume: 353, Issue:12, 2005
Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:11, 2005
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:5 Suppl, 2005
Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats.Biological psychiatry, , Feb-15, Volume: 57, Issue:4, 2005
Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.Psychiatry and clinical neurosciences, , Volume: 59, Issue:4, 2005
[Rabbit syndrome due to olanzapine].Psychiatrische Praxis, , Volume: 32, Issue:4, 2005
Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:7, 2005
The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.European archives of psychiatry and clinical neuroscience, , Volume: 254, Issue:6, 2004
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:8, 2004
Tardive dyskinesia rates with atypical antipsychotics in older adults.The Journal of clinical psychiatry, , Volume: 65 Suppl 9, 2004
Tardive dyskinesia associated with olanzapine in a neuroleptic-naive patient with schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:5, 2004
Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:1, 2004
Tardive dystonia induced by atypical neuroleptics: a case report with olanzapine.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 14, Issue:1, 2004
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.The American journal of psychiatry, , Volume: 161, Issue:3, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.The international journal of neuropsychopharmacology, , Volume: 6, Issue:4, 2003
Rapid onset of dyskinesia induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 57, Issue:6, 2003
Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Differential effects of antipsychotics on haloperidol-induced vacuous chewing movements and subcortical gene expression in the rat.European journal of pharmacology, , Sep-12, Volume: 477, Issue:2, 2003
Successful therapy of tardive dyskinesia in a 71-year-old woman with a combination of tetrabenazine, olanzapine and tiapride.International journal of clinical practice, , Volume: 57, Issue:2, 2003
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.Wiener klinische Wochenschrift, , Jan-31, Volume: 115, Issue:1-2, 2003
Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine.Behavioural pharmacology, , Volume: 14, Issue:3, 2003
Olanzepine-induced tardive dyskinesia.The British journal of psychiatry : the journal of mental science, , Volume: 182, 2003
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:5, 2003
Clozapine is more efficacious for tongue dystonia than olanzapine.Psychopharmacology, , Volume: 162, Issue:1, 2002
[Improvement of tardive dyskinesia after treatment with olanzapine].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.Journal of pain and symptom management, , Volume: 23, Issue:6, 2002
Olanzapine and improvement of tardive dyskinesia.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:7, 2002
Tardive dyskinesias and antipsychotics: a review.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:3, 2002
Movement disorders associated with atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 63 Suppl 4, 2002
Rapid onset of tardive dyskinesia in Huntington disease with olanzapine.Journal of clinical psychopharmacology, , Volume: 22, Issue:4, 2002
Improvement of tardive dyskinesia following switch from neuroleptics to olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:4, 2002
Use of atypical antipsychotics in a Veterans Affairs hospital.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:6, 2002
Effects of development on olanzapine-associated adverse events.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 41, Issue:12, 2002
Olanzapine in the treatment of tardive dyskinesia: a report of 2 cases.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 16, Issue:4, 2001
Ondansetron for tardive dyskinesia.The American journal of psychiatry, , Volume: 158, Issue:4, 2001
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.Schizophrenia bulletin, , Volume: 27, Issue:4, 2001
Effect of chronic olanzapine treatment on striatal synaptic organization.Synapse (New York, N.Y.), , Volume: 39, Issue:1, 2001
Tardive dystonia associated with olanzapine therapy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 22, Issue:4, 2001
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.Biological psychiatry, , Jan-01, Volume: 49, Issue:1, 2001
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 13, Issue:4, 2001
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Aug-28, Volume: 57, Issue:4, 2001
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.The international journal of neuropsychopharmacology, , Volume: 4, Issue:3, 2001
The treatment of tardive dyskinesia and tardive dystonia.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Tardive dyskinesia in older patients.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].Der Nervenarzt, , Volume: 71, Issue:5, 2000
Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.South Dakota journal of medicine, , Volume: 53, Issue:2, 2000
Remission of tardive dyskinesia after changing from flupenthixol to olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 15, Issue:5, 2000
Risperidone and tardive dyskinesia: a case of blepharospasm.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:5, 2000
New antipsychotic medications: more than old wine and new bottles.Bulletin of the Menninger Clinic, ,Winter, Volume: 64, Issue:1, 2000
Low-dose olanzapine for levodopa induced dyskinesias.Neurology, , Sep-26, Volume: 55, Issue:6, 2000
Improvement of tardive dyskinesia in a bipolar patient with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 15, Issue:7, 2000
[Atypical antipsychotics].Der Nervenarzt, , Volume: 71, Issue:5, 2000
Drug review "surprises" reader.Canadian family physician Medecin de famille canadien, , Volume: 46, 2000
Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 12, Issue:1, 2000
Rabbit syndrome treated with olanzapine.The British journal of psychiatry : the journal of mental science, , Volume: 176, 2000
Olanzapine to treat the acute mania of bipolar disorder.South Dakota journal of medicine, , Volume: 53, Issue:12, 2000
A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.International clinical psychopharmacology, , Volume: 14, Issue:3, 1999
Olanzapine. A pharmacoeconomic review of its use in schizophrenia.PharmacoEconomics, , Volume: 15, Issue:6, 1999
Improvement of tardive dyskinesia following treatment with olanzapine.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 9, Issue:4, 1999
Olanzapine in the long-term treatment of schizophrenia.The British journal of psychiatry. Supplement, , Issue:37, 1999
Olanzapine in the treatment of tardive dyskinesia: a report of two cases.Journal of clinical psychopharmacology, , Volume: 19, Issue:1, 1999
Tardive dyskinesia in affective disorders.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Conventional vs. newer antipsychotics in elderly patients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Winter, Volume: 7, Issue:1, 1999
Tardive dyskinesia associated with olanzapine monotherapy.The Journal of clinical psychiatry, , Volume: 60, Issue:12, 1999
Olanzapine-induced tardive dystonia.The American journal of psychiatry, , Volume: 156, Issue:10, 1999
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.The British journal of psychiatry : the journal of mental science, , Volume: 174, 1999
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.Biological psychiatry, , Feb-15, Volume: 45, Issue:4, 1999
Tardive dyskinesia associated with olanzapine.Annals of internal medicine, , Jul-06, Volume: 131, Issue:1, 1999
Olanzapine and tardive dyskinesia.The British journal of psychiatry : the journal of mental science, , Volume: 175, 1999
Tardive dyskinesia and atypical antipsychotic drugs.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Emerging roles for novel antipsychotic medications in the treatment of schizophrenia.The Psychiatric clinics of North America, , Volume: 21, Issue:1, 1998
Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:6, 1998
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Metronome or alternating Pisa syndrome: a form of tardive dystonia under clozapine treatment.International clinical psychopharmacology, , Volume: 13, Issue:5, 1998
Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 19, Issue:5, 1998
The routine use of atypical antipsychotic agents: maintenance treatment.The Journal of clinical psychiatry, , Volume: 59 Suppl 19, 1998
Marked reduction of tardive dyskinesia with olanzapine.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Olanzapine for the treatment of tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 59, Issue:7, 1998
The relationship of pharmacology to side effects.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.The American journal of psychiatry, , Volume: 154, Issue:9, 1997
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.Journal of clinical psychopharmacology, , Volume: 17, Issue:5, 1997
Olanzapine motor side effect.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 16, Issue:1, 1997
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 14, Issue:2, 1996
Side effect profiles of new antipsychotic agents.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Olanzapine: a new typical antipsychotic drug.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 14, Issue:2, 1996
The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:3
[Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions].Psychiatria polska, , Volume: 48, Issue:6
Comment on Nasrallah et al: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 12, Issue:6
Dose-Dependent Effects of Lithium Treatment on the Aggravation of Antipsychotic-Induced Pisa Syndrome.Clinical neuropharmacology, , Volume: 43, Issue:3
Treatment of respiratory dyskinesia with olanzapine.Psychosomatics, , Volume: 40, Issue:3
Treatment with atypical antipsychotics: new indications and new populations.Journal of psychiatric research, , Volume: 35, Issue:3
Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study.General hospital psychiatry, , Volume: 22, Issue:2
Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases.Clinical neuropharmacology, , Volume: 28, Issue:4
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.Journal of affective disorders, , 12-01, Volume: 277, 2020
Clinical Pearls in palliative medicine.Disease-a-month : DM, , Volume: 63, Issue:6, 2017
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients.The American journal of emergency medicine, , Volume: 65, 2023
Late-Onset Dystonia With Low-Dose Olanzapine in an Older Person: A Case Report.The Senior care pharmacist, , Oct-01, Volume: 36, Issue:10, 2021
[A case suspected of dystonia with marked cerebellar atrophy with torsion dystonia of the neck and cerebellar ataxia that developed during pharmacologic schizophrenia treatment].Rinsho shinkeigaku = Clinical neurology, , Aug-07, Volume: 60, Issue:8, 2020
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
Olanzapine as a possible replacement choice for paliperidone-induced Pisa syndrome: a case report.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 24, Issue:6, 2016
Olanzapine-related repetitive focal seizures with lingual dystonia.Epileptic disorders : international epilepsy journal with videotape, , Volume: 18, Issue:1, 2016
Dementia with Lewy bodies presenting marked tongue protrusion and bite due to lingual dystonia: A case report.Rinsho shinkeigaku = Clinical neurology, , 06-22, Volume: 56, Issue:6, 2016
Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.Clinical schizophrenia & related psychoses, , Volume: 7, Issue:4, 2014
Blonanserin improved dystonia induced by risperidone or olanzapine in two patients with schizophrenia.The Journal of neuropsychiatry and clinical neurosciences, , Apr-01, Volume: 26, Issue:2, 2014
Does propofol induction in patients on olanzapine increase the susceptibility to dystonic reactions?Acta anaesthesiologica Scandinavica, , Volume: 55, Issue:5, 2011
Acute respiratory distress due to antipsychotic drugs.Pharmacopsychiatry, , Volume: 43, Issue:3, 2010
A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.Journal of psychiatric research, , Volume: 43, Issue:5, 2009
Chronic Pisa syndrome associated with switching antipsychotics from olanzapine to ziprasidone.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-01, Volume: 33, Issue:1, 2009
Olanzapine-induced oculogyric crisis in a patient with schizophrenia.Indian journal of medical sciences, , Volume: 62, Issue:6, 2008
Parkinsonism and tardive antecollis in frontotemporal dementia--increased sensitivity to newer antipsychotics?European journal of neurology, , Volume: 15, Issue:2, 2008
Acute olanzapine-induced akathisia and dystonia in a patient discontinued from fluoxetine.The Journal of emergency medicine, , Volume: 30, Issue:3, 2006
Clozapine effective in olanzapine-induced Pisa syndrome.The Annals of pharmacotherapy, , Volume: 40, Issue:12, 2006
Reappearance of tardive dystonia with olanzapine treated with clozapine.Schizophrenia research, , Jul-15, Volume: 76, Issue:2-3, 2005
Treatment of tardive pharyngolaryngeal dystonia with olanzapine.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Improvement of generalised dystonia by olanzapine treatment.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 11, Issue:1, 2004
Acute dystonia caused by low dosage of olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 15, Issue:2, 2003
Clozapine is more efficacious for tongue dystonia than olanzapine.Psychopharmacology, , Volume: 162, Issue:1, 2002
The treatment of tardive dyskinesia and tardive dystonia.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Tardive dyskinesia associated with olanzapine monotherapy.The Journal of clinical psychiatry, , Volume: 60, Issue:12, 1999
Risperidone-induced tardive dystonia and psychosis.Lancet (London, England), , Mar-20, Volume: 353, Issue:9157, 1999
Olanzapine-induced tardive dystonia.The American journal of psychiatry, , Volume: 156, Issue:10, 1999
[Acute dystonia].Nederlands tijdschrift voor geneeskunde, , Feb-28, Volume: 142, Issue:9, 1998
Acute dystonia with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:7, 1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Safety of olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Oculogyric Crisis Due to Low-Dose Olanzapine: A Case Report.Clinical neuropharmacology, , Volume: 44, Issue:6
Acute dystonia with intramuscular olanzapine in adolescent mania: a report.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:11-12
Treatment of patients with tardive dystonia with olanzapine.Clinical neuropharmacology, , Volume: 25, Issue:2
Dose-Dependent Effects of Lithium Treatment on the Aggravation of Antipsychotic-Induced Pisa Syndrome.Clinical neuropharmacology, , Volume: 43, Issue:3
Facial edema as an adverse drug reaction to olanzapine in a patient with cancer receiving palliative care.Palliative & supportive care, , Volume: 20, Issue:5, 2022
Lessons of the month 2: Olanzapine-induced hypothermia and hand oedema.Clinical medicine (London, England), , Volume: 22, Issue:3, 2022
Olanzapine associated palpebral edema: An uncommon adverse effect of a commonly prescribed drug.Asian journal of psychiatry, , Volume: 36, 2018
Olanzapine as a cause of peripheric edema in an elderly man.Aging clinical and experimental research, , Volume: 25, Issue:1, 2013
Olanzapine-induced limb edema simulating episodic angioedema with eosinophilia.The Journal of dermatology, , Volume: 39, Issue:12, 2012
[Edema related to treatment with olanzapine].Psychiatrische Praxis, , Volume: 36, Issue:3, 2009
Bilateral pedal edema associated with olanzapine use in manic episode of bipolar disorder: report of two cases.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 31, Issue:7, 2007
Olanzapine-associated bilateral eyelid edema.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Case report: edema related to olanzapine therapy.Canadian family physician Medecin de famille canadien, , Volume: 52, 2006
Olanzapine-associated bilateral pedal edema.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
Peripheral oedema in patients taking olanzapine.International clinical psychopharmacology, , Volume: 18, Issue:1, 2003
Facial edema with olanzapine.General hospital psychiatry, , Volume: 35, Issue:6
Dose-Dependent Facial Edema Secondary to Olanzapine in a Medium-Long Stay Psychiatry Ward: Case Report and Review of Cases.Journal of clinical psychopharmacology, , Volume: 42, Issue:2
Olanzapine-induced bilateral pedal edema: a case report.General hospital psychiatry, , Volume: 22, Issue:4
Olanzapine-associated Edema Decreasing Serum Lithium Concentrations: A Case Report.Journal of clinical psychopharmacology, , Volume: 40, Issue:5
Anti-NMDA (a-NMDAR) receptor encephalitis related to acute consumption of metamphetamine: Relevance of differential diagnosis.Revista espanola de anestesiologia y reanimacion, , Volume: 64, Issue:3, 2017
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3. Rapid tranquilisation in acute psychotic agitation.Emergency medicine journal : EMJ, , Volume: 28, Issue:1, 2011
[Quetiapine, an antipsychotic agent to consider in the differential diagnosis of convulsions].Revista espanola de anestesiologia y reanimacion, , Volume: 57, Issue:5, 2010
Managing the acutely agitated and psychotic patient.CNS spectrums, , Volume: 12, Issue:10 Suppl 1, 2007
Recurrent Catatonia: Infection and Immunity in an Idiopathic Illness.Journal of psychiatric practice, , 01-01, Volume: 29, Issue:1, 2023
Reversible splenial lesion syndrome with a hyperosmolar hyperglycemic state and neuroleptic malignant syndrome caused by olanzapine.Journal of diabetes investigation, , Volume: 8, Issue:3, 2017
[Patient with encephalitis presenting with olanzapine-responsive malignant catatonia].Rinsho shinkeigaku = Clinical neurology, , Volume: 50, Issue:5, 2010
Pediatric Acute-Onset Neuropsychiatric Syndrome and Catatonia: A Case Report.Psychosomatics, , Volume: 61, Issue:1
A Case of Olanzapine-Induced Cutaneous Eruption.The American journal of case reports, , Oct-01, Volume: 24, 2023
Olanzapine-induced peripheral eosinophilia and eosinophilic pleural effusion: A case report.Medicine, , Volume: 97, Issue:7, 2018
Eosinophilic myocarditis during treatment with olanzapine - report of two possible cases.BMC psychiatry, , Mar-17, Volume: 16, 2016
Eosinophilia Associated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
Olanzapine-induced limb edema simulating episodic angioedema with eosinophilia.The Journal of dermatology, , Volume: 39, Issue:12, 2012
[Eosinophilic myocarditis and sudden unexpected death in a younger patient treated with antipsychotics].Ugeskrift for laeger, , Oct-31, Volume: 173, Issue:44, 2011
Iatrogenic eosinophilic pleural effusion.European respiratory review : an official journal of the European Respiratory Society, , Volume: 20, Issue:120, 2011
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
Eosinophilia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:3, 2002
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Antipsychotic drugs in epilepsy.Neurologia i neurochirurgia polska, , Volume: 53, Issue:6, 2019
Antiepileptic effect of olanzapine in epilepsy patients with atypical depressive comorbidity.Epileptic disorders : international epilepsy journal with videotape, , Jun-01, Volume: 20, Issue:3, 2018
Development of forced normalisation psychosis with ethosuximide.BMJ case reports, , Dec-07, Volume: 2017, 2017
Levetiracetam associated acute hepatic failure requiring liver transplantation: case report.Journal of neurology, , Volume: 263, Issue:4, 2016
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 12, Issue:1, 2015
Interventions for psychotic symptoms concomitant with epilepsy.The Cochrane database of systematic reviews, , Dec-21, Issue:12, 2015
Folie à deux: double case-report of shared delusions with a fatal outcome.La Clinica terapeutica, , Volume: 162, Issue:1, 2011
Weight gain induced with olanzapine in adolescent.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Complete atrioventricular block-induced Torsade de pointes, manifested by epilepsy.The Korean journal of internal medicine, , Volume: 26, Issue:1, 2011
Interventions for psychotic symptoms concomitant with epilepsy.The Cochrane database of systematic reviews, , Oct-08, Issue:4, 2008
Possession states precipitated by nortriptyline.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine.Epilepsia, , Volume: 46, Issue:5, 2005
First case of lacosamide-induced psychosis.Clinical neuropharmacology, , Volume: 36, Issue:1
Psychiatric symptoms in a case of intracranial tuberculosis.Psychosomatics, , Volume: 43, Issue:1
Long-term chemogenetic suppression of seizures in a multifocal rat model of temporal lobe epilepsy.Epilepsia, , Volume: 62, Issue:3, 2021
Postictal psychosis treated successfully with olanzapine.The Journal of clinical psychiatry, , Volume: 73, Issue:9, 2012
Olanzapine for recurrent excessive irritability and psychotic symptoms after mesial temporal lobectomy in a patient with temporal lobe epilepsy.Epilepsy & behavior : E&B, , Volume: 9, Issue:3, 2006
Olanzapine for recurrent aggression in a patient with temporal lobe epilepsy who had temporal lobectomy.Journal of psychopharmacology (Oxford, England), , Volume: 17, Issue:3, 2003
Misdiagnosis of schizophrenia for a patient with epilepsy.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:1, 2001
A Case of Olanzapine-Induced Cutaneous Eruption.The American journal of case reports, , Oct-01, Volume: 24, 2023
Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.Die Pharmazie, , 09-01, Volume: 77, Issue:7, 2022
Skin rash occurring with olanzapine pamoate, but not with oral olanzapine, in a male with juvenile idiopathic arthritis.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:3, 2013
Acute generalized exanthematous pustulosis induced by olanzapine.Acta medica (Hradec Kralove), , Volume: 49, Issue:1, 2006
Acute Angle Closure in a Patient Using Olanzapine.Psychiatria Danubina, ,Summer, Volume: 34, Issue:2, 2022
A Case Report: Anti-Psychotic Agents Related Ocular Toxicity.Medicine, , Volume: 95, Issue:15, 2016
Olanzapine therapy in hallucinatory visions related to Bonnet syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 26, Issue:3, 2005
Side effects of olanzapine.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Facial ulcer treated with olanzapine.Clinical and experimental dermatology, , Volume: 38, Issue:5, 2013
Occupational airborne allergic contact dermatitis to olanzapine.Dermatitis : contact, atopic, occupational, drug, , Volume: 23, Issue:6
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.The Cochrane database of systematic reviews, , 09-21, Volume: 9, 2018
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.Journal of affective disorders, , Jan-01, Volume: 207, 2017
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
[Olanzapine in therapy of a somatoform disorder].Psychiatrische Praxis, , Volume: 30, Issue:8, 2003
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:5, 2003
Hypothalamic JNK1-hepatic fatty acid synthase axis mediates a metabolic rewiring that prevents hepatic steatosis in male mice treated with olanzapine via intraperitoneal: Additional effects of PTP1B inhibition.Redox biology, , Volume: 63, 2023
Anthocyanins from Molecules (Basel, Switzerland), , Oct-12, Volume: 26, Issue:20, 2021
Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane.The Journal of nutritional biochemistry, , Volume: 81, 2020
Up-regulation of hepatic fatty acid transporters and inhibition/down-regulation of hepatic OCTN2 contribute to olanzapine-induced liver steatosis.Toxicology letters, , Volume: 316, 2019
Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway.Acta pharmacologica Sinica, , Volume: 40, Issue:8, 2019
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.Psychoneuroendocrinology, , Volume: 108, 2019
Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
First report of manic-like symptoms in a COVID-19 patient with no previous history of a psychiatric disorder.Journal of affective disorders, , 12-01, Volume: 277, 2020
Olanzapine-Induced Fever.The primary care companion for CNS disorders, , 02-28, Volume: 21, Issue:1, 2019
A Case of Olanzapine-Induced Fever.Psychopharmacology bulletin, , 01-26, Volume: 47, Issue:1, 2017
Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine.Pharmacological reports : PR, , Volume: 65, Issue:2, 2013
Unexpected hospitalisation side effects in an elderly man.Internal and emergency medicine, , Volume: 6, Issue:2, 2011
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
Hyperthermia and rhabdomyolysis in an adolescent treated with topiramate and olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:1, 2008
Olanzapine withdrawal/discontinuation-induced hyperthermia in rats.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 31, Issue:7, 2007
Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats.Brain research, , Aug-27, Volume: 1018, Issue:2, 2004
Clozapine reverses hyperthermia and sympathetically mediated cutaneous vasoconstriction induced by 3,4-methylenedioxymethamphetamine (ecstasy) in rabbits and rats.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Jul-16, Volume: 23, Issue:15, 2003
New treatment for Ecstasy-related hyperthermia.Internal medicine journal, , Volume: 33, Issue:12, 2003
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].Minerva anestesiologica, , Volume: 69, Issue:6, 2003
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat.The Journal of pharmacology and experimental therapeutics, , Volume: 292, Issue:2, 2000
Possible neuroleptic malignant syndrome associated with olanzapine.The Annals of pharmacotherapy, , Volume: 34, Issue:5, 2000
Fever, delirium, autonomic instability, and monocytosis associated with olanzapine.Journal of postgraduate medicine, , Volume: 49, Issue:1
Reconsidering Olanzapine as a Possible Culprit for Drug Fever, defying "Incomplete Neuromalignant Syndrome".The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, , Volume: 168, Issue:4
The Utilization of Atypical Antipsychotics in the Pain Medicine Physician's Armamentarium.Psychopharmacology bulletin, , 06-20, Volume: 48, Issue:4, 2018
Current status of atypical antipsychotics for the treatment of fibromyalgia.Drugs of today (Barcelona, Spain : 1998), , Volume: 50, Issue:6, 2014
Decreased pain and improved quality of life in fibromyalgia patients treated with olanzapine, an atypical neuroleptic.Pain practice : the official journal of World Institute of Pain, , Volume: 6, Issue:2, 2006
Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:1, 2005
Olanzapine for the treatment of fibromyalgia symptoms.Journal of pain and symptom management, , Volume: 22, Issue:2, 2001
Olanzapine treatment improved quality of life in a patient with fibromyalgia syndrome: a psychological evaluation.Acta reumatologica portuguesa, , Volume: 36, Issue:3
Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 62, Issue:9, 2023
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.Swiss medical weekly, , Volume: 143, 2013
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.BMC psychiatry, , Mar-24, Volume: 10, 2010
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 9, Issue:3, 2007
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.Pharmacotherapy, , Volume: 26, Issue:6, 2006
[Endocrine side effects among psychiatric patients treated with antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:2, 2006
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.Psychoneuroendocrinology, , Volume: 31, Issue:5, 2006
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
Olanzapine-induced galactorrhea in a woman with psychotic illness.The Australian and New Zealand journal of psychiatry, , Volume: 38, Issue:4, 2004
Olanzapine-induced galactorrhea.Psychopharmacology, , Volume: 162, Issue:1, 2002
Quetiapine for olanzapine-induced galactorrhea.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.The American journal of psychiatry, , Volume: 155, Issue:10, 1998
Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.Journal of sex & marital therapy, , Volume: 29, Issue:2
Pharmacological interventions for the treatment of disordered and problem gambling.The Cochrane database of systematic reviews, , 09-22, Volume: 9, 2022
Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics.Psychopharmacology, , Volume: 222, Issue:1, 2012
A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers.Pharmacology, biochemistry, and behavior, , Volume: 89, Issue:3, 2008
Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial.The Journal of clinical psychiatry, , Volume: 69, Issue:3, 2008
Three cases of schizophrenia for which olanzapine was effective after early acute phase.Psychiatry and clinical neurosciences, , Volume: 62, Issue:1, 2008
Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists: A Retrospective Cohort Study.Journal of clinical psychopharmacology, , Volume: 39, Issue:6
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.Gynecologic oncology, , Volume: 156, Issue:3, 2020
Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.BMJ open, , 01-17, Volume: 9, Issue:1, 2019
Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study.Tumori, , Volume: 105, Issue:3, 2019
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
Olanzapine treatment for tics in an adult woman with severe tourette syndrome.Acta neurologica Taiwanica, , Volume: 21, Issue:4, 2012
[Neuroleptic adverse effects with emphasis on weight gain].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 37, Issue:4, 2009
Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:5, 2008
[Gilles-de-la-Tourette Syndrome as a Tardive Dyskinesia].Psychiatrische Praxis, , Volume: 34, Issue:5, 2007
Olanzapine in Gilles de la Tourette syndrome: beyond tics.Acta neurologica Belgica, , Volume: 105, Issue:4, 2005
Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 14, Issue:2, 2004
[Treatment of tics in Tourette syndrome with atypical antipsychotic drugs].Ugeskrift for laeger, , Aug-05, Volume: 164, Issue:32, 2002
An open-label study of the treatment efficacy of olanzapine for Tourette's disorder.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Low blood glucose and olanzapine.The American journal of psychiatry, , Volume: 158, Issue:3, 2001
Ziprasidone: a new atypical antipsychotic.Expert opinion on pharmacotherapy, , Volume: 2, Issue:6, 2001
Olanzapine in Tourette's disorder.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 39, Issue:2, 2000
Olanzapine in Tourette's disorder.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 39, Issue:2, 2000
Effective open-label treatment of tourette's disorder with olanzapine.International clinical psychopharmacology, , Volume: 15, Issue:1, 2000
Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs. low-dose pimozide.Journal of neurology, , Volume: 247, Issue:6, 2000
Olanzapine in Tourette syndrome.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
Open-label olanzapine treatment in five preadolescent children.Journal of child and adolescent psychopharmacology, , Volume: 8, Issue:2, 1998
[Olanzapine in Tourette's syndrome: a report of three cases].Actas espanolas de psiquiatria, , Volume: 30, Issue:2
The Radiosensitizing Effect of Olanzapine as an Antipsychotic Medication on Glioblastoma Cell.Current radiopharmaceuticals, , Volume: 15, Issue:1, 2022
Olanzapine inhibits proliferation, migration and anchorage-independent growth in human glioblastoma cell lines and enhances temozolomide's antiproliferative effect.Journal of neuro-oncology, , Volume: 122, Issue:1, 2015
Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?British journal of pharmacology, , Volume: 164, Issue:5, 2011
The Radiosensitizing Effect of Olanzapine as an Antipsychotic Medication on Glioblastoma Cell.Current radiopharmaceuticals, , Volume: 15, Issue:1, 2022
Olanzapine induced autophagy through suppression of NF-κB activation in human glioma cells.CNS neuroscience & therapeutics, , Volume: 25, Issue:9, 2019
Olanzapine inhibits the proliferation and induces the differentiation of glioma stem-like cells through modulating the Wnt signaling pathway in vitro.European review for medical and pharmacological sciences, , Volume: 19, Issue:13, 2015
Autophagy involvement in olanzapine-mediated cytotoxic effects in human glioma cells.Asian Pacific journal of cancer prevention : APJCP, , Volume: 15, Issue:19, 2014
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 9, Issue:3, 2007
[Endocrine side effects among psychiatric patients treated with antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:2, 2006
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.Pharmacotherapy, , Volume: 26, Issue:6, 2006
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.Psychoneuroendocrinology, , Volume: 31, Issue:5, 2006
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Olanzapine-induced gynecomastia.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:8, 2005
Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.Journal of sex & marital therapy, , Volume: 29, Issue:2
Delirium with visual hallucinations induced by low-dose olanzapine.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 22, Issue:3, 2022
Refractory Psychosis After Carbon Monoxide Poisoning: a Case Report.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 32, Issue:2, 2022
Delusional.Schizophrenia bulletin, , Dec-01, Volume: 46, Issue:6, 2020
Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India.Asian journal of psychiatry, , Volume: 54, 2020
Acute transient psychotic disorder precipitated by Brexit vote.BMJ case reports, , Oct-01, Volume: 12, Issue:10, 2019
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
Can typical and atypical antipsychotics show differential effectiveness in treating paranoia and hallucinations in schizophrenia?BMJ case reports, , Mar-31, Volume: 12, Issue:3, 2019
[A case of late-onset paraphrenia in a very elderly patient receiving home medical care].Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, , Volume: 55, Issue:4, 2018
Dhat syndrome as the prodrome of schizophrenia: Understanding the cultural distress.Asian journal of psychiatry, , Volume: 25, 2017
"Musical Ear Syndrome"-Musical hallucinations in a patient with severe hearing loss-A report.Asian journal of psychiatry, , Volume: 29, 2017
Anti-NMDA (a-NMDAR) receptor encephalitis related to acute consumption of metamphetamine: Relevance of differential diagnosis.Revista espanola de anestesiologia y reanimacion, , Volume: 64, Issue:3, 2017
Development of forced normalisation psychosis with ethosuximide.BMJ case reports, , Dec-07, Volume: 2017, 2017
Delusional infestation.The American journal of emergency medicine, , Volume: 35, Issue:2, 2017
A Case of Chronic Peduncular Hallucinosis in a 90-Year-Old Woman Successfully Treated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 36, Issue:3, 2016
[Buccolingual dyskinesia with justified hallucinations].Revista de neurologia, , Nov-16, Volume: 59, Issue:10, 2014
Topiramate improves psychiatric symptoms in a patient with Lewy body dementia.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 27, Issue:4, 2014
Add-on oral olanzapine worsens hallucinations in schizoaffective disorder.BMJ case reports, , Oct-21, Volume: 2014, 2014
Psychiatric manifestations of primary Sjögren's syndrome: a case report and literature review.BMJ case reports, , May-23, Volume: 2014, 2014
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.BMC psychiatry, , Sep-30, Volume: 13, 2013
A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.The Journal of clinical psychiatry, , Volume: 74, Issue:10, 2013
Lilliputian hallucinations in schizophrenia: a case report.African journal of psychiatry, , Volume: 15, Issue:5, 2012
Postictal psychosis treated successfully with olanzapine.The Journal of clinical psychiatry, , Volume: 73, Issue:9, 2012
Repetitive transcranial magnetic stimulation to treat early-onset auditory hallucinations.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:9, 2012
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 13, Issue:3, 2011
Peduncular hallucinosis.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:2, 2011
A potential case of peduncular hallucinosis treated successfully with olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Evaluation of the therapeutic effect of theta burst stimulation on drug-resistant auditory hallucinations in a schizophrenic patient and its impact on cognitive function and neuronal excitability: a case study.Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, , Volume: 121, Issue:5, 2010
Psychosis secondary to traumatic brain injury.Brain injury, , Volume: 23, Issue:4, 2009
[Turner-syndrome and psychosis: a case report and brief review of the literature].Psychiatrische Praxis, , Volume: 36, Issue:5, 2009
Reversal of head drop after discontinuation of olanzapine in a DLB patient.Movement disorders : official journal of the Movement Disorder Society, , Sep-15, Volume: 23, Issue:12, 2008
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Treatment of catatonia with electroconvulsive therapy in an 11-year-old girl.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:3, 2008
Item response analysis of the Positive and Negative Syndrome Scale.BMC psychiatry, , Nov-15, Volume: 7, 2007
Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Homatropine and psychosis in Weill-Marchesani syndrome.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 45, Issue:7, 2006
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 13, Issue:2, 2006
Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.Schizophrenia research, , Feb-28, Volume: 82, Issue:2-3, 2006
Olanzapine therapy in hallucinatory visions related to Bonnet syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 26, Issue:3, 2005
Evidence-based medicine and medicine-based evidence.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 26, Issue:3, 2005
Olanzapine-induced gynecomastia.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:8, 2005
Hypnopompic hallucinations during olanzapine treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:7, 2004
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.International journal of geriatric psychiatry, , Volume: 19, Issue:2, 2004
Charles-Bonnet syndrome and musical hallucination.International psychogeriatrics, , Volume: 16, Issue:4, 2004
P300 alterations in schizophrenic patients experiencing auditory hallucinations.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 14, Issue:3, 2004
Dependence and chronic psychosis with D-nor-pseudoephedrine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:8, 2003
Do atypical antipsychotics fail to exert cognitive sparing effects?Neuroreport, , Mar-03, Volume: 14, Issue:3, 2003
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.Dementia and geriatric cognitive disorders, , Volume: 13, Issue:2, 2002
Olanzapine treatment for dopaminergic-induced hallucinations.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:5, 2002
Atypical neuroleptic malignant syndrome associated with olanzapine.Pharmacotherapy, , Volume: 22, Issue:5, 2002
Using antipsychotics in elderly patients.The Practitioner, , Volume: 246, Issue:1639, 2002
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Aug-28, Volume: 57, Issue:4, 2001
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Aug-28, Volume: 57, Issue:4, 2001
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.The Journal of clinical psychiatry, , Volume: 62, Issue:1, 2001
Olanzapine for psychosis in Parkinson's disease.Neurology, , Jun-26, Volume: 56, Issue:12, 2001
Diabetic ketoacidosis associated with olanzapine in an adolescent patient.The Journal of pediatrics, , Volume: 138, Issue:6, 2001
Possible risperidone-induced visual hallucinations.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 39, Issue:9, 2000
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Sep-26, Volume: 55, Issue:6, 2000
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
Olanzapine: extrapyramidal side effects in the elderly.Australian and New Zealand journal of medicine, , Volume: 29, Issue:3, 1999
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 14, Issue:6, 1999
Olanzapine in dementia with Lewy bodies: a clinical study.International journal of geriatric psychiatry, , Volume: 14, Issue:6, 1999
Olanzapine overdose.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.Journal of neurology, neurosurgery, and psychiatry, , Volume: 65, Issue:5, 1998
Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
Antipsychotic-induced paroxysmal perceptual alteration.Clinical neuropharmacology, , Volume: 31, Issue:3
Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: a 24-month follow-up of 68 patients.American journal of Alzheimer's disease and other dementias, , Volume: 18, Issue:4
Hereditary spastic paraplegia and psychosis: connected by the corpus callosum?Psychosomatics, , Volume: 53, Issue:1
Psychosis in a Patient with Davidoff-Dyke-Masson Syndrome.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:1
Isolated nocturnal auditory hallucinations: a case report.General hospital psychiatry, , Volume: 33, Issue:5
[Psychotic episode due to Hashimoto's thyroiditis].Psychiatrike = Psychiatriki, , Volume: 27, Issue:2
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.Journal of clinical psychopharmacology, , Volume: 41, Issue:4
Uncommon side effects associated with olanzapine. A case report.Pharmacopsychiatry, , Volume: 36, Issue:2
Psychiatric symptoms in a case of intracranial tuberculosis.Psychosomatics, , Volume: 43, Issue:1
Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients.The American journal of emergency medicine, , Volume: 65, 2023
Pharmacological interventions for the treatment of disordered and problem gambling.The Cochrane database of systematic reviews, , 09-22, Volume: 9, 2022
Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial.Human psychopharmacology, , Volume: 36, Issue:1, 2021
Neurotropism of SARS-CoV-2: COVID-19 presenting with an acute manic episode.BMJ case reports, , Jun-14, Volume: 13, Issue:6, 2020
The Use, Safety, and Efficacy of Olanzapine in a Level I Pediatric Trauma Center Emergency Department Over a 10-Year Period.Pediatric emergency care, , Volume: 36, Issue:2, 2020
The Utilization of Atypical Antipsychotics in the Pain Medicine Physician's Armamentarium.Psychopharmacology bulletin, , 06-20, Volume: 48, Issue:4, 2018
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Olanzapine versus droperidol for the treatment of primary headache in the emergency department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, , Volume: 15, Issue:9, 2008
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.The Journal of clinical psychiatry, , Volume: 67, Issue:11, 2006
Olanzapine for the management of pain in an adolescent girl.Journal of child and adolescent psychopharmacology, , Volume: 15, Issue:6, 2005
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
Lipid resuscitation: listening to our patients and learning from our models.Anesthesia and analgesia, , Volume: 114, Issue:4, 2012
Fatal pulmonary embolism following antipsychotic treatment and physical restraint.Pharmacopsychiatry, , Volume: 42, Issue:5, 2009
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Developed catatonia with rhabdomyolysis and exacerbated cardiac failure upon switching from clozapine to olanzapine owing to cardiomyopathy during clozapine medication - A case report.Asian journal of psychiatry, , Volume: 80, 2023
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
Fatal pulmonary embolism following antipsychotic treatment and physical restraint.Pharmacopsychiatry, , Volume: 42, Issue:5, 2009
[A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy].Der Nervenarzt, , Volume: 74, Issue:7, 2003
Effects of lactational exposure of olanzapine and risperidone on hematology and lymphoid organs histopathology: a comparative study in mice neonates.European journal of pharmacology, , May-25, Volume: 634, Issue:1-3, 2010
Olanzapine (Zyprexa): suspected serious reactions.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jul-11, Volume: 163, Issue:1, 2000
Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum.Forensic science international, , Jun-10, Volume: 229, Issue:1-3, 2013
LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood.Forensic science international, , Jun-10, Volume: 229, Issue:1-3, 2013
Assessing the matrix effects of hemolyzed samples in bioanalysis.Bioanalysis, , Volume: 1, Issue:6, 2009
Treating mania in Wilson's disease with lithium.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 20, Issue:4, 2008
Wilson's disease associated with delusional disorder.Psychiatry and clinical neurosciences, , Volume: 60, Issue:6, 2006
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 13, Issue:4, 2001
A comparative study of beneficial effects of Olanzapine and sodium valproate on aggressive behavior of patients who are on methadone maintenance therapy: a randomized triple blind clinical trial.European review for medical and pharmacological sciences, , Volume: 17, Issue:8, 2013
Venlafaxine for acute heroin detoxification: a double-blind, randomized, control trial.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Effects of olanzapine on aggressiveness in heroin dependent patients.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders.Clinical neuropharmacology, , Volume: 30, Issue:3
Olanzapine for cisplatin-induced hiccups: observations from a 338-patient study.Annals of palliative medicine, , Volume: 11, Issue:7, 2022
Clinical Pearls in palliative medicine.Disease-a-month : DM, , Volume: 63, Issue:6, 2017
Olanzapine and baclofen for the treatment of intractable hiccups.Pharmacotherapy, , Volume: 34, Issue:1, 2014
Treatment of intractable hiccups with olanzapine following recent severe traumatic brain injury.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 18, Issue:4, 2006
Hiccups associated with switching from olanzapine to aripiprazole in a patient with paranoid schizophrenia.Clinical neuropharmacology, , Volume: 37, Issue:3
Olanzapine in the management of psychosis in Huntington’s disease: a case report.Actas espanolas de psiquiatria, , Volume: 47, Issue:5, 2019
Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.Drugs, , Volume: 77, Issue:1, 2017
Biological Perspectives: Huntington's Disease.Perspectives in psychiatric care, , Volume: 51, Issue:3, 2015
Neuroleptic Malignant Syndrome Induced by Olanzapine in a Patient with Huntington's Disease.Journal of Huntington's disease, , Volume: 1, Issue:1, 2012
[A case of affective disorder with psychotic symptoms as late manifestation of Huntington's Chorea].Psychiatrische Praxis, , Volume: 38, Issue:6, 2011
Hypersexual features in Huntington's disease.Singapore medical journal, , Volume: 52, Issue:6, 2011
Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 22, Issue:3, 2010
Premorbid combat related ptsd in Huntington's disease - Case report.Psychiatria Danubina, , Volume: 22, Issue:2, 2010
[Huntington's disease: a negative family history case report demonstrating reduction of psychiatric symptoms with olanzapine].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 31, Issue:2, 2009
Functional and motor response to low dose olanzapine in Huntington's disease: case report.Arquivos de neuro-psiquiatria, , Volume: 62, Issue:4, 2004
Olanzapine-associated seizure.The Annals of pharmacotherapy, , Volume: 37, Issue:1, 2003
Riluzole and olanzapine in Huntington's disease.European journal of neurology, , Volume: 9, Issue:2, 2002
High-dose olanzapine in Huntington's disease.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
Olanzapine in Huntington's disease.Acta neurologica Scandinavica, , Volume: 105, Issue:6, 2002
Apraxia of eyelid closure in Huntington's disease.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 109, Issue:2, 2002
Rapid onset of tardive dyskinesia in Huntington disease with olanzapine.Journal of clinical psychopharmacology, , Volume: 22, Issue:4, 2002
Short-term effects of olanzapine in Huntington disease.Neuropsychiatry, neuropsychology, and behavioral neurology, , Volume: 14, Issue:1, 2001
Olanzapine and Huntington's disease.Journal of clinical psychopharmacology, , Volume: 21, Issue:2, 2001
Improvement of Huntington's disease with olanzapine and valproate.The New England journal of medicine, , Sep-28, Volume: 343, Issue:13, 2000
Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report.Arquivos de neuro-psiquiatria, , Volume: 57, Issue:3B, 1999
The use of olanzapine for movement disorder in Huntington's disease: a first case report.Journal of neurology, neurosurgery, and psychiatry, , Volume: 67, Issue:1, 1999
Olanzapine for Huntington's disease: an open label study.Clinical neuropharmacology, , Volume: 25, Issue:5
[Olanzapine improves chorea in patients with Huntington's disease].Revista de neurologia, , Volume: 35, Issue:6
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
Mania in a case of hyperparathyroidism.Psychosomatics, , Volume: 48, Issue:3
Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , 06-08, Volume: 84, Issue:Pt A, 2018
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).The American journal of psychiatry, , Volume: 168, Issue:9, 2011
Switching antipsychotic medications: not enough, too often, or just right?The American journal of psychiatry, , Volume: 168, Issue:9, 2011
The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 70, Issue:3, 2009
The risks and benefits of switching antipsychotics: a case study approach.Perspectives in psychiatric care, , Volume: 45, Issue:1, 2009
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.Schizophrenia research, , Volume: 98, Issue:1-3, 2008
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:3, 2006
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
[Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].Medizinische Klinik (Munich, Germany : 1983), , Jul-15, Volume: 98, Issue:7, 2003
Fasting or the short-term consumption of a ketogenic diet protects against antipsychotic-induced hyperglycaemia in mice.The Journal of physiology, , Volume: 600, Issue:11, 2022
Voluntary physical activity protects against olanzapine-induced hyperglycemia.Journal of applied physiology (Bethesda, Md. : 1985), , 02-01, Volume: 130, Issue:2, 2021
GLP1 receptor agonism protects against acute olanzapine-induced hyperglycemia.American journal of physiology. Endocrinology and metabolism, , 12-01, Volume: 319, Issue:6, 2020
Female mice are protected against acute olanzapine-induced hyperglycemia.Psychoneuroendocrinology, , Volume: 110, 2019
Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome.Psychopharmacology, , Volume: 236, Issue:5, 2019
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.Toxicology and applied pharmacology, , 09-01, Volume: 378, 2019
Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.International journal of molecular sciences, , Feb-01, Volume: 20, Issue:3, 2019
AMPK β1 activation suppresses antipsychotic-induced hyperglycemia in mice.FASEB journal : official publication of the Federation of American Societies for Experimental Biology, , Volume: 33, Issue:12, 2019
Exercise Protects Against Olanzapine-Induced Hyperglycemia in Male C57BL/6J Mice.Scientific reports, , 01-15, Volume: 8, Issue:1, 2018
AICAR Prevents Acute Olanzapine-Induced Disturbances in Glucose Homeostasis.The Journal of pharmacology and experimental therapeutics, , Volume: 365, Issue:3, 2018
Obesity exacerbates the acute metabolic side effects of olanzapine.Psychoneuroendocrinology, , Volume: 88, 2018
Glucagon receptor knockout mice are protected against acute olanzapine-induced hyperglycemia.Psychoneuroendocrinology, , Volume: 82, 2017
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.Internal medicine (Tokyo, Japan), , Volume: 56, Issue:3, 2017
Mechanism Underlying Induction of Hyperglycemia in Rats by Single Administration of Olanzapine.Biological & pharmaceutical bulletin, , Volume: 39, Issue:5, 2016
Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data.Schizophrenia research, , Volume: 154, Issue:1-3, 2014
The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation.Cell structure and function, , Volume: 38, Issue:2, 2013
Olanzapine-induced hyperglycemia: possible involvement of histaminergic, dopaminergic and adrenergic functions in the central nervous system.Neuroendocrinology, , Volume: 98, Issue:3, 2013
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance.PloS one, , Volume: 7, Issue:8, 2012
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
Severe hyperglycemia induced by olanzapine was improved with a recovery of insulin secretion after switching to risperidone and introducing insulin therapy.Internal medicine (Tokyo, Japan), , Volume: 49, Issue:23, 2010
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.Journal of psychiatric research, , Volume: 43, Issue:11, 2009
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.Human psychopharmacology, , Volume: 24, Issue:3, 2009
Rapidly developing hyperglycemia during treatment with olanzapine.The Annals of pharmacotherapy, , Volume: 42, Issue:4, 2008
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:12, 2008
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
Relative risk of glucose elevation during antipsychotic exposure in a Veterans Administration population.International clinical psychopharmacology, , Volume: 22, Issue:1, 2007
Olanzapine-induced hyperglycemia in anorexia nervosa.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks.Diabetes care, , Volume: 30, Issue:1, 2007
Case report: lack of control of diabetes and weight gain in a patient on initiation and rechallenge of therapy with olanzapine.Journal of managed care pharmacy : JMCP, , Volume: 12, Issue:3, 2006
[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].Medicina clinica, , Apr-01, Volume: 126, Issue:12, 2006
Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.Psychiatry and clinical neurosciences, , Volume: 60, Issue:1, 2006
Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.Journal of the Indian Medical Association, , Volume: 103, Issue:12, 2005
Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors.Journal of clinical psychopharmacology, , Volume: 25, Issue:2, 2005
Diabetes mellitus during olanzapine and quetiapine treatment in Japan.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
[Atypical antipsychotic-associated impaired glucose tolerance].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 107, Issue:8, 2005
Newer antipsychotics and glucose metabolism: a comparison between olanzapine and risperidone.Psychiatria Danubina, , Volume: 17, Issue:1-2, 2005
The incidence of hyperglycemia in patients treated with olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Hyperglycemia associated with antipsychotic treatment in a multicenter drug safety project.Pharmacopsychiatry, , Volume: 37 Suppl 1, 2004
Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
Safety in treating bipolar disorder.The Journal of family practice, , Volume: Suppl, 2003
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Hyperglycemia from olanzapine treatment in adolescents.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 13, Issue:1, 2003
Should lipids be monitored during the first year of treatment with an atypical antipsychotic?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Diabetes mellitus associated with atypical anti-psychotic medications.Diabetes technology & therapeutics, , Volume: 5, Issue:4, 2003
Glucose intolerance with atypical antipsychotics.Drug safety, , Volume: 25, Issue:15, 2002
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.The Journal of clinical endocrinology and metabolism, , Volume: 87, Issue:6, 2002
Olanzapine-induced destabilization of diabetes in the absence of weight gain.Acta psychiatrica Scandinavica, , Volume: 105, Issue:3, 2002
Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report.International journal of geriatric psychiatry, , Volume: 17, Issue:4, 2002
Olanzapine-associated diabetes mellitus.Pharmacotherapy, , Volume: 22, Issue:7, 2002
Weight gain and hyperglycaemia associated with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:2, 2002
Fatality from olanzapine induced hyperglycemia.Journal of forensic sciences, , Volume: 47, Issue:4, 2002
Ziprasidone alternative for olanzapine-induced hyperglycemia.The American journal of psychiatry, , Volume: 159, Issue:9, 2002
[Uncontrolled hyperglycemia with ketosis associated with olanzapine therapy].Revista clinica espanola, , Volume: 202, Issue:12, 2002
Hyperglycemia and hypertriglyceridemia secondary to olanzapine.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 11, Issue:3, 2001
Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy.Pharmacotherapy, , Volume: 21, Issue:11, 2001
Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature.Pharmacotherapy, , Volume: 21, Issue:11, 2001
Hyperglycemia in patients with schizophrenia who are treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 21, Issue:3, 2001
Atypical antipsychotic drugs and hyperglycemia in adolescents.JAMA, , Nov-28, Volume: 286, Issue:20, 2001
Olanzapine-related hyperglycemia in a nondiabetic woman.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:5, 2001
Atypical antipsychotics and hyperglycaemia.International clinical psychopharmacology, , Volume: 16, Issue:2, 2001
Hyperglycemia associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 23, 2001
Hyperglycemia and olanzapine.The American journal of psychiatry, , Volume: 156, Issue:6, 1999
[Hyperglycemia and ketoacidosis associated with olanzapine].Der Nervenarzt, , Volume: 70, Issue:9, 1999
[The hyperglycemic dehydration syndrome].Nederlands tijdschrift voor geneeskunde, , Oct-10, Volume: 142, Issue:41, 1998
Hyperglycemia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature.Journal of intensive care medicine, , Volume: 22, Issue:1
Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy.American journal of therapeutics, , Volume: 10, Issue:5
Olanzapine and quick-response hyperglycemia.Psychosomatics, , Volume: 44, Issue:2
Reversible splenial lesion syndrome with a hyperosmolar hyperglycemic state and neuroleptic malignant syndrome caused by olanzapine.Journal of diabetes investigation, , Volume: 8, Issue:3, 2017
Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Olanzapine-induced hyperglycemic hyperosmolar nonketotic coma: a case report.Journal of clinical psychopharmacology, , Volume: 24, Issue:6, 2004
Olanzapine-lnduced hyperglycemic nonketonic coma.The Annals of pharmacotherapy, , Volume: 35, Issue:3, 2001
Antipsychotic Therapy-Induced New Onset Diabetic Ketoacidosis.American journal of therapeutics, , Volume: 23, Issue:6
Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.International journal of molecular sciences, , Feb-01, Volume: 20, Issue:3, 2019
Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia.American journal of physiology. Endocrinology and metabolism, , 08-01, Volume: 315, Issue:2, 2018
Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance.The Journal of endocrinology, , Volume: 227, Issue:2, 2015
Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.PloS one, , Volume: 8, Issue:1, 2013
Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.Psychopharmacology, , Volume: 213, Issue:1, 2011
Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance.Diabetes, , Volume: 59, Issue:10, 2010
Insulin resistance following continuous, chronic olanzapine treatment: an animal model.Schizophrenia research, , Volume: 104, Issue:1-3, 2008
Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
A parametric analysis of olanzapine-induced weight gain in female rats.Psychopharmacology, , Volume: 181, Issue:1, 2005
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp.The Journal of clinical endocrinology and metabolism, , Volume: 88, Issue:12, 2003
Hyperinsulinemia in psychiatric patients treated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:1, 2002
Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.Neuropharmacology, , 10-01, Volume: 197, 2021
Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.Brain research, , Aug-27, Volume: 1618, 2015
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
Effect of environmental cues on the behavioral efficacy of haloperidol, olanzapine, and clozapine in rats.Behavioural pharmacology, , Volume: 25, Issue:4, 2014
Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:4, 2014
Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity.Neuropharmacology, , Volume: 75, 2013
Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype: focus on hyperactivity.Journal of child and adolescent psychopharmacology, , Volume: 20, Issue:2, 2010
Does electroconvulsive therapy afford protection against olanzapine-induced parkinsonism? A case report.The journal of ECT, , Volume: 25, Issue:2, 2009
Effects of acute versus chronic treatment with typical or atypical antipsychotics on d-amphetamine-induced sensorimotor gating deficits in rats.Psychopharmacology, , Volume: 156, Issue:2-3, 2001
Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.International journal of molecular sciences, , Feb-01, Volume: 20, Issue:3, 2019
Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, , Volume: 50, Issue:4, 2018
Atypical Antipsychotics and the Risk of Hyperlipidemia: A Sequence Symmetry Analysis.Drug safety, , Volume: 38, Issue:7, 2015
The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation.Cell structure and function, , Volume: 38, Issue:2, 2013
Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 64, Issue:1, 2013
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.Schizophrenia research, , Volume: 98, Issue:1-3, 2008
Confounding by indication and the risk of hyperlipidemia in observational studies of antipsychotics.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.The Journal of clinical psychiatry, , Volume: 68, Issue:10, 2007
Severe hyperlipidemia associated with olanzapine and quetiapine use.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].Medicina clinica, , Apr-01, Volume: 126, Issue:12, 2006
Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.Psychiatry and clinical neurosciences, , Volume: 60, Issue:1, 2006
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine.Pharmacoepidemiology and drug safety, , Volume: 14, Issue:6, 2005
Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.International clinical psychopharmacology, , Volume: 20, Issue:2, 2005
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current opinion in pediatrics, , Volume: 17, Issue:2, 2005
Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders.Schizophrenia research, , Dec-01, Volume: 80, Issue:1, 2005
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
Dyslipidemia and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
A study of matrix effects on an LC/MS/MS assay for olanzapine and desmethyl olanzapine.Journal of pharmaceutical and biomedical analysis, , Sep-03, Volume: 35, Issue:5, 2004
Should lipids be monitored during the first year of treatment with an atypical antipsychotic?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Eruptive xanthomas associated with olanzapine use.Archives of dermatology, , Volume: 139, Issue:8, 2003
The effects of novel antipsychotics on glucose and lipid levels.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.Archives of general psychiatry, , Volume: 59, Issue:11, 2002
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Novel antipsychotics and severe hyperlipidemia.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Nuclear receptor 5A2 regulation of Agrp underlies olanzapine-induced hyperphagia.Molecular psychiatry, , Volume: 28, Issue:5, 2023
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.The international journal of neuropsychopharmacology, , 09-28, Volume: 25, Issue:9, 2022
The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain.The Journal of experimental medicine, , 07-05, Volume: 218, Issue:7, 2021
Metabolomic profiles associated with a mouse model of antipsychotic-induced food intake and weight gain.Scientific reports, , 10-29, Volume: 10, Issue:1, 2020
A role of neuropeptide CART in hyperphagia and weight gain induced by olanzapine treatment in rats.Brain research, , 09-15, Volume: 1695, 2018
The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C.The Journal of clinical investigation, , Sep-01, Volume: 127, Issue:9, 2017
Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by histamine H1 receptor agonist in female rats.Endocrinology, , Volume: 155, Issue:12, 2014
Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats.Psychoneuroendocrinology, , Volume: 42, 2014
Hypothalamic ghrelin signalling mediates olanzapine-induced hyperphagia and weight gain in female rats.The international journal of neuropsychopharmacology, , Volume: 17, Issue:5, 2014
Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:9, 2012
Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats.The international journal of neuropsychopharmacology, , Volume: 15, Issue:2, 2012
A role for hypothalamic AMP-activated protein kinase in the mediation of hyperphagia and weight gain induced by chronic treatment with olanzapine in female rats.Cellular and molecular neurobiology, , Volume: 31, Issue:7, 2011
Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone.Behavioural brain research, , Jan-20, Volume: 216, Issue:2, 2011
Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation.PloS one, , Volume: 6, Issue:6, 2011
Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.Obesity (Silver Spring, Md.), , Volume: 18, Issue:10, 2010
Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.Psychopharmacology, , Volume: 203, Issue:4, 2009
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:12, 2008
Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagiaThe Journal of pharmacology and experimental therapeutics, , Volume: 326, Issue:3, 2008
Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats.Journal of psychopharmacology (Oxford, England), , Volume: 22, Issue:5, 2008
Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:4, 2007
Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:1, 2003
Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation.Psychiatry and clinical neurosciences, , Volume: 77, Issue:9, 2023
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.Psychiatry research, , Volume: 322, 2023
Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 62, Issue:9, 2023
Paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuating impairment of the dopamine D2 receptor and TGF-β1 signaling pathways in the hypothalamus and pituitary.Journal of ethnopharmacology, , Jul-15, Volume: 257, 2020
The ancient Chinese formula Longdan Xiegan Tang improves antipsychotic-induced hyperprolactinemia by repairing the hypothalamic and pituitary TGF-β1 signaling in rats.Journal of ethnopharmacology, , May-23, Volume: 254, 2020
Prolactin response to antipsychotics: An inpatient study.PloS one, , Volume: 15, Issue:2, 2020
Pharmacokinetics and Bioequivalence of 2 Olanzapine Orally Disintegrating Tablet Products in Healthy Chinese Subjects Under Fed and Fasting Conditions.Clinical pharmacology in drug development, , Volume: 9, Issue:5, 2020
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.The Journal of clinical psychiatry, , Volume: 77, Issue:12, 2016
[Treatment of Olanzapine-induced Hyperprolactinemia by Shaoyao Gancao Decoction].Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, , Volume: 36, Issue:12, 2016
Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses.BMJ (Clinical research ed.), , Nov-24, Volume: 355, 2016
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.CNS spectrums, , Volume: 21, Issue:6, 2016
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:11, 2015
Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-01, Volume: 45, 2013
Herbal medicine (Shakuyaku-kanzo-to) improves olanzapine-associated hyperprolactinemia: a case report.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.Neuro endocrinology letters, , Volume: 32, Issue:4, 2011
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.Human psychopharmacology, , Volume: 25, Issue:3, 2010
Hyperprolactinaemia and acute psychosis: prolactinoma or medication-induced phenomenon?The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:5, 2010
Management of a patient with schizophrenia and underlying pituitary macroadenoma.Annals of the Academy of Medicine, Singapore, , Volume: 39, Issue:11, 2010
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
Effects of lactational exposure of olanzapine and risperidone on hematology and lymphoid organs histopathology: a comparative study in mice neonates.European journal of pharmacology, , May-25, Volume: 634, Issue:1-3, 2010
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
Neuroleptics and migraine.Central nervous system agents in medicinal chemistry, , Volume: 9, Issue:1, 2009
Olanzapine for the treatment of bipolar disorder in children and adolescents.Expert opinion on pharmacotherapy, , Volume: 9, Issue:3, 2008
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.Pharmacy world & science : PWS, , Volume: 30, Issue:1, 2008
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.The American journal of managed care, , Volume: 13, Issue:7 Suppl, 2007
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.Journal of clinical pharmacy and therapeutics, , Volume: 32, Issue:2, 2007
A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:2, 2007
Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.Neuro endocrinology letters, , Volume: 28, Issue:6, 2007
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.Pharmacotherapy, , Volume: 26, Issue:6, 2006
A crossover study of prolactin changes associated with risperidone and olanzapine.The Journal of clinical psychiatry, , Volume: 67, Issue:9, 2006
Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.The Journal of clinical psychiatry, , Volume: 66, Issue:6, 2005
Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.Postgraduate medicine, , Volume: 116, Issue:4, 2004
Possible impact of dropout in a study of high-dose olanzapine and prolactin levels.The Journal of clinical psychiatry, , Volume: 65, Issue:8, 2004
A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.Annals of the New York Academy of Sciences, , Volume: 1032, 2004
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
Safety in treating bipolar disorder.The Journal of family practice, , Volume: Suppl, 2003
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.Psychoneuroendocrinology, , Volume: 28 Suppl 2, 2003
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder.Psychiatry research, , Aug-05, Volume: 111, Issue:1, 2002
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Risperidone side effects.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Hyperprolactinemia and male sexual dysfunction.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.The American journal of psychiatry, , Volume: 155, Issue:10, 1998
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.Schizophrenia research, , Jul-25, Volume: 26, Issue:1, 1997
[Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine].Psychiatria polska, , Volume: 39, Issue:6
Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder.Rivista di psichiatria, , Volume: 54, Issue:1
Haloperidol-induced impotence improved by switching to olanzapine.General hospital psychiatry, , Volume: 22, Issue:5
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.The Cochrane database of systematic reviews, , 09-21, Volume: 9, 2018
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.Journal of affective disorders, , Jan-01, Volume: 207, 2017
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.BMC psychiatry, , Apr-02, Volume: 15, 2015
Implications of atypical antipsychotic prescribing in the intensive care unit.Journal of critical care, , Volume: 30, Issue:4, 2015
Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine.Schizophrenia research, , Volume: 135, Issue:1-3, 2012
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Clinical schizophrenia & related psychoses, , Volume: 6, Issue:2, 2012
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:1, 2008
Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
The clinical picture of olanzapine poisoning with special reference to fluctuating mental status.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:1, 2004
A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 11, Issue:3, 2001
Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.Journal of clinical psychopharmacology, , Volume: 21, Issue:5, 2001
Use of olanzapine in hereditary coproporphyria.Psychosomatics, , Volume: 40, Issue:5
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.Schizophrenia bulletin, , 03-15, Volume: 49, Issue:2, 2023
Antipsychotic-Induced Metabolic Syndrome: A Review.Metabolic syndrome and related disorders, , Volume: 21, Issue:6, 2023
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.PLoS medicine, , Volume: 13, Issue:8, 2016
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
[The clinical picture of acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
Acute pancreatitis associated with lisinopril and olanzapine.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Feb-01, Volume: 67, Issue:3, 2010
An epidemiologic study of psychotropic medication and obesity-related chronic illnesses in older psychiatric patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 54, Issue:4, 2009
Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.The Journal of clinical psychiatry, , Volume: 68, Issue:10, 2007
Speech and language difficulties in a patient with schizophrenia-like disorder: a case report.Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria, , Volume: 20, Issue:3
Challenges Faced When Caring for Foreign Nationals With Comorbid Medical and Psychiatric Problems in the General Hospital.Psychosomatics, , Volume: 59, Issue:1
Uncommon side effects associated with olanzapine. A case report.Pharmacopsychiatry, , Volume: 36, Issue:2
Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.CNS drugs, , Volume: 31, Issue:9, 2017
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.CNS spectrums, , Volume: 19, Issue:4, 2014
Monosymptomatic hypochondriacal psychosis presenting with recurrent oral mucosal ulcers and multiple skin lesions responding to olanzapine treatment.International journal of dermatology, , Volume: 45, Issue:10, 2006
Monosymptomatic hypochondriacal psychosis: atypical presentation and response to olanzapine.The Journal of clinical psychiatry, , Volume: 66, Issue:6, 2005
A male case of monosymptomatic hypochondriacal psychosis responding to olanzapine: a case report.Pharmacopsychiatry, , Volume: 37, Issue:5, 2004
Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis.The Journal of clinical psychiatry, , Volume: 63, Issue:2, 2002
A case of monosymptomatic hypochondriacal psychosis treated with olanzapine.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 12, Issue:4, 2000
[Delusional bromosis: treatment with amisulpiride and olanzapine].Annales de dermatologie et de venereologie, , Volume: 134, Issue:6-7
Olanzapine treatment of monosymptomatic hypochondriacal psychosis.General hospital psychiatry, , Volume: 26, Issue:2
Olanzapine-induced hypoglycemia in anorexia nervosa.Endocrine, , Volume: 46, Issue:3, 2014
Severe recurrent hypoglycaemia following discontinuation of olanzapine.Acute medicine, , Volume: 10, Issue:1, 2011
Hypoglycaemia induced by second generation antipsychotic agents in schizophrenic non-diabetic patients.BMJ (Clinical research ed.), , May-26, Volume: 338, 2009
Olanzapine and hypoglycemic coma in a frail elderly woman. A case report.Pharmacopsychiatry, , Volume: 36, Issue:4, 2003
Low blood glucose and olanzapine.The American journal of psychiatry, , Volume: 158, Issue:3, 2001
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.The American journal of case reports, , Dec-01, Volume: 23, 2022
Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study.Annals of internal medicine, , Aug-19, Volume: 161, Issue:4, 2014
Cardiotoxicity in a citalopram and olanzapine overdose.The Journal of emergency medicine, , Volume: 45, Issue:4, 2013
Massive pulmonary emboli associated with olanzapine.Irish medical journal, , Volume: 101, Issue:6, 2008
Elderly patient with delirium after myocardial infarction.Journal of the National Medical Association, , Volume: 98, Issue:4, 2006
Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam.The Journal of clinical psychiatry, , Volume: 66, Issue:12, 2005
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current opinion in pediatrics, , Volume: 17, Issue:2, 2005
Severe cardiovascular side effects of olanzapine in an elderly patient: case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine.Journal of clinical pharmacology, , Volume: 42, Issue:1, 2002
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder.General hospital psychiatry, , Volume: 31, Issue:4
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
Orthostatic hypotensive effect of antipsychotic drugs in Wistar rats by in vivo and in vitro studies of alpha1-adrenoceptor function.Psychopharmacology, , Volume: 199, Issue:1, 2008
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Olanzapine for schizophrenia.The Medical letter on drugs and therapeutics, , Jan-17, Volume: 39, Issue:992, 1997
Olanzapine: interaction study with imipramine.Journal of clinical pharmacology, , Volume: 37, Issue:10, 1997
Lessons of the month 2: Olanzapine-induced hypothermia and hand oedema.Clinical medicine (London, England), , Volume: 22, Issue:3, 2022
The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors.International clinical psychopharmacology, , Volume: 34, Issue:1, 2019
Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy.BMJ case reports, , Dec-02, Volume: 2017, 2017
Hypothermia associated with antipsychotic drug use: a clinical case series and review of current literature.Journal of clinical pharmacology, , Volume: 52, Issue:7, 2012
[Hypothermia under olanzapine treatment: clinical case series and review of current literature].Der Nervenarzt, , Volume: 83, Issue:5, 2012
A case of severe hypothermia following single-dose administration of olanzapine: a case report.Journal of clinical pharmacology, , Volume: 52, Issue:2, 2012
Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats.Pharmacology, biochemistry, and behavior, , Volume: 97, Issue:1, 2010
Hypothermia in a hemodialysis patient treated with olanzapine monotherapy.Journal of clinical psychopharmacology, , Volume: 23, Issue:3, 2003
Severe cardiovascular side effects of olanzapine in an elderly patient: case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Repeated episodes of hypothermia in a subject treated with haloperidol, levomepromazine, olanzapine, and thioridazine.Journal of clinical psychopharmacology, , Volume: 21, Issue:1, 2001
Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat.The Journal of pharmacology and experimental therapeutics, , Volume: 292, Issue:2, 2000
[Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon].Annales francaises d'anesthesie et de reanimation, , Volume: 18, Issue:6, 1999
Antagonism by pimozide of olanzapine-induced hypothermia.Fundamental & clinical pharmacology, , Volume: 13, Issue:5, 1999
Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome.The Medical journal of Australia, , Aug-17, Volume: 169, Issue:4, 1998
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder.General hospital psychiatry, , Volume: 31, Issue:4
Olanzapine-associated hypothermia.Psychosomatics, , Volume: 45, Issue:2
Iatrogenic eosinophilic pleural effusion.European respiratory review : an official journal of the European Respiratory Society, , Volume: 20, Issue:120, 2011
Irreversible priapism during olanzapine and lithium therapy.The Australian and New Zealand journal of psychiatry, , Volume: 38, Issue:5, 2004
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
Antipsychotic-Related Prolactin Levels and Sexual Dysfunction in Mentally Ill Youth: A 3-Month Cohort Study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 62, Issue:9, 2023
Management of sexual dysfunction due to antipsychotic drug therapy.The Cochrane database of systematic reviews, , Nov-14, Volume: 11, 2012
Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 19, Issue:8, 2009
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 9, Issue:3, 2007
Sildenafil use in patients with olanzapine-induced erectile dysfunction.International journal of impotence research, , Volume: 14, Issue:6, 2002
Priapism associated with conventional and atypical antipsychotic medications: a review.The Journal of clinical psychiatry, , Volume: 62, Issue:5, 2001
Olanzapine-induced priapism.The American journal of psychiatry, , Volume: 158, Issue:12, 2001
Haloperidol-induced impotence improved by switching to olanzapine.General hospital psychiatry, , Volume: 22, Issue:5
Paliperidone Palmitate-Induced Retrograde Ejaculation.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:2
Masturbatory guilt leading to severe depression and erectile dysfunction.Journal of sex & marital therapy, , Volume: 28, Issue:4
Spontaneous Ejaculations in an Adolescent With Olanzapine Use: Case Report.Clinical neuropharmacology, , Volume: 39, Issue:3
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.The international journal of neuropsychopharmacology, , 09-28, Volume: 25, Issue:9, 2022
Exacerbation of mood symptoms associated to primary and secondary carnitine deficiency: a case report.Boletin de la Asociacion Medica de Puerto Rico, , Volume: 105, Issue:3, 2013
Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial.The Journal of clinical psychiatry, , Volume: 69, Issue:3, 2008
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:6, 2008
Olanzapine augmentation of fluoxetine in the treatment of pathological skin picking.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:11, 2004
Treatment of self-mutilation with olanzapine.Journal of cutaneous medicine and surgery, , Volume: 4, Issue:3, 2000
Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists: A Retrospective Cohort Study.Journal of clinical psychopharmacology, , Volume: 39, Issue:6
Psychopharmacological treatment in borderline personality disorder.Actas espanolas de psiquiatria, , Volume: 36, Issue:1
The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.Current neuropharmacology, , Volume: 22, Issue:1, 2024
Hypothalamic JNK1-hepatic fatty acid synthase axis mediates a metabolic rewiring that prevents hepatic steatosis in male mice treated with olanzapine via intraperitoneal: Additional effects of PTP1B inhibition.Redox biology, , Volume: 63, 2023
Human macrophages stimulate expression of inflammatory mediators in adipocytes; effects of second-generation antipsychotics and glucocorticoids on cellular cross-talk.Psychoneuroendocrinology, , Volume: 125, 2021
Olanzapine Induces Inflammation and Immune Response via Activating ER Stress in the Rat Prefrontal Cortex.Current medical science, , Volume: 41, Issue:4, 2021
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 133, 2021
JNK downregulation improves olanzapine-induced insulin resistance by suppressing IRS1Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 142, 2021
Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting.Pharmacopsychiatry, , Volume: 53, Issue:1, 2020
Role of TRPV1/TRPV3 channels in olanzapine-induced metabolic alteration: Possible involvement in hypothalamic energy-sensing, appetite regulation, inflammation and mesolimbic pathway.Toxicology and applied pharmacology, , 09-01, Volume: 402, 2020
Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats.Behavioural brain research, , 01-27, Volume: 378, 2020
Olanzapine-induced endoplasmic reticulum stress and inflammation in the hypothalamus were inhibited by an ER stress inhibitor 4-phenylbutyrate.Psychoneuroendocrinology, , Volume: 104, 2019
Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.International journal of molecular sciences, , Feb-01, Volume: 20, Issue:3, 2019
Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons.Psychoneuroendocrinology, , Volume: 109, 2019
Lithium is able to minimize olanzapine oxidative-inflammatory induction on macrophage cells.PloS one, , Volume: 14, Issue:1, 2019
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons.Psychoneuroendocrinology, , Volume: 104, 2019
Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells.Journal of psychiatric research, , Volume: 105, 2018
Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, , Volume: 50, Issue:4, 2018
Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue.Psychoneuroendocrinology, , Volume: 95, 2018
Activation of indoleamine 2, 3- dioxygenase pathway by olanzapine augments antidepressant effects of venlafaxine in mice.Psychiatry research, , Volume: 258, 2017
Effects of olanzapine on LPS-induced inflammation in rat primary glia cells.Innate immunity, , Volume: 22, Issue:1, 2016
Olanzapine modulation of hepatic oxidative stress and inflammation in socially isolated rats.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Jan-01, Volume: 81, 2016
Effects of olanzapine on the elevation of macrophage infiltration and pro-inflammatory cytokine expression in female rats.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:12, 2014
Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state.Brain research, , Sep-02, Volume: 1350, 2010
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.Current protocols in cytometry, , Volume: Chapter 13, 2010
Açaí (Euterpe oleracea Mart.) reduces the inflammatory response triggered in vitro by the antipsychotic drug olanzapine in RAW 264.7 macrophage cells.Acta scientiarum polonorum. Technologia alimentaria, , Volume: 20, Issue:2
Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.Annals of palliative medicine, , Volume: 12, Issue:3, 2023
Manic syndrome in mitochondrial membrane protein-associated neurodegeneration: A case report.Psychiatry and clinical neurosciences, , Volume: 76, Issue:10, 2022
Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report.Neuropsychopharmacology reports, , Volume: 42, Issue:3, 2022
Hyperventilation and Respiratory Alkalosis After Olanzapine for Insomnia: A Case Report.A&A practice, , Oct-20, Volume: 15, Issue:10, 2021
Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.Medicine, , Volume: 98, Issue:3, 2019
Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.Scientific reports, , 11-02, Volume: 8, Issue:1, 2018
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Betahistine decreases olanzapine-induced weight gain and somnolence in humans.Journal of psychopharmacology (Oxford, England), , Volume: 30, Issue:3, 2016
Olanzapine for Nausea, Delirium, Anxiety, Insomnia, and Cachexia #315.Journal of palliative medicine, , Volume: 19, Issue:11, 2016
Treatment of Subjective Total Insomnia After Suicide Attempt With Olanzapine and Electroconvulsive Therapy.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
[Real-world analysis of concurrent diseases and medicine use among patients with insomnia].Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, , Volume: 39, Issue:18, 2014
Treatment of paradoxical insomnia with atypical antipsychotic drugs. A comparison of olanzapine and risperidone.Neurosciences (Riyadh, Saudi Arabia), , Volume: 18, Issue:1, 2013
Could pramipexole induce acute mania? A case report.Bipolar disorders, , Volume: 15, Issue:4, 2013
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 22, Issue:10, 2012
Insomnia treatment by olanzapine. Is sleep state misperception a psychotic disorder?Neurosciences (Riyadh, Saudi Arabia), , Volume: 15, Issue:2, 2010
Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 44, Issue:3, 2010
Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:5, 2005
A case report of olanzapine-induced fecal incontinence.The Journal of clinical psychiatry, , Volume: 64, Issue:3, 2003
Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports.Acta psychiatrica Scandinavica, , Volume: 107, Issue:5, 2003
Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
Olanzapine for nightmares and sleep disturbance in posttraumatic stress disorder (PTSD)Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 45, Issue:7, 2000
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
Zolpidem related persistent genital arousal disorder: An interesting case.Psychiatrike = Psychiatriki, , Volume: 30, Issue:4
Thymoquinone attenuates olanzapine-induced metabolic disorders in rats.Molecular biology reports, , Volume: 50, Issue:11, 2023
The mechanisms underlying olanzapine-induced insulin resistance via the brown adipose tissue and the therapy in rats.Adipocyte, , Volume: 11, Issue:1, 2022
Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls.PloS one, , Volume: 17, Issue:11, 2022
Fenofibrate ameliorates olanzapine's side effects without altering its central effect: emphasis on FGF-21-adiponectin axis.Behavioural pharmacology, , 12-01, Volume: 32, Issue:8, 2021
Anthocyanins from Molecules (Basel, Switzerland), , Oct-12, Volume: 26, Issue:20, 2021
Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats.Journal of ethnopharmacology, , Jun-28, Volume: 274, 2021
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 133, 2021
Olanzapine-induced insulin resistance may occur via attenuation of central KSchizophrenia research, , Volume: 228, 2021
JNK downregulation improves olanzapine-induced insulin resistance by suppressing IRS1Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 142, 2021
Benserazide, an Inhibitor of Peripheral Kynurenine Metabolism, Attenuates Olanzapine-Induced Weight Gain, Insulin Resistance, and Dyslipidemia in C57Bl/6j Mice.Molecular neurobiology, , Volume: 57, Issue:1, 2020
Identification and characterization of proteins that are differentially expressed in adipose tissue of olanzapine-induced insulin resistance rat by iTRAQ quantitative proteomics.Journal of proteomics, , 02-10, Volume: 212, 2020
Berberine attenuates olanzapine induced-metabolic syndrome.JPMA. The Journal of the Pakistan Medical Association, , Volume: 69(Suppl 3), Issue:8, 2019
Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance.Scientific reports, , 02-07, Volume: 9, Issue:1, 2019
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons.Psychoneuroendocrinology, , Volume: 104, 2019
The IRS/PI3K/Akt signaling pathway mediates olanzapine-induced hepatic insulin resistance in male rats.Life sciences, , Jan-15, Volume: 217, 2019
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.Psychoneuroendocrinology, , Volume: 108, 2019
Female mice are protected against acute olanzapine-induced hyperglycemia.Psychoneuroendocrinology, , Volume: 110, 2019
The Probiotic Mixture VSL#3 Reverses Olanzapine-Induced Metabolic Dysfunction in Mice.Methods in molecular biology (Clifton, N.J.), , Volume: 2011, 2019
Insulin resistance induced by olanzapine and other second-generation antipsychotics in Chinese patients with schizophrenia: a comparative review and meta-analysis.European journal of clinical pharmacology, , Volume: 75, Issue:12, 2019
One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects.The international journal of neuropsychopharmacology, , 05-01, Volume: 22, Issue:5, 2019
Olanzapine Induced Dysmetabolic Changes Involving Tissue Chromium Mobilization in Female Rats.International journal of molecular sciences, , Feb-01, Volume: 20, Issue:3, 2019
Effects of acute olanzapine exposure on central insulin-mediated regulation of whole body fuel selection and feeding.Psychoneuroendocrinology, , Volume: 98, 2018
Antenatal antipsychotic exposure induces multigenerational and gender-specific programming of adiposity and glucose tolerance in adult mouse offspring.Diabetes & metabolism, , Volume: 44, Issue:3, 2018
Obesity exacerbates the acute metabolic side effects of olanzapine.Psychoneuroendocrinology, , Volume: 88, 2018
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5, 2018
Neuropsychiatric disorders: Side effects of olanzapine worsened by metabolic dysfunction.Nature reviews. Endocrinology, , Volume: 14, Issue:3, 2018
Macrophage migration inhibitory factor mediates metabolic dysfunction induced by atypical antipsychotic therapy.The Journal of clinical investigation, , 11-01, Volume: 128, Issue:11, 2018
Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue.Psychoneuroendocrinology, , Volume: 95, 2018
Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.JAMA psychiatry, , 08-01, Volume: 75, Issue:8, 2018
Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.Human psychopharmacology, , Volume: 32, Issue:4, 2017
In male rats, the ability of central insulin to suppress glucose production is impaired by olanzapine, whereas glucose uptake is left intact.Journal of psychiatry & neuroscience : JPN, , Volume: 42, Issue:6, 2017
Roman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expression.Journal of psychopharmacology (Oxford, England), , Volume: 31, Issue:11, 2017
Chronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin Resistance.PloS one, , Volume: 11, Issue:12, 2016
Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder.The Journal of clinical psychiatry, , Volume: 77, Issue:12, 2016
Meal-induced insulin sensitization is preserved after acute olanzapine administration in female Sprague-Dawley rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 388, Issue:5, 2015
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar disorders, , Volume: 17, Issue:5, 2015
Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance.The Journal of endocrinology, , Volume: 227, Issue:2, 2015
Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female Sprague-Dawley rats.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:12, 2015
An evaluation of the effects of the novel antipsychotic drug lurasidone on glucose tolerance and insulin resistance: a comparison with olanzapine.PloS one, , Volume: 9, Issue:9, 2014
Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study.Pharmacopsychiatry, , Volume: 47, Issue:4-5, 2014
A novel insulin receptor-signaling platform and its link to insulin resistance and type 2 diabetes.Cellular signalling, , Volume: 26, Issue:6, 2014
The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:4, 2014
Subchronic olanzapine treatment decreases the expression of pancreatic glucose transporter 2 in rat pancreatic β cells.Journal of endocrinological investigation, , Volume: 37, Issue:7, 2014
Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.Diabetes, , Volume: 62, Issue:9, 2013
Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.PloS one, , Volume: 8, Issue:1, 2013
Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls.Journal of clinical psychopharmacology, , Volume: 33, Issue:6, 2013
A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.Psychopharmacology, , Volume: 230, Issue:1, 2013
Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.Journal of psychiatry & neuroscience : JPN, , Volume: 37, Issue:6, 2012
Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats.Neuropharmacology, , Volume: 62, Issue:3, 2012
Acute peripheral but not central administration of olanzapine induces hyperglycemia associated with hepatic and extra-hepatic insulin resistance.PloS one, , Volume: 7, Issue:8, 2012
Insulin secretion and sensitivity after single-dose amisulpride, olanzapine or placebo in young male subjects: double blind, cross-over glucose clamp study.Pharmacopsychiatry, , Volume: 45, Issue:6, 2012
Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 22, Issue:1, 2012
Association of serum retinol-binding protein 4 with insulin resistance and metabolic parameters during olanzapine therapy.Clinical endocrinology, , Volume: 76, Issue:2, 2012
Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study.International journal of psychiatry in clinical practice, , Volume: 16, Issue:1, 2012
The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study.Pharmacopsychiatry, , Volume: 45, Issue:3, 2012
Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.Schizophrenia bulletin, , Volume: 38, Issue:1, 2012
Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.Archives of physiology and biochemistry, , Volume: 117, Issue:4, 2011
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.Neuro endocrinology letters, , Volume: 32, Issue:4, 2011
Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.Psychopharmacology, , Volume: 213, Issue:1, 2011
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.Diabetes, obesity & metabolism, , Volume: 13, Issue:8, 2011
The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-16, Volume: 34, Issue:6, 2010
Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance.Diabetes, , Volume: 59, Issue:10, 2010
Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.International journal of obesity (2005), , Volume: 34, Issue:6, 2010
Increased food intake and energy expenditure following administration of olanzapine to healthy men.Obesity (Silver Spring, Md.), , Volume: 18, Issue:8, 2010
Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state.Brain research, , Sep-02, Volume: 1350, 2010
Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats.Neuropsychobiology, , Volume: 61, Issue:3, 2010
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
30 days of continuous olanzapine infusion determines energy imbalance, glucose intolerance, insulin resistance, and dyslipidemia in mice.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.Pharmacopsychiatry, , Volume: 42, Issue:1, 2009
Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.Journal of psychiatric practice, , Volume: 15, Issue:4, 2009
Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 70, Issue:1, 2009
Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.Human psychopharmacology, , Volume: 24, Issue:3, 2009
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Insulin resistance following continuous, chronic olanzapine treatment: an animal model.Schizophrenia research, , Volume: 104, Issue:1-3, 2008
Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: a case report.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-01, Volume: 32, Issue:1, 2008
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.Journal of psychiatric research, , Volume: 42, Issue:13, 2008
Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia.International clinical psychopharmacology, , Volume: 22, Issue:4, 2007
Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.Collegium antropologicum, , Volume: 31, Issue:4, 2007
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.Schizophrenia research, , Volume: 89, Issue:1-3, 2007
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks: response to Hardy et al.Diabetes care, , Volume: 30, Issue:7, 2007
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.International clinical psychopharmacology, , Volume: 22, Issue:2, 2007
Metabolic effects of the atypical antipsychotics.Southern medical journal, , Volume: 100, Issue:8, 2007
Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:3, 2006
Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain.European journal of pharmacology, , Dec-03, Volume: 551, Issue:1-3, 2006
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.Psychopharmacology, , Volume: 186, Issue:4, 2006
Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:1, 2006
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.The Journal of clinical psychiatry, , Volume: 67, Issue:5, 2006
Newer antipsychotics and glucose metabolism: a comparison between olanzapine and risperidone.Psychiatria Danubina, , Volume: 17, Issue:1-2, 2005
Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs.Diabetes, , Volume: 54, Issue:3, 2005
Olanzapine-induced hyperglycemia: role of humoral insulin resistance-inducing factors.Journal of clinical psychopharmacology, , Volume: 25, Issue:2, 2005
A parametric analysis of olanzapine-induced weight gain in female rats.Psychopharmacology, , Volume: 181, Issue:1, 2005
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 7, Issue:3, 2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Archives of general psychiatry, , Volume: 62, Issue:1, 2005
Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells.Molecular psychiatry, , Volume: 10, Issue:12, 2005
[Effect of atypical antipsychotics on metabolism].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 6, Issue:2, 2004
Atypical antipsychotics and diabetes mellitus.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:2, 2004
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp.The Journal of clinical endocrinology and metabolism, , Volume: 88, Issue:12, 2003
Olanzapine induces insulin resistance: results from a prospective study.The Journal of clinical psychiatry, , Volume: 64, Issue:12, 2003
Hyperinsulinemia in psychiatric patients treated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:1, 2002
Insulin Resistance-Related Proteins Are Overexpressed in Patients and Rats Treated With Olanzapine and Are Reverted by Pueraria in the Rat Model.Journal of clinical psychopharmacology, , Volume: 39, Issue:3
[The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].Psychiatria polska, , Volume: 49, Issue:2
Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 35, Issue:3
Increased infection rates associated with second-generation antipsychotics.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , 02-01, Volume: 33, Issue:1, 2021
Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction?Journal of psychiatric practice, , Volume: 24, Issue:2, 2018
Reversible delayed onset olanzapine-associated leukopenia and neutropenia in a clozapine-naive patient on concomitant depot antipsychotic.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Prolongation of clozapine-induced leukopenia with olanzapine treatment.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:5, 2006
Olanzapine-induced leucopenia and neutropenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:6, 2005
Continuing treatment with novel antipsychotic drugs despite leukopenia or thrombocytopenia.Archives of general psychiatry, , Volume: 58, Issue:7, 2001
Dose-dependent olanzapine-associated leukopenia: three case reports.International clinical psychopharmacology, , Volume: 16, Issue:2, 2001
[Is bone marrow inhibition a special risk in connection with olanzapine (Zyprexa) treatment?].Ugeskrift for laeger, , Oct-30, Volume: 162, Issue:44, 2000
Olanzapine appears haematologically safe in patients who developed blood dyscrasia on clozapine and risperidone.International clinical psychopharmacology, , Volume: 15, Issue:4, 2000
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
Reversible leucopenia related to olanzapine.Movement disorders : official journal of the Movement Disorder Society, , Volume: 14, Issue:5, 1999
[A case of leukopenia in treatment with risperidone in an adolescent].L'Encephale, , Volume: 26, Issue:5
Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.CPT: pharmacometrics & systems pharmacology, , Volume: 10, Issue:9, 2021
Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats.Behavioural brain research, , 01-27, Volume: 378, 2020
Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.Drug design, development and therapy, , Volume: 13, 2019
Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.Expert review of neurotherapeutics, , Volume: 10, Issue:5, 2010
Serum levels of olanzapine in a non-fatal overdose.Journal of analytical toxicology, , Volume: 31, Issue:2, 2007
Antipsychotic Safety in Liver Disease: A Narrative Review and Practical Guide for the Clinician.Journal of the Academy of Consultation-Liaison Psychiatry, , Volume: 64, Issue:1
Olanzapine for Non-Chemotherapy Related Nausea and Emesis in Patients with a Palliative Care Consult.Journal of pain and symptom management, , Volume: 66, Issue:4, 2023
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTScientific reports, , 01-11, Volume: 11, Issue:1, 2021
'Hidden' corrected QT interval prolongation induced by olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 53, Issue:11, 2019
Absence of Change in Corrected QT Interval in Children and Adolescents Receiving Antipsychotic Treatment: A 12 Month Study.Journal of child and adolescent psychopharmacology, , Volume: 26, Issue:5, 2016
Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care.Clinical toxicology (Philadelphia, Pa.), , Volume: 52, Issue:1, 2014
Effects of olanzapine on the PR and QT intervals in patients with schizophrenia.Schizophrenia research, , Volume: 152, Issue:1, 2014
Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.Human psychopharmacology, , Volume: 28, Issue:3, 2013
Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Arsenic trioxide and olanzapine co-administration: case analysis.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, , Volume: 17, Issue:3, 2011
Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.Human psychopharmacology, , Volume: 26, Issue:6, 2011
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).The American journal of psychiatry, , Volume: 168, Issue:2, 2011
[Medication associated long QT syndrome].Praxis, , Dec-02, Volume: 98, Issue:24, 2009
QTc changes after 6 months of second-generation antipsychotic treatment in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:4, 2008
A pilot observational crossover study of QTc interval changes associated with switching between olanzapine and risperidone.The Journal of clinical psychiatry, , Volume: 68, Issue:5, 2007
[Long QT syndrome due to olanzapine administration].Kardiologia polska, , Volume: 64, Issue:9, 2006
Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine.International journal of cardiology, , May-10, Volume: 109, Issue:2, 2006
Olanzapine-induced QTc prolongation in a patient with Wolff-Parkinson-White syndrome.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.Journal of clinical psychopharmacology, , Volume: 24, Issue:1, 2004
Antipsychotic induced prolongation of QTc interval treated with magnesium.Journal of psychopharmacology (Oxford, England), , Volume: 17, Issue:3, 2003
QTc prolongation: chlorpromazine and high-dosage olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
[A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy].Der Nervenarzt, , Volume: 74, Issue:7, 2003
Antipsychotic drugs and QT interval prolongation.The Psychiatric quarterly, ,Fall, Volume: 74, Issue:3, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.European journal of pharmacology, , Aug-16, Volume: 450, Issue:1, 2002
Olanzapine: a proarrhythmic drug?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 47, Issue:7, 2002
Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:2, 2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.The Journal of clinical psychiatry, , Volume: 62, Issue:3, 2001
[QT prolongation and second-generation antipsychotics: overdose and therapeutic dosage].Therapie, , Volume: 59, Issue:5
The utility of intramuscular ziprasidone in the management of acute psychotic agitation.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:3
QTc prolongation and high-dose olanzapine.Psychosomatics, , Volume: 44, Issue:2
Reversal of pathologic cardiac parameters after transition from clozapine to olanzapine treatment: a case report.Clinical neuropharmacology, , Volume: 24, Issue:2
Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 05-10, Volume: 41, Issue:14, 2023
Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.Cancer chemotherapy and pharmacology, , Volume: 84, Issue:1, 2019
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.Medicine, , Volume: 97, Issue:37, 2018
Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.Anticancer research, , Volume: 37, Issue:11, 2017
Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses.BMJ (Clinical research ed.), , Nov-24, Volume: 355, 2016
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.Cell biochemistry and biophysics, , Volume: 72, Issue:2, 2015
Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 18, Issue:8, 2010
Re: Olanzapine-induced delirium.Journal of pain and symptom management, , Volume: 29, Issue:2, 2005
Olanzapine-induced delirium in a terminally ill cancer patient.Journal of pain and symptom management, , Volume: 28, Issue:2, 2004
Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.Journal of pain and symptom management, , Volume: 25, Issue:6, 2003
Use of electroconvulsive therapy in an adolescent with systemic lupus erythematosus for management of depression.The journal of ECT, , Volume: 29, Issue:3, 2013
Olanzapine-induced neutropenia in a patient with systemiclupus erythematosus: a role of FcγRIIIb polymorphism?Lupus, , Volume: 21, Issue:1, 2012
Olanzapine-induced agranulocytosis in systemic lupus erythematosus: a case report.General hospital psychiatry, , Volume: 29, Issue:1
Olanzapine induced acute Meige's syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 21, Issue:2, 2009
Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Marked improvement of Meige's syndrome with olanzapine in a schizophrenic patient.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 14, Issue:3, 2002
The antipsychotic olanzapine reduces memory deficits and neuronal abnormalities in a male rat model of Autism.Journal of chemical neuroanatomy, , Volume: 132, 2023
Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.Metabolic brain disease, , Volume: 32, Issue:5, 2017
Neuroleptics and enrichment environment treatment in memory disorders and other central nervous system function observed in prenatally stressed rats.Human & experimental toxicology, , Volume: 34, Issue:5, 2015
The influence of aripiprazole, olanzapine and enriched environment on depressant-like behavior, spatial memory dysfunction and hippocampal level of BDNF in prenatally stressed rats.Pharmacological reports : PR, , Volume: 66, Issue:3, 2014
Olanzapine treatment of adolescent rats causes enduring specific memory impairments and alters cortical development and function.PloS one, , Volume: 8, Issue:2, 2013
A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia.Schizophrenia research, , Volume: 144, Issue:1-3, 2013
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.Pharmacological reports : PR, , Volume: 65, Issue:1, 2013
Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice.Pharmacology, biochemistry, and behavior, , Volume: 99, Issue:4, 2011
Effects of olanzapine and clozapine on memory acquisition, consolidation and retrieval in mice using the elevated plus maze test.Neuroscience letters, , Sep-01, Volume: 501, Issue:3, 2011
Aripiprazole add-on treatment in a patient with schizoaffective disorder: neurocognitive outcomes.Pharmacopsychiatry, , Volume: 43, Issue:6, 2010
Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:4, 2010
Influence of olanzapine on memory functions.Psychiatria Danubina, , Volume: 21, Issue:1, 2009
Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300.Schizophrenia research, , Volume: 101, Issue:1-3, 2008
Delta9-Tetrahydrocannabinol-induced cognitive deficits are reversed by olanzapine but not haloperidol in rats.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia.Pharmacopsychiatry, , Volume: 41, Issue:3, 2008
The role of sedation tests in identifying sedative drug effects in healthy volunteers and their power to dissociate sedative-related impairments from memory dysfunctions.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:6, 2007
Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile.Bioorganic & medicinal chemistry letters, , Oct-01, Volume: 17, Issue:19, 2007
The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:3, 2006
Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 30, Issue:8, 2005
Patient outcomes in schizophrenia II: the impact of cognition.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets.Psychosomatics, , Volume: 47, Issue:1
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 9, Issue:3, 2007
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder.Psychiatry research, , Aug-05, Volume: 111, Issue:1, 2002
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 30, Issue:9, 2020
Pica disorder as a symptom of depression in a patient with bipolar disorder and intellectual disability.Actas espanolas de psiquiatria, , Volume: 48, Issue:1, 2020
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
Phelan-McDermid syndrome due to BMJ case reports, , Sep-28, Volume: 2017, 2017
Obsessive slowness presenting as catatonia in a patient with Borderline Intelligence.Asian journal of psychiatry, , Volume: 18, 2015
Psychopharmacological Management of Problem Behaviors in Mowat-Wilson Syndrome.Journal of child and adolescent psychopharmacology, , Volume: 25, Issue:8, 2015
Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.BMC psychiatry, , Oct-04, Volume: 13, 2013
Minimum effective and relapse-associated doses of risperidone and olanzapine in aggressive, intellectually disabled adults.Journal of clinical psychopharmacology, , Volume: 31, Issue:2, 2011
Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study.Journal of intellectual disability research : JIDR, , Volume: 55, Issue:2, 2011
The use of Pro Re Nata or Statim medications for behavioral control: a summary of experience at a tertiary care children's mental health center.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:1, 2011
Does electroconvulsive therapy afford protection against olanzapine-induced parkinsonism? A case report.The journal of ECT, , Volume: 25, Issue:2, 2009
Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine.The American journal of psychiatry, , Volume: 165, Issue:11, 2008
Effect of olanzapine on disruptive behavior in institutionalized patients with severe intellectual disability--a case series.Collegium antropologicum, , Volume: 32, Issue:2, 2008
Treatment of pica behavior with olanzapine.CNS spectrums, , Volume: 13, Issue:1, 2008
Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities.Journal of intellectual disability research : JIDR, , Volume: 52, Issue:Pt 2, 2008
Risperidone-induced enuresis in two children with autistic disorder.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:4, 2007
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:8, 2001
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.Journal of intellectual disability research : JIDR, , Volume: 44 ( Pt 2), 2000
Olanzapine for chronic, stereotypic self-injurious behaviour: a pilot study in seven adults with intellectual disability.Journal of intellectual disability research : JIDR, , Volume: 44 ( Pt 6), 2000
Olanzapine-induced neuroleptic malignant syndrome with mental retardation.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Metabolic disorders induced by psychotropic drugs.Annales d'endocrinologie, , Volume: 84, Issue:3, 2023
Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:2, 2022
Peripheral mechanisms of acute olanzapine induced metabolic dysfunction: A review of in vivo models and treatment approaches.Behavioural brain research, , 02-26, Volume: 400, 2021
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine.The American journal of Chinese medicine, , Volume: 49, Issue:8, 2021
Occurrence of metabolic diseases associated with antipsychotic use among Korean patients with schizophrenia.International journal of clinical pharmacology and therapeutics, , Volume: 59, Issue:4, 2021
Coadministration of metformin prevents olanzapine-induced metabolic dysfunction and regulates the gut-liver axis in rats.Psychopharmacology, , Volume: 238, Issue:1, 2021
Epigenetic histone modulations of PPARγ and related pathways contribute to olanzapine-induced metabolic disorders.Pharmacological research, , Volume: 155, 2020
Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.Psychopharmacology, , Volume: 237, Issue:11, 2020
Carnosic acid prevented olanzapine-induced metabolic disorders through AMPK activation.Molecular biology reports, , Volume: 47, Issue:10, 2020
Berberine attenuated olanzapine-induced metabolic alterations in mice: Targeting transient receptor potential vanilloid type 1 and 3 channels.Life sciences, , Apr-15, Volume: 247, 2020
Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome.Psychopharmacology, , Volume: 236, Issue:5, 2019
The Probiotic Mixture VSL#3 Reverses Olanzapine-Induced Metabolic Dysfunction in Mice.Methods in molecular biology (Clifton, N.J.), , Volume: 2011, 2019
Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 48, 2018
Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies.Drug safety, , Volume: 40, Issue:9, 2017
Exercise prevents downregulation of hippocampal presynaptic proteins following olanzapine-elicited metabolic dysregulation in rats: Distinct roles of inhibitory and excitatory terminals.Neuroscience, , Aug-20, Volume: 301, 2015
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients.Neuropsychobiology, , Volume: 72, Issue:1, 2015
Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics.Journal of clinical psychopharmacology, , Volume: 35, Issue:5, 2015
GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.Metabolic brain disease, , Volume: 30, Issue:2, 2015
Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.Journal of psychiatric research, , Volume: 53, 2014
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.The international journal of neuropsychopharmacology, , Volume: 17, Issue:1, 2014
Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.The international journal of neuropsychopharmacology, , Volume: 17, Issue:1, 2014
No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia.Schizophrenia research, , Volume: 146, Issue:1-3, 2013
The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study.Pharmacopsychiatry, , Volume: 45, Issue:3, 2012
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.Acta psychiatrica Scandinavica, , Volume: 124, Issue:3, 2011
Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats.Behavioural brain research, , Mar-01, Volume: 217, Issue:2, 2011
The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela.Schizophrenia research, , Volume: 126, Issue:1-3, 2011
Beneficial effect of the insulin sensitizer (HSP inducer) BGP-15 on olanzapine-induced metabolic disorders.Brain research bulletin, , Nov-20, Volume: 83, Issue:6, 2010
Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 118, Issue:1-3, 2010
A murine model of atypical antipsychotic-induced weight gain and metabolic dysregulation.Current protocols in neuroscience, , Volume: Chapter 9, 2010
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.Pharmacopsychiatry, , Volume: 42, Issue:1, 2009
Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagiaThe Journal of pharmacology and experimental therapeutics, , Volume: 326, Issue:3, 2008
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:4, 2007
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.Journal of medicinal chemistry, , Oct-18, Volume: 50, Issue:21, 2007
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.The Annals of pharmacotherapy, , Volume: 40, Issue:12, 2006
A parametric analysis of olanzapine-induced weight gain in female rats.Psychopharmacology, , Volume: 181, Issue:1, 2005
Atypical antipsychotics: impaired glucose metabolism.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Oct-02, Volume: 165, Issue:7, 2001
Is Sitagliptin Effective for Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients? A Double-blind Placebo-controlled Clinical Trial.Journal of clinical psychopharmacology, , Volume: 40, Issue:5
Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients.The American journal of emergency medicine, , Volume: 65, 2023
The Utilization of Atypical Antipsychotics in the Pain Medicine Physician's Armamentarium.Psychopharmacology bulletin, , 06-20, Volume: 48, Issue:4, 2018
Neuroleptics and migraine.Central nervous system agents in medicinal chemistry, , Volume: 9, Issue:1, 2009
Olanzapine in the treatment of refractory migraine and chronic daily headache.Headache, , Volume: 42, Issue:6, 2002
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Reversal of rabbit syndrome with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:1, 2000
Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.Journal of geriatric psychiatry and neurology, , Volume: 28, Issue:1, 2015
Olanzapine-induced tardive dystonia: a case report.The Journal of neuropsychiatry and clinical neurosciences, , Apr-01, Volume: 26, Issue:2, 2014
[Buccolingual dyskinesia with justified hallucinations].Revista de neurologia, , Nov-16, Volume: 59, Issue:10, 2014
Pisa syndrome secondary to rivastigmine: a case report.La Clinica terapeutica, , Volume: 163, Issue:1, 2012
Perphenazine suspension: a new, old treatment, side effects and continuous use.The Psychiatric quarterly, , Volume: 83, Issue:3, 2012
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.The Journal of clinical psychiatry, , Volume: 72, Issue:3, 2011
Blood lactate levels in patients receiving first- or second- generation antipsychotics.Croatian medical journal, , Volume: 52, Issue:1, 2011
Olanzapine induced tardive dyskinesia treated successfully with quetiapine: a case report.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-15, Volume: 35, Issue:1, 2011
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?The Journal of clinical psychiatry, , Volume: 71, Issue:11, 2010
Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats.Biological psychiatry, , Mar-01, Volume: 55, Issue:5, 2004
The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.European archives of psychiatry and clinical neuroscience, , Volume: 254, Issue:6, 2004
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.Psychopharmacology, , Volume: 169, Issue:3-4, 2003
Clinical issues associated with maintenance treatment of patients with schizophrenia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Sep-01, Volume: 59, Issue:17 Suppl 5, 2002
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:8, 2001
Risperidone side effects.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.The Journal of clinical psychiatry, , Volume: 61 Suppl 3, 2000
Olanzapine-induced task specific tardive dystonia and its response to carbamazepine: a case report.Neurology India, , Volume: 60, Issue:6
Atypical antipsychotics in multiple sclerosis: A review of their in vivo immunomodulatory effects.Multiple sclerosis and related disorders, , Volume: 58, 2022
Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia.The journal of ECT, , Volume: 26, Issue:4, 2010
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 13, Issue:2, 2006
[Demyelinating disease].Ryoikibetsu shokogun shirizu, , Issue:40, 2003
Priapism following olanzapine administration in a patient with multiple sclerosis.Psychosomatics, , Volume: 39, Issue:3
Neuroleptic malignant syndrome and catatonia in a patient with dementia.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:6, 2008
The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 31, Issue:2, 2007
Stuporous catatonia in an elderly bipolar patient: response to olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:5, 2006
[Alterations of gait parameters under external cueing in schizophrenic patients: a switch study].Psychiatrische Praxis, , Volume: 31 Suppl 1, 2004
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].Minerva anestesiologica, , Volume: 69, Issue:6, 2003
Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects.Journal of psychiatry & neuroscience : JPN, , Volume: 28, Issue:4, 2003
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 13, Issue:4, 2001
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Possible neuroleptic malignant syndrome associated with olanzapine.The Annals of pharmacotherapy, , Volume: 34, Issue:5, 2000
Atypical Neuroleptic Malignant Syndrome: Case Reports and Diagnostic Challenges.Journal of psychoactive drugs, , Volume: 54, Issue:3
Cyclosporine-Olanzapine Drug-Drug Interaction.The primary care companion for CNS disorders, , Apr-26, Volume: 20, Issue:2, 2018
Fatal agranulocytosis: the use of olanzapine in a patient with schizophrenia and myelodysplasia.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-30, Volume: 31, Issue:1, 2007
Developed catatonia with rhabdomyolysis and exacerbated cardiac failure upon switching from clozapine to olanzapine owing to cardiomyopathy during clozapine medication - A case report.Asian journal of psychiatry, , Volume: 80, 2023
Adolescent with treatment-refractory schizophrenia and clozapine-induced cardiomyopathy managed with high-dose olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 20, Issue:6, 2010
[Neuroleptic adverse effects with emphasis on weight gain].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 37, Issue:4, 2009
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current opinion in pediatrics, , Volume: 17, Issue:2, 2005
Masked clozapine-induced cardiomyopathy.Journal of the American Board of Family Medicine : JABFM, , Volume: 21, Issue:1
Determination of olanzapine in a postmortem case.Journal of analytical toxicology, , Volume: 22, Issue:7
Challenges in managing a mother with a dual diagnosis of peripartum cardiomyopathy and paranoid schizophrenia - a case report.General hospital psychiatry, , Volume: 35, Issue:6
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).The American journal of psychiatry, , Volume: 168, Issue:2, 2011
Atypical antipsychotic drugs in the treatment of delusional parasitosis.International journal of psychiatry in medicine, , Volume: 37, Issue:1, 2007
Elderly patient with delirium after myocardial infarction.Journal of the National Medical Association, , Volume: 98, Issue:4, 2006
Delayed olanzapine induced myocarditis and rhabdomyolysis.Postgraduate medical journal, , Volume: 98, Issue:1165, 2022
Clozapine-Induced Myocarditis in a Young Man with Refractory Schizophrenia: Case Report of a Rare Adverse Event and Review of the Literature.The American journal of case reports, , Jul-06, Volume: 23, 2022
Eosinophilic myocarditis during treatment with olanzapine - report of two possible cases.BMC psychiatry, , Mar-17, Volume: 16, 2016
[Eosinophilic myocarditis and sudden unexpected death in a younger patient treated with antipsychotics].Ugeskrift for laeger, , Oct-31, Volume: 173, Issue:44, 2011
Successful clozapine retrial after suspected myocarditis.The American journal of psychiatry, , Volume: 167, Issue:3, 2010
[Neuroleptic adverse effects with emphasis on weight gain].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 37, Issue:4, 2009
Olanzapine-associated myoclonus.Epilepsy research, , Volume: 98, Issue:2-3, 2012
[A 74-year-old unconscious woman with myoclonia and seizures].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Sep-07, Volume: 126, Issue:17, 2006
Case report of withdrawal syndrome after olanzapine discontinuation.Journal of clinical psychopharmacology, , Volume: 20, Issue:4, 2000
Olanzapine-induced myoclonic status.Clinical neuropharmacology, , Volume: 28, Issue:3
A single fatal dose of olanzapine.Neurology India, , Volume: 57, Issue:4
The Use of Olanzapine for Nonmedical Opioid Use in a Patient with Cancer Receiving Palliative Care.Journal of palliative medicine, , Volume: 25, Issue:2, 2022
A Case of Blunted Orally Disintegrating Olanzapine Effect Due to Coadministered Psyllium.The Journal of clinical psychiatry, , 02-23, Volume: 82, Issue:2, 2021
An open-label randomized trial of intramuscular olanzapine versus oral clonidine for symptomatic treatment of opioid withdrawal in the emergency department.Clinical toxicology (Philadelphia, Pa.), , Volume: 57, Issue:8, 2019
Craving Behavior from Opioid Addiction Controlled with Olanzapine in an Advanced Cancer Patient: A Case Report.Journal of palliative medicine, , Volume: 21, Issue:9, 2018
Olanzapine suppresses the rewarding and discriminative stimulus effects induced by morphine.Synapse (New York, N.Y.), , Volume: 66, Issue:2, 2012
Steroid responsive psychotic depression.The Australian and New Zealand journal of psychiatry, , Volume: 43, Issue:7, 2009
Serotonin syndrome: a complex but easily avoidable condition.General hospital psychiatry, , Volume: 30, Issue:3
Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Journal of pediatric hematology/oncology, , 10-01, Volume: 45, Issue:7, 2023
Olanzapine Improves Cachexia in a Breast Cancer Patient under Home Hospice Care.Journal of palliative medicine, , Volume: 25, Issue:1, 2022
Facial edema as an adverse drug reaction to olanzapine in a patient with cancer receiving palliative care.Palliative & supportive care, , Volume: 20, Issue:5, 2022
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.Investigational new drugs, , Volume: 40, Issue:1, 2022
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.Journal of pediatric hematology/oncology, , 11-01, Volume: 44, Issue:8, 2022
Olanzapine in oncology palliative care.Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, ,Summer, Volume: 35, Issue:4, 2022
Olanzapine was an effective additional antiemetic for children and young people undergoing highly emetogenic chemotherapy.Archives of disease in childhood. Education and practice edition, , Volume: 107, Issue:4, 2022
Efficacy of Olanzapine for Symptom Relief in Cancer Patients.Journal of pain & palliative care pharmacotherapy, , Volume: 36, Issue:4, 2022
The Use of Olanzapine for Nonmedical Opioid Use in a Patient with Cancer Receiving Palliative Care.Journal of palliative medicine, , Volume: 25, Issue:2, 2022
Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.Future oncology (London, England), , Volume: 17, Issue:16, 2021
Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTScientific reports, , 01-11, Volume: 11, Issue:1, 2021
Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 29, Issue:10, 2021
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:11, 2020
Olanzapine Versus Haloperidol for Treatment of Delirium in Patients with Advanced Cancer: A Phase III Randomized Clinical Trial.The oncologist, , Volume: 25, Issue:3, 2020
Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.JAMA oncology, , 06-01, Volume: 6, Issue:6, 2020
Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction.Journal of palliative medicine, , Volume: 23, Issue:7, 2020
Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial.Pediatric blood & cancer, , Volume: 67, Issue:9, 2020
Olanzapine for the Treatment of Breakthrough Vomiting in Children Receiving Moderate and High Emetogenic Chemotherapy.Indian pediatrics, , 11-15, Volume: 57, Issue:11, 2020
The Benefits of Olanzapine in Palliating Symptoms.Current treatment options in oncology, , 11-26, Volume: 22, Issue:1, 2020
[no title available]Revue medicale suisse, , 09-09, Volume: 16, Issue:705, 2020
Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:4, 2020
Efficacy of olanzapine for quality of life improvement among patients with malignant tumor: A systematic review.Cancer reports (Hoboken, N.J.), , Volume: 2, Issue:4, 2019
Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:8, 2019
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.Journal of global oncology, , Volume: 5, 2019
Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.The oncologist, , Volume: 24, Issue:6, 2019
The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:8, 2019
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.The Cochrane database of systematic reviews, , 09-21, Volume: 9, 2018
Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins.Cellular signalling, , Volume: 42, 2018
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.International journal of clinical oncology, , Volume: 23, Issue:2, 2018
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.Journal of global oncology, , Volume: 4, 2018
Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.British journal of clinical pharmacology, , Volume: 83, Issue:7, 2017
NCCN Guidelines Insights: Antiemesis, Version 2.2017.Journal of the National Comprehensive Cancer Network : JNCCN, , Volume: 15, Issue:7, 2017
[Differential diagnosis and treatment of nausea and vomiting associated with cancer or its treatment].Magyar onkologia, , Sep-20, Volume: 61, Issue:3, 2017
Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.Current opinion in supportive and palliative care, , Volume: 10, Issue:2, 2016
Novel Therapeutic Strategies for Delirium in Patients With Cancer: A Preliminary Study.The American journal of hospice & palliative care, , Volume: 33, Issue:5, 2016
Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:6, 2016
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.Annals of palliative medicine, , Volume: 5, Issue:3, 2016
Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 23, Issue:9, 2015
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.Journal of palliative medicine, , Volume: 18, Issue:11, 2015
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.Biochimica et biophysica acta, , Volume: 1848, Issue:10 Pt B, 2015
Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.Hospital practice (1995), , Volume: 43, Issue:4, 2015
Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review.Pediatric blood & cancer, , Volume: 62, Issue:3, 2015
Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 97, Issue:3, 2014
Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.Journal of cancer research and clinical oncology, , Volume: 140, Issue:1, 2014
Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.Asian Pacific journal of cancer prevention : APJCP, , Volume: 15, Issue:22, 2014
Olanzapine: palliative medicine update.The American journal of hospice & palliative care, , Volume: 30, Issue:1, 2013
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 21, Issue:6, 2013
Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction.Journal of pain and symptom management, , Volume: 44, Issue:4, 2012
Subcutaneous olanzapine for hyperactive or mixed delirium in patients with advanced cancer: a preliminary study.Journal of pain and symptom management, , Volume: 40, Issue:5, 2010
Olanzapine for nausea and vomiting.The American journal of hospice & palliative care, , Volume: 27, Issue:6, 2010
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.Journal of experimental & clinical cancer research : CR, , Sep-23, Volume: 28, 2009
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 15, Issue:11, 2007
Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.European journal of cancer care, , Volume: 16, Issue:4, 2007
[Olanzapine use in cancer patients for refractory vomiting].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 33, Issue:3, 2006
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.Cancer investigation, , Volume: 22, Issue:3, 2004
A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients.Journal of pain and symptom management, , Volume: 25, Issue:5, 2003
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.Journal of pain and symptom management, , Volume: 23, Issue:6, 2002
Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project.Expert review of anticancer therapy, , Volume: 2, Issue:4, 2002
Olanzapine in the management of cancer pain.Journal of pain and symptom management, , Volume: 23, Issue:4, 2002
Are antipsychotic drugs potentially chemopreventive agents for cancer?European journal of clinical pharmacology, , Volume: 55, Issue:6, 1999
An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients.Psychosomatics, , Volume: 43, Issue:3
Clocking delirium: the value of the Clock Drawing Test with case illustrations.The American journal of hospice & palliative care, , Volume: 25, Issue:5
Olanzapine and mirtazapine for multiple palliation.The journal of supportive oncology, , Volume: 1, Issue:1
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics.Journal of clinical psychopharmacology, , Volume: 25, Issue:4, 2005
[Clinical course of acute poisoning with olanzapine].Przeglad lekarski, , Volume: 62, Issue:6, 2005
The clinical picture of olanzapine poisoning with special reference to fluctuating mental status.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:1, 2004
Atypical psychotropic medications and their adverse effects: a review for the African-American primary care physician.Journal of the National Medical Association, , Volume: 95, Issue:2, 2003
Delayed-Onset olanzapine-induced rhabdomyolysis.BMJ case reports, , Mar-10, Volume: 16, Issue:3, 2023
[Neuroleptic malignant syndrome caused by olanzapine, risperidone and haloperidol].Ugeskrift for laeger, , 11-07, Volume: 184, Issue:45, 2022
Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report.Journal of medical case reports, , Oct-06, Volume: 16, Issue:1, 2022
Neuroleptic malignant syndrome with abnormally elevated cardiac troponin I: a case report.The Journal of international medical research, , Volume: 48, Issue:11, 2020
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.Bosnian journal of basic medical sciences, , May-20, Volume: 19, Issue:2, 2019
Atypical neuroleptic malignant syndrome - A case report.Asian journal of psychiatry, , Volume: 43, 2019
Olanzapine as a cause of neuroleptic malignant syndrome, bibliographic review following a clinical case.Actas espanolas de psiquiatria, , Volume: 46, Issue:3, 2018
Dantrolene for Treatment of Suspected Neuroleptic Malignant Syndrome.Journal of emergency nursing, , Volume: 44, Issue:2, 2018
Olanzapine induced neuroleptic malignant syndrome, treated with electroconvulsive therapy (ECT)-A case report.Asian journal of psychiatry, , Volume: 30, 2017
Reversible splenial lesion syndrome with a hyperosmolar hyperglycemic state and neuroleptic malignant syndrome caused by olanzapine.Journal of diabetes investigation, , Volume: 8, Issue:3, 2017
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
Olanzapine-induced atypical neuroleptic malignant syndrome in an adolescent man with anorexia nervosa.Eating and weight disorders : EWD, , Volume: 21, Issue:2, 2016
A Woman in Her 60s With Fever and Altered Mental Status in a Psychiatric Hospital.Chest, , Volume: 150, Issue:6, 2016
Neuroleptic malignant syndrome in a patient on long-term olanzapine treatment at a stable dose: Successful treatment with dantrolene.Brain injury, , Volume: 29, Issue:5, 2015
Electroconvulsive in a Schizophrenic Patient With Neuroleptic Malignant Syndrome and Rhabdomyolysis.The journal of ECT, , Volume: 31, Issue:3, 2015
An atypical case of neuroleptic malignant syndrome precipitated by valproate.BMJ case reports, , Mar-06, Volume: 2014, 2014
[Electroconvulsion therapy for neuroleptic malignant syndrome].Tijdschrift voor psychiatrie, , Volume: 56, Issue:9, 2014
[Association of atypical neuroleptics with anticonvulsants and malignant syndrome. Report of 2 cases].The Pan African medical journal, , Volume: 18, 2014
Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary.BMJ case reports, , Jun-23, Volume: 2014, 2014
Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care.Clinical toxicology (Philadelphia, Pa.), , Volume: 52, Issue:1, 2014
Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment.The Australian and New Zealand journal of psychiatry, , Volume: 47, Issue:10, 2013
Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine.Pharmacological reports : PR, , Volume: 65, Issue:2, 2013
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.Swiss medical weekly, , Volume: 143, 2013
Atypical neuroleptic malignant syndrome in H1N1 pneumonia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 25, Issue:1, 2013
Neuroleptic Malignant Syndrome Induced by Olanzapine in a Patient with Huntington's Disease.Journal of Huntington's disease, , Volume: 1, Issue:1, 2012
Olanzapine-induced neuroleptic malignant syndrome in a patient with probable dementia with Lewy bodies.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome.The Annals of pharmacotherapy, , Volume: 45, Issue:11, 2011
Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs.Biological research for nursing, , Volume: 13, Issue:1, 2011
Unexpected hospitalisation side effects in an elderly man.Internal and emergency medicine, , Volume: 6, Issue:2, 2011
Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
[Intensive care treatment for neuroleptic malignant syndrome].Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, , Volume: 45, Issue:7-8, 2010
Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia.Psychiatry and clinical neurosciences, , Volume: 63, Issue:1, 2009
Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine.Journal of medical toxicology : official journal of the American College of Medical Toxicology, , Volume: 5, Issue:1, 2009
In response to Morris et al.'s "Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine".Journal of medical toxicology : official journal of the American College of Medical Toxicology, , Volume: 5, Issue:4, 2009
Atypical neuroleptic malignant syndrome in an adolescent.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:2, 2008
Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine.The American journal of psychiatry, , Volume: 165, Issue:11, 2008
Neuroleptic malignant syndrome and catatonia in a patient with dementia.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:6, 2008
Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
[Use of olanzapine in adolescent with bipolar disorder after neuroleptic malignant syndrome].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:1, 2008
Neuroleptic malignant syndrome presenting with acute renal failure.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy.Pharmacotherapy, , Volume: 28, Issue:3, 2008
Neuroleptic malignant syndrome variant in a patient receiving donepezil and olanzapine.Nature clinical practice. Neurology, , Volume: 4, Issue:3, 2008
Late-onset neuroleptic malignant syndrome in a patient using olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:3, 2007
Comments on the report of neuroleptic malignant syndrome induced by ziprasidone.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 8, Issue:2, 2007
Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine.Indian journal of medical sciences, , Volume: 61, Issue:10, 2007
Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report.Psychiatria Danubina, , Volume: 18, Issue:1-2, 2006
Persistent amnesia as a sequel of olanzapine-induced neuroleptic malignant syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 18, Issue:4, 2006
Olanzapine-associated neuroleptic malignant syndrome.Pharmacotherapy, , Volume: 26, Issue:8, 2006
Neuroleptic malignant syndrome due to three atypical antipsychotics in a child.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:4, 2005
Atypical neuroleptic malignant syndrome caused by olanzapine.Acta psychiatrica Scandinavica, , Volume: 112, Issue:3, 2005
Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly.Southern medical journal, , Volume: 98, Issue:1, 2005
NMS after clozapine initiation.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 44, Issue:11, 2005
Neuroleptic malignant syndrome and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 14, Issue:3, 2004
Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:6, 2004
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].Minerva anestesiologica, , Volume: 69, Issue:6, 2003
Olanzapine induced "typical" neuroleptic malignant syndrome.Journal of clinical psychopharmacology, , Volume: 23, Issue:1, 2003
[Neuroleptic malignant syndrome in a patient treated with olanzapine].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Oct-23, Volume: 123, Issue:20, 2003
Neuroleptic malignant syndrome after addition of paroxetine to olanzapine.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
Atypical (olanzapine) plus conventional (fluphenazine) neuroleptic treatment associated with the neuroleptic malignant syndrome.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
Olanzapine elevation of serum creatine kinase.The Journal of clinical psychiatry, , Volume: 64, Issue:4, 2003
[Life threatening neuroleptic malignant syndrome due to olanzapine].Psychiatrische Praxis, , Volume: 30, Issue:5, 2003
Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.Pharmacotherapy, , Volume: 23, Issue:2, 2003
Neuroleptic malignant syndrome and low-dose olanzapine.The American journal of psychiatry, , Volume: 160, Issue:4, 2003
Olanzapine induced neuroleptic malignant syndrome--a case review.Human psychopharmacology, , Volume: 18, Issue:4, 2003
Olanzapine-associated neuroleptic malignant syndrome.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:5, 2002
Lethal catatonia.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:4, 2002
ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment.The journal of ECT, , Volume: 18, Issue:2, 2002
Olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome: case report.International journal of geriatric psychiatry, , Volume: 17, Issue:4, 2002
Atypical neuroleptic malignant syndrome associated with olanzapine.Pharmacotherapy, , Volume: 22, Issue:5, 2002
Movement disorders associated with atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 63 Suppl 4, 2002
Neuroleptic malignant syndrome due to olanzapine.Psychopharmacology bulletin, ,Summer, Volume: 35, Issue:3, 2001
Lethal catatonia responding to high-dose olanzapine therapy.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:4, 2001
Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.The American journal of psychiatry, , Volume: 158, Issue:4, 2001
Neuropletic malignant syndrome and olanzapine.Journal of clinical psychopharmacology, , Volume: 20, Issue:6, 2000
[Malignant neuroleptic syndrome in treatment with the new, atypical antipsychotic agents, risperidone and olanzapine].Ugeskrift for laeger, , Mar-27, Volume: 162, Issue:13, 2000
Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment.Acta psychiatrica Scandinavica, , Volume: 102, Issue:3, 2000
[Neuroleptic malignant syndrome and atypical antipsychotics].Medicina clinica, , Sep-09, Volume: 115, Issue:7, 2000
Neuroleptic malignant syndrome associated with olanzapine therapy: a case report.The Journal of emergency medicine, , Volume: 19, Issue:4, 2000
Possible neuroleptic malignant syndrome associated with olanzapine.The Annals of pharmacotherapy, , Volume: 34, Issue:5, 2000
Finding drug link to reaction.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Aug-01, Volume: 56, Issue:15, 1999
Olanzapine and NMS.Psychiatric services (Washington, D.C.), , Volume: 50, Issue:6, 1999
Neuroleptic malignant syndrome after the initiation of olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Olanzapine-induced neuroleptic malignant syndrome.Archives of general psychiatry, , Volume: 56, Issue:1, 1999
Atypical neuroleptic malignant syndrome?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:7, 1999
Recurrence of neuroleptic malignant syndrome with olanzapine treatment.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
[Neuroleptic malignant syndrome after treatment with olanzapine].Ugeskrift for laeger, , Mar-08, Volume: 161, Issue:10, 1999
[Neuroleptic malignant syndrome associated with olanzapine].Medicina clinica, , Sep-04, Volume: 113, Issue:6, 1999
Atypical antipsychotics and neuroleptic malignant syndrome.The British journal of psychiatry : the journal of mental science, , Volume: 175, 1999
Olanzapine-induced neuroleptic malignant syndrome with mental retardation.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Neuroleptic malignant syndrome associated with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 32, Issue:6, 1998
Case report: possible neuroleptic malignant syndrome associated with olanzapine.Journal of clinical psychopharmacology, , Volume: 18, Issue:6, 1998
Neuroleptic malignant syndrome associated with olanzapine.The Annals of pharmacotherapy, , Volume: 32, Issue:11, 1998
[Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine].Arquivos de neuro-psiquiatria, , Volume: 56, Issue:4, 1998
Side effect profiles of new antipsychotic agents.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Atypical Neuroleptic Malignant Syndrome: Case Reports and Diagnostic Challenges.Journal of psychoactive drugs, , Volume: 54, Issue:3
Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia.The West Virginia medical journal, , Volume: 98, Issue:2
Olazapine induced neuroleptic malignant syndrome.Actas espanolas de psiquiatria, , Volume: 34, Issue:2
[Olanzapine-associated neuroleptic malignant syndrome. A case report and favorable response to risperidone].Actas espanolas de psiquiatria, , Volume: 35, Issue:2
[Neuroleptic malignant syndrome associated with quetiapine after withdrawal of olanzapine and donepezil, with EEG differential diagnosis of Creutzfeldt-Jakob disease].Revista espanola de geriatria y gerontologia, , Volume: 51, Issue:5
Olanzapine usage associated with neuroleptic malignant syndrome.Psychosomatics, , Volume: 42, Issue:6
Olanzapine and neuroleptic malignant syndrome.Psychosomatics, , Volume: 43, Issue:6
Reconsidering Olanzapine as a Possible Culprit for Drug Fever, defying "Incomplete Neuromalignant Syndrome".The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, , Volume: 168, Issue:4
Neuroleptic malignant syndrome associated with olanzapine therapy.Psychosomatics, , Volume: 40, Issue:3
Olanzapine induced neuroleptic malignant syndrome.Indian journal of pharmacology, , Volume: 45, Issue:1
A Case Report of Neurosyphilis Limbic Encephalitis With Reversible Geschwind Syndrome and Mood Disorder.Journal of psychiatric practice, , Volume: 25, Issue:3, 2019
Olanzapine treatment in Jarisch-Herxheimer reaction due to neurosyphilis with dementia: a case report.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:8, 2009
Effectiveness of olanzapine in neurosyphilis related organic psychosis: a case report.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:5, 2007
A Comparative Study of Aripiprazole, Olanzapine, and L-Methylfolate Augmentation in Treatment Resistant Obsessive-Compulsive Disorder.The Psychiatric quarterly, , Volume: 92, Issue:4, 2021
Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life.Psychiatry research, , Volume: 276, 2019
Memantine as an Adjuvant Treatment for Obsessive Compulsive Symptoms in Manic Phase of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Journal of clinical psychopharmacology, , Volume: 37, Issue:2, 2017
Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients.Journal of clinical psychopharmacology, , Volume: 36, Issue:4, 2016
Treatment of comorbid bipolar disorder and anxiety disorders: A great challenge to modern psychiatry.The Australian and New Zealand journal of psychiatry, , Volume: 50, Issue:7, 2016
[The Usefulness of Clonazepam as an Augmentative Treatment in a Case of Severe Childhood Onset Obsessive-Compulsive Disorder].Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Winter, Volume: 26, Issue:4, 2015
Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis.BMC psychiatry, , Nov-29, Volume: 14, 2014
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.CNS spectrums, , Volume: 19, Issue:4, 2014
Topiramate as an adjuvant treatment for obsessive compulsive symptoms in patients with bipolar disorder: a randomized double blind placebo controlled clinical trial.Journal of affective disorders, , Volume: 166, 2014
Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.The Journal of clinical psychiatry, , Volume: 73, Issue:11, 2012
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.Psychological medicine, , Volume: 41, Issue:11, 2011
Raynaud’s phenomenon in a patient with schizophrenia and obsessive-compulsive disorder: a case report.Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Summer, Volume: 22, Issue:2, 2011
Second-generation antipsychotics for obsessive compulsive disorder.The Cochrane database of systematic reviews, , Dec-08, Issue:12, 2010
Fronto-limbic abnormalities in a patient with compulsive hoarding: a 99mTc-ECD SPECT study.Psychiatry and clinical neurosciences, , Volume: 64, Issue:5, 2010
Impact of obsessive-compulsive disorder on the antimanic response to olanzapine therapy in youth with bipolar disorder.Bipolar disorders, , Volume: 12, Issue:2, 2010
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.The Journal of clinical psychiatry, , Volume: 70, Issue:6, 2009
8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 18, Issue:5, 2008
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:6, 2008
Nature against nurture: calcification in the right thalamus in a young man with anorexia nervosa and obsessive-compulsive personality disorder.CNS spectrums, , Volume: 13, Issue:10, 2008
Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder.Psychiatry and clinical neurosciences, , Volume: 62, Issue:3, 2008
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Proton magnetic resonance spectroscopy reveals an abnormality in the anterior cingulate of a subgroup of obsessive-compulsive disorder patients.Psychiatry research, , Jan-15, Volume: 154, Issue:1, 2007
Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine.Pharmacopsychiatry, , Volume: 40, Issue:2, 2007
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.Molecular psychiatry, , Volume: 11, Issue:7, 2006
[Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 108, Issue:12, 2006
Creating more effective antidepressants: clues from the clinic.Drug discovery today, , Volume: 11, Issue:13-14, 2006
Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:4, 2005
The paradox of quetiapine in obsessive-compulsive disorder.CNS spectrums, , Volume: 10, Issue:5, 2005
[Obsessive-compulsive symptoms treatment in: schizophrenia].Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:7, 2005
Olanzapine in Gilles de la Tourette syndrome: beyond tics.Acta neurologica Belgica, , Volume: 105, Issue:4, 2005
Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome--a pilot study.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 14, Issue:2, 2004
Effective use of olanzapine for obsessive-compulsive symptoms in a patient with bipolar disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:8, 2004
Adolescent weight loss during treatment with olanzapine.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.Biological psychiatry, , Mar-01, Volume: 55, Issue:5, 2004
Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Obsessive-compulsive symptoms with olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:3, 2004
Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:4, 2003
Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
Reply to Dr Mahendran. We have not found reported cases of [obsessive-compulsive] OC arising from de novo with olanzapine treatment.The Australian and New Zealand journal of psychiatry, , Volume: 37, Issue:1, 2003
Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:5, 2002
Norepinephrine in the treatment of olanzapine overdose.Anaesthesia, , Volume: 57, Issue:10, 2002
Emergence of compulsive symptoms with olanzapine treatment.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:4, 2002
Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder.Psychopharmacology, , Volume: 162, Issue:1, 2002
Refractory obsessive-compulsive disorder: state-of-the-art treatment.The Journal of clinical psychiatry, , Volume: 63 Suppl 6, 2002
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.The Journal of clinical psychiatry, , Volume: 63, Issue:2, 2002
Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:4, 2001
Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Antibodies against human putamen in adolescents with anorexia nervosa.The International journal of eating disorders, , Volume: 29, Issue:4, 2001
Priapism associated with polypharmacy.The Journal of clinical psychiatry, , Volume: 62, Issue:2, 2001
Short-term effects of olanzapine in Huntington disease.Neuropsychiatry, neuropsychology, and behavioral neurology, , Volume: 14, Issue:1, 2001
Olanzapine and obsessive-compulsive symptoms.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 10, Issue:5, 2000
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.The Journal of clinical psychiatry, , Volume: 61, Issue:7, 2000
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.International clinical psychopharmacology, , Volume: 15, Issue:3, 2000
Olanzapine treatment of obsessive-compulsive disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 45, Issue:4, 2000
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.East African medical journal, , Volume: 77, Issue:2, 2000
Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder.The British journal of psychiatry : the journal of mental science, , Volume: 177, 2000
Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.Pharmacopsychiatry, , Volume: 33, Issue:6, 2000
Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.Psychiatry research, , Oct-30, Volume: 96, Issue:2, 2000
Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.The Journal of clinical psychiatry, , Volume: 60, Issue:8, 1999
Olanzapine-induced obsessive-compulsive disorder.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Open-label olanzapine treatment in five preadolescent children.Journal of child and adolescent psychopharmacology, , Volume: 8, Issue:2, 1998
Provocation of obsessive-compulsive behaviour and tremor by olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:6, 1998
Worsening of obsessive-compulsive symptoms following treatment with olanzapine.The American journal of psychiatry, , Volume: 155, Issue:6, 1998
Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , May-15, Volume: 55, Issue:10, 1998
Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.Journal of clinical psychopharmacology, , Volume: 18, Issue:5, 1998
Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.Psychopharmacology bulletin, , Volume: 32, Issue:1, 1996
Olanzapine-induced clinical seizure: a case report.Clinical neuropharmacology, , Volume: 32, Issue:5
Olanzapine-lithium encephalopathy.Psychosomatics, , Volume: 42, Issue:4
Neuropsychiatric sequelae in a case of St. Louis encephalitis.General hospital psychiatry, , Volume: 22, Issue:2
Pediatric Acute-Onset Neuropsychiatric Syndrome and Catatonia: A Case Report.Psychosomatics, , Volume: 61, Issue:1
Obsessive-compulsive disorder with mitochondrial disease.Psychosomatics, , Volume: 49, Issue:6
Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia.Indian journal of pharmacology, , Volume: 44, Issue:5
Adjunct Aripiprazole for Obsessive-Compulsive Symptoms Associated With Second-Generation Antipsychotics in 2 Patients With Schizophrenia: Anti-obsessional Efficacy of Partial Agonism.Journal of clinical psychopharmacology, , Volume: 40, Issue:4
[Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia].Psychiatria polska, , Volume: 35, Issue:1
Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia.Clinical neuropharmacology, , Volume: 34, Issue:6
Occupational allergic contact dermatitis to olanzapine.Contact dermatitis, , Volume: 62, Issue:2, 2010
Occupational airborne allergic contact dermatitis to olanzapine.Dermatitis : contact, atopic, occupational, drug, , Volume: 23, Issue:6
[Osteoporosis risk factors among patients with schizophrenia].Przeglad lekarski, , Volume: 63, Issue:3, 2006
Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
[Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics].Psychiatria polska, , Volume: 39, Issue:6
Resurgence of Eating Disorders with Olanzapine.Journal of palliative medicine, , Volume: 22, Issue:2, 2019
Chemotherapy-induced acute psychosis in a patient with malignant germ cell tumour.BMJ case reports, , Apr-09, Volume: 2015, 2015
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
The Use, Safety, and Efficacy of Olanzapine in a Level I Pediatric Trauma Center Emergency Department Over a 10-Year Period.Pediatric emergency care, , Volume: 36, Issue:2, 2020
A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, , Volume: 23, Issue:1, 2016
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.Journal of palliative medicine, , Volume: 18, Issue:11, 2015
A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.BMC psychiatry, , Jan-14, Volume: 14, 2014
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
A clinical paradigm of delusions of parasitosis.Journal of the American Academy of Dermatology, , Volume: 59, Issue:4, 2008
Duloxetine for childhood depression with pain and dissociative symptoms.European child & adolescent psychiatry, , Volume: 15, Issue:8, 2006
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 13, Issue:2, 2006
Massive creatine kinase elevations with quetiapine: report of two cases.Pharmacopsychiatry, , Volume: 39, Issue:1, 2006
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.Schizophrenia research, , Oct-15, Volume: 78, Issue:2-3, 2005
[Olanzapine in therapy of a somatoform disorder].Psychiatrische Praxis, , Volume: 30, Issue:8, 2003
Report of three case studies with olanzapine for chronic pain.The journal of pain, , Volume: 4, Issue:3, 2003
Olanzapine in the management of cancer pain.Journal of pain and symptom management, , Volume: 23, Issue:4, 2002
A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain.Journal of pain and symptom management, , Volume: 23, Issue:6, 2002
Central dopaminergic system plays a role in the analgesic action of paracetamol: Preclinical evidence.Indian journal of pharmacology, , Volume: 49, Issue:1
Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.Annals of palliative medicine, , Volume: 12, Issue:3, 2023
Olanzapine, an Atypical Antipsychotic, Inhibits Survivin Expression and Sensitizes Cancer Cells to Chemotherapeutic Agents.Anticancer research, , Volume: 37, Issue:11, 2017
Asymptomatic Elevation of Amylase and Lipase After Olanzapine Treatment.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
Olanzapine-induced acute pancreatitis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, , Volume: 26, Issue:3, 2015
Acute pancreatitis associated with lisinopril and olanzapine.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Feb-01, Volume: 67, Issue:3, 2010
[Acute pancreatitis induced by olanzapine].Annales francaises d'anesthesie et de reanimation, , Volume: 28, Issue:10, 2009
Olanzapine-induced chylomicronemia presenting as acute pancreatitis.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Fatal hyponatremia and other metabolic disturbances associated with psychotropic drug polypharmacy.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Olanzapine-induced pancreatitis: a case report.JOP : Journal of the pancreas, , Sep-10, Volume: 5, Issue:5, 2004
Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 42, Issue:10, 2003
Olanzapine-induced diabetic ketoacidosis.The Annals of pharmacotherapy, , Volume: 35, Issue:12, 2001
Olanzapine-induced acute pancreatitis.The Annals of pharmacotherapy, , Volume: 34, Issue:10, 2000
Olanzapine and pancreatitis.The British journal of psychiatry : the journal of mental science, , Volume: 177, 2000
Olanzapine-induced diabetes due to pancreatitis.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, , Volume: 24, Issue:6
[Pancreatitis coincident with valproate and olanzapine use].Neurologia (Barcelona, Spain), , Volume: 21, Issue:1
Olanzapine-induced Pancytopenia: A Rare but Worrying Complication.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 27, Issue:1, 2017
Olanzapine and pancytopenia with severe folate deficiency.European journal of clinical pharmacology, , Volume: 66, Issue:5, 2010
Olanzapine-induced pancytopenia.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:10, 2008
One further case of pancytopenia induced by olanzapine in a Parkinson's disease patient.European neurology, , Volume: 45, Issue:1, 2001
New-onset psychosis following initiation of eye movement desensitization and reprocessing therapy.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 32, Issue:2, 2020
A Case Report of Neurosyphilis Limbic Encephalitis With Reversible Geschwind Syndrome and Mood Disorder.Journal of psychiatric practice, , Volume: 25, Issue:3, 2019
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
Can typical and atypical antipsychotics show differential effectiveness in treating paranoia and hallucinations in schizophrenia?BMJ case reports, , Mar-31, Volume: 12, Issue:3, 2019
[Hemoperfusion with activated charcoal on valproic acid poisoning. A case report].Medicina intensiva, , Volume: 39, Issue:7, 2015
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 13, Issue:3, 2011
Psychosis secondary to traumatic brain injury.Brain injury, , Volume: 23, Issue:4, 2009
Atypical neuroleptic malignant syndrome in an adolescent.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:2, 2008
Lowered seizure threshold on olanzapine.The British journal of psychiatry : the journal of mental science, , Volume: 178, Issue:1, 2001
[Hyperglycemia and ketoacidosis associated with olanzapine].Der Nervenarzt, , Volume: 70, Issue:9, 1999
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 14, Issue:6, 1999
Paranoia and agitation associated with olanzapine treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:2, 1998
Treatment of psychotic depression.The American journal of psychiatry, , Volume: 154, Issue:11, 1997
Delusional infestation.The American journal of emergency medicine, , Volume: 35, Issue:2, 2017
Self inflicted corneal abrasions due to delusional parasitosis.BMJ case reports, , Jul-28, Volume: 2011, 2011
Delusions of parasitosis.The American journal of emergency medicine, , Volume: 27, Issue:8, 2009
Atypical antipsychotic drugs in the treatment of delusional parasitosis.International journal of psychiatry in medicine, , Volume: 37, Issue:1, 2007
Successful treatment of delusions of parasitosis with olanzapine.Archives of dermatology, , Volume: 142, Issue:3, 2006
Drug-induced Pressure Ulcers in a Middle-aged Patient with Early-stage Parkinson's Disease.Internal medicine (Tokyo, Japan), , May-15, Volume: 57, Issue:10, 2018
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.Brain and behavior, , Volume: 7, Issue:6, 2017
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.The Annals of pharmacotherapy, , Volume: 51, Issue:8, 2017
Atypical antipsychotic drugs in the treatment of Parkinson's disease.Journal of pharmacy practice, , Volume: 24, Issue:6, 2011
Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 22, Issue:1, 2010
Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 17, Issue:3, 2007
Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis.Medicinski arhiv, , Volume: 60, Issue:4, 2006
[The efficacy of olanzapine for delusion in patients with Parkinson's disease].No to shinkei = Brain and nerve, , Volume: 57, Issue:6, 2005
[Clozapine for the treatment of psychosis in 3 elderly patients with Parkinson's disease].Nederlands tijdschrift voor geneeskunde, , Nov-27, Volume: 148, Issue:48, 2004
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
Optimizing atypical antipsychotic treatment strategies in the elderly.Journal of the American Geriatrics Society, , Volume: 52, Issue:12 Suppl, 2004
Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.Psychiatry and clinical neurosciences, , Volume: 57, Issue:6, 2003
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
Olanzapine treatment for dopaminergic-induced hallucinations.Movement disorders : official journal of the Movement Disorder Society, , Volume: 17, Issue:5, 2002
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.Biological psychiatry, , Sep-01, Volume: 52, Issue:5, 2002
[Usefulness of olanzapine in the levodopa-induced psychosis in patients with Parkinson's disease].Neurologia (Barcelona, Spain), , Volume: 17, Issue:1, 2002
One further case of pancytopenia induced by olanzapine in a Parkinson's disease patient.European neurology, , Volume: 45, Issue:1, 2001
Olanzapine for psychosis in Parkinson's disease.Neurology, , Jun-26, Volume: 56, Issue:12, 2001
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Aug-28, Volume: 57, Issue:4, 2001
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Aug-28, Volume: 57, Issue:4, 2001
The economic consequences of a drug-drug interaction.Journal of clinical psychopharmacology, , Volume: 21, Issue:1, 2001
Quetiapine for l-dopa-induced psychosis in PD.Neurology, , Apr-11, Volume: 54, Issue:7, 2000
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.Neurology, , Sep-26, Volume: 55, Issue:6, 2000
Worsening of motor features of parkinsonism with olanzapine.Movement disorders : official journal of the Movement Disorder Society, , Volume: 14, Issue:6, 1999
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 11, Issue:3, 1999
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 14, Issue:6, 1999
Olanzapine in dementia with Lewy bodies: a clinical study.International journal of geriatric psychiatry, , Volume: 14, Issue:6, 1999
Olanzapine: extrapyramidal side effects in the elderly.Australian and New Zealand journal of medicine, , Volume: 29, Issue:3, 1999
Management of psychotic aspects of Parkinson's disease.The Journal of clinical psychiatry, , Volume: 60 Suppl 8, 1999
Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.Journal of neurology, neurosurgery, and psychiatry, , Volume: 65, Issue:5, 1998
Olanzapine can worsen parkinsonism.Neurology, , Volume: 50, Issue:4, 1998
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.Neurology, , Volume: 50, Issue:4, 1998
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.Neurology, , Volume: 47, Issue:4, 1996
Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study.Clinical neuropharmacology, , Volume: 21, Issue:5
Olanzapine and neuroleptic malignant syndrome.Psychosomatics, , Volume: 43, Issue:6
[Clozapine and olanzapine in the treatment of the psychotic disorders in Parkinson's disease].Revista de neurologia, , Volume: 39, Issue:7
Management of Parkinson disease.The Journal of the American Board of Family Practice, , Volume: 11, Issue:2
[The role of olanzapine in Parkinsonian dopaminergic psychosis].Revista de neurologia, , Volume: 35, Issue:7
Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia.Psychosomatics, , Volume: 42, Issue:6
Olanzapine usage associated with neuroleptic malignant syndrome.Psychosomatics, , Volume: 42, Issue:6
Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study.Pharmacoepidemiology and drug safety, , Volume: 29, Issue:6, 2020
Paradoxical worsening of parkinsonism upon neuroleptic withdrawal: More common than we think?Parkinsonism & related disorders, , Volume: 52, 2018
Secondary parkinsonism with Mumps infection.Parkinsonism & related disorders, , Volume: 21, Issue:10, 2015
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 54, Issue:9, 2015
Neurological Adverse Effects of Antipsychotics in Children and Adolescents.Journal of clinical psychopharmacology, , Volume: 35, Issue:6, 2015
Atypical antipsychotic use and parkinsonism in dementia: effects of drug, dose, and sex.The American journal of geriatric pharmacotherapy, , Volume: 10, Issue:6, 2012
Blood lactate levels in patients receiving first- or second- generation antipsychotics.Croatian medical journal, , Volume: 52, Issue:1, 2011
Does electroconvulsive therapy afford protection against olanzapine-induced parkinsonism? A case report.The journal of ECT, , Volume: 25, Issue:2, 2009
Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia.Human psychopharmacology, , Volume: 20, Issue:1, 2005
Worsening of motor features of parkinsonism with olanzapine.Movement disorders : official journal of the Movement Disorder Society, , Volume: 14, Issue:6, 1999
In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.Psychiatry research, , Apr-26, Volume: 90, Issue:2, 1999
Interaction between olanzapine and haloperidol.Journal of clinical psychopharmacology, , Volume: 19, Issue:3, 1999
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
Safety of olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
The relationship of pharmacology to side effects.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Old disease, new look? A first report of parkinsonism due to scurvy, and of refeeding-induced worsening of scurvy.Psychosomatics, , Volume: 54, Issue:3
Schizophrenia-like olfactory dysfunction induced by acute and postnatal phencyclidine exposure in rats.Schizophrenia research, , Volume: 199, 2018
Local-global processing in early-onset schizophrenia: evidence for an impairment in shifting the spatial scale of attention.Brain and cognition, , Volume: 51, Issue:1, 2003
Diurnal variation in Cotard's syndrome (copresent with Capgras delusion) following traumatic brain injury.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:4, 2000
Personality disorder among youth with first episode psychotic mania: An important target for specific treatment?Early intervention in psychiatry, , Volume: 16, Issue:3, 2022
Quasi-psychosis in covert Narcissistic Personality Disorder-A case report.Asian journal of psychiatry, , Volume: 32, 2018
Twelve-month prospective, multinational, observational study of factors associated with recovery from mania in bipolar disorder in patients treated with atypical antipsychotics.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:4, 2010
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.Bipolar disorders, , Volume: 7 Suppl 3, 2005
Olanzapine improves social dysfunction in cluster B personality disorder.Human psychopharmacology, , Volume: 17, Issue:5, 2002
Broad therapeutic uses of atypical antipsychotic medications.Biological psychiatry, , Dec-01, Volume: 50, Issue:11, 2001
Olanzapine-induced photo-allergic reaction.The Australian and New Zealand journal of psychiatry, , Volume: 52, Issue:8, 2018
Photo-onycholysis caused by olanzapine and aripiprazole.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Photosensitivity might be associated with drug-induced hypersensitivity syndrome.Dermatology (Basel, Switzerland), , Volume: 214, Issue:4, 2007
Pica disorder as a symptom of depression in a patient with bipolar disorder and intellectual disability.Actas espanolas de psiquiatria, , Volume: 48, Issue:1, 2020
Pica associated with initiation of atypical antipsychotic drugs: Report of two cases.Psychiatry and clinical neurosciences, , Volume: 70, Issue:8, 2016
Administration of olanzapine as an antiemetic agent changes glucose homeostasis in cisplatin-treated rats.Biological & pharmaceutical bulletin, , Volume: 38, Issue:4, 2015
Olanzapine-associated pica in a schizophrenia patient.Psychiatry and clinical neurosciences, , Volume: 64, Issue:4, 2010
Treatment of pica behavior with olanzapine.CNS spectrums, , Volume: 13, Issue:1, 2008
Antipsychotics and pituitary tumors: an analysis of the European pharmacovigilance database (EudraVigilance).International clinical psychopharmacology, , Volume: 34, Issue:2, 2019
Hyperprolactinaemia and acute psychosis: prolactinoma or medication-induced phenomenon?The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:5, 2010
Management of a patient with schizophrenia and underlying pituitary macroadenoma.Annals of the Academy of Medicine, Singapore, , Volume: 39, Issue:11, 2010
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.Pharmacotherapy, , Volume: 26, Issue:6, 2006
Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:1, 2005
Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder.Rivista di psichiatria, , Volume: 54, Issue:1
A case-control study of antipsychotic use and pneumonia-related mortality in the United Kingdom.Acta psychiatrica Scandinavica, , Volume: 147, Issue:3, 2023
Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.Schizophrenia bulletin, , 04-29, Volume: 47, Issue:3, 2021
Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study.The Journal of clinical psychiatry, , Volume: 74, Issue:1, 2013
Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
Reference Brain and Blood Concentrations of Olanzapine in Postmortem Cases.Journal of analytical toxicology, , Nov-01, Volume: 42, Issue:9, 2018
Postmortem redistribution of olanzapine following intramuscular administration of olanzapine pamoate in dogs.Forensic science international, , Volume: 257, 2015
Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation.Biological psychiatry, , May-15, Volume: 69, Issue:10, 2011
Postmortem tissue distribution of olanzapine and citalopram in a drug intoxication.Journal of forensic sciences, , Volume: 50, Issue:3, 2005
[3H]RX 821002 in human dorsolateral prefrontal cortex: no changes in postmortem tissue from subjects with schizophrenia.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
Tissue distribution of olanzapine in a postmortem case.The American journal of forensic medicine and pathology, , Volume: 22, Issue:3, 2001
The Benefits of Olanzapine in Palliating Symptoms.Current treatment options in oncology, , 11-26, Volume: 22, Issue:1, 2020
Delirium associated with olanzapine use in the elderly.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 17, Issue:2, 2017
A patient with schizophrenia presenting with post-lobotomy catatonia treated with olanzapine: a case report.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 17, Issue:3, 2017
Pharmacological and psychosomatic treatments for an elderly patient with severe nausea and vomiting in reaction to postoperative stress.Clinical journal of gastroenterology, , Volume: 8, Issue:5, 2015
[Chronic conversion somatic disorder: a case report].Recenti progressi in medicina, , Volume: 104, Issue:2, 2013
A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study.Minerva anestesiologica, , Volume: 78, Issue:9, 2012
A potential case of peduncular hallucinosis treated successfully with olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Olanzapine for recurrent excessive irritability and psychotic symptoms after mesial temporal lobectomy in a patient with temporal lobe epilepsy.Epilepsy & behavior : E&B, , Volume: 9, Issue:3, 2006
Heart transplantation and schizophrenia.Psychosomatics, , Volume: 44, Issue:3
Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial.Psychosomatics, , Volume: 51, Issue:5
Individual risk profiles for postoperative delirium after joint replacement surgery.Psychosomatics, , Volume: 52, Issue:5
Antipsychotic prophylaxis in surgical patients modestly decreases delirium incidence--but not duration--in high-incidence samples: a meta-analysis.General hospital psychiatry, , Volume: 35, Issue:4
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).BMJ open, , 01-31, Volume: 13, Issue:1, 2023
Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.CNS spectrums, , Volume: 27, Issue:3, 2022
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.Psychiatry research, , Volume: 296, 2021
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.Acta psychiatrica Scandinavica, , Volume: 139, Issue:1, 2019
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.JAMA psychiatry, , 07-01, Volume: 74, Issue:7, 2017
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.Internal medicine (Tokyo, Japan), , Volume: 56, Issue:3, 2017
Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain.JAMA psychiatry, , 11-01, Volume: 74, Issue:11, 2017
Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.BMJ open, , Mar-25, Volume: 4, Issue:3, 2014
Prediabetes in patients treated with antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 73, Issue:4, 2012
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.Journal of psychiatric research, , Volume: 43, Issue:11, 2009
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Potential for detection bias in the association between olanzapine and diabetes.The Journal of clinical psychiatry, , Volume: 65, Issue:2, 2004
Delusion of denial of pregnancy: A case report.Asian journal of psychiatry, , Volume: 45, 2019
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.The American journal of psychiatry, , 06-01, Volume: 175, Issue:6, 2018
Prophylactic use of olanzapine and quetiapine from pregnancy to the postpartum period in women with bipolar disorder: a case series.The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, , Volume: 30, Issue:21, 2017
Dilemma of treating schizophrenia during pregnancy: a Case series and a review of literature.BMC psychiatry, , 08-29, Volume: 17, Issue:1, 2017
Atypical antipsychotic use and outcomes in an urban maternal mental health service.International journal of psychiatry in medicine, , Volume: 51, Issue:6, 2016
A Woman With Major Depression With Psychotic Features Requesting a Termination of Pregnancy.The American journal of psychiatry, , Volume: 173, Issue:1, 2016
Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review.Basic & clinical pharmacology & toxicology, , Volume: 116, Issue:4, 2015
Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.Bipolar disorders, , Volume: 17, Issue:6, 2015
Antipsychotic use in pregnancy.Expert opinion on pharmacotherapy, , Volume: 16, Issue:9, 2015
[Epidural labor analgesia for a primipara with schizophrenia].Masui. The Japanese journal of anesthesiology, , Volume: 59, Issue:8, 2010
Antipsychotics in pregnancy.Journal of psychiatric and mental health nursing, , Volume: 17, Issue:2, 2010
Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study.The British journal of psychiatry : the journal of mental science, , Volume: 192, Issue:5, 2008
Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:1, 2008
The clinical dilemma--prescribing in pregnancy.Psychiatria Danubina, , Volume: 20, Issue:1, 2008
Olanzapine plasma concentration in a newborn.Journal of psychopharmacology (Oxford, England), , Volume: 22, Issue:8, 2008
Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.The American journal of psychiatry, , Volume: 164, Issue:8, 2007
Olanzapine exposure during pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:8, 2007
A case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain.The Journal of clinical psychiatry, , Volume: 68, Issue:12, 2007
Managing psychosis in pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:3, 2007
The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities.The American journal of psychiatry, , Volume: 164, Issue:11, 2007
Meningocele and ankyloblepharon following in utero exposure to olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:5, 2006
Hip dysplasia following a case of olanzapine exposed pregnancy: a questionable association.Archives of women's mental health, , Volume: 9, Issue:4, 2006
Women are not the same as men: specific clinical issues for female patients with bipolar disorder.Bipolar disorders, , Volume: 7 Suppl 1, 2005
Treatment of perinatal delusional disorder: a case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Olanzapine and pregnancy.Pharmacopsychiatry, , Volume: 35, Issue:3, 2002
[Olanzapine and pregnancy].Orvosi hetilap, , Jan-21, Volume: 142, Issue:3, 2001
Olanzapine in pregnancy.The Annals of pharmacotherapy, , Volume: 35, Issue:10, 2001
Maternal obesity and risk of neural tube defects.Canadian family physician Medecin de famille canadien, , Volume: 47, 2001
Antipsychotics during pregnancy.The American journal of psychiatry, , Volume: 157, Issue:8, 2000
Olanzapine-exposed pregnancies and lactation: early experience.Journal of clinical psychopharmacology, , Volume: 20, Issue:4, 2000
[Schizophrenia and depression. Special aspects in the therapy of women].Der Nervenarzt, , Volume: 69, Issue:7 Suppl Be, 1998
Atypical presentations of pregnancy-specific generalized anxiety disorders in women without a previous psychiatric background.Psychosomatics, , Volume: 56, Issue:3
The antipsychotic olanzapine reduces memory deficits and neuronal abnormalities in a male rat model of Autism.Journal of chemical neuroanatomy, , Volume: 132, 2023
Maternal immune activation and repeated maternal separation alter offspring conditioned avoidance response learning and antipsychotic response in male rats.Behavioural brain research, , 04-09, Volume: 403, 2021
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.Progress in neuro-psychopharmacology & biological psychiatry, , 06-08, Volume: 108, 2021
Memory deterioration based on the tobacco smoke exposure and methylazoxymethanol acetate administration vs. aripiprazole, olanzapine and enrichment environment conditions.Pharmacology, biochemistry, and behavior, , Volume: 189, 2020
Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model.Journal of psychiatric research, , Volume: 115, 2019
Antenatal antipsychotic exposure induces multigenerational and gender-specific programming of adiposity and glucose tolerance in adult mouse offspring.Diabetes & metabolism, , Volume: 44, Issue:3, 2018
The influence of aripiprazole and olanzapine on neurotransmitters level in frontal cortex of prenatally stressed rats.Environmental toxicology and pharmacology, , Volume: 46, 2016
The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol.Pharmacological reports : PR, , Volume: 68, Issue:2, 2016
Neuroleptics and enrichment environment treatment in memory disorders and other central nervous system function observed in prenatally stressed rats.Human & experimental toxicology, , Volume: 34, Issue:5, 2015
Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.Brain research, , Aug-27, Volume: 1618, 2015
Antipsychotic use in pregnancy.Expert opinion on pharmacotherapy, , Volume: 16, Issue:9, 2015
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.Pharmacological reports : PR, , Volume: 65, Issue:1, 2013
Birth weight and use of olanzapine in pregnancy: a prospective comparative study.Journal of clinical psychopharmacology, , Volume: 30, Issue:3, 2010
Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study.The British journal of psychiatry : the journal of mental science, , Volume: 192, Issue:5, 2008
Meningocele and ankyloblepharon following in utero exposure to olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:5, 2006
Hip dysplasia following a case of olanzapine exposed pregnancy: a questionable association.Archives of women's mental health, , Volume: 9, Issue:4, 2006
Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats.Pharmacology, biochemistry, and behavior, , Volume: 72, Issue:3, 2002
Clinical Pearls in palliative medicine.Disease-a-month : DM, , Volume: 63, Issue:6, 2017
Switching among antipsychotics--focus on side effects.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Primary delusional parasitosis treated with olanzapine.International psychogeriatrics, , Volume: 19, Issue:6, 2007
[A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy].Der Nervenarzt, , Volume: 74, Issue:7, 2003
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Lithium, antipsychotics, and risk of psoriasis.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
Exacerbation of chronic large plaque psoriasis associated with Olanzepine therapy.Journal of the European Academy of Dermatology and Venereology : JEADV, , Volume: 14, Issue:4, 2000
Psoriasis during therapy with olanzapine.European journal of dermatology : EJD, , Volume: 13, Issue:4
Comparison of efficacy and frequency of akathisia and dystonia between olanzapine, metoclopramide and prochlorperazine in ED headache patients.The American journal of emergency medicine, , Volume: 65, 2023
An open-label clinical trial of oral transmucosal haloperidol and oral transmucosal olanzapine in the treatment of terminal delirium at home.Trials, , Apr-14, Volume: 23, Issue:1, 2022
Cost-Effectiveness of Midazolam Versus Haloperidol Versus Olanzapine for the Management of Acute Agitation in the Accident and Emergency Department.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 25, Issue:7, 2022
Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular.International clinical psychopharmacology, , 01-01, Volume: 37, Issue:1, 2022
Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report.Neuropsychopharmacology reports, , Volume: 42, Issue:3, 2022
Psychopharmacology of agitation in acute psychotic and manic episodes.Current opinion in psychiatry, , 05-01, Volume: 35, Issue:3, 2022
A Prospective Study of Intramuscular Droperidol or Olanzapine for Acute Agitation in the Emergency Department: A Natural Experiment Owing to Drug Shortages.Annals of emergency medicine, , Volume: 78, Issue:2, 2021
Brief psychotic disorder with delusion content related to the COVID-19 outbreak.Psychiatrike = Psychiatriki, , Apr-19, Volume: 32, Issue:1, 2021
Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis.Schizophrenia research, , Volume: 229, 2021
The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.Expert opinion on investigational drugs, , Volume: 29, Issue:3, 2020
CSF studies which ultimately led to the possible diagnosis of anti-NMDAR encephalitis.BMJ case reports, , May-07, Volume: 13, Issue:5, 2020
The Use, Safety, and Efficacy of Olanzapine in a Level I Pediatric Trauma Center Emergency Department Over a 10-Year Period.Pediatric emergency care, , Volume: 36, Issue:2, 2020
Neurotropism of SARS-CoV-2: COVID-19 presenting with an acute manic episode.BMJ case reports, , Jun-14, Volume: 13, Issue:6, 2020
Use of olanzapine to treat agitation in traumatic brain injury: study protocol for a randomised controlled trial.Trials, , Jul-20, Volume: 21, Issue:1, 2020
Parenteral Antipsychotic Choice and Its Association With Emergency Department Length of Stay for Acute Agitation Secondary to Alcohol Intoxication.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, , Volume: 26, Issue:1, 2019
The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 57, 2019
Rescue Sedation When Treating Acute Agitation in the Emergency Department With Intramuscular Antipsychotics.The Journal of emergency medicine, , Volume: 56, Issue:5, 2019
Management of a complex patient - intravenous olanzapine use.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 26, Issue:6, 2018
Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation).The Cochrane database of systematic reviews, , 01-08, Volume: 1, 2018
Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department.Annals of emergency medicine, , Volume: 72, Issue:4, 2018
Evidence-Based Review of Pharmacotherapy for Acute Agitation. Part 1: Onset of Efficacy.The Journal of emergency medicine, , Volume: 54, Issue:3, 2018
A Prospective Observational Study of Patients Receiving Intravenous and Intramuscular Olanzapine in the Emergency Department.Annals of emergency medicine, , Volume: 69, Issue:3, 2017
Midazolam-Droperidol, Droperidol, or Olanzapine for Acute Agitation: A Randomized Clinical Trial.Annals of emergency medicine, , Volume: 69, Issue:3, 2017
Use of Orally Disintegrating Olanzapine During Electroconvulsive Therapy for Prevention of Postictal Agitation.Journal of psychiatric practice, , Volume: 22, Issue:6, 2016
Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.Journal of child and adolescent psychopharmacology, , Volume: 26, Issue:5, 2016
A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, , Volume: 23, Issue:1, 2016
Droperidol for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , 12-15, Volume: 12, 2016
Assessment and management of agitation in psychiatry: Expert consensus.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 17, Issue:2, 2016
Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.Schizophrenia research, , Volume: 176, Issue:2-3, 2016
Intramuscular olanzapine for agitated patients: A systematic review and meta-analysis of randomized controlled trials.Journal of psychiatric research, , Volume: 68, 2015
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.Journal of the Formosan Medical Association = Taiwan yi zhi, , Volume: 114, Issue:5, 2015
A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.Human psychopharmacology, , Volume: 29, Issue:1, 2014
A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 24, Issue:3, 2014
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.Journal of clinical psychopharmacology, , Volume: 34, Issue:1, 2014
[Emergency psychopharmacotherapy in Hungary -- preliminary data].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 16, Issue:1, 2014
Topiramate improves psychiatric symptoms in a patient with Lewy body dementia.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 27, Issue:4, 2014
A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior.Journal of clinical psychopharmacology, , Volume: 34, Issue:3, 2014
A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.BMC psychiatry, , Jan-11, Volume: 13, 2013
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.Current medical research and opinion, , Volume: 29, Issue:3, 2013
Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial.Annals of emergency medicine, , Volume: 61, Issue:1, 2013
Benzodiazepines for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , Apr-30, Issue:4, 2013
Potential complications of combining intramuscular olanzapine with benzodiazepines in emergency department patients.The Journal of emergency medicine, , Volume: 43, Issue:5, 2012
A comparison of the safety of olanzapine and haloperidol in combination with benzodiazepines in emergency department patients with acute agitation.The Journal of emergency medicine, , Volume: 43, Issue:5, 2012
A naturalistic study of intramuscular haloperidol versus intramuscular olanzapine for the management of acute agitation.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Olanzapine in ED patients: differential effects on oxygenation in patients with alcohol intoxication.The American journal of emergency medicine, , Volume: 30, Issue:7, 2012
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3. Rapid tranquilisation in acute psychotic agitation.Emergency medicine journal : EMJ, , Volume: 28, Issue:1, 2011
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 33, Issue:1, 2011
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.American journal of therapeutics, , Volume: 18, Issue:4, 2011
A new clinical protocol for the pharmacological management of acute behavioural disturbance.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 19, Issue:5, 2011
[The clinical picture of acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
Symptoms of agitated depression and/or akathisia.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.Journal of clinical psychopharmacology, , Volume: 30, Issue:3, 2010
Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.The Journal of clinical psychiatry, , Volume: 71, Issue:4, 2010
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Akathisia and second-generation antipsychotic drugs.Current opinion in psychiatry, , Volume: 22, Issue:3, 2009
Haloperidol plus promethazine for psychosis-induced aggression.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
Intravenous olanzapine--another option for the acutely agitated patient?Emergency medicine Australasia : EMA, , Volume: 21, Issue:3, 2009
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:1, 2009
Does electroconvulsive therapy afford protection against olanzapine-induced parkinsonism? A case report.The journal of ECT, , Volume: 25, Issue:2, 2009
[Haloperidol plus promethazine for agitated patients--a systematic review].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 31, Issue:3, 2009
Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Intramuscular haloperidol versus intramuscular olanzapine for treatment of acute agitation: a cost-minimization study.Pharmacotherapy, , Volume: 29, Issue:8, 2009
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder.Pharmacopsychiatry, , Volume: 41, Issue:5, 2008
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.The American journal of psychiatry, , Volume: 165, Issue:7, 2008
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.Clinical drug investigation, , Volume: 28, Issue:5, 2008
A naturalistic study of consecutive agitated emergency department patients treated with intramuscular olanzapine prior to consent.The American journal of psychiatry, , Volume: 165, Issue:4, 2008
Behavioral and psychological symptoms of dementia (BPSD) in elderly demented subjects: is the long lasting use of atypical antipsychotic drugs useful and safe?Archives of gerontology and geriatrics, , Volume: 44 Suppl 1, 2007
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.The Journal of clinical psychiatry, , Volume: 68, Issue:12, 2007
An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.Human psychopharmacology, , Volume: 22, Issue:7, 2007
Atypical antipsychotic agents ineffective for AD.DukeMedicine healthnews, , Volume: 13, Issue:1, 2007
[Clinical and therapeutic aspects of agitation].L'Encephale, , Volume: 33 Pt 3, 2007
Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine.BMJ (Clinical research ed.), , Oct-27, Volume: 335, Issue:7625, 2007
Managing the acutely agitated and psychotic patient.CNS spectrums, , Volume: 12, Issue:10 Suppl 1, 2007
Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 19, Issue:4, 2007
Atypical antipsychotics for the treatment of dementia-related behaviors: an update.Medicine and health, Rhode Island, , Volume: 90, Issue:6, 2007
Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial.Dementia and geriatric cognitive disorders, , Volume: 21, Issue:1, 2006
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.The Cochrane database of systematic reviews, , Jan-25, Issue:1, 2006
Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.Schizophrenia research, , Feb-28, Volume: 82, Issue:2-3, 2006
Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:6, 2006
[New formulations of olanzapine in the treatment of acute agitation].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Injectable atypical antipsychotics for agitation in borderline personality disorder.Pharmacopsychiatry, , Volume: 39, Issue:3, 2006
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:8, 2005
Intramuscular olanzapine: a review of its use in the management of acute agitation.CNS drugs, , Volume: 19, Issue:2, 2005
A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.Clinical therapeutics, , Volume: 27, Issue:10, 2005
Atypical antipsychotics: special formulations for acute agitation.Journal of psychosocial nursing and mental health services, , Volume: 43, Issue:10, 2005
Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.International journal of geriatric psychiatry, , Volume: 20, Issue:11, 2005
Are high initial doses of olanzapine required to reduce agitation associated with schizophrenia?Journal of clinical psychopharmacology, , Volume: 24, Issue:1, 2004
Score tests for dose effect in the presence of non-responders.Statistics in medicine, , Dec-15, Volume: 23, Issue:23, 2004
The clinical picture of olanzapine poisoning with special reference to fluctuating mental status.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:1, 2004
Olanzapine in the treatment of agitation in hospitalized patients with schizophrenia and schizoaffective and schizofreniform disorders.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 10, Issue:5, 2004
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.The American journal of emergency medicine, , Volume: 22, Issue:3, 2004
Intramuscular olanzapine in the management of acute agitation.The Annals of pharmacotherapy, , Volume: 38, Issue:12, 2004
Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Olanzapine and hypoglycemic coma in a frail elderly woman. A case report.Pharmacopsychiatry, , Volume: 36, Issue:4, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
Calming versus sedative effects of intramuscular olanzapine in agitated patients.The American journal of emergency medicine, , Volume: 21, Issue:3, 2003
[Drug-induced akathisia].Nederlands tijdschrift voor geneeskunde, , Jan-19, Volume: 146, Issue:3, 2002
The efficacy of olanzapine, as needed, to treat acute agitation in juveniles.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 12, Issue:1, 2002
Continuum of care: stabilizing the acutely agitated patient.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Sep-01, Volume: 59, Issue:17 Suppl 5, 2002
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.Archives of general psychiatry, , Volume: 59, Issue:5, 2002
Recent developments in pharmacotherapy for the acutely psychotic patient.Journal of emergency nursing, , Volume: 28, Issue:6 Suppl, 2002
Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 26, Issue:4, 2002
Combination of olanzapine and divalproex for agitation in individuals with profound mental retardation.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.The Journal of clinical psychiatry, , Volume: 62, Issue:1, 2001
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.The American journal of psychiatry, , Volume: 158, Issue:7, 2001
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Lethal catatonia responding to high-dose olanzapine therapy.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:4, 2001
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Fall, Volume: 9, Issue:4, 2001
Neuroleptic malignant syndrome due to olanzapine.Psychopharmacology bulletin, ,Summer, Volume: 35, Issue:3, 2001
Rationale and guidelines for the inpatient treatment of acute psychosis.The Journal of clinical psychiatry, , Volume: 61 Suppl 14, 2000
Measuring neuroleptic-induced akathisia by three-channel actometry.Schizophrenia research, , Nov-30, Volume: 40, Issue:2, 1999
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
Treatment with atypical antipsychotics: new indications and new populations.Journal of psychiatric research, , Volume: 35, Issue:3
A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients.General hospital psychiatry, , Volume: 32, Issue:4
Atypical presentations of pregnancy-specific generalized anxiety disorders in women without a previous psychiatric background.Psychosomatics, , Volume: 56, Issue:3
Mania in a case of hyperparathyroidism.Psychosomatics, , Volume: 48, Issue:3
[Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: results from NATURA study].Actas espanolas de psiquiatria, , Volume: 36, Issue:3
The use of atypical antipsychotics after traumatic brain injury.The Journal of head trauma rehabilitation, , Volume: 23, Issue:2
Olanzapine orally-disintegrating tablet in severe psychotic agitation: a naturalistic study.Actas espanolas de psiquiatria, , Volume: 35, Issue:1
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
Fahr's Disease Presenting with Manic Symptoms.JNMA; journal of the Nepal Medical Association, , Volume: 56, Issue:209
[Proposal for Latin America of an algorithm for the management of agitated patients with olanzapine and its switch to oral administration].Vertex (Buenos Aires, Argentina), , Volume: 14, Issue:51
Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.American journal of Alzheimer's disease and other dementias, , Volume: 21, Issue:2
The utility of intramuscular ziprasidone in the management of acute psychotic agitation.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:3
Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients.General hospital psychiatry, , Volume: 30, Issue:4
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:3, 2013
A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.Psychiatry research, , Dec-15, Volume: 129, Issue:2, 2004
Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD).Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.International journal of geriatric psychiatry, , Volume: 18, Issue:5, 2003
Men and women respond differently to antipsychotic drugs.Neuropharmacology, , Volume: 163, 2020
Harmala Alkaloids Identify Ayahausca Intoxication in a Urine Drug Screen.Journal of analytical toxicology, , May-01, Volume: 43, Issue:4, 2019
[Mirtazapine-Induced Mania: A Case Report].Acta medica portuguesa, , Oct-01, Volume: 32, Issue:10, 2019
Cannabis and delusional zoopathy: A mole that ran amok.Asian journal of psychiatry, , Volume: 30, 2017
Antiepileptic-induced Psychosis as a Possible Predictor of Post-temporal Lobectomy Alternative Psychosis.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 26, Issue:3, 2016
[Treatment-resistant psychosis due to interaction between ritonavir and olanzapine: case report and literature review].Tijdschrift voor psychiatrie, , Volume: 58, Issue:4, 2016
The Psychotic Couple--Sharing Drugs or Delusions?Journal of the South Carolina Medical Association (1975), , Volume: 110, Issue:4, 2015
Mephentermine dependence syndrome - A new emerging trend of substance use.Asian journal of psychiatry, , Volume: 17, 2015
Strategies to prevent the neuropsychiatric side-effects of corticosteroids: a case report and review of the literature.Current opinion in organ transplantation, , Volume: 19, Issue:2, 2014
Olanzapine as a cause of peripheric edema in an elderly man.Aging clinical and experimental research, , Volume: 25, Issue:1, 2013
Synthetic cannabinoid-induced psychosis: two adolescent cases.Journal of child and adolescent psychopharmacology, , Volume: 22, Issue:5, 2012
[Designer drug induced psychosis].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 14, Issue:2, 2012
Is it medication-induced psychosis or prodromal psychosis unmasked by medication?The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 23, Issue:3, 2011
[Mood disorder after malaria prophylaxis with mefloquine (two case reports)].L'Encephale, , Volume: 37, Issue:5, 2011
Ibogaine-associated psychosis in schizophrenia: a case report.Journal of clinical psychopharmacology, , Volume: 31, Issue:5, 2011
Treatment for amphetamine psychosis.The Cochrane database of systematic reviews, , Jan-21, Issue:1, 2009
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Treatment for amphetamine psychosis.The Cochrane database of systematic reviews, , 10-08, Issue:4, 2008
Methamphetamine psychosis in which tardive dystonia was successfully treated with clonazepam.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Memory-sparing cognitive deterioration in the elderly: what is the diagnosis?Reviews in neurological diseases, ,Spring, Volume: 2, Issue:2, 2005
The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis.Acta psychiatrica Scandinavica, , Volume: 112, Issue:2, 2005
A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 88 Suppl 3, 2005
Psychosis associated with interferon alfa therapy for chronic hepatitis B.The Annals of pharmacotherapy, , Volume: 37, Issue:3, 2003
Dependence and chronic psychosis with D-nor-pseudoephedrine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:8, 2003
Olanzapine: a proarrhythmic drug?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 47, Issue:7, 2002
Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.Biological psychiatry, , Sep-01, Volume: 52, Issue:5, 2002
[Usefulness of olanzapine in the levodopa-induced psychosis in patients with Parkinson's disease].Neurologia (Barcelona, Spain), , Volume: 17, Issue:1, 2002
Ecstasy-induced psychotic disorder: six-month follow-up study.European addiction research, , Volume: 8, Issue:3, 2002
Improvement of hallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine: case report.Journal of clinical psychopharmacology, , Volume: 21, Issue:3, 2001
Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:1, 2001
Induction of manic symptoms by novel antipsychotics.The British journal of psychiatry : the journal of mental science, , Volume: 176, 2000
Olanzapine treatment of methamphetamine psychosis.Journal of clinical psychopharmacology, , Volume: 20, Issue:3, 2000
Quetiapine for l-dopa-induced psychosis in PD.Neurology, , Apr-11, Volume: 54, Issue:7, 2000
Complicated delirium in a cancer patient successfully treated with olanzapine.Journal of pain and symptom management, , Volume: 17, Issue:3, 1999
Olanzapine-induced psychotic mania in bipolar schizoaffective disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:6, 1999
A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.International clinical psychopharmacology, , Volume: 14, Issue:3, 1999
Olanzapine-induced psychotic mania in bipolar schizo-affective disorder.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 14, Issue:7, 1999
Worsening of motor features of parkinsonism with olanzapine.Movement disorders : official journal of the Movement Disorder Society, , Volume: 14, Issue:6, 1999
Management of psychotic aspects of Parkinson's disease.The Journal of clinical psychiatry, , Volume: 60 Suppl 8, 1999
Isoniazid-induced psychosis.The Annals of pharmacotherapy, , Volume: 32, Issue:9, 1998
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.Neurology, , Volume: 50, Issue:4, 1998
Olanzapine-lithium encephalopathy.Psychosomatics, , Volume: 42, Issue:4
Citalopram-induced diplopia.Psychosomatics, , Volume: 46, Issue:1
Persistent psychosis after a single ingestion of 'ecstasy'.Psychosomatics, , Volume: 42, Issue:6
Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV.Psychosomatics, , Volume: 44, Issue:5
First case of lacosamide-induced psychosis.Clinical neuropharmacology, , Volume: 36, Issue:1
Suicidal and homicidal behaviors related to dextromethorphan abuse in a middle-aged woman.Journal of addiction medicine, , Volume: 7, Issue:2
[Isotretinoin Therapy for Acne Vulgaris and First Episode Psychosis in an Adolescent Patient].Revista colombiana de psiquiatria, , Volume: 46, Issue:1
[The role of olanzapine in Parkinsonian dopaminergic psychosis].Revista de neurologia, , Volume: 35, Issue:7
Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study.Clinical neuropharmacology, , Volume: 21, Issue:5
Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.Drugs & aging, , Volume: 40, Issue:1, 2023
Residual or re-emergent impaired insight into delusions following remission is unrelated to later relapse during a randomized clinical trial of continuation pharmacotherapy for psychotic depression - The STOP-PD II Study.Journal of affective disorders, , 03-15, Volume: 325, 2023
Olanzapine and Weight Loss in Early-Onset Schizophrenia.The primary care companion for CNS disorders, , 04-06, Volume: 25, Issue:2, 2023
Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.The international journal of neuropsychopharmacology, , 07-31, Volume: 26, Issue:7, 2023
Probable Olanzapine-Related Idiopathic Intracranial Hypertension in an Adolescent With First-Episode Psychosis.Psychopharmacology bulletin, , 08-11, Volume: 53, Issue:3, 2023
Unraveling ethnic disparities in antipsychotic prescribing among patients with psychosis: A retrospective cohort study based on electronic clinical records.Schizophrenia research, , Volume: 260, 2023
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).Journal of psychopharmacology (Oxford, England), , Volume: 37, Issue:10, 2023
Predictors of hospitalisation and recovery following full antipsychotic discontinuation in first episode psychosis. A naturalistic retrospective cohort study.Schizophrenia research, , Volume: 261, 2023
Psychosis susceptibility zinc finger protein 804A (ZNF804A) gene polymorphism in schizophrenia patients treated with olanzapine in North Indian population.The International journal of neuroscience, , Volume: 133, Issue:5, 2023
Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular.International clinical psychopharmacology, , 01-01, Volume: 37, Issue:1, 2022
Comparative Outcomes of Commonly Used Off-Label Atypical Antipsychotics in the Treatment of Dementia-Related Psychosis: A Network Meta-analysis.Advances in therapy, , Volume: 39, Issue:5, 2022
Psychopharmacology of agitation in acute psychotic and manic episodes.Current opinion in psychiatry, , 05-01, Volume: 35, Issue:3, 2022
Refractory Psychosis After Carbon Monoxide Poisoning: a Case Report.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 32, Issue:2, 2022
Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study.Psychiatry research, , Volume: 314, 2022
Proportion of subjects with psychotic features in bipolar disorder correlated with treatment response by antipsychotics for acute mania.Psychiatry and clinical neurosciences, , Volume: 76, Issue:11, 2022
Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 129, Issue:11, 2022
Case Report: De Novo and Persistent Psychosis After Withdrawal From Chronic Opioid Therapy.Journal of psychiatric practice, , 09-01, Volume: 28, Issue:5, 2022
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis.The American journal of psychiatry, , 12-01, Volume: 179, Issue:12, 2022
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review.The journal of prevention of Alzheimer's disease, , Volume: 8, Issue:4, 2021
New Antipsychotic Medications in the Last Decade.Current psychiatry reports, , 11-29, Volume: 23, Issue:12, 2021
Situational analysis of prevailing practices in the management of first-episode psychosis in Chennai, India.Early intervention in psychiatry, , Volume: 15, Issue:3, 2021
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:1, 2021
Using Claims Data to Assess Treatment Quality of First-Episode Psychosis.Psychiatric services (Washington, D.C.), , 03-01, Volume: 72, Issue:3, 2021
The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.Psychopharmacology, , Volume: 238, Issue:3, 2021
Early intervention services, patterns of prescription and rates of discontinuation of antipsychotic treatment in first-episode psychosis.Early intervention in psychiatry, , Volume: 15, Issue:6, 2021
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.Drug and alcohol dependence, , 02-01, Volume: 219, 2021
Prescribing pattern of antipsychotic medication for first-episode psychosis: a retrospective cohort study.BMJ open, , 01-31, Volume: 11, Issue:1, 2021
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.The American journal of psychiatry, , 05-01, Volume: 178, Issue:5, 2021
Risk and Prevention of Aggression in Patients With Psychotic Disorders.The American journal of psychiatry, , 03-01, Volume: 178, Issue:3, 2021
Brief psychotic disorder with delusion content related to the COVID-19 outbreak.Psychiatrike = Psychiatriki, , Apr-19, Volume: 32, Issue:1, 2021
The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study.Schizophrenia research, , Volume: 231, 2021
The Antipsychotic Risperidone Alters Dihydroceramide and Ceramide Composition and Plasma Membrane Function in Leukocytes In Vitro and In Vivo.International journal of molecular sciences, , Apr-10, Volume: 22, Issue:8, 2021
A Case of Blunted Orally Disintegrating Olanzapine Effect Due to Coadministered Psyllium.The Journal of clinical psychiatry, , 02-23, Volume: 82, Issue:2, 2021
Effect of Bifidobacterium on olanzapine-induced body weight and appetite changes in patients with psychosis.Psychopharmacology, , Volume: 238, Issue:9, 2021
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:6, 2021
The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis.Substance use & misuse, , Volume: 56, Issue:12, 2021
Men and women respond differently to antipsychotic drugs.Neuropharmacology, , Volume: 163, 2020
Clozapine Treatment and Offending: A Within-Subject Study of Patients With Psychotic Disorders in Sweden.Schizophrenia bulletin, , 02-26, Volume: 46, Issue:2, 2020
Delusional.Schizophrenia bulletin, , Dec-01, Volume: 46, Issue:6, 2020
Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects.Therapeutic drug monitoring, , Volume: 42, Issue:2, 2020
Reduction in the prescription of Olanzapine as a first-line treatment for first episode psychosis following the implementation of clinical practice guidelines.Schizophrenia research, , Volume: 215, 2020
[Miss V: Delusion of pregnancy during pre-menopause].L'Encephale, , Volume: 46, Issue:1, 2020
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.The international journal of neuropsychopharmacology, , 04-23, Volume: 23, Issue:4, 2020
Prolactin response to antipsychotics: An inpatient study.PloS one, , Volume: 15, Issue:2, 2020
Duration of untreated psychosis and response to treatment: an analysis of response in the OPTiMiSE cohort.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 32, 2020
Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial.JAMA psychiatry, , 07-01, Volume: 77, Issue:7, 2020
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.The Journal of clinical psychiatry, , 03-17, Volume: 81, Issue:2, 2020
New-onset psychosis following initiation of eye movement desensitization and reprocessing therapy.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 32, Issue:2, 2020
Neurotropism of SARS-CoV-2: COVID-19 presenting with an acute manic episode.BMJ case reports, , Jun-14, Volume: 13, Issue:6, 2020
Antipsychotics in Postpartum Psychosis.American journal of therapeutics, , Jun-22, Volume: 28, Issue:3, 2020
Reactive Psychosis in a Health Care Worker During the COVID-19 Pandemic.The primary care companion for CNS disorders, , 07-09, Volume: 22, Issue:4, 2020
A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.Asian journal of psychiatry, , Volume: 53, 2020
Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial.Schizophrenia research, , Volume: 223, 2020
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.The lancet. Psychiatry, , Volume: 7, Issue:11, 2020
Three Cases of COVID-19-related First Onset Brief Reactive Psychosis.The Israel Medical Association journal : IMAJ, , Volume: 22, Issue:10, 2020
Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India.Asian journal of psychiatry, , Volume: 54, 2020
Exploring Patterns of Disturbed Eating in Psychosis: A Scoping Review.Nutrients, , Dec-18, Volume: 12, Issue:12, 2020
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.Early intervention in psychiatry, , Volume: 13, Issue:3, 2019
Immunomodulatory effects of antipsychotic treatment on gene expression in first-episode psychosis.Journal of psychiatric research, , Volume: 109, 2019
Call for "High-Dose" Olanzapine Research in Treatment-Resistant Psychosis.The Journal of nervous and mental disease, , Volume: 207, Issue:1, 2019
l-Arginine metabolism before and after 10 weeks of antipsychotic treatment in first-episode psychotic patients.Schizophrenia research, , Volume: 206, 2019
Do reductions in ghrelin contribute towards antipsychotic-induced weight gain?Schizophrenia research, , Volume: 210, 2019
The pharmacological management of agitated and aggressive behaviour: A systematic review and meta-analysis.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 57, 2019
Complexity in Evaluation and Pharmacological Treatment of Early Onset Psychosis with Mood Symptoms: Childhood Onset Schizophrenia or Affective Disorder?Journal of child and adolescent psychopharmacology, , Volume: 29, Issue:3, 2019
Antipsychotic-induced weight gain and birth weight in psychosis: A fetal programming model.Journal of psychiatric research, , Volume: 115, 2019
Erotomania in Depressive Psychosis: Mood Incongruent Delusion in a Depressive Young Woman.Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, , Volume: 29, Issue:6, 2019
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis.BMJ open, , 06-27, Volume: 9, Issue:6, 2019
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.Toxicology and applied pharmacology, , 09-01, Volume: 378, 2019
Examination of heterogeneity in treatment response to antipsychotic medications.Schizophrenia research, , Volume: 211, 2019
Maintenance Treatment for Psychotic Depressive Disorders: Progress and Remaining Challenges.JAMA, , 08-20, Volume: 322, Issue:7, 2019
Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.Schizophrenia research, , Volume: 212, 2019
Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.The Journal of clinical psychiatry, , 08-27, Volume: 80, Issue:5, 2019
Acute transient psychotic disorder precipitated by Brexit vote.BMJ case reports, , Oct-01, Volume: 12, Issue:10, 2019
[Amisulpride, a one-of-a-kind and highly efficacious antipsychotic agent in the treatment of first-episode psychosis].Nederlands tijdschrift voor geneeskunde, , 10-17, Volume: 163, 2019
Olanzapine in the management of psychosis in Huntington’s disease: a case report.Actas espanolas de psiquiatria, , Volume: 47, Issue:5, 2019
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
Continuing Antipsychotic Medication for Patients With Psychotic Depression in Remission.JAMA, , 12-24, Volume: 322, Issue:24, 2019
[Evidence-based treatment of acute psychotic episode and schizophrenia in children and adolescents].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 119, Issue:12, 2019
Quasi-psychosis in covert Narcissistic Personality Disorder-A case report.Asian journal of psychiatry, , Volume: 32, 2018
Olanzapine Versus Risperidone in Children and Adolescents with Psychosis: A Meta-Analysis of Randomized Controlled Trials.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:4, 2018
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 49, 2018
No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment.Acta psychiatrica Scandinavica, , Volume: 138, Issue:2, 2018
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.The American journal of psychiatry, , 06-01, Volume: 175, Issue:6, 2018
Management of a complex patient - intravenous olanzapine use.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 26, Issue:6, 2018
Stabilization treatment of remitted psychotic depression: the STOP-PD study.Acta psychiatrica Scandinavica, , Volume: 138, Issue:3, 2018
Olanzapine associated palpebral edema: An uncommon adverse effect of a commonly prescribed drug.Asian journal of psychiatry, , Volume: 36, 2018
Rapid remission of first-episode schizophrenia with standardised treatment.The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Antipsychotic treatments: who is really failing here? - Authors' reply.The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Antipsychotic treatments: who is really failing here?The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
Switch-associated adverse events: focus on olanzapine.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 26, Issue:6, 2018
Association between olanzapine treatment and brain cortical thickness and gray/white matter contrast is moderated by cholesterol in psychotic disorders.Psychiatry research. Neuroimaging, , 12-30, Volume: 282, 2018
Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 19, Issue:sup3, 2018
Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.Psychiatria Danubina, , Volume: 29, Issue:2, 2017
Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study.Brain and behavior, , Volume: 7, Issue:6, 2017
Anti-NMDA receptor encephalitis presenting as a primary psychotic disorder.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 29, Issue:3, 2017
A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.Journal of clinical psychopharmacology, , Volume: 37, Issue:5, 2017
The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.Acta psychiatrica Scandinavica, , Volume: 136, Issue:5, 2017
Potential diagnostic markers of olanzapine efficiency for acute psychosis: a focus on peripheral biogenic amines.BMC psychiatry, , Dec-08, Volume: 17, Issue:1, 2017
Development of forced normalisation psychosis with ethosuximide.BMJ case reports, , Dec-07, Volume: 2017, 2017
Mapping the evidence on pharmacological interventions for non-affective psychosis in humanitarian non-specialised settings: a UNHCR clinical guidance.BMC medicine, , Dec-11, Volume: 15, Issue:1, 2017
Cognition and Dopamine DThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:1, 2017
Delusional infestation.The American journal of emergency medicine, , Volume: 35, Issue:2, 2017
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.Journal of psychiatric research, , Volume: 85, 2017
Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics.Psychiatry research, , Volume: 247, 2017
Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:6, 2017
Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.Journal of clinical psychopharmacology, , Volume: 37, Issue:3, 2017
Therapeutic Drug Monitoring in Children and Adolescents Under Pharmacotherapy With Olanzapine in Daily Clinical Practice.Therapeutic drug monitoring, , Volume: 39, Issue:3, 2017
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.The Annals of pharmacotherapy, , Volume: 51, Issue:8, 2017
Treatment response in nonpsychotic vs psychotic manias - A follow up study from India.Asian journal of psychiatry, , Volume: 26, 2017
Psychosis and catatonia as presenting features of anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis.Asian journal of psychiatry, , Volume: 27, 2017
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.Psychopharmacology, , Volume: 234, Issue:17, 2017
Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.Human psychopharmacology, , Volume: 32, Issue:4, 2017
Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study.Psychiatry research, , Volume: 255, 2017
First episode psychosis in an adult patient with tuberous sclerosis.The Australian and New Zealand journal of psychiatry, , Volume: 50, Issue:3, 2016
Olanzapine-induced ischemic colitis.Revista espanola de enfermedades digestivas, , Volume: 108, Issue:8, 2016
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.Journal of clinical psychopharmacology, , Volume: 36, Issue:3, 2016
Porencephalic cyst and late onset brief psychotic disorder.BMJ case reports, , Apr-06, Volume: 2016, 2016
SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study.Human psychopharmacology, , Volume: 31, Issue:3, 2016
The predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis: Haloperidol versus olanzapine.Psychiatry research, , Jul-30, Volume: 241, 2016
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.American family physician, , Aug-15, Volume: 94, Issue:4, 2016
Antiepileptic-induced Psychosis as a Possible Predictor of Post-temporal Lobectomy Alternative Psychosis.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 26, Issue:3, 2016
Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.The Journal of clinical psychiatry, , Volume: 77, Issue:10, 2016
Use of Orally Disintegrating Olanzapine During Electroconvulsive Therapy for Prevention of Postictal Agitation.Journal of psychiatric practice, , Volume: 22, Issue:6, 2016
Trends in the Outpatient Utilization of Antipsychotic Drugs in the City of Zagreb in the Ten-Year Period as a Tool to Assess Drug Prescribing Rationality.Psychiatria Danubina, , Volume: 28, Issue:4, 2016
Haloperidol for long-term aggression in psychosis.The Cochrane database of systematic reviews, , 11-27, Volume: 11, 2016
Droperidol for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , 12-15, Volume: 12, 2016
Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder.The Journal of clinical psychiatry, , Volume: 77, Issue:12, 2016
Atypical antipsychotic use and outcomes in an urban maternal mental health service.International journal of psychiatry in medicine, , Volume: 51, Issue:6, 2016
Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.Journal of geriatric psychiatry and neurology, , Volume: 28, Issue:1, 2015
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.Psychiatric services (Washington, D.C.), , Volume: 66, Issue:6, 2015
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.Schizophrenia bulletin, , Volume: 41, Issue:3, 2015
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.Journal of the Formosan Medical Association = Taiwan yi zhi, , Volume: 114, Issue:5, 2015
Case records of the Massachusetts General Hospital. Case 10-2015. A 15-year-old girl with Graves’ disease and psychotic symptoms.The New England journal of medicine, , Mar-26, Volume: 372, Issue:13, 2015
The impact of antipsychotic polytherapy costs in the public health care in Sao Paulo, Brazil.PloS one, , Volume: 10, Issue:4, 2015
Chemotherapy-induced acute psychosis in a patient with malignant germ cell tumour.BMJ case reports, , Apr-09, Volume: 2015, 2015
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar disorders, , Volume: 17, Issue:5, 2015
Phosphorylation of transcription factor specificity protein 4 is increased in peripheral blood mononuclear cells of first-episode psychosis.PloS one, , Volume: 10, Issue:4, 2015
Graves' hyperthyroidism-induced psychosis in a patient with periventricular nodular heterotopia.Psychiatry and clinical neurosciences, , Volume: 69, Issue:8, 2015
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.Clinical pharmacokinetics, , Volume: 54, Issue:11, 2015
The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.Journal of primary health care, , Jun-01, Volume: 7, Issue:2, 2015
Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms.Human psychopharmacology, , Volume: 30, Issue:4, 2015
[Eating disorders in psychiatric patients during treatment with second generation antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:7, 2015
Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.Journal of child and adolescent psychopharmacology, , Volume: 25, Issue:7, 2015
Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: An 8-week randomised controlled trial.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 30, Issue:8, 2015
Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 23, Issue:12, 2015
Interventions for psychotic symptoms concomitant with epilepsy.The Cochrane database of systematic reviews, , Dec-21, Issue:12, 2015
Psychotic disorder after contact with a potentially rabid animal and post-exposure prophylactic anti-rabies treatment.Clinical schizophrenia & related psychoses, , Volume: 8, Issue:3, 2014
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.Psychological medicine, , Volume: 44, Issue:1, 2014
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.The international journal of neuropsychopharmacology, , Volume: 17, Issue:1, 2014
The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:4, 2014
Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care.Clinical toxicology (Philadelphia, Pa.), , Volume: 52, Issue:1, 2014
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.Journal of clinical psychopharmacology, , Volume: 34, Issue:1, 2014
A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.BMC psychiatry, , Jan-14, Volume: 14, 2014
Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.Journal of affective disorders, , Volume: 160, 2014
An exploratory randomized controlled study of a healthy living intervention in early intervention services for psychosis: the INTERvention to encourage ACTivity, improve diet, and reduce weight gain (INTERACT) study.The Journal of clinical psychiatry, , Volume: 75, Issue:5, 2014
[Woman in her 30s with chronic fatigue].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Feb-25, Volume: 134, Issue:4, 2014
An atypical case of neuroleptic malignant syndrome precipitated by valproate.BMJ case reports, , Mar-06, Volume: 2014, 2014
Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study.Comprehensive psychiatry, , Volume: 55, Issue:5, 2014
[Emergency psychopharmacotherapy in Hungary -- preliminary data].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 16, Issue:1, 2014
Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain.Human psychopharmacology, , Volume: 29, Issue:4, 2014
Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects.Journal of biomedical nanotechnology, , Volume: 10, Issue:6, 2014
Olanzapine-induced tardive dystonia: a case report.The Journal of neuropsychiatry and clinical neurosciences, , Apr-01, Volume: 26, Issue:2, 2014
Effects of antipsychotic drugs on insight in schizophrenia.Psychiatry research, , Aug-15, Volume: 218, Issue:1-2, 2014
Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.International clinical psychopharmacology, , Volume: 29, Issue:6, 2014
Olanzapine treatment during pregnancy and breastfeeding: a chance for women with psychotic illness?Psychopharmacology, , Volume: 231, Issue:15, 2014
No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain.Psychiatry research, , Oct-30, Volume: 219, Issue:2, 2014
Efficacy and safety of combined paliperidone palmitate and olanzapine pamoate in resistant schizoaffective disorder.Journal of clinical psychopharmacology, , Volume: 34, Issue:5, 2014
The impact of insight in a first-episode mania with psychosis population on outcome at 18 months.Journal of affective disorders, , Volume: 167, 2014
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.CNS spectrums, , Volume: 19, Issue:5, 2014
Olanzapine-induced methylation alters cadherin gene families and associated pathways implicated in psychosis.BMC neuroscience, , Sep-29, Volume: 15, 2014
Use of very-high-dose olanzapine in treatment-resistant schizophrenia.Schizophrenia research, , Volume: 159, Issue:2-3, 2014
Add-on oral olanzapine worsens hallucinations in schizoaffective disorder.BMJ case reports, , Oct-21, Volume: 2014, 2014
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 15, Issue:3, 2014
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.Psychopharmacology, , Volume: 227, Issue:4, 2013
Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.The Journal of clinical psychiatry, , Volume: 74, Issue:2, 2013
Pharmaco-epidemiological description of the population of the Marche Region (central Italy) treated with the antipsychotic drug olanzapine.Annali dell'Istituto superiore di sanita, , Volume: 49, Issue:1, 2013
Comparative safety of antipsychotics: another look at the risk of diabetes.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 58, Issue:4, 2013
Skin rash occurring with olanzapine pamoate, but not with oral olanzapine, in a male with juvenile idiopathic arthritis.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:3, 2013
The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.Journal of clinical psychopharmacology, , Volume: 33, Issue:3, 2013
Benzodiazepines for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews, , Apr-30, Issue:4, 2013
Movement disorders in elderly users of risperidone and first generation antipsychotic agents: a Canadian population-based study.PloS one, , Volume: 8, Issue:5, 2013
Psychotic symptoms in a woman with severe Anorexia Nervosa : psychotic symptoms in Anorexia Nervosa.Eating and weight disorders : EWD, , Volume: 18, Issue:1, 2013
[Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 15, Issue:2, 2013
Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.Behavioral and brain functions : BBF, , Jul-19, Volume: 9, 2013
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.Psychiatry research, , Dec-15, Volume: 210, Issue:2, 2013
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.BMC psychiatry, , Sep-30, Volume: 13, 2013
[Combination of second generation antipsychotics -- case report].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 15, Issue:3, 2013
Atypical antipsychotics for psychosis in adolescents.The Cochrane database of systematic reviews, , Oct-15, Issue:10, 2013
Neurocognitive effectiveness of quetiapine, olanzapine, risperidone, and ziprasidone: a pragmatic, randomized trial.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 28, Issue:3, 2013
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:3, 2013
The investigation of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: olanzapine monotherapy.Psychoneuroendocrinology, , Volume: 38, Issue:3, 2013
Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-10, Volume: 40, 2013
[Acute catatonia: Questions, diagnosis and prognostics, and the place of atypical antipsychotics].L'Encephale, , Volume: 39, Issue:3, 2013
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.Psychiatry research, , Apr-30, Volume: 206, Issue:2-3, 2013
In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation.International clinical psychopharmacology, , Volume: 28, Issue:2, 2013
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.The Journal of clinical psychiatry, , Volume: 74, Issue:1, 2013
Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice.BMC psychiatry, , Dec-17, Volume: 12, 2012
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.Schizophrenia bulletin, , Volume: 38, Issue:4, 2012
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.The Journal of clinical psychiatry, , Volume: 73, Issue:2, 2012
Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis.Psychopharmacology, , Volume: 219, Issue:1, 2012
Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study.International journal of psychiatry in clinical practice, , Volume: 16, Issue:1, 2012
Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.The Journal of clinical psychiatry, , Volume: 73, Issue:1, 2012
Olanzapine-associated myoclonus.Epilepsy research, , Volume: 98, Issue:2-3, 2012
Antipsychotics and mortality in Parkinsonism.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 20, Issue:2, 2012
Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.Clinical drug investigation, , Apr-01, Volume: 32, Issue:4, 2012
Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.Clinical schizophrenia & related psychoses, , Volume: 6, Issue:1, 2012
A case of prolonged duration of untreated psychosis: barriers to treatment and strategies to improve the outcome.Clinical schizophrenia & related psychoses, , Volume: 6, Issue:1, 2012
Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:5, 2012
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:5, 2012
Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial.European archives of psychiatry and clinical neuroscience, , Volume: 262, Issue:7, 2012
Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
A case of akathisia after switching from branded to generic high-dose olanzapine.The Journal of clinical psychiatry, , Volume: 73, Issue:4, 2012
Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol?Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:10, 2012
A father with postpartum psychosis.BMJ case reports, , May-08, Volume: 2012, 2012
One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.Psychiatry research, , Dec-30, Volume: 200, Issue:2-3, 2012
Duration of untreated negative and positive symptoms of psychosis and cognitive impairment in first episode psychosis.Schizophrenia research, , Volume: 141, Issue:2-3, 2012
Postictal psychosis treated successfully with olanzapine.The Journal of clinical psychiatry, , Volume: 73, Issue:9, 2012
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis.Journal of clinical psychopharmacology, , Volume: 32, Issue:6, 2012
Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis.Asian journal of psychiatry, , Volume: 5, Issue:4, 2012
Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:6, 2011
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
Blood lactate levels in patients receiving first- or second- generation antipsychotics.Croatian medical journal, , Volume: 52, Issue:1, 2011
Metabolic effects of olanzapine in patients with newly diagnosed psychosis.Journal of clinical psychopharmacology, , Volume: 31, Issue:2, 2011
Folie à deux: double case-report of shared delusions with a fatal outcome.La Clinica terapeutica, , Volume: 162, Issue:1, 2011
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Olanzapine-induced agranulocytosis in an adolescent male with psychosis.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:2, 2011
Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 33, Issue:1, 2011
Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.BMC psychiatry, , May-17, Volume: 11, 2011
[A case of affective disorder with psychotic symptoms as late manifestation of Huntington's Chorea].Psychiatrische Praxis, , Volume: 38, Issue:6, 2011
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).The American journal of psychiatry, , Volume: 168, Issue:9, 2011
Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).The Journal of clinical psychiatry, , Volume: 72, Issue:7, 2011
Does propofol induction in patients on olanzapine increase the susceptibility to dystonic reactions?Acta anaesthesiologica Scandinavica, , Volume: 55, Issue:5, 2011
A six-to-ten weeks' follow-up study on the effects of olanzapine on abdominal fat and other metabolic parameters in patients with psychoses--an imaging-based study with controls.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 21, Issue:1, 2011
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.Neuro endocrinology letters, , Volume: 32, Issue:4, 2011
The heterogeneity of antipsychotic response in the treatment of schizophrenia.Psychological medicine, , Volume: 41, Issue:6, 2011
Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.BMC psychiatry, , Aug-31, Volume: 11, 2011
Switching antipsychotic medications: not enough, too often, or just right?The American journal of psychiatry, , Volume: 168, Issue:9, 2011
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.Schizophrenia research, , Volume: 125, Issue:2-3, 2011
Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women.Psychiatry research, , May-15, Volume: 187, Issue:1-2, 2011
Relapse prevention and remission attainment in first-episode non-affective psychosis. A randomized, controlled 1-year follow-up comparison of haloperidol, risperidone and olanzapine.Journal of psychiatric research, , Volume: 45, Issue:6, 2011
High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.Journal of clinical psychopharmacology, , Volume: 31, Issue:1, 2011
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.The Journal of clinical psychiatry, , Volume: 72, Issue:10, 2011
[Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].La Clinica terapeutica, , Volume: 162, Issue:4, 2011
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.Pharmacotherapy, , Volume: 31, Issue:8, 2011
[Rapid tranquillisation; review of the literature and recommendations].Tijdschrift voor psychiatrie, , Volume: 53, Issue:10, 2011
Atypical antipsychotic drugs in the treatment of Parkinson's disease.Journal of pharmacy practice, , Volume: 24, Issue:6, 2011
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.Neuro endocrinology letters, , Volume: 32, Issue:5, 2011
Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Olanzapine and breast-feeding: changes of plasma concentrations of olanzapine in a breast-fed infant over a period of 5 months.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Plasma orexin A, ghrelin, cholecystokinin, visfatin, leptin and agouti-related protein levels during 6-week olanzapine treatment in first-episode male patients with psychosis.International clinical psychopharmacology, , Volume: 25, Issue:3, 2010
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:2, 2010
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Antibodies to measles in individuals with recent onset psychosis.Schizophrenia research, , Volume: 119, Issue:1-3, 2010
An unusual late presentation of subacute sclerosing panencephalitis with psychotic symptoms.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 22, Issue:1, 2010
Successful clozapine retrial after suspected myocarditis.The American journal of psychiatry, , Volume: 167, Issue:3, 2010
Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.Pharmacopsychiatry, , Volume: 43, Issue:4, 2010
Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics.The journal of sexual medicine, , Volume: 7, Issue:10, 2010
Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment.The Annals of pharmacotherapy, , Volume: 44, Issue:4, 2010
Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone.BMC psychiatry, , Mar-24, Volume: 10, 2010
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.Bipolar disorders, , Volume: 12, Issue:2, 2010
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
Hyperprolactinaemia and acute psychosis: prolactinoma or medication-induced phenomenon?The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:5, 2010
Antipsychotics in pregnancy.Journal of psychiatric and mental health nursing, , Volume: 17, Issue:2, 2010
Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan.Journal of clinical psychopharmacology, , Volume: 30, Issue:3, 2010
Practical limitations of prescribing olanzapine depot (Relprevv).Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 18, Issue:3, 2010
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 49, Issue:6, 2010
Aripiprazole add-on treatment in a patient with schizoaffective disorder: neurocognitive outcomes.Pharmacopsychiatry, , Volume: 43, Issue:6, 2010
[Sydenham chorea and psychosis].Tijdschrift voor psychiatrie, , Volume: 52, Issue:4, 2010
Antipsychotic dosing: still a work in progress.The American journal of psychiatry, , Volume: 167, Issue:6, 2010
Gender, psychosis and psychotropic drugs: differences and similarities.Psychiatria Danubina, , Volume: 22, Issue:2, 2010
Increase in brain-derived neurotrophic factor in first episode psychotic patients after treatment with atypical antipsychotics.International clinical psychopharmacology, , Volume: 25, Issue:4, 2010
Insomnia treatment by olanzapine. Is sleep state misperception a psychotic disorder?Neurosciences (Riyadh, Saudi Arabia), , Volume: 15, Issue:2, 2010
Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 22, Issue:3, 2010
Metabolic syndrome with the atypical antipsychotics.Current opinion in endocrinology, diabetes, and obesity, , Volume: 17, Issue:5, 2010
Randomized-controlled trials in people at ultra high risk of psychosis: a review of treatment effectiveness.Schizophrenia research, , Volume: 123, Issue:1, 2010
Effect of early dysphoric response and cannabis use on discontinuation of olanzapine or risperidone in patients with early psychosis.Pharmacopsychiatry, , Volume: 43, Issue:7, 2010
The potential role of appetite in predicting weight changes during treatment with olanzapine.BMC psychiatry, , Sep-14, Volume: 10, 2010
Effect of adjunctive duloxetine on the plasma concentrations of clozapine, olanzapine, and risperidone in patients with psychotic disorders.Journal of clinical psychopharmacology, , Volume: 30, Issue:5, 2010
Association between symptom improvement and change of body mass index, lipid profile, and leptin, ghrelin, and cholecystokinin levels during 6-week olanzapine treatment in patients with first-episode psychosis.Journal of clinical psychopharmacology, , Volume: 30, Issue:5, 2010
An exploratory analysis of factors associated with weight change in a 16-week trial of oral vs. orally disintegrating olanzapine: the PLATYPUS study.International journal of clinical practice, , Volume: 64, Issue:11, 2010
The case report of treatment strategy for Anorexia nervosa with psychotic elements in adolescent.Collegium antropologicum, , Volume: 34, Issue:3, 2010
Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.BMC psychiatry, , Nov-03, Volume: 10, 2010
Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?The Journal of clinical psychiatry, , Volume: 71, Issue:11, 2010
Switching and combining antipsychotics.CNS spectrums, , Volume: 15, Issue:4 Suppl 6, 2010
Stability of medication in early psychosis: a comparison between second-generation and low-dose first-generation antipsychotics.Early intervention in psychiatry, , Volume: 3, Issue:1, 2009
Olanzapine treatment in Jarisch-Herxheimer reaction due to neurosyphilis with dementia: a case report.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:8, 2009
Impact of patient selection criteria and treatment history on comparisons of alternative therapies: a case study of atypical antipsychotics.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12, Issue:4, 2009
[Turner-syndrome and psychosis: a case report and brief review of the literature].Psychiatrische Praxis, , Volume: 36, Issue:5, 2009
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.Journal of psychiatric research, , Volume: 43, Issue:5, 2009
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
The risks and benefits of switching antipsychotics: a case study approach.Perspectives in psychiatric care, , Volume: 45, Issue:1, 2009
Plasma homovanillic acid and family history of psychotic disorders in bipolar I patients.Pharmacological research, , Volume: 59, Issue:4, 2009
Olanzapine compared to quetiapine in adolescents with a first psychotic episode.European child & adolescent psychiatry, , Volume: 18, Issue:7, 2009
Status epilepticus in a patient treated with olanzapine and mirtazapine.International journal of clinical pharmacology and therapeutics, , Volume: 47, Issue:2, 2009
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
[Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL].L'Encephale, , Volume: 35, Issue:1, 2009
Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone.Psychoneuroendocrinology, , Volume: 34, Issue:7, 2009
Psychosis secondary to traumatic brain injury.Brain injury, , Volume: 23, Issue:4, 2009
Akathisia and second-generation antipsychotic drugs.Current opinion in psychiatry, , Volume: 22, Issue:3, 2009
Medication adherence for children and adolescents with first-episode psychosis following hospitalization.European child & adolescent psychiatry, , Volume: 18, Issue:10, 2009
Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison.The Journal of clinical psychiatry, , Apr-21, Volume: 70, Issue:5, 2009
Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis.The British journal of psychiatry : the journal of mental science, , Volume: 194, Issue:5, 2009
Asenapine effects in animal models of psychosis and cognitive function.Psychopharmacology, , Volume: 206, Issue:4, 2009
Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.Current medical research and opinion, , Volume: 25, Issue:7, 2009
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.The Journal of clinical psychiatry, , Volume: 70, Issue:7, 2009
[Therapeutic intervention for group with risk of psychosis--Sendai At-risk Mental State And First Episode].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 111, Issue:3, 2009
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.International clinical psychopharmacology, , Volume: 24, Issue:5, 2009
A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study.Schizophrenia research, , Volume: 113, Issue:1, 2009
Steroid responsive psychotic depression.The Australian and New Zealand journal of psychiatry, , Volume: 43, Issue:7, 2009
Haloperidol plus promethazine for psychosis-induced aggression.The Cochrane database of systematic reviews, , Jul-08, Issue:3, 2009
Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation.Journal of psychiatric practice, , Volume: 15, Issue:4, 2009
A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).Archives of general psychiatry, , Volume: 66, Issue:8, 2009
Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.Therapeutic drug monitoring, , Volume: 31, Issue:6, 2009
Olanzapine for the treatment of acquired neurogenic stuttering.Journal of psychiatric practice, , Volume: 15, Issue:6, 2009
Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.The Israel journal of psychiatry and related sciences, , Volume: 46, Issue:3, 2009
Hunger and negative alliesthesia to aspartame and sucrose in patients treated with antipsychotic drugs and controls.Eating and weight disorders : EWD, , Volume: 14, Issue:4, 2009
[Edema related to treatment with olanzapine].Psychiatrische Praxis, , Volume: 36, Issue:3, 2009
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
The Bipolar Comprehensive Outcomes Study (BCOS): baseline findings of an Australian cohort study.Journal of affective disorders, , Volume: 107, Issue:1-3, 2008
Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.Schizophrenia research, , Volume: 99, Issue:1-3, 2008
Effect of olanzapine on cognition during treatment of behavioral and psychiatric symptoms in patients with dementia: a post-hoc analysis.International journal of geriatric psychiatry, , Volume: 23, Issue:4, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.The American journal of psychiatry, , Volume: 165, Issue:7, 2008
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.BMC medicine, , Jun-30, Volume: 6, 2008
[Atypical antipsychotics in first-episode psychosis: a review].L'Encephale, , Volume: 34, Issue:2, 2008
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.Journal of clinical psychopharmacology, , Volume: 28, Issue:4, 2008
Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:4, 2008
Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder.Pharmacopsychiatry, , Volume: 41, Issue:5, 2008
The InterSePT suicide scale for prediction of imminent suicidal behaviors.Psychiatry research, , Oct-30, Volume: 161, Issue:1, 2008
Olanzapine-induced rabbit syndrome.Southern medical journal, , Volume: 101, Issue:10, 2008
Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder.BMC psychiatry, , Sep-15, Volume: 8, 2008
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.The American journal of psychiatry, , Volume: 165, Issue:11, 2008
Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia.Archives of general psychiatry, , Volume: 65, Issue:10, 2008
Interventions for psychotic symptoms concomitant with epilepsy.The Cochrane database of systematic reviews, , Oct-08, Issue:4, 2008
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Septo-optic dysplasia and psychiatric disorders: a case report.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 21, Issue:4, 2008
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:12, 2008
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.Journal of clinical psychopharmacology, , Volume: 28, Issue:3, 2008
Did CATIE influence antipsychotic use?Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
Lessons to be learned from CATIE and CUtLASS.Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week randomized, double-blind, placebo-controlled trial.The Journal of clinical psychiatry, , Volume: 69, Issue:5, 2008
A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.Clinical drug investigation, , Volume: 28, Issue:5, 2008
Resolution of low voltage electrical injury induced psychosis with olanzapine.Brain injury, , Volume: 22, Issue:4, 2008
Rapidly developing hyperglycemia during treatment with olanzapine.The Annals of pharmacotherapy, , Volume: 42, Issue:4, 2008
Clinical and pharmacoeconomic evaluation of switch to olanzapine in veterans with schizophrenia or schizoaffective disorder.Psychopharmacology bulletin, , Volume: 41, Issue:1, 2008
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 69, Issue:3, 2008
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Water, water, everywhere, nor any drop to drink: climate change delusion.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:4, 2008
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.Human psychopharmacology, , Volume: 23, Issue:4, 2008
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.The Journal of clinical psychiatry, , Volume: 69, Issue:1, 2008
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.Journal of psychiatric research, , Volume: 42, Issue:13, 2008
Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:1, 2008
Neuroleptic malignant syndrome presenting with acute renal failure.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs.Psychiatry research, , Mar-15, Volume: 158, Issue:2, 2008
A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.Current medical research and opinion, , Volume: 24, Issue:3, 2008
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.Human psychopharmacology, , Volume: 23, Issue:3, 2008
Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia.Biological psychiatry, , Apr-15, Volume: 63, Issue:8, 2008
Evaluating dose response from flexible dose clinical trials.BMC psychiatry, , Jan-07, Volume: 8, 2008
Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:1, 2008
Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels.Schizophrenia research, , Volume: 98, Issue:1-3, 2008
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents.Journal of child and adolescent psychopharmacology, , Volume: 17, Issue:5, 2007
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Analysis of treatment effectiveness in longitudinal observational data.Journal of biopharmaceutical statistics, , Volume: 17, Issue:5, 2007
Olanzapine exposure during pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:8, 2007
Atypical antipsychotics: new drugs, new challenges.Cleveland Clinic journal of medicine, , Volume: 74, Issue:8, 2007
Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.Human psychopharmacology, , Volume: 22, Issue:7, 2007
Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes.The American journal of psychiatry, , Volume: 164, Issue:8, 2007
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
The use of atypical antipsychotics in French psychiatric hospitals.Pharmacy world & science : PWS, , Volume: 29, Issue:5, 2007
Discontinuation of risperidone, olanzapine, and haloperidol in first-episode psychosis.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Olanzapine-induced chylomicronemia presenting as acute pancreatitis.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Early use of clozapine for poorly responding first-episode psychosis.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Plasma lipids, lipoproteins and hormones levels during olanzapine treatment in psychosis and depression.Medicinski arhiv, , Volume: 61, Issue:2, 2007
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Dec-05, Volume: 144B, Issue:8, 2007
Quetiapine in the successful combination treatment of an assaultive patient with treatment-resistant schizoaffective disorder.Behavioral medicine (Washington, D.C.), ,Spring, Volume: 33, Issue:1, 2007
Late-onset neuroleptic malignant syndrome in a patient using olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:3, 2007
Managing psychosis in pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:3, 2007
Olanzapine-associated bilateral eyelid edema.Journal of clinical psychopharmacology, , Volume: 27, Issue:2, 2007
Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.CNS spectrums, , Volume: 12, Issue:3 Suppl 4, 2007
Characteristics of psychotic patients with foreign accent syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 19, Issue:1, 2007
Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?Psychiatric services (Washington, D.C.), , Volume: 58, Issue:2, 2007
Datapoints: The ups and downs of dosing second-generation antipsychotics.Psychiatric services (Washington, D.C.), , Volume: 58, Issue:1, 2007
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.CNS spectrums, , Volume: 12, Issue:1, 2007
Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.Human psychopharmacology, , Volume: 22, Issue:1, 2007
Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 17, Issue:3, 2007
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.Journal of psychiatric research, , Volume: 41, Issue:8, 2007
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Item response analysis of the Positive and Negative Syndrome Scale.BMC psychiatry, , Nov-15, Volume: 7, 2007
[New formulations of olanzapine in the treatment of acute agitation].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Treatment of psychosis: 30 years of progress.Journal of clinical pharmacy and therapeutics, , Volume: 31, Issue:6, 2006
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.The American journal of psychiatry, , Volume: 163, Issue:12, 2006
Persistent amnesia as a sequel of olanzapine-induced neuroleptic malignant syndrome.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 18, Issue:4, 2006
Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:11, 2006
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.The Journal of clinical psychiatry, , Volume: 67, Issue:10, 2006
"My new Alfa Romeo GT is not in the garage any more": Cognitive behavioural therapy of panic disorder with agoraphobia co morbid with psychosis.Psychiatria Danubina, , Volume: 18, Issue:3-4, 2006
Monosymptomatic hypochondriacal psychosis presenting with recurrent oral mucosal ulcers and multiple skin lesions responding to olanzapine treatment.International journal of dermatology, , Volume: 45, Issue:10, 2006
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.Acta psychiatrica Scandinavica, , Volume: 114, Issue:5, 2006
Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.Journal of clinical psychopharmacology, , Volume: 26, Issue:5, 2006
Olanzapine and haloperidol in first episode psychosis: two-year data.Schizophrenia research, , Volume: 86, Issue:1-3, 2006
[Efficacy and adverse reactions of antipsychotics for neuropsychiatric symptoms in dementia: a systematic review].Nederlands tijdschrift voor geneeskunde, , Jul-15, Volume: 150, Issue:28, 2006
Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder.Bipolar disorders, , Volume: 8, Issue:4, 2006
Persistent psychosis after treatment with interferon alpha: a case report.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Serum creatine kinase levels in chronic psychosis patients--a comparison between atypical and conventional antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.Journal of psychiatric research, , Volume: 40, Issue:7, 2006
Serum prolactin, leptin, lipids and lipoproteins levels during antipsychotics treatment in Parkinson's disease and related psychosis.Medicinski arhiv, , Volume: 60, Issue:4, 2006
Hip dysplasia following a case of olanzapine exposed pregnancy: a questionable association.Archives of women's mental health, , Volume: 9, Issue:4, 2006
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.Archives of general psychiatry, , Volume: 63, Issue:6, 2006
Insight in first-episode psychosis.Psychological medicine, , Volume: 36, Issue:10, 2006
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.Schizophrenia research, , Volume: 86, Issue:1-3, 2006
Injectable atypical antipsychotics for agitation in borderline personality disorder.Pharmacopsychiatry, , Volume: 39, Issue:3, 2006
Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
The rational use of medications in acute psychotic presentations -- the case for less is more.Journal of psychiatry & neuroscience : JPN, , Volume: 31, Issue:3, 2006
A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.The Journal of clinical psychiatry, , Volume: 67, Issue:4, 2006
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.Journal of clinical psychopharmacology, , Volume: 26, Issue:2, 2006
Anticholinergics in dementia and other confounding problems.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:4, 2006
Hypersalivation induced by olanzapine with fluvoxamine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:4, 2006
Influence of the catechol-O-methyltransferase Val108/158Met polymorphism on the plasma concentration of catecholamine metabolites and on clinical features in type I bipolar disorder--a preliminary report.Journal of affective disorders, , Volume: 92, Issue:2-3, 2006
Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.Acta psychiatrica Scandinavica. Supplementum, , Issue:430, 2006
Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis.Psychopathology, , Volume: 39, Issue:3, 2006
Management of psychosis in Australian general practice.Australian family physician, , Volume: 35, Issue:3, 2006
Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 18, Issue:1, 2006
Psychosis of Alzheimer disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 13, Issue:2, 2006
Stevens-Johnson syndrome (SJS) leading to resolution of mania.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:2, 2006
Massive creatine kinase elevations with quetiapine: report of two cases.Pharmacopsychiatry, , Volume: 39, Issue:1, 2006
Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.Schizophrenia research, , Feb-28, Volume: 82, Issue:2-3, 2006
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.The Cochrane database of systematic reviews, , Jan-25, Issue:1, 2006
Real-life switching strategies with second-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Jan-31, Volume: 81, Issue:2-3, 2006
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.Biological psychiatry, , Jan-15, Volume: 59, Issue:2, 2006
Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.Bulletin of experimental biology and medicine, , Volume: 140, Issue:6, 2005
[Love, humor and psychosis in an atypical depression].L'Encephale, , Volume: 31 Pt 2, 2005
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.Clinical therapeutics, , Volume: 27, Issue:12, 2005
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients.The Journal of clinical psychiatry, , Volume: 66, Issue:12, 2005
Atypical antipsychotics: special formulations for acute agitation.Journal of psychosocial nursing and mental health services, , Volume: 43, Issue:10, 2005
Comments on article by Albers et al: "Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy".Journal of clinical psychopharmacology, , Volume: 25, Issue:6, 2005
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychotics.International psychogeriatrics, , Volume: 17, Issue:4, 2005
Serum creatine kinase elevation as a possible complication of therapy with olanzapine.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 372, Issue:2, 2005
Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Atypical anti-psychotics in the real world--a naturalistic comparative outcome study.Scottish medical journal, , Volume: 50, Issue:3, 2005
Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:5 Suppl, 2005
Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders.Schizophrenia research, , Dec-01, Volume: 80, Issue:1, 2005
Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:8, 2005
Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients.Schizophrenia research, , Oct-15, Volume: 78, Issue:2-3, 2005
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.The American journal of psychiatry, , Volume: 162, Issue:8, 2005
Monosymptomatic hypochondriacal psychosis: atypical presentation and response to olanzapine.The Journal of clinical psychiatry, , Volume: 66, Issue:6, 2005
Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode.Schizophrenia research, , Oct-15, Volume: 78, Issue:2-3, 2005
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.Schizophrenia research, , Jul-01, Volume: 76, Issue:1, 2005
Delusional wife: a case of diagnostic ambiguity and treatment challenge.Journal of psychiatric practice, , Volume: 11, Issue:3, 2005
Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.Schizophrenia research, , Sep-15, Volume: 77, Issue:2-3, 2005
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses.The Cochrane database of systematic reviews, , Apr-18, Issue:2, 2005
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Apr-18, Issue:2, 2005
Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone.International clinical psychopharmacology, , Volume: 20, Issue:3, 2005
Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy.Journal of clinical psychopharmacology, , Volume: 25, Issue:2, 2005
Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine: a case report.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Acute psychosis with a mediastinal carcinoma metastasis.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 11, Issue:1, 2005
Bipolar depression: the role of atypical antipsychotics.Expert review of neurotherapeutics, , Volume: 4, Issue:6 Suppl 2, 2004
[Cerebral infarct and atypical antipsychotic agents].Psychologie & neuropsychiatrie du vieillissement, , Volume: 2, Issue:4, 2004
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.Annals of the New York Academy of Sciences, , Volume: 1032, 2004
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.Schizophrenia bulletin, , Volume: 30, Issue:3, 2004
[Clozapine for the treatment of psychosis in 3 elderly patients with Parkinson's disease].Nederlands tijdschrift voor geneeskunde, , Nov-27, Volume: 148, Issue:48, 2004
A comparison of two novel antipsychotics in first episode non-affective psychosis: one-year outcome on symptoms, motor side effects and cognition.Psychiatry research, , Dec-15, Volume: 129, Issue:2, 2004
[Management of the atypical antipsychotic olanzapine in a clinical environment with particular regard to therapeutic drug monitoring (TDM) in a German State hospital].Psychiatrische Praxis, , Volume: 31 Suppl 1, 2004
A case of venous thromboembolism probably associated with hyperprolactinemia after the addition of olanzapine to typical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Optimizing atypical antipsychotic treatment strategies in the elderly.Journal of the American Geriatrics Society, , Volume: 52, Issue:12 Suppl, 2004
Pharmacology of antipsychotics in the elderly: a focus on atypicals.Journal of the American Geriatrics Society, , Volume: 52, Issue:12 Suppl, 2004
Neuroleptic malignant syndrome in a child treated with an atypical antipsychotic.Journal of toxicology. Clinical toxicology, , Volume: 42, Issue:6, 2004
[Intoxications with atypical antipsychotic drugs--data of the Acute Intoxication Unit in Wrocław].Przeglad lekarski, , Volume: 61, Issue:4, 2004
Prevalence and outcomes of pharmaceutical industry-sponsored clinical trials involving clozapine, risperidone, or olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:9, 2004
Antipsychotic drug prescribing in the elderly is cause for concern.International clinical psychopharmacology, , Volume: 19, Issue:6, 2004
A male case of monosymptomatic hypochondriacal psychosis responding to olanzapine: a case report.Pharmacopsychiatry, , Volume: 37, Issue:5, 2004
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Blepharospasm associated with olanzapine: a case report.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:6, 2004
Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.The American journal of psychiatry, , Volume: 161, Issue:9, 2004
Variables associated with high olanzapine dosing in a state hospital.The Journal of clinical psychiatry, , Volume: 65, Issue:8, 2004
Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.The Journal of clinical psychiatry, , Volume: 65 Suppl 11, 2004
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.Journal of clinical psychopharmacology, , Volume: 24, Issue:4, 2004
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
The management of psychogeriatric patient.Archives of gerontology and geriatrics. Supplement, , Issue:9, 2004
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.Journal of clinical psychopharmacology, , Volume: 24, Issue:2, 2004
Weight gain during long-term treatment with olanzapine: a case series.International clinical psychopharmacology, , Volume: 19, Issue:4, 2004
Tardive dyskinesia rates with atypical antipsychotics in older adults.The Journal of clinical psychiatry, , Volume: 65 Suppl 9, 2004
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior.The Journal of clinical psychiatry, , Volume: 65, Issue:5, 2004
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Novel antipsychotics in bipolar and schizoaffective mania.Acta psychiatrica Scandinavica, , Volume: 109, Issue:6, 2004
Olanzapine in the treatment of agitation in hospitalized patients with schizophrenia and schizoaffective and schizofreniform disorders.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 10, Issue:5, 2004
Management of diabetes mellitus occurring during treatment with olanzapine: report of six cases and clinical implications.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:1, 2004
Comparison of risperidone and olanzapine as used under "real-world" conditions in a state psychiatric hospital.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:3, 2004
Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder.Psychopharmacology, , Volume: 175, Issue:4, 2004
Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Hyperglycemia associated with antipsychotic treatment in a multicenter drug safety project.Pharmacopsychiatry, , Volume: 37 Suppl 1, 2004
Olanzapine-induced galactorrhea in a woman with psychotic illness.The Australian and New Zealand journal of psychiatry, , Volume: 38, Issue:4, 2004
Open label study of the effect of amantadine on weight gain induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 58, Issue:2, 2004
Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:1, 2004
New antipsychotics and schizophrenia: a review on efficacy and side effects.Current medicinal chemistry, , Volume: 11, Issue:3, 2004
Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease.International journal of geriatric psychiatry, , Volume: 19, Issue:2, 2004
Switching elderly chronic psychotic patients to olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:2, 2004
Olanzapine treatment of eight adolescent patients with psychosis.Human psychopharmacology, , Volume: 19, Issue:1, 2004
Olanzapine excretion into breast milk: a case report.Journal of clinical psychopharmacology, , Volume: 24, Issue:1, 2004
Dropout rates with olanzapine or risperidone: a multi-centre observational study.European journal of clinical pharmacology, , Volume: 59, Issue:12, 2004
Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.Psychopharmacology, , Volume: 172, Issue:3, 2004
A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 29, Issue:1, 2004
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.International journal of geriatric psychiatry, , Volume: 18, Issue:9, 2003
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.Southern medical journal, , Volume: 96, Issue:7, 2003
Olanzapine for cocaine cravings and relapse prevention.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
Comparison of three antipsychotics in the emergency psychiatric setting.Human psychopharmacology, , Volume: 18, Issue:6, 2003
Olanzapine for psychotic and behavioral disturbances in Alzheimer disease.The Annals of pharmacotherapy, , Volume: 37, Issue:9, 2003
Potential use of olanzapine in treatment of substance dependence disorders.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Risperidone and olanzapine in adults with intellectual disability: a clinical naturalistic study.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.Biological psychiatry, , Aug-15, Volume: 54, Issue:4, 2003
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.The American journal of psychiatry, , Volume: 160, Issue:8, 2003
[Life threatening neuroleptic malignant syndrome due to olanzapine].Psychiatrische Praxis, , Volume: 30, Issue:5, 2003
QTc prolongation: chlorpromazine and high-dosage olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
High-dose olanzapine-induced improvement of preexisting type 2 diabetes mellitus in schizophrenic patients.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Hyperglycemia from olanzapine treatment in adolescents.Journal of child and adolescent psychopharmacology, ,Spring, Volume: 13, Issue:1, 2003
Pulmonary embolism possibly associated with olanzapine treatment.BMJ (Clinical research ed.), , Dec-13, Volume: 327, Issue:7428, 2003
High-dose olanzapine and prolactin levels.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
Pharmacologic management of psychosis in the elderly: a critical review.Journal of geriatric psychiatry and neurology, , Volume: 16, Issue:4, 2003
A 1-year open-label trial of olanzapine in school-age children with schizophrenia.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 13, Issue:3, 2003
Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:9, 2003
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:6, 2003
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.The international journal of neuropsychopharmacology, , Volume: 6, Issue:4, 2003
Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.Current medical research and opinion, , Volume: 19, Issue:6, 2003
Effects of olanzapine on lipid abnormalities in elderly psychotic patients.Drugs & aging, , Volume: 20, Issue:12, 2003
Psychotic disorder in a case with Hallervorden-Spatz disease.Acta psychiatrica Scandinavica, , Volume: 108, Issue:5, 2003
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
The efficacy and safety of olanzapine for the treatment of geriatric psychosis.Journal of clinical psychopharmacology, , Volume: 23, Issue:2, 2003
Comparative effectiveness of antipsychotic drugs.The American journal of psychiatry, , Volume: 160, Issue:3, 2003
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Issue:1, 2003
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).Archives of general psychiatry, , Volume: 60, Issue:1, 2003
Olanzapine and pregnancy.Pharmacopsychiatry, , Volume: 35, Issue:3, 2002
Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study.Pharmacopsychiatry, , Volume: 35, Issue:3, 2002
One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.Psychiatric services (Washington, D.C.), , Volume: 53, Issue:7, 2002
Clinical and economic outcomes associated with olanzapine for the treatment of psychotic symptoms in a county mental health population.Clinical therapeutics, , Volume: 24, Issue:5, 2002
Tardive dyskinesias and antipsychotics: a review.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:3, 2002
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Weight gain and hyperglycaemia associated with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:2, 2002
Olanzapine-induced destabilization of diabetes in the absence of weight gain.Acta psychiatrica Scandinavica, , Volume: 105, Issue:3, 2002
Eosinophilia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:3, 2002
Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis.The Journal of clinical psychiatry, , Volume: 63, Issue:2, 2002
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.The Journal of clinical psychiatry, , Volume: 63, Issue:2, 2002
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.Dementia and geriatric cognitive disorders, , Volume: 13, Issue:2, 2002
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.The American journal of psychiatry, , Volume: 159, Issue:2, 2002
Are the atypical antipsychotic drugs antidepressants?Journal of clinical psychopharmacology, , Volume: 22, Issue:1, 2002
Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis.Pharmacotherapy, , Volume: 22, Issue:1, 2002
Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.Schizophrenia bulletin, , Volume: 28, Issue:4, 2002
[Schizoaffective disorder: clinical symptoms and present-day approach to treatment].Medicina (Kaunas, Lithuania), , Volume: 38, Issue:11, 2002
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
Recent developments in pharmacotherapy for the acutely psychotic patient.Journal of emergency nursing, , Volume: 28, Issue:6 Suppl, 2002
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
The effects of novel antipsychotics on glucose and lipid levels.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.International clinical psychopharmacology, , Volume: 17, Issue:6, 2002
Using antipsychotics in elderly patients.The Practitioner, , Volume: 246, Issue:1639, 2002
Olanzapine-induced hyperventilation: case report.Journal of psychiatry & neuroscience : JPN, , Volume: 27, Issue:5, 2002
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:3, 2002
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.Schizophrenia research, , Oct-01, Volume: 57, Issue:2-3, 2002
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 12, Issue:2, 2002
Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication.Therapeutic drug monitoring, , Volume: 24, Issue:4, 2002
Use of olanzapine for elderly patients with psychotic disorders: a review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 13, Issue:4, 2001
Olanzapine versus haloperidol in schizoaffective disorder, bipolar type.Journal of affective disorders, , Volume: 67, Issue:1-3, 2001
An open trial of olanzapine in the treatment of patients with psychotic depression.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 13, Issue:3, 2001
Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose.The Journal of clinical psychiatry, , Volume: 62, Issue:12, 2001
[Diabetes mellitus induced by olanzapine. A case report].Revista medica de Chile, , Volume: 129, Issue:10, 2001
Body weight gain, insulin, and leptin in olanzapine-treated patients.The Journal of clinical psychiatry, , Volume: 62, Issue:11, 2001
Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia.International journal of geriatric psychiatry, , Volume: 16 Suppl 1, 2001
Acute, progressive akinetic-rigid syndrome induced by neuroleptics in a case of Wilson's disease.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 13, Issue:4, 2001
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Fall, Volume: 9, Issue:4, 2001
Olanzapine-induced priapism.The American journal of psychiatry, , Volume: 158, Issue:12, 2001
Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:8, 2001
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:11, 2001
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.The Journal of clinical psychiatry, , Volume: 62, Issue:9, 2001
Olanzapine in pregnancy.The Annals of pharmacotherapy, , Volume: 35, Issue:10, 2001
[Importance of blood glucose level when starting antipsychotic treatment].Presse medicale (Paris, France : 1983), , Sep-22, Volume: 30, Issue:26, 2001
Olanzapine induces remarkable weight gain in adolescent patients.European child & adolescent psychiatry, , Volume: 10, Issue:3, 2001
Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database.The American journal of psychiatry, , Volume: 158, Issue:9, 2001
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.The Journal of clinical psychiatry, , Volume: 62, Issue:7, 2001
Priapism associated with conventional and atypical antipsychotic medications: a review.The Journal of clinical psychiatry, , Volume: 62, Issue:5, 2001
Hypothesis and hypothesis testing in the clinical trial.The Journal of clinical psychiatry, , Volume: 62 Suppl 9, 2001
The pharmacology of weight gain with antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 7, 2001
Use of olanzapine in non-psychotic psychiatric disorders.Expert opinion on pharmacotherapy, , Volume: 2, Issue:4, 2001
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 158, Issue:5, 2001
A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates.Neurocase, , Volume: 7, Issue:2, 2001
Effect of amantadine on weight gain during olanzapine treatment.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 11, Issue:2, 2001
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.The Journal of clinical psychiatry, , Volume: 62, Issue:2, 2001
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.The Journal of clinical psychiatry, , Volume: 62, Issue:1, 2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Introduction: a new era in the pharmacotherapy of psychotic disorders.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Rapid tranquilization with olanzapine in acute psychosis: a case series.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.The American journal of psychiatry, , Volume: 158, Issue:3, 2001
Consistency of atypical antipsychotic superiority to placebo in recent clinical trials.Biological psychiatry, , Jan-01, Volume: 49, Issue:1, 2001
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 21, Issue:4, 2000
Switching clozapine responders to olanzapine.The Journal of clinical psychiatry, , Volume: 61, Issue:12, 2000
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.Journal of psychopharmacology (Oxford, England), , Volume: 14, Issue:4, 2000
[Effective treatment of depressive disorder with psychotic symptoms by olanzapine combination therapy].Deutsche medizinische Wochenschrift (1946), , Dec-15, Volume: 125, Issue:50, 2000
New treatments for bipolar disorder: the role of atypical neuroleptic agents.The Journal of clinical psychiatry, , Volume: 61 Suppl 14, 2000
Rationale and guidelines for the inpatient treatment of acute psychosis.The Journal of clinical psychiatry, , Volume: 61 Suppl 14, 2000
A case of monosymptomatic hypochondriacal psychosis treated with olanzapine.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 12, Issue:4, 2000
Comparison of cost, dosage and clinical preference for risperidone and olanzapine.Schizophrenia research, , Dec-15, Volume: 46, Issue:2-3, 2000
Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution.The Journal of clinical psychiatry, , Volume: 61, Issue:11, 2000
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.The Journal of clinical psychiatry, , Volume: 61, Issue:11, 2000
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.The Journal of clinical psychiatry, , Volume: 61, Issue:10, 2000
Polypharmacy of 2 atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.Archives of general psychiatry, , Volume: 57, Issue:10, 2000
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17, Issue:6, 2000
Remission of tardive dyskinesia after changing from flupenthixol to olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 15, Issue:5, 2000
Esotropia associated with olanzapine.Journal of clinical psychopharmacology, , Volume: 20, Issue:4, 2000
Electroencephalogram alterations during treatment with olanzapine.Psychopharmacology, , Volume: 150, Issue:2, 2000
Olanzapine and weight gain.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 45, Issue:5, 2000
Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability.Journal of intellectual disability research : JIDR, , Volume: 44 ( Pt 2), 2000
Anticholinergic differences among patients receiving standard clinical doses of olanzapine or clozapine.Journal of clinical psychopharmacology, , Volume: 20, Issue:3, 2000
Adverse events related to olanzapine.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 12, Issue:1, 2000
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Issue:2, 2000
Recurrent priapism during treatment with clozapine and olanzapine.The American journal of psychiatry, , Volume: 157, Issue:4, 2000
Olanzapine use in the elderly: a retrospective analysis.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 45, Issue:2, 2000
Tardive dyskinesia in older patients.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
[Away from life into a trance. Story of an admission].Psychiatrische Praxis, , Volume: 27, Issue:1, 2000
Olanzapine and tardive dyskinesia.The British journal of psychiatry : the journal of mental science, , Volume: 175, 1999
Olanzapine-induced psychotic mania in bipolar schizo-affective disorder.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 14, Issue:7, 1999
Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service.The Australian and New Zealand journal of psychiatry, , Volume: 33, Issue:6, 1999
[New antipsychotic agents].L'Encephale, , Volume: 25 Spec No 3, 1999
Olanzapine increases weight and serum triglyceride levels.The Journal of clinical psychiatry, , Volume: 60, Issue:11, 1999
Hypomania-like syndrome induced by olanzapine.International clinical psychopharmacology, , Volume: 14, Issue:6, 1999
Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Nov-01, Volume: 56, Issue:21, 1999
Recurrence of neuroleptic malignant syndrome with olanzapine treatment.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
Weight gain associated with antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 60 Suppl 21, 1999
Early relapse of psychotic symptoms after an initial response to olanzapine.Acta psychiatrica Scandinavica, , Volume: 100, Issue:4, 1999
Olanzapine-induced psychotic mania in bipolar schizoaffective disorder.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:6, 1999
Reversible leucopenia related to olanzapine.Movement disorders : official journal of the Movement Disorder Society, , Volume: 14, Issue:5, 1999
Experience with the atypical antipsychotics--risperidone and olanzapine in the elderly.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 11, Issue:3, 1999
Risperidone-induced tardive dystonia and psychosis.Lancet (London, England), , Mar-20, Volume: 353, Issue:9157, 1999
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?The Journal of clinical psychiatry, , Volume: 60, Issue:7, 1999
Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:4, 1999
Olanzapine for psychosis in patients with Parkinson's disease with and without dementia.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 11, Issue:3, 1999
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.European journal of nuclear medicine, , Volume: 26, Issue:8, 1999
The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.Biological psychiatry, , Aug-01, Volume: 46, Issue:3, 1999
Hypofrontal symptoms from olanzapine: a case report.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 11, Issue:1, 1999
Clozapine: a comparison with other novel antipsychotics.The Journal of clinical psychiatry, , Volume: 60 Suppl 12, 1999
Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:3, 1999
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
Management of psychotic aspects of Parkinson's disease.The Journal of clinical psychiatry, , Volume: 60 Suppl 8, 1999
Antipsychotics from theory to practice: integrating clinical and basic data.The Journal of clinical psychiatry, , Volume: 60 Suppl 8, 1999
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.The British journal of psychiatry : the journal of mental science, , Volume: 174, 1999
Review of recent clinical studies with olanzapine.The British journal of psychiatry. Supplement, , Issue:37, 1999
Use of high-dose olanzapine in refractory psychosis.The American journal of psychiatry, , Volume: 156, Issue:4, 1999
Tardive dyskinesia in affective disorders.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication.Therapeutic drug monitoring, , Volume: 21, Issue:1, 1999
Olanzapine in the treatment of tardive dyskinesia: a report of two cases.Journal of clinical psychopharmacology, , Volume: 19, Issue:1, 1999
An open trial of olanzapine in patients with treatment-refractory psychoses.Journal of clinical psychopharmacology, , Volume: 19, Issue:1, 1999
Conventional vs. newer antipsychotics in elderly patients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Winter, Volume: 7, Issue:1, 1999
Olanzapine versus haloperidol treatment in first-episode psychosis.The American journal of psychiatry, , Volume: 156, Issue:1, 1999
Neuroleptic malignant syndrome associated with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 32, Issue:6, 1998
Hyperglycemia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Return of menstruation after switching from risperidone to olanzapine.Journal of clinical psychopharmacology, , Volume: 18, Issue:6, 1998
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
Olanzapine-induced mania.The Journal of the American Osteopathic Association, , Volume: 98, Issue:10, 1998
Olanzapine and negative symptoms.The Journal of clinical psychiatry, , Volume: 59, Issue:10, 1998
Metronome or alternating Pisa syndrome: a form of tardive dystonia under clozapine treatment.International clinical psychopharmacology, , Volume: 13, Issue:5, 1998
Novel antipsychotics and new onset diabetes.Biological psychiatry, , Oct-15, Volume: 44, Issue:8, 1998
Quality of life and atypical antipsychotics.Journal of clinical psychopharmacology, , Volume: 18, Issue:5, 1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Hypothermia induced by risperidone and olanzapine in a patient with Prader-Willi syndrome.The Medical journal of Australia, , Aug-17, Volume: 169, Issue:4, 1998
Open-label olanzapine treatment in five preadolescent children.Journal of child and adolescent psychopharmacology, , Volume: 8, Issue:2, 1998
Acute dystonia with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:7, 1998
Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.Journal of clinical psychopharmacology, , Volume: 18, Issue:4, 1998
Olanzapine-induced weight gain.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 10, Issue:1, 1998
Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".Journal of clinical psychopharmacology, , Volume: 18, Issue:2, 1998
Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".Journal of clinical psychopharmacology, , Volume: 18, Issue:2, 1998
Paranoia and agitation associated with olanzapine treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:2, 1998
Emergency treatment of acute psychosis.The Journal of clinical psychiatry, , Volume: 59 Suppl 1, 1998
Antipsychotic agents and bipolar disorder.The Journal of clinical psychiatry, , Volume: 59 Suppl 1, 1998
New antipsychotic drugs produce better outcomes.Healthcare benchmarks, , Volume: 4, Issue:10, 1997
New antipsychotic medications: strategies for evaluation and selected findings.Schizophrenia research, , Oct-30, Volume: 27, Issue:2-3, 1997
[New antipsychotic drugs].Harefuah, , Volume: 133, Issue:1-2, 1997
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.Journal of clinical psychopharmacology, , Volume: 17, Issue:5, 1997
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.The American journal of psychiatry, , Volume: 154, Issue:9, 1997
From chlorpromazine to olanzapine: a brief history of antipsychotics.Psychiatric services (Washington, D.C.), , Volume: 48, Issue:9, 1997
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Olanzapine: a novel atypical neuroleptic agent.Lancet (London, England), , May-03, Volume: 349, Issue:9061, 1997
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.The American journal of psychiatry, , Volume: 154, Issue:4, 1997
Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.Drugs, , Volume: 53, Issue:2, 1997
Antipsychotic drug choices now include olanzapine.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Dec-01, Volume: 53, Issue:23, 1996
Evaluating outcomes of treatments for persons with psychotic disorders.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Side effect profiles of new antipsychotic agents.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease.Neurology, , Volume: 47, Issue:4, 1996
Olanzapine: a new typical antipsychotic drug.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 14, Issue:2, 1996
Introduction.The Journal of clinical psychiatry, , Volume: 78, Issue:8
[Prescription of olanzapine in children and adolescent psychiatric patients].L'Encephale, , Volume: 33, Issue:2
Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders.Clinical neuropharmacology, , Volume: 30, Issue:2
Metabolic Syndrome Reversal With Cariprazine.Journal of clinical psychopharmacology, , Volume: 39, Issue:4
Psychosis in Anorexia Nervosa: A Case Report and Review of the Literature.Psychosomatics, , Volume: 61, Issue:2
Olanzapine-induced agranulocytosis in systemic lupus erythematosus: a case report.General hospital psychiatry, , Volume: 29, Issue:1
Antipsychotic medication dispensing and associated odds ratios of death in elderly veterans and war widows, 2001.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:11-12
Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy.Journal of psychiatric research, , Volume: 41, Issue:3-4
Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:3
Psychiatric symptoms in a case of intracranial tuberculosis.Psychosomatics, , Volume: 43, Issue:1
Relationship between smoking and psychotic symptoms in a patient treated with oral olanzapine. A case report.Actas espanolas de psiquiatria, , Volume: 42, Issue:5
Olanzapine for the treatment of psychiatric illness and urticaria: a case report.Psychosomatics, , Volume: 55, Issue:6
A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning.Journal of sex & marital therapy, , Volume: 32, Issue:4
Acute necrotizing pancreatitis following olanzapine therapy.Tropical gastroenterology : official journal of the Digestive Diseases Foundation, , Volume: 35, Issue:2
Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.American journal of Alzheimer's disease and other dementias, , Volume: 21, Issue:2
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 9, Issue:2
[Treatment of non cognitive symptoms of Alzheimer's disease].Revista de neurologia, , Volume: 42, Issue:8
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
Psychosis in a Patient with Davidoff-Dyke-Masson Syndrome.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:1
Psychotic syndrome secondary to meningioma treated with a low dose of olanzapine.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 37, Issue:2
Diagnosis and Treatment of Eclamptic Psychosis in the Postpartum Period: A Case Report.Psychosomatics, , Volume: 56, Issue:5
Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia.Psychosomatics, , Volume: 42, Issue:6
Authors' response to comments regarding risperidone versus olanzapine Markov model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 8, Issue:5
[Psychotic episode due to Hashimoto's thyroiditis].Psychiatrike = Psychiatriki, , Volume: 27, Issue:2
Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.Human psychopharmacology, , Volume: 26, Issue:4-5
[Randomized, open label study on the use of ranitidine at different doses for the management of weight gain associated with olanzapine administration].Vertex (Buenos Aires, Argentina), , Volume: 14, Issue:52
Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients.General hospital psychiatry, , Volume: 30, Issue:4
[Protective effect of olanzapine in psychotic disorder induced by interferon-alpha].Recenti progressi in medicina, , Volume: 94, Issue:7-8
The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:3
[Psychosis associated to megacisterna magna].Anales del sistema sanitario de Navarra, , Volume: 28, Issue:1
Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 8, Issue:2
Urinary retention during combined treatment of postpsychotic depression with duloxetine and olanzapine.Clinical neuropharmacology, , Volume: 31, Issue:5
[Cycloid psychoses. A case report].Actas espanolas de psiquiatria, , Volume: 32, Issue:5
The utility of intramuscular ziprasidone in the management of acute psychotic agitation.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:3
[Clozapine and olanzapine in the treatment of the psychotic disorders in Parkinson's disease].Revista de neurologia, , Volume: 39, Issue:7
Hypothermia and rhabdomyolysis following olanzapine injection in an adolescent with schizophreniform disorder.General hospital psychiatry, , Volume: 31, Issue:4
Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 7, Issue:5
Treatment of narcolepsy complicated by psychotic symptoms.Psychosomatics, , Volume: 50, Issue:4
Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 12, Issue:4
Olanzapine treatment of monosymptomatic hypochondriacal psychosis.General hospital psychiatry, , Volume: 26, Issue:2
Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.Irish journal of medical science, , Volume: 172, Issue:4
Tuberous sclerosis with psychosis.Psychosomatics, , Volume: 44, Issue:6
A case report of confusional psychosis with abrupt onset and rapid resolution of symptoms.Psychosomatics, , Volume: 52, Issue:5
Priapism after a suicide attempt by ingestion of olanzapine and gabapentin.Psychosomatics, , Volume: 42, Issue:3
[Treatment of schizophrenia in subjects with substance use disorders: A review].Actas espanolas de psiquiatria, , Volume: 29, Issue:2
Hereditary spastic paraplegia and psychosis: connected by the corpus callosum?Psychosomatics, , Volume: 53, Issue:1
Propofol infusion for the retrieval of the acutely psychotic patient.Air medical journal, , Volume: 31, Issue:1
Low voltage electrical injury induces psychosis.Psychosomatics, , Volume: 53, Issue:2
Neuropsychiatric sequelae in a case of St. Louis encephalitis.General hospital psychiatry, , Volume: 22, Issue:2
Thrombocytopenia possibly associated with olanzapine and subsequently with benztropine mesylate.Psychosomatics, , Volume: 41, Issue:3
Olanzapine treatment of premenstrual onset psychosis: a case report.General hospital psychiatry, , Volume: 35, Issue:4
Second-generation antipsychotics in the emergency care setting. A prospective naturalistic study.General hospital psychiatry, , Volume: 22, Issue:2
[Methodological proposals for the evaluation of the mood stabilizing effect of an antipsychotic drug].L'Encephale, , Volume: 25, Issue:6
Use of olanzapine in hereditary coproporphyria.Psychosomatics, , Volume: 40, Issue:5
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
Combination Therapy of Long-Acting Injectable Second-Generation Antipsychotics and Oral Antipsychotics: A Retrospective Chart Review and Prescribers' Attitude Survey.Journal of clinical psychopharmacology, , Volume: 42, Issue:1
Management of Parkinson disease.The Journal of the American Board of Family Practice, , Volume: 11, Issue:2
The Effect of Valproic Acid on Olanzapine Serum Concentration: A Study Including 2791 Patients Treated With Olanzapine Tablets or Long-Acting Injections.Journal of clinical psychopharmacology, , Volume: 39, Issue:6
[Effectiveness results of olanzapine in acute psychotic patients with agitation in the emergency room setting: results from NATURA study].Actas espanolas de psiquiatria, , Volume: 36, Issue:3
Clinical News.Clinical schizophrenia & related psychoses, , Volume: 11, Issue:1
An Unexpected Case of Diabetic Ketoacidosis on the Psychiatry Ward: Olanzapine-Associated Adult Ketosis-Prone Type 2 Diabetes Mellitus.Canadian journal of diabetes, , Volume: 44, Issue:3, 2020
Postpartum psychosis in mothers with SARS-CoV-2 infection: A case series from India.Asian journal of psychiatry, , Volume: 54, 2020
Managing psychosis in pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:3, 2007
Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder.Bipolar disorders, , Volume: 8, Issue:4, 2006
Olanzapine excretion into breast milk: a case report.Journal of clinical psychopharmacology, , Volume: 24, Issue:1, 2004
Challenges in managing a mother with a dual diagnosis of peripartum cardiomyopathy and paranoid schizophrenia - a case report.General hospital psychiatry, , Volume: 35, Issue:6
Acute massive pulmonary embolism during antipsychotic treatment: case report with opinion.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 23, Issue:6, 2023
Acute massıve pulmonary embolism assocıated wıth olanzapıne.The American journal of emergency medicine, , Volume: 35, Issue:10, 2017
Pulmonary thromboembolism associated with olanzapine treatment.Chinese medical journal, , Feb-05, Volume: 128, Issue:3, 2015
Pulmonary embolism in a psychiatric patient.The American journal of psychiatry, , Nov-01, Volume: 171, Issue:11, 2014
Fatal pulmonary embolism following antipsychotic treatment and physical restraint.Pharmacopsychiatry, , Volume: 42, Issue:5, 2009
Thrombosis and psychosis--possible association with the antiphospholipid syndrome and anticardiolipin antibodies.Irish medical journal, , Volume: 102, Issue:2, 2009
Pulmonary thromboembolism associated with olanzapine and risperidone.The Journal of emergency medicine, , Volume: 35, Issue:2, 2008
Olanzapine: a new risk factor for pulmonary embolus?The American journal of forensic medicine and pathology, , Volume: 29, Issue:4, 2008
Massive pulmonary emboli associated with olanzapine.Irish medical journal, , Volume: 101, Issue:6, 2008
[Venous thromboembolic disease and olanzapine].Medicina clinica, , Oct-21, Volume: 127, Issue:15, 2006
Pulmonary embolism associated with olanzapine.Thrombosis and haemostasis, , Volume: 96, Issue:5, 2006
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
Adverse drug reactions in Canada.Canadian family physician Medecin de famille canadien, , Volume: 51, 2005
Olanzapine-induced vasculitis.The American journal of geriatric pharmacotherapy, , Volume: 3, Issue:1, 2005
Olanzapine and venous thromboembolism.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Pulmonary embolism possibly associated with olanzapine treatment.BMJ (Clinical research ed.), , Dec-13, Volume: 327, Issue:7428, 2003
Acute massive pulmonary embolism associated with olanzapine therapy and no significant personal history in a young male--case report and literature review.Pneumologia (Bucharest, Romania), , Volume: 60, Issue:2
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.Psychiatry research, , Volume: 322, 2023
Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.Schizophrenia bulletin, , 06-21, Volume: 48, Issue:4, 2022
Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.Expert review of pharmacoeconomics & outcomes research, , Volume: 20, Issue:5, 2020
Maintenance Treatment for Psychotic Depressive Disorders: Progress and Remaining Challenges.JAMA, , 08-20, Volume: 322, Issue:7, 2019
Continuing Antipsychotic Medication for Patients With Psychotic Depression in Remission.JAMA, , 12-24, Volume: 322, Issue:24, 2019
Delusion of denial of pregnancy: A case report.Asian journal of psychiatry, , Volume: 45, 2019
Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.Journal of medical economics, , Volume: 22, Issue:5, 2019
Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.Schizophrenia research, , Volume: 201, 2018
Recurrent Hyperammonemia Associated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 37, Issue:3, 2017
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.Journal of medical economics, , Volume: 20, Issue:11, 2017
Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy.BMJ case reports, , Dec-02, Volume: 2017, 2017
Effects of antipsychotics on insight in schizophrenia: results from independent samples of first-episode and acutely relapsed patients.International clinical psychopharmacology, , Volume: 31, Issue:4, 2016
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.Journal of medical economics, , Volume: 19, Issue:9, 2016
Add-on oral olanzapine worsens hallucinations in schizoaffective disorder.BMJ case reports, , Oct-21, Volume: 2014, 2014
A case of late-onset angioedema associated with clozapine and redevelopment of angioedema with olanzapine.Journal of clinical psychopharmacology, , Volume: 34, Issue:4, 2014
[Antipsychotic-induced priapism and management challenges: a case report].L'Encephale, , Volume: 40, Issue:6, 2014
Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.BMC psychiatry, , Sep-16, Volume: 13, 2013
Comparably high retention and low relapse rates in different subpopulations of bipolar patients in a German non-interventional study.BMC psychiatry, , Jul-17, Volume: 13, 2013
[Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 15, Issue:2, 2013
[Follow-up of a 16-year-old adolescent with early-onset schizophrenia and catatonic symptoms].L'Encephale, , Volume: 39 Suppl 1, 2013
A case of catatonia in a 14-year-old girl with schizophrenia treated with electroconvulsive therapy.Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 41, Issue:1, 2013
[The comparative study on the efficacy of the combination of serotonin reuptake inhibitor antidepressants and antipsychotics in the treatment of recurrent depressive disorders].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 112, Issue:11 Pt 2, 2012
Predictors of relapse or recurrence in bipolar I disorder.Journal of affective disorders, , Volume: 136, Issue:3, 2012
Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 15, Issue:1, 2012
Repeated activation of mania by atypical antipsychotics in a patient.BMJ case reports, , Nov-27, Volume: 2012, 2012
A case of prolonged duration of untreated psychosis: barriers to treatment and strategies to improve the outcome.Clinical schizophrenia & related psychoses, , Volume: 6, Issue:1, 2012
Variables as mediators or moderators in predicting relapse to any type of mood episode in a bipolar maintenance study.The Journal of clinical psychiatry, , Volume: 73, Issue:7, 2012
Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twenty-four months: implications for clinical practice.BMC psychiatry, , Dec-17, Volume: 12, 2012
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.Journal of medical economics, , Volume: 15, Issue:5, 2012
Severe recurrent hypoglycaemia following discontinuation of olanzapine.Acute medicine, , Volume: 10, Issue:1, 2011
Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching.International clinical psychopharmacology, , Volume: 26, Issue:1, 2011
Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention.Bipolar disorders, , Volume: 13, Issue:1, 2011
Minimum effective and relapse-associated doses of risperidone and olanzapine in aggressive, intellectually disabled adults.Journal of clinical psychopharmacology, , Volume: 31, Issue:2, 2011
Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia.The journal of ECT, , Volume: 26, Issue:4, 2010
Pernicious anaemia presenting as catatonia without signs of anaemia or macrocytosis.The British journal of psychiatry : the journal of mental science, , Volume: 197, Issue:3, 2010
In search of optimal lithium levels and olanzapine doses in the long-term treatment of bipolar I disorder. A post-hoc analysis of the maintenance study by Tohen et al. 2005.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 25, Issue:8, 2010
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.The Journal of clinical psychiatry, , Volume: 70, Issue:7, 2009
Olanzapine in long-term treatment for bipolar disorder.The Cochrane database of systematic reviews, , Jan-21, Issue:1, 2009
Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER.Current medical research and opinion, , Volume: 25, Issue:7, 2009
Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.Revista de saude publica, , Volume: 43 Suppl 1, 2009
Treatment of periodic catatonia with atypical antipsychotic, olanzapine.Psychiatry and clinical neurosciences, , Volume: 62, Issue:4, 2008
Neuroleptic malignant syndrome and catatonia in a patient with dementia.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:6, 2008
Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Valproate or olanzapine add-on to lithium: an 8-week, randomized, open-label study in Italian patients with a manic relapse.Journal of affective disorders, , Volume: 99, Issue:1-3, 2007
Clozapine/olanzapine-induced recurrence or deterioration of binge eating-related eating disorders.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 114, Issue:8, 2007
[The influence of atypical neuroleptics on the immune system of patients with schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:3, 2007
A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.The European journal of health economics : HEPAC : health economics in prevention and care, , Volume: 7, Issue:3, 2006
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.Acta psychiatrica Scandinavica, , Volume: 114, Issue:5, 2006
Monosymptomatic hypochondriacal psychosis presenting with recurrent oral mucosal ulcers and multiple skin lesions responding to olanzapine treatment.International journal of dermatology, , Volume: 45, Issue:10, 2006
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.Psychopharmacology, , Volume: 189, Issue:2, 2006
Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.Journal of clinical psychopharmacology, , Volume: 26, Issue:6, 2006
Meningocele and ankyloblepharon following in utero exposure to olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:5, 2006
Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder.Schizophrenia research, , Feb-28, Volume: 82, Issue:2-3, 2006
Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report.Psychiatria Danubina, , Volume: 18, Issue:1-2, 2006
Capgras syndrome in the modern era: self misidentification on an ID picture.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:1, 2005
Reappearance of tardive dystonia with olanzapine treated with clozapine.Schizophrenia research, , Jul-15, Volume: 76, Issue:2-3, 2005
Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.The British journal of psychiatry : the journal of mental science, , Volume: 184, 2004
Olanzapine-induced diabetes in a seven-year-old boy.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.Current medical research and opinion, , Volume: 20, Issue:7, 2004
[Life threatening neuroleptic malignant syndrome due to olanzapine].Psychiatrische Praxis, , Volume: 30, Issue:5, 2003
[Long-term therapy with intuition].MMW Fortschritte der Medizin, , May-26, Volume: 145 Suppl 2, 2003
Dependence and chronic psychosis with D-nor-pseudoephedrine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:8, 2003
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.Wiener klinische Wochenschrift, , Jan-31, Volume: 115, Issue:1-2, 2003
Olanzapine for recurrent aggression in a patient with temporal lobe epilepsy who had temporal lobectomy.Journal of psychopharmacology (Oxford, England), , Volume: 17, Issue:3, 2003
Olanzapine augmentation in the treatment of melancholia: the trajectory of improvement in rapid responders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
[Drug-induced akathisia].Nederlands tijdschrift voor geneeskunde, , Jan-19, Volume: 146, Issue:3, 2002
Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:5, 2002
Olanzapine-induced priapism.The American journal of psychiatry, , Volume: 158, Issue:12, 2001
Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder.Journal of clinical psychopharmacology, , Volume: 21, Issue:5, 2001
Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:1, 2001
St. John's wort and schizophrenia.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Aug-08, Volume: 163, Issue:3, 2000
Pharmacologic treatment of schizophrenia.Biological psychiatry, , Nov-15, Volume: 46, Issue:10, 1999
Recurrence of neuroleptic malignant syndrome with olanzapine treatment.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
Risperidone-induced tardive dystonia and psychosis.Lancet (London, England), , Mar-20, Volume: 353, Issue:9157, 1999
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.Biological psychiatry, , Aug-01, Volume: 46, Issue:3, 1999
Olanzapine in the long-term treatment of schizophrenia.The British journal of psychiatry. Supplement, , Issue:37, 1999
Early relapse of psychotic symptoms after an initial response to olanzapine.Acta psychiatrica Scandinavica, , Volume: 100, Issue:4, 1999
[Neuroleptic malignant syndrome: case report with recurrence associated with the use of olanzapine].Arquivos de neuro-psiquiatria, , Volume: 56, Issue:4, 1998
Hyperglycemia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
New antipsychotic medications: strategies for evaluation and selected findings.Schizophrenia research, , Oct-30, Volume: 27, Issue:2-3, 1997
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 48, Issue:12, 1997
Adjunctive use of olanzapine in mood disorders: five case reports.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 9, Issue:4, 1997
Atypical antipsychotic drugs and long-term outcome in schizophrenia.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost.The Journal of international medical research, , Volume: 31, Issue:3
Clinical News.Clinical schizophrenia & related psychoses, , Volume: 11, Issue:1
Olanzapine-lithium encephalopathy.Psychosomatics, , Volume: 42, Issue:4
Recurrent mania associated with repeated brain injury.General hospital psychiatry, , Volume: 26, Issue:6
Thrombocytopenia possibly associated with olanzapine and subsequently with benztropine mesylate.Psychosomatics, , Volume: 41, Issue:3
Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 7, Issue:5
[Initiation of treatment with olanzapine in a patient hospitalized at UMD].L'Encephale, , Volume: 26, Issue:3
[Mineralization of the basal ganglia as the supposed cause of poor tolerance of zuclopenthixol in a patient with long-term untreated paranoid schizophrenia].Psychiatria polska, , Volume: 47, Issue:4
Hiccups associated with switching from olanzapine to aripiprazole in a patient with paranoid schizophrenia.Clinical neuropharmacology, , Volume: 37, Issue:3
[Remission and relapse in the outpatient treatment of patients with schizophrenia. Outcomes at 3 years].Actas espanolas de psiquiatria, , Volume: 36, Issue:4
[Olanzapine versus haloperidol: effectiveness in functionality and health state in a sample of Venezuelan patients with schizophrenia].Vertex (Buenos Aires, Argentina), , Volume: 19, Issue:81
Treatment of schizophrenia: advances during the decade of the brain.British journal of hospital medicine, , Volume: 56, Issue:11
[Antipsychotics in clinical practice. The refractory schizophrenic patients treatment].Psychiatria polska, , Volume: 42, Issue:6
Spontaneous recovery from progressive multifocal leukoencephalopathy in a patient with non-active sarcoidosis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, , Volume: 14 Suppl 3, 2010
Hyperprolactinaemia and acute psychosis: prolactinoma or medication-induced phenomenon?The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:5, 2010
Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia.Acta psychiatrica Scandinavica, , Volume: 118, Issue:3, 2008
Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.Acta psychiatrica Scandinavica, , Volume: 102, Issue:2, 2000
Recovery from new-onset diabetes in a schizophrenic man after withdrawal of olanzapine.Psychosomatics, , Volume: 43, Issue:1
Atypical Antipsychotic Safety in the CICU.The American journal of cardiology, , 01-15, Volume: 163, 2022
A Prospective Observational Study of Patients Receiving Intravenous and Intramuscular Olanzapine in the Emergency Department.Annals of emergency medicine, , Volume: 69, Issue:3, 2017
Acute respiratory distress due to antipsychotic drugs.Pharmacopsychiatry, , Volume: 43, Issue:3, 2010
Neonatal withdrawal syndrome following in utero exposure to paroxetine, clonazepam and olanzapine.Journal of perinatology : official journal of the California Perinatal Association, , Volume: 27, Issue:8, 2007
Olanzapine overdose in children and adolescents: two case reports and a review of the literature.Journal of child and adolescent psychopharmacology, , Volume: 15, Issue:6, 2005
Olanzapine-induced respiratory failure.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Successful treatment of antipsychotic-induced restless legs syndrome with gabapentin.Asian journal of psychiatry, , Volume: 9, 2014
Restless legs syndrome associated with the combined use of quetiapine and venlafaxine.Journal of clinical psychopharmacology, , Volume: 34, Issue:1, 2014
Olanzapine-induced restless legs syndrome.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 21, Issue:9, 2014
Could pramipexole induce acute mania? A case report.Bipolar disorders, , Volume: 15, Issue:4, 2013
Restless leg syndrome associated with olanzapine: a case series.Current drug safety, , Volume: 5, Issue:2, 2010
Refractory restless legs syndrome likely caused by olanzapine.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, , Feb-15, Volume: 5, Issue:1, 2009
Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:5, 2009
[Drug-induced akathisia].Nederlands tijdschrift voor geneeskunde, , Jan-19, Volume: 146, Issue:3, 2002
Restless legs syndrome and periodic limb movements of sleep: global therapeutic considerations.Sleep medicine reviews, , Volume: 6, Issue:4, 2002
Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Olanzapine-induced restless leg syndrome: a case report and review of literature.Indian journal of pharmacology, , Volume: 46, Issue:4
Zolpidem related persistent genital arousal disorder: An interesting case.Psychiatrike = Psychiatriki, , Volume: 30, Issue:4
Hypertrophic discoid lupus erythematosus.Dermatology online journal, , Nov-15, Volume: 16, Issue:11, 2010
Effectiveness of clozapine and olanzapine: a comparison in severe, psychotically ill patients.The international journal of neuropsychopharmacology, , Volume: 4, Issue:2, 2001
The Role of Total White Blood Cell Count in Antipsychotic Treatment for Patients with Schizophrenia.Current neuropharmacology, , Volume: 22, Issue:1, 2024
Psychosis susceptibility zinc finger protein 804A (ZNF804A) gene polymorphism in schizophrenia patients treated with olanzapine in North Indian population.The International journal of neuroscience, , Volume: 133, Issue:5, 2023
Association Between Sexual Dysfunction and Dose of Atypical Antipsychotics: Essential to Learn the Basics.Journal of clinical pharmacology, , Volume: 63, Issue:1, 2023
Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse.Schizophrenia bulletin, , 01-03, Volume: 49, Issue:1, 2023
Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.Current neuropharmacology, , Volume: 21, Issue:2, 2023
Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).BMJ open, , 01-31, Volume: 13, Issue:1, 2023
Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.BMJ mental health, , Volume: 26, Issue:1, 2023
Anti-inflammatory effects of 2nd generation antipsychotics in patients with schizophrenia: A systematic review and meta-analysis.Journal of psychiatric research, , Volume: 160, 2023
Relapse in patients with schizophrenia and amisulpride-induced hyperprolactinemia or olanzapine-induced metabolic disturbance after switching to other antipsychotics.Psychiatry research, , Volume: 322, 2023
Analysis of the correlation between clinical efficacy and blood concentration of olanzapine in schizophrenia patients.Medicine, , Mar-10, Volume: 102, Issue:10, 2023
Delayed-Onset olanzapine-induced rhabdomyolysis.BMJ case reports, , Mar-10, Volume: 16, Issue:3, 2023
Interhemispheric differences of pyramidal cells in the primary motor cortices of schizophrenia patients investigated postmortem.Cerebral cortex (New York, N.Y. : 1991), , 06-20, Volume: 33, Issue:13, 2023
Olanzapine and Weight Loss in Early-Onset Schizophrenia.The primary care companion for CNS disorders, , 04-06, Volume: 25, Issue:2, 2023
Herbal Therapies for Weight Gain and Metabolic Abnormalities Induced by Atypical Antipsychotics: A Review Article.Current drug discovery technologies, , Volume: 20, Issue:5, 2023
Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China.Asian journal of psychiatry, , Volume: 84, 2023
[no title available]Ugeskrift for laeger, , May-08, Volume: 185, Issue:19, 2023
Therapeutic outcomes wide association scan of different antipsychotics in patients with schizophrenia: Randomized clinical trials and multi-ancestry validation.Psychiatry and clinical neurosciences, , Volume: 77, Issue:9, 2023
Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis.Military Medical Research, , 06-02, Volume: 10, Issue:1, 2023
Short-term antipsychotic treatment response in early-onset, typical-onset, and late-onset first episode schizophrenia.Schizophrenia research, , Volume: 257, 2023
Weight Gain and Metabolic Changes in Patients With First-Episode Psychosis or Early-Phase Schizophrenia Treated With Olanzapine: A Meta-Analysis.The international journal of neuropsychopharmacology, , 07-31, Volume: 26, Issue:7, 2023
Antipsychotic-Induced Metabolic Syndrome: A Review.Metabolic syndrome and related disorders, , Volume: 21, Issue:6, 2023
Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial.BMC psychiatry, , 06-29, Volume: 23, Issue:1, 2023
Comparison between olanzapine and aripiprazole treatment for 104 weeks after hospital discharge in schizophrenia spectrum disorders: a multicenter retrospective cohort study in a real-world setting.Psychopharmacology, , Volume: 240, Issue:9, 2023
Early non-response as a predictor of later non-response to antipsychotics in schizophrenia: a randomized trial.BMC medicine, , 07-19, Volume: 21, Issue:1, 2023
Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric Trial.Pharmacopsychiatry, , Volume: 56, Issue:5, 2023
Neonatal phencyclidine as a model of sex-biased schizophrenia symptomatology in adolescent mice.Psychopharmacology, , Volume: 240, Issue:10, 2023
Prefrontal cortex-specific Dcc deletion induces schizophrenia-related behavioral phenotypes and fail to be rescued by olanzapine treatment.European journal of pharmacology, , Oct-05, Volume: 956, 2023
Association of smoking cigarettes, age, and sex with serum concentrations of olanzapine in patients with schizophrenia.Biochemia medica, , Oct-15, Volume: 33, Issue:3, 2023
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).Journal of psychopharmacology (Oxford, England), , Volume: 37, Issue:10, 2023
Risk evaluation of diabetic ketoacidosis associated with antipsychotics among patients with schizophrenia in the Japanese adverse event report database.Journal of psychosomatic research, , Volume: 175, 2023
Clinical practice guideline on pharmacological and psychological management of adult patients with schizophrenia spectrum disorders and a comorbid substance use.Adicciones, , Apr-01, Volume: 34, Issue:2, 2022
Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions.CNS spectrums, , Volume: 27, Issue:5, 2022
Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study.European archives of psychiatry and clinical neuroscience, , Volume: 272, Issue:4, 2022
Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia.CNS spectrums, , Volume: 27, Issue:3, 2022
Antipsychotic medication for women with schizophrenia spectrum disorders.Psychological medicine, , Volume: 52, Issue:4, 2022
New insight into the CATIE study by constrained confidence partitioning. An innovative technique towards personalized antipsychotic drug therapy in schizophrenia treatment.Schizophrenia research, , Volume: 239, 2022
A longitudinal study of alterations of circulating DJ-1 and miR203a-3p in association to olanzapine medication in a sample of first episode patients with schizophrenia.Journal of psychiatric research, , Volume: 146, 2022
PCSK9 mediates dyslipidemia induced by olanzapine treatment in schizophrenia patients.Psychopharmacology, , Volume: 239, Issue:1, 2022
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.The Annals of pharmacotherapy, , Volume: 56, Issue:9, 2022
Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study.Acta psychiatrica Scandinavica, , Volume: 145, Issue:5, 2022
Risk of treatment discontinuation and psychiatric hospitalization associated with early dose reduction of antipsychotic treatment in first-episode schizophrenia: A nationwide, health insurance data-based study.Psychiatry and clinical neurosciences, , Volume: 76, Issue:5, 2022
Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, , Jun-05, Volume: 274, 2022
The promise and pitfalls of antipsychotic co-initiation in schizophrenia.The lancet. Psychiatry, , Volume: 9, Issue:4, 2022
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.The lancet. Psychiatry, , Volume: 9, Issue:4, 2022
Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments.BMC psychiatry, , 03-21, Volume: 22, Issue:1, 2022
Olanzapine-samidorphan combination tablets for the treatment of schizophrenia and bipolar I disorder - what is it, and will it be used?Expert review of neurotherapeutics, , Volume: 22, Issue:5, 2022
Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia.Molecules (Basel, Switzerland), , Apr-14, Volume: 27, Issue:8, 2022
The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:4, 2022
Clinical Outcomes after Clozapine Discontinuation in Patients with Schizophrenia: A Systematic Review.Pharmacopsychiatry, , Volume: 55, Issue:4, 2022
Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.Schizophrenia bulletin, , 06-21, Volume: 48, Issue:4, 2022
Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications.Psychiatry research, , Volume: 313, 2022
Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials.Schizophrenia bulletin, , 06-21, Volume: 48, Issue:4, 2022
Olanzapine/Samidorphan: A New Combination Treatment for Schizophrenia and Bipolar I Disorder Intended to Reduce Weight Gain.CNS drugs, , Volume: 36, Issue:6, 2022
miR143-3p-Mediated NRG-1-Dependent Mitochondrial Dysfunction Contributes to Olanzapine Resistance in Refractory Schizophrenia.Biological psychiatry, , 09-01, Volume: 92, Issue:5, 2022
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:9, 2022
Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial.Schizophrenia research, , Volume: 246, 2022
Analysis of color vision and cognitive function in first-episode schizophrenia before and after antipsychotic treatment.Journal of psychiatric research, , Volume: 152, 2022
Kynurenine pathway metabolites and therapeutic response to olanzapine in female patients with schizophrenia: A longitudinal study.CNS neuroscience & therapeutics, , Volume: 28, Issue:10, 2022
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.Pharmacopsychiatry, , Volume: 55, Issue:5, 2022
Clozapine-Induced Myocarditis in a Young Man with Refractory Schizophrenia: Case Report of a Rare Adverse Event and Review of the Literature.The American journal of case reports, , Jul-06, Volume: 23, 2022
Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia.Metabolomics : Official journal of the Metabolomic Society, , 07-11, Volume: 18, Issue:7, 2022
Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States.Advances in therapy, , Volume: 39, Issue:9, 2022
Changing the Antipsychotic in Early Nonimprovers to Amisulpride or Olanzapine: Randomized, Double-Blind Trial in Patients With Schizophrenia.Schizophrenia bulletin, , 11-18, Volume: 48, Issue:6, 2022
Driving fitness in clinically stable outpatients with chronic schizophrenia.Comprehensive psychiatry, , Volume: 118, 2022
Samidorphan for the treatment of weight gain associated with olanzapine in patients with schizophrenia and bipolar disorder.Expert review of clinical pharmacology, , Volume: 15, Issue:9, 2022
Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.Schizophrenia research, , Volume: 248, 2022
Second-generation antipsychotic olanzapine attenuates behavioral and prefrontal cortex synaptic plasticity deficits in a neurodevelopmental schizophrenia-related rat model.Journal of chemical neuroanatomy, , Volume: 125, 2022
Cost-utility analysis of lurasidone for the first-line treatment of schizophrenia in China.Frontiers in public health, , Volume: 10, 2022
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosis.The American journal of psychiatry, , 12-01, Volume: 179, Issue:12, 2022
Reviewing the Potential Therapeutic Approaches Targeting the Modulation of Gastrointestinal Microflora in Schizophrenia.International journal of molecular sciences, , Dec-17, Volume: 23, Issue:24, 2022
Practice of prescribing antipsychotics in schizophrenia during 2013-2018 based on data from the National Health Fund.Psychiatria polska, , Aug-31, Volume: 56, Issue:4, 2022
The Importance of Conduct Disorder in the Treatment of Violence in Schizophrenia: Efficacy of Clozapine Compared With Olanzapine and Haloperidol.The American journal of psychiatry, , 03-01, Volume: 178, Issue:3, 2021
Pragmatic antipsychotics trial-caution in interpretation.The lancet. Psychiatry, , Volume: 8, Issue:2, 2021
Pragmatic antipsychotics trial-caution in interpretation - Authors' reply.The lancet. Psychiatry, , Volume: 8, Issue:2, 2021
Altered mRNA expression levels of autophagy- and apoptosis-related genes in the FOXO pathway in schizophrenia patients treated with olanzapine.Neuroscience letters, , 02-16, Volume: 746, 2021
Nanostructured Lipid Carriers for Intranasal Administration of Olanzapine in the Management of Schizophrenia.Current molecular pharmacology, , Volume: 14, Issue:3, 2021
Transcriptome analysis of human induced excitatory neurons supports a strong effect of clozapine on cholesterol biosynthesis.Schizophrenia research, , Volume: 228, 2021
Maternal immune activation and repeated maternal separation alter offspring conditioned avoidance response learning and antipsychotic response in male rats.Behavioural brain research, , 04-09, Volume: 403, 2021
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.The American journal of psychiatry, , 05-01, Volume: 178, Issue:5, 2021
Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis.Schizophrenia research, , Volume: 229, 2021
Risk and Prevention of Aggression in Patients With Psychotic Disorders.The American journal of psychiatry, , 03-01, Volume: 178, Issue:3, 2021
Antipsychotic Treatment Duration in Children and Adolescents: A Register-Based Nationwide Study.Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:6, 2021
A Case of Self-Cannibalism: An Extremely Rare Type of Self-Mutilation With Multiple Risk Factors.The Journal of nervous and mental disease, , 04-01, Volume: 209, Issue:4, 2021
A meta-analysis comparing short-term weight and cardiometabolic changes between olanzapine/samidorphan and olanzapine.Scientific reports, , 04-07, Volume: 11, Issue:1, 2021
The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study.Schizophrenia research, , Volume: 231, 2021
The effect of prohibiting outside food during COVID-19 pandemic on the body weight of schizophrenic patients taking olanzapine or clozapine: a retrospective self-controlled study.Annals of palliative medicine, , Volume: 10, Issue:5, 2021
Case report: Olanzapine post-injection delirium/sedation syndrome mimicking brainstem-thrombosis.Acta neurologica Belgica, , Volume: 121, Issue:5, 2021
Catatonic Symptoms Successfully Treated with Olanzapine in an Adolescent with Schizophrenia.Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:4, 2021
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.Schizophrenia research, , Volume: 232, 2021
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.Journal of clinical pharmacology, , Volume: 61, Issue:11, 2021
Metabolomics-based understanding of the olanzapine-induced weight gain in female first-episode drug-naïve patients with schizophrenia.Journal of psychiatric research, , Volume: 140, 2021
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.The international journal of neuropsychopharmacology, , 10-23, Volume: 24, Issue:10, 2021
Rethinking olanzapine therapy for schizophrenia.Asian journal of psychiatry, , Volume: 62, 2021
Patterns of antipsychotic prescriptions in patients with schizophrenia in China: A national survey.Asian journal of psychiatry, , Volume: 62, 2021
Second-Generation Antipsychotics and Suicide: A Commentary.The Journal of clinical psychiatry, , 07-20, Volume: 82, Issue:5, 2021
Conserved immunomodulatory transcriptional networks underlie antipsychotic-induced weight gain.Translational psychiatry, , 07-22, Volume: 11, Issue:1, 2021
Comparative Study of Sexual Side Effects in Female Patients With Schizophrenia Receiving Risperidone or Olanzapine.The primary care companion for CNS disorders, , Jul-22, Volume: 23, Issue:4, 2021
Olanzapine/Samidorphan: First Approval.Drugs, , Volume: 81, Issue:12, 2021
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Alteration in the mRNA expression profile of the autophagy-related mTOR pathway in schizophrenia patients treated with olanzapine.BMC psychiatry, , 08-04, Volume: 21, Issue:1, 2021
What to Do About Missed Doses? A Retrospective Study of Olanzapine in the Elderly.Drug design, development and therapy, , Volume: 15, 2021
Occurrence of metabolic diseases associated with antipsychotic use among Korean patients with schizophrenia.International journal of clinical pharmacology and therapeutics, , Volume: 59, Issue:4, 2021
Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.Neuropharmacology, , 10-01, Volume: 197, 2021
Olanzapine Induces Inflammation and Immune Response via Activating ER Stress in the Rat Prefrontal Cortex.Current medical science, , Volume: 41, Issue:4, 2021
Association between the improvement in depressive symptoms and serum BDNF levels in drug-naive first episode patients with schizophrenia: A longitudinal follow-up.Psychoneuroendocrinology, , Volume: 133, 2021
MicroRNA-195 predicts olanzapine response in drug-free patients with schizophrenia: A prospective cohort study.Journal of psychopharmacology (Oxford, England), , Volume: 35, Issue:1, 2021
Real-world effectiveness of olanzapine and risperidone in the treatment of schizophrenia in Brazil over a 16-year follow-up period; findings and implications.Expert review of clinical pharmacology, , Volume: 14, Issue:2, 2021
Liraglutide does not change bone turnover in clozapine- and olanzapine-treated schizophrenia overweight patients with prediabetes - randomized controlled trial.Psychiatry research, , Volume: 296, 2021
Efficacy and dropout rates of antipsychotic medications for methamphetamine psychosis: A systematic review and network meta-analysis.Drug and alcohol dependence, , 02-01, Volume: 219, 2021
The two-cell model of glucose metabolism: a hypothesis of schizophrenia.Molecular psychiatry, , Volume: 26, Issue:6, 2021
1MeTIQ and olanzapine, despite their neurochemical impact, did not ameliorate performance in fear conditioning and social interaction tests in an MK-801 rat model of schizophrenia.Pharmacological reports : PR, , Volume: 73, Issue:2, 2021
Therapeutic potential of TAK-071, a muscarinic MNeuroscience letters, , 11-01, Volume: 764, 2021
Increased Homotopic Connectivity in the Prefrontal Cortex Modulated by Olanzapine Predicts Therapeutic Efficacy in Patients with Schizophrenia.Neural plasticity, , Volume: 2021, 2021
A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials?Translational psychiatry, , 10-06, Volume: 11, Issue:1, 2021
New Antipsychotic Medications in the Last Decade.Current psychiatry reports, , 11-29, Volume: 23, Issue:12, 2021
Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia.Scientific reports, , 11-30, Volume: 11, Issue:1, 2021
Increased regional homogeneity modulated by metacognitive training predicts therapeutic efficacy in patients with schizophrenia.European archives of psychiatry and clinical neuroscience, , Volume: 271, Issue:4, 2021
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.CNS spectrums, , Volume: 26, Issue:4, 2021
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology, , Volume: 31, Issue:1, 2021
Interacting effects of the MAM model of schizophrenia and antipsychotic treatment: Untargeted proteomics approach in adipose tissue.Progress in neuro-psychopharmacology & biological psychiatry, , 06-08, Volume: 108, 2021
Amisulpride - is it as all other medicines or is it different? An update.Psychiatria polska, , Oct-31, Volume: 54, Issue:5, 2020
How Much of an Advance Is the Addition of Samidorphan to Olanzapine?The American journal of psychiatry, , 12-01, Volume: 177, Issue:12, 2020
The side effect profile of Clozapine in real world data of three large mental health hospitals.PloS one, , Volume: 15, Issue:12, 2020
Men and women respond differently to antipsychotic drugs.Neuropharmacology, , Volume: 163, 2020
Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects.Therapeutic drug monitoring, , Volume: 42, Issue:2, 2020
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.European archives of psychiatry and clinical neuroscience, , Volume: 270, Issue:1, 2020
Reduction in the prescription of Olanzapine as a first-line treatment for first episode psychosis following the implementation of clinical practice guidelines.Schizophrenia research, , Volume: 215, 2020
Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naive, first-episode schizophrenia: A global-brain functional connectivity analysis.Schizophrenia research, , Volume: 215, 2020
Open-Label, Randomized, Single-Dose, 2-Period, 2-Sequence Crossover, Comparative Pharmacokinetic Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine Under Fasting and Fed Conditions.Clinical pharmacology in drug development, , Volume: 9, Issue:5, 2020
Switching strategies for antipsychotic monotherapy in schizophrenia: a multi-center cohort study of aripiprazole.Psychopharmacology, , Volume: 237, Issue:1, 2020
Rosuvastatin improves olanzapine's effects on behavioral impairment and hippocampal, hepatic and metabolic damages in isolated reared male rats.Behavioural brain research, , 01-27, Volume: 378, 2020
Relationship between metabolic syndrome and acylated/desacylated ghrelin ratio in patients with schizophrenia under olanzapine medication.Journal of psychopharmacology (Oxford, England), , Volume: 34, Issue:1, 2020
In vivo 5-HTPsychiatry research. Neuroimaging, , 01-30, Volume: 295, 2020
Differential benefits of olanzapine on executive function in schizophrenia patients: Preliminary findings.Human psychopharmacology, , Volume: 35, Issue:1, 2020
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.The American journal of psychiatry, , 04-01, Volume: 177, Issue:4, 2020
In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine.The British journal of psychiatry : the journal of mental science, , Volume: 217, Issue:3, 2020
[Pharmacotherapy of schizophrenia].Der Nervenarzt, , Volume: 91, Issue:1, 2020
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.Clinical therapeutics, , Volume: 42, Issue:1, 2020
Memory deterioration based on the tobacco smoke exposure and methylazoxymethanol acetate administration vs. aripiprazole, olanzapine and enrichment environment conditions.Pharmacology, biochemistry, and behavior, , Volume: 189, 2020
Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.The international journal of neuropsychopharmacology, , 04-23, Volume: 23, Issue:4, 2020
Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.Progress in neuro-psychopharmacology & biological psychiatry, , 06-08, Volume: 100, 2020
Prolactin response to antipsychotics: An inpatient study.PloS one, , Volume: 15, Issue:2, 2020
The treatment of acute agitation associated with schizophrenia or bipolar disorder: investigational drugs in early stages of their clinical development, and their clinical context and potential place in therapy.Expert opinion on investigational drugs, , Volume: 29, Issue:3, 2020
A Retrospective Analysis of Steady-State Olanzapine Concentrations in Chinese Patients Using Therapeutic Drug Monitoring: Effects of Valproate and Other Factors.Therapeutic drug monitoring, , Volume: 42, Issue:4, 2020
The association of genetic polymorphisms in CYP1A2, UGT1A4, and ABCB1 with autonomic nervous system dysfunction in schizophrenia patients treated with olanzapine.BMC psychiatry, , 02-18, Volume: 20, Issue:1, 2020
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.The Journal of clinical psychiatry, , 03-03, Volume: 81, Issue:2, 2020
Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.The Journal of clinical psychiatry, , 03-10, Volume: 81, Issue:2, 2020
Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.The Journal of clinical psychiatry, , 03-17, Volume: 81, Issue:2, 2020
Metabolic Effects of 7 Antipsychotics on Patients With Schizophrenia: A Short-Term, Randomized, Open-Label, Multicenter, Pharmacologic Trial.The Journal of clinical psychiatry, , 03-24, Volume: 81, Issue:3, 2020
Comparative cost-effectiveness of amisulpride and olanzapine in the treatment of schizophrenia in China.Expert review of pharmacoeconomics & outcomes research, , Volume: 20, Issue:3, 2020
Remission Is not Associated with DRD2 rs1800497 and DAT1 rs28363170 Genetic Variants in Male Schizophrenic Patients after 6-months Monotherapy with Olanzapine.Psychiatria Danubina, ,Spring, Volume: 32, Issue:1, 2020
Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome.Brain, behavior, and immunity, , Volume: 88, 2020
Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine.International journal of psychiatry in clinical practice, , Volume: 24, Issue:3, 2020
Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia.Journal of clinical pharmacology, , Volume: 60, Issue:10, 2020
Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real-World Study Across Antipsychotics.Clinical and translational science, , Volume: 13, Issue:6, 2020
Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients.Drug development research, , Volume: 81, Issue:6, 2020
Blood plasma proteomic modulation induced by olanzapine and risperidone in schizophrenia patients.Journal of proteomics, , 07-30, Volume: 224, 2020
Neurocognitive effects of atypical antipsychotics in patients with first-episode schizophrenia.Nordic journal of psychiatry, , Volume: 74, Issue:8, 2020
Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia.Scientific reports, , 06-22, Volume: 10, Issue:1, 2020
[A case suspected of dystonia with marked cerebellar atrophy with torsion dystonia of the neck and cerebellar ataxia that developed during pharmacologic schizophrenia treatment].Rinsho shinkeigaku = Clinical neurology, , Aug-07, Volume: 60, Issue:8, 2020
Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial.Psychopharmacology, , Volume: 237, Issue:11, 2020
Cost-effectiveness of aripiprazole orally disintegrating tablets in the treatment of schizophrenia in China.Expert review of pharmacoeconomics & outcomes research, , Volume: 20, Issue:5, 2020
Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis.Journal of analytical toxicology, , Dec-12, Volume: 44, Issue:8, 2020
Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.The American journal of psychiatry, , 12-01, Volume: 177, Issue:12, 2020
FADS1 modulates metabolic syndrome in schizophrenia patients receiving olanzapine monotherapy.Asian journal of psychiatry, , Volume: 54, 2020
Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis.Journal of psychiatric research, , Volume: 129, 2020
Metabolic profile of methylazoxymethanol model of schizophrenia in rats and effects of three antipsychotics in long-acting formulation.Toxicology and applied pharmacology, , 11-01, Volume: 406, 2020
A randomized-controlled trial of blonanserin and olanzapine as adjunct to antipsychotics in the treatment of patients with schizophrenia and dopamine supersensitivity psychosis: The ROADS study.Asian journal of psychiatry, , Volume: 53, 2020
Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial.Schizophrenia research, , Volume: 223, 2020
Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis.Scientific reports, , 10-12, Volume: 10, Issue:1, 2020
What is the "best intro"-explanatory versus pragmatic antipsychotic drug trials.The lancet. Psychiatry, , Volume: 7, Issue:12, 2020
Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.The lancet. Psychiatry, , Volume: 7, Issue:11, 2020
Nitrogen and sulfur co-doped graphene quantum dots/nanocellulose nanohybrid for electrochemical sensing of anti-schizophrenic drug olanzapine in pharmaceuticals and human biological fluids.International journal of biological macromolecules, , Dec-15, Volume: 165, Issue:Pt B, 2020
The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial.Schizophrenia research, , Volume: 206, 2019
[Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year].L'Encephale, , Volume: 45, Issue:3, 2019
Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine.European archives of psychiatry and clinical neuroscience, , Volume: 269, Issue:8, 2019
Meta-analysis of ghrelin alterations in schizophrenia: Effects of olanzapine.Schizophrenia research, , Volume: 206, 2019
Effects of omega-3 fatty acids on metabolic syndrome in patients with schizophrenia: a 12-week randomized placebo-controlled trial.Psychopharmacology, , Volume: 236, Issue:4, 2019
Algorithm-based pharmacotherapy for first-episode schizophrenia involuntarily hospitalized: A retrospective analysis of real-world practice.Early intervention in psychiatry, , Volume: 13, Issue:1, 2019
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.Psychopharmacology, , Volume: 236, Issue:2, 2019
Association of blood cell counts with the risk of olanzapine- or clozapine-induced dyslipidemia in Chinese schizophrenia patients.Human psychopharmacology, , Volume: 34, Issue:4, 2019
The risk factors, frequency and diagnosis of atypical antipsychotic drug-induced hypothermia: practical advice for doctors.International clinical psychopharmacology, , Volume: 34, Issue:1, 2019
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.Toxicology and applied pharmacology, , 09-01, Volume: 378, 2019
Hummingbird Study: a study protocol for a multicentre exploratory trial to assess the acceptance and performance of a digital medicine system in adults with schizophrenia, schizoaffective disorder or first-episode psychosis.BMJ open, , 06-27, Volume: 9, Issue:6, 2019
Involuntary Facial Twitching in a Patient with Schizophrenia on Treatment with Long Acting Injectable Olanzapine.Psychopharmacology bulletin, , 06-20, Volume: 49, Issue:2, 2019
Acute followed by continuation right unilateral ultrabrief ECT for 12 months in first episode schizophrenia-a single case report.Asian journal of psychiatry, , Volume: 43, 2019
Hospitalization risk in patients with schizophrenia treated with dose-equivalent antipsychotics.The American journal of managed care, , Volume: 25, Issue:14 Suppl, 2019
Prefrontal Coexpression of Schizophrenia Risk Genes Is Associated With Treatment Response in Patients.Biological psychiatry, , 07-01, Volume: 86, Issue:1, 2019
Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.Medical decision making : an international journal of the Society for Medical Decision Making, , Volume: 39, Issue:5, 2019
Examination of heterogeneity in treatment response to antipsychotic medications.Schizophrenia research, , Volume: 211, 2019
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.Early intervention in psychiatry, , Volume: 13, Issue:3, 2019
Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life.Psychiatry research, , Volume: 276, 2019
Can typical and atypical antipsychotics show differential effectiveness in treating paranoia and hallucinations in schizophrenia?BMJ case reports, , Mar-31, Volume: 12, Issue:3, 2019
One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- or olanzapine-treated patients.Acta psychiatrica Scandinavica, , Volume: 139, Issue:1, 2019
Quantitative efficacy of three antipsychotic drugs for schizophrenia based on a real-world study in China.Acta pharmacologica Sinica, , Volume: 40, Issue:12, 2019
Effects of olanzapine during cognitive and emotional processing in schizophrenia: A review of functional magnetic resonance imaging findings.Human psychopharmacology, , Volume: 34, Issue:3, 2019
Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report.Journal of psychiatric practice, , Volume: 25, Issue:2, 2019
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.The American journal of psychiatry, , 06-01, Volume: 176, Issue:6, 2019
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons.Psychoneuroendocrinology, , Volume: 104, 2019
Ketogenic diet and olanzapine treatment alone and in combination reduce a pharmacologically-induced prepulse inhibition deficit in female mice.Schizophrenia research, , Volume: 212, 2019
Insulin resistance induced by olanzapine and other second-generation antipsychotics in Chinese patients with schizophrenia: a comparative review and meta-analysis.European journal of clinical pharmacology, , Volume: 75, Issue:12, 2019
Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.Schizophrenia research, , Volume: 212, 2019
An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes.Journal of psychopharmacology (Oxford, England), , Volume: 33, Issue:10, 2019
Risk Factors for Noncompliance with Antipsychotic Medication in Long-Term Treated Chronic Schizophrenia Patients.Psychiatria Danubina, , Volume: 31, Issue:Suppl 3, 2019
Effect of lurasidone vs olanzapine on neurotrophic biomarkers in unmedicated schizophrenia: A randomized controlled trial.Journal of psychiatric research, , Volume: 112, 2019
Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial.Medicine, , Volume: 98, Issue:38, 2019
[Amisulpride, a one-of-a-kind and highly efficacious antipsychotic agent in the treatment of first-episode psychosis].Nederlands tijdschrift voor geneeskunde, , 10-17, Volume: 163, 2019
An unusual bullous eruption: olanzapine induced pseudoporphyria.BMJ case reports, , Nov-02, Volume: 12, Issue:11, 2019
Antipsychotic drugs in epilepsy.Neurologia i neurochirurgia polska, , Volume: 53, Issue:6, 2019
Enhanced baseline activity in the left ventromedial putamen predicts individual treatment response in drug-naive, first-episode schizophrenia: Results from two independent study samples.EBioMedicine, , Volume: 46, 2019
Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial.Psychopharmacology, , Volume: 236, Issue:6, 2019
Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance.Scientific reports, , 02-07, Volume: 9, Issue:1, 2019
Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.Journal of medical economics, , Volume: 22, Issue:5, 2019
[Evidence-based treatment of acute psychotic episode and schizophrenia in children and adolescents].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 119, Issue:12, 2019
Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment.Expert opinion on pharmacotherapy, , Volume: 20, Issue:1, 2019
Butyl Methacrylate-Co-Ethylene Glycol Dimethacrylate Monolith for Online in-Tube SPME-UHPLC-MS/MS to Determine Chlopromazine, Clozapine, Quetiapine, Olanzapine, and Their Metabolites in Plasma Samples.Molecules (Basel, Switzerland), , Jan-16, Volume: 24, Issue:2, 2019
Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.Medicine, , Volume: 98, Issue:3, 2019
Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia.PloS one, , Volume: 13, Issue:7, 2018
Effects of ABCB1 gene polymorphisms on autonomic nervous system activity during atypical antipsychotic treatment in schizophrenia.BMC psychiatry, , 07-17, Volume: 18, Issue:1, 2018
Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.Applied health economics and health policy, , Volume: 16, Issue:5, 2018
Dorsal hand skin hyperpigmentation following oral olanzapine (Zyprexa) use.Contact dermatitis, , Volume: 79, Issue:4, 2018
Atypical Antipsychotic Administration in Schizophrenic Patients Leads to Elevated Lipoprotein-Associated Phospholipase A2 Levels and Increased Cardiovascular Risk: A Retrospective Cohort Study.Basic & clinical pharmacology & toxicology, , Volume: 123, Issue:6, 2018
Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.BMC psychiatry, , 12-04, Volume: 18, Issue:1, 2018
Inverse association between negative symptoms and body mass index in chronic schizophrenia.Schizophrenia research, , Volume: 192, 2018
Rapid remission of first-episode schizophrenia with standardised treatment.The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia.BMJ open, , 08-17, Volume: 8, Issue:8, 2018
Treatment effects of olanzapine on homotopic connectivity in drug-free schizophrenia at rest.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 19, Issue:sup3, 2018
Effects of four atypical antipsychotics on autonomic nervous system activity in schizophrenia.Schizophrenia research, , Volume: 193, 2018
The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.The pharmacogenomics journal, , 05-22, Volume: 18, Issue:3, 2018
The validity and sensitivity of PANSS-6 in treatment-resistant schizophrenia.Acta psychiatrica Scandinavica, , Volume: 138, Issue:5, 2018
Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis.BMC psychiatry, , 09-05, Volume: 18, Issue:1, 2018
A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-02, Volume: 81, 2018
One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia.Psychiatry research, , Volume: 270, 2018
[Schizophrenia and antipsychotics: Metabolic alterations and therapeutic effectivity].Vertex (Buenos Aires, Argentina), , Volume: 29, Issue:138, 2018
Understanding the influence of antipsychotic drugs on global methylation events and its relevance in treatment response.Epigenomics, , Volume: 10, Issue:3, 2018
The incidence, psychiatric co-morbidity and pharmacological treatment of severe mental disorders in children and adolescents.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 49, 2018
Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study.Psychopharmacology, , Volume: 235, Issue:4, 2018
Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , 06-08, Volume: 84, Issue:Pt A, 2018
Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.The Cochrane database of systematic reviews, , Jan-22, Volume: 1, 2018
Metabolic risk factors in schizophrenia and bipolar disorder: The effect of comedication with selective serotonin reuptake inhibitors and antipsychotics.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 48, 2018
Frontal activity measured by near-infrared spectroscopy in patients taking different atypical antipsychotic drugs: A cross-sectional study.Psychiatry research. Neuroimaging, , 03-30, Volume: 273, 2018
Switch-associated adverse events: focus on olanzapine.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 26, Issue:6, 2018
Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study.Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5, 2018
Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.Psychopharmacology, , Volume: 235, Issue:12, 2018
Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction?Journal of psychiatric practice, , Volume: 24, Issue:2, 2018
Importance of intervention timing in the effectiveness of antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-02, Volume: 81, 2018
Schizophrenia-like olfactory dysfunction induced by acute and postnatal phencyclidine exposure in rats.Schizophrenia research, , Volume: 199, 2018
Impact of histamine receptors H1 and H3 polymorphisms on antipsychotic-induced weight gain.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 19, Issue:sup3, 2018
Early prediction of olanzapine-induced weight gain for schizophrenia patients.Psychiatry research, , Volume: 263, 2018
Antipsychotic treatments: who is really failing here?The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Long-acting olanzapine injection during pregnancy and breastfeeding: a case report.Archives of women's mental health, , Volume: 21, Issue:5, 2018
Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.Schizophrenia bulletin, , 10-17, Volume: 44, Issue:6, 2018
[The effect of antipsychotic drug on monoamine receptors in peripheral blood mononuclear cells: affinity linked mechanism].Biomeditsinskaia khimiia, , Volume: 64, Issue:2, 2018
Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.Clinical therapeutics, , Volume: 40, Issue:11, 2018
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.Journal of clinical psychopharmacology, , Volume: 38, Issue:6, 2018
Olanzapine, blonanserin, and aripiprazole associated with different frontostriatal reward system activation in patients with schizophrenia.Schizophrenia research, , Volume: 197, 2018
Antipsychotic treatments: who is really failing here? - Authors' reply.The lancet. Psychiatry, , Volume: 5, Issue:10, 2018
Evaluation of antioxidant potencial of novel CaAl and NiAl layered double hydroxides loaded with olanzapine.Life sciences, , Aug-15, Volume: 207, 2018
Relationship between antipsychotic blood levels and treatment failure during the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.Schizophrenia research, , Volume: 201, 2018
A Longitudinal Study of Alterations of S100B, sRAGE and Fas Ligand in Association to Olanzapine Medication in a Sample of First Episode Patients with Schizophrenia.CNS & neurological disorders drug targets, , Volume: 17, Issue:5, 2018
High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.BMC psychiatry, , 06-08, Volume: 18, Issue:1, 2018
Multidisciplinary Management of Adolescent Early-Onset, Treatment-Resistant Schizophrenia Complicated by Avoidant/Restrictive Food Intake Disorder and Catatonia in Acute Exacerbations.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:9, 2018
Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:7, 2018
Recurrent Hyperammonemia Associated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 37, Issue:3, 2017
Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Jun-15, Volume: 104, 2017
Pharmacoepigenomic responses of antipsychotic drugs on pharmacogenes are likely to be modulated by miRNAs.Epigenomics, , Volume: 9, Issue:6, 2017
Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia.Psychiatria polska, , Feb-26, Volume: 51, Issue:1, 2017
Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.Psychoneuroendocrinology, , Volume: 81, 2017
A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy.Nordic journal of psychiatry, , Volume: 71, Issue:6, 2017
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.Psychopharmacology, , Volume: 234, Issue:17, 2017
Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.Human psychopharmacology, , Volume: 32, Issue:4, 2017
Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study.Psychiatry research, , Volume: 255, 2017
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.JAMA psychiatry, , 07-01, Volume: 74, Issue:7, 2017
Olanzapine modulates the default-mode network homogeneity in recurrent drug-free schizophrenia at rest.The Australian and New Zealand journal of psychiatry, , Volume: 51, Issue:10, 2017
Ketamine-induced behavioural and brain oxidative changes in mice: an assessment of possible beneficial effects of zinc as mono- or adjunct therapy.Psychopharmacology, , Volume: 234, Issue:18, 2017
Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study.PloS one, , Volume: 12, Issue:6, 2017
Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders.Psychopharmacology bulletin, , 05-15, Volume: 47, Issue:2, 2017
Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.Psychiatria Danubina, , Volume: 29, Issue:2, 2017
Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study.Nordic journal of psychiatry, , Volume: 71, Issue:7, 2017
Follow-up study of patients treated with olanzapine pamoate in France in real-life treatment situation.L'Encephale, , Volume: 43, Issue:4, 2017
Sleepwalking Is Associated With Coadministration of Olanzapine and Propranolol: A Case Report.Journal of clinical psychopharmacology, , Volume: 37, Issue:5, 2017
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.Journal of medical economics, , Volume: 20, Issue:11, 2017
Effects of haloperidol, olanzapine, ziprasidone, and PHA-543613 on spatial learning and memory in the Morris water maze test in naïve and MK-801-treated mice.Brain and behavior, , Volume: 7, Issue:8, 2017
The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.Acta psychiatrica Scandinavica, , Volume: 136, Issue:5, 2017
Dilemma of treating schizophrenia during pregnancy: a Case series and a review of literature.BMC psychiatry, , 08-29, Volume: 17, Issue:1, 2017
Roman high and low avoidance rats differ in their response to chronic olanzapine treatment at the level of body weight regulation, glucose homeostasis, and cortico-mesolimbic gene expression.Journal of psychopharmacology (Oxford, England), , Volume: 31, Issue:11, 2017
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.Clinical therapeutics, , Volume: 39, Issue:10, 2017
Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.Journal of psychiatric research, , Volume: 95, 2017
Liraglutide for the Treatment of Antipsychotic Drug-Induced Weight Gain.JAMA psychiatry, , 11-01, Volume: 74, Issue:11, 2017
The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis.BMC psychiatry, , 11-21, Volume: 17, Issue:1, 2017
Occurrence of post-injection delirium/sedation syndrome after application of olanzapine long-acting injection during one year period.Psychiatria Danubina, , Volume: 29, Issue:4, 2017
Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.Journal of clinical psychopharmacology, , Volume: 37, Issue:3, 2017
Dhat syndrome as the prodrome of schizophrenia: Understanding the cultural distress.Asian journal of psychiatry, , Volume: 25, 2017
Leukocyte telomere length in Hispanic schizophrenia patients under treatment with olanzapine.Journal of psychiatric research, , Volume: 90, 2017
Real-world Effectiveness of Antipsychotics for the Treatment of Negative Symptoms in Patients with Schizophrenia with Predominantly Negative Symptoms.Pharmacopsychiatry, , Volume: 50, Issue:2, 2017
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.Internal medicine (Tokyo, Japan), , Volume: 56, Issue:3, 2017
A Case of Olanzapine-Induced Fever.Psychopharmacology bulletin, , 01-26, Volume: 47, Issue:1, 2017
Atypical Antipsychotics and the Risks of Acute Kidney Injury and Related Outcomes Among Older Adults: A Replication Analysis and an Evaluation of Adapted Confounding Control Strategies.Drugs & aging, , Volume: 34, Issue:3, 2017
A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia.Schizophrenia research, , Volume: 185, 2017
Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.Current medical research and opinion, , Volume: 33, Issue:5, 2017
Genetic and epigenetic regulation on the transcription of GABRB2: Genotype-dependent hydroxymethylation and methylation alterations in schizophrenia.Journal of psychiatric research, , Volume: 88, 2017
[Treatment-resistant schizophrenia: Neutropenia with olanzapine and clozapine, and stabilization with two depot antipsychotics].Vertex (Buenos Aires, Argentina), , Volume: 28, Issue:132, 2017
Prescription preferences in antipsychotics and attitude towards the pharmaceutical industry in Belgium.Journal of medical ethics, , Volume: 43, Issue:6, 2017
Olanzapine modulation of long- and short-range functional connectivity in the resting brain in a sample of patients with schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 27, Issue:1, 2017
Relative risks of cardiovascular disease in people prescribed olanzapine, risperidone and quetiapine.Schizophrenia research, , Volume: 183, 2017
Level of serum thioredoxin and correlation with neurocognitive functions in patients with schizophrenia using clozapine and other atypical antipsychotics.Psychiatry research, , Volume: 247, 2017
The atypical antipsychotic olanzapine disturbs depotentiation by modulating mAChRs and impairs reversal learning.Neuropharmacology, , 03-01, Volume: 114, 2017
An assessor-blinded, randomized comparison of efficacy and tolerability of switching from olanzapine to ziprasidone and the combination of both in schizophrenia spectrum disorders.Journal of psychiatric research, , Volume: 85, 2017
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.Psychopharmacology, , Volume: 234, Issue:1, 2017
An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia.Psychiatric services (Washington, D.C.), , 03-01, Volume: 68, Issue:3, 2017
Cognition and Dopamine DThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 25, Issue:1, 2017
A patient with schizophrenia presenting with post-lobotomy catatonia treated with olanzapine: a case report.Psychogeriatrics : the official journal of the Japanese Psychogeriatric Society, , Volume: 17, Issue:3, 2017
[Post-injection syndrome and olanzapine pamoate: A severe case report].L'Encephale, , Volume: 43, Issue:4, 2017
Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.Schizophrenia research, , Volume: 176, Issue:2-3, 2016
Clinical Correlates of Oral Glucose Tolerance Test Performance in Olanzapine-Treated Patients with Schizophrenia or Schizoaffective Disorder.The Journal of clinical psychiatry, , Volume: 77, Issue:12, 2016
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.The Journal of clinical psychiatry, , Volume: 77, Issue:12, 2016
Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study.Acta medica Iranica, , Volume: 54, Issue:11, 2016
Dimensions of schizophrenia and their time course of response to a second generation antipsychotic olanzapine-A clinical study.Asian journal of psychiatry, , Volume: 24, 2016
Haloperidol for long-term aggression in psychosis.The Cochrane database of systematic reviews, , 11-27, Volume: 11, 2016
The effects of olanzapine treatment on brain regional glucose metabolism in neuroleptic-naive first-episode schizophrenic patients.Human psychopharmacology, , Volume: 31, Issue:6, 2016
Trends in the Outpatient Utilization of Antipsychotic Drugs in the City of Zagreb in the Ten-Year Period as a Tool to Assess Drug Prescribing Rationality.Psychiatria Danubina, , Volume: 28, Issue:4, 2016
Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.The Journal of clinical psychiatry, , Volume: 77, Issue:10, 2016
[Cognitive effectiveness of risperidone and olanzapine in first-episode schizophrenia].Zhonghua yi xue za zhi, , Oct-11, Volume: 96, Issue:37, 2016
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.CNS spectrums, , Volume: 21, Issue:6, 2016
First and second generation antipsychotics differentially affect structural and functional properties of rat hippocampal neuron synapses.Neuroscience, , Nov-19, Volume: 337, 2016
LAI versus oral: A case-control study on subjective experience of antipsychotic maintenance treatment.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 37, 2016
Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats.Pharmacological reports : PR, , Volume: 68, Issue:5, 2016
Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study.Acta psychiatrica Scandinavica, , Volume: 134, Issue:5, 2016
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Jul-02, Volume: 7, 2016
The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia.Psychiatric services (Washington, D.C.), , 12-01, Volume: 67, Issue:12, 2016
Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.Clinical pharmacology in drug development, , Volume: 5, Issue:6, 2016
Asenapine: A Review in Schizophrenia.CNS drugs, , Volume: 30, Issue:7, 2016
Delirium with anticholinergic symptoms after a combination of paliperidone and olanzapine pamoate in a patient known to smoke cannabis: an unfortunate coincidence.BMJ case reports, , Jun-22, Volume: 2016, 2016
Post authorization safety study comparing quetiapine to risperidone and olanzapine.Human psychopharmacology, , Volume: 31, Issue:4, 2016
Fluoxetine Adjunctive Therapy for Obsessive-Compulsive Symptoms Associated With Olanzapine in Schizophrenic Patients.Journal of clinical psychopharmacology, , Volume: 36, Issue:4, 2016
[The effects of blood serum from schizophrenia patients under olanzapine monotherapy on the ultrastructure of astrocytes in human fetal brain organotypic culture].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 116, Issue:5, 2016
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.Journal of medical economics, , Volume: 19, Issue:9, 2016
Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis.European journal of clinical pharmacology, , Volume: 72, Issue:8, 2016
Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine.Translational psychiatry, , Apr-19, Volume: 6, 2016
A Case Report: Anti-Psychotic Agents Related Ocular Toxicity.Medicine, , Volume: 95, Issue:15, 2016
Risperidone (depot) for schizophrenia.The Cochrane database of systematic reviews, , Apr-14, Volume: 4, 2016
[Treatment-resistant psychosis due to interaction between ritonavir and olanzapine: case report and literature review].Tijdschrift voor psychiatrie, , Volume: 58, Issue:4, 2016
Chlorpromazine versus atypical antipsychotic drugs for schizophrenia.The Cochrane database of systematic reviews, , Apr-05, Volume: 4, 2016
Multiple Long-Acting Injectable Antipsychotics for Treatment-Resistant Schizophrenia: Case Report.Journal of clinical psychopharmacology, , Volume: 36, Issue:3, 2016
Did FDA Decisionmaking Affect Anti-Psychotic Drug Prescribing in Children?: A Time-Trend Analysis.PloS one, , Volume: 11, Issue:3, 2016
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Betahistine to Counteract Olanzapine-Associated Weight Gain.Journal of clinical psychopharmacology, , Volume: 36, Issue:3, 2016
Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.Clinical trials (London, England), , Volume: 13, Issue:3, 2016
Eosinophilic myocarditis during treatment with olanzapine - report of two possible cases.BMC psychiatry, , Mar-17, Volume: 16, 2016
Association between SCAP and SREBF1 gene polymorphisms and metabolic syndrome in schizophrenia patients treated with atypical antipsychotics.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 17, Issue:6, 2016
Altered expression of developmental regulators of parvalbumin and somatostatin neurons in the prefrontal cortex in schizophrenia.Schizophrenia research, , Volume: 177, Issue:1-3, 2016
Antipsychotic Drugs Differentially Affect mRNA Expression of Genes Encoding the Neuregulin 1-Downstream ErbB4-PI3K Pathway.Pharmacology, , Volume: 98, Issue:1-2, 2016
Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia.PloS one, , Volume: 11, Issue:3, 2016
Plasma metabonomics study of first-Episode schizophrenia treated with olanzapine in female patients.Neuroscience letters, , Mar-23, Volume: 617, 2016
The influence of aripiprazole and olanzapine on the anxiolytic-like effect observed in prenatally stressed rats (animal model of schizophrenia) exposed to the ethyl alcohol.Pharmacological reports : PR, , Volume: 68, Issue:2, 2016
Eosinophilia Associated With Olanzapine.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia.Psychopharmacology, , Volume: 233, Issue:8, 2016
Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.PloS one, , Volume: 11, Issue:2, 2016
Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.JAMA psychiatry, , Volume: 73, Issue:3, 2016
Effects of antipsychotics on insight in schizophrenia: results from independent samples of first-episode and acutely relapsed patients.International clinical psychopharmacology, , Volume: 31, Issue:4, 2016
Antipsychotic prescribing and its correlates in New Zealand.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 24, Issue:4, 2016
A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine.Journal of psychiatric practice, , Volume: 22, Issue:1, 2016
Olanzapine Prevents the PCP-induced Reduction in the Neurite Outgrowth of Prefrontal Cortical Neurons via NRG1.Scientific reports, , Jan-19, Volume: 6, 2016
Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.Expert opinion on drug safety, , Volume: 15, Issue:3, 2016
Tyrosine hydroxylase localization in the nucleus accumbens in schizophrenia.Brain structure & function, , Volume: 221, Issue:9, 2016
Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 31, 2016
Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients.Brain, behavior, and immunity, , Volume: 52, 2016
Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?Nordic journal of psychiatry, , Volume: 70, Issue:3, 2016
Association of orexin receptor polymorphisms with antipsychotic-induced weight gain.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 17, Issue:3, 2016
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.Journal of medical economics, , Volume: 19, Issue:2, 2016
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.Acta psychiatrica Scandinavica, , Volume: 133, Issue:1, 2016
Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.Schizophrenia bulletin, , Volume: 42, Issue:1, 2016
Quality of Life and Hormonal, Biochemical, and Anthropometric Profile Between Olanzapine and Risperidone Users.The Psychiatric quarterly, , Volume: 87, Issue:2, 2016
Olanzapine vs. Risperidone in Schizophrenia: A Cross-sectional Comparison of Quality of Life of Caregivers.Indian journal of physiology and pharmacology, , Volume: 60, Issue:2, 2016
Efficacy of ranitidine in olanzapine-induced weight gain: a dose-response study.Early intervention in psychiatry, , Volume: 10, Issue:6, 2016
[Treatment of Olanzapine-induced Hyperprolactinemia by Shaoyao Gancao Decoction].Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, , Volume: 36, Issue:12, 2016
[Using the cumulative odds Logit model to explore the application of the questionnaire derived from PANSS].Yao xue xue bao = Acta pharmaceutica Sinica, , Volume: 51, Issue:10, 2016
Lower phosphorylated glycogen synthase kinase-3B levels in platelets of patients with schizophrenia: increment by olanzapine treatment.European archives of psychiatry and clinical neuroscience, , Volume: 265, Issue:2, 2015
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:11, 2015
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.The journal of mental health policy and economics, , Volume: 18, Issue:4, 2015
Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.The Journal of clinical psychiatry, , Volume: 76, Issue:11, 2015
Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.BMC psychiatry, , Nov-13, Volume: 15, 2015
Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study.Pharmacopsychiatry, , Volume: 48, Issue:7, 2015
Heat stroke during treatment with olanzapine, trihexyphenidyl, and trazodone in a patient with schizophrenia.Acta neuropsychiatrica, , Volume: 27, Issue:6, 2015
What evidence is there to show which antipsychotics are more diabetogenic than others?Psychiatria Danubina, , Volume: 27 Suppl 1, 2015
[The perception gap between clinical trials and clinical practice].Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology, , Volume: 28, Issue:1, 2015
Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.Journal of child and adolescent psychopharmacology, , Volume: 25, Issue:7, 2015
[Clozapine and Olanzapine Associated Atrial Fibrillation: A Case Report].Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Fall, Volume: 26, Issue:3, 2015
[Eating disorders in psychiatric patients during treatment with second generation antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:7, 2015
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients.Neuropsychobiology, , Volume: 72, Issue:1, 2015
Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats.Journal of biomedical nanotechnology, , Volume: 11, Issue:8, 2015
Mucoadhesive Amphiphilic Methacrylic Copolymer-Functionalized Poly(ε-caprolactone) Nanocapsules for Nose-to-Brain Delivery of Olanzapine.Journal of biomedical nanotechnology, , Volume: 11, Issue:8, 2015
Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study.BMC psychiatry, , Aug-05, Volume: 15, 2015
A double amino-acid change in the HLA-A peptide-binding groove is associated with response to psychotropic treatment in patients with schizophrenia.Translational psychiatry, , Jul-28, Volume: 5, 2015
Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia.BMC psychiatry, , Jul-25, Volume: 15, 2015
Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.JAMA psychiatry, , Volume: 72, Issue:9, 2015
A2BP1 gene polymorphisms association with olanzapine-induced weight gain.Pharmacological research, , Volume: 99, 2015
Olanzapine-Induced Reversible Pellagroid Skin Lesion.Current drug safety, , Volume: 10, Issue:3, 2015
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.The Journal of nervous and mental disease, , Volume: 203, Issue:7, 2015
Treating Schizophrenia With 2 Long-Acting Injectable Antipsychotic Drugs: A Case Report.Journal of clinical psychopharmacology, , Volume: 35, Issue:4, 2015
Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.Brain research, , Aug-27, Volume: 1618, 2015
Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia.Schizophrenia research, , Volume: 166, Issue:1-3, 2015
Olanzapine and risperidone plasma concentration therapeutic drug monitoring: A feasibility study.Journal of psychopharmacology (Oxford, England), , Volume: 29, Issue:8, 2015
Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.European child & adolescent psychiatry, , Volume: 24, Issue:12, 2015
Olanzapine-induced acute pancreatitis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, , Volume: 26, Issue:3, 2015
Altered expression of CDC42 signaling pathway components in cortical layer 3 pyramidal cells in schizophrenia.Biological psychiatry, , Dec-01, Volume: 78, Issue:11, 2015
Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.Psychopharmacology, , Volume: 232, Issue:17, 2015
A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.Applied health economics and health policy, , Volume: 13, Issue:5, 2015
Salience network and olanzapine in schizophrenia: implications for treatment in anorexia nervosa.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 60, Issue:3 Suppl 2, 2015
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.BMC psychiatry, , Apr-02, Volume: 15, 2015
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.Bipolar disorders, , Volume: 17, Issue:5, 2015
Generic Olanzapine Substitution in Patients With Schizophrenia: Assessment of Serum Concentrations and Therapeutic Response After Switching.Therapeutic drug monitoring, , Volume: 37, Issue:6, 2015
Effects of olanzapine on serum protein phosphorylation patterns in patients with schizophrenia.Proteomics. Clinical applications, , Volume: 9, Issue:9-10, 2015
Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.Journal of the Formosan Medical Association = Taiwan yi zhi, , Volume: 114, Issue:5, 2015
Olanzapine: evaluation of the in vivo cytogenetic effect.Human psychopharmacology, , Volume: 30, Issue:3, 2015
The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.Schizophrenia bulletin, , Volume: 41, Issue:3, 2015
Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?Basic & clinical pharmacology & toxicology, , Volume: 117, Issue:3, 2015
Clozapine revisited: Impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 27, Issue:2, 2015
Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis.TheScientificWorldJournal, , Volume: 2015, 2015
Effectiveness of different dosing regimens of risperidone and olanzapine in schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 25, Issue:3, 2015
Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain.Psychiatry research, , Feb-28, Volume: 225, Issue:3, 2015
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.Schizophrenia research, , Volume: 161, Issue:2-3, 2015
"Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels.International journal of psychiatry in clinical practice, , Volume: 19, Issue:2, 2015
Pregnancy exposure to olanzapine, quetiapine, risperidone, aripiprazole and risk of congenital malformations. A systematic review.Basic & clinical pharmacology & toxicology, , Volume: 116, Issue:4, 2015
Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin.Progress in neuro-psychopharmacology & biological psychiatry, , Apr-03, Volume: 58, 2015
Olanzapine-induced DNA methylation in the hippocampus and cerebellum in genes mapped to human 22q11 and implicated in schizophrenia.Psychiatric genetics, , Volume: 25, Issue:2, 2015
"Schizophrenia past clozapine": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing.Pharmacopsychiatry, , Volume: 48, Issue:1, 2015
Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.JAMA psychiatry, , Volume: 72, Issue:1, 2015
Anandamide is involved in appetite-related amygdala hyperactivations in schizophrenia patients treated with olanzapine: a functional magnetic resonance imaging study.Journal of clinical psychopharmacology, , Volume: 35, Issue:1, 2015
Switching to iloperidone: An omnibus of clinically relevant observations from a 12-week, open-label, randomized clinical trial in 500 persons with schizophrenia.Clinical schizophrenia & related psychoses, , Volume: 8, Issue:4, 2015
Management of depressive symptoms in schizophrenia.Clinical schizophrenia & related psychoses, , Volume: 9, Issue:1, 2015
GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine.The Journal of neuropsychiatry and clinical neurosciences, , Volume: 27, Issue:2, 2015
Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.Journal of psychiatry & neuroscience : JPN, , Volume: 40, Issue:2, 2015
Electroconvulsive in a Schizophrenic Patient With Neuroleptic Malignant Syndrome and Rhabdomyolysis.The journal of ECT, , Volume: 31, Issue:3, 2015
CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.Therapeutic drug monitoring, , Volume: 37, Issue:2, 2015
Olanzapine-induced triglyceride and aminotransferase elevations without weight gain or hyperglycemia normalized after switching to aripiprazole.Journal of psychiatric practice, , Volume: 20, Issue:4, 2014
[Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].Tijdschrift voor psychiatrie, , Volume: 56, Issue:4, 2014
Quality of life in patients with schizophrenia: the impact of socio-economic factors and adverse effects of atypical antipsychotics drugs.The Psychiatric quarterly, , Volume: 85, Issue:3, 2014
Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 34, Issue:4, 2014
Effects of antipsychotic drugs on insight in schizophrenia.Psychiatry research, , Aug-15, Volume: 218, Issue:1-2, 2014
Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia.Psychiatry research, , Aug-15, Volume: 218, Issue:1-2, 2014
Blonanserin improved dystonia induced by risperidone or olanzapine in two patients with schizophrenia.The Journal of neuropsychiatry and clinical neurosciences, , Apr-01, Volume: 26, Issue:2, 2014
A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior.Journal of clinical psychopharmacology, , Volume: 34, Issue:3, 2014
Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain.Human psychopharmacology, , Volume: 29, Issue:4, 2014
A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 24, Issue:7, 2014
Completed and attempted suicides among 18,154 subjects with schizophrenia included in a large simple trial.The Journal of clinical psychiatry, , Volume: 75, Issue:3, 2014
[Antipsychotic-induced priapism and management challenges: a case report].L'Encephale, , Volume: 40, Issue:6, 2014
Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial.BMJ open, , Mar-25, Volume: 4, Issue:3, 2014
[Ultrastructural changes in platelets and their relationship with serotonin metabolism in patients with schizophrenia treated with olanzapine].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 114, Issue:2, 2014
Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.The Journal of clinical psychiatry, , Volume: 75, Issue:6, 2014
Association between serum testosterone levels, body mass index (BMI) and insulin in male patients with schizophrenia treated with atypical antipsychotics--olanzapine or risperidone.Neuro endocrinology letters, , Volume: 35, Issue:1, 2014
Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain.Pharmacogenomics, , Volume: 15, Issue:4, 2014
Do prior authorization policies discourage first-line antipsychotic use in patients newly discharged from a hospitalization for schizophrenia in Saskatchewan?Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, , Volume: 21, Issue:1, 2014
Olanzapine ameliorates neuropathological changes and increases IGF-1 expression in frontal cortex of C57BL/6 mice exposed to cuprizone.Psychiatry research, , May-30, Volume: 216, Issue:3, 2014
Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.Journal of psychiatric research, , Volume: 53, 2014
Cost-effectiveness analysis: a proposal of new reporting standards in statistical analysis.Journal of biopharmaceutical statistics, , Volume: 24, Issue:2, 2014
Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients.Psychopharmacology, , Volume: 231, Issue:18, 2014
Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine.BMJ open, , Mar-04, Volume: 4, Issue:3, 2014
No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients.Pharmacogenetics and genomics, , Volume: 24, Issue:5, 2014
Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment.Schizophrenia research, , Volume: 154, Issue:1-3, 2014
Atypical antipsychotics and hyperglycemic emergencies: multicentre, retrospective cohort study of administrative data.Schizophrenia research, , Volume: 154, Issue:1-3, 2014
Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia.Expert review of pharmacoeconomics & outcomes research, , Volume: 14, Issue:2, 2014
Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.BMC psychiatry, , Feb-23, Volume: 14, 2014
A trial evaluating gradual- or immediate-switch strategies from risperidone, olanzapine, or aripiprazole to iloperidone in patients with schizophrenia.Schizophrenia research, , Volume: 153, Issue:1-3, 2014
The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.Journal of clinical psychopharmacology, , Volume: 34, Issue:2, 2014
Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment.International journal of methods in psychiatric research, , Volume: 23, Issue:4, 2014
Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.The Journal of clinical psychiatry, , Volume: 75, Issue:3, 2014
Safety of antipsychotic drugs: focus on therapeutic and adverse effects.Expert opinion on drug safety, , Volume: 13, Issue:8, 2014
Quantitative drug benefit-risk assessment: utility of modeling and simulation to optimize drug safety in older adults.The Annals of pharmacotherapy, , Volume: 48, Issue:3, 2014
Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:4, 2014
A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.Human psychopharmacology, , Volume: 29, Issue:1, 2014
A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.BMC psychiatry, , Jan-14, Volume: 14, 2014
Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia.Psychiatry and clinical neurosciences, , Volume: 68, Issue:5, 2014
A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 24, Issue:3, 2014
Fatal water intoxication during olanzapine treatment: a case report.Legal medicine (Tokyo, Japan), , Volume: 16, Issue:2, 2014
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.The Journal of nervous and mental disease, , Volume: 202, Issue:1, 2014
Rapid tranquilization of severely agitated patients with schizophrenia spectrum disorders: a naturalistic, rater-blinded, randomized, controlled study with oral haloperidol, risperidone, and olanzapine.Journal of clinical psychopharmacology, , Volume: 34, Issue:1, 2014
Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature.Schizophrenia research, , Volume: 152, Issue:1, 2014
Predictive value of prospective memory for remission in first-episode schizophrenia.Perspectives in psychiatric care, , Volume: 50, Issue:2, 2014
Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.CNS spectrums, , Volume: 19, Issue:5, 2014
Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 17, Issue:4, 2014
Effects of olanzapine on the PR and QT intervals in patients with schizophrenia.Schizophrenia research, , Volume: 152, Issue:1, 2014
Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.Nordic journal of psychiatry, , Volume: 68, Issue:6, 2014
Predictors of response to second generation antipsychotics in drug naïve patients with schizophrenia: a 1 year follow-up study in Shanghai.Psychiatry research, , Jan-30, Volume: 215, Issue:1, 2014
The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.Journal of psychopharmacology (Oxford, England), , Volume: 28, Issue:4, 2014
Elevated viral restriction factor levels in cortical blood vessels in schizophrenia.Biological psychiatry, , Jul-15, Volume: 76, Issue:2, 2014
Olanzapine postinjection delirium/sedation syndrome: an unrecognized diagnosis in the emergency department.The Journal of emergency medicine, , Volume: 47, Issue:1, 2014
A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 39, Issue:6, 2014
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.CNS spectrums, , Volume: 19, Issue:4, 2014
Saffron aqueous extract prevents metabolic syndrome in patients with schizophrenia on olanzapine treatment: a randomized triple blind placebo controlled study.Pharmacopsychiatry, , Volume: 47, Issue:4-5, 2014
Can an early weight management program (WMP) prevent olanzapine (OLZ)-induced disturbances in body weight, blood glucose and lipid metabolism? Twenty-four- and 48-week results from a 6-month randomized trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 15, Issue:3, 2014
Metabolic changes in first-episode early-onset schizophrenia with second-generation antipsychotics.Early intervention in psychiatry, , Volume: 8, Issue:3, 2014
Depression and impulsivity as pathways to violence: implications for antiaggressive treatment.Schizophrenia bulletin, , Volume: 40, Issue:4, 2014
Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia.British journal of clinical pharmacology, , Volume: 77, Issue:5, 2014
Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 34, Issue:4, 2014
Comparison of health services use associated with ziprasidone and olanzapine among schizophrenia and bipolar disorder patients in the USA.Clinical drug investigation, , Volume: 34, Issue:7, 2014
Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.International clinical psychopharmacology, , Volume: 29, Issue:6, 2014
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6, 2014
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.Journal of medicinal chemistry, , Nov-26, Volume: 57, Issue:22, 2014
Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.Clinical schizophrenia & related psychoses, , Volume: 7, Issue:4, 2014
Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.Psychological medicine, , Volume: 44, Issue:1, 2014
[Ultrastructural changes in platelets of schizophrenia patients: a link with serotonin metabolism and therapeutic efficacy].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 114, Issue:11, 2014
[Post-injection syndrome after depot injection of olanzapine].Nederlands tijdschrift voor geneeskunde, , Volume: 159, 2014
Topiramate improves psychiatric symptoms in a patient with Lewy body dementia.Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, , Volume: 27, Issue:4, 2014
Schizophrenia gene expression profile reverted to normal levels by antipsychotics.The international journal of neuropsychopharmacology, , Oct-31, Volume: 18, Issue:4, 2014
Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: evidence from heart rate variability analysis.Scientific reports, , Dec-09, Volume: 4, 2014
The Chinese First-Episode Schizophrenia Trial: background and study design.East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 24, Issue:4, 2014
Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.Schizophrenia research, , Volume: 160, Issue:1-3, 2014
Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.BMC psychiatry, , Dec-02, Volume: 14, 2014
SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.Pharmacogenomics, , Volume: 15, Issue:12, 2014
Cannabis and schizophrenia.The Cochrane database of systematic reviews, , Oct-14, Issue:10, 2014
Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.European journal of clinical pharmacology, , Volume: 70, Issue:12, 2014
Use of very-high-dose olanzapine in treatment-resistant schizophrenia.Schizophrenia research, , Volume: 159, Issue:2-3, 2014
Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments.Schizophrenia research, , Volume: 159, Issue:2-3, 2014
HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.International journal of psychiatry in clinical practice, , Volume: 18, Issue:4, 2014
Dose reduction of risperidone and olanzapine and estimated dopamine D₂ receptor occupancy in stable patients with schizophrenia: findings from an open-label, randomized, controlled study.The Journal of clinical psychiatry, , Volume: 75, Issue:11, 2014
Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.Schizophrenia research, , Volume: 158, Issue:1-3, 2014
Second-generation antipsychotic medications and risk of pneumonia in schizophrenia.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
A comparison of the PANSS pentagonal and Van Der Gaag 5-factor models for assessing change over time.Psychiatry research, , May-15, Volume: 207, Issue:1-2, 2013
In vivo pharmacological evaluations of novel olanzapine analogues in rats: a potential new avenue for the treatment of schizophrenia.PloS one, , Volume: 8, Issue:12, 2013
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.The Journal of clinical psychiatry, , Volume: 74, Issue:11, 2013
Quetiapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Nov-18, Issue:11, 2013
Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.Clinical therapeutics, , Volume: 35, Issue:12, 2013
Efficacy and safety of long acting injectable atypical antipsychotics: a review.Current clinical pharmacology, , Volume: 8, Issue:3, 2013
Atypical antipsychotics for psychosis in adolescents.The Cochrane database of systematic reviews, , Oct-15, Issue:10, 2013
Mirtazapine add-on improves olanzapine effect on negative symptoms of schizophrenia.Journal of clinical psychopharmacology, , Volume: 33, Issue:6, 2013
Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia.Psychiatry research, , Dec-30, Volume: 210, Issue:3, 2013
Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.Journal of child and adolescent psychopharmacology, , Volume: 23, Issue:8, 2013
A pilot double-blind comparison of d-serine and high-dose olanzapine in treatment-resistant patients with schizophrenia.Schizophrenia research, , Volume: 150, Issue:2-3, 2013
Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia.BMC psychiatry, , Oct-03, Volume: 13, 2013
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study.BMC psychiatry, , Sep-30, Volume: 13, 2013
Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis.Schizophrenia research, , Volume: 150, Issue:2-3, 2013
Drug therapy versus electroconvulsive therapy for refractory schizophrenia: report of a case with 14 years of follow-up.International journal of psychiatry in medicine, , Volume: 45, Issue:3, 2013
Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.BMC psychiatry, , Sep-16, Volume: 13, 2013
Drug safety evaluation of olanzapine pamoate.Expert opinion on drug safety, , Volume: 12, Issue:6, 2013
Real-world use patterns of olanzapine long-acting injection in the United States: comparison to the recommended dosing strategy.Current medical research and opinion, , Volume: 29, Issue:11, 2013
Antipsychotics promote the differentiation of oligodendrocyte progenitor cells by regulating oligodendrocyte lineage transcription factors 1 and 2.Life sciences, , Oct-06, Volume: 93, Issue:12-14, 2013
Metabolic and body mass parameters after treatment with JNJ-37822681, a novel fast-dissociating D2 receptor antagonist, vs olanzapine in patients with schizophrenia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 25, Issue:3, 2013
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.Psychiatry research, , Dec-15, Volume: 210, Issue:2, 2013
Estimated dopamine D₂ receptor occupancy and remission in schizophrenia: analysis of the CATIE data.Journal of clinical psychopharmacology, , Volume: 33, Issue:5, 2013
Safety of olanzapine use in adolescents.Expert opinion on drug safety, , Volume: 12, Issue:5, 2013
Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.Behavioral and brain functions : BBF, , Jul-19, Volume: 9, 2013
Antipsychotic polypharmacy in a treatment-refractory schizophrenia population receiving adjunctive treatment with electroconvulsive therapy.The journal of ECT, , Volume: 29, Issue:4, 2013
Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.Journal of medical economics, , Volume: 16, Issue:9, 2013
Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment.JAMA psychiatry, , Volume: 70, Issue:9, 2013
The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.Psychopharmacology, , Volume: 230, Issue:1, 2013
Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.Schizophrenia bulletin, , Volume: 39, Issue:5, 2013
[Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 15, Issue:2, 2013
Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia.The Psychiatric quarterly, , Volume: 84, Issue:1, 2013
The antipsychotic olanzapine induces apoptosis in insulin-secreting pancreatic β cells by blocking PERK-mediated translational attenuation.Cell structure and function, , Volume: 38, Issue:2, 2013
Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.Journal of medical economics, , Volume: 16, Issue:9, 2013
Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.Neuro endocrinology letters, , Volume: 34, Issue:4, 2013
Fever development in neuroleptic malignant syndrome during treatment with olanzapine and clozapine.Pharmacological reports : PR, , Volume: 65, Issue:2, 2013
Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters.PloS one, , Volume: 8, Issue:5, 2013
Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-01, Volume: 45, 2013
Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:9, 2013
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia.BMC psychiatry, , May-22, Volume: 13, 2013
[Olanzapine].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 71, Issue:4, 2013
[Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, , Volume: 38, Issue:4, 2013
Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Expert opinion on drug metabolism & toxicology, , Volume: 9, Issue:9, 2013
Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain.Journal of clinical psychopharmacology, , Volume: 33, Issue:3, 2013
A latent variable approach in simultaneous modeling of longitudinal and dropout data in schizophrenia trials.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:11, 2013
A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia.Schizophrenia research, , Volume: 147, Issue:1, 2013
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.Pharmacological reports : PR, , Volume: 65, Issue:1, 2013
Endocannabinoid metabolism in the prefrontal cortex in schizophrenia.Schizophrenia research, , Volume: 147, Issue:1, 2013
A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.Psychopharmacology, , Volume: 230, Issue:1, 2013
Sex differences in the effect of four second-generation antipsychotics on QTc interval in patients with schizophrenia.Human psychopharmacology, , Volume: 28, Issue:3, 2013
Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.Journal of psychosocial nursing and mental health services, , Volume: 51, Issue:3, 2013
Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study.The Journal of clinical psychiatry, , Volume: 74, Issue:5, 2013
Clozapine and visuospatial processing in treatment-resistant schizophrenia.Cognitive neuropsychiatry, , Volume: 18, Issue:6, 2013
A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation.BMC psychiatry, , Jan-11, Volume: 13, 2013
Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.Journal of psychopharmacology (Oxford, England), , Volume: 27, Issue:4, 2013
Socio demographic profile and utilization pattern of antipsychotic drugs among schizophrenic inpatients: a cross sectional study from western region of Nepal.BMC psychiatry, , Mar-22, Volume: 13, 2013
Schizophrenia presenting with Koro-like symptoms.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 25, Issue:1, 2013
Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia.Psychopharmacology, , Volume: 225, Issue:3, 2013
Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia.The Journal of steroid biochemistry and molecular biology, , Volume: 133, 2013
Does early improvement predict response to the fast-dissociating D₂ receptor antagonist JNJ-37822681 in patients with acute schizophrenia?European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:9, 2013
Early prediction of clinical and functional outcome in schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:8, 2013
Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type.Psychiatry research, , Jan-30, Volume: 211, Issue:1, 2013
Predictors of clinical remission following a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.Psychiatry research, , Apr-30, Volume: 206, Issue:2-3, 2013
Paliperidone-related Pisa syndrome.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation.International clinical psychopharmacology, , Volume: 28, Issue:2, 2013
Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.The Journal of clinical psychiatry, , Volume: 74, Issue:1, 2013
Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 64, Issue:1, 2013
Consensus statement on the use of intramuscular aripiprazole for the rapid control of agitation in bipolar mania and schizophrenia.Current medical research and opinion, , Volume: 29, Issue:3, 2013
Persistent negative symptoms in first episode patients with schizophrenia: results from the European First Episode Schizophrenia Trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:3, 2013
A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.Molecular psychiatry, , Volume: 18, Issue:5, 2013
Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 23, Issue:2, 2013
Atypical neuroleptic malignant syndrome in H1N1 pneumonia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 25, Issue:1, 2013
Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
Schizophrenia past clozapine: what works?Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.Pharmacopsychiatry, , Volume: 46, Issue:3, 2013
Lessons learned in the conduct of a global, large simple trial of treatments indicated for schizophrenia.Contemporary clinical trials, , Volume: 34, Issue:2, 2013
Efficacy and tolerability of high dose olanzapine in Japanese patients with treatment-resistant schizophrenia.Asian journal of psychiatry, , Volume: 6, Issue:1, 2013
A case of catatonia in a 14-year-old girl with schizophrenia treated with electroconvulsive therapy.Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 41, Issue:1, 2013
No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in patients with schizophrenia.Schizophrenia research, , Volume: 146, Issue:1-3, 2013
Effects of olanzapine on 31P MRS metabolic markers in schizophrenia.Human psychopharmacology, , Volume: 28, Issue:1, 2013
A randomized controlled trial of olanzapine improving memory deficits in Han Chinese patients with first-episode schizophrenia.Schizophrenia research, , Volume: 144, Issue:1-3, 2013
Diabetes resolution following discontinuation of a second-generation antipsychotic.Clinical schizophrenia & related psychoses, , Volume: 6, Issue:4, 2013
Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses.CNS spectrums, , Volume: 18, Issue:2, 2013
White-matter microstructure in previously drug-naive patients with schizophrenia after 6 weeks of treatment.Psychological medicine, , Volume: 43, Issue:11, 2013
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.Psychopharmacology, , Volume: 226, Issue:3, 2013
Aripiprazole versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Feb-28, Issue:2, 2013
Long-term (3-year) neurocognitive effectiveness of antipsychotic medications in first-episode non-affective psychosis: a randomized comparison of haloperidol, olanzapine, and risperidone.Psychopharmacology, , Volume: 227, Issue:4, 2013
Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.The Journal of clinical psychiatry, , Volume: 74, Issue:2, 2013
Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India.International journal of psychiatry in clinical practice, , Volume: 17, Issue:1, 2013
Effectiveness of sulpiride in adult patients with schizophrenia.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.Schizophrenia bulletin, , Volume: 39, Issue:3, 2013
Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.Schizophrenia bulletin, , Volume: 38, Issue:4, 2012
Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.Comprehensive psychiatry, , Volume: 53, Issue:1, 2012
Inclusion complex of methyl-β-cyclodextrin and olanzapine as potential drug delivery system for schizophrenia.Carbohydrate polymers, , Aug-01, Volume: 89, Issue:4, 2012
A case of severe hypothermia following single-dose administration of olanzapine: a case report.Journal of clinical pharmacology, , Volume: 52, Issue:2, 2012
Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 13, Issue:1, 2012
Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 22, Issue:1, 2012
Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:6, 2012
Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study.The Journal of clinical psychiatry, , Volume: 73, Issue:2, 2012
Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine.The pharmacogenomics journal, , Volume: 12, Issue:6, 2012
Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:1, 2012
Cortical opioid markers in schizophrenia and across postnatal development.Cerebral cortex (New York, N.Y. : 1991), , Volume: 22, Issue:5, 2012
Analysis of gene variants previously associated with iloperidone response in patients with schizophrenia who are treated with risperidone.The Journal of clinical psychiatry, , Volume: 73, Issue:3, 2012
Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia.The pharmacogenomics journal, , Volume: 12, Issue:3, 2012
Hypothermia associated with antipsychotic drug use: a clinical case series and review of current literature.Journal of clinical pharmacology, , Volume: 52, Issue:7, 2012
Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia.Schizophrenia bulletin, , Volume: 38, Issue:3, 2012
Gene-gene interactions of the INSIG1 and INSIG2 in metabolic syndrome in schizophrenic patients treated with atypical antipsychotics.The pharmacogenomics journal, , Volume: 12, Issue:1, 2012
Addressing non-adherence to antipsychotic medication: a harm-reduction approach.Journal of psychiatric and mental health nursing, , Volume: 19, Issue:1, 2012
Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.Pharmacopsychiatry, , Volume: 45, Issue:2, 2012
Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.Schizophrenia bulletin, , Volume: 38, Issue:3, 2012
Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 36, Issue:2, 2012
Executive function predicts response to antiaggression treatment in schizophrenia: a randomized controlled trial.The Journal of clinical psychiatry, , Volume: 73, Issue:1, 2012
The differential effect of risperidone and olanzapine on insulin sensitivity after 3 weeks of treatment: a HOMA pilot study.Pharmacopsychiatry, , Volume: 45, Issue:3, 2012
Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 18, Issue:1, 2012
The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.The Journal of clinical psychiatry, , Volume: 73, Issue:4, 2012
Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study.Progress in neuro-psychopharmacology & biological psychiatry, , Apr-27, Volume: 37, Issue:1, 2012
Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia.Current medical research and opinion, , Volume: 28, Issue:3, 2012
Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics.Psychopharmacology, , Volume: 222, Issue:1, 2012
Olanzapine-induced eccrine squamous syringometaplasia.The American Journal of dermatopathology, , Volume: 34, Issue:4, 2012
Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine.Schizophrenia research, , Volume: 135, Issue:1-3, 2012
Repetitive transcranial magnetic stimulation to treat early-onset auditory hallucinations.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:9, 2012
Nitric oxide in patients with schizophrenia: the relationship with the severity of illness and the antipsychotic treatment.Expert opinion on pharmacotherapy, , Volume: 13, Issue:14, 2012
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:5, 2012
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Clinical schizophrenia & related psychoses, , Volume: 6, Issue:2, 2012
Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis.BMC psychiatry, , Aug-31, Volume: 12, 2012
One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.Psychiatry research, , Dec-30, Volume: 200, Issue:2-3, 2012
Second-generation long-acting injectable antipsychotic agents: an overview.Drug and therapeutics bulletin, , Volume: 50, Issue:9, 2012
Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Drug safety, , Oct-01, Volume: 35, Issue:10, 2012
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.The Journal of clinical psychiatry, , Volume: 73, Issue:8, 2012
Antipsychotic monotherapy and polypharmacy in the treatment of outpatients with schizophrenia in the European Schizophrenia Outpatient Health Outcomes Study.The Journal of nervous and mental disease, , Volume: 200, Issue:7, 2012
Lilliputian hallucinations in schizophrenia: a case report.African journal of psychiatry, , Volume: 15, Issue:5, 2012
Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 15, Issue:1, 2012
A review of olanzapine pamoate.Expert opinion on pharmacotherapy, , Volume: 13, Issue:11, 2012
Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine.Neuro endocrinology letters, , Volume: 33, Issue:5, 2012
Olanzapine in schizophrenia and affective disorders.Drug safety, , Dec-01, Volume: 35, Issue:12, 2012
The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study.International clinical psychopharmacology, , Volume: 27, Issue:6, 2012
Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.Journal of clinical psychopharmacology, , Volume: 32, Issue:4, 2012
Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment.Translational psychiatry, , Jun-19, Volume: 2, 2012
Repeated activation of mania by atypical antipsychotics in a patient.BMJ case reports, , Nov-27, Volume: 2012, 2012
Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study.BMC psychiatry, , Dec-04, Volume: 12, 2012
UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.Clinical pharmacology and therapeutics, , Volume: 92, Issue:2, 2012
Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients.Psychiatry research, , Dec-30, Volume: 200, Issue:2-3, 2012
Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells.Prostaglandins, leukotrienes, and essential fatty acids, , Volume: 87, Issue:1, 2012
[The lipid metabolism abnormality in patients administered with olanzapine].Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, , Volume: 32, Issue:5-6, 2012
Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.The Journal of clinical psychiatry, , Volume: 73, Issue:11, 2012
Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 22, Issue:18, 2012
Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data.BMC psychiatry, , May-30, Volume: 12, 2012
Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine.Schizophrenia research, , Volume: 141, Issue:1, 2012
Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.Psychiatry and clinical neurosciences, , Volume: 66, Issue:4, 2012
State and trait markers of emotionally charged visual event-related potentials (P300) in drug-naïve schizophrenia.Psychiatry and clinical neurosciences, , Volume: 66, Issue:4, 2012
Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey.BMC oral health, , Aug-18, Volume: 12, 2012
Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Dysregulation of adipocytokines related to second-generation antipsychotics in normal fasting glucose patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
Subjective and biological weight-related parameters in adolescents and young adults with schizophrenia spectrum disorder under clozapine or olanzapine treatment.Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 40, Issue:3, 2012
Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial.European archives of psychiatry and clinical neuroscience, , Volume: 262, Issue:7, 2012
Atomoxetine-induced vocal tics in a patient with schizophrenia.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 24, Issue:4, 2012
Neurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:5, 2012
The voices go, but the song remains the same: how can we rescue cognition in early-onset schizophrenia?Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 51, Issue:5, 2012
Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.Journal of psychopharmacology (Oxford, England), , Volume: 26, Issue:9, 2012
Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.The Journal of pharmacology and experimental therapeutics, , Volume: 342, Issue:1, 2012
Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia.Acta psychiatrica Scandinavica, , Volume: 126, Issue:1, 2012
Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.Psychiatry research, , Oct-30, Volume: 199, Issue:3, 2012
Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study.Human psychopharmacology, , Volume: 27, Issue:3, 2012
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.Behavioural pharmacology, , Volume: 23, Issue:7, 2012
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 22, Issue:10, 2012
Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.Journal of medical economics, , Volume: 15, Issue:5, 2012
Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
Social cognition and visual perception in schizophrenia inpatients treated with first-and second-generation antipsychotic drugs.Clinical schizophrenia & related psychoses, , Volume: 6, Issue:1, 2012
[Metabolic syndrome in patients with schizophrenia and antipsychotic treatment].Medicina clinica, , Nov-17, Volume: 139, Issue:12, 2012
Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version).East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, , Volume: 22, Issue:1, 2012
A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.Psychiatry research, , Jul-30, Volume: 198, Issue:2, 2012
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.International clinical psychopharmacology, , Volume: 27, Issue:4, 2012
A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.Journal of clinical psychopharmacology, , Volume: 32, Issue:2, 2012
Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone.Singapore medical journal, , Volume: 53, Issue:7, 2012
Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility.Schizophrenia research, , Volume: 137, Issue:1-3, 2012
Development and validation of a GC-EI-MS method with reduced adsorption loss for the quantification of olanzapine in human plasma.Analytical and bioanalytical chemistry, , Volume: 403, Issue:7, 2012
Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.Clinical drug investigation, , Apr-01, Volume: 32, Issue:4, 2012
Antipsychotic drug treatment for elderly people with late-onset schizophrenia.The Cochrane database of systematic reviews, , Feb-15, Issue:2, 2012
Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.Pharmacopsychiatry, , Volume: 45, Issue:5, 2012
Risperidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Jan-19, Issue:1, 2011
Olanzapine pamoate for the treatment of schizophrenia.Expert opinion on pharmacotherapy, , Volume: 12, Issue:4, 2011
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.Current medical research and opinion, , Volume: 27, Issue:4, 2011
Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.British journal of clinical pharmacology, , Volume: 71, Issue:3, 2011
Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.The Journal of clinical psychiatry, , Volume: 72, Issue:6, 2011
Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia.BMC psychiatry, , Feb-15, Volume: 11, 2011
Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.Schizophrenia research, , Volume: 128, Issue:1-3, 2011
EEG alterations during treatment with olanzapine.European archives of psychiatry and clinical neuroscience, , Volume: 261, Issue:7, 2011
Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.Diabetes, obesity & metabolism, , Volume: 13, Issue:8, 2011
Treatment strategy in schizophrenia combined with eating disorder.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Antipsychotic treatment--side-effect and/or metabolic syndrome.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.The Journal of clinical psychiatry, , Volume: 72, Issue:11, 2011
Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
A potential case of peduncular hallucinosis treated successfully with olanzapine.Clinical schizophrenia & related psychoses, , Volume: 5, Issue:1, 2011
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.Psychological medicine, , Volume: 41, Issue:11, 2011
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clinical drug investigation, , Volume: 31, Issue:7, 2011
A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia.Journal of clinical psychopharmacology, , Volume: 31, Issue:3, 2011
The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone.Progress in neuro-psychopharmacology & biological psychiatry, , Jul-01, Volume: 35, Issue:5, 2011
Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.Molecular psychiatry, , Volume: 16, Issue:6, 2011
Evidence for a SULT4A1 haplotype correlating with baseline psychopathology and atypical antipsychotic response.Pharmacogenomics, , Volume: 12, Issue:4, 2011
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.The Journal of clinical psychiatry, , Volume: 72, Issue:4, 2011
Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling.Psychopharmacology, , Volume: 218, Issue:2, 2011
Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol.Schizophrenia research, , Volume: 130, Issue:1-3, 2011
The GiSAS study: rationale and design of a pragmatic randomized controlled trial on aripiprazole, olanzapine and haloperidol in the long-term treatment of schizophrenia.Contemporary clinical trials, , Volume: 32, Issue:5, 2011
Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia.Schizophrenia research, , Volume: 131, Issue:1-3, 2011
Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.BMC psychiatry, , May-17, Volume: 11, 2011
Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.Acta psychiatrica Scandinavica, , Volume: 124, Issue:3, 2011
Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.Psychiatry research, , Aug-15, Volume: 188, Issue:3, 2011
Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?Clinical pharmacokinetics, , Volume: 50, Issue:7, 2011
Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat.Archives of physiology and biochemistry, , Volume: 117, Issue:4, 2011
Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study.The American journal of psychiatry, , Volume: 168, Issue:9, 2011
Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone.Journal of psychiatric research, , Volume: 45, Issue:10, 2011
Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.Pharmacopsychiatry, , Volume: 44, Issue:4, 2011
Changes in the metabolic parameters and QTc interval after switching from olanzapine to aripiprazole in Japanese patients with stable schizophrenia.Journal of clinical psychopharmacology, , Volume: 31, Issue:4, 2011
Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol.Pharmacopsychiatry, , Volume: 44, Issue:5, 2011
Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.Pharmacogenetics and genomics, , Volume: 21, Issue:9, 2011
A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).The American journal of psychiatry, , Volume: 168, Issue:9, 2011
A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden.Nordic journal of psychiatry, , Volume: 65, Issue:6, 2011
Raynaud’s phenomenon in a patient with schizophrenia and obsessive-compulsive disorder: a case report.Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Summer, Volume: 22, Issue:2, 2011
Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC).Pharmacoepidemiology and drug safety, , Volume: 20, Issue:11, 2011
Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.Psychiatry research, , Sep-30, Volume: 189, Issue:2, 2011
Clozapine-induced weight loss?Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 23, Issue:3, 2011
A 12-month randomized, open-label study of the metabolic effects of olanzapine and risperidone in psychotic patients: influence of valproic acid augmentation.The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia.Human psychopharmacology, , Volume: 26, Issue:6, 2011
Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine.Human psychopharmacology, , Volume: 26, Issue:6, 2011
Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).The Journal of clinical psychiatry, , Volume: 72, Issue:7, 2011
The emerging role of atypical antipsychotics in the treatment of tardive dyskinesia induced by other atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 72, Issue:7, 2011
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 13, Issue:3, 2011
Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.Neuro endocrinology letters, , Volume: 32, Issue:4, 2011
Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study.The British journal of psychiatry : the journal of mental science, , Volume: 199, Issue:3, 2011
Ibogaine-associated psychosis in schizophrenia: a case report.Journal of clinical psychopharmacology, , Volume: 31, Issue:5, 2011
Switching antipsychotic medications: not enough, too often, or just right?The American journal of psychiatry, , Volume: 168, Issue:9, 2011
Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress.Neuroscience research, , Volume: 71, Issue:4, 2011
Impact of olanzapine on cognitive functions in patients with schizophrenia during an observation period of six months.Psychiatria Danubina, , Volume: 23 Suppl 1, 2011
Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.The Journal of clinical psychiatry, , Volume: 72, Issue:10, 2011
High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.Journal of clinical psychopharmacology, , Volume: 31, Issue:1, 2011
[Effectiveness of antipsychotics in schizophrenia and related disorders. Results of a naturalistic study].La Clinica terapeutica, , Volume: 162, Issue:4, 2011
DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.Proceedings of the National Academy of Sciences of the United States of America, , Jan-18, Volume: 108, Issue:3, 2011
Association between HTR2C polymorphisms and metabolic syndrome in patients with schizophrenia treated with atypical antipsychotics.Schizophrenia research, , Volume: 125, Issue:2-3, 2011
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.European child & adolescent psychiatry, , Volume: 20, Issue:11-12, 2011
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 3. Rapid tranquilisation in acute psychotic agitation.Emergency medicine journal : EMJ, , Volume: 28, Issue:1, 2011
Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia.BMC psychiatry, , Sep-23, Volume: 11, 2011
Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.Neuromolecular medicine, , Volume: 13, Issue:4, 2011
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 35, Issue:2, 2011
Phospholipase A₂ activity in first episode schizophrenia: associations with symptom severity and outcome at week 12.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 12, Issue:8, 2011
TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.Neuroscience letters, , Oct-31, Volume: 504, Issue:3, 2011
Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.Current medical research and opinion, , Volume: 27, Issue:1, 2011
Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome.The Annals of pharmacotherapy, , Volume: 45, Issue:11, 2011
Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials.Schizophrenia research, , Volume: 126, Issue:1-3, 2011
Neutropenia associated with quetiapine, olanzapine, and aripiprazole.The Australian and New Zealand journal of psychiatry, , Volume: 45, Issue:1, 2011
Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex.Psychopharmacology, , Volume: 214, Issue:3, 2011
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.Schizophrenia research, , Volume: 125, Issue:2-3, 2011
An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-15, Volume: 35, Issue:1, 2011
The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 56, Issue:10, 2011
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).The American journal of psychiatry, , Volume: 168, Issue:2, 2011
[Sexual disturbances during the treatment with neuroleptics in patients with schizophrenia and schizophrenia spectrum disorders].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 111, Issue:9 Pt 2, 2011
The different trajectories of antipsychotic response: antipsychotics versus placebo.Psychological medicine, , Volume: 41, Issue:7, 2011
Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching.International clinical psychopharmacology, , Volume: 26, Issue:1, 2011
The heterogeneity of antipsychotic response in the treatment of schizophrenia.Psychological medicine, , Volume: 41, Issue:6, 2011
"Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial.The Journal of clinical psychiatry, , Volume: 72, Issue:8, 2011
Angiotensin II type 1 receptor blockers improve insulin sensitivity in patients with schizophrenia being treated with olanzapine.Psychopharmacology, , Volume: 213, Issue:1, 2011
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.The Journal of clinical psychiatry, , Volume: 72, Issue:3, 2011
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.The Journal of clinical psychiatry, , Volume: 72, Issue:3, 2011
Cost-effectiveness analysis of olanzapine and risperidone in Norway.The journal of mental health policy and economics, , Volume: 14, Issue:3, 2011
Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.Neuro endocrinology letters, , Volume: 32, Issue:5, 2011
Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.The Journal of clinical psychiatry, , Volume: 72, Issue:12, 2011
Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.Human psychopharmacology, , Volume: 26, Issue:1, 2011
Cognitive efficacy of quetiapine and olanzapine in early-onset first-episode psychosis.Schizophrenia bulletin, , Volume: 37, Issue:2, 2011
Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.Molecular psychiatry, , Volume: 16, Issue:1, 2011
Association study of MDR1 and 5-HT2C genetic polymorphisms and antipsychotic-induced metabolic disturbances in female patients with schizophrenia.The pharmacogenomics journal, , Volume: 11, Issue:1, 2011
Comparison of short-acting intramuscular antipsychotic medication: impact on length of stay and cost.American journal of therapeutics, , Volume: 18, Issue:4, 2011
Anterior internal capsule volumes increase in patients with schizophrenia switched from typical antipsychotics to olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:5, 2011
Acute respiratory distress due to antipsychotic drugs.Pharmacopsychiatry, , Volume: 43, Issue:3, 2010
Adolescent with treatment-refractory schizophrenia and clozapine-induced cardiomyopathy managed with high-dose olanzapine.Journal of child and adolescent psychopharmacology, , Volume: 20, Issue:6, 2010
Management of a patient with schizophrenia and underlying pituitary macroadenoma.Annals of the Academy of Medicine, Singapore, , Volume: 39, Issue:11, 2010
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.The Cochrane database of systematic reviews, , Dec-08, Issue:12, 2010
Switching and combining antipsychotics.CNS spectrums, , Volume: 15, Issue:4 Suppl 6, 2010
Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?The Journal of clinical psychiatry, , Volume: 71, Issue:11, 2010
Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controllJournal of clinical psychopharmacology, , Volume: 30, Issue:6, 2010
Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.Drugs, , Dec-03, Volume: 70, Issue:17, 2010
Clozapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Nov-10, Issue:11, 2010
Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.Psychopharmacology bulletin, , Volume: 43, Issue:2, 2010
Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.BMC psychiatry, , Nov-03, Volume: 10, 2010
A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients.Experimental and clinical psychopharmacology, , Volume: 18, Issue:5, 2010
Lipid peroxidation in patients with schizophrenia.Psychiatry and clinical neurosciences, , Volume: 64, Issue:5, 2010
Alterations in metabotropic glutamate receptor 1α and regulator of G protein signaling 4 in the prefrontal cortex in schizophrenia.The American journal of psychiatry, , Volume: 167, Issue:12, 2010
The potential role of appetite in predicting weight changes during treatment with olanzapine.BMC psychiatry, , Sep-14, Volume: 10, 2010
Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 20, Issue:12, 2010
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study.The Journal of clinical psychiatry, , Volume: 71, Issue:11, 2010
Long-acting injectable olanzaoine. Inadequate assessment and a risk of overdose.Prescrire international, , Volume: 19, Issue:107, 2010
[Epidural labor analgesia for a primipara with schizophrenia].Masui. The Japanese journal of anesthesiology, , Volume: 59, Issue:8, 2010
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.Schizophrenia research, , Volume: 123, Issue:2-3, 2010
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Expert opinion on drug safety, , Volume: 9, Issue:5, 2010
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia.Pharmacogenetics and genomics, , Volume: 20, Issue:9, 2010
Olanzapine-associated pica in a schizophrenia patient.Psychiatry and clinical neurosciences, , Volume: 64, Issue:4, 2010
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:7, 2010
What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?Journal of clinical psychopharmacology, , Volume: 30, Issue:4, 2010
Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra.Nordic journal of psychiatry, , Volume: 64, Issue:4, 2010
Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics.Neuroscience letters, , Aug-02, Volume: 479, Issue:3, 2010
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.BMC psychiatry, , Jun-10, Volume: 10, 2010
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.BMC psychiatry, , Jun-10, Volume: 10, 2010
Cochrane for clinicians. Aripiprazole vs. other atypical antipsychotics for schizophrenia.American family physician, , Jun-01, Volume: 81, Issue:11, 2010
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:9, 2010
Higher motor activity in schizophrenia patients treated with olanzapine versus risperidone.Journal of clinical psychopharmacology, , Volume: 30, Issue:2, 2010
[Effect of side-effects and complications caused by atypical neuroleptics on the effectiveness of therapy in patients with schizophrenia].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 110, Issue:3, 2010
Impact of smoking cessation on psychiatric inpatients treated with clozapine or olanzapine.Journal of psychiatric practice, , Volume: 16, Issue:2, 2010
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 49, Issue:6, 2010
Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
Tardive dystonia induced by switch of atypical antipsychotics.Pharmacopsychiatry, , Volume: 43, Issue:5, 2010
Olanzapine in male and female adolescent patients with schizophrenia and related disorders: minor sex differences in outcomes.Journal of clinical psychopharmacology, , Volume: 30, Issue:3, 2010
Clinical predictors of response to olanzapine or risperidone during acute episode of schizophrenia.Psychiatry research, , Aug-30, Volume: 179, Issue:1, 2010
Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
Olanzapine: a review of rapid and long-acting parenteral formulations.Drugs of today (Barcelona, Spain : 1998), , Volume: 46, Issue:3, 2010
Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.Schizophrenia research, , Volume: 120, Issue:1-3, 2010
Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:1, 2010
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.The pharmacogenomics journal, , Volume: 10, Issue:1, 2010
Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.Psychopharmacology bulletin, , Volume: 43, Issue:4, 2010
Extrastriatal dopamine D(2) receptor occupancy in olanzapine-treated patients with schizophrenia.European archives of psychiatry and clinical neuroscience, , Volume: 260, Issue:4, 2010
Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:2, 2010
Predictors of adherence to atypical antipsychotics (risperidone or olanzapine) in older patients with schizophrenia: an open study of 3(1/2) years duration.International journal of geriatric psychiatry, , Volume: 25, Issue:4, 2010
Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 35, Issue:4, 2010
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.The American journal of psychiatry, , Volume: 167, Issue:2, 2010
Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 44, Issue:3, 2010
Antibodies to measles in individuals with recent onset psychosis.Schizophrenia research, , Volume: 119, Issue:1-3, 2010
[Antipsychotic agents and stimulants: a judicious combination?].Tijdschrift voor psychiatrie, , Volume: 52, Issue:1, 2010
Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials.Journal of clinical pharmacology, , Volume: 50, Issue:3, 2010
The effects of psychopathology on subjective experience of side effects of antipsychotics in patients with schizophrenia.International clinical psychopharmacology, , Volume: 25, Issue:2, 2010
Amisulpride versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Jan-20, Issue:1, 2010
Quetiapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Jan-20, Issue:1, 2010
Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure--an impact similar to male gender or smoking in schizophrenic patients.European journal of clinical pharmacology, , Volume: 66, Issue:5, 2010
Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation.The Journal of clinical psychiatry, , Volume: 71, Issue:4, 2010
Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors.The international journal of neuropsychopharmacology, , Volume: 13, Issue:10, 2010
Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Apr-16, Volume: 34, Issue:3, 2010
Effect of aripiprazole, risperidone, and olanzapine on the acoustic startle response in Japanese chronic schizophrenia.Psychopharmacology, , Volume: 209, Issue:2, 2010
Drug attitude as predictor for effectiveness in first-episode schizophrenia: Results of an open randomized trial (EUFEST).European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 20, Issue:5, 2010
Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder.Pharmacopsychiatry, , Volume: 43, Issue:4, 2010
Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 118, Issue:1-3, 2010
Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics.The journal of sexual medicine, , Volume: 7, Issue:10, 2010
Reduced serum BDNF levels in patients with chronic schizophrenic disorder in relapse, who were treated with typical or atypical antipsychotics.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:2 Pt 2, 2010
Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 11, Issue:2 Pt 2, 2010
Olanzapine versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Mar-17, Issue:3, 2010
Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.Paediatric drugs, , Volume: 12, Issue:3, 2010
Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
Olanzapine: in adolescents with schizophrenia or bipolar I disorder.CNS drugs, , Volume: 24, Issue:5, 2010
Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 55, Issue:3, 2010
Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients.Human psychopharmacology, , Volume: 25, Issue:3, 2010
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.Pharmacogenetics and genomics, , Volume: 20, Issue:6, 2010
The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-16, Volume: 34, Issue:6, 2010
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 71, Issue:9, 2010
The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs.Pharmacopsychiatry, , Volume: 43, Issue:3, 2010
Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.BMC psychiatry, , Mar-31, Volume: 9, 2009
Olanzapine pamoate - blockbuster or damp squib?International journal of clinical practice, , Volume: 63, Issue:4, 2009
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.BMC psychiatry, , Mar-28, Volume: 9, 2009
A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 70, Issue:4, 2009
Drug prescription patterns in schizophrenia outpatients: analysis of data from a German health insurance fund.Pharmacopsychiatry, , Volume: 42, Issue:2, 2009
Comparing the effects of high-dose vitamin E with those of placebo on insulin resistance in patients with schizophrenia treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.Human psychopharmacology, , Volume: 24, Issue:3, 2009
Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia.Psychopharmacology, , Volume: 206, Issue:1, 2009
Psychosis secondary to traumatic brain injury.Brain injury, , Volume: 23, Issue:4, 2009
Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.Psychiatry and clinical neurosciences, , Volume: 63, Issue:4, 2009
Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.International clinical psychopharmacology, , Volume: 24, Issue:5, 2009
Weight loss during therapy with olanzapine orally disintegrating tablets: two case reports.Psychiatria Danubina, , Volume: 21, Issue:1, 2009
Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol.Schizophrenia research, , Volume: 110, Issue:1-3, 2009
In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.Journal of psychiatric research, , Volume: 43, Issue:11, 2009
[Pattern and evolution of the prescription of olanzapine during one year: Results of the cohort study ECOL].L'Encephale, , Volume: 35, Issue:1, 2009
Comparison of treatment completion rates for olanzapine pamoate and risperidone microspheres.International journal of clinical practice, , Volume: 63, Issue:6, 2009
Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients.Neuropsychobiology, , Volume: 59, Issue:1, 2009
The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials.The Journal of clinical psychiatry, , Volume: 70, Issue:2, 2009
Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population.Current medical research and opinion, , Volume: 25, Issue:3, 2009
Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR).European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 24, Issue:5, 2009
Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant schizophrenia.Psychiatria Danubina, , Volume: 21, Issue:2, 2009
[Acquired stuttering in a psychotic patient].Tijdschrift voor psychiatrie, , Volume: 51, Issue:1, 2009
Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.Behavioural pharmacology, , Volume: 20, Issue:1, 2009
Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.PharmacoEconomics, , Volume: 27, Issue:1, 2009
The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.Archives of general psychiatry, , Volume: 66, Issue:6, 2009
[The European Schizophrenia Outpatient Health Outcomes Study: observational study over 36 months of the French cohort of schizophrenic outpatients treated with antipsychotics].Revue d'epidemiologie et de sante publique, , Volume: 57, Issue:1, 2009
The risks and benefits of switching antipsychotics: a case study approach.Perspectives in psychiatric care, , Volume: 45, Issue:1, 2009
Targeting cognition in schizophrenia research: from etiology to treatment.The American journal of psychiatry, , Volume: 166, Issue:6, 2009
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.Pharmacopsychiatry, , Volume: 42, Issue:1, 2009
Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.International journal of clinical practice, , Volume: 63, Issue:8, 2009
Olanzapine-induced "restless arms syndrome".Journal of clinical psychopharmacology, , Volume: 29, Issue:1, 2009
Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.Journal of clinical psychopharmacology, , Volume: 29, Issue:1, 2009
Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:1, 2009
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 24, Issue:3, 2009
Validating novel targets for pharmacological interventions in schizophrenia.The American journal of psychiatry, , Volume: 166, Issue:7, 2009
The promotion of olanzapine in primary care: an examination of internal industry documents.Social science & medicine (1982), , Volume: 69, Issue:1, 2009
Four cases of venous thromboembolism associated with olanzapine.Psychiatry and clinical neurosciences, , Volume: 63, Issue:1, 2009
Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 48, Issue:1, 2009
Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 34, Issue:5, 2009
Lack of an inverse relationship between duration of untreated psychosis and cognitive function in first episode schizophrenia.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Results of phase 3 of the CATIE schizophrenia trial.Schizophrenia research, , Volume: 107, Issue:1, 2009
Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 70, Issue:1, 2009
Aripiprazole for the management of olanzapine-induced weight gain.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia.Current medical research and opinion, , Volume: 25, Issue:9, 2009
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.Schizophrenia research, , Volume: 107, Issue:1, 2009
A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.Biological psychiatry, , Mar-15, Volume: 65, Issue:6, 2009
Time-lapse mapping of cortical changes in schizophrenia with different treatments.Cerebral cortex (New York, N.Y. : 1991), , Volume: 19, Issue:5, 2009
Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.BMC psychiatry, , Jul-14, Volume: 9, 2009
Hypoglycaemia induced by second generation antipsychotic agents in schizophrenic non-diabetic patients.BMJ (Clinical research ed.), , May-26, Volume: 338, 2009
Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia.DNA and cell biology, , Volume: 28, Issue:10, 2009
Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.International journal of clinical practice, , Volume: 63, Issue:1, 2009
Bayesian adaptive non-inferiority with safety assessment: retrospective case study to highlight potential benefits and limitations of the approach.Journal of psychiatric research, , Volume: 43, Issue:5, 2009
Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Waist circumference is the best anthropometric predictor for insulin resistance in nondiabetic patients with schizophrenia treated with clozapine but not olanzapine.Journal of psychiatric practice, , Volume: 15, Issue:4, 2009
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:1, 2009
Impact of patient selection criteria and treatment history on comparisons of alternative therapies: a case study of atypical antipsychotics.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12, Issue:4, 2009
Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.Revista de saude publica, , Volume: 43 Suppl 1, 2009
Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 34, Issue:13, 2009
Medication nonadherence and treatment outcome in patients with schizophrenia or schizoaffective disorder with suboptimal prior response.The Journal of clinical psychiatry, , Volume: 70, Issue:7, 2009
FDA panel OKs 3 antipsychotic drugs for pediatric use, cautions against overuse.JAMA, , Aug-26, Volume: 302, Issue:8, 2009
Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 3, 2009
Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study.Journal of psychiatric research, , Volume: 43, Issue:3, 2009
[Complex therapy of schizophrenia].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 11, Issue:1, 2009
Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
[Comment on: "Lack of insight in schizophrenia: a review. Part I: theoretical concept, clinical aspects and Amador's model" of S. Raffard, S. Bayard, D., Capdevielle, F. Garcia, J.-P. Boulenger et M.-C. Gely-Nargeot].L'Encephale, , Volume: 35, Issue:4, 2009
Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:4, 2009
Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 23, Issue:6, 2009
[Influence of serotonin (5-HT) 2A-receptor and transporter (5HTT) gene polymorphism upon the effect of olanzapine].Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, , Volume: 29, Issue:4, 2009
Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 19, Issue:8, 2009
Late-onset cholestatic hepatitis induced by olanzapine in a patient with schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Nov-13, Volume: 33, Issue:8, 2009
[Effect of antipsychotic drugs on life quality of schizophrenic patients: one year follow-up study].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, , Volume: 34, Issue:9, 2009
Clinical trials design lessons from the CATIE study.The American journal of psychiatry, , Volume: 166, Issue:11, 2009
Possible olanzapine-induced hepatotoxicity in a young Chinese patient.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 15, Issue:5, 2009
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.The Journal of clinical psychiatry, , Volume: 70, Issue:11, 2009
Aripiprazole versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Oct-07, Issue:4, 2009
Ziprasidone versus other atypical antipsychotics for schizophrenia.The Cochrane database of systematic reviews, , Oct-07, Issue:4, 2009
Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12, Issue:4, 2009
Severe psychotic disorder and agranulocytosis--a therapeutic dilemma.Pharmacopsychiatry, , Volume: 42, Issue:6, 2009
Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration.Journal of clinical psychopharmacology, , Volume: 29, Issue:3, 2009
Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study.The Israel journal of psychiatry and related sciences, , Volume: 46, Issue:3, 2009
Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia.Psychiatry research, , Jul-15, Volume: 173, Issue:1, 2009
Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis.The British journal of psychiatry : the journal of mental science, , Volume: 194, Issue:5, 2009
Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.Journal of clinical psychopharmacology, , Volume: 29, Issue:2, 2009
Thrombosis and psychosis--possible association with the antiphospholipid syndrome and anticardiolipin antibodies.Irish medical journal, , Volume: 102, Issue:2, 2009
Expression changes of serotonin receptor gene subtype 5HT3a in peripheral blood mononuclear cells from schizophrenic patients treated with haloperidol and Olanzapin.Iranian journal of allergy, asthma, and immunology, , Volume: 8, Issue:3, 2009
Hunger and negative alliesthesia to aspartame and sucrose in patients treated with antipsychotic drugs and controls.Eating and weight disorders : EWD, , Volume: 14, Issue:4, 2009
A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.The Journal of clinical psychiatry, , Volume: 70, Issue:4, 2009
Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:1, 2008
Applying long-acting injectable antipsychotics in first-episode schizophrenia to achieve first remission.CNS drugs, , Volume: 22, Issue:3, 2008
Frequency and effects of psychosocial interventions additional to olanzapine treatment in routine care of schizophrenic patients.Social psychiatry and psychiatric epidemiology, , Volume: 43, Issue:5, 2008
Olanzapine and risperidone block a high dose of methamphetamine-induced schizophrenia-like behavioral abnormalities and accompanied apoptosis in the medial prefrontal cortex.Schizophrenia research, , Volume: 101, Issue:1-3, 2008
Cerebrospinal fluid D-serine and glycine concentrations are unaltered and unaffected by olanzapine therapy in male schizophrenic patients.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 18, Issue:5, 2008
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 165, Issue:3, 2008
Metabotropic glutamate receptor agonists for schizophrenia.The British journal of psychiatry : the journal of mental science, , Volume: 192, Issue:2, 2008
Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients.The international journal of neuropsychopharmacology, , Volume: 11, Issue:5, 2008
Olanzapine in adolescents with schizophrenia who manifest suicidal behaviour.Early intervention in psychiatry, , Volume: 2, Issue:2, 2008
Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia.Internal medicine (Tokyo, Japan), , Volume: 47, Issue:3, 2008
Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes.Schizophrenia research, , Volume: 100, Issue:1-3, 2008
A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Determinants of atypical antipsychotic use among antipsychotic users in community-dwelling elderly, 1996-2004.Current medical research and opinion, , Volume: 24, Issue:3, 2008
Large intraindividual variability of olanzapine serum concentrations in adolescent patients.Therapeutic drug monitoring, , Volume: 30, Issue:1, 2008
The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP).Therapeutic drug monitoring, , Volume: 30, Issue:1, 2008
Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.Human psychopharmacology, , Volume: 23, Issue:3, 2008
Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and olanzapine-induced weight gain among Korean schizophrenic patients.Journal of clinical pharmacy and therapeutics, , Volume: 33, Issue:1, 2008
A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.Journal of clinical psychopharmacology, , Volume: 28, Issue:1, 2008
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.Journal of clinical psychopharmacology, , Volume: 28, Issue:1, 2008
Sex, race, and smoking impact olanzapine exposure.Journal of clinical pharmacology, , Volume: 48, Issue:2, 2008
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.Schizophrenia research, , Volume: 100, Issue:1-3, 2008
Reduced attentional engagement contributes to deficits in prefrontal inhibitory control in schizophrenia.Biological psychiatry, , Apr-15, Volume: 63, Issue:8, 2008
Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research.Schizophrenia bulletin, , Volume: 34, Issue:2, 2008
Evaluating dose response from flexible dose clinical trials.BMC psychiatry, , Jan-07, Volume: 8, 2008
Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:6, 2008
Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.Psychopharmacology, , Volume: 196, Issue:4, 2008
Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain.Human psychopharmacology, , Volume: 23, Issue:4, 2008
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.Journal of psychiatric research, , Volume: 42, Issue:11, 2008
Pharmacogenetic study of atypical antipsychotic drug response: involvement of the norepinephrine transporter gene.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Jun-05, Volume: 147B, Issue:4, 2008
Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia.Pharmacoepidemiology and drug safety, , Volume: 17, Issue:7, 2008
The Schizophrenia Outpatient Health Outcomes (SOHO) study: 3-year results of antipsychotic treatment discontinuation and related clinical factors in Spain.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 23, Issue:1, 2008
Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients.Journal of psychiatric research, , Volume: 42, Issue:2, 2008
Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300.Schizophrenia research, , Volume: 101, Issue:1-3, 2008
Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.Human psychopharmacology, , Volume: 23, Issue:4, 2008
Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients.European journal of clinical pharmacology, , Volume: 64, Issue:1, 2008
Inconclusive evidence for the efficacy of olanzapine in the treatment of negative symptoms in schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:1, 2008
A randomized, flexible-dose, quasi-naturalistic comparison of quetiapine, risperidone, and olanzapine in the short-term treatment of schizophrenia: the QUERISOLA trial.Schizophrenia research, , Volume: 98, Issue:1-3, 2008
The use of individually tailored environmental supports to improve medication adherence and outcomes in schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:3, 2008
Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study.The Journal of clinical psychiatry, , Volume: 69, Issue:1, 2008
Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Olanzapine plasma concentration in a newborn.Journal of psychopharmacology (Oxford, England), , Volume: 22, Issue:8, 2008
Telmisartan, an angiotensin II type-1 receptor blocker, improved insulin resistance in a schizophrenic patient treated with olanzapine: a case report.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-01, Volume: 32, Issue:1, 2008
Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study.Schizophrenia research, , Volume: 101, Issue:1-3, 2008
Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia.Acta psychiatrica Scandinavica, , Volume: 117, Issue:5, 2008
Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine.Drug metabolism letters, , Volume: 2, Issue:2, 2008
Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia.Journal of psychiatric research, , Volume: 42, Issue:13, 2008
Olanzapine: a new risk factor for pulmonary embolus?The American journal of forensic medicine and pathology, , Volume: 29, Issue:4, 2008
Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.The Journal of clinical psychiatry, , Volume: 69, Issue:9, 2008
High-dose olanzapine versus clozapine.The Journal of clinical psychiatry, , Volume: 69, Issue:10, 2008
[Psychiatric consequences of bariatric surgery in a schizophrenic patient: case report].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:4, 2008
[Depression in schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:10, 2008
[The possibility of high-quality remission in the long chronic course of schizophrenia].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 108, Issue:11, 2008
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913).BMC psychiatry, , Dec-22, Volume: 8, 2008
Lack of association between clinical and cognitive change in first-episode psychosis: the first 6 weeks of treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:12, 2008
Bofu-tsusho-san effectively attenuates the weight gain observed after receiving olanzapine.Psychiatry and clinical neurosciences, , Volume: 62, Issue:6, 2008
Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.The Journal of clinical psychiatry, , Volume: 69, Issue:12, 2008
Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Influence of olanzapine on QT variability and complexity measures of heart rate in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 28, Issue:6, 2008
Correlates of response to Olanzapine in a North Indian Schizophrenia sample.Psychiatry research, , Dec-15, Volume: 161, Issue:3, 2008
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
A population-based cost-effectiveness analysis of olanzapine and risperidone among ambulatory patients with schizophrenia.The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, ,Fall, Volume: 15, Issue:3, 2008
Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .Current medical research and opinion, , Volume: 24, Issue:11, 2008
A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Effects of second-generation antipsychotic medication on smooth pursuit performance in antipsychotic-naive schizophrenia.Archives of general psychiatry, , Volume: 65, Issue:10, 2008
Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.Schizophrenia research, , Volume: 106, Issue:2-3, 2008
Shift from first generation antipsychotics to olanzapine may improve health-related quality of life of stable but residually symptomatic schizophrenic outpatients: a prospective, randomized study.International journal of technology assessment in health care, ,Fall, Volume: 24, Issue:4, 2008
Olanzapine orally disintegrating tablet: a review of efficacy and compliance.CNS neuroscience & therapeutics, ,Fall, Volume: 14, Issue:3, 2008
[Olanzapine].Deutsche medizinische Wochenschrift (1946), , Volume: 133, Issue:39, 2008
Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-12, Volume: 32, Issue:8, 2008
Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 28, Issue:5, 2008
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.The American journal of psychiatry, , Volume: 165, Issue:11, 2008
Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder.BMC psychiatry, , Sep-15, Volume: 8, 2008
The InterSePT suicide scale for prediction of imminent suicidal behaviors.Psychiatry research, , Oct-30, Volume: 161, Issue:1, 2008
LORETA functional imaging in antipsychotic-naive and olanzapine-, clozapine- and risperidone-treated patients with schizophrenia.Neuropsychobiology, , Volume: 58, Issue:1, 2008
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.Schizophrenia research, , Volume: 105, Issue:1-3, 2008
Olanzapine treatment and weight gain: considering the lipid side effects of antipsychotics.The American journal of psychiatry, , Volume: 165, Issue:9, 2008
Considerations regarding the use of metformin with olanzapine.The American journal of psychiatry, , Volume: 165, Issue:9, 2008
Treatment of severe agitation with olanzapine in 166 patients with schizophrenia, schizoaffective, or bipolar I disorder.Pharmacopsychiatry, , Volume: 41, Issue:5, 2008
A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:4, 2008
Clozapine versus "high-dose" olanzapine in refractory early-onset schizophrenia: an open-label extension study.Journal of child and adolescent psychopharmacology, , Volume: 18, Issue:4, 2008
Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine.Journal of Korean medical science, , Volume: 23, Issue:4, 2008
The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.Psychiatry research, , Sep-30, Volume: 160, Issue:3, 2008
A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.Acta psychiatrica Scandinavica, , Volume: 118, Issue:3, 2008
Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia.Acta psychiatrica Scandinavica, , Volume: 118, Issue:3, 2008
Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study.Diabetes & metabolism, , Volume: 34, Issue:5, 2008
Olanzapine improves deficient sensory inhibition in DBA/2 mice.Brain research, , Oct-03, Volume: 1233, 2008
Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes.Pharmacogenomics, , Volume: 9, Issue:8, 2008
Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications.Human psychopharmacology, , Volume: 23, Issue:7, 2008
Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine. 3-month follow-up.Neuropsychobiology, , Volume: 57, Issue:4, 2008
Statistical evaluation of olanzapine efficacy in catamnesticly investigated patients.Medicinski arhiv, , Volume: 62, Issue:2, 2008
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.Clinical drug investigation, , Volume: 28, Issue:9, 2008
Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study.Journal of clinical psychopharmacology, , Volume: 28, Issue:4, 2008
Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia.Schizophrenia research, , Volume: 104, Issue:1-3, 2008
Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 53, Issue:6, 2008
Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 18, Issue:10, 2008
A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Olanzapine-induced oculogyric crisis in a patient with schizophrenia.Indian journal of medical sciences, , Volume: 62, Issue:6, 2008
Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.BMC medicine, , Jun-30, Volume: 6, 2008
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 69, Issue:7, 2008
Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-01, Volume: 32, Issue:6, 2008
Clinical experiences and clinical trials.CNS spectrums, , Volume: 13, Issue:6, 2008
Intramuscular olanzapine in patients with schizophrenia: an observational study in an emergency room.Bulletin de la Societe des sciences medicales du Grand-Duche de Luxembourg, , Issue:2, 2008
Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 18, Issue:8, 2008
Strategies of treatment with olanzapine in schizophrenic patients during stable phase: results of a pilot study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 18, Issue:9, 2008
Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone.International clinical psychopharmacology, , Volume: 23, Issue:4, 2008
Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study.International clinical psychopharmacology, , Volume: 23, Issue:4, 2008
Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.Human psychopharmacology, , Volume: 23, Issue:6, 2008
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.The Journal of clinical psychiatry, , Volume: 69 Suppl 4, 2008
Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.The pharmacogenomics journal, , Volume: 8, Issue:3, 2008
D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:2, 2008
Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison.Biological psychiatry, , Mar-01, Volume: 63, Issue:5, 2008
Possible association between the -2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-01, Volume: 32, Issue:1, 2008
Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia.Molecular psychiatry, , Volume: 13, Issue:2, 2008
Emerging from schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:3, 2008
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 33, Issue:3, 2008
Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia.Pharmacopsychiatry, , Volume: 41, Issue:3, 2008
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.Journal of clinical psychopharmacology, , Volume: 28, Issue:3, 2008
Problems with CATIE. Phase 1: Looking back--what the clinician needs to know.Connecticut medicine, , Volume: 72, Issue:4, 2008
An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:5, 2008
What CATIE found: results from the schizophrenia trial.Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
Did CATIE influence antipsychotic use?Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
Lessons to be learned from CATIE and CUtLASS.Psychiatric services (Washington, D.C.), , Volume: 59, Issue:5, 2008
Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives.Schizophrenia research, , Volume: 103, Issue:1-3, 2008
Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.Schizophrenia research, , Volume: 102, Issue:1-3, 2008
Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.Current medical research and opinion, , Volume: 24, Issue:5, 2008
Cost of antipsychotic polypharmacy in the treatment of schizophrenia.BMC psychiatry, , Apr-04, Volume: 8, 2008
Weight gain due to long term antipsychotic treatment of persistent mental disorders.Psychiatria Danubina, , Volume: 20, Issue:1, 2008
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial.Lancet (London, England), , Mar-29, Volume: 371, Issue:9618, 2008
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 23, Issue:8, 2008
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.Psychiatry research, , May-30, Volume: 159, Issue:1-2, 2008
Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study.PharmacoEconomics, , Volume: 26, Issue:4, 2008
Olanzapine metabolic side effects: a weight gain issue?Internal and emergency medicine, , Volume: 3, Issue:3, 2008
Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
High-dose olanzapine for treatment-resistant schizophrenia.The Journal of clinical psychiatry, , Volume: 69, Issue:2, 2008
Clinical and pharmacoeconomic evaluation of switch to olanzapine in veterans with schizophrenia or schizoaffective disorder.Psychopharmacology bulletin, , Volume: 41, Issue:1, 2008
Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.Schizophrenia research, , Volume: 99, Issue:1-3, 2008
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 69, Issue:3, 2008
Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis.Journal of clinical psychopharmacology, , Volume: 28, Issue:2, 2008
A pilot observational crossover study of QTc interval changes associated with switching between olanzapine and risperidone.The Journal of clinical psychiatry, , Volume: 68, Issue:5, 2007
Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-30, Volume: 31, Issue:1, 2007
A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis.Journal of clinical psychopharmacology, , Volume: 27, Issue:3, 2007
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.Archives of general psychiatry, , Volume: 64, Issue:6, 2007
Is the superior efficacy of new generation antipsychotics an artifact of LOCF?Schizophrenia bulletin, , Volume: 33, Issue:1, 2007
A fMRI investigation of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics.The international journal of neuropsychopharmacology, , Volume: 10, Issue:4, 2007
Second generation antipsychotics and risk of diabetes type II--comparison between olanzapine and risperidone.Collegium antropologicum, , Volume: 31, Issue:4, 2007
Comparison of the in-vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine.The international journal of neuropsychopharmacology, , Volume: 10, Issue:2, 2007
Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale.Psychopharmacology bulletin, , Volume: 40, Issue:2, 2007
Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:12, 2007
Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.The Journal of clinical psychiatry, , Volume: 68, Issue:12, 2007
Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Oct-05, Volume: 144B, Issue:7, 2007
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.Schizophrenia research, , Volume: 89, Issue:1-3, 2007
Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Olanzapine monotherapy for late-onset vocal tics in a schizophrenic patient.Psychiatry and clinical neurosciences, , Volume: 61, Issue:6, 2007
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
Olanzapine-induced tardive dystonia successfully treated by tetrabenazine.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 19, Issue:4, 2007
Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 19, Issue:4, 2007
Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients.Neuro endocrinology letters, , Volume: 28, Issue:6, 2007
The roadmap for antipsychotic psychopharmacology: an overview.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.Journal of evaluation in clinical practice, , Volume: 13, Issue:3, 2007
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.The Journal of clinical psychiatry, , Volume: 68, Issue:11, 2007
Decreased lipoprotein lipase as a risk factor for atypical neuroleptic-induced hypertriglyceridemia.The Journal of clinical psychiatry, , Volume: 68, Issue:5, 2007
Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia.Neuropsychobiology, , Volume: 55, Issue:1, 2007
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
Association study of olanzapine-induced weight gain and therapeutic response with SERT gene polymorphisms in female schizophrenic patients.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:7, 2007
Impairment in error monitoring predicts poor executive function in schizophrenia patients.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Item response analysis of the Positive and Negative Syndrome Scale.BMC psychiatry, , Nov-15, Volume: 7, 2007
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 15, Issue:6, 2007
The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 31, Issue:2, 2007
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.Journal of psychiatric research, , Volume: 41, Issue:8, 2007
The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities.The American journal of psychiatry, , Volume: 164, Issue:11, 2007
Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.The Journal of clinical psychiatry, , Volume: 68, Issue:10, 2007
Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients.International clinical psychopharmacology, , Volume: 22, Issue:1, 2007
The effectiveness criterion: balancing efficacy against the risks of weight gain.The Journal of clinical psychiatry, , Volume: 68 Suppl 12, 2007
Managing the acutely agitated and psychotic patient.CNS spectrums, , Volume: 12, Issue:10 Suppl 1, 2007
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.CNS spectrums, , Volume: 12, Issue:1, 2007
Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia.International clinical psychopharmacology, , Volume: 22, Issue:4, 2007
Risperidone versus olanzapine for treatment of schizophrenia.Schizophrenia bulletin, , Volume: 33, Issue:6, 2007
Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.Psychoneuroendocrinology, , Volume: 32, Issue:2, 2007
Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?Archives of general psychiatry, , Volume: 64, Issue:10, 2007
The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined.Schizophrenia research, , Volume: 90, Issue:1-3, 2007
Show me the evidence: using number needed to treat.Southern medical journal, , Volume: 100, Issue:9, 2007
Evidence-based psychiatry: outcomes and decisions.Southern medical journal, , Volume: 100, Issue:9, 2007
The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.Psychopharmacology, , Volume: 191, Issue:2, 2007
Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol.The American journal of psychiatry, , Volume: 164, Issue:10, 2007
Abnormalities in the fatty acid composition of the postmortem orbitofrontal cortex of schizophrenic patients: gender differences and partial normalization with antipsychotic medications.Schizophrenia research, , Volume: 91, Issue:1-3, 2007
Lilly investigated in US over the marketing of olanzapine.BMJ (Clinical research ed.), , Jan-27, Volume: 334, Issue:7586, 2007
An examination of factors affecting persistence with initial antipsychotic treatment in patients with schizophrenia.Current medical research and opinion, , Volume: 23, Issue:1, 2007
Analysis of treatment effectiveness in longitudinal observational data.Journal of biopharmaceutical statistics, , Volume: 17, Issue:5, 2007
Alteration in serum neural cell adhesion molecule in patients of schizophrenia.Human psychopharmacology, , Volume: 22, Issue:2, 2007
Low baseline serotonin-2A receptors predict clinical response to olanzapine in first-episode schizophrenia patients.Psychiatry research, , Oct-31, Volume: 153, Issue:2, 2007
Neuroreceptor gene polymorphisms and olanzapine depressive symptom response in schizophrenia.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Olanzapine-induced diabetic ketoacidosis in a Chinese man.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 13, Issue:1, 2007
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia.Psychopharmacology bulletin, , Volume: 40, Issue:1, 2007
Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?Psychiatric services (Washington, D.C.), , Volume: 58, Issue:2, 2007
Retrospective database analysis on the effectiveness of typical and atypical antipsychotic drugs in an outpatient clinic setting.Human psychopharmacology, , Volume: 22, Issue:8, 2007
Schizophrenic patients treated with clozapine or olanzapine perform better on theory of mind tasks than those treated with risperidone or typical antipsychotic medications.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.International clinical psychopharmacology, , Volume: 22, Issue:2, 2007
Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia.Biological psychiatry, , Oct-01, Volume: 62, Issue:7, 2007
Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.Schizophrenia research, , Volume: 91, Issue:1-3, 2007
Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.Psychopharmacology, , Volume: 192, Issue:3, 2007
An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.Human psychopharmacology, , Volume: 22, Issue:7, 2007
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.Proceedings of the National Academy of Sciences of the United States of America, , Feb-27, Volume: 104, Issue:9, 2007
Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia.European archives of psychiatry and clinical neuroscience, , Volume: 257, Issue:7, 2007
Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Dec-05, Volume: 144B, Issue:8, 2007
How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.Psychopharmacology, , Volume: 195, Issue:2, 2007
Metabolic effects of the atypical antipsychotics.Southern medical journal, , Volume: 100, Issue:8, 2007
Changes in cortical volume with olanzapine in chronic schizophrenia.Pharmacopsychiatry, , Volume: 40, Issue:4, 2007
[Clinical and therapeutic aspects of agitation].L'Encephale, , Volume: 33 Pt 3, 2007
Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:7, 2007
A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.The Journal of clinical psychiatry, , Volume: 68, Issue:3, 2007
Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Treatment with amisulpride and olanzapine improve neuropsychological function in schizophrenia.Human psychopharmacology, , Volume: 22, Issue:7, 2007
Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.The American journal of psychiatry, , Volume: 164, Issue:4, 2007
An open-label study of olanzapine in children and adolescents with schizophrenia.Journal of psychiatric practice, , Volume: 13, Issue:2, 2007
Gender differences in response to antipsychotic treatment in outpatients with schizophrenia.Psychiatry research, , Dec-03, Volume: 153, Issue:3, 2007
CUtLASS confirms CATIE.Archives of general psychiatry, , Volume: 64, Issue:8, 2007
Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
First- vs second-generation antipsychotic drugs in schizophrenia.Archives of general psychiatry, , Volume: 64, Issue:8, 2007
Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients--a cost analysis.International journal of clinical pharmacology and therapeutics, , Volume: 45, Issue:5, 2007
Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: Olanzapine versus haloperidol.Cognitive neuropsychiatry, , Volume: 12, Issue:4, 2007
Megaloblastic anemia and osteopenia in an adolescent diagnosed with schizophrenia.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 46, Issue:4, 2007
Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 46, Issue:8, 2007
Pisa syndrome resolved after switching to olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 19, Issue:2, 2007
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.The British journal of psychiatry : the journal of mental science, , Volume: 191, 2007
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.CNS spectrums, , Volume: 12, Issue:3 Suppl 4, 2007
Diabetes and psychosis: olanzapine may not be the culprit.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 13, Issue:4, 2007
Cognition, functioning and quality of life in schizophrenia treatment: results of a one-year randomized controlled trial of olanzapine and quetiapine.Schizophrenia research, , Volume: 96, Issue:1-3, 2007
Comments on "Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine".Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 29, Issue:1, 2007
Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
[Hematological alterations associated to olanzapine use after clozapine-induced neutropenia].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 29, Issue:1, 2007
Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 22, Issue:7, 2007
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
Comments on the report of neuroleptic malignant syndrome induced by ziprasidone.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 8, Issue:2, 2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.The American journal of psychiatry, , Volume: 164, Issue:3, 2007
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.Nature medicine, , Volume: 13, Issue:9, 2007
Prolongation of clozapine-induced neutropenia with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:2, 2007
Managing psychosis in pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:3, 2007
A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:2, 2007
Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia.Schizophrenia research, , Volume: 95, Issue:1-3, 2007
Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 17, Issue:11, 2007
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.Pharmacopsychiatry, , Volume: 40, Issue:1, 2007
Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:10, 2007
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain.Journal of psychiatric research, , Volume: 41, Issue:5, 2007
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.Schizophrenia research, , Volume: 93, Issue:1-3, 2007
Perazine and carbamazepine in comparison to olanzapine in schizophrenia.Neuropsychobiology, , Volume: 55, Issue:2, 2007
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.Psychopharmacology, , Volume: 193, Issue:4, 2007
Reversible delayed onset olanzapine-associated leukopenia and neutropenia in a clozapine-naive patient on concomitant depot antipsychotic.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone.Schizophrenia research, , Volume: 94, Issue:1-3, 2007
Association of acute symptoms and compliance attitude in noncompliant patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
[A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 9, Issue:3, 2007
[Prescription of traditional neuroleptics in the remission period for schizophrenic patients with excess of body mass caused by atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 107, Issue:2, 2007
[The influence of atypical neuroleptics on the immune system of patients with schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:3, 2007
Early use of clozapine for poorly responding first-episode psychosis.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
[Glutamate dysmetabolism in patients with schizophrenia].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:3, 2007
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:2, 2007
Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.Archives of general psychiatry, , Volume: 63, Issue:6, 2006
Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.The Journal of clinical psychiatry, , Volume: 67, Issue:5, 2006
Switching to risperidone after unsuccessful treatment of olanzapine in the first-episode schizophrenia: an open trial.Progress in neuro-psychopharmacology & biological psychiatry, , Aug-30, Volume: 30, Issue:6, 2006
The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-30, Volume: 30, Issue:8, 2006
Plasma concentrations of high-dose olanzapine in a double-blind crossover study.Human psychopharmacology, , Volume: 21, Issue:6, 2006
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.Journal of psychiatric research, , Volume: 40, Issue:7, 2006
Hospitalization risks in the treatment of schizophrenia: comparison of antipsychotic medications.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Electrical brain activity and response to olanzapine in schizophrenia: a study with LORETA images of P300.Progress in neuro-psychopharmacology & biological psychiatry, , Sep-30, Volume: 30, Issue:7, 2006
Decision models in the evaluation of psychotropic drugs : useful tool or useless toy?The European journal of health economics : HEPAC : health economics in prevention and care, , Volume: 7, Issue:3, 2006
Successful switch to olanzapine after rhabdomyolysis caused by water intoxication and clozapine use.Pharmacopsychiatry, , Volume: 39, Issue:4, 2006
Atypical antipsychotics, tardive dyskinesia, and D(2) receptors.The American journal of psychiatry, , Volume: 163, Issue:8, 2006
A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.The European journal of health economics : HEPAC : health economics in prevention and care, , Volume: 7, Issue:3, 2006
[Molecular pharmacogenetic study on antipsychotic-drug therapy responders with depression or schizophrenia].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 108, Issue:6, 2006
Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.CNS & neurological disorders drug targets, , Volume: 5, Issue:4, 2006
Association between the interleukin-1 receptor antagonist gene and negative symptom improvement during antipsychotic treatment.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Dec-05, Volume: 141B, Issue:8, 2006
A model of anticholinergic activity of atypical antipsychotic medications.Schizophrenia research, , Volume: 88, Issue:1-3, 2006
[Optimizing the antipsychotic potency of olanzapine by augmentation--a critical review].Psychiatrische Praxis, , Volume: 33, Issue:6, 2006
Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia.American journal of epidemiology, , Oct-01, Volume: 164, Issue:7, 2006
An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:4, 2006
Self-cannibalism: an unusual case of self-mutilation.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:10, 2006
[Osteoporosis risk factors among patients with schizophrenia].Przeglad lekarski, , Volume: 63, Issue:3, 2006
Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning.Journal of clinical psychopharmacology, , Volume: 26, Issue:5, 2006
The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 26, Issue:5, 2006
Constructing an Index for the Subjective Well-being Under Neuroleptics scale (SWN), short form: applying structural equation modeling for testing reliability and validity of the index.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, , Volume: 15, Issue:7, 2006
Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.Psychiatry research, , Nov-15, Volume: 144, Issue:2-3, 2006
Ethical concerns regarding olanzapine versus placebo in patients prodromally symptomatic for psychosis.The American journal of psychiatry, , Volume: 163, Issue:10, 2006
Early changes of plasma lipids during treatment with atypical antipsychotics.International clinical psychopharmacology, , Volume: 21, Issue:6, 2006
The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone.The Journal of clinical psychiatry, , Volume: 67, Issue:9, 2006
A crossover study of prolactin changes associated with risperidone and olanzapine.The Journal of clinical psychiatry, , Volume: 67, Issue:9, 2006
Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.The Journal of clinical psychiatry, , Volume: 67, Issue:9, 2006
Positive findings for negative symptoms of schizophrenia: no longer untreatable?Acta psychiatrica Scandinavica, , Volume: 114, Issue:5, 2006
Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia.Human psychopharmacology, , Volume: 21, Issue:4, 2006
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.Acta psychiatrica Scandinavica, , Volume: 114, Issue:5, 2006
Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.Therapeutic drug monitoring, , Volume: 28, Issue:5, 2006
The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia.Therapeutic drug monitoring, , Volume: 28, Issue:5, 2006
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.Human psychopharmacology, , Volume: 21, Issue:4, 2006
Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 89, Issue:8, 2006
[Long QT syndrome due to olanzapine administration].Kardiologia polska, , Volume: 64, Issue:9, 2006
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine.Psychopharmacology, , Volume: 189, Issue:2, 2006
Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design.Psychopharmacology bulletin, , Volume: 39, Issue:1, 2006
[Endocrine side effects among psychiatric patients treated with antipsychotics].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:2, 2006
Reduced thalamic volume in patients with chronic schizophrenia after switching from typical antipsychotic medications to olanzapine.The American journal of psychiatry, , Volume: 163, Issue:11, 2006
Olanzapine: a 5-year perspective.Expert review of neurotherapeutics, , Volume: 6, Issue:6, 2006
Is olanzapine a brain-sparing medication?Archives of general psychiatry, , Volume: 63, Issue:11, 2006
The effect of variable cigarette consumption on the interaction with clozapine and olanzapine.European journal of clinical pharmacology, , Volume: 62, Issue:12, 2006
A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.The Journal of clinical psychiatry, , Volume: 67, Issue:10, 2006
Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.The Journal of clinical psychiatry, , Volume: 67, Issue:10, 2006
Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study.Journal of clinical psychopharmacology, , Volume: 26, Issue:6, 2006
Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.Journal of clinical psychopharmacology, , Volume: 26, Issue:6, 2006
Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use.Journal of clinical psychopharmacology, , Volume: 26, Issue:6, 2006
A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Efficacy with high-dose aripiprazole after olanzapine-related metabolic disturbances.The Annals of pharmacotherapy, , Volume: 40, Issue:12, 2006
Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:11, 2006
Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.PharmacoEconomics, , Volume: 24, Issue:12, 2006
Clinical trial-based cost-effectiveness analyses of antipsychotic use.The American journal of psychiatry, , Volume: 163, Issue:12, 2006
Effectiveness of switching antipsychotic medications.The American journal of psychiatry, , Volume: 163, Issue:12, 2006
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.The American journal of psychiatry, , Volume: 163, Issue:12, 2006
Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: effects of dose, diagnosis, age, sex, smoking, and comedication.Therapeutic drug monitoring, , Volume: 28, Issue:6, 2006
Treatment of psychosis: 30 years of progress.Journal of clinical pharmacy and therapeutics, , Volume: 31, Issue:6, 2006
Cerebellar and thalamic metabolic changes visualized by [18]-FDG-PET in olanzapine-induced acute akathisia.Neuro endocrinology letters, , Volume: 27, Issue:6, 2006
Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 67, Issue:11, 2006
[New formulations of olanzapine in the treatment of acute agitation].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
[Akathisia in the course of olanzapine treatment].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 28, Issue:4, 2006
Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report.Psychiatria Danubina, , Volume: 18, Issue:1-2, 2006
Reversible neutropenia with olanzapine following clozapine-induced neutropenia.The American journal of psychiatry, , Volume: 163, Issue:7, 2006
Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.Archives of general psychiatry, , Volume: 63, Issue:7, 2006
Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-30, Volume: 30, Issue:8, 2006
[The use of atypical antipsychotics in the long-term care of schizophrenia].L'Encephale, , Volume: 32 Pt 3, 2006
Gender differences in prolactin elevation induced by olanzapine in Japanese drug-naïve schizophrenic patients.Progress in neuro-psychopharmacology & biological psychiatry, , Dec-30, Volume: 30, Issue:8, 2006
Growth hormone therapy may diminish olanzapine serum level.Medical hypotheses, , Volume: 67, Issue:4, 2006
Neurological soft signs and positive treatment response to olanzapine in chronic schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:1, 2006
The effects of celecoxib augmentation on cytokine levels in schizophrenia.The international journal of neuropsychopharmacology, , Volume: 9, Issue:3, 2006
Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine.Biological psychiatry, , Mar-15, Volume: 59, Issue:6, 2006
Influence of atypical neuroleptics on executive functioning in patients with schizophrenia: a randomized, double-blind comparison of olanzapine vs. clozapine.The international journal of neuropsychopharmacology, , Volume: 9, Issue:2, 2006
The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:3, 2006
Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine.Psychoneuroendocrinology, , Volume: 31, Issue:2, 2006
One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia.Schizophrenia research, , Jan-01, Volume: 81, Issue:1, 2006
Electroencephalogram slowing, sleepiness and treatment response in patients with schizophrenia during olanzapine treatment.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:1, 2006
Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:1, 2006
Estimating transitions between symptom severity states over time in schizophrenia: a Bayesian meta-analytic approach.Statistics in medicine, , Sep-15, Volume: 25, Issue:17, 2006
An economic comparison of risperidone and olanzapine use within an integrated managed mental health program.Administration and policy in mental health, , Volume: 33, Issue:2, 2006
Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.Psychopharmacology, , Volume: 183, Issue:4, 2006
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Jan-31, Volume: 81, Issue:2-3, 2006
Atypical antipsychotic drugs and organization of long-term semantic memory: multidimensional scaling and cluster analyses of category fluency performance in schizophrenia.The international journal of neuropsychopharmacology, , Volume: 9, Issue:6, 2006
Treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions.Child and adolescent psychiatric clinics of North America, , Volume: 15, Issue:1, 2006
A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia.Schizophrenia research, , Feb-15, Volume: 82, Issue:1, 2006
The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration.International journal of geriatric psychiatry, , Volume: 21, Issue:2, 2006
Antipsychotic drugs and schizophrenia.The New England journal of medicine, , Jan-19, Volume: 354, Issue:3, 2006
Antipsychotic drugs and schizophrenia.The New England journal of medicine, , Jan-19, Volume: 354, Issue:3, 2006
Antipsychotic drugs and schizophrenia.The New England journal of medicine, , Jan-19, Volume: 354, Issue:3, 2006
Antipsychotic drugs and schizophrenia.The New England journal of medicine, , Jan-19, Volume: 354, Issue:3, 2006
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.Acta psychiatrica Scandinavica, , Volume: 113, Issue:2, 2006
Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.The Journal of clinical psychiatry, , Volume: 67, Issue:1, 2006
Pharmacological management of akathisia in combination with psychological interventions by a mental health nurse consultant.Journal of psychiatric and mental health nursing, , Volume: 13, Issue:1, 2006
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.The American journal of psychiatry, , Volume: 163, Issue:2, 2006
Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 12, Issue:2, 2006
Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.Journal of clinical pharmacy and therapeutics, , Volume: 31, Issue:1, 2006
Galantamine may improve attention and speech in schizophrenia.Human psychopharmacology, , Volume: 21, Issue:2, 2006
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.Psychoneuroendocrinology, , Volume: 31, Issue:5, 2006
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.BMC psychiatry, , Feb-21, Volume: 6, 2006
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.The American journal of psychiatry, , Volume: 163, Issue:3, 2006
Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 18, Issue:1, 2006
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.Schizophrenia research, , Volume: 83, Issue:1, 2006
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:4, 2006
Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:10, 2006
Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.Acta psychiatrica Scandinavica. Supplementum, , Issue:430, 2006
Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report.Pharmacopsychiatry, , Volume: 39, Issue:2, 2006
Selecting antipsychotics in schizophrenia: lessons from CATIE.Journal of psychopharmacology (Oxford, England), , Volume: 20, Issue:3, 2006
Weight gain associated with the alpha2a-adrenergic receptor -1,291 C/G polymorphism and olanzapine treatment.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Jun-05, Volume: 141B, Issue:4, 2006
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.The American journal of psychiatry, , Volume: 163, Issue:4, 2006
Weight change in treatment with olanzapine and a psychoeducational approach.Eating behaviors, , Volume: 7, Issue:2, 2006
Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.Psychopharmacology, , Volume: 186, Issue:4, 2006
Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 51, Issue:3, 2006
[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].Medicina clinica, , Apr-01, Volume: 126, Issue:12, 2006
Risperidone versus olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Apr-19, Issue:2, 2006
Prolongation of clozapine-induced leukopenia with olanzapine treatment.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:5, 2006
A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms.Journal of clinical psychopharmacology, , Volume: 26, Issue:2, 2006
Pharmacogenetics of antipsychotic-induced weight gain.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 12, Issue:5, 2006
Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis.The American journal of psychiatry, , Volume: 163, Issue:5, 2006
Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.The Journal of clinical psychiatry, , Volume: 67, Issue:4, 2006
Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:5, 2006
Effect of olanzapine treatment on platelet glutamine synthetase-like protein and glutamate dehydrogenase immunoreactivity in schizophrenia.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 7, Issue:2, 2006
A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:8, 2006
Why do physicians switch from one antipsychotic agent to another? The "physician drug stereotype".Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 26, Issue:3, 2006
Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics.Psychopharmacology, , Volume: 187, Issue:2, 2006
Injectable atypical antipsychotics for agitation in borderline personality disorder.Pharmacopsychiatry, , Volume: 39, Issue:3, 2006
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.Schizophrenia research, , Volume: 86, Issue:1-3, 2006
Rapid leptin elevation after initiation of olanzapine?Neuropsychobiology, , Volume: 54, Issue:3, 2006
Long-term treatment with atypical antipsychotics and risk of weight gain.Drug safety, , Volume: 29, Issue:6, 2006
Effect of therapy with atypical antipsychotic drugs on prolactin concentration in patients with schizophrenia and schizoaffective disorders.Bulletin of experimental biology and medicine, , Volume: 140, Issue:6, 2005
Olanzapine-induced obesity and diabetes in Indian patients: a prospective trial comparing olanzapine with typical antipsychotics.Journal of the Indian Medical Association, , Volume: 103, Issue:12, 2005
Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 30, Issue:2, 2005
Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia.International clinical psychopharmacology, , Volume: 20, Issue:1, 2005
Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients.International clinical psychopharmacology, , Volume: 20, Issue:1, 2005
Switching depot antipsychotic drug responders to oral olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:1, 2005
Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Olanzapine treatment of residual positive and negative symptoms.The American journal of psychiatry, , Volume: 162, Issue:1, 2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.Archives of general psychiatry, , Volume: 62, Issue:1, 2005
Clinical outcome and olanzapine plasma levels in acute schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:1, 2005
Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.BMC psychiatry, , Jan-13, Volume: 5, 2005
The use of atypical antipsychotics in the treatment of schizophrenia in North Staffordshire.Human psychopharmacology, , Volume: 20, Issue:2, 2005
Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.Journal of clinical pharmacy and therapeutics, , Volume: 30, Issue:1, 2005
Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia.Acta psychiatrica Scandinavica, , Volume: 111, Issue:2, 2005
Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:1, 2005
Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study.Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Olanzapine vs. other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study.Acta psychiatrica Scandinavica, , Volume: 111, Issue:3, 2005
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
Diabetes mellitus during olanzapine and quetiapine treatment in Japan.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being.Pharmacopsychiatry, , Volume: 38, Issue:1, 2005
The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients.International clinical psychopharmacology, , Volume: 20, Issue:2, 2005
Olanzapine increases plasma ghrelin level in patients with schizophrenia.Psychoneuroendocrinology, , Volume: 30, Issue:1, 2005
Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.International clinical psychopharmacology, , Volume: 20, Issue:2, 2005
Comparison of large versus smaller randomized trials for mental health-related interventions.The American journal of psychiatry, , Volume: 162, Issue:3, 2005
Comparison of clozapine use in Maryland and in Victoria, Australia.Psychiatric services (Washington, D.C.), , Volume: 56, Issue:3, 2005
Capgras syndrome in the modern era: self misidentification on an ID picture.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:1, 2005
Health care costs for schizophrenia patients started on olanzapine versus risperidone.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Mar-15, Volume: 62, Issue:6, 2005
Focus on the metabolic consequences of long-term treatment with olanzapine, quetiapine and risperidone: are there differences?The international journal of neuropsychopharmacology, , Volume: 8, Issue:2, 2005
D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.Biological psychiatry, , Mar-15, Volume: 57, Issue:6, 2005
A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.The international journal of neuropsychopharmacology, , Volume: 8, Issue:3, 2005
Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.Pharmacoepidemiology and drug safety, , Volume: 14, Issue:6, 2005
Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection.Therapeutic drug monitoring, , Volume: 27, Issue:2, 2005
Antipsychotic drug effects on brain morphology in first-episode psychosis.Archives of general psychiatry, , Volume: 62, Issue:4, 2005
Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone.International clinical psychopharmacology, , Volume: 20, Issue:3, 2005
The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study.Schizophrenia research, , Jun-01, Volume: 75, Issue:1, 2005
[Parameters of platelet serotonin system in patients with schizophrenia treated with olanzapine: a search for the serotonergic predictors of therapeutic efficacy].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 105, Issue:3, 2005
Internet in clinical research based on a pilot experience.Contemporary clinical trials, , Volume: 26, Issue:2, 2005
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Apr-18, Issue:2, 2005
Risperidone versus olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Apr-18, Issue:2, 2005
Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: a multivariate analysis of a large naturalistic study in the hospital setting.Medicina clinica, , Apr-09, Volume: 124, Issue:13, 2005
The paradox of quetiapine in obsessive-compulsive disorder.CNS spectrums, , Volume: 10, Issue:5, 2005
Evidence for onset of antipsychotic effects within the first 24 hours of treatment.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis.Pharmacogenetics and genomics, , Volume: 15, Issue:4, 2005
Brain electrical activity changes in treatment refractory schizophrenics after olanzapine treatment.International journal of psychophysiology : official journal of the International Organization of Psychophysiology, , Volume: 56, Issue:3, 2005
Effects of olanzapine on auditory P300 and mismatch negativity (MMN) in schizophrenia spectrum disorders.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:4, 2005
The association of weight gain and olanzapine plasma concentrations.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
The influence of olanzapine versus risperidone on facial expression of emotions in schizophrenia--preliminary results of a facial electromyogram study.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:5, 2005
Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.Schizophrenia research, , Sep-15, Volume: 77, Issue:2-3, 2005
Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review.CNS drugs, , Volume: 19, Issue:5, 2005
Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment.Schizophrenia research, , Sep-15, Volume: 77, Issue:2-3, 2005
Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol.The Journal of nervous and mental disease, , Volume: 193, Issue:6, 2005
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.BMC psychiatry, , May-27, Volume: 5, 2005
Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation.Schizophrenia research, , Jul-01, Volume: 76, Issue:1, 2005
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.International clinical psychopharmacology, , Volume: 20, Issue:4, 2005
Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:6, 2005
Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 29, Issue:6, 2005
Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia.Psychiatry research, , May-30, Volume: 139, Issue:1, 2005
Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved.Acta psychiatrica Scandinavica, , Volume: 112, Issue:1, 2005
Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.The Journal of clinical psychiatry, , Volume: 66, Issue:6, 2005
Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review.CNS drugs, , Volume: 19, Issue:6, 2005
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.Drug metabolism and pharmacokinetics, , Volume: 20, Issue:3, 2005
Executive function assessment of patients with schizophrenic disorder residual type in olanzapine treatment: an open study.Human psychopharmacology, , Volume: 20, Issue:6, 2005
Methodological concerns in a trial of ziprasidone and olanzapine.The American journal of psychiatry, , Volume: 162, Issue:7, 2005
Methodological concerns in a trial of ziprasidone and olanzapine.The American journal of psychiatry, , Volume: 162, Issue:7, 2005
Olanzapine and haloperidol for residual symptoms.The American journal of psychiatry, , Volume: 162, Issue:7, 2005
Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics.Journal of clinical psychopharmacology, , Volume: 25, Issue:4, 2005
Flexible-dose clinical trials: predictors and outcomes of antipsychotic dose adjustments.Journal of clinical psychopharmacology, , Volume: 25, Issue:4, 2005
Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics.The Journal of clinical psychiatry, , Volume: 66, Issue:7, 2005
Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey.Pharmacopsychiatry, , Volume: 38, Issue:4, 2005
Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.Psychiatry and clinical neurosciences, , Volume: 59, Issue:4, 2005
A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia.Schizophrenia research, , Nov-15, Volume: 79, Issue:2-3, 2005
Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia.The American journal of psychiatry, , Volume: 162, Issue:8, 2005
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Effectiveness of clozapine, olanzapine, quetiapine, risperidone, and haloperidol monotherapy in reducing hostile and aggressive behavior in outpatients treated for schizophrenia: a prospective naturalistic study (IC-SOHO).European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
[Obsessive-compulsive symptoms treatment in: schizophrenia].Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:7, 2005
Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.The Journal of clinical psychiatry, , Volume: 66, Issue:8, 2005
Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients.Schizophrenia research, , Oct-15, Volume: 78, Issue:2-3, 2005
Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 30, Issue:12, 2005
Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:8, 2005
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
Olanzapine and weight gain.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
[Prescription of psychotropic drugs for schizophrenic outpatients in Hungary].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 7, Issue:1, 2005
Patient outcomes in schizophrenia I: correlates with sociodemographic variables, psychopathology, and side effects.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Patient outcomes in schizophrenia II: the impact of cognition.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 20, Issue:5-6, 2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.The New England journal of medicine, , Sep-22, Volume: 353, Issue:12, 2005
The choice of antipsychotic drugs for schizophrenia.The New England journal of medicine, , Sep-22, Volume: 353, Issue:12, 2005
Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone.Human psychopharmacology, , Volume: 20, Issue:8, 2005
Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.The Journal of clinical psychiatry, , Volume: 66, Issue:9, 2005
Assessing cardiovascular risks of olanzapine treatment: a 6-month study versus haloperidol in schizophrenia patients.International clinical psychopharmacology, , Volume: 20, Issue:6, 2005
Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.Psychiatry and clinical neurosciences, , Volume: 59, Issue:5, 2005
Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.Nordic journal of psychiatry, , Volume: 59, Issue:3, 2005
Olanzapine: a critical review of recent literature.Expert opinion on pharmacotherapy, , Volume: 6, Issue:12, 2005
Clinical implications of Brief Psychiatric Rating Scale scores.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.The American journal of psychiatry, , Volume: 162, Issue:10, 2005
NMS after clozapine initiation.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 44, Issue:11, 2005
A crossover study on lipid and weight changes associated with olanzapine and risperidone.Psychopharmacology, , Volume: 183, Issue:3, 2005
Unusual suspect for antipsychotic-induced diabetes.Drug discovery today, , Oct-15, Volume: 10, Issue:20, 2005
[Atypical antipsychotic-associated impaired glucose tolerance].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 107, Issue:8, 2005
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.Journal of psychopharmacology (Oxford, England), , Volume: 19, Issue:6 Suppl, 2005
The CATIE schizophrenia effectiveness trial.Schizophrenia research, , Dec-01, Volume: 80, Issue:1, 2005
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.The British journal of psychiatry : the journal of mental science, , Volume: 187, 2005
Augmentation of olanzapine in treatment-resistant schizophrenia.Journal of psychiatry & neuroscience : JPN, , Volume: 30, Issue:6, 2005
A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.Clinical therapeutics, , Volume: 27, Issue:10, 2005
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.Statistics in medicine, , Jan-15, Volume: 24, Issue:1, 2005
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:11, 2005
Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.BMC medicine, , Dec-23, Volume: 3, 2005
Early effects of treatment on regional cerebral blood flow in first episode schizophrenia patients evaluated with 99Tc-ECD-SPECT.Neuro endocrinology letters, , Volume: 26, Issue:6, 2005
Olanzapine versus risperidone in newly admitted acutely ill psychotic patients.The Journal of clinical psychiatry, , Volume: 66, Issue:12, 2005
The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia.Psychiatry and clinical neurosciences, , Volume: 59, Issue:6, 2005
Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.PharmacoEconomics, , Volume: 23 Suppl 1, 2005
Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis.PharmacoEconomics, , Volume: 23 Suppl 1, 2005
[Neuroleptic drug utilization among schizophrenic outpatients].Revue d'epidemiologie et de sante publique, , Volume: 53, Issue:6, 2005
Ambulatory use of olanzapine and risperidone: a population-based study on persistence and the use of concomitant therapy in the treatment of schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:14, 2005
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study.Clinical therapeutics, , Volume: 27, Issue:12, 2005
Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 88, Issue:9, 2005
Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Serum ghrelin concentrations in patients receiving olanzapine or risperidone.Psychopharmacology, , Volume: 172, Issue:2, 2004
Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.Psychopharmacology, , Volume: 172, Issue:3, 2004
Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , Jan-01, Volume: 124B, Issue:1, 2004
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:1, 2004
A neurobehavioral screening of the ckr mouse mutant: implications for an animal model of schizophrenia.Brain research bulletin, , Jan-15, Volume: 62, Issue:4, 2004
Are high initial doses of olanzapine required to reduce agitation associated with schizophrenia?Journal of clinical psychopharmacology, , Volume: 24, Issue:1, 2004
Olanzapine treatment of eight adolescent patients with psychosis.Human psychopharmacology, , Volume: 19, Issue:1, 2004
High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.Biological psychiatry, , Jan-15, Volume: 55, Issue:2, 2004
Cost comparisons of olanzapine and risperidone in treating schizophrenia.The Annals of pharmacotherapy, , Volume: 38, Issue:1, 2004
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:1, 2004
Comparisons of psychotropic drug prescribing patterns in acute psychiatric wards across Europe.European journal of clinical pharmacology, , Volume: 60, Issue:1, 2004
Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.Pharmacopsychiatry, , Volume: 37, Issue:1, 2004
Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:2, 2004
Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period.Psychopharmacology, , Volume: 175, Issue:2, 2004
Ethnicity and prescription patterns for haloperidol, risperidone, and olanzapine.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:2, 2004
Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database.CNS drugs, , Volume: 18, Issue:3, 2004
Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.Current medicinal chemistry, , Volume: 11, Issue:3, 2004
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.Current medicinal chemistry, , Volume: 11, Issue:3, 2004
New antipsychotics and schizophrenia: a review on efficacy and side effects.Current medicinal chemistry, , Volume: 11, Issue:3, 2004
The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia.Life sciences, , Mar-05, Volume: 74, Issue:16, 2004
Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:1, 2004
Olanzapine use in a patient with schizophrenia and the risk of diabetes.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:1, 2004
Valproate for hostility in schizophrenia patients.The Journal of clinical psychiatry, , Volume: 65, Issue:1, 2004
Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.The Journal of neuropsychiatry and clinical neurosciences, ,Winter, Volume: 16, Issue:1, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:3, 2004
Potential for detection bias in the association between olanzapine and diabetes.The Journal of clinical psychiatry, , Volume: 65, Issue:2, 2004
Open label study of the effect of amantadine on weight gain induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 58, Issue:2, 2004
Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial.Biological psychiatry, , Mar-01, Volume: 55, Issue:5, 2004
[Current pharmacotherapy of schizophrenia].Orvosi hetilap, , Jan-18, Volume: 145, Issue:3, 2004
Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients.Pharmacopsychiatry, , Volume: 37, Issue:2, 2004
P300 alterations in schizophrenic patients experiencing auditory hallucinations.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 14, Issue:3, 2004
Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Score tests for dose effect in the presence of non-responders.Statistics in medicine, , Dec-15, Volume: 23, Issue:23, 2004
Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.Journal of clinical psychopharmacology, , Volume: 24, Issue:6, 2004
Absence of effect of olanzapine on primary polydipsia: results of a double-blind, randomized study.Journal of clinical psychopharmacology, , Volume: 24, Issue:6, 2004
Subchronic effects of olanzapine on sleep EEG in schizophrenic patients with predominantly negative symptoms.Pharmacopsychiatry, , Volume: 37, Issue:4, 2004
The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders.European archives of psychiatry and clinical neuroscience, , Volume: 254, Issue:6, 2004
Reversible neutropenia during treatment with olanzapine: three case reports.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:4, 2004
Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia.Journal of clinical pharmacology, , Volume: 44, Issue:12, 2004
Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial.Pharmacopsychiatry, , Volume: 37, Issue:6, 2004
EEG abnormalities under treatment with atypical antipsychotics: effects of olanzapine and amisulpride as compared to haloperidol.Pharmacopsychiatry, , Volume: 37, Issue:6, 2004
Effects of changing from typical to atypical antipsychotic drugs on subjective sleep quality in patients with schizophrenia in a Japanese population.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.The Journal of clinical psychiatry, , Volume: 65, Issue:11, 2004
Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.Journal of clinical pharmacy and therapeutics, , Volume: 29, Issue:5, 2004
Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
[Rehospitalization rates of newly diagnosed schizophrenic patients on atypical neuroleptic medication].Psychiatrische Praxis, , Volume: 31 Suppl 1, 2004
Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
[Alterations of gait parameters under external cueing in schizophrenic patients: a switch study].Psychiatrische Praxis, , Volume: 31 Suppl 1, 2004
Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia.The American journal of psychiatry, , Volume: 161, Issue:10, 2004
[Diabetes as a complication in treatment with second-generation antipsychotics].Ugeskrift for laeger, , Aug-23, Volume: 166, Issue:35, 2004
Skin hyperpigmentation induced by olanzapine, a novel antipsychotic agent.International journal of dermatology, , Volume: 43, Issue:10, 2004
Heavy smoking, reduced olanzapine levels, and treatment effects: a case report.Therapeutic drug monitoring, , Volume: 26, Issue:5, 2004
The validity and reliability of the global index of safety (GIS).Current medical research and opinion, , Volume: 20, Issue:11, 2004
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.Controlled clinical trials, , Volume: 25, Issue:6, 2004
Heart rate variability during sleep in patients with schizophrenia treated with olanzapine.International clinical psychopharmacology, , Volume: 19, Issue:6, 2004
Is it worth while changing clinically stable schizophrenic out-patients with mild to moderate residual symptoms and/or side effects from conventional to atypical antipsychotics? A prospective, randomised study with olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:8, 2004
Dyslipidemia and atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 28, Issue:6, 2004
A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.The Journal of clinical psychiatry, , Volume: 65 Suppl 18, 2004
Weight gain and new onset diabetes associated with olanzapine and risperidone.Journal of general internal medicine, , Volume: 19, Issue:12, 2004
Effects of typical and atypical antipsychotics on human glycine transporters.Schizophrenia research, , Nov-01, Volume: 71, Issue:1, 2004
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.Schizophrenia bulletin, , Volume: 30, Issue:3, 2004
Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia.Schizophrenia bulletin, , Volume: 30, Issue:3, 2004
Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
Normalization of impaired cognitive functions failed to improve clinical symptomatology in a schizophrenic patient.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:6, 2004
[Introduction of new anti-psychotic drugs and changes in the clinical practice].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 106, Issue:7, 2004
Safety and tolerability of olanzapine compared with other antipsychotics in the treatment of elderly patients with schizophrenia: a naturalistic study.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 19, Issue:6, 2004
Hypnopompic hallucinations during olanzapine treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:7, 2004
Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study.Annals of the New York Academy of Sciences, , Volume: 1032, 2004
[Treatment of "the premonitory state of schizophrenia" with atypical antipsychotics].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 106, Issue:11, 2004
The effects of clozapine and high-dose olanzapine on brain function in treatment-resistant schizophrenia: a case study.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.Current medical research and opinion, , Volume: 20, Issue:12, 2004
Atypical antipsychotics: matching receptor profile to individual patient's clinical profile.CNS spectrums, , Volume: 9, Issue:10 Suppl 1, 2004
Neurologic soft signs and olanzapine treatment in chronic schizophrenia.Journal of clinical psychopharmacology, , Volume: 24, Issue:5, 2004
Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:9, 2004
Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.The American journal of psychiatry, , Volume: 161, Issue:9, 2004
Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.The American journal of psychiatry, , Volume: 161, Issue:9, 2004
Variables associated with high olanzapine dosing in a state hospital.The Journal of clinical psychiatry, , Volume: 65, Issue:8, 2004
Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets.Psychopharmacology, , Volume: 175, Issue:3, 2004
[Zyprexa--various dosage forms, the goal: improving the prognosis for patients with schizophrenia and bipolar disorders].Krankenpflege Journal, , Volume: 42, Issue:3-4, 2004
Schizophrenia.Clinical evidence, , Issue:12, 2004
Obesity in schizophrenic outpatients receiving antipsychotics in Taiwan.Psychiatry and clinical neurosciences, , Volume: 58, Issue:4, 2004
Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia.Psychiatry and clinical neurosciences, , Volume: 58, Issue:4, 2004
Long-term olanzapine treatment and p300 parameters in schizophrenia.Neuropsychobiology, , Volume: 50, Issue:2, 2004
A comparison of type 2 diabetes outcomes among persons with and without severe mental illnesses.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:8, 2004
Comments on cost analysis of risperidone versus olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:6, 2004
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone.The Journal of clinical psychiatry, , Volume: 65, Issue:6, 2004
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
First person account: My dream life, a normal life.Schizophrenia bulletin, , Volume: 30, Issue:4, 2004
Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial.The American journal of psychiatry, , Volume: 161, Issue:8, 2004
Re: treatment noncompliance with orally disintegrating olanzapine tablets.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:6, 2004
Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine.Biological psychiatry, , Aug-01, Volume: 56, Issue:3, 2004
[A change of immune profile of patients with schizophrenia during treatment].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 104, Issue:4, 2004
Cognitive effects of olanzapine treatment in schizophrenia.MedGenMed : Medscape general medicine, , May-10, Volume: 6, Issue:2, 2004
Economic outcomes associated with olanzapine versus risperidone in the treatment of uncontrolled schizophrenia.Current medical research and opinion, , Volume: 20, Issue:7, 2004
Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders.The British journal of psychiatry : the journal of mental science, , Volume: 185, 2004
Obsessive-compulsive symptoms with olanzapine.The international journal of neuropsychopharmacology, , Volume: 7, Issue:3, 2004
Cognitive function and depression in symptom resolution in schizophrenia patients treated with an atypical antipsychotic.Brain and cognition, , Volume: 55, Issue:3, 2004
Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia.MedGenMed : Medscape general medicine, , Jan-20, Volume: 6, Issue:1, 2004
Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.Journal of clinical psychopharmacology, , Volume: 24, Issue:2, 2004
Weight gain during long-term treatment with olanzapine: a case series.International clinical psychopharmacology, , Volume: 19, Issue:4, 2004
Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia.International clinical psychopharmacology, , Volume: 19, Issue:4, 2004
[Expectations and developments in atypical antipsychotics].Praxis, , Aug-25, Volume: 93, Issue:35, 2004
Tardive dyskinesia associated with olanzapine in a neuroleptic-naive patient with schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:5, 2004
Tardive dyskinesia rates with atypical antipsychotics in older adults.The Journal of clinical psychiatry, , Volume: 65 Suppl 9, 2004
A preliminary study of the comparative effects of olanzapine and risperidone on cognition in schizophrenia.Human psychopharmacology, , Volume: 19, Issue:4, 2004
Olanzapine- and clozapine-induced stuttering. A case series.Pharmacopsychiatry, , Volume: 37, Issue:3, 2004
Atypical antipsychotics and diabetes mellitus.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 5, Issue:2, 2004
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.The American journal of psychiatry, , Volume: 161, Issue:6, 2004
The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 14, Issue:4, 2004
Patterns of concomitant psychotropic medication use during a 2-year study comparing clozapine and olanzapine for the prevention of suicidal behavior.The Journal of clinical psychiatry, , Volume: 65, Issue:5, 2004
Atypical antipsychotics and diabetes mellitus: an association.The Israel Medical Association journal : IMAJ, , Volume: 6, Issue:5, 2004
Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia.The American journal of emergency medicine, , Volume: 22, Issue:3, 2004
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.The Journal of clinical psychiatry, , Volume: 65 Suppl 6, 2004
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.The Journal of clinical psychiatry, , Volume: 65, Issue:4, 2004
Improvement in prosocial functioning after a switch to ziprasidone treatment.CNS spectrums, , Volume: 9, Issue:5, 2004
Olanzapine in the treatment of agitation in hospitalized patients with schizophrenia and schizoaffective and schizofreniform disorders.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 10, Issue:5, 2004
COMT158 polymorphism and hostility.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, , May-15, Volume: 127B, Issue:1, 2004
Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:1, 2004
Serum adiponectin concentrations during treatment with olanzapine or risperidone: a pilot study.International clinical psychopharmacology, , Volume: 19, Issue:1, 2004
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.International clinical psychopharmacology, , Volume: 19, Issue:1, 2004
An excitement subscale of the Positive and Negative Syndrome Scale.Schizophrenia research, , Jun-01, Volume: 68, Issue:2-3, 2004
The incidence of hyperglycemia in patients treated with olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Adherence to conventional and atypical antipsychotics after hospital discharge.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.Psychopharmacology, , Volume: 175, Issue:4, 2004
A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.International clinical psychopharmacology, , Volume: 19, Issue:2, 2004
Aripirazole-olanzapine combination for treatment of schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 49, Issue:2, 2004
Improvement in social cognition in patients with schizophrenia associated with treatment with olanzapine.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Treatment of tardive pharyngolaryngeal dystonia with olanzapine.Schizophrenia research, , Feb-01, Volume: 66, Issue:2-3, 2004
Weight change after an atypical antipsychotic switch.The Annals of pharmacotherapy, , Volume: 37, Issue:10, 2003
Racial disparity in the use of atypical antipsychotic medications among veterans.The American journal of psychiatry, , Volume: 160, Issue:10, 2003
Schizophrenia, VI: Treatments.The American journal of psychiatry, , Volume: 160, Issue:10, 2003
[3-D ultrasound-assisted gait analysis of schizophrenic patients. Comparison between conventional neuroleptics and olanzapine].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
[Neuroleptics and cognition].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
[Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].Psychiatrische Praxis, , Volume: 30 Suppl 2, 2003
Prepulse inhibition of acoustic startle in subjects with schizophrenia treated with olanzapine or haloperidol.Psychiatry research, , Aug-30, Volume: 120, Issue:1, 2003
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:11, 2003
Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex.Neuroscience letters, , Oct-09, Volume: 349, Issue:3, 2003
Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial.Psychiatry and clinical neurosciences, , Volume: 57, Issue:5, 2003
Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder.International journal of geriatric psychiatry, , Volume: 18, Issue:9, 2003
Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.The Journal of clinical psychiatry, , Volume: 64, Issue:7, 2003
An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: comparisons with placebo, haloperidol, risperidone, or clozapine.The Journal of clinical psychiatry, , Volume: 64, Issue:8, 2003
Eruptive xanthomas associated with olanzapine use.Archives of dermatology, , Volume: 139, Issue:8, 2003
Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.Human psychopharmacology, , Volume: 18, Issue:6, 2003
Effect of nizatidine on olanzapine-associated weight gain in schizophrenic patients in Korea: a pilot study.Human psychopharmacology, , Volume: 18, Issue:6, 2003
A Canadian multicenter trial assessing memory and executive functions in patients with schizophrenia spectrum disorders treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 23, Issue:4, 2003
Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.International clinical psychopharmacology, , Volume: 18, Issue:5, 2003
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.Biological psychiatry, , Aug-15, Volume: 54, Issue:4, 2003
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome.Biological psychiatry, , Aug-15, Volume: 54, Issue:4, 2003
Quetiapine in the successful treatment of schizophrenia with comorbid alcohol and drug dependence: a case report.International journal of psychiatry in medicine, , Volume: 33, Issue:1, 2003
Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:11, 2003
Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.Pharmacological research, , Volume: 48, Issue:4, 2003
Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.The American journal of psychiatry, , Volume: 160, Issue:8, 2003
Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia.The international journal of neuropsychopharmacology, , Volume: 6, Issue:2, 2003
Economic evaluations of novel antipsychotic medications: a literature review.Schizophrenia research, , Apr-01, Volume: 60, Issue:2-3, 2003
[An introduction to antipsychotics].Ryoikibetsu shokogun shirizu, , Issue:38, 2003
A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.Clinical therapeutics, , Volume: 25, Issue:5, 2003
Treatment noncompliance with orally disintegrating olanzapine tablets.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Potential risk of diabetes mellitus with the use of atypical antipsychotic medication.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Should lipids be monitored during the first year of treatment with an atypical antipsychotic?Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:5, 2003
Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
[3H]RX 821002 in human dorsolateral prefrontal cortex: no changes in postmortem tissue from subjects with schizophrenia.Psychiatry research, , Jul-15, Volume: 119, Issue:1-2, 2003
Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.Psychopharmacology, , Volume: 170, Issue:2, 2003
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.Psychopharmacology, , Volume: 169, Issue:3-4, 2003
Rehospitalization risk with second-generation and depot antipsychotics.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 15, Issue:1, 2003
Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.PharmacoEconomics, , Volume: 21, Issue:10, 2003
Procedural learning in schizophrenia after 6 months of double-blind treatment with olanzapine, risperidone, and haloperidol.Psychopharmacology, , Volume: 169, Issue:3-4, 2003
Chlorpromazine equivalent doses for the newer atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 64, Issue:6, 2003
Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia.The Journal of clinical psychiatry, , Volume: 64, Issue:6, 2003
Calming versus sedative effects of intramuscular olanzapine in agitated patients.The American journal of emergency medicine, , Volume: 21, Issue:3, 2003
Safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:4, 2003
Olanzapine induced neuroleptic malignant syndrome--a case review.Human psychopharmacology, , Volume: 18, Issue:4, 2003
Treatment of cervical dystonia by olanzapine.Human psychopharmacology, , Volume: 18, Issue:4, 2003
The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.International journal of geriatric psychiatry, , Volume: 18, Issue:5, 2003
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.Schizophrenia research, , Jul-01, Volume: 62, Issue:1-2, 2003
The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment.Acta psychiatrica Scandinavica. Supplementum, , Issue:416, 2003
The effect of olanzapine on anxiety among patients with schizophrenia: preliminary findings.Journal of clinical psychopharmacology, , Volume: 23, Issue:5, 2003
The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain.Human psychopharmacology, , Volume: 18, Issue:7, 2003
Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
The effects of an educational intervention on antipsychotic-induced weight gain.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing, , Volume: 35, Issue:3, 2003
Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study.Acta psychiatrica Scandinavica, , Volume: 107, Issue:5, 2003
Effect of antipsychotic drugs on brain-derived neurotrophic factor expression under reduced N-methyl-D-aspartate receptor activity.Journal of neuroscience research, , Jun-01, Volume: 72, Issue:5, 2003
[Rhabdomyolysis associated with respiratory infection in chronic psychiatric patients during neuroleptic treatment].Minerva anestesiologica, , Volume: 69, Issue:6, 2003
Effects of olanzapine on lipid abnormalities in elderly psychotic patients.Drugs & aging, , Volume: 20, Issue:12, 2003
5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia.Psychopharmacology bulletin, ,Spring, Volume: 37, Issue:2, 2003
Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.Schizophrenia research, , Jun-01, Volume: 61, Issue:2-3, 2003
Comparative effectiveness of antipsychotic drugs.The American journal of psychiatry, , Volume: 160, Issue:3, 2003
New generation antipsychotics for first episode schizophrenia.The Cochrane database of systematic reviews, , Issue:4, 2003
Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.Current medical research and opinion, , Volume: 19, Issue:6, 2003
Olanzapine effects on auditory sensory gating in schizophrenia.The American journal of psychiatry, , Volume: 160, Issue:11, 2003
[A case of delirium after olanzapine intoxication].Der Nervenarzt, , Volume: 74, Issue:11, 2003
Minimum effective doses of haloperidol for the treatment of first psychotic episode: a comparative study with risperidone and olanzapine.The international journal of neuropsychopharmacology, , Volume: 6, Issue:4, 2003
Acute dystonia caused by low dosage of olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 15, Issue:2, 2003
Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults.Schizophrenia bulletin, , Volume: 29, Issue:3, 2003
Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia.Journal of neural transmission (Vienna, Austria : 1996), , Volume: 110, Issue:5, 2003
Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:6, 2003
Pharmacological approaches to the management of schizophrenia.The Medical journal of Australia, , 05-05, Volume: 178, Issue:S9, 2003
Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity.Schizophrenia research, , Nov-15, Volume: 64, Issue:2-3, 2003
Cost evaluation of risperidone compared with olanzapine.Psychiatric services (Washington, D.C.), , Volume: 54, Issue:5, 2003
Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.International journal of geriatric psychiatry, , Volume: 18, Issue:11, 2003
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
Role of ethnicity in predicting antipsychotic medication adherence.The Annals of pharmacotherapy, , Volume: 37, Issue:5, 2003
Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study.Journal of clinical psychopharmacology, , Volume: 23, Issue:6, 2003
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses.International clinical psychopharmacology, , Volume: 18, Issue:3, 2003
The influence of olanzapine on immune cells in patients with schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:3, 2003
Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:3, 2003
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
Reducing the risk for suicide in schizophrenia and affective disorders.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.The Journal of clinical psychiatry, , Volume: 64, Issue:9, 2003
Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study.Psychiatry and clinical neurosciences, , Volume: 57, Issue:6, 2003
Rapid onset of dyskinesia induced by olanzapine.Psychiatry and clinical neurosciences, , Volume: 57, Issue:6, 2003
Pilot study: access to fitness facility and exercise levels in olanzapine-treated patients.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:9, 2003
Fungal dermatitis with olanzapine in schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:9, 2003
Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia.Therapeutic drug monitoring, , Volume: 25, Issue:6, 2003
Optimal treatment project for schizophrenia: results from a randomized, controlled, longitudinal study.Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 105, Issue:9, 2003
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.JAMA, , Nov-26, Volume: 290, Issue:20, 2003
High-dose olanzapine and prolactin levels.The Journal of clinical psychiatry, , Volume: 64, Issue:10, 2003
Similarities and differences among antipsychotics.The Journal of clinical psychiatry, , Volume: 64 Suppl 17, 2003
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 103, Issue:11, 2003
Tc-99 HMPAO SPECT study of regional cerebral blood flow in olanzapine-treated schizophrenic patients.European archives of psychiatry and clinical neuroscience, , Volume: 253, Issue:1, 2003
Clinical trial response and dropout rates with olanzapine versus risperidone.The Annals of pharmacotherapy, , Volume: 37, Issue:4, 2003
Measurement of simple reaction time in antipsychotic treatment of patients with schizophrenia.Wiener klinische Wochenschrift, , Jan-31, Volume: 115, Issue:1-2, 2003
Olanzapine induces insulin resistance: results from a prospective study.The Journal of clinical psychiatry, , Volume: 64, Issue:12, 2003
Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 13, Issue:2, 2003
Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 48, Issue:11, 2003
Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials.Psychoneuroendocrinology, , Volume: 28 Suppl 2, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex.Neuropharmacology, , Volume: 44, Issue:4, 2003
Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine.Journal of clinical psychopharmacology, , Volume: 23, Issue:2, 2003
Olanzapine and risperidone.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Mar-01, Volume: 60, Issue:5, 2003
Do atypical antipsychotics fail to exert cognitive sparing effects?Neuroreport, , Mar-03, Volume: 14, Issue:3, 2003
Local-global processing in early-onset schizophrenia: evidence for an impairment in shifting the spatial scale of attention.Brain and cognition, , Volume: 51, Issue:1, 2003
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.The Journal of clinical psychiatry, , Volume: 64, Issue:2, 2003
Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3, 2003
Comparative effectiveness of antipsychotic drugs.The American journal of psychiatry, , Volume: 160, Issue:3, 2003
Comparative effectiveness of antipsychotic drugs.The American journal of psychiatry, , Volume: 160, Issue:3, 2003
Schizophrenia.Clinical evidence, , Issue:10, 2003
An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia.Schizophrenia research, , Jan-01, Volume: 59, Issue:1, 2003
The impact of the Food and Drug Administration Modernization Act on the recruitment of children for research.Ethical human sciences and services : an international journal of critical inquiry, ,Summer, Volume: 5, Issue:2, 2003
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 13, Issue:1, 2003
Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol.International clinical psychopharmacology, , Volume: 18, Issue:1, 2003
Optimal dose of risperidone and olanzapine for patients with schizophrenia in Taiwan.International clinical psychopharmacology, , Volume: 18, Issue:1, 2003
Peripheral oedema in patients taking olanzapine.International clinical psychopharmacology, , Volume: 18, Issue:1, 2003
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:1, 2003
Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.Schizophrenia research, , Mar-01, Volume: 60, Issue:1, 2003
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).Archives of general psychiatry, , Volume: 60, Issue:1, 2003
High-dose olanzapine-induced improvement of preexisting type 2 diabetes mellitus in schizophrenic patients.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Reply to Dr Mahendran. We have not found reported cases of [obsessive-compulsive] OC arising from de novo with olanzapine treatment.The Australian and New Zealand journal of psychiatry, , Volume: 37, Issue:1, 2003
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Issue:1, 2003
A prospective, open-label trial of olanzapine in adolescents with schizophrenia.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 42, Issue:2, 2003
Effects of olanzapine on auditory P300 in schizophrenia.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 27, Issue:1, 2003
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.The American journal of psychiatry, , Volume: 160, Issue:2, 2003
The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment.Acta psychiatrica Scandinavica, , Volume: 107, Issue:3, 2003
Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study.Psychopharmacology, , Volume: 169, Issue:3-4, 2003
Heart-rate variability (HRV) in the ECG trace of routine EEGs: fast monitoring for the anticholinergic effects of clozapine and olanzapine?Pharmacopsychiatry, , Volume: 35, Issue:3, 2002
A transcranial magnetic stimulation study of the effects of olanzapine and risperidone on motor cortical excitability in patients with schizophrenia.Psychopharmacology, , Volume: 162, Issue:1, 2002
One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics.Psychiatric services (Washington, D.C.), , Volume: 53, Issue:7, 2002
Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine.Psychiatric services (Washington, D.C.), , Volume: 53, Issue:7, 2002
A possible association between high normal and high dose olanzapine and prolongation of the PR interval.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:2, 2002
Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.Schizophrenia research, , Jul-01, Volume: 56, Issue:1-2, 2002
Disruption of prepulse inhibition of startle reflex in a neurodevelopmental model of schizophrenia: reversal by clozapine, olanzapine and risperidone but not by haloperidol.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 27, Issue:1, 2002
Antipsychotic prescribing practices in the Veterans Healthcare Administration--New York metropolitan region.Schizophrenia bulletin, , Volume: 28, Issue:1, 2002
Efficacy of olanzapine and risperidone for treatment-refractory schizophrenia among long-stay state hospital patients.Psychiatric services (Washington, D.C.), , Volume: 53, Issue:6, 2002
Atypical antipsychotics and cognition in schizophrenia.Archives of general psychiatry, , Volume: 59, Issue:6, 2002
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.The Journal of clinical psychiatry, , Volume: 63, Issue:5, 2002
Sex differences in clinical response to olanzapine compared with haloperidol.Psychiatry research, , May-15, Volume: 110, Issue:1, 2002
Effect of olanzapine on glutamate levels in cerebrospinal fluid of patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 22, Issue:3, 2002
Motor-induced brain activation in cortical, subcortical and cerebellar regions in schizophrenic inpatients. A whole brain fMRI fingertapping study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:3, 2002
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.Archives of general psychiatry, , Volume: 59, Issue:5, 2002
Clinical and neuropsychological correlates of the P300 in schizophrenia.Schizophrenia research, , May-01, Volume: 55, Issue:1-2, 2002
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.CNS drugs, , Volume: 16, Issue:4, 2002
Subcortical overactivation in untreated schizophrenic patients: a functional magnetic resonance image finger-tapping study.Psychiatry and clinical neurosciences, , Volume: 56, Issue:1, 2002
Serotonin syndrome and atypical antipsychotics.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.Biological psychiatry, , Mar-15, Volume: 51, Issue:6, 2002
Significant dissociation of brain and plasma kinetics with antipsychotics.Molecular psychiatry, , Volume: 7, Issue:3, 2002
New-onset seizure associated with quetiapine and olanzapine.The Annals of pharmacotherapy, , Volume: 36, Issue:3, 2002
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
Implicit and explicit learning in schizophrenics treated with olanzapine and with classic neuroleptics.Psychopharmacology, , Volume: 160, Issue:3, 2002
[Atypical neuroleptics in the treatment of aggression and hostility in schizophrenic patients].Fortschritte der Neurologie-Psychiatrie, , Volume: 70, Issue:3, 2002
A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.Managed care interface, , Volume: 15, Issue:2, 2002
Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.The Journal of clinical psychiatry, , Volume: 63, Issue:2, 2002
Olanzapine for violent schizophrenia and Klinefelter syndrome.The American journal of psychiatry, , Volume: 159, Issue:3, 2002
Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.The American journal of psychiatry, , Volume: 159, Issue:3, 2002
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.The American journal of psychiatry, , Volume: 159, Issue:2, 2002
Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication.International clinical psychopharmacology, , Volume: 17, Issue:1, 2002
Increasing insulin dose for olanzapine-related diabetes.The American journal of psychiatry, , Volume: 159, Issue:1, 2002
Elevation of prolactin levels by atypical antipsychotics.The American journal of psychiatry, , Volume: 159, Issue:1, 2002
Economic evaluations of olanzapine and risperidone.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Jul-15, Volume: 59, Issue:14, 2002
The first-episode of schizophrenia: a challenge for treatment.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17 Suppl 4, 2002
Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs.International clinical psychopharmacology, , Volume: 17, Issue:6, 2002
Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.Journal of clinical psychopharmacology, , Volume: 22, Issue:5, 2002
Weight gain associated with atypical antipsychotics.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 41, Issue:11, 2002
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:3, 2002
Effects of olanzapine and clozapine upon pulse rate variability.Depression and anxiety, , Volume: 16, Issue:3, 2002
Excessive recruitment of neural systems subserving logical reasoning in schizophrenia.Brain : a journal of neurology, , Volume: 125, Issue:Pt 8, 2002
Clinical issues associated with maintenance treatment of patients with schizophrenia.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Sep-01, Volume: 59, Issue:17 Suppl 5, 2002
Continuum of care: stabilizing the acutely agitated patient.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Sep-01, Volume: 59, Issue:17 Suppl 5, 2002
[Olanzapine-induced diabetes mellitus].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
Effect of zotepine, olanzapine and risperidone on hostility in schizophrenic patients.Schizophrenia research, , Oct-01, Volume: 57, Issue:2-3, 2002
Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.Schizophrenia research, , Oct-01, Volume: 57, Issue:2-3, 2002
Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study.Schizophrenia research, , Oct-01, Volume: 57, Issue:2-3, 2002
From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications.The American journal of psychiatry, , Volume: 159, Issue:9, 2002
Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial.The journal of ECT, , Volume: 18, Issue:2, 2002
[Zyprexa with superior effectiveness-risk relation. For every therapy situation a suitable dosage form].Krankenpflege Journal, , Volume: 40, Issue:3-4, 2002
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 12, Issue:2, 2002
The value of atypical antipsychotics in the treatment of schizophrenia.Managed care (Langhorne, Pa.), , Volume: 11, Issue:7 Suppl, 2002
Weight loss associated with olanzapine treatment.Journal of clinical psychopharmacology, , Volume: 22, Issue:4, 2002
Emergence of compulsive symptoms with olanzapine treatment.The Australian and New Zealand journal of psychiatry, , Volume: 36, Issue:4, 2002
An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.Archives of general psychiatry, , Volume: 59, Issue:11, 2002
Dissolution profile, tolerability, and acceptability of the orally disintegrating olanzapine tablet in patients with schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 47, Issue:8, 2002
Marked improvement of Meige's syndrome with olanzapine in a schizophrenic patient.The Journal of neuropsychiatry and clinical neurosciences, ,Summer, Volume: 14, Issue:3, 2002
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.BMJ (Clinical research ed.), , Aug-03, Volume: 325, Issue:7358, 2002
Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia.The International journal of neuroscience, , Volume: 112, Issue:7, 2002
Differential effects of olanzapine and risperidone on cognition in schizophrenia? A saccadic eye movement study.The Journal of neuropsychiatry and clinical neurosciences, ,Fall, Volume: 14, Issue:4, 2002
A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.Current medical research and opinion, , Volume: 18, Issue:6, 2002
[Zyprexa (olanzapine)--new possibilities in the treatment of schizophrenia].Voenno-meditsinskii zhurnal, , Volume: 323, Issue:9, 2002
Comparable dopamine 2 receptor occupancy.The American journal of psychiatry, , Volume: 159, Issue:12, 2002
Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:6, 2002
Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:6, 2002
Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study.Journal of clinical psychopharmacology, , Volume: 22, Issue:6, 2002
5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia.Journal of clinical psychopharmacology, , Volume: 22, Issue:6, 2002
D-fenfluramine-evoked serotonergic responses in olanzapine-treated schizophrenic patients.Psychiatry research, , Dec-15, Volume: 113, Issue:1-2, 2002
Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia.Journal of clinical pharmacy and therapeutics, , Volume: 27, Issue:6, 2002
Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:7-8, 2002
Olanzapine-associated neuroleptic malignant syndrome.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 26, Issue:5, 2002
Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific.The Journal of clinical psychiatry, , Volume: 63, Issue:7, 2002
Prescribing second-generation antipsychotics and the evolving standard of care in Italy.Pharmacopsychiatry, , Volume: 35, Issue:6, 2002
Olanzapine treatment for patients with schizophrenia and cocaine abuse.The Journal of clinical psychiatry, , Volume: 63, Issue:12, 2002
Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder.Psychiatry research, , Aug-05, Volume: 111, Issue:1, 2002
"Normalization" of brain activation in schizophrenia. An fMRI study.Schizophrenia research, , Dec-01, Volume: 58, Issue:2-3, 2002
Fatality from olanzapine induced hyperglycemia.Journal of forensic sciences, , Volume: 47, Issue:4, 2002
Use of olanzapine for elderly patients with psychotic disorders: a review.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 13, Issue:4, 2001
Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study).BMC psychiatry, , Volume: 1, 2001
Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study.Schizophrenia bulletin, , Volume: 27, Issue:4, 2001
Olanzapine versus other antipsychotics in the treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 62, Issue:10, 2001
Service use and costs of treating schizophrenia with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 62, Issue:10, 2001
[Clinical and pharmacological studies of the second generation antipsychotics].Fukuoka igaku zasshi = Hukuoka acta medica, , Volume: 92, Issue:11, 2001
[Heart rate variability in schizophrenic patients treated with antipsychotic agents].Harefuah, , Volume: 140, Issue:12, 2001
Olanzapine treatment for patients with schizophrenia and substance abuse.Journal of substance abuse treatment, , Volume: 21, Issue:4, 2001
The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:4, 2001
[Efficacy of rispolept and zyprexa in the treatment of patients with schizophrenia].Voenno-meditsinskii zhurnal, , Volume: 322, Issue:10, 2001
The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia.Journal of clinical psychopharmacology, , Volume: 21, Issue:6, 2001
[Olanzapine and pregnancy. 2 case reports].Der Nervenarzt, , Volume: 72, Issue:11, 2001
Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.Biological psychiatry, , Dec-01, Volume: 50, Issue:11, 2001
Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial.Journal of clinical psychopharmacology, , Volume: 21, Issue:1, 2001
Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia.Neuroscience, , Volume: 107, Issue:4, 2001
Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.European archives of psychiatry and clinical neuroscience, , Volume: 251, Issue:3, 2001
P300 and symptom improvement in schizophrenia.Psychopharmacology, , Volume: 158, Issue:1, 2001
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:11, 2001
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.The Journal of clinical psychiatry, , Volume: 62, Issue:9, 2001
Global index of safety (GIS): a new instrument to assess drug safety.Journal of clinical epidemiology, , Volume: 54, Issue:11, 2001
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.The international journal of neuropsychopharmacology, , Volume: 4, Issue:3, 2001
Autonomic responses of blood vessels and sweat glands in patients with schizophrenia treated with olanzapine or clozapine.Psychopharmacology, , Volume: 157, Issue:4, 2001
Are African American patients at a higher risk for olanzapine-induced glucose intolerance?Psychopharmacology, , Volume: 157, Issue:3, 2001
Review of atypical antipsychotics and weight gain.The Journal of clinical psychiatry, , Volume: 62 Suppl 23, 2001
Hyperglycemia associated with the use of atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 23, 2001
Ziprasidone: a new atypical antipsychotic.Expert opinion on pharmacotherapy, , Volume: 2, Issue:6, 2001
Re: Weight change with antipsychotic use.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:7, 2001
Agranulocytosis and neutropenia with typical and atypical neuroleptics.The American journal of psychiatry, , Volume: 158, Issue:10, 2001
Association of olanzapine-induced weight gain with an increase in body fat.The American journal of psychiatry, , Volume: 158, Issue:10, 2001
[Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy].Der Nervenarzt, , Volume: 72, Issue:9, 2001
D2 receptor occupancy under recommended and high doses of olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 15, Issue:3, 2001
Tissue distribution of olanzapine in a postmortem case.The American journal of forensic medicine and pathology, , Volume: 22, Issue:3, 2001
The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 25, Issue:4, 2001
Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.Psychiatry research, , Aug-25, Volume: 107, Issue:2, 2001
Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task.Psychological medicine, , Volume: 31, Issue:6, 2001
Maternal obesity and risk of neural tube defects.Canadian family physician Medecin de famille canadien, , Volume: 47, 2001
Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.The Journal of clinical psychiatry, , Volume: 62, Issue:7, 2001
A sensitive high-performance liquid chromatographic method using electrochemical detection for the analysis of olanzapine and desmethylolanzapine in plasma of schizophrenic patients using a new solid-phase extraction procedure.Journal of chromatography. B, Biomedical sciences and applications, , Jan-05, Volume: 750, Issue:1, 2001
Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.Journal of clinical psychopharmacology, , Volume: 21, Issue:4, 2001
Effectiveness of clozapine and olanzapine: a comparison in severe, psychotically ill patients.The international journal of neuropsychopharmacology, , Volume: 4, Issue:2, 2001
Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study.Psychopharmacology, , Volume: 156, Issue:1, 2001
Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study.International clinical psychopharmacology, , Volume: 16, Issue:4, 2001
Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study.International clinical psychopharmacology, , Volume: 16, Issue:4, 2001
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.Clinical therapeutics, , Volume: 23, Issue:6, 2001
Writer's cramp induced by olanzapine.Journal of neurology, , Volume: 248, Issue:5, 2001
The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.The Journal of nervous and mental disease, , Volume: 189, Issue:6, 2001
A program for treating olanzapine-related weight gain.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:7, 2001
Olanzapine-induced somnambulism.The American journal of psychiatry, , Volume: 158, Issue:7, 2001
Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.The American journal of psychiatry, , Volume: 158, Issue:7, 2001
Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 16, Issue:4, 2001
Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients.Psychoneuroendocrinology, , Volume: 26, Issue:6, 2001
Tolerability and effectiveness of atypical antipsychotics in male geriatric inpatients.International journal of geriatric psychiatry, , Volume: 16, Issue:2, 2001
Interaction of olanzapine with fluvoxamine.Psychopharmacology, , Volume: 155, Issue:2, 2001
Antiaggressive action of atypical antipsychotics in patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 21, Issue:3, 2001
Hyperglycemia in patients with schizophrenia who are treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 21, Issue:3, 2001
Cognitive behavior therapy for weight gain.The American journal of psychiatry, , Volume: 158, Issue:6, 2001
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Hypothesis and hypothesis testing in the clinical trial.The Journal of clinical psychiatry, , Volume: 62 Suppl 9, 2001
Dopamine receptor responsivity in schizophrenic patients in a drug-free state and after treatment with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 25, Issue:3, 2001
Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone.Schizophrenia research, , Apr-30, Volume: 49, Issue:3, 2001
The pharmacology of weight gain with antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 7, 2001
Antipsychotic-induced weight gain: a review of the literature.The Journal of clinical psychiatry, , Volume: 62 Suppl 7, 2001
Olanzapine-induced diabetes mellitus.The Annals of pharmacotherapy, , Volume: 35, Issue:5, 2001
Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:5, 2001
Olanzapine and negative and positive symptoms.The American journal of psychiatry, , Volume: 158, Issue:5, 2001
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.The American journal of psychiatry, , Volume: 158, Issue:5, 2001
Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents.Psychopharmacology, , Mar-01, Volume: 154, Issue:2, 2001
Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis.The Journal of clinical psychiatry, , Volume: 62, Issue:3, 2001
Neuroleptic malignant syndrome after addition of haloperidol to atypical antipsychotic.The American journal of psychiatry, , Volume: 158, Issue:4, 2001
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.Schizophrenia research, , Mar-01, Volume: 48, Issue:1, 2001
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.The Journal of clinical psychiatry, , Volume: 62, Issue:2, 2001
Priapism associated with polypharmacy.The Journal of clinical psychiatry, , Volume: 62, Issue:2, 2001
Dose-dependent olanzapine-associated leukopenia: three case reports.International clinical psychopharmacology, , Volume: 16, Issue:2, 2001
Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Weight change and atypical antipsychotic treatment in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Introduction: a new era in the pharmacotherapy of psychotic disorders.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.The American journal of psychiatry, , Volume: 158, Issue:3, 2001
Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:1, 2001
Olanzapine: an updated review of its use in the management of schizophrenia.Drugs, , Volume: 61, Issue:1, 2001
[Olanzapine and pregnancy].Orvosi hetilap, , Jan-21, Volume: 142, Issue:3, 2001
Current and novel approaches to the drug treatment of schizophrenia.Journal of medicinal chemistry, , Feb-15, Volume: 44, Issue:4, 2001
Olanzapine: concordant response in monozygotic twins with schizophrenia.The British journal of psychiatry : the journal of mental science, , Volume: 178, Issue:1, 2001
Misdiagnosis of schizophrenia for a patient with epilepsy.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:1, 2001
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.The American journal of psychiatry, , Volume: 158, Issue:2, 2001
Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.Annual review of medicine, , Volume: 52, 2001
Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.Schizophrenia research, , Jan-15, Volume: 47, Issue:1, 2001
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.Biological psychiatry, , Jan-01, Volume: 49, Issue:1, 2001
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 21, Issue:1, 2001
Adverse events related to olanzapine.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
The treatment of tardive dyskinesia and tardive dystonia.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
[Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders].Wiener klinische Wochenschrift, , Dec-22, Volume: 112, Issue:24, 2000
Olanzapine: an atypical antipsychotic for schizophrenia.Expert opinion on pharmacotherapy, , Volume: 1, Issue:2, 2000
Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.PharmacoEconomics, , Volume: 18, Issue:6, 2000
Exacerbation of chronic large plaque psoriasis associated with Olanzepine therapy.Journal of the European Academy of Dermatology and Venereology : JEADV, , Volume: 14, Issue:4, 2000
The effectiveness of combining lithium with olanzapine in the treatment of resistant schizophrenia.The Journal of clinical psychiatry, , Volume: 61, Issue:12, 2000
Switching clozapine responders to olanzapine.The Journal of clinical psychiatry, , Volume: 61, Issue:12, 2000
[The experience of application of olanzapine: an atypical neuroleptic in acute schizophrenia].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 100, Issue:4, 2000
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia.The Journal of clinical psychiatry, , Volume: 61 Suppl 3, 2000
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.Archives of general psychiatry, , Volume: 57, Issue:3, 2000
New antipsychotic medications: more than old wine and new bottles.Bulletin of the Menninger Clinic, ,Winter, Volume: 64, Issue:1, 2000
Olanzapine. Keep an eye on this neuroleptic.Canadian family physician Medecin de famille canadien, , Volume: 46, 2000
Intoxication with olanzapine.The American journal of psychiatry, , Volume: 157, Issue:2, 2000
Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia.Journal of clinical psychopharmacology, , Volume: 20, Issue:3, 2000
Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.The American journal of psychiatry, , Volume: 157, Issue:5, 2000
Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia.The American journal of psychiatry, , Volume: 157, Issue:6, 2000
Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.The American journal of psychiatry, , Volume: 157, Issue:6, 2000
Novel antipsychotic use in schizophrenia.The Journal of clinical psychiatry, , Volume: 61, Issue:3, 2000
[Atypical antipsychotics].Der Nervenarzt, , Volume: 71, Issue:5, 2000
[New i.e. atypical neuroleptic agents for negative symptoms of schizophrenia: results and methodological problems of evaluation].Der Nervenarzt, , Volume: 71, Issue:5, 2000
The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia.The Journal of clinical psychiatry, , Volume: 61, Issue:5, 2000
A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia.Pharmacopsychiatry, , Volume: 33, Issue:3, 2000
Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.East African medical journal, , Volume: 77, Issue:2, 2000
Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.Clinical therapeutics, , Volume: 22, Issue:5, 2000
In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 23, Issue:1, 2000
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.International clinical psychopharmacology, , Volume: 15, Issue:3, 2000
Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.Psychopharmacology, , Volume: 150, Issue:2, 2000
Risperidone versus other atypical antipsychotic medication for schizophrenia.The Cochrane database of systematic reviews, , Issue:3, 2000
Antipsychotics during pregnancy.The American journal of psychiatry, , Volume: 157, Issue:8, 2000
Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine.Psychopharmacology, , Volume: 150, Issue:3, 2000
Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia.Acta psychiatrica Scandinavica, , Volume: 102, Issue:2, 2000
Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.PharmacoEconomics, , Volume: 17, Issue:4, 2000
Olanzapine overdose.Anaesthesia, , Volume: 55, Issue:9, 2000
Olanzapine: safe during clozapine-induced agranulocytosis.Journal of clinical psychopharmacology, , Volume: 20, Issue:2, 2000
St. John's wort and schizophrenia.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Aug-08, Volume: 163, Issue:3, 2000
Olanzapine: keep an eye on this neuroleptic.Canadian family physician Medecin de famille canadien, , Volume: 46, 2000
[Atypical antipsychotic drugs].Nederlands tijdschrift voor geneeskunde, , Aug-19, Volume: 144, Issue:34, 2000
Olanzapine and obsessive-compulsive symptoms.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 10, Issue:5, 2000
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17, Issue:6, 2000
Olanzapine for schizophrenia.The Cochrane database of systematic reviews, , Issue:2, 2000
Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.International clinical psychopharmacology, , Volume: 15, Issue:5, 2000
First person account: I and I, dancing fool, challenge you the world to a duel.Schizophrenia bulletin, , Volume: 26, Issue:3, 2000
Olanzapine optimal dose: results of an open-label multicenter study in schizophrenic patients. Olanzapine Late-Phase II Study Group.Psychiatry and clinical neurosciences, , Volume: 54, Issue:4, 2000
Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia.Journal of clinical psychopharmacology, , Volume: 20, Issue:5, 2000
Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine.Schizophrenia research, , Jun-16, Volume: 43, Issue:2-3, 2000
Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment.Acta psychiatrica Scandinavica, , Volume: 102, Issue:3, 2000
Risperidone side effects.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.The Journal of clinical psychiatry, , Volume: 61, Issue:9, 2000
Risperidone and tardive dyskinesia: a case of blepharospasm.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:5, 2000
The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.Clinical therapeutics, , Volume: 22, Issue:9, 2000
The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.Clinical therapeutics, , Volume: 22, Issue:9, 2000
Rabbit syndrome treated with olanzapine.The British journal of psychiatry : the journal of mental science, , Volume: 176, 2000
[Bullae induced by acute neuroleptic intoxication].Annales de dermatologie et de venereologie, , Volume: 127, Issue:10, 2000
Disposition of olanzapine in Chinese schizophrenic patients.International journal of clinical pharmacology and therapeutics, , Volume: 38, Issue:10, 2000
Neuroleptic malignant syndrome associated with olanzapine therapy: a case report.The Journal of emergency medicine, , Volume: 19, Issue:4, 2000
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.The Journal of clinical psychiatry, , Volume: 61, Issue:10, 2000
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.BMJ (Clinical research ed.), , Dec-02, Volume: 321, Issue:7273, 2000
Olanzapine and pancreatitis.The British journal of psychiatry : the journal of mental science, , Volume: 177, 2000
Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.The Journal of clinical psychiatry, , Volume: 61, Issue:11, 2000
Olanzapine-induced neutropenia in patients with history of clozapine treatment: two case reports from a state psychiatric institution.The Journal of clinical psychiatry, , Volume: 61, Issue:11, 2000
Hematologic reference ranges in a population of patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 20, Issue:6, 2000
Neuropletic malignant syndrome and olanzapine.Journal of clinical psychopharmacology, , Volume: 20, Issue:6, 2000
[Atypical neuroleptics in child- and adolescent psychiatry].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 28, Issue:1, 2000
Olanzapine prolongation of granulocytopenia after clozapine discontinuation.Journal of clinical psychopharmacology, , Volume: 20, Issue:6, 2000
Atypical neuroleptics in child and adolescent psychiatry.European child & adolescent psychiatry, , Volume: 9 Suppl 1, 2000
Neuroleptic therapy influences basal ganglia activation: a functional magnetic resonance imaging study comparing controls to haloperidol- and olanzapine-treated inpatients.Psychiatry and clinical neurosciences, , Volume: 54, Issue:6, 2000
[Olanzapine (Zyprexa)].Presse medicale (Paris, France : 1983), , Dec-09, Volume: 29, Issue:38, 2000
Drug review "surprises" reader.Canadian family physician Medecin de famille canadien, , Volume: 46, 2000
Reversal of rabbit syndrome with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:1, 2000
Epidemic of schizophrenia in children or inappropriate prescribing?The Medical journal of Australia, , Nov-20, Volume: 173, Issue:10, 2000
D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study.Journal of psychopharmacology (Oxford, England), , Volume: 14, Issue:4, 2000
Quality of life and new antipsychotics in schizophrenia. Are patients better off?The International journal of social psychiatry, ,Winter, Volume: 45, Issue:4, 1999
Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.Psychiatry research, , Nov-08, Volume: 92, Issue:1, 1999
Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.European archives of psychiatry and clinical neuroscience, , Volume: 249 Suppl 2, 1999
Differential olanzapine plasma concentrations by sex in a fixed-dose study.Schizophrenia research, , Nov-30, Volume: 40, Issue:2, 1999
Reduction of tardive dystonia with olanzapine.The American journal of psychiatry, , Volume: 156, Issue:12, 1999
Olanzapine increases weight and serum triglyceride levels.The Journal of clinical psychiatry, , Volume: 60, Issue:11, 1999
Retention rates in placebo- and nonplacebo-controlled clinical trials of schizophrenia.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:9, 1999
Pharmacologic treatment of schizophrenia.Biological psychiatry, , Nov-15, Volume: 46, Issue:10, 1999
High-dose olanzapine therapy in schizophrenia.The Annals of pharmacotherapy, , Volume: 33, Issue:11, 1999
Body mass index increase of 58% associated with olanzapine.The American journal of psychiatry, , Volume: 156, Issue:11, 1999
A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 60, Issue:10, 1999
Weight gain associated with antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 60 Suppl 21, 1999
Evaluation of outcomes for atypical antipsychotic therapy and psychosocial rehabilitation in a community mental health center setting. Based on a presentation by Douglas Noordsy, MD.The American journal of managed care, , Volume: 5, Issue:10 Suppl, 1999
The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.The American journal of managed care, , Volume: 5, Issue:10 Suppl, 1999
Olanzapine. A pharmacoeconomic review of its use in schizophrenia.PharmacoEconomics, , Volume: 15, Issue:6, 1999
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.PharmacoEconomics, , Volume: 15, Issue:5, 1999
Pustular eruption induced by olanzapine, a novel antipsychotic agent.Journal of the American Academy of Dermatology, , Volume: 41, Issue:5 Pt 2, 1999
Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting.The Journal of clinical psychiatry, , Volume: 60 Suppl 19, 1999
Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 60 Suppl 19, 1999
Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Olanzapine for patients with treatment-resistant schizophrenia: a naturalistic case-series outcome study.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:7, 1999
A new mechanism for the actions of olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 44, Issue:6, 1999
[Clinical efficacy of olanzapine].Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, , Volume: 19, Issue:3, 1999
Focus on olanzapine.Current medical research and opinion, , Volume: 15, Issue:2, 1999
Olanzapine-induced elevation of plasma triglyceride levels.The American journal of psychiatry, , Volume: 156, Issue:9, 1999
In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine.Psychiatry research, , Apr-26, Volume: 90, Issue:2, 1999
Benefits of olanzapine as first-line schizophrenia therapy.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Aug-01, Volume: 56, Issue:15, 1999
Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, , Volume: 8, Issue:5, 1999
Olanzapine-induced agranulocytosis.Lancet (London, England), , Aug-14, Volume: 354, Issue:9178, 1999
[Severe intoxication probably from olanzapine (Zyprexa). Beneficial effect of glucagon].Annales francaises d'anesthesie et de reanimation, , Volume: 18, Issue:6, 1999
Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?The Journal of clinical psychiatry, , Volume: 60, Issue:7, 1999
Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:4, 1999
Clozapine-olanzapine: a potentially dangerous switch. A report of two cases.Journal of clinical pharmacy and therapeutics, , Volume: 24, Issue:3, 1999
In vivo effects of olanzapine on striatal dopamine D(2)/D(3) receptor binding in schizophrenic patients: an iodine-123 iodobenzamide single-photon emission tomography study.European journal of nuclear medicine, , Volume: 26, Issue:8, 1999
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.Biological psychiatry, , Aug-01, Volume: 46, Issue:3, 1999
The psychosis of schizophrenia: prevalence, response to atypical antipsychotics, and prediction of outcome.Biological psychiatry, , Aug-01, Volume: 46, Issue:3, 1999
Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol.Medical care, , Volume: 37, Issue:7, 1999
Drug metabolism and atypical antipsychotics.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 9, Issue:4, 1999
Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 82, Issue:4, 1999
Marked elevation of serum creatine kinase associated with olanzapine therapy.The Annals of pharmacotherapy, , Volume: 33, Issue:6, 1999
Novel antipsychotics: comparison of weight gain liabilities.The Journal of clinical psychiatry, , Volume: 60, Issue:6, 1999
Clozapine to olanzapine.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Olanzapine overdose.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
A dilemma born of progress: switching from clozapine to a newer antipsychotic.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency.Biological psychiatry, , Jul-01, Volume: 46, Issue:1, 1999
Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response.Biological psychiatry, , Jul-01, Volume: 46, Issue:1, 1999
Tardive dyskinesia associated with olanzapine.Annals of internal medicine, , Jul-06, Volume: 131, Issue:1, 1999
Olanzapine and NMS.Psychiatric services (Washington, D.C.), , Volume: 50, Issue:6, 1999
Clozapine: a comparison with other novel antipsychotics.The Journal of clinical psychiatry, , Volume: 60 Suppl 12, 1999
Weight gain and antipsychotic medications.The Journal of clinical psychiatry, , Volume: 60, Issue:5, 1999
Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine.Journal of psychiatry & neuroscience : JPN, , Volume: 24, Issue:3, 1999
Schizophrenia and schizoaffective disorder treated with high doses of olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:3, 1999
The role of typical and atypical antipsychotic medications in the management of agitation and aggression.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.The Journal of clinical psychiatry, , Volume: 60 Suppl 10, 1999
Antipsychotics from theory to practice: integrating clinical and basic data.The Journal of clinical psychiatry, , Volume: 60 Suppl 8, 1999
Side effects of olanzapine.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Olanzapine-induced obsessive-compulsive disorder.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Plasma olanzapine and clinical response.Journal of clinical psychopharmacology, , Volume: 19, Issue:2, 1999
New-onset panic attacks in a patient treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:2, 1999
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.The British journal of psychiatry : the journal of mental science, , Volume: 174, 1999
Olanzapine: a basic science update.The British journal of psychiatry. Supplement, , Issue:37, 1999
Olanzapine: preclinical pharmacology and recent findings.The British journal of psychiatry. Supplement, , Issue:37, 1999
Review of recent clinical studies with olanzapine.The British journal of psychiatry. Supplement, , Issue:37, 1999
Olanzapine in the long-term treatment of schizophrenia.The British journal of psychiatry. Supplement, , Issue:37, 1999
Cognitive deficit in schizophrenia and its neurochemical basis.The British journal of psychiatry. Supplement, , Issue:37, 1999
Tardive dyskinesia in affective disorders.The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?The Journal of clinical psychiatry, , Volume: 60 Suppl 5, 1999
Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Antipsychotic drugs and relapse prevention.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Tardive dyskinesia and atypical antipsychotic drugs.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Cognitive improvement in schizophrenia with novel antipsychotic medications.Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?Schizophrenia research, , Mar-01, Volume: 35 Suppl, 1999
Hyperprolactinemia and male sexual dysfunction.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Olanzapine treatment after clozapine-induced granulocytopenia in 3 patients.The Journal of clinical psychiatry, , Volume: 60, Issue:2, 1999
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.Biological psychiatry, , Feb-15, Volume: 45, Issue:4, 1999
Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.The American journal of psychiatry, , Volume: 156, Issue:2, 1999
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials.Schizophrenia research, , Jan-04, Volume: 35, Issue:1, 1999
In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.Psychopharmacology, , Volume: 141, Issue:2, 1999
Conventional vs. newer antipsychotics in elderly patients.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Winter, Volume: 7, Issue:1, 1999
British experience with high-dose olanzapine for treatment-refractory schizophrenia.The American journal of psychiatry, , Volume: 156, Issue:1, 1999
Olanzapine versus haloperidol treatment in first-episode psychosis.The American journal of psychiatry, , Volume: 156, Issue:1, 1999
Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol.PharmacoEconomics, , Volume: 13, Issue:5 Pt 2, 1998
Olanzapine therapy in elderly patients with schizophrenia.Psychopharmacology bulletin, , Volume: 34, Issue:4, 1998
Schizophrenia treatment: the use of atypical drugs--risperdal, zyperexa, and clozaril.The international journal of psychiatric nursing research, , Volume: 4, Issue:2, 1998
Atypical antipsychotics and formulary decisions.The American journal of managed care, , Volume: 4 Suppl, 1998
A cost-effectiveness clinical decision analysis model for schizophrenia.The American journal of managed care, , Volume: 4, Issue:3, 1998
Use of atypical neuroleptics in child and adolescent psychiatry.The Journal of clinical psychiatry, , Volume: 59, Issue:12, 1998
Aggression, agitation, and mania with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:10, 1998
Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response.The Journal of clinical psychiatry, , Volume: 59, Issue:11, 1998
Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia.International clinical psychopharmacology, , Volume: 13, Issue:6, 1998
The routine use of atypical antipsychotic agents: maintenance treatment.The Journal of clinical psychiatry, , Volume: 59 Suppl 19, 1998
Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome.The Journal of clinical psychiatry, , Volume: 59 Suppl 19, 1998
Common treatment goals of antipsychotics: acute treatment.The Journal of clinical psychiatry, , Volume: 59 Suppl 19, 1998
Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment.Journal of psychiatry & neuroscience : JPN, , Volume: 23, Issue:5, 1998
Olanzapine.Hospital medicine (London, England : 1998), , Volume: 59, Issue:9, 1998
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
[Use of novel agents in the treatment of schizophrenia and a look to the future].Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, , Volume: 18, Issue:3, 1998
Novel antipsychotics and new onset diabetes.Biological psychiatry, , Oct-15, Volume: 44, Issue:8, 1998
Treatment refractory schizophrenia: how should we proceed?The Psychiatric quarterly, ,Winter, Volume: 69, Issue:4, 1998
Olanzapine: efficacy in treating the positive and negative symptoms of schizophrenia.Mental health care, , Volume: 1, Issue:6, 1998
Quality of life and atypical antipsychotics.Journal of clinical psychopharmacology, , Volume: 18, Issue:5, 1998
Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse.Schizophrenia research, , Sep-07, Volume: 33, Issue:1-2, 1998
Olanzapine augmentation of clozapine.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 10, Issue:3, 1998
Olanzapine use in women with antipsychotic-induced hyperprolactinemia.The American journal of psychiatry, , Volume: 155, Issue:10, 1998
Treatment of special populations with the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Severe akathisia during olanzapine treatment of acute schizophrenia.Pharmacopsychiatry, , Volume: 31, Issue:4, 1998
Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:6, 1998
Two new atypical antipsychotics: advantages and disadvantages.South Dakota journal of medicine, , Volume: 51, Issue:8, 1998
Olanzapine for the treatment of tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 59, Issue:7, 1998
[Schizophrenia and depression. Special aspects in the therapy of women].Der Nervenarzt, , Volume: 69, Issue:7 Suppl Be, 1998
Olanzapine for primary negative symptoms.The American journal of psychiatry, , Volume: 155, Issue:8, 1998
Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.Journal of clinical psychopharmacology, , Volume: 18, Issue:4, 1998
Olanzapine-induced reversible priaprism: a case report.Journal of clinical psychopharmacology, , Volume: 18, Issue:4, 1998
The new antipsychotic compounds: is a clinical choice algorithm possible?The Western journal of medicine, , Volume: 169, Issue:1, 1998
Experiences with clozapine and olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 32, Issue:3, 1998
Olanzapine-induced manic-like syndrome.The Journal of clinical psychiatry, , Volume: 59, Issue:6, 1998
Hypersalivation coincident with olanzapine treatment.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
Worsening of obsessive-compulsive symptoms following treatment with olanzapine.The American journal of psychiatry, , Volume: 155, Issue:6, 1998
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.Biological psychiatry, , Jun-01, Volume: 43, Issue:11, 1998
Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , May-15, Volume: 55, Issue:10, 1998
The effects of risperidone and olanzapine on the indications for clozapine.Psychopharmacology bulletin, , Volume: 34, Issue:1, 1998
The relationship between negative symptoms of schizophrenia and extrapyramidal side effects with haloperidol and olanzapine.Psychopharmacology bulletin, , Volume: 34, Issue:1, 1998
Comments on article by Tran and associates, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".Journal of clinical psychopharmacology, , Volume: 18, Issue:2, 1998
Comments on article by Tran and colleagues, "Double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders".Journal of clinical psychopharmacology, , Volume: 18, Issue:2, 1998
Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia.The Psychiatric clinics of North America, , Volume: 21, Issue:1, 1998
Emerging roles for novel antipsychotic medications in the treatment of schizophrenia.The Psychiatric clinics of North America, , Volume: 21, Issue:1, 1998
Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 37, Issue:4, 1998
Management of treatment-resistant schizophrenia with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:2, 1998
Paranoia and agitation associated with olanzapine treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:2, 1998
Marketing of antipsychotic drugs attacked.BMJ (Clinical research ed.), , Feb-28, Volume: 316, Issue:7132, 1998
Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject.The British journal of psychiatry : the journal of mental science, , Volume: 172, 1998
Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
Marked reduction of tardive dyskinesia with olanzapine.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.Archives of general psychiatry, , Volume: 55, Issue:3, 1998
Treatment of the refractory schizophrenic patient.The Journal of clinical psychiatry, , Volume: 59 Suppl 1, 1998
Olanzapine on trial.The American journal of psychiatry, , Volume: 155, Issue:1, 1998
Olanzapine on trial.The American journal of psychiatry, , Volume: 155, Issue:1, 1998
Olanzapine on trial.The American journal of psychiatry, , Volume: 155, Issue:1, 1998
Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 18, Issue:1, 1998
Effects of antipsychotics on the clinical and psychosocial behavior of patients with schizophrenia.Schizophrenia research, , Dec-19, Volume: 28, Issue:2-3, 1997
Olanzapine, sertindole and schizophrenia.Drug and therapeutics bulletin, , Volume: 35, Issue:11, 1997
[Olanzapine--a new atypical neuroleptic. A chance for advancement in the therapy of schizophrenia].Der Nervenarzt, , Volume: 68, Issue:7 Suppl Ol, 1997
[Olanzapine. A new antipsychotic agent].Ugeskrift for laeger, , Nov-24, Volume: 159, Issue:48, 1997
New antipsychotic medications: strategies for evaluation and selected findings.Schizophrenia research, , Oct-30, Volume: 27, Issue:2-3, 1997
Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.The Journal of clinical psychiatry, , Volume: 58, Issue:11, 1997
Prolongation of clozapine-induced granulocytopenia associated with olanzapine.Journal of clinical psychopharmacology, , Volume: 17, Issue:6, 1997
Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 17, Issue:6, 1997
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.Psychiatric services (Washington, D.C.), , Volume: 48, Issue:12, 1997
Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia.The Annals of pharmacotherapy, , Volume: 31, Issue:11, 1997
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.Schizophrenia research, , Jul-25, Volume: 26, Issue:1, 1997
High-dose olanzapine for treatment-refractory schizophrenia.The American journal of psychiatry, , Volume: 154, Issue:11, 1997
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.Journal of clinical psychopharmacology, , Volume: 17, Issue:5, 1997
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.The American journal of psychiatry, , Volume: 154, Issue:9, 1997
Switching antipsychotic medications.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Dosing the antipsychotic medication olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Olanzapine and the new generation of antipsychotic agents: patterns of use.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Safety of olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Efficacy of olanzapine: an overview of pivotal clinical trials.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 58, Issue:5, 1997
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 7, Issue:2, 1997
Olanzapine: a novel atypical neuroleptic agent.Lancet (London, England), , May-03, Volume: 349, Issue:9061, 1997
The promise of new drugs for schizophrenia treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 42, Issue:3, 1997
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.The American journal of psychiatry, , Volume: 154, Issue:4, 1997
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.The American journal of psychiatry, , Volume: 154, Issue:4, 1997
Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.Drugs, , Volume: 53, Issue:2, 1997
Olanzapine for schizophrenia.The Medical letter on drugs and therapeutics, , Jan-17, Volume: 39, Issue:992, 1997
[Olanzapin: a new perspective in the management of schizophrenia. X. Congress of the World Psychiatric Association, Madrid, August 1996].Fortschritte der Neurologie-Psychiatrie, , Volume: 64, Issue:11 Suppl O, 1996
Evaluating outcomes of treatments for persons with psychotic disorders.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Side effect profiles of new antipsychotic agents.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Atypical antipsychotic drugs and long-term outcome in schizophrenia.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Cognitive function in schizophrenic patients.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.Psychopharmacology, , Volume: 124, Issue:1-2, 1996
Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.Psychopharmacology bulletin, , Volume: 32, Issue:1, 1996
Olanzapine: a new atypical antipsychotic.Journal of psychosocial nursing and mental health services, , Volume: 34, Issue:8, 1996
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 14, Issue:2, 1996
The new generation of antipsychotic drugs.International clinical psychopharmacology, , Volume: 11 Suppl 2, 1996
Using the proportional odds model to assess the relationship between a multi-item and a global item efficacy scale in a psychiatric clinical trial.Journal of biopharmaceutical statistics, , Volume: 6, Issue:2, 1996
Advances in CNS Drugs. Recent advances and considerations in the treatment of schizophrenia.The Journal of clinical psychiatry, , Volume: 57, Issue:7, 1996
First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia.International clinical psychopharmacology, , Volume: 10, Issue:4, 1995
Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics.Journal of clinical psychopharmacology, , Volume: 15, Issue:1 Suppl 1, 1995
[Cardiovascular risk of haloperidol vs. atypical anti-psychotic drugs in schizophrenia treatment].Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, , Volume: 114, Issue:3
[Cognition, schizophrenia and the effect of antipsychotics].L'Encephale, , Volume: 32, Issue:3 Pt 1
Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia.The West Virginia medical journal, , Volume: 98, Issue:2
A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia.Clinical neuropharmacology, , Volume: 29, Issue:3
The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 11, Issue:1
Effects of Dose, Age, Sex, Body Weight, and Smoking on Plasma Concentrations of Olanzapine and N-desmethyl Olanzapine in Inpatients With Schizophrenia.Journal of clinical psychopharmacology, , Volume: 41, Issue:3
Psoriasis during therapy with olanzapine.European journal of dermatology : EJD, , Volume: 13, Issue:4
Weight and blood pressure changes after switching second-generation antipsychotics in a population of veterans with schizophrenia-related disorders.Journal of the American Pharmacists Association : JAPhA, , Volume: 47, Issue:2
Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.Journal of the American Pharmacists Association : JAPhA, , Volume: 47, Issue:3
Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.Journal of clinical psychopharmacology, , Volume: 41, Issue:4
Therapeutic drug monitoring of olanzapine: Easy and reliable method for clinical correlation.Indian journal of pharmacology, , Volume: 53, Issue:1
Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:3
Cost-effectiveness of olanzapine as a first-line treatment: a comment.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 9, Issue:5
[Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].Rivista di psichiatria, , Volume: 49, Issue:3
[Clinical impact of atypical antipsychotics: prospective 6-month study of inpatients treated with risperidone or olanzapine].Therapie, , Volume: 56, Issue:6
Predictors of risk for relapse in patients with schizophrenia or schizoaffective disorder during olanzapine drug therapy.Journal of psychiatric research, , Volume: 41, Issue:3-4
Masked clozapine-induced cardiomyopathy.Journal of the American Board of Family Medicine : JABFM, , Volume: 21, Issue:1
Treatment of catatonia with olanzapine and amantadine.Psychosomatics, , Volume: 48, Issue:6
Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.Human psychopharmacology, , Volume: 26, Issue:4-5
Recent evidence and potential mechanisms underlying weight gain and insulin resistance due to atypical antipsychotics.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 35, Issue:3
Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost.The Journal of international medical research, , Volume: 31, Issue:3
Clinical News.Clinical schizophrenia & related psychoses, , Volume: 11, Issue:1
[The influence of antipsychotic therapy on the cognitive functions of schizophrenic patients].Psychiatria polska, , Volume: 47, Issue:4
Cannabinoid type 1 receptor gene polymorphisms are not associated with olanzapine-induced weight gain.Human psychopharmacology, , Volume: 26, Issue:4-5
The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia.Harvard review of psychiatry, , Volume: 21, Issue:1
Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study.Advances in therapy, , Volume: 24, Issue:1
Treatment with atypical antipsychotics: new indications and new populations.Journal of psychiatric research, , Volume: 35, Issue:3
Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature.The Journal of the American Board of Family Practice, , Volume: 14, Issue:4
[Olanzapine effects on emotional recognition in treatment refractory schizophrenics].Actas espanolas de psiquiatria, , Volume: 31, Issue:5
[Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: results of multicenter, 18-week, double-blind clinical trial].Psychiatria polska, , Volume: 37, Issue:4
Age and disease severity predict choice of atypical neuroleptic: a signal detection approach to physicians' prescribing decisions.Journal of psychiatric research, , Volume: 37, Issue:6
[Subjective and objective assessment of memory functions in patients with schizophrenia treated with olanzapine].Psychiatria polska, , Volume: 36, Issue:6
[Effect of olanzapine treatment on cognitive functions in patients with schizophrenia].Psychiatria polska, , Volume: 36, Issue:6
Speech and language difficulties in a patient with schizophrenia-like disorder: a case report.Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria, , Volume: 20, Issue:3
Heart transplantation and schizophrenia.Psychosomatics, , Volume: 44, Issue:3
International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 11, Issue:6
[Treatment of schizophrenia in subjects with substance use disorders: A review].Actas espanolas de psiquiatria, , Volume: 29, Issue:2
[Incidence of extrapyramidal symptoms during treatment with olanzapine, haloperidol and risperidone: results of an observational study].Actas espanolas de psiquiatria, , Volume: 29, Issue:1
[Subjective and objective evaluation of treating schizophrenia with classic or atypical drugs].Psychiatria polska, , Volume: 35, Issue:1
[Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia].Psychiatria polska, , Volume: 35, Issue:1
Visceral and subcutaneous fat in patients treated with olanzapine: a case series.Clinical neuropharmacology, , Volume: 33, Issue:5
Reversal of pathologic cardiac parameters after transition from clozapine to olanzapine treatment: a case report.Clinical neuropharmacology, , Volume: 24, Issue:2
[Viewpoint of schizophrenic patients: a European survey].L'Encephale, , Volume: 27, Issue:1
Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia.Clinical neuropharmacology, , Volume: 34, Issue:6
High-dose olanzapine for treatment-refractory schizophrenia.Clinical neuropharmacology, , Volume: 26, Issue:2
Comparing the side effect profile of the atypical antipsychotics.West African journal of medicine, , Volume: 21, Issue:4
[The influence of atypical antipsychotics on brain functioning in schizophrenia. A proton magnetic resonance study].Psychiatria polska, , Volume: 44, Issue:3
The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 7, Issue:1
Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 26, Issue:5
Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12 Suppl 3
[Impact of olanzapine on quality of life of patients with schizophrenia: one-year follow-up with the Seville Quality of Life Questionnaire].Actas espanolas de psiquiatria, , Volume: 32, Issue:1
[Olanzapine in the first episode of schizophrenia in young adults].Psychiatria polska, , Volume: 36, Issue:6 Suppl
Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 15, Issue:3-4
Impact of serotonin receptor 2A gene haplotypes on C-peptide levels in clozapine- and olanzapine-treated patients.Human psychopharmacology, , Volume: 25, Issue:4
Propofol infusion for the retrieval of the acutely psychotic patient.Air medical journal, , Volume: 31, Issue:1
Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.Irish journal of medical science, , Volume: 172, Issue:4
Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.Journal of sex & marital therapy, , Volume: 29, Issue:2
Allelic frequencies of 3' Ig heavy chain locus enhancer HS1,2-A associated with Ig levels in patients with schizophrenia.International journal of immunopathology and pharmacology, , Volume: 22, Issue:1
Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics.Journal of the American Pharmacists Association : JAPhA, , Volume: 49, Issue:2
Olanzapine-induced EDTA-dependent pseudothrombocytopenia.Psychosomatics, , Volume: 43, Issue:5
Cost analysis of schizophrenia treatment with second-generation antipsychotic medications in North Carolina's Medicaid program.Journal of the American Pharmacists Association : JAPhA, , Volume: 47, Issue:1
[Antipsychotics--clever choices].Lakartidningen, , Volume: 104, Issue:7
Low delta sleep predicted a good clinical response to olanzapine administration in schizophrenic patients.Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion, , Volume: 56, Issue:3
Some aspects of psychodynamic response to novel atypical antipsychotics.Harvard review of psychiatry, , Volume: 7, Issue:4
Olanzapine-induced task specific tardive dystonia and its response to carbamazepine: a case report.Neurology India, , Volume: 60, Issue:6
Betahistine-Associated Weight Loss and Improved Cognitive and Negative Symptoms: Domain in Early-Onset Schizophrenia.American journal of therapeutics, , Volume: 26, Issue:6
Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia.Indian journal of pharmacology, , Volume: 44, Issue:5
[Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].L'Encephale, , Volume: 25, Issue:4
Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 7, Issue:5
Assessing cost-effectiveness of drug interventions for schizophrenia.The Australian and New Zealand journal of psychiatry, , Volume: 39, Issue:1-2
Near fatal ketoacidosis with olanzapine treatment.Psychosomatics, , Volume: 43, Issue:4
[Influence of serotonergic transmission on response to olanzapine].Actas espanolas de psiquiatria, , Volume: 30, Issue:5
Model-Guided Antipsychotic Dose Reduction in Schizophrenia: A Pilot, Single-Blind Randomized Controlled Trial.Journal of clinical psychopharmacology, , Volume: 39, Issue:4
[Safety and tolerability of olanzapine versus risperidone: a one-year randomized study in outpatients with schizophrenia with prominent negative symptoms].Actas espanolas de psiquiatria, , Volume: 35, Issue:2
[Olanzapine-associated neuroleptic malignant syndrome. A case report and favorable response to risperidone].Actas espanolas de psiquiatria, , Volume: 35, Issue:2
[Schizophrenia-like psychotic symptoms in a patient with confirmed Huntington's disease: a case report].Psychiatria polska, , Volume: 46, Issue:4
[First episode psychoses: psychosocial, interpersonal and cognitive bases for a therapeutic approach].La Clinica terapeutica, , Volume: 158, Issue:1
[Olanzapine--high potency antipsychotic drug inducing significant weight gain: a case report].Srpski arhiv za celokupno lekarstvo, , Volume: 136, Issue:5-6
Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 8, Issue:2
A Double-Blind, Placebo-Controlled Trial of Bupropion Add-on to Olanzapine or Risperidone in Overweight Individuals With Schizophrenia.Journal of clinical psychopharmacology, , Volume: 41, Issue:6
The art of prescribing. Principles of switching novel antipsychotic medications.Perspectives in psychiatric care, , Volume: 41, Issue:1
The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:3
Olanzapine-Associated Portal and Superior Mesenteric Vein Thrombosis.American journal of therapeutics, , Volume: 27, Issue:4
Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 20, Issue:2
Role of 5HT1A and 5HT2A receptors and default mode network in olanzapine-induced somnambulism.Neurology India, , Volume: 65, Issue:2
Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia.Journal of dual diagnosis, , Volume: 13, Issue:1
Paliperidone Extended Release Versus Olanzapine in Treatment-Resistant Schizophrenia: A Randomized, Double-Blind, Multicenter Study.Journal of clinical psychopharmacology, , Volume: 42, Issue:4
Insulin Resistance-Related Proteins Are Overexpressed in Patients and Rats Treated With Olanzapine and Are Reverted by Pueraria in the Rat Model.Journal of clinical psychopharmacology, , Volume: 39, Issue:3
[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].L'Encephale, , Volume: 31, Issue:2
Reducing Restraint With Clozapine in Involuntarily Admitted Patients With Schizophrenia.American journal of therapeutics, , Volume: 24, Issue:2
Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.Clinical therapeutics, , Volume: 20, Issue:6
[Antipsychotics in clinical practice. The refractory schizophrenic patients treatment].Psychiatria polska, , Volume: 42, Issue:6
Rating of textual associations in organized and nonorganized sentences for the assessment of semantic networks in schizophrenia.Comprehensive psychiatry, , Volume: 46, Issue:3
Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients.Indian journal of physiology and pharmacology, , Volume: 53, Issue:1
Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 12, Issue:5
Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases.Clinical neuropharmacology, , Volume: 28, Issue:4
Effects of Age, Sex, and Comedication on the Plasma Concentrations of Olanzapine in Chinese Patients With Schizophrenia Based on Therapeutic Drug Monitoring Data.Journal of clinical psychopharmacology, , Volume: 42, Issue:6
Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia.The American journal on addictions, , Volume: 16, Issue:4
Olanzapine-induced clinical seizure: a case report.Clinical neuropharmacology, , Volume: 32, Issue:5
A Randomized, 8-Week Study of the Effects of Extended-Release Paliperidone and Olanzapine on Heart Rate Variability in Patients With Schizophrenia.Journal of clinical psychopharmacology, , Volume: 39, Issue:3
Reconsidering Olanzapine as a Possible Culprit for Drug Fever, defying "Incomplete Neuromalignant Syndrome".The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, , Volume: 168, Issue:4
[The European schizophrenia outpatient health outcomes (SOHO) study: baseline findings of the Spanish sample].Actas espanolas de psiquiatria, , Volume: 32, Issue:4
[Olanzapine versus haloperidol: effectiveness in functionality and health state in a sample of Venezuelan patients with schizophrenia].Vertex (Buenos Aires, Argentina), , Volume: 19, Issue:81
[Antipsychotics in clinical practice. Treatment of the first schizophrenic episode].Psychiatria polska, , Volume: 42, Issue:6
[Ultrastructural changes of lymphocytes in patients with schizophrenia treated with olanzapine].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 116, Issue:3
[Functional status and quality of life in Latin American outpatients with schizophrenia treated with atypical or typical antipsychotics: outcomes of the 12 months schizophrenia outpatient health outcomes (IC-SOHO) Study].Vertex (Buenos Aires, Argentina), , Volume: 16, Issue:63
DEVELOPMENT OF OLANZAPINE LOADED PNA MICROGELS FOR DEPOT DRUG DELIVERY IN TREATMENT OF SCHIZOPHRENIA: IN VITRO AN IN VIVO RELEASE PROFILE.Acta poloniae pharmaceutica, , Volume: 73, Issue:1
A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia.Archives of medical research, , Volume: 33, Issue:6
Long-Term Treatment with Olanzapine in Hospital Conditions: Prevalence and Predictors of the Metabolic Syndrome.Srpski arhiv za celokupno lekarstvo, , Volume: 143, Issue:11-12
[Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].Psychiatria polska, , Volume: 38, Issue:3
Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro).Journal of clinical psychopharmacology, , Volume: 43, Issue:3
Significant predictors for olanzapine pharmacokinetics: a systematic review of population pharmacokinetic studies.Expert review of clinical pharmacology, , Volume: 16, Issue:6
Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study.General hospital psychiatry, , Volume: 83
Olanzapine.British journal of hospital medicine, , Volume: 58, Issue:9
Care maps: atypical antipsychotics. Introduction.Nursing standard (Royal College of Nursing (Great Britain) : 1987), , Volume: 18, Issue:36
Paliperidone Palmitate-Induced Retrograde Ejaculation.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:2
Correlation between plasma homovanillic acid levels and the response to atypical antipsychotics in male patients with schizophrenia.Clinical neuropharmacology, , Volume: 28, Issue:6
[Evaluation of therapeutical appropriateness in psychiatric treatment of schizophrenia, by integrating computer data records with clinical audit results].Rivista di psichiatria, , Volume: 50, Issue:6
Atypical antipsychotics in elderly patients with dementia or schizophrenia: review of recent literature.Harvard review of psychiatry, , Volume: 13, Issue:6
Ziprasidone-related agranulocytosis following olanzapine-induced neutropenia.General hospital psychiatry, , Volume: 28, Issue:1
[SSRI antidepressants and negative schizophrenic symptoms: differences between paroxetine and fluvoxamine in patients treated with olanzapine].Rivista di psichiatria, , Volume: 44, Issue:5
The utility of intramuscular ziprasidone in the management of acute psychotic agitation.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:3
Breastfed Infants Exposed to Combined Antipsychotics: Two Case Reports.American journal of therapeutics, , Volume: 23, Issue:6
Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia.Neuro endocrinology letters, , Volume: 25, Issue:1-2
Lost time, found hope and sorrow: the search for self, connection, and purpose during "awakenings" on the new antipsychotics.Harvard review of psychiatry, , Volume: 5, Issue:4
[Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].Actas luso-espanolas de neurologia, psiquiatria y ciencias afines, , Volume: 25, Issue:4
A Case of Schizophrenia With Catatonia Resistant to Lorazepam and Olanzapine Monotherapy But Responsive to Combination Treatment: Is It Time to Consider Using Select Second-Generation Antipsychotics Earlier in the Treatment Algorithm for This Patient TypeClinical neuropharmacology, , Volume: 42, Issue:2
Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain.Journal of psychiatric research, , Volume: 41, Issue:1-2
Acute Necrotizing Pancreatitis Following Olanzapine Treatment and 759C/T Polymorphism of HTR2C Gene: A Case Report.In vivo (Athens, Greece), , Volume: 29, Issue:5
Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 3, Issue:3
Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia: Results From the Randomized NeSSy Trial.Journal of clinical psychopharmacology, , Volume: 39, Issue:6
[The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].Psychiatria polska, , Volume: 49, Issue:2
[Guidelines for the use of second-generation long-acting antipsychotics].Psychiatria polska, , Volume: 49, Issue:2
Combination of olanzapine with opioid-agonists in the treatment of heroin-addicted patients affected by comorbid schizophrenia spectrum disorders.Clinical neuropharmacology, , Volume: 30, Issue:3
Treatment of schizophrenia: advances during the decade of the brain.British journal of hospital medicine, , Volume: 56, Issue:11
A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:1
[Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 year follow-up naturalistic study].Actas espanolas de psiquiatria, , Volume: 34, Issue:1
New drug seen as breakthrough in treatment of schizophrenia.Irish medical journal, , Volume: 89, Issue:4
[Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine].Psychiatria polska, , Volume: 39, Issue:6
[Subjective and objective evaluation of olanzapine treatment in schizophrenia].Psychiatria polska, , Volume: 38, Issue:5
[Decrease in mineral bone density in schizophrenic patients treated with 2nd generation antipsychotics].Psychiatria polska, , Volume: 39, Issue:6
Improvement of dumping syndrome and oversecretion of glucose-dependent insulinotropic polypeptide following a switch from olanzapine to quetiapine in a patient with schizophrenia.General hospital psychiatry, , Volume: 37, Issue:4
Comparison of olanzapine and risperidone use in psychiatric rehabilitation.Therapie, , Volume: 60, Issue:6
[Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].Actas espanolas de psiquiatria, , Volume: 32, Issue:5
Esperienze di switch a cariprazina in pazienti schizofrenici con comparsa di effetti collaterali/comorbilità mediche.Rivista di psichiatria, , Volume: 54, Issue:6
[Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions].Psychiatria polska, , Volume: 48, Issue:6
[Remission and relapse in the outpatient treatment of patients with schizophrenia. Outcomes at 3 years].Actas espanolas de psiquiatria, , Volume: 36, Issue:4
Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.The American journal on addictions, , Volume: 15, Issue:2
Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report.Clinical neuropharmacology, , Volume: 23, Issue:5
Adjunct Aripiprazole for Obsessive-Compulsive Symptoms Associated With Second-Generation Antipsychotics in 2 Patients With Schizophrenia: Anti-obsessional Efficacy of Partial Agonism.Journal of clinical psychopharmacology, , Volume: 40, Issue:4
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 9, Issue:2
Is Sitagliptin Effective for Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients? A Double-blind Placebo-controlled Clinical Trial.Journal of clinical psychopharmacology, , Volume: 40, Issue:5
[RODOS: risperidone olanzapine drug outcome studies in schizophrenia].L'Encephale, , Volume: 28 Spec No 2 Pt 2
[A case of leukopenia in treatment with risperidone in an adolescent].L'Encephale, , Volume: 26, Issue:5
Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: a prospective open label observational study.Indian journal of pharmacology, , Volume: 46, Issue:5
A bibliometric analysis of scientific production on atypical antipsychotic drugs from ItalyRivista di psichiatria, , Volume: 52, Issue:6
A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning.Journal of sex & marital therapy, , Volume: 32, Issue:4
Late-Onset Cholestatic Liver Injury During Combination Treatment With Chlorpromazine and Olanzapine: A Case Report.Journal of clinical psychopharmacology, , Volume: 39, Issue:2
[Follow-up of a 16-year-old adolescent with early-onset schizophrenia and catatonic symptoms].L'Encephale, , Volume: 39 Suppl 1, 2013
[Hypothermia under olanzapine treatment: clinical case series and review of current literature].Der Nervenarzt, , Volume: 83, Issue:5, 2012
Successful use of olanzapine in adolescent monozygotic twins with catatonic schizophrenia resistant to electroconvulsive therapy: case report.Neuro endocrinology letters, , Volume: 29, Issue:1, 2008
Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam.The Australian and New Zealand journal of psychiatry, , Volume: 35, Issue:3, 2001
An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
Facial edema with olanzapine.General hospital psychiatry, , Volume: 35, Issue:6
Complexity in Evaluation and Pharmacological Treatment of Early Onset Psychosis with Mood Symptoms: Childhood Onset Schizophrenia or Affective Disorder?Journal of child and adolescent psychopharmacology, , Volume: 29, Issue:3, 2019
Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.Journal of child and adolescent psychopharmacology, , Volume: 26, Issue:5, 2016
A case report on the relationship between treatment-resistant childhood-onset schizophrenia and an abnormally enlarged cavum septum pellucidum combined with cavum vergae.Chinese medical journal, , Volume: 125, Issue:7, 2012
Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia.Schizophrenia research, , Volume: 116, Issue:1, 2010
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.Schizophrenia bulletin, , Volume: 34, Issue:1, 2008
Olanzapine and blepharoclonus.The Journal of clinical psychiatry, , Volume: 68, Issue:9, 2007
A 1-year open-label trial of olanzapine in school-age children with schizophrenia.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 13, Issue:3, 2003
Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study.Journal of child and adolescent psychopharmacology, ,Fall, Volume: 13, Issue:3, 2003
Treatment of childhood-onset schizophrenia with olanzapine.Journal of child and adolescent psychopharmacology, ,Summer, Volume: 10, Issue:2, 2000
Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia.Journal of clinical psychopharmacology, , Volume: 20, Issue:2, 2000
Psychosis in a Patient with Davidoff-Dyke-Masson Syndrome.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:1
The clinical dilemma--prescribing in pregnancy.Psychiatria Danubina, , Volume: 20, Issue:1, 2008
Three cases of schizophrenia for which olanzapine was effective after early acute phase.Psychiatry and clinical neurosciences, , Volume: 62, Issue:1, 2008
[Hebephrenic schizophrenia].L'Encephale, , Volume: 31 Pt 2, 2005
Olanzapine-associated priapism.Journal of clinical psychopharmacology, , Volume: 21, Issue:2, 2001
[New therapeutic strategies in schizophrenia: apropos of acute decompensation treated with olanzapine].L'Encephale, , Volume: 26, Issue:2
Association of the genetic polymorphisms of metabolizing enzymes, transporters, target receptors and their interactions with treatment response to olanzapine in chinese han schizophrenia patients.Psychiatry research, , Volume: 293, 2020
Delusion of denial of pregnancy: A case report.Asian journal of psychiatry, , Volume: 45, 2019
Failure of rechallenge clozapine after agranulocytosis: A case report.L'Encephale, , Volume: 45, Issue:5, 2019
Olanzapine-Induced Fever.The primary care companion for CNS disorders, , 02-28, Volume: 21, Issue:1, 2019
Cyclosporine-Olanzapine Drug-Drug Interaction.The primary care companion for CNS disorders, , Apr-26, Volume: 20, Issue:2, 2018
[Electroconvulsive Therapy (ECT) of a 15-year-old female patient suffering from a severe delusional depression: a case report].Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie, , Volume: 46, Issue:6, 2018
Venous thrombosis during olanzapine treatment: a complex association.The Netherlands journal of medicine, , Volume: 76, Issue:6, 2018
Risperidone versus olanzapine in the acute treatment of Persistent Delusional Disorder: A retrospective analysis.Psychiatry research, , Volume: 253, 2017
Clozapine Treatment of Olanzapine-induced Tardive Dyskinesia: A Case Report.Journal of psychiatric practice, , Volume: 23, Issue:1, 2017
Worsening of Myasthenia Gravis After Administration of Antipsychotics for Treatment of Schizophrenia: A Case Report and Review of Literature.Journal of clinical psychopharmacology, , Volume: 37, Issue:5, 2017
Benefit of extending the dosing interval of olanzapine on schizophrenics during maintenance treatment.Asian journal of psychiatry, , Volume: 30, 2017
Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.The Journal of clinical psychiatry, , Volume: 77, Issue:10, 2016
Olanzapine as a possible replacement choice for paliperidone-induced Pisa syndrome: a case report.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 24, Issue:6, 2016
The dermatoscope: a new tool for delusional parasitosis.Clinical and experimental dermatology, , Volume: 41, Issue:6, 2016
A Case Report of Camptocormia Coinciding With Olanzapine Use.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
Asymptomatic Elevation of Amylase and Lipase After Olanzapine Treatment.Journal of clinical psychopharmacology, , Volume: 36, Issue:2, 2016
Erotomania and psychotic depression.The Australian and New Zealand journal of psychiatry, , Volume: 49, Issue:11, 2015
[Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics].Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, , Volume: 115, Issue:3, 2015
Are reduplicative paramnesia and clonal pluralization overlapping constructs?Psychiatria Danubina, , Volume: 27, Issue:1, 2015
Successful treatment of antipsychotic-induced restless legs syndrome with gabapentin.Asian journal of psychiatry, , Volume: 9, 2014
Olanzapine treatment during pregnancy and breastfeeding: a chance for women with psychotic illness?Psychopharmacology, , Volume: 231, Issue:15, 2014
Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.Psychiatry research, , Oct-30, Volume: 219, Issue:2, 2014
Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment.The Australian and New Zealand journal of psychiatry, , Volume: 47, Issue:10, 2013
Herbal medicine (Shakuyaku-kanzo-to) improves olanzapine-associated hyperprolactinemia: a case report.Journal of clinical psychopharmacology, , Volume: 33, Issue:1, 2013
[Hypothermia under olanzapine treatment: clinical case series and review of current literature].Der Nervenarzt, , Volume: 83, Issue:5, 2012
Antipsychotic treatment of acute paranoid schizophrenia patients with olanzapine results in altered glycosylation of serum glycoproteins.Journal of proteome research, , Jul-06, Volume: 11, Issue:7, 2012
[The Danish Mental Health Act does not prevent serious suicide attempts in patients with severe schizophrenia].Ugeskrift for laeger, , Jun-18, Volume: 174, Issue:25, 2012
Continuation of ECT after recovery from transient, ECT-induced, postictal cortical blindness.The journal of ECT, , Volume: 28, Issue:1, 2012
Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients.Pharmacological reports : PR, , Volume: 64, Issue:3, 2012
Liver toxicity due to olanzapine.Revista espanola de enfermedades digestivas, , Volume: 104, Issue:11, 2012
A case of Klingsor Syndrome: when there is no longer psychosis.The Israel journal of psychiatry and related sciences, , Volume: 48, Issue:1, 2011
Life-threatening hyponatraemia and intramuscular olanzapine: the world's longest therapeutic trial.BMJ case reports, , Dec-20, Volume: 2011, 2011
Folie à deux: double case-report of shared delusions with a fatal outcome.La Clinica terapeutica, , Volume: 162, Issue:1, 2011
Polymorphisms of the 5-HT2A receptor gene and clinical response to olanzapine in paranoid schizophrenia.Neuropsychobiology, , Volume: 64, Issue:4, 2011
Atypical anti-psychotics in delusional parasitosis: a retrospective case series of 20 patients.International journal of dermatology, , Volume: 49, Issue:1, 2010
Valid grounds for the switch of original antipsychotics with generics.Psychiatria Danubina, , Volume: 22, Issue:1, 2010
Impact of tobacco smoking cessation on stable clozapine or olanzapine treatment.The Annals of pharmacotherapy, , Volume: 44, Issue:4, 2010
SSRIs as a treatment alternative for monosymptomatic delusional disorders.The Australian and New Zealand journal of psychiatry, , Volume: 44, Issue:3, 2010
[Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection].Gastroenterologia y hepatologia, , Volume: 33, Issue:2, 2010
Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.Journal of psychopharmacology (Oxford, England), , Volume: 24, Issue:7, 2010
Large squamous cell carcinoma of the face and paranoid schizophrenia: a calamitous combination.Clinical and experimental dermatology, , Volume: 35, Issue:6, 2010
[Medication associated long QT syndrome].Praxis, , Dec-02, Volume: 98, Issue:24, 2009
Religious delusions in an evangelical Christian woman with anorexia nervosa.Journal of psychiatric practice, , Volume: 15, Issue:6, 2009
Fatal pulmonary embolism following antipsychotic treatment and physical restraint.Pharmacopsychiatry, , Volume: 42, Issue:5, 2009
Influence of olanzapine on memory functions.Psychiatria Danubina, , Volume: 21, Issue:1, 2009
Olanzapine monotherapy in a long-term treatment for schizophrenia: case study.Psychiatria Danubina, , Volume: 21, Issue:1, 2009
Safety and antipsychotic efficacy of "forced" intramuscular olanzapine over five days: a case report.Progress in neuro-psychopharmacology & biological psychiatry, , Mar-17, Volume: 33, Issue:2, 2009
Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia.Psychiatry and clinical neurosciences, , Volume: 63, Issue:1, 2009
Four cases of venous thromboembolism associated with olanzapine.Psychiatry and clinical neurosciences, , Volume: 63, Issue:1, 2009
Chronic Pisa syndrome associated with switching antipsychotics from olanzapine to ziprasidone.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-01, Volume: 33, Issue:1, 2009
Successful treatment of delusional disorder of the somatic type or "delusional parasitosis" with olanzapine.Pharmacopsychiatry, , Volume: 41, Issue:3, 2008
Successful re-exposure to clozapine following uneventful rechallenge with olanzapine in a patient with neutropenia related to both agents.Progress in neuro-psychopharmacology & biological psychiatry, , May-15, Volume: 32, Issue:4, 2008
A case of paranoid schizophrenia complicated by scleroderma with associated esophageal dysmotility.Journal of psychiatric practice, , Volume: 14, Issue:2, 2008
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting.Journal of psychiatric research, , Volume: 42, Issue:11, 2008
Three cases of schizophrenia for which olanzapine was effective after early acute phase.Psychiatry and clinical neurosciences, , Volume: 62, Issue:1, 2008
Contribution of leptin to the formation of neuroleptic obesity in patients with schizophrenia during antipsychotic therapy.Bulletin of experimental biology and medicine, , Volume: 146, Issue:3, 2008
A clinical paradigm of delusions of parasitosis.Journal of the American Academy of Dermatology, , Volume: 59, Issue:4, 2008
Massive pulmonary emboli associated with olanzapine.Irish medical journal, , Volume: 101, Issue:6, 2008
Olanzapine treatment during breast feeding: a case report.Therapeutic drug monitoring, , Volume: 30, Issue:3, 2008
A patient treated with olanzapine developing diabetes de novo: proposal for hyperglycaemia screening.The Netherlands journal of medicine, , Volume: 65, Issue:9, 2007
Metabolic syndrome in drug-naïve first-episode psychosis treated with atypical antipsychotics.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:7, 2007
Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.Human psychopharmacology, , Volume: 22, Issue:1, 2007
Fatal agranulocytosis: the use of olanzapine in a patient with schizophrenia and myelodysplasia.Progress in neuro-psychopharmacology & biological psychiatry, , Jan-30, Volume: 31, Issue:1, 2007
Bradyarrhythmic shock associated with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:1, 2007
Atypical antipsychotic drugs in the treatment of delusional parasitosis.International journal of psychiatry in medicine, , Volume: 37, Issue:1, 2007
[Treatment resistant schizophrenia, residual subtype: symptom improvement after additional treatment with amisulpride].Psychiatrische Praxis, , Volume: 33, Issue:1, 2006
Risperidone alternative for a schizophrenic patient with olanzapine-exacerbated diabetic mellitus.Psychiatry and clinical neurosciences, , Volume: 60, Issue:1, 2006
Clozapine effective in olanzapine-induced Pisa syndrome.The Annals of pharmacotherapy, , Volume: 40, Issue:12, 2006
Wilson's disease associated with delusional disorder.Psychiatry and clinical neurosciences, , Volume: 60, Issue:6, 2006
Olanzapine-associated neuroleptic malignant syndrome.Pharmacotherapy, , Volume: 26, Issue:8, 2006
Hypotension secondary to the combination of intramuscular olanzapine and intramuscular lorazepam.The Journal of clinical psychiatry, , Volume: 66, Issue:12, 2005
Olanzapine-induced acute rhabdomyolysis-a case report.Pharmacopsychiatry, , Volume: 38, Issue:1, 2005
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
Postmortem tissue distribution of olanzapine and citalopram in a drug intoxication.Journal of forensic sciences, , Volume: 50, Issue:3, 2005
Reappearance of tardive dystonia with olanzapine treated with clozapine.Schizophrenia research, , Jul-15, Volume: 76, Issue:2-3, 2005
Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Treatment of perinatal delusional disorder: a case report.International journal of psychiatry in medicine, , Volume: 33, Issue:4, 2003
Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder.The Journal of clinical psychiatry, , Volume: 64, Issue:5, 2003
Reversal of antipsychotic-induced weight gain during quetiapine treatment.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia.The Journal of clinical psychiatry, , Volume: 63, Issue:11, 2002
[Mnestic impairment under olanzapine overdosage in an elderly patient].Psychiatrische Praxis, , Volume: 29, Issue:8, 2002
Severe hypertriglyceridemia associated with olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:10, 2002
Ziprasidone alternative for olanzapine-induced hyperglycemia.The American journal of psychiatry, , Volume: 159, Issue:9, 2002
Olanzapine for the treatment of monosymptomatic hypochondriacal psychosis.The Journal of clinical psychiatry, , Volume: 63, Issue:2, 2002
Atypical neuroleptic malignant syndrome associated with olanzapine.Pharmacotherapy, , Volume: 22, Issue:5, 2002
Olanzapine-induced respiratory failure.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, ,Summer, Volume: 9, Issue:3, 2001
Olanzapine induces remarkable weight gain in adolescent patients.European child & adolescent psychiatry, , Volume: 10, Issue:3, 2001
Manic symptoms induced by olanzapine.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 11, Issue:2, 2001
Continuing treatment with novel antipsychotic drugs despite leukopenia or thrombocytopenia.Archives of general psychiatry, , Volume: 58, Issue:7, 2001
Tardive dystonia associated with olanzapine therapy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 22, Issue:4, 2001
Treatment of preexisting diabetes with olanzapine.The Journal of clinical psychiatry, , Volume: 62, Issue:9, 2001
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Panic disorder associated with clozapine.The American journal of psychiatry, , Volume: 157, Issue:12, 2000
Overdose and death with olanzapine: two case reports.The American journal of forensic medicine and pathology, , Volume: 21, Issue:3, 2000
Olanzapine appears haematologically safe in patients who developed blood dyscrasia on clozapine and risperidone.International clinical psychopharmacology, , Volume: 15, Issue:4, 2000
Case report of withdrawal syndrome after olanzapine discontinuation.Journal of clinical psychopharmacology, , Volume: 20, Issue:4, 2000
H(2) antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients.Biological psychiatry, , Jul-15, Volume: 48, Issue:2, 2000
Healthy outcome under olanzapine treatment in a pregnant woman.Pharmacopsychiatry, , Volume: 33, Issue:2, 2000
[Chronic and therapy refractory Fregoli syndrome].Psychiatrische Praxis, , Volume: 27, Issue:1, 2000
Olanzapine serum concentrations lowered by concomitant treatment with carbamazepine.Journal of clinical psychopharmacology, , Volume: 20, Issue:1, 2000
Stalking behavior in delusional jealousy.Journal of forensic sciences, , Volume: 45, Issue:1, 2000
Tardive dyskinesia associated with olanzapine monotherapy.The Journal of clinical psychiatry, , Volume: 60, Issue:12, 1999
Neuroleptic malignant syndrome after the initiation of olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Olanzapine-induced ketoacidosis with diabetes mellitus.The American journal of psychiatry, , Volume: 156, Issue:9, 1999
[Neuroleptic malignant syndrome associated with olanzapine].Medicina clinica, , Sep-04, Volume: 113, Issue:6, 1999
Olanzapine-induced neuroleptic malignant syndrome.Archives of general psychiatry, , Volume: 56, Issue:1, 1999
Olanzapine and pregnancy.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:2, 1998
Aggression, agitation, and mania with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:10, 1998
Case report: possible neuroleptic malignant syndrome associated with olanzapine.Journal of clinical psychopharmacology, , Volume: 18, Issue:6, 1998
Acute dystonia with olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:7, 1998
Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis.International clinical psychopharmacology, , Volume: 13, Issue:3, 1998
Effects of olanzapine on polydipsia and intermittent hyponatremia.The Journal of clinical psychiatry, , Volume: 58, Issue:12, 1997
Propranolol treatment of olanzapine-induced akathisia.The American journal of psychiatry, , Volume: 154, Issue:9, 1997
Hiccups associated with switching from olanzapine to aripiprazole in a patient with paranoid schizophrenia.Clinical neuropharmacology, , Volume: 37, Issue:3
Delayed Onset Postinjection Delirium/Sedation Syndrome Associated With Olanzapine Pamoate: A Case Report.Journal of clinical psychopharmacology, , Volume: 39, Issue:5
[Calcium balance and regulation in schizophrenic patients treated with second generation antipsychotics].Psychiatria polska, , Volume: 39, Issue:6
[Mineralization of the basal ganglia as the supposed cause of poor tolerance of zuclopenthixol in a patient with long-term untreated paranoid schizophrenia].Psychiatria polska, , Volume: 47, Issue:4
[Use of high-dose olanzapine for treatment of acute relapse of schizophrenia in a patient with bad tolerance of typical neuroleptics. Case report].Psychiatria polska, , Volume: 38, Issue:3
[Initiation of treatment with olanzapine in a patient hospitalized at UMD].L'Encephale, , Volume: 26, Issue:3
Recovery from new-onset diabetes in a schizophrenic man after withdrawal of olanzapine.Psychosomatics, , Volume: 43, Issue:1
Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection.Clinical neuropharmacology, , Volume: 42, Issue:2
Olanzapine-induced neutropenia.Psychosomatics, , Volume: 41, Issue:2
Challenges in managing a mother with a dual diagnosis of peripartum cardiomyopathy and paranoid schizophrenia - a case report.General hospital psychiatry, , Volume: 35, Issue:6
Facial edema with olanzapine.General hospital psychiatry, , Volume: 35, Issue:6
Olanzapine-induced retarded ejaculation: role of paroxetine comedication? A case report.Therapie, , Volume: 56, Issue:4
Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.CNS spectrums, , Volume: 12, Issue:3 Suppl 4, 2007
Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables.Journal of psychiatric research, , Volume: 41, Issue:8, 2007
Anorexia nervosa with chronic episodes for more than 30 years in a patient with a comorbid schizotypal personality disorder.Psychiatry and clinical neurosciences, , Volume: 61, Issue:4, 2007
Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder.Schizophrenia research, , Nov-01, Volume: 71, Issue:1, 2004
Serotonin syndrome and atypical antipsychotics.The American journal of psychiatry, , Volume: 159, Issue:4, 2002
Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.Psychiatry research, , Oct-30, Volume: 96, Issue:2, 2000
Long-term chemogenetic suppression of seizures in a multifocal rat model of temporal lobe epilepsy.Epilepsia, , Volume: 62, Issue:3, 2021
Generalised tonic-clonic seizures on the subtherapeutic dose of olanzapine.BMJ case reports, , Dec-29, Volume: 12, Issue:12, 2019
Olanzapine-related repetitive focal seizures with lingual dystonia.Epileptic disorders : international epilepsy journal with videotape, , Volume: 18, Issue:1, 2016
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, , Volume: 12, Issue:1, 2015
Cardiotoxicity in a citalopram and olanzapine overdose.The Journal of emergency medicine, , Volume: 45, Issue:4, 2013
Seizure after intrathecal baclofen bolus in a multiple sclerosis patient treated with oxcarbazepine.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 32, Issue:2, 2011
Long-term cognitive deficits accompanied by reduced neurogenesis after soman poisoning.Neurotoxicology, , Volume: 30, Issue:1, 2009
Neurotoxicity with therapeutic lithium levels: a case report.Journal of psychiatric practice, , Volume: 15, Issue:1, 2009
The effect of olanzapine pretreatment on acute cocaine toxicity in mice.Clinical toxicology (Philadelphia, Pa.), , Volume: 47, Issue:6, 2009
Serum levels of olanzapine in a non-fatal overdose.Journal of analytical toxicology, , Volume: 31, Issue:2, 2007
Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report.Psychiatria Danubina, , Volume: 18, Issue:1-2, 2006
[A 74-year-old unconscious woman with myoclonia and seizures].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Sep-07, Volume: 126, Issue:17, 2006
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?Current opinion in pediatrics, , Volume: 17, Issue:2, 2005
Seizures associated with memantine use.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Feb-15, Volume: 62, Issue:4, 2005
The impact of neuroleptic medication on seizure threshold and duration in electroconvulsive therapy.Ideggyogyaszati szemle, , Nov-20, Volume: 57, Issue:11-12, 2004
Antipsychotic medication and seizures: a review.Drugs of today (Barcelona, Spain : 1998), , Volume: 39, Issue:7, 2003
Olanzapine-associated seizure.The Annals of pharmacotherapy, , Volume: 37, Issue:1, 2003
EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects.Human psychopharmacology, , Volume: 18, Issue:8, 2003
[Brain tumor].Ryoikibetsu shokogun shirizu, , Issue:40, 2003
New-onset seizure associated with quetiapine and olanzapine.The Annals of pharmacotherapy, , Volume: 36, Issue:3, 2002
Lowered seizure threshold on olanzapine.The British journal of psychiatry : the journal of mental science, , Volume: 178, Issue:1, 2001
Seizures caused by possible interaction between olanzapine and clomipramine.Journal of clinical psychopharmacology, , Volume: 20, Issue:2, 2000
Electroencephalogram alterations during treatment with olanzapine.Psychopharmacology, , Volume: 150, Issue:2, 2000
Seizure associated with olanzapine.The Annals of pharmacotherapy, , Volume: 33, Issue:5, 1999
The relationship of pharmacology to side effects.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Side effect profiles of new antipsychotic agents.The Journal of clinical psychiatry, , Volume: 57 Suppl 11, 1996
Olanzapine-induced clinical seizure: a case report.Clinical neuropharmacology, , Volume: 32, Issue:5
Psychosis in a Patient with Davidoff-Dyke-Masson Syndrome.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:1
A Case of Self-Cannibalism: An Extremely Rare Type of Self-Mutilation With Multiple Risk Factors.The Journal of nervous and mental disease, , 04-01, Volume: 209, Issue:4, 2021
A case of Klingsor Syndrome: when there is no longer psychosis.The Israel journal of psychiatry and related sciences, , Volume: 48, Issue:1, 2011
Low-dose olanzapine for self-mutilation behavior in patients with borderline personality disorder.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
Treatment of self-mutilation with olanzapine.Journal of cutaneous medicine and surgery, , Volume: 4, Issue:3, 2000
Association Between Sexual Dysfunction and Dose of Atypical Antipsychotics: Essential to Learn the Basics.Journal of clinical pharmacology, , Volume: 63, Issue:1, 2023
Management of sexual dysfunction due to antipsychotic drug therapy.The Cochrane database of systematic reviews, , Nov-14, Volume: 11, 2012
Changes in sexual function and gonadal axis hormones after switching to aripiprazole in male schizophrenia patients: a prospective pilot study.International clinical psychopharmacology, , Volume: 27, Issue:4, 2012
Hypersexual features in Huntington's disease.Singapore medical journal, , Volume: 52, Issue:6, 2011
Excessive masturbation associated with olanzapine in a pediatric case.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 34, Issue:7, 2010
Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics.The journal of sexual medicine, , Volume: 7, Issue:10, 2010
Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia.Pharmacopsychiatry, , Volume: 42, Issue:4, 2009
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone.Psychoneuroendocrinology, , Volume: 34, Issue:7, 2009
Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia.Psychoneuroendocrinology, , Volume: 34, Issue:1, 2009
Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 19, Issue:8, 2009
A naturalistic, 9-month follow-up, comparing olanzapine and conventional antipsychotics on sexual function and hormonal profile for males with schizophrenia.Journal of psychopharmacology (Oxford, England), , Volume: 21, Issue:2, 2007
An empirical evaluation of the Arizona sexual experience scale and a simple one-item screening test for assessing antipsychotic-related sexual dysfunction in outpatients with schizophrenia and schizoaffective disorder.Schizophrenia research, , Jan-31, Volume: 81, Issue:2-3, 2006
Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.Schizophrenia research, , Volume: 86, Issue:1-3, 2006
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 21, Issue:4, 2006
Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.Psychoneuroendocrinology, , Volume: 31, Issue:5, 2006
Antipsychotic treatment and sexual functioning in first-time neuroleptic-treated schizophrenic patients.International clinical psychopharmacology, , Volume: 20, Issue:1, 2005
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:1, 2004
Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels.Annals of the New York Academy of Sciences, , Volume: 1032, 2004
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.The Journal of clinical psychiatry, , Volume: 65, Issue:3, 2004
Paliperidone Palmitate-Induced Retrograde Ejaculation.Clinical schizophrenia & related psychoses, , Volume: 12, Issue:2
Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study.Journal of sex & marital therapy, , Volume: 29, Issue:2
A randomized open-label comparison of the impact of olanzapine versus risperidone on sexual functioning.Journal of sex & marital therapy, , Volume: 32, Issue:4
Olanzapine-induced retarded ejaculation: role of paroxetine comedication? A case report.Therapie, , Volume: 56, Issue:4
Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial.Journal of psychiatric research, , Volume: 36, Issue:3
Delusional infestation.The American journal of emergency medicine, , Volume: 35, Issue:2, 2017
The Psychotic Couple--Sharing Drugs or Delusions?Journal of the South Carolina Medical Association (1975), , Volume: 110, Issue:4, 2015
Folie à deux: double case-report of shared delusions with a fatal outcome.La Clinica terapeutica, , Volume: 162, Issue:1, 2011
Shared psychotic disorder ("folie a deux") between mother and 15 years old son.Collegium antropologicum, , Volume: 32, Issue:4, 2008
Olanzapine poisoning in patients treated at the National Poison Control Centre in Belgrade, Serbia in 2017 and 2018: a brief review of serum concentrations and clinical symptoms.Arhiv za higijenu rada i toksikologiju, , Jul-07, Volume: 73, Issue:2, 2022
"Schizophrenia past clozapine": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing.Pharmacopsychiatry, , Volume: 48, Issue:1, 2015
Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Hypersalivation induced by olanzapine with fluvoxamine.Progress in neuro-psychopharmacology & biological psychiatry, , Volume: 30, Issue:4, 2006
Hypersalivation coincident with olanzapine treatment.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
Monosymptomatic hypochondriacal psychosis presenting with recurrent oral mucosal ulcers and multiple skin lesions responding to olanzapine treatment.International journal of dermatology, , Volume: 45, Issue:10, 2006
Eruptive xanthomas associated with olanzapine use.Archives of dermatology, , Volume: 139, Issue:8, 2003
Olanzapine is effective in the management of some self-induced dermatoses: three case reports.Cutis, , Volume: 66, Issue:2, 2000
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
Olanzapine and clozapine differently affect sleep in patients with schizophrenia: results from a double-blind, polysomnographic study and review of the literature.Schizophrenia research, , Volume: 152, Issue:1, 2014
Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain.Anesthesiology, , Volume: 116, Issue:1, 2012
Olanzapine-induced "restless arms syndrome".Journal of clinical psychopharmacology, , Volume: 29, Issue:1, 2009
A clinical paradigm of delusions of parasitosis.Journal of the American Academy of Dermatology, , Volume: 59, Issue:4, 2008
Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia.Pharmacopsychiatry, , Volume: 41, Issue:3, 2008
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.The American journal of psychiatry, , Volume: 164, Issue:7, 2007
Olanzapine use in adolescent anorexia nervosa.Eating and weight disorders : EWD, , Volume: 11, Issue:2, 2006
Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review.International clinical psychopharmacology, , Volume: 21, Issue:4, 2006
A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.The Journal of clinical psychiatry, , Volume: 65, Issue:12, 2004
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Sleep-related eating disorder induced by olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:7, 2002
Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study.The American journal of psychiatry, , Volume: 159, Issue:10, 2002
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.Archives of general psychiatry, , Volume: 57, Issue:9, 2000
Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
[The use of olanzapine in sleep disorders. An open trial with nine patients].Revista de neurologia, , Volume: 38, Issue:9
Isolated nocturnal auditory hallucinations: a case report.General hospital psychiatry, , Volume: 33, Issue:5
The effect of Olanzapine and Sertraline on personality disorder in patients with methadone maintenance therapy.Psychiatria Danubina, , Volume: 22, Issue:4, 2010
Atypical antipsychotic drugs in the treatment of delusional parasitosis.International journal of psychiatry in medicine, , Volume: 37, Issue:1, 2007
Olanzapine augmentation of fluoxetine in body dysmorphic disorder.The American journal of psychiatry, , Volume: 162, Issue:5, 2005
[Olanzapine in therapy of a somatoform disorder].Psychiatrische Praxis, , Volume: 30, Issue:8, 2003
Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report.The Journal of clinical psychiatry, , Volume: 62, Issue:4, 2001
A safety signal of somnambulism with the use of antipsychotics and lithium: A pharmacovigilance disproportionality analysis.British journal of clinical pharmacology, , Volume: 87, Issue:10, 2021
Sleepwalking Is Associated With Coadministration of Olanzapine and Propranolol: A Case Report.Journal of clinical psychopharmacology, , Volume: 37, Issue:5, 2017
A case of atypical antipsychotic-induced somnambulism: a class effect.The Journal of clinical psychiatry, , Volume: 74, Issue:4, 2013
Somnambulism secondary to olanzapine treatment in one patient with bipolar disorder.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Sleep-related eating disorder induced by olanzapine.The Journal of clinical psychiatry, , Volume: 63, Issue:7, 2002
Olanzapine-induced somnambulism.The American journal of psychiatry, , Volume: 158, Issue:7, 2001
Olanzapine-Related Somnambulism: A Systematic Review of Literature and a Case Report of Anorexia Nervosa.Journal of clinical psychopharmacology, , Volume: 41, Issue:6
Role of 5HT1A and 5HT2A receptors and default mode network in olanzapine-induced somnambulism.Neurology India, , Volume: 65, Issue:2
Olanzapine toxicity in unconjugated hyperbilirubinaemia (Gilbert's syndrome).The British journal of psychiatry : the journal of mental science, , Volume: 182, 2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.Schizophrenia research, , May-01, Volume: 61, Issue:1, 2003
Speech disturbance and marked decrease in function seen in several older patients on olanzapine.Journal of the American Geriatrics Society, , Volume: 46, Issue:10, 1998
Anti-NMDA (a-NMDAR) receptor encephalitis related to acute consumption of metamphetamine: Relevance of differential diagnosis.Revista espanola de anestesiologia y reanimacion, , Volume: 64, Issue:3, 2017
Status epilepticus in a patient treated with olanzapine and mirtazapine.International journal of clinical pharmacology and therapeutics, , Volume: 47, Issue:2, 2009
Olanzapine-induced myoclonic status.Clinical neuropharmacology, , Volume: 28, Issue:3
Fatal status epilepticus associated with olanzapine therapy.The Annals of pharmacotherapy, , Volume: 33, Issue:7-8
Diagnosis and Treatment of Eclamptic Psychosis in the Postpartum Period: A Case Report.Psychosomatics, , Volume: 56, Issue:5
Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy.Anticancer research, , Volume: 37, Issue:12, 2017
Pharmacological and psychosomatic treatments for an elderly patient with severe nausea and vomiting in reaction to postoperative stress.Clinical journal of gastroenterology, , Volume: 8, Issue:5, 2015
[Use of orally disintegrating olanzapine tablet for patients with cancerous peritonitis and postoperative gastric cancer receiving home palliative care].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 39, Issue:4, 2012
Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition.European journal of cancer care, , Volume: 16, Issue:3, 2007
Improvement of dumping syndrome and oversecretion of glucose-dependent insulinotropic polypeptide following a switch from olanzapine to quetiapine in a patient with schizophrenia.General hospital psychiatry, , Volume: 37, Issue:4
New-onset psychosis following initiation of eye movement desensitization and reprocessing therapy.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 32, Issue:2, 2020
[no title available]Journal of child and adolescent psychopharmacology, , Volume: 30, Issue:9, 2020
Repeated olanzapine treatment mitigates PTSD like symptoms in rats with changes in cell signaling factors.Brain research bulletin, , Volume: 140, 2018
Olanzapine monotherapy in posttraumatic stress disorder: efficacy in a randomized, double-blind, placebo-controlled study.Human psychopharmacology, , Volume: 27, Issue:4, 2012
Premorbid combat related ptsd in Huntington's disease - Case report.Psychiatria Danubina, , Volume: 22, Issue:2, 2010
Posttraumatic brain injury psychosis successfully treated with olanzapine.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-01, Volume: 34, Issue:1, 2010
The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials.International clinical psychopharmacology, , Volume: 23, Issue:1, 2008
[Antipsychotics, anticonvulsants, antiadrenergics and other drugs: what to do when posttraumatic stress disorder does not respond to selective serotonin reuptake inhibitors?].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 29 Suppl 2, 2007
Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review.International clinical psychopharmacology, , Volume: 21, Issue:4, 2006
Combined use of ECT with duloxetine and olanzapine: a case report.The journal of ECT, , Volume: 22, Issue:2, 2006
Creating more effective antidepressants: clues from the clinic.Drug discovery today, , Volume: 11, Issue:13-14, 2006
Olanzapine versus fluphenazine in an open trial in patients with psychotic combat-related post-traumatic stress disorder.Psychopharmacology, , Volume: 175, Issue:4, 2004
Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports.Acta psychiatrica Scandinavica, , Volume: 107, Issue:5, 2003
Olanzapine treatment for post-traumatic stress disorder: an open-label study.International clinical psychopharmacology, , Volume: 16, Issue:6, 2001
Treatment of posttraumatic stress disorder with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:2, 2001
Olanzapine in the treatment of post-traumatic stress disorder: a pilot study.International clinical psychopharmacology, , Volume: 16, Issue:4, 2001
Olanzapine-lnduced hyperglycemic nonketonic coma.The Annals of pharmacotherapy, , Volume: 35, Issue:3, 2001
Olanzapine for the treatment of acquired neurogenic stuttering.Journal of psychiatric practice, , Volume: 15, Issue:6, 2009
[Acquired stuttering in a psychotic patient].Tijdschrift voor psychiatrie, , Volume: 51, Issue:1, 2009
Comments on Bothe, Davidow, Bramlett, Franic, and Ingham (2006).American journal of speech-language pathology, , Volume: 17, Issue:1, 2008
Olanzapine- and clozapine-induced stuttering. A case series.Pharmacopsychiatry, , Volume: 37, Issue:3, 2004
Alleviating stuttering with pharmacological interventions.Expert opinion on pharmacotherapy, , Volume: 5, Issue:7, 2004
Management of child and adolescent stuttering with olanzapine: three case reports.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 11, Issue:4, 1999
Stuttering treated with olanzapine: a case report.Actas espanolas de psiquiatria, , Volume: 40, Issue:4
Olanzapine in the treatment of developmental stuttering: a double-blind, placebo-controlled trial.Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 16, Issue:2
Olanzapine/samidorphan precipitated opioid withdrawal in a patient taking transdermal fentanyl.Clinical toxicology (Philadelphia, Pa.), , Volume: 60, Issue:7, 2022
A Potential Case of Acute Ketamine Withdrawal: Clinical Implications for the Treatment of Refractory Depression.The American journal of psychiatry, , Volume: 178, Issue:7, 2021
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.Bosnian journal of basic medical sciences, , May-20, Volume: 19, Issue:2, 2019
An open-label randomized trial of intramuscular olanzapine versus oral clonidine for symptomatic treatment of opioid withdrawal in the emergency department.Clinical toxicology (Philadelphia, Pa.), , Volume: 57, Issue:8, 2019
Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database.Journal of clinical psychopharmacology, , Volume: 38, Issue:1, 2018
Antipsychotics for cocaine or psychostimulant dependence: systematic review and meta-analysis of randomized, placebo-controlled trials.The Journal of clinical psychiatry, , Volume: 74, Issue:12, 2013
Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.Schizophrenia research, , Volume: 107, Issue:2-3, 2009
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2, 2009
Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:1, 2008
Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers.Experimental and clinical psychopharmacology, , Volume: 16, Issue:3, 2008
Effects of olanzapine on ethanol withdrawal syndrome in rats.European journal of pharmacology, , Jan-28, Volume: 579, Issue:1-3, 2008
Gamma-hydroxybutyric acid (GHB) withdrawal: a case report.Journal of psychoactive drugs, , Volume: 39, Issue:3, 2007
Managing psychosis in pregnancy.The Australian and New Zealand journal of psychiatry, , Volume: 41, Issue:3, 2007
Olanzapine withdrawal/discontinuation-induced hyperthermia in rats.Progress in neuro-psychopharmacology & biological psychiatry, , Oct-01, Volume: 31, Issue:7, 2007
Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats.Alcoholism, clinical and experimental research, , Volume: 31, Issue:9, 2007
Tiagabine withdrawal-emergent mania.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:8, 2006
Dependence and chronic psychosis with D-nor-pseudoephedrine.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 18, Issue:8, 2003
Olanzapine and serotonin toxicity.Psychiatry and clinical neurosciences, , Volume: 57, Issue:2, 2003
Decreased density of [3H]TCP binding following antipsychotic drug withdrawal in rats.Life sciences, , Apr-19, Volume: 70, Issue:22, 2002
Characterization of olanzapine-induced weight gain in rats.Journal of psychopharmacology (Oxford, England), , Volume: 16, Issue:4, 2002
Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.International clinical psychopharmacology, , Volume: 17, Issue:2, 2002
Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 46, Issue:1, 2001
The treatment of tardive dyskinesia and tardive dystonia.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Expected incidence of tardive dyskinesia associated with atypical antipsychotics.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Case report of withdrawal syndrome after olanzapine discontinuation.Journal of clinical psychopharmacology, , Volume: 20, Issue:4, 2000
Olanzapine for treatment-refractory psychosis in patients responsive to, but intolerant of, clozapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:4, 1999
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.Journal of clinical psychopharmacology, , Volume: 19, Issue:5, 1999
Clozapine-olanzapine: a potentially dangerous switch. A report of two cases.Journal of clinical pharmacy and therapeutics, , Volume: 24, Issue:3, 1999
Olanzapine for the treatment of tardive dyskinesia.The Journal of clinical psychiatry, , Volume: 59, Issue:7, 1998
Olanzapine-induced manic-like syndrome.The Journal of clinical psychiatry, , Volume: 59, Issue:6, 1998
Emergence of koro after abrupt cessation of olanzapine.The Journal of clinical psychiatry, , Volume: 59, Issue:2, 1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Similarities and differences between the subchronic and withdrawal effects of clozapine and olanzapine on forelimb force steadiness.Psychopharmacology, , Volume: 132, Issue:4, 1997
[Olanzapine efficacy in the treatment of cocaine abuse in methadone maintenance patients. Interaction with plasma levels].Actas espanolas de psiquiatria, , Volume: 29, Issue:4
Delirium Associated With Fluoxetine Discontinuation: A Case Report.Clinical neuropharmacology, , Volume: 40, Issue:3
[Psychotic syndrome after withdrawal of cyproheptadine: remission with olanzapine].Actas espanolas de psiquiatria, , Volume: 28, Issue:4
Outcome predictors in cocaine dependence treatment trials.The American journal on addictions, , Volume: 15, Issue:6
[no title available]Ugeskrift for laeger, , May-08, Volume: 185, Issue:19, 2023
Monitoring for post-injection delirium/sedation syndrome with long-acting olanzapine during the COVID-19 pandemic.The Australian and New Zealand journal of psychiatry, , Volume: 54, Issue:7, 2020
Long-acting injectable olanzapine: post-injection syndrome.Prescrire international, , Volume: 26, Issue:179, 2017
Dhat syndrome as the prodrome of schizophrenia: Understanding the cultural distress.Asian journal of psychiatry, , Volume: 25, 2017
Occurrence of post-injection delirium/sedation syndrome after application of olanzapine long-acting injection during one year period.Psychiatria Danubina, , Volume: 29, Issue:4, 2017
Olanzapine as a possible replacement choice for paliperidone-induced Pisa syndrome: a case report.Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 24, Issue:6, 2016
Postinjection Delirium Syndrome Associated With Olanzapine Long-Acting Injectable.Journal of clinical psychopharmacology, , Volume: 36, Issue:4, 2016
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.BMC psychiatry, , Apr-02, Volume: 15, 2015
Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?Basic & clinical pharmacology & toxicology, , Volume: 117, Issue:3, 2015
[Post-injection syndrome after depot injection of olanzapine].Nederlands tijdschrift voor geneeskunde, , Volume: 159, 2014
Olanzapine postinjection delirium/sedation syndrome: an unrecognized diagnosis in the emergency department.The Journal of emergency medicine, , Volume: 47, Issue:1, 2014
[Post-injection delirium/sedation syndrome following injection of olanzapine pamoate: a new syndrome in emergency psychiatry].Tijdschrift voor psychiatrie, , Volume: 56, Issue:4, 2014
Long-acting injectable olanzapine can give rise to a condition consistent with central anticholinergic syndrome.Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Nov-12, Volume: 133, Issue:21, 2013
Pisa syndrome secondary to rivastigmine: a case report.La Clinica terapeutica, , Volume: 163, Issue:1, 2012
The need to consider mood disorders, and especially chronic mania, in cases of Diogenes syndrome (squalor syndrome).International psychogeriatrics, , Volume: 23, Issue:3, 2011
A case of Klingsor Syndrome: when there is no longer psychosis.The Israel journal of psychiatry and related sciences, , Volume: 48, Issue:1, 2011
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism.BMC psychiatry, , Jun-10, Volume: 10, 2010
Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.BMC psychiatry, , Jun-10, Volume: 10, 2010
Rowell's syndrome in the course of treatment with sodium valproate: a case report and review of the literature data.Clinical and experimental dermatology, , Volume: 34, Issue:6, 2009
Olanzapine-induced rabbit syndrome.Southern medical journal, , Volume: 101, Issue:10, 2008
Pisa syndrome resolved after switching to olanzapine.The Journal of neuropsychiatry and clinical neurosciences, ,Spring, Volume: 19, Issue:2, 2007
Homatropine and psychosis in Weill-Marchesani syndrome.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 45, Issue:7, 2006
Clozapine effective in olanzapine-induced Pisa syndrome.The Annals of pharmacotherapy, , Volume: 40, Issue:12, 2006
Olanzapine therapy in hallucinatory visions related to Bonnet syndrome.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, , Volume: 26, Issue:3, 2005
[Rabbit syndrome due to olanzapine].Psychiatrische Praxis, , Volume: 32, Issue:4, 2005
[Brief case report. Duloxetine in Cotard syndrome].Psychiatrische Praxis, , Volume: 32, Issue:8, 2005
Charles-Bonnet syndrome and musical hallucination.International psychogeriatrics, , Volume: 16, Issue:4, 2004
Cotard's syndrome and electroconvulsive therapy.Psychiatric services (Washington, D.C.), , Volume: 55, Issue:11, 2004
Coexistence of Capgras and Frégoli syndromes in a single patient. Clinical, neuroimaging and neuropsychological findings.European psychiatry : the journal of the Association of European Psychiatrists, , Volume: 17, Issue:4, 2002
A case report of olanzapine-induced hypersensitivity syndrome.The American journal of the medical sciences, , Volume: 321, Issue:2, 2001
Reversal of rabbit syndrome with olanzapine.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:1, 2000
Diurnal variation in Cotard's syndrome (copresent with Capgras delusion) following traumatic brain injury.The Australian and New Zealand journal of psychiatry, , Volume: 34, Issue:4, 2000
[The hyperglycemic dehydration syndrome].Nederlands tijdschrift voor geneeskunde, , Oct-10, Volume: 142, Issue:41, 1998
Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment.Journal of psychiatry & neuroscience : JPN, , Volume: 23, Issue:5, 1998
Metronome or alternating Pisa syndrome: a form of tardive dystonia under clozapine treatment.International clinical psychopharmacology, , Volume: 13, Issue:5, 1998
[Olanzapine long-acting post-injection syndrome: a case report and brief review].Actas espanolas de psiquiatria, , Volume: 41, Issue:1
Postinjection Delirium/Sedation Syndrome After 31st Long-Acting Olanzapine Depot Injection.Clinical neuropharmacology, , Volume: 42, Issue:2
[Psychotic syndrome after withdrawal of cyproheptadine: remission with olanzapine].Actas espanolas de psiquiatria, , Volume: 28, Issue:4
A case of catatonia due to posterior reversible encephalopathy syndrome treated successfully with antihypertensives and adjunctive olanzapine.General hospital psychiatry, , Volume: 33, Issue:3
Dose-Dependent Effects of Lithium Treatment on the Aggravation of Antipsychotic-Induced Pisa Syndrome.Clinical neuropharmacology, , Volume: 43, Issue:3
Delayed Onset Postinjection Delirium/Sedation Syndrome Associated With Olanzapine Pamoate: A Case Report.Journal of clinical psychopharmacology, , Volume: 39, Issue:5
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.Drug safety, , Volume: 36, Issue:6, 2013
[The clinical picture of acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
Olanzapine and delirium: lesson from clinical practice.The Australian and New Zealand journal of psychiatry, , Volume: 42, Issue:5, 2008
Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients.General hospital psychiatry, , Volume: 30, Issue:4
Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.Journal of psychopharmacology (Oxford, England), , Volume: 27, Issue:4, 2013
Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial.The American journal of psychiatry, , Volume: 165, Issue:10, 2008
Thrombocytopenia and Spontaneous Intracranial Hemorrhage After Olanzapine Therapy.The Journal of the American Osteopathic Association, , Jul-01, Volume: 117, Issue:7, 2017
Valproic Acid-related anticonvulsant hypersensitivity syndrome and subsequent olanzapine-related neutropenia and thrombocytopenia: a case report.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Thrombocytopenia and fatality associated with olanzapine.European journal of clinical pharmacology, , Volume: 60, Issue:4, 2004
Continuing treatment with novel antipsychotic drugs despite leukopenia or thrombocytopenia.Archives of general psychiatry, , Volume: 58, Issue:7, 2001
Olanzapine-induced thrombocytopenia in association with idiopathic thrombocytopenic purpura.The British journal of psychiatry : the journal of mental science, , Volume: 173, 1998
Thrombocytopenia possibly associated with olanzapine and subsequently with benztropine mesylate.Psychosomatics, , Volume: 41, Issue:3
Olanzapine-induced EDTA-dependent pseudothrombocytopenia.Psychosomatics, , Volume: 43, Issue:5
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.Molecular psychiatry, , Volume: 11, Issue:7, 2006
Atypical antipsychotics in the treatment of children and adolescents: clinical applications.The Journal of clinical psychiatry, , Volume: 65 Suppl 6, 2004
Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial.Psychiatry research, , Oct-30, Volume: 96, Issue:2, 2000
Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.Psychopharmacology, , Volume: 183, Issue:4, 2006
Antipsychotic Treatment and Tobacco Craving in People With Schizophrenia.Journal of dual diagnosis, , Volume: 13, Issue:1
Clinical News.Clinical schizophrenia & related psychoses, , Volume: 11, Issue:1
Black hairy tongue associated with olanzapine treatment: a case report.The Mount Sinai journal of medicine, New York, , Volume: 73, Issue:6, 2006
Black hairy tongue with a fixed dose combination of olanzapine and fluoxetine.Indian journal of pharmacology, , Volume: 48, Issue:3
Black Hairy Tongue Associated With Olanzapine Use in a Female Dementia Patient: A Case Report.Journal of clinical psychopharmacology, , Volume: 42, Issue:2
Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey.BMC oral health, , Aug-18, Volume: 12, 2012
Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.The Australian and New Zealand journal of psychiatry, , Volume: 44, Issue:3, 2010
Severe dopaminergic pathways damage in a case of chronic toluene abuse.Clinical neurology and neurosurgery, , Volume: 111, Issue:10, 2009
Psychogenic tremor in a patient with a major depressive episode.South Dakota medicine : the journal of the South Dakota State Medical Association, , Volume: 62, Issue:6, 2009
Olanzapine-induced rabbit syndrome.Southern medical journal, , Volume: 101, Issue:10, 2008
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Effects of H1 antagonists on cholinomimetic-induced tremulous jaw movements: studies of diphenhydramine, doxepin, and mepyramine.Pharmacology, biochemistry, and behavior, , Volume: 65, Issue:4, 2000
Conventional psychotropic-induced tremor extinguished by olanzapine.The American journal of psychiatry, , Volume: 155, Issue:8, 1998
Provocation of obsessive-compulsive behaviour and tremor by olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:6, 1998
Similarities and differences between the subchronic and withdrawal effects of clozapine and olanzapine on forelimb force steadiness.Psychopharmacology, , Volume: 132, Issue:4, 1997
Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.BMC psychiatry, , Apr-02, Volume: 15, 2015
Post-Injection Delirium/Sedation Syndrome after Olanzapine Long-Acting Intramuscular Injection - Who is at Risk?Basic & clinical pharmacology & toxicology, , Volume: 117, Issue:3, 2015
Relatively mild symptoms after an olanzapine intoxication in a 2-year-old girl with excessively high serum levels.Journal of child and adolescent psychopharmacology, , Volume: 21, Issue:1, 2011
[A 74-year-old unconscious woman with myoclonia and seizures].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Sep-07, Volume: 126, Issue:17, 2006
A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy.BMC medical genomics, , 11-03, Volume: 16, Issue:1, 2023
Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Journal of pediatric hematology/oncology, , 10-01, Volume: 45, Issue:7, 2023
Olanzapine for Non-Chemotherapy Related Nausea and Emesis in Patients with a Palliative Care Consult.Journal of pain and symptom management, , Volume: 66, Issue:4, 2023
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).The oncologist, , 08-03, Volume: 28, Issue:8, 2023
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.JAMA network open, , 05-01, Volume: 6, Issue:5, 2023
Benefits and risks of off-label olanzapine use for symptom management in cancer patients-a case report.Annals of palliative medicine, , Volume: 12, Issue:3, 2023
Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B).BMJ open, , 04-03, Volume: 13, Issue:4, 2023
Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 29, Issue:1, 2023
Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.Cancer treatment reviews, , Volume: 115, 2023
Olanzapine was an effective additional antiemetic for children and young people undergoing highly emetogenic chemotherapy.Archives of disease in childhood. Education and practice edition, , Volume: 107, Issue:4, 2022
The emerging role of olanzapine in paediatric CINV control: A review.Medicine, , Dec-16, Volume: 101, Issue:50, 2022
Olanzapine for the Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review to Identify the Best Way to Administer the Drug.Current oncology (Toronto, Ont.), , 10-31, Volume: 29, Issue:11, 2022
Slow Uptake of an Effective Therapy: Patterns of Olanzapine Prescribing for Those Receiving Highly Emetogenic Chemotherapy.JCO oncology practice, , Volume: 18, Issue:12, 2022
Efficacy of Olanzapine for Symptom Relief in Cancer Patients.Journal of pain & palliative care pharmacotherapy, , Volume: 36, Issue:4, 2022
Olanzapine in oncology palliative care.Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, ,Summer, Volume: 35, Issue:4, 2022
[Administration Period of Olanzapine as an Antiemetic Drug for Patients on FEC Therapy-A Survey].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 49, Issue:6, 2022
Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor Antagonist.Asian Pacific journal of cancer prevention : APJCP, , Jun-01, Volume: 23, Issue:6, 2022
Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report.Neuropsychopharmacology reports, , Volume: 42, Issue:3, 2022
Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.Annals of hematology, , Volume: 101, Issue:8, 2022
Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 30, Issue:7, 2022
Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.BMC cancer, , Mar-23, Volume: 22, Issue:1, 2022
Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthracyBMJ open, , Mar-02, Volume: 12, Issue:3, 2022
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.Journal of pediatric hematology/oncology, , 11-01, Volume: 44, Issue:8, 2022
A pooled analysis of adding olanzapine to guideline-recommended antiemetic therapy for breast cancer patients treated with an anthracycline and cyclophosphamide in prospective and retrospective studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 30, Issue:3, 2022
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 30, Issue:2, 2022
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.Investigational new drugs, , Volume: 40, Issue:1, 2022
Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: a prospective trial.Annals of palliative medicine, , Volume: 10, Issue:3, 2021
Patient-perceived symptomatic benefits of olanzapine treatment for nausea and vomiting in patients with advanced cancer who received palliative care through consultation teams: a multicenter prospective observational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 29, Issue:10, 2021
Olanzapine Administration Reduces Chemotherapy-Induced Nausea Behavior in Rats.Biological research for nursing, , Volume: 23, Issue:4, 2021
Low-dose olanzapine, sedation and chemotherapy-induced nausea and vomiting: a prospective randomized controlled study.Future oncology (London, England), , Volume: 17, Issue:16, 2021
Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.The oncologist, , Volume: 26, Issue:6, 2021
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 29, Issue:7, 2021
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.BMC cancer, , Jul-19, Volume: 21, Issue:1, 2021
Investigation of the Real-World Situation and Risk Factors Associated with Olanzapine Prescribed to Diabetes Patients by Using a Japanese Claims Database.Biological & pharmaceutical bulletin, , Volume: 44, Issue:8, 2021
Treatment of Cannabinoid Hyperemesis With Olanzapine: A Case Series.Journal of psychiatric practice, , 07-28, Volume: 27, Issue:4, 2021
Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?Annals of palliative medicine, , Volume: 10, Issue:3, 2021
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly emetogenic chemotherapy (HEC) patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 29, Issue:8, 2021
Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analyESMO open, , Volume: 5, Issue:1, 2020
Olanzapine versus Metoclopramide for Treatment of Nausea and Vomiting in Advanced Cancer Patients with Incomplete Malignant Bowel Obstruction.Journal of palliative medicine, , Volume: 23, Issue:7, 2020
Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial.Pediatric blood & cancer, , Volume: 67, Issue:9, 2020
Olanzapine is an effective antiemetic agent.Annals of palliative medicine, , Volume: 9, Issue:3, 2020
Olanzapine: is it enough for CINV prevention?Annals of palliative medicine, , Volume: 9, Issue:4, 2020
Olanzapine for the Treatment of Advanced Cancer-Related Chronic Nausea and/or Vomiting: A Randomized Pilot Trial.JAMA oncology, , 06-01, Volume: 6, Issue:6, 2020
The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature.BMC palliative care, , Apr-22, Volume: 19, Issue:1, 2020
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.Breast (Edinburgh, Scotland), , Volume: 50, 2020
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.Gynecologic oncology, , Volume: 156, Issue:3, 2020
Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:4, 2020
A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin.International journal of clinical pharmacy, , Volume: 42, Issue:2, 2020
A new standard prophylaxis for emesis caused by cisplatin? - Authors' reply.The Lancet. Oncology, , Volume: 21, Issue:3, 2020
A new standard prophylaxis for emesis caused by cisplatin?The Lancet. Oncology, , Volume: 21, Issue:3, 2020
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:11, 2020
Time to re-think the olanzapine dose.The Lancet. Oncology, , Volume: 21, Issue:2, 2020
Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:3, 2020
The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.International journal of clinical oncology, , Volume: 25, Issue:2, 2020
Olanzapine as a rescue antiemetic in hematopoietic stem cell transplant.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, , Volume: 26, Issue:4, 2020
A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.Breast (Edinburgh, Scotland), , Volume: 54, 2020
The Use, Safety, and Efficacy of Olanzapine in a Level I Pediatric Trauma Center Emergency Department Over a 10-Year Period.Pediatric emergency care, , Volume: 36, Issue:2, 2020
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatinBMJ open, , 12-17, Volume: 10, Issue:12, 2020
The Benefits of Olanzapine in Palliating Symptoms.Current treatment options in oncology, , 11-26, Volume: 22, Issue:1, 2020
Olanzapine for the Treatment of Breakthrough Vomiting in Children Receiving Moderate and High Emetogenic Chemotherapy.Indian pediatrics, , 11-15, Volume: 57, Issue:11, 2020
A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide.Annals of palliative medicine, , Volume: 8, Issue:4, 2019
Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.BMJ open, , 01-17, Volume: 9, Issue:1, 2019
Antiemetic use of olanzapine in patients with advanced cancer: results from an open-label multicenter study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:8, 2019
Short-course olanzapine to prevent delayed emesis following carboplatin/paclitaxel for gynecologic cancer: a randomised study.Tumori, , Volume: 105, Issue:3, 2019
Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.Journal of global oncology, , Volume: 5, 2019
Reply to: Comment on: Olanzapine for chemotherapy-induced nausea: Lessons learned from child and adolescent psychiatry.Pediatric blood & cancer, , Volume: 66, Issue:1, 2019
Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.Cancer chemotherapy and pharmacology, , Volume: 84, Issue:1, 2019
Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:3, 2019
Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.BMJ open, , 07-04, Volume: 9, Issue:7, 2019
The nature of nausea: prevalence, etiology, and treatment in patients with advanced cancer not receiving antineoplastic treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 27, Issue:8, 2019
Effectiveness of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis.The oncologist, , Volume: 24, Issue:6, 2019
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.International journal of clinical oncology, , Volume: 23, Issue:2, 2018
Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 26, Issue:2, 2018
Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.International journal of clinical pharmacy, , Volume: 40, Issue:5, 2018
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparative Study From Sudan.Journal of global oncology, , Volume: 4, 2018
Olanzapine with ondansetron and dexamethasone for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in lung cancer.Medicine, , Volume: 97, Issue:37, 2018
Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.The oncologist, , Volume: 23, Issue:5, 2018
Olanzapine plus aprepitant, palonosetron, and dexamethasone for nausea and vomiting in patients with breast cancer receiving anthracycline: A retrospective study.Scientific reports, , 11-02, Volume: 8, Issue:1, 2018
Control of Nausea and Vomiting in Patients Receiving Anthracycline/Cyclophosphamide Chemotherapy for Breast Cancer.Anticancer research, , Volume: 38, Issue:2, 2018
Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiviJapanese journal of clinical oncology, , Oct-01, Volume: 48, Issue:10, 2018
Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation.Clinical lymphoma, myeloma & leukemia, , Volume: 18, Issue:2, 2018
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.The Cochrane database of systematic reviews, , 09-21, Volume: 9, 2018
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.Investigational new drugs, , Volume: 36, Issue:1, 2018
Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving HigBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, , Volume: 24, Issue:10, 2018
[Differential diagnosis and treatment of nausea and vomiting associated with cancer or its treatment].Magyar onkologia, , Sep-20, Volume: 61, Issue:3, 2017
Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy.Medical oncology (Northwood, London, England), , Dec-16, Volume: 35, Issue:1, 2017
Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 25, Issue:1, 2017
A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 25, Issue:2, 2017
Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.British journal of clinical pharmacology, , Volume: 83, Issue:7, 2017
Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.Critical reviews in oncology/hematology, , Volume: 112, 2017
New options and controversies in the management of chemotherapy-induced nausea and vomiting.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Jun-01, Volume: 74, Issue:11, 2017
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.Japanese journal of clinical oncology, , Sep-01, Volume: 47, Issue:9, 2017
NCCN Guidelines Insights: Antiemesis, Version 2.2017.Journal of the National Comprehensive Cancer Network : JNCCN, , Volume: 15, Issue:7, 2017
Olanzapine Reduces Chemotherapy-induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High-dose Melphalan Before Stem Cell Transplantation: A Retrospective Study.Clinical lymphoma, myeloma & leukemia, , Volume: 17, Issue:9, 2017
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
Olanzapine in the Management of Difficult to Control Nausea and Vomiting in a Palliative Care Population: A Case Series.Journal of palliative medicine, , Volume: 19, Issue:1, 2016
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2, 2016
Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.JAMA oncology, , Volume: 2, Issue:2, 2016
Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:5, 2016
Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:6, 2016
Emerging Role of Olanzapine for Prevention and Treatment of Chemotherapy-Induced Nausea and Vomiting.Pharmacotherapy, , Volume: 36, Issue:2, 2016
Effect of olanzapine for breast cancer patients resistant to triplet antiemetic therapy with nausea due to anthracycline-containing adjuvant chemotherapy.Japanese journal of clinical oncology, , Volume: 46, Issue:5, 2016
Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.Current opinion in supportive and palliative care, , Volume: 10, Issue:2, 2016
A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.Asia-Pacific journal of clinical oncology, , Volume: 12, Issue:3, 2016
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.Annals of palliative medicine, , Volume: 5, Issue:3, 2016
Olanzapine for Nausea, Delirium, Anxiety, Insomnia, and Cachexia #315.Journal of palliative medicine, , Volume: 19, Issue:11, 2016
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.The New England journal of medicine, , Jul-14, Volume: 375, Issue:2, 2016
CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.The New England journal of medicine, , Jul-14, Volume: 375, Issue:2, 2016
A double-blind randomized Phase II study of olanzapine 10 mg versus 5 mg for emesis induced by highly emetogenic chemotherapy.Japanese journal of clinical oncology, , Volume: 45, Issue:2, 2015
QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist.European journal of cancer care, , Volume: 24, Issue:3, 2015
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.Cell biochemistry and biophysics, , Volume: 72, Issue:2, 2015
A review of olanzapine as an antiemetic in chemotherapy-induced nausea and vomiting and in palliative care patients.Critical reviews in oncology/hematology, , Volume: 95, Issue:2, 2015
Administration of olanzapine as an antiemetic agent changes glucose homeostasis in cisplatin-treated rats.Biological & pharmaceutical bulletin, , Volume: 38, Issue:4, 2015
Olanzapine in the treatment of refractory nausea and vomiting: a case report and review of the literature.Journal of pain & palliative care pharmacotherapy, , Volume: 29, Issue:2, 2015
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.Biochimica et biophysica acta, , Volume: 1848, Issue:10 Pt B, 2015
Pharmacological and psychosomatic treatments for an elderly patient with severe nausea and vomiting in reaction to postoperative stress.Clinical journal of gastroenterology, , Volume: 8, Issue:5, 2015
Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.Hospital practice (1995), , Volume: 43, Issue:4, 2015
Prophylactic Use of Antiemetics for Prevention of Opioid-Induced Nausea and Vomiting: A Questionnaire Survey among Japanese Physicians.Journal of palliative medicine, , Volume: 18, Issue:11, 2015
Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review.Pediatric blood & cancer, , Volume: 62, Issue:3, 2015
Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.Asian Pacific journal of cancer prevention : APJCP, , Volume: 15, Issue:22, 2014
A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting.Scientific reports, , Apr-28, Volume: 4, 2014
Olanzapine for intractable nausea and vomiting in palliative care patients not receiving chemotherapy.Journal of palliative medicine, , Volume: 17, Issue:5, 2014
Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 22, Issue:4, 2014
Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.Journal of cancer research and clinical oncology, , Volume: 140, Issue:1, 2014
Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.European journal of pharmacology, , Jan-05, Volume: 722, 2014
Effects of low-dose olanzapine on duloxetine-related nausea and vomiting for the treatment of major depressive disorder.Journal of clinical psychopharmacology, , Volume: 34, Issue:4, 2014
Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 97, Issue:3, 2014
The safety of olanzapine in young children: a systematic review and meta-analysis.Drug safety, , Volume: 37, Issue:10, 2014
Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.Journal of pain and symptom management, , Volume: 47, Issue:3, 2014
Olanzapine: palliative medicine update.The American journal of hospice & palliative care, , Volume: 30, Issue:1, 2013
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 21, Issue:6, 2013
Usefulness of olanzapine as an adjunct to opioid treatment and for the treatment of neuropathic pain.Anesthesiology, , Volume: 116, Issue:1, 2012
Olanzapine for the relief of nausea in patients with advanced cancer and incomplete bowel obstruction.Journal of pain and symptom management, , Volume: 44, Issue:4, 2012
Olanzapine for nausea and vomiting.The American journal of hospice & palliative care, , Volume: 27, Issue:6, 2010
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting.Journal of experimental & clinical cancer research : CR, , Sep-23, Volume: 28, 2009
Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.Current opinion in supportive and palliative care, , Volume: 2, Issue:1, 2008
[Medical treatment of chemotherapy-induced nausea and vomiting].Ugeskrift for laeger, , Feb-26, Volume: 169, Issue:9, 2007
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.Journal of the National Comprehensive Cancer Network : JNCCN, , Volume: 5, Issue:1, 2007
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 15, Issue:11, 2007
Emerging drugs for chemotherapy-induced emesis.Expert opinion on emerging drugs, , Volume: 11, Issue:1, 2006
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 13, Issue:7, 2005
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.Cancer investigation, , Volume: 22, Issue:3, 2004
Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer.Journal of pain and symptom management, , Volume: 25, Issue:6, 2003
A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients.Journal of pain and symptom management, , Volume: 25, Issue:5, 2003
Olanzapine Treatment for Refractory Nausea and Vomiting After Transarterial Embolization for Cerebral Arteriovenous Malformation.American journal of therapeutics, , Volume: 27, Issue:6
Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen: A prospective, nonrandomized, open-label study.Indian journal of pharmacology, , Volume: 49, Issue:6
Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.The journal of supportive oncology, , Volume: 9, Issue:5
Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report.Psycho-oncology, , Volume: 9, Issue:1
Fatal water intoxication during olanzapine treatment: a case report.Legal medicine (Tokyo, Japan), , Volume: 16, Issue:2, 2014
Successful switch to olanzapine after rhabdomyolysis caused by water intoxication and clozapine use.Pharmacopsychiatry, , Volume: 39, Issue:4, 2006
[Atypical antipsychotic-associated impaired glucose tolerance].Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, , Volume: 107, Issue:8, 2005
Absence of effect of olanzapine on primary polydipsia: results of a double-blind, randomized study.Journal of clinical psychopharmacology, , Volume: 24, Issue:6, 2004
Treatment of psychogenic polydipsia: comparison of risperidone and olanzapine, and the effects of an adjunctive angiotensin-II receptor blocking drug (irbesartan).The Australian and New Zealand journal of psychiatry, , Volume: 35, Issue:1, 2001
Clozapine to olanzapine.The American journal of psychiatry, , Volume: 156, Issue:7, 1999
Self-harm, Unintentional Injury, and Suicide in Bipolar Disorder During Maintenance Mood Stabilizer Treatment: A UK Population-Based Electronic Health Records Study.JAMA psychiatry, , 06-01, Volume: 73, Issue:6, 2016
A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study.Minerva anestesiologica, , Volume: 78, Issue:9, 2012
Dental conditions in inpatients with schizophrenia: a large-scale multi-site survey.BMC oral health, , Aug-18, Volume: 12, 2012
Plasma concentrations of high-dose olanzapine in a double-blind crossover study.Human psychopharmacology, , Volume: 21, Issue:6, 2006
Influence of fluoxetine on olanzapine pharmacokinetics.AAPS pharmSci, , Volume: 4, Issue:2, 2002
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.The Journal of clinical psychiatry, , Volume: 61, Issue:7, 2000
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
[The use of antipsychotics in patients with dementia].Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 30, Issue:3, 2008
The switching of risperidone to olanzapine in elderly nursing-home patients with dementia: a retrospective study.CNS spectrums, , Volume: 12, Issue:1, 2007
Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users.Journal of clinical psychopharmacology, , Volume: 27, Issue:6, 2007
Psychosis of Alzheimer disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 14, Issue:3, 2006
Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, , Volume: 13, Issue:8, 2005
Memory-sparing cognitive deterioration in the elderly: what is the diagnosis?Reviews in neurological diseases, ,Spring, Volume: 2, Issue:2, 2005
Olanzapine as a possible treatment of behavioral symptoms in vascular dementia: risks of cerebrovascular events. A controlled, open-label study.Journal of neurology, , Volume: 252, Issue:10, 2005
[Cerebral infarct and atypical antipsychotic agents].Psychologie & neuropsychiatrie du vieillissement, , Volume: 2, Issue:4, 2004
[A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy].Der Nervenarzt, , Volume: 74, Issue:7, 2003
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia.Southern medical journal, , Volume: 96, Issue:7, 2003
Atypical antipsychotics in Parkinson-sensitive populations.Journal of geriatric psychiatry and neurology, ,Fall, Volume: 15, Issue:3, 2002
Olanzapine as a possible treatment for anxiety due to vascular dementia: an open study.American journal of Alzheimer's disease and other dementias, , Volume: 19, Issue:2
Olanzapine and Weight Loss in Early-Onset Schizophrenia.The primary care companion for CNS disorders, , 04-06, Volume: 25, Issue:2, 2023
Dramatic Weight Loss Following Addition of Aripiprazole to Olanzapine in a Patient With Treatment-resistant Schizophrenia: A Case Report.Journal of psychiatric practice, , Volume: 25, Issue:2, 2019
Multidisciplinary Management of Adolescent Early-Onset, Treatment-Resistant Schizophrenia Complicated by Avoidant/Restrictive Food Intake Disorder and Catatonia in Acute Exacerbations.Journal of child and adolescent psychopharmacology, , Volume: 28, Issue:9, 2018
Is there an interrelationship between the effects of antipsychotics on psychopathology and on metabolism?Nordic journal of psychiatry, , Volume: 70, Issue:3, 2016
Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 23, Issue:9, 2015
Dopamine D2/3 receptor antagonism reduces activity-based anorexia.Translational psychiatry, , Aug-04, Volume: 5, 2015
Phosphorylation of hypothalamic AMPK on serine(485/491) related to sustained weight loss by alpha-lipoic acid in mice treated with olanzapine.Psychopharmacology, , Volume: 231, Issue:20, 2014
Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.Journal of psychopharmacology (Oxford, England), , Volume: 27, Issue:4, 2013
In a randomized placebo-controlled add-on study orlistat significantly reduced clozapine-induced constipation.International clinical psychopharmacology, , Volume: 28, Issue:2, 2013
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.Journal of clinical psychopharmacology, , Volume: 32, Issue:5, 2012
Clozapine-induced weight loss?Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 23, Issue:3, 2011
Treatment strategy in schizophrenia combined with eating disorder.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.The Journal of clinical psychiatry, , Volume: 72, Issue:3, 2011
Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.BMC psychiatry, , Mar-28, Volume: 9, 2009
Weight loss during therapy with olanzapine orally disintegrating tablets: two case reports.Psychiatria Danubina, , Volume: 21, Issue:1, 2009
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial.Human psychopharmacology, , Volume: 23, Issue:3, 2008
Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.Progress in neuro-psychopharmacology & biological psychiatry, , Feb-15, Volume: 32, Issue:2, 2008
Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.Psychiatry research, , May-30, Volume: 159, Issue:1-2, 2008
A case of paranoid schizophrenia complicated by scleroderma with associated esophageal dysmotility.Journal of psychiatric practice, , Volume: 14, Issue:2, 2008
Considerations regarding the use of metformin with olanzapine.The American journal of psychiatry, , Volume: 165, Issue:9, 2008
Influence of topiramate on olanzapine-related weight gain in women: an 18-month follow-up observation.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial.The Journal of clinical psychiatry, , Volume: 67, Issue:4, 2006
Extensive weight loss in a patient with schizophrenia after switching from olanzapine to aripiprazole. A case report.Pharmacopsychiatry, , Volume: 39, Issue:2, 2006
Adverse drug reactions in Canada.Canadian family physician Medecin de famille canadien, , Volume: 51, 2005
Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.Nordic journal of psychiatry, , Volume: 59, Issue:3, 2005
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.The Journal of clinical psychiatry, , Volume: 66, Issue:2, 2005
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.The American journal of psychiatry, , Volume: 162, Issue:9, 2005
Influence of topiramate on olanzapine-related adiposity in women: a random, double-blind, placebo-controlled study.Journal of clinical psychopharmacology, , Volume: 25, Issue:3, 2005
Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets.Psychopharmacology, , Volume: 175, Issue:3, 2004
Weight loss dynamics during combined fluoxetine and olanzapine treatment.BMC pharmacology, , Oct-21, Volume: 4, 2004
Weight decline in patients switching from olanzapine to quetiapine.Schizophrenia research, , Sep-01, Volume: 70, Issue:1, 2004
Adolescent weight loss during treatment with olanzapine.Journal of child and adolescent psychopharmacology, ,Winter, Volume: 14, Issue:4, 2004
Olanzapine treatment of an adolescent girl with anorexia nervosa.Human psychopharmacology, , Volume: 18, Issue:5, 2003
Reversal of antipsychotic-induced weight gain during quetiapine treatment.International clinical psychopharmacology, , Volume: 18, Issue:6, 2003
Weight loss associated with olanzapine treatment.Journal of clinical psychopharmacology, , Volume: 22, Issue:4, 2002
A program for treating olanzapine-related weight gain.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:7, 2001
Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine.Nutrition (Burbank, Los Angeles County, Calif.), , Volume: 25, Issue:7-8
Psychosis in Anorexia Nervosa: A Case Report and Review of the Literature.Psychosomatics, , Volume: 61, Issue:2
Betahistine-Associated Weight Loss and Improved Cognitive and Negative Symptoms: Domain in Early-Onset Schizophrenia.American journal of therapeutics, , Volume: 26, Issue:6
Mania in a case of hyperparathyroidism.Psychosomatics, , Volume: 48, Issue:3
[Treatment-resistant psychosis due to interaction between ritonavir and olanzapine: case report and literature review].Tijdschrift voor psychiatrie, , Volume: 58, Issue:4, 2016
Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient.Biological psychiatry, , Oct-15, Volume: 44, Issue:8, 1998
Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV.Psychosomatics, , Volume: 44, Issue:5
Acute Angle Closure in a Patient Using Olanzapine.Psychiatria Danubina, ,Summer, Volume: 34, Issue:2, 2022
Olanzapine-Induced Acute Angle Closure.The American journal of case reports, , Nov-22, Volume: 22, 2021
Acute angle closure glaucoma precipitated by olanzapine.International journal of geriatric psychiatry, , Volume: 30, Issue:10, 2015
Olanzapine-induced tardive oculogyric crisis.Journal of clinical psychopharmacology, , Volume: 29, Issue:6, 2009
Olanzapine-induced oculogyric crisis in a patient with schizophrenia.Indian journal of medical sciences, , Volume: 62, Issue:6, 2008
Olanzapine-induced oculogyric crisis.Journal of clinical psychopharmacology, , Volume: 26, Issue:4, 2006
Olanzapine-induced oculogyric crisis.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:4, 2006
Oculogyric Crisis Due to Low-Dose Olanzapine: A Case Report.Clinical neuropharmacology, , Volume: 44, Issue:6
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.The American journal of case reports, , Dec-01, Volume: 23, 2022
[The clinical picture of acute olanzapine poisonings].Przeglad lekarski, , Volume: 68, Issue:8, 2011
Olanzapine overdose: a series of analytically confirmed cases.International clinical psychopharmacology, , Volume: 22, Issue:3, 2007
Olanzapine overdose mimicking opioid intoxication.Annals of emergency medicine, , Volume: 34, Issue:2, 1999
Potential torsades de pointes triggered by hypokalemia related to olanzapine in a patient with implantable cardioverter-defibrillator.Journal of clinical psychopharmacology, , Volume: 34, Issue:5, 2014
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.Drug safety, , Volume: 36, Issue:6, 2013
Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Complete atrioventricular block-induced Torsade de pointes, manifested by epilepsy.The Korean journal of internal medicine, , Volume: 26, Issue:1, 2011
[Long QT syndrome due to olanzapine administration].Kardiologia polska, , Volume: 64, Issue:9, 2006
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.Postgraduate medicine, , Volume: 116, Issue:4, 2004
Antipsychotic drugs and QT interval prolongation.The Psychiatric quarterly, ,Fall, Volume: 74, Issue:3, 2003
Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics.The Journal of clinical psychiatry, , Volume: 62 Suppl 2, 2001
[Cardiovascular risk of haloperidol vs. atypical anti-psychotic drugs in schizophrenia treatment].Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, , Volume: 114, Issue:3
[QT prolongation and second-generation antipsychotics: overdose and therapeutic dosage].Therapie, , Volume: 59, Issue:5
Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
"My new Alfa Romeo GT is not in the garage any more": Cognitive behavioural therapy of panic disorder with agoraphobia co morbid with psychosis.Psychiatria Danubina, , Volume: 18, Issue:3-4, 2006
Potential effectiveness and safety of olanzapine in refractory panic disorder.Depression and anxiety, , Volume: 21, Issue:1, 2005
Olanzapine augmentation in panic disorder: a case report.Pharmacopsychiatry, , Volume: 37, Issue:5, 2004
Usefulness of olanzapine in refractory panic attacks.Journal of clinical psychopharmacology, , Volume: 23, Issue:1, 2003
Panic disorder associated with clozapine.The American journal of psychiatry, , Volume: 157, Issue:12, 2000
Olanzapine and panic attacks.The American journal of psychiatry, , Volume: 157, Issue:4, 2000
New-onset panic attacks in a patient treated with olanzapine.Journal of clinical psychopharmacology, , Volume: 19, Issue:2, 1999
Are dexmedetomidine and olanzapine suitable to control delirium in critically ill elderly patients? A retrospective cohort study.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 139, 2021
Olanzapine: palliative medicine update.The American journal of hospice & palliative care, , Volume: 30, Issue:1, 2013
A reorientation strategy for reducing delirium in the critically ill. Results of an interventional study.Minerva anestesiologica, , Volume: 78, Issue:9, 2012
[Delusion in the critical patient].Medicina intensiva, , Volume: 32 Spec No. 1, 2008
Reply to the comment by Skrobik et al.Intensive care medicine, , Volume: 30, Issue:7, 2004
Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden.CNS drugs, , Volume: 36, Issue:5, 2022
Continuation of Atypical Antipsychotic Medication During Early Pregnancy and the Risk of Gestational Diabetes.The American journal of psychiatry, , 06-01, Volume: 175, Issue:6, 2018
Antipsychotics in pregnancy.Journal of psychiatric and mental health nursing, , Volume: 17, Issue:2, 2010
A case of olanzapine-induced gestational diabetes mellitus in the absence of weight gain.The Journal of clinical psychiatry, , Volume: 68, Issue:12, 2007
Thrombosis and psychosis--possible association with the antiphospholipid syndrome and anticardiolipin antibodies.Irish medical journal, , Volume: 102, Issue:2, 2009
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
Mania: psychiatric manifestations of the antiphospholipid syndrome.Psychosomatics, , Volume: 49, Issue:5
Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database.Drug safety, , Volume: 36, Issue:6, 2013
Increased risk of antipsychotic-related QT prolongation during nighttime: a 24-hour holter electrocardiogram recording study.Journal of clinical psychopharmacology, , Volume: 32, Issue:1, 2012
Methodological challenges in the coding and adjudication of sudden deaths in a large simple trial with observational follow-up: the ziprasidone observational study of cardiac outcomes (ZODIAC).Pharmacoepidemiology and drug safety, , Volume: 20, Issue:11, 2011
[Eosinophilic myocarditis and sudden unexpected death in a younger patient treated with antipsychotics].Ugeskrift for laeger, , Oct-31, Volume: 173, Issue:44, 2011
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).The American journal of psychiatry, , Volume: 168, Issue:2, 2011
Olanzapine: sudden cardiac death, urinary incontinence.Prescrire international, , Volume: 19, Issue:109, 2010
Antipsychotic drugs and QT interval prolongation.The Psychiatric quarterly, ,Fall, Volume: 74, Issue:3, 2003
Risk evaluation of diabetic ketoacidosis associated with antipsychotics among patients with schizophrenia in the Japanese adverse event report database.Journal of psychosomatic research, , Volume: 175, 2023
An Unexpected Case of Diabetic Ketoacidosis on the Psychiatry Ward: Olanzapine-Associated Adult Ketosis-Prone Type 2 Diabetes Mellitus.Canadian journal of diabetes, , Volume: 44, Issue:3, 2020
Acute-Onset Type 1 Diabetes that Developed During the Administration of Olanzapine.Internal medicine (Tokyo, Japan), , Volume: 56, Issue:3, 2017
Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.Psychiatria Danubina, , Volume: 29, Issue:2, 2017
Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.Psychopharmacology, , Volume: 233, Issue:21-22, 2016
Severe recurrent hypoglycaemia following discontinuation of olanzapine.Acute medicine, , Volume: 10, Issue:1, 2011
Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC).The American journal of psychiatry, , Volume: 168, Issue:2, 2011
Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.The Journal of clinical psychiatry, , Volume: 70, Issue:5, 2009
Diabetes and psychosis: olanzapine may not be the culprit.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 13, Issue:4, 2007
Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine.Drug safety, , Volume: 30, Issue:7, 2007
Olanzapine-induced diabetic ketoacidosis in a Chinese man.Hong Kong medical journal = Xianggang yi xue za zhi, , Volume: 13, Issue:1, 2007
Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine.Journal of clinical psychopharmacology, , Volume: 27, Issue:4, 2007
Olanzapine-induced hyperglycemic ketoacidosis and corresponding acetone concentrations post-mortem: a forensic interpretation.Forensic science international, , Aug-24, Volume: 171, Issue:1, 2007
Diabetic ketoacidosis and severe dyslipidemia in an adult psychotic man with olanzapine treatment.Journal of clinical psychopharmacology, , Volume: 26, Issue:1, 2006
Atypical antipsychotics and diabetes mellitus: an association.The Israel Medical Association journal : IMAJ, , Volume: 6, Issue:5, 2004
Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications.The American journal of psychiatry, , Volume: 161, Issue:9, 2004
Fatal olanzapine-induced hyperglycemic ketoacidosis.The American journal of forensic medicine and pathology, , Volume: 25, Issue:2, 2004
Modulating effects of olanzapine on the development of diabetic ketoacidosis.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 21, Issue:3, 2004
Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine.Journal of psychopharmacology (Oxford, England), , Volume: 18, Issue:3, 2004
Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine.Southern medical journal, , Volume: 96, Issue:7, 2003
New-onset diabetes and ketoacidosis with atypical antipsychotics.Schizophrenia research, , Jan-01, Volume: 59, Issue:1, 2003
[Olanzapine-induced diabetes mellitus].Psychiatrische Praxis, , Volume: 29, Issue:6, 2002
Increasing insulin dose for olanzapine-related diabetes.The American journal of psychiatry, , Volume: 159, Issue:1, 2002
Atypical antipsychotics and hyperglycaemia.International clinical psychopharmacology, , Volume: 16, Issue:2, 2001
Diabetic ketoacidosis associated with olanzapine in an adolescent patient.The Journal of pediatrics, , Volume: 138, Issue:6, 2001
Olanzapine-induced diabetic ketoacidosis.The Annals of pharmacotherapy, , Volume: 35, Issue:12, 2001
Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature.Pharmacotherapy, , Volume: 21, Issue:11, 2001
Diabetic ketoacidosis with olanzapine treatment.Diabetes care, , Volume: 22, Issue:6, 1999
[Hyperglycemia and ketoacidosis associated with olanzapine].Der Nervenarzt, , Volume: 70, Issue:9, 1999
Olanzapine-induced ketoacidosis with diabetes mellitus.The American journal of psychiatry, , Volume: 156, Issue:9, 1999
Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature.The Journal of the American Board of Family Practice, , Volume: 14, Issue:4
Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature.Journal of intensive care medicine, , Volume: 22, Issue:1
Near fatal ketoacidosis with olanzapine treatment.Psychosomatics, , Volume: 43, Issue:4
New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment.Psychosomatics, , Volume: 40, Issue:5
Antipsychotic Therapy-Induced New Onset Diabetic Ketoacidosis.American journal of therapeutics, , Volume: 23, Issue:6
Tiagabine withdrawal-emergent mania.The Australian and New Zealand journal of psychiatry, , Volume: 40, Issue:8, 2006
Seizures, coma, and coagulopathy following olanzapine overdose.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 50, Issue:2, 2005
Misdiagnosis of schizophrenia for a patient with epilepsy.Psychiatric services (Washington, D.C.), , Volume: 52, Issue:1, 2001
Severe ischemic colitis following olanzapine use - A case report.Revista espanola de enfermedades digestivas, , Volume: 108, Issue:9, 2016
Olanzapine-induced ischemic colitis.Revista espanola de enfermedades digestivas, , Volume: 108, Issue:8, 2016
Olanzapine and benztropine as a cause of ischemic colitis in a 27-year-old man.Journal of clinical gastroenterology, , Volume: 46, Issue:6, 2012
A Potential Case of Acute Ketamine Withdrawal: Clinical Implications for the Treatment of Refractory Depression.The American journal of psychiatry, , Volume: 178, Issue:7, 2021
Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.Medicine, , Volume: 98, Issue:3, 2019
Acute phenibut withdrawal: A comprehensive literature review and illustrative case report.Bosnian journal of basic medical sciences, , May-20, Volume: 19, Issue:2, 2019
Treatment of first-episode psychosis in patients with autism-spectrum disorder and intellectual deficiencyJournal of psychiatry & neuroscience : JPN, , Nov-01, Volume: 44, Issue:6, 2019
Combined treatment with a selective PDE10A inhibitor TAK-063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic-like effects without affecting plasma prolactin levels and cataleptic responses in rodents.Pharmacology research & perspectives, , Volume: 6, Issue:1, 2018
Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment.Psychopharmacology, , Volume: 234, Issue:17, 2017
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.Journal of affective disorders, , Jan-01, Volume: 207, 2017
Intravenous midazolam-droperidol combination, droperidol or olanzapine monotherapy for methamphetamine-related acute agitation: subgroup analysis of a randomized controlled trial.Addiction (Abingdon, England), , Volume: 112, Issue:7, 2017
Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.CNS drugs, , Volume: 31, Issue:9, 2017
Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.CNS spectrums, , Volume: 22, Issue:4, 2017
Sleepwalking Is Associated With Coadministration of Olanzapine and Propranolol: A Case Report.Journal of clinical psychopharmacology, , Volume: 37, Issue:5, 2017
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 54, Issue:9, 2015
Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.Clinical schizophrenia & related psychoses, , Volume: 7, Issue:4, 2014
Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient.Clinical toxicology (Philadelphia, Pa.), , Volume: 51, Issue:3, 2013
Could pramipexole induce acute mania? A case report.Bipolar disorders, , Volume: 15, Issue:4, 2013
Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.The Journal of clinical psychiatry, , Volume: 74, Issue:2, 2013
Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?Clinical schizophrenia & related psychoses, , Volume: 6, Issue:2, 2012
Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.Journal of clinical psychopharmacology, , Volume: 32, Issue:3, 2012
A double-blind, randomized, placebo-controlled study with JNJ-37822681, a novel, highly selective, fast dissociating D₂ receptor antagonist in the treatment of acute exacerbation of schizophrenia.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 22, Issue:10, 2012
A case of akathisia after switching from branded to generic high-dose olanzapine.The Journal of clinical psychiatry, , Volume: 73, Issue:4, 2012
Symptoms of agitated depression and/or akathisia.Psychiatria Danubina, , Volume: 23, Issue:1, 2011
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 49, Issue:6, 2010
The subjective experience of taking antipsychotic medication: a content analysis of Internet data.Acta psychiatrica Scandinavica, , Volume: 120, Issue:2, 2009
Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.Journal of clinical psychopharmacology, , Volume: 27, Issue:5, 2007
An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:4, 2006
Pharmacological management of akathisia in combination with psychological interventions by a mental health nurse consultant.Journal of psychiatric and mental health nursing, , Volume: 13, Issue:1, 2006
[Akathisia in the course of olanzapine treatment].Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology, , Volume: 8, Issue:4, 2006
Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial.The Journal of clinical psychiatry, , Volume: 67, Issue:11, 2006
Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine.The Annals of pharmacotherapy, , Volume: 40, Issue:4, 2006
Acute olanzapine-induced akathisia and dystonia in a patient discontinued from fluoxetine.The Journal of emergency medicine, , Volume: 30, Issue:3, 2006
Cerebellar and thalamic metabolic changes visualized by [18]-FDG-PET in olanzapine-induced acute akathisia.Neuro endocrinology letters, , Volume: 27, Issue:6, 2006
Patients' opinions of olanzapine and risperidone following long-term treatment: results from a cross-sectional survey.Pharmacopsychiatry, , Volume: 38, Issue:4, 2005
Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) as a subjective measure of drug-induced parkinsonism and akathisia.Human psychopharmacology, , Volume: 20, Issue:1, 2005
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA, , Mar-03, Volume: 291, Issue:9, 2004
Neurologic soft signs and olanzapine treatment in chronic schizophrenia.Journal of clinical psychopharmacology, , Volume: 24, Issue:5, 2004
Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.JAMA, , Nov-26, Volume: 290, Issue:20, 2003
Movement disorders associated with atypical antipsychotic drugs.The Journal of clinical psychiatry, , Volume: 63 Suppl 4, 2002
[Drug-induced akathisia].Nederlands tijdschrift voor geneeskunde, , Jan-19, Volume: 146, Issue:3, 2002
Atypical antipsychotics: experience and use in the elderly.International journal of clinical practice, , Volume: 56, Issue:7, 2002
Quetiapine for olanzapine-induced galactorrhea.The American journal of psychiatry, , Volume: 159, Issue:6, 2002
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
Efficacy and safety of olanzapine, an atypical antipsychotic, in patients with schizophrenia: results of an open-label multicenter study in Japan.Psychiatry and clinical neurosciences, , Volume: 55, Issue:4, 2001
The treatment of tardive dyskinesia and tardive dystonia.The Journal of clinical psychiatry, , Volume: 61 Suppl 4, 2000
Adverse events related to olanzapine.The Journal of clinical psychiatry, , Volume: 61 Suppl 8, 2000
New antipsychotic medications: more than old wine and new bottles.Bulletin of the Menninger Clinic, ,Winter, Volume: 64, Issue:1, 2000
Olanzapine overdose in a 1-year-old male.Pediatric emergency care, , Volume: 15, Issue:4, 1999
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.The American journal of psychiatry, , Volume: 156, Issue:5, 1999
Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.Biological psychiatry, , Feb-15, Volume: 45, Issue:4, 1999
Measuring neuroleptic-induced akathisia by three-channel actometry.Schizophrenia research, , Nov-30, Volume: 40, Issue:2, 1999
[Olanzapine as an alternative in clozapine-induced akathisia?].Psychiatrische Praxis, , Volume: 26, Issue:6, 1999
Aggression, agitation, and mania with olanzapine.Canadian journal of psychiatry. Revue canadienne de psychiatrie, , Volume: 43, Issue:10, 1998
Assessment of EPS and tardive dyskinesia in clinical trials. Collaborative Working Group on Clinical Trial Evaluations.The Journal of clinical psychiatry, , Volume: 59 Suppl 12, 1998
Severe akathisia during olanzapine treatment of acute schizophrenia.Pharmacopsychiatry, , Volume: 31, Issue:4, 1998
Differential sensitivities to risperidone and olanzapine in a human immunodeficiency virus patient.Biological psychiatry, , Oct-15, Volume: 44, Issue:8, 1998
Open-label olanzapine treatment in five preadolescent children.Journal of child and adolescent psychopharmacology, , Volume: 8, Issue:2, 1998
Alleviation of sulpiride induced tardive akathisia by olanzapine: case report.Neurologia (Barcelona, Spain), , Volume: 13, Issue:9, 1998
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.The American journal of psychiatry, , Volume: 155, Issue:7, 1998
Propranolol treatment of olanzapine-induced akathisia.The American journal of psychiatry, , Volume: 154, Issue:9, 1997
Safety of olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Dosing the antipsychotic medication olanzapine.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
The relationship of pharmacology to side effects.The Journal of clinical psychiatry, , Volume: 58 Suppl 10, 1997
Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 14, Issue:2, 1996
Safety/Toxicity (227)
| Article | Year |
|---|
Risk evaluation of diabetic ketoacidosis associated with antipsychotics among patients with schizophrenia in the Japanese adverse event report database.
Journal of psychosomatic research, , Volume: 175 | 2023 |
Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: A systematic review and network meta-analysis.
Medicine, , Sep-22, Volume: 102, Issue:38 | 2023 |
Comparative Safety Analysis of Oral Antipsychotics for In-Hospital Adverse Clinical Events in Older Adults After Major Surgery : A Nationwide Cohort Study.
Annals of internal medicine, , Volume: 176, Issue:9 | 2023 |
Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.
The Psychiatric quarterly, , Volume: 94, Issue:4 | 2023 |
Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Journal of pediatric hematology/oncology, , 10-01, Volume: 45, Issue:7 | 2023 |
Toxicity manifestations and sex differences due to MARTA olanzapine.
The Journal of toxicological sciences, , Volume: 48, Issue:4 | 2023 |
Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.
Cancer treatment reviews, , Volume: 115 | 2023 |
Predicting serotonin toxicity in serotonin reuptake inhibitor overdose.
Clinical toxicology (Philadelphia, Pa.), , Volume: 61, Issue:1 | 2023 |
Depicting Risperidone Safety Profiles in Clinical Trials Across Different Diagnoses Using a Dopamine D
Clinical drug investigation, , Volume: 42, Issue:12 | 2022 |
Antipsychotic Safety in Liver Disease: A Narrative Review and Practical Guide for the Clinician.
Journal of the Academy of Consultation-Liaison Psychiatry, , Volume: 64, Issue:1 | |
Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.
Schizophrenia research, , Volume: 248 | 2022 |
Efficacy and safety of antipsychotics and antidepressants in the treatment of anorexia nervosa: a systematic review.
Revista Colombiana de psiquiatria (English ed.), , Volume: 51, Issue:3 | |
Meta-Analysis of the Efficacy and Safety of Olanzapine versus Clozapine when Treating Senile Dementia.
Computational and mathematical methods in medicine, , Volume: 2022 | 2022 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:9 | 2022 |
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
The international journal of neuropsychopharmacology, , 09-28, Volume: 25, Issue:9 | 2022 |
Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis.
Psychological medicine, , Volume: 53, Issue:9 | 2023 |
Comparative effectiveness and safety of antipsychotic drugs in patients with schizophrenia initiating or reinitiating treatment: A Real-World Observational Study.
Acta psychiatrica Scandinavica, , Volume: 145, Issue:5 | 2022 |
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.
Journal of pediatric hematology/oncology, , 11-01, Volume: 44, Issue:8 | 2022 |
Atypical Antipsychotic Safety in the CICU.
The American journal of cardiology, , 01-15, Volume: 163 | 2022 |
Molecular Consequences of Depression Treatment: A Potential In Vitro Mechanism for Antidepressants-Induced Reprotoxic Side Effects.
International journal of molecular sciences, , Nov-01, Volume: 22, Issue:21 | 2021 |
Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review.
The journal of prevention of Alzheimer's disease, , Volume: 8, Issue:4 | 2021 |
Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 47, Issue:3 | 2022 |
The Influence of Substance Use on Side Effects of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Psychosis.
Substance use & misuse, , Volume: 56, Issue:12 | 2021 |
Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.
BMC cancer, , Jul-19, Volume: 21, Issue:1 | 2021 |
The Use of Physostigmine in the Diagnosis and Treatment of Anticholinergic Toxicity After Olanzapine Overdose: Literature Review and Case Report.
Journal of the Academy of Consultation-Liaison Psychiatry, , Volume: 62, Issue:3 | |
Second-generation antipsychotics induce cardiotoxicity by disrupting spliceosome signaling: Implications from proteomic and transcriptomic analyses.
Pharmacological research, , Volume: 170 | 2021 |
A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
Schizophrenia research, , Volume: 232 | 2021 |
A safety signal of somnambulism with the use of antipsychotics and lithium: A pharmacovigilance disproportionality analysis.
British journal of clinical pharmacology, , Volume: 87, Issue:10 | 2021 |
Olanzapine induced reproductive toxicity in male rats.
Scientific reports, , 02-26, Volume: 11, Issue:1 | 2021 |
Safety of Intravenous Olanzapine Administration at a Tertiary Academic Medical Center.
The Annals of pharmacotherapy, , Volume: 55, Issue:9 | 2021 |
A Retrospective Comparison of the Effectiveness and Safety of Intravenous Olanzapine Versus Intravenous Haloperidol for Agitation in Adult Intensive Care Unit Patients.
Journal of intensive care medicine, , Volume: 37, Issue:2 | 2022 |
Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 133 | 2021 |
The side effect profile of Clozapine in real world data of three large mental health hospitals.
PloS one, , Volume: 15, Issue:12 | 2020 |
Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.
Schizophrenia bulletin, , 04-29, Volume: 47, Issue:3 | 2021 |
Safety and effectiveness of olanzapine and droperidol for chemical restraint for non-consenting adults: a systematic review and meta-analysis.
Australasian emergency care, , Volume: 24, Issue:2 | 2021 |
Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial.
Human psychopharmacology, , Volume: 36, Issue:1 | 2021 |
The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults.
The Journal of clinical psychiatry, , 06-30, Volume: 81, Issue:4 | 2020 |
Poloxamer-407-Co-Poly (2-Acrylamido-2-Methylpropane Sulfonic Acid) Cross-linked Nanogels for Solubility Enhancement of Olanzapine: Synthesis, Characterization, and Toxicity Evaluation.
AAPS PharmSciTech, , May-17, Volume: 21, Issue:5 | 2020 |
Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.
CNS spectrums, , Volume: 26, Issue:4 | 2021 |
Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.
The Journal of clinical psychiatry, , 03-03, Volume: 81, Issue:2 | 2020 |
Neuroprotective effects of olanzapine against rotenone-induced toxicity in PC12 cells.
Acta pharmacologica Sinica, , Volume: 41, Issue:4 | 2020 |
Olanzapine-mediated cardiotoxicity is associated with altered energy metabolism in isolated rat hearts.
Acta biochimica Polonica, , Jan-30, Volume: 67, Issue:1 | 2020 |
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Gynecologic oncology, , Volume: 156, Issue:3 | 2020 |
In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine.
The British journal of psychiatry : the journal of mental science, , Volume: 217, Issue:3 | 2020 |
The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
International journal of clinical oncology, , Volume: 25, Issue:2 | 2020 |
Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics?
Journal of affective disorders, , 01-15, Volume: 261 | 2020 |
Efficacy and safety of electroacupuncture on metabolic syndrome due to olanzapine and risperidone: Study protocol for a randomized controlled pilot trial.
Medicine, , Volume: 98, Issue:38 | 2019 |
Radioprotective effect of olanzapine as an anti-psychotic drug against genotoxicity and apoptosis induced by ionizing radiation on human lymphocytes.
Molecular biology reports, , Volume: 46, Issue:6 | 2019 |
Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.
Journal of clinical psychopharmacology, , Volume: 39, Issue:4 | |
Switch-associated adverse events: focus on olanzapine.
Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, , Volume: 26, Issue:6 | 2018 |
Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
Clinical therapeutics, , Volume: 40, Issue:11 | 2018 |
Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis.
BMC psychiatry, , 09-05, Volume: 18, Issue:1 | 2018 |
Analysis of Toxicity Effects of Buspirone, Cetirizine and Olanzapine on Human Blood Lymphocytes: in Vitro Model.
Current clinical pharmacology, , Volume: 13, Issue:2 | 2018 |
Obesity exacerbates the acute metabolic side effects of olanzapine.
Psychoneuroendocrinology, , Volume: 88 | 2018 |
The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis.
BMC psychiatry, , 11-21, Volume: 17, Issue:1 | 2017 |
The Use, Safety, and Efficacy of Olanzapine in a Level I Pediatric Trauma Center Emergency Department Over a 10-Year Period.
Pediatric emergency care, , Volume: 36, Issue:2 | 2020 |
Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies.
Drug safety, , Volume: 40, Issue:9 | 2017 |
Do not treat the numbers: lithium toxicity.
BMJ case reports, , Jun-02, Volume: 2017 | 2017 |
Metabolic adverse effects of olanzapine on cognitive dysfunction: A possible relationship between BDNF and TNF-alpha.
Psychoneuroendocrinology, , Volume: 81 | 2017 |
Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Jun-15, Volume: 104 | 2017 |
Management of Hepatotoxicity Induced by the Use of Olanzapine.
Journal of child and adolescent psychopharmacology, , Volume: 27, Issue:3 | 2017 |
Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 27, Issue:7 | 2017 |
Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
Critical reviews in oncology/hematology, , Volume: 112 | 2017 |
Testing of bioactive-nanovesicles on hepatotoxicity of atypical antipsychotics via digital holography.
Colloids and surfaces. B, Biointerfaces, , Apr-01, Volume: 152 | 2017 |
A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia.
Schizophrenia research, , Volume: 185 | 2017 |
The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study.
CNS drugs, , Volume: 30, Issue:11 | 2016 |
A Case Report: Anti-Psychotic Agents Related Ocular Toxicity.
Medicine, , Volume: 95, Issue:15 | 2016 |
Second-Generation Antipsychotics During the Lactation Period: A Comparative Systematic Review on Infant Safety.
Journal of clinical psychopharmacology, , Volume: 36, Issue:3 | 2016 |
Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.
Expert opinion on drug safety, , Volume: 15, Issue:3 | 2016 |
Brain stem as a target site for the metabolic side effects of olanzapine.
Journal of neurophysiology, , Volume: 115, Issue:3 | 2016 |
Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.
BMC psychiatry, , Nov-13, Volume: 15 | 2015 |
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2 | 2016 |
Neurological Adverse Effects of Antipsychotics in Children and Adolescents.
Journal of clinical psychopharmacology, , Volume: 35, Issue:6 | 2015 |
Involvement of oxidative stress and mitochondrial/lysosomal cross-talk in olanzapine cytotoxicity in freshly isolated rat hepatocytes.
Xenobiotica; the fate of foreign compounds in biological systems, , Volume: 46, Issue:4 | 2016 |
Neuromotor Adverse Effects in 342 Youth During 12 Weeks of Naturalistic Treatment With 5 Second-Generation Antipsychotics.
Journal of the American Academy of Child and Adolescent Psychiatry, , Volume: 54, Issue:9 | 2015 |
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2 | 2016 |
Evaluation of the safety profile of Zolafren®, a generic olanzapine formulation, in patients with bipolar disorder: a post-authorization safety study.
Advances in therapy, , Volume: 32, Issue:5 | 2015 |
Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.
International journal of medical sciences, , Volume: 12, Issue:2 | 2015 |
Comparative cardiovascular safety of risperidone and olanzapine, based on electrocardiographic parameters and blood pressure: a prospective open label observational study.
Indian journal of pharmacology, , Volume: 46, Issue:5 | |
Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: A comparison of efficacy, safety, and side effects.
Palliative & supportive care, , Volume: 13, Issue:4 | 2015 |
The safety of olanzapine in young children: a systematic review and meta-analysis.
Drug safety, , Volume: 37, Issue:10 | 2014 |
Safety of antipsychotic drugs: focus on therapeutic and adverse effects.
Expert opinion on drug safety, , Volume: 13, Issue:8 | 2014 |
Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine.
Psychiatry research, , Oct-30, Volume: 219, Issue:2 | 2014 |
Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.
International clinical psychopharmacology, , Volume: 29, Issue:6 | 2014 |
Quality of life in patients with schizophrenia: the impact of socio-economic factors and adverse effects of atypical antipsychotics drugs.
The Psychiatric quarterly, , Volume: 85, Issue:3 | 2014 |
Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects.
Journal of biomedical nanotechnology, , Volume: 10, Issue:6 | 2014 |
A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior.
Journal of clinical psychopharmacology, , Volume: 34, Issue:3 | 2014 |
Quantitative drug benefit-risk assessment: utility of modeling and simulation to optimize drug safety in older adults.
The Annals of pharmacotherapy, , Volume: 48, Issue:3 | 2014 |
A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
Human psychopharmacology, , Volume: 29, Issue:1 | 2014 |
A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection.
BMC psychiatry, , Jan-14, Volume: 14 | 2014 |
Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysis.
Psychiatry and clinical neurosciences, , Volume: 68, Issue:7 | 2014 |
A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, , Volume: 24, Issue:3 | 2014 |
Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence-based practice.
The Journal of clinical psychiatry, , Volume: 74, Issue:11 | 2013 |
Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care.
Clinical toxicology (Philadelphia, Pa.), , Volume: 52, Issue:1 | 2014 |
Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Clinical therapeutics, , Volume: 35, Issue:12 | 2013 |
Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium.
BMC psychiatry, , Sep-30, Volume: 13 | 2013 |
Drug safety evaluation of olanzapine pamoate.
Expert opinion on drug safety, , Volume: 12, Issue:6 | 2013 |
The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
Clinical drug investigation, , Volume: 33, Issue:10 | 2013 |
Indirect comparison analysis of efficacy and safety between olanzapine and aripiprazole for schizophrenia.
British journal of clinical pharmacology, , Volume: 77, Issue:5 | 2014 |
Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.
The international journal of neuropsychopharmacology, , Volume: 17, Issue:1 | 2014 |
Long-term Use (81)
| Article | Year |
|---|
Treatment of severe tardive dyskinesia with concurrent administration of olanzapine, clonazepam, baclofen, and gabapentin: a case report.
The Journal of international medical research, , Volume: 51, Issue:10 | 2023 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Journal of psychopharmacology (Oxford, England), , Volume: 36, Issue:9 | 2022 |
The mechanisms underlying olanzapine-induced insulin resistance via the brown adipose tissue and the therapy in rats.
Adipocyte, , Volume: 11, Issue:1 | 2022 |
Late-Onset Dystonia With Low-Dose Olanzapine in an Older Person: A Case Report.
The Senior care pharmacist, , Oct-01, Volume: 36, Issue:10 | 2021 |
Crosstalk of hypothalamic chemerin, histamine, and AMPK in diet-and olanzapine-induced obesity in rats.
Life sciences, , Nov-01, Volume: 284 | 2021 |
Central retinal vein occlusion in a patient using the antipsychotic drug olanzapine: a case report.
Journal of medical case reports, , May-29, Volume: 15, Issue:1 | 2021 |
Antipsychotic long-term treatment in children and young people: a systematic review and meta-analysis of efficacy and tolerability across mental health and neurodevelopmental conditions.
CNS spectrums, , Volume: 27, Issue:5 | 2022 |
Identification and characterization of proteins that are differentially expressed in adipose tissue of olanzapine-induced insulin resistance rat by iTRAQ quantitative proteomics.
Journal of proteomics, , 02-10, Volume: 212 | 2020 |
Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance.
Scientific reports, , 02-07, Volume: 9, Issue:1 | 2019 |
Chronic Atypical Antipsychotic Use Is Associated With Reduced Need for Postoperative Nausea and Vomiting Rescue in the Postanesthesia Care Unit: A Propensity-Matched Retrospective Observational Study.
Anesthesia and analgesia, , Volume: 130, Issue:1 | 2020 |
An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers.
Human brain mapping, , Volume: 39, Issue:1 | 2018 |
Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling.
Progress in neuro-psychopharmacology & biological psychiatry, , 06-02, Volume: 76 | 2017 |
Chronic Olanzapine Treatment Induces Disorders of Plasma Fatty Acid Profile in Balb/c Mice: A Potential Mechanism for Olanzapine-Induced Insulin Resistance.
PloS one, , Volume: 11, Issue:12 | 2016 |
Blepharospasm: an uncommon adverse effect caused by long-term administration of olanzapine.
Journal of basic and clinical physiology and pharmacology, , Jan-01, Volume: 28, Issue:1 | 2017 |
Chlorpromazine versus atypical antipsychotic drugs for schizophrenia.
The Cochrane database of systematic reviews, , Apr-05, Volume: 4 | 2016 |
Effects of neuroleptics administration on adult neurogenesis in the rat hypothalamus.
Pharmacological reports : PR, , Volume: 67, Issue:6 | 2015 |
Effects of antipsychotic drugs on the expression of synapse-associated proteins in the frontal cortex of rats subjected to immobilization stress.
Psychiatry research, , Oct-30, Volume: 229, Issue:3 | 2015 |
Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.
International clinical psychopharmacology, , Volume: 29, Issue:6 | 2014 |
Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects.
Journal of biomedical nanotechnology, , Volume: 10, Issue:6 | 2014 |
Safety and efficacy of olanzapine in the long-term treatment of Japanese patients with bipolar I disorder, depression: an integrated analysis.
Psychiatry and clinical neurosciences, , Volume: 68, Issue:7 | 2014 |
Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period.
Pharmacological reports : PR, , Volume: 65, Issue:1 | 2013 |
Effects of fluoxetine, tianeptine and olanzapine on unpredictable chronic mild stress-induced depression-like behavior in mice.
Life sciences, , Dec-17, Volume: 91, Issue:25-26 | 2012 |
Energy metabolism, leptin, and biochemical parameters are altered in rats subjected to the chronic administration of olanzapine.
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999), , Volume: 34, Issue:2 | 2012 |
Effects of antipsychotic drugs on BDNF, GSK-3β, and β-catenin expression in rats subjected to immobilization stress.
Neuroscience research, , Volume: 71, Issue:4 | 2011 |
Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation.
PloS one, , Volume: 6, Issue:6 | 2011 |
Concomitant use of carbamazepine and olanzapine and the effect on some behavioral functions in rats.
Pharmacological reports : PR, , Volume: 63, Issue:2 | 2011 |
Olanzapine plus fluoxetine treatment increases Nt-3 protein levels in the rat prefrontal cortex.
Neuroscience letters, , Jun-22, Volume: 497, Issue:2 | 2011 |
Treatment with olanzapine, fluoxetine and olanzapine/fluoxetine alters citrate synthase activity in rat brain.
Neuroscience letters, , Jan-10, Volume: 487, Issue:3 | 2011 |
Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.
Molecular psychiatry, , Volume: 16, Issue:5 | 2011 |
Antipsychotic-induced gene regulation in multiple brain regions.
Journal of neurochemistry, , Volume: 113, Issue:1 | 2010 |
Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain.
Brain research bulletin, , Dec-16, Volume: 80, Issue:6 | 2009 |
Lithium, antipsychotics, and risk of psoriasis.
Journal of clinical psychopharmacology, , Volume: 29, Issue:2 | 2009 |
Long-term treatments with low- and high dose olanzapine change hepatocyte numbers in rats. A stereological and histopathological study.
Archives of medical research, , Volume: 40, Issue:3 | 2009 |
A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
The Journal of clinical psychiatry, , Volume: 70, Issue:6 | 2009 |
Chronic administration of olanzapine affects Behavioral Satiety Sequence and feeding behavior in female mice.
Eating and weight disorders : EWD, , Volume: 13, Issue:3 | 2008 |
Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study.
Diabetes & metabolism, , Volume: 34, Issue:5 | 2008 |
Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine.
Progress in neuro-psychopharmacology & biological psychiatry, , Aug-01, Volume: 32, Issue:6 | 2008 |
Olanzapine (LY170053, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine), but not the novel atypical antipsychotic ST2472 (9-piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), chronic administration induces weight gain, hyperphagia
The Journal of pharmacology and experimental therapeutics, , Volume: 326, Issue:3 | 2008 |
Lack of effect of antipsychotics on BNDF and NGF levels in hippocampus of Wistar rats.
Metabolic brain disease, , Volume: 23, Issue:2 | 2008 |
Antipsychotic-induced oxidative stress in rat brain.
Neurotoxicity research, , Volume: 13, Issue:1 | 2008 |
Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats.
Journal of psychopharmacology (Oxford, England), , Volume: 22, Issue:2 | 2008 |
Effects of chronic treatment of olanzapine and haloperidol on peptide YY binding densities in the rat brain.
Experimental neurology, , Volume: 209, Issue:1 | 2008 |
Obsessive-compulsive disorder followed by psychotic episode in long-term ecstasy misuse.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, , Volume: 10, Issue:4 Pt 2 | 2009 |
Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats.
Life sciences, , Sep-01, Volume: 81, Issue:12 | 2007 |
Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain.
Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 376, Issue:1-2 | 2007 |
The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 32, Issue:4 | 2007 |
A decision model to compare health care costs of olanzapine and risperidone treatment for schizophrenia in Germany.
The European journal of health economics : HEPAC : health economics in prevention and care, , Volume: 7, Issue:3 | 2006 |
Long-term use of atypical antipsychotics in bipolar disorder.
Pharmacotherapy, , Volume: 26, Issue:8 | 2006 |
The effect of long-term antipsychotic treatment on prolactin.
Journal of child and adolescent psychopharmacology, , Volume: 16, Issue:3 | 2006 |
Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects.
Psychopharmacology, , Volume: 186, Issue:4 | 2006 |
Modification of spatial recognition memory and object discrimination after chronic administration of haloperidol, amitriptyline, sodium valproate or olanzapine in normal and anhedonic rats.
The international journal of neuropsychopharmacology, , Volume: 10, Issue:3 | 2007 |
A regional comparison of developing diabetes among VA patients exposed to typical and atypical antipsychotics relative to corticosteroids and proton pump inhibitors.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, , Volume: 18, Issue:1 | |
Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.
Obesity (Silver Spring, Md.), , Volume: 14, Issue:1 | 2006 |
Differential effects of long-term treatment with typical and atypical antipsychotics on NGF and BDNF levels in rat striatum and hippocampus.
Schizophrenia research, , Feb-15, Volume: 82, Issue:1 | 2006 |
Chronic olanzapine treatment causes differential expression of genes in frontal cortex of rats as revealed by DNA microarray technique.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 31, Issue:9 | 2006 |
Long-term exposure to the atypical antipsychotic olanzapine differently up-regulates extracellular signal-regulated kinases 1 and 2 phosphorylation in subcellular compartments of rat prefrontal cortex.
Molecular pharmacology, , Volume: 69, Issue:4 | 2006 |
Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data.
Psychopharmacology, , Volume: 184, Issue:1 | 2006 |
Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine.
Psychoneuroendocrinology, , Volume: 31, Issue:2 | 2006 |
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
The Journal of pharmacology and experimental therapeutics, , Volume: 315, Issue:3 | 2005 |
Gonadotrophin-releasing hormone agonist treatment of aggression in Alzheimer's disease: a case report.
International psychogeriatrics, , Volume: 17, Issue:2 | 2005 |
Effects of chronic neuroleptic treatments on nutrient selection, body weight, and body composition in the male rat under dietary self-selection.
Behavioural brain research, , Sep-08, Volume: 163, Issue:2 | 2005 |
Effects of chronic administration of olanzapine, amitriptyline, haloperidol or sodium valproate in naive and anhedonic rats.
The international journal of neuropsychopharmacology, , Volume: 9, Issue:4 | 2006 |
Olanzapine attenuates the okadaic acid-induced spatial memory impairment and hippocampal cell death in rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 30, Issue:8 | 2005 |
Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder.
Psychopharmacology, , Volume: 181, Issue:1 | 2005 |
Olanzapine induced thrombocythemia in Sprague-Dawley rats.
Drug and chemical toxicology, , Volume: 27, Issue:4 | 2004 |
Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine.
Brain research, , Oct-29, Volume: 1025, Issue:1-2 | 2004 |
Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity.
Biological psychiatry, , Jun-01, Volume: 55, Issue:11 | 2004 |
Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain.
Biological psychiatry, , Jun-01, Volume: 55, Issue:11 | 2004 |
An animal model of antipsychotic-induced weight gain.
Behavioural brain research, , Jun-04, Volume: 152, Issue:1 | 2004 |
Inhibition of stress-induced dopamine output in the rat prefrontal cortex by chronic treatment with olanzapine.
Biological psychiatry, , Mar-01, Volume: 55, Issue:5 | 2004 |
Long-term antidepressant efficacy and safety of olanzapine/fluoxetine combination: a 76-week open-label study.
The Journal of clinical psychiatry, , Volume: 64, Issue:11 | 2003 |
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:3 | 2003 |
Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation.
The Journal of pharmacology and experimental therapeutics, , Volume: 305, Issue:3 | 2003 |
Treatment of patients with tardive dystonia with olanzapine.
Clinical neuropharmacology, , Volume: 25, Issue:2 | |
Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia.
Neuroscience, , Volume: 107, Issue:4 | 2001 |
Influence of olanzapine on cognitive functions and catalepsy in rats after single and chronic administration.
Polish journal of pharmacology, , Volume: 51, Issue:4 | |
Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain.
Psychopharmacology, , Volume: 144, Issue:3 | 1999 |
Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 19, Issue:5 | 1998 |
Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions.
Proceedings of the National Academy of Sciences of the United States of America, , Sep-15, Volume: 95, Issue:19 | 1998 |
Atypical antipsychotic drugs and long-term outcome in schizophrenia.
The Journal of clinical psychiatry, , Volume: 57 Suppl 11 | 1996 |
Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 14, Issue:2 | 1996 |
Pharmacokinetics (80)
| Article | Year |
|---|
Significant predictors for olanzapine pharmacokinetics: a systematic review of population pharmacokinetic studies.
Expert review of clinical pharmacology, , Volume: 16, Issue:6 | |
Population pharmacokinetics and dosing optimization of olanzapine in Chinese paediatric patients: Based on the impact of sex and concomitant valproate on clearance.
Journal of clinical pharmacy and therapeutics, , Volume: 47, Issue:11 | 2022 |
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
The international journal of neuropsychopharmacology, , 09-28, Volume: 25, Issue:9 | 2022 |
[Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics].
Psychiatrike = Psychiatriki, , Jun-10, Volume: 33, Issue:2 | 2022 |
Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.
CPT: pharmacometrics & systems pharmacology, , Volume: 10, Issue:9 | 2021 |
Pharmacodynamic Interactions Between Ketamine and Psychiatric Medications Used in the Treatment of Depression: A Systematic Review.
The international journal of neuropsychopharmacology, , 10-23, Volume: 24, Issue:10 | 2021 |
Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
Journal of clinical pharmacology, , Volume: 61, Issue:11 | 2021 |
Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 133 | 2021 |
Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination.
Clinical pharmacokinetics, , Volume: 60, Issue:5 | 2021 |
Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.
Schizophrenia bulletin, , 04-29, Volume: 47, Issue:3 | 2021 |
The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults.
The Journal of clinical psychiatry, , 06-30, Volume: 81, Issue:4 | 2020 |
Population pharmacokinetics of olanzapine in children.
British journal of clinical pharmacology, , Volume: 87, Issue:2 | 2021 |
Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models.
Drug metabolism reviews, , Volume: 52, Issue:1 | 2020 |
Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.
CPT: pharmacometrics & systems pharmacology, , Volume: 9, Issue:2 | 2020 |
A platinum black-modified microelectrode for in situ olanzapine detection in microliter volumes of undiluted serum.
Journal of neural transmission (Vienna, Austria : 1996), , Volume: 127, Issue:2 | 2020 |
Open-Label, Randomized, Single-Dose, 2-Period, 2-Sequence Crossover, Comparative Pharmacokinetic Study to Evaluate Bioequivalence of 2 Oral Formulations of Olanzapine Under Fasting and Fed Conditions.
Clinical pharmacology in drug development, , Volume: 9, Issue:5 | 2020 |
Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
Clinical drug investigation, , Volume: 40, Issue:1 | 2020 |
Olanzapine exposure diminishes perfusion and decreases volume of sensorimotor cortex in rats.
Pharmacological reports : PR, , Volume: 71, Issue:5 | 2019 |
A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
Clinical drug investigation, , Volume: 39, Issue:5 | 2019 |
Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
Clinical therapeutics, , Volume: 40, Issue:11 | 2018 |
Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia.
BMJ open, , 08-17, Volume: 8, Issue:8 | 2018 |
Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.
Acta psychiatrica Scandinavica, , Volume: 139, Issue:1 | 2019 |
Supported liquid extraction and LC-MS-MS determination of iloperidone and olanzapine in rat plasma: Application to a pharmacokinetic study.
Journal of chromatographic science, , Nov-01, Volume: 56, Issue:10 | 2018 |
Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.
British journal of clinical pharmacology, , Volume: 84, Issue:3 | 2018 |
A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy.
Nordic journal of psychiatry, , Volume: 71, Issue:6 | 2017 |
Investigations on pharmacokinetics and biodistribution of polymeric and solid lipid nanoparticulate systems of atypical antipsychotic drug: effect of material used and surface modification.
Drug development and industrial pharmacy, , Volume: 43, Issue:4 | 2017 |
Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss.
Psychological medicine, , Volume: 46, Issue:15 | 2016 |
Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis.
European journal of clinical pharmacology, , Volume: 72, Issue:8 | 2016 |
SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study.
Human psychopharmacology, , Volume: 31, Issue:3 | 2016 |
Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3.
Human psychopharmacology, , Volume: 31, Issue:2 | 2016 |
In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.
Molecular psychiatry, , Volume: 21, Issue:11 | 2016 |
Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study.
Pharmacopsychiatry, , Volume: 48, Issue:7 | 2015 |
Concurrent determination of olanzapine, risperidone and 9-hydroxyrisperidone in human plasma by ultra performance liquid chromatography with diode array detection method: application to pharmacokinetic study.
Biomedical chromatography : BMC, , Volume: 30, Issue:2 | 2016 |
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.
Clinical pharmacokinetics, , Volume: 54, Issue:11 | 2015 |
The development and validation of a method for quantifying olanzapine in human plasma by liquid chromatography tandem mass spectrometry and its application in a pharmacokinetic study.
Clinical and experimental pharmacology & physiology, , Volume: 42, Issue:3 | 2015 |
Abnormal olanzapine toxicokinetic profiles--population pharmacokinetic analysis.
Toxicology mechanisms and methods, , Volume: 25, Issue:1 | 2015 |
Effect of fosamprenavir/ritonavir on the pharmacokinetics of single-dose olanzapine in healthy volunteers.
International journal of antimicrobial agents, , Volume: 44, Issue:2 | 2014 |
Evaluation of brain targeting efficiency of intranasal microemulsion containing olanzapine: pharmacodynamic and pharmacokinetic consideration.
Drug delivery, , Volume: 23, Issue:1 | 2016 |
Pharmacokinetics of olanzapine long-acting injection: the clinical perspective.
International clinical psychopharmacology, , Volume: 29, Issue:6 | 2014 |
Dopamine D2 receptor occupancy as a predictor of catalepsy in rats: a pharmacokinetic-pharmacodynamic modeling approach.
Pharmaceutical research, , Volume: 31, Issue:10 | 2014 |
Single- and multiple-dose pharmacokinetic, safety, and tolerability profiles of olanzapine long-acting injection: an open-label, multicenter, nonrandomized study in patients with schizophrenia.
Clinical therapeutics, , Volume: 35, Issue:12 | 2013 |
Reduced cortical volume and elevated astrocyte density in rats chronically treated with antipsychotic drugs-linking magnetic resonance imaging findings to cellular pathology.
Biological psychiatry, , Jun-15, Volume: 75, Issue:12 | 2014 |
Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats.
Neuroscience, , Volume: 255 | 2013 |
The possibility that requiring high-dose olanzapine cannot be explained by pharmacokinetics in the treatment of acute-phase schizophrenia.
Psychiatry research, , Dec-15, Volume: 210, Issue:2 | 2013 |
Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers.
Pharmacogenomics, , Volume: 14, Issue:10 | 2013 |
Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression.
Expert opinion on drug metabolism & toxicology, , Volume: 9, Issue:2 | 2013 |
Pharmacokinetics and bioequivalence of 2 tablet formulations of olanzapine in healthy Chinese volunteers: a randomized, open-label, single-dose study.
Arzneimittel-Forschung, , Volume: 62, Issue:11 | 2012 |
Does olanzapine warrant clinical pharmacokinetic monitoring in schizophrenia?
Clinical pharmacokinetics, , Volume: 50, Issue:7 | 2011 |
Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.
Pharmaceutical research, , Volume: 28, Issue:10 | 2011 |
Genetic variation in CYP3A43 explains racial difference in olanzapine clearance.
Molecular psychiatry, , Volume: 16, Issue:6 | 2011 |
Anterior internal capsule volumes increase in patients with schizophrenia switched from typical antipsychotics to olanzapine.
Journal of psychopharmacology (Oxford, England), , Volume: 25, Issue:5 | 2011 |
Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: a population pharmacokinetic model.
Paediatric drugs, , Volume: 12, Issue:3 | 2010 |
Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors.
Progress in neuro-psychopharmacology & biological psychiatry, , Dec-12, Volume: 32, Issue:8 | 2008 |
Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: a clinical, two-group, naturalistic study.
Clinical drug investigation, , Volume: 28, Issue:9 | 2008 |
Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
European journal of pharmacology, , Apr-28, Volume: 584, Issue:2-3 | 2008 |
Changes in cortical volume with olanzapine in chronic schizophrenia.
Pharmacopsychiatry, , Volume: 40, Issue:4 | 2007 |
A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia.
Schizophrenia research, , Volume: 94, Issue:1-3 | 2007 |
Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia.
Neuropsychobiology, , Volume: 55, Issue:1 | 2007 |
Selegiline transdermal system: an examination of the potential for CYP450-dependent pharmacokinetic interactions with 3 psychotropic medications.
Journal of clinical pharmacology, , Volume: 47, Issue:2 | 2007 |
Reduced thalamic volume in patients with chronic schizophrenia after switching from typical antipsychotic medications to olanzapine.
The American journal of psychiatry, , Volume: 163, Issue:11 | 2006 |
[Reversed phase high-performance liquid chromatography for determination of plasma olanzapine and pharmacokinetics of olanzapine in healthy Chinese volunteers].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University, , Volume: 26, Issue:9 | 2006 |
A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects.
Clinical therapeutics, , Volume: 28, Issue:6 | 2006 |
Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects.
British journal of clinical pharmacology, , Volume: 61, Issue:4 | 2006 |
Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers.
Journal of clinical pharmacology, , Volume: 46, Issue:2 | 2006 |
Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.
Drug metabolism and pharmacokinetics, , Volume: 20, Issue:3 | 2005 |
Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia.
Journal of clinical pharmacology, , Volume: 44, Issue:12 | 2004 |
Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia.
The American journal of psychiatry, , Volume: 161, Issue:10 | 2004 |
The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers.
Journal of clinical pharmacology, , Volume: 44, Issue:7 | 2004 |
Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.
Current medicinal chemistry, , Volume: 11, Issue:3 | 2004 |
Olanzapine pharmacokinetics are similar in Chinese and Caucasian subjects.
British journal of clinical pharmacology, , Volume: 56, Issue:2 | 2003 |
Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
Journal of clinical psychopharmacology, , Volume: 22, Issue:5 | 2002 |
Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers.
Journal of clinical psychopharmacology, , Volume: 22, Issue:4 | 2002 |
Influence of fluoxetine on olanzapine pharmacokinetics.
AAPS pharmSci, , Volume: 4, Issue:2 | 2002 |
[Olanzapine: pharmacology, pharmacokinetics and therapeutic drug monitoring].
Fortschritte der Neurologie-Psychiatrie, , Volume: 69, Issue:11 | 2001 |
Pharmacokinetics and tissue distribution of olanzapine in rats.
Biopharmaceutics & drug disposition, , Volume: 20, Issue:8 | 1999 |
Olanzapine pharmacokinetics in pediatric and adolescent inpatients with childhood-onset schizophrenia.
Journal of clinical psychopharmacology, , Volume: 20, Issue:2 | 2000 |
Olanzapine. Pharmacokinetic and pharmacodynamic profile.
Clinical pharmacokinetics, , Volume: 37, Issue:3 | 1999 |
A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism.
European journal of clinical pharmacology, , Volume: 54, Issue:8 | 1998 |
Lack of effect of olanzapine on the pharmacokinetics of a single aminophylline dose in healthy men.
Pharmacotherapy, , Volume: 18, Issue:6 | |
Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection.
Journal of pharmaceutical and biomedical analysis, , Volume: 14, Issue:5 | 1996 |
Bioavailability (47)
| Article | Year |
|---|
Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization.
International journal of molecular sciences, , Sep-06, Volume: 23, Issue:18 | 2022 |
Comparative, Single-Dose, 2-Way Cross-Over Bioavailability Study of Two Olanzapine 10 Mg Tablet Formulations in Healthy Volunteers Under Fasting Conditions.
Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki), , Jul-13, Volume: 43, Issue:2 | 2022 |
Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine.
CNS spectrums, , Volume: 28, Issue:3 | 2023 |
[Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics].
Psychiatrike = Psychiatriki, , Jun-10, Volume: 33, Issue:2 | 2022 |
Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.
CPT: pharmacometrics & systems pharmacology, , Volume: 10, Issue:9 | 2021 |
Relevance of production method on the physical stability and in vitro biopharmaceutical performances of olanzapine orodispersible film.
International journal of pharmaceutics, , Jun-15, Volume: 603 | 2021 |
The gut microbiome influences the bioavailability of olanzapine in rats.
EBioMedicine, , Volume: 66 | 2021 |
Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation.
International journal of pharmaceutics, , Oct-15, Volume: 588 | 2020 |
Poloxamer-407-Co-Poly (2-Acrylamido-2-Methylpropane Sulfonic Acid) Cross-linked Nanogels for Solubility Enhancement of Olanzapine: Synthesis, Characterization, and Toxicity Evaluation.
AAPS PharmSciTech, , May-17, Volume: 21, Issue:5 | 2020 |
Sustained delivery of olanzapine from sunflower oil-based polyol-urethane nanoparticles synthesised through a cyclic carbonate ring-opening reaction.
IET nanobiotechnology, , Volume: 13, Issue:7 | 2019 |
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5 | 2019 |
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, , 11-15, Volume: 294, Issue:46 | 2019 |
Surface modified niosomes of olanzapine for brain targeting via nasal route; preparation, optimization, and
Journal of liposome research, , Volume: 30, Issue:2 | 2020 |
Development of a population pharmacokinetic model of olanzapine for Chinese health volunteers and patients with schizophrenia.
BMJ open, , 08-17, Volume: 8, Issue:8 | 2018 |
Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study.
Clinical pharmacology in drug development, , Volume: 8, Issue:4 | 2019 |
Evaluation of antioxidant potencial of novel CaAl and NiAl layered double hydroxides loaded with olanzapine.
Life sciences, , Aug-15, Volume: 207 | 2018 |
Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers.
International journal of biological macromolecules, , Apr-15, Volume: 110 | 2018 |
Bionanocomposite systems based on montmorillonite and biopolymers for the controlled release of olanzapine.
Materials science & engineering. C, Materials for biological applications, , Jun-01, Volume: 75 | 2017 |
Testing of bioactive-nanovesicles on hepatotoxicity of atypical antipsychotics via digital holography.
Colloids and surfaces. B, Biointerfaces, , Apr-01, Volume: 152 | 2017 |
Solid microcrystalline dispersion films as a new strategy to improve the dissolution rate of poorly water soluble drugs: A case study using olanzapine.
International journal of pharmaceutics, , Jul-11, Volume: 508, Issue:1-2 | 2016 |
Development of micro-fibrous solid dispersions of poorly water-soluble drugs in sucrose using temperature-controlled centrifugal spinning.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 103 | 2016 |
Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles.
Artificial cells, nanomedicine, and biotechnology, , Volume: 45, Issue:2 | 2017 |
Nanoencapsulation Improves Relative Bioavailability and Antipsychotic Effect of Olanzapine in Rats.
Journal of biomedical nanotechnology, , Volume: 11, Issue:8 | 2015 |
The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.
Clinical pharmacokinetics, , Volume: 54, Issue:11 | 2015 |
Intranasal drug delivery of olanzapine-loaded chitosan nanoparticles.
AAPS PharmSciTech, , Volume: 15, Issue:6 | 2014 |
[Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
Rivista di psichiatria, , Volume: 49, Issue:3 | |
Inclusion complex of methyl-β-cyclodextrin and olanzapine as potential drug delivery system for schizophrenia.
Carbohydrate polymers, , Aug-01, Volume: 89, Issue:4 | 2012 |
Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.
Journal of medicinal chemistry, , Mar-27, Volume: 57, Issue:6 | 2014 |
Mental state deterioration after switching from brand-name to generic olanzapine in an adolescent with bipolar affective disorder, autism and intellectual disability: a case study.
BMC psychiatry, , Oct-04, Volume: 13 | 2013 |
The psychopharmacology algorithm project at the Harvard South Shore Program: an update on schizophrenia.
Harvard review of psychiatry, , Volume: 21, Issue:1 | |
Single dose bioequivalence study of two brands of olanzapine 10 mg tablets in Iranian healthy volunteers.
Drug research, , Volume: 63, Issue:7 | 2013 |
Pharmacokinetics and bioequivalence of 2 tablet formulations of olanzapine in healthy Chinese volunteers: a randomized, open-label, single-dose study.
Arzneimittel-Forschung, , Volume: 62, Issue:11 | 2012 |
Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 22, Issue:18 | 2012 |
Brain delivery of olanzapine by intranasal administration of transfersomal vesicles.
Journal of liposome research, , Volume: 22, Issue:4 | 2012 |
Phospholipid based colloidal poloxamer-nanocubic vesicles for brain targeting via the nasal route.
Colloids and surfaces. B, Biointerfaces, , Dec-01, Volume: 100 | 2012 |
Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial.
Progress in neuro-psychopharmacology & biological psychiatry, , Mar-30, Volume: 36, Issue:2 | 2012 |
Natural oils as skin permeation enhancers for transdermal delivery of olanzapine: in vitro and in vivo evaluation.
Current drug delivery, , Volume: 9, Issue:2 | 2012 |
Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies.
Acta biomaterialia, , Volume: 7, Issue:12 | 2011 |
Development and validation of a liquid chromatography-isotope dilution tandem mass spectrometry for determination of olanzapine in human plasma and its application to bioavailability study.
Yao xue xue bao = Acta pharmaceutica Sinica, , Volume: 45, Issue:6 | 2010 |
Controlled release matrix tablets of olanzapine: influence of polymers on the in vitro release and bioavailability.
AAPS PharmSciTech, , Volume: 11, Issue:3 | 2010 |
A single-dose, randomized, two-way crossover study comparing two olanzapine tablet products in healthy adult male volunteers under fasting conditions.
Clinical therapeutics, , Volume: 31, Issue:3 | 2009 |
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.
Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 378, Issue:5 | 2008 |
Development and validation of a sensitive liquid chromatography/electrospray tandem mass spectrometry assay for the quantification of olanzapine in human plasma.
Journal of pharmaceutical and biomedical analysis, , Jun-07, Volume: 41, Issue:3 | 2006 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
CNS drugs, , Volume: 16, Issue:4 | 2002 |
QSAR model for drug human oral bioavailability.
Journal of medicinal chemistry, , Jun-29, Volume: 43, Issue:13 | 2000 |
Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , May-15, Volume: 55, Issue:10 | 1998 |
Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 25, Issue:5 | 1997 |
Dosage (422)
| Article | Year |
|---|
CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.
Scientific reports, , 10-28, Volume: 13, Issue:1 | 2023 |
Second International Consensus Study of Antipsychotic Dosing (ICSAD-2).
Journal of psychopharmacology (Oxford, England), , Volume: 37, Issue:10 | 2023 |
Significant predictors for olanzapine pharmacokinetics: a systematic review of population pharmacokinetic studies.
Expert review of clinical pharmacology, , Volume: 16, Issue:6 | |
Coadministration of olanzapine causes minor impacts on the diabetogenic outcomes induced by dexamethasone treatment in rats.
Life sciences, , Jun-01, Volume: 322 | 2023 |
A review of various analytical methods for the estimation of olanzapine: An antipsychotic drug.
Biomedical chromatography : BMC, , Volume: 37, Issue:7 | 2023 |
Coma, Severe Hypotension, and Pinpoint Pupils After Olanzapine Intoxication in the Intensive Care Unit with Symptom Reversal After Administration of Flumazenil.
The American journal of case reports, , Dec-01, Volume: 23 | 2022 |
Investigating the effects of antipsychotics on brain insulin action: Study protocol for a multi-modality magnetic resonance imaging (MRI) study in healthy controls.
PloS one, , Volume: 17, Issue:11 | 2022 |
Effects of Age, Sex, and Comedication on the Plasma Concentrations of Olanzapine in Chinese Patients With Schizophrenia Based on Therapeutic Drug Monitoring Data.
Journal of clinical psychopharmacology, , Volume: 42, Issue:6 | |
Development and evaluation of a drug-in-adhesive transdermal delivery system for delivery of olanzapine.
Expert opinion on drug delivery, , Volume: 19, Issue:11 | 2022 |
Neuroleptic malignant syndrome secondary to olanzapine, a presentation with severe acute kidney injury requiring hemodialysis: a case report.
Journal of medical case reports, , Oct-06, Volume: 16, Issue:1 | 2022 |
Antipsychotic Safety in Liver Disease: A Narrative Review and Practical Guide for the Clinician.
Journal of the Academy of Consultation-Liaison Psychiatry, , Volume: 64, Issue:1 | |
Amorphous and Co-Amorphous Olanzapine Stability in Formulations Intended for Wet Granulation and Pelletization.
International journal of molecular sciences, , Sep-06, Volume: 23, Issue:18 | 2022 |
Pharmacological interventions for the treatment of disordered and problem gambling.
The Cochrane database of systematic reviews, , 09-22, Volume: 9 | 2022 |
Population pharmacokinetics and dosing optimization of olanzapine in Chinese paediatric patients: Based on the impact of sex and concomitant valproate on clearance.
Journal of clinical pharmacy and therapeutics, , Volume: 47, Issue:11 | 2022 |
Olanzapine in oncology palliative care.
Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, ,Summer, Volume: 35, Issue:4 | 2022 |
Comorbidities and the right dose: antipsychotics.
Expert opinion on drug metabolism & toxicology, , Volume: 18, Issue:7-8 | |
Driving fitness in clinically stable outpatients with chronic schizophrenia.
Comprehensive psychiatry, , Volume: 118 | 2022 |
Efficacy of Olanzapine 5 mg versus 10 mg for the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving High Emetic Risk Chemotherapy without Neurokinin-1 Receptor Antagonist.
Asian Pacific journal of cancer prevention : APJCP, , Jun-01, Volume: 23, Issue:6 | 2022 |
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Turk psikiyatri dergisi = Turkish journal of psychiatry, ,Summer, Volume: 33, Issue:2 | 2022 |
Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.
Schizophrenia bulletin, , 06-21, Volume: 48, Issue:4 | 2022 |
Serum levels of olanzapine are associated with acute cognitive effects in bipolar disorder.
Psychiatry research, , Volume: 310 | 2022 |
Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
The lancet. Psychiatry, , Volume: 9, Issue:4 | 2022 |
Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials.
Schizophrenia bulletin, , 05-07, Volume: 48, Issue:3 | 2022 |
Efficacy and Safety of Olanzapine in Children Receiving Highly Emetogenic Chemotherapy: A Randomized, Double-blind Placebo-controlled Phase 3 Trial.
Journal of pediatric hematology/oncology, , 11-01, Volume: 44, Issue:8 | 2022 |
Olanzapine/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia.
The Annals of pharmacotherapy, , Volume: 56, Issue:9 | 2022 |
Effect of CYP2C19 polymorphisms on serum valproic level acid in Chinese Han patients with schizophrenia.
Scientific reports, , 11-30, Volume: 11, Issue:1 | 2021 |
Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular.
International clinical psychopharmacology, , 01-01, Volume: 37, Issue:1 | 2022 |
Antipsychotic medication for women with schizophrenia spectrum disorders.
Psychological medicine, , Volume: 52, Issue:4 | 2022 |
Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 47, Issue:3 | 2022 |
Inpatient treatment of anorexia nervosa with adjunctive valproate: a case series of 14 young and adolescent patients.
Eating and weight disorders : EWD, , Volume: 27, Issue:3 | 2022 |
Extrapyramidal Symptoms Induced by Treatment for Delirium: A Case Report.
Critical care nurse, , Jun-01, Volume: 41, Issue:3 | 2021 |
Prescribing pattern of antipsychotic medication for first-episode psychosis: a retrospective cohort study.
BMJ open, , 01-31, Volume: 11, Issue:1 | 2021 |
Antipsychotics and hemodialysis: A systematic review.
Asian journal of psychiatry, , Volume: 55 | 2021 |
The Psychopharmacology Algorithm Project at the Harvard South Shore Program: An update on management of behavioral and psychological symptoms in dementia.
Psychiatry research, , Volume: 295 | 2021 |
Occurrence of metabolic diseases associated with antipsychotic use among Korean patients with schizophrenia.
International journal of clinical pharmacology and therapeutics, , Volume: 59, Issue:4 | 2021 |
Augmentation with Atypical Antipsychotics for Treatment-Resistant Depression.
Journal of affective disorders, , 02-01, Volume: 280, Issue:Pt A | 2021 |
Standardizing the Effective Correlated Dosage of Olanzapine and Empagliflozin in Female Wistar Rats.
Current gene therapy, , Volume: 21, Issue:1 | 2021 |
A comprehensive entomological survey and evaluation of the efficacy of different therapies on a suspected delusional parasitosis case.
Brain and behavior, , Volume: 11, Issue:1 | 2021 |
Measurement of the amorphous fraction of olanzapine incorporated in a co-amorphous formulation.
International journal of pharmaceutics, , Oct-15, Volume: 588 | 2020 |
Population pharmacokinetics of olanzapine in children.
British journal of clinical pharmacology, , Volume: 87, Issue:2 | 2021 |
Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults-a propensity score matched cohort study.
Pharmacoepidemiology and drug safety, , Volume: 29, Issue:6 | 2020 |
The effects of aripiprazole and olanzapine on pupillary light reflex and its relationship with pharmacogenetics in a randomized multiple-dose trial.
British journal of clinical pharmacology, , Volume: 86, Issue:10 | 2020 |
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:11 | 2020 |
The dosage-dependent effects of cevimeline in preventing olanzapine-induced metabolic side-effects in female rats.
Pharmacology, biochemistry, and behavior, , Volume: 191 | 2020 |
A Retrospective Analysis of Steady-State Olanzapine Concentrations in Chinese Patients Using Therapeutic Drug Monitoring: Effects of Valproate and Other Factors.
Therapeutic drug monitoring, , Volume: 42, Issue:4 | 2020 |
Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models.
Drug metabolism reviews, , Volume: 52, Issue:1 | 2020 |
Olanzapine increases AMPK-NPY orexigenic signaling by disrupting H1R-GHSR1a interaction in the hypothalamic neurons of mice.
Psychoneuroendocrinology, , Volume: 114 | 2020 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
The American journal of psychiatry, , 04-01, Volume: 177, Issue:4 | 2020 |
Effects of long-term antipsychotics treatment on body weight: A population-based cohort study.
Journal of psychopharmacology (Oxford, England), , Volume: 34, Issue:1 | 2020 |
Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
Clinical drug investigation, , Volume: 40, Issue:1 | 2020 |
A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.
European archives of psychiatry and clinical neuroscience, , Volume: 270, Issue:1 | 2020 |
Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial.
JAMA, , 08-20, Volume: 322, Issue:7 | 2019 |
Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects.
Therapeutic drug monitoring, , Volume: 42, Issue:2 | 2020 |
Olanzapine exposure diminishes perfusion and decreases volume of sensorimotor cortex in rats.
Pharmacological reports : PR, , Volume: 71, Issue:5 | 2019 |
Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.
Medical decision making : an international journal of the Society for Medical Decision Making, , Volume: 39, Issue:5 | 2019 |
Pathological Concentration of C-reactive Protein is Correlated to Increased Concentrations of Quetiapine, But Not of Risperidone, Olanzapine and Aripiprazole in a Naturalistic Setting.
Pharmacopsychiatry, , Volume: 53, Issue:1 | 2020 |
A Phase I Open-Label Study to Evaluate the Effects of Rifampin on the Pharmacokinetics of Olanzapine and Samidorphan Administered in Combination in Healthy Human Subjects.
Clinical drug investigation, , Volume: 39, Issue:5 | 2019 |
Hormonal imbalance and pituitary adenoma during antipsychotic treatment in an adolescent with bipolar affective disorder.
Rivista di psichiatria, , Volume: 54, Issue:1 | |
Switching to paliperidone extended release in patients with schizophrenia dissatisfied with previous olanzapine treatment: Post hoc analysis of an open-label, prospective study.
Medicine, , Volume: 98, Issue:3 | 2019 |
[Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year].
L'Encephale, , Volume: 45, Issue:3 | 2019 |
Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.
BMC psychiatry, , 12-04, Volume: 18, Issue:1 | 2018 |
Resistance is not futile: treatment-refractory schizophrenia - overview, evaluation and treatment.
Expert opinion on pharmacotherapy, , Volume: 20, Issue:1 | 2019 |
Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.
Acta psychiatrica Scandinavica, , Volume: 139, Issue:1 | 2019 |
High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
BMC psychiatry, , 06-08, Volume: 18, Issue:1 | 2018 |
Second-generation antipsychotic and diabetes mellitus in children and adolescents.
La Pediatria medica e chirurgica : Medical and surgical pediatrics, , Dec-13, Volume: 39, Issue:4 | 2017 |
Predictors of remission during acute treatment of first-episode schizophrenia patients involuntarily hospitalized and treated with algorithm-based pharmacotherapy: Secondary analysis of an observational study.
Early intervention in psychiatry, , Volume: 13, Issue:3 | 2019 |
Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study.
Journal of psychopharmacology (Oxford, England), , Volume: 32, Issue:5 | 2018 |
Occurrence of post-injection delirium/sedation syndrome after application of olanzapine long-acting injection during one year period.
Psychiatria Danubina, , Volume: 29, Issue:4 | 2017 |
Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation.
British journal of clinical pharmacology, , Volume: 84, Issue:3 | 2018 |
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Clinical therapeutics, , Volume: 39, Issue:10 | 2017 |
A Pilot Study of the Usefulness of a Single Olanzapine Plasma Concentration as an Indicator of Early Drug Effect in a Small Sample of First-Episode Psychosis Patients.
Journal of clinical psychopharmacology, , Volume: 37, Issue:5 | 2017 |
Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.
CNS drugs, , Volume: 31, Issue:9 | 2017 |
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.
Investigational new drugs, , Volume: 36, Issue:1 | 2018 |
Algorithm-based pharmacotherapy for first-episode schizophrenia involuntarily hospitalized: A retrospective analysis of real-world practice.
Early intervention in psychiatry, , Volume: 13, Issue:1 | 2019 |
A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy.
Nordic journal of psychiatry, , Volume: 71, Issue:6 | 2017 |
Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders: A Retrospective Multicenter Study.
Journal of clinical psychopharmacology, , Volume: 37, Issue:3 | 2017 |
A randomized, double-blind, comparison of the efficacy and safety of low-dose olanzapine plus low-dose trifluoperazine versus full-dose olanzapine in the acute treatment of schizophrenia.
Schizophrenia research, , Volume: 185 | 2017 |
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia.
The Journal of clinical psychiatry, , Volume: 77, Issue:12 | 2016 |
Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage: A Double-Blind Randomized Controlled Trial.
The Journal of clinical psychiatry, , Volume: 77, Issue:10 | 2016 |
Can lipid nanoparticles improve intestinal absorption?
International journal of pharmaceutics, , Dec-30, Volume: 515, Issue:1-2 | 2016 |
Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats.
Psychoneuroendocrinology, , Volume: 73 | 2016 |
Adverse Renal, Endocrine, Hepatic, and Metabolic Events during Maintenance Mood Stabilizer Treatment for Bipolar Disorder: A Population-Based Cohort Study.
PLoS medicine, , Volume: 13, Issue:8 | 2016 |
Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.
Clinical pharmacology in drug development, , Volume: 5, Issue:6 | 2016 |
Role of moisture on the physical stability of polymorphic olanzapine.
International journal of pharmaceutics, , Jul-25, Volume: 509, Issue:1-2 | 2016 |
Dementia with Lewy bodies presenting marked tongue protrusion and bite due to lingual dystonia: A case report.
Rinsho shinkeigaku = Clinical neurology, , 06-22, Volume: 56, Issue:6 | 2016 |
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.
Annals of palliative medicine, , Volume: 5, Issue:3 | 2016 |
DEVELOPMENT OF OLANZAPINE LOADED PNA MICROGELS FOR DEPOT DRUG DELIVERY IN TREATMENT OF SCHIZOPHRENIA: IN VITRO AN IN VIVO RELEASE PROFILE.
Acta poloniae pharmaceutica, , Volume: 73, Issue:1 | |
Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
PloS one, , Volume: 11, Issue:2 | 2016 |
Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:6 | 2016 |
A Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral Olanzapine.
Journal of psychiatric practice, , Volume: 22, Issue:1 | 2016 |
Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:5 | 2016 |
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
The journal of mental health policy and economics, , Volume: 18, Issue:4 | 2015 |
A Large Retrospective Cohort of Patients Receiving Intravenous Olanzapine in the Emergency Department.
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine, , Volume: 23, Issue:1 | 2016 |
Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings.
European journal of clinical pharmacology, , Volume: 72, Issue:3 | 2016 |
Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study.
Pharmacopsychiatry, , Volume: 48, Issue:7 | 2015 |
Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice.
Bipolar disorders, , Volume: 17, Issue:6 | 2015 |
MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol.
Behavioural pharmacology, , Volume: 26, Issue:8 Spec No | 2015 |
Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.
Schizophrenia bulletin, , Volume: 42, Issue:1 | 2016 |
Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms.
Human psychopharmacology, , Volume: 30, Issue:4 | 2015 |
Skating on thin ice: pragmatic prescribing for medication refractory schizophrenia.
BMC psychiatry, , Jul-25, Volume: 15 | 2015 |
Interactions (30)
| Article | Year |
|---|
[Smoking cessation and drug interactions].
Ugeskrift for laeger, , 08-29, Volume: 184, Issue:35 | 2022 |
Clinical significance of potential drug-drug interactions in older adults with psychiatric disorders: a retrospective study.
BMC psychiatry, , 08-22, Volume: 22, Issue:1 | 2022 |
Multiple-day administration of fosaprepitant combined with tropisetron and olanzapine improves the prevention of nausea and vomiting in patients receiving chemotherapy prior to autologous hematopoietic stem cell transplant: a retrospective study.
Annals of hematology, , Volume: 101, Issue:8 | 2022 |
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin
BMJ open, , 12-17, Volume: 10, Issue:12 | 2020 |
Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analy
ESMO open, , Volume: 5, Issue:1 | 2020 |
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Gynecologic oncology, , Volume: 156, Issue:3 | 2020 |
Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.
CPT: pharmacometrics & systems pharmacology, , Volume: 9, Issue:2 | 2020 |
Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 28, Issue:3 | 2020 |
Efficacy and Safety of Asenapine Versus Olanzapine in Combination With Divalproex for Acute Mania: A Randomized Controlled Trial.
Journal of clinical psychopharmacology, , Volume: 39, Issue:4 | |
A phase II trial of prophylactic olanzapine combined with palonosetron and dexamethasone for preventing nausea and vomiting induced by cisplatin.
Asia-Pacific journal of clinical oncology, , Volume: 12, Issue:3 | 2016 |
The effects in rats of lisdexamfetamine in combination with olanzapine on mesocorticolimbic dopamine efflux, striatal dopamine D2 receptor occupancy and stimulus generalization to a D-amphetamine cue.
Neuropharmacology, , Volume: 101 | 2016 |
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, , Volume: 24, Issue:2 | 2016 |
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer.
Cell biochemistry and biophysics, , Volume: 72, Issue:2 | 2015 |
Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine.
Progress in neuro-psychopharmacology & biological psychiatry, , Jan-03, Volume: 48 | 2014 |
Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.
Behavioural pharmacology, , Volume: 23, Issue:7 | 2012 |
A case report on the relationship between treatment-resistant childhood-onset schizophrenia and an abnormally enlarged cavum septum pellucidum combined with cavum vergae.
Chinese medical journal, , Volume: 125, Issue:7 | 2012 |
An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm.
Behavioural pharmacology, , Volume: 20, Issue:2 | 2009 |
Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 34, Issue:5 | 2009 |
Drug interactions with smoking.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Sep-15, Volume: 64, Issue:18 | 2007 |
Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder.
The Tohoku journal of experimental medicine, , Volume: 213, Issue:1 | 2007 |
Sublingual use of olanzapine in combination with alprazolam to treat agitation in a terminally ill patient receiving parenteral nutrition.
European journal of cancer care, , Volume: 16, Issue:3 | 2007 |
Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex.
The Journal of clinical psychiatry, , Volume: 67, Issue:8 | 2006 |
Pharmacological management of akathisia in combination with psychological interventions by a mental health nurse consultant.
Journal of psychiatric and mental health nursing, , Volume: 13, Issue:1 | 2006 |
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
The Journal of clinical psychiatry, , Volume: 66, Issue:11 | 2005 |
Transport of carbamazepine and drug interactions at blood-brain barrier.
Acta pharmacologica Sinica, , Volume: 27, Issue:2 | 2006 |
UDP-glucuronosyltransferases and clinical drug-drug interactions.
Pharmacology & therapeutics, , Volume: 106, Issue:1 | 2005 |
Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania.
The British journal of psychiatry : the journal of mental science, , Volume: 185 | 2004 |
Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 28, Issue:1 | 2003 |
Efficacy of electroconvulsive therapy combined with antipsychotic medication in treatment-resistant schizophrenia: a prospective, open trial.
The journal of ECT, , Volume: 18, Issue:2 | 2002 |
Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, , Volume: 23, Issue:3 | 2000 |